cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	30.44	3.14e-114	4.25e-107	0.92	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	30.43	3.65e-114	4.25e-107	0.92	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
LUAD	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	30.08	1.34e-112	9.42e-106	1.07	0.81	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	29.55	3.36e-110	1.73e-103	1.31	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	29.46	9.13e-110	3.65e-103	1.31	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
LUAD	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-29.21	1.23e-108	4.06e-102	-1.08	-0.8	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-29.17	1.98e-108	5.92e-102	-1.08	-0.8	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	29.13	2.97e-108	8.23e-102	1.05	0.8	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	28.99	1.25e-107	3.22e-101	1.31	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	28.79	1.08e-106	2.59e-100	1.25	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
LUAD	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-28.74	1.71e-106	3.85e-100	-1.08	-0.8	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	28.52	1.92e-105	4.06e-99	1.29	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	28.49	2.52e-105	5.04e-99	1.28	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
LUAD	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	28.47	3.29e-105	6.22e-99	0.95	0.79	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	28.42	5.25e-105	9.44e-99	1.05	0.79	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	28.38	8.12e-105	1.39e-98	1.3	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
LUAD	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-28.29	2.23e-104	3.48e-98	-1.06	-0.79	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	28.26	2.87e-104	4.3e-98	0.9	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
LUAD	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-28.22	4.26e-104	5.53e-98	-1.06	-0.79	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
LUAD	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-28.22	4.32e-104	5.53e-98	-1.05	-0.79	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
LUAD	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-28.22	4.32e-104	5.53e-98	-1.05	-0.79	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	28.19	6.04e-104	7.01e-98	1.05	0.79	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	28.1	1.61e-103	1.56e-97	1.29	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
LUAD	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-28.04	3.11e-103	2.94e-97	-1.06	-0.79	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
LUAD	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-27.93	1e-102	8.4e-97	-1.06	-0.79	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
LUAD	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-27.93	1e-102	8.4e-97	-1.06	-0.79	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	27.86	2.04e-102	1.47e-96	1.29	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	27.81	3.62e-102	2.5e-96	1.26	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	27.75	6.99e-102	4.74e-96	0.9	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
LUAD	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-27.57	4.39e-101	2.68e-95	-1.07	-0.78	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-27.46	1.42e-100	7.75e-95	-1.05	-0.78	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	27.45	1.6e-100	8.57e-95	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	27.24	1.56e-99	7.71e-94	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	27.24	1.56e-99	7.71e-94	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	27.17	3.44e-99	1.59e-93	1.3	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	26.93	4.29e-98	1.86e-92	1.28	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	26.93	4.29e-98	1.86e-92	1.28	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
LUAD	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-26.79	1.91e-97	7.71e-92	-1.01	-0.77	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	26.63	1.15e-96	4.29e-91	0.93	0.77	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	26.44	8.18e-96	2.83e-90	0.93	0.77	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
LUAD	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	26.32	3.04e-95	1.02e-89	1	0.77	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	26.22	9.21e-95	3.03e-89	0.87	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	26.15	2.07e-94	6.52e-89	0.97	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	26.13	2.53e-94	7.84e-89	0.88	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
LUAD	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	26.12	2.76e-94	8.47e-89	1.03	0.77	Shingles;	chr7:38346957	chr7:38343894~38350022:-
LUAD	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	26.11	2.9e-94	8.75e-89	0.93	0.77	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	26.08	4.45e-94	1.3e-88	0.91	0.77	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-26.07	4.52e-94	1.31e-88	-0.92	-0.77	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	26.07	4.82e-94	1.39e-88	0.92	0.77	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	26.03	7.35e-94	2.08e-88	0.97	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	26	1.01e-93	2.81e-88	0.92	0.76	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	25.95	1.64e-93	4.47e-88	0.92	0.76	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	25.95	1.7e-93	4.49e-88	0.92	0.76	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-25.94	2e-93	5.24e-88	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	25.88	3.66e-93	9.4e-88	0.92	0.76	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	25.87	4.08e-93	1.03e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-25.86	4.33e-93	1.07e-87	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-25.86	4.33e-93	1.07e-87	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	25.85	5.14e-93	1.26e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	25.82	7.29e-93	1.75e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-25.8	9.11e-93	2.16e-87	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-25.8	9.11e-93	2.16e-87	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	25.77	1.26e-92	2.9e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	25.75	1.47e-92	3.28e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	25.72	1.99e-92	4.42e-87	0.87	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	25.71	2.27e-92	4.97e-87	0.87	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	25.71	2.4e-92	5.23e-87	0.87	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
LUAD	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-25.63	5.39e-92	1.13e-86	-1.03	-0.76	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-25.62	6.24e-92	1.3e-86	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-25.6	7.79e-92	1.6e-86	-0.91	-0.76	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	25.36	1.07e-90	2.08e-85	1.24	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
LUAD	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-25.23	4.23e-90	8.15e-85	-1.03	-0.75	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	25.12	1.38e-89	2.58e-84	0.91	0.75	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
LUAD	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	24.98	6.77e-89	1.26e-83	0.97	0.75	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-24.94	9.77e-89	1.79e-83	-0.95	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	24.85	2.59e-88	4.66e-83	0.95	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	24.77	6.17e-88	1.1e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	24.77	6.36e-88	1.13e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	24.76	6.78e-88	1.2e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	24.75	7.82e-88	1.37e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	24.75	7.82e-88	1.37e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-24.64	2.52e-87	4.29e-82	-0.85	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-24.52	9.8e-87	1.63e-81	-0.96	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
LUAD	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-24.48	1.44e-86	2.38e-81	-0.94	-0.74	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
LUAD	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-24.45	2.2e-86	3.59e-81	-1.02	-0.74	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	24.44	2.37e-86	3.83e-81	0.86	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-24.33	8.03e-86	1.28e-80	-0.96	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	24.33	8.03e-86	1.28e-80	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-24.29	1.14e-85	1.81e-80	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	24.24	2.07e-85	3.25e-80	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	24.2	3.18e-85	4.98e-80	0.85	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	24.19	3.46e-85	5.38e-80	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	24.12	7.6e-85	1.15e-79	0.85	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	24.12	7.6e-85	1.15e-79	0.85	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-24.1	9.93e-85	1.49e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-24.08	1.16e-84	1.73e-79	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-24.05	1.71e-84	2.54e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-24.02	2.41e-84	3.52e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-24.02	2.41e-84	3.52e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-24	3.02e-84	4.36e-79	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-23.97	4.12e-84	5.9e-79	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-23.97	4.12e-84	5.9e-79	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-23.95	4.89e-84	6.98e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-23.91	7.38e-84	1.05e-78	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-23.86	1.4e-83	1.73e-78	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-23.81	2.25e-83	2.57e-78	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	23.78	3.25e-83	3.69e-78	0.92	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-23.78	3.33e-83	3.72e-78	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-23.78	3.33e-83	3.72e-78	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	23.78	3.33e-83	3.72e-78	0.94	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	23.78	3.33e-83	3.72e-78	0.94	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	23.78	3.33e-83	3.72e-78	0.94	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-23.75	4.63e-83	5.06e-78	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-23.75	4.63e-83	5.06e-78	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	23.71	7.22e-83	7.78e-78	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	23.69	8.58e-83	9.18e-78	1.16	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
LUAD	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-23.68	9.49e-83	9.99e-78	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-23.68	9.49e-83	9.99e-78	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-23.68	9.49e-83	9.99e-78	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-23.67	1.11e-82	1.16e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-23.65	1.35e-82	1.4e-77	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-23.61	1.95e-82	2.02e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-23.59	2.54e-82	2.61e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-23.59	2.54e-82	2.61e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-23.59	2.54e-82	2.61e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-23.58	2.94e-82	3.02e-77	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	23.58	2.97e-82	3.02e-77	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	23.58	3.01e-82	3.05e-77	0.94	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-23.57	3.21e-82	3.26e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	23.56	3.72e-82	3.75e-77	0.95	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	23.52	5.38e-82	5.39e-77	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	23.51	6.32e-82	6.29e-77	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	23.51	6.35e-82	6.3e-77	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	23.51	6.35e-82	6.3e-77	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	23.5	6.59e-82	6.48e-77	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	23.5	7.18e-82	7.04e-77	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	23.48	8.33e-82	8.14e-77	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-23.48	8.55e-82	8.33e-77	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-23.48	8.63e-82	8.39e-77	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-23.47	9.4e-82	9.09e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	23.46	1.08e-81	1.04e-76	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	23.44	1.3e-81	1.25e-76	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-23.44	1.31e-81	1.25e-76	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-23.44	1.31e-81	1.25e-76	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-23.43	1.47e-81	1.39e-76	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-23.43	1.47e-81	1.39e-76	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-23.43	1.51e-81	1.43e-76	-0.89	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-23.41	1.74e-81	1.64e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-23.39	2.28e-81	2.13e-76	-0.84	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
LUAD	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	23.38	2.64e-81	2.45e-76	0.68	0.73	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	23.37	2.93e-81	2.71e-76	0.88	0.73	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-23.35	3.48e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	23.35	3.49e-81	3.2e-76	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	23.34	4.15e-81	3.72e-76	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	23.32	5.13e-81	4.59e-76	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	23.32	5.18e-81	4.62e-76	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-23.31	5.42e-81	4.82e-76	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-23.3	6.26e-81	5.53e-76	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-23.28	7.91e-81	6.96e-76	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-23.28	7.97e-81	6.99e-76	-1.17	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
LUAD	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-23.26	9.03e-81	7.87e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-23.26	9.03e-81	7.87e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-23.26	9.03e-81	7.87e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-23.26	9.6e-81	8.31e-76	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-23.26	9.6e-81	8.31e-76	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	23.23	1.27e-80	1.09e-75	0.93	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	23.23	1.28e-80	1.09e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	23.23	1.31e-80	1.12e-75	0.88	0.73	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-23.23	1.34e-80	1.13e-75	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-23.23	1.34e-80	1.13e-75	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-23.22	1.42e-80	1.2e-75	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-23.22	1.43e-80	1.21e-75	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-23.21	1.68e-80	1.4e-75	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-23.21	1.69e-80	1.42e-75	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	23.2	1.88e-80	1.57e-75	0.93	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	23.19	1.95e-80	1.62e-75	0.95	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	23.19	2.13e-80	1.77e-75	0.95	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	23.16	2.7e-80	2.22e-75	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	23.16	2.92e-80	2.38e-75	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	23.16	2.92e-80	2.38e-75	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	23.16	2.92e-80	2.38e-75	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	23.16	2.99e-80	2.42e-75	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	23.16	2.99e-80	2.42e-75	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	23.16	2.99e-80	2.42e-75	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-23.15	3.08e-80	2.49e-75	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-23.14	3.5e-80	2.81e-75	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-23.14	3.5e-80	2.81e-75	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-23.13	4.14e-80	3.31e-75	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	23.12	4.36e-80	3.45e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	23.12	4.36e-80	3.45e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	23.12	4.36e-80	3.45e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	23.12	4.36e-80	3.45e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	23.1	5.73e-80	4.48e-75	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	23.09	6.4e-80	4.97e-75	0.84	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-23.08	7.01e-80	5.44e-75	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	23.07	7.31e-80	5.66e-75	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	23.05	9.66e-80	7.38e-75	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	23.05	9.66e-80	7.38e-75	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	23.05	9.66e-80	7.38e-75	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-23.04	1.06e-79	8.03e-75	-0.94	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	23.04	1.06e-79	8.05e-75	0.96	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	23.02	1.27e-79	9.61e-75	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	23.02	1.37e-79	1.03e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-22.98	2.09e-79	1.56e-74	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	22.98	2.14e-79	1.59e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	22.97	2.19e-79	1.63e-74	1.19	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	22.97	2.23e-79	1.66e-74	0.92	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-22.97	2.33e-79	1.72e-74	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	22.96	2.7e-79	1.98e-74	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	22.96	2.7e-79	1.98e-74	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	22.95	2.7e-79	1.98e-74	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	22.94	3.09e-79	2.26e-74	1.18	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-22.93	3.41e-79	2.47e-74	-1.14	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-22.93	3.41e-79	2.47e-74	-1.14	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-22.93	3.51e-79	2.53e-74	-0.89	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-22.93	3.53e-79	2.55e-74	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
LUAD	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	22.92	3.78e-79	2.71e-74	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	22.92	3.78e-79	2.71e-74	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	22.91	4.27e-79	3.05e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-22.91	4.32e-79	3.09e-74	-0.85	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	22.91	4.54e-79	3.23e-74	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	22.9	4.73e-79	3.35e-74	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
LUAD	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-22.9	4.9e-79	3.46e-74	-0.66	-0.72	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
LUAD	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-22.9	5.09e-79	3.57e-74	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-22.9	5.09e-79	3.57e-74	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-22.89	5.31e-79	3.7e-74	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-22.89	5.31e-79	3.7e-74	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	22.89	5.51e-79	3.83e-74	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-22.87	6.99e-79	4.82e-74	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	22.87	7.24e-79	4.98e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-22.84	9.21e-79	6.31e-74	-1.09	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	22.82	1.14e-78	7.81e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	22.82	1.18e-78	8.04e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	22.82	1.24e-78	8.46e-74	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-22.8	1.49e-78	1.01e-73	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	22.8	1.52e-78	1.03e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-22.8	1.55e-78	1.04e-73	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	22.78	1.86e-78	1.25e-73	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	22.78	1.86e-78	1.25e-73	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-22.77	1.95e-78	1.3e-73	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-22.77	1.95e-78	1.3e-73	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	22.77	1.95e-78	1.3e-73	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	22.74	2.71e-78	1.8e-73	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	22.74	2.76e-78	1.83e-73	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	22.74	2.76e-78	1.83e-73	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	22.74	2.84e-78	1.88e-73	0.92	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	22.73	3.04e-78	2.01e-73	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	22.72	3.59e-78	2.35e-73	0.92	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	22.71	3.82e-78	2.5e-73	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	22.71	4.06e-78	2.65e-73	0.92	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	22.7	4.23e-78	2.75e-73	0.92	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	22.69	4.71e-78	3.06e-73	0.92	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-22.66	6.83e-78	4.39e-73	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	22.65	8.11e-78	5.2e-73	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	22.63	9.95e-78	6.36e-73	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	22.6	1.31e-77	8.32e-73	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	22.59	1.46e-77	9.22e-73	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-22.58	1.58e-77	9.95e-73	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-22.57	1.9e-77	1.19e-72	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	22.55	2.19e-77	1.37e-72	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	22.55	2.2e-77	1.38e-72	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-22.54	2.71e-77	1.69e-72	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	22.53	2.91e-77	1.81e-72	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	22.52	3.04e-77	1.89e-72	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	22.52	3.1e-77	1.92e-72	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-22.52	3.18e-77	1.95e-72	-1.12	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-22.52	3.18e-77	1.95e-72	-1.12	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-22.52	3.18e-77	1.95e-72	-1.12	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-22.52	3.2e-77	1.97e-72	-0.83	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-22.51	3.72e-77	2.27e-72	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-22.5	3.96e-77	2.41e-72	-0.92	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	22.5	3.98e-77	2.41e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	22.5	3.98e-77	2.41e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	22.5	3.98e-77	2.41e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	22.49	4.47e-77	2.71e-72	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-22.47	5.39e-77	3.22e-72	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-22.47	5.39e-77	3.22e-72	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	22.47	5.4e-77	3.22e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	22.47	5.4e-77	3.22e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-22.45	6.98e-77	4.15e-72	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-22.43	8.61e-77	5.1e-72	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	22.42	9.1e-77	5.38e-72	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	22.42	1e-76	5.93e-72	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	22.4	1.24e-76	7.33e-72	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	22.4	1.24e-76	7.33e-72	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	22.39	1.35e-76	7.92e-72	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	22.36	1.82e-76	1.07e-71	0.92	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	22.35	1.98e-76	1.16e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	22.35	2.04e-76	1.19e-71	0.9	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	22.34	2.25e-76	1.31e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-22.34	2.26e-76	1.31e-71	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	22.34	2.27e-76	1.32e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	22.34	2.42e-76	1.4e-71	1.12	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	22.33	2.71e-76	1.57e-71	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-22.32	2.91e-76	1.68e-71	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-22.31	3.19e-76	1.84e-71	-1.13	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	22.31	3.22e-76	1.85e-71	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	22.29	4.05e-76	2.32e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	22.28	4.27e-76	2.44e-71	0.91	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	22.28	4.5e-76	2.57e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	22.28	4.69e-76	2.67e-71	0.9	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-22.25	6.12e-76	3.49e-71	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	22.25	6.32e-76	3.58e-71	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	22.23	7.46e-76	4.22e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	22.22	8.37e-76	4.72e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	22.22	9e-76	5.07e-71	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	22.2	1.12e-75	6.32e-71	1.16	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	22.19	1.18e-75	6.62e-71	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	22.18	1.42e-75	7.91e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	22.17	1.55e-75	8.62e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	22.17	1.55e-75	8.62e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	22.17	1.58e-75	8.76e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	22.17	1.58e-75	8.76e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	22.17	1.58e-75	8.76e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	22.15	1.94e-75	1.07e-70	0.8	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
LUAD	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	22.14	2.13e-75	1.17e-70	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	22.12	2.6e-75	1.43e-70	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	22.1	3.3e-75	1.81e-70	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	22.08	4.01e-75	2.2e-70	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	22.06	4.76e-75	2.6e-70	1.16	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	22.04	5.94e-75	3.24e-70	1.16	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	22.04	6.14e-75	3.34e-70	0.91	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	22.04	6.14e-75	3.34e-70	0.91	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	22.03	6.75e-75	3.66e-70	1.17	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	22.03	6.75e-75	3.66e-70	1.17	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
LUAD	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	22.02	8.12e-75	4.39e-70	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	22	9.61e-75	5.19e-70	0.92	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-21.96	1.46e-74	7.85e-70	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-21.96	1.46e-74	7.85e-70	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-21.96	1.46e-74	7.85e-70	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	21.96	1.52e-74	8.12e-70	0.83	0.71	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-21.96	1.58e-74	8.47e-70	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	21.95	1.65e-74	8.79e-70	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
LUAD	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	21.94	1.81e-74	9.61e-70	0.65	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
LUAD	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	21.93	2.19e-74	1.16e-69	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	21.91	2.59e-74	1.34e-69	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
LUAD	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	21.89	3.25e-74	1.68e-69	0.64	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	21.89	3.39e-74	1.75e-69	0.65	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	21.88	3.62e-74	1.87e-69	0.65	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
LUAD	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	21.88	3.82e-74	1.97e-69	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	21.86	4.36e-74	2.23e-69	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-21.86	4.36e-74	2.23e-69	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-21.86	4.36e-74	2.23e-69	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	21.83	6.36e-74	3.22e-69	0.89	0.71	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-21.82	6.75e-74	3.4e-69	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	21.82	6.8e-74	3.41e-69	0.88	0.71	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	21.82	6.8e-74	3.41e-69	0.88	0.71	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	21.82	6.8e-74	3.41e-69	0.88	0.71	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-21.81	7.59e-74	3.8e-69	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	21.8	8.65e-74	4.32e-69	0.82	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	21.8	8.9e-74	4.43e-69	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	21.8	9.09e-74	4.51e-69	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	21.79	1.02e-73	5.05e-69	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	21.79	1.02e-73	5.05e-69	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-21.78	1.1e-73	5.44e-69	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	21.78	1.13e-73	5.56e-69	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	21.78	1.14e-73	5.59e-69	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-21.75	1.51e-73	7.36e-69	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-21.75	1.51e-73	7.36e-69	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	21.74	1.64e-73	7.98e-69	0.88	0.7	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	21.74	1.64e-73	7.98e-69	0.88	0.7	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	21.74	1.74e-73	8.42e-69	0.88	0.7	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	21.73	1.84e-73	8.93e-69	0.65	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	21.73	1.96e-73	9.45e-69	0.88	0.7	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	21.73	1.98e-73	9.55e-69	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	21.7	2.51e-73	1.2e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	21.7	2.64e-73	1.26e-68	1.14	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	21.7	2.64e-73	1.26e-68	1.14	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	21.68	3.2e-73	1.52e-68	0.8	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	21.68	3.31e-73	1.57e-68	0.88	0.7	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	21.68	3.35e-73	1.58e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	21.66	3.89e-73	1.84e-68	0.88	0.7	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	21.66	3.89e-73	1.84e-68	0.88	0.7	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	21.66	3.94e-73	1.86e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	21.66	4.09e-73	1.93e-68	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	21.65	4.35e-73	2.04e-68	0.88	0.7	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	21.65	4.35e-73	2.04e-68	0.88	0.7	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	21.65	4.43e-73	2.07e-68	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	21.65	4.72e-73	2.2e-68	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	21.65	4.72e-73	2.2e-68	0.87	0.7	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	21.64	4.98e-73	2.32e-68	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	21.63	5.74e-73	2.62e-68	0.88	0.7	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	21.63	5.88e-73	2.68e-68	0.88	0.7	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	21.62	6.23e-73	2.84e-68	0.88	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	21.61	7.13e-73	3.24e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
LUAD	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	21.61	7.43e-73	3.37e-68	0.65	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
LUAD	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	21.59	8.35e-73	3.78e-68	0.86	0.7	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	21.59	8.47e-73	3.83e-68	1.17	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-21.58	1.03e-72	4.65e-68	-0.94	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	21.57	1.09e-72	4.91e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	21.56	1.27e-72	5.7e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	21.55	1.31e-72	5.86e-68	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	21.55	1.38e-72	6.16e-68	0.88	0.7	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	21.55	1.39e-72	6.22e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	21.55	1.39e-72	6.22e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
LUAD	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	21.55	1.42e-72	6.33e-68	1.13	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	21.55	1.43e-72	6.37e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	21.55	1.44e-72	6.39e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
LUAD	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-21.54	1.55e-72	6.89e-68	-1.04	-0.7	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-21.52	1.81e-72	8.04e-68	-1.05	-0.7	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
LUAD	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	21.51	2.06e-72	9.12e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	21.51	2.06e-72	9.12e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	21.51	2.07e-72	9.12e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	21.51	2.15e-72	9.45e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	21.51	2.15e-72	9.45e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	21.51	2.15e-72	9.45e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	21.5	2.45e-72	1.07e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	21.5	2.46e-72	1.08e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	21.49	2.51e-72	1.1e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	21.49	2.74e-72	1.2e-67	0.88	0.7	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	21.49	2.74e-72	1.2e-67	0.88	0.7	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-21.49	2.76e-72	1.2e-67	-0.85	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-21.48	2.78e-72	1.21e-67	-1.05	-0.7	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	21.48	2.8e-72	1.21e-67	0.87	0.7	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	21.48	2.8e-72	1.21e-67	0.87	0.7	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	21.48	2.8e-72	1.21e-67	0.87	0.7	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	21.48	2.8e-72	1.21e-67	0.87	0.7	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	21.48	2.92e-72	1.26e-67	0.88	0.7	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-21.48	2.97e-72	1.28e-67	-1.05	-0.7	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-21.48	2.97e-72	1.28e-67	-1.05	-0.7	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-21.47	3.11e-72	1.34e-67	-1.05	-0.7	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	21.47	3.12e-72	1.34e-67	0.89	0.7	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
LUAD	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	21.47	3.16e-72	1.35e-67	0.87	0.7	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	21.47	3.16e-72	1.35e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	21.47	3.17e-72	1.35e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	21.47	3.17e-72	1.35e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	21.47	3.17e-72	1.35e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-21.47	3.22e-72	1.37e-67	-1.05	-0.7	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	21.44	4.65e-72	1.97e-67	0.85	0.7	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	21.44	4.72e-72	1.99e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	21.43	5.26e-72	2.22e-67	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	21.42	5.76e-72	2.43e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
LUAD	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	21.42	5.8e-72	2.44e-67	0.64	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	21.41	6.1e-72	2.56e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	21.41	6.1e-72	2.56e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-21.41	6.48e-72	2.71e-67	-1.04	-0.7	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-21.41	6.48e-72	2.71e-67	-1.04	-0.7	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	21.41	6.5e-72	2.71e-67	0.88	0.7	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	21.41	6.5e-72	2.71e-67	0.88	0.7	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	21.4	7.25e-72	3.02e-67	0.64	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	21.4	7.36e-72	3.05e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	21.4	7.36e-72	3.05e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	21.4	7.36e-72	3.05e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	21.4	7.36e-72	3.05e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	21.4	7.42e-72	3.07e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-21.38	8.9e-72	3.68e-67	-1.04	-0.7	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	21.38	9.28e-72	3.83e-67	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	21.35	1.2e-71	4.92e-67	0.87	0.7	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-21.35	1.21e-71	4.99e-67	-1.06	-0.7	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-21.34	1.35e-71	5.54e-67	-0.95	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	21.34	1.38e-71	5.65e-67	1.12	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
LUAD	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	21.31	1.84e-71	7.54e-67	0.65	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	21.3	2.22e-71	9.04e-67	0.88	0.7	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	21.28	2.7e-71	1.09e-66	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	21.28	2.7e-71	1.09e-66	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	21.28	2.7e-71	1.09e-66	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	21.26	3.28e-71	1.32e-66	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	21.26	3.41e-71	1.38e-66	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-21.25	3.55e-71	1.43e-66	-1.05	-0.7	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
LUAD	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	21.24	3.89e-71	1.56e-66	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-21.24	4.12e-71	1.65e-66	-0.98	-0.7	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-21.23	4.55e-71	1.82e-66	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-21.23	4.55e-71	1.82e-66	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-21.23	4.55e-71	1.82e-66	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-21.22	4.87e-71	1.94e-66	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-21.21	5.71e-71	2.27e-66	-0.87	-0.7	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	21.2	6.07e-71	2.41e-66	0.88	0.7	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	21.19	7.1e-71	2.81e-66	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	21.19	7.1e-71	2.81e-66	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	21.19	7.1e-71	2.81e-66	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	21.19	7.23e-71	2.86e-66	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	21.19	7.27e-71	2.87e-66	0.85	0.69	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	21.18	7.58e-71	2.99e-66	0.88	0.69	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-21.17	8.63e-71	3.4e-66	-1.05	-0.69	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	21.16	9.77e-71	3.84e-66	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-21.16	1.01e-70	3.97e-66	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	21.16	1.03e-70	4.05e-66	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	21.16	1.04e-70	4.08e-66	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	21.15	1.11e-70	4.36e-66	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	21.14	1.18e-70	4.62e-66	0.87	0.69	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	21.14	1.23e-70	4.78e-66	0.87	0.69	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	21.14	1.25e-70	4.85e-66	1.12	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-21.1	1.93e-70	7.42e-66	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-21.1	1.93e-70	7.42e-66	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-21.1	1.93e-70	7.42e-66	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-21.1	1.94e-70	7.43e-66	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	21.09	2.14e-70	8.17e-66	1.13	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
LUAD	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	21.06	3.11e-70	1.18e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	21.05	3.21e-70	1.22e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	21.04	3.54e-70	1.34e-65	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	21.04	3.64e-70	1.38e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	21.03	4e-70	1.5e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	21.03	4e-70	1.5e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-21.02	4.56e-70	1.72e-65	-0.87	-0.69	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	21.01	4.92e-70	1.85e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	21.01	4.92e-70	1.85e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-21	5.65e-70	2.11e-65	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	21	5.7e-70	2.13e-65	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	21	5.94e-70	2.22e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	21	5.94e-70	2.22e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	20.99	6.19e-70	2.31e-65	0.89	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	20.98	6.79e-70	2.52e-65	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	20.98	6.97e-70	2.59e-65	0.88	0.69	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	20.98	7.27e-70	2.7e-65	0.64	0.69	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	20.96	8.7e-70	3.21e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	20.96	8.76e-70	3.23e-65	0.87	0.69	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-20.93	1.23e-69	4.44e-65	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	20.93	1.24e-69	4.47e-65	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	20.91	1.58e-69	5.67e-65	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	20.9	1.81e-69	6.48e-65	0.87	0.69	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	20.9	1.81e-69	6.48e-65	0.87	0.69	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	20.88	2.22e-69	7.94e-65	0.87	0.69	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	20.86	2.54e-69	9.04e-65	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	20.85	2.89e-69	1.03e-64	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	20.85	3.13e-69	1.11e-64	0.86	0.69	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	20.85	3.13e-69	1.11e-64	0.86	0.69	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	20.83	3.6e-69	1.27e-64	0.87	0.69	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	20.83	3.65e-69	1.29e-64	0.87	0.69	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	20.82	3.99e-69	1.41e-64	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	20.82	4e-69	1.41e-64	0.86	0.69	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	20.82	4.33e-69	1.52e-64	0.77	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	20.79	5.67e-69	1.98e-64	0.87	0.69	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	20.78	6.19e-69	2.16e-64	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-20.77	6.83e-69	2.38e-64	-1.05	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	20.76	7.99e-69	2.78e-64	0.87	0.69	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	20.76	8.39e-69	2.92e-64	0.9	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	20.75	8.49e-69	2.95e-64	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-20.73	1.08e-68	3.74e-64	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-20.73	1.13e-68	3.9e-64	-1.04	-0.69	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-20.73	1.14e-68	3.93e-64	-1.03	-0.69	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	20.72	1.28e-68	4.43e-64	0.89	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	20.72	1.29e-68	4.43e-64	0.86	0.69	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	20.72	1.29e-68	4.44e-64	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-20.71	1.41e-68	4.84e-64	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	20.7	1.58e-68	5.43e-64	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	20.69	1.68e-68	5.74e-64	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	20.69	1.68e-68	5.74e-64	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	20.68	1.98e-68	6.73e-64	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	20.68	1.98e-68	6.73e-64	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	20.67	2.16e-68	7.33e-64	0.86	0.69	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-20.67	2.18e-68	7.4e-64	-0.81	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
LUAD	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	20.65	2.79e-68	9.46e-64	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	20.65	2.79e-68	9.46e-64	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	20.64	2.86e-68	9.69e-64	0.78	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
LUAD	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	20.63	3.35e-68	1.13e-63	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	20.63	3.35e-68	1.13e-63	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	20.62	3.61e-68	1.21e-63	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	20.61	4.23e-68	1.42e-63	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	20.57	6.67e-68	2.23e-63	0.86	0.68	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-20.57	6.7e-68	2.24e-63	-0.77	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	20.56	7.53e-68	2.51e-63	0.85	0.68	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	20.55	8.19e-68	2.73e-63	0.87	0.68	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	20.55	8.22e-68	2.74e-63	0.86	0.68	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	20.54	8.94e-68	2.97e-63	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	20.54	9.05e-68	3.01e-63	0.87	0.68	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
LUAD	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	20.49	1.57e-67	5.2e-63	0.85	0.68	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-20.48	1.73e-67	5.72e-63	-0.88	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	20.47	2e-67	6.59e-63	0.87	0.68	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	20.41	3.6e-67	1.18e-62	0.85	0.68	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	20.36	6.65e-67	2.18e-62	0.84	0.68	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-20.35	7.42e-67	2.43e-62	-1.05	-0.68	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-20.34	8.4e-67	2.74e-62	-0.88	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	20.33	8.8e-67	2.87e-62	0.85	0.68	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	20.32	9.83e-67	3.2e-62	0.85	0.68	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	20.3	1.24e-66	4.04e-62	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	20.28	1.51e-66	4.92e-62	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	20.28	1.53e-66	4.95e-62	0.84	0.68	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	20.27	1.65e-66	5.35e-62	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	20.26	1.94e-66	6.27e-62	0.85	0.68	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	20.21	3.21e-66	1.03e-61	1.07	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	20.21	3.48e-66	1.12e-61	0.85	0.68	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	20.13	7.88e-66	2.52e-61	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	20.12	9.32e-66	2.98e-61	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	20.07	1.52e-65	4.86e-61	0.85	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	20.03	2.26e-65	7.19e-61	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	19.89	1.09e-64	3.42e-60	0.75	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	19.86	1.58e-64	4.95e-60	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	19.73	6.09e-64	1.89e-59	0.85	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	19.73	6.45e-64	2e-59	0.91	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	19.7	8.95e-64	2.77e-59	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
LUAD	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	19.68	1.12e-63	3.46e-59	0.6	0.67	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-19.67	1.29e-63	3.97e-59	-0.6	-0.67	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
LUAD	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-19.66	1.3e-63	4.01e-59	-0.89	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	19.63	1.81e-63	5.55e-59	0.8	0.67	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	19.62	2.1e-63	6.42e-59	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	19.6	2.75e-63	8.4e-59	0.74	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	19.5	8.11e-63	2.47e-58	0.85	0.66	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	19.47	1.1e-62	3.34e-58	0.94	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	19.43	1.62e-62	4.9e-58	0.87	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	19.39	2.65e-62	7.98e-58	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	19.38	3.04e-62	9.13e-58	0.82	0.66	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	19.35	3.97e-62	1.19e-57	0.92	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-19.32	5.69e-62	1.7e-57	-0.82	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	19.26	1.11e-61	3.27e-57	0.8	0.66	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	19.25	1.23e-61	3.63e-57	0.8	0.66	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-19.23	1.43e-61	4.22e-57	-1.03	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-19.23	1.54e-61	4.53e-57	-0.8	-0.66	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	19.2	1.97e-61	5.8e-57	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	19.19	2.32e-61	6.78e-57	0.81	0.66	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	19.19	2.32e-61	6.78e-57	0.81	0.66	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	19.19	2.32e-61	6.78e-57	0.81	0.66	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	19.14	4.14e-61	1.21e-56	0.81	0.66	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-19.13	4.5e-61	1.31e-56	-0.87	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	19.12	5.02e-61	1.46e-56	0.81	0.66	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	19.11	5.8e-61	1.68e-56	0.81	0.66	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-19.02	1.47e-60	4.25e-56	-1.03	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	19.02	1.52e-60	4.4e-56	0.76	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
LUAD	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-19.01	1.61e-60	4.64e-56	-0.6	-0.66	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-19.01	1.61e-60	4.64e-56	-0.6	-0.66	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	19.01	1.66e-60	4.77e-56	0.82	0.65	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	19	1.87e-60	5.37e-56	0.82	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	18.99	1.93e-60	5.56e-56	0.82	0.65	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	18.99	1.99e-60	5.73e-56	0.81	0.65	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	18.99	1.99e-60	5.73e-56	0.81	0.65	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	18.98	2.18e-60	6.25e-56	0.81	0.65	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-18.98	2.27e-60	6.49e-56	-1.03	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-18.98	2.27e-60	6.49e-56	-1.03	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	18.95	3.31e-60	9.42e-56	0.81	0.65	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	18.94	3.37e-60	9.54e-56	0.81	0.65	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	18.94	3.37e-60	9.54e-56	0.81	0.65	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	18.94	3.37e-60	9.54e-56	0.81	0.65	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	18.94	3.37e-60	9.54e-56	0.81	0.65	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	18.94	3.5e-60	9.88e-56	0.75	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	18.94	3.66e-60	1.03e-55	0.81	0.65	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	18.93	3.75e-60	1.06e-55	0.8	0.65	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	18.92	4.43e-60	1.24e-55	0.81	0.65	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-18.91	4.63e-60	1.3e-55	-1.05	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-18.9	5.16e-60	1.44e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-18.9	5.16e-60	1.44e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-18.9	5.16e-60	1.44e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	18.9	5.37e-60	1.5e-55	0.81	0.65	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	18.9	5.37e-60	1.5e-55	0.81	0.65	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	18.88	6.5e-60	1.81e-55	0.82	0.65	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-18.86	8.05e-60	2.22e-55	-0.9	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
LUAD	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-18.86	8.26e-60	2.27e-55	-0.59	-0.65	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	18.85	9.1e-60	2.5e-55	0.81	0.65	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	18.85	9.64e-60	2.64e-55	0.81	0.65	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	18.84	1e-59	2.74e-55	0.8	0.65	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	18.83	1.11e-59	3.03e-55	0.83	0.65	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	18.83	1.2e-59	3.27e-55	0.8	0.65	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	18.81	1.38e-59	3.73e-55	0.81	0.65	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-18.81	1.41e-59	3.82e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-18.81	1.41e-59	3.82e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	18.78	1.9e-59	5.09e-55	0.8	0.65	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	18.78	1.98e-59	5.28e-55	0.81	0.65	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	18.78	1.98e-59	5.28e-55	0.81	0.65	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	18.78	1.98e-59	5.28e-55	0.81	0.65	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	18.78	2.11e-59	5.61e-55	0.84	0.65	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	18.77	2.33e-59	6.18e-55	0.83	0.65	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	18.77	2.33e-59	6.18e-55	0.83	0.65	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	18.76	2.39e-59	6.32e-55	0.99	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	18.76	2.48e-59	6.56e-55	0.71	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
LUAD	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	18.75	2.85e-59	7.5e-55	0.79	0.65	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	18.75	2.88e-59	7.59e-55	0.8	0.65	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	18.73	3.47e-59	9.08e-55	0.8	0.65	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	18.73	3.47e-59	9.08e-55	0.8	0.65	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-18.72	3.74e-59	9.77e-55	-0.82	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	18.71	4.29e-59	1.12e-54	0.83	0.65	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-18.7	4.56e-59	1.19e-54	-1.01	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	18.7	4.78e-59	1.24e-54	0.81	0.65	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	18.69	5.46e-59	1.42e-54	0.83	0.65	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	18.69	5.46e-59	1.42e-54	0.83	0.65	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	18.67	6.41e-59	1.65e-54	0.91	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	18.67	6.41e-59	1.65e-54	0.91	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	18.67	6.57e-59	1.69e-54	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	18.66	7.69e-59	1.97e-54	0.8	0.65	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	18.66	7.69e-59	1.97e-54	0.8	0.65	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	18.65	7.97e-59	2.04e-54	0.81	0.65	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	18.65	8.07e-59	2.06e-54	0.8	0.65	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	18.65	8.12e-59	2.07e-54	0.8	0.65	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	18.65	8.12e-59	2.07e-54	0.8	0.65	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	18.65	8.12e-59	2.07e-54	0.8	0.65	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	18.65	8.29e-59	2.11e-54	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	18.65	8.65e-59	2.2e-54	0.81	0.65	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	18.63	9.8e-59	2.49e-54	0.8	0.65	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-18.63	9.84e-59	2.5e-54	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-18.63	1.04e-58	2.64e-54	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
LUAD	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	18.61	1.31e-58	3.31e-54	0.58	0.65	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	18.61	1.31e-58	3.31e-54	0.81	0.65	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	18.61	1.33e-58	3.36e-54	0.8	0.65	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	18.59	1.58e-58	3.98e-54	0.8	0.65	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	18.59	1.58e-58	3.98e-54	0.8	0.65	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	18.58	1.84e-58	4.61e-54	0.79	0.65	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	18.58	1.84e-58	4.61e-54	0.79	0.65	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	18.57	1.88e-58	4.68e-54	0.79	0.65	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	18.57	1.88e-58	4.68e-54	0.8	0.65	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	18.56	2.18e-58	5.42e-54	0.79	0.65	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-18.56	2.28e-58	5.66e-54	-0.73	-0.65	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	18.55	2.41e-58	5.99e-54	0.78	0.65	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	18.55	2.46e-58	6.11e-54	0.9	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	18.55	2.53e-58	6.28e-54	0.82	0.65	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-18.54	2.82e-58	6.99e-54	-0.98	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	18.54	2.84e-58	7.02e-54	0.8	0.65	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	18.53	2.92e-58	7.23e-54	0.8	0.65	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-18.53	2.95e-58	7.28e-54	-0.73	-0.65	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	18.53	3.02e-58	7.46e-54	0.81	0.65	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	18.53	3.05e-58	7.53e-54	0.8	0.65	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	18.53	3.05e-58	7.53e-54	0.8	0.65	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-18.5	4.2e-58	1.03e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
LUAD	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	18.49	4.63e-58	1.14e-53	0.89	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	18.49	4.66e-58	1.14e-53	0.79	0.64	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-18.48	5.09e-58	1.25e-53	-0.79	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
LUAD	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	18.48	5.38e-58	1.32e-53	0.79	0.64	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	18.47	5.58e-58	1.36e-53	0.81	0.64	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-18.47	5.88e-58	1.44e-53	-0.77	-0.64	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	18.45	6.91e-58	1.69e-53	0.8	0.64	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	18.44	7.77e-58	1.89e-53	0.8	0.64	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-18.44	7.83e-58	1.9e-53	-0.82	-0.64	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	18.43	8.49e-58	2.06e-53	0.8	0.64	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	18.43	8.53e-58	2.06e-53	0.79	0.64	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	18.43	8.76e-58	2.11e-53	0.8	0.64	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	18.43	8.76e-58	2.11e-53	0.8	0.64	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	18.43	8.76e-58	2.11e-53	0.8	0.64	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	18.43	8.76e-58	2.11e-53	0.8	0.64	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-18.43	8.95e-58	2.16e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-18.43	9.18e-58	2.21e-53	-0.82	-0.64	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	18.43	9.26e-58	2.23e-53	0.82	0.64	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	18.42	9.98e-58	2.39e-53	0.79	0.64	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	18.42	1.05e-57	2.49e-53	0.8	0.64	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-18.41	1.11e-57	2.63e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
LUAD	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	18.41	1.12e-57	2.66e-53	0.78	0.64	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	18.41	1.12e-57	2.66e-53	0.78	0.64	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
LUAD	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-18.41	1.16e-57	2.75e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	18.4	1.26e-57	2.99e-53	0.8	0.64	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	18.39	1.35e-57	3.19e-53	0.8	0.64	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	18.39	1.35e-57	3.19e-53	0.8	0.64	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-18.38	1.59e-57	3.73e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-18.37	1.63e-57	3.82e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	18.37	1.69e-57	3.95e-53	0.73	0.64	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-18.36	1.86e-57	4.33e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-18.36	1.87e-57	4.34e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-18.36	1.87e-57	4.34e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	18.36	1.93e-57	4.47e-53	0.8	0.64	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	18.36	1.98e-57	4.58e-53	0.79	0.64	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-18.35	2.12e-57	4.88e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	18.35	2.22e-57	5.09e-53	0.8	0.64	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	18.35	2.22e-57	5.09e-53	0.8	0.64	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-18.34	2.31e-57	5.29e-53	-0.78	-0.64	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-18.34	2.34e-57	5.35e-53	-0.92	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
LUAD	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-18.33	2.76e-57	6.28e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
LUAD	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	18.32	2.85e-57	6.48e-53	0.77	0.64	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
LUAD	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-18.32	3.04e-57	6.91e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	18.31	3.38e-57	7.68e-53	0.8	0.64	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	18.28	4.38e-57	9.93e-53	0.8	0.64	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	18.27	4.81e-57	1.09e-52	0.79	0.64	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	18.27	4.81e-57	1.09e-52	0.79	0.64	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	18.27	4.81e-57	1.09e-52	0.79	0.64	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	18.27	4.81e-57	1.09e-52	0.79	0.64	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	18.27	4.85e-57	1.09e-52	0.56	0.64	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	18.27	5.31e-57	1.19e-52	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
LUAD	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	18.26	5.55e-57	1.24e-52	0.8	0.64	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	18.26	5.55e-57	1.24e-52	0.8	0.64	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-18.25	6.34e-57	1.42e-52	-0.72	-0.64	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	18.24	7.09e-57	1.58e-52	0.8	0.64	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	18.23	7.45e-57	1.66e-52	0.79	0.64	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	18.23	8.06e-57	1.8e-52	0.79	0.64	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	18.23	8.06e-57	1.8e-52	0.79	0.64	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	18.22	8.31e-57	1.85e-52	0.79	0.64	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	18.22	9.04e-57	2.01e-52	0.78	0.64	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	18.22	9.04e-57	2.01e-52	0.78	0.64	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	18.22	9.04e-57	2.01e-52	0.78	0.64	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	18.22	9.04e-57	2.01e-52	0.78	0.64	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
LUAD	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-18.21	9.14e-57	2.03e-52	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	18.21	9.8e-57	2.16e-52	0.81	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
LUAD	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	18.2	1.03e-56	2.28e-52	0.87	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	18.18	1.27e-56	2.79e-52	0.82	0.64	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-18.18	1.29e-56	2.84e-52	-0.89	-0.64	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	18.18	1.3e-56	2.86e-52	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
LUAD	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-18.17	1.43e-56	3.13e-52	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-18.17	1.43e-56	3.13e-52	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	18.17	1.46e-56	3.2e-52	0.79	0.64	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	18.17	1.56e-56	3.4e-52	0.79	0.64	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	18.15	1.78e-56	3.88e-52	0.88	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	18.15	1.85e-56	4.03e-52	0.79	0.64	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-18.13	2.39e-56	5.2e-52	-0.87	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
LUAD	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-18.13	2.41e-56	5.24e-52	-0.82	-0.64	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-18.12	2.45e-56	5.33e-52	-0.82	-0.64	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	18.11	2.77e-56	6.01e-52	0.79	0.64	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	18.11	2.8e-56	6.07e-52	0.81	0.64	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	18.1	3.17e-56	6.86e-52	0.82	0.64	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-18.09	3.54e-56	7.65e-52	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	18.09	3.67e-56	7.92e-52	0.81	0.64	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	18.07	4.51e-56	9.69e-52	0.82	0.64	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	18.05	5.22e-56	1.12e-51	0.8	0.64	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	18.03	6.8e-56	1.45e-51	0.8	0.64	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	18.02	7.86e-56	1.68e-51	0.78	0.63	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	18.02	7.86e-56	1.68e-51	0.78	0.63	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-18.01	8.39e-56	1.79e-51	-0.79	-0.63	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-18	9.42e-56	2e-51	-0.71	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
LUAD	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-17.98	1.19e-55	2.52e-51	-0.82	-0.63	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	17.97	1.31e-55	2.78e-51	0.81	0.63	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	17.96	1.36e-55	2.88e-51	0.77	0.63	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
LUAD	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-17.96	1.49e-55	3.16e-51	-0.96	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	17.95	1.62e-55	3.41e-51	0.78	0.63	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	17.95	1.62e-55	3.41e-51	0.78	0.63	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	17.94	1.76e-55	3.7e-51	0.8	0.63	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	17.94	1.82e-55	3.83e-51	0.78	0.63	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	17.93	1.92e-55	4.03e-51	0.8	0.63	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	17.93	2.08e-55	4.35e-51	0.81	0.63	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	17.93	2.08e-55	4.35e-51	0.81	0.63	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	17.92	2.11e-55	4.41e-51	0.79	0.63	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	17.92	2.12e-55	4.43e-51	0.77	0.63	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-17.92	2.15e-55	4.49e-51	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-17.92	2.15e-55	4.49e-51	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-17.92	2.15e-55	4.49e-51	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-17.92	2.15e-55	4.49e-51	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	17.88	3.39e-55	7.02e-51	0.79	0.63	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-17.88	3.41e-55	7.04e-51	-0.79	-0.63	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	17.87	3.68e-55	7.59e-51	0.87	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	17.87	3.73e-55	7.7e-51	0.81	0.63	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	17.87	3.82e-55	7.87e-51	0.72	0.63	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
LUAD	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	17.86	4.09e-55	8.4e-51	0.77	0.63	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	17.86	4.09e-55	8.4e-51	0.77	0.63	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	17.86	4.09e-55	8.4e-51	0.77	0.63	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
LUAD	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	17.86	4.22e-55	8.66e-51	0.87	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	17.86	4.22e-55	8.66e-51	0.87	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
LUAD	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	17.84	5.07e-55	1.04e-50	0.77	0.63	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	17.83	5.52e-55	1.13e-50	0.77	0.63	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	17.83	6.12e-55	1.25e-50	0.81	0.63	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	17.83	6.12e-55	1.25e-50	0.81	0.63	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-17.82	6.41e-55	1.31e-50	-0.72	-0.63	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	17.81	7.2e-55	1.46e-50	0.77	0.63	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	17.8	8.06e-55	1.64e-50	0.77	0.63	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	17.8	8.37e-55	1.7e-50	0.79	0.63	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	17.79	8.53e-55	1.73e-50	0.79	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-17.79	8.95e-55	1.81e-50	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-17.78	1.03e-54	2.07e-50	-0.87	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	17.76	1.3e-54	2.61e-50	0.81	0.63	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	17.75	1.42e-54	2.85e-50	0.78	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-17.75	1.42e-54	2.85e-50	-0.8	-0.63	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-17.73	1.69e-54	3.37e-50	-0.8	-0.63	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	17.73	1.73e-54	3.45e-50	0.77	0.63	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-17.73	1.74e-54	3.47e-50	-0.77	-0.63	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	17.72	1.96e-54	3.9e-50	0.71	0.63	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	17.72	1.97e-54	3.92e-50	0.79	0.63	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	17.72	2e-54	3.98e-50	0.83	0.63	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	17.72	2e-54	3.98e-50	0.83	0.63	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-17.7	2.32e-54	4.62e-50	-0.8	-0.63	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
LUAD	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	17.7	2.36e-54	4.68e-50	0.55	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	17.7	2.39e-54	4.74e-50	0.8	0.63	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	17.68	3.06e-54	6.06e-50	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	17.68	3.06e-54	6.06e-50	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-17.67	3.14e-54	6.2e-50	-0.8	-0.63	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	17.67	3.27e-54	6.45e-50	0.81	0.63	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-17.66	3.45e-54	6.78e-50	-0.77	-0.63	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	17.65	4.19e-54	8.24e-50	1.07	0.63	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	17.64	4.36e-54	8.57e-50	0.78	0.63	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	17.63	5.25e-54	1.03e-49	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
LUAD	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	17.62	5.37e-54	1.05e-49	0.83	0.63	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	17.59	7.58e-54	1.48e-49	0.79	0.63	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	17.59	7.63e-54	1.49e-49	0.76	0.63	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	17.59	8e-54	1.56e-49	0.83	0.63	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	17.58	8.28e-54	1.61e-49	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
LUAD	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	17.56	1.1e-53	2.14e-49	0.8	0.62	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	17.54	1.27e-53	2.46e-49	0.8	0.62	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-17.54	1.3e-53	2.52e-49	-1.03	-0.62	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	17.54	1.33e-53	2.57e-49	0.76	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
LUAD	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	17.52	1.59e-53	3.08e-49	0.8	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	17.52	1.69e-53	3.25e-49	0.8	0.62	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	17.52	1.72e-53	3.31e-49	0.76	0.62	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	17.5	1.95e-53	3.75e-49	0.81	0.62	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-17.5	1.98e-53	3.81e-49	-0.74	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-17.5	2.09e-53	4e-49	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	17.49	2.21e-53	4.23e-49	0.78	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
LUAD	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-17.49	2.22e-53	4.26e-49	-1.01	-0.62	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-17.49	2.32e-53	4.44e-49	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-17.47	2.79e-53	5.34e-49	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-17.47	2.79e-53	5.34e-49	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-17.46	3.02e-53	5.78e-49	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-17.46	3.22e-53	6.15e-49	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	17.45	3.4e-53	6.48e-49	0.79	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
LUAD	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	17.44	3.68e-53	7e-49	0.75	0.62	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
LUAD	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	17.44	3.96e-53	7.53e-49	0.94	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
LUAD	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-17.43	4.51e-53	8.57e-49	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-17.42	4.64e-53	8.81e-49	-0.67	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	17.4	6.17e-53	1.17e-48	0.79	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-17.38	7.23e-53	1.36e-48	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-17.37	7.93e-53	1.49e-48	-0.72	-0.62	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
LUAD	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-17.37	8.35e-53	1.57e-48	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	17.36	9.16e-53	1.72e-48	0.81	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	17.35	9.89e-53	1.85e-48	0.76	0.62	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	17.35	9.89e-53	1.85e-48	0.76	0.62	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	17.35	1.03e-52	1.92e-48	0.76	0.62	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	17.34	1.08e-52	2.02e-48	0.79	0.62	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	17.34	1.08e-52	2.02e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
LUAD	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	17.34	1.14e-52	2.12e-48	0.75	0.62	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	17.33	1.24e-52	2.32e-48	0.76	0.62	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	17.31	1.6e-52	2.97e-48	0.79	0.62	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-17.3	1.74e-52	3.22e-48	-0.72	-0.62	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	17.29	1.97e-52	3.65e-48	0.82	0.62	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	17.28	2.23e-52	4.13e-48	0.79	0.62	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	17.24	3.12e-52	5.74e-48	0.75	0.62	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-17.24	3.12e-52	5.74e-48	-0.75	-0.62	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-17.23	3.49e-52	6.39e-48	-0.77	-0.62	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-17.23	3.49e-52	6.39e-48	-0.85	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-17.23	3.49e-52	6.39e-48	-0.85	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	17.23	3.73e-52	6.83e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	17.22	3.96e-52	7.24e-48	0.77	0.62	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-17.21	4.49e-52	8.2e-48	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-17.19	5.86e-52	1.06e-47	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	17.18	6.03e-52	1.09e-47	0.79	0.62	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	17.18	6.03e-52	1.09e-47	0.79	0.62	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-17.17	6.81e-52	1.23e-47	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	17.16	7.66e-52	1.38e-47	0.75	0.62	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	17.16	7.69e-52	1.39e-47	0.76	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
LUAD	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-17.13	1.09e-51	1.95e-47	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	17.13	1.12e-51	2e-47	0.75	0.62	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	17.11	1.28e-51	2.29e-47	0.79	0.62	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	17.1	1.52e-51	2.71e-47	0.77	0.61	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
LUAD	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	17.09	1.54e-51	2.75e-47	0.75	0.61	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	17.09	1.56e-51	2.77e-47	0.76	0.61	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-17.09	1.63e-51	2.91e-47	-0.77	-0.61	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	17.07	2.02e-51	3.58e-47	0.75	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-17.05	2.41e-51	4.26e-47	-0.79	-0.61	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	17.04	2.66e-51	4.7e-47	0.78	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-17.04	2.87e-51	5.06e-47	-0.75	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-17.03	2.95e-51	5.2e-47	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	17.03	3.21e-51	5.64e-47	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
LUAD	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	17.03	3.22e-51	5.66e-47	0.79	0.61	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	17.03	3.24e-51	5.69e-47	0.77	0.61	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-17.02	3.26e-51	5.73e-47	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-17	4.37e-51	7.65e-47	-0.77	-0.61	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-16.99	4.91e-51	8.57e-47	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	16.96	6.5e-51	1.13e-46	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	16.96	6.58e-51	1.14e-46	0.8	0.61	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	16.96	6.73e-51	1.17e-46	0.82	0.61	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	16.94	7.77e-51	1.34e-46	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	16.94	8.28e-51	1.43e-46	0.8	0.61	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	16.91	1.16e-50	1.99e-46	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
LUAD	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-16.9	1.18e-50	2.03e-46	-0.79	-0.61	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-16.88	1.45e-50	2.48e-46	-0.78	-0.61	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-16.88	1.51e-50	2.58e-46	-0.68	-0.61	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	16.88	1.55e-50	2.64e-46	0.71	0.61	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
LUAD	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-16.87	1.65e-50	2.82e-46	-0.75	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
LUAD	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	16.87	1.71e-50	2.92e-46	0.71	0.61	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
LUAD	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	16.85	2.01e-50	3.42e-46	0.77	0.61	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-16.81	3.18e-50	5.36e-46	-0.74	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	16.8	3.52e-50	5.92e-46	0.75	0.61	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	16.79	4.1e-50	6.9e-46	0.75	0.61	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	16.79	4.1e-50	6.9e-46	0.75	0.61	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	16.75	6.13e-50	1.02e-45	0.78	0.61	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-16.75	6.27e-50	1.05e-45	-0.54	-0.61	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
LUAD	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	16.74	6.92e-50	1.15e-45	0.75	0.61	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	16.73	7.83e-50	1.3e-45	0.78	0.61	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	16.71	9.07e-50	1.51e-45	0.81	0.61	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-16.69	1.2e-49	1.98e-45	-0.88	-0.61	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
LUAD	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-16.68	1.23e-49	2.04e-45	-0.66	-0.61	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
LUAD	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	16.66	1.56e-49	2.58e-45	0.77	0.6	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
LUAD	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-16.62	2.31e-49	3.8e-45	-0.66	-0.6	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
LUAD	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-16.61	2.55e-49	4.19e-45	-0.54	-0.6	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-16.61	2.55e-49	4.19e-45	-0.54	-0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	16.61	2.73e-49	4.48e-45	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	16.58	3.65e-49	5.97e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-16.57	3.92e-49	6.42e-45	-0.76	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-16.57	4.13e-49	6.76e-45	-0.75	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-16.46	1.24e-48	2.02e-44	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	16.46	1.27e-48	2.06e-44	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	16.46	1.37e-48	2.22e-44	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	16.44	1.59e-48	2.58e-44	0.76	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	16.43	1.77e-48	2.88e-44	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	16.42	2e-48	3.25e-44	0.75	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-16.41	2.33e-48	3.77e-44	-0.77	-0.6	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-16.41	2.33e-48	3.77e-44	-0.77	-0.6	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-16.41	2.33e-48	3.77e-44	-0.77	-0.6	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	16.39	2.76e-48	4.45e-44	0.74	0.6	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-16.38	3.06e-48	4.93e-44	-0.78	-0.6	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	16.37	3.39e-48	5.46e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	16.36	3.58e-48	5.75e-44	0.7	0.6	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	16.36	3.74e-48	6e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
LUAD	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-16.36	3.9e-48	6.25e-44	-0.65	-0.6	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
LUAD	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	16.36	3.94e-48	6.31e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	16.36	3.94e-48	6.31e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
LUAD	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-16.33	5.32e-48	8.51e-44	-0.77	-0.6	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
LUAD	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	16.33	5.4e-48	8.64e-44	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-16.32	5.45e-48	8.71e-44	-0.77	-0.6	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	16.32	5.47e-48	8.74e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
LUAD	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-16.32	5.96e-48	9.51e-44	-0.77	-0.6	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	16.31	6.38e-48	1.02e-43	0.69	0.6	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	16.31	6.38e-48	1.02e-43	0.69	0.6	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-16.3	6.78e-48	1.08e-43	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
LUAD	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-16.29	7.5e-48	1.19e-43	-0.77	-0.6	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-16.29	7.5e-48	1.19e-43	-0.77	-0.6	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-16.29	7.52e-48	1.2e-43	-0.77	-0.6	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	16.29	7.96e-48	1.26e-43	0.77	0.6	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-16.28	8.45e-48	1.34e-43	-0.77	-0.6	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-16.28	8.65e-48	1.37e-43	-0.77	-0.6	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-16.28	8.65e-48	1.37e-43	-0.77	-0.6	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	16.28	8.68e-48	1.37e-43	0.7	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
LUAD	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	16.25	1.16e-47	1.83e-43	0.77	0.6	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	16.24	1.3e-47	2.05e-43	0.76	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	16.24	1.35e-47	2.13e-43	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	16.23	1.41e-47	2.22e-43	0.73	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
LUAD	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	16.23	1.42e-47	2.23e-43	0.75	0.59	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	16.23	1.53e-47	2.41e-43	0.69	0.59	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
LUAD	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-16.22	1.63e-47	2.56e-43	-0.52	-0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	16.19	2.22e-47	3.48e-43	0.74	0.59	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-16.19	2.23e-47	3.5e-43	-0.76	-0.59	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
LUAD	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	16.17	2.66e-47	4.15e-43	0.63	0.59	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
LUAD	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	16.17	2.72e-47	4.25e-43	0.74	0.59	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	16.17	2.83e-47	4.42e-43	0.76	0.59	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	16.16	3.08e-47	4.81e-43	0.69	0.59	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-16.14	3.76e-47	5.84e-43	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
LUAD	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	16.12	4.68e-47	7.26e-43	0.75	0.59	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
LUAD	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-16.1	5.92e-47	9.17e-43	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
LUAD	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-16.09	6.57e-47	1.02e-42	-0.76	-0.59	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-16.09	6.57e-47	1.02e-42	-0.76	-0.59	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-16.08	7.12e-47	1.1e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
LUAD	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	16.08	7.36e-47	1.14e-42	0.59	0.59	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	16.07	7.67e-47	1.18e-42	0.75	0.59	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	16.07	8.32e-47	1.28e-42	0.72	0.59	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	16.05	9.41e-47	1.45e-42	0.77	0.59	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-16.05	9.93e-47	1.53e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	16.04	1.06e-46	1.62e-42	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
LUAD	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-16.04	1.07e-46	1.63e-42	-0.5	-0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
LUAD	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-16.04	1.08e-46	1.65e-42	-0.77	-0.59	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-16.04	1.14e-46	1.74e-42	-0.95	-0.59	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-16.03	1.26e-46	1.92e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
LUAD	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	16.02	1.31e-46	2e-42	0.73	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
LUAD	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-16.01	1.43e-46	2.18e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-16	1.66e-46	2.52e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-16	1.69e-46	2.56e-42	-0.7	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
LUAD	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	15.99	1.77e-46	2.69e-42	0.58	0.59	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
LUAD	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	15.99	1.81e-46	2.74e-42	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-15.98	1.96e-46	2.97e-42	-0.76	-0.59	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	15.98	2.1e-46	3.18e-42	0.74	0.59	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	15.97	2.22e-46	3.35e-42	0.75	0.59	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	15.97	2.29e-46	3.45e-42	0.74	0.59	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	15.97	2.31e-46	3.49e-42	0.7	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
LUAD	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-15.96	2.54e-46	3.82e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-15.96	2.54e-46	3.82e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-15.95	2.94e-46	4.4e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
LUAD	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	15.91	4.43e-46	6.56e-42	0.75	0.59	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-15.89	5.1e-46	7.52e-42	-0.72	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	15.89	5.28e-46	7.78e-42	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
LUAD	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-15.88	5.6e-46	8.25e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-15.88	5.6e-46	8.25e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
LUAD	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	15.88	5.82e-46	8.56e-42	0.58	0.59	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
LUAD	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-15.87	6.26e-46	9.19e-42	-0.77	-0.59	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-15.87	6.26e-46	9.19e-42	-0.77	-0.59	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-15.87	6.37e-46	9.35e-42	-0.65	-0.59	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	15.87	6.45e-46	9.47e-42	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
LUAD	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-15.86	7.02e-46	1.03e-41	-0.58	-0.59	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
LUAD	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-15.86	7.22e-46	1.06e-41	-0.79	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	15.86	7.27e-46	1.06e-41	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
LUAD	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-15.85	7.89e-46	1.15e-41	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
LUAD	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-15.85	8.11e-46	1.18e-41	-0.79	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
LUAD	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	15.83	9.81e-46	1.43e-41	0.75	0.59	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	15.83	9.97e-46	1.45e-41	0.76	0.59	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	15.83	1.02e-45	1.49e-41	0.67	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
LUAD	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	15.82	1.06e-45	1.53e-41	0.66	0.59	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
LUAD	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	15.82	1.1e-45	1.6e-41	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-15.81	1.26e-45	1.82e-41	-0.67	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	15.8	1.36e-45	1.97e-41	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
LUAD	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-15.79	1.43e-45	2.06e-41	-0.66	-0.58	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
LUAD	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-15.79	1.44e-45	2.08e-41	-0.76	-0.58	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-15.79	1.48e-45	2.14e-41	-0.74	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-15.79	1.55e-45	2.24e-41	-0.58	-0.58	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
LUAD	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	15.79	1.57e-45	2.26e-41	0.75	0.58	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
LUAD	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-15.78	1.6e-45	2.31e-41	-0.81	-0.58	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-15.78	1.65e-45	2.38e-41	-0.81	-0.58	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	15.76	1.99e-45	2.87e-41	0.65	0.58	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
LUAD	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-15.76	2.03e-45	2.92e-41	-0.7	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	15.75	2.21e-45	3.18e-41	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	15.75	2.21e-45	3.18e-41	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-15.73	2.65e-45	3.81e-41	-0.76	-0.58	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-15.71	3.4e-45	4.86e-41	-0.79	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
LUAD	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	15.71	3.43e-45	4.9e-41	0.75	0.58	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
LUAD	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	15.71	3.59e-45	5.12e-41	0.71	0.58	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	15.7	3.74e-45	5.33e-41	0.65	0.58	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
LUAD	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-15.7	3.98e-45	5.67e-41	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	15.68	4.52e-45	6.42e-41	0.73	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	15.68	4.66e-45	6.62e-41	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	15.68	4.75e-45	6.74e-41	0.59	0.58	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
LUAD	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	15.68	4.8e-45	6.81e-41	0.68	0.58	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
LUAD	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	15.68	4.93e-45	7e-41	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	15.67	5.44e-45	7.71e-41	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
LUAD	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	15.65	6.27e-45	8.87e-41	0.75	0.58	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	15.64	7.29e-45	1.03e-40	0.73	0.58	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
LUAD	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	15.63	7.92e-45	1.12e-40	0.65	0.58	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
LUAD	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	15.62	8.44e-45	1.19e-40	0.71	0.58	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
LUAD	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	15.61	9.42e-45	1.32e-40	0.73	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-15.59	1.15e-44	1.61e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
LUAD	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	15.59	1.24e-44	1.73e-40	0.8	0.58	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
LUAD	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	15.59	1.25e-44	1.75e-40	0.58	0.58	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	15.58	1.39e-44	1.95e-40	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
LUAD	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-15.58	1.4e-44	1.95e-40	-0.82	-0.58	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
LUAD	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-15.56	1.66e-44	2.31e-40	-0.74	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-15.53	2.27e-44	3.17e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
LUAD	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	15.52	2.41e-44	3.36e-40	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	15.52	2.52e-44	3.5e-40	0.69	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-15.52	2.59e-44	3.6e-40	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
LUAD	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	15.51	2.72e-44	3.78e-40	0.65	0.58	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
LUAD	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-15.51	2.84e-44	3.94e-40	-0.73	-0.58	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	15.51	2.84e-44	3.94e-40	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-15.5	3.15e-44	4.35e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-15.49	3.37e-44	4.65e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	15.49	3.39e-44	4.67e-40	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-15.49	3.4e-44	4.68e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	15.49	3.44e-44	4.72e-40	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
LUAD	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	15.49	3.46e-44	4.75e-40	0.74	0.58	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
LUAD	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-15.49	3.48e-44	4.78e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-15.49	3.48e-44	4.78e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-15.48	3.81e-44	5.22e-40	-0.66	-0.58	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-15.47	3.95e-44	5.41e-40	-0.65	-0.58	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
LUAD	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	15.47	4.04e-44	5.53e-40	0.75	0.58	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	15.47	4.04e-44	5.53e-40	0.75	0.58	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	15.46	4.78e-44	6.54e-40	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
LUAD	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-15.45	5.07e-44	6.94e-40	-0.5	-0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
LUAD	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-15.45	5.26e-44	7.18e-40	-0.75	-0.58	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	15.44	5.61e-44	7.64e-40	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
LUAD	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-15.44	5.73e-44	7.8e-40	-0.65	-0.58	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-15.41	8.12e-44	1.1e-39	-0.68	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
LUAD	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-15.4	8.25e-44	1.12e-39	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-15.4	8.25e-44	1.12e-39	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
LUAD	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	15.39	9.69e-44	1.31e-39	0.75	0.57	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	15.38	1.02e-43	1.37e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	15.38	1.03e-43	1.39e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	15.37	1.2e-43	1.61e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
LUAD	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	15.37	1.22e-43	1.65e-39	0.73	0.57	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	15.36	1.31e-43	1.76e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	15.36	1.31e-43	1.76e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
LUAD	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-15.36	1.33e-43	1.79e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	15.36	1.35e-43	1.81e-39	0.73	0.57	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
LUAD	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-15.35	1.51e-43	2.01e-39	-0.8	-0.57	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	15.34	1.57e-43	2.09e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	15.34	1.58e-43	2.1e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	15.34	1.59e-43	2.12e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
LUAD	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	15.34	1.61e-43	2.15e-39	0.56	0.57	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
LUAD	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	15.34	1.62e-43	2.16e-39	0.56	0.57	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
LUAD	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-15.34	1.66e-43	2.21e-39	-0.74	-0.57	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-15.34	1.67e-43	2.23e-39	-0.64	-0.57	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
LUAD	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	15.33	1.73e-43	2.3e-39	0.75	0.57	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	15.33	1.74e-43	2.32e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
LUAD	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-15.32	1.89e-43	2.52e-39	-0.9	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
LUAD	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-15.32	1.94e-43	2.57e-39	-0.72	-0.57	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-15.32	1.94e-43	2.57e-39	-0.72	-0.57	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-15.32	1.94e-43	2.57e-39	-0.72	-0.57	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-15.32	1.94e-43	2.57e-39	-0.72	-0.57	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
LUAD	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	15.32	1.94e-43	2.57e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
LUAD	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-15.32	2.04e-43	2.7e-39	-0.72	-0.57	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	15.32	2.05e-43	2.72e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
LUAD	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-15.31	2.11e-43	2.78e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	15.3	2.33e-43	3.07e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	15.3	2.35e-43	3.1e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
LUAD	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	15.3	2.38e-43	3.12e-39	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	15.29	2.55e-43	3.34e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
LUAD	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-15.29	2.57e-43	3.37e-39	-0.57	-0.57	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
LUAD	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	15.29	2.66e-43	3.49e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-15.28	2.85e-43	3.73e-39	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	15.28	2.94e-43	3.84e-39	0.69	0.57	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
LUAD	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	15.28	2.97e-43	3.88e-39	0.74	0.57	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	15.28	2.99e-43	3.91e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
LUAD	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-15.28	3.06e-43	4e-39	-0.59	-0.57	Breast cancer;	chr11:743813	chr11:779617~780755:+
LUAD	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	15.28	3.08e-43	4.01e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
LUAD	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	15.27	3.42e-43	4.45e-39	0.72	0.57	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-15.26	3.5e-43	4.54e-39	-0.7	-0.57	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
LUAD	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	15.26	3.62e-43	4.69e-39	0.81	0.57	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-15.26	3.79e-43	4.9e-39	-0.68	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-15.26	3.79e-43	4.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-15.26	3.79e-43	4.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	15.26	3.81e-43	4.93e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	15.26	3.81e-43	4.93e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
LUAD	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-15.26	3.84e-43	4.96e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-15.26	3.84e-43	4.96e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	15.25	3.87e-43	5e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	15.25	3.87e-43	5e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	15.25	4.02e-43	5.18e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
LUAD	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
LUAD	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
LUAD	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
LUAD	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
LUAD	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	15.25	4.26e-43	5.45e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
LUAD	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-15.24	4.32e-43	5.51e-39	-0.72	-0.57	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-15.24	4.32e-43	5.51e-39	-0.72	-0.57	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-15.24	4.39e-43	5.6e-39	-0.75	-0.57	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	15.24	4.57e-43	5.83e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
LUAD	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-15.24	4.63e-43	5.89e-39	-0.75	-0.57	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	15.23	4.74e-43	6.03e-39	0.66	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
LUAD	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	15.23	5.04e-43	6.4e-39	0.57	0.57	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
LUAD	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-15.23	5.15e-43	6.54e-39	-0.72	-0.57	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
LUAD	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-15.22	5.28e-43	6.7e-39	-0.57	-0.57	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
LUAD	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-15.22	5.51e-43	6.99e-39	-0.74	-0.57	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
LUAD	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-15.21	6.07e-43	7.68e-39	-0.62	-0.57	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-15.21	6.08e-43	7.7e-39	-0.62	-0.57	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-15.21	6.09e-43	7.71e-39	-0.62	-0.57	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
LUAD	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	15.21	6.12e-43	7.74e-39	0.78	0.57	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
LUAD	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	15.21	6.22e-43	7.86e-39	0.68	0.57	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	15.21	6.24e-43	7.88e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	15.2	6.64e-43	8.37e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
LUAD	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-15.19	7.39e-43	9.3e-39	-0.57	-0.57	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-15.19	7.39e-43	9.3e-39	-0.57	-0.57	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
LUAD	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-15.19	7.49e-43	9.41e-39	-0.56	-0.57	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
LUAD	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-15.18	7.95e-43	9.97e-39	-0.64	-0.57	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
LUAD	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-15.18	8.33e-43	1.04e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
LUAD	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	15.18	8.38e-43	1.05e-38	0.79	0.57	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	15.18	8.49e-43	1.06e-38	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
LUAD	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	15.18	8.5e-43	1.06e-38	0.73	0.57	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	15.17	8.92e-43	1.11e-38	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	15.17	8.92e-43	1.11e-38	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
LUAD	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	15.17	8.98e-43	1.12e-38	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	15.17	9.11e-43	1.14e-38	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	15.17	9.19e-43	1.15e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
LUAD	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-15.17	9.57e-43	1.19e-38	-0.72	-0.57	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-15.16	9.75e-43	1.22e-38	-0.72	-0.57	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-15.16	9.75e-43	1.22e-38	-0.72	-0.57	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	15.16	9.78e-43	1.22e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-15.16	9.79e-43	1.22e-38	-0.75	-0.57	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
LUAD	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-15.16	9.98e-43	1.24e-38	-0.72	-0.57	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-15.16	1.03e-42	1.28e-38	-0.72	-0.57	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-15.16	1.05e-42	1.3e-38	-0.72	-0.57	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	15.16	1.05e-42	1.3e-38	0.57	0.57	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
LUAD	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-15.16	1.05e-42	1.31e-38	-0.65	-0.57	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
LUAD	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-15.15	1.1e-42	1.36e-38	-0.72	-0.57	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	15.15	1.1e-42	1.36e-38	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
LUAD	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-15.15	1.12e-42	1.39e-38	-0.72	-0.57	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	15.15	1.13e-42	1.39e-38	0.75	0.57	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-15.15	1.16e-42	1.43e-38	-0.72	-0.57	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-15.15	1.16e-42	1.43e-38	-0.72	-0.57	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-15.15	1.17e-42	1.44e-38	-0.72	-0.57	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-15.15	1.19e-42	1.46e-38	-0.72	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	15.14	1.2e-42	1.48e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	15.14	1.23e-42	1.51e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
LUAD	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	15.14	1.25e-42	1.54e-38	0.57	0.57	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
LUAD	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	15.14	1.25e-42	1.54e-38	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
LUAD	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-15.13	1.39e-42	1.71e-38	-0.9	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
LUAD	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	15.13	1.42e-42	1.74e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
LUAD	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	15.11	1.75e-42	2.14e-38	0.74	0.57	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
LUAD	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	15.11	1.76e-42	2.15e-38	0.78	0.57	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
LUAD	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-15.11	1.77e-42	2.16e-38	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	15.1	1.86e-42	2.28e-38	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
LUAD	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	15.1	1.87e-42	2.28e-38	0.56	0.57	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
LUAD	cis	rs858239	0.614	rs2014816	ENSG00000230658.1	KLHL7-AS1	15.1	1.9e-42	2.32e-38	0.7	0.57	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-15.1	1.98e-42	2.41e-38	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
LUAD	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	15.09	2.01e-42	2.45e-38	0.78	0.57	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
LUAD	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	15.09	2.06e-42	2.5e-38	0.57	0.57	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	15.09	2.06e-42	2.5e-38	0.57	0.57	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
LUAD	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-15.09	2.17e-42	2.64e-38	-0.61	-0.57	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-15.09	2.18e-42	2.65e-38	-0.71	-0.57	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-15.09	2.18e-42	2.65e-38	-0.71	-0.57	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	15.09	2.2e-42	2.67e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	15.08	2.27e-42	2.76e-38	0.67	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
LUAD	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-15.08	2.28e-42	2.76e-38	-0.72	-0.57	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
LUAD	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-15.08	2.38e-42	2.88e-38	-0.62	-0.57	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
LUAD	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-15.08	2.39e-42	2.9e-38	-0.89	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
LUAD	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-15.07	2.55e-42	3.08e-38	-0.71	-0.57	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-15.07	2.62e-42	3.17e-38	-0.74	-0.57	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
LUAD	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	15.06	2.73e-42	3.3e-38	0.56	0.57	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
LUAD	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	15.06	2.76e-42	3.33e-38	0.57	0.57	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	15.06	2.76e-42	3.33e-38	0.57	0.57	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
LUAD	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-15.06	2.85e-42	3.43e-38	-0.74	-0.57	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-15.06	2.87e-42	3.45e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-15.06	2.87e-42	3.45e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
LUAD	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	15.05	3.03e-42	3.64e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-15.05	3.12e-42	3.75e-38	-0.74	-0.57	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-15.05	3.15e-42	3.77e-38	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-15.05	3.18e-42	3.82e-38	-0.9	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
LUAD	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-15.05	3.33e-42	3.99e-38	-0.58	-0.57	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	15.05	3.34e-42	3.99e-38	0.57	0.57	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
LUAD	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-15.05	3.34e-42	4e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
LUAD	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	15.04	3.35e-42	4.01e-38	0.82	0.57	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-15.04	3.39e-42	4.05e-38	-0.73	-0.57	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	15.04	3.42e-42	4.08e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	15.04	3.42e-42	4.08e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
LUAD	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-15.04	3.44e-42	4.1e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-15.04	3.44e-42	4.1e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-15.04	3.44e-42	4.1e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	15.04	3.55e-42	4.22e-38	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
LUAD	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-15.03	3.83e-42	4.55e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
LUAD	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-15.03	4e-42	4.75e-38	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	15.02	4.17e-42	4.94e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-15.02	4.42e-42	5.23e-38	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	15.01	4.59e-42	5.42e-38	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	15.01	4.64e-42	5.47e-38	0.7	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	15.01	4.69e-42	5.54e-38	0.69	0.56	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
LUAD	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	15.01	4.98e-42	5.87e-38	0.57	0.56	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
LUAD	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	15	5.06e-42	5.97e-38	0.67	0.56	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
LUAD	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-15	5.26e-42	6.19e-38	-0.89	-0.56	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
LUAD	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	15	5.42e-42	6.36e-38	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
LUAD	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	14.99	5.84e-42	6.84e-38	0.79	0.56	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
LUAD	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	14.99	6.05e-42	7.09e-38	0.69	0.56	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	14.99	6.05e-42	7.09e-38	0.69	0.56	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	14.99	6.09e-42	7.13e-38	0.6	0.56	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-14.99	6.1e-42	7.13e-38	-0.6	-0.56	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	14.98	6.46e-42	7.55e-38	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
LUAD	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	14.98	6.49e-42	7.58e-38	0.71	0.56	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-14.98	6.49e-42	7.58e-38	-0.71	-0.56	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-14.98	6.49e-42	7.58e-38	-0.71	-0.56	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-14.98	6.49e-42	7.58e-38	-0.71	-0.56	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-14.98	6.54e-42	7.63e-38	-0.71	-0.56	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-14.98	6.8e-42	7.93e-38	-0.74	-0.56	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-14.97	7.34e-42	8.53e-38	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-14.97	7.34e-42	8.53e-38	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-14.97	7.6e-42	8.82e-38	-0.71	-0.56	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
LUAD	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-14.96	7.79e-42	9.01e-38	-0.64	-0.56	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
LUAD	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	14.96	7.84e-42	9.05e-38	0.63	0.56	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
LUAD	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-14.96	7.99e-42	9.22e-38	-0.7	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-14.95	8.54e-42	9.83e-38	-0.82	-0.56	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	14.95	8.96e-42	1.03e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
LUAD	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-14.95	9.18e-42	1.05e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-14.95	9.18e-42	1.05e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
LUAD	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	14.95	9.26e-42	1.06e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	14.94	9.35e-42	1.07e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	14.94	9.47e-42	1.08e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
LUAD	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	14.94	9.64e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	14.94	9.64e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	14.94	9.64e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	14.94	9.64e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	14.94	9.65e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	14.94	9.69e-42	1.11e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	14.94	9.69e-42	1.11e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
LUAD	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-14.94	9.69e-42	1.11e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
LUAD	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	14.94	9.81e-42	1.12e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	14.94	9.81e-42	1.12e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	14.94	9.85e-42	1.12e-37	0.74	0.56	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-14.94	9.85e-42	1.12e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-14.94	9.86e-42	1.12e-37	-0.71	-0.56	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-14.94	9.89e-42	1.13e-37	-0.59	-0.56	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
LUAD	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	14.94	1.03e-41	1.17e-37	0.64	0.56	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
LUAD	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-14.93	1.04e-41	1.18e-37	-0.57	-0.56	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
LUAD	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-14.93	1.04e-41	1.18e-37	-0.57	-0.56	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-14.93	1.04e-41	1.18e-37	-0.57	-0.56	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
LUAD	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	14.93	1.04e-41	1.18e-37	0.74	0.56	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
LUAD	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-14.93	1.05e-41	1.19e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-14.93	1.1e-41	1.24e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	14.92	1.22e-41	1.38e-37	0.71	0.56	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	14.92	1.24e-41	1.39e-37	0.63	0.56	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
LUAD	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
LUAD	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-14.92	1.25e-41	1.4e-37	-0.99	-0.56	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-14.92	1.25e-41	1.41e-37	-0.72	-0.56	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
LUAD	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	14.91	1.27e-41	1.42e-37	0.71	0.56	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	14.91	1.29e-41	1.45e-37	0.71	0.56	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	14.91	1.38e-41	1.54e-37	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-14.91	1.39e-41	1.55e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	14.91	1.4e-41	1.57e-37	0.71	0.56	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-14.9	1.42e-41	1.58e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-14.9	1.46e-41	1.63e-37	-0.72	-0.56	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-14.9	1.47e-41	1.64e-37	-0.72	-0.56	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	14.9	1.52e-41	1.69e-37	0.75	0.56	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
LUAD	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-14.9	1.55e-41	1.73e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
LUAD	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	14.89	1.58e-41	1.75e-37	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
LUAD	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-14.89	1.6e-41	1.78e-37	-0.61	-0.56	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
LUAD	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-14.89	1.6e-41	1.78e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
LUAD	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-14.89	1.6e-41	1.78e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
LUAD	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-14.89	1.6e-41	1.78e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
LUAD	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-14.89	1.65e-41	1.83e-37	-0.91	-0.56	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-14.89	1.67e-41	1.84e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	14.88	1.74e-41	1.93e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	14.88	1.74e-41	1.93e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	14.88	1.76e-41	1.95e-37	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	14.87	1.97e-41	2.17e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	14.87	2e-41	2.2e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	14.87	2.05e-41	2.26e-37	0.74	0.56	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
LUAD	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-14.87	2.08e-41	2.28e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-14.87	2.08e-41	2.28e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-14.86	2.12e-41	2.33e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-14.86	2.12e-41	2.33e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-14.86	2.15e-41	2.35e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
LUAD	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	14.86	2.17e-41	2.37e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	14.86	2.17e-41	2.37e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	14.86	2.17e-41	2.37e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
LUAD	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	14.86	2.21e-41	2.42e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
LUAD	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	14.86	2.31e-41	2.51e-37	0.7	0.56	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
LUAD	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-14.86	2.32e-41	2.53e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-14.85	2.52e-41	2.73e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
LUAD	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-14.85	2.53e-41	2.74e-37	-0.73	-0.56	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
LUAD	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	14.84	2.7e-41	2.91e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	14.84	2.81e-41	3.03e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-14.83	2.92e-41	3.14e-37	-0.72	-0.56	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-14.83	2.92e-41	3.14e-37	-0.72	-0.56	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
LUAD	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	14.82	3.2e-41	3.44e-37	0.63	0.56	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
LUAD	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	14.82	3.23e-41	3.46e-37	0.67	0.56	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
LUAD	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-14.82	3.23e-41	3.47e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
LUAD	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-14.82	3.32e-41	3.56e-37	-0.61	-0.56	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
LUAD	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-14.81	3.64e-41	3.88e-37	-0.56	-0.56	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
LUAD	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	14.81	3.89e-41	4.14e-37	0.55	0.56	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	14.8	3.93e-41	4.18e-37	0.74	0.56	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
LUAD	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-14.8	4.23e-41	4.49e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
LUAD	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	14.79	4.41e-41	4.67e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	14.79	4.42e-41	4.69e-37	0.67	0.56	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	14.79	4.53e-41	4.8e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
LUAD	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	14.79	4.66e-41	4.92e-37	0.73	0.56	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	14.78	4.89e-41	5.16e-37	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
LUAD	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	14.78	5.06e-41	5.34e-37	0.67	0.56	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	14.78	5.06e-41	5.34e-37	0.67	0.56	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	14.78	5.06e-41	5.34e-37	0.67	0.56	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	14.78	5.3e-41	5.59e-37	0.67	0.56	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	14.77	5.33e-41	5.61e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	14.77	5.36e-41	5.64e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
LUAD	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-14.77	5.37e-41	5.64e-37	-0.57	-0.56	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-14.77	5.37e-41	5.64e-37	-0.57	-0.56	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-14.77	5.37e-41	5.64e-37	-0.57	-0.56	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
LUAD	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	14.77	5.38e-41	5.65e-37	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-14.77	5.51e-41	5.79e-37	-0.66	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
LUAD	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-14.77	5.58e-41	5.85e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
LUAD	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	14.77	5.58e-41	5.85e-37	0.56	0.56	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
LUAD	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	14.77	5.71e-41	5.99e-37	0.72	0.56	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
LUAD	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	14.77	5.84e-41	6.12e-37	0.56	0.56	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
LUAD	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	14.77	5.87e-41	6.15e-37	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-14.76	6.41e-41	6.7e-37	-0.99	-0.56	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	14.76	6.44e-41	6.72e-37	0.71	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
LUAD	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	14.76	6.45e-41	6.73e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
LUAD	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-14.75	6.74e-41	7.01e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
LUAD	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	14.75	6.88e-41	7.15e-37	0.72	0.56	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
LUAD	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	14.75	7.05e-41	7.32e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
LUAD	cis	rs3091242	0.806	rs35189848	ENSG00000261349.1	RP3-465N24.5	14.75	7.21e-41	7.48e-37	0.62	0.56	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.836	rs35346083	ENSG00000261349.1	RP3-465N24.5	14.75	7.21e-41	7.48e-37	0.62	0.56	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25266102~25267136:-
LUAD	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	14.74	7.49e-41	7.76e-37	0.66	0.56	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
LUAD	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	14.74	7.6e-41	7.87e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
LUAD	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	14.73	8.17e-41	8.45e-37	0.67	0.56	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
LUAD	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	14.73	8.28e-41	8.56e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
LUAD	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	14.73	8.28e-41	8.56e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
LUAD	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	14.73	8.28e-41	8.56e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
LUAD	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-14.73	8.43e-41	8.71e-37	-0.55	-0.56	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	14.73	8.48e-41	8.76e-37	0.56	0.56	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
LUAD	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	14.73	8.5e-41	8.77e-37	0.66	0.56	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
LUAD	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-14.73	8.71e-41	8.99e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
LUAD	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	14.72	8.94e-41	9.22e-37	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
LUAD	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-14.72	9.08e-41	9.33e-37	-0.66	-0.56	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
LUAD	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-14.72	9.5e-41	9.76e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
LUAD	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	14.72	9.78e-41	1e-36	0.67	0.56	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
LUAD	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-14.71	1e-40	1.02e-36	-0.56	-0.56	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
LUAD	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	14.71	1.03e-40	1.06e-36	0.64	0.56	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
LUAD	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-14.71	1.04e-40	1.07e-36	-0.56	-0.56	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
LUAD	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	14.7	1.1e-40	1.13e-36	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
LUAD	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	14.7	1.12e-40	1.14e-36	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
LUAD	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-14.7	1.12e-40	1.14e-36	-0.7	-0.56	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	14.69	1.24e-40	1.26e-36	0.61	0.56	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
LUAD	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-14.69	1.29e-40	1.31e-36	-0.76	-0.56	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
LUAD	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	14.68	1.46e-40	1.48e-36	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
LUAD	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	14.68	1.46e-40	1.48e-36	0.86	0.56	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
LUAD	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-14.67	1.51e-40	1.53e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-14.67	1.51e-40	1.53e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-14.67	1.53e-40	1.54e-36	-0.59	-0.56	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-14.67	1.53e-40	1.54e-36	-0.59	-0.56	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-14.67	1.53e-40	1.54e-36	-0.59	-0.56	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	14.67	1.54e-40	1.55e-36	0.7	0.56	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	14.67	1.58e-40	1.59e-36	0.67	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	14.67	1.62e-40	1.63e-36	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
LUAD	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	14.67	1.63e-40	1.63e-36	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
LUAD	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	14.66	1.68e-40	1.69e-36	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-14.66	1.71e-40	1.71e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
LUAD	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-14.66	1.72e-40	1.72e-36	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
LUAD	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-14.65	1.82e-40	1.82e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-14.65	1.82e-40	1.82e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-14.65	1.87e-40	1.87e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	14.65	1.92e-40	1.91e-36	0.55	0.56	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
LUAD	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-14.65	1.97e-40	1.96e-36	-0.57	-0.56	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
LUAD	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-14.64	2.02e-40	2e-36	-0.94	-0.56	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
LUAD	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	14.64	2.04e-40	2.03e-36	0.72	0.56	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	14.64	2.04e-40	2.03e-36	0.72	0.56	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
LUAD	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	14.64	2.16e-40	2.14e-36	0.66	0.56	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	14.63	2.39e-40	2.35e-36	0.66	0.55	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-14.62	2.49e-40	2.45e-36	-0.72	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
LUAD	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-14.62	2.51e-40	2.47e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
LUAD	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-14.62	2.54e-40	2.49e-36	-0.7	-0.55	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-14.62	2.54e-40	2.49e-36	-0.7	-0.55	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-14.62	2.56e-40	2.51e-36	-0.7	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	14.62	2.66e-40	2.61e-36	0.66	0.55	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
LUAD	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-14.62	2.69e-40	2.64e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
LUAD	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-14.61	2.75e-40	2.69e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-14.61	2.77e-40	2.71e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	14.61	2.83e-40	2.77e-36	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
LUAD	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-14.61	2.89e-40	2.82e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-14.61	2.92e-40	2.85e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
LUAD	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-14.61	2.94e-40	2.87e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
LUAD	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-14.6	3.11e-40	3.03e-36	-0.55	-0.55	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
LUAD	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-14.6	3.14e-40	3.06e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
LUAD	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	14.6	3.27e-40	3.18e-36	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
LUAD	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-14.59	3.48e-40	3.38e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
LUAD	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-14.59	3.55e-40	3.45e-36	-0.56	-0.55	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
LUAD	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-14.58	3.98e-40	3.86e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
LUAD	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	14.58	4e-40	3.87e-36	0.67	0.55	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	14.57	4.25e-40	4.11e-36	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-14.57	4.27e-40	4.13e-36	-0.71	-0.55	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
LUAD	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-14.57	4.28e-40	4.13e-36	-0.57	-0.55	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-14.57	4.41e-40	4.25e-36	-0.56	-0.55	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
LUAD	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-14.57	4.5e-40	4.34e-36	-0.7	-0.55	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-14.56	4.53e-40	4.37e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
LUAD	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-14.56	4.7e-40	4.53e-36	-0.98	-0.55	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
LUAD	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	14.55	5.15e-40	4.95e-36	0.77	0.55	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-14.55	5.27e-40	5.07e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-14.55	5.45e-40	5.23e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-14.55	5.45e-40	5.23e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-14.55	5.45e-40	5.23e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-14.55	5.45e-40	5.23e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
LUAD	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	14.55	5.51e-40	5.28e-36	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-14.54	5.83e-40	5.59e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-14.54	6.07e-40	5.81e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
LUAD	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	14.53	6.13e-40	5.86e-36	0.77	0.55	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-14.53	6.57e-40	6.27e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-14.53	6.57e-40	6.27e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-14.53	6.57e-40	6.27e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-14.53	6.57e-40	6.27e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
LUAD	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-14.53	6.7e-40	6.39e-36	-0.57	-0.55	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
LUAD	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	14.52	7.13e-40	6.78e-36	0.66	0.55	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	14.52	7.13e-40	6.78e-36	0.66	0.55	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
LUAD	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-14.52	7.21e-40	6.85e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
LUAD	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	14.51	7.96e-40	7.55e-36	0.63	0.55	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
LUAD	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-14.5	8.71e-40	8.25e-36	-0.61	-0.55	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
LUAD	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-14.49	9.21e-40	8.72e-36	-0.98	-0.55	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
LUAD	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-14.49	9.21e-40	8.72e-36	-0.98	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-14.49	9.21e-40	8.72e-36	-0.98	-0.55	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-14.49	9.79e-40	9.26e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
LUAD	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	14.48	1.02e-39	9.66e-36	0.56	0.55	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
LUAD	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	14.48	1.06e-39	1e-35	0.63	0.55	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
LUAD	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	14.48	1.06e-39	1e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
LUAD	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-14.48	1.06e-39	1e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-14.48	1.06e-39	1e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	14.48	1.09e-39	1.03e-35	0.7	0.55	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	14.47	1.14e-39	1.07e-35	0.7	0.55	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	14.47	1.2e-39	1.12e-35	0.73	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
LUAD	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	14.46	1.31e-39	1.23e-35	0.59	0.55	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	14.44	1.54e-39	1.43e-35	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
LUAD	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	14.44	1.54e-39	1.44e-35	0.7	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
LUAD	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	14.44	1.55e-39	1.45e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	14.44	1.55e-39	1.45e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
LUAD	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	14.44	1.56e-39	1.45e-35	0.66	0.55	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
LUAD	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	14.44	1.6e-39	1.49e-35	0.72	0.55	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
LUAD	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-14.44	1.68e-39	1.56e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-14.44	1.68e-39	1.56e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-14.44	1.68e-39	1.56e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-14.43	1.72e-39	1.6e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	14.43	1.73e-39	1.61e-35	0.73	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-14.43	1.74e-39	1.62e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-14.43	1.75e-39	1.62e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	14.43	1.76e-39	1.64e-35	0.64	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
LUAD	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	14.43	1.77e-39	1.65e-35	0.66	0.55	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	14.43	1.82e-39	1.69e-35	0.66	0.55	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
LUAD	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	14.43	1.82e-39	1.69e-35	0.72	0.55	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
LUAD	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	14.42	1.97e-39	1.82e-35	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	14.41	2.13e-39	1.97e-35	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
LUAD	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	14.41	2.27e-39	2.09e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	14.41	2.27e-39	2.09e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
LUAD	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	14.4	2.34e-39	2.16e-35	0.56	0.55	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
LUAD	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	14.4	2.34e-39	2.16e-35	0.56	0.55	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
LUAD	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-14.4	2.35e-39	2.16e-35	-0.66	-0.55	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
LUAD	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	14.39	2.55e-39	2.34e-35	0.66	0.55	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
LUAD	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-14.39	2.55e-39	2.34e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
LUAD	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	14.39	2.58e-39	2.36e-35	0.77	0.55	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
LUAD	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-14.38	2.82e-39	2.58e-35	-0.98	-0.55	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
LUAD	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-14.38	2.83e-39	2.59e-35	-0.65	-0.55	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
LUAD	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	14.38	2.89e-39	2.64e-35	0.55	0.55	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
LUAD	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-14.38	2.94e-39	2.69e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-14.38	2.94e-39	2.69e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-14.38	2.94e-39	2.69e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
LUAD	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	14.37	3.09e-39	2.82e-35	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-14.37	3.1e-39	2.82e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
LUAD	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-14.36	3.52e-39	3.18e-35	-0.61	-0.55	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
LUAD	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-14.35	3.95e-39	3.55e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-14.35	3.95e-39	3.55e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-14.35	3.96e-39	3.56e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
LUAD	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	14.34	4.22e-39	3.79e-35	0.62	0.55	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
LUAD	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-14.34	4.26e-39	3.83e-35	-0.55	-0.55	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
LUAD	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	14.34	4.41e-39	3.95e-35	0.68	0.55	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
LUAD	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	14.34	4.42e-39	3.96e-35	0.8	0.55	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
LUAD	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	14.34	4.47e-39	4e-35	0.74	0.55	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
LUAD	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	14.33	4.7e-39	4.21e-35	0.7	0.55	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
LUAD	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	14.33	4.77e-39	4.27e-35	0.45	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-14.33	4.78e-39	4.27e-35	-0.46	-0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
LUAD	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-14.33	5.01e-39	4.47e-35	-0.87	-0.55	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
LUAD	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-14.33	5.12e-39	4.57e-35	-0.56	-0.55	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
LUAD	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	14.32	5.22e-39	4.65e-35	0.83	0.55	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
LUAD	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-14.32	5.41e-39	4.82e-35	-0.86	-0.55	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
LUAD	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-14.32	5.48e-39	4.88e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
LUAD	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	14.32	5.56e-39	4.94e-35	0.8	0.55	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	14.32	5.56e-39	4.94e-35	0.8	0.55	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
LUAD	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	14.32	5.59e-39	4.97e-35	0.7	0.55	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-14.31	5.7e-39	5.06e-35	-0.56	-0.55	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-14.31	5.74e-39	5.09e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-14.31	5.74e-39	5.09e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	14.31	6.26e-39	5.55e-35	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	14.3	6.33e-39	5.6e-35	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	14.3	6.53e-39	5.77e-35	0.68	0.55	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
LUAD	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	14.3	6.55e-39	5.79e-35	0.55	0.55	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-14.29	7.02e-39	6.19e-35	-0.7	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-14.29	7.29e-39	6.41e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-14.29	7.29e-39	6.41e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-14.29	7.29e-39	6.41e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-14.29	7.29e-39	6.41e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
LUAD	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	14.29	7.5e-39	6.59e-35	0.65	0.55	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-14.29	7.57e-39	6.65e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
LUAD	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-14.28	8.01e-39	7.03e-35	-0.6	-0.55	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
LUAD	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-14.28	8.31e-39	7.28e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-14.28	8.31e-39	7.28e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-14.28	8.38e-39	7.34e-35	-0.57	-0.55	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-14.28	8.42e-39	7.37e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-14.28	8.42e-39	7.37e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
LUAD	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	14.27	8.65e-39	7.57e-35	0.55	0.55	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
LUAD	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-14.27	8.93e-39	7.8e-35	-0.96	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-14.26	9.53e-39	8.3e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	14.26	1.01e-38	8.7e-35	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
LUAD	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-14.26	1.03e-38	8.87e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
LUAD	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-14.25	1.08e-38	9.31e-35	-0.68	-0.54	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
LUAD	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	14.25	1.11e-38	9.59e-35	0.62	0.54	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
LUAD	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	14.25	1.12e-38	9.67e-35	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
LUAD	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	14.24	1.17e-38	1.01e-34	0.61	0.54	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	14.24	1.17e-38	1.01e-34	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
LUAD	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	14.24	1.17e-38	1.01e-34	0.54	0.54	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
LUAD	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-14.24	1.18e-38	1.02e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	14.24	1.19e-38	1.03e-34	0.54	0.54	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
LUAD	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-14.24	1.26e-38	1.09e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	14.23	1.39e-38	1.2e-34	0.57	0.54	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	14.22	1.5e-38	1.29e-34	0.57	0.54	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
LUAD	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	14.22	1.54e-38	1.32e-34	0.75	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
LUAD	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-14.21	1.61e-38	1.37e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	14.21	1.67e-38	1.43e-34	0.69	0.54	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
LUAD	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	14.21	1.68e-38	1.44e-34	0.8	0.54	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
LUAD	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-14.2	1.73e-38	1.47e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	14.2	1.73e-38	1.47e-34	0.69	0.54	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	14.2	1.73e-38	1.48e-34	0.73	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	14.2	1.75e-38	1.49e-34	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
LUAD	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	14.2	1.79e-38	1.53e-34	0.69	0.54	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	14.2	1.8e-38	1.53e-34	0.7	0.54	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-14.2	1.85e-38	1.58e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-14.2	1.87e-38	1.59e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-14.19	1.9e-38	1.62e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-14.19	1.9e-38	1.62e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	14.19	1.98e-38	1.69e-34	0.57	0.54	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
LUAD	cis	rs6538678	0.857	rs4762626	ENSG00000199506.1	RNU6-247P	-14.18	2.1e-38	1.78e-34	-0.8	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95792529~95792635:-
LUAD	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-14.18	2.12e-38	1.8e-34	-0.74	-0.54	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
LUAD	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-14.18	2.2e-38	1.86e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-14.18	2.23e-38	1.88e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-14.18	2.25e-38	1.9e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-14.18	2.25e-38	1.9e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-14.18	2.25e-38	1.9e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-14.18	2.26e-38	1.91e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
LUAD	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-14.18	2.29e-38	1.93e-34	-0.46	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
LUAD	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-14.17	2.49e-38	2.1e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	14.17	2.52e-38	2.12e-34	0.69	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	14.17	2.56e-38	2.15e-34	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
LUAD	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-14.16	2.59e-38	2.18e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	14.16	2.66e-38	2.24e-34	0.57	0.54	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	14.16	2.66e-38	2.24e-34	0.57	0.54	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	14.16	2.66e-38	2.24e-34	0.57	0.54	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
LUAD	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-14.15	2.83e-38	2.38e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
LUAD	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	14.15	2.86e-38	2.4e-34	0.55	0.54	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-14.15	2.9e-38	2.43e-34	-0.68	-0.54	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-14.15	2.9e-38	2.43e-34	-0.68	-0.54	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	14.15	2.93e-38	2.45e-34	0.57	0.54	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	14.15	2.93e-38	2.45e-34	0.57	0.54	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
LUAD	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-14.15	2.93e-38	2.45e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	14.15	2.94e-38	2.46e-34	0.57	0.54	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
LUAD	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-14.15	2.97e-38	2.49e-34	-0.74	-0.54	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
LUAD	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-14.14	3.16e-38	2.64e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	14.14	3.41e-38	2.84e-34	0.68	0.54	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	14.14	3.41e-38	2.84e-34	0.68	0.54	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-14.13	3.61e-38	3e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-14.12	3.91e-38	3.25e-34	-0.7	-0.54	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
LUAD	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-14.12	3.93e-38	3.26e-34	-0.74	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	14.12	4.17e-38	3.46e-34	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-14.11	4.24e-38	3.52e-34	-0.96	-0.54	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-14.11	4.34e-38	3.6e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-14.11	4.34e-38	3.6e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
LUAD	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-14.11	4.59e-38	3.8e-34	-0.69	-0.54	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	14.1	4.74e-38	3.92e-34	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	14.1	4.75e-38	3.93e-34	0.67	0.54	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-14.1	4.77e-38	3.94e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-14.1	4.77e-38	3.94e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	14.1	4.81e-38	3.97e-34	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	14.1	4.92e-38	4.06e-34	0.56	0.54	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
LUAD	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-14.1	4.93e-38	4.06e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-14.1	4.93e-38	4.06e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-14.1	4.93e-38	4.06e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-14.09	5.19e-38	4.27e-34	-0.56	-0.54	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	14.09	5.28e-38	4.34e-34	0.49	0.54	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
LUAD	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	14.09	5.3e-38	4.35e-34	0.57	0.54	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	14.09	5.61e-38	4.58e-34	0.56	0.54	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	14.09	5.61e-38	4.58e-34	0.56	0.54	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
LUAD	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-14.08	5.99e-38	4.88e-34	-0.55	-0.54	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
LUAD	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-14.08	6.24e-38	5.09e-34	-0.87	-0.54	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
LUAD	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	14.07	6.51e-38	5.3e-34	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
LUAD	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	14.07	6.82e-38	5.54e-34	0.53	0.54	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	14.07	6.82e-38	5.54e-34	0.53	0.54	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
LUAD	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	14.07	6.82e-38	5.54e-34	0.68	0.54	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-14.06	7.4e-38	5.99e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
LUAD	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	14.06	7.43e-38	6.01e-34	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
LUAD	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	14.06	7.43e-38	6.01e-34	0.68	0.54	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	14.06	7.43e-38	6.01e-34	0.68	0.54	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	14.06	7.47e-38	6.04e-34	0.68	0.54	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-14.06	7.47e-38	6.04e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-14.06	7.47e-38	6.04e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-14.06	7.47e-38	6.04e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
LUAD	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-14.06	7.53e-38	6.09e-34	-0.45	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
LUAD	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	14.05	8.09e-38	6.53e-34	0.57	0.54	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
LUAD	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-14.04	8.64e-38	6.96e-34	-0.56	-0.54	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	14.04	8.65e-38	6.97e-34	0.68	0.54	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
LUAD	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-14.04	8.82e-38	7.1e-34	-0.45	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	14.03	9.8e-38	7.86e-34	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
LUAD	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	14.03	1.02e-37	8.16e-34	0.82	0.54	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
LUAD	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	14.03	1.02e-37	8.16e-34	0.82	0.54	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
LUAD	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	14.02	1.06e-37	8.44e-34	0.68	0.54	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	14.02	1.06e-37	8.44e-34	0.68	0.54	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	14.02	1.06e-37	8.44e-34	0.68	0.54	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	14.02	1.07e-37	8.53e-34	0.68	0.54	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-14.02	1.08e-37	8.64e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-14.02	1.08e-37	8.64e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	14.01	1.24e-37	9.82e-34	0.56	0.54	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	14.01	1.24e-37	9.82e-34	0.56	0.54	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
LUAD	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-14	1.29e-37	1.02e-33	-0.87	-0.54	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
LUAD	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-14	1.3e-37	1.03e-33	-0.69	-0.54	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-14	1.38e-37	1.09e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-14	1.38e-37	1.09e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-14	1.41e-37	1.1e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
LUAD	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-13.99	1.46e-37	1.14e-33	-0.69	-0.54	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	13.99	1.46e-37	1.14e-33	0.66	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	13.99	1.47e-37	1.15e-33	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
LUAD	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-13.99	1.48e-37	1.15e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-13.99	1.48e-37	1.15e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
LUAD	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	13.99	1.51e-37	1.18e-33	0.78	0.54	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
LUAD	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-13.98	1.58e-37	1.23e-33	-0.65	-0.54	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	13.98	1.6e-37	1.25e-33	0.68	0.54	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	13.98	1.6e-37	1.25e-33	0.68	0.54	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	13.98	1.67e-37	1.3e-33	0.57	0.54	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-13.98	1.69e-37	1.32e-33	-0.54	-0.54	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
LUAD	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-13.98	1.71e-37	1.33e-33	-0.86	-0.54	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-13.97	1.78e-37	1.39e-33	-0.54	-0.54	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
LUAD	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-13.97	1.82e-37	1.41e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
LUAD	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-13.97	1.83e-37	1.42e-33	-0.64	-0.54	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-13.97	1.83e-37	1.42e-33	-0.64	-0.54	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
LUAD	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-13.97	1.87e-37	1.46e-33	-0.54	-0.54	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
LUAD	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-13.96	1.99e-37	1.54e-33	-0.87	-0.54	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-13.96	2.03e-37	1.57e-33	-0.54	-0.54	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-13.96	2.03e-37	1.57e-33	-0.54	-0.54	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
LUAD	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-13.96	2.05e-37	1.58e-33	-0.45	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
LUAD	cis	rs6538678	0.824	rs7299632	ENSG00000199506.1	RNU6-247P	-13.96	2.07e-37	1.6e-33	-0.8	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95792529~95792635:-
LUAD	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-13.95	2.24e-37	1.73e-33	-0.66	-0.54	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
LUAD	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-13.94	2.33e-37	1.8e-33	-0.86	-0.54	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-13.94	2.33e-37	1.8e-33	-0.86	-0.54	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
LUAD	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	13.94	2.39e-37	1.84e-33	0.68	0.54	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-13.94	2.46e-37	1.89e-33	-0.68	-0.54	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	13.94	2.46e-37	1.89e-33	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-13.93	2.59e-37	1.99e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
LUAD	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	13.93	2.61e-37	2e-33	0.79	0.54	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
LUAD	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-13.93	2.69e-37	2.06e-33	-0.68	-0.54	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	13.93	2.79e-37	2.13e-33	0.68	0.54	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	13.93	2.79e-37	2.13e-33	0.66	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
LUAD	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	13.93	2.79e-37	2.13e-33	0.62	0.54	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
LUAD	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	13.93	2.82e-37	2.16e-33	0.78	0.54	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
LUAD	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-13.92	2.86e-37	2.18e-33	-0.76	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
LUAD	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	13.92	2.97e-37	2.26e-33	0.56	0.54	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	13.92	2.99e-37	2.28e-33	0.49	0.54	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	13.92	3.07e-37	2.33e-33	0.61	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
LUAD	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	13.92	3.1e-37	2.36e-33	0.56	0.54	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
LUAD	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	13.91	3.14e-37	2.38e-33	0.79	0.54	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
LUAD	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	13.91	3.14e-37	2.38e-33	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	13.91	3.14e-37	2.38e-33	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	13.91	3.23e-37	2.45e-33	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
LUAD	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-13.91	3.33e-37	2.52e-33	-0.66	-0.54	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
LUAD	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	13.91	3.43e-37	2.59e-33	0.56	0.54	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-13.91	3.44e-37	2.6e-33	-0.54	-0.54	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	13.9	3.5e-37	2.65e-33	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-13.9	3.54e-37	2.67e-33	-0.64	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
LUAD	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	13.9	3.69e-37	2.78e-33	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
LUAD	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	13.9	3.72e-37	2.8e-33	0.61	0.54	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
LUAD	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	13.89	3.83e-37	2.88e-33	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	13.89	3.83e-37	2.88e-33	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	13.89	3.86e-37	2.9e-33	0.99	0.54	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
LUAD	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-13.89	3.86e-37	2.9e-33	-0.59	-0.54	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
LUAD	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	13.89	4.02e-37	3.02e-33	0.56	0.54	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-13.89	4.09e-37	3.07e-33	-0.62	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
LUAD	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-13.89	4.15e-37	3.11e-33	-0.56	-0.53	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
LUAD	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-13.89	4.19e-37	3.14e-33	-0.56	-0.53	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-13.89	4.19e-37	3.14e-33	-0.56	-0.53	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
LUAD	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	13.89	4.21e-37	3.16e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
LUAD	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	13.89	4.22e-37	3.16e-33	0.83	0.53	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
LUAD	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	13.88	4.23e-37	3.17e-33	0.67	0.53	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
LUAD	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	13.88	4.29e-37	3.21e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
LUAD	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-13.88	4.33e-37	3.24e-33	-0.66	-0.53	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	13.88	4.4e-37	3.28e-33	0.67	0.53	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-13.88	4.49e-37	3.35e-33	-0.58	-0.53	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-13.88	4.49e-37	3.35e-33	-0.58	-0.53	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-13.88	4.49e-37	3.35e-33	-0.58	-0.53	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	13.88	4.55e-37	3.39e-33	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-13.88	4.56e-37	3.4e-33	-0.48	-0.53	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
LUAD	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	13.88	4.57e-37	3.41e-33	0.67	0.53	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-13.88	4.65e-37	3.47e-33	-0.58	-0.53	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	13.87	4.68e-37	3.48e-33	0.48	0.53	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
LUAD	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	13.87	4.77e-37	3.55e-33	0.67	0.53	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
LUAD	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	13.87	4.79e-37	3.56e-33	0.68	0.53	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	13.87	4.88e-37	3.62e-33	0.71	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
LUAD	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	13.87	4.95e-37	3.68e-33	0.61	0.53	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
LUAD	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	13.87	5.11e-37	3.79e-33	0.66	0.53	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
LUAD	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-13.86	5.17e-37	3.83e-33	-0.54	-0.53	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-13.86	5.4e-37	4e-33	-0.67	-0.53	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-13.86	5.4e-37	4e-33	-0.67	-0.53	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-13.86	5.4e-37	4e-33	-0.67	-0.53	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	13.86	5.48e-37	4.06e-33	0.62	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
LUAD	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	13.86	5.5e-37	4.07e-33	0.99	0.53	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
LUAD	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	13.86	5.6e-37	4.14e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
LUAD	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	13.85	5.92e-37	4.36e-33	0.72	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	13.83	7.06e-37	5.18e-33	0.72	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	13.82	7.71e-37	5.64e-33	0.6	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
LUAD	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	13.82	7.71e-37	5.64e-33	0.67	0.53	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
LUAD	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-13.82	8e-37	5.84e-33	-0.45	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
LUAD	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	13.82	8.07e-37	5.89e-33	0.67	0.53	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	13.82	8.07e-37	5.89e-33	0.64	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
LUAD	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-13.82	8.11e-37	5.92e-33	-0.53	-0.53	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-13.82	8.29e-37	6.04e-33	-0.53	-0.53	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
LUAD	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	13.82	8.33e-37	6.07e-33	0.68	0.53	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-13.82	8.47e-37	6.17e-33	-0.69	-0.53	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
LUAD	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	13.81	8.55e-37	6.22e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
LUAD	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	13.81	8.55e-37	6.23e-33	0.9	0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	13.81	8.6e-37	6.26e-33	0.55	0.53	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-13.81	8.9e-37	6.47e-33	-0.63	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
LUAD	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	13.81	8.95e-37	6.51e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
LUAD	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-13.81	8.96e-37	6.51e-33	-0.68	-0.53	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
LUAD	cis	rs6538678	0.746	rs4762630	ENSG00000199506.1	RNU6-247P	-13.81	8.96e-37	6.51e-33	-0.78	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95792529~95792635:-
LUAD	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	13.81	9.26e-37	6.72e-33	0.55	0.53	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
LUAD	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-13.8	9.37e-37	6.8e-33	-0.64	-0.53	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
LUAD	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-13.8	9.78e-37	7.08e-33	-0.56	-0.53	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
LUAD	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-13.8	9.98e-37	7.22e-33	-0.82	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
LUAD	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-13.8	1.02e-36	7.36e-33	-0.87	-0.53	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-13.8	1.02e-36	7.4e-33	-0.85	-0.53	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
LUAD	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-13.78	1.16e-36	8.37e-33	-0.6	-0.53	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	13.78	1.16e-36	8.38e-33	0.61	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
LUAD	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	13.78	1.19e-36	8.57e-33	0.71	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
LUAD	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-13.77	1.29e-36	9.22e-33	-0.67	-0.53	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	13.76	1.43e-36	1.02e-32	0.67	0.53	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-13.76	1.44e-36	1.03e-32	-0.54	-0.53	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-13.76	1.44e-36	1.03e-32	-0.54	-0.53	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-13.76	1.46e-36	1.04e-32	-0.69	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-13.76	1.51e-36	1.08e-32	-0.57	-0.53	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-13.75	1.65e-36	1.18e-32	-0.53	-0.53	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-13.75	1.66e-36	1.18e-32	-0.69	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
LUAD	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-13.75	1.68e-36	1.2e-32	-0.77	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
LUAD	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	13.74	1.76e-36	1.25e-32	0.63	0.53	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	13.74	1.76e-36	1.25e-32	0.7	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
LUAD	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-13.74	1.85e-36	1.32e-32	-0.53	-0.53	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
LUAD	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	13.73	1.91e-36	1.36e-32	0.56	0.53	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
LUAD	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	13.73	1.91e-36	1.36e-32	0.54	0.53	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-13.73	2.07e-36	1.46e-32	-0.69	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	13.72	2.21e-36	1.56e-32	0.61	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
LUAD	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-13.72	2.23e-36	1.58e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
LUAD	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-13.72	2.28e-36	1.61e-32	-0.55	-0.53	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-13.71	2.3e-36	1.62e-32	-0.53	-0.53	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-13.71	2.31e-36	1.63e-32	-0.53	-0.53	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-13.71	2.36e-36	1.66e-32	-0.53	-0.53	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	13.71	2.39e-36	1.69e-32	0.67	0.53	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
LUAD	cis	rs6538678	0.824	rs2367583	ENSG00000199506.1	RNU6-247P	-13.7	2.54e-36	1.79e-32	-0.79	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95792529~95792635:-
LUAD	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-13.7	2.56e-36	1.8e-32	-0.53	-0.53	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	13.7	2.59e-36	1.82e-32	0.72	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
LUAD	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	13.7	2.61e-36	1.83e-32	0.57	0.53	Breast cancer;	chr11:750849	chr11:779617~780755:+
LUAD	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	13.7	2.65e-36	1.86e-32	0.56	0.53	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-13.7	2.66e-36	1.87e-32	-0.53	-0.53	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
LUAD	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-13.69	2.81e-36	1.97e-32	-0.59	-0.53	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
LUAD	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-13.69	3.05e-36	2.12e-32	-0.79	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
LUAD	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-13.69	3.05e-36	2.12e-32	-0.79	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
LUAD	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-13.68	3.34e-36	2.32e-32	-0.79	-0.53	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
LUAD	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-13.68	3.36e-36	2.34e-32	-0.91	-0.53	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-13.67	3.68e-36	2.55e-32	-0.96	-0.53	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	13.66	3.87e-36	2.68e-32	0.8	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
LUAD	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-13.66	4.01e-36	2.77e-32	-0.67	-0.53	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	13.65	4.14e-36	2.86e-32	0.7	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	13.65	4.18e-36	2.88e-32	0.56	0.53	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	13.65	4.18e-36	2.88e-32	0.56	0.53	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
LUAD	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	13.64	4.8e-36	3.3e-32	0.88	0.53	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
LUAD	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-13.64	5.03e-36	3.45e-32	-0.55	-0.53	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
LUAD	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	13.63	5.35e-36	3.67e-32	0.44	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
LUAD	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-13.63	5.43e-36	3.72e-32	-0.55	-0.53	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-13.62	5.7e-36	3.9e-32	-0.53	-0.53	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-13.62	5.7e-36	3.9e-32	-0.53	-0.53	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-13.62	5.7e-36	3.9e-32	-0.53	-0.53	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	13.61	6.22e-36	4.26e-32	0.53	0.53	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-13.61	6.23e-36	4.26e-32	-0.67	-0.53	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
LUAD	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	13.61	6.33e-36	4.32e-32	0.73	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
LUAD	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-13.61	6.38e-36	4.36e-32	-0.53	-0.53	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	13.61	6.53e-36	4.46e-32	0.6	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
LUAD	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	13.61	6.71e-36	4.58e-32	0.53	0.53	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	13.59	7.59e-36	5.18e-32	0.66	0.53	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-13.59	7.62e-36	5.2e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-13.59	7.62e-36	5.2e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-13.59	7.62e-36	5.2e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
LUAD	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	13.59	7.71e-36	5.26e-32	0.5	0.53	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
LUAD	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	13.59	7.93e-36	5.4e-32	0.65	0.53	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
LUAD	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-13.59	8.01e-36	5.46e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
LUAD	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	13.59	8.19e-36	5.57e-32	0.62	0.53	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
LUAD	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-13.57	9.23e-36	6.26e-32	-0.67	-0.53	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	13.57	9.46e-36	6.41e-32	0.56	0.53	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	13.57	9.49e-36	6.43e-32	0.7	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	13.57	9.75e-36	6.6e-32	0.56	0.53	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
LUAD	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-13.57	9.88e-36	6.69e-32	-0.89	-0.53	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-13.57	9.88e-36	6.69e-32	-0.89	-0.53	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-13.57	9.88e-36	6.69e-32	-0.89	-0.53	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
LUAD	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-13.57	9.88e-36	6.69e-32	-0.89	-0.53	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
LUAD	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	13.56	1.01e-35	6.82e-32	0.55	0.53	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	13.56	1.01e-35	6.83e-32	0.56	0.53	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	13.56	1.05e-35	7.08e-32	0.56	0.53	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
LUAD	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-13.56	1.08e-35	7.32e-32	-0.57	-0.53	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
LUAD	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-13.55	1.16e-35	7.84e-32	-0.66	-0.53	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-13.55	1.17e-35	7.88e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-13.55	1.17e-35	7.88e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
LUAD	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-13.55	1.17e-35	7.89e-32	-0.58	-0.53	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-13.55	1.18e-35	7.94e-32	-0.64	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
LUAD	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	13.55	1.18e-35	7.96e-32	0.71	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	13.54	1.25e-35	8.38e-32	0.56	0.53	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
LUAD	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-13.54	1.25e-35	8.38e-32	-0.57	-0.53	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
LUAD	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	13.54	1.33e-35	8.91e-32	0.85	0.53	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
LUAD	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-13.54	1.33e-35	8.96e-32	-0.84	-0.53	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
LUAD	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-13.53	1.37e-35	9.18e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
LUAD	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-13.53	1.46e-35	9.78e-32	-0.68	-0.52	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
LUAD	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	13.53	1.46e-35	9.78e-32	0.66	0.52	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
LUAD	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	13.52	1.51e-35	1.01e-31	0.61	0.52	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	13.52	1.62e-35	1.09e-31	0.62	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	13.52	1.64e-35	1.09e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
LUAD	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-13.51	1.69e-35	1.13e-31	-0.82	-0.52	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
LUAD	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	13.51	1.75e-35	1.17e-31	0.78	0.52	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	13.51	1.79e-35	1.2e-31	0.47	0.52	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
LUAD	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	13.5	1.89e-35	1.26e-31	0.72	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-13.5	1.93e-35	1.29e-31	-0.61	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
LUAD	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	13.5	1.94e-35	1.3e-31	0.84	0.52	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
LUAD	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-13.5	1.95e-35	1.3e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
LUAD	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	13.5	1.98e-35	1.32e-31	0.56	0.52	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
LUAD	cis	rs6538678	0.746	rs1865736	ENSG00000199506.1	RNU6-247P	-13.49	2.02e-35	1.34e-31	-0.79	-0.52	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95792529~95792635:-
LUAD	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	13.49	2.12e-35	1.41e-31	0.56	0.52	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
LUAD	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-13.49	2.18e-35	1.45e-31	-0.66	-0.52	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-13.49	2.19e-35	1.45e-31	-0.54	-0.52	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-13.49	2.2e-35	1.46e-31	-0.53	-0.52	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
LUAD	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-13.49	2.21e-35	1.47e-31	-0.82	-0.52	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
LUAD	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	13.48	2.28e-35	1.51e-31	0.55	0.52	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
LUAD	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	13.48	2.29e-35	1.52e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
LUAD	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	13.48	2.34e-35	1.55e-31	0.67	0.52	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	13.48	2.43e-35	1.61e-31	0.65	0.52	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	13.47	2.45e-35	1.62e-31	0.7	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	13.47	2.55e-35	1.68e-31	0.56	0.52	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	13.47	2.61e-35	1.72e-31	0.71	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
LUAD	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-13.47	2.64e-35	1.74e-31	-0.66	-0.52	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-13.47	2.64e-35	1.74e-31	-0.66	-0.52	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
LUAD	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-13.47	2.65e-35	1.75e-31	-0.57	-0.52	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	13.47	2.67e-35	1.76e-31	0.61	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	13.46	2.81e-35	1.85e-31	0.47	0.52	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
LUAD	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-13.46	2.81e-35	1.85e-31	-0.55	-0.52	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
LUAD	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	13.46	2.89e-35	1.9e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
LUAD	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	13.46	2.93e-35	1.93e-31	0.63	0.52	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	13.45	2.99e-35	1.97e-31	0.71	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
LUAD	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-13.45	3e-35	1.97e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
LUAD	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	13.45	3.03e-35	1.99e-31	0.55	0.52	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-13.45	3.04e-35	1.99e-31	-0.52	-0.52	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
LUAD	cis	rs6538678	0.784	rs7297403	ENSG00000199506.1	RNU6-247P	-13.45	3.14e-35	2.06e-31	-0.77	-0.52	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95792529~95792635:-
LUAD	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-13.45	3.25e-35	2.13e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
LUAD	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-13.44	3.31e-35	2.16e-31	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
LUAD	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-13.44	3.31e-35	2.17e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
LUAD	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-13.44	3.31e-35	2.17e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
LUAD	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	13.44	3.38e-35	2.21e-31	0.53	0.52	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	13.44	3.38e-35	2.21e-31	0.53	0.52	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	13.44	3.38e-35	2.21e-31	0.53	0.52	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-13.44	3.4e-35	2.22e-31	-0.54	-0.52	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-13.44	3.49e-35	2.27e-31	-0.66	-0.52	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-13.43	3.81e-35	2.48e-31	-0.53	-0.52	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-13.43	3.81e-35	2.48e-31	-0.53	-0.52	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	13.43	3.81e-35	2.48e-31	0.47	0.52	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
LUAD	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	13.43	3.87e-35	2.52e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	13.43	3.87e-35	2.52e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	13.43	3.93e-35	2.56e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	13.43	3.96e-35	2.58e-31	0.62	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
LUAD	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	13.42	4.07e-35	2.65e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	13.42	4.17e-35	2.71e-31	0.66	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
LUAD	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	13.42	4.4e-35	2.85e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
LUAD	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-13.41	4.51e-35	2.92e-31	-0.71	-0.52	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	13.41	4.72e-35	3.05e-31	0.47	0.52	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	13.41	4.82e-35	3.11e-31	0.47	0.52	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
LUAD	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-13.4	5.06e-35	3.27e-31	-0.71	-0.52	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-13.4	5.08e-35	3.28e-31	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
LUAD	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	13.4	5.19e-35	3.35e-31	0.72	0.52	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	13.39	5.37e-35	3.46e-31	0.53	0.52	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	13.39	5.5e-35	3.54e-31	0.55	0.52	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
LUAD	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-13.39	5.64e-35	3.63e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
LUAD	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-13.39	5.7e-35	3.66e-31	-0.67	-0.52	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	13.39	5.8e-35	3.72e-31	0.47	0.52	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
LUAD	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	13.38	5.96e-35	3.82e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
LUAD	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	13.38	5.97e-35	3.83e-31	0.57	0.52	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
LUAD	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-13.38	6e-35	3.85e-31	-0.89	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	13.38	6.11e-35	3.92e-31	0.47	0.52	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
LUAD	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-13.38	6.15e-35	3.94e-31	-0.57	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
LUAD	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-13.38	6.29e-35	4.03e-31	-0.67	-0.52	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
LUAD	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	13.38	6.31e-35	4.04e-31	0.57	0.52	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
LUAD	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	13.38	6.33e-35	4.05e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
LUAD	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-13.38	6.34e-35	4.06e-31	-0.44	-0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
LUAD	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	13.38	6.38e-35	4.08e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
LUAD	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	13.37	6.79e-35	4.34e-31	0.55	0.52	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	13.37	6.79e-35	4.34e-31	0.55	0.52	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
LUAD	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-13.37	6.82e-35	4.36e-31	-0.57	-0.52	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-13.37	7.05e-35	4.5e-31	-0.66	-0.52	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
LUAD	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-13.37	7.15e-35	4.56e-31	-0.89	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
LUAD	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-13.36	7.24e-35	4.62e-31	-0.7	-0.52	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	13.36	7.49e-35	4.77e-31	0.47	0.52	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
LUAD	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	13.36	7.49e-35	4.78e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
LUAD	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-13.36	7.51e-35	4.78e-31	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
LUAD	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-13.36	7.77e-35	4.95e-31	-0.57	-0.52	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
LUAD	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-13.35	8.25e-35	5.25e-31	-0.89	-0.52	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-13.35	8.5e-35	5.4e-31	-0.54	-0.52	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
LUAD	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-13.34	8.77e-35	5.57e-31	-0.88	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
LUAD	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	13.34	8.8e-35	5.59e-31	0.72	0.52	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
LUAD	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-13.34	8.9e-35	5.65e-31	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	13.34	9.3e-35	5.9e-31	0.47	0.52	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	13.34	9.3e-35	5.9e-31	0.47	0.52	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
LUAD	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-13.34	9.41e-35	5.97e-31	-0.65	-0.52	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	13.34	9.55e-35	6.06e-31	0.65	0.52	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	13.33	1.06e-34	6.71e-31	0.54	0.52	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-13.32	1.1e-34	6.99e-31	-0.75	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
LUAD	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-13.32	1.14e-34	7.21e-31	-0.65	-0.52	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	13.32	1.16e-34	7.3e-31	0.47	0.52	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	13.32	1.16e-34	7.3e-31	0.47	0.52	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
LUAD	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	13.31	1.22e-34	7.71e-31	0.69	0.52	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	13.31	1.24e-34	7.81e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
LUAD	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-13.31	1.25e-34	7.84e-31	-0.57	-0.52	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
LUAD	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-13.31	1.25e-34	7.88e-31	-0.44	-0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
LUAD	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-13.3	1.32e-34	8.28e-31	-0.57	-0.52	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
LUAD	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-13.3	1.37e-34	8.58e-31	-0.89	-0.52	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
LUAD	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-13.3	1.37e-34	8.59e-31	-0.65	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
LUAD	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	13.3	1.38e-34	8.67e-31	0.55	0.52	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	13.29	1.46e-34	9.15e-31	0.56	0.52	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	13.29	1.5e-34	9.42e-31	0.66	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
LUAD	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-13.29	1.57e-34	9.83e-31	-0.66	-0.52	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	13.28	1.69e-34	1.06e-30	0.55	0.52	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	13.27	1.83e-34	1.14e-30	0.55	0.52	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	13.27	1.83e-34	1.14e-30	0.52	0.52	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-13.27	1.91e-34	1.19e-30	-0.52	-0.52	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	13.26	1.95e-34	1.21e-30	0.52	0.52	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	13.26	2.01e-34	1.25e-30	0.52	0.52	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
LUAD	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	13.26	2.06e-34	1.29e-30	0.74	0.52	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
LUAD	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	13.26	2.08e-34	1.3e-30	0.54	0.52	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	13.26	2.09e-34	1.3e-30	0.54	0.52	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
LUAD	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-13.25	2.16e-34	1.34e-30	-0.62	-0.52	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
LUAD	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	13.25	2.22e-34	1.37e-30	0.55	0.52	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
LUAD	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-13.25	2.25e-34	1.4e-30	-0.66	-0.52	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	13.25	2.27e-34	1.41e-30	0.47	0.52	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	13.25	2.28e-34	1.41e-30	0.64	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	13.25	2.32e-34	1.44e-30	0.47	0.52	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	13.25	2.32e-34	1.44e-30	0.47	0.52	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
LUAD	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-13.24	2.37e-34	1.46e-30	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
LUAD	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-13.24	2.38e-34	1.47e-30	-0.76	-0.52	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
LUAD	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	13.24	2.42e-34	1.49e-30	0.74	0.52	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	13.24	2.46e-34	1.52e-30	0.6	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
LUAD	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-13.24	2.48e-34	1.53e-30	-0.86	-0.52	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	13.24	2.5e-34	1.54e-30	0.47	0.52	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	13.24	2.5e-34	1.54e-30	0.47	0.52	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
LUAD	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-13.24	2.56e-34	1.58e-30	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
LUAD	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	13.23	2.57e-34	1.59e-30	0.5	0.52	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
LUAD	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-13.23	2.6e-34	1.6e-30	-0.56	-0.52	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-13.23	2.6e-34	1.6e-30	-0.65	-0.52	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-13.23	2.6e-34	1.6e-30	-0.65	-0.52	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
LUAD	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-13.23	2.63e-34	1.62e-30	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
LUAD	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-13.23	2.65e-34	1.63e-30	-0.66	-0.52	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
LUAD	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-13.23	2.74e-34	1.69e-30	-0.8	-0.52	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-13.23	2.74e-34	1.69e-30	-0.8	-0.52	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	13.23	2.75e-34	1.69e-30	0.47	0.52	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	13.23	2.75e-34	1.69e-30	0.47	0.52	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	13.23	2.75e-34	1.69e-30	0.47	0.52	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	13.23	2.75e-34	1.69e-30	0.47	0.52	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
LUAD	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-13.23	2.78e-34	1.71e-30	-0.52	-0.52	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
LUAD	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	13.22	2.9e-34	1.78e-30	0.67	0.52	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
LUAD	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-13.22	2.99e-34	1.84e-30	-0.66	-0.52	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
LUAD	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-13.22	3.04e-34	1.86e-30	-0.7	-0.52	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
LUAD	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-13.22	3.05e-34	1.87e-30	-0.51	-0.52	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-13.21	3.12e-34	1.91e-30	-0.65	-0.52	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	13.21	3.13e-34	1.92e-30	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
LUAD	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	13.21	3.15e-34	1.93e-30	0.72	0.52	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
LUAD	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	13.21	3.4e-34	2.08e-30	0.66	0.52	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-13.21	3.4e-34	2.08e-30	-0.88	-0.52	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
LUAD	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	13.2	3.57e-34	2.18e-30	0.63	0.52	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-13.2	3.7e-34	2.26e-30	-0.56	-0.52	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
LUAD	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-13.2	3.72e-34	2.27e-30	-0.62	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
LUAD	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	13.2	3.72e-34	2.27e-30	0.65	0.52	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	13.2	3.77e-34	2.3e-30	0.67	0.52	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
LUAD	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-13.19	3.83e-34	2.34e-30	-0.66	-0.52	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	13.19	3.89e-34	2.38e-30	0.47	0.52	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
LUAD	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-13.19	3.94e-34	2.4e-30	-0.69	-0.52	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	13.19	4.04e-34	2.46e-30	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	13.18	4.2e-34	2.56e-30	0.46	0.52	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
LUAD	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-13.18	4.25e-34	2.59e-30	-0.7	-0.52	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-13.18	4.25e-34	2.59e-30	-0.7	-0.52	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	13.18	4.39e-34	2.67e-30	0.61	0.52	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-13.18	4.49e-34	2.73e-30	-0.71	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-13.18	4.49e-34	2.73e-30	-0.71	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
LUAD	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	13.18	4.52e-34	2.74e-30	0.66	0.52	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
LUAD	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-13.18	4.54e-34	2.75e-30	-0.43	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
LUAD	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-13.17	4.63e-34	2.81e-30	-0.64	-0.51	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
LUAD	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-13.17	4.64e-34	2.81e-30	-0.72	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
LUAD	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	13.17	4.64e-34	2.81e-30	0.52	0.51	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	13.17	4.64e-34	2.81e-30	0.52	0.51	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	13.17	4.64e-34	2.81e-30	0.52	0.51	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-13.17	4.85e-34	2.93e-30	-0.65	-0.51	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-13.17	4.98e-34	3.02e-30	-0.89	-0.51	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
LUAD	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	13.16	5.31e-34	3.21e-30	0.53	0.51	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
LUAD	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	13.16	5.32e-34	3.21e-30	0.64	0.51	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-13.16	5.53e-34	3.33e-30	-0.66	-0.51	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
LUAD	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-13.15	5.75e-34	3.46e-30	-0.7	-0.51	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
LUAD	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-13.15	5.8e-34	3.48e-30	-0.89	-0.51	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
LUAD	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-13.15	5.8e-34	3.48e-30	-0.89	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
LUAD	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-13.15	6.16e-34	3.7e-30	-0.7	-0.51	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
LUAD	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	13.14	6.17e-34	3.7e-30	0.74	0.51	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
LUAD	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-13.14	6.19e-34	3.72e-30	-0.65	-0.51	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
LUAD	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	13.14	6.32e-34	3.79e-30	0.67	0.51	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
LUAD	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-13.13	6.86e-34	4.11e-30	-0.79	-0.51	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
LUAD	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	13.13	6.91e-34	4.14e-30	0.68	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
LUAD	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-13.13	7.08e-34	4.24e-30	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	13.13	7.19e-34	4.3e-30	0.6	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
LUAD	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	13.13	7.33e-34	4.38e-30	0.47	0.51	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
LUAD	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-13.12	7.71e-34	4.61e-30	-0.7	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
LUAD	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	13.12	7.75e-34	4.63e-30	0.63	0.51	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
LUAD	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	13.12	7.82e-34	4.67e-30	0.57	0.51	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
LUAD	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	13.12	8.16e-34	4.86e-30	0.83	0.51	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
LUAD	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	13.12	8.25e-34	4.91e-30	0.65	0.51	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	13.11	8.39e-34	4.99e-30	0.46	0.51	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
LUAD	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	13.11	8.61e-34	5.12e-30	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
LUAD	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-13.11	8.85e-34	5.26e-30	-0.57	-0.51	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
LUAD	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-13.11	9.08e-34	5.4e-30	-0.53	-0.51	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
LUAD	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-13.1	9.27e-34	5.51e-30	-0.87	-0.51	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-13.1	9.38e-34	5.57e-30	-0.65	-0.51	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
LUAD	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-13.1	9.59e-34	5.69e-30	-0.57	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
LUAD	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-13.09	1e-33	5.95e-30	-0.57	-0.51	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	13.09	1.07e-33	6.32e-30	0.65	0.51	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-13.08	1.11e-33	6.56e-30	-0.56	-0.51	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
LUAD	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	13.08	1.12e-33	6.64e-30	0.66	0.51	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	13.08	1.12e-33	6.64e-30	0.66	0.51	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	13.08	1.13e-33	6.71e-30	0.61	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
LUAD	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-13.08	1.14e-33	6.72e-30	-0.58	-0.51	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
LUAD	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-13.08	1.15e-33	6.8e-30	-0.64	-0.51	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-13.08	1.15e-33	6.8e-30	-0.64	-0.51	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
LUAD	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	13.08	1.15e-33	6.8e-30	0.65	0.51	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
LUAD	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	13.08	1.2e-33	7.08e-30	0.62	0.51	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
LUAD	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	13.07	1.24e-33	7.26e-30	0.54	0.51	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-13.07	1.25e-33	7.33e-30	-0.57	-0.51	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
LUAD	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	13.07	1.27e-33	7.47e-30	0.65	0.51	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	13.07	1.31e-33	7.69e-30	0.69	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-13.06	1.35e-33	7.89e-30	-0.64	-0.51	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-13.06	1.36e-33	7.97e-30	-0.46	-0.51	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
LUAD	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	13.06	1.36e-33	7.98e-30	0.69	0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
LUAD	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-13.06	1.42e-33	8.28e-30	-0.66	-0.51	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-13.06	1.43e-33	8.36e-30	-0.59	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
LUAD	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	13.06	1.46e-33	8.5e-30	0.67	0.51	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
LUAD	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-13.06	1.46e-33	8.52e-30	-0.7	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
LUAD	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-13.06	1.47e-33	8.57e-30	-0.56	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
LUAD	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	13.05	1.57e-33	9.17e-30	0.52	0.51	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-13.05	1.6e-33	9.32e-30	-0.52	-0.51	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-13.05	1.6e-33	9.32e-30	-0.52	-0.51	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
LUAD	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-13.05	1.61e-33	9.36e-30	-0.73	-0.51	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
LUAD	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	13.05	1.61e-33	9.37e-30	0.83	0.51	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
LUAD	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-13.04	1.63e-33	9.49e-30	-0.67	-0.51	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
LUAD	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-13.04	1.64e-33	9.54e-30	-0.56	-0.51	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
LUAD	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-13.04	1.64e-33	9.56e-30	-0.69	-0.51	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
LUAD	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-13.04	1.66e-33	9.63e-30	-0.7	-0.51	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
LUAD	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-13.04	1.66e-33	9.68e-30	-0.8	-0.51	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
LUAD	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-13.04	1.67e-33	9.69e-30	-0.56	-0.51	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-13.04	1.7e-33	9.87e-30	-0.56	-0.51	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-13.04	1.7e-33	9.87e-30	-0.56	-0.51	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-13.04	1.7e-33	9.87e-30	-0.56	-0.51	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
LUAD	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	13.04	1.78e-33	1.03e-29	0.68	0.51	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
LUAD	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-13.03	1.81e-33	1.05e-29	-0.56	-0.51	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-13.03	1.81e-33	1.05e-29	-0.56	-0.51	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-13.03	1.81e-33	1.05e-29	-0.56	-0.51	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
LUAD	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-13.03	1.83e-33	1.06e-29	-0.87	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	13.03	1.84e-33	1.06e-29	0.6	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
LUAD	cis	rs6538678	0.824	rs2887026	ENSG00000199506.1	RNU6-247P	-13.03	1.88e-33	1.09e-29	-0.76	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-13.03	1.89e-33	1.09e-29	-0.64	-0.51	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-13.03	1.89e-33	1.09e-29	-0.64	-0.51	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-13.03	1.9e-33	1.1e-29	-0.56	-0.51	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-13.03	1.9e-33	1.1e-29	-0.56	-0.51	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	13.03	1.97e-33	1.14e-29	0.65	0.51	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
LUAD	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-13.02	1.98e-33	1.14e-29	-0.88	-0.51	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	13.02	1.99e-33	1.15e-29	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
LUAD	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-13.02	2.01e-33	1.16e-29	-0.57	-0.51	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.824	rs4762631	ENSG00000199506.1	RNU6-247P	-13.02	2.1e-33	1.21e-29	-0.76	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95792529~95792635:-
LUAD	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	13.02	2.18e-33	1.25e-29	0.62	0.51	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
LUAD	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-13.01	2.24e-33	1.29e-29	-0.64	-0.51	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-13.01	2.24e-33	1.29e-29	-0.64	-0.51	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
LUAD	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	13.01	2.33e-33	1.34e-29	0.64	0.51	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	13.01	2.33e-33	1.34e-29	0.64	0.51	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	13.01	2.35e-33	1.35e-29	0.46	0.51	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
LUAD	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-13	2.4e-33	1.38e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
LUAD	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	13	2.41e-33	1.38e-29	0.55	0.51	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-13	2.43e-33	1.4e-29	-0.56	-0.51	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-12.99	2.68e-33	1.54e-29	-0.56	-0.51	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
LUAD	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-12.99	2.75e-33	1.57e-29	-0.49	-0.51	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
LUAD	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	12.98	3.02e-33	1.72e-29	0.51	0.51	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-12.98	3.02e-33	1.72e-29	-0.64	-0.51	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-12.98	3.02e-33	1.72e-29	-0.64	-0.51	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-12.98	3.02e-33	1.72e-29	-0.64	-0.51	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-12.98	3.09e-33	1.76e-29	-0.69	-0.51	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
LUAD	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	12.98	3.11e-33	1.77e-29	0.51	0.51	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
LUAD	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-12.98	3.14e-33	1.79e-29	-0.57	-0.51	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
LUAD	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	12.98	3.17e-33	1.8e-29	0.62	0.51	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	12.98	3.19e-33	1.81e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
LUAD	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	12.98	3.2e-33	1.82e-29	0.51	0.51	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	12.98	3.2e-33	1.82e-29	0.51	0.51	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	12.97	3.37e-33	1.91e-29	0.51	0.51	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	12.97	3.45e-33	1.95e-29	0.46	0.51	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
LUAD	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-12.96	3.77e-33	2.13e-29	-0.56	-0.51	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
LUAD	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	12.96	3.79e-33	2.14e-29	0.54	0.51	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-12.96	3.84e-33	2.17e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
LUAD	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-12.95	3.91e-33	2.21e-29	-0.55	-0.51	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
LUAD	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	12.95	3.98e-33	2.24e-29	0.58	0.51	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
LUAD	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-12.95	4.13e-33	2.33e-29	-0.56	-0.51	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	12.95	4.25e-33	2.39e-29	0.46	0.51	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	12.95	4.25e-33	2.39e-29	0.46	0.51	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
LUAD	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-12.94	4.33e-33	2.43e-29	-0.57	-0.51	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
LUAD	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-12.94	4.43e-33	2.49e-29	-0.78	-0.51	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	12.94	4.44e-33	2.5e-29	0.51	0.51	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
LUAD	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	12.94	4.46e-33	2.5e-29	0.68	0.51	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
LUAD	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-12.94	4.52e-33	2.54e-29	-0.53	-0.51	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
LUAD	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-12.94	4.52e-33	2.54e-29	-0.53	-0.51	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
LUAD	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-12.94	4.54e-33	2.55e-29	-0.63	-0.51	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-12.94	4.57e-33	2.56e-29	-0.63	-0.51	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-12.94	4.65e-33	2.61e-29	-0.59	-0.51	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	12.94	4.67e-33	2.62e-29	0.65	0.51	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	12.94	4.68e-33	2.63e-29	0.54	0.51	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-12.93	4.77e-33	2.67e-29	-0.56	-0.51	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	12.93	4.79e-33	2.68e-29	0.46	0.51	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	12.93	4.79e-33	2.68e-29	0.46	0.51	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	12.93	4.79e-33	2.68e-29	0.46	0.51	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	12.93	5.03e-33	2.82e-29	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
LUAD	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-12.92	5.26e-33	2.94e-29	-0.43	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
LUAD	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-12.92	5.29e-33	2.96e-29	-0.63	-0.51	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	12.92	5.34e-33	2.99e-29	0.54	0.51	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-12.92	5.38e-33	3.01e-29	-0.56	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
LUAD	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	12.91	5.83e-33	3.25e-29	0.51	0.51	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	12.91	5.88e-33	3.27e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	12.91	5.88e-33	3.27e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	12.91	5.9e-33	3.28e-29	0.46	0.51	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	12.91	5.9e-33	3.28e-29	0.46	0.51	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	12.91	5.9e-33	3.28e-29	0.46	0.51	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	12.91	5.93e-33	3.3e-29	0.46	0.51	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
LUAD	cis	rs6538678	0.824	rs1436120	ENSG00000199506.1	RNU6-247P	12.91	5.95e-33	3.31e-29	0.72	0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95792529~95792635:-
LUAD	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-12.91	6.28e-33	3.48e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-12.91	6.28e-33	3.48e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-12.91	6.28e-33	3.48e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
LUAD	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	12.9	6.4e-33	3.55e-29	0.63	0.51	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	12.9	6.54e-33	3.63e-29	0.46	0.51	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
LUAD	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-12.9	6.56e-33	3.64e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	12.9	6.6e-33	3.66e-29	0.46	0.51	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
LUAD	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-12.9	6.61e-33	3.66e-29	-0.68	-0.51	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
LUAD	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	12.9	6.75e-33	3.74e-29	0.65	0.51	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
LUAD	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-12.9	6.77e-33	3.75e-29	-0.57	-0.51	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
LUAD	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-12.89	6.94e-33	3.84e-29	-0.56	-0.51	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
LUAD	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-12.89	6.96e-33	3.85e-29	-0.69	-0.51	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	12.89	7.05e-33	3.9e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
LUAD	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	12.89	7.12e-33	3.93e-29	0.51	0.51	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	12.89	7.22e-33	3.99e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
LUAD	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	12.89	7.33e-33	4.05e-29	0.51	0.51	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
LUAD	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-12.89	7.33e-33	4.05e-29	-0.77	-0.51	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
LUAD	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-12.89	7.42e-33	4.09e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
LUAD	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-12.88	7.77e-33	4.27e-29	-0.56	-0.51	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-12.88	7.77e-33	4.27e-29	-0.56	-0.51	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-12.88	7.81e-33	4.3e-29	-0.7	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
LUAD	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-12.88	8.11e-33	4.45e-29	-0.68	-0.51	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-12.88	8.18e-33	4.49e-29	-0.63	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
LUAD	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	12.88	8.39e-33	4.6e-29	0.75	0.51	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
LUAD	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-12.87	8.44e-33	4.63e-29	-0.65	-0.51	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-12.87	8.54e-33	4.68e-29	-0.65	-0.51	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
LUAD	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	12.87	8.7e-33	4.77e-29	0.51	0.51	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
LUAD	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-12.87	8.85e-33	4.85e-29	-0.68	-0.51	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
LUAD	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-12.87	8.92e-33	4.88e-29	-0.74	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
LUAD	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
LUAD	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-12.86	1.01e-32	5.48e-29	-0.64	-0.51	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
LUAD	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-12.86	1.01e-32	5.48e-29	-0.51	-0.51	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	12.85	1.02e-32	5.56e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-12.85	1.05e-32	5.71e-29	-0.63	-0.51	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-12.85	1.05e-32	5.72e-29	-0.56	-0.51	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
LUAD	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	12.84	1.13e-32	6.11e-29	0.63	0.51	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
LUAD	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-12.84	1.16e-32	6.3e-29	-0.64	-0.51	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
LUAD	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-12.84	1.17e-32	6.35e-29	-0.88	-0.51	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
LUAD	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	12.84	1.2e-32	6.48e-29	0.51	0.51	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	12.84	1.22e-32	6.62e-29	0.51	0.51	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
LUAD	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-12.83	1.25e-32	6.73e-29	-0.55	-0.51	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
LUAD	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-12.83	1.26e-32	6.81e-29	-0.62	-0.51	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
LUAD	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-12.83	1.28e-32	6.94e-29	-0.51	-0.5	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-12.83	1.31e-32	7.06e-29	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
LUAD	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-12.83	1.32e-32	7.15e-29	-0.78	-0.5	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
LUAD	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-12.83	1.35e-32	7.28e-29	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
LUAD	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-12.82	1.39e-32	7.51e-29	-0.55	-0.5	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
LUAD	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-12.82	1.4e-32	7.52e-29	-0.71	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
LUAD	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-12.82	1.45e-32	7.81e-29	-0.79	-0.5	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-12.82	1.45e-32	7.81e-29	-0.81	-0.5	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
LUAD	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-12.82	1.48e-32	7.95e-29	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
LUAD	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-12.82	1.48e-32	7.96e-29	-0.5	-0.5	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	12.81	1.51e-32	8.11e-29	0.54	0.5	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
LUAD	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	12.81	1.53e-32	8.2e-29	0.78	0.5	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
LUAD	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-12.81	1.56e-32	8.35e-29	-0.55	-0.5	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	12.81	1.56e-32	8.39e-29	0.45	0.5	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
LUAD	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-12.81	1.62e-32	8.67e-29	-0.53	-0.5	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
LUAD	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	12.81	1.63e-32	8.73e-29	0.69	0.5	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
LUAD	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-12.81	1.65e-32	8.82e-29	-0.5	-0.5	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-12.81	1.65e-32	8.84e-29	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
LUAD	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	12.8	1.66e-32	8.92e-29	0.71	0.5	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
LUAD	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	12.8	1.68e-32	8.97e-29	0.54	0.5	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	12.8	1.68e-32	8.97e-29	0.54	0.5	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	12.8	1.68e-32	8.97e-29	0.54	0.5	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	12.8	1.68e-32	8.97e-29	0.54	0.5	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	12.8	1.68e-32	9e-29	0.45	0.5	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
LUAD	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-12.8	1.71e-32	9.09e-29	-0.55	-0.5	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	12.8	1.76e-32	9.35e-29	0.64	0.5	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
LUAD	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	12.8	1.8e-32	9.59e-29	0.62	0.5	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
LUAD	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-12.79	1.82e-32	9.66e-29	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
LUAD	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	12.79	1.82e-32	9.69e-29	0.55	0.5	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
LUAD	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	12.79	1.84e-32	9.79e-29	0.77	0.5	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
LUAD	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-12.79	1.92e-32	1.02e-28	-0.56	-0.5	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
LUAD	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	12.79	1.95e-32	1.03e-28	0.69	0.5	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
LUAD	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-12.79	1.95e-32	1.04e-28	-0.55	-0.5	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
LUAD	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	12.79	1.96e-32	1.04e-28	0.69	0.5	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
LUAD	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-12.79	1.97e-32	1.05e-28	-0.7	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
LUAD	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-12.78	2.02e-32	1.07e-28	-0.56	-0.5	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-12.78	2.02e-32	1.07e-28	-0.56	-0.5	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
LUAD	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-12.78	2.04e-32	1.08e-28	-0.68	-0.5	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-12.78	2.18e-32	1.15e-28	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
LUAD	cis	rs67383717	0.643	rs72756397	ENSG00000175611.10	LINC00476	-12.77	2.23e-32	1.18e-28	-0.53	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95790861	chr9:95759231~95875977:-
LUAD	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-12.77	2.27e-32	1.2e-28	-0.7	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
LUAD	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-12.77	2.27e-32	1.2e-28	-0.7	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
LUAD	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-12.77	2.39e-32	1.26e-28	-0.51	-0.5	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-12.77	2.42e-32	1.27e-28	-0.55	-0.5	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.818	rs7976294	ENSG00000199506.1	RNU6-247P	-12.76	2.52e-32	1.32e-28	-0.71	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95792529~95792635:-
LUAD	cis	rs6538678	0.818	rs1036429	ENSG00000199506.1	RNU6-247P	-12.76	2.52e-32	1.32e-28	-0.71	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95792529~95792635:-
LUAD	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-12.76	2.52e-32	1.33e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
LUAD	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-12.76	2.54e-32	1.34e-28	-0.68	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
LUAD	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-12.76	2.62e-32	1.38e-28	-0.55	-0.5	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
LUAD	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-12.76	2.62e-32	1.38e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
LUAD	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-12.76	2.62e-32	1.38e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
LUAD	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-12.76	2.65e-32	1.39e-28	-0.56	-0.5	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
LUAD	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-12.75	2.68e-32	1.41e-28	-0.68	-0.5	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-12.75	2.68e-32	1.41e-28	-0.68	-0.5	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
LUAD	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-12.75	2.68e-32	1.41e-28	-0.56	-0.5	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
LUAD	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-12.75	2.85e-32	1.49e-28	-0.54	-0.5	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	12.75	2.88e-32	1.51e-28	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
LUAD	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	12.75	2.89e-32	1.51e-28	0.54	0.5	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-12.75	2.89e-32	1.52e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	12.74	2.96e-32	1.55e-28	0.64	0.5	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
LUAD	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-12.74	3e-32	1.57e-28	-0.67	-0.5	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
LUAD	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-12.74	3.05e-32	1.6e-28	-0.52	-0.5	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	12.74	3.07e-32	1.6e-28	0.51	0.5	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-12.74	3.12e-32	1.63e-28	-0.64	-0.5	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
LUAD	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	12.74	3.22e-32	1.68e-28	0.54	0.5	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	12.74	3.22e-32	1.68e-28	0.54	0.5	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-12.73	3.26e-32	1.7e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
LUAD	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	12.73	3.28e-32	1.71e-28	0.51	0.5	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
LUAD	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-12.73	3.36e-32	1.75e-28	-0.55	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
LUAD	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-12.73	3.4e-32	1.77e-28	-0.85	-0.5	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-12.73	3.49e-32	1.82e-28	-0.88	-0.5	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
LUAD	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	12.72	3.79e-32	1.97e-28	0.52	0.5	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
LUAD	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-12.72	3.8e-32	1.97e-28	-0.51	-0.5	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
LUAD	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	12.72	3.83e-32	1.99e-28	0.66	0.5	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	12.72	3.86e-32	2e-28	0.46	0.5	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	12.72	3.86e-32	2e-28	0.46	0.5	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	12.72	3.87e-32	2.01e-28	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
LUAD	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-12.72	3.9e-32	2.02e-28	-0.68	-0.5	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	12.71	3.97e-32	2.06e-28	0.64	0.5	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
LUAD	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	12.71	3.98e-32	2.06e-28	0.69	0.5	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
LUAD	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-12.71	4e-32	2.07e-28	-0.55	-0.5	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
LUAD	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	12.71	4.15e-32	2.15e-28	0.5	0.5	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
LUAD	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-12.71	4.15e-32	2.15e-28	-0.68	-0.5	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
LUAD	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-12.71	4.16e-32	2.15e-28	-0.63	-0.5	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
LUAD	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-12.71	4.21e-32	2.17e-28	-0.56	-0.5	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-12.71	4.26e-32	2.2e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
LUAD	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-12.71	4.28e-32	2.21e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-12.7	4.36e-32	2.25e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
LUAD	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	12.7	4.4e-32	2.27e-28	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
LUAD	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
LUAD	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-12.7	4.55e-32	2.34e-28	-0.88	-0.5	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
LUAD	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-12.7	4.55e-32	2.34e-28	-0.88	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	12.7	4.63e-32	2.38e-28	0.45	0.5	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
LUAD	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-12.7	4.71e-32	2.42e-28	-0.64	-0.5	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
LUAD	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-12.7	4.73e-32	2.43e-28	-0.55	-0.5	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
LUAD	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-12.69	4.83e-32	2.48e-28	-0.54	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
LUAD	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	12.69	4.91e-32	2.52e-28	0.53	0.5	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
LUAD	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	12.69	4.93e-32	2.53e-28	0.47	0.5	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
LUAD	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-12.69	4.93e-32	2.53e-28	-0.55	-0.5	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
LUAD	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-12.69	4.94e-32	2.54e-28	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-12.69	4.96e-32	2.54e-28	-0.55	-0.5	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	12.69	5.03e-32	2.58e-28	0.58	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
LUAD	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-12.69	5.11e-32	2.62e-28	-0.55	-0.5	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
LUAD	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	12.68	5.3e-32	2.71e-28	0.67	0.5	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-12.68	5.3e-32	2.71e-28	-0.69	-0.5	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
LUAD	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-12.68	5.36e-32	2.74e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-12.68	5.36e-32	2.74e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-12.68	5.36e-32	2.74e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-12.68	5.4e-32	2.76e-28	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
LUAD	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-12.68	5.48e-32	2.8e-28	-0.55	-0.5	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
LUAD	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-12.68	5.48e-32	2.8e-28	-0.52	-0.5	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
LUAD	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-12.68	5.66e-32	2.89e-28	-0.55	-0.5	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-12.68	5.66e-32	2.89e-28	-0.55	-0.5	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
LUAD	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	12.68	5.7e-32	2.91e-28	0.54	0.5	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-12.67	5.82e-32	2.96e-28	-0.55	-0.5	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-12.67	5.82e-32	2.96e-28	-0.55	-0.5	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-12.67	5.82e-32	2.96e-28	-0.55	-0.5	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
LUAD	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-12.67	5.85e-32	2.98e-28	-0.88	-0.5	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
LUAD	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-12.67	5.89e-32	3e-28	-0.64	-0.5	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	12.67	5.91e-32	3.01e-28	0.46	0.5	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
LUAD	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-12.67	5.92e-32	3.01e-28	-0.55	-0.5	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-12.67	5.92e-32	3.01e-28	-0.55	-0.5	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	12.67	6.07e-32	3.08e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	12.67	6.07e-32	3.08e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	12.67	6.16e-32	3.13e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
LUAD	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-12.67	6.27e-32	3.18e-28	-0.5	-0.5	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-12.67	6.27e-32	3.18e-28	-0.5	-0.5	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	12.67	6.29e-32	3.19e-28	0.5	0.5	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	12.66	6.37e-32	3.23e-28	0.67	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-12.66	6.5e-32	3.29e-28	-0.87	-0.5	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
LUAD	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
LUAD	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-12.66	6.55e-32	3.32e-28	-0.54	-0.5	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
LUAD	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-12.66	6.61e-32	3.34e-28	-0.62	-0.5	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	12.66	6.66e-32	3.37e-28	0.45	0.5	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
LUAD	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-12.66	6.84e-32	3.46e-28	-0.55	-0.5	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	12.66	6.85e-32	3.47e-28	0.58	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
LUAD	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	12.66	6.9e-32	3.49e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
LUAD	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-12.66	6.92e-32	3.5e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
LUAD	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	12.65	7.01e-32	3.54e-28	0.64	0.5	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
LUAD	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-12.65	7.19e-32	3.63e-28	-0.55	-0.5	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
LUAD	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-12.65	7.24e-32	3.65e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-12.65	7.24e-32	3.65e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-12.65	7.24e-32	3.65e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-12.65	7.31e-32	3.68e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	12.65	7.47e-32	3.76e-28	0.45	0.5	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
LUAD	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	12.65	7.53e-32	3.79e-28	0.65	0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-12.65	7.55e-32	3.8e-28	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-12.65	7.56e-32	3.8e-28	-0.69	-0.5	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-12.65	7.57e-32	3.81e-28	-0.67	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
LUAD	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-12.65	7.57e-32	3.81e-28	-0.54	-0.5	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
LUAD	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	12.64	7.7e-32	3.87e-28	0.62	0.5	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
LUAD	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-12.64	7.87e-32	3.95e-28	-0.55	-0.5	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-12.64	7.87e-32	3.95e-28	-0.55	-0.5	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	12.64	7.87e-32	3.95e-28	0.45	0.5	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
LUAD	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	12.64	8.01e-32	4.02e-28	0.51	0.5	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	12.64	8.06e-32	4.04e-28	0.67	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	12.64	8.39e-32	4.2e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
LUAD	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-12.63	8.46e-32	4.23e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-12.63	8.55e-32	4.28e-28	-0.56	-0.5	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
LUAD	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	12.63	8.56e-32	4.28e-28	0.67	0.5	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
LUAD	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-12.63	8.97e-32	4.48e-28	-0.74	-0.5	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
LUAD	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-12.63	9e-32	4.49e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-12.63	9e-32	4.49e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
LUAD	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
LUAD	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-12.62	9.43e-32	4.7e-28	-0.59	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
LUAD	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	12.62	9.47e-32	4.72e-28	0.51	0.5	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	12.62	9.62e-32	4.79e-28	0.5	0.5	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-12.61	1.04e-31	5.15e-28	-0.45	-0.5	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
LUAD	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-12.61	1.04e-31	5.17e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-12.61	1.06e-31	5.26e-28	-0.69	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
LUAD	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-12.61	1.06e-31	5.28e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
LUAD	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-12.61	1.07e-31	5.31e-28	-0.55	-0.5	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
LUAD	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-12.61	1.07e-31	5.32e-28	-0.5	-0.5	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
LUAD	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-12.61	1.08e-31	5.36e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	12.61	1.1e-31	5.46e-28	0.55	0.5	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
LUAD	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-12.61	1.12e-31	5.53e-28	-0.7	-0.5	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-12.6	1.15e-31	5.68e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
LUAD	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-12.6	1.18e-31	5.81e-28	-0.55	-0.5	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
LUAD	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-12.6	1.18e-31	5.85e-28	-0.88	-0.5	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
LUAD	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-12.6	1.19e-31	5.85e-28	-0.55	-0.5	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-12.6	1.19e-31	5.85e-28	-0.55	-0.5	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
LUAD	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	12.6	1.19e-31	5.87e-28	0.52	0.5	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-12.6	1.19e-31	5.89e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
LUAD	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-12.59	1.25e-31	6.14e-28	-0.55	-0.5	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-12.59	1.25e-31	6.16e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
LUAD	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-12.59	1.26e-31	6.22e-28	-0.64	-0.5	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
LUAD	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-12.59	1.27e-31	6.25e-28	-0.63	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
LUAD	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-12.59	1.28e-31	6.31e-28	-0.64	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	12.59	1.31e-31	6.44e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-12.59	1.31e-31	6.46e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
LUAD	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-12.58	1.35e-31	6.65e-28	-0.52	-0.5	Breast cancer;	chr11:825777	chr11:779617~780755:+
LUAD	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-12.58	1.37e-31	6.71e-28	-0.66	-0.5	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
LUAD	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	12.58	1.44e-31	7.07e-28	0.68	0.5	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
LUAD	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-12.58	1.44e-31	7.07e-28	-0.66	-0.5	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
LUAD	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	12.57	1.52e-31	7.45e-28	0.78	0.5	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
LUAD	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-12.57	1.53e-31	7.51e-28	-0.69	-0.5	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
LUAD	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	12.57	1.56e-31	7.63e-28	0.66	0.5	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
LUAD	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-12.57	1.56e-31	7.65e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-12.57	1.61e-31	7.85e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-12.57	1.61e-31	7.85e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
LUAD	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-12.57	1.63e-31	7.96e-28	-0.7	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
LUAD	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-12.57	1.63e-31	7.96e-28	-0.55	-0.5	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
LUAD	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-12.57	1.63e-31	7.97e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-12.57	1.64e-31	7.99e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
LUAD	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-12.56	1.65e-31	8.05e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
LUAD	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-12.56	1.66e-31	8.09e-28	-0.56	-0.5	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
LUAD	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-12.56	1.67e-31	8.16e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
LUAD	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	12.56	1.69e-31	8.25e-28	0.62	0.5	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
LUAD	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-12.56	1.69e-31	8.25e-28	-0.77	-0.5	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	12.56	1.69e-31	8.26e-28	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
LUAD	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-12.56	1.74e-31	8.45e-28	-0.73	-0.5	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-12.56	1.74e-31	8.47e-28	-0.76	-0.5	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
LUAD	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	12.56	1.8e-31	8.74e-28	0.54	0.5	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	12.56	1.8e-31	8.74e-28	0.54	0.5	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
LUAD	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-12.55	1.83e-31	8.87e-28	-0.82	-0.5	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-12.55	1.98e-31	9.57e-28	-0.5	-0.5	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	12.54	2.02e-31	9.78e-28	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
LUAD	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-12.54	2.04e-31	9.88e-28	-0.62	-0.5	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
LUAD	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-12.54	2.06e-31	9.94e-28	-0.53	-0.5	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
LUAD	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-12.54	2.1e-31	1.01e-27	-0.55	-0.5	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
LUAD	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	12.54	2.1e-31	1.01e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
LUAD	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-12.54	2.14e-31	1.03e-27	-0.55	-0.5	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
LUAD	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	12.54	2.18e-31	1.05e-27	0.63	0.5	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
LUAD	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-12.53	2.2e-31	1.06e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-12.53	2.2e-31	1.06e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
LUAD	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-12.53	2.28e-31	1.1e-27	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
LUAD	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-12.53	2.37e-31	1.14e-27	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
LUAD	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-12.53	2.38e-31	1.14e-27	-0.85	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
LUAD	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	12.52	2.4e-31	1.15e-27	0.65	0.5	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
LUAD	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-12.52	2.43e-31	1.16e-27	-0.61	-0.5	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
LUAD	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	12.52	2.43e-31	1.17e-27	0.51	0.5	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
LUAD	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-12.52	2.48e-31	1.19e-27	-0.66	-0.5	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-12.52	2.48e-31	1.19e-27	-0.66	-0.5	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-12.52	2.48e-31	1.19e-27	-0.66	-0.5	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
LUAD	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	12.52	2.52e-31	1.21e-27	0.5	0.5	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
LUAD	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	12.52	2.55e-31	1.22e-27	0.78	0.5	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
LUAD	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-12.52	2.55e-31	1.22e-27	-0.66	-0.5	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
LUAD	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	12.51	2.65e-31	1.27e-27	0.65	0.5	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	12.51	2.65e-31	1.27e-27	0.65	0.5	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	12.51	2.65e-31	1.27e-27	0.65	0.5	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-12.51	2.68e-31	1.28e-27	-0.62	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
LUAD	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	12.51	2.69e-31	1.29e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	12.51	2.69e-31	1.29e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	12.51	2.69e-31	1.29e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	12.51	2.83e-31	1.35e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	12.51	2.83e-31	1.35e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	12.51	2.83e-31	1.35e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
LUAD	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	12.51	2.87e-31	1.37e-27	0.65	0.5	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-12.51	2.87e-31	1.37e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
LUAD	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-12.5	2.93e-31	1.39e-27	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-12.5	2.95e-31	1.4e-27	-0.82	-0.5	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
LUAD	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-12.5	3e-31	1.43e-27	-0.63	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
LUAD	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-12.5	3.05e-31	1.45e-27	-0.66	-0.5	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-12.5	3.05e-31	1.45e-27	-0.66	-0.5	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-12.5	3.09e-31	1.47e-27	-0.66	-0.5	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
LUAD	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	12.5	3.18e-31	1.51e-27	0.51	0.5	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
LUAD	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	12.49	3.33e-31	1.58e-27	0.64	0.49	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
LUAD	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	12.49	3.43e-31	1.62e-27	0.7	0.49	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
LUAD	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	12.49	3.46e-31	1.63e-27	0.47	0.49	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
LUAD	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	12.48	3.54e-31	1.68e-27	0.74	0.49	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
LUAD	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-12.48	3.57e-31	1.69e-27	-0.54	-0.49	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
LUAD	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	12.47	3.87e-31	1.83e-27	0.61	0.49	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
LUAD	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	12.47	3.99e-31	1.88e-27	0.51	0.49	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-12.47	4.02e-31	1.89e-27	-0.55	-0.49	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
LUAD	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-12.47	4.05e-31	1.9e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.824	rs4762633	ENSG00000199506.1	RNU6-247P	-12.47	4.08e-31	1.92e-27	-0.71	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95792529~95792635:-
LUAD	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-12.47	4.12e-31	1.93e-27	-0.62	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
LUAD	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	12.47	4.23e-31	1.98e-27	0.47	0.49	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
LUAD	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	12.46	4.39e-31	2.05e-27	0.62	0.49	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
LUAD	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-12.46	4.39e-31	2.05e-27	-0.68	-0.49	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
LUAD	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-12.46	4.39e-31	2.05e-27	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
LUAD	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-12.45	4.75e-31	2.21e-27	-0.76	-0.49	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
LUAD	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	12.45	4.75e-31	2.21e-27	0.63	0.49	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
LUAD	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-12.45	4.84e-31	2.25e-27	-0.63	-0.49	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-12.45	4.84e-31	2.25e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-12.45	4.85e-31	2.26e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	12.45	4.87e-31	2.26e-27	0.61	0.49	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	12.45	4.87e-31	2.26e-27	0.61	0.49	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
LUAD	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-12.45	5e-31	2.32e-27	-0.63	-0.49	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
LUAD	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-12.44	5.18e-31	2.41e-27	-0.67	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
LUAD	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-12.44	5.22e-31	2.42e-27	-0.62	-0.49	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
LUAD	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-12.44	5.49e-31	2.54e-27	-0.54	-0.49	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-12.44	5.5e-31	2.55e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
LUAD	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-12.44	5.56e-31	2.58e-27	-0.71	-0.49	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
LUAD	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	12.43	5.67e-31	2.62e-27	0.81	0.49	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-12.43	5.68e-31	2.63e-27	-0.44	-0.49	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
LUAD	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-12.43	5.8e-31	2.68e-27	-0.54	-0.49	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
LUAD	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-12.43	5.83e-31	2.7e-27	-0.49	-0.49	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
LUAD	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-12.43	5.88e-31	2.72e-27	-0.83	-0.49	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-12.43	5.96e-31	2.75e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	12.43	5.98e-31	2.76e-27	0.59	0.49	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
LUAD	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	12.43	6e-31	2.77e-27	0.62	0.49	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
LUAD	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-12.43	6.02e-31	2.78e-27	-0.67	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
LUAD	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-12.43	6.06e-31	2.8e-27	-0.63	-0.49	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-12.43	6.06e-31	2.8e-27	-0.63	-0.49	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
LUAD	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-12.42	6.26e-31	2.89e-27	-0.84	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
LUAD	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	12.42	6.36e-31	2.93e-27	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
LUAD	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-12.42	6.41e-31	2.96e-27	-0.64	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
LUAD	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	12.42	6.43e-31	2.97e-27	0.79	0.49	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
LUAD	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	12.42	6.53e-31	3.01e-27	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
LUAD	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-12.42	6.56e-31	3.02e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
LUAD	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-12.42	6.64e-31	3.06e-27	-0.76	-0.49	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
LUAD	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-12.42	6.72e-31	3.09e-27	-0.67	-0.49	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-12.42	6.72e-31	3.09e-27	-0.67	-0.49	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
LUAD	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-12.42	6.76e-31	3.11e-27	-0.62	-0.49	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
LUAD	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-12.42	6.78e-31	3.12e-27	-0.52	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
LUAD	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	12.41	6.9e-31	3.17e-27	0.82	0.49	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-12.41	7.34e-31	3.36e-27	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
LUAD	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-12.41	7.37e-31	3.38e-27	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
LUAD	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	12.41	7.46e-31	3.42e-27	0.63	0.49	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
LUAD	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-12.4	7.62e-31	3.49e-27	-0.71	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-12.4	7.66e-31	3.51e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
LUAD	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	12.4	7.76e-31	3.55e-27	0.51	0.49	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	12.4	7.76e-31	3.55e-27	0.51	0.49	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
LUAD	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-12.4	7.86e-31	3.59e-27	-0.65	-0.49	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-12.4	7.86e-31	3.59e-27	-0.65	-0.49	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-12.4	7.86e-31	3.59e-27	-0.65	-0.49	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-12.4	7.86e-31	3.59e-27	-0.65	-0.49	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
LUAD	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	12.4	7.91e-31	3.61e-27	0.71	0.49	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
LUAD	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	12.4	7.91e-31	3.61e-27	0.71	0.49	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
LUAD	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-12.4	7.93e-31	3.62e-27	-0.63	-0.49	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
LUAD	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	12.4	7.99e-31	3.65e-27	0.62	0.49	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	12.4	8.04e-31	3.67e-27	0.59	0.49	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-12.39	8.25e-31	3.77e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-12.39	8.4e-31	3.83e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
LUAD	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	12.39	8.52e-31	3.89e-27	0.51	0.49	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-12.39	8.61e-31	3.93e-27	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-12.39	8.94e-31	4.07e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
LUAD	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	12.39	8.98e-31	4.09e-27	0.61	0.49	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
LUAD	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-12.38	9.06e-31	4.13e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
LUAD	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	12.38	9.27e-31	4.21e-27	0.61	0.49	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-12.38	9.39e-31	4.26e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
LUAD	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	12.38	9.54e-31	4.33e-27	0.65	0.49	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
LUAD	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-12.38	9.55e-31	4.33e-27	-0.54	-0.49	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-12.38	9.55e-31	4.33e-27	-0.54	-0.49	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-12.38	9.55e-31	4.33e-27	-0.54	-0.49	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-12.38	9.55e-31	4.33e-27	-0.54	-0.49	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	12.38	9.56e-31	4.33e-27	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
LUAD	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	12.38	9.61e-31	4.35e-27	0.61	0.49	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-12.38	9.84e-31	4.46e-27	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
LUAD	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-12.38	9.89e-31	4.48e-27	-0.5	-0.49	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
LUAD	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	12.37	1e-30	4.54e-27	0.71	0.49	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
LUAD	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	12.37	1.01e-30	4.59e-27	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
LUAD	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-12.37	1.02e-30	4.6e-27	-0.66	-0.49	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
LUAD	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	12.37	1.04e-30	4.72e-27	0.62	0.49	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-12.37	1.07e-30	4.83e-27	-0.62	-0.49	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-12.37	1.07e-30	4.83e-27	-0.62	-0.49	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
LUAD	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-12.37	1.07e-30	4.83e-27	-0.51	-0.49	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
LUAD	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-12.37	1.07e-30	4.83e-27	-0.65	-0.49	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
LUAD	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	12.37	1.08e-30	4.87e-27	0.48	0.49	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-12.37	1.09e-30	4.91e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
LUAD	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	12.37	1.09e-30	4.91e-27	0.49	0.49	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
LUAD	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-12.36	1.11e-30	5e-27	-0.52	-0.49	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
LUAD	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-12.36	1.11e-30	5.02e-27	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
LUAD	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-12.36	1.12e-30	5.03e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
LUAD	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	12.36	1.12e-30	5.03e-27	0.7	0.49	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
LUAD	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-12.36	1.13e-30	5.09e-27	-0.67	-0.49	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	12.36	1.15e-30	5.19e-27	0.62	0.49	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
LUAD	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-12.35	1.21e-30	5.44e-27	-0.66	-0.49	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	12.35	1.22e-30	5.45e-27	0.65	0.49	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
LUAD	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-12.35	1.22e-30	5.45e-27	-0.51	-0.49	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	12.35	1.23e-30	5.5e-27	0.51	0.49	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-12.35	1.24e-30	5.55e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-12.35	1.24e-30	5.57e-27	-0.54	-0.49	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-12.35	1.24e-30	5.57e-27	-0.54	-0.49	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-12.35	1.25e-30	5.58e-27	-0.54	-0.49	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-12.35	1.25e-30	5.59e-27	-0.54	-0.49	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-12.35	1.25e-30	5.59e-27	-0.54	-0.49	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-12.35	1.25e-30	5.59e-27	-0.54	-0.49	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
LUAD	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-12.35	1.27e-30	5.69e-27	-0.58	-0.49	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
LUAD	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-12.35	1.3e-30	5.79e-27	-0.48	-0.49	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-12.35	1.3e-30	5.8e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-12.35	1.31e-30	5.84e-27	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
LUAD	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-12.35	1.32e-30	5.87e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
LUAD	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	12.34	1.39e-30	6.17e-27	0.56	0.49	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
LUAD	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	12.34	1.39e-30	6.2e-27	0.71	0.49	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	12.34	1.42e-30	6.32e-27	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	12.34	1.43e-30	6.34e-27	0.56	0.49	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	12.33	1.45e-30	6.44e-27	0.44	0.49	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
LUAD	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-12.33	1.45e-30	6.46e-27	-0.52	-0.49	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
LUAD	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
LUAD	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	12.33	1.49e-30	6.6e-27	0.61	0.49	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
LUAD	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	12.33	1.5e-30	6.62e-27	0.53	0.49	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
LUAD	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	12.33	1.54e-30	6.8e-27	0.61	0.49	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
LUAD	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-12.33	1.58e-30	6.98e-27	-0.58	-0.49	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
LUAD	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-12.33	1.59e-30	7e-27	-0.69	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
LUAD	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	12.32	1.61e-30	7.09e-27	0.59	0.49	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
LUAD	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	12.32	1.62e-30	7.16e-27	0.5	0.49	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	12.32	1.64e-30	7.24e-27	0.67	0.49	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
LUAD	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-12.32	1.65e-30	7.26e-27	-0.59	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-12.32	1.66e-30	7.33e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
LUAD	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	12.32	1.67e-30	7.35e-27	0.79	0.49	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
LUAD	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-12.32	1.73e-30	7.61e-27	-0.62	-0.49	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-12.31	1.78e-30	7.81e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-12.31	1.82e-30	8e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-12.31	1.83e-30	8.04e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-12.31	1.83e-30	8.04e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
LUAD	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	12.31	1.83e-30	8.05e-27	0.67	0.49	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
LUAD	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	12.31	1.88e-30	8.23e-27	0.49	0.49	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
LUAD	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-12.31	1.9e-30	8.34e-27	-0.51	-0.49	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
LUAD	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	12.3	1.94e-30	8.5e-27	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
LUAD	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-12.3	2.01e-30	8.8e-27	-0.52	-0.49	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	12.3	2.09e-30	9.14e-27	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
LUAD	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-12.29	2.12e-30	9.29e-27	-0.62	-0.49	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
LUAD	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-12.29	2.18e-30	9.52e-27	-0.69	-0.49	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
LUAD	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-12.29	2.23e-30	9.74e-27	-0.6	-0.49	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
LUAD	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	12.29	2.25e-30	9.81e-27	0.53	0.49	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
LUAD	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	12.29	2.26e-30	9.84e-27	0.62	0.49	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
LUAD	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-12.29	2.27e-30	9.91e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
LUAD	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-12.29	2.28e-30	9.95e-27	-0.54	-0.49	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
LUAD	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-12.29	2.29e-30	9.97e-27	-0.52	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
LUAD	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	12.29	2.3e-30	1e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	12.29	2.3e-30	1e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	12.28	2.33e-30	1.02e-26	0.67	0.49	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-12.28	2.34e-30	1.02e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
LUAD	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	12.28	2.42e-30	1.05e-26	0.72	0.49	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
LUAD	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	12.28	2.46e-30	1.07e-26	0.53	0.49	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
LUAD	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-12.28	2.48e-30	1.08e-26	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
LUAD	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	12.27	2.64e-30	1.14e-26	0.59	0.49	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
LUAD	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	12.27	2.66e-30	1.15e-26	0.71	0.49	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
LUAD	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-12.26	2.82e-30	1.22e-26	-0.71	-0.49	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-12.26	2.84e-30	1.23e-26	-0.62	-0.49	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-12.26	2.84e-30	1.23e-26	-0.62	-0.49	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
LUAD	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	12.26	2.89e-30	1.25e-26	0.54	0.49	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
LUAD	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	12.26	2.92e-30	1.26e-26	0.81	0.49	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
LUAD	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-12.26	2.97e-30	1.28e-26	-0.48	-0.49	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-12.26	3.04e-30	1.31e-26	-0.54	-0.49	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-12.26	3.04e-30	1.31e-26	-0.54	-0.49	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-12.26	3.04e-30	1.31e-26	-0.54	-0.49	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
LUAD	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-12.26	3.04e-30	1.31e-26	-0.69	-0.49	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-12.26	3.06e-30	1.32e-26	-0.62	-0.49	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
LUAD	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	12.25	3.1e-30	1.34e-26	0.61	0.49	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
LUAD	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	12.25	3.11e-30	1.34e-26	0.46	0.49	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
LUAD	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	12.25	3.28e-30	1.41e-26	0.7	0.49	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
LUAD	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-12.24	3.4e-30	1.46e-26	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	12.24	3.41e-30	1.47e-26	0.44	0.49	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
LUAD	cis	rs10935480	0.577	rs10804683	ENSG00000239445.4	ST3GAL6-AS1	-12.24	3.48e-30	1.5e-26	-0.61	-0.49	Blood protein levels;	chr3:98661882	chr3:98714330~98732651:-
LUAD	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	12.24	3.5e-30	1.51e-26	0.61	0.49	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-12.24	3.65e-30	1.56e-26	-0.7	-0.49	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-12.24	3.69e-30	1.58e-26	-0.62	-0.49	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
LUAD	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	12.24	3.7e-30	1.59e-26	0.63	0.49	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-12.23	3.73e-30	1.6e-26	-0.62	-0.49	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-12.23	3.76e-30	1.61e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-12.23	3.76e-30	1.61e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-12.23	3.78e-30	1.62e-26	-0.6	-0.49	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-12.23	3.78e-30	1.62e-26	-0.6	-0.49	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
LUAD	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-12.23	3.83e-30	1.64e-26	-0.99	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
LUAD	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-12.23	3.87e-30	1.65e-26	-0.62	-0.49	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-12.23	3.99e-30	1.7e-26	-0.61	-0.49	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
LUAD	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-12.23	4.06e-30	1.73e-26	-0.54	-0.49	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
LUAD	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	12.22	4.15e-30	1.77e-26	0.55	0.49	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
LUAD	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	12.22	4.22e-30	1.79e-26	0.6	0.49	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-12.22	4.22e-30	1.79e-26	-0.61	-0.49	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-12.22	4.22e-30	1.79e-26	-0.61	-0.49	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
LUAD	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	12.22	4.26e-30	1.81e-26	0.7	0.49	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
LUAD	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	12.22	4.29e-30	1.82e-26	0.52	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
LUAD	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	12.22	4.33e-30	1.83e-26	0.67	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
LUAD	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	12.22	4.36e-30	1.85e-26	0.7	0.49	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
LUAD	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	12.22	4.37e-30	1.85e-26	0.81	0.49	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
LUAD	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-12.22	4.38e-30	1.86e-26	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
LUAD	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-12.22	4.4e-30	1.86e-26	-0.54	-0.49	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
LUAD	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-12.22	4.41e-30	1.87e-26	-0.78	-0.49	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-12.21	4.57e-30	1.93e-26	-0.6	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
LUAD	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-12.21	4.61e-30	1.95e-26	-0.59	-0.49	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
LUAD	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-12.21	4.75e-30	2.01e-26	-0.61	-0.49	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-12.21	4.84e-30	2.05e-26	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
LUAD	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	12.2	4.94e-30	2.09e-26	0.62	0.49	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
LUAD	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-12.2	4.97e-30	2.1e-26	-0.81	-0.49	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
LUAD	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	12.2	5.01e-30	2.12e-26	0.79	0.49	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
LUAD	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-12.2	5.04e-30	2.13e-26	-0.53	-0.49	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
LUAD	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	12.2	5.15e-30	2.17e-26	0.72	0.49	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
LUAD	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	12.2	5.16e-30	2.18e-26	0.62	0.49	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
LUAD	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-12.2	5.16e-30	2.18e-26	-0.53	-0.49	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-12.2	5.2e-30	2.19e-26	-0.53	-0.49	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
LUAD	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	12.2	5.25e-30	2.21e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
LUAD	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-12.2	5.26e-30	2.22e-26	-0.53	-0.49	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
LUAD	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	12.2	5.39e-30	2.27e-26	0.58	0.49	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
LUAD	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
LUAD	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	12.19	5.65e-30	2.37e-26	0.7	0.49	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
LUAD	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	12.19	5.77e-30	2.43e-26	0.58	0.49	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-12.19	5.82e-30	2.45e-26	-0.6	-0.49	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
LUAD	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-12.19	5.83e-30	2.45e-26	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
LUAD	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-12.19	5.89e-30	2.47e-26	-0.53	-0.49	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	12.18	5.94e-30	2.5e-26	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
LUAD	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	12.18	6.11e-30	2.56e-26	0.6	0.49	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-12.18	6.12e-30	2.57e-26	-0.61	-0.49	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	12.18	6.2e-30	2.6e-26	0.58	0.49	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	12.18	6.45e-30	2.7e-26	0.58	0.49	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	12.18	6.45e-30	2.7e-26	0.58	0.49	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
LUAD	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-12.17	6.59e-30	2.76e-26	-0.53	-0.49	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	12.17	6.62e-30	2.77e-26	0.54	0.49	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
LUAD	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-12.17	6.71e-30	2.81e-26	-0.6	-0.49	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-12.17	6.78e-30	2.83e-26	-0.53	-0.49	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	12.17	6.81e-30	2.85e-26	0.65	0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
LUAD	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	12.17	6.97e-30	2.91e-26	0.84	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
LUAD	cis	rs67383717	0.689	rs1836404	ENSG00000175611.10	LINC00476	-12.17	6.98e-30	2.91e-26	-0.52	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95787982	chr9:95759231~95875977:-
LUAD	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	12.17	7.02e-30	2.93e-26	0.69	0.49	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
LUAD	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-12.17	7.07e-30	2.95e-26	-0.54	-0.49	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
LUAD	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	12.16	7.44e-30	3.1e-26	0.69	0.48	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	12.16	7.6e-30	3.16e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
LUAD	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	12.16	7.77e-30	3.23e-26	0.77	0.48	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
LUAD	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-12.16	7.82e-30	3.25e-26	-0.61	-0.48	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
LUAD	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-12.15	7.86e-30	3.27e-26	-0.61	-0.48	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-12.15	7.89e-30	3.28e-26	-0.61	-0.48	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-12.15	7.9e-30	3.28e-26	-0.65	-0.48	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
LUAD	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	12.15	8.01e-30	3.33e-26	0.52	0.48	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
LUAD	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-12.15	8.16e-30	3.39e-26	-0.67	-0.48	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
LUAD	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	12.15	8.27e-30	3.43e-26	0.66	0.48	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	12.15	8.4e-30	3.48e-26	0.58	0.48	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
LUAD	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-12.15	8.41e-30	3.49e-26	-0.63	-0.48	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	12.14	8.8e-30	3.65e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	12.14	8.8e-30	3.65e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
LUAD	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	12.14	8.85e-30	3.66e-26	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
LUAD	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-12.14	8.86e-30	3.67e-26	-0.61	-0.48	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
LUAD	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-12.14	8.9e-30	3.68e-26	-0.61	-0.48	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
LUAD	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-12.14	8.91e-30	3.69e-26	-0.61	-0.48	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
LUAD	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-12.14	8.92e-30	3.69e-26	-0.61	-0.48	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
LUAD	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	12.14	8.98e-30	3.71e-26	0.6	0.48	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
LUAD	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	12.14	9.08e-30	3.75e-26	0.71	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
LUAD	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	12.14	9.08e-30	3.75e-26	0.61	0.48	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
LUAD	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-12.14	9.23e-30	3.81e-26	-0.65	-0.48	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-12.14	9.23e-30	3.81e-26	-0.65	-0.48	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	12.14	9.27e-30	3.82e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	12.14	9.28e-30	3.83e-26	0.38	0.48	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
LUAD	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-12.14	9.32e-30	3.84e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	12.13	9.63e-30	3.96e-26	0.45	0.48	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
LUAD	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-12.13	9.87e-30	4.06e-26	-0.73	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-12.13	9.93e-30	4.09e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-12.13	9.93e-30	4.09e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	12.13	1.01e-29	4.16e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
LUAD	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-12.13	1.02e-29	4.19e-26	-0.61	-0.48	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-12.13	1.02e-29	4.19e-26	-0.61	-0.48	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-12.13	1.02e-29	4.19e-26	-0.61	-0.48	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-12.13	1.02e-29	4.19e-26	-0.61	-0.48	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
LUAD	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
LUAD	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-12.12	1.08e-29	4.43e-26	-0.6	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-12.12	1.09e-29	4.48e-26	-0.65	-0.48	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-12.12	1.09e-29	4.48e-26	-0.65	-0.48	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
LUAD	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-12.12	1.1e-29	4.49e-26	-0.65	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
LUAD	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-12.12	1.1e-29	4.49e-26	-0.65	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
LUAD	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-12.12	1.11e-29	4.56e-26	-0.61	-0.48	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
LUAD	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	12.12	1.12e-29	4.61e-26	0.7	0.48	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
LUAD	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	12.11	1.15e-29	4.71e-26	0.6	0.48	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	12.11	1.16e-29	4.73e-26	0.58	0.48	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	12.11	1.16e-29	4.73e-26	0.58	0.48	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
LUAD	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	12.11	1.17e-29	4.77e-26	0.65	0.48	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	12.11	1.17e-29	4.79e-26	0.6	0.48	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
LUAD	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-12.11	1.22e-29	4.97e-26	-0.6	-0.48	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
LUAD	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	12.11	1.25e-29	5.1e-26	0.48	0.48	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-12.1	1.3e-29	5.32e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-12.1	1.33e-29	5.41e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.895	rs7137751	ENSG00000199506.1	RNU6-247P	-12.1	1.35e-29	5.5e-26	-0.65	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95792529~95792635:-
LUAD	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	12.1	1.36e-29	5.55e-26	0.71	0.48	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
LUAD	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	12.1	1.37e-29	5.58e-26	0.7	0.48	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
LUAD	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-12.09	1.38e-29	5.61e-26	-0.69	-0.48	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
LUAD	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-12.09	1.4e-29	5.69e-26	-0.53	-0.48	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-12.09	1.43e-29	5.8e-26	-0.53	-0.48	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
LUAD	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-12.09	1.48e-29	5.99e-26	-0.64	-0.48	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	12.09	1.48e-29	6e-26	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
LUAD	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-12.09	1.51e-29	6.1e-26	-0.52	-0.48	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
LUAD	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	12.08	1.51e-29	6.14e-26	0.58	0.48	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
LUAD	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	12.08	1.53e-29	6.2e-26	0.7	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
LUAD	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-12.08	1.56e-29	6.32e-26	-0.6	-0.48	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-12.08	1.56e-29	6.32e-26	-0.6	-0.48	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	12.08	1.57e-29	6.36e-26	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
LUAD	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-12.08	1.59e-29	6.42e-26	-0.62	-0.48	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-12.08	1.6e-29	6.47e-26	-0.61	-0.48	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-12.08	1.6e-29	6.47e-26	-0.61	-0.48	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	12.08	1.62e-29	6.55e-26	0.61	0.48	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
LUAD	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-12.08	1.62e-29	6.55e-26	-0.6	-0.48	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
LUAD	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	12.08	1.62e-29	6.55e-26	0.77	0.48	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
LUAD	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	12.08	1.62e-29	6.55e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	12.08	1.62e-29	6.55e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
LUAD	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	12.08	1.63e-29	6.57e-26	0.57	0.48	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
LUAD	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-12.08	1.66e-29	6.69e-26	-0.61	-0.48	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	12.07	1.69e-29	6.81e-26	0.43	0.48	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
LUAD	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	12.07	1.72e-29	6.94e-26	0.52	0.48	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
LUAD	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	12.07	1.76e-29	7.11e-26	0.61	0.48	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
LUAD	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-12.07	1.76e-29	7.12e-26	-0.65	-0.48	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
LUAD	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	12.07	1.76e-29	7.12e-26	0.63	0.48	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-12.07	1.79e-29	7.2e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-12.07	1.79e-29	7.2e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-12.07	1.79e-29	7.2e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	12.06	1.83e-29	7.36e-26	0.6	0.48	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-12.06	1.85e-29	7.44e-26	-0.6	-0.48	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
LUAD	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	12.06	1.87e-29	7.49e-26	0.69	0.48	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-12.06	1.88e-29	7.54e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	12.06	1.88e-29	7.55e-26	0.58	0.48	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	12.06	1.88e-29	7.55e-26	0.58	0.48	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
LUAD	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-12.06	1.91e-29	7.67e-26	-0.69	-0.48	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
LUAD	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-12.06	1.94e-29	7.76e-26	-0.62	-0.48	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-12.06	1.94e-29	7.76e-26	-0.62	-0.48	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
LUAD	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	12.06	1.97e-29	7.91e-26	0.69	0.48	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
LUAD	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-12.06	1.97e-29	7.91e-26	-0.88	-0.48	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
LUAD	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	12.05	2.02e-29	8.07e-26	0.59	0.48	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
LUAD	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	12.05	2.09e-29	8.37e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	12.05	2.09e-29	8.37e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
LUAD	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	12.05	2.19e-29	8.75e-26	0.57	0.48	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	12.04	2.21e-29	8.79e-26	0.38	0.48	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
LUAD	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	12.04	2.21e-29	8.81e-26	0.57	0.48	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	12.04	2.21e-29	8.81e-26	0.38	0.48	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
LUAD	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-12.04	2.31e-29	9.2e-26	-0.6	-0.48	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
LUAD	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	12.04	2.34e-29	9.3e-26	0.7	0.48	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-12.04	2.36e-29	9.36e-26	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	12.04	2.4e-29	9.51e-26	0.38	0.48	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
LUAD	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	12.03	2.43e-29	9.64e-26	0.57	0.48	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-12.03	2.47e-29	9.75e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	12.03	2.49e-29	9.83e-26	0.53	0.48	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
LUAD	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-12.03	2.52e-29	9.95e-26	-0.6	-0.48	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
LUAD	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	12.03	2.6e-29	1.02e-25	0.7	0.48	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
LUAD	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	12.03	2.6e-29	1.02e-25	0.7	0.48	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
LUAD	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	12.02	2.67e-29	1.05e-25	0.6	0.48	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	12.02	2.68e-29	1.06e-25	0.61	0.48	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	12.02	2.69e-29	1.06e-25	0.61	0.48	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-12.02	2.71e-29	1.07e-25	-0.69	-0.48	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
LUAD	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	12.02	2.72e-29	1.07e-25	0.65	0.48	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
LUAD	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	12.02	2.78e-29	1.09e-25	0.58	0.48	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
LUAD	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	12.02	2.79e-29	1.1e-25	0.61	0.48	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	12.02	2.79e-29	1.1e-25	0.61	0.48	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
LUAD	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	12.02	2.81e-29	1.11e-25	0.69	0.48	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
LUAD	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-12.02	2.83e-29	1.11e-25	-0.61	-0.48	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
LUAD	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-12.02	2.89e-29	1.14e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
LUAD	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-12.01	2.91e-29	1.14e-25	-0.47	-0.48	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
LUAD	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	12.01	3.02e-29	1.18e-25	0.69	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
LUAD	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-12.01	3.17e-29	1.24e-25	-0.6	-0.48	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
LUAD	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-12	3.2e-29	1.25e-25	-0.6	-0.48	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-12	3.23e-29	1.26e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	12	3.44e-29	1.34e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	12	3.44e-29	1.34e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
LUAD	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
LUAD	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	11.99	3.53e-29	1.38e-25	0.59	0.48	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
LUAD	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-11.99	3.56e-29	1.39e-25	-0.6	-0.48	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-11.99	3.58e-29	1.39e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-11.99	3.64e-29	1.42e-25	-0.55	-0.48	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
LUAD	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	11.99	3.76e-29	1.46e-25	0.58	0.48	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
LUAD	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-11.97	4.26e-29	1.65e-25	-0.6	-0.48	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	11.97	4.38e-29	1.7e-25	0.57	0.48	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	11.97	4.38e-29	1.7e-25	0.57	0.48	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	11.97	4.38e-29	1.7e-25	0.57	0.48	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
LUAD	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-11.97	4.47e-29	1.73e-25	-0.6	-0.48	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	11.97	4.55e-29	1.76e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
LUAD	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	11.97	4.58e-29	1.77e-25	0.7	0.48	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-11.97	4.59e-29	1.78e-25	-0.62	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
LUAD	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	11.97	4.61e-29	1.79e-25	0.7	0.48	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-11.96	4.64e-29	1.8e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-11.96	4.68e-29	1.81e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-11.96	4.68e-29	1.81e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-11.96	4.68e-29	1.81e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-11.96	4.68e-29	1.81e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-11.96	4.7e-29	1.82e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	11.96	4.7e-29	1.82e-25	0.6	0.48	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-11.96	4.72e-29	1.82e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
LUAD	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-11.96	4.86e-29	1.88e-25	-0.64	-0.48	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-11.96	4.86e-29	1.88e-25	-0.54	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
LUAD	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-11.96	4.88e-29	1.88e-25	-0.69	-0.48	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-11.96	4.88e-29	1.88e-25	-0.69	-0.48	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
LUAD	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	11.96	4.9e-29	1.89e-25	0.69	0.48	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
LUAD	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-11.96	5.05e-29	1.95e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-11.95	5.07e-29	1.95e-25	-0.69	-0.48	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-11.95	5.29e-29	2.03e-25	-0.61	-0.48	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	11.95	5.35e-29	2.06e-25	0.57	0.48	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
LUAD	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	11.95	5.5e-29	2.11e-25	0.48	0.48	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
LUAD	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-11.95	5.51e-29	2.12e-25	-0.53	-0.48	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
LUAD	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	11.95	5.51e-29	2.12e-25	0.69	0.48	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
LUAD	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	11.94	5.57e-29	2.14e-25	0.38	0.48	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
LUAD	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-11.94	5.72e-29	2.19e-25	-0.77	-0.48	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-11.94	5.72e-29	2.19e-25	-0.77	-0.48	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
LUAD	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-11.94	5.75e-29	2.2e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-11.94	5.75e-29	2.2e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
LUAD	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-11.94	6.08e-29	2.33e-25	-0.61	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
LUAD	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-11.93	6.1e-29	2.33e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-11.93	6.12e-29	2.34e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	11.93	6.3e-29	2.41e-25	0.57	0.48	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
LUAD	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	11.93	6.32e-29	2.42e-25	0.68	0.48	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
LUAD	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-11.93	6.39e-29	2.44e-25	-0.6	-0.48	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	11.93	6.43e-29	2.46e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-11.93	6.44e-29	2.46e-25	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-11.93	6.56e-29	2.5e-25	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
LUAD	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-11.92	6.93e-29	2.64e-25	-0.6	-0.48	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
LUAD	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	11.92	6.95e-29	2.65e-25	0.7	0.48	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
LUAD	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-11.92	7.17e-29	2.72e-25	-0.58	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
LUAD	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	11.92	7.2e-29	2.73e-25	0.76	0.48	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
LUAD	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-11.91	7.42e-29	2.81e-25	-0.6	-0.48	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
LUAD	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-11.91	7.5e-29	2.84e-25	-0.47	-0.48	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
LUAD	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	11.91	7.56e-29	2.86e-25	0.58	0.48	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	11.91	7.56e-29	2.86e-25	0.58	0.48	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	11.91	7.6e-29	2.88e-25	0.57	0.48	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-11.91	7.74e-29	2.93e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-11.91	7.92e-29	2.99e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-11.91	7.92e-29	2.99e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
LUAD	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-11.91	7.92e-29	2.99e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
LUAD	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	11.9	8.1e-29	3.06e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	11.9	8.31e-29	3.14e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	11.9	8.31e-29	3.14e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	11.9	8.31e-29	3.14e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
LUAD	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	11.9	8.37e-29	3.16e-25	0.59	0.48	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
LUAD	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-11.9	8.38e-29	3.16e-25	-0.6	-0.48	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
LUAD	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	11.9	8.43e-29	3.18e-25	0.58	0.48	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-11.9	8.48e-29	3.2e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
LUAD	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-11.9	8.61e-29	3.25e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-11.9	8.61e-29	3.25e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-11.9	8.61e-29	3.25e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-11.9	8.62e-29	3.25e-25	-0.64	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-11.9	8.65e-29	3.26e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	11.89	8.99e-29	3.38e-25	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
LUAD	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-11.89	9.26e-29	3.48e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-11.89	9.36e-29	3.52e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
LUAD	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-11.89	9.4e-29	3.53e-25	-0.69	-0.48	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
LUAD	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	11.89	9.41e-29	3.53e-25	0.6	0.48	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-11.89	9.44e-29	3.54e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
LUAD	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-11.89	9.46e-29	3.55e-25	-0.58	-0.48	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
LUAD	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	11.89	9.48e-29	3.56e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-11.89	9.54e-29	3.58e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-11.89	9.54e-29	3.58e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-11.89	9.54e-29	3.58e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	11.89	9.6e-29	3.6e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	11.89	9.6e-29	3.6e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	11.88	9.72e-29	3.64e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
LUAD	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-11.88	1e-28	3.76e-25	-0.58	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-11.88	1.01e-28	3.77e-25	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-11.88	1.02e-28	3.81e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-11.88	1.04e-28	3.88e-25	-0.6	-0.48	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
LUAD	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	11.87	1.08e-28	4.05e-25	0.6	0.48	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	11.87	1.08e-28	4.05e-25	0.6	0.48	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
LUAD	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	11.87	1.1e-28	4.09e-25	0.68	0.48	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	11.87	1.13e-28	4.2e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	11.87	1.13e-28	4.21e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
LUAD	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-11.87	1.14e-28	4.26e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	11.87	1.15e-28	4.3e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
LUAD	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-11.87	1.16e-28	4.33e-25	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-11.86	1.18e-28	4.41e-25	-0.77	-0.48	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
LUAD	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.2e-28	4.46e-25	-0.64	-0.48	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
LUAD	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	11.86	1.22e-28	4.52e-25	0.57	0.48	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-11.86	1.23e-28	4.59e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-11.86	1.24e-28	4.61e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	11.85	1.28e-28	4.75e-25	0.58	0.48	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
LUAD	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	11.85	1.29e-28	4.78e-25	0.68	0.48	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
LUAD	cis	rs1263173	0.566	rs4225	ENSG00000254851.1	RP11-109L13.1	-11.85	1.32e-28	4.89e-25	-0.61	-0.48	HDL cholesterol;	chr11:116832955	chr11:117135528~117138582:+
LUAD	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-11.85	1.33e-28	4.91e-25	-0.95	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
LUAD	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-11.85	1.33e-28	4.92e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
LUAD	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-11.85	1.33e-28	4.92e-25	-0.61	-0.48	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
LUAD	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-11.85	1.36e-28	5.02e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-11.84	1.4e-28	5.2e-25	-0.6	-0.48	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-11.84	1.43e-28	5.31e-25	-0.6	-0.48	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-11.84	1.43e-28	5.31e-25	-0.6	-0.48	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-11.84	1.52e-28	5.62e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
LUAD	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.56e-28	5.77e-25	-0.64	-0.47	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	11.83	1.58e-28	5.83e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
LUAD	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-11.83	1.59e-28	5.86e-25	-0.6	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
LUAD	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.59e-28	5.87e-25	-0.64	-0.47	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
LUAD	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	11.83	1.6e-28	5.88e-25	0.69	0.47	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
LUAD	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	11.83	1.6e-28	5.9e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
LUAD	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.62e-28	5.97e-25	-0.64	-0.47	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.62e-28	5.97e-25	-0.64	-0.47	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.62e-28	5.97e-25	-0.64	-0.47	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
LUAD	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	11.83	1.63e-28	6e-25	0.6	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	11.83	1.63e-28	6e-25	0.6	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
LUAD	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-11.83	1.63e-28	6e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	11.83	1.68e-28	6.17e-25	0.55	0.47	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
LUAD	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	11.82	1.71e-28	6.28e-25	0.7	0.47	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	11.82	1.71e-28	6.28e-25	0.7	0.47	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
LUAD	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-11.82	1.73e-28	6.36e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-11.82	1.75e-28	6.42e-25	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-11.82	1.76e-28	6.45e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-11.82	1.8e-28	6.59e-25	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-11.82	1.81e-28	6.62e-25	-0.64	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
LUAD	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	11.82	1.82e-28	6.67e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	11.82	1.82e-28	6.68e-25	0.55	0.47	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
LUAD	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	11.82	1.84e-28	6.73e-25	0.67	0.47	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
LUAD	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	11.81	1.89e-28	6.91e-25	0.6	0.47	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
LUAD	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
LUAD	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-11.81	1.95e-28	7.12e-25	-0.6	-0.47	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
LUAD	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-11.81	1.96e-28	7.15e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
LUAD	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-11.81	1.96e-28	7.16e-25	-0.63	-0.47	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-11.81	1.96e-28	7.16e-25	-0.63	-0.47	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
LUAD	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	11.81	1.96e-28	7.16e-25	0.7	0.47	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	11.81	1.96e-28	7.16e-25	0.7	0.47	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
LUAD	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-11.81	1.97e-28	7.19e-25	-0.51	-0.47	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
LUAD	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-11.81	1.99e-28	7.28e-25	-0.6	-0.47	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-11.81	1.99e-28	7.28e-25	-0.6	-0.47	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-11.8	2.03e-28	7.41e-25	-0.64	-0.47	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	11.8	2.03e-28	7.42e-25	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
LUAD	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	11.8	2.07e-28	7.57e-25	0.6	0.47	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	11.8	2.1e-28	7.67e-25	0.64	0.47	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
LUAD	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	11.8	2.12e-28	7.71e-25	0.65	0.47	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-11.8	2.19e-28	7.96e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-11.8	2.2e-28	7.99e-25	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
LUAD	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-11.79	2.36e-28	8.59e-25	-0.58	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	11.79	2.38e-28	8.63e-25	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
LUAD	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	11.79	2.4e-28	8.7e-25	0.53	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
LUAD	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	11.79	2.41e-28	8.74e-25	0.58	0.47	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-11.79	2.43e-28	8.82e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	11.78	2.46e-28	8.93e-25	0.6	0.47	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	11.78	2.48e-28	9.01e-25	0.48	0.47	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
LUAD	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	11.78	2.49e-28	9.05e-25	0.59	0.47	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	11.78	2.5e-28	9.06e-25	0.59	0.47	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	11.78	2.5e-28	9.06e-25	0.59	0.47	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
LUAD	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.5e-28	9.07e-25	-0.58	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
LUAD	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-11.78	2.5e-28	9.08e-25	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	11.78	2.56e-28	9.26e-25	0.62	0.47	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	11.78	2.56e-28	9.28e-25	0.63	0.47	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
LUAD	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-11.78	2.58e-28	9.33e-25	-0.6	-0.47	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-11.78	2.58e-28	9.33e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	11.78	2.59e-28	9.36e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-11.78	2.6e-28	9.41e-25	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-11.78	2.63e-28	9.51e-25	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-11.78	2.63e-28	9.53e-25	-0.6	-0.47	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	11.77	2.68e-28	9.67e-25	0.63	0.47	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	11.77	2.69e-28	9.71e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
LUAD	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	11.77	2.69e-28	9.72e-25	0.68	0.47	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
LUAD	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-11.77	2.87e-28	1.04e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
LUAD	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	11.77	2.87e-28	1.04e-24	0.59	0.47	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000211970.3	IGHV4-61	-11.77	2.88e-28	1.04e-24	-0.37	-0.47	Kawasaki disease;	chr14:106637576	chr14:106639119~106639657:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-11.77	2.88e-28	1.04e-24	-0.57	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
LUAD	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	11.77	2.93e-28	1.05e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	11.77	2.93e-28	1.05e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	11.77	2.93e-28	1.05e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-11.76	2.93e-28	1.06e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-11.76	2.93e-28	1.06e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
LUAD	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-11.76	2.95e-28	1.06e-24	-0.63	-0.47	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-11.76	2.95e-28	1.06e-24	-0.63	-0.47	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-11.76	2.99e-28	1.08e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
LUAD	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	11.76	3.1e-28	1.11e-24	0.66	0.47	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
LUAD	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-11.76	3.15e-28	1.13e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	11.75	3.23e-28	1.16e-24	0.6	0.47	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
LUAD	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	11.75	3.26e-28	1.17e-24	0.57	0.47	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
LUAD	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-11.75	3.33e-28	1.2e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
LUAD	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	11.75	3.34e-28	1.2e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
LUAD	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-11.75	3.37e-28	1.21e-24	-0.48	-0.47	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-11.75	3.37e-28	1.21e-24	-0.48	-0.47	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-11.75	3.37e-28	1.21e-24	-0.48	-0.47	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
LUAD	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-11.75	3.37e-28	1.21e-24	-0.48	-0.47	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
LUAD	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-11.75	3.4e-28	1.22e-24	-0.52	-0.47	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
LUAD	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	11.75	3.45e-28	1.24e-24	0.6	0.47	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
LUAD	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-11.75	3.45e-28	1.24e-24	-0.63	-0.47	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	11.75	3.46e-28	1.24e-24	0.59	0.47	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	11.75	3.49e-28	1.25e-24	0.57	0.47	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
LUAD	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-11.74	3.71e-28	1.33e-24	-0.6	-0.47	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
LUAD	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	11.74	3.75e-28	1.34e-24	0.59	0.47	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-11.74	3.79e-28	1.35e-24	-0.48	-0.47	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
LUAD	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	11.74	3.82e-28	1.37e-24	0.67	0.47	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
LUAD	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-11.73	3.94e-28	1.41e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	11.73	3.94e-28	1.41e-24	0.56	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
LUAD	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	11.73	3.95e-28	1.41e-24	0.59	0.47	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
LUAD	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-11.73	4.03e-28	1.44e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
LUAD	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-11.73	4.08e-28	1.45e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
LUAD	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-11.73	4.18e-28	1.49e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-11.73	4.18e-28	1.49e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	11.73	4.18e-28	1.49e-24	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
LUAD	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	11.72	4.24e-28	1.51e-24	0.69	0.47	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
LUAD	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-11.72	4.27e-28	1.52e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-11.72	4.36e-28	1.55e-24	-0.53	-0.47	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
LUAD	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	11.72	4.41e-28	1.57e-24	0.65	0.47	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
LUAD	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	11.72	4.43e-28	1.57e-24	0.69	0.47	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-11.72	4.47e-28	1.59e-24	-0.59	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
LUAD	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	11.72	4.51e-28	1.6e-24	0.58	0.47	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
LUAD	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	11.72	4.51e-28	1.6e-24	0.68	0.47	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	11.72	4.51e-28	1.6e-24	0.68	0.47	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	11.72	4.51e-28	1.6e-24	0.68	0.47	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
LUAD	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-11.72	4.58e-28	1.63e-24	-0.8	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
LUAD	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-11.72	4.62e-28	1.64e-24	-0.63	-0.47	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-11.72	4.62e-28	1.64e-24	-0.63	-0.47	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
LUAD	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	11.72	4.64e-28	1.64e-24	0.58	0.47	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	11.71	4.65e-28	1.65e-24	0.58	0.47	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
LUAD	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	11.71	4.7e-28	1.66e-24	0.76	0.47	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-11.71	4.74e-28	1.68e-24	-0.48	-0.47	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	11.71	4.85e-28	1.72e-24	0.57	0.47	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	11.71	5e-28	1.77e-24	0.64	0.47	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	11.71	5.01e-28	1.77e-24	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	11.71	5.03e-28	1.78e-24	0.53	0.47	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
LUAD	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	11.71	5.03e-28	1.78e-24	0.59	0.47	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	11.71	5.03e-28	1.78e-24	0.59	0.47	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	11.71	5.03e-28	1.78e-24	0.59	0.47	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
LUAD	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	11.7	5.17e-28	1.82e-24	0.66	0.47	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
LUAD	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-11.7	5.2e-28	1.83e-24	-0.48	-0.47	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-11.7	5.2e-28	1.83e-24	-0.48	-0.47	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	11.7	5.28e-28	1.86e-24	0.56	0.47	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	11.7	5.28e-28	1.86e-24	0.56	0.47	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
LUAD	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	11.7	5.28e-28	1.86e-24	0.56	0.47	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
LUAD	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-11.7	5.28e-28	1.86e-24	-0.66	-0.47	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
LUAD	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	11.7	5.28e-28	1.86e-24	0.6	0.47	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
LUAD	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	11.7	5.31e-28	1.87e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	11.7	5.31e-28	1.87e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	11.7	5.32e-28	1.88e-24	0.6	0.47	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	11.7	5.37e-28	1.89e-24	0.65	0.47	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	11.7	5.4e-28	1.9e-24	0.59	0.47	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	11.7	5.51e-28	1.94e-24	0.59	0.47	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
LUAD	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-11.7	5.56e-28	1.96e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
LUAD	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-11.69	5.64e-28	1.99e-24	-0.6	-0.47	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-11.69	5.74e-28	2.02e-24	-0.66	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
LUAD	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-11.69	5.76e-28	2.02e-24	-0.63	-0.47	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
LUAD	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	11.69	5.89e-28	2.07e-24	0.59	0.47	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	11.69	5.89e-28	2.07e-24	0.59	0.47	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
LUAD	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-11.69	5.89e-28	2.07e-24	-0.58	-0.47	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
LUAD	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	11.69	5.93e-28	2.08e-24	0.59	0.47	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
LUAD	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	11.69	6e-28	2.1e-24	0.76	0.47	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
LUAD	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-11.69	6.02e-28	2.11e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	11.69	6.02e-28	2.11e-24	0.58	0.47	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
LUAD	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	11.69	6.08e-28	2.13e-24	0.68	0.47	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
LUAD	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	11.68	6.19e-28	2.17e-24	0.56	0.47	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
LUAD	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-11.68	6.54e-28	2.29e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-11.68	6.54e-28	2.29e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
LUAD	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-11.67	6.74e-28	2.36e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	11.67	6.78e-28	2.37e-24	0.71	0.47	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
LUAD	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-11.67	6.94e-28	2.42e-24	-0.63	-0.47	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
LUAD	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	11.67	6.99e-28	2.44e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
LUAD	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-11.67	7.07e-28	2.47e-24	-0.59	-0.47	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
LUAD	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.13e-28	2.49e-24	-0.63	-0.47	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
LUAD	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-11.67	7.27e-28	2.54e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
LUAD	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	11.66	7.36e-28	2.56e-24	0.56	0.47	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	11.66	7.36e-28	2.56e-24	0.56	0.47	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-11.66	7.43e-28	2.59e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-11.66	7.43e-28	2.59e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-11.66	7.46e-28	2.6e-24	-0.83	-0.47	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
LUAD	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-11.66	7.5e-28	2.61e-24	-0.58	-0.47	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
LUAD	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	11.66	7.53e-28	2.62e-24	0.57	0.47	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
LUAD	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-11.66	7.79e-28	2.71e-24	-0.5	-0.47	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
LUAD	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	11.66	7.97e-28	2.77e-24	0.5	0.47	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
LUAD	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-11.66	8.01e-28	2.78e-24	-0.65	-0.47	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
LUAD	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	11.65	8.16e-28	2.84e-24	0.48	0.47	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
LUAD	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	11.65	8.19e-28	2.85e-24	0.6	0.47	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	11.65	8.23e-28	2.86e-24	0.59	0.47	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	11.65	8.37e-28	2.91e-24	0.6	0.47	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-11.65	8.58e-28	2.98e-24	-0.37	-0.47	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
LUAD	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-11.64	9.02e-28	3.13e-24	-0.6	-0.47	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
LUAD	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	11.64	9.03e-28	3.13e-24	0.57	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
LUAD	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	11.64	9.22e-28	3.19e-24	0.59	0.47	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
LUAD	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	11.64	9.37e-28	3.25e-24	0.88	0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
LUAD	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	11.64	9.42e-28	3.26e-24	0.59	0.47	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
LUAD	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-11.64	9.46e-28	3.27e-24	-0.62	-0.47	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	11.64	9.51e-28	3.29e-24	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
LUAD	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-11.63	9.8e-28	3.39e-24	-0.59	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
LUAD	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	11.63	9.8e-28	3.39e-24	0.67	0.47	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-11.63	9.88e-28	3.42e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-11.63	1e-27	3.47e-24	-0.6	-0.47	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
LUAD	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	11.63	1.01e-27	3.48e-24	0.6	0.47	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-11.63	1.02e-27	3.54e-24	-0.58	-0.47	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-11.63	1.03e-27	3.55e-24	-0.55	-0.47	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
LUAD	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-11.63	1.03e-27	3.56e-24	-0.58	-0.47	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
LUAD	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	11.63	1.03e-27	3.57e-24	0.59	0.47	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
LUAD	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	11.63	1.04e-27	3.6e-24	0.56	0.47	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-11.63	1.05e-27	3.63e-24	-0.57	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
LUAD	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	11.63	1.06e-27	3.65e-24	0.56	0.47	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
LUAD	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	11.62	1.08e-27	3.71e-24	0.56	0.47	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-11.62	1.08e-27	3.72e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
LUAD	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-11.62	1.08e-27	3.74e-24	-0.62	-0.47	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
LUAD	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-11.62	1.13e-27	3.88e-24	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-11.62	1.13e-27	3.88e-24	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
LUAD	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-11.62	1.14e-27	3.92e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
LUAD	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-11.61	1.16e-27	4e-24	-0.7	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
LUAD	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-11.61	1.17e-27	4.04e-24	-0.48	-0.47	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	11.61	1.22e-27	4.21e-24	0.59	0.47	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-11.61	1.24e-27	4.26e-24	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
LUAD	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-11.61	1.27e-27	4.35e-24	-0.56	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
LUAD	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	11.6	1.28e-27	4.4e-24	0.67	0.47	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	11.6	1.28e-27	4.4e-24	0.67	0.47	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	11.6	1.28e-27	4.4e-24	0.67	0.47	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
LUAD	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-11.6	1.3e-27	4.46e-24	-0.83	-0.47	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-11.6	1.3e-27	4.46e-24	-0.83	-0.47	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
LUAD	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	11.6	1.31e-27	4.49e-24	0.47	0.47	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-11.6	1.37e-27	4.69e-24	-0.6	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
LUAD	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-11.6	1.38e-27	4.72e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	11.6	1.39e-27	4.75e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	11.6	1.39e-27	4.75e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-11.6	1.39e-27	4.77e-24	-0.68	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
LUAD	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-11.59	1.45e-27	4.95e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
LUAD	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	11.59	1.49e-27	5.08e-24	0.67	0.47	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
LUAD	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-11.59	1.52e-27	5.2e-24	-0.53	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
LUAD	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-11.58	1.57e-27	5.35e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-11.58	1.57e-27	5.35e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
LUAD	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-11.58	1.62e-27	5.53e-24	-0.5	-0.47	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
LUAD	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-11.58	1.67e-27	5.69e-24	-0.58	-0.47	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
LUAD	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
LUAD	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	11.57	1.76e-27	5.97e-24	0.64	0.47	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-11.57	1.76e-27	5.98e-24	-0.66	-0.47	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
LUAD	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-11.57	1.78e-27	6.07e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-11.57	1.81e-27	6.16e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
LUAD	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-11.57	1.81e-27	6.16e-24	-0.58	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
LUAD	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-11.57	1.81e-27	6.16e-24	-0.58	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
LUAD	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-11.57	1.81e-27	6.16e-24	-0.58	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	11.56	1.83e-27	6.23e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
LUAD	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	11.56	1.85e-27	6.29e-24	0.69	0.47	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
LUAD	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	11.56	1.88e-27	6.38e-24	0.62	0.47	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
LUAD	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	11.56	1.9e-27	6.44e-24	0.6	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
LUAD	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	11.56	1.9e-27	6.44e-24	0.57	0.47	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	11.56	1.91e-27	6.48e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	11.56	1.93e-27	6.55e-24	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
LUAD	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	11.56	1.94e-27	6.58e-24	0.67	0.47	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-11.56	1.99e-27	6.73e-24	-0.65	-0.47	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-11.56	1.99e-27	6.74e-24	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-11.56	2e-27	6.77e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
LUAD	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	11.55	2.03e-27	6.86e-24	0.56	0.47	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
LUAD	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	11.55	2.05e-27	6.94e-24	0.72	0.47	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
LUAD	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-11.55	2.06e-27	6.96e-24	-0.59	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	11.55	2.14e-27	7.21e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
LUAD	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	11.55	2.16e-27	7.3e-24	0.59	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
LUAD	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	11.55	2.18e-27	7.34e-24	0.44	0.47	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
LUAD	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-11.55	2.19e-27	7.4e-24	-0.65	-0.47	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
LUAD	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-11.54	2.23e-27	7.5e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
LUAD	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-11.54	2.25e-27	7.57e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	11.54	2.25e-27	7.59e-24	0.52	0.47	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	11.54	2.25e-27	7.59e-24	0.52	0.47	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	11.54	2.26e-27	7.62e-24	0.62	0.47	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
LUAD	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-11.54	2.28e-27	7.66e-24	-0.56	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-11.54	2.28e-27	7.66e-24	-0.56	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-11.54	2.3e-27	7.74e-24	-0.56	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	11.54	2.36e-27	7.92e-24	0.65	0.47	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	11.53	2.41e-27	8.1e-24	0.56	0.47	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
LUAD	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	11.53	2.46e-27	8.28e-24	0.54	0.47	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
LUAD	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	11.52	2.68e-27	8.99e-24	0.59	0.47	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
LUAD	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	11.52	2.81e-27	9.39e-24	0.59	0.46	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	11.52	2.82e-27	9.43e-24	0.57	0.46	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-11.52	2.82e-27	9.45e-24	-0.64	-0.46	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-11.51	3.01e-27	1.01e-23	-0.59	-0.46	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000223648.3	IGHV3-64	11.51	3.11e-27	1.04e-23	0.47	0.46	Kawasaki disease;	chr14:106637576	chr14:106643132~106658258:-
LUAD	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	11.5	3.17e-27	1.06e-23	0.67	0.46	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
LUAD	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-11.5	3.25e-27	1.08e-23	-0.56	-0.46	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	11.5	3.27e-27	1.09e-23	0.57	0.46	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-11.5	3.28e-27	1.09e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-11.5	3.28e-27	1.09e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-11.5	3.28e-27	1.09e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000223648.3	IGHV3-64	11.5	3.28e-27	1.09e-23	0.46	0.46	Kawasaki disease;	chr14:106649820	chr14:106643132~106658258:-
LUAD	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
LUAD	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	11.5	3.29e-27	1.1e-23	0.59	0.46	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	11.5	3.29e-27	1.1e-23	0.59	0.46	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	11.5	3.34e-27	1.11e-23	0.71	0.46	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	11.5	3.34e-27	1.11e-23	0.71	0.46	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
LUAD	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	11.5	3.37e-27	1.12e-23	0.6	0.46	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
LUAD	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	11.5	3.38e-27	1.13e-23	0.59	0.46	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
LUAD	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-11.5	3.39e-27	1.13e-23	-0.52	-0.46	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
LUAD	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-11.5	3.45e-27	1.15e-23	-0.57	-0.46	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
LUAD	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	11.49	3.51e-27	1.17e-23	0.64	0.46	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
LUAD	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	11.49	3.59e-27	1.19e-23	0.48	0.46	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
LUAD	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-11.49	3.63e-27	1.2e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
LUAD	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	11.49	3.65e-27	1.21e-23	0.57	0.46	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
LUAD	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	11.49	3.66e-27	1.22e-23	0.41	0.46	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
LUAD	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	11.49	3.74e-27	1.24e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	11.49	3.74e-27	1.24e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
LUAD	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	11.48	3.8e-27	1.26e-23	0.59	0.46	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	11.48	3.8e-27	1.26e-23	0.59	0.46	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-11.48	3.81e-27	1.26e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-11.48	3.81e-27	1.26e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-11.48	3.92e-27	1.3e-23	-0.75	-0.46	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
LUAD	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	11.48	3.93e-27	1.3e-23	0.57	0.46	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	11.48	3.96e-27	1.31e-23	0.44	0.46	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
LUAD	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	11.48	4.11e-27	1.36e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
LUAD	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	11.48	4.15e-27	1.37e-23	0.56	0.46	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
LUAD	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	11.47	4.18e-27	1.38e-23	0.59	0.46	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
LUAD	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	11.47	4.24e-27	1.4e-23	0.67	0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
LUAD	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	11.47	4.33e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
LUAD	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	11.47	4.43e-27	1.46e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
LUAD	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-11.47	4.43e-27	1.46e-23	-0.47	-0.46	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
LUAD	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	11.47	4.46e-27	1.47e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
LUAD	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	11.46	4.58e-27	1.51e-23	0.54	0.46	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
LUAD	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-11.46	4.58e-27	1.51e-23	-0.56	-0.46	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
LUAD	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-11.46	4.68e-27	1.54e-23	-0.59	-0.46	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	11.45	5e-27	1.64e-23	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
LUAD	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-11.45	5.16e-27	1.7e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
LUAD	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-11.45	5.24e-27	1.72e-23	-0.7	-0.46	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
LUAD	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-11.45	5.3e-27	1.74e-23	-0.57	-0.46	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
LUAD	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-11.45	5.32e-27	1.75e-23	-0.62	-0.46	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
LUAD	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-11.45	5.41e-27	1.78e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
LUAD	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	11.44	5.46e-27	1.79e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	11.44	5.46e-27	1.79e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	11.44	5.5e-27	1.81e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
LUAD	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	11.44	5.55e-27	1.82e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	11.44	5.55e-27	1.82e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	11.44	5.55e-27	1.82e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	11.44	5.55e-27	1.82e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
LUAD	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	11.44	5.68e-27	1.86e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	11.44	5.68e-27	1.86e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	11.44	5.68e-27	1.86e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	11.44	5.68e-27	1.86e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
LUAD	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	11.44	5.79e-27	1.9e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
LUAD	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	11.44	5.91e-27	1.93e-23	0.54	0.46	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
LUAD	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-11.44	5.92e-27	1.94e-23	-0.58	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
LUAD	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	11.44	5.96e-27	1.95e-23	0.59	0.46	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
LUAD	cis	rs904251	0.828	rs1757178	ENSG00000279942.1	RP1-153P14.7	11.44	5.97e-27	1.95e-23	0.44	0.46	Cognitive performance;	chr6:37518534	chr6:37567716~37571460:+
LUAD	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-11.43	6e-27	1.96e-23	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	11.43	6.09e-27	1.99e-23	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
LUAD	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-11.43	6.1e-27	1.99e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	11.42	6.71e-27	2.19e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	11.42	6.71e-27	2.19e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	11.42	6.71e-27	2.19e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	11.42	6.9e-27	2.25e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	11.42	6.9e-27	2.25e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.861	rs1776456	ENSG00000279942.1	RP1-153P14.7	-11.42	6.92e-27	2.26e-23	-0.44	-0.46	Cognitive performance;	chr6:37516922	chr6:37567716~37571460:+
LUAD	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	11.42	7.01e-27	2.28e-23	0.62	0.46	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
LUAD	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-11.41	7.19e-27	2.34e-23	-0.58	-0.46	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
LUAD	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-11.41	7.26e-27	2.36e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
LUAD	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	11.41	7.26e-27	2.36e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
LUAD	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-11.41	7.42e-27	2.41e-23	-0.58	-0.46	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-11.41	7.42e-27	2.41e-23	-0.58	-0.46	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
LUAD	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	11.41	7.5e-27	2.44e-23	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	11.41	7.5e-27	2.44e-23	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
LUAD	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-11.41	7.53e-27	2.44e-23	-0.53	-0.46	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
LUAD	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	11.41	7.63e-27	2.47e-23	0.57	0.46	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
LUAD	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	11.41	7.77e-27	2.52e-23	0.75	0.46	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
LUAD	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-11.41	7.81e-27	2.53e-23	-0.63	-0.46	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
LUAD	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	11.4	7.93e-27	2.57e-23	0.59	0.46	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
LUAD	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-11.4	8.5e-27	2.75e-23	-0.61	-0.46	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	11.4	8.53e-27	2.76e-23	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
LUAD	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-11.4	8.54e-27	2.76e-23	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-11.39	8.9e-27	2.87e-23	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	11.39	8.98e-27	2.89e-23	0.59	0.46	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	11.39	8.98e-27	2.89e-23	0.59	0.46	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-11.38	9.47e-27	3.05e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
LUAD	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	11.38	9.56e-27	3.08e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	11.38	9.72e-27	3.13e-23	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
LUAD	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	11.38	9.8e-27	3.15e-23	0.58	0.46	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
LUAD	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-11.38	1.02e-26	3.29e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
LUAD	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	11.37	1.05e-26	3.38e-23	0.66	0.46	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
LUAD	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	11.37	1.06e-26	3.39e-23	0.59	0.46	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	11.37	1.06e-26	3.39e-23	0.59	0.46	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-11.37	1.07e-26	3.42e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	11.37	1.08e-26	3.46e-23	0.59	0.46	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-11.36	1.15e-26	3.7e-23	-0.66	-0.46	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-11.36	1.17e-26	3.75e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
LUAD	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	11.36	1.21e-26	3.87e-23	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
LUAD	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	11.36	1.22e-26	3.9e-23	0.67	0.46	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
LUAD	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	11.36	1.23e-26	3.93e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
LUAD	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-11.35	1.23e-26	3.94e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-11.35	1.27e-26	4.04e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-11.35	1.27e-26	4.04e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
LUAD	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-11.35	1.28e-26	4.09e-23	-0.7	-0.46	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
LUAD	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	11.35	1.31e-26	4.18e-23	0.64	0.46	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-11.35	1.32e-26	4.21e-23	-0.51	-0.46	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
LUAD	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-11.35	1.33e-26	4.25e-23	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
LUAD	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-11.35	1.34e-26	4.27e-23	-0.61	-0.46	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
LUAD	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	11.35	1.34e-26	4.27e-23	0.57	0.46	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
LUAD	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	11.34	1.37e-26	4.37e-23	0.56	0.46	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
LUAD	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	11.34	1.4e-26	4.45e-23	0.58	0.46	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-11.34	1.43e-26	4.54e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-11.34	1.43e-26	4.54e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-11.34	1.43e-26	4.54e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-11.34	1.43e-26	4.54e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
LUAD	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	11.34	1.43e-26	4.54e-23	0.58	0.46	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
LUAD	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-11.34	1.44e-26	4.57e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-11.34	1.44e-26	4.57e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
LUAD	cis	rs904251	0.737	rs914347	ENSG00000279942.1	RP1-153P14.7	-11.34	1.44e-26	4.57e-23	-0.43	-0.46	Cognitive performance;	chr6:37517194	chr6:37567716~37571460:+
LUAD	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-11.33	1.49e-26	4.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-11.33	1.49e-26	4.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	11.33	1.52e-26	4.8e-23	0.56	0.46	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
LUAD	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-11.33	1.53e-26	4.85e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-11.33	1.53e-26	4.85e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-11.33	1.56e-26	4.94e-23	-0.73	-0.46	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	11.33	1.57e-26	4.95e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
LUAD	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	11.33	1.57e-26	4.97e-23	0.64	0.46	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
LUAD	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-11.33	1.57e-26	4.97e-23	-0.77	-0.46	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
LUAD	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	11.33	1.58e-26	4.98e-23	0.59	0.46	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	11.33	1.58e-26	4.98e-23	0.59	0.46	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	11.33	1.58e-26	4.98e-23	0.59	0.46	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-11.33	1.58e-26	5e-23	-0.64	-0.46	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	11.33	1.59e-26	5.01e-23	0.56	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
LUAD	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
LUAD	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	11.32	1.66e-26	5.24e-23	0.52	0.46	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
LUAD	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	11.32	1.69e-26	5.32e-23	0.51	0.46	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	11.32	1.69e-26	5.33e-23	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
LUAD	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	11.32	1.73e-26	5.44e-23	0.47	0.46	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
LUAD	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
LUAD	cis	rs3091242	0.806	rs35189848	ENSG00000224183.1	SDHDP6	11.31	1.77e-26	5.57e-23	0.59	0.46	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.836	rs35346083	ENSG00000224183.1	SDHDP6	11.31	1.77e-26	5.57e-23	0.59	0.46	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25294164~25294643:-
LUAD	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	11.31	1.79e-26	5.62e-23	0.55	0.46	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
LUAD	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	11.31	1.83e-26	5.76e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	11.31	1.84e-26	5.79e-23	0.56	0.46	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	11.31	1.84e-26	5.79e-23	0.56	0.46	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	11.31	1.88e-26	5.89e-23	0.47	0.46	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
LUAD	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-11.3	1.93e-26	6.06e-23	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
LUAD	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-11.3	1.94e-26	6.08e-23	-0.56	-0.46	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-11.3	1.94e-26	6.08e-23	-0.56	-0.46	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-11.3	1.94e-26	6.08e-23	-0.56	-0.46	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-11.3	1.94e-26	6.08e-23	-0.56	-0.46	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
LUAD	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	11.3	1.94e-26	6.09e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	11.3	1.94e-26	6.09e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	11.3	1.94e-26	6.09e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	11.3	1.94e-26	6.09e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
LUAD	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	11.3	2e-26	6.27e-23	0.54	0.46	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
LUAD	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-11.3	2.01e-26	6.28e-23	-0.56	-0.46	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
LUAD	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-11.3	2.03e-26	6.36e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-11.3	2.03e-26	6.36e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-11.3	2.03e-26	6.36e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
LUAD	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-11.3	2.05e-26	6.4e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-11.3	2.05e-26	6.4e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
LUAD	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	11.3	2.07e-26	6.48e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
LUAD	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-11.3	2.1e-26	6.56e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
LUAD	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-11.3	2.1e-26	6.57e-23	-0.58	-0.46	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
LUAD	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-11.3	2.1e-26	6.57e-23	-0.64	-0.46	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-11.3	2.11e-26	6.59e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-11.3	2.11e-26	6.59e-23	-0.49	-0.46	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
LUAD	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-11.29	2.16e-26	6.75e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-11.29	2.16e-26	6.75e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
LUAD	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	11.29	2.17e-26	6.77e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
LUAD	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	11.29	2.25e-26	7.01e-23	0.58	0.46	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
LUAD	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	11.29	2.28e-26	7.11e-23	0.47	0.46	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	11.29	2.29e-26	7.13e-23	0.56	0.46	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
LUAD	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	11.28	2.34e-26	7.28e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
LUAD	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	11.28	2.35e-26	7.32e-23	0.53	0.46	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
LUAD	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	11.28	2.37e-26	7.37e-23	0.55	0.46	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	11.28	2.37e-26	7.37e-23	0.55	0.46	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	11.28	2.37e-26	7.37e-23	0.55	0.46	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-11.28	2.43e-26	7.56e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-11.28	2.43e-26	7.57e-23	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
LUAD	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	11.28	2.48e-26	7.7e-23	0.47	0.46	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
LUAD	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	11.28	2.48e-26	7.71e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
LUAD	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	11.28	2.5e-26	7.78e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-11.27	2.54e-26	7.89e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-11.27	2.55e-26	7.91e-23	-0.52	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
LUAD	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-11.27	2.56e-26	7.93e-23	-0.64	-0.46	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
LUAD	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	11.27	2.59e-26	8.02e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
LUAD	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	11.27	2.74e-26	8.49e-23	0.71	0.46	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
LUAD	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-11.27	2.76e-26	8.54e-23	-0.58	-0.46	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
LUAD	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-11.26	2.79e-26	8.63e-23	-0.58	-0.46	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
LUAD	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	11.26	2.89e-26	8.94e-23	0.55	0.46	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
LUAD	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	11.26	2.94e-26	9.08e-23	0.56	0.46	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
LUAD	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	11.26	2.94e-26	9.08e-23	0.56	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-11.26	2.96e-26	9.14e-23	-0.58	-0.46	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-11.26	2.96e-26	9.14e-23	-0.58	-0.46	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-11.25	3.12e-26	9.63e-23	-0.64	-0.46	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
LUAD	cis	rs904251	0.797	rs1776460	ENSG00000279942.1	RP1-153P14.7	-11.25	3.14e-26	9.68e-23	-0.43	-0.46	Cognitive performance;	chr6:37517708	chr6:37567716~37571460:+
LUAD	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
LUAD	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-11.25	3.15e-26	9.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-11.25	3.15e-26	9.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-11.25	3.15e-26	9.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
LUAD	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	11.25	3.16e-26	9.74e-23	0.53	0.46	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
LUAD	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	11.25	3.23e-26	9.93e-23	0.56	0.46	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
LUAD	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	11.25	3.25e-26	1e-22	0.47	0.46	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
LUAD	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-11.24	3.32e-26	1.02e-22	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	11.24	3.33e-26	1.02e-22	0.55	0.46	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
LUAD	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	11.24	3.61e-26	1.11e-22	0.54	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
LUAD	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-11.23	3.68e-26	1.13e-22	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000211970.3	IGHV4-61	-11.23	3.72e-26	1.14e-22	-0.36	-0.46	Kawasaki disease;	chr14:106649820	chr14:106639119~106639657:-
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-11.23	3.74e-26	1.15e-22	-0.63	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	11.23	3.77e-26	1.16e-22	0.56	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
LUAD	cis	rs2658782	0.547	rs2085334	ENSG00000279684.1	RP11-755E23.2	-11.23	3.78e-26	1.16e-22	-0.63	-0.46	Pulmonary function decline;	chr11:93447884	chr11:93286629~93288903:-
LUAD	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-11.23	3.83e-26	1.17e-22	-0.47	-0.46	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
LUAD	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	11.23	3.86e-26	1.18e-22	0.51	0.46	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
LUAD	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	11.23	3.9e-26	1.19e-22	0.58	0.46	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	11.23	3.91e-26	1.2e-22	0.56	0.46	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
LUAD	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	11.23	3.92e-26	1.2e-22	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	11.22	3.96e-26	1.21e-22	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
LUAD	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	11.22	3.97e-26	1.21e-22	0.56	0.46	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
LUAD	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	11.22	3.99e-26	1.22e-22	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	11.22	3.99e-26	1.22e-22	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
LUAD	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	11.22	4e-26	1.22e-22	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	11.22	4.01e-26	1.23e-22	0.55	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
LUAD	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	11.22	4.03e-26	1.23e-22	0.55	0.46	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	11.22	4.03e-26	1.23e-22	0.55	0.46	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	11.22	4.03e-26	1.23e-22	0.55	0.46	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	11.22	4.03e-26	1.23e-22	0.56	0.46	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
LUAD	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	11.22	4.07e-26	1.24e-22	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	11.22	4.07e-26	1.24e-22	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
LUAD	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	11.22	4.15e-26	1.27e-22	0.65	0.46	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
LUAD	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	11.22	4.24e-26	1.29e-22	0.55	0.46	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	11.21	4.36e-26	1.33e-22	0.47	0.46	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
LUAD	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-11.21	4.36e-26	1.33e-22	-0.55	-0.46	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
LUAD	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	11.21	4.39e-26	1.34e-22	0.64	0.46	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
LUAD	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	11.21	4.39e-26	1.34e-22	0.64	0.46	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
LUAD	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	11.21	4.39e-26	1.34e-22	0.64	0.46	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
LUAD	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	11.21	4.44e-26	1.35e-22	0.58	0.46	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	11.21	4.5e-26	1.37e-22	0.55	0.46	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
LUAD	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-11.21	4.51e-26	1.37e-22	-0.55	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
LUAD	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-11.21	4.52e-26	1.38e-22	-0.71	-0.46	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
LUAD	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	11.21	4.61e-26	1.4e-22	0.69	0.46	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
LUAD	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	11.21	4.68e-26	1.42e-22	0.52	0.46	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	11.21	4.68e-26	1.42e-22	0.52	0.46	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
LUAD	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-11.21	4.68e-26	1.42e-22	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
LUAD	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	11.21	4.72e-26	1.43e-22	0.56	0.45	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-11.2	4.77e-26	1.45e-22	-0.64	-0.45	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-11.2	4.77e-26	1.45e-22	-0.64	-0.45	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-11.2	4.77e-26	1.45e-22	-0.64	-0.45	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
LUAD	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	11.2	4.89e-26	1.49e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	11.2	4.95e-26	1.5e-22	0.55	0.45	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-11.2	5.15e-26	1.56e-22	-0.65	-0.45	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
LUAD	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-11.19	5.31e-26	1.61e-22	-0.55	-0.45	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	11.19	5.35e-26	1.62e-22	0.55	0.45	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
LUAD	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	11.19	5.36e-26	1.62e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
LUAD	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-11.19	5.36e-26	1.62e-22	-0.51	-0.45	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
LUAD	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-11.19	5.51e-26	1.67e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
LUAD	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	11.19	5.56e-26	1.68e-22	0.67	0.45	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
LUAD	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	11.18	5.71e-26	1.73e-22	0.56	0.45	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	11.18	5.86e-26	1.77e-22	0.55	0.45	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
LUAD	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	11.18	5.9e-26	1.78e-22	0.55	0.45	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-11.18	5.9e-26	1.78e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-11.18	5.9e-26	1.78e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-11.18	5.9e-26	1.78e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-11.18	5.9e-26	1.78e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
LUAD	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	11.18	5.97e-26	1.8e-22	0.6	0.45	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	11.18	6.13e-26	1.85e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
LUAD	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	11.17	6.21e-26	1.87e-22	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
LUAD	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-11.17	6.35e-26	1.91e-22	-0.63	-0.45	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	11.17	6.39e-26	1.93e-22	0.46	0.45	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
LUAD	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-11.17	6.42e-26	1.93e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	11.17	6.46e-26	1.95e-22	0.55	0.45	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-11.17	6.65e-26	2e-22	-0.62	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
LUAD	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	11.17	6.66e-26	2e-22	0.55	0.45	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
LUAD	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-11.17	6.69e-26	2.01e-22	-0.52	-0.45	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	11.17	6.69e-26	2.01e-22	0.55	0.45	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
LUAD	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	11.17	6.73e-26	2.03e-22	0.55	0.45	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
LUAD	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-11.16	6.89e-26	2.07e-22	-0.63	-0.45	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
LUAD	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	11.16	6.89e-26	2.07e-22	0.47	0.45	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
LUAD	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-11.16	6.89e-26	2.07e-22	-0.52	-0.45	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
LUAD	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-11.16	6.93e-26	2.08e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-11.16	6.93e-26	2.08e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
LUAD	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-11.16	7.03e-26	2.11e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
LUAD	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-11.16	7.06e-26	2.12e-22	-0.6	-0.45	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
LUAD	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	11.16	7.11e-26	2.13e-22	0.47	0.45	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	11.16	7.11e-26	2.13e-22	0.47	0.45	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	11.16	7.11e-26	2.13e-22	0.47	0.45	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
LUAD	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-11.16	7.22e-26	2.17e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-11.16	7.22e-26	2.17e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	11.16	7.29e-26	2.19e-22	0.55	0.45	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
LUAD	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	11.16	7.38e-26	2.21e-22	0.57	0.45	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
LUAD	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	11.15	7.44e-26	2.23e-22	0.47	0.45	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
LUAD	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-11.15	7.52e-26	2.26e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-11.15	7.52e-26	2.26e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-11.15	7.52e-26	2.26e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-11.15	7.52e-26	2.26e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-11.15	7.59e-26	2.27e-22	-0.65	-0.45	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-11.15	7.59e-26	2.27e-22	-0.65	-0.45	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-11.15	7.59e-26	2.27e-22	-0.65	-0.45	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	11.15	7.63e-26	2.29e-22	0.58	0.45	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
LUAD	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	11.15	7.65e-26	2.29e-22	0.59	0.45	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
LUAD	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	11.15	7.67e-26	2.3e-22	0.53	0.45	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-11.15	7.68e-26	2.3e-22	-0.51	-0.45	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	11.15	7.7e-26	2.31e-22	0.55	0.45	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	11.15	7.7e-26	2.31e-22	0.55	0.45	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	11.15	7.7e-26	2.31e-22	0.55	0.45	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	11.15	7.82e-26	2.34e-22	0.55	0.45	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	11.15	7.82e-26	2.34e-22	0.55	0.45	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	11.15	7.82e-26	2.34e-22	0.55	0.45	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
LUAD	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-11.15	7.85e-26	2.35e-22	-0.56	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
LUAD	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-11.15	8.08e-26	2.42e-22	-0.5	-0.45	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
LUAD	cis	rs992157	0.644	rs6741757	ENSG00000261338.2	RP11-378A13.1	11.14	8.16e-26	2.44e-22	0.47	0.45	Colorectal cancer;	chr2:218318025	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	11.14	8.17e-26	2.44e-22	0.55	0.45	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	11.14	8.21e-26	2.45e-22	0.55	0.45	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	11.14	8.44e-26	2.52e-22	0.55	0.45	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
LUAD	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-11.14	8.5e-26	2.54e-22	-0.58	-0.45	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	11.14	8.53e-26	2.55e-22	0.47	0.45	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	11.14	8.62e-26	2.57e-22	0.55	0.45	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	11.14	8.62e-26	2.57e-22	0.55	0.45	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	11.14	8.65e-26	2.58e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
LUAD	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-11.14	8.71e-26	2.6e-22	-0.63	-0.45	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
LUAD	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-11.14	8.72e-26	2.6e-22	-0.58	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
LUAD	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	11.13	9.07e-26	2.7e-22	0.47	0.45	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
LUAD	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-11.13	9.13e-26	2.72e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
LUAD	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	11.13	9.57e-26	2.85e-22	0.6	0.45	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
LUAD	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	11.13	9.63e-26	2.86e-22	0.55	0.45	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	11.13	9.63e-26	2.86e-22	0.55	0.45	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	11.12	9.74e-26	2.9e-22	0.55	0.45	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
LUAD	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-11.12	9.76e-26	2.9e-22	-0.57	-0.45	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
LUAD	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	11.12	9.79e-26	2.91e-22	0.6	0.45	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
LUAD	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-11.12	9.82e-26	2.92e-22	-0.58	-0.45	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-11.12	9.83e-26	2.92e-22	-0.57	-0.45	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
LUAD	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-11.12	1e-25	2.98e-22	-0.72	-0.45	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
LUAD	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	11.12	1.02e-25	3.03e-22	0.54	0.45	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
LUAD	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-11.12	1.05e-25	3.1e-22	-0.46	-0.45	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
LUAD	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-11.12	1.05e-25	3.13e-22	-0.6	-0.45	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	11.11	1.08e-25	3.19e-22	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	11.11	1.08e-25	3.2e-22	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	11.11	1.08e-25	3.2e-22	0.54	0.45	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
LUAD	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-11.11	1.09e-25	3.23e-22	-0.51	-0.45	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
LUAD	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	11.11	1.09e-25	3.23e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
LUAD	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	11.11	1.1e-25	3.25e-22	0.59	0.45	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
LUAD	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-11.11	1.11e-25	3.3e-22	-0.69	-0.45	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
LUAD	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	11.11	1.12e-25	3.31e-22	0.69	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
LUAD	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	11.11	1.12e-25	3.31e-22	0.55	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
LUAD	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	11.11	1.12e-25	3.32e-22	0.68	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
LUAD	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-11.11	1.12e-25	3.32e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	11.11	1.13e-25	3.35e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
LUAD	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	11.11	1.14e-25	3.38e-22	0.97	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	11.11	1.14e-25	3.38e-22	0.97	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
LUAD	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	11.11	1.15e-25	3.38e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
LUAD	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	11.11	1.15e-25	3.38e-22	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
LUAD	cis	rs904251	0.861	rs1757180	ENSG00000279942.1	RP1-153P14.7	-11.1	1.16e-25	3.42e-22	-0.43	-0.45	Cognitive performance;	chr6:37518369	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-11.1	1.16e-25	3.43e-22	-0.57	-0.45	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
LUAD	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-11.1	1.16e-25	3.43e-22	-0.55	-0.45	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
LUAD	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	11.1	1.16e-25	3.43e-22	0.6	0.45	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
LUAD	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	11.1	1.16e-25	3.43e-22	0.6	0.45	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	11.1	1.16e-25	3.43e-22	0.36	0.45	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
LUAD	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	11.1	1.17e-25	3.46e-22	0.58	0.45	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	11.1	1.2e-25	3.53e-22	0.54	0.45	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	11.1	1.2e-25	3.55e-22	0.55	0.45	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	11.1	1.21e-25	3.56e-22	0.55	0.45	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
LUAD	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-11.1	1.23e-25	3.63e-22	-0.53	-0.45	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
LUAD	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	11.1	1.23e-25	3.64e-22	0.65	0.45	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
LUAD	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-11.1	1.24e-25	3.65e-22	-0.49	-0.45	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
LUAD	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	11.1	1.24e-25	3.66e-22	0.55	0.45	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	11.1	1.24e-25	3.66e-22	0.55	0.45	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
LUAD	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	11.1	1.24e-25	3.66e-22	0.54	0.45	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
LUAD	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-11.1	1.25e-25	3.67e-22	-0.58	-0.45	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
LUAD	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-11.09	1.29e-25	3.8e-22	-0.57	-0.45	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
LUAD	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-11.09	1.29e-25	3.81e-22	-0.55	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	11.09	1.31e-25	3.85e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	11.09	1.31e-25	3.85e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
LUAD	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-11.09	1.32e-25	3.88e-22	-0.58	-0.45	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
LUAD	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	11.09	1.33e-25	3.92e-22	0.66	0.45	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
LUAD	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-11.09	1.34e-25	3.93e-22	-0.59	-0.45	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
LUAD	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-11.09	1.34e-25	3.94e-22	-0.77	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
LUAD	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	11.09	1.34e-25	3.94e-22	0.47	0.45	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
LUAD	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	11.09	1.34e-25	3.94e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	11.09	1.34e-25	3.94e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	11.09	1.36e-25	4e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	11.09	1.36e-25	4e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
LUAD	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-11.09	1.36e-25	4e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
LUAD	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	11.09	1.36e-25	4.01e-22	0.69	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
LUAD	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	11.08	1.39e-25	4.09e-22	0.57	0.45	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
LUAD	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-11.08	1.4e-25	4.09e-22	-0.58	-0.45	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-11.08	1.4e-25	4.09e-22	-0.58	-0.45	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-11.08	1.42e-25	4.15e-22	-0.67	-0.45	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-11.08	1.42e-25	4.15e-22	-0.67	-0.45	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-11.08	1.42e-25	4.15e-22	-0.67	-0.45	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
LUAD	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	11.08	1.42e-25	4.16e-22	0.46	0.45	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
LUAD	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	11.08	1.44e-25	4.22e-22	0.55	0.45	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
LUAD	cis	rs1799949	0.757	rs9915489	ENSG00000198496.9	NBR2	-11.08	1.46e-25	4.27e-22	-0.48	-0.45	Menopause (age at onset);	chr17:43021209	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-11.08	1.47e-25	4.3e-22	-0.47	-0.45	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
LUAD	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	11.08	1.49e-25	4.36e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-11.07	1.51e-25	4.43e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-11.07	1.52e-25	4.44e-22	-0.57	-0.45	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-11.07	1.52e-25	4.44e-22	-0.57	-0.45	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-11.07	1.52e-25	4.44e-22	-0.57	-0.45	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-11.07	1.53e-25	4.46e-22	-0.57	-0.45	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	11.07	1.53e-25	4.48e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-11.07	1.54e-25	4.51e-22	-0.7	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
LUAD	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-11.07	1.55e-25	4.53e-22	-0.7	-0.45	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
LUAD	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.57e-25	4.58e-22	-0.62	-0.45	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	11.07	1.58e-25	4.62e-22	0.55	0.45	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	11.07	1.6e-25	4.68e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	11.07	1.61e-25	4.68e-22	0.55	0.45	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	11.07	1.61e-25	4.68e-22	0.55	0.45	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	11.07	1.61e-25	4.68e-22	0.55	0.45	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	11.07	1.61e-25	4.68e-22	0.55	0.45	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	11.07	1.62e-25	4.72e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
LUAD	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	11.07	1.64e-25	4.79e-22	0.55	0.45	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	11.07	1.64e-25	4.79e-22	0.55	0.45	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
LUAD	cis	rs6538678	0.895	rs1436124	ENSG00000199506.1	RNU6-247P	-11.07	1.64e-25	4.79e-22	-0.59	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95792529~95792635:-
LUAD	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	11.06	1.65e-25	4.82e-22	0.41	0.45	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
LUAD	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-11.06	1.66e-25	4.83e-22	-0.63	-0.45	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-11.06	1.66e-25	4.84e-22	-0.71	-0.45	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
LUAD	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	11.06	1.67e-25	4.86e-22	0.59	0.45	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	11.06	1.67e-25	4.86e-22	0.59	0.45	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	11.06	1.67e-25	4.86e-22	0.59	0.45	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
LUAD	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	11.06	1.67e-25	4.87e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	11.06	1.68e-25	4.88e-22	0.54	0.45	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	11.06	1.68e-25	4.88e-22	0.54	0.45	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
LUAD	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	11.06	1.69e-25	4.93e-22	0.62	0.45	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
LUAD	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	11.06	1.71e-25	4.98e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
LUAD	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	11.06	1.72e-25	5e-22	0.46	0.45	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	11.06	1.72e-25	5e-22	0.46	0.45	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
LUAD	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	11.06	1.73e-25	5.03e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
LUAD	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	11.06	1.73e-25	5.03e-22	0.67	0.45	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
LUAD	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	11.06	1.74e-25	5.05e-22	0.68	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
LUAD	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-11.06	1.74e-25	5.06e-22	-0.58	-0.45	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-11.06	1.74e-25	5.06e-22	-0.58	-0.45	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
LUAD	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	11.06	1.75e-25	5.07e-22	0.46	0.45	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
LUAD	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	11.06	1.77e-25	5.14e-22	0.46	0.45	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
LUAD	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	11.06	1.77e-25	5.15e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
LUAD	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-11.06	1.78e-25	5.16e-22	-0.57	-0.45	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
LUAD	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	11.06	1.79e-25	5.19e-22	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	11.06	1.79e-25	5.2e-22	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
LUAD	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	11.05	1.81e-25	5.27e-22	0.54	0.45	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	11.05	1.81e-25	5.27e-22	0.47	0.45	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
LUAD	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-11.05	1.86e-25	5.38e-22	-0.51	-0.45	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
LUAD	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-11.05	1.86e-25	5.38e-22	-0.54	-0.45	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
LUAD	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	11.05	1.87e-25	5.41e-22	0.58	0.45	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
LUAD	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	11.05	1.87e-25	5.41e-22	0.68	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
LUAD	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	11.05	1.88e-25	5.44e-22	0.46	0.45	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
LUAD	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-11.05	1.88e-25	5.46e-22	-0.57	-0.45	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-11.05	1.89e-25	5.47e-22	-0.57	-0.45	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-11.05	1.89e-25	5.47e-22	-0.57	-0.45	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-11.05	1.89e-25	5.47e-22	-0.57	-0.45	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-11.05	1.89e-25	5.48e-22	-0.58	-0.45	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-11.05	1.91e-25	5.52e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	11.05	1.91e-25	5.52e-22	0.54	0.45	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	11.05	1.91e-25	5.52e-22	0.54	0.45	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
LUAD	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	11.05	1.92e-25	5.55e-22	0.56	0.45	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
LUAD	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	11.05	1.92e-25	5.55e-22	0.58	0.45	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-11.05	1.93e-25	5.57e-22	-0.52	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
LUAD	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	11.05	1.94e-25	5.61e-22	0.61	0.45	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
LUAD	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-11.05	1.95e-25	5.64e-22	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	11.05	1.97e-25	5.69e-22	0.54	0.45	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	11.04	2e-25	5.77e-22	0.46	0.45	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
LUAD	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-11.04	2.04e-25	5.9e-22	-0.58	-0.45	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-11.04	2.05e-25	5.93e-22	-0.54	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
LUAD	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	11.04	2.05e-25	5.93e-22	0.55	0.45	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
LUAD	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	11.04	2.06e-25	5.94e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
LUAD	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-11.04	2.06e-25	5.96e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-11.04	2.08e-25	6.01e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-11.04	2.09e-25	6.03e-22	-0.52	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
LUAD	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	11.04	2.11e-25	6.07e-22	0.59	0.45	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	11.04	2.11e-25	6.07e-22	0.59	0.45	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
LUAD	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	11.04	2.12e-25	6.1e-22	0.68	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
LUAD	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	11.04	2.13e-25	6.14e-22	0.42	0.45	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
LUAD	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-11.03	2.17e-25	6.26e-22	-0.55	-0.45	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
LUAD	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	11.03	2.18e-25	6.27e-22	0.59	0.45	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
LUAD	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	11.03	2.27e-25	6.53e-22	0.61	0.45	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	11.03	2.28e-25	6.56e-22	0.54	0.45	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	11.03	2.28e-25	6.56e-22	0.54	0.45	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	11.03	2.28e-25	6.56e-22	0.54	0.45	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	11.03	2.28e-25	6.56e-22	0.54	0.45	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	11.03	2.29e-25	6.59e-22	0.47	0.45	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	11.03	2.31e-25	6.64e-22	0.55	0.45	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
LUAD	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-11.03	2.33e-25	6.69e-22	-0.5	-0.45	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
LUAD	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-11.02	2.37e-25	6.79e-22	-0.59	-0.45	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	11.02	2.39e-25	6.86e-22	0.54	0.45	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
LUAD	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-11.02	2.4e-25	6.87e-22	-0.58	-0.45	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	11.02	2.44e-25	6.99e-22	0.54	0.45	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
LUAD	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	11.02	2.46e-25	7.04e-22	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
LUAD	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	11.02	2.46e-25	7.04e-22	0.47	0.45	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
LUAD	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-11.02	2.5e-25	7.15e-22	-0.71	-0.45	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
LUAD	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	11.02	2.5e-25	7.17e-22	0.46	0.45	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
LUAD	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	11.01	2.58e-25	7.39e-22	0.62	0.45	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	11.01	2.59e-25	7.41e-22	0.54	0.45	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	11.01	2.59e-25	7.41e-22	0.54	0.45	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	11.01	2.59e-25	7.42e-22	0.54	0.45	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
LUAD	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	11.01	2.6e-25	7.42e-22	0.95	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	11.01	2.6e-25	7.42e-22	0.95	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
LUAD	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-11.01	2.6e-25	7.44e-22	-0.57	-0.45	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
LUAD	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	11.01	2.6e-25	7.44e-22	0.62	0.45	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
LUAD	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	11.01	2.62e-25	7.49e-22	0.44	0.45	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
LUAD	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-11.01	2.63e-25	7.5e-22	-0.57	-0.45	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	11.01	2.64e-25	7.55e-22	0.54	0.45	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	11.01	2.65e-25	7.57e-22	0.69	0.45	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	11.01	2.66e-25	7.58e-22	0.55	0.45	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
LUAD	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	11.01	2.66e-25	7.59e-22	0.47	0.45	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
LUAD	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	11.01	2.67e-25	7.63e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
LUAD	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-11.01	2.69e-25	7.67e-22	-0.68	-0.45	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
LUAD	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	11.01	2.7e-25	7.71e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
LUAD	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	11	2.83e-25	8.06e-22	0.57	0.45	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
LUAD	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	11	2.9e-25	8.26e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	11	2.91e-25	8.28e-22	0.54	0.45	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
LUAD	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-11	2.91e-25	8.3e-22	-0.56	-0.45	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
LUAD	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-11	2.95e-25	8.39e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
LUAD	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-11	2.96e-25	8.43e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	11	3.05e-25	8.67e-22	0.54	0.45	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	11	3.05e-25	8.67e-22	0.54	0.45	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	11	3.06e-25	8.71e-22	0.56	0.45	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	11	3.06e-25	8.71e-22	0.56	0.45	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
LUAD	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	11	3.07e-25	8.73e-22	0.56	0.45	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
LUAD	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	10.99	3.09e-25	8.78e-22	0.62	0.45	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
LUAD	cis	rs904251	0.766	rs1757175	ENSG00000279942.1	RP1-153P14.7	-10.99	3.14e-25	8.93e-22	-0.43	-0.45	Cognitive performance;	chr6:37518918	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.828	rs1757174	ENSG00000279942.1	RP1-153P14.7	-10.99	3.14e-25	8.93e-22	-0.43	-0.45	Cognitive performance;	chr6:37518919	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.861	rs1757173	ENSG00000279942.1	RP1-153P14.7	-10.99	3.14e-25	8.93e-22	-0.43	-0.45	Cognitive performance;	chr6:37519176	chr6:37567716~37571460:+
LUAD	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-10.99	3.15e-25	8.95e-22	-0.52	-0.45	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
LUAD	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	10.99	3.22e-25	9.15e-22	0.56	0.45	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
LUAD	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-10.99	3.27e-25	9.27e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-10.99	3.31e-25	9.38e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
LUAD	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	10.99	3.31e-25	9.4e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
LUAD	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-10.99	3.32e-25	9.42e-22	-0.57	-0.45	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	10.99	3.33e-25	9.43e-22	0.55	0.45	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	10.99	3.33e-25	9.43e-22	0.55	0.45	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
LUAD	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	10.98	3.42e-25	9.69e-22	0.59	0.45	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	10.98	3.42e-25	9.7e-22	0.54	0.45	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	10.98	3.46e-25	9.8e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-10.98	3.49e-25	9.89e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
LUAD	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	10.98	3.58e-25	1.01e-21	0.57	0.45	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	10.98	3.58e-25	1.01e-21	0.57	0.45	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
LUAD	cis	rs904251	0.861	rs2776875	ENSG00000279942.1	RP1-153P14.7	-10.98	3.58e-25	1.01e-21	-0.43	-0.45	Cognitive performance;	chr6:37519020	chr6:37567716~37571460:+
LUAD	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	10.98	3.59e-25	1.02e-21	0.67	0.45	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
LUAD	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-10.98	3.65e-25	1.03e-21	-0.57	-0.45	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
LUAD	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	10.97	3.7e-25	1.04e-21	0.55	0.45	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	10.97	3.71e-25	1.05e-21	0.56	0.45	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
LUAD	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-10.97	3.84e-25	1.08e-21	-0.57	-0.45	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-10.97	3.84e-25	1.08e-21	-0.57	-0.45	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-10.97	3.84e-25	1.08e-21	-0.57	-0.45	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-10.97	3.84e-25	1.08e-21	-0.57	-0.45	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
LUAD	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-10.97	3.84e-25	1.08e-21	-0.64	-0.45	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
LUAD	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	10.97	3.84e-25	1.08e-21	0.56	0.45	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	10.97	3.84e-25	1.08e-21	0.56	0.45	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	10.97	3.84e-25	1.08e-21	0.56	0.45	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
LUAD	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-10.97	3.84e-25	1.08e-21	-0.5	-0.45	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
LUAD	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	10.97	3.88e-25	1.09e-21	0.46	0.45	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	10.97	3.88e-25	1.09e-21	0.46	0.45	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	10.97	3.88e-25	1.09e-21	0.46	0.45	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	10.97	3.88e-25	1.09e-21	0.54	0.45	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
LUAD	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	10.97	3.94e-25	1.11e-21	0.56	0.45	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	10.97	3.97e-25	1.12e-21	0.54	0.45	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	10.97	3.97e-25	1.12e-21	0.54	0.45	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
LUAD	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	10.96	4.03e-25	1.13e-21	0.59	0.45	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
LUAD	cis	rs904251	0.861	rs1757169	ENSG00000279942.1	RP1-153P14.7	-10.96	4.07e-25	1.14e-21	-0.43	-0.45	Cognitive performance;	chr6:37519300	chr6:37567716~37571460:+
LUAD	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	10.96	4.1e-25	1.15e-21	0.53	0.45	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
LUAD	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-10.96	4.1e-25	1.15e-21	-0.71	-0.45	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
LUAD	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-10.96	4.12e-25	1.16e-21	-0.54	-0.45	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
LUAD	cis	rs904251	0.861	rs1757183	ENSG00000279942.1	RP1-153P14.7	10.96	4.13e-25	1.16e-21	0.42	0.45	Cognitive performance;	chr6:37517014	chr6:37567716~37571460:+
LUAD	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-10.96	4.2e-25	1.18e-21	-0.47	-0.45	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	10.96	4.2e-25	1.18e-21	0.55	0.45	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	10.96	4.21e-25	1.18e-21	0.52	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
LUAD	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	10.96	4.23e-25	1.19e-21	0.63	0.45	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
LUAD	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	10.96	4.24e-25	1.19e-21	0.54	0.45	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	10.96	4.24e-25	1.19e-21	0.54	0.45	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	10.96	4.24e-25	1.19e-21	0.54	0.45	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	10.96	4.24e-25	1.19e-21	0.54	0.45	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	10.96	4.26e-25	1.2e-21	0.72	0.45	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-10.96	4.28e-25	1.2e-21	-0.55	-0.45	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-10.96	4.37e-25	1.23e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
LUAD	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	10.95	4.38e-25	1.23e-21	0.57	0.45	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	10.95	4.38e-25	1.23e-21	0.57	0.45	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	10.95	4.38e-25	1.23e-21	0.57	0.45	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	10.95	4.39e-25	1.23e-21	0.54	0.45	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
LUAD	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-10.95	4.4e-25	1.23e-21	-0.41	-0.45	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
LUAD	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	10.95	4.42e-25	1.24e-21	0.54	0.45	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
LUAD	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	10.95	4.51e-25	1.26e-21	0.57	0.45	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
LUAD	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	10.95	4.52e-25	1.27e-21	0.47	0.45	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
LUAD	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	10.95	4.59e-25	1.28e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
LUAD	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-10.95	4.73e-25	1.32e-21	-0.56	-0.45	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	10.95	4.77e-25	1.33e-21	0.57	0.45	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	10.95	4.78e-25	1.33e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-10.95	4.78e-25	1.34e-21	-0.51	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
LUAD	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	10.94	4.85e-25	1.35e-21	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
LUAD	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	10.94	4.88e-25	1.36e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
LUAD	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	10.94	4.88e-25	1.36e-21	0.65	0.45	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
LUAD	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	10.94	4.89e-25	1.37e-21	0.55	0.45	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	10.94	4.97e-25	1.39e-21	0.54	0.45	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
LUAD	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-10.94	4.99e-25	1.39e-21	-0.57	-0.45	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
LUAD	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	10.94	5.08e-25	1.42e-21	0.53	0.45	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
LUAD	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	10.94	5.12e-25	1.43e-21	0.56	0.45	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	10.94	5.12e-25	1.43e-21	0.56	0.45	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	10.94	5.12e-25	1.43e-21	0.56	0.45	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-10.94	5.21e-25	1.45e-21	-0.65	-0.45	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
LUAD	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	10.93	5.31e-25	1.48e-21	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
LUAD	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-10.93	5.34e-25	1.49e-21	-0.6	-0.45	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
LUAD	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	10.93	5.36e-25	1.49e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	10.93	5.36e-25	1.49e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
LUAD	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	10.93	5.4e-25	1.5e-21	0.62	0.45	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
LUAD	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	10.93	5.43e-25	1.51e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
LUAD	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	10.93	5.44e-25	1.51e-21	0.63	0.45	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
LUAD	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	10.93	5.45e-25	1.51e-21	0.54	0.45	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	10.93	5.45e-25	1.51e-21	0.54	0.45	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	10.93	5.45e-25	1.51e-21	0.56	0.45	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-10.93	5.49e-25	1.52e-21	-0.6	-0.45	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
LUAD	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	10.93	5.52e-25	1.53e-21	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
LUAD	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	10.93	5.67e-25	1.57e-21	0.59	0.45	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	10.93	5.67e-25	1.57e-21	0.59	0.45	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
LUAD	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	10.92	5.72e-25	1.59e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
LUAD	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	10.92	5.74e-25	1.59e-21	0.62	0.45	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
LUAD	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	10.92	5.78e-25	1.6e-21	0.55	0.45	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
LUAD	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	10.92	5.81e-25	1.61e-21	0.55	0.45	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	10.92	5.83e-25	1.62e-21	0.54	0.45	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	10.92	5.89e-25	1.63e-21	0.56	0.45	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	10.92	5.89e-25	1.63e-21	0.56	0.45	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	10.92	5.9e-25	1.63e-21	0.54	0.45	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
LUAD	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-10.92	5.95e-25	1.65e-21	-0.52	-0.45	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
LUAD	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-10.92	5.97e-25	1.65e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-10.92	5.97e-25	1.65e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-10.92	5.97e-25	1.65e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-10.92	5.97e-25	1.65e-21	-0.52	-0.45	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
LUAD	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	10.92	6.02e-25	1.67e-21	0.57	0.45	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
LUAD	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	10.92	6.03e-25	1.67e-21	0.42	0.45	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
LUAD	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	10.92	6.08e-25	1.68e-21	0.57	0.45	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
LUAD	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	10.91	6.38e-25	1.76e-21	0.56	0.45	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
LUAD	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	10.91	6.38e-25	1.76e-21	0.56	0.45	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
LUAD	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	10.91	6.47e-25	1.79e-21	0.55	0.45	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
LUAD	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-10.91	6.5e-25	1.79e-21	-0.57	-0.45	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	10.91	6.57e-25	1.81e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	10.91	6.57e-25	1.81e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	10.91	6.57e-25	1.81e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
LUAD	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	10.91	6.65e-25	1.84e-21	0.58	0.45	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
LUAD	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	10.91	6.7e-25	1.85e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	10.91	6.7e-25	1.85e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
LUAD	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	10.91	6.75e-25	1.86e-21	0.55	0.45	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
LUAD	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	10.91	6.77e-25	1.86e-21	0.54	0.45	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
LUAD	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	10.91	6.78e-25	1.87e-21	0.56	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
LUAD	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	10.9	6.88e-25	1.89e-21	0.66	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
LUAD	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	10.9	6.91e-25	1.9e-21	0.54	0.45	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-10.9	6.95e-25	1.91e-21	-0.54	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-10.9	6.95e-25	1.91e-21	-0.54	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
LUAD	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-10.9	6.98e-25	1.92e-21	-0.41	-0.45	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
LUAD	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-10.9	7.14e-25	1.96e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
LUAD	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	10.9	7.16e-25	1.97e-21	0.57	0.45	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
LUAD	cis	rs904251	0.828	rs2797803	ENSG00000279942.1	RP1-153P14.7	-10.9	7.19e-25	1.98e-21	-0.43	-0.45	Cognitive performance;	chr6:37519564	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	10.9	7.22e-25	1.98e-21	0.56	0.45	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	10.9	7.22e-25	1.98e-21	0.56	0.45	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-10.9	7.25e-25	1.99e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	10.9	7.27e-25	2e-21	0.56	0.44	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
LUAD	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-10.9	7.3e-25	2e-21	-0.5	-0.44	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.864	rs7308921	ENSG00000199506.1	RNU6-247P	10.9	7.35e-25	2.02e-21	0.56	0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-10.9	7.41e-25	2.03e-21	-0.57	-0.44	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	10.89	7.58e-25	2.08e-21	0.57	0.44	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	10.89	7.77e-25	2.13e-21	0.35	0.44	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
LUAD	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	10.89	7.82e-25	2.14e-21	0.55	0.44	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	10.89	7.82e-25	2.14e-21	0.54	0.44	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	10.89	7.82e-25	2.14e-21	0.54	0.44	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	10.89	7.91e-25	2.17e-21	0.53	0.44	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	10.89	7.94e-25	2.18e-21	0.55	0.44	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-10.89	7.95e-25	2.18e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-10.89	7.98e-25	2.19e-21	-0.57	-0.44	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-10.89	7.99e-25	2.19e-21	-0.57	-0.44	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-10.89	7.99e-25	2.19e-21	-0.57	-0.44	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	10.89	8.02e-25	2.2e-21	0.54	0.44	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.861	rs2776877	ENSG00000279942.1	RP1-153P14.7	-10.89	8.04e-25	2.2e-21	-0.43	-0.44	Cognitive performance;	chr6:37519359	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.864	rs2797801	ENSG00000279942.1	RP1-153P14.7	-10.89	8.04e-25	2.2e-21	-0.43	-0.44	Cognitive performance;	chr6:37519385	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.797	rs2776878	ENSG00000279942.1	RP1-153P14.7	-10.89	8.04e-25	2.2e-21	-0.43	-0.44	Cognitive performance;	chr6:37519497	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	10.89	8.07e-25	2.21e-21	0.55	0.44	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
LUAD	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-10.88	8.22e-25	2.25e-21	-0.65	-0.44	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	10.88	8.26e-25	2.26e-21	0.54	0.44	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
LUAD	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	10.88	8.28e-25	2.27e-21	0.52	0.44	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
LUAD	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-10.88	8.29e-25	2.27e-21	-0.64	-0.44	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
LUAD	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-10.88	8.34e-25	2.28e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
LUAD	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-10.88	8.34e-25	2.28e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
LUAD	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	10.88	8.36e-25	2.29e-21	0.59	0.44	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-10.88	8.51e-25	2.33e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-10.88	8.6e-25	2.35e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	10.88	8.61e-25	2.35e-21	0.55	0.44	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
LUAD	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	10.88	8.62e-25	2.35e-21	0.54	0.44	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	10.88	8.62e-25	2.35e-21	0.54	0.44	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-10.88	8.64e-25	2.36e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-10.88	8.66e-25	2.37e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	10.87	8.88e-25	2.42e-21	0.56	0.44	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
LUAD	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-10.87	8.97e-25	2.45e-21	-0.54	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
LUAD	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-10.87	8.99e-25	2.45e-21	-0.57	-0.44	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
LUAD	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-10.87	9.02e-25	2.46e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-10.87	9.02e-25	2.46e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-10.87	9.02e-25	2.46e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-10.87	9.02e-25	2.46e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-10.87	9.07e-25	2.47e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
LUAD	cis	rs2658782	0.526	rs7127240	ENSG00000279684.1	RP11-755E23.2	-10.87	9.21e-25	2.51e-21	-0.62	-0.44	Pulmonary function decline;	chr11:93451726	chr11:93286629~93288903:-
LUAD	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-10.87	9.28e-25	2.52e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-10.87	9.28e-25	2.52e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	10.87	9.47e-25	2.58e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-10.87	9.51e-25	2.59e-21	-0.57	-0.44	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
LUAD	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-10.87	9.52e-25	2.59e-21	-0.64	-0.44	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-10.87	9.52e-25	2.59e-21	-0.64	-0.44	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-10.87	9.52e-25	2.59e-21	-0.64	-0.44	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
LUAD	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-10.87	9.6e-25	2.61e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-10.87	9.62e-25	2.62e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
LUAD	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
LUAD	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-10.86	9.96e-25	2.71e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
LUAD	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-10.86	1.01e-24	2.73e-21	-0.66	-0.44	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
LUAD	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	10.86	1.02e-24	2.76e-21	0.53	0.44	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
LUAD	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-10.86	1.02e-24	2.76e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	10.86	1.02e-24	2.76e-21	0.55	0.44	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-10.86	1.02e-24	2.76e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-10.86	1.02e-24	2.78e-21	-0.57	-0.44	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	10.86	1.03e-24	2.78e-21	0.56	0.44	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
LUAD	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-10.86	1.03e-24	2.8e-21	-0.45	-0.44	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	10.86	1.03e-24	2.8e-21	0.68	0.44	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
LUAD	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	10.86	1.03e-24	2.8e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	10.86	1.03e-24	2.8e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	10.86	1.03e-24	2.8e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	10.86	1.03e-24	2.8e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
LUAD	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	10.86	1.04e-24	2.82e-21	0.6	0.44	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
LUAD	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	10.86	1.04e-24	2.82e-21	0.57	0.44	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	10.86	1.04e-24	2.82e-21	0.57	0.44	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-10.85	1.08e-24	2.92e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-10.85	1.09e-24	2.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-10.85	1.09e-24	2.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-10.85	1.09e-24	2.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-10.85	1.09e-24	2.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
LUAD	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-10.85	1.1e-24	2.97e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
LUAD	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-10.85	1.1e-24	2.97e-21	-0.63	-0.44	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	10.85	1.11e-24	3e-21	0.54	0.44	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	10.85	1.11e-24	3e-21	0.46	0.44	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-10.85	1.12e-24	3.03e-21	-0.57	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
LUAD	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-10.85	1.14e-24	3.08e-21	-0.55	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-10.85	1.14e-24	3.08e-21	-0.49	-0.44	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
LUAD	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-10.85	1.15e-24	3.09e-21	-0.57	-0.44	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	10.84	1.16e-24	3.13e-21	0.53	0.44	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
LUAD	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	10.84	1.17e-24	3.14e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	10.84	1.18e-24	3.17e-21	0.54	0.44	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	10.84	1.18e-24	3.17e-21	0.54	0.44	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
LUAD	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	10.84	1.18e-24	3.19e-21	0.68	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
LUAD	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-10.84	1.19e-24	3.19e-21	-0.64	-0.44	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
LUAD	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	10.84	1.19e-24	3.2e-21	0.6	0.44	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-10.84	1.2e-24	3.22e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
LUAD	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	10.84	1.21e-24	3.25e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	10.84	1.21e-24	3.25e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	10.84	1.21e-24	3.25e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
LUAD	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	10.84	1.22e-24	3.28e-21	0.54	0.44	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
LUAD	cis	rs6538678	1	rs6538678	ENSG00000199506.1	RNU6-247P	-10.84	1.23e-24	3.29e-21	-0.6	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95792529~95792635:-
LUAD	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	10.84	1.23e-24	3.3e-21	0.57	0.44	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	10.84	1.24e-24	3.32e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-10.84	1.25e-24	3.36e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-10.84	1.25e-24	3.37e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.861	rs914349	ENSG00000279942.1	RP1-153P14.7	-10.84	1.26e-24	3.37e-21	-0.4	-0.44	Cognitive performance;	chr6:37516939	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	10.83	1.27e-24	3.42e-21	0.56	0.44	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	10.83	1.27e-24	3.42e-21	0.56	0.44	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	10.83	1.27e-24	3.42e-21	0.56	0.44	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	10.83	1.27e-24	3.42e-21	0.56	0.44	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-10.83	1.29e-24	3.46e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
LUAD	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	10.83	1.29e-24	3.47e-21	0.56	0.44	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
LUAD	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	10.83	1.29e-24	3.47e-21	0.56	0.44	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
LUAD	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	10.83	1.31e-24	3.5e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
LUAD	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-10.83	1.32e-24	3.54e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-10.83	1.33e-24	3.55e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
LUAD	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-10.83	1.33e-24	3.55e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-10.83	1.33e-24	3.55e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	10.83	1.34e-24	3.59e-21	0.54	0.44	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-10.83	1.36e-24	3.64e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	10.83	1.37e-24	3.66e-21	0.54	0.44	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
LUAD	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	10.83	1.37e-24	3.66e-21	0.59	0.44	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
LUAD	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	10.83	1.37e-24	3.67e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
LUAD	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	10.82	1.38e-24	3.69e-21	0.64	0.44	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
LUAD	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-10.82	1.38e-24	3.69e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-10.82	1.38e-24	3.69e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	10.82	1.4e-24	3.73e-21	0.35	0.44	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
LUAD	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	10.82	1.4e-24	3.75e-21	0.55	0.44	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
LUAD	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
LUAD	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-10.82	1.41e-24	3.77e-21	-0.53	-0.44	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
LUAD	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	10.82	1.41e-24	3.77e-21	0.57	0.44	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
LUAD	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	10.82	1.41e-24	3.78e-21	0.57	0.44	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
LUAD	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	10.82	1.43e-24	3.83e-21	0.55	0.44	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
LUAD	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-10.82	1.45e-24	3.86e-21	-0.52	-0.44	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
LUAD	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	10.82	1.45e-24	3.88e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	10.82	1.45e-24	3.88e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	10.82	1.47e-24	3.91e-21	0.57	0.44	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-10.82	1.47e-24	3.91e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
LUAD	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	10.82	1.47e-24	3.92e-21	0.57	0.44	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	10.82	1.47e-24	3.93e-21	0.57	0.44	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
LUAD	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-10.82	1.48e-24	3.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-10.82	1.48e-24	3.95e-21	-0.57	-0.44	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-10.82	1.48e-24	3.95e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-10.82	1.48e-24	3.95e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-10.82	1.48e-24	3.96e-21	-0.35	-0.44	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-10.82	1.5e-24	4e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
LUAD	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	10.81	1.51e-24	4.02e-21	0.63	0.44	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
LUAD	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
LUAD	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	10.81	1.52e-24	4.04e-21	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
LUAD	cis	rs6538678	0.833	rs10859966	ENSG00000199506.1	RNU6-247P	10.81	1.52e-24	4.05e-21	0.54	0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	10.81	1.53e-24	4.06e-21	0.57	0.44	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
LUAD	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	10.81	1.54e-24	4.09e-21	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
LUAD	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-10.81	1.55e-24	4.14e-21	-0.57	-0.44	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
LUAD	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
LUAD	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	10.81	1.57e-24	4.17e-21	0.59	0.44	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
LUAD	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	10.81	1.58e-24	4.18e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
LUAD	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	10.81	1.58e-24	4.19e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	10.81	1.58e-24	4.19e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	10.81	1.58e-24	4.19e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-10.81	1.59e-24	4.21e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
LUAD	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	10.81	1.59e-24	4.21e-21	0.53	0.44	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
LUAD	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-10.81	1.59e-24	4.22e-21	-0.62	-0.44	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-10.81	1.59e-24	4.22e-21	-0.62	-0.44	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
LUAD	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	10.81	1.6e-24	4.24e-21	0.71	0.44	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-10.81	1.62e-24	4.3e-21	-0.57	-0.44	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
LUAD	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-10.8	1.65e-24	4.37e-21	-0.51	-0.44	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
LUAD	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-10.8	1.66e-24	4.38e-21	-0.53	-0.44	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	10.8	1.68e-24	4.43e-21	0.35	0.44	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
LUAD	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	10.8	1.69e-24	4.47e-21	0.58	0.44	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	10.8	1.7e-24	4.49e-21	0.54	0.44	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
LUAD	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	10.8	1.7e-24	4.51e-21	0.44	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
LUAD	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-10.8	1.71e-24	4.51e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-10.8	1.72e-24	4.56e-21	-0.56	-0.44	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
LUAD	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-10.8	1.73e-24	4.57e-21	-0.58	-0.44	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	10.8	1.73e-24	4.58e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-10.8	1.76e-24	4.65e-21	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
LUAD	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	10.8	1.78e-24	4.69e-21	0.57	0.44	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
LUAD	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	10.8	1.78e-24	4.69e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-10.79	1.8e-24	4.74e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
LUAD	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	10.79	1.82e-24	4.8e-21	0.71	0.44	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
LUAD	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	10.79	1.82e-24	4.8e-21	0.71	0.44	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
LUAD	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-10.79	1.83e-24	4.83e-21	-0.49	-0.44	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
LUAD	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	10.79	1.83e-24	4.83e-21	0.57	0.44	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
LUAD	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	10.79	1.84e-24	4.85e-21	0.61	0.44	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
LUAD	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-10.79	1.85e-24	4.87e-21	-0.57	-0.44	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-10.79	1.85e-24	4.89e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
LUAD	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	10.79	1.87e-24	4.92e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	10.79	1.87e-24	4.92e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	10.79	1.87e-24	4.92e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-10.79	1.87e-24	4.93e-21	-0.91	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
LUAD	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	10.79	1.88e-24	4.95e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-10.79	1.9e-24	5e-21	-0.66	-0.44	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
LUAD	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-10.79	1.9e-24	5.01e-21	-0.62	-0.44	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
LUAD	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-10.79	1.94e-24	5.09e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
LUAD	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-10.79	1.95e-24	5.12e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-10.79	1.95e-24	5.12e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
LUAD	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	10.79	1.95e-24	5.13e-21	0.66	0.44	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
LUAD	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-10.78	1.96e-24	5.15e-21	-0.53	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
LUAD	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	10.78	1.97e-24	5.17e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	10.78	1.97e-24	5.17e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
LUAD	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	10.78	1.97e-24	5.18e-21	0.57	0.44	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
LUAD	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-10.78	1.99e-24	5.23e-21	-0.64	-0.44	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
LUAD	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-10.78	1.99e-24	5.23e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-10.78	2.01e-24	5.27e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-10.78	2.01e-24	5.27e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
LUAD	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-10.78	2.01e-24	5.27e-21	-0.56	-0.44	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	10.78	2.01e-24	5.28e-21	0.56	0.44	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
LUAD	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	10.78	2.02e-24	5.3e-21	0.61	0.44	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
LUAD	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	10.78	2.03e-24	5.33e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	10.78	2.03e-24	5.33e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	10.78	2.03e-24	5.33e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-10.78	2.06e-24	5.39e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-10.78	2.07e-24	5.42e-21	-0.56	-0.44	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-10.78	2.07e-24	5.42e-21	-0.56	-0.44	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
LUAD	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	10.78	2.08e-24	5.45e-21	0.53	0.44	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
LUAD	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-10.78	2.1e-24	5.5e-21	-0.63	-0.44	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
LUAD	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-10.78	2.13e-24	5.57e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-10.78	2.13e-24	5.57e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
LUAD	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	10.77	2.15e-24	5.62e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
LUAD	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-10.77	2.17e-24	5.67e-21	-0.54	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
LUAD	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-10.77	2.17e-24	5.67e-21	-0.54	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
LUAD	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-10.77	2.19e-24	5.72e-21	-0.57	-0.44	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
LUAD	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-10.77	2.2e-24	5.76e-21	-0.56	-0.44	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
LUAD	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-10.77	2.22e-24	5.79e-21	-0.63	-0.44	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
LUAD	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-10.77	2.22e-24	5.79e-21	-0.57	-0.44	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
LUAD	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	10.77	2.23e-24	5.83e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	10.77	2.25e-24	5.87e-21	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-10.77	2.25e-24	5.88e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-10.77	2.25e-24	5.88e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-10.77	2.25e-24	5.88e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-10.77	2.27e-24	5.92e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	10.77	2.28e-24	5.94e-21	0.56	0.44	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	10.77	2.28e-24	5.94e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
LUAD	cis	rs6538678	0.824	rs7307510	ENSG00000199506.1	RNU6-247P	-10.77	2.31e-24	6.01e-21	-0.63	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95792529~95792635:-
LUAD	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	10.76	2.4e-24	6.25e-21	0.57	0.44	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
LUAD	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	10.76	2.41e-24	6.27e-21	0.57	0.44	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-10.76	2.42e-24	6.29e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
LUAD	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	10.76	2.43e-24	6.31e-21	0.54	0.44	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
LUAD	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	10.76	2.43e-24	6.32e-21	0.6	0.44	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-10.76	2.44e-24	6.34e-21	-0.65	-0.44	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-10.76	2.44e-24	6.34e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
LUAD	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	10.76	2.47e-24	6.42e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
LUAD	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	10.75	2.54e-24	6.61e-21	0.54	0.44	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
LUAD	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	10.75	2.69e-24	6.97e-21	0.46	0.44	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-10.75	2.7e-24	7e-21	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
LUAD	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	10.75	2.77e-24	7.17e-21	0.56	0.44	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-10.74	2.79e-24	7.22e-21	-0.65	-0.44	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
LUAD	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	10.74	2.79e-24	7.24e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	10.74	2.79e-24	7.24e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	10.74	2.79e-24	7.24e-21	0.54	0.44	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	10.74	2.79e-24	7.24e-21	0.54	0.44	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	10.74	2.82e-24	7.3e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
LUAD	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	10.74	2.83e-24	7.32e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
LUAD	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	10.74	2.83e-24	7.32e-21	0.64	0.44	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	10.74	2.83e-24	7.33e-21	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
LUAD	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-10.74	2.84e-24	7.36e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-10.74	2.84e-24	7.36e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-10.74	2.84e-24	7.36e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
LUAD	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-10.74	2.85e-24	7.39e-21	-0.63	-0.44	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	10.74	2.88e-24	7.45e-21	0.53	0.44	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	10.74	2.88e-24	7.45e-21	0.53	0.44	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	10.74	2.88e-24	7.45e-21	0.53	0.44	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-10.74	2.88e-24	7.46e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-10.74	2.89e-24	7.47e-21	-0.51	-0.44	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
LUAD	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	10.74	2.89e-24	7.47e-21	0.57	0.44	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
LUAD	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	10.74	2.91e-24	7.52e-21	0.57	0.44	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	10.74	2.91e-24	7.54e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	10.74	2.91e-24	7.54e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
LUAD	cis	rs2487048	1	rs2487046	ENSG00000226334.1	RP11-217B7.2	-10.74	2.93e-24	7.56e-21	-0.58	-0.44	Intraocular pressure;	chr9:104929948	chr9:104927553~104928892:+
LUAD	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	10.74	2.94e-24	7.59e-21	0.54	0.44	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
LUAD	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
LUAD	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	10.74	2.98e-24	7.7e-21	0.56	0.44	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
LUAD	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	10.74	3e-24	7.75e-21	0.6	0.44	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
LUAD	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-10.74	3.02e-24	7.79e-21	-0.55	-0.44	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
LUAD	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	10.73	3.03e-24	7.82e-21	0.55	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
LUAD	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-10.73	3.04e-24	7.84e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
LUAD	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-10.73	3.05e-24	7.87e-21	-0.42	-0.44	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
LUAD	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-10.73	3.06e-24	7.89e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
LUAD	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	10.73	3.07e-24	7.92e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
LUAD	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	10.73	3.09e-24	7.97e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-10.73	3.1e-24	7.99e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-10.73	3.12e-24	8.05e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-10.73	3.12e-24	8.05e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
LUAD	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	10.73	3.13e-24	8.06e-21	0.55	0.44	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-10.73	3.14e-24	8.09e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-10.73	3.2e-24	8.23e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	10.73	3.22e-24	8.29e-21	0.55	0.44	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
LUAD	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	10.73	3.23e-24	8.31e-21	0.49	0.44	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-10.73	3.26e-24	8.4e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-10.73	3.26e-24	8.4e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
LUAD	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	10.72	3.33e-24	8.55e-21	0.55	0.44	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	10.72	3.37e-24	8.68e-21	0.67	0.44	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
LUAD	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-10.72	3.38e-24	8.68e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-10.72	3.38e-24	8.7e-21	-0.56	-0.44	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
LUAD	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	10.72	3.4e-24	8.74e-21	0.53	0.44	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
LUAD	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
LUAD	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	10.72	3.43e-24	8.8e-21	0.53	0.44	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
LUAD	cis	rs1757171	0.504	rs11969056	ENSG00000279942.1	RP1-153P14.7	-10.72	3.43e-24	8.81e-21	-0.41	-0.44	Cognitive performance;	chr6:37516509	chr6:37567716~37571460:+
LUAD	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-10.72	3.45e-24	8.87e-21	-0.56	-0.44	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-10.72	3.46e-24	8.88e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
LUAD	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	10.72	3.48e-24	8.93e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
LUAD	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	10.72	3.5e-24	8.98e-21	0.53	0.44	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
LUAD	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	10.72	3.54e-24	9.08e-21	0.54	0.44	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
LUAD	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-10.72	3.6e-24	9.22e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-10.71	3.61e-24	9.24e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
LUAD	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	10.71	3.62e-24	9.27e-21	0.54	0.44	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
LUAD	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-10.71	3.63e-24	9.29e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
LUAD	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	10.71	3.68e-24	9.42e-21	0.61	0.44	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
LUAD	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-10.71	3.7e-24	9.48e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
LUAD	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-10.71	3.72e-24	9.53e-21	-0.4	-0.44	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	10.71	3.79e-24	9.71e-21	0.57	0.44	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	10.71	3.82e-24	9.76e-21	0.56	0.44	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	10.71	3.83e-24	9.79e-21	0.53	0.44	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-10.71	3.83e-24	9.8e-21	-0.52	-0.44	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
LUAD	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-10.71	3.86e-24	9.85e-21	-0.55	-0.44	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-10.71	3.86e-24	9.85e-21	-0.55	-0.44	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
LUAD	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-10.71	3.87e-24	9.88e-21	-0.74	-0.44	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-10.71	3.89e-24	9.91e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-10.71	3.89e-24	9.91e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	10.71	3.91e-24	9.96e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
LUAD	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-10.71	3.92e-24	9.97e-21	-0.74	-0.44	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
LUAD	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	10.7	3.94e-24	1e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-10.7	3.94e-24	1e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
LUAD	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-10.7	3.97e-24	1.01e-20	-0.57	-0.44	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
LUAD	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-10.7	3.97e-24	1.01e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
LUAD	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	10.7	3.99e-24	1.02e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
LUAD	cis	rs904251	0.797	rs1757181	ENSG00000279942.1	RP1-153P14.7	10.7	4e-24	1.02e-20	0.41	0.44	Cognitive performance;	chr6:37517952	chr6:37567716~37571460:+
LUAD	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-10.7	4.02e-24	1.02e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-10.7	4.04e-24	1.03e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
LUAD	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-10.7	4.05e-24	1.03e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	10.7	4.05e-24	1.03e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	10.7	4.05e-24	1.03e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
LUAD	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
LUAD	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	10.7	4.09e-24	1.04e-20	0.57	0.44	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
LUAD	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	10.7	4.1e-24	1.04e-20	0.58	0.44	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
LUAD	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-10.7	4.13e-24	1.05e-20	-0.65	-0.44	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
LUAD	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-10.7	4.14e-24	1.05e-20	-0.7	-0.44	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
LUAD	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-10.7	4.18e-24	1.06e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	10.7	4.2e-24	1.07e-20	0.54	0.44	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-10.7	4.2e-24	1.07e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-10.7	4.22e-24	1.07e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-10.7	4.25e-24	1.08e-20	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
LUAD	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	10.7	4.25e-24	1.08e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	10.7	4.25e-24	1.08e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
LUAD	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-10.7	4.28e-24	1.08e-20	-0.54	-0.44	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
LUAD	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	10.69	4.36e-24	1.1e-20	0.53	0.44	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	10.69	4.37e-24	1.1e-20	0.54	0.44	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
LUAD	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-10.69	4.37e-24	1.1e-20	-0.53	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
LUAD	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	10.69	4.38e-24	1.11e-20	0.67	0.44	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	10.69	4.39e-24	1.11e-20	0.67	0.44	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
LUAD	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-10.69	4.41e-24	1.11e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-10.69	4.43e-24	1.12e-20	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
LUAD	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-10.69	4.44e-24	1.12e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-10.69	4.49e-24	1.13e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-10.69	4.5e-24	1.13e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
LUAD	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-10.69	4.53e-24	1.14e-20	-0.72	-0.44	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
LUAD	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-10.69	4.58e-24	1.15e-20	-0.55	-0.44	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
LUAD	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	10.69	4.59e-24	1.16e-20	0.74	0.44	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
LUAD	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-10.69	4.59e-24	1.16e-20	-0.57	-0.44	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-10.69	4.59e-24	1.16e-20	-0.57	-0.44	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-10.69	4.59e-24	1.16e-20	-0.57	-0.44	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-10.69	4.61e-24	1.16e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-10.69	4.64e-24	1.17e-20	-0.57	-0.44	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-10.69	4.64e-24	1.17e-20	-0.57	-0.44	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
LUAD	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-10.69	4.66e-24	1.17e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-10.69	4.67e-24	1.17e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-10.68	4.68e-24	1.18e-20	-0.55	-0.44	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
LUAD	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-10.68	4.72e-24	1.19e-20	-0.63	-0.44	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-10.68	4.72e-24	1.19e-20	-0.63	-0.44	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-10.68	4.72e-24	1.19e-20	-0.63	-0.44	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
LUAD	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-10.68	4.75e-24	1.19e-20	-0.51	-0.44	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
LUAD	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-10.68	4.78e-24	1.2e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
LUAD	cis	rs6538678	0.963	rs11108310	ENSG00000199506.1	RNU6-247P	-10.68	4.79e-24	1.2e-20	-0.57	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	10.68	4.8e-24	1.21e-20	0.56	0.44	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	10.68	4.8e-24	1.21e-20	0.56	0.44	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
LUAD	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	10.68	4.82e-24	1.21e-20	0.53	0.44	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
LUAD	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	10.68	4.84e-24	1.22e-20	0.54	0.44	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
LUAD	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	10.68	4.87e-24	1.22e-20	0.55	0.44	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-10.68	4.92e-24	1.23e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-10.68	4.93e-24	1.24e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
LUAD	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	10.68	4.94e-24	1.24e-20	0.57	0.44	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-10.68	4.95e-24	1.24e-20	-0.55	-0.44	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
LUAD	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	10.68	4.95e-24	1.24e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
LUAD	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-10.68	5.07e-24	1.27e-20	-0.55	-0.44	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
LUAD	cis	rs6538678	0.864	rs10777747	ENSG00000199506.1	RNU6-247P	-10.68	5.09e-24	1.27e-20	-0.56	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95792529~95792635:-
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-10.68	5.09e-24	1.28e-20	-0.47	-0.44	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
LUAD	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-10.67	5.14e-24	1.29e-20	-0.63	-0.44	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
LUAD	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-10.67	5.18e-24	1.29e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-10.67	5.18e-24	1.3e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-10.67	5.22e-24	1.31e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-10.67	5.22e-24	1.31e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
LUAD	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-10.67	5.22e-24	1.31e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-10.67	5.29e-24	1.32e-20	-0.55	-0.44	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
LUAD	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	10.67	5.31e-24	1.33e-20	0.59	0.44	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
LUAD	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-10.67	5.34e-24	1.33e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-10.67	5.34e-24	1.33e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	10.67	5.35e-24	1.34e-20	0.35	0.44	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
LUAD	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-10.67	5.41e-24	1.35e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
LUAD	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	10.67	5.51e-24	1.37e-20	0.42	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
LUAD	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	10.67	5.57e-24	1.39e-20	0.55	0.44	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
LUAD	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	10.66	5.65e-24	1.41e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
LUAD	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-10.66	5.7e-24	1.42e-20	-0.55	-0.44	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
LUAD	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	10.66	5.84e-24	1.46e-20	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
LUAD	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	10.66	5.87e-24	1.46e-20	0.56	0.44	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
LUAD	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-10.66	5.88e-24	1.47e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
LUAD	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-10.66	5.94e-24	1.48e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
LUAD	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	10.66	5.98e-24	1.49e-20	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
LUAD	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-10.66	6.02e-24	1.5e-20	-0.53	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
LUAD	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-10.66	6.05e-24	1.5e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
LUAD	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	10.66	6.06e-24	1.5e-20	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-10.66	6.07e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-10.66	6.07e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-10.65	6.09e-24	1.51e-20	-0.5	-0.44	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	10.65	6.1e-24	1.51e-20	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
LUAD	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-10.65	6.12e-24	1.52e-20	-0.62	-0.44	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
LUAD	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-10.65	6.17e-24	1.53e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-10.65	6.17e-24	1.53e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-10.65	6.2e-24	1.54e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-10.65	6.2e-24	1.54e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	10.65	6.21e-24	1.54e-20	0.56	0.44	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	10.65	6.21e-24	1.54e-20	0.56	0.44	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
LUAD	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	10.65	6.23e-24	1.54e-20	0.53	0.44	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
LUAD	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	10.65	6.25e-24	1.55e-20	0.57	0.44	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	10.65	6.27e-24	1.55e-20	0.62	0.44	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
LUAD	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-10.65	6.33e-24	1.57e-20	-0.45	-0.44	Height;	chr3:53074760	chr3:53064283~53065091:-
LUAD	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-10.65	6.51e-24	1.61e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
LUAD	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-10.65	6.52e-24	1.61e-20	-0.87	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
LUAD	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-10.65	6.53e-24	1.61e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-10.65	6.53e-24	1.61e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
LUAD	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-10.64	6.66e-24	1.65e-20	-0.55	-0.44	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	10.64	6.68e-24	1.65e-20	0.56	0.44	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	10.64	6.71e-24	1.66e-20	0.54	0.44	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-10.64	6.73e-24	1.66e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
LUAD	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	10.64	6.78e-24	1.67e-20	0.53	0.44	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
LUAD	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	10.64	6.85e-24	1.69e-20	0.61	0.44	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
LUAD	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	10.64	6.85e-24	1.69e-20	0.61	0.44	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
LUAD	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	10.64	6.97e-24	1.72e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	10.64	6.97e-24	1.72e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	10.64	6.97e-24	1.72e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
LUAD	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	10.64	6.98e-24	1.72e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
LUAD	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-10.64	7.06e-24	1.74e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-10.64	7.08e-24	1.75e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-10.64	7.1e-24	1.75e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
LUAD	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	10.63	7.31e-24	1.8e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
LUAD	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-10.63	7.37e-24	1.81e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-10.63	7.37e-24	1.81e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-10.63	7.37e-24	1.81e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
LUAD	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-10.63	7.43e-24	1.83e-20	-0.59	-0.44	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
LUAD	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	10.63	7.44e-24	1.83e-20	0.61	0.44	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
LUAD	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-10.63	7.49e-24	1.84e-20	-0.56	-0.44	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
LUAD	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-10.63	7.5e-24	1.85e-20	-0.67	-0.44	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
LUAD	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	10.63	7.59e-24	1.87e-20	0.58	0.44	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
LUAD	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-10.63	7.7e-24	1.89e-20	-0.56	-0.44	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-10.62	7.89e-24	1.94e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-10.62	7.89e-24	1.94e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-10.62	7.89e-24	1.94e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-10.62	7.89e-24	1.94e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-10.62	8.04e-24	1.97e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	10.62	8.08e-24	1.98e-20	0.35	0.44	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
LUAD	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-10.62	8.19e-24	2.01e-20	-0.64	-0.44	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
LUAD	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-10.62	8.23e-24	2.02e-20	-0.42	-0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
LUAD	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	10.62	8.27e-24	2.03e-20	0.54	0.44	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
LUAD	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-10.62	8.28e-24	2.03e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-10.62	8.28e-24	2.03e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
LUAD	cis	rs904251	0.861	rs1757171	ENSG00000279942.1	RP1-153P14.7	-10.62	8.32e-24	2.04e-20	-0.42	-0.44	Cognitive performance;	chr6:37519268	chr6:37567716~37571460:+
LUAD	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-10.62	8.35e-24	2.05e-20	-0.61	-0.44	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
LUAD	cis	rs1757171	0.542	rs1757186	ENSG00000279942.1	RP1-153P14.7	-10.62	8.39e-24	2.06e-20	-0.4	-0.44	Cognitive performance;	chr6:37516335	chr6:37567716~37571460:+
LUAD	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	10.62	8.4e-24	2.06e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
LUAD	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-10.62	8.45e-24	2.07e-20	-0.48	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	10.61	8.65e-24	2.12e-20	0.56	0.44	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-10.61	8.67e-24	2.12e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
LUAD	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	10.61	8.77e-24	2.15e-20	0.54	0.44	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
LUAD	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-10.61	8.81e-24	2.16e-20	-0.7	-0.44	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
LUAD	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-10.61	8.82e-24	2.16e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-10.61	8.82e-24	2.16e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
LUAD	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	10.61	8.87e-24	2.17e-20	0.92	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
LUAD	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	10.61	8.96e-24	2.19e-20	0.54	0.44	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	10.61	8.96e-24	2.19e-20	0.54	0.44	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-10.61	8.98e-24	2.2e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
LUAD	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-10.61	9.03e-24	2.21e-20	-0.58	-0.44	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	10.61	9.11e-24	2.23e-20	0.53	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-10.61	9.12e-24	2.23e-20	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
LUAD	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-10.61	9.32e-24	2.28e-20	-0.54	-0.44	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-10.6	9.45e-24	2.31e-20	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
LUAD	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-10.6	9.48e-24	2.32e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-10.6	9.56e-24	2.34e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
LUAD	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	10.6	9.61e-24	2.35e-20	0.6	0.44	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
LUAD	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-10.6	9.63e-24	2.35e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	10.6	9.7e-24	2.37e-20	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
LUAD	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-10.6	9.7e-24	2.37e-20	-0.53	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
LUAD	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	10.6	9.86e-24	2.41e-20	0.53	0.44	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	10.6	9.96e-24	2.43e-20	0.54	0.44	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
LUAD	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-10.6	1e-23	2.44e-20	-0.67	-0.44	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
LUAD	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-10.6	1.02e-23	2.47e-20	-0.5	-0.44	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
LUAD	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-10.6	1.02e-23	2.48e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-10.6	1.02e-23	2.48e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-10.6	1.02e-23	2.48e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
LUAD	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-10.6	1.02e-23	2.48e-20	-0.58	-0.44	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	10.59	1.02e-23	2.49e-20	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-10.59	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	10.59	1.03e-23	2.49e-20	0.53	0.43	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
LUAD	cis	rs11089937	1	rs6001121	ENSG00000211639.2	IGLV4-60	10.59	1.03e-23	2.51e-20	0.45	0.43	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22162199~22162681:+
LUAD	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-10.59	1.04e-23	2.52e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
LUAD	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	10.59	1.04e-23	2.53e-20	0.58	0.43	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	10.59	1.04e-23	2.53e-20	0.58	0.43	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
LUAD	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-10.59	1.04e-23	2.53e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-10.59	1.04e-23	2.53e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
LUAD	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	10.59	1.05e-23	2.54e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
LUAD	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-10.59	1.05e-23	2.56e-20	-0.5	-0.43	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	10.59	1.05e-23	2.56e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
LUAD	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	10.59	1.06e-23	2.57e-20	0.56	0.43	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
LUAD	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	10.59	1.08e-23	2.62e-20	0.55	0.43	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	10.59	1.08e-23	2.62e-20	0.55	0.43	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
LUAD	cis	rs6538678	0.895	rs4762637	ENSG00000199506.1	RNU6-247P	-10.59	1.09e-23	2.63e-20	-0.55	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95792529~95792635:-
LUAD	cis	rs694739	0.857	rs574835	ENSG00000236935.1	AP003774.1	10.59	1.1e-23	2.67e-20	0.43	0.43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343196	chr11:64325050~64329504:-
LUAD	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-10.59	1.1e-23	2.67e-20	-0.68	-0.43	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
LUAD	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-10.59	1.11e-23	2.69e-20	-0.65	-0.43	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
LUAD	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-10.58	1.12e-23	2.71e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-10.58	1.12e-23	2.71e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	10.58	1.12e-23	2.71e-20	0.57	0.43	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
LUAD	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-10.58	1.12e-23	2.72e-20	-0.52	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
LUAD	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	10.58	1.13e-23	2.73e-20	0.56	0.43	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	10.58	1.14e-23	2.76e-20	0.54	0.43	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
LUAD	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-10.58	1.15e-23	2.77e-20	-0.55	-0.43	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-10.58	1.15e-23	2.79e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-10.58	1.19e-23	2.87e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-10.58	1.19e-23	2.88e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
LUAD	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-10.58	1.19e-23	2.88e-20	-0.58	-0.43	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-10.58	1.19e-23	2.88e-20	-0.58	-0.43	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-10.58	1.19e-23	2.88e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-10.58	1.2e-23	2.89e-20	-0.53	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
LUAD	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	10.58	1.21e-23	2.91e-20	0.6	0.43	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
LUAD	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	10.58	1.21e-23	2.92e-20	0.58	0.43	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
LUAD	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	10.57	1.24e-23	2.98e-20	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
LUAD	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-10.57	1.24e-23	2.99e-20	-0.53	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
LUAD	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-10.57	1.24e-23	3e-20	-0.51	-0.43	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	10.57	1.25e-23	3e-20	0.53	0.43	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-10.57	1.26e-23	3.03e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
LUAD	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-10.57	1.27e-23	3.07e-20	-0.45	-0.43	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
LUAD	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-10.57	1.28e-23	3.09e-20	-0.55	-0.43	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
LUAD	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-10.57	1.28e-23	3.09e-20	-0.51	-0.43	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-10.57	1.28e-23	3.09e-20	-0.56	-0.43	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
LUAD	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	10.57	1.29e-23	3.1e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	10.57	1.29e-23	3.1e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	10.57	1.3e-23	3.13e-20	0.46	0.43	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
LUAD	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	10.56	1.33e-23	3.19e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	10.56	1.33e-23	3.19e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
LUAD	cis	rs904251	0.797	rs1757177	ENSG00000279942.1	RP1-153P14.7	-10.56	1.35e-23	3.25e-20	-0.41	-0.43	Cognitive performance;	chr6:37518594	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	10.56	1.35e-23	3.25e-20	0.54	0.43	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.522	rs882322	ENSG00000279942.1	RP1-153P14.7	-10.56	1.36e-23	3.26e-20	-0.4	-0.43	Cognitive performance;	chr6:37516327	chr6:37567716~37571460:+
LUAD	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-10.56	1.36e-23	3.27e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
LUAD	cis	rs6538678	0.746	rs12820313	ENSG00000199506.1	RNU6-247P	-10.56	1.36e-23	3.27e-20	-0.57	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95792529~95792635:-
LUAD	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	10.56	1.37e-23	3.28e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
LUAD	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-10.56	1.38e-23	3.31e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
LUAD	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	10.56	1.4e-23	3.35e-20	0.56	0.43	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	10.56	1.41e-23	3.38e-20	0.53	0.43	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	10.56	1.41e-23	3.38e-20	0.53	0.43	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
LUAD	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-10.56	1.41e-23	3.38e-20	-0.49	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-10.56	1.41e-23	3.38e-20	-0.49	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
LUAD	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	10.56	1.41e-23	3.39e-20	0.69	0.43	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
LUAD	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-10.56	1.44e-23	3.44e-20	-0.72	-0.43	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
LUAD	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	10.56	1.44e-23	3.44e-20	0.59	0.43	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
LUAD	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	10.55	1.46e-23	3.49e-20	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
LUAD	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-10.55	1.46e-23	3.51e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	10.55	1.49e-23	3.57e-20	0.54	0.43	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-10.55	1.51e-23	3.61e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	10.55	1.53e-23	3.67e-20	0.56	0.43	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	10.55	1.53e-23	3.67e-20	0.56	0.43	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	10.55	1.55e-23	3.7e-20	0.53	0.43	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	10.55	1.55e-23	3.7e-20	0.53	0.43	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-10.55	1.55e-23	3.71e-20	-0.45	-0.43	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
LUAD	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	10.55	1.55e-23	3.71e-20	0.54	0.43	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-10.55	1.56e-23	3.72e-20	-0.52	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
LUAD	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-10.55	1.56e-23	3.73e-20	-0.51	-0.43	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
LUAD	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	10.54	1.58e-23	3.78e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-10.54	1.58e-23	3.78e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	10.54	1.58e-23	3.78e-20	0.53	0.43	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
LUAD	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	10.54	1.58e-23	3.78e-20	0.55	0.43	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
LUAD	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	10.54	1.59e-23	3.8e-20	0.57	0.43	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
LUAD	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-10.54	1.61e-23	3.84e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
LUAD	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	10.54	1.61e-23	3.85e-20	0.58	0.43	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	10.54	1.61e-23	3.85e-20	0.58	0.43	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
LUAD	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	10.54	1.62e-23	3.86e-20	0.55	0.43	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-10.54	1.63e-23	3.88e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-10.54	1.63e-23	3.88e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	10.54	1.63e-23	3.89e-20	0.53	0.43	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-10.54	1.63e-23	3.89e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-10.54	1.64e-23	3.9e-20	-0.55	-0.43	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
LUAD	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	10.54	1.66e-23	3.95e-20	0.58	0.43	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
LUAD	cis	rs904251	0.504	rs12202664	ENSG00000279942.1	RP1-153P14.7	-10.54	1.67e-23	3.97e-20	-0.41	-0.43	Cognitive performance;	chr6:37513422	chr6:37567716~37571460:+
LUAD	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
LUAD	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	10.54	1.7e-23	4.05e-20	0.58	0.43	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
LUAD	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	10.54	1.7e-23	4.05e-20	0.53	0.43	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-10.54	1.71e-23	4.07e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
LUAD	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	10.54	1.71e-23	4.07e-20	0.58	0.43	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	10.54	1.71e-23	4.07e-20	0.58	0.43	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
LUAD	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-10.54	1.72e-23	4.08e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
LUAD	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	10.54	1.72e-23	4.09e-20	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
LUAD	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-10.53	1.73e-23	4.11e-20	-0.55	-0.43	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	10.53	1.73e-23	4.11e-20	0.56	0.43	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
LUAD	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	10.53	1.73e-23	4.12e-20	0.44	0.43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
LUAD	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-10.53	1.74e-23	4.13e-20	-0.58	-0.43	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
LUAD	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	10.53	1.75e-23	4.15e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	10.53	1.75e-23	4.15e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
LUAD	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	10.53	1.75e-23	4.17e-20	0.6	0.43	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
LUAD	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	10.53	1.76e-23	4.18e-20	0.56	0.43	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	10.53	1.76e-23	4.19e-20	0.52	0.43	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
LUAD	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	10.53	1.79e-23	4.24e-20	0.58	0.43	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
LUAD	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	10.53	1.79e-23	4.26e-20	0.55	0.43	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	10.53	1.81e-23	4.3e-20	0.55	0.43	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	10.53	1.81e-23	4.3e-20	0.55	0.43	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	10.53	1.81e-23	4.3e-20	0.55	0.43	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	10.53	1.81e-23	4.3e-20	0.55	0.43	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-10.53	1.81e-23	4.3e-20	-0.55	-0.43	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	10.53	1.83e-23	4.34e-20	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	10.53	1.83e-23	4.35e-20	0.56	0.43	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
LUAD	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-10.53	1.84e-23	4.36e-20	-0.66	-0.43	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
LUAD	cis	rs6538678	0.746	rs703693	ENSG00000199506.1	RNU6-247P	-10.53	1.85e-23	4.39e-20	-0.59	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95792529~95792635:-
LUAD	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	10.53	1.86e-23	4.41e-20	0.55	0.43	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
LUAD	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	10.53	1.86e-23	4.41e-20	0.48	0.43	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
LUAD	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	10.52	1.88e-23	4.46e-20	0.59	0.43	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
LUAD	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-10.52	1.89e-23	4.48e-20	-0.51	-0.43	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
LUAD	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	10.52	1.9e-23	4.49e-20	0.53	0.43	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
LUAD	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-10.52	1.91e-23	4.52e-20	-0.49	-0.43	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
LUAD	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	10.52	1.91e-23	4.52e-20	0.42	0.43	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
LUAD	cis	rs904251	0.523	rs1776454	ENSG00000279942.1	RP1-153P14.7	-10.52	1.93e-23	4.56e-20	-0.4	-0.43	Cognitive performance;	chr6:37514323	chr6:37567716~37571460:+
LUAD	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	10.52	1.95e-23	4.62e-20	0.52	0.43	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
LUAD	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-10.52	1.99e-23	4.7e-20	-0.52	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
LUAD	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	10.52	2e-23	4.72e-20	0.55	0.43	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
LUAD	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-10.52	2e-23	4.72e-20	-0.51	-0.43	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	10.52	2e-23	4.73e-20	0.55	0.43	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	10.52	2.02e-23	4.76e-20	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-10.52	2.02e-23	4.77e-20	-0.48	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
LUAD	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-10.52	2.02e-23	4.77e-20	-0.77	-0.43	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
LUAD	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-10.52	2.03e-23	4.79e-20	-0.55	-0.43	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-10.51	2.05e-23	4.84e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-10.51	2.05e-23	4.84e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
LUAD	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	10.51	2.05e-23	4.84e-20	0.64	0.43	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
LUAD	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	10.51	2.08e-23	4.91e-20	0.6	0.43	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	10.51	2.08e-23	4.91e-20	0.6	0.43	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	10.51	2.08e-23	4.91e-20	0.6	0.43	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
LUAD	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	10.51	2.09e-23	4.94e-20	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-10.51	2.1e-23	4.95e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
LUAD	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-10.51	2.1e-23	4.97e-20	-0.55	-0.43	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	10.51	2.14e-23	5.05e-20	0.53	0.43	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	10.51	2.15e-23	5.06e-20	0.52	0.43	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	10.51	2.16e-23	5.08e-20	0.56	0.43	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-10.5	2.24e-23	5.28e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
LUAD	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-10.5	2.27e-23	5.33e-20	-0.51	-0.43	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	10.5	2.27e-23	5.35e-20	0.53	0.43	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
LUAD	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	10.5	2.28e-23	5.37e-20	0.55	0.43	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
LUAD	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	10.5	2.3e-23	5.42e-20	0.5	0.43	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
LUAD	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	10.5	2.33e-23	5.47e-20	0.53	0.43	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
LUAD	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	10.5	2.33e-23	5.48e-20	0.55	0.43	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	10.5	2.33e-23	5.48e-20	0.55	0.43	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
LUAD	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-10.5	2.34e-23	5.49e-20	-0.4	-0.43	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
LUAD	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	10.5	2.35e-23	5.51e-20	0.75	0.43	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
LUAD	cis	rs904251	0.504	rs9380677	ENSG00000279942.1	RP1-153P14.7	-10.5	2.35e-23	5.52e-20	-0.4	-0.43	Cognitive performance;	chr6:37512590	chr6:37567716~37571460:+
LUAD	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	10.5	2.38e-23	5.59e-20	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
LUAD	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-10.5	2.39e-23	5.61e-20	-0.53	-0.43	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
LUAD	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-10.49	2.44e-23	5.72e-20	-0.52	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
LUAD	cis	rs6538678	0.929	rs10735336	ENSG00000199506.1	RNU6-247P	-10.49	2.45e-23	5.75e-20	-0.56	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95792529~95792635:-
LUAD	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	10.49	2.45e-23	5.75e-20	0.56	0.43	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
LUAD	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	10.49	2.46e-23	5.77e-20	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
LUAD	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-10.49	2.48e-23	5.82e-20	-0.54	-0.43	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-10.49	2.48e-23	5.82e-20	-0.54	-0.43	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-10.49	2.48e-23	5.82e-20	-0.54	-0.43	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
LUAD	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-10.49	2.5e-23	5.87e-20	-0.58	-0.43	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
LUAD	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	10.49	2.57e-23	6.02e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	10.49	2.59e-23	6.06e-20	0.4	0.43	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
LUAD	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	10.49	2.6e-23	6.09e-20	0.69	0.43	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
LUAD	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-10.49	2.64e-23	6.17e-20	-0.55	-0.43	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
LUAD	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	10.48	2.65e-23	6.2e-20	0.54	0.43	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
LUAD	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	10.48	2.66e-23	6.21e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	10.48	2.66e-23	6.21e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	10.48	2.66e-23	6.21e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	10.48	2.66e-23	6.21e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.523	rs2776872	ENSG00000279942.1	RP1-153P14.7	-10.48	2.69e-23	6.28e-20	-0.4	-0.43	Cognitive performance;	chr6:37515011	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs1757191	ENSG00000279942.1	RP1-153P14.7	-10.48	2.69e-23	6.28e-20	-0.4	-0.43	Cognitive performance;	chr6:37515095	chr6:37567716~37571460:+
LUAD	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-10.48	2.69e-23	6.29e-20	-0.65	-0.43	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
LUAD	cis	rs904251	0.523	rs2797799	ENSG00000279942.1	RP1-153P14.7	-10.48	2.69e-23	6.29e-20	-0.4	-0.43	Cognitive performance;	chr6:37515844	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	10.48	2.7e-23	6.32e-20	0.55	0.43	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.36e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.36e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.36e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.37e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.37e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	10.48	2.73e-23	6.38e-20	0.56	0.43	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
LUAD	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	10.48	2.74e-23	6.4e-20	0.59	0.43	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	10.48	2.74e-23	6.4e-20	0.59	0.43	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
LUAD	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-10.48	2.75e-23	6.4e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
LUAD	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	10.48	2.77e-23	6.45e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	10.48	2.79e-23	6.51e-20	0.55	0.43	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	10.48	2.79e-23	6.51e-20	0.55	0.43	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	10.48	2.79e-23	6.51e-20	0.55	0.43	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	10.48	2.79e-23	6.51e-20	0.55	0.43	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-10.48	2.8e-23	6.51e-20	-0.57	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
LUAD	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-10.48	2.8e-23	6.52e-20	-0.63	-0.43	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
LUAD	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-10.48	2.82e-23	6.58e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
LUAD	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-10.48	2.83e-23	6.59e-20	-0.55	-0.43	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
LUAD	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-10.48	2.83e-23	6.6e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
LUAD	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	10.48	2.84e-23	6.61e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
LUAD	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	10.48	2.86e-23	6.65e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
LUAD	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	10.47	2.9e-23	6.76e-20	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
LUAD	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	10.47	2.91e-23	6.77e-20	0.58	0.43	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
LUAD	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	10.47	2.91e-23	6.77e-20	0.58	0.43	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
LUAD	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	10.47	2.95e-23	6.86e-20	0.53	0.43	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
LUAD	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-10.47	2.97e-23	6.91e-20	-0.54	-0.43	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
LUAD	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	10.47	2.97e-23	6.91e-20	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.523	rs914348	ENSG00000279942.1	RP1-153P14.7	-10.47	3e-23	6.97e-20	-0.4	-0.43	Cognitive performance;	chr6:37516953	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	10.47	3.03e-23	7.05e-20	0.55	0.43	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
LUAD	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-10.47	3.04e-23	7.07e-20	-0.55	-0.43	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
LUAD	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	10.47	3.07e-23	7.13e-20	0.59	0.43	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	10.47	3.09e-23	7.18e-20	0.59	0.43	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
LUAD	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	10.46	3.16e-23	7.33e-20	0.56	0.43	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	10.46	3.17e-23	7.35e-20	0.54	0.43	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	10.46	3.17e-23	7.35e-20	0.54	0.43	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
LUAD	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-10.46	3.18e-23	7.38e-20	-0.65	-0.43	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
LUAD	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-10.46	3.18e-23	7.38e-20	-0.55	-0.43	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
LUAD	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	10.46	3.18e-23	7.38e-20	0.53	0.43	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	10.46	3.2e-23	7.43e-20	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
LUAD	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	10.46	3.21e-23	7.45e-20	0.53	0.43	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
LUAD	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	10.46	3.28e-23	7.58e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
LUAD	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	10.46	3.28e-23	7.59e-20	0.55	0.43	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	10.46	3.28e-23	7.59e-20	0.55	0.43	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-10.46	3.34e-23	7.73e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
LUAD	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
LUAD	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	10.46	3.35e-23	7.74e-20	0.51	0.43	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
LUAD	cis	rs6538678	0.712	rs10777748	ENSG00000199506.1	RNU6-247P	-10.46	3.37e-23	7.79e-20	-0.57	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95792529~95792635:-
LUAD	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	10.46	3.38e-23	7.81e-20	0.43	0.43	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
LUAD	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	10.46	3.4e-23	7.85e-20	0.54	0.43	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
LUAD	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-10.46	3.41e-23	7.87e-20	-0.53	-0.43	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
LUAD	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-10.46	3.42e-23	7.9e-20	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
LUAD	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	10.45	3.44e-23	7.95e-20	0.9	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
LUAD	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	10.45	3.47e-23	8e-20	0.54	0.43	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
LUAD	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-10.45	3.49e-23	8.05e-20	-0.49	-0.43	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
LUAD	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-10.45	3.49e-23	8.05e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-10.45	3.5e-23	8.07e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-10.45	3.5e-23	8.07e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-10.45	3.5e-23	8.07e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-10.45	3.5e-23	8.07e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
LUAD	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	10.45	3.52e-23	8.12e-20	0.59	0.43	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
LUAD	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	10.45	3.52e-23	8.12e-20	0.55	0.43	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
LUAD	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-10.45	3.56e-23	8.2e-20	-0.69	-0.43	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
LUAD	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	10.45	3.57e-23	8.23e-20	0.55	0.43	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	10.45	3.57e-23	8.23e-20	0.55	0.43	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	10.45	3.57e-23	8.23e-20	0.55	0.43	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	10.45	3.57e-23	8.23e-20	0.55	0.43	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-10.45	3.57e-23	8.23e-20	-0.53	-0.43	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
LUAD	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-10.45	3.57e-23	8.23e-20	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-10.45	3.57e-23	8.23e-20	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
LUAD	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-10.45	3.62e-23	8.33e-20	-0.51	-0.43	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
LUAD	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-10.45	3.69e-23	8.5e-20	-0.56	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
LUAD	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	10.45	3.69e-23	8.5e-20	0.44	0.43	Height;	chr3:53073764	chr3:53064283~53065091:-
LUAD	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	10.45	3.71e-23	8.55e-20	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
LUAD	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	10.45	3.72e-23	8.56e-20	0.55	0.43	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
LUAD	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-10.44	3.76e-23	8.66e-20	-0.51	-0.43	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
LUAD	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-10.44	3.77e-23	8.67e-20	-0.54	-0.43	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
LUAD	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	10.44	3.77e-23	8.67e-20	0.58	0.43	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
LUAD	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-10.44	3.85e-23	8.85e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-10.44	3.86e-23	8.87e-20	-0.54	-0.43	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-10.44	3.89e-23	8.95e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-10.44	3.89e-23	8.95e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
LUAD	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-10.44	3.99e-23	9.16e-20	-0.53	-0.43	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	10.44	3.99e-23	9.17e-20	0.53	0.43	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
LUAD	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	10.44	4.01e-23	9.21e-20	0.48	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
LUAD	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	10.44	4.05e-23	9.3e-20	0.51	0.43	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
LUAD	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	10.43	4.08e-23	9.36e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	10.43	4.08e-23	9.36e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	10.43	4.08e-23	9.36e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
LUAD	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	10.43	4.08e-23	9.36e-20	0.54	0.43	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	10.43	4.08e-23	9.36e-20	0.54	0.43	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-10.43	4.09e-23	9.38e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
LUAD	cis	rs6538678	0.864	rs4762249	ENSG00000199506.1	RNU6-247P	10.43	4.1e-23	9.4e-20	0.54	0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95792529~95792635:-
LUAD	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-10.43	4.14e-23	9.49e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-10.43	4.14e-23	9.49e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-10.43	4.14e-23	9.49e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	10.43	4.17e-23	9.56e-20	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
LUAD	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	10.43	4.19e-23	9.6e-20	0.55	0.43	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
LUAD	cis	rs904251	0.504	rs1757188	ENSG00000279942.1	RP1-153P14.7	-10.43	4.23e-23	9.69e-20	-0.4	-0.43	Cognitive performance;	chr6:37516032	chr6:37567716~37571460:+
LUAD	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-10.43	4.28e-23	9.81e-20	-0.5	-0.43	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
LUAD	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-10.43	4.3e-23	9.86e-20	-0.49	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
LUAD	cis	rs6538678	0.929	rs10745733	ENSG00000199506.1	RNU6-247P	-10.43	4.34e-23	9.94e-20	-0.56	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95792529~95792635:-
LUAD	cis	rs6538678	0.926	rs10745734	ENSG00000199506.1	RNU6-247P	-10.43	4.34e-23	9.94e-20	-0.56	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95792529~95792635:-
LUAD	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-10.43	4.38e-23	1e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	10.43	4.39e-23	1e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
LUAD	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-10.43	4.41e-23	1.01e-19	-0.52	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
LUAD	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-10.42	4.44e-23	1.02e-19	-0.57	-0.43	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
LUAD	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	10.42	4.49e-23	1.03e-19	0.59	0.43	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
LUAD	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-10.42	4.55e-23	1.04e-19	-0.51	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
LUAD	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	10.42	4.59e-23	1.05e-19	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
LUAD	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	10.42	4.61e-23	1.05e-19	0.47	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
LUAD	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	10.42	4.62e-23	1.06e-19	0.49	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	10.42	4.62e-23	1.06e-19	0.55	0.43	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
LUAD	cis	rs11089937	0.963	rs2073454	ENSG00000211639.2	IGLV4-60	10.42	4.66e-23	1.07e-19	0.44	0.43	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22162199~22162681:+
LUAD	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-10.42	4.67e-23	1.07e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
LUAD	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
LUAD	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	10.42	4.68e-23	1.07e-19	0.55	0.43	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-10.42	4.68e-23	1.07e-19	-0.29	-0.43	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
LUAD	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	10.42	4.7e-23	1.07e-19	0.48	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
LUAD	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-10.42	4.71e-23	1.07e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-10.41	4.85e-23	1.11e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
LUAD	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-10.41	4.85e-23	1.11e-19	-0.47	-0.43	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-10.41	4.85e-23	1.11e-19	-0.47	-0.43	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
LUAD	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	10.41	4.88e-23	1.11e-19	0.63	0.43	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
LUAD	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-10.41	4.91e-23	1.12e-19	-0.65	-0.43	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
LUAD	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	10.41	4.97e-23	1.13e-19	0.52	0.43	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
LUAD	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-10.41	4.98e-23	1.13e-19	-0.51	-0.43	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
LUAD	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
LUAD	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	10.41	5.02e-23	1.14e-19	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
LUAD	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-10.41	5.03e-23	1.15e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-10.41	5.03e-23	1.15e-19	-0.52	-0.43	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-10.41	5.03e-23	1.15e-19	-0.44	-0.43	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
LUAD	cis	rs904251	0.523	rs2797794	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37512828	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2776920	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37512829	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.504	rs2797795	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37512907	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2797796	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37513110	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2776870	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37513588	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2797798	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37513661	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2776871	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37513983	chr6:37567716~37571460:+
LUAD	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-10.41	5.15e-23	1.17e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	10.41	5.2e-23	1.18e-19	0.55	0.43	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	10.41	5.2e-23	1.18e-19	0.55	0.43	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	10.41	5.2e-23	1.18e-19	0.55	0.43	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
LUAD	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-10.41	5.22e-23	1.18e-19	-0.69	-0.43	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
LUAD	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-10.41	5.25e-23	1.19e-19	-0.47	-0.43	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
LUAD	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	10.4	5.27e-23	1.19e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	10.4	5.27e-23	1.19e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	10.4	5.27e-23	1.19e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	10.4	5.27e-23	1.19e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
LUAD	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	10.4	5.27e-23	1.19e-19	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	10.4	5.32e-23	1.2e-19	0.55	0.43	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
LUAD	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	10.4	5.34e-23	1.21e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
LUAD	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-10.4	5.44e-23	1.23e-19	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
LUAD	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-10.4	5.5e-23	1.24e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
LUAD	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-10.4	5.52e-23	1.25e-19	-0.38	-0.43	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
LUAD	cis	rs6538678	0.929	rs7962359	ENSG00000199506.1	RNU6-247P	-10.4	5.52e-23	1.25e-19	-0.56	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	10.4	5.59e-23	1.26e-19	0.55	0.43	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-10.4	5.61e-23	1.27e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-10.4	5.64e-23	1.27e-19	-0.56	-0.43	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-10.4	5.66e-23	1.28e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
LUAD	cis	rs17837474	0.656	rs17273	ENSG00000276597.1	TRBV11-3	10.4	5.67e-23	1.28e-19	0.63	0.43	Cancer;	chr7:142407435	chr7:142554836~142555318:+
LUAD	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-10.39	5.77e-23	1.3e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-10.39	5.83e-23	1.32e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	10.39	5.84e-23	1.32e-19	0.53	0.43	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-10.39	5.84e-23	1.32e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-10.39	5.84e-23	1.32e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	10.39	5.87e-23	1.32e-19	0.55	0.43	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
LUAD	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-10.39	5.88e-23	1.32e-19	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
LUAD	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	10.39	5.9e-23	1.33e-19	0.57	0.43	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
LUAD	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-10.39	5.93e-23	1.34e-19	-0.64	-0.43	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	10.39	5.94e-23	1.34e-19	0.55	0.43	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
LUAD	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-10.39	5.97e-23	1.34e-19	-0.4	-0.43	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
LUAD	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-10.39	6.01e-23	1.35e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
LUAD	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-10.39	6.04e-23	1.36e-19	-0.81	-0.43	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
LUAD	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	10.39	6.16e-23	1.39e-19	0.39	0.43	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
LUAD	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	10.39	6.2e-23	1.39e-19	0.52	0.43	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	10.39	6.22e-23	1.4e-19	0.51	0.43	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	10.39	6.22e-23	1.4e-19	0.55	0.43	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	10.38	6.25e-23	1.41e-19	0.53	0.43	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-10.38	6.26e-23	1.41e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-10.38	6.26e-23	1.41e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
LUAD	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	10.38	6.28e-23	1.41e-19	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
LUAD	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	10.38	6.32e-23	1.42e-19	0.59	0.43	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
LUAD	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-10.38	6.44e-23	1.45e-19	-0.49	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	10.38	6.48e-23	1.46e-19	0.34	0.43	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
LUAD	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	10.38	6.5e-23	1.46e-19	0.53	0.43	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
LUAD	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-10.38	6.53e-23	1.47e-19	-0.48	-0.43	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
LUAD	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	10.38	6.62e-23	1.48e-19	0.54	0.43	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
LUAD	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-10.38	6.63e-23	1.49e-19	-0.49	-0.43	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
LUAD	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	10.38	6.64e-23	1.49e-19	0.55	0.43	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
LUAD	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-10.38	6.72e-23	1.51e-19	-0.5	-0.43	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
LUAD	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-10.38	6.72e-23	1.51e-19	-0.54	-0.43	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
LUAD	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-10.37	6.8e-23	1.53e-19	-0.47	-0.43	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
LUAD	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	10.37	6.86e-23	1.54e-19	0.58	0.43	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
LUAD	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-10.37	6.9e-23	1.55e-19	-0.64	-0.43	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
LUAD	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	10.37	6.95e-23	1.56e-19	0.52	0.43	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	10.37	6.95e-23	1.56e-19	0.52	0.43	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
LUAD	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	10.37	6.97e-23	1.56e-19	0.41	0.43	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	10.37	7.06e-23	1.58e-19	0.53	0.43	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	10.37	7.13e-23	1.6e-19	0.54	0.43	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	10.37	7.13e-23	1.6e-19	0.53	0.43	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	10.37	7.21e-23	1.61e-19	0.51	0.43	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
LUAD	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-10.37	7.26e-23	1.62e-19	-0.47	-0.43	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
LUAD	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-10.37	7.37e-23	1.65e-19	-0.58	-0.43	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
LUAD	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-10.36	7.42e-23	1.66e-19	-0.56	-0.43	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.523	rs9369005	ENSG00000279942.1	RP1-153P14.7	-10.36	7.57e-23	1.69e-19	-0.39	-0.43	Cognitive performance;	chr6:37515333	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	10.36	7.57e-23	1.69e-19	0.54	0.43	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	10.36	7.57e-23	1.69e-19	0.51	0.43	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-10.36	7.68e-23	1.71e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	10.36	7.69e-23	1.72e-19	0.51	0.43	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
LUAD	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-10.36	7.77e-23	1.73e-19	-0.54	-0.43	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
LUAD	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
LUAD	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	10.36	7.86e-23	1.75e-19	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	10.36	7.86e-23	1.75e-19	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
LUAD	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	10.36	7.86e-23	1.75e-19	0.52	0.43	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	10.36	7.87e-23	1.75e-19	0.53	0.43	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
LUAD	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-10.36	7.9e-23	1.76e-19	-0.48	-0.43	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-10.36	7.92e-23	1.77e-19	-0.57	-0.43	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-10.36	8.04e-23	1.79e-19	-0.54	-0.43	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
LUAD	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-10.35	8.13e-23	1.81e-19	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
LUAD	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	10.35	8.17e-23	1.82e-19	0.57	0.43	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-10.35	8.2e-23	1.83e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
LUAD	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	10.35	8.22e-23	1.83e-19	0.54	0.43	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
LUAD	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-10.35	8.22e-23	1.83e-19	-0.56	-0.43	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	10.35	8.31e-23	1.85e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
LUAD	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-10.35	8.32e-23	1.85e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-10.35	8.36e-23	1.86e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
LUAD	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	10.35	8.37e-23	1.86e-19	0.63	0.43	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
LUAD	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	10.35	8.43e-23	1.87e-19	0.52	0.43	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
LUAD	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-10.35	8.44e-23	1.88e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	10.35	8.45e-23	1.88e-19	0.55	0.43	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-10.35	8.45e-23	1.88e-19	-0.56	-0.43	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
LUAD	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-10.35	8.5e-23	1.89e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
LUAD	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	10.35	8.53e-23	1.9e-19	0.55	0.43	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
LUAD	cis	rs6538678	0.777	rs10745736	ENSG00000199506.1	RNU6-247P	-10.35	8.54e-23	1.9e-19	-0.59	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95792529~95792635:-
LUAD	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	10.35	8.55e-23	1.9e-19	0.5	0.43	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	10.35	8.66e-23	1.92e-19	0.52	0.43	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-10.35	8.68e-23	1.93e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
LUAD	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	10.35	8.74e-23	1.94e-19	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
LUAD	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-10.34	8.79e-23	1.95e-19	-0.53	-0.43	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
LUAD	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-10.34	8.92e-23	1.98e-19	-0.57	-0.43	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	10.34	8.96e-23	1.99e-19	0.55	0.43	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-10.34	8.99e-23	1.99e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-10.34	8.99e-23	1.99e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
LUAD	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-10.34	8.99e-23	1.99e-19	-0.47	-0.43	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
LUAD	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	10.34	9.04e-23	2e-19	0.52	0.43	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	10.34	9.04e-23	2e-19	0.52	0.43	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	10.34	9.04e-23	2e-19	0.52	0.43	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
LUAD	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	10.34	9.06e-23	2.01e-19	0.52	0.43	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
LUAD	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	10.34	9.11e-23	2.02e-19	0.54	0.43	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	10.34	9.11e-23	2.02e-19	0.54	0.43	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	10.34	9.11e-23	2.02e-19	0.54	0.43	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
LUAD	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	10.34	9.24e-23	2.05e-19	0.57	0.43	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
LUAD	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	10.34	9.24e-23	2.05e-19	0.57	0.43	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
LUAD	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-10.34	9.25e-23	2.05e-19	-0.64	-0.43	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
LUAD	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	10.34	9.29e-23	2.06e-19	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	10.34	9.29e-23	2.06e-19	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	10.34	9.29e-23	2.06e-19	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
LUAD	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	10.34	9.34e-23	2.07e-19	0.57	0.43	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
LUAD	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	10.34	9.35e-23	2.07e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	10.34	9.49e-23	2.1e-19	0.52	0.43	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	10.34	9.49e-23	2.1e-19	0.52	0.43	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	10.34	9.49e-23	2.1e-19	0.52	0.43	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
LUAD	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	10.34	9.52e-23	2.1e-19	0.38	0.43	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-10.34	9.53e-23	2.11e-19	-0.64	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
LUAD	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-10.33	9.58e-23	2.12e-19	-0.52	-0.43	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
LUAD	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	10.33	9.59e-23	2.12e-19	0.52	0.43	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
LUAD	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
LUAD	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	10.33	9.59e-23	2.12e-19	0.5	0.43	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	10.33	9.59e-23	2.12e-19	0.5	0.43	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	10.33	9.59e-23	2.12e-19	0.5	0.43	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
LUAD	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	10.33	9.63e-23	2.13e-19	0.55	0.43	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
LUAD	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	10.33	9.63e-23	2.13e-19	0.55	0.43	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
LUAD	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	10.33	9.75e-23	2.15e-19	0.5	0.43	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	10.33	9.81e-23	2.17e-19	0.52	0.43	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
LUAD	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-10.33	9.86e-23	2.18e-19	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
LUAD	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	10.33	9.87e-23	2.18e-19	0.53	0.43	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
LUAD	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	10.33	1e-22	2.21e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
LUAD	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-10.33	1.01e-22	2.22e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-10.33	1.01e-22	2.22e-19	-0.52	-0.43	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
LUAD	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	10.33	1.01e-22	2.22e-19	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-10.33	1.01e-22	2.23e-19	-0.48	-0.43	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	10.33	1.02e-22	2.25e-19	0.5	0.43	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
LUAD	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-10.33	1.03e-22	2.27e-19	-0.57	-0.43	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
LUAD	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-10.33	1.03e-22	2.27e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-10.33	1.03e-22	2.28e-19	-0.56	-0.43	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-10.33	1.04e-22	2.28e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-10.33	1.04e-22	2.28e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-10.33	1.04e-22	2.28e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
LUAD	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-10.33	1.04e-22	2.28e-19	-0.54	-0.43	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
LUAD	cis	rs6538678	0.929	rs10777744	ENSG00000199506.1	RNU6-247P	-10.33	1.04e-22	2.28e-19	-0.55	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95792529~95792635:-
LUAD	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-10.33	1.04e-22	2.29e-19	-0.66	-0.43	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
LUAD	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	10.33	1.04e-22	2.29e-19	0.57	0.43	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
LUAD	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	10.32	1.04e-22	2.29e-19	0.55	0.43	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-10.32	1.05e-22	2.31e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-10.32	1.06e-22	2.33e-19	-0.42	-0.43	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
LUAD	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-10.32	1.06e-22	2.34e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
LUAD	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-10.32	1.07e-22	2.34e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-10.32	1.07e-22	2.35e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-10.32	1.07e-22	2.35e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-10.32	1.07e-22	2.35e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-10.32	1.08e-22	2.36e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
LUAD	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	10.32	1.09e-22	2.39e-19	0.59	0.43	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
LUAD	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-10.32	1.1e-22	2.42e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	10.32	1.11e-22	2.44e-19	0.57	0.43	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-10.32	1.11e-22	2.44e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-10.32	1.11e-22	2.44e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
LUAD	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	10.32	1.12e-22	2.45e-19	0.5	0.43	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
LUAD	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-10.32	1.13e-22	2.47e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
LUAD	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-10.32	1.13e-22	2.48e-19	-0.75	-0.43	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
LUAD	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-10.31	1.14e-22	2.49e-19	-0.46	-0.43	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
LUAD	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
LUAD	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-10.31	1.15e-22	2.51e-19	-0.55	-0.43	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
LUAD	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	10.31	1.15e-22	2.52e-19	0.44	0.43	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
LUAD	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	10.31	1.17e-22	2.55e-19	0.55	0.43	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-10.31	1.17e-22	2.55e-19	-0.48	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
LUAD	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	10.31	1.17e-22	2.55e-19	0.57	0.43	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	10.31	1.17e-22	2.56e-19	0.34	0.43	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
LUAD	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	10.31	1.17e-22	2.56e-19	0.57	0.43	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
LUAD	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
LUAD	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	10.31	1.19e-22	2.6e-19	0.62	0.43	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
LUAD	cis	rs11089937	1	rs11089937	ENSG00000211639.2	IGLV4-60	10.31	1.19e-22	2.61e-19	0.44	0.43	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22162199~22162681:+
LUAD	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	10.31	1.2e-22	2.61e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
LUAD	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	10.31	1.2e-22	2.62e-19	0.54	0.43	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
LUAD	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	10.31	1.21e-22	2.64e-19	0.55	0.43	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
LUAD	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-10.31	1.21e-22	2.64e-19	-0.51	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
LUAD	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
LUAD	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-10.31	1.23e-22	2.68e-19	-0.63	-0.43	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
LUAD	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	10.3	1.24e-22	2.7e-19	0.51	0.43	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	10.3	1.24e-22	2.71e-19	0.5	0.43	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	10.3	1.25e-22	2.72e-19	0.53	0.43	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
LUAD	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-10.3	1.25e-22	2.73e-19	-0.46	-0.43	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
LUAD	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-10.3	1.26e-22	2.74e-19	-0.48	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
LUAD	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-10.3	1.27e-22	2.76e-19	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
LUAD	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-10.3	1.27e-22	2.76e-19	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
LUAD	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-10.3	1.27e-22	2.77e-19	-0.55	-0.43	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
LUAD	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	10.3	1.28e-22	2.78e-19	0.76	0.43	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-10.3	1.29e-22	2.81e-19	-0.53	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
LUAD	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-10.3	1.3e-22	2.82e-19	-0.55	-0.43	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
LUAD	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-10.3	1.3e-22	2.83e-19	-0.63	-0.43	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
LUAD	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	10.3	1.31e-22	2.84e-19	0.58	0.43	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
LUAD	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	10.3	1.32e-22	2.87e-19	0.52	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
LUAD	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	10.3	1.33e-22	2.88e-19	0.51	0.42	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
LUAD	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	10.3	1.33e-22	2.88e-19	0.54	0.42	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
LUAD	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	10.3	1.33e-22	2.89e-19	0.54	0.42	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	10.3	1.34e-22	2.9e-19	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
LUAD	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	10.3	1.34e-22	2.91e-19	0.54	0.42	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	10.3	1.34e-22	2.91e-19	0.54	0.42	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	10.3	1.34e-22	2.91e-19	0.54	0.42	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	10.3	1.34e-22	2.91e-19	0.54	0.42	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
LUAD	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-10.29	1.35e-22	2.92e-19	-0.63	-0.42	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
LUAD	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	10.29	1.35e-22	2.94e-19	0.53	0.42	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
LUAD	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-10.29	1.36e-22	2.95e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
LUAD	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	10.29	1.36e-22	2.96e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
LUAD	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	10.29	1.37e-22	2.97e-19	0.52	0.42	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	10.29	1.37e-22	2.97e-19	0.52	0.42	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	10.29	1.37e-22	2.97e-19	0.52	0.42	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	10.29	1.37e-22	2.97e-19	0.52	0.42	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
LUAD	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-10.29	1.37e-22	2.98e-19	-0.53	-0.42	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
LUAD	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-10.29	1.37e-22	2.98e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
LUAD	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	10.29	1.38e-22	2.99e-19	0.47	0.42	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
LUAD	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	10.29	1.38e-22	2.99e-19	0.5	0.42	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
LUAD	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-10.29	1.39e-22	3.01e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-10.29	1.39e-22	3.01e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
LUAD	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	10.29	1.39e-22	3.01e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
LUAD	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-10.29	1.4e-22	3.03e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-10.29	1.4e-22	3.03e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	10.29	1.41e-22	3.05e-19	0.52	0.42	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	10.29	1.42e-22	3.07e-19	0.53	0.42	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	10.29	1.42e-22	3.08e-19	0.52	0.42	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
LUAD	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-10.29	1.42e-22	3.08e-19	-0.46	-0.42	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
LUAD	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	10.29	1.44e-22	3.11e-19	0.5	0.42	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
LUAD	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	10.29	1.44e-22	3.12e-19	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
LUAD	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	10.29	1.44e-22	3.12e-19	0.53	0.42	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
LUAD	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-10.29	1.44e-22	3.13e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
LUAD	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	10.29	1.45e-22	3.13e-19	0.53	0.42	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
LUAD	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	10.29	1.45e-22	3.14e-19	0.61	0.42	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-10.28	1.47e-22	3.18e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-10.28	1.47e-22	3.18e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
LUAD	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-10.28	1.48e-22	3.21e-19	-0.54	-0.42	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
LUAD	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-10.28	1.53e-22	3.3e-19	-0.47	-0.42	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
LUAD	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-10.28	1.53e-22	3.31e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-10.28	1.54e-22	3.32e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-10.28	1.54e-22	3.32e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-10.28	1.54e-22	3.32e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-10.28	1.54e-22	3.32e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
LUAD	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-10.28	1.54e-22	3.33e-19	-0.47	-0.42	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
LUAD	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	10.28	1.55e-22	3.35e-19	0.51	0.42	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	10.28	1.55e-22	3.35e-19	0.51	0.42	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
LUAD	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-10.28	1.56e-22	3.37e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-10.28	1.58e-22	3.42e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-10.28	1.58e-22	3.42e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	10.28	1.59e-22	3.42e-19	0.52	0.42	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-10.27	1.6e-22	3.44e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
LUAD	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	10.27	1.6e-22	3.45e-19	0.54	0.42	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	10.27	1.6e-22	3.45e-19	0.54	0.42	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
LUAD	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	10.27	1.6e-22	3.46e-19	0.52	0.42	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-10.27	1.61e-22	3.48e-19	-0.41	-0.42	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	10.27	1.62e-22	3.5e-19	0.5	0.42	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	10.27	1.65e-22	3.56e-19	0.5	0.42	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	10.27	1.65e-22	3.56e-19	0.5	0.42	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	10.27	1.65e-22	3.56e-19	0.5	0.42	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
LUAD	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	10.27	1.66e-22	3.57e-19	0.68	0.42	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
LUAD	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	10.27	1.67e-22	3.59e-19	0.51	0.42	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	10.27	1.68e-22	3.61e-19	0.53	0.42	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-10.27	1.68e-22	3.61e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
LUAD	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	10.27	1.68e-22	3.62e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
LUAD	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-10.27	1.68e-22	3.63e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
LUAD	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.68e-22	3.63e-19	-0.56	-0.42	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.68e-22	3.63e-19	-0.56	-0.42	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.69e-22	3.63e-19	-0.56	-0.42	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
LUAD	cis	rs2729354	0.779	rs2511984	ENSG00000265566.2	RN7SL605P	-10.27	1.7e-22	3.65e-19	-0.64	-0.42	Blood protein levels;	chr11:57511260	chr11:57528085~57528365:-
LUAD	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	10.27	1.72e-22	3.7e-19	0.54	0.42	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	10.27	1.72e-22	3.7e-19	0.54	0.42	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	10.26	1.76e-22	3.78e-19	0.53	0.42	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
LUAD	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-10.26	1.77e-22	3.8e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-10.26	1.77e-22	3.8e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
LUAD	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	10.26	1.78e-22	3.82e-19	0.5	0.42	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
LUAD	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
LUAD	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	10.26	1.79e-22	3.84e-19	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
LUAD	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	10.26	1.8e-22	3.86e-19	0.5	0.42	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
LUAD	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-10.26	1.82e-22	3.91e-19	-0.47	-0.42	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
LUAD	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	10.26	1.82e-22	3.91e-19	0.51	0.42	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
LUAD	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-10.26	1.86e-22	3.99e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
LUAD	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-10.26	1.89e-22	4.04e-19	-0.52	-0.42	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
LUAD	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-10.25	1.9e-22	4.06e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	10.25	1.9e-22	4.07e-19	0.52	0.42	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
LUAD	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-10.25	1.9e-22	4.07e-19	-0.39	-0.42	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	10.25	1.91e-22	4.09e-19	0.34	0.42	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
LUAD	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-10.25	1.92e-22	4.11e-19	-0.47	-0.42	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
LUAD	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	10.25	1.93e-22	4.13e-19	0.48	0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
LUAD	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-10.25	1.93e-22	4.14e-19	-0.52	-0.42	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-10.25	1.94e-22	4.14e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
LUAD	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	10.25	1.96e-22	4.2e-19	0.53	0.42	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
LUAD	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	10.25	1.97e-22	4.2e-19	0.5	0.42	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
LUAD	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-10.25	1.97e-22	4.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-10.25	1.97e-22	4.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-10.25	1.98e-22	4.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
LUAD	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-10.25	1.98e-22	4.23e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
LUAD	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-10.25	2.01e-22	4.29e-19	-0.45	-0.42	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
LUAD	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-10.25	2.01e-22	4.29e-19	-0.47	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
LUAD	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-10.25	2.04e-22	4.36e-19	-0.48	-0.42	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
LUAD	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-10.25	2.05e-22	4.38e-19	-0.38	-0.42	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
LUAD	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	10.24	2.07e-22	4.42e-19	0.54	0.42	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
LUAD	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	10.24	2.09e-22	4.47e-19	0.75	0.42	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	10.24	2.09e-22	4.47e-19	0.75	0.42	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	10.24	2.1e-22	4.48e-19	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
LUAD	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-10.24	2.13e-22	4.55e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
LUAD	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	10.24	2.13e-22	4.55e-19	0.54	0.42	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
LUAD	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-10.24	2.14e-22	4.56e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-10.24	2.14e-22	4.56e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
LUAD	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-10.24	2.19e-22	4.66e-19	-0.63	-0.42	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
LUAD	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	10.24	2.19e-22	4.68e-19	0.64	0.42	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
LUAD	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-10.24	2.21e-22	4.71e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
LUAD	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	10.24	2.21e-22	4.71e-19	0.62	0.42	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
LUAD	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	10.24	2.21e-22	4.71e-19	0.62	0.42	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
LUAD	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-10.24	2.24e-22	4.77e-19	-0.47	-0.42	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
LUAD	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-10.23	2.24e-22	4.78e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
LUAD	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	10.23	2.27e-22	4.84e-19	0.56	0.42	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
LUAD	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	10.23	2.28e-22	4.84e-19	0.75	0.42	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
LUAD	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	10.23	2.28e-22	4.85e-19	0.52	0.42	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
LUAD	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	10.23	2.29e-22	4.86e-19	0.57	0.42	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
LUAD	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	10.23	2.3e-22	4.89e-19	0.52	0.42	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
LUAD	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-10.23	2.3e-22	4.89e-19	-0.47	-0.42	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
LUAD	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-10.23	2.31e-22	4.91e-19	-0.6	-0.42	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
LUAD	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-10.23	2.31e-22	4.92e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	10.23	2.32e-22	4.93e-19	0.5	0.42	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-10.23	2.32e-22	4.94e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	10.23	2.36e-22	5.02e-19	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
LUAD	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	10.23	2.36e-22	5.02e-19	0.41	0.42	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
LUAD	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	10.23	2.36e-22	5.02e-19	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-10.23	2.37e-22	5.04e-19	-0.51	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
LUAD	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	10.23	2.39e-22	5.07e-19	0.56	0.42	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
LUAD	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-10.23	2.41e-22	5.11e-19	-0.54	-0.42	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
LUAD	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	10.22	2.44e-22	5.18e-19	0.5	0.42	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	10.22	2.45e-22	5.21e-19	0.52	0.42	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
LUAD	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	10.22	2.47e-22	5.24e-19	0.6	0.42	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
LUAD	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	10.22	2.51e-22	5.32e-19	0.52	0.42	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	10.22	2.52e-22	5.34e-19	0.51	0.42	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
LUAD	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-10.22	2.53e-22	5.37e-19	-0.47	-0.42	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-10.22	2.53e-22	5.37e-19	-0.47	-0.42	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-10.22	2.53e-22	5.37e-19	-0.47	-0.42	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
LUAD	cis	rs904251	0.523	rs1776455	ENSG00000279942.1	RP1-153P14.7	-10.22	2.54e-22	5.38e-19	-0.39	-0.42	Cognitive performance;	chr6:37515147	chr6:37567716~37571460:+
LUAD	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-10.22	2.55e-22	5.39e-19	-0.56	-0.42	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-10.22	2.55e-22	5.39e-19	-0.56	-0.42	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
LUAD	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	10.22	2.55e-22	5.41e-19	0.5	0.42	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
LUAD	cis	rs1823913	1	rs4853561	ENSG00000280083.1	RP11-317J9.1	10.22	2.58e-22	5.47e-19	0.54	0.42	Obesity-related traits;	chr2:191242980	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs6704784	ENSG00000280083.1	RP11-317J9.1	10.22	2.58e-22	5.47e-19	0.54	0.42	Obesity-related traits;	chr2:191244832	chr2:191154118~191156070:-
LUAD	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	10.22	2.59e-22	5.48e-19	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
LUAD	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-10.22	2.59e-22	5.48e-19	-0.5	-0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
LUAD	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-10.22	2.59e-22	5.49e-19	-0.47	-0.42	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-10.22	2.59e-22	5.49e-19	-0.47	-0.42	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-10.22	2.59e-22	5.49e-19	-0.47	-0.42	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-10.22	2.6e-22	5.49e-19	-0.47	-0.42	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
LUAD	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-10.22	2.6e-22	5.49e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-10.22	2.6e-22	5.49e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-10.22	2.6e-22	5.49e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-10.22	2.6e-22	5.49e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
LUAD	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	10.22	2.6e-22	5.51e-19	0.5	0.42	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
LUAD	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-10.22	2.61e-22	5.52e-19	-0.5	-0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
LUAD	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	10.22	2.61e-22	5.52e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	10.22	2.61e-22	5.52e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	10.22	2.61e-22	5.52e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	10.22	2.61e-22	5.52e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
LUAD	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	10.22	2.61e-22	5.53e-19	0.48	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
LUAD	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	10.22	2.62e-22	5.53e-19	0.5	0.42	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
LUAD	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	10.22	2.62e-22	5.55e-19	0.52	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
LUAD	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	10.22	2.63e-22	5.56e-19	0.49	0.42	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
LUAD	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	10.22	2.64e-22	5.57e-19	0.57	0.42	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
LUAD	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-10.22	2.64e-22	5.58e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-10.22	2.64e-22	5.58e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
LUAD	cis	rs1823913	1	rs1454749	ENSG00000280083.1	RP11-317J9.1	-10.21	2.68e-22	5.67e-19	-0.54	-0.42	Obesity-related traits;	chr2:191240909	chr2:191154118~191156070:-
LUAD	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-10.21	2.69e-22	5.68e-19	-0.47	-0.42	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-10.21	2.7e-22	5.7e-19	-0.56	-0.42	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
LUAD	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-10.21	2.7e-22	5.71e-19	-0.56	-0.42	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-10.21	2.74e-22	5.77e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-10.21	2.74e-22	5.77e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-10.21	2.78e-22	5.87e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
LUAD	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	10.21	2.79e-22	5.88e-19	0.51	0.42	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
LUAD	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-10.21	2.82e-22	5.93e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
LUAD	cis	rs3096299	0.719	rs2965818	ENSG00000274627.1	RP11-104N10.2	10.21	2.82e-22	5.93e-19	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89516797~89522217:+
LUAD	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-10.21	2.83e-22	5.97e-19	-0.44	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
LUAD	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
LUAD	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-10.21	2.83e-22	5.97e-19	-0.5	-0.42	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
LUAD	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-10.21	2.84e-22	5.99e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
LUAD	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-10.21	2.86e-22	6.02e-19	-0.61	-0.42	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
LUAD	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-10.21	2.87e-22	6.04e-19	-0.47	-0.42	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	10.21	2.88e-22	6.06e-19	0.39	0.42	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
LUAD	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	10.2	2.89e-22	6.09e-19	0.61	0.42	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	10.2	2.89e-22	6.09e-19	0.61	0.42	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
LUAD	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	10.2	2.9e-22	6.1e-19	0.51	0.42	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
LUAD	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-10.2	2.9e-22	6.11e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
LUAD	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-10.2	2.93e-22	6.17e-19	-0.47	-0.42	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-10.2	2.94e-22	6.18e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-10.2	2.94e-22	6.18e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	10.2	2.94e-22	6.19e-19	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-10.2	2.95e-22	6.2e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
LUAD	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-10.2	2.96e-22	6.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-10.2	2.96e-22	6.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
LUAD	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	10.2	2.98e-22	6.26e-19	0.56	0.42	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
LUAD	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-10.2	3.04e-22	6.38e-19	-0.59	-0.42	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
LUAD	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	10.2	3.06e-22	6.43e-19	0.5	0.42	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-10.2	3.06e-22	6.43e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-10.2	3.06e-22	6.43e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	10.2	3.06e-22	6.43e-19	0.5	0.42	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	10.2	3.07e-22	6.45e-19	0.53	0.42	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	10.2	3.1e-22	6.51e-19	0.39	0.42	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	10.2	3.12e-22	6.54e-19	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
LUAD	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-10.2	3.12e-22	6.54e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
LUAD	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-10.2	3.13e-22	6.57e-19	-0.44	-0.42	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
LUAD	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-10.2	3.14e-22	6.58e-19	-0.46	-0.42	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-10.2	3.14e-22	6.58e-19	-0.46	-0.42	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-10.2	3.14e-22	6.58e-19	-0.46	-0.42	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-10.2	3.14e-22	6.58e-19	-0.46	-0.42	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-10.2	3.14e-22	6.58e-19	-0.29	-0.42	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-10.2	3.14e-22	6.58e-19	-0.29	-0.42	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
LUAD	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-10.2	3.14e-22	6.59e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
LUAD	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	10.2	3.15e-22	6.6e-19	0.48	0.42	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
LUAD	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	10.19	3.16e-22	6.63e-19	0.57	0.42	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-10.19	3.18e-22	6.66e-19	-0.29	-0.42	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
LUAD	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-10.19	3.2e-22	6.71e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
LUAD	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	10.19	3.21e-22	6.73e-19	0.55	0.42	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
LUAD	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	10.19	3.25e-22	6.81e-19	0.53	0.42	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
LUAD	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-10.19	3.28e-22	6.86e-19	-0.47	-0.42	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-10.19	3.28e-22	6.86e-19	-0.47	-0.42	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
LUAD	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-10.19	3.3e-22	6.91e-19	-0.56	-0.42	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
LUAD	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	10.19	3.33e-22	6.97e-19	0.5	0.42	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
LUAD	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-10.19	3.34e-22	6.98e-19	-0.54	-0.42	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
LUAD	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	10.19	3.35e-22	7e-19	0.57	0.42	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
LUAD	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	10.19	3.38e-22	7.07e-19	0.54	0.42	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
LUAD	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	10.19	3.4e-22	7.1e-19	0.5	0.42	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-10.19	3.4e-22	7.1e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	10.18	3.45e-22	7.2e-19	0.51	0.42	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
LUAD	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	10.18	3.45e-22	7.21e-19	0.54	0.42	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	10.18	3.5e-22	7.32e-19	0.52	0.42	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.523	rs10807184	ENSG00000279942.1	RP1-153P14.7	-10.18	3.51e-22	7.33e-19	-0.39	-0.42	Cognitive performance;	chr6:37515937	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	10.18	3.51e-22	7.34e-19	0.52	0.42	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	10.18	3.51e-22	7.34e-19	0.43	0.42	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
LUAD	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	10.18	3.53e-22	7.36e-19	0.49	0.42	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
LUAD	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	10.18	3.6e-22	7.52e-19	0.54	0.42	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
LUAD	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	10.18	3.64e-22	7.6e-19	0.5	0.42	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-10.18	3.66e-22	7.62e-19	-0.29	-0.42	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-10.18	3.66e-22	7.62e-19	-0.29	-0.42	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-10.18	3.66e-22	7.62e-19	-0.29	-0.42	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
LUAD	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	10.18	3.67e-22	7.64e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	10.18	3.67e-22	7.64e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	10.18	3.67e-22	7.64e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
LUAD	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-10.18	3.72e-22	7.74e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
LUAD	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	10.17	3.78e-22	7.87e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
LUAD	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	10.17	3.8e-22	7.9e-19	0.55	0.42	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
LUAD	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	10.17	3.85e-22	8.01e-19	0.51	0.42	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	10.17	3.87e-22	8.05e-19	0.51	0.42	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
LUAD	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-10.17	3.89e-22	8.09e-19	-0.66	-0.42	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-10.17	3.91e-22	8.13e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-10.17	3.91e-22	8.13e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-10.17	3.91e-22	8.13e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
LUAD	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	10.17	3.91e-22	8.14e-19	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	10.17	3.91e-22	8.14e-19	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-10.17	3.95e-22	8.22e-19	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-10.17	3.95e-22	8.22e-19	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
LUAD	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	10.17	3.96e-22	8.24e-19	0.54	0.42	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
LUAD	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-10.17	4e-22	8.32e-19	-0.47	-0.42	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-10.16	4.09e-22	8.5e-19	-0.29	-0.42	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-10.16	4.09e-22	8.5e-19	-0.29	-0.42	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
LUAD	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-10.16	4.11e-22	8.54e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
LUAD	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-10.16	4.11e-22	8.54e-19	-0.44	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-10.16	4.12e-22	8.55e-19	-0.59	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
LUAD	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-10.16	4.2e-22	8.72e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
LUAD	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	10.16	4.21e-22	8.73e-19	0.63	0.42	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
LUAD	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-10.16	4.22e-22	8.75e-19	-0.5	-0.42	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-10.16	4.24e-22	8.8e-19	-0.51	-0.42	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-10.16	4.25e-22	8.81e-19	-0.29	-0.42	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
LUAD	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	10.16	4.26e-22	8.82e-19	0.59	0.42	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	10.16	4.26e-22	8.82e-19	0.59	0.42	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-10.16	4.33e-22	8.97e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-10.16	4.33e-22	8.97e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
LUAD	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-10.16	4.33e-22	8.97e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-10.16	4.33e-22	8.97e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-10.16	4.33e-22	8.97e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-10.16	4.33e-22	8.97e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.523	rs2776874	ENSG00000279942.1	RP1-153P14.7	-10.16	4.35e-22	9e-19	-0.38	-0.42	Cognitive performance;	chr6:37515421	chr6:37567716~37571460:+
LUAD	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-10.16	4.35e-22	9e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	10.16	4.38e-22	9.05e-19	0.55	0.42	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-10.16	4.38e-22	9.07e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-10.16	4.38e-22	9.07e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
LUAD	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-10.15	4.42e-22	9.14e-19	-0.38	-0.42	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
LUAD	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	10.15	4.43e-22	9.17e-19	0.5	0.42	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
LUAD	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	10.15	4.44e-22	9.18e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-10.15	4.45e-22	9.2e-19	-0.29	-0.42	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
LUAD	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-10.15	4.46e-22	9.22e-19	-0.46	-0.42	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-10.15	4.46e-22	9.22e-19	-0.46	-0.42	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-10.15	4.46e-22	9.22e-19	-0.46	-0.42	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-10.15	4.46e-22	9.22e-19	-0.46	-0.42	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
LUAD	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	10.15	4.48e-22	9.25e-19	0.53	0.42	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	10.15	4.48e-22	9.25e-19	0.53	0.42	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
LUAD	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	10.15	4.48e-22	9.26e-19	0.52	0.42	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
LUAD	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	10.15	4.5e-22	9.3e-19	0.58	0.42	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
LUAD	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-10.15	4.51e-22	9.32e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
LUAD	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-10.15	4.52e-22	9.33e-19	-0.47	-0.42	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
LUAD	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-10.15	4.53e-22	9.36e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-10.15	4.54e-22	9.38e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	10.15	4.59e-22	9.45e-19	0.53	0.42	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	10.15	4.59e-22	9.45e-19	0.53	0.42	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
LUAD	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-10.15	4.62e-22	9.52e-19	-0.52	-0.42	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
LUAD	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	10.15	4.63e-22	9.54e-19	0.49	0.42	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-10.15	4.65e-22	9.57e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
LUAD	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-10.15	4.65e-22	9.57e-19	-0.46	-0.42	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-10.15	4.65e-22	9.57e-19	-0.46	-0.42	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
LUAD	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	10.15	4.69e-22	9.65e-19	0.5	0.42	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
LUAD	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-10.15	4.73e-22	9.74e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-10.15	4.73e-22	9.74e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-10.15	4.73e-22	9.74e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
LUAD	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-10.15	4.74e-22	9.74e-19	-0.47	-0.42	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	10.15	4.78e-22	9.83e-19	0.56	0.42	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
LUAD	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-10.14	4.8e-22	9.87e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
LUAD	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-10.14	4.88e-22	1e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-10.14	4.91e-22	1.01e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-10.14	4.91e-22	1.01e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
LUAD	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	10.14	4.92e-22	1.01e-18	0.5	0.42	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	10.14	4.92e-22	1.01e-18	0.5	0.42	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-10.14	4.94e-22	1.01e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-10.14	4.94e-22	1.01e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-10.14	4.96e-22	1.02e-18	-0.5	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
LUAD	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-10.14	4.97e-22	1.02e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-10.14	5.01e-22	1.03e-18	-0.52	-0.42	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
LUAD	cis	rs904251	0.965	rs62406516	ENSG00000279942.1	RP1-153P14.7	-10.14	5.06e-22	1.04e-18	-0.4	-0.42	Cognitive performance;	chr6:37471588	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	10.14	5.1e-22	1.05e-18	0.54	0.42	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-10.14	5.1e-22	1.05e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	10.14	5.12e-22	1.05e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
LUAD	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	10.14	5.2e-22	1.07e-18	0.53	0.42	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
LUAD	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	10.14	5.22e-22	1.07e-18	0.5	0.42	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
LUAD	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	10.14	5.22e-22	1.07e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-10.13	5.23e-22	1.07e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-10.13	5.23e-22	1.07e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	10.13	5.24e-22	1.07e-18	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
LUAD	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	10.13	5.26e-22	1.08e-18	0.53	0.42	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
LUAD	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	10.13	5.27e-22	1.08e-18	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	10.13	5.27e-22	1.08e-18	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
LUAD	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-10.13	5.31e-22	1.09e-18	-0.52	-0.42	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
LUAD	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-10.13	5.35e-22	1.1e-18	-0.46	-0.42	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
LUAD	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	10.13	5.35e-22	1.1e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
LUAD	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-10.13	5.42e-22	1.11e-18	-0.59	-0.42	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
LUAD	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	10.13	5.45e-22	1.12e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-10.13	5.47e-22	1.12e-18	-0.29	-0.42	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
LUAD	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-10.13	5.5e-22	1.13e-18	-0.47	-0.42	Height;	chr3:53084188	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	10.13	5.52e-22	1.13e-18	0.51	0.42	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	10.13	5.52e-22	1.13e-18	0.51	0.42	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-10.13	5.57e-22	1.14e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-10.13	5.57e-22	1.14e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
LUAD	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	10.13	5.59e-22	1.14e-18	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
LUAD	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-10.13	5.64e-22	1.15e-18	-0.5	-0.42	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
LUAD	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-10.13	5.65e-22	1.16e-18	-0.46	-0.42	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
LUAD	cis	rs694739	0.726	rs17857342	ENSG00000236935.1	AP003774.1	10.12	5.77e-22	1.18e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371433	chr11:64325050~64329504:-
LUAD	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-10.12	5.89e-22	1.2e-18	-0.44	-0.42	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-10.12	5.89e-22	1.2e-18	-0.44	-0.42	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-10.12	5.89e-22	1.2e-18	-0.44	-0.42	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	10.12	5.9e-22	1.2e-18	0.52	0.42	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
LUAD	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-10.12	6.02e-22	1.23e-18	-0.45	-0.42	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-10.12	6.02e-22	1.23e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
LUAD	cis	rs1757171	0.542	rs3818985	ENSG00000279942.1	RP1-153P14.7	-10.12	6.08e-22	1.24e-18	-0.39	-0.42	Cognitive performance;	chr6:37516438	chr6:37567716~37571460:+
LUAD	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-10.12	6.1e-22	1.24e-18	-0.53	-0.42	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-10.12	6.1e-22	1.24e-18	-0.55	-0.42	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
LUAD	cis	rs2006771	0.846	rs6518754	ENSG00000236132.1	CTA-440B3.1	-10.12	6.11e-22	1.24e-18	-0.47	-0.42	Nonsyndromic cleft lip with cleft palate;	chr22:31701789	chr22:31816379~31817491:-
LUAD	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-10.12	6.15e-22	1.25e-18	-0.5	-0.42	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-10.12	6.16e-22	1.25e-18	-0.29	-0.42	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-10.12	6.16e-22	1.25e-18	-0.29	-0.42	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
LUAD	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-10.11	6.2e-22	1.26e-18	-0.56	-0.42	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-10.11	6.25e-22	1.27e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-10.11	6.27e-22	1.28e-18	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-10.11	6.27e-22	1.28e-18	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	10.11	6.29e-22	1.28e-18	0.53	0.42	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
LUAD	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	10.11	6.33e-22	1.29e-18	0.53	0.42	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	10.11	6.33e-22	1.29e-18	0.53	0.42	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	10.11	6.33e-22	1.29e-18	0.53	0.42	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	10.11	6.33e-22	1.29e-18	0.53	0.42	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
LUAD	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-10.11	6.37e-22	1.29e-18	-0.5	-0.42	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-10.11	6.43e-22	1.31e-18	-0.51	-0.42	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
LUAD	cis	rs904251	0.561	rs1757189	ENSG00000279942.1	RP1-153P14.7	-10.11	6.43e-22	1.31e-18	-0.39	-0.42	Cognitive performance;	chr6:37515951	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs10947675	ENSG00000279942.1	RP1-153P14.7	-10.11	6.46e-22	1.31e-18	-0.39	-0.42	Cognitive performance;	chr6:37512196	chr6:37567716~37571460:+
LUAD	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-10.11	6.48e-22	1.32e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
LUAD	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	10.11	6.49e-22	1.32e-18	0.49	0.42	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	10.11	6.49e-22	1.32e-18	0.49	0.42	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
LUAD	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-10.11	6.53e-22	1.33e-18	-0.46	-0.42	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-10.11	6.53e-22	1.33e-18	-0.46	-0.42	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
LUAD	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-10.11	6.55e-22	1.33e-18	-0.74	-0.42	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
LUAD	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-10.11	6.55e-22	1.33e-18	-0.74	-0.42	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
LUAD	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	10.11	6.6e-22	1.34e-18	0.4	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
LUAD	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-10.11	6.6e-22	1.34e-18	-0.46	-0.42	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-10.11	6.6e-22	1.34e-18	-0.46	-0.42	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-10.11	6.6e-22	1.34e-18	-0.46	-0.42	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-10.11	6.6e-22	1.34e-18	-0.46	-0.42	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-10.11	6.61e-22	1.34e-18	-0.29	-0.42	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-10.11	6.61e-22	1.34e-18	-0.29	-0.42	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-10.11	6.61e-22	1.34e-18	-0.29	-0.42	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-10.11	6.61e-22	1.34e-18	-0.29	-0.42	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
LUAD	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-10.11	6.62e-22	1.34e-18	-0.44	-0.42	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
LUAD	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	10.11	6.63e-22	1.35e-18	0.64	0.42	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
LUAD	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	10.11	6.7e-22	1.36e-18	0.49	0.42	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-10.11	6.72e-22	1.36e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
LUAD	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-10.1	6.77e-22	1.37e-18	-0.63	-0.42	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
LUAD	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-10.1	6.77e-22	1.37e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
LUAD	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	10.1	6.86e-22	1.39e-18	0.54	0.42	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
LUAD	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-10.1	6.86e-22	1.39e-18	-0.57	-0.42	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
LUAD	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	10.1	6.97e-22	1.41e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
LUAD	cis	rs6538678	0.864	rs10777749	ENSG00000199506.1	RNU6-247P	-10.1	7.1e-22	1.44e-18	-0.53	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95792529~95792635:-
LUAD	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	10.1	7.16e-22	1.45e-18	0.53	0.42	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	10.1	7.24e-22	1.47e-18	0.49	0.42	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
LUAD	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	10.1	7.27e-22	1.47e-18	0.47	0.42	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-10.09	7.33e-22	1.48e-18	-0.46	-0.42	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
LUAD	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-10.09	7.33e-22	1.48e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
LUAD	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-10.09	7.37e-22	1.49e-18	-0.46	-0.42	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
LUAD	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	10.09	7.38e-22	1.49e-18	0.46	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-10.09	7.42e-22	1.5e-18	-0.29	-0.42	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
LUAD	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	10.09	7.42e-22	1.5e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-10.09	7.46e-22	1.51e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-10.09	7.46e-22	1.51e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-10.09	7.46e-22	1.51e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
LUAD	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-10.09	7.6e-22	1.54e-18	-0.46	-0.42	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
LUAD	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-10.09	7.63e-22	1.54e-18	-0.63	-0.42	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
LUAD	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-10.09	7.66e-22	1.55e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
LUAD	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	10.09	7.68e-22	1.55e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	10.09	7.68e-22	1.55e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-10.09	7.7e-22	1.55e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-10.09	7.7e-22	1.55e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
LUAD	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	10.09	7.74e-22	1.56e-18	0.52	0.42	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
LUAD	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	10.09	7.8e-22	1.57e-18	0.52	0.42	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
LUAD	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-10.09	7.8e-22	1.57e-18	-0.43	-0.42	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-10.09	7.8e-22	1.57e-18	-0.43	-0.42	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-10.09	7.8e-22	1.57e-18	-0.43	-0.42	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
LUAD	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-10.09	7.84e-22	1.58e-18	-0.47	-0.42	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
LUAD	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	10.09	7.88e-22	1.59e-18	0.55	0.42	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
LUAD	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-10.08	7.99e-22	1.61e-18	-0.46	-0.42	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
LUAD	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	10.08	8.02e-22	1.62e-18	0.63	0.42	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
LUAD	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	10.08	8.02e-22	1.62e-18	0.63	0.42	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
LUAD	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-10.08	8.05e-22	1.62e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-10.08	8.09e-22	1.63e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-10.08	8.16e-22	1.64e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-10.08	8.21e-22	1.65e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-10.08	8.21e-22	1.65e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-10.08	8.21e-22	1.65e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-10.08	8.21e-22	1.65e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-10.08	8.24e-22	1.66e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-10.08	8.35e-22	1.68e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-10.08	8.35e-22	1.68e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
LUAD	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-10.08	8.38e-22	1.69e-18	-0.44	-0.42	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
LUAD	cis	rs7044106	0.791	rs4836831	ENSG00000226752.6	PSMD5-AS1	-10.08	8.39e-22	1.69e-18	-0.47	-0.42	Hip circumference adjusted for BMI;	chr9:120734292	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-10.08	8.44e-22	1.7e-18	-0.47	-0.42	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
LUAD	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-10.08	8.47e-22	1.7e-18	-0.43	-0.42	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
LUAD	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-10.08	8.47e-22	1.7e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-10.08	8.59e-22	1.73e-18	-0.53	-0.42	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-10.08	8.59e-22	1.73e-18	-0.53	-0.42	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
LUAD	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-10.08	8.63e-22	1.73e-18	-0.61	-0.42	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
LUAD	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	10.07	8.66e-22	1.74e-18	0.63	0.42	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
LUAD	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	10.07	8.7e-22	1.75e-18	0.66	0.42	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
LUAD	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-10.07	8.72e-22	1.75e-18	-0.5	-0.42	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
LUAD	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-10.07	8.85e-22	1.78e-18	-0.63	-0.42	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
LUAD	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	10.07	9.12e-22	1.83e-18	0.44	0.42	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
LUAD	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	10.07	9.16e-22	1.84e-18	0.54	0.42	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
LUAD	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-10.07	9.2e-22	1.85e-18	-0.47	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
LUAD	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	10.07	9.24e-22	1.85e-18	0.66	0.42	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-10.07	9.33e-22	1.87e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
LUAD	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-10.07	9.33e-22	1.87e-18	-0.44	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
LUAD	cis	rs2006771	0.81	rs2006648	ENSG00000236132.1	CTA-440B3.1	10.07	9.4e-22	1.88e-18	0.46	0.42	Nonsyndromic cleft lip with cleft palate;	chr22:31685943	chr22:31816379~31817491:-
LUAD	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	10.06	9.47e-22	1.9e-18	0.49	0.42	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-10.06	9.54e-22	1.91e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
LUAD	cis	rs694739	0.657	rs11231770	ENSG00000236935.1	AP003774.1	10.06	9.62e-22	1.93e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373153	chr11:64325050~64329504:-
LUAD	cis	rs694739	0.687	rs11231771	ENSG00000236935.1	AP003774.1	10.06	9.62e-22	1.93e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373170	chr11:64325050~64329504:-
LUAD	cis	rs694739	0.628	rs10897487	ENSG00000236935.1	AP003774.1	10.06	9.62e-22	1.93e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373232	chr11:64325050~64329504:-
LUAD	cis	rs694739	0.654	rs10897488	ENSG00000236935.1	AP003774.1	10.06	9.62e-22	1.93e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373334	chr11:64325050~64329504:-
LUAD	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	10.06	9.64e-22	1.93e-18	0.5	0.42	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	10.06	9.64e-22	1.93e-18	0.5	0.42	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-10.06	9.72e-22	1.94e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-10.06	9.72e-22	1.94e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-10.06	9.72e-22	1.94e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-10.06	9.72e-22	1.94e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-10.06	9.74e-22	1.95e-18	-0.47	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
LUAD	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	10.06	9.8e-22	1.96e-18	0.66	0.42	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
LUAD	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-10.06	9.89e-22	1.98e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
LUAD	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	10.06	9.92e-22	1.98e-18	0.73	0.42	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
LUAD	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-10.06	9.97e-22	1.99e-18	-0.5	-0.42	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
LUAD	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	10.06	9.98e-22	1.99e-18	0.63	0.42	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
LUAD	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-10.06	1e-21	2e-18	-0.5	-0.42	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
LUAD	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	10.06	1e-21	2e-18	0.5	0.42	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
LUAD	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	10.06	1.01e-21	2.02e-18	0.53	0.42	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
LUAD	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	10.06	1.01e-21	2.03e-18	0.54	0.42	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	10.06	1.01e-21	2.03e-18	0.54	0.42	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
LUAD	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	10.05	1.03e-21	2.05e-18	0.51	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	10.05	1.03e-21	2.05e-18	0.51	0.42	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	10.05	1.03e-21	2.05e-18	0.51	0.42	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
LUAD	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	10.05	1.03e-21	2.06e-18	0.5	0.42	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
LUAD	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-10.05	1.03e-21	2.06e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	10.05	1.04e-21	2.07e-18	0.51	0.42	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	10.05	1.05e-21	2.09e-18	0.5	0.42	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	10.05	1.06e-21	2.1e-18	0.51	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
LUAD	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-10.05	1.07e-21	2.14e-18	-0.52	-0.42	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
LUAD	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	10.05	1.08e-21	2.15e-18	0.4	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
LUAD	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	10.05	1.08e-21	2.15e-18	0.4	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
LUAD	cis	rs904251	0.525	rs12200378	ENSG00000279942.1	RP1-153P14.7	-10.05	1.08e-21	2.15e-18	-0.39	-0.42	Cognitive performance;	chr6:37457528	chr6:37567716~37571460:+
LUAD	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-10.05	1.09e-21	2.17e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-10.05	1.09e-21	2.17e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-10.05	1.09e-21	2.17e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
LUAD	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-10.05	1.09e-21	2.18e-18	-0.47	-0.42	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
LUAD	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-10.05	1.1e-21	2.2e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-10.05	1.1e-21	2.2e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-10.04	1.12e-21	2.23e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-10.04	1.12e-21	2.23e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	10.04	1.12e-21	2.24e-18	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-10.04	1.13e-21	2.24e-18	-0.29	-0.42	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
LUAD	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-10.04	1.13e-21	2.25e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.6	rs2270687	ENSG00000279942.1	RP1-153P14.7	-10.04	1.13e-21	2.25e-18	-0.39	-0.42	Cognitive performance;	chr6:37450487	chr6:37567716~37571460:+
LUAD	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-10.04	1.14e-21	2.27e-18	-0.5	-0.42	Height;	chr11:118703207	chr11:118704607~118750263:+
LUAD	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-10.04	1.14e-21	2.27e-18	-0.51	-0.42	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-10.04	1.14e-21	2.27e-18	-0.51	-0.42	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
LUAD	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	10.04	1.14e-21	2.27e-18	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
LUAD	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	10.04	1.15e-21	2.28e-18	0.5	0.42	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
LUAD	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	10.04	1.15e-21	2.29e-18	0.66	0.42	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-10.04	1.15e-21	2.29e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-10.04	1.17e-21	2.32e-18	-0.52	-0.42	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
LUAD	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-10.04	1.17e-21	2.33e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-10.04	1.17e-21	2.33e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
LUAD	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	10.04	1.18e-21	2.33e-18	0.73	0.42	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
LUAD	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	10.04	1.18e-21	2.34e-18	0.4	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
LUAD	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	10.04	1.2e-21	2.38e-18	0.51	0.42	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
LUAD	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	10.04	1.21e-21	2.4e-18	0.5	0.42	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-10.03	1.21e-21	2.4e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-10.03	1.22e-21	2.41e-18	-0.52	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
LUAD	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-10.03	1.23e-21	2.44e-18	-0.53	-0.42	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
LUAD	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-10.03	1.24e-21	2.46e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-10.03	1.25e-21	2.48e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-10.03	1.25e-21	2.48e-18	-0.29	-0.42	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-10.03	1.25e-21	2.48e-18	-0.29	-0.42	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
LUAD	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-10.03	1.25e-21	2.48e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
LUAD	cis	rs35955747	0.539	rs738685	ENSG00000236132.1	CTA-440B3.1	10.03	1.25e-21	2.48e-18	0.46	0.42	Neutrophil count;Sum basophil neutrophil counts;	chr22:31636292	chr22:31816379~31817491:-
LUAD	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	10.03	1.27e-21	2.52e-18	0.55	0.42	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
LUAD	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	10.03	1.28e-21	2.53e-18	0.5	0.42	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
LUAD	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	10.03	1.28e-21	2.53e-18	0.5	0.42	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
LUAD	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	10.03	1.29e-21	2.55e-18	0.49	0.42	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
LUAD	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	10.03	1.3e-21	2.56e-18	0.48	0.42	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	10.03	1.3e-21	2.56e-18	0.48	0.42	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	10.03	1.3e-21	2.58e-18	0.52	0.42	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
LUAD	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-10.02	1.32e-21	2.61e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
LUAD	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-10.02	1.32e-21	2.62e-18	-0.62	-0.42	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
LUAD	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	10.02	1.34e-21	2.65e-18	0.47	0.42	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-10.02	1.34e-21	2.65e-18	-0.61	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
LUAD	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	10.02	1.34e-21	2.65e-18	0.47	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
LUAD	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	10.02	1.35e-21	2.67e-18	0.52	0.42	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
LUAD	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-10.02	1.35e-21	2.67e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-10.02	1.35e-21	2.67e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-10.02	1.36e-21	2.68e-18	-0.51	-0.42	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
LUAD	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-10.02	1.36e-21	2.69e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
LUAD	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-10.02	1.37e-21	2.71e-18	-0.44	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
LUAD	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-10.02	1.38e-21	2.72e-18	-0.53	-0.42	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-10.02	1.39e-21	2.73e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	10.02	1.4e-21	2.75e-18	0.42	0.42	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
LUAD	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-10.02	1.4e-21	2.75e-18	-0.53	-0.42	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
LUAD	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-10.02	1.4e-21	2.75e-18	-0.48	-0.42	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
LUAD	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	10.02	1.41e-21	2.79e-18	0.52	0.42	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
LUAD	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-10.02	1.42e-21	2.8e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
LUAD	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	10.01	1.43e-21	2.83e-18	0.5	0.42	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
LUAD	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-10.01	1.44e-21	2.83e-18	-0.52	-0.42	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
LUAD	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-10.01	1.46e-21	2.87e-18	-0.52	-0.42	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
LUAD	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	10.01	1.46e-21	2.88e-18	0.52	0.42	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
LUAD	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	10.01	1.47e-21	2.89e-18	0.49	0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
LUAD	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	10.01	1.48e-21	2.91e-18	0.55	0.42	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
LUAD	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-10.01	1.48e-21	2.92e-18	-0.5	-0.42	Height;	chr11:118703185	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-10.01	1.48e-21	2.92e-18	-0.5	-0.42	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
LUAD	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-10.01	1.48e-21	2.92e-18	-0.46	-0.42	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
LUAD	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	10.01	1.48e-21	2.92e-18	0.51	0.42	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
LUAD	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	10.01	1.49e-21	2.93e-18	0.47	0.42	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
LUAD	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-10.01	1.49e-21	2.94e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.6	rs11756241	ENSG00000279942.1	RP1-153P14.7	-10.01	1.52e-21	2.99e-18	-0.39	-0.42	Cognitive performance;	chr6:37477325	chr6:37567716~37571460:+
LUAD	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	10.01	1.52e-21	2.99e-18	0.51	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
LUAD	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	10.01	1.52e-21	2.99e-18	0.63	0.42	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
LUAD	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	10.01	1.54e-21	3.03e-18	0.51	0.42	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	10.01	1.54e-21	3.03e-18	0.51	0.42	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	10.01	1.55e-21	3.04e-18	0.49	0.42	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
LUAD	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-10	1.56e-21	3.07e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
LUAD	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	10	1.56e-21	3.07e-18	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
LUAD	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-10	1.6e-21	3.14e-18	-0.37	-0.41	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
LUAD	cis	rs904251	0.6	rs1874736	ENSG00000279942.1	RP1-153P14.7	-10	1.6e-21	3.14e-18	-0.39	-0.41	Cognitive performance;	chr6:37480218	chr6:37567716~37571460:+
LUAD	cis	rs904251	1	rs10947673	ENSG00000279942.1	RP1-153P14.7	-10	1.61e-21	3.16e-18	-0.39	-0.41	Cognitive performance;	chr6:37477303	chr6:37567716~37571460:+
LUAD	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-10	1.62e-21	3.18e-18	-0.55	-0.41	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-10	1.62e-21	3.18e-18	-0.55	-0.41	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-10	1.62e-21	3.18e-18	-0.55	-0.41	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	10	1.64e-21	3.22e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
LUAD	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	10	1.65e-21	3.23e-18	0.4	0.41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
LUAD	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	10	1.65e-21	3.23e-18	0.52	0.41	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
LUAD	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-10	1.65e-21	3.24e-18	-0.63	-0.41	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
LUAD	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-10	1.65e-21	3.24e-18	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
LUAD	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-10	1.66e-21	3.26e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
LUAD	cis	rs1823913	1	rs4853568	ENSG00000280083.1	RP11-317J9.1	10	1.67e-21	3.27e-18	0.53	0.41	Obesity-related traits;	chr2:191261464	chr2:191154118~191156070:-
LUAD	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-10	1.68e-21	3.29e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-10	1.68e-21	3.3e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
LUAD	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-9.99	1.7e-21	3.34e-18	-0.52	-0.41	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
LUAD	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-9.99	1.72e-21	3.37e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
LUAD	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	9.99	1.73e-21	3.38e-18	0.66	0.41	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	9.99	1.73e-21	3.38e-18	0.66	0.41	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
LUAD	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-9.99	1.74e-21	3.42e-18	-0.5	-0.41	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
LUAD	cis	rs6538678	0.833	rs1898178	ENSG00000199506.1	RNU6-247P	-9.99	1.75e-21	3.43e-18	-0.52	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95792529~95792635:-
LUAD	cis	rs6538678	0.833	rs1898177	ENSG00000199506.1	RNU6-247P	-9.99	1.75e-21	3.43e-18	-0.52	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95792529~95792635:-
LUAD	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-9.99	1.76e-21	3.44e-18	-0.46	-0.41	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
LUAD	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-9.99	1.76e-21	3.44e-18	-0.44	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
LUAD	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	9.99	1.77e-21	3.46e-18	0.49	0.41	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
LUAD	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-9.99	1.79e-21	3.51e-18	-0.54	-0.41	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
LUAD	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-9.99	1.81e-21	3.54e-18	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
LUAD	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-9.99	1.82e-21	3.56e-18	-0.52	-0.41	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
LUAD	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-9.99	1.83e-21	3.57e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
LUAD	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-9.99	1.83e-21	3.59e-18	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
LUAD	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	9.98	1.85e-21	3.61e-18	0.47	0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
LUAD	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-9.98	1.85e-21	3.62e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-9.98	1.85e-21	3.62e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-9.98	1.85e-21	3.62e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
LUAD	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-9.98	1.86e-21	3.62e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
LUAD	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-9.98	1.86e-21	3.62e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-9.98	1.86e-21	3.63e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-9.98	1.86e-21	3.63e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-9.98	1.86e-21	3.63e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
LUAD	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	9.98	1.86e-21	3.64e-18	0.51	0.41	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-9.98	1.88e-21	3.67e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
LUAD	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	9.98	1.89e-21	3.68e-18	0.7	0.41	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
LUAD	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-9.98	1.9e-21	3.71e-18	-0.54	-0.41	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
LUAD	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-9.98	1.93e-21	3.77e-18	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
LUAD	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	9.98	1.94e-21	3.78e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	9.98	1.94e-21	3.78e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
LUAD	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	9.98	1.95e-21	3.81e-18	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
LUAD	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	9.98	1.96e-21	3.82e-18	0.51	0.41	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
LUAD	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	9.98	1.97e-21	3.83e-18	0.66	0.41	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	9.98	1.97e-21	3.83e-18	0.66	0.41	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
LUAD	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	9.98	1.97e-21	3.85e-18	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
LUAD	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	9.98	1.99e-21	3.88e-18	0.4	0.41	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
LUAD	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	9.97	2e-21	3.9e-18	0.73	0.41	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	9.97	2e-21	3.9e-18	0.73	0.41	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
LUAD	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-9.97	2.01e-21	3.91e-18	-0.63	-0.41	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
LUAD	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-9.97	2.02e-21	3.93e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-9.97	2.02e-21	3.93e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
LUAD	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-9.97	2.02e-21	3.94e-18	-0.47	-0.41	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
LUAD	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-9.97	2.03e-21	3.95e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
LUAD	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-9.97	2.05e-21	3.99e-18	-0.58	-0.41	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
LUAD	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	9.97	2.06e-21	4e-18	0.49	0.41	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
LUAD	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-9.97	2.06e-21	4.01e-18	-0.49	-0.41	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
LUAD	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	9.97	2.09e-21	4.06e-18	0.49	0.41	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-9.97	2.09e-21	4.07e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
LUAD	cis	rs1757171	0.542	rs3818986	ENSG00000279942.1	RP1-153P14.7	-9.97	2.12e-21	4.11e-18	-0.39	-0.41	Cognitive performance;	chr6:37516573	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-9.97	2.13e-21	4.15e-18	-0.42	-0.41	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
LUAD	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-9.97	2.14e-21	4.15e-18	-0.54	-0.41	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
LUAD	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-9.97	2.15e-21	4.17e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-9.97	2.16e-21	4.2e-18	-0.42	-0.41	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
LUAD	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	9.97	2.16e-21	4.2e-18	0.61	0.41	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
LUAD	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	9.97	2.17e-21	4.21e-18	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
LUAD	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-9.96	2.2e-21	4.26e-18	-0.62	-0.41	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
LUAD	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	9.96	2.2e-21	4.27e-18	0.7	0.41	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
LUAD	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	9.96	2.23e-21	4.33e-18	0.46	0.41	Height;	chr3:53085313	chr3:53064283~53065091:-
LUAD	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-9.96	2.24e-21	4.35e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
LUAD	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-9.96	2.25e-21	4.35e-18	-0.51	-0.41	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
LUAD	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-9.96	2.25e-21	4.36e-18	-0.6	-0.41	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
LUAD	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	9.96	2.25e-21	4.36e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
LUAD	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-9.96	2.26e-21	4.38e-18	-0.45	-0.41	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-9.96	2.29e-21	4.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
LUAD	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	9.96	2.3e-21	4.45e-18	0.67	0.41	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
LUAD	cis	rs694739	0.595	rs11542299	ENSG00000236935.1	AP003774.1	9.96	2.3e-21	4.46e-18	0.4	0.41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371333	chr11:64325050~64329504:-
LUAD	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-9.96	2.34e-21	4.54e-18	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
LUAD	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	9.96	2.35e-21	4.55e-18	0.39	0.41	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
LUAD	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-9.95	2.4e-21	4.64e-18	-0.65	-0.41	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
LUAD	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-9.95	2.41e-21	4.67e-18	-0.52	-0.41	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	9.95	2.43e-21	4.71e-18	0.39	0.41	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
LUAD	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-9.95	2.45e-21	4.73e-18	-0.59	-0.41	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
LUAD	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	9.95	2.45e-21	4.73e-18	0.43	0.41	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
LUAD	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	9.95	2.49e-21	4.82e-18	0.86	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	9.95	2.53e-21	4.88e-18	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
LUAD	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-9.95	2.54e-21	4.91e-18	-0.43	-0.41	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
LUAD	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-9.95	2.55e-21	4.93e-18	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
LUAD	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-9.94	2.59e-21	5.01e-18	-0.81	-0.41	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
LUAD	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	9.94	2.6e-21	5.01e-18	0.49	0.41	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	9.94	2.62e-21	5.05e-18	0.52	0.41	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
LUAD	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-9.94	2.62e-21	5.06e-18	-0.56	-0.41	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
LUAD	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	9.94	2.64e-21	5.1e-18	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
LUAD	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-9.94	2.65e-21	5.12e-18	-0.62	-0.41	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
LUAD	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	9.94	2.69e-21	5.17e-18	0.4	0.41	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
LUAD	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-9.94	2.69e-21	5.18e-18	-0.49	-0.41	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
LUAD	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	9.94	2.69e-21	5.19e-18	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	9.94	2.73e-21	5.25e-18	0.39	0.41	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-9.94	2.74e-21	5.27e-18	-0.29	-0.41	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
LUAD	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	9.94	2.76e-21	5.32e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	9.94	2.76e-21	5.32e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
LUAD	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-9.94	2.77e-21	5.33e-18	-0.49	-0.41	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
LUAD	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	9.94	2.78e-21	5.35e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
LUAD	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	9.93	2.8e-21	5.39e-18	0.49	0.41	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-9.93	2.81e-21	5.4e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
LUAD	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	9.93	2.81e-21	5.41e-18	0.43	0.41	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	9.93	2.81e-21	5.41e-18	0.43	0.41	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	9.93	2.81e-21	5.41e-18	0.43	0.41	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
LUAD	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-9.93	2.86e-21	5.5e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
LUAD	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	9.93	2.88e-21	5.53e-18	0.39	0.41	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	9.93	2.88e-21	5.53e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	9.93	2.88e-21	5.53e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	9.93	2.88e-21	5.53e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-9.93	2.93e-21	5.63e-18	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
LUAD	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-9.93	2.97e-21	5.71e-18	-0.47	-0.41	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
LUAD	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	9.92	3.09e-21	5.92e-18	0.84	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
LUAD	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	9.92	3.1e-21	5.94e-18	0.46	0.41	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
LUAD	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	9.92	3.15e-21	6.04e-18	0.5	0.41	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
LUAD	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	9.92	3.18e-21	6.09e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	9.92	3.2e-21	6.14e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	9.92	3.2e-21	6.14e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	9.92	3.28e-21	6.28e-18	0.39	0.41	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	9.92	3.28e-21	6.28e-18	0.54	0.41	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
LUAD	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-9.92	3.29e-21	6.29e-18	-0.51	-0.41	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
LUAD	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-9.91	3.32e-21	6.36e-18	-0.51	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
LUAD	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-9.91	3.33e-21	6.38e-18	-0.52	-0.41	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
LUAD	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	9.91	3.34e-21	6.38e-18	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
LUAD	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-9.91	3.34e-21	6.39e-18	-0.55	-0.41	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-9.91	3.34e-21	6.39e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	9.91	3.35e-21	6.41e-18	0.51	0.41	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
LUAD	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-9.91	3.37e-21	6.45e-18	-0.45	-0.41	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
LUAD	cis	rs904251	1	rs12212090	ENSG00000279942.1	RP1-153P14.7	-9.91	3.4e-21	6.5e-18	-0.39	-0.41	Cognitive performance;	chr6:37464032	chr6:37567716~37571460:+
LUAD	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	9.91	3.42e-21	6.54e-18	0.51	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	9.91	3.43e-21	6.55e-18	0.51	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
LUAD	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-9.91	3.43e-21	6.56e-18	-0.51	-0.41	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
LUAD	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-9.91	3.5e-21	6.69e-18	-0.64	-0.41	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
LUAD	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-9.91	3.52e-21	6.71e-18	-0.52	-0.41	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
LUAD	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	9.91	3.55e-21	6.78e-18	0.43	0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
LUAD	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	9.9	3.59e-21	6.86e-18	0.45	0.41	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
LUAD	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-9.9	3.7e-21	7.05e-18	-0.52	-0.41	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
LUAD	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-9.9	3.74e-21	7.12e-18	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
LUAD	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-9.9	3.79e-21	7.23e-18	-0.51	-0.41	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
LUAD	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-9.89	3.9e-21	7.42e-18	-0.37	-0.41	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
LUAD	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-9.89	3.91e-21	7.44e-18	-0.5	-0.41	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
LUAD	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	9.89	3.97e-21	7.55e-18	0.54	0.41	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
LUAD	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-9.89	4e-21	7.61e-18	-0.54	-0.41	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-9.89	4.04e-21	7.68e-18	-0.49	-0.41	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
LUAD	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	9.89	4.13e-21	7.85e-18	0.53	0.41	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
LUAD	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-9.89	4.15e-21	7.89e-18	-0.45	-0.41	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
LUAD	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	9.89	4.15e-21	7.89e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
LUAD	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-9.89	4.18e-21	7.94e-18	-0.51	-0.41	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
LUAD	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	9.89	4.2e-21	7.97e-18	0.41	0.41	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
LUAD	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	9.89	4.2e-21	7.98e-18	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
LUAD	cis	rs944289	0.616	rs1742867	ENSG00000257826.1	RP11-116N8.4	9.89	4.21e-21	8e-18	0.43	0.41	Thyroid cancer;	chr14:36067937	chr14:36061026~36067190:-
LUAD	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	9.88	4.23e-21	8.03e-18	0.54	0.41	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
LUAD	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	9.88	4.25e-21	8.06e-18	0.54	0.41	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
LUAD	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	9.88	4.25e-21	8.06e-18	0.52	0.41	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
LUAD	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-9.88	4.35e-21	8.25e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
LUAD	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	9.88	4.35e-21	8.25e-18	0.51	0.41	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
LUAD	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-9.88	4.36e-21	8.28e-18	-0.51	-0.41	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	9.88	4.39e-21	8.32e-18	0.5	0.41	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
LUAD	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	9.88	4.4e-21	8.34e-18	0.66	0.41	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
LUAD	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-9.88	4.43e-21	8.39e-18	-0.43	-0.41	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
LUAD	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-9.88	4.43e-21	8.4e-18	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
LUAD	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	9.88	4.5e-21	8.52e-18	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	9.88	4.5e-21	8.52e-18	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	9.88	4.5e-21	8.52e-18	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
LUAD	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-9.88	4.51e-21	8.54e-18	-0.47	-0.41	Temperament;	chr17:14075460	chr17:14024514~14025488:+
LUAD	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-9.88	4.52e-21	8.55e-18	-0.42	-0.41	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
LUAD	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	9.88	4.53e-21	8.58e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
LUAD	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	9.88	4.54e-21	8.6e-18	0.54	0.41	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-9.88	4.55e-21	8.61e-18	-0.31	-0.41	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.69	rs7674713	ENSG00000245958.5	RP11-33B1.1	-9.88	4.57e-21	8.65e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119401102	chr4:119454791~119552025:+
LUAD	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	9.88	4.57e-21	8.66e-18	0.47	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
LUAD	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	9.87	4.6e-21	8.71e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	9.87	4.6e-21	8.71e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
LUAD	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	9.87	4.62e-21	8.73e-18	0.47	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
LUAD	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-9.87	4.63e-21	8.76e-18	-0.49	-0.41	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
LUAD	cis	rs2006771	0.618	rs470072	ENSG00000236132.1	CTA-440B3.1	-9.87	4.77e-21	9.01e-18	-0.47	-0.41	Nonsyndromic cleft lip with cleft palate;	chr22:31867145	chr22:31816379~31817491:-
LUAD	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-9.87	4.78e-21	9.04e-18	-0.62	-0.41	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
LUAD	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-9.87	4.8e-21	9.06e-18	-0.45	-0.41	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
LUAD	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-9.87	4.81e-21	9.1e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-9.87	4.93e-21	9.31e-18	-0.51	-0.41	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-9.87	4.93e-21	9.31e-18	-0.51	-0.41	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
LUAD	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-9.87	4.95e-21	9.34e-18	-0.37	-0.41	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	9.87	4.95e-21	9.34e-18	0.54	0.41	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	9.87	4.95e-21	9.34e-18	0.54	0.41	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	9.87	4.95e-21	9.34e-18	0.54	0.41	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
LUAD	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	9.87	4.96e-21	9.36e-18	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
LUAD	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	9.86	5.12e-21	9.65e-18	0.54	0.41	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	9.86	5.12e-21	9.65e-18	0.54	0.41	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	9.86	5.12e-21	9.65e-18	0.54	0.41	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
LUAD	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	9.86	5.15e-21	9.7e-18	0.51	0.41	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	9.86	5.21e-21	9.81e-18	0.6	0.41	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
LUAD	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	9.86	5.22e-21	9.83e-18	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	9.86	5.22e-21	9.83e-18	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
LUAD	cis	rs11089937	0.864	rs5757041	ENSG00000211639.2	IGLV4-60	9.86	5.23e-21	9.86e-18	0.41	0.41	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22162199~22162681:+
LUAD	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	9.86	5.27e-21	9.92e-18	0.51	0.41	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	9.86	5.27e-21	9.92e-18	0.51	0.41	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
LUAD	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-9.86	5.28e-21	9.94e-18	-0.45	-0.41	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
LUAD	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-9.86	5.33e-21	1e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
LUAD	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	9.86	5.35e-21	1.01e-17	0.69	0.41	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
LUAD	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-9.86	5.37e-21	1.01e-17	-0.39	-0.41	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
LUAD	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	9.86	5.39e-21	1.01e-17	0.68	0.41	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
LUAD	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	9.85	5.45e-21	1.02e-17	0.51	0.41	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	9.85	5.45e-21	1.02e-17	0.51	0.41	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	9.85	5.45e-21	1.02e-17	0.51	0.41	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	9.85	5.45e-21	1.02e-17	0.51	0.41	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	9.85	5.48e-21	1.03e-17	0.28	0.41	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
LUAD	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	9.85	5.51e-21	1.03e-17	0.51	0.41	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
LUAD	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	9.85	5.55e-21	1.04e-17	0.67	0.41	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	9.85	5.55e-21	1.04e-17	0.67	0.41	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
LUAD	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-9.85	5.56e-21	1.04e-17	-0.45	-0.41	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	9.85	5.71e-21	1.07e-17	0.54	0.41	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	9.85	5.71e-21	1.07e-17	0.54	0.41	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
LUAD	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-9.85	5.73e-21	1.07e-17	-0.52	-0.41	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
LUAD	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	9.85	5.74e-21	1.08e-17	0.51	0.41	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
LUAD	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-9.85	5.77e-21	1.08e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
LUAD	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-9.85	5.81e-21	1.09e-17	-0.43	-0.41	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
LUAD	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	9.85	5.82e-21	1.09e-17	0.38	0.41	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
LUAD	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	9.85	5.87e-21	1.1e-17	0.54	0.41	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-9.84	5.89e-21	1.1e-17	-0.36	-0.41	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
LUAD	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	9.84	5.94e-21	1.11e-17	0.55	0.41	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
LUAD	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	9.84	5.98e-21	1.12e-17	0.47	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
LUAD	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	9.84	6.01e-21	1.13e-17	0.67	0.41	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
LUAD	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	9.84	6.05e-21	1.13e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
LUAD	cis	rs11089937	0.825	rs5757012	ENSG00000211639.2	IGLV4-60	9.84	6.12e-21	1.15e-17	0.41	0.41	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22162199~22162681:+
LUAD	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-9.84	6.12e-21	1.15e-17	-0.42	-0.41	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
LUAD	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	9.84	6.14e-21	1.15e-17	0.49	0.41	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
LUAD	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-9.84	6.25e-21	1.17e-17	-0.66	-0.41	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
LUAD	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	9.84	6.27e-21	1.17e-17	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-9.84	6.32e-21	1.18e-17	-0.28	-0.41	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
LUAD	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	9.84	6.32e-21	1.18e-17	0.43	0.41	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
LUAD	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-9.84	6.34e-21	1.18e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-9.84	6.36e-21	1.19e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-9.84	6.36e-21	1.19e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
LUAD	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-9.83	6.43e-21	1.2e-17	-0.74	-0.41	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
LUAD	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-9.83	6.45e-21	1.21e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
LUAD	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-9.83	6.48e-21	1.21e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
LUAD	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	9.83	6.5e-21	1.21e-17	0.51	0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-9.83	6.54e-21	1.22e-17	-0.28	-0.41	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-9.83	6.57e-21	1.23e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
LUAD	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-9.83	6.65e-21	1.24e-17	-0.46	-0.41	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
LUAD	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-9.83	6.68e-21	1.25e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
LUAD	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-9.83	6.77e-21	1.26e-17	-0.37	-0.41	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
LUAD	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-9.83	6.77e-21	1.26e-17	-0.37	-0.41	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
LUAD	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-9.83	6.8e-21	1.27e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-9.83	6.8e-21	1.27e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
LUAD	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-9.83	6.85e-21	1.28e-17	-0.44	-0.41	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
LUAD	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-9.83	6.85e-21	1.28e-17	-0.44	-0.41	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
LUAD	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-9.83	6.85e-21	1.28e-17	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
LUAD	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	9.83	6.88e-21	1.28e-17	0.77	0.41	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
LUAD	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-9.83	6.89e-21	1.28e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
LUAD	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-9.82	6.95e-21	1.3e-17	-0.51	-0.41	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
LUAD	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	9.82	7.03e-21	1.31e-17	0.59	0.41	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
LUAD	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	9.82	7.03e-21	1.31e-17	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-9.82	7.24e-21	1.35e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
LUAD	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	9.82	7.26e-21	1.35e-17	0.77	0.41	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
LUAD	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	9.82	7.29e-21	1.35e-17	0.53	0.41	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	9.82	7.29e-21	1.35e-17	0.53	0.41	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
LUAD	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-9.82	7.32e-21	1.36e-17	-0.53	-0.41	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
LUAD	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-9.82	7.39e-21	1.37e-17	-0.55	-0.41	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
LUAD	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-9.82	7.41e-21	1.38e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
LUAD	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	9.82	7.42e-21	1.38e-17	0.54	0.41	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
LUAD	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-9.82	7.42e-21	1.38e-17	-0.58	-0.41	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
LUAD	cis	rs904251	0.6	rs4714068	ENSG00000279942.1	RP1-153P14.7	-9.82	7.49e-21	1.39e-17	-0.38	-0.41	Cognitive performance;	chr6:37487866	chr6:37567716~37571460:+
LUAD	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	9.81	7.56e-21	1.4e-17	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-9.81	7.59e-21	1.41e-17	-0.28	-0.41	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
LUAD	cis	rs904251	0.523	rs12202055	ENSG00000279942.1	RP1-153P14.7	-9.81	7.79e-21	1.45e-17	-0.38	-0.41	Cognitive performance;	chr6:37518304	chr6:37567716~37571460:+
LUAD	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-9.81	7.95e-21	1.47e-17	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
LUAD	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	9.81	8.08e-21	1.5e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
LUAD	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	9.81	8.13e-21	1.51e-17	0.54	0.41	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-9.81	8.16e-21	1.51e-17	-0.55	-0.41	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
LUAD	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-9.81	8.17e-21	1.51e-17	-0.53	-0.41	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
LUAD	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	9.81	8.18e-21	1.52e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-9.8	8.35e-21	1.55e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-9.8	8.35e-21	1.55e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
LUAD	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-9.8	8.35e-21	1.55e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	9.8	8.38e-21	1.55e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	9.8	8.38e-21	1.55e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	9.8	8.38e-21	1.55e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	9.8	8.38e-21	1.55e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
LUAD	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-9.8	8.38e-21	1.55e-17	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
LUAD	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	9.8	8.4e-21	1.56e-17	0.56	0.41	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
LUAD	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-9.8	8.41e-21	1.56e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
LUAD	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	9.8	8.41e-21	1.56e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-9.8	8.61e-21	1.59e-17	-0.28	-0.41	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
LUAD	cis	rs904251	1	rs904251	ENSG00000279942.1	RP1-153P14.7	-9.8	8.66e-21	1.6e-17	-0.39	-0.41	Cognitive performance;	chr6:37483920	chr6:37567716~37571460:+
LUAD	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	9.8	8.68e-21	1.6e-17	0.5	0.41	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	9.8	8.68e-21	1.6e-17	0.5	0.41	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	9.8	8.68e-21	1.6e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	9.8	8.68e-21	1.6e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
LUAD	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	9.8	8.7e-21	1.61e-17	0.56	0.41	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
LUAD	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-9.8	8.72e-21	1.61e-17	-0.42	-0.41	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
LUAD	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-9.8	8.81e-21	1.63e-17	-0.44	-0.41	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
LUAD	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-9.8	8.82e-21	1.63e-17	-0.45	-0.41	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
LUAD	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-9.8	8.85e-21	1.63e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
LUAD	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	9.8	8.86e-21	1.64e-17	0.56	0.41	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
LUAD	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	9.79	8.95e-21	1.65e-17	0.42	0.41	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
LUAD	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	9.79	8.95e-21	1.65e-17	0.69	0.41	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
LUAD	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-9.79	8.96e-21	1.65e-17	-0.84	-0.41	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
LUAD	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-9.79	9.01e-21	1.66e-17	-0.5	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
LUAD	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	9.79	9.01e-21	1.66e-17	0.55	0.41	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
LUAD	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
LUAD	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	9.79	9.08e-21	1.67e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-9.79	9.08e-21	1.68e-17	-0.45	-0.41	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-9.79	9.08e-21	1.68e-17	-0.45	-0.41	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
LUAD	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	9.79	9.16e-21	1.69e-17	0.37	0.41	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
LUAD	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-9.79	9.16e-21	1.69e-17	-0.37	-0.41	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-9.79	9.18e-21	1.69e-17	-0.28	-0.41	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
LUAD	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-9.79	9.19e-21	1.69e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
LUAD	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-9.79	9.19e-21	1.69e-17	-0.5	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-9.79	9.27e-21	1.71e-17	-0.28	-0.41	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
LUAD	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	9.79	9.34e-21	1.72e-17	0.56	0.41	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
LUAD	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-9.79	9.54e-21	1.76e-17	-0.47	-0.41	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
LUAD	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-9.79	9.54e-21	1.76e-17	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
LUAD	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	9.79	9.59e-21	1.76e-17	0.49	0.41	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	9.79	9.59e-21	1.76e-17	0.49	0.41	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	9.79	9.59e-21	1.76e-17	0.49	0.41	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
LUAD	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	9.79	9.62e-21	1.77e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-9.79	9.62e-21	1.77e-17	-0.28	-0.41	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
LUAD	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	9.78	9.7e-21	1.78e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
LUAD	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	9.78	9.85e-21	1.81e-17	0.47	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
LUAD	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	9.78	9.85e-21	1.81e-17	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
LUAD	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-9.78	9.88e-21	1.82e-17	-0.46	-0.41	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
LUAD	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	9.78	9.96e-21	1.83e-17	0.67	0.41	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	9.78	9.96e-21	1.83e-17	0.67	0.41	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
LUAD	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	9.78	9.97e-21	1.83e-17	0.57	0.41	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
LUAD	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	9.78	9.99e-21	1.84e-17	0.92	0.41	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
LUAD	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	9.78	1e-20	1.85e-17	0.49	0.41	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
LUAD	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	9.78	1.01e-20	1.85e-17	0.59	0.41	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
LUAD	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-9.78	1.01e-20	1.85e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
LUAD	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-9.78	1.03e-20	1.88e-17	-0.49	-0.41	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
LUAD	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	9.78	1.03e-20	1.89e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
LUAD	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-9.78	1.03e-20	1.89e-17	-0.56	-0.41	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
LUAD	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	9.78	1.03e-20	1.9e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
LUAD	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-9.78	1.04e-20	1.92e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
LUAD	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	9.77	1.05e-20	1.93e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	9.77	1.05e-20	1.93e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
LUAD	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	9.77	1.06e-20	1.94e-17	0.54	0.41	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	9.77	1.06e-20	1.94e-17	0.54	0.41	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
LUAD	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	9.77	1.06e-20	1.94e-17	0.69	0.41	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
LUAD	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	9.77	1.07e-20	1.95e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-9.77	1.08e-20	1.98e-17	-0.47	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
LUAD	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-9.77	1.09e-20	2e-17	-0.49	-0.41	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
LUAD	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	9.77	1.1e-20	2.01e-17	0.66	0.41	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
LUAD	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-9.77	1.1e-20	2.01e-17	-0.47	-0.41	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
LUAD	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-9.77	1.11e-20	2.03e-17	-0.72	-0.41	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
LUAD	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	9.77	1.11e-20	2.04e-17	0.5	0.41	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
LUAD	cis	rs944289	0.646	rs375095	ENSG00000257826.1	RP11-116N8.4	9.77	1.12e-20	2.05e-17	0.42	0.41	Thyroid cancer;	chr14:36066043	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs394246	ENSG00000257826.1	RP11-116N8.4	9.77	1.12e-20	2.05e-17	0.42	0.41	Thyroid cancer;	chr14:36066074	chr14:36061026~36067190:-
LUAD	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-9.77	1.12e-20	2.05e-17	-0.52	-0.41	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-9.77	1.12e-20	2.05e-17	-0.52	-0.41	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
LUAD	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-9.77	1.12e-20	2.05e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-9.77	1.12e-20	2.05e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-9.77	1.12e-20	2.05e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-9.77	1.12e-20	2.06e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	9.77	1.13e-20	2.07e-17	0.38	0.41	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
LUAD	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	9.77	1.13e-20	2.07e-17	0.67	0.41	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
LUAD	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-9.77	1.13e-20	2.07e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-9.76	1.15e-20	2.11e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
LUAD	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-9.76	1.16e-20	2.12e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
LUAD	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-9.76	1.17e-20	2.14e-17	-0.37	-0.41	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
LUAD	cis	rs1823913	0.927	rs56209234	ENSG00000280083.1	RP11-317J9.1	-9.76	1.17e-20	2.14e-17	-0.52	-0.41	Obesity-related traits;	chr2:191261748	chr2:191154118~191156070:-
LUAD	cis	rs1757171	0.542	rs3818986	ENSG00000204110.6	RP1-153P14.8	-9.76	1.18e-20	2.16e-17	-0.42	-0.41	Cognitive performance;	chr6:37516573	chr6:37507348~37535616:+
LUAD	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	9.76	1.18e-20	2.16e-17	0.52	0.41	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
LUAD	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-9.76	1.19e-20	2.17e-17	-0.48	-0.41	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
LUAD	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	9.76	1.19e-20	2.18e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	9.76	1.19e-20	2.18e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
LUAD	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	9.76	1.2e-20	2.18e-17	0.54	0.41	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
LUAD	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	9.76	1.2e-20	2.19e-17	0.48	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
LUAD	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-9.76	1.2e-20	2.19e-17	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	9.76	1.2e-20	2.19e-17	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
LUAD	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	9.76	1.21e-20	2.21e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
LUAD	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	9.76	1.22e-20	2.23e-17	0.68	0.41	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
LUAD	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-9.76	1.22e-20	2.23e-17	-0.43	-0.41	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
LUAD	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	9.76	1.23e-20	2.24e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	9.76	1.23e-20	2.24e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	9.76	1.23e-20	2.24e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	9.76	1.23e-20	2.24e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
LUAD	cis	rs1823913	0.927	rs35339956	ENSG00000280083.1	RP11-317J9.1	-9.75	1.24e-20	2.26e-17	-0.52	-0.41	Obesity-related traits;	chr2:191261668	chr2:191154118~191156070:-
LUAD	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-9.75	1.25e-20	2.28e-17	-0.51	-0.41	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-9.75	1.25e-20	2.28e-17	-0.51	-0.41	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
LUAD	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	9.75	1.26e-20	2.29e-17	0.5	0.41	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
LUAD	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	9.75	1.26e-20	2.29e-17	0.46	0.41	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.6	rs12211110	ENSG00000279942.1	RP1-153P14.7	-9.75	1.27e-20	2.32e-17	-0.38	-0.41	Cognitive performance;	chr6:37498456	chr6:37567716~37571460:+
LUAD	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	9.75	1.29e-20	2.35e-17	0.48	0.41	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
LUAD	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	9.75	1.29e-20	2.35e-17	0.48	0.41	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	9.75	1.29e-20	2.36e-17	0.38	0.41	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
LUAD	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	9.75	1.29e-20	2.36e-17	0.56	0.41	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
LUAD	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	9.75	1.31e-20	2.38e-17	0.47	0.41	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
LUAD	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-9.75	1.31e-20	2.39e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-9.75	1.32e-20	2.4e-17	-0.28	-0.41	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-9.75	1.32e-20	2.4e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
LUAD	cis	rs904251	0.6	rs9380673	ENSG00000279942.1	RP1-153P14.7	-9.75	1.32e-20	2.41e-17	-0.38	-0.41	Cognitive performance;	chr6:37447349	chr6:37567716~37571460:+
LUAD	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-9.75	1.33e-20	2.42e-17	-0.47	-0.41	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
LUAD	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-9.75	1.33e-20	2.42e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
LUAD	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	9.74	1.36e-20	2.47e-17	0.46	0.41	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-9.74	1.36e-20	2.47e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	9.74	1.36e-20	2.48e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	9.74	1.36e-20	2.48e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
LUAD	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	9.74	1.37e-20	2.5e-17	0.55	0.41	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
LUAD	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-9.74	1.38e-20	2.5e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
LUAD	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	9.74	1.39e-20	2.52e-17	0.5	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
LUAD	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-9.74	1.41e-20	2.55e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-9.74	1.41e-20	2.55e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
LUAD	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-9.74	1.41e-20	2.55e-17	-0.45	-0.41	Height;	chr3:53080524	chr3:53064283~53065091:-
LUAD	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-9.74	1.42e-20	2.58e-17	-0.49	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-9.74	1.42e-20	2.58e-17	-0.49	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
LUAD	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	9.74	1.42e-20	2.58e-17	0.5	0.41	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	9.74	1.42e-20	2.58e-17	0.5	0.41	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	9.74	1.43e-20	2.6e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	9.74	1.44e-20	2.6e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
LUAD	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-9.74	1.45e-20	2.63e-17	-0.46	-0.41	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
LUAD	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-9.73	1.46e-20	2.65e-17	-0.48	-0.41	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
LUAD	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-9.73	1.46e-20	2.65e-17	-0.51	-0.41	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
LUAD	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	9.73	1.46e-20	2.65e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
LUAD	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-9.73	1.48e-20	2.68e-17	-0.5	-0.41	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
LUAD	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	9.73	1.48e-20	2.68e-17	0.55	0.41	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
LUAD	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-9.73	1.49e-20	2.7e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	9.73	1.49e-20	2.71e-17	0.51	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
LUAD	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	9.73	1.49e-20	2.71e-17	0.49	0.41	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
LUAD	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	9.73	1.5e-20	2.71e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
LUAD	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-9.73	1.51e-20	2.73e-17	-0.44	-0.41	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
LUAD	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.73e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
LUAD	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	9.73	1.51e-20	2.74e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	9.73	1.51e-20	2.74e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
LUAD	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-9.73	1.52e-20	2.75e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	9.73	1.54e-20	2.78e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	9.73	1.54e-20	2.79e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
LUAD	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	9.73	1.55e-20	2.8e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-9.73	1.55e-20	2.8e-17	-0.28	-0.41	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
LUAD	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	9.73	1.55e-20	2.8e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
LUAD	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-9.73	1.55e-20	2.8e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
LUAD	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	9.73	1.56e-20	2.82e-17	0.42	0.41	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-9.73	1.56e-20	2.82e-17	-0.28	-0.41	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
LUAD	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	9.73	1.57e-20	2.84e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	9.73	1.58e-20	2.85e-17	0.36	0.41	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-9.73	1.58e-20	2.85e-17	-0.48	-0.41	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
LUAD	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	9.72	1.58e-20	2.86e-17	0.5	0.41	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-9.72	1.61e-20	2.9e-17	-0.36	-0.41	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-9.72	1.63e-20	2.94e-17	-0.49	-0.41	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-9.72	1.63e-20	2.94e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
LUAD	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	9.72	1.63e-20	2.95e-17	0.6	0.41	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
LUAD	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	9.72	1.64e-20	2.96e-17	0.39	0.41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
LUAD	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-9.72	1.66e-20	2.99e-17	-0.57	-0.41	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
LUAD	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	9.72	1.67e-20	3.01e-17	0.58	0.41	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
LUAD	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	9.72	1.68e-20	3.03e-17	0.51	0.41	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
LUAD	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	9.72	1.71e-20	3.07e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	9.71	1.72e-20	3.1e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
LUAD	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-9.71	1.72e-20	3.1e-17	-0.5	-0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
LUAD	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	9.71	1.72e-20	3.1e-17	0.54	0.4	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	9.71	1.72e-20	3.1e-17	0.54	0.4	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	9.71	1.72e-20	3.1e-17	0.54	0.4	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
LUAD	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	9.71	1.77e-20	3.18e-17	0.5	0.4	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
LUAD	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-9.71	1.77e-20	3.19e-17	-0.48	-0.4	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
LUAD	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-9.71	1.77e-20	3.19e-17	-0.37	-0.4	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
LUAD	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	9.71	1.78e-20	3.19e-17	0.51	0.4	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
LUAD	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-9.71	1.78e-20	3.19e-17	-0.5	-0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-9.71	1.78e-20	3.2e-17	-0.55	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
LUAD	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	9.71	1.81e-20	3.25e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
LUAD	cis	rs944289	0.646	rs367883	ENSG00000257826.1	RP11-116N8.4	9.71	1.83e-20	3.29e-17	0.42	0.4	Thyroid cancer;	chr14:36063400	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs368181	ENSG00000257826.1	RP11-116N8.4	9.71	1.83e-20	3.29e-17	0.42	0.4	Thyroid cancer;	chr14:36065621	chr14:36061026~36067190:-
LUAD	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	9.71	1.84e-20	3.3e-17	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-9.71	1.86e-20	3.33e-17	-0.41	-0.4	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
LUAD	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	9.71	1.86e-20	3.34e-17	0.53	0.4	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
LUAD	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-9.7	1.88e-20	3.37e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-9.7	1.88e-20	3.38e-17	-0.28	-0.4	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-9.7	1.89e-20	3.39e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
LUAD	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-9.7	1.9e-20	3.42e-17	-0.49	-0.4	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
LUAD	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	9.7	1.93e-20	3.47e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
LUAD	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	9.7	1.94e-20	3.47e-17	0.67	0.4	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	9.7	1.94e-20	3.47e-17	0.67	0.4	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
LUAD	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-9.7	1.94e-20	3.48e-17	-0.44	-0.4	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
LUAD	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
LUAD	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	9.7	1.98e-20	3.55e-17	0.49	0.4	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
LUAD	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-9.7	1.98e-20	3.55e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
LUAD	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-9.7	1.99e-20	3.56e-17	-0.59	-0.4	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
LUAD	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	9.7	2e-20	3.59e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	9.7	2e-20	3.59e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	9.7	2e-20	3.59e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
LUAD	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-9.7	2e-20	3.59e-17	-0.51	-0.4	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
LUAD	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	9.7	2.01e-20	3.59e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
LUAD	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-9.69	2.03e-20	3.62e-17	-0.51	-0.4	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-9.69	2.03e-20	3.62e-17	-0.51	-0.4	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
LUAD	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-9.69	2.05e-20	3.66e-17	-0.44	-0.4	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
LUAD	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	9.69	2.05e-20	3.66e-17	0.54	0.4	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
LUAD	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	9.69	2.1e-20	3.74e-17	0.41	0.4	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-9.69	2.1e-20	3.75e-17	-0.28	-0.4	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-9.69	2.1e-20	3.75e-17	-0.28	-0.4	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
LUAD	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	9.69	2.1e-20	3.75e-17	0.54	0.4	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
LUAD	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-9.69	2.11e-20	3.77e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
LUAD	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-9.69	2.15e-20	3.83e-17	-0.45	-0.4	Height;	chr3:52991821	chr3:53064283~53065091:-
LUAD	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-9.69	2.18e-20	3.88e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
LUAD	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	9.69	2.19e-20	3.89e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
LUAD	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	9.69	2.19e-20	3.9e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	9.69	2.19e-20	3.9e-17	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
LUAD	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-9.69	2.19e-20	3.9e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-9.69	2.19e-20	3.9e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-9.69	2.19e-20	3.9e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-9.69	2.19e-20	3.9e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
LUAD	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-9.69	2.19e-20	3.91e-17	-0.48	-0.4	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
LUAD	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-9.68	2.21e-20	3.94e-17	-0.57	-0.4	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-9.68	2.21e-20	3.94e-17	-0.57	-0.4	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
LUAD	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
LUAD	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-9.68	2.22e-20	3.95e-17	-0.56	-0.4	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
LUAD	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
LUAD	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	9.68	2.23e-20	3.97e-17	0.56	0.4	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
LUAD	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	9.68	2.23e-20	3.97e-17	0.43	0.4	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
LUAD	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	9.68	2.24e-20	3.97e-17	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	9.68	2.24e-20	3.97e-17	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	9.68	2.24e-20	3.97e-17	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	9.68	2.26e-20	4.01e-17	0.7	0.4	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
LUAD	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-9.68	2.26e-20	4.02e-17	-0.52	-0.4	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
LUAD	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-9.68	2.27e-20	4.03e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
LUAD	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	9.68	2.27e-20	4.03e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
LUAD	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	9.68	2.27e-20	4.03e-17	0.5	0.4	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-9.68	2.28e-20	4.05e-17	-0.36	-0.4	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
LUAD	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-9.68	2.29e-20	4.06e-17	-0.55	-0.4	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
LUAD	cis	rs944289	0.646	rs1742868	ENSG00000257826.1	RP11-116N8.4	-9.68	2.29e-20	4.07e-17	-0.42	-0.4	Thyroid cancer;	chr14:36067743	chr14:36061026~36067190:-
LUAD	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-9.68	2.3e-20	4.08e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
LUAD	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	9.68	2.3e-20	4.08e-17	0.45	0.4	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
LUAD	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	9.68	2.3e-20	4.09e-17	0.59	0.4	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
LUAD	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-9.68	2.32e-20	4.11e-17	-0.44	-0.4	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
LUAD	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	9.68	2.34e-20	4.14e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
LUAD	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	9.68	2.34e-20	4.15e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
LUAD	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	9.68	2.36e-20	4.19e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-9.68	2.39e-20	4.23e-17	-0.36	-0.4	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-9.67	2.4e-20	4.25e-17	-0.41	-0.4	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
LUAD	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	9.67	2.4e-20	4.25e-17	0.45	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
LUAD	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	9.67	2.41e-20	4.26e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	9.67	2.41e-20	4.26e-17	0.34	0.4	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	9.67	2.41e-20	4.27e-17	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
LUAD	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	9.67	2.43e-20	4.3e-17	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
LUAD	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-9.67	2.43e-20	4.31e-17	-0.41	-0.4	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
LUAD	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	9.67	2.44e-20	4.32e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	9.67	2.44e-20	4.32e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	9.67	2.44e-20	4.32e-17	0.5	0.4	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
LUAD	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-9.67	2.45e-20	4.33e-17	-0.57	-0.4	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
LUAD	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	9.67	2.45e-20	4.34e-17	0.48	0.4	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
LUAD	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-9.67	2.45e-20	4.34e-17	-0.41	-0.4	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000280411.1	IGHV1-69-2	-9.67	2.48e-20	4.38e-17	-0.28	-0.4	Kawasaki disease;	chr14:106686149	chr14:106762092~106762588:-
LUAD	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-9.67	2.51e-20	4.43e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
LUAD	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	9.67	2.51e-20	4.43e-17	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
LUAD	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-9.67	2.53e-20	4.47e-17	-0.45	-0.4	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-9.67	2.53e-20	4.47e-17	-0.45	-0.4	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-9.67	2.54e-20	4.48e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-9.67	2.54e-20	4.49e-17	-0.51	-0.4	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
LUAD	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-9.67	2.55e-20	4.49e-17	-0.56	-0.4	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
LUAD	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-9.67	2.55e-20	4.51e-17	-0.41	-0.4	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
LUAD	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	9.67	2.55e-20	4.51e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
LUAD	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-9.67	2.55e-20	4.51e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
LUAD	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-9.67	2.56e-20	4.52e-17	-0.45	-0.4	Height;	chr3:52992698	chr3:53064283~53065091:-
LUAD	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	9.67	2.57e-20	4.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	9.67	2.57e-20	4.54e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
LUAD	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	9.66	2.61e-20	4.6e-17	0.46	0.4	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
LUAD	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-9.66	2.64e-20	4.65e-17	-0.55	-0.4	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
LUAD	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	9.66	2.64e-20	4.65e-17	0.53	0.4	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
LUAD	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	9.66	2.65e-20	4.67e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	9.66	2.65e-20	4.67e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	9.66	2.65e-20	4.67e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
LUAD	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	9.66	2.65e-20	4.67e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
LUAD	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-9.66	2.68e-20	4.71e-17	-0.47	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
LUAD	cis	rs8062405	0.931	rs12928404	ENSG00000259982.1	CDC37P1	9.66	2.71e-20	4.77e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28700294~28701540:-
LUAD	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	9.66	2.72e-20	4.79e-17	0.48	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
LUAD	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-9.66	2.73e-20	4.8e-17	-0.49	-0.4	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
LUAD	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-9.66	2.73e-20	4.81e-17	-0.56	-0.4	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
LUAD	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-9.66	2.75e-20	4.83e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-9.66	2.75e-20	4.83e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
LUAD	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-9.66	2.81e-20	4.94e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
LUAD	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	9.65	2.82e-20	4.95e-17	0.58	0.4	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
LUAD	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-9.65	2.83e-20	4.97e-17	-0.43	-0.4	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
LUAD	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
LUAD	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	9.65	2.86e-20	5.02e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
LUAD	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.93e-20	5.13e-17	-0.41	-0.4	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
LUAD	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	9.65	2.95e-20	5.17e-17	0.56	0.4	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
LUAD	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-9.65	2.96e-20	5.18e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	9.65	2.98e-20	5.22e-17	0.53	0.4	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
LUAD	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	9.65	2.98e-20	5.22e-17	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
LUAD	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	9.65	2.99e-20	5.23e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
LUAD	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	9.65	3e-20	5.25e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-9.65	3.02e-20	5.28e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-9.65	3.02e-20	5.28e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-9.65	3.02e-20	5.28e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-9.65	3.02e-20	5.29e-17	-0.28	-0.4	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
LUAD	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	9.65	3.02e-20	5.29e-17	0.68	0.4	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	9.65	3.02e-20	5.29e-17	0.68	0.4	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
LUAD	cis	rs5769707	0.777	rs739243	ENSG00000188511.11	C22orf34	9.65	3.02e-20	5.29e-17	0.45	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49414524~49657542:-
LUAD	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-9.65	3.04e-20	5.32e-17	-0.41	-0.4	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-9.65	3.04e-20	5.32e-17	-0.41	-0.4	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
LUAD	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-9.64	3.07e-20	5.37e-17	-0.65	-0.4	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
LUAD	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-9.64	3.11e-20	5.43e-17	-0.51	-0.4	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
LUAD	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-9.64	3.12e-20	5.45e-17	-0.56	-0.4	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
LUAD	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	9.64	3.12e-20	5.45e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
LUAD	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	9.64	3.13e-20	5.46e-17	0.53	0.4	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
LUAD	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-9.64	3.13e-20	5.47e-17	-0.47	-0.4	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
LUAD	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	9.64	3.15e-20	5.5e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	9.64	3.16e-20	5.51e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	9.64	3.16e-20	5.51e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	9.64	3.17e-20	5.52e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-9.64	3.17e-20	5.53e-17	-0.45	-0.4	Height;	chr3:52989412	chr3:53064283~53065091:-
LUAD	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	9.64	3.18e-20	5.54e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	9.64	3.18e-20	5.55e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	9.64	3.18e-20	5.55e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	9.64	3.18e-20	5.55e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
LUAD	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-9.64	3.19e-20	5.56e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
LUAD	cis	rs944289	0.675	rs398745	ENSG00000257826.1	RP11-116N8.4	9.64	3.19e-20	5.57e-17	0.42	0.4	Thyroid cancer;	chr14:36066975	chr14:36061026~36067190:-
LUAD	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	9.64	3.2e-20	5.59e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
LUAD	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-9.64	3.21e-20	5.59e-17	-0.54	-0.4	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-9.64	3.24e-20	5.65e-17	-0.36	-0.4	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-9.64	3.27e-20	5.71e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	9.64	3.3e-20	5.74e-17	0.36	0.4	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
LUAD	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	9.64	3.31e-20	5.76e-17	0.55	0.4	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
LUAD	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	9.63	3.32e-20	5.78e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
LUAD	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-9.63	3.34e-20	5.82e-17	-0.55	-0.4	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
LUAD	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	9.63	3.35e-20	5.83e-17	0.56	0.4	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
LUAD	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	9.63	3.41e-20	5.94e-17	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-9.63	3.41e-20	5.94e-17	-0.28	-0.4	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
LUAD	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-9.63	3.43e-20	5.96e-17	-0.41	-0.4	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-9.63	3.43e-20	5.96e-17	-0.41	-0.4	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
LUAD	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-9.63	3.43e-20	5.96e-17	-0.49	-0.4	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
LUAD	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	9.63	3.43e-20	5.98e-17	0.56	0.4	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
LUAD	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	9.63	3.44e-20	5.98e-17	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	9.63	3.47e-20	6.03e-17	0.42	0.4	Height;	chr3:53082835	chr3:53064283~53065091:-
LUAD	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	9.63	3.48e-20	6.05e-17	0.56	0.4	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-9.63	3.49e-20	6.07e-17	-0.56	-0.4	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
LUAD	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-9.63	3.5e-20	6.08e-17	-0.45	-0.4	Height;	chr3:52972039	chr3:53064283~53065091:-
LUAD	cis	rs944289	0.616	rs408783	ENSG00000257826.1	RP11-116N8.4	9.63	3.52e-20	6.11e-17	0.42	0.4	Thyroid cancer;	chr14:36065667	chr14:36061026~36067190:-
LUAD	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	9.63	3.53e-20	6.14e-17	0.47	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
LUAD	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-9.63	3.54e-20	6.16e-17	-0.57	-0.4	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
LUAD	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-9.63	3.57e-20	6.21e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
LUAD	cis	rs4273100	0.646	rs6587216	ENSG00000262319.1	CTC-457L16.2	9.63	3.58e-20	6.22e-17	0.48	0.4	Schizophrenia;	chr17:19321084	chr17:19141017~19143689:-
LUAD	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-9.62	3.6e-20	6.25e-17	-0.56	-0.4	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
LUAD	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	9.62	3.62e-20	6.27e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	9.62	3.62e-20	6.29e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
LUAD	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	9.62	3.64e-20	6.32e-17	0.55	0.4	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
LUAD	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-9.62	3.64e-20	6.32e-17	-0.53	-0.4	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-9.62	3.65e-20	6.33e-17	-0.4	-0.4	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
LUAD	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	9.62	3.66e-20	6.34e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	9.62	3.66e-20	6.34e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	9.62	3.66e-20	6.34e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	9.62	3.66e-20	6.34e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
LUAD	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-9.62	3.67e-20	6.37e-17	-0.46	-0.4	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-9.62	3.68e-20	6.38e-17	-0.28	-0.4	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
LUAD	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-9.62	3.69e-20	6.39e-17	-0.51	-0.4	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
LUAD	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-9.62	3.74e-20	6.48e-17	-0.41	-0.4	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
LUAD	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-9.62	3.74e-20	6.49e-17	-0.48	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	9.62	3.76e-20	6.51e-17	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
LUAD	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-9.62	3.78e-20	6.54e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
LUAD	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	9.62	3.78e-20	6.55e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
LUAD	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	9.62	3.79e-20	6.56e-17	0.52	0.4	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
LUAD	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	9.62	3.8e-20	6.58e-17	0.58	0.4	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
LUAD	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	9.62	3.81e-20	6.59e-17	0.61	0.4	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
LUAD	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
LUAD	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-9.62	3.87e-20	6.7e-17	-0.49	-0.4	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
LUAD	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	9.61	3.96e-20	6.85e-17	0.61	0.4	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	9.61	3.98e-20	6.88e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
LUAD	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-9.61	4.05e-20	7e-17	-0.46	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
LUAD	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-9.61	4.08e-20	7.04e-17	-0.36	-0.4	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
LUAD	cis	rs944289	0.646	rs396043	ENSG00000257826.1	RP11-116N8.4	9.61	4.11e-20	7.1e-17	0.42	0.4	Thyroid cancer;	chr14:36071815	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs429041	ENSG00000257826.1	RP11-116N8.4	9.61	4.11e-20	7.1e-17	0.42	0.4	Thyroid cancer;	chr14:36071930	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs368772	ENSG00000257826.1	RP11-116N8.4	9.61	4.11e-20	7.1e-17	0.42	0.4	Thyroid cancer;	chr14:36071955	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs4981320	ENSG00000257826.1	RP11-116N8.4	9.61	4.11e-20	7.1e-17	0.42	0.4	Thyroid cancer;	chr14:36072456	chr14:36061026~36067190:-
LUAD	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-9.61	4.12e-20	7.11e-17	-0.45	-0.4	Height;	chr3:53009621	chr3:53064283~53065091:-
LUAD	cis	rs694739	0.628	rs475032	ENSG00000236935.1	AP003774.1	-9.61	4.12e-20	7.12e-17	-0.38	-0.4	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373265	chr11:64325050~64329504:-
LUAD	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	9.61	4.13e-20	7.13e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
LUAD	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-9.61	4.18e-20	7.21e-17	-0.5	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
LUAD	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-9.61	4.2e-20	7.25e-17	-0.57	-0.4	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
LUAD	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	9.61	4.22e-20	7.29e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
LUAD	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	9.6	4.23e-20	7.3e-17	0.45	0.4	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
LUAD	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-9.6	4.3e-20	7.42e-17	-0.49	-0.4	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
LUAD	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-9.6	4.32e-20	7.46e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-9.6	4.35e-20	7.49e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
LUAD	cis	rs944289	0.616	rs410546	ENSG00000257826.1	RP11-116N8.4	9.6	4.44e-20	7.65e-17	0.41	0.4	Thyroid cancer;	chr14:36071858	chr14:36061026~36067190:-
LUAD	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	9.6	4.48e-20	7.7e-17	0.5	0.4	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
LUAD	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	9.6	4.53e-20	7.78e-17	0.46	0.4	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-9.6	4.56e-20	7.83e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-9.6	4.57e-20	7.84e-17	-0.46	-0.4	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
LUAD	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
LUAD	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	9.59	4.64e-20	7.96e-17	0.38	0.4	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
LUAD	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	9.59	4.65e-20	7.98e-17	0.45	0.4	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
LUAD	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	9.59	4.65e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	9.59	4.67e-20	8e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
LUAD	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	9.59	4.72e-20	8.09e-17	0.64	0.4	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
LUAD	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-9.59	4.73e-20	8.11e-17	-0.51	-0.4	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-9.59	4.75e-20	8.13e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-9.59	4.79e-20	8.19e-17	-0.53	-0.4	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
LUAD	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	9.59	4.81e-20	8.23e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	9.59	4.81e-20	8.23e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	9.59	4.81e-20	8.24e-17	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	9.59	4.81e-20	8.24e-17	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
LUAD	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-9.59	4.92e-20	8.42e-17	-0.53	-0.4	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
LUAD	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	9.59	4.95e-20	8.46e-17	0.65	0.4	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	9.59	4.95e-20	8.46e-17	0.65	0.4	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	9.59	4.95e-20	8.46e-17	0.65	0.4	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	9.59	4.95e-20	8.46e-17	0.65	0.4	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	9.58	4.98e-20	8.5e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	9.58	4.98e-20	8.5e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	9.58	4.98e-20	8.5e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
LUAD	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-9.58	5e-20	8.53e-17	-0.54	-0.4	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
LUAD	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	9.58	5e-20	8.54e-17	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
LUAD	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-9.58	5.01e-20	8.56e-17	-0.44	-0.4	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
LUAD	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	9.58	5.02e-20	8.57e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	9.58	5.04e-20	8.6e-17	0.45	0.4	Height;	chr3:53091453	chr3:53064283~53065091:-
LUAD	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	9.58	5.09e-20	8.69e-17	0.61	0.4	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
LUAD	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-9.58	5.1e-20	8.7e-17	-0.45	-0.4	Height;	chr3:53007328	chr3:53064283~53065091:-
LUAD	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	9.58	5.11e-20	8.71e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
LUAD	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-9.58	5.14e-20	8.76e-17	-0.5	-0.4	Height;	chr11:118809363	chr11:118704607~118750263:+
LUAD	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-9.58	5.14e-20	8.77e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
LUAD	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	9.58	5.14e-20	8.77e-17	0.54	0.4	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
LUAD	cis	rs944289	0.616	rs448145	ENSG00000257826.1	RP11-116N8.4	9.58	5.15e-20	8.79e-17	0.41	0.4	Thyroid cancer;	chr14:36069722	chr14:36061026~36067190:-
LUAD	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	9.58	5.17e-20	8.81e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	9.58	5.19e-20	8.86e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	9.58	5.25e-20	8.95e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	9.58	5.26e-20	8.95e-17	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	9.58	5.3e-20	9.03e-17	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
LUAD	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-9.58	5.31e-20	9.03e-17	-0.44	-0.4	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
LUAD	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-9.58	5.31e-20	9.05e-17	-0.45	-0.4	Height;	chr3:52989619	chr3:53064283~53065091:-
LUAD	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	9.57	5.42e-20	9.22e-17	0.51	0.4	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	9.57	5.42e-20	9.22e-17	0.32	0.4	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-9.57	5.44e-20	9.26e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	9.57	5.46e-20	9.28e-17	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
LUAD	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	9.57	5.51e-20	9.38e-17	0.47	0.4	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
LUAD	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	9.57	5.52e-20	9.39e-17	0.45	0.4	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
LUAD	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	9.57	5.56e-20	9.46e-17	0.47	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	9.57	5.56e-20	9.46e-17	0.47	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
LUAD	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-9.57	5.6e-20	9.51e-17	-0.55	-0.4	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
LUAD	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-9.57	5.63e-20	9.57e-17	-0.31	-0.4	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
LUAD	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	9.57	5.64e-20	9.59e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
LUAD	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	9.57	5.66e-20	9.61e-17	0.4	0.4	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
LUAD	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	9.57	5.66e-20	9.62e-17	0.64	0.4	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
LUAD	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-9.57	5.67e-20	9.63e-17	-0.43	-0.4	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
LUAD	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	9.57	5.71e-20	9.69e-17	0.5	0.4	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
LUAD	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-9.57	5.72e-20	9.71e-17	-0.4	-0.4	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
LUAD	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	9.57	5.76e-20	9.78e-17	0.45	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
LUAD	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	9.57	5.76e-20	9.78e-17	0.67	0.4	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
LUAD	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-9.57	5.79e-20	9.82e-17	-0.46	-0.4	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
LUAD	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-9.57	5.79e-20	9.82e-17	-0.46	-0.4	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
LUAD	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-9.57	5.79e-20	9.82e-17	-0.46	-0.4	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
LUAD	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	9.56	5.91e-20	1e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	9.56	5.95e-20	1.01e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	9.56	6.01e-20	1.02e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	9.56	6.01e-20	1.02e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
LUAD	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	9.56	6.1e-20	1.03e-16	0.49	0.4	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	9.56	6.11e-20	1.04e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	9.56	6.14e-20	1.04e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
LUAD	cis	rs1757171	0.504	rs11969056	ENSG00000204110.6	RP1-153P14.8	-9.56	6.2e-20	1.05e-16	-0.4	-0.4	Cognitive performance;	chr6:37516509	chr6:37507348~37535616:+
LUAD	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	9.56	6.26e-20	1.06e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
LUAD	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-9.56	6.27e-20	1.06e-16	-0.41	-0.4	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
LUAD	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	9.56	6.31e-20	1.07e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
LUAD	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	9.56	6.31e-20	1.07e-16	0.35	0.4	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
LUAD	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
LUAD	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-9.55	6.37e-20	1.08e-16	-0.41	-0.4	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
LUAD	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	9.55	6.43e-20	1.09e-16	0.52	0.4	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
LUAD	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	9.55	6.43e-20	1.09e-16	0.52	0.4	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
LUAD	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	9.55	6.56e-20	1.11e-16	0.39	0.4	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
LUAD	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
LUAD	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
LUAD	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	9.55	6.57e-20	1.11e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-9.55	6.62e-20	1.12e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-9.55	6.64e-20	1.12e-16	-0.49	-0.4	Height;	chr11:118737823	chr11:118704607~118750263:+
LUAD	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-9.55	6.65e-20	1.12e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-9.55	6.65e-20	1.12e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
LUAD	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-9.55	6.69e-20	1.13e-16	-0.4	-0.4	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
LUAD	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-9.55	6.7e-20	1.13e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
LUAD	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	9.55	6.72e-20	1.13e-16	0.5	0.4	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
LUAD	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-9.55	6.74e-20	1.14e-16	-0.46	-0.4	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
LUAD	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-9.55	6.86e-20	1.16e-16	-0.5	-0.4	Height;	chr11:118808920	chr11:118704607~118750263:+
LUAD	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-9.55	6.87e-20	1.16e-16	-0.43	-0.4	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
LUAD	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	9.54	6.94e-20	1.17e-16	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
LUAD	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	9.54	6.96e-20	1.17e-16	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
LUAD	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	9.54	7.11e-20	1.19e-16	0.54	0.4	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
LUAD	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-9.54	7.15e-20	1.2e-16	-0.47	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
LUAD	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	9.54	7.16e-20	1.2e-16	0.47	0.4	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
LUAD	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-9.54	7.17e-20	1.2e-16	-0.45	-0.4	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
LUAD	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	9.54	7.18e-20	1.21e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.79	rs4635115	ENSG00000271584.1	RP11-89C3.4	9.54	7.18e-20	1.21e-16	0.64	0.4	Body mass index;	chr11:111076352	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	9.54	7.27e-20	1.22e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
LUAD	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	9.54	7.27e-20	1.22e-16	0.61	0.4	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	9.54	7.27e-20	1.22e-16	0.61	0.4	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-9.54	7.3e-20	1.23e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
LUAD	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	9.54	7.32e-20	1.23e-16	0.43	0.4	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
LUAD	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	9.54	7.34e-20	1.23e-16	0.49	0.4	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
LUAD	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	9.54	7.41e-20	1.24e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	9.54	7.41e-20	1.24e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
LUAD	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	9.54	7.46e-20	1.25e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
LUAD	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	9.53	7.46e-20	1.25e-16	0.49	0.4	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
LUAD	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	9.53	7.49e-20	1.25e-16	0.64	0.4	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
LUAD	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	9.53	7.49e-20	1.26e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-9.53	7.5e-20	1.26e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	9.53	7.51e-20	1.26e-16	0.37	0.4	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-9.53	7.6e-20	1.27e-16	-0.4	-0.4	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
LUAD	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	9.53	7.65e-20	1.28e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
LUAD	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-9.53	7.71e-20	1.29e-16	-0.67	-0.4	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	9.53	7.93e-20	1.33e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	9.53	7.93e-20	1.33e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-9.53	8e-20	1.34e-16	-0.27	-0.4	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
LUAD	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-9.53	8.01e-20	1.34e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
LUAD	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	9.53	8.06e-20	1.35e-16	0.78	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
LUAD	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	9.52	8.12e-20	1.36e-16	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
LUAD	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	9.52	8.14e-20	1.36e-16	0.38	0.4	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	9.52	8.17e-20	1.36e-16	0.32	0.4	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	9.52	8.18e-20	1.37e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-9.52	8.24e-20	1.38e-16	-0.45	-0.4	Height;	chr3:53093751	chr3:53064283~53065091:-
LUAD	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-9.52	8.27e-20	1.38e-16	-0.4	-0.4	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
LUAD	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	9.52	8.34e-20	1.39e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	9.52	8.34e-20	1.39e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	9.52	8.36e-20	1.39e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	9.52	8.38e-20	1.4e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
LUAD	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	9.52	8.43e-20	1.41e-16	0.5	0.4	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	9.52	8.43e-20	1.41e-16	0.5	0.4	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
LUAD	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	9.52	8.43e-20	1.41e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
LUAD	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	9.52	8.44e-20	1.41e-16	0.49	0.4	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
LUAD	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	9.52	8.52e-20	1.42e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
LUAD	cis	rs5769707	0.749	rs7286706	ENSG00000188511.11	C22orf34	9.52	8.53e-20	1.42e-16	0.45	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49414524~49657542:-
LUAD	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-9.52	8.54e-20	1.42e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
LUAD	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	9.52	8.57e-20	1.43e-16	0.5	0.4	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-9.52	8.61e-20	1.43e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
LUAD	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-9.52	8.65e-20	1.44e-16	-0.45	-0.4	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
LUAD	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-9.52	8.66e-20	1.44e-16	-0.39	-0.4	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
LUAD	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	9.51	8.89e-20	1.48e-16	0.61	0.4	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
LUAD	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	9.51	8.92e-20	1.48e-16	0.48	0.4	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
LUAD	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
LUAD	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
LUAD	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	9.51	8.99e-20	1.49e-16	0.86	0.4	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
LUAD	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	9.51	8.99e-20	1.49e-16	0.46	0.4	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	9.51	9e-20	1.5e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-9.51	9.04e-20	1.5e-16	-0.48	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
LUAD	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
LUAD	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	9.51	9.13e-20	1.52e-16	0.45	0.4	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	9.51	9.15e-20	1.52e-16	0.27	0.4	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
LUAD	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	9.51	9.21e-20	1.53e-16	0.57	0.4	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
LUAD	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	9.51	9.24e-20	1.53e-16	0.9	0.4	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
LUAD	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	9.51	9.27e-20	1.54e-16	0.49	0.4	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	9.51	9.27e-20	1.54e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	9.51	9.27e-20	1.54e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
LUAD	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	9.51	9.3e-20	1.54e-16	0.48	0.4	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-9.51	9.35e-20	1.55e-16	-0.34	-0.4	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-9.51	9.41e-20	1.56e-16	-0.47	-0.4	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
LUAD	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-9.51	9.49e-20	1.57e-16	-0.39	-0.4	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-9.51	9.49e-20	1.57e-16	-0.39	-0.4	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
LUAD	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	9.5	9.6e-20	1.59e-16	0.57	0.4	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
LUAD	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	9.5	9.61e-20	1.59e-16	0.54	0.4	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
LUAD	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-9.5	9.71e-20	1.61e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-9.5	9.8e-20	1.62e-16	-0.5	-0.4	Height;	chr11:118791319	chr11:118704607~118750263:+
LUAD	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-9.5	9.83e-20	1.63e-16	-0.77	-0.4	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
LUAD	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	9.5	9.87e-20	1.63e-16	0.45	0.4	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
LUAD	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	9.5	9.89e-20	1.64e-16	0.45	0.4	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
LUAD	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-9.5	9.96e-20	1.65e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
LUAD	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	9.5	9.96e-20	1.65e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-9.5	1e-19	1.66e-16	-0.45	-0.4	Height;	chr3:53015087	chr3:53064283~53065091:-
LUAD	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	9.5	1.01e-19	1.67e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-9.5	1.03e-19	1.7e-16	-0.44	-0.4	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
LUAD	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-9.5	1.03e-19	1.7e-16	-0.51	-0.4	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
LUAD	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	9.49	1.04e-19	1.71e-16	0.5	0.4	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	9.49	1.04e-19	1.71e-16	0.5	0.4	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000280411.1	IGHV1-69-2	-9.49	1.04e-19	1.71e-16	-0.28	-0.4	Kawasaki disease;	chr14:106776758	chr14:106762092~106762588:-
LUAD	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-9.49	1.04e-19	1.71e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	9.49	1.05e-19	1.73e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
LUAD	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	9.49	1.05e-19	1.73e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	9.49	1.05e-19	1.73e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
LUAD	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-9.49	1.06e-19	1.74e-16	-0.4	-0.4	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
LUAD	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-9.49	1.06e-19	1.75e-16	-0.47	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
LUAD	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	9.49	1.06e-19	1.75e-16	0.78	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
LUAD	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	9.49	1.07e-19	1.77e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-9.49	1.07e-19	1.77e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-9.49	1.07e-19	1.77e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
LUAD	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	9.49	1.07e-19	1.77e-16	0.5	0.4	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
LUAD	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	9.49	1.09e-19	1.79e-16	0.86	0.4	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
LUAD	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	9.49	1.09e-19	1.8e-16	0.64	0.4	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
LUAD	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-9.49	1.09e-19	1.8e-16	-0.4	-0.4	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
LUAD	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	9.49	1.1e-19	1.81e-16	0.5	0.4	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	9.49	1.1e-19	1.81e-16	0.5	0.4	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
LUAD	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	9.49	1.1e-19	1.81e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-9.49	1.1e-19	1.81e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-9.49	1.1e-19	1.81e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
LUAD	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	9.49	1.1e-19	1.82e-16	0.53	0.4	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-9.49	1.11e-19	1.82e-16	-0.31	-0.4	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
LUAD	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-9.49	1.11e-19	1.82e-16	-0.43	-0.4	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
LUAD	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	9.49	1.12e-19	1.84e-16	0.49	0.4	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
LUAD	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-9.48	1.13e-19	1.86e-16	-0.55	-0.4	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
LUAD	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	9.48	1.14e-19	1.88e-16	0.53	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
LUAD	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	9.48	1.14e-19	1.88e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	9.48	1.14e-19	1.88e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
LUAD	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-9.48	1.14e-19	1.88e-16	-0.51	-0.4	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-9.48	1.14e-19	1.88e-16	-0.51	-0.4	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-9.48	1.16e-19	1.9e-16	-0.51	-0.4	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-9.48	1.17e-19	1.92e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	9.48	1.17e-19	1.92e-16	0.53	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
LUAD	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-9.48	1.18e-19	1.93e-16	-0.42	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
LUAD	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-9.48	1.19e-19	1.95e-16	-0.53	-0.4	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
LUAD	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-9.48	1.19e-19	1.96e-16	-0.56	-0.4	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
LUAD	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-9.48	1.19e-19	1.96e-16	-0.48	-0.4	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
LUAD	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-9.48	1.2e-19	1.98e-16	-0.49	-0.4	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
LUAD	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	9.47	1.22e-19	2.01e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	9.47	1.22e-19	2.01e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
LUAD	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-9.47	1.22e-19	2.01e-16	-0.5	-0.4	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
LUAD	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	9.47	1.23e-19	2.01e-16	0.67	0.4	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
LUAD	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-9.47	1.23e-19	2.01e-16	-0.47	-0.4	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
LUAD	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	9.47	1.23e-19	2.02e-16	0.66	0.4	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	9.47	1.23e-19	2.02e-16	0.66	0.4	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	9.47	1.23e-19	2.02e-16	0.66	0.4	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
LUAD	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-9.47	1.23e-19	2.02e-16	-0.49	-0.4	Height;	chr11:118746590	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-9.47	1.24e-19	2.03e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	9.47	1.25e-19	2.04e-16	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
LUAD	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	9.47	1.25e-19	2.04e-16	0.6	0.4	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
LUAD	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	9.47	1.25e-19	2.05e-16	0.45	0.4	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	9.47	1.26e-19	2.06e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
LUAD	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	9.47	1.26e-19	2.07e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	9.47	1.26e-19	2.07e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
LUAD	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-9.47	1.27e-19	2.07e-16	-0.47	-0.4	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
LUAD	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	9.47	1.27e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-9.47	1.27e-19	2.08e-16	-0.45	-0.4	Height;	chr3:53034139	chr3:53064283~53065091:-
LUAD	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-9.47	1.27e-19	2.08e-16	-0.4	-0.4	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
LUAD	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-9.47	1.27e-19	2.08e-16	-0.45	-0.4	Height;	chr3:53027361	chr3:53064283~53065091:-
LUAD	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
LUAD	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-9.47	1.28e-19	2.1e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
LUAD	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-9.47	1.28e-19	2.1e-16	-0.41	-0.4	Height;	chr3:52994045	chr3:53064283~53065091:-
LUAD	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-9.47	1.28e-19	2.1e-16	-0.41	-0.4	Height;	chr3:52994990	chr3:53064283~53065091:-
LUAD	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	9.47	1.29e-19	2.11e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	9.47	1.29e-19	2.11e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
LUAD	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	9.47	1.29e-19	2.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
LUAD	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	9.47	1.29e-19	2.11e-16	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
LUAD	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	9.47	1.3e-19	2.12e-16	0.66	0.4	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	9.47	1.3e-19	2.12e-16	0.66	0.4	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	9.47	1.3e-19	2.12e-16	0.66	0.4	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	9.47	1.3e-19	2.12e-16	0.32	0.4	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	9.47	1.3e-19	2.12e-16	0.32	0.4	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	9.47	1.3e-19	2.12e-16	0.32	0.4	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
LUAD	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	9.47	1.3e-19	2.13e-16	0.49	0.4	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	9.47	1.3e-19	2.13e-16	0.49	0.4	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	9.47	1.31e-19	2.13e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	9.47	1.31e-19	2.14e-16	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
LUAD	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-9.46	1.34e-19	2.18e-16	-0.49	-0.4	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
LUAD	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	9.46	1.34e-19	2.18e-16	0.62	0.4	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
LUAD	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	9.46	1.35e-19	2.2e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	9.46	1.36e-19	2.21e-16	0.4	0.4	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
LUAD	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-9.46	1.36e-19	2.21e-16	-0.56	-0.4	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
LUAD	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	9.46	1.36e-19	2.21e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-9.46	1.36e-19	2.22e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-9.46	1.37e-19	2.23e-16	-0.49	-0.4	Height;	chr11:118786602	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-9.46	1.39e-19	2.26e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-9.46	1.42e-19	2.31e-16	-0.4	-0.4	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-9.46	1.42e-19	2.31e-16	-0.4	-0.4	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	9.46	1.42e-19	2.31e-16	0.32	0.4	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	9.46	1.42e-19	2.31e-16	0.32	0.4	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
LUAD	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	9.46	1.42e-19	2.31e-16	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
LUAD	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	9.46	1.42e-19	2.31e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
LUAD	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	9.46	1.42e-19	2.31e-16	0.51	0.4	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	9.46	1.42e-19	2.31e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	9.46	1.42e-19	2.31e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	9.46	1.42e-19	2.31e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	9.45	1.43e-19	2.32e-16	0.27	0.4	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
LUAD	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-9.45	1.43e-19	2.33e-16	-0.4	-0.4	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	9.45	1.46e-19	2.36e-16	0.32	0.4	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	9.45	1.46e-19	2.36e-16	0.32	0.4	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	9.45	1.46e-19	2.36e-16	0.32	0.4	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
LUAD	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-9.45	1.46e-19	2.38e-16	-0.42	-0.4	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
LUAD	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-9.45	1.47e-19	2.38e-16	-0.47	-0.4	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
LUAD	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-9.45	1.47e-19	2.38e-16	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
LUAD	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	9.45	1.48e-19	2.4e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	9.45	1.48e-19	2.4e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
LUAD	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	9.45	1.49e-19	2.42e-16	0.45	0.4	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
LUAD	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	9.45	1.49e-19	2.42e-16	0.51	0.4	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
LUAD	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-9.45	1.49e-19	2.42e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-9.45	1.49e-19	2.42e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-9.45	1.5e-19	2.43e-16	-0.47	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	9.45	1.5e-19	2.44e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-9.45	1.51e-19	2.45e-16	-0.27	-0.4	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
LUAD	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	9.45	1.52e-19	2.46e-16	0.6	0.4	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-9.45	1.52e-19	2.47e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-9.45	1.52e-19	2.47e-16	-0.39	-0.4	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-9.45	1.52e-19	2.47e-16	-0.39	-0.4	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
LUAD	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	9.45	1.53e-19	2.48e-16	0.44	0.4	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
LUAD	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	9.45	1.53e-19	2.49e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
LUAD	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-9.44	1.54e-19	2.5e-16	-0.45	-0.4	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	9.44	1.55e-19	2.51e-16	0.32	0.4	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
LUAD	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	9.44	1.55e-19	2.51e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
LUAD	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-9.44	1.55e-19	2.51e-16	-0.39	-0.4	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
LUAD	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-9.44	1.55e-19	2.51e-16	-0.4	-0.4	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
LUAD	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	9.44	1.58e-19	2.56e-16	0.39	0.4	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
LUAD	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-9.44	1.58e-19	2.56e-16	-0.44	-0.4	Height;	chr3:53094335	chr3:53064283~53065091:-
LUAD	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-9.44	1.61e-19	2.6e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-9.44	1.61e-19	2.6e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
LUAD	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-9.44	1.61e-19	2.6e-16	-0.38	-0.4	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
LUAD	cis	rs1061377	0.862	rs12508577	ENSG00000249207.1	RP11-360F5.1	-9.44	1.61e-19	2.6e-16	-0.44	-0.4	Uric acid levels;	chr4:39107779	chr4:39112677~39126818:-
LUAD	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-9.44	1.61e-19	2.61e-16	-0.4	-0.4	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
LUAD	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	9.44	1.62e-19	2.62e-16	0.6	0.4	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	9.44	1.62e-19	2.62e-16	0.32	0.4	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
LUAD	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	9.44	1.63e-19	2.63e-16	0.46	0.4	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
LUAD	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-9.44	1.63e-19	2.63e-16	-0.48	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
LUAD	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	9.44	1.63e-19	2.64e-16	0.38	0.4	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
LUAD	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-9.44	1.64e-19	2.66e-16	-0.4	-0.4	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
LUAD	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-9.44	1.64e-19	2.66e-16	-0.51	-0.4	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
LUAD	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-9.44	1.65e-19	2.66e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
LUAD	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-9.44	1.66e-19	2.68e-16	-0.48	-0.4	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
LUAD	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-9.43	1.68e-19	2.7e-16	-0.46	-0.4	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
LUAD	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	9.43	1.71e-19	2.75e-16	0.49	0.4	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
LUAD	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	9.43	1.72e-19	2.77e-16	0.42	0.4	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	9.43	1.72e-19	2.77e-16	0.42	0.4	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
LUAD	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	9.43	1.72e-19	2.77e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	9.43	1.72e-19	2.77e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	9.43	1.72e-19	2.77e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	9.43	1.72e-19	2.77e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-9.43	1.72e-19	2.78e-16	-0.45	-0.4	Height;	chr3:52949886	chr3:53064283~53065091:-
LUAD	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-9.43	1.73e-19	2.78e-16	-0.41	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
LUAD	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	9.43	1.75e-19	2.83e-16	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
LUAD	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-9.43	1.77e-19	2.85e-16	-0.49	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
LUAD	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	9.43	1.78e-19	2.86e-16	0.65	0.39	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
LUAD	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-9.43	1.79e-19	2.87e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-9.43	1.79e-19	2.87e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
LUAD	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	9.43	1.79e-19	2.88e-16	0.44	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
LUAD	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	9.43	1.81e-19	2.9e-16	0.42	0.39	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
LUAD	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	9.43	1.81e-19	2.91e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-9.42	1.83e-19	2.93e-16	-0.38	-0.39	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
LUAD	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-9.42	1.84e-19	2.96e-16	-0.48	-0.39	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
LUAD	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	9.42	1.85e-19	2.98e-16	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
LUAD	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	9.42	1.86e-19	2.98e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	9.42	1.87e-19	3e-16	0.64	0.39	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
LUAD	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	9.42	1.88e-19	3.01e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
LUAD	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	9.42	1.88e-19	3.01e-16	0.43	0.39	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
LUAD	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	9.42	1.89e-19	3.03e-16	0.6	0.39	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	9.42	1.89e-19	3.03e-16	0.6	0.39	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
LUAD	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	9.42	1.9e-19	3.04e-16	0.49	0.39	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
LUAD	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	9.42	1.9e-19	3.04e-16	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
LUAD	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	9.42	1.91e-19	3.06e-16	0.49	0.39	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	9.42	1.91e-19	3.06e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	9.42	1.92e-19	3.07e-16	0.32	0.39	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	9.42	1.92e-19	3.08e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	9.42	1.92e-19	3.08e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	9.42	1.92e-19	3.08e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	9.42	1.92e-19	3.08e-16	0.38	0.39	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
LUAD	cis	rs944289	0.616	rs395212	ENSG00000257826.1	RP11-116N8.4	-9.42	1.93e-19	3.09e-16	-0.41	-0.39	Thyroid cancer;	chr14:36065759	chr14:36061026~36067190:-
LUAD	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	9.42	1.93e-19	3.1e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
LUAD	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.1e-16	0.49	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.1e-16	0.48	0.39	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.1e-16	0.48	0.39	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
LUAD	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	9.42	1.94e-19	3.11e-16	0.39	0.39	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
LUAD	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.11e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.11e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
LUAD	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-9.42	1.94e-19	3.11e-16	-0.53	-0.39	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
LUAD	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-9.42	1.95e-19	3.11e-16	-0.45	-0.39	Height;	chr3:52975027	chr3:53064283~53065091:-
LUAD	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	9.41	1.97e-19	3.15e-16	0.49	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
LUAD	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	9.41	1.98e-19	3.16e-16	0.39	0.39	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
LUAD	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-9.41	1.98e-19	3.16e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
LUAD	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	9.41	1.98e-19	3.16e-16	0.55	0.39	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
LUAD	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	9.41	1.99e-19	3.18e-16	0.49	0.39	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-9.41	1.99e-19	3.19e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
LUAD	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	9.41	1.99e-19	3.19e-16	0.49	0.39	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
LUAD	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	9.41	2e-19	3.19e-16	0.5	0.39	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
LUAD	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	9.41	2.02e-19	3.23e-16	0.51	0.39	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
LUAD	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-9.41	2.02e-19	3.23e-16	-0.45	-0.39	Height;	chr3:52967831	chr3:53064283~53065091:-
LUAD	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-9.41	2.02e-19	3.23e-16	-0.45	-0.39	Height;	chr3:52971094	chr3:53064283~53065091:-
LUAD	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	9.41	2.03e-19	3.24e-16	0.55	0.39	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
LUAD	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	9.41	2.04e-19	3.26e-16	0.39	0.39	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
LUAD	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-9.41	2.06e-19	3.29e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-9.41	2.06e-19	3.29e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
LUAD	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-9.41	2.07e-19	3.3e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-9.41	2.07e-19	3.3e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-9.41	2.07e-19	3.3e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
LUAD	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-9.41	2.08e-19	3.31e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-9.41	2.08e-19	3.31e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-9.41	2.08e-19	3.31e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-9.41	2.08e-19	3.31e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
LUAD	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	9.41	2.08e-19	3.32e-16	0.64	0.39	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	9.41	2.09e-19	3.32e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	9.41	2.09e-19	3.32e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	9.41	2.09e-19	3.32e-16	0.44	0.39	Height;	chr3:53073584	chr3:53064283~53065091:-
LUAD	cis	rs1757171	0.534	rs2797793	ENSG00000279942.1	RP1-153P14.7	9.41	2.11e-19	3.35e-16	0.36	0.39	Cognitive performance;	chr6:37509486	chr6:37567716~37571460:+
LUAD	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	9.41	2.12e-19	3.37e-16	0.5	0.39	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	9.41	2.13e-19	3.38e-16	0.32	0.39	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	9.41	2.13e-19	3.38e-16	0.32	0.39	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
LUAD	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	9.4	2.14e-19	3.4e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
LUAD	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	9.4	2.15e-19	3.41e-16	0.53	0.39	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
LUAD	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	9.4	2.19e-19	3.48e-16	0.52	0.39	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
LUAD	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	9.4	2.21e-19	3.51e-16	0.39	0.39	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
LUAD	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-9.4	2.22e-19	3.52e-16	-0.36	-0.39	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-9.4	2.22e-19	3.52e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-9.4	2.22e-19	3.52e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
LUAD	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-9.4	2.24e-19	3.55e-16	-0.64	-0.39	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
LUAD	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-9.4	2.24e-19	3.55e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	9.4	2.24e-19	3.55e-16	0.46	0.39	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	9.4	2.24e-19	3.55e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
LUAD	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	9.4	2.25e-19	3.57e-16	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
LUAD	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	9.4	2.25e-19	3.57e-16	0.65	0.39	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
LUAD	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	9.4	2.26e-19	3.59e-16	0.5	0.39	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
LUAD	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-9.4	2.27e-19	3.6e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	9.39	2.31e-19	3.66e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	9.39	2.31e-19	3.66e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-9.39	2.31e-19	3.67e-16	-0.44	-0.39	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
LUAD	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	9.39	2.34e-19	3.7e-16	0.39	0.39	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	9.39	2.34e-19	3.7e-16	0.39	0.39	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
LUAD	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	9.39	2.34e-19	3.71e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
LUAD	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	9.39	2.35e-19	3.72e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	9.39	2.38e-19	3.77e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-9.39	2.38e-19	3.78e-16	-0.44	-0.39	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
LUAD	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-9.39	2.39e-19	3.78e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
LUAD	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	9.39	2.39e-19	3.79e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
LUAD	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	9.39	2.4e-19	3.8e-16	0.39	0.39	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	9.39	2.4e-19	3.8e-16	0.39	0.39	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	9.39	2.4e-19	3.8e-16	0.39	0.39	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	9.39	2.4e-19	3.8e-16	0.39	0.39	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
LUAD	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-9.39	2.42e-19	3.83e-16	-0.43	-0.39	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-9.39	2.42e-19	3.83e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
LUAD	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	9.39	2.44e-19	3.85e-16	0.46	0.39	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
LUAD	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	9.39	2.44e-19	3.85e-16	0.65	0.39	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
LUAD	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	9.39	2.47e-19	3.9e-16	0.55	0.39	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
LUAD	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-9.39	2.48e-19	3.92e-16	-0.44	-0.39	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
LUAD	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	9.39	2.49e-19	3.93e-16	0.63	0.39	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
LUAD	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	9.39	2.5e-19	3.95e-16	0.65	0.39	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
LUAD	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-9.38	2.5e-19	3.95e-16	-0.45	-0.39	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
LUAD	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-9.38	2.52e-19	3.97e-16	-0.44	-0.39	Height;	chr3:53070344	chr3:53064283~53065091:-
LUAD	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	9.38	2.52e-19	3.98e-16	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
LUAD	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-9.38	2.52e-19	3.99e-16	-0.44	-0.39	Height;	chr3:53085518	chr3:53064283~53065091:-
LUAD	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-9.38	2.54e-19	4.01e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
LUAD	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	9.38	2.54e-19	4.01e-16	0.84	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
LUAD	cis	rs7924176	0.601	rs10824107	ENSG00000213731.2	RAB5CP1	-9.38	2.54e-19	4.01e-16	-0.42	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74423435~74424014:-
LUAD	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-9.38	2.55e-19	4.02e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
LUAD	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	9.38	2.57e-19	4.05e-16	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
LUAD	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	9.38	2.6e-19	4.11e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
LUAD	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	9.38	2.61e-19	4.12e-16	0.44	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
LUAD	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-9.38	2.62e-19	4.13e-16	-0.39	-0.39	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
LUAD	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-9.38	2.63e-19	4.14e-16	-0.37	-0.39	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
LUAD	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-9.38	2.63e-19	4.14e-16	-0.56	-0.39	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
LUAD	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	9.38	2.63e-19	4.15e-16	0.48	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
LUAD	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	9.38	2.63e-19	4.15e-16	0.54	0.39	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	9.38	2.63e-19	4.15e-16	0.54	0.39	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	9.38	2.66e-19	4.19e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
LUAD	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-9.38	2.67e-19	4.21e-16	-0.46	-0.39	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
LUAD	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
LUAD	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	9.38	2.69e-19	4.23e-16	0.39	0.39	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
LUAD	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	9.38	2.69e-19	4.23e-16	0.65	0.39	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
LUAD	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	9.38	2.7e-19	4.25e-16	0.53	0.39	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
LUAD	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	9.37	2.71e-19	4.27e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	9.37	2.71e-19	4.27e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-9.37	2.71e-19	4.27e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
LUAD	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	9.37	2.72e-19	4.29e-16	0.44	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
LUAD	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	9.37	2.72e-19	4.29e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
LUAD	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-9.37	2.74e-19	4.31e-16	-0.39	-0.39	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
LUAD	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	9.37	2.77e-19	4.36e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
LUAD	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	9.37	2.78e-19	4.37e-16	0.39	0.39	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
LUAD	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	9.37	2.79e-19	4.39e-16	0.65	0.39	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-9.37	2.79e-19	4.39e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-9.37	2.79e-19	4.39e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
LUAD	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	9.37	2.8e-19	4.4e-16	0.3	0.39	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
LUAD	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-9.37	2.8e-19	4.41e-16	-0.42	-0.39	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
LUAD	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	9.37	2.82e-19	4.43e-16	0.6	0.39	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
LUAD	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	9.37	2.84e-19	4.46e-16	0.48	0.39	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
LUAD	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-9.37	2.84e-19	4.47e-16	-0.48	-0.39	Height;	chr11:118760944	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-9.37	2.85e-19	4.47e-16	-0.48	-0.39	Height;	chr11:118742526	chr11:118704607~118750263:+
LUAD	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	9.37	2.86e-19	4.49e-16	0.45	0.39	Height;	chr3:53072864	chr3:53064283~53065091:-
LUAD	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	9.37	2.87e-19	4.51e-16	0.36	0.39	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	9.37	2.87e-19	4.51e-16	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
LUAD	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	9.37	2.88e-19	4.52e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-9.37	2.88e-19	4.52e-16	-0.47	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	9.37	2.89e-19	4.53e-16	0.31	0.39	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-9.37	2.9e-19	4.55e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-9.37	2.91e-19	4.56e-16	-0.48	-0.39	Height;	chr11:118747911	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-9.37	2.93e-19	4.6e-16	-0.48	-0.39	Height;	chr11:118737916	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-9.36	2.97e-19	4.66e-16	-0.47	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
LUAD	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-9.36	2.99e-19	4.69e-16	-0.64	-0.39	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-9.36	3e-19	4.7e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-9.36	3e-19	4.7e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-9.36	3e-19	4.7e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-9.36	3e-19	4.7e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-9.36	3.02e-19	4.73e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	9.36	3.02e-19	4.73e-16	0.51	0.39	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	9.36	3.02e-19	4.73e-16	0.51	0.39	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	9.36	3.02e-19	4.73e-16	0.51	0.39	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
LUAD	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-9.36	3.03e-19	4.75e-16	-0.47	-0.39	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
LUAD	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-9.36	3.06e-19	4.79e-16	-0.39	-0.39	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
LUAD	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	9.36	3.06e-19	4.79e-16	0.61	0.39	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
LUAD	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	9.36	3.07e-19	4.81e-16	0.44	0.39	Temperament;	chr17:14068990	chr17:14024514~14025488:+
LUAD	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-9.36	3.08e-19	4.82e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
LUAD	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	9.36	3.09e-19	4.83e-16	0.52	0.39	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
LUAD	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	9.36	3.09e-19	4.84e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-9.36	3.12e-19	4.89e-16	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
LUAD	cis	rs944289	0.646	rs408283	ENSG00000257826.1	RP11-116N8.4	-9.36	3.14e-19	4.9e-16	-0.41	-0.39	Thyroid cancer;	chr14:36073503	chr14:36061026~36067190:-
LUAD	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-9.36	3.14e-19	4.91e-16	-0.46	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
LUAD	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	9.36	3.17e-19	4.96e-16	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
LUAD	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	9.35	3.18e-19	4.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	9.35	3.18e-19	4.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	9.35	3.18e-19	4.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	9.35	3.18e-19	4.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	9.35	3.21e-19	5.01e-16	0.65	0.39	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
LUAD	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-9.35	3.21e-19	5.02e-16	-0.48	-0.39	Height;	chr11:118764443	chr11:118704607~118750263:+
LUAD	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	9.35	3.22e-19	5.03e-16	0.6	0.39	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
LUAD	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	9.35	3.22e-19	5.03e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
LUAD	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	9.35	3.26e-19	5.09e-16	0.46	0.39	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
LUAD	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-9.35	3.27e-19	5.1e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	9.35	3.28e-19	5.12e-16	0.64	0.39	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	9.35	3.28e-19	5.12e-16	0.64	0.39	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-9.35	3.29e-19	5.13e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
LUAD	cis	rs944289	0.589	rs63360860	ENSG00000257826.1	RP11-116N8.4	9.35	3.32e-19	5.18e-16	0.41	0.39	Thyroid cancer;	chr14:36068846	chr14:36061026~36067190:-
LUAD	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-9.35	3.34e-19	5.21e-16	-0.38	-0.39	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
LUAD	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-9.35	3.35e-19	5.22e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-9.35	3.36e-19	5.24e-16	-0.48	-0.39	Height;	chr11:118749988	chr11:118704607~118750263:+
LUAD	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	9.35	3.37e-19	5.26e-16	0.38	0.39	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
LUAD	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	9.35	3.37e-19	5.26e-16	0.43	0.39	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
LUAD	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	9.35	3.43e-19	5.35e-16	0.54	0.39	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
LUAD	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	9.34	3.46e-19	5.39e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	9.34	3.47e-19	5.4e-16	0.31	0.39	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	9.34	3.47e-19	5.4e-16	0.31	0.39	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	9.34	3.47e-19	5.4e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
LUAD	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	9.34	3.49e-19	5.43e-16	0.46	0.39	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	9.34	3.51e-19	5.46e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
LUAD	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	9.34	3.51e-19	5.46e-16	0.39	0.39	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
LUAD	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	9.34	3.55e-19	5.52e-16	0.66	0.39	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	9.34	3.56e-19	5.53e-16	0.31	0.39	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	9.34	3.56e-19	5.53e-16	0.31	0.39	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
LUAD	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-9.34	3.57e-19	5.55e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-9.34	3.57e-19	5.55e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
LUAD	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	9.34	3.57e-19	5.56e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	9.34	3.64e-19	5.66e-16	0.31	0.39	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	9.34	3.64e-19	5.66e-16	0.31	0.39	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	9.34	3.64e-19	5.66e-16	0.31	0.39	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	9.34	3.64e-19	5.66e-16	0.31	0.39	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
LUAD	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	9.34	3.68e-19	5.72e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
LUAD	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-9.34	3.72e-19	5.77e-16	-0.47	-0.39	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
LUAD	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-9.33	3.73e-19	5.8e-16	-0.41	-0.39	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
LUAD	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	9.33	3.75e-19	5.82e-16	0.8	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
LUAD	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-9.33	3.76e-19	5.83e-16	-0.3	-0.39	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-9.33	3.76e-19	5.83e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-9.33	3.76e-19	5.83e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	9.33	3.76e-19	5.84e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	9.33	3.76e-19	5.84e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	9.33	3.78e-19	5.86e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
LUAD	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
LUAD	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-9.33	3.84e-19	5.94e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
LUAD	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	9.33	3.86e-19	5.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	9.33	3.86e-19	5.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
LUAD	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-9.33	3.87e-19	5.99e-16	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
LUAD	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	9.33	3.88e-19	6e-16	0.65	0.39	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-9.33	3.88e-19	6.01e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-9.33	3.88e-19	6.01e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-9.33	3.89e-19	6.03e-16	-0.38	-0.39	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
LUAD	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	9.33	3.91e-19	6.05e-16	0.62	0.39	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
LUAD	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-9.33	3.93e-19	6.08e-16	-0.59	-0.39	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
LUAD	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	9.33	3.93e-19	6.08e-16	0.39	0.39	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	9.33	3.93e-19	6.08e-16	0.39	0.39	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
LUAD	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	9.33	3.96e-19	6.12e-16	0.52	0.39	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-9.33	3.97e-19	6.14e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
LUAD	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	9.33	4e-19	6.18e-16	0.44	0.39	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
LUAD	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-9.33	4.02e-19	6.22e-16	-0.47	-0.39	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
LUAD	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-9.33	4.03e-19	6.23e-16	-0.56	-0.39	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
LUAD	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-9.32	4.06e-19	6.28e-16	-0.48	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
LUAD	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
LUAD	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-9.32	4.17e-19	6.43e-16	-0.56	-0.39	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
LUAD	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-9.32	4.17e-19	6.44e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
LUAD	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-9.32	4.21e-19	6.51e-16	-0.39	-0.39	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
LUAD	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-9.32	4.21e-19	6.51e-16	-0.42	-0.39	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
LUAD	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	9.32	4.32e-19	6.67e-16	0.65	0.39	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	9.32	4.32e-19	6.67e-16	0.65	0.39	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
LUAD	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-9.32	4.32e-19	6.67e-16	-0.55	-0.39	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	9.32	4.33e-19	6.68e-16	0.31	0.39	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	9.32	4.33e-19	6.68e-16	0.31	0.39	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
LUAD	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-9.31	4.41e-19	6.8e-16	-0.48	-0.39	Height;	chr11:118773873	chr11:118704607~118750263:+
LUAD	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-9.31	4.45e-19	6.86e-16	-0.38	-0.39	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
LUAD	cis	rs6964833	0.873	rs4717905	ENSG00000123965.13	PMS2P5	9.31	4.49e-19	6.92e-16	0.61	0.39	Menarche (age at onset);	chr7:74668903	chr7:74894116~74897835:+
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-9.31	4.5e-19	6.93e-16	-0.46	-0.39	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
LUAD	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	9.31	4.51e-19	6.95e-16	0.43	0.39	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	9.31	4.51e-19	6.95e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
LUAD	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-9.31	4.52e-19	6.95e-16	-0.49	-0.39	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000211970.3	IGHV4-61	-9.31	4.57e-19	7.02e-16	-0.31	-0.39	Kawasaki disease;	chr14:106716993	chr14:106639119~106639657:-
LUAD	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	9.31	4.58e-19	7.04e-16	0.65	0.39	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-9.31	4.61e-19	7.08e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	9.31	4.72e-19	7.26e-16	0.33	0.39	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	9.3	4.8e-19	7.38e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-9.3	4.82e-19	7.4e-16	-0.44	-0.39	Height;	chr3:53097932	chr3:53064283~53065091:-
LUAD	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	9.3	4.82e-19	7.4e-16	0.39	0.39	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
LUAD	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-9.3	4.82e-19	7.41e-16	-0.39	-0.39	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
LUAD	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-9.3	4.9e-19	7.52e-16	-0.44	-0.39	Height;	chr3:53069965	chr3:53064283~53065091:-
LUAD	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	9.3	4.94e-19	7.58e-16	0.45	0.39	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	9.3	4.97e-19	7.62e-16	0.31	0.39	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	9.3	4.97e-19	7.62e-16	0.31	0.39	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
LUAD	cis	rs7924176	0.564	rs11000920	ENSG00000213731.2	RAB5CP1	-9.3	4.99e-19	7.65e-16	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74423435~74424014:-
LUAD	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	9.3	5.03e-19	7.71e-16	0.37	0.39	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
LUAD	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	9.3	5.09e-19	7.79e-16	0.61	0.39	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
LUAD	cis	rs4273100	1	rs12602286	ENSG00000262319.1	CTC-457L16.2	9.3	5.1e-19	7.81e-16	0.51	0.39	Schizophrenia;	chr17:19333641	chr17:19141017~19143689:-
LUAD	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
LUAD	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	9.3	5.12e-19	7.84e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	9.29	5.17e-19	7.92e-16	0.65	0.39	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
LUAD	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	9.29	5.22e-19	7.99e-16	0.42	0.39	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
LUAD	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-9.29	5.29e-19	8.08e-16	-0.55	-0.39	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	9.29	5.29e-19	8.09e-16	0.31	0.39	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
LUAD	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	9.29	5.33e-19	8.15e-16	0.43	0.39	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	9.29	5.34e-19	8.16e-16	0.31	0.39	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
LUAD	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	9.29	5.35e-19	8.17e-16	0.46	0.39	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
LUAD	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	9.29	5.37e-19	8.21e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
LUAD	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-9.29	5.38e-19	8.22e-16	-0.44	-0.39	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
LUAD	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	9.29	5.41e-19	8.26e-16	0.55	0.39	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
LUAD	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	9.29	5.44e-19	8.31e-16	0.55	0.39	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
LUAD	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-9.29	5.46e-19	8.34e-16	-0.52	-0.39	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
LUAD	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	9.29	5.53e-19	8.44e-16	0.49	0.39	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
LUAD	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-9.28	5.65e-19	8.61e-16	-0.48	-0.39	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
LUAD	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-9.28	5.68e-19	8.67e-16	-0.51	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
LUAD	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-9.28	5.72e-19	8.73e-16	-0.48	-0.39	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
LUAD	cis	rs7924176	0.54	rs61866073	ENSG00000213731.2	RAB5CP1	-9.28	5.74e-19	8.75e-16	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:74423435~74424014:-
LUAD	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-9.28	5.78e-19	8.81e-16	-0.33	-0.39	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
LUAD	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-9.28	5.79e-19	8.83e-16	-0.44	-0.39	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
LUAD	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	9.28	5.83e-19	8.88e-16	0.46	0.39	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
LUAD	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	9.28	5.88e-19	8.96e-16	0.45	0.39	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	9.28	5.9e-19	8.98e-16	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	9.28	5.9e-19	8.98e-16	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
LUAD	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	9.28	5.92e-19	9.02e-16	0.58	0.39	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
LUAD	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	9.27	6.04e-19	9.19e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	9.27	6.05e-19	9.21e-16	0.64	0.39	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	9.27	6.13e-19	9.32e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
LUAD	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	9.27	6.19e-19	9.42e-16	0.38	0.39	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
LUAD	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	9.27	6.25e-19	9.5e-16	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
LUAD	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	9.27	6.26e-19	9.51e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	9.27	6.26e-19	9.51e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
LUAD	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	9.27	6.27e-19	9.52e-16	0.59	0.39	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
LUAD	cis	rs321358	0.79	rs10502128	ENSG00000271584.1	RP11-89C3.4	9.27	6.3e-19	9.56e-16	0.62	0.39	Body mass index;	chr11:111076827	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.848	rs57168185	ENSG00000271584.1	RP11-89C3.4	9.27	6.3e-19	9.56e-16	0.62	0.39	Body mass index;	chr11:111078120	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	9.27	6.34e-19	9.63e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
LUAD	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	9.27	6.37e-19	9.68e-16	0.38	0.39	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
LUAD	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	9.27	6.39e-19	9.7e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
LUAD	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-9.27	6.44e-19	9.77e-16	-0.46	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
LUAD	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	9.27	6.44e-19	9.77e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
LUAD	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	9.26	6.53e-19	9.92e-16	0.52	0.39	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
LUAD	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-9.26	6.54e-19	9.93e-16	-0.46	-0.39	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
LUAD	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-9.26	6.58e-19	9.98e-16	-0.46	-0.39	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
LUAD	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-9.26	6.58e-19	9.98e-16	-0.46	-0.39	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
LUAD	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-9.26	6.59e-19	9.99e-16	-0.5	-0.39	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-9.26	6.59e-19	9.99e-16	-0.5	-0.39	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
LUAD	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	9.26	6.6e-19	1e-15	0.54	0.39	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
LUAD	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	9.26	6.6e-19	1e-15	0.54	0.39	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
LUAD	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	9.26	6.62e-19	1e-15	0.52	0.39	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
LUAD	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-9.26	6.63e-19	1.01e-15	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
LUAD	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-9.26	6.68e-19	1.01e-15	-0.41	-0.39	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
LUAD	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	9.26	6.68e-19	1.01e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
LUAD	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	9.26	6.68e-19	1.01e-15	0.5	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
LUAD	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-9.26	6.71e-19	1.02e-15	-0.43	-0.39	Height;	chr3:53064759	chr3:53064283~53065091:-
LUAD	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-9.26	6.74e-19	1.02e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-9.26	6.74e-19	1.02e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-9.26	6.74e-19	1.02e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
LUAD	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-9.26	6.78e-19	1.03e-15	-0.4	-0.39	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
LUAD	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-9.26	6.85e-19	1.04e-15	-0.54	-0.39	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
LUAD	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-9.26	6.85e-19	1.04e-15	-0.54	-0.39	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
LUAD	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	9.26	6.86e-19	1.04e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	9.26	6.86e-19	1.04e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
LUAD	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	9.26	6.88e-19	1.04e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	9.26	6.92e-19	1.05e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
LUAD	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	9.26	6.95e-19	1.05e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	9.26	6.95e-19	1.05e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	9.26	6.95e-19	1.05e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	9.26	6.95e-19	1.05e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
LUAD	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-9.26	6.97e-19	1.05e-15	-0.64	-0.39	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
LUAD	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	9.26	6.99e-19	1.06e-15	0.44	0.39	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
LUAD	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-9.26	6.99e-19	1.06e-15	-0.53	-0.39	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
LUAD	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-9.26	7e-19	1.06e-15	-0.42	-0.39	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
LUAD	cis	rs904251	0.58	rs62408367	ENSG00000279942.1	RP1-153P14.7	-9.25	7.08e-19	1.07e-15	-0.36	-0.39	Cognitive performance;	chr6:37477037	chr6:37567716~37571460:+
LUAD	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-9.25	7.1e-19	1.07e-15	-0.43	-0.39	Height;	chr3:53047596	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	9.25	7.12e-19	1.07e-15	0.39	0.39	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
LUAD	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	9.25	7.14e-19	1.08e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
LUAD	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	9.25	7.18e-19	1.08e-15	0.84	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
LUAD	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	9.25	7.2e-19	1.09e-15	0.54	0.39	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
LUAD	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	9.25	7.32e-19	1.11e-15	0.43	0.39	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
LUAD	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	9.25	7.34e-19	1.11e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	9.25	7.35e-19	1.11e-15	0.39	0.39	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
LUAD	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	9.25	7.46e-19	1.12e-15	0.51	0.39	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
LUAD	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-9.25	7.54e-19	1.14e-15	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
LUAD	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	9.24	7.65e-19	1.15e-15	0.44	0.39	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
LUAD	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	9.24	7.65e-19	1.15e-15	0.44	0.39	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
LUAD	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-9.24	7.65e-19	1.15e-15	-0.55	-0.39	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-9.24	7.65e-19	1.15e-15	-0.55	-0.39	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
LUAD	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-9.24	7.68e-19	1.16e-15	-0.39	-0.39	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
LUAD	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-9.24	7.69e-19	1.16e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
LUAD	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-9.24	7.74e-19	1.17e-15	-0.42	-0.39	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
LUAD	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-9.24	7.77e-19	1.17e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
LUAD	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-9.24	7.84e-19	1.18e-15	-0.36	-0.39	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
LUAD	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-9.24	7.91e-19	1.19e-15	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
LUAD	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	9.24	7.92e-19	1.19e-15	0.45	0.39	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
LUAD	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-9.24	8e-19	1.2e-15	-0.44	-0.39	Height;	chr3:52977358	chr3:53064283~53065091:-
LUAD	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	9.24	8.01e-19	1.2e-15	0.65	0.39	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	9.24	8.01e-19	1.2e-15	0.65	0.39	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	9.24	8.01e-19	1.2e-15	0.65	0.39	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
LUAD	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	9.24	8.17e-19	1.23e-15	0.54	0.39	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	9.24	8.17e-19	1.23e-15	0.54	0.39	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	9.24	8.17e-19	1.23e-15	0.54	0.39	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
LUAD	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	9.24	8.2e-19	1.23e-15	0.61	0.39	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	9.24	8.21e-19	1.23e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-9.24	8.21e-19	1.23e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
LUAD	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	9.24	8.23e-19	1.24e-15	0.6	0.39	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	9.24	8.26e-19	1.24e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
LUAD	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	9.23	8.36e-19	1.25e-15	0.39	0.39	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
LUAD	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-9.23	8.46e-19	1.27e-15	-0.5	-0.39	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
LUAD	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-9.23	8.59e-19	1.29e-15	-0.51	-0.39	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
LUAD	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-9.23	8.67e-19	1.3e-15	-0.3	-0.39	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-9.23	8.72e-19	1.31e-15	-0.29	-0.39	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	9.23	8.73e-19	1.31e-15	0.38	0.39	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
LUAD	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	9.23	8.74e-19	1.31e-15	0.46	0.39	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
LUAD	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-9.23	8.75e-19	1.31e-15	-0.42	-0.39	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
LUAD	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-9.23	8.84e-19	1.32e-15	-0.4	-0.39	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-9.23	8.86e-19	1.33e-15	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
LUAD	cis	rs944289	0.561	rs371191	ENSG00000257826.1	RP11-116N8.4	9.23	8.91e-19	1.33e-15	0.41	0.39	Thyroid cancer;	chr14:36064000	chr14:36061026~36067190:-
LUAD	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	9.23	8.92e-19	1.33e-15	0.39	0.39	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
LUAD	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-9.23	8.94e-19	1.34e-15	-0.46	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
LUAD	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	9.22	8.96e-19	1.34e-15	0.53	0.39	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
LUAD	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-9.22	8.97e-19	1.34e-15	-0.45	-0.39	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
LUAD	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	9.22	9.03e-19	1.35e-15	0.42	0.39	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-9.22	9.05e-19	1.35e-15	-0.29	-0.39	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
LUAD	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	9.22	9.1e-19	1.36e-15	0.44	0.39	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-9.22	9.15e-19	1.37e-15	-0.3	-0.39	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
LUAD	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	9.22	9.15e-19	1.37e-15	0.49	0.39	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
LUAD	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	9.22	9.29e-19	1.39e-15	0.41	0.39	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
LUAD	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-9.22	9.3e-19	1.39e-15	-0.39	-0.39	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
LUAD	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-9.22	9.32e-19	1.39e-15	-0.44	-0.39	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
LUAD	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	9.22	9.36e-19	1.4e-15	0.45	0.39	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
LUAD	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	9.22	9.37e-19	1.4e-15	0.53	0.39	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
LUAD	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	9.22	9.38e-19	1.4e-15	0.46	0.39	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
LUAD	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-9.22	9.38e-19	1.4e-15	-0.53	-0.39	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
LUAD	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	9.22	9.38e-19	1.4e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-9.22	9.4e-19	1.4e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-9.22	9.4e-19	1.4e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
LUAD	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	9.22	9.42e-19	1.4e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	9.22	9.42e-19	1.4e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
LUAD	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-9.22	9.44e-19	1.41e-15	-0.46	-0.39	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
LUAD	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-9.22	9.47e-19	1.41e-15	-0.36	-0.39	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
LUAD	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	9.22	9.51e-19	1.42e-15	0.54	0.39	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	9.22	9.51e-19	1.42e-15	0.54	0.39	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	9.22	9.51e-19	1.42e-15	0.54	0.39	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	9.22	9.51e-19	1.42e-15	0.54	0.39	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-9.22	9.54e-19	1.42e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
LUAD	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-9.22	9.55e-19	1.42e-15	-0.46	-0.39	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
LUAD	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-9.22	9.62e-19	1.43e-15	-0.36	-0.39	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
LUAD	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-9.22	9.67e-19	1.44e-15	-0.48	-0.39	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
LUAD	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	9.22	9.69e-19	1.44e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	9.22	9.69e-19	1.44e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	9.22	9.69e-19	1.44e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	9.21	9.73e-19	1.45e-15	0.39	0.39	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
LUAD	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-9.21	9.76e-19	1.45e-15	-0.45	-0.39	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
LUAD	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	9.21	9.77e-19	1.45e-15	0.58	0.39	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
LUAD	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-9.21	9.8e-19	1.46e-15	-0.45	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
LUAD	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	9.21	9.83e-19	1.46e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
LUAD	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	9.21	9.92e-19	1.48e-15	0.44	0.39	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
LUAD	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	9.21	9.94e-19	1.48e-15	0.44	0.39	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
LUAD	cis	rs7924176	0.521	rs11516630	ENSG00000213731.2	RAB5CP1	-9.21	1.01e-18	1.5e-15	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs10509347	ENSG00000213731.2	RAB5CP1	-9.21	1.01e-18	1.5e-15	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:74423435~74424014:-
LUAD	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	9.21	1.01e-18	1.5e-15	0.59	0.39	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
LUAD	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-9.21	1.01e-18	1.5e-15	-0.44	-0.39	Height;	chr3:53027969	chr3:53064283~53065091:-
LUAD	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-9.21	1.01e-18	1.5e-15	-0.44	-0.39	Height;	chr3:53029908	chr3:53064283~53065091:-
LUAD	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	9.21	1.01e-18	1.5e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
LUAD	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	9.21	1.01e-18	1.51e-15	0.5	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
LUAD	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	9.21	1.02e-18	1.51e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	9.21	1.02e-18	1.51e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	9.21	1.02e-18	1.51e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-9.21	1.02e-18	1.51e-15	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
LUAD	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	9.21	1.02e-18	1.51e-15	0.48	0.39	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	9.21	1.02e-18	1.51e-15	0.48	0.39	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
LUAD	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-9.21	1.03e-18	1.53e-15	-0.4	-0.39	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
LUAD	cis	rs944289	0.557	rs8016147	ENSG00000257826.1	RP11-116N8.4	-9.21	1.04e-18	1.54e-15	-0.41	-0.39	Thyroid cancer;	chr14:36111685	chr14:36061026~36067190:-
LUAD	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	9.21	1.04e-18	1.55e-15	0.52	0.39	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
LUAD	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	9.21	1.05e-18	1.55e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	9.21	1.05e-18	1.55e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
LUAD	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	9.2	1.06e-18	1.57e-15	0.62	0.39	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	9.2	1.06e-18	1.57e-15	0.62	0.39	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	9.2	1.07e-18	1.59e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
LUAD	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-9.2	1.08e-18	1.6e-15	-0.36	-0.39	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
LUAD	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	9.2	1.1e-18	1.62e-15	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	9.2	1.1e-18	1.62e-15	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	9.2	1.1e-18	1.63e-15	0.48	0.39	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	9.2	1.1e-18	1.63e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	9.2	1.11e-18	1.64e-15	0.31	0.39	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
LUAD	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-9.2	1.11e-18	1.64e-15	-0.53	-0.39	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
LUAD	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-9.2	1.11e-18	1.64e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-9.2	1.11e-18	1.64e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
LUAD	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	9.2	1.13e-18	1.67e-15	0.39	0.39	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
LUAD	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	9.19	1.14e-18	1.69e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
LUAD	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-9.19	1.15e-18	1.7e-15	-0.46	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-9.19	1.16e-18	1.72e-15	-0.29	-0.39	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-9.19	1.16e-18	1.72e-15	-0.29	-0.39	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-9.19	1.16e-18	1.72e-15	-0.29	-0.39	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
LUAD	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	9.19	1.18e-18	1.74e-15	0.43	0.39	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
LUAD	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	9.19	1.18e-18	1.74e-15	0.43	0.39	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
LUAD	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-9.19	1.18e-18	1.74e-15	-0.62	-0.39	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
LUAD	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-9.19	1.18e-18	1.74e-15	-0.46	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
LUAD	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	9.19	1.19e-18	1.76e-15	0.54	0.39	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	9.19	1.19e-18	1.76e-15	0.54	0.39	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
LUAD	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	9.19	1.21e-18	1.77e-15	0.49	0.39	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
LUAD	cis	rs944289	0.617	rs1958614	ENSG00000257826.1	RP11-116N8.4	-9.19	1.21e-18	1.79e-15	-0.41	-0.39	Thyroid cancer;	chr14:36118107	chr14:36061026~36067190:-
LUAD	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	9.19	1.22e-18	1.79e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
LUAD	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	9.19	1.23e-18	1.81e-15	0.52	0.39	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
LUAD	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	9.18	1.23e-18	1.81e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-9.18	1.23e-18	1.82e-15	-0.44	-0.39	Height;	chr3:52936861	chr3:53064283~53065091:-
LUAD	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-9.18	1.23e-18	1.82e-15	-0.44	-0.39	Height;	chr3:52938846	chr3:53064283~53065091:-
LUAD	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-9.18	1.24e-18	1.82e-15	-0.45	-0.39	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
LUAD	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	9.18	1.25e-18	1.83e-15	0.62	0.39	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
LUAD	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-9.18	1.26e-18	1.85e-15	-0.47	-0.39	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
LUAD	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-9.18	1.26e-18	1.85e-15	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
LUAD	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	9.18	1.26e-18	1.86e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	9.18	1.26e-18	1.86e-15	0.35	0.39	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
LUAD	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-9.18	1.28e-18	1.88e-15	-0.43	-0.39	Height;	chr3:53052712	chr3:53064283~53065091:-
LUAD	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	9.18	1.28e-18	1.88e-15	0.43	0.39	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
LUAD	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	9.18	1.28e-18	1.88e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	9.18	1.28e-18	1.88e-15	0.54	0.39	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
LUAD	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-9.18	1.28e-18	1.88e-15	-0.45	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
LUAD	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	9.18	1.29e-18	1.9e-15	0.44	0.39	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
LUAD	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	9.18	1.3e-18	1.9e-15	0.62	0.39	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	9.18	1.32e-18	1.94e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
LUAD	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-9.18	1.32e-18	1.94e-15	-0.46	-0.39	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
LUAD	cis	rs944289	0.561	rs395660	ENSG00000257826.1	RP11-116N8.4	9.18	1.32e-18	1.94e-15	0.41	0.39	Thyroid cancer;	chr14:36063593	chr14:36061026~36067190:-
LUAD	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	9.18	1.33e-18	1.95e-15	0.52	0.39	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-9.17	1.35e-18	1.98e-15	-0.29	-0.39	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
LUAD	cis	rs944289	0.589	rs847516	ENSG00000257826.1	RP11-116N8.4	9.17	1.36e-18	1.99e-15	0.4	0.39	Thyroid cancer;	chr14:36060593	chr14:36061026~36067190:-
LUAD	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	9.17	1.36e-18	1.99e-15	0.44	0.39	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
LUAD	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	9.17	1.38e-18	2.01e-15	0.47	0.39	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
LUAD	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-9.17	1.39e-18	2.03e-15	-0.48	-0.39	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
LUAD	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	9.17	1.39e-18	2.03e-15	0.61	0.39	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-9.17	1.4e-18	2.05e-15	-0.29	-0.39	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
LUAD	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	9.17	1.41e-18	2.06e-15	0.54	0.39	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
LUAD	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-9.17	1.41e-18	2.06e-15	-0.36	-0.39	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	9.17	1.41e-18	2.07e-15	0.31	0.39	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
LUAD	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	9.17	1.41e-18	2.07e-15	0.57	0.39	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
LUAD	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-9.17	1.42e-18	2.07e-15	-0.47	-0.39	Height;	chr11:118761813	chr11:118704607~118750263:+
LUAD	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-9.17	1.42e-18	2.07e-15	-0.45	-0.39	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
LUAD	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	9.17	1.43e-18	2.08e-15	0.47	0.39	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-9.16	1.44e-18	2.1e-15	-0.44	-0.39	Height;	chr3:53029854	chr3:53064283~53065091:-
LUAD	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-9.16	1.44e-18	2.11e-15	-0.4	-0.39	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-9.16	1.46e-18	2.13e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
LUAD	cis	rs7924176	0.521	rs12359775	ENSG00000213731.2	RAB5CP1	-9.16	1.48e-18	2.16e-15	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:74423435~74424014:-
LUAD	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-9.16	1.48e-18	2.16e-15	-0.47	-0.39	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	9.16	1.48e-18	2.16e-15	0.31	0.39	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	9.16	1.48e-18	2.16e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	9.16	1.48e-18	2.16e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
LUAD	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
LUAD	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	9.16	1.49e-18	2.17e-15	0.34	0.39	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-9.16	1.51e-18	2.19e-15	-0.47	-0.39	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
LUAD	cis	rs7924176	0.521	rs11000986	ENSG00000213731.2	RAB5CP1	-9.16	1.51e-18	2.2e-15	-0.4	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs10824147	ENSG00000213731.2	RAB5CP1	-9.16	1.51e-18	2.2e-15	-0.4	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:74423435~74424014:-
LUAD	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	9.16	1.53e-18	2.22e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	9.16	1.53e-18	2.22e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	9.16	1.53e-18	2.22e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	9.16	1.53e-18	2.22e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
LUAD	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	9.16	1.54e-18	2.23e-15	0.52	0.39	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
LUAD	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	9.15	1.56e-18	2.26e-15	0.47	0.39	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
LUAD	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-9.15	1.57e-18	2.27e-15	-0.46	-0.39	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
LUAD	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	9.15	1.58e-18	2.29e-15	0.45	0.39	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
LUAD	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	9.15	1.59e-18	2.3e-15	0.61	0.39	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	9.15	1.59e-18	2.31e-15	0.38	0.39	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
LUAD	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	9.15	1.6e-18	2.31e-15	0.45	0.39	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
LUAD	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-9.15	1.6e-18	2.33e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-9.15	1.6e-18	2.33e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-9.15	1.62e-18	2.35e-15	-0.27	-0.39	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-9.15	1.64e-18	2.37e-15	-0.47	-0.38	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
LUAD	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-9.15	1.64e-18	2.38e-15	-0.48	-0.38	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
LUAD	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	9.15	1.65e-18	2.39e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	9.15	1.65e-18	2.39e-15	0.54	0.38	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.521	rs10824137	ENSG00000213731.2	RAB5CP1	9.15	1.65e-18	2.39e-15	0.41	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:74423435~74424014:-
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	9.15	1.66e-18	2.4e-15	0.38	0.38	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
LUAD	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	9.15	1.67e-18	2.41e-15	0.38	0.38	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	9.15	1.67e-18	2.41e-15	0.38	0.38	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
LUAD	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-9.15	1.68e-18	2.43e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
LUAD	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	9.15	1.68e-18	2.44e-15	0.45	0.38	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
LUAD	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	9.14	1.69e-18	2.45e-15	0.51	0.38	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	9.14	1.69e-18	2.45e-15	0.51	0.38	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
LUAD	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-9.14	1.69e-18	2.45e-15	-0.59	-0.38	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
LUAD	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	9.14	1.69e-18	2.45e-15	0.54	0.38	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-9.14	1.71e-18	2.47e-15	-0.31	-0.38	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	9.14	1.71e-18	2.47e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
LUAD	cis	rs7924176	0.521	rs11001022	ENSG00000213731.2	RAB5CP1	-9.14	1.71e-18	2.47e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:74423435~74424014:-
LUAD	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	9.14	1.71e-18	2.47e-15	0.51	0.38	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
LUAD	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	9.14	1.72e-18	2.49e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
LUAD	cis	rs7924176	0.521	rs10762599	ENSG00000213731.2	RAB5CP1	-9.14	1.72e-18	2.49e-15	-0.41	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:74423435~74424014:-
LUAD	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	9.14	1.73e-18	2.5e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-9.14	1.74e-18	2.51e-15	-0.3	-0.38	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
LUAD	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	9.14	1.75e-18	2.53e-15	0.54	0.38	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
LUAD	cis	rs944289	0.533	rs2780313	ENSG00000257826.1	RP11-116N8.4	9.14	1.77e-18	2.55e-15	0.39	0.38	Thyroid cancer;	chr14:36059216	chr14:36061026~36067190:-
LUAD	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-9.14	1.79e-18	2.58e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-9.14	1.79e-18	2.59e-15	-0.3	-0.38	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
LUAD	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	9.14	1.8e-18	2.6e-15	0.49	0.38	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
LUAD	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	9.14	1.82e-18	2.62e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	9.14	1.82e-18	2.62e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
LUAD	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	9.14	1.82e-18	2.63e-15	0.45	0.38	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
LUAD	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	9.13	1.83e-18	2.63e-15	0.43	0.38	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
LUAD	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	9.13	1.83e-18	2.64e-15	0.52	0.38	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
LUAD	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-9.13	1.84e-18	2.65e-15	-0.59	-0.38	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
LUAD	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-9.13	1.85e-18	2.66e-15	-0.42	-0.38	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
LUAD	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-9.13	1.85e-18	2.66e-15	-0.36	-0.38	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
LUAD	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-9.13	1.85e-18	2.66e-15	-0.36	-0.38	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
LUAD	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-9.13	1.86e-18	2.68e-15	-0.45	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
LUAD	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-9.13	1.87e-18	2.69e-15	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	9.13	1.87e-18	2.69e-15	0.37	0.38	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
LUAD	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-9.13	1.87e-18	2.7e-15	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
LUAD	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-9.13	1.88e-18	2.71e-15	-0.38	-0.38	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
LUAD	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	9.13	1.9e-18	2.73e-15	0.35	0.38	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
LUAD	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-9.13	1.92e-18	2.76e-15	-0.43	-0.38	Temperament;	chr17:14007232	chr17:14024514~14025488:+
LUAD	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	9.13	1.93e-18	2.77e-15	0.54	0.38	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
LUAD	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-9.13	1.93e-18	2.78e-15	-0.42	-0.38	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
LUAD	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	9.13	1.94e-18	2.79e-15	0.64	0.38	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	9.13	1.94e-18	2.79e-15	0.64	0.38	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
LUAD	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	9.13	1.95e-18	2.81e-15	0.47	0.38	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	9.13	1.95e-18	2.81e-15	0.47	0.38	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	9.13	1.97e-18	2.83e-15	0.47	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-9.13	1.97e-18	2.83e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-9.13	1.97e-18	2.83e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-9.13	1.97e-18	2.83e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
LUAD	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-9.12	1.97e-18	2.83e-15	-0.42	-0.38	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
LUAD	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-9.12	1.99e-18	2.85e-15	-0.44	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
LUAD	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	9.12	1.99e-18	2.85e-15	0.53	0.38	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	9.12	2.01e-18	2.88e-15	0.53	0.38	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	9.12	2.01e-18	2.88e-15	0.53	0.38	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	9.12	2.01e-18	2.88e-15	0.53	0.38	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
LUAD	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	9.12	2.04e-18	2.92e-15	0.48	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
LUAD	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-9.12	2.05e-18	2.93e-15	-0.41	-0.38	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
LUAD	cis	rs7924176	0.521	rs11000999	ENSG00000213731.2	RAB5CP1	-9.12	2.05e-18	2.94e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:74423435~74424014:-
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	9.12	2.07e-18	2.97e-15	0.38	0.38	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
LUAD	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-9.12	2.08e-18	2.98e-15	-0.52	-0.38	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
LUAD	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	9.12	2.13e-18	3.04e-15	0.6	0.38	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
LUAD	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-9.12	2.13e-18	3.06e-15	-0.51	-0.38	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
LUAD	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	9.11	2.17e-18	3.11e-15	0.53	0.38	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
LUAD	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-9.11	2.18e-18	3.11e-15	-0.42	-0.38	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
LUAD	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	9.11	2.18e-18	3.11e-15	0.55	0.38	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
LUAD	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	9.11	2.18e-18	3.12e-15	0.44	0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
LUAD	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	9.11	2.19e-18	3.14e-15	0.46	0.38	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
LUAD	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	9.11	2.2e-18	3.14e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	9.11	2.2e-18	3.15e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	9.11	2.2e-18	3.15e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	9.11	2.2e-18	3.15e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
LUAD	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	9.11	2.26e-18	3.23e-15	0.45	0.38	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
LUAD	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-9.11	2.27e-18	3.24e-15	-0.47	-0.38	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
LUAD	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-9.11	2.27e-18	3.24e-15	-0.47	-0.38	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
LUAD	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	9.11	2.27e-18	3.24e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
LUAD	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-9.11	2.27e-18	3.24e-15	-0.48	-0.38	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
LUAD	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-9.11	2.28e-18	3.25e-15	-0.54	-0.38	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
LUAD	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-9.11	2.28e-18	3.25e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
LUAD	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-9.11	2.28e-18	3.26e-15	-0.48	-0.38	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
LUAD	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-9.11	2.28e-18	3.26e-15	-0.5	-0.38	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
LUAD	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	9.11	2.3e-18	3.28e-15	0.54	0.38	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
LUAD	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-9.11	2.3e-18	3.28e-15	-0.44	-0.38	Height;	chr3:52941053	chr3:53064283~53065091:-
LUAD	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	9.11	2.3e-18	3.29e-15	0.46	0.38	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
LUAD	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-9.1	2.31e-18	3.3e-15	-0.5	-0.38	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
LUAD	cis	rs2337406	0.714	rs2337463	ENSG00000274576.2	IGHV2-70	-9.1	2.32e-18	3.31e-15	-0.43	-0.38	Alzheimer's disease (late onset);	chr14:106816066	chr14:106770577~106771020:-
LUAD	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	9.1	2.33e-18	3.32e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
LUAD	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	9.1	2.33e-18	3.32e-15	0.42	0.38	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
LUAD	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-9.1	2.34e-18	3.33e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
LUAD	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	9.1	2.34e-18	3.34e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
LUAD	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	9.1	2.36e-18	3.37e-15	0.45	0.38	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-9.1	2.38e-18	3.39e-15	-0.44	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	9.1	2.39e-18	3.41e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-9.1	2.42e-18	3.45e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
LUAD	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-9.1	2.42e-18	3.45e-15	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	9.1	2.44e-18	3.47e-15	0.37	0.38	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	9.1	2.44e-18	3.47e-15	0.37	0.38	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	9.1	2.44e-18	3.47e-15	0.37	0.38	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	9.1	2.45e-18	3.48e-15	0.38	0.38	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	9.1	2.45e-18	3.48e-15	0.53	0.38	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-9.1	2.46e-18	3.49e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	9.1	2.46e-18	3.49e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
LUAD	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	9.1	2.49e-18	3.54e-15	0.54	0.38	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	9.1	2.5e-18	3.55e-15	0.48	0.38	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
LUAD	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	9.09	2.51e-18	3.57e-15	0.45	0.38	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
LUAD	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	9.09	2.52e-18	3.57e-15	0.54	0.38	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	9.09	2.52e-18	3.57e-15	0.54	0.38	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
LUAD	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	9.09	2.52e-18	3.58e-15	0.47	0.38	Height;	chr11:118758322	chr11:118704607~118750263:+
LUAD	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-9.09	2.52e-18	3.58e-15	-0.48	-0.38	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	9.09	2.53e-18	3.59e-15	0.3	0.38	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
LUAD	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-9.09	2.53e-18	3.59e-15	-0.38	-0.38	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
LUAD	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-9.09	2.53e-18	3.59e-15	-0.44	-0.38	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
LUAD	cis	rs7924176	0.58	rs12360119	ENSG00000213731.2	RAB5CP1	-9.09	2.54e-18	3.6e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs10824142	ENSG00000213731.2	RAB5CP1	-9.09	2.55e-18	3.61e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs11000965	ENSG00000213731.2	RAB5CP1	-9.09	2.55e-18	3.61e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs12357370	ENSG00000213731.2	RAB5CP1	-9.09	2.55e-18	3.61e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:74423435~74424014:-
LUAD	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-9.09	2.55e-18	3.62e-15	-0.59	-0.38	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	9.09	2.58e-18	3.66e-15	0.37	0.38	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
LUAD	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	9.09	2.62e-18	3.71e-15	0.44	0.38	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
LUAD	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	9.09	2.62e-18	3.71e-15	0.44	0.38	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
LUAD	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	9.09	2.62e-18	3.72e-15	0.53	0.38	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	9.09	2.62e-18	3.72e-15	0.53	0.38	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
LUAD	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	9.09	2.63e-18	3.73e-15	0.51	0.38	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
LUAD	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	9.09	2.65e-18	3.75e-15	0.49	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
LUAD	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	9.09	2.65e-18	3.76e-15	0.45	0.38	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
LUAD	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-9.09	2.65e-18	3.76e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-9.09	2.65e-18	3.76e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
LUAD	cis	rs7924176	0.601	rs2131957	ENSG00000213731.2	RAB5CP1	-9.09	2.67e-18	3.79e-15	-0.41	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107171	chr10:74423435~74424014:-
LUAD	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	9.09	2.68e-18	3.8e-15	0.48	0.38	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
LUAD	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	9.08	2.73e-18	3.87e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
LUAD	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-9.08	2.74e-18	3.88e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	9.08	2.74e-18	3.88e-15	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	9.08	2.74e-18	3.88e-15	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	9.08	2.74e-18	3.88e-15	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	9.08	2.74e-18	3.88e-15	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
LUAD	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	9.08	2.75e-18	3.89e-15	0.44	0.38	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
LUAD	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	9.08	2.75e-18	3.89e-15	0.37	0.38	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
LUAD	cis	rs7924176	0.521	rs7899920	ENSG00000213731.2	RAB5CP1	9.08	2.76e-18	3.9e-15	0.4	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:74423435~74424014:-
LUAD	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	9.08	2.78e-18	3.93e-15	0.46	0.38	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	9.08	2.79e-18	3.94e-15	0.38	0.38	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
LUAD	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-9.08	2.79e-18	3.95e-15	-0.5	-0.38	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
LUAD	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-9.08	2.8e-18	3.95e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000211970.3	IGHV4-61	-9.08	2.8e-18	3.95e-15	-0.29	-0.38	Kawasaki disease;	chr14:106777570	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-9.08	2.82e-18	3.98e-15	-0.34	-0.38	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
LUAD	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	9.08	2.83e-18	4e-15	0.54	0.38	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.521	rs61863363	ENSG00000213731.2	RAB5CP1	-9.08	2.84e-18	4.01e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:74423435~74424014:-
LUAD	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-9.08	2.85e-18	4.03e-15	-0.5	-0.38	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
LUAD	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-9.08	2.85e-18	4.03e-15	-0.4	-0.38	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
LUAD	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	9.08	2.85e-18	4.03e-15	0.55	0.38	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
LUAD	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	9.08	2.87e-18	4.04e-15	0.45	0.38	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
LUAD	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	9.08	2.87e-18	4.04e-15	0.45	0.38	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
LUAD	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	9.08	2.87e-18	4.05e-15	0.53	0.38	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	9.08	2.87e-18	4.05e-15	0.53	0.38	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	9.08	2.87e-18	4.05e-15	0.53	0.38	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	9.08	2.88e-18	4.06e-15	0.29	0.38	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
LUAD	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	9.07	2.93e-18	4.13e-15	0.46	0.38	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	9.07	2.93e-18	4.13e-15	0.46	0.38	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
LUAD	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-9.07	2.93e-18	4.13e-15	-0.36	-0.38	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
LUAD	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-9.07	2.94e-18	4.14e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-9.07	2.94e-18	4.15e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
LUAD	cis	rs7924176	0.564	rs6480727	ENSG00000213731.2	RAB5CP1	-9.07	2.96e-18	4.17e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74423435~74424014:-
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000223648.3	IGHV3-64	9.07	2.98e-18	4.2e-15	0.39	0.38	Kawasaki disease;	chr14:106813798	chr14:106643132~106658258:-
LUAD	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	9.07	2.99e-18	4.2e-15	0.44	0.38	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
LUAD	cis	rs7924176	0.521	rs11000960	ENSG00000213731.2	RAB5CP1	-9.07	3e-18	4.22e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:74423435~74424014:-
LUAD	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	9.07	3e-18	4.22e-15	0.54	0.38	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.521	rs7098200	ENSG00000213731.2	RAB5CP1	9.07	3e-18	4.23e-15	0.4	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:74423435~74424014:-
LUAD	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-9.07	3.04e-18	4.27e-15	-0.41	-0.38	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
LUAD	cis	rs7924176	0.521	rs1904062	ENSG00000213731.2	RAB5CP1	-9.07	3.04e-18	4.27e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:74423435~74424014:-
LUAD	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	9.07	3.05e-18	4.29e-15	0.36	0.38	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
LUAD	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	9.07	3.05e-18	4.29e-15	0.48	0.38	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
LUAD	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-9.07	3.05e-18	4.29e-15	-0.53	-0.38	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-9.07	3.06e-18	4.31e-15	-0.29	-0.38	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-9.07	3.07e-18	4.32e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
LUAD	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	9.07	3.08e-18	4.33e-15	0.47	0.38	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
LUAD	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	9.07	3.1e-18	4.36e-15	0.36	0.38	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
LUAD	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-9.07	3.11e-18	4.36e-15	-0.42	-0.38	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
LUAD	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-9.07	3.11e-18	4.37e-15	-0.41	-0.38	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
LUAD	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-9.07	3.12e-18	4.38e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
LUAD	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	9.07	3.12e-18	4.39e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
LUAD	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-9.07	3.16e-18	4.43e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
LUAD	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-9.07	3.16e-18	4.44e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	9.06	3.22e-18	4.52e-15	0.61	0.38	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000211972.2	IGHV3-66	9.06	3.26e-18	4.57e-15	0.31	0.38	Kawasaki disease;	chr14:106776758	chr14:106675017~106675544:-
LUAD	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	9.06	3.31e-18	4.64e-15	0.54	0.38	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
LUAD	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	9.06	3.31e-18	4.64e-15	0.46	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
LUAD	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-9.06	3.32e-18	4.66e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
LUAD	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	9.06	3.36e-18	4.71e-15	0.47	0.38	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
LUAD	cis	rs1061377	0.585	rs2163271	ENSG00000249207.1	RP11-360F5.1	-9.06	3.38e-18	4.74e-15	-0.42	-0.38	Uric acid levels;	chr4:39076525	chr4:39112677~39126818:-
LUAD	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-9.06	3.39e-18	4.75e-15	-0.51	-0.38	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
LUAD	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	9.06	3.41e-18	4.78e-15	0.5	0.38	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
LUAD	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-9.06	3.41e-18	4.78e-15	-0.42	-0.38	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
LUAD	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-9.06	3.42e-18	4.79e-15	-0.41	-0.38	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
LUAD	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-9.05	3.42e-18	4.79e-15	-0.52	-0.38	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
LUAD	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	9.05	3.43e-18	4.8e-15	0.6	0.38	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
LUAD	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-9.05	3.45e-18	4.83e-15	-0.39	-0.38	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
LUAD	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	9.05	3.45e-18	4.84e-15	0.54	0.38	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
LUAD	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-9.05	3.46e-18	4.84e-15	-0.46	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
LUAD	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	9.05	3.49e-18	4.88e-15	0.37	0.38	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
LUAD	cis	rs944289	0.617	rs12431579	ENSG00000257826.1	RP11-116N8.4	-9.05	3.57e-18	5e-15	-0.39	-0.38	Thyroid cancer;	chr14:36125191	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	9.05	3.58e-18	5e-15	0.37	0.38	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	9.05	3.58e-18	5e-15	0.37	0.38	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	9.05	3.58e-18	5e-15	0.37	0.38	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
LUAD	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-9.05	3.58e-18	5.01e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-9.05	3.59e-18	5.02e-15	-0.39	-0.38	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-9.05	3.59e-18	5.02e-15	-0.39	-0.38	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
LUAD	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-9.05	3.59e-18	5.02e-15	-0.45	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
LUAD	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	9.05	3.63e-18	5.07e-15	0.51	0.38	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
LUAD	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	9.05	3.69e-18	5.15e-15	0.37	0.38	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
LUAD	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	9.04	3.7e-18	5.16e-15	0.47	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
LUAD	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	9.04	3.7e-18	5.16e-15	0.6	0.38	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-9.04	3.71e-18	5.17e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
LUAD	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-9.04	3.72e-18	5.18e-15	-0.43	-0.38	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
LUAD	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	9.04	3.73e-18	5.19e-15	0.47	0.38	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
LUAD	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-9.04	3.73e-18	5.2e-15	-0.59	-0.38	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
LUAD	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	9.04	3.74e-18	5.21e-15	0.53	0.38	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	9.04	3.75e-18	5.22e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
LUAD	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	9.04	3.76e-18	5.24e-15	0.47	0.38	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
LUAD	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-9.04	3.78e-18	5.27e-15	-0.38	-0.38	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
LUAD	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	9.04	3.82e-18	5.32e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
LUAD	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-9.04	3.84e-18	5.34e-15	-0.5	-0.38	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	9.04	3.84e-18	5.34e-15	0.38	0.38	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
LUAD	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-9.04	3.84e-18	5.35e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-9.04	3.84e-18	5.35e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-9.04	3.84e-18	5.35e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
LUAD	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	9.04	3.86e-18	5.37e-15	0.36	0.38	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
LUAD	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-9.04	3.88e-18	5.39e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
LUAD	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-9.04	3.9e-18	5.42e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
LUAD	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	9.04	3.9e-18	5.42e-15	0.52	0.38	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	9.04	3.93e-18	5.46e-15	0.54	0.38	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	9.04	3.93e-18	5.46e-15	0.54	0.38	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	9.04	3.96e-18	5.5e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
LUAD	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	9.04	3.96e-18	5.5e-15	0.4	0.38	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
LUAD	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	9.04	3.98e-18	5.53e-15	0.42	0.38	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
LUAD	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-9.03	4e-18	5.56e-15	-0.55	-0.38	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
LUAD	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-9.03	4.03e-18	5.59e-15	-0.4	-0.38	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
LUAD	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-9.03	4.03e-18	5.59e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
LUAD	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	9.03	4.04e-18	5.6e-15	0.5	0.38	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
LUAD	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	9.03	4.04e-18	5.6e-15	0.5	0.38	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
LUAD	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	9.03	4.04e-18	5.6e-15	0.5	0.38	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
LUAD	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	9.03	4.04e-18	5.6e-15	0.48	0.38	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	9.03	4.04e-18	5.61e-15	0.3	0.38	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
LUAD	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	9.03	4.07e-18	5.64e-15	0.53	0.38	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-9.03	4.15e-18	5.75e-15	-0.5	-0.38	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
LUAD	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-9.03	4.16e-18	5.76e-15	-0.3	-0.38	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
LUAD	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	9.03	4.17e-18	5.77e-15	0.55	0.38	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
LUAD	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	9.03	4.18e-18	5.79e-15	0.39	0.38	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	9.03	4.18e-18	5.79e-15	0.39	0.38	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-9.03	4.18e-18	5.79e-15	-0.39	-0.38	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-9.03	4.18e-18	5.79e-15	-0.39	-0.38	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-9.03	4.18e-18	5.79e-15	-0.39	-0.38	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-9.03	4.18e-18	5.79e-15	-0.39	-0.38	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
LUAD	cis	rs7924176	0.521	rs12415957	ENSG00000213731.2	RAB5CP1	9.03	4.2e-18	5.81e-15	0.4	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:74423435~74424014:-
LUAD	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-9.03	4.2e-18	5.81e-15	-0.44	-0.38	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
LUAD	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	9.03	4.24e-18	5.87e-15	0.54	0.38	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	9.03	4.25e-18	5.88e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
LUAD	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	9.03	4.28e-18	5.92e-15	0.47	0.38	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	9.03	4.28e-18	5.92e-15	0.47	0.38	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
LUAD	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	9.03	4.31e-18	5.96e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
LUAD	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-9.03	4.32e-18	5.97e-15	-0.39	-0.38	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
LUAD	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	9.03	4.32e-18	5.97e-15	0.54	0.38	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
LUAD	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-9.02	4.34e-18	5.99e-15	-0.45	-0.38	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
LUAD	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-9.02	4.34e-18	6e-15	-0.59	-0.38	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-9.02	4.34e-18	6e-15	-0.59	-0.38	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
LUAD	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	9.02	4.38e-18	6.06e-15	0.55	0.38	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.521	rs7477710	ENSG00000213731.2	RAB5CP1	-9.02	4.41e-18	6.1e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:74423435~74424014:-
LUAD	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-9.02	4.42e-18	6.1e-15	-0.37	-0.38	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
LUAD	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	9.02	4.44e-18	6.12e-15	0.61	0.38	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
LUAD	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-9.02	4.44e-18	6.13e-15	-0.43	-0.38	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
LUAD	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	9.02	4.47e-18	6.17e-15	0.41	0.38	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
LUAD	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	9.02	4.48e-18	6.18e-15	0.53	0.38	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
LUAD	cis	rs35955747	0.601	rs5749302	ENSG00000236132.1	CTA-440B3.1	-9.02	4.55e-18	6.27e-15	-0.44	-0.38	Neutrophil count;Sum basophil neutrophil counts;	chr22:31554632	chr22:31816379~31817491:-
LUAD	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-9.02	4.57e-18	6.3e-15	-0.52	-0.38	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
LUAD	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-9.02	4.57e-18	6.3e-15	-0.52	-0.38	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
LUAD	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	9.02	4.57e-18	6.3e-15	0.46	0.38	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
LUAD	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	9.02	4.57e-18	6.31e-15	0.53	0.38	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-9.02	4.58e-18	6.31e-15	-0.5	-0.38	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
LUAD	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	9.02	4.58e-18	6.32e-15	0.47	0.38	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
LUAD	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-9.02	4.61e-18	6.35e-15	-0.44	-0.38	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
LUAD	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-9.02	4.62e-18	6.37e-15	-0.46	-0.38	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
LUAD	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-9.02	4.63e-18	6.38e-15	-0.42	-0.38	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
LUAD	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-9.02	4.65e-18	6.4e-15	-0.43	-0.38	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
LUAD	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	9.02	4.65e-18	6.41e-15	0.44	0.38	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
LUAD	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	9.02	4.66e-18	6.41e-15	0.44	0.38	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
LUAD	cis	rs1061377	0.56	rs6531690	ENSG00000249207.1	RP11-360F5.1	-9.01	4.68e-18	6.45e-15	-0.42	-0.38	Uric acid levels;	chr4:39072583	chr4:39112677~39126818:-
LUAD	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-9.01	4.75e-18	6.53e-15	-0.35	-0.38	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
LUAD	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-9.01	4.75e-18	6.53e-15	-0.35	-0.38	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
LUAD	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	9.01	4.77e-18	6.57e-15	0.45	0.38	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
LUAD	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-9.01	4.84e-18	6.66e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-9.01	4.85e-18	6.67e-15	-0.26	-0.38	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
LUAD	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-9.01	4.87e-18	6.7e-15	-0.5	-0.38	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
LUAD	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-9.01	4.89e-18	6.72e-15	-0.47	-0.38	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
LUAD	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-9.01	4.89e-18	6.73e-15	-0.36	-0.38	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
LUAD	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	9.01	4.9e-18	6.74e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	9.01	4.9e-18	6.74e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	9.01	4.91e-18	6.75e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
LUAD	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	9.01	4.92e-18	6.76e-15	0.47	0.38	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000223648.3	IGHV3-64	9.01	4.92e-18	6.76e-15	0.38	0.38	Kawasaki disease;	chr14:106816039	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	9.01	4.95e-18	6.81e-15	0.53	0.38	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	9.01	4.96e-18	6.81e-15	0.53	0.38	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
LUAD	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-9.01	5e-18	6.87e-15	-0.49	-0.38	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
LUAD	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-9.01	5.02e-18	6.9e-15	-0.41	-0.38	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
LUAD	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	9	5.06e-18	6.94e-15	0.37	0.38	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
LUAD	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-9	5.08e-18	6.98e-15	-0.41	-0.38	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
LUAD	cis	rs11690935	0.959	rs6738445	ENSG00000228389.1	AC068039.4	-9	5.1e-18	7e-15	-0.45	-0.38	Schizophrenia;	chr2:171743105	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	9	5.1e-18	7e-15	0.37	0.38	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	9	5.1e-18	7e-15	0.37	0.38	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	9	5.1e-18	7e-15	0.37	0.38	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	9	5.1e-18	7e-15	0.37	0.38	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
LUAD	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	9	5.13e-18	7.04e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
LUAD	cis	rs10129255	1	rs11621409	ENSG00000223648.3	IGHV3-64	9	5.14e-18	7.05e-15	0.38	0.38	Kawasaki disease;	chr14:106695603	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	9	5.14e-18	7.06e-15	0.53	0.38	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
LUAD	cis	rs1789	0.592	rs6812708	ENSG00000273133.1	RP11-799M12.2	-9	5.15e-18	7.07e-15	-0.57	-0.38	Blood protein levels;	chr4:15539986	chr4:15563698~15564253:-
LUAD	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	9	5.18e-18	7.1e-15	0.57	0.38	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-9	5.2e-18	7.14e-15	-0.39	-0.38	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	9	5.24e-18	7.18e-15	0.57	0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
LUAD	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	9	5.24e-18	7.19e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
LUAD	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	9	5.27e-18	7.22e-15	0.55	0.38	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-9	5.3e-18	7.26e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-9	5.3e-18	7.27e-15	-0.39	-0.38	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
LUAD	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-9	5.32e-18	7.29e-15	-0.47	-0.38	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
LUAD	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	9	5.34e-18	7.31e-15	0.47	0.38	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
LUAD	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	9	5.36e-18	7.34e-15	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
LUAD	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	9	5.38e-18	7.37e-15	0.43	0.38	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
LUAD	cis	rs7924176	0.601	rs10824072	ENSG00000213731.2	RAB5CP1	-9	5.42e-18	7.42e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74114134	chr10:74423435~74424014:-
LUAD	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-9	5.45e-18	7.46e-15	-0.58	-0.38	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
LUAD	cis	rs7924176	0.564	rs10762588	ENSG00000213731.2	RAB5CP1	-8.99	5.48e-18	7.5e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.564	rs4564273	ENSG00000213731.2	RAB5CP1	-8.99	5.48e-18	7.5e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74423435~74424014:-
LUAD	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-8.99	5.54e-18	7.57e-15	-0.45	-0.38	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
LUAD	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	8.99	5.56e-18	7.61e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
LUAD	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-8.99	5.58e-18	7.63e-15	-0.39	-0.38	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
LUAD	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-8.99	5.58e-18	7.63e-15	-0.4	-0.38	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
LUAD	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	8.99	5.6e-18	7.65e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	8.99	5.6e-18	7.65e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
LUAD	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	8.99	5.8e-18	7.91e-15	0.37	0.38	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
LUAD	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-8.99	5.82e-18	7.94e-15	-0.46	-0.38	Height;	chr11:118781100	chr11:118704607~118750263:+
LUAD	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-8.99	5.83e-18	7.95e-15	-0.52	-0.38	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
LUAD	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	8.99	5.84e-18	7.96e-15	0.6	0.38	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	8.99	5.84e-18	7.96e-15	0.6	0.38	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	8.99	5.84e-18	7.96e-15	0.6	0.38	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
LUAD	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-8.98	5.97e-18	8.14e-15	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
LUAD	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	8.98	6.01e-18	8.19e-15	0.39	0.38	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	8.98	6.01e-18	8.19e-15	0.39	0.38	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
LUAD	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-8.98	6.02e-18	8.21e-15	-0.39	-0.38	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
LUAD	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-8.98	6.05e-18	8.24e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
LUAD	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-8.98	6.09e-18	8.3e-15	-0.47	-0.38	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
LUAD	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-8.98	6.09e-18	8.3e-15	-0.47	-0.38	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
LUAD	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	8.98	6.11e-18	8.32e-15	0.39	0.38	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
LUAD	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-8.98	6.11e-18	8.33e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
LUAD	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-8.98	6.12e-18	8.34e-15	-0.46	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
LUAD	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	8.98	6.22e-18	8.47e-15	0.44	0.38	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	8.98	6.23e-18	8.48e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	8.98	6.23e-18	8.48e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-8.98	6.27e-18	8.53e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
LUAD	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-8.98	6.29e-18	8.55e-15	-0.47	-0.38	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
LUAD	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	8.98	6.3e-18	8.57e-15	0.43	0.38	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
LUAD	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	8.98	6.36e-18	8.64e-15	0.53	0.38	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	8.98	6.36e-18	8.64e-15	0.53	0.38	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
LUAD	cis	rs1061377	0.585	rs1367296	ENSG00000249207.1	RP11-360F5.1	-8.97	6.46e-18	8.77e-15	-0.42	-0.38	Uric acid levels;	chr4:39066895	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-8.97	6.49e-18	8.82e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	8.97	6.58e-18	8.93e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	8.97	6.58e-18	8.93e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
LUAD	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	8.97	6.59e-18	8.94e-15	0.5	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
LUAD	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-8.97	6.6e-18	8.95e-15	-0.39	-0.38	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-8.97	6.6e-18	8.96e-15	-0.26	-0.38	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
LUAD	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-8.97	6.63e-18	8.99e-15	-0.52	-0.38	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
LUAD	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	8.97	6.65e-18	9.03e-15	0.49	0.38	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
LUAD	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	8.97	6.68e-18	9.06e-15	0.54	0.38	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
LUAD	cis	rs62229266	1	rs62229266	ENSG00000231106.2	LINC01436	8.97	6.7e-18	9.09e-15	0.52	0.38	Mitral valve prolapse;	chr21:36087973	chr21:36005338~36007838:+
LUAD	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	8.97	6.72e-18	9.11e-15	0.75	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	8.97	6.72e-18	9.11e-15	0.75	0.38	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	8.97	6.72e-18	9.11e-15	0.75	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	8.97	6.72e-18	9.11e-15	0.75	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
LUAD	cis	rs7924176	0.601	rs7099026	ENSG00000213731.2	RAB5CP1	-8.97	6.74e-18	9.13e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74423435~74424014:-
LUAD	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	8.97	6.76e-18	9.17e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	8.97	6.77e-18	9.18e-15	0.54	0.38	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
LUAD	cis	rs1061377	0.608	rs35168672	ENSG00000249207.1	RP11-360F5.1	-8.97	6.79e-18	9.2e-15	-0.42	-0.38	Uric acid levels;	chr4:39078902	chr4:39112677~39126818:-
LUAD	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-8.97	6.81e-18	9.22e-15	-0.44	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
LUAD	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-8.96	6.9e-18	9.35e-15	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	8.96	7e-18	9.47e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	8.96	7e-18	9.47e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
LUAD	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	8.96	7.02e-18	9.5e-15	0.43	0.38	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
LUAD	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	8.96	7.04e-18	9.52e-15	0.44	0.38	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
LUAD	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	8.96	7.05e-18	9.53e-15	0.38	0.38	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
LUAD	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-8.96	7.06e-18	9.54e-15	-0.26	-0.38	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
LUAD	cis	rs7924176	0.502	rs1874151	ENSG00000213731.2	RAB5CP1	-8.96	7.12e-18	9.61e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107856	chr10:74423435~74424014:-
LUAD	cis	rs944289	0.589	rs847514	ENSG00000257826.1	RP11-116N8.4	8.96	7.22e-18	9.74e-15	0.4	0.38	Thyroid cancer;	chr14:36060904	chr14:36061026~36067190:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-8.96	7.25e-18	9.78e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
LUAD	cis	rs7429990	0.895	rs35790549	ENSG00000229759.1	MRPS18AP1	8.96	7.27e-18	9.8e-15	0.44	0.38	Educational attainment (years of education);	chr3:48029998	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	8.96	7.37e-18	9.93e-15	0.52	0.38	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
LUAD	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	8.96	7.39e-18	9.95e-15	0.49	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-8.96	7.41e-18	9.98e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
LUAD	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	8.95	7.47e-18	1.01e-14	0.64	0.38	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
LUAD	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-8.95	7.49e-18	1.01e-14	-0.44	-0.38	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
LUAD	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	8.95	7.5e-18	1.01e-14	0.52	0.38	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
LUAD	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	8.95	7.52e-18	1.01e-14	0.6	0.38	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
LUAD	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-8.95	7.55e-18	1.02e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
LUAD	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-8.95	7.58e-18	1.02e-14	-0.51	-0.38	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
LUAD	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	8.95	7.59e-18	1.02e-14	0.54	0.38	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
LUAD	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-8.95	7.66e-18	1.03e-14	-0.49	-0.38	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
LUAD	cis	rs944289	0.617	rs1958617	ENSG00000257826.1	RP11-116N8.4	-8.95	7.71e-18	1.04e-14	-0.4	-0.38	Thyroid cancer;	chr14:36118418	chr14:36061026~36067190:-
LUAD	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-8.95	7.77e-18	1.04e-14	-0.39	-0.38	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
LUAD	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	8.95	7.77e-18	1.04e-14	0.47	0.38	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
LUAD	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-8.95	7.83e-18	1.05e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-8.95	7.83e-18	1.05e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
LUAD	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	8.95	7.84e-18	1.05e-14	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
LUAD	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	8.95	7.93e-18	1.06e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
LUAD	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-8.95	7.97e-18	1.07e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-8.95	7.97e-18	1.07e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	8.95	7.97e-18	1.07e-14	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
LUAD	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	8.95	7.98e-18	1.07e-14	0.37	0.38	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
LUAD	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	8.94	8.1e-18	1.09e-14	0.55	0.38	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
LUAD	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-8.94	8.12e-18	1.09e-14	-0.37	-0.38	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
LUAD	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-8.94	8.15e-18	1.09e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
LUAD	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-8.94	8.22e-18	1.1e-14	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	8.94	8.31e-18	1.11e-14	0.37	0.38	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-8.94	8.32e-18	1.11e-14	-0.26	-0.38	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
LUAD	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-8.94	8.35e-18	1.12e-14	-0.41	-0.38	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-8.94	8.35e-18	1.12e-14	-0.41	-0.38	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
LUAD	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	8.94	8.49e-18	1.14e-14	0.45	0.38	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000223648.3	IGHV3-64	8.94	8.53e-18	1.14e-14	0.37	0.38	Kawasaki disease;	chr14:106815190	chr14:106643132~106658258:-
LUAD	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-8.94	8.54e-18	1.14e-14	-0.39	-0.38	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
LUAD	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	8.94	8.56e-18	1.14e-14	0.5	0.38	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
LUAD	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-8.94	8.57e-18	1.15e-14	-0.41	-0.38	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
LUAD	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	8.94	8.59e-18	1.15e-14	0.44	0.38	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
LUAD	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-8.94	8.6e-18	1.15e-14	-0.38	-0.38	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	8.94	8.7e-18	1.16e-14	0.52	0.38	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-8.93	8.73e-18	1.17e-14	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
LUAD	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	8.93	8.88e-18	1.19e-14	0.45	0.38	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
LUAD	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-8.93	8.9e-18	1.19e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
LUAD	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-8.93	8.91e-18	1.19e-14	-0.47	-0.38	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
LUAD	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	8.93	9.04e-18	1.21e-14	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
LUAD	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	8.93	9.15e-18	1.22e-14	0.37	0.38	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
LUAD	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	8.93	9.15e-18	1.22e-14	0.54	0.38	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
LUAD	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-8.93	9.21e-18	1.23e-14	-0.4	-0.38	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
LUAD	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-8.93	9.24e-18	1.23e-14	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	8.93	9.27e-18	1.23e-14	0.37	0.38	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
LUAD	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-8.93	9.28e-18	1.24e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
LUAD	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-8.92	9.42e-18	1.25e-14	-0.47	-0.38	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
LUAD	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	8.92	9.43e-18	1.26e-14	0.44	0.38	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	8.92	9.43e-18	1.26e-14	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
LUAD	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	8.92	9.46e-18	1.26e-14	0.45	0.38	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106776648	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106776833	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106777009	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106777263	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106778385	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106778427	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106778702	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106779073	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106779163	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106779174	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106779234	chr14:106122420~106122709:-
LUAD	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	8.92	9.6e-18	1.28e-14	0.35	0.38	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
LUAD	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
LUAD	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-8.92	9.67e-18	1.28e-14	-0.47	-0.38	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
LUAD	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-8.92	9.74e-18	1.29e-14	-0.5	-0.38	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
LUAD	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-8.92	9.74e-18	1.29e-14	-0.41	-0.38	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
LUAD	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-8.92	9.81e-18	1.3e-14	-0.4	-0.38	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-8.92	9.83e-18	1.31e-14	-0.44	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
LUAD	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	8.92	9.84e-18	1.31e-14	0.54	0.38	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	8.92	9.95e-18	1.32e-14	0.53	0.38	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
LUAD	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	8.92	1.01e-17	1.34e-14	0.61	0.38	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
LUAD	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-8.92	1.01e-17	1.34e-14	-0.47	-0.38	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
LUAD	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	8.91	1.02e-17	1.35e-14	0.45	0.38	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
LUAD	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	8.91	1.03e-17	1.36e-14	0.54	0.38	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-8.91	1.03e-17	1.37e-14	-0.28	-0.38	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-8.91	1.03e-17	1.37e-14	-0.28	-0.38	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-8.91	1.03e-17	1.37e-14	-0.28	-0.38	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
LUAD	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	8.91	1.03e-17	1.37e-14	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-8.91	1.04e-17	1.37e-14	-0.44	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
LUAD	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-8.91	1.04e-17	1.38e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
LUAD	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-8.91	1.04e-17	1.38e-14	-0.52	-0.38	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
LUAD	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	8.91	1.05e-17	1.39e-14	0.47	0.38	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
LUAD	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	8.91	1.05e-17	1.39e-14	0.39	0.38	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000223648.3	IGHV3-64	8.91	1.05e-17	1.39e-14	0.37	0.38	Kawasaki disease;	chr14:106777570	chr14:106643132~106658258:-
LUAD	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	8.91	1.05e-17	1.39e-14	0.53	0.38	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	8.91	1.05e-17	1.39e-14	0.53	0.38	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	8.91	1.05e-17	1.39e-14	0.53	0.38	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
LUAD	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-8.91	1.05e-17	1.39e-14	-0.48	-0.38	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
LUAD	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-8.91	1.05e-17	1.39e-14	-0.34	-0.38	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-8.91	1.06e-17	1.41e-14	-0.58	-0.38	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
LUAD	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	8.91	1.06e-17	1.41e-14	0.43	0.38	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
LUAD	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-8.91	1.07e-17	1.42e-14	-0.39	-0.38	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
LUAD	cis	rs7924176	0.564	rs12572820	ENSG00000213731.2	RAB5CP1	-8.91	1.08e-17	1.43e-14	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74117387	chr10:74423435~74424014:-
LUAD	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-8.91	1.09e-17	1.44e-14	-0.43	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
LUAD	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	8.91	1.09e-17	1.44e-14	0.6	0.38	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	8.91	1.09e-17	1.44e-14	0.6	0.38	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	8.91	1.09e-17	1.44e-14	0.6	0.38	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
LUAD	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	8.9	1.1e-17	1.45e-14	0.5	0.38	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	8.9	1.1e-17	1.45e-14	0.5	0.38	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
LUAD	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	8.9	1.1e-17	1.45e-14	0.45	0.38	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
LUAD	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	8.9	1.11e-17	1.46e-14	0.47	0.38	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
LUAD	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-8.9	1.13e-17	1.49e-14	-0.58	-0.38	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	8.9	1.13e-17	1.49e-14	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
LUAD	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-8.9	1.13e-17	1.49e-14	-0.38	-0.38	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
LUAD	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	8.9	1.14e-17	1.5e-14	0.45	0.38	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
LUAD	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-8.9	1.14e-17	1.51e-14	-0.36	-0.38	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
LUAD	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-8.9	1.14e-17	1.51e-14	-0.38	-0.38	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	8.9	1.15e-17	1.51e-14	0.56	0.38	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
LUAD	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	8.9	1.15e-17	1.52e-14	0.52	0.38	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	8.9	1.15e-17	1.52e-14	0.52	0.38	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
LUAD	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-8.9	1.15e-17	1.52e-14	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
LUAD	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	8.9	1.16e-17	1.52e-14	0.43	0.38	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
LUAD	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	8.9	1.17e-17	1.54e-14	0.6	0.38	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
LUAD	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-8.9	1.18e-17	1.55e-14	-0.58	-0.38	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
LUAD	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-8.89	1.19e-17	1.57e-14	-0.45	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
LUAD	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-8.89	1.19e-17	1.57e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
LUAD	cis	rs9326248	0.861	rs4938348	ENSG00000280143.1	AP000892.6	8.89	1.2e-17	1.58e-14	0.51	0.38	Blood protein levels;	chr11:117151161	chr11:117204967~117210292:+
LUAD	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	8.89	1.2e-17	1.58e-14	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
LUAD	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	8.89	1.21e-17	1.59e-14	0.6	0.38	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	8.89	1.21e-17	1.59e-14	0.6	0.38	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	8.89	1.21e-17	1.59e-14	0.6	0.38	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	8.89	1.21e-17	1.59e-14	0.6	0.38	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-8.89	1.22e-17	1.61e-14	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
LUAD	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-8.89	1.23e-17	1.61e-14	-0.58	-0.38	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
LUAD	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-8.89	1.23e-17	1.62e-14	-0.46	-0.38	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
LUAD	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-8.89	1.23e-17	1.62e-14	-0.45	-0.38	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
LUAD	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-8.89	1.24e-17	1.62e-14	-0.48	-0.38	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
LUAD	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-8.89	1.24e-17	1.62e-14	-0.48	-0.38	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
LUAD	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-8.89	1.26e-17	1.66e-14	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	8.89	1.26e-17	1.66e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	8.89	1.26e-17	1.66e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	8.89	1.26e-17	1.66e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	8.89	1.26e-17	1.66e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
LUAD	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	8.89	1.26e-17	1.66e-14	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	8.89	1.26e-17	1.66e-14	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
LUAD	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-8.89	1.27e-17	1.66e-14	-0.58	-0.38	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
LUAD	cis	rs904251	0.802	rs2646933	ENSG00000204110.6	RP1-153P14.8	-8.89	1.28e-17	1.68e-14	-0.43	-0.38	Cognitive performance;	chr6:37434294	chr6:37507348~37535616:+
LUAD	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-8.88	1.28e-17	1.68e-14	-0.39	-0.38	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
LUAD	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-8.88	1.29e-17	1.69e-14	-0.58	-0.38	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
LUAD	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-8.88	1.3e-17	1.7e-14	-0.43	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000254174.1	IGHV1-12	8.88	1.3e-17	1.7e-14	0.33	0.38	Alzheimer's disease (late onset);	chr14:106777154	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-8.88	1.31e-17	1.72e-14	-0.3	-0.38	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
LUAD	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-8.88	1.32e-17	1.73e-14	-0.49	-0.38	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
LUAD	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-8.88	1.33e-17	1.74e-14	-0.45	-0.38	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-8.88	1.33e-17	1.74e-14	-0.45	-0.38	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
LUAD	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	8.88	1.33e-17	1.75e-14	0.5	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
LUAD	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	8.88	1.34e-17	1.76e-14	0.53	0.38	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	8.87	1.4e-17	1.83e-14	0.35	0.38	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
LUAD	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-8.87	1.44e-17	1.88e-14	-0.41	-0.37	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
LUAD	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
LUAD	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	8.87	1.45e-17	1.89e-14	0.46	0.37	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
LUAD	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-8.87	1.46e-17	1.9e-14	-0.51	-0.37	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
LUAD	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-8.87	1.48e-17	1.93e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-8.87	1.48e-17	1.93e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-8.87	1.48e-17	1.93e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
LUAD	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	8.87	1.49e-17	1.94e-14	0.55	0.37	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
LUAD	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	8.87	1.49e-17	1.94e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
LUAD	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-8.86	1.5e-17	1.95e-14	-0.56	-0.37	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-8.86	1.5e-17	1.96e-14	-0.38	-0.37	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	8.86	1.5e-17	1.96e-14	0.52	0.37	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	8.86	1.5e-17	1.96e-14	0.52	0.37	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-8.86	1.52e-17	1.98e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-8.86	1.53e-17	1.99e-14	-0.35	-0.37	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
LUAD	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-8.86	1.53e-17	1.99e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
LUAD	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-8.86	1.53e-17	1.99e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
LUAD	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	8.86	1.53e-17	1.99e-14	0.41	0.37	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
LUAD	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	8.86	1.53e-17	1.99e-14	0.53	0.37	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
LUAD	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	8.86	1.54e-17	2e-14	0.45	0.37	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
LUAD	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	8.86	1.54e-17	2.01e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
LUAD	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	8.86	1.55e-17	2.02e-14	0.47	0.37	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
LUAD	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-8.86	1.57e-17	2.04e-14	-0.59	-0.37	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	8.86	1.57e-17	2.04e-14	0.38	0.37	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-8.86	1.57e-17	2.04e-14	-0.26	-0.37	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
LUAD	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-8.86	1.59e-17	2.06e-14	-0.39	-0.37	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-8.86	1.59e-17	2.06e-14	-0.39	-0.37	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
LUAD	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-8.86	1.6e-17	2.08e-14	-0.38	-0.37	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
LUAD	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	8.86	1.6e-17	2.08e-14	0.53	0.37	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-8.86	1.61e-17	2.09e-14	-0.29	-0.37	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
LUAD	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	8.86	1.61e-17	2.09e-14	0.49	0.37	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
LUAD	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	8.85	1.62e-17	2.1e-14	0.46	0.37	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
LUAD	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-8.85	1.62e-17	2.11e-14	-0.45	-0.37	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
LUAD	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-8.85	1.62e-17	2.11e-14	-0.49	-0.37	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
LUAD	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-8.85	1.62e-17	2.11e-14	-0.49	-0.37	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
LUAD	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-8.85	1.63e-17	2.11e-14	-0.44	-0.37	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
LUAD	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-8.85	1.64e-17	2.13e-14	-0.45	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
LUAD	cis	rs7924176	0.58	rs7912162	ENSG00000213731.2	RAB5CP1	-8.85	1.65e-17	2.14e-14	-0.4	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74423435~74424014:-
LUAD	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	8.85	1.66e-17	2.15e-14	0.53	0.37	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
LUAD	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-8.85	1.66e-17	2.15e-14	-0.44	-0.37	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
LUAD	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-8.85	1.66e-17	2.16e-14	-0.37	-0.37	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
LUAD	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-8.85	1.67e-17	2.16e-14	-0.53	-0.37	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-8.85	1.67e-17	2.16e-14	-0.53	-0.37	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-8.85	1.68e-17	2.18e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
LUAD	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	8.85	1.69e-17	2.19e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
LUAD	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-8.85	1.69e-17	2.19e-14	-0.36	-0.37	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
LUAD	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-8.85	1.69e-17	2.19e-14	-0.4	-0.37	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
LUAD	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	8.85	1.69e-17	2.19e-14	0.34	0.37	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	8.85	1.69e-17	2.19e-14	0.34	0.37	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	8.85	1.69e-17	2.19e-14	0.34	0.37	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
LUAD	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	8.85	1.69e-17	2.19e-14	0.38	0.37	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
LUAD	cis	rs13423976	0.663	rs7559097	ENSG00000231367.4	AC016995.3	-8.85	1.7e-17	2.2e-14	-0.47	-0.37	Gut microbiome composition (summer);	chr2:38517625	chr2:38406719~38515740:-
LUAD	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	8.85	1.71e-17	2.21e-14	0.46	0.37	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	8.85	1.71e-17	2.21e-14	0.52	0.37	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
LUAD	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	8.85	1.72e-17	2.23e-14	0.46	0.37	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.706	rs11156904	ENSG00000257826.1	RP11-116N8.4	-8.85	1.73e-17	2.24e-14	-0.39	-0.37	Thyroid cancer;	chr14:36085688	chr14:36061026~36067190:-
LUAD	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	8.85	1.74e-17	2.25e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
LUAD	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	8.85	1.74e-17	2.25e-14	0.52	0.37	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
LUAD	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-8.84	1.75e-17	2.26e-14	-0.51	-0.37	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.564	rs12569971	ENSG00000213731.2	RAB5CP1	-8.84	1.76e-17	2.27e-14	-0.4	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74194617	chr10:74423435~74424014:-
LUAD	cis	rs6964833	0.873	rs4717905	ENSG00000277053.3	GTF2IP1	-8.84	1.76e-17	2.27e-14	-0.53	-0.37	Menarche (age at onset);	chr7:74668903	chr7:75185385~75237696:-
LUAD	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-8.84	1.76e-17	2.28e-14	-0.41	-0.37	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
LUAD	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-8.84	1.76e-17	2.28e-14	-0.38	-0.37	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
LUAD	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-8.84	1.77e-17	2.29e-14	-0.53	-0.37	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
LUAD	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	8.84	1.78e-17	2.31e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
LUAD	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-8.84	1.78e-17	2.31e-14	-0.58	-0.37	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
LUAD	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-8.84	1.8e-17	2.32e-14	-0.45	-0.37	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
LUAD	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-8.84	1.81e-17	2.34e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	8.84	1.82e-17	2.35e-14	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	8.84	1.85e-17	2.39e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
LUAD	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	8.84	1.85e-17	2.39e-14	0.59	0.37	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
LUAD	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-8.84	1.86e-17	2.4e-14	-0.56	-0.37	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
LUAD	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-8.84	1.86e-17	2.4e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
LUAD	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-8.84	1.87e-17	2.41e-14	-0.49	-0.37	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
LUAD	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-8.84	1.87e-17	2.41e-14	-0.46	-0.37	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
LUAD	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	8.84	1.87e-17	2.41e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
LUAD	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-8.83	1.89e-17	2.44e-14	-0.44	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
LUAD	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-8.83	1.89e-17	2.44e-14	-0.41	-0.37	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
LUAD	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	8.83	1.89e-17	2.44e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
LUAD	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-8.83	1.9e-17	2.45e-14	-0.36	-0.37	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
LUAD	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	8.83	1.91e-17	2.47e-14	0.54	0.37	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
LUAD	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	8.83	1.92e-17	2.47e-14	0.44	0.37	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
LUAD	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-8.83	1.92e-17	2.47e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-8.83	1.92e-17	2.47e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	8.83	1.94e-17	2.5e-14	0.43	0.37	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
LUAD	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	8.83	1.94e-17	2.5e-14	0.4	0.37	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-8.83	1.94e-17	2.5e-14	-0.39	-0.37	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
LUAD	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-8.83	1.94e-17	2.51e-14	-0.43	-0.37	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000254174.1	IGHV1-12	8.83	1.94e-17	2.51e-14	0.34	0.37	Alzheimer's disease (late onset);	chr14:106776118	chr14:106122420~106122709:-
LUAD	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-8.83	1.97e-17	2.54e-14	-0.35	-0.37	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	8.83	1.98e-17	2.56e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
LUAD	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-8.83	1.99e-17	2.56e-14	-0.41	-0.37	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
LUAD	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-8.83	2e-17	2.57e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
LUAD	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-8.83	2e-17	2.58e-14	-0.53	-0.37	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
LUAD	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-8.83	2e-17	2.58e-14	-0.51	-0.37	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
LUAD	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	8.83	2.02e-17	2.6e-14	0.44	0.37	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
LUAD	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	8.83	2.02e-17	2.6e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
LUAD	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	8.83	2.03e-17	2.62e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	8.83	2.03e-17	2.62e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	8.83	2.03e-17	2.62e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
LUAD	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	8.83	2.04e-17	2.62e-14	0.46	0.37	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
LUAD	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	8.82	2.04e-17	2.62e-14	0.45	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
LUAD	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	8.82	2.06e-17	2.64e-14	0.41	0.37	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
LUAD	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-8.82	2.06e-17	2.65e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
LUAD	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	8.82	2.06e-17	2.65e-14	0.34	0.37	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	8.82	2.06e-17	2.65e-14	0.34	0.37	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
LUAD	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-8.82	2.11e-17	2.71e-14	-0.45	-0.37	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-8.82	2.11e-17	2.71e-14	-0.45	-0.37	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-8.82	2.11e-17	2.71e-14	-0.45	-0.37	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
LUAD	cis	rs944289	0.617	rs1537428	ENSG00000257826.1	RP11-116N8.4	8.82	2.11e-17	2.72e-14	0.39	0.37	Thyroid cancer;	chr14:36117579	chr14:36061026~36067190:-
LUAD	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	8.82	2.12e-17	2.72e-14	0.44	0.37	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-8.82	2.12e-17	2.73e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
LUAD	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	8.82	2.13e-17	2.74e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
LUAD	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-8.82	2.15e-17	2.77e-14	-0.48	-0.37	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
LUAD	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-8.82	2.16e-17	2.77e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-8.82	2.16e-17	2.77e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-8.82	2.16e-17	2.77e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
LUAD	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	8.82	2.16e-17	2.78e-14	0.45	0.37	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
LUAD	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-8.81	2.2e-17	2.82e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
LUAD	cis	rs904251	0.965	rs1317563	ENSG00000279942.1	RP1-153P14.7	-8.81	2.21e-17	2.83e-14	-0.35	-0.37	Cognitive performance;	chr6:37484078	chr6:37567716~37571460:+
LUAD	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-8.81	2.21e-17	2.84e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
LUAD	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	8.81	2.25e-17	2.89e-14	0.53	0.37	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	8.81	2.25e-17	2.89e-14	0.53	0.37	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
LUAD	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	8.81	2.26e-17	2.9e-14	0.47	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
LUAD	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	8.81	2.27e-17	2.91e-14	0.4	0.37	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
LUAD	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	8.81	2.28e-17	2.92e-14	0.41	0.37	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	8.81	2.28e-17	2.92e-14	0.41	0.37	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
LUAD	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	8.81	2.3e-17	2.94e-14	0.55	0.37	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-8.81	2.3e-17	2.95e-14	-0.29	-0.37	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
LUAD	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-8.81	2.31e-17	2.96e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-8.81	2.31e-17	2.96e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-8.81	2.32e-17	2.97e-14	-0.35	-0.37	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-8.81	2.33e-17	2.99e-14	-0.29	-0.37	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
LUAD	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	8.81	2.35e-17	3.01e-14	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
LUAD	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-8.81	2.36e-17	3.02e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
LUAD	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	8.81	2.37e-17	3.03e-14	0.32	0.37	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
LUAD	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	8.8	2.38e-17	3.04e-14	0.51	0.37	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	8.8	2.38e-17	3.04e-14	0.51	0.37	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	8.8	2.38e-17	3.04e-14	0.51	0.37	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	8.8	2.38e-17	3.04e-14	0.51	0.37	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
LUAD	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	8.8	2.38e-17	3.05e-14	0.47	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-8.8	2.39e-17	3.05e-14	-0.29	-0.37	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
LUAD	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	8.8	2.39e-17	3.06e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
LUAD	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	8.8	2.4e-17	3.07e-14	0.44	0.37	Height;	chr11:118737823	chr11:118688039~118690600:-
LUAD	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-8.8	2.41e-17	3.08e-14	-0.42	-0.37	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
LUAD	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-8.8	2.44e-17	3.12e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
LUAD	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	8.8	2.45e-17	3.13e-14	0.53	0.37	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
LUAD	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-8.8	2.46e-17	3.14e-14	-0.43	-0.37	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
LUAD	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	8.8	2.47e-17	3.15e-14	0.39	0.37	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
LUAD	cis	rs944289	0.617	rs2415314	ENSG00000257826.1	RP11-116N8.4	-8.8	2.47e-17	3.16e-14	-0.39	-0.37	Thyroid cancer;	chr14:36115335	chr14:36061026~36067190:-
LUAD	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	8.8	2.47e-17	3.16e-14	0.38	0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
LUAD	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	8.8	2.47e-17	3.16e-14	0.43	0.37	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
LUAD	cis	rs944289	0.617	rs7156229	ENSG00000257826.1	RP11-116N8.4	-8.8	2.49e-17	3.18e-14	-0.4	-0.37	Thyroid cancer;	chr14:36114780	chr14:36061026~36067190:-
LUAD	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-8.8	2.49e-17	3.18e-14	-0.53	-0.37	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
LUAD	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	8.8	2.51e-17	3.2e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	8.8	2.51e-17	3.2e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
LUAD	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-8.8	2.51e-17	3.21e-14	-0.45	-0.37	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-8.8	2.52e-17	3.22e-14	-0.45	-0.37	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
LUAD	cis	rs35955747	0.633	rs1916	ENSG00000236132.1	CTA-440B3.1	-8.8	2.52e-17	3.22e-14	-0.42	-0.37	Neutrophil count;Sum basophil neutrophil counts;	chr22:31496135	chr22:31816379~31817491:-
LUAD	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-8.8	2.55e-17	3.25e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
LUAD	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-8.8	2.55e-17	3.25e-14	-0.39	-0.37	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
LUAD	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	8.79	2.57e-17	3.27e-14	0.4	0.37	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
LUAD	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	8.79	2.62e-17	3.34e-14	0.38	0.37	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
LUAD	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	8.79	2.63e-17	3.35e-14	0.52	0.37	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	8.79	2.64e-17	3.36e-14	0.51	0.37	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	8.79	2.64e-17	3.36e-14	0.51	0.37	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000254174.1	IGHV1-12	8.79	2.64e-17	3.36e-14	0.33	0.37	Alzheimer's disease (late onset);	chr14:106777623	chr14:106122420~106122709:-
LUAD	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
LUAD	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	8.79	2.68e-17	3.41e-14	0.51	0.37	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
LUAD	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	8.79	2.68e-17	3.41e-14	0.39	0.37	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
LUAD	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-8.79	2.69e-17	3.43e-14	-0.53	-0.37	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
LUAD	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	8.79	2.71e-17	3.45e-14	0.46	0.37	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
LUAD	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-8.79	2.72e-17	3.46e-14	-0.57	-0.37	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
LUAD	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	8.79	2.75e-17	3.5e-14	0.43	0.37	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
LUAD	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-8.79	2.75e-17	3.5e-14	-0.49	-0.37	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
LUAD	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	8.78	2.78e-17	3.53e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
LUAD	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	8.78	2.78e-17	3.54e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
LUAD	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	8.78	2.79e-17	3.54e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
LUAD	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-8.78	2.79e-17	3.55e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-8.78	2.79e-17	3.55e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-8.78	2.79e-17	3.55e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-8.78	2.79e-17	3.55e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
LUAD	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-8.78	2.79e-17	3.55e-14	-0.78	-0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
LUAD	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-8.78	2.8e-17	3.56e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-8.78	2.82e-17	3.59e-14	-0.29	-0.37	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
LUAD	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	8.78	2.83e-17	3.59e-14	0.37	0.37	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
LUAD	cis	rs4908760	0.811	rs301806	ENSG00000232912.4	RP5-1115A15.1	8.78	2.83e-17	3.59e-14	0.34	0.37	Vitiligo;	chr1:8422018	chr1:8424645~8434838:+
LUAD	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-8.78	2.84e-17	3.6e-14	-0.43	-0.37	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
LUAD	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	8.78	2.84e-17	3.61e-14	0.43	0.37	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-8.78	2.88e-17	3.65e-14	-0.28	-0.37	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-8.78	2.88e-17	3.65e-14	-0.28	-0.37	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-8.78	2.88e-17	3.65e-14	-0.28	-0.37	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-8.78	2.88e-17	3.65e-14	-0.28	-0.37	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
LUAD	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-8.78	2.89e-17	3.68e-14	-0.48	-0.37	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
LUAD	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-8.78	2.93e-17	3.72e-14	-0.43	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
LUAD	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	8.78	2.93e-17	3.72e-14	0.47	0.37	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
LUAD	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-8.78	2.94e-17	3.72e-14	-0.5	-0.37	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-8.78	2.94e-17	3.73e-14	-0.43	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-8.78	2.95e-17	3.75e-14	-0.29	-0.37	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
LUAD	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	8.78	2.96e-17	3.76e-14	0.43	0.37	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
LUAD	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	8.78	2.96e-17	3.76e-14	0.43	0.37	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
LUAD	cis	rs7924176	0.564	rs12359146	ENSG00000213731.2	RAB5CP1	-8.78	2.97e-17	3.76e-14	-0.4	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74205914	chr10:74423435~74424014:-
LUAD	cis	rs1061377	0.621	rs11096974	ENSG00000249207.1	RP11-360F5.1	-8.78	2.98e-17	3.78e-14	-0.41	-0.37	Uric acid levels;	chr4:39062039	chr4:39112677~39126818:-
LUAD	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-8.78	2.98e-17	3.78e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
LUAD	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-8.78	2.99e-17	3.79e-14	-0.48	-0.37	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-8.78	2.99e-17	3.79e-14	-0.48	-0.37	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
LUAD	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-8.77	3e-17	3.8e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
LUAD	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-8.77	3e-17	3.8e-14	-0.44	-0.37	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
LUAD	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-8.77	3e-17	3.81e-14	-0.47	-0.37	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
LUAD	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-8.77	3.02e-17	3.82e-14	-0.49	-0.37	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-8.77	3.03e-17	3.84e-14	-0.29	-0.37	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
LUAD	cis	rs11846409	0.587	rs1806881	ENSG00000274576.2	IGHV2-70	8.77	3.07e-17	3.88e-14	0.4	0.37	Rheumatic heart disease;	chr14:106650770	chr14:106770577~106771020:-
LUAD	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-8.77	3.07e-17	3.89e-14	-0.48	-0.37	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
LUAD	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-8.77	3.07e-17	3.89e-14	-0.45	-0.37	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
LUAD	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-8.77	3.07e-17	3.89e-14	-0.45	-0.37	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
LUAD	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-8.77	3.07e-17	3.89e-14	-0.45	-0.37	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
LUAD	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-8.77	3.07e-17	3.89e-14	-0.36	-0.37	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
LUAD	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	8.77	3.08e-17	3.89e-14	0.48	0.37	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-8.77	3.1e-17	3.92e-14	-0.28	-0.37	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
LUAD	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	8.77	3.11e-17	3.94e-14	0.43	0.37	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
LUAD	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-8.77	3.11e-17	3.94e-14	-0.48	-0.37	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
LUAD	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-8.77	3.12e-17	3.95e-14	-0.41	-0.37	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
LUAD	cis	rs944289	0.617	rs12432682	ENSG00000257826.1	RP11-116N8.4	-8.77	3.14e-17	3.97e-14	-0.39	-0.37	Thyroid cancer;	chr14:36114058	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.617	rs7156269	ENSG00000257826.1	RP11-116N8.4	-8.77	3.14e-17	3.97e-14	-0.39	-0.37	Thyroid cancer;	chr14:36114849	chr14:36061026~36067190:-
LUAD	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	8.77	3.15e-17	3.98e-14	0.38	0.37	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
LUAD	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	8.77	3.16e-17	4e-14	0.42	0.37	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
LUAD	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	8.77	3.18e-17	4.02e-14	0.44	0.37	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
LUAD	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-8.77	3.18e-17	4.03e-14	-0.49	-0.37	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
LUAD	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-8.77	3.19e-17	4.04e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
LUAD	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-8.77	3.19e-17	4.04e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
LUAD	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	8.77	3.21e-17	4.06e-14	0.51	0.37	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	8.77	3.21e-17	4.06e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.601	rs7089391	ENSG00000213731.2	RAB5CP1	-8.77	3.21e-17	4.06e-14	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74423435~74424014:-
LUAD	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	8.77	3.22e-17	4.06e-14	0.34	0.37	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
LUAD	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	8.77	3.22e-17	4.06e-14	0.44	0.37	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
LUAD	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-8.77	3.22e-17	4.07e-14	-0.4	-0.37	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
LUAD	cis	rs944289	0.617	rs1475715	ENSG00000257826.1	RP11-116N8.4	-8.76	3.23e-17	4.08e-14	-0.39	-0.37	Thyroid cancer;	chr14:36116017	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	8.76	3.24e-17	4.1e-14	0.29	0.37	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	8.76	3.25e-17	4.1e-14	0.29	0.37	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
LUAD	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	8.76	3.25e-17	4.11e-14	0.39	0.37	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
LUAD	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	8.76	3.27e-17	4.13e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
LUAD	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-8.76	3.3e-17	4.17e-14	-0.4	-0.37	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
LUAD	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-8.76	3.31e-17	4.18e-14	-0.4	-0.37	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
LUAD	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	8.76	3.34e-17	4.22e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
LUAD	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-8.76	3.36e-17	4.24e-14	-0.49	-0.37	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
LUAD	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-8.76	3.37e-17	4.25e-14	-0.41	-0.37	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
LUAD	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-8.76	3.38e-17	4.27e-14	-0.57	-0.37	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
LUAD	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-8.76	3.39e-17	4.28e-14	-0.42	-0.37	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
LUAD	cis	rs944289	0.616	rs6571735	ENSG00000257826.1	RP11-116N8.4	-8.76	3.41e-17	4.3e-14	-0.38	-0.37	Thyroid cancer;	chr14:36089428	chr14:36061026~36067190:-
LUAD	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	8.76	3.42e-17	4.31e-14	0.4	0.37	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
LUAD	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	8.76	3.42e-17	4.31e-14	0.42	0.37	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	8.76	3.42e-17	4.31e-14	0.42	0.37	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
LUAD	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-8.76	3.44e-17	4.33e-14	-0.44	-0.37	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
LUAD	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-8.76	3.44e-17	4.34e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
LUAD	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-8.76	3.46e-17	4.37e-14	-0.49	-0.37	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	8.76	3.47e-17	4.37e-14	0.29	0.37	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
LUAD	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	8.76	3.48e-17	4.38e-14	0.39	0.37	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
LUAD	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	8.76	3.48e-17	4.39e-14	0.47	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
LUAD	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-8.76	3.48e-17	4.39e-14	-0.45	-0.37	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
LUAD	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	8.76	3.48e-17	4.39e-14	0.4	0.37	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
LUAD	cis	rs16863064	0.66	rs1007308	ENSG00000279891.1	FLJ42393	-8.75	3.49e-17	4.41e-14	-0.49	-0.37	Schizophrenia;	chr3:188171935	chr3:188178543~188180812:+
LUAD	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-8.75	3.5e-17	4.41e-14	-0.49	-0.37	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
LUAD	cis	rs4908760	0.811	rs301802	ENSG00000232912.4	RP5-1115A15.1	8.75	3.5e-17	4.41e-14	0.33	0.37	Vitiligo;	chr1:8437247	chr1:8424645~8434838:+
LUAD	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-8.75	3.5e-17	4.42e-14	-0.46	-0.37	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
LUAD	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-8.75	3.52e-17	4.43e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
LUAD	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-8.75	3.53e-17	4.45e-14	-0.41	-0.37	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
LUAD	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	8.75	3.56e-17	4.48e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
LUAD	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-8.75	3.56e-17	4.48e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	8.75	3.56e-17	4.48e-14	0.29	0.37	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
LUAD	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-8.75	3.59e-17	4.52e-14	-0.42	-0.37	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
LUAD	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-8.75	3.59e-17	4.53e-14	-0.4	-0.37	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
LUAD	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-8.75	3.6e-17	4.54e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
LUAD	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-8.75	3.61e-17	4.55e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
LUAD	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	8.75	3.62e-17	4.55e-14	0.41	0.37	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
LUAD	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-8.75	3.62e-17	4.56e-14	-0.52	-0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-8.75	3.64e-17	4.58e-14	-0.37	-0.37	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
LUAD	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	8.75	3.66e-17	4.61e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	8.75	3.66e-17	4.61e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	8.75	3.66e-17	4.61e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
LUAD	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	8.75	3.67e-17	4.61e-14	0.38	0.37	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
LUAD	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-8.75	3.67e-17	4.62e-14	-0.45	-0.37	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
LUAD	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-8.75	3.7e-17	4.65e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-8.75	3.7e-17	4.65e-14	-0.29	-0.37	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
LUAD	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-8.75	3.71e-17	4.66e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-8.75	3.71e-17	4.66e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-8.75	3.72e-17	4.67e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
LUAD	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-8.75	3.72e-17	4.68e-14	-0.41	-0.37	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
LUAD	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	8.74	3.76e-17	4.73e-14	0.43	0.37	Height;	chr11:118703185	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	8.74	3.76e-17	4.73e-14	0.43	0.37	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
LUAD	cis	rs7924176	0.601	rs12414280	ENSG00000213731.2	RAB5CP1	-8.74	3.77e-17	4.73e-14	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74423435~74424014:-
LUAD	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
LUAD	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-8.74	3.77e-17	4.74e-14	-0.29	-0.37	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-8.74	3.77e-17	4.74e-14	-0.29	-0.37	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
LUAD	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	8.74	3.81e-17	4.79e-14	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
LUAD	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-8.74	3.81e-17	4.79e-14	-0.41	-0.37	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	8.74	3.82e-17	4.79e-14	0.37	0.37	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
LUAD	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-8.74	3.83e-17	4.81e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	8.74	3.86e-17	4.84e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
LUAD	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-8.74	3.87e-17	4.86e-14	-0.37	-0.37	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
LUAD	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	8.74	3.9e-17	4.89e-14	0.45	0.37	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
LUAD	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	8.74	3.98e-17	4.99e-14	0.44	0.37	Height;	chr11:118737916	chr11:118688039~118690600:-
LUAD	cis	rs944289	0.617	rs1159048	ENSG00000257826.1	RP11-116N8.4	-8.74	3.99e-17	5e-14	-0.39	-0.37	Thyroid cancer;	chr14:36115428	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	8.74	3.99e-17	5.01e-14	0.36	0.37	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
LUAD	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	8.74	4.03e-17	5.05e-14	0.39	0.37	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	8.74	4.03e-17	5.05e-14	0.39	0.37	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	8.74	4.04e-17	5.06e-14	0.37	0.37	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
LUAD	cis	rs7924176	0.549	rs2395076	ENSG00000213731.2	RAB5CP1	-8.74	4.05e-17	5.08e-14	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74423435~74424014:-
LUAD	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-8.73	4.06e-17	5.09e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-8.73	4.06e-17	5.09e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
LUAD	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	8.73	4.08e-17	5.11e-14	0.35	0.37	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
LUAD	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	8.73	4.08e-17	5.11e-14	0.4	0.37	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
LUAD	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	8.73	4.09e-17	5.12e-14	0.57	0.37	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
LUAD	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-8.73	4.1e-17	5.14e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
LUAD	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-8.73	4.12e-17	5.16e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
LUAD	cis	rs944289	0.617	rs7151738	ENSG00000257826.1	RP11-116N8.4	-8.73	4.12e-17	5.16e-14	-0.39	-0.37	Thyroid cancer;	chr14:36114670	chr14:36061026~36067190:-
LUAD	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-8.73	4.18e-17	5.23e-14	-0.42	-0.37	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
LUAD	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-8.73	4.21e-17	5.27e-14	-0.57	-0.37	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
LUAD	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	8.73	4.22e-17	5.28e-14	0.4	0.37	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
LUAD	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-8.73	4.22e-17	5.28e-14	-0.5	-0.37	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
LUAD	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	8.73	4.23e-17	5.29e-14	0.4	0.37	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
LUAD	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	8.73	4.26e-17	5.33e-14	0.42	0.37	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
LUAD	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-8.73	4.35e-17	5.43e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	8.73	4.37e-17	5.46e-14	0.36	0.37	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	8.73	4.38e-17	5.47e-14	0.53	0.37	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
LUAD	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-8.73	4.38e-17	5.47e-14	-0.38	-0.37	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
LUAD	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	8.72	4.4e-17	5.5e-14	0.4	0.37	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
LUAD	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-8.72	4.4e-17	5.5e-14	-0.44	-0.37	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
LUAD	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
LUAD	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-8.72	4.45e-17	5.55e-14	-0.42	-0.37	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
LUAD	cis	rs7924176	0.601	rs7093532	ENSG00000213731.2	RAB5CP1	-8.72	4.47e-17	5.57e-14	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74423435~74424014:-
LUAD	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-8.72	4.56e-17	5.68e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
LUAD	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-8.72	4.63e-17	5.77e-14	-0.47	-0.37	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
LUAD	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-8.72	4.67e-17	5.82e-14	-0.35	-0.37	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
LUAD	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-8.72	4.67e-17	5.82e-14	-0.35	-0.37	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
LUAD	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	8.72	4.68e-17	5.83e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
LUAD	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	8.72	4.69e-17	5.84e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
LUAD	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-8.72	4.7e-17	5.86e-14	-0.49	-0.37	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
LUAD	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	8.72	4.71e-17	5.87e-14	0.41	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
LUAD	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-8.72	4.72e-17	5.88e-14	-0.4	-0.37	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	8.71	4.77e-17	5.94e-14	0.37	0.37	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
LUAD	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-8.71	4.79e-17	5.97e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
LUAD	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-8.71	4.8e-17	5.98e-14	-0.4	-0.37	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
LUAD	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	8.71	4.83e-17	6.02e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
LUAD	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-8.71	4.86e-17	6.05e-14	-0.44	-0.37	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
LUAD	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-8.71	4.86e-17	6.05e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
LUAD	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-8.71	4.9e-17	6.09e-14	-0.44	-0.37	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
LUAD	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	8.71	4.9e-17	6.09e-14	0.43	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	8.71	4.9e-17	6.09e-14	0.43	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
LUAD	cis	rs4908760	0.757	rs301807	ENSG00000232912.4	RP5-1115A15.1	8.71	4.91e-17	6.1e-14	0.34	0.37	Vitiligo;	chr1:8424763	chr1:8424645~8434838:+
LUAD	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-8.71	4.91e-17	6.11e-14	-0.44	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
LUAD	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-8.71	4.96e-17	6.16e-14	-0.44	-0.37	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
LUAD	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-8.71	4.98e-17	6.19e-14	-0.37	-0.37	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
LUAD	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-8.71	4.99e-17	6.21e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	8.71	5.01e-17	6.23e-14	0.43	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
LUAD	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-8.71	5.04e-17	6.26e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
LUAD	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-8.71	5.04e-17	6.26e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
LUAD	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-8.71	5.04e-17	6.26e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
LUAD	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-8.71	5.04e-17	6.26e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
LUAD	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-8.71	5.04e-17	6.26e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
LUAD	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-8.71	5.09e-17	6.32e-14	-0.37	-0.37	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
LUAD	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-8.71	5.09e-17	6.33e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-8.7	5.13e-17	6.37e-14	-0.43	-0.37	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
LUAD	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-8.7	5.14e-17	6.38e-14	-0.41	-0.37	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
LUAD	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-8.7	5.15e-17	6.4e-14	-0.45	-0.37	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
LUAD	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	8.7	5.3e-17	6.57e-14	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
LUAD	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-8.7	5.33e-17	6.61e-14	-0.42	-0.37	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
LUAD	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	8.7	5.34e-17	6.62e-14	0.45	0.37	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
LUAD	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-8.7	5.35e-17	6.63e-14	-0.52	-0.37	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
LUAD	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-8.7	5.37e-17	6.65e-14	-0.84	-0.37	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
LUAD	cis	rs944289	0.617	rs1952708	ENSG00000257826.1	RP11-116N8.4	-8.7	5.41e-17	6.7e-14	-0.39	-0.37	Thyroid cancer;	chr14:36113126	chr14:36061026~36067190:-
LUAD	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	8.7	5.41e-17	6.7e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
LUAD	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-8.7	5.41e-17	6.7e-14	-0.51	-0.37	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
LUAD	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-8.7	5.42e-17	6.71e-14	-0.47	-0.37	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
LUAD	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-8.7	5.42e-17	6.72e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
LUAD	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-8.7	5.46e-17	6.76e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
LUAD	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-8.7	5.49e-17	6.8e-14	-0.47	-0.37	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
LUAD	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-8.69	5.51e-17	6.82e-14	-0.45	-0.37	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
LUAD	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-8.69	5.53e-17	6.84e-14	-0.43	-0.37	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
LUAD	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-8.69	5.55e-17	6.87e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-8.69	5.55e-17	6.87e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
LUAD	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-8.69	5.59e-17	6.92e-14	-0.4	-0.37	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-8.69	5.59e-17	6.92e-14	-0.36	-0.37	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
LUAD	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-8.69	5.62e-17	6.95e-14	-0.34	-0.37	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
LUAD	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-8.69	5.62e-17	6.96e-14	-0.42	-0.37	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
LUAD	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	8.69	5.65e-17	6.99e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
LUAD	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	8.69	5.72e-17	7.08e-14	0.38	0.37	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
LUAD	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-8.69	5.75e-17	7.11e-14	-0.4	-0.37	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
LUAD	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-8.69	5.75e-17	7.12e-14	-0.46	-0.37	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
LUAD	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-8.69	5.77e-17	7.14e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
LUAD	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	8.69	5.79e-17	7.17e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
LUAD	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-8.69	5.8e-17	7.18e-14	-0.46	-0.37	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
LUAD	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	8.69	5.84e-17	7.22e-14	0.51	0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
LUAD	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-8.69	5.85e-17	7.24e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
LUAD	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-8.69	5.86e-17	7.24e-14	-0.45	-0.37	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
LUAD	cis	rs944289	0.646	rs8007617	ENSG00000257826.1	RP11-116N8.4	-8.69	5.87e-17	7.26e-14	-0.38	-0.37	Thyroid cancer;	chr14:36088883	chr14:36061026~36067190:-
LUAD	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
LUAD	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	8.69	5.92e-17	7.32e-14	0.39	0.37	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
LUAD	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-8.68	5.95e-17	7.34e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
LUAD	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	8.68	5.96e-17	7.35e-14	0.36	0.37	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
LUAD	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	8.68	6.02e-17	7.44e-14	0.45	0.37	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
LUAD	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	8.68	6.07e-17	7.49e-14	0.44	0.37	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
LUAD	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-8.68	6.12e-17	7.55e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-8.68	6.15e-17	7.59e-14	-0.42	-0.37	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
LUAD	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-8.68	6.15e-17	7.59e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
LUAD	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	8.68	6.16e-17	7.6e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	8.68	6.16e-17	7.6e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
LUAD	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-8.68	6.21e-17	7.66e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
LUAD	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-8.68	6.28e-17	7.73e-14	-0.41	-0.37	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
LUAD	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	8.68	6.28e-17	7.74e-14	0.43	0.37	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
LUAD	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
LUAD	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-8.68	6.31e-17	7.77e-14	-0.47	-0.37	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
LUAD	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-8.68	6.31e-17	7.78e-14	-0.43	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
LUAD	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	8.68	6.36e-17	7.83e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
LUAD	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	8.68	6.37e-17	7.84e-14	0.39	0.37	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
LUAD	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	8.67	6.42e-17	7.9e-14	0.48	0.37	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
LUAD	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-8.67	6.48e-17	7.98e-14	-0.35	-0.37	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
LUAD	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-8.67	6.51e-17	8.01e-14	-0.53	-0.37	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
LUAD	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-8.67	6.53e-17	8.04e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-8.67	6.53e-17	8.04e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-8.67	6.53e-17	8.04e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-8.67	6.53e-17	8.04e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
LUAD	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-8.67	6.55e-17	8.05e-14	-0.51	-0.37	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	8.67	6.6e-17	8.11e-14	0.52	0.37	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
LUAD	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-8.67	6.6e-17	8.12e-14	-0.45	-0.37	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-8.67	6.62e-17	8.14e-14	-0.44	-0.37	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-8.67	6.62e-17	8.14e-14	-0.44	-0.37	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-8.67	6.62e-17	8.15e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	8.67	6.64e-17	8.16e-14	0.36	0.37	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
LUAD	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-8.67	6.72e-17	8.26e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
LUAD	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	8.67	6.73e-17	8.27e-14	0.49	0.37	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
LUAD	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-8.67	6.78e-17	8.32e-14	-0.42	-0.37	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-8.67	6.78e-17	8.32e-14	-0.42	-0.37	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-8.67	6.78e-17	8.32e-14	-0.42	-0.37	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-8.67	6.78e-17	8.32e-14	-0.42	-0.37	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	8.67	6.79e-17	8.34e-14	0.36	0.37	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	8.67	6.79e-17	8.34e-14	0.36	0.37	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
LUAD	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-8.67	6.84e-17	8.4e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
LUAD	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-8.67	6.9e-17	8.47e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
LUAD	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-8.67	6.9e-17	8.47e-14	-0.31	-0.37	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	8.66	6.92e-17	8.49e-14	0.43	0.37	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
LUAD	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-8.66	6.93e-17	8.5e-14	-0.38	-0.37	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
LUAD	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-8.66	6.94e-17	8.52e-14	-0.37	-0.37	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-8.66	6.95e-17	8.52e-14	-0.29	-0.37	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
LUAD	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-8.66	7.01e-17	8.6e-14	-0.38	-0.37	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
LUAD	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-8.66	7.04e-17	8.63e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-8.66	7.1e-17	8.7e-14	-0.43	-0.37	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
LUAD	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	8.66	7.1e-17	8.71e-14	0.43	0.37	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
LUAD	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	8.66	7.11e-17	8.72e-14	0.44	0.37	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
LUAD	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	8.66	7.17e-17	8.78e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
LUAD	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	8.66	7.26e-17	8.89e-14	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
LUAD	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-8.66	7.39e-17	9.05e-14	-0.44	-0.37	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
LUAD	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	8.66	7.42e-17	9.08e-14	0.44	0.37	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
LUAD	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-8.66	7.44e-17	9.11e-14	-0.39	-0.37	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
LUAD	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-8.65	7.49e-17	9.16e-14	-0.42	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
LUAD	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	8.65	7.5e-17	9.18e-14	0.56	0.37	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
LUAD	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.55e-17	9.23e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
LUAD	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-8.65	7.56e-17	9.25e-14	-0.52	-0.37	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
LUAD	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	8.65	7.6e-17	9.29e-14	0.44	0.37	Depression;	chr6:28240757	chr6:28176188~28176674:+
LUAD	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-8.65	7.6e-17	9.29e-14	-0.45	-0.37	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
LUAD	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	8.65	7.67e-17	9.38e-14	0.44	0.37	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
LUAD	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
LUAD	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-8.65	7.76e-17	9.48e-14	-0.45	-0.37	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
LUAD	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-8.65	7.76e-17	9.48e-14	-0.45	-0.37	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
LUAD	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-8.65	7.78e-17	9.5e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
LUAD	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-8.65	7.8e-17	9.52e-14	-0.47	-0.37	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
LUAD	cis	rs13423976	0.6	rs35776111	ENSG00000231367.4	AC016995.3	8.65	7.83e-17	9.56e-14	0.48	0.37	Gut microbiome composition (summer);	chr2:38515087	chr2:38406719~38515740:-
LUAD	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	8.65	7.87e-17	9.61e-14	0.42	0.37	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
LUAD	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-8.65	7.89e-17	9.63e-14	-0.58	-0.37	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
LUAD	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-8.65	7.91e-17	9.66e-14	-0.38	-0.37	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	8.65	7.95e-17	9.71e-14	0.38	0.37	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	8.65	7.96e-17	9.71e-14	0.37	0.37	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
LUAD	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	8.65	8e-17	9.76e-14	0.43	0.37	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
LUAD	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-8.65	8.03e-17	9.8e-14	-0.37	-0.37	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
LUAD	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-8.64	8.07e-17	9.84e-14	-0.41	-0.37	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
LUAD	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-8.64	8.11e-17	9.89e-14	-0.38	-0.37	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
LUAD	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-8.64	8.14e-17	9.93e-14	-0.39	-0.37	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
LUAD	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	8.64	8.2e-17	9.99e-14	0.55	0.37	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
LUAD	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	8.64	8.2e-17	1e-13	0.51	0.37	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-8.64	8.21e-17	1e-13	-0.31	-0.37	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
LUAD	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	8.64	8.22e-17	1e-13	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
LUAD	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-8.64	8.24e-17	1e-13	-0.44	-0.37	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
LUAD	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-8.64	8.25e-17	1.01e-13	-0.47	-0.37	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	8.64	8.29e-17	1.01e-13	0.31	0.37	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
LUAD	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-8.64	8.34e-17	1.02e-13	-0.41	-0.37	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
LUAD	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	8.64	8.37e-17	1.02e-13	0.34	0.37	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	8.64	8.37e-17	1.02e-13	0.43	0.37	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
LUAD	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-8.64	8.43e-17	1.03e-13	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
LUAD	cis	rs7924176	0.668	rs7895133	ENSG00000213731.2	RAB5CP1	-8.64	8.51e-17	1.04e-13	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74247697	chr10:74423435~74424014:-
LUAD	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-8.64	8.52e-17	1.04e-13	-0.52	-0.37	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
LUAD	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	8.64	8.53e-17	1.04e-13	0.46	0.37	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
LUAD	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	8.64	8.6e-17	1.05e-13	0.42	0.37	Height;	chr11:118703207	chr11:118688039~118690600:-
LUAD	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-8.64	8.6e-17	1.05e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
LUAD	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-8.64	8.64e-17	1.05e-13	-0.46	-0.37	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
LUAD	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	8.64	8.66e-17	1.05e-13	0.43	0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
LUAD	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	8.64	8.67e-17	1.05e-13	0.41	0.37	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
LUAD	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-8.63	8.75e-17	1.06e-13	-0.43	-0.37	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
LUAD	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-8.63	8.75e-17	1.06e-13	-0.39	-0.37	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
LUAD	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-8.63	8.75e-17	1.06e-13	-0.46	-0.37	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
LUAD	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-8.63	8.75e-17	1.06e-13	-0.46	-0.37	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
LUAD	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-8.63	8.75e-17	1.06e-13	-0.46	-0.37	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	8.63	8.81e-17	1.07e-13	0.36	0.37	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
LUAD	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-8.63	8.82e-17	1.07e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-8.63	8.82e-17	1.07e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
LUAD	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	8.63	8.83e-17	1.07e-13	0.42	0.37	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-8.63	8.85e-17	1.07e-13	-0.29	-0.37	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
LUAD	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	8.63	8.87e-17	1.08e-13	0.32	0.37	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
LUAD	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-8.63	8.92e-17	1.08e-13	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
LUAD	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-8.63	8.93e-17	1.08e-13	-0.44	-0.37	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
LUAD	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	8.63	8.95e-17	1.09e-13	0.33	0.37	Asthma;	chr2:102440033	chr2:102438713~102440475:+
LUAD	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
LUAD	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-8.63	8.98e-17	1.09e-13	-0.42	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
LUAD	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	8.63	8.98e-17	1.09e-13	0.48	0.37	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
LUAD	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	8.63	8.98e-17	1.09e-13	0.48	0.37	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
LUAD	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-8.63	8.99e-17	1.09e-13	-0.45	-0.37	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
LUAD	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-8.63	9.09e-17	1.1e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	8.63	9.12e-17	1.11e-13	0.25	0.37	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
LUAD	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	8.63	9.18e-17	1.11e-13	0.48	0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
LUAD	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	8.63	9.18e-17	1.11e-13	0.43	0.37	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
LUAD	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-8.63	9.19e-17	1.11e-13	-0.4	-0.37	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-8.63	9.26e-17	1.12e-13	-0.39	-0.37	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
LUAD	cis	rs2337406	0.925	rs11851094	ENSG00000254174.1	IGHV1-12	8.63	9.31e-17	1.13e-13	0.33	0.37	Alzheimer's disease (late onset);	chr14:106688967	chr14:106122420~106122709:-
LUAD	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-8.63	9.34e-17	1.13e-13	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
LUAD	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-8.62	9.4e-17	1.14e-13	-0.42	-0.37	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
LUAD	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-8.62	9.43e-17	1.14e-13	-0.36	-0.37	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
LUAD	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-8.62	9.52e-17	1.15e-13	-0.38	-0.37	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
LUAD	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	8.62	9.55e-17	1.16e-13	0.43	0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
LUAD	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	8.62	9.57e-17	1.16e-13	0.43	0.37	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
LUAD	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	8.62	9.66e-17	1.17e-13	0.43	0.37	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
LUAD	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	8.62	9.66e-17	1.17e-13	0.52	0.37	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
LUAD	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-8.62	9.71e-17	1.17e-13	-0.45	-0.37	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
LUAD	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	8.62	9.8e-17	1.18e-13	0.43	0.37	Height;	chr11:118747911	chr11:118688039~118690600:-
LUAD	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-8.62	1e-16	1.21e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
LUAD	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	8.62	1e-16	1.21e-13	0.46	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
LUAD	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-8.61	1.02e-16	1.23e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
LUAD	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-8.61	1.02e-16	1.23e-13	-0.52	-0.37	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	8.61	1.02e-16	1.23e-13	0.36	0.37	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
LUAD	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-8.61	1.03e-16	1.24e-13	-0.45	-0.37	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
LUAD	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	8.61	1.03e-16	1.25e-13	0.42	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
LUAD	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-8.61	1.03e-16	1.25e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
LUAD	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	8.61	1.03e-16	1.25e-13	0.5	0.37	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
LUAD	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-8.61	1.03e-16	1.25e-13	-0.46	-0.37	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
LUAD	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	8.61	1.04e-16	1.25e-13	0.42	0.37	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
LUAD	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-8.61	1.04e-16	1.25e-13	-0.52	-0.37	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
LUAD	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-8.61	1.04e-16	1.26e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
LUAD	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-8.61	1.05e-16	1.26e-13	-0.57	-0.37	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
LUAD	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	8.61	1.06e-16	1.27e-13	0.42	0.37	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
LUAD	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	8.61	1.06e-16	1.27e-13	0.47	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
LUAD	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	8.61	1.08e-16	1.3e-13	0.44	0.37	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
LUAD	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	8.61	1.08e-16	1.3e-13	0.52	0.37	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	8.61	1.08e-16	1.3e-13	0.43	0.37	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
LUAD	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102379885	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102381261	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102381819	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102382514	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102382943	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102388870	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102389644	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102389988	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	8.61	1.09e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
LUAD	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-8.61	1.09e-16	1.31e-13	-0.45	-0.37	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-8.61	1.09e-16	1.31e-13	-0.45	-0.37	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-8.6	1.1e-16	1.33e-13	-0.51	-0.37	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-8.6	1.1e-16	1.33e-13	-0.51	-0.37	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	8.6	1.11e-16	1.33e-13	0.27	0.37	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
LUAD	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-8.6	1.11e-16	1.33e-13	-0.47	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
LUAD	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-8.6	1.11e-16	1.34e-13	-0.45	-0.37	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
LUAD	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-8.6	1.11e-16	1.34e-13	-0.45	-0.37	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
LUAD	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	8.6	1.11e-16	1.34e-13	0.47	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
LUAD	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	8.6	1.12e-16	1.35e-13	0.4	0.37	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
LUAD	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
LUAD	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-8.6	1.13e-16	1.36e-13	-0.43	-0.37	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
LUAD	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-8.6	1.14e-16	1.36e-13	-0.42	-0.37	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	8.6	1.14e-16	1.37e-13	0.43	0.37	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
LUAD	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-8.6	1.14e-16	1.37e-13	-0.4	-0.37	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
LUAD	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-8.6	1.14e-16	1.37e-13	-0.47	-0.37	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
LUAD	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	8.6	1.15e-16	1.38e-13	0.45	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
LUAD	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-8.6	1.15e-16	1.38e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
LUAD	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	8.6	1.15e-16	1.38e-13	0.54	0.36	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
LUAD	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	8.6	1.15e-16	1.38e-13	0.42	0.36	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
LUAD	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	8.6	1.15e-16	1.38e-13	0.44	0.36	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	8.6	1.15e-16	1.38e-13	0.44	0.36	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	8.6	1.15e-16	1.38e-13	0.44	0.36	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
LUAD	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-8.6	1.16e-16	1.39e-13	-0.38	-0.36	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-8.6	1.16e-16	1.39e-13	-0.38	-0.36	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
LUAD	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	8.6	1.16e-16	1.39e-13	0.45	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	8.6	1.16e-16	1.39e-13	0.45	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
LUAD	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	8.6	1.16e-16	1.4e-13	0.43	0.36	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	8.6	1.17e-16	1.4e-13	0.44	0.36	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
LUAD	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-8.6	1.17e-16	1.41e-13	-0.41	-0.36	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	8.59	1.18e-16	1.41e-13	0.29	0.36	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
LUAD	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-8.59	1.18e-16	1.42e-13	-0.41	-0.36	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
LUAD	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-8.59	1.19e-16	1.42e-13	-0.45	-0.36	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
LUAD	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-8.59	1.2e-16	1.43e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
LUAD	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	8.59	1.2e-16	1.43e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
LUAD	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-8.59	1.2e-16	1.43e-13	-0.5	-0.36	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
LUAD	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-8.59	1.2e-16	1.44e-13	-0.4	-0.36	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
LUAD	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-8.59	1.21e-16	1.45e-13	-0.4	-0.36	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
LUAD	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-8.59	1.21e-16	1.45e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
LUAD	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	8.59	1.21e-16	1.45e-13	0.43	0.36	Height;	chr11:118746590	chr11:118688039~118690600:-
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000223648.3	IGHV3-64	8.59	1.22e-16	1.46e-13	0.37	0.36	Kawasaki disease;	chr14:106705271	chr14:106643132~106658258:-
LUAD	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-8.59	1.23e-16	1.48e-13	-0.43	-0.36	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-8.59	1.23e-16	1.48e-13	-0.43	-0.36	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
LUAD	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	8.59	1.23e-16	1.48e-13	0.46	0.36	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
LUAD	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	8.59	1.24e-16	1.48e-13	0.5	0.36	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
LUAD	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	8.59	1.24e-16	1.48e-13	0.43	0.36	Height;	chr11:118742526	chr11:118688039~118690600:-
LUAD	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-8.59	1.24e-16	1.48e-13	-0.38	-0.36	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
LUAD	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-8.59	1.25e-16	1.49e-13	-0.45	-0.36	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-8.59	1.26e-16	1.5e-13	-0.43	-0.36	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
LUAD	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-8.59	1.26e-16	1.5e-13	-0.45	-0.36	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-8.59	1.26e-16	1.5e-13	-0.45	-0.36	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-8.59	1.27e-16	1.51e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000223648.3	IGHV3-64	8.59	1.27e-16	1.51e-13	0.37	0.36	Kawasaki disease;	chr14:106705441	chr14:106643132~106658258:-
LUAD	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	8.58	1.27e-16	1.52e-13	0.7	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
LUAD	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	8.58	1.27e-16	1.52e-13	0.51	0.36	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
LUAD	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-8.58	1.28e-16	1.52e-13	-0.48	-0.36	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
LUAD	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	8.58	1.28e-16	1.53e-13	0.45	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
LUAD	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-8.58	1.29e-16	1.54e-13	-0.39	-0.36	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	8.58	1.29e-16	1.54e-13	0.42	0.36	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	8.58	1.29e-16	1.54e-13	0.42	0.36	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	8.58	1.29e-16	1.54e-13	0.42	0.36	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	8.58	1.29e-16	1.54e-13	0.42	0.36	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
LUAD	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	8.58	1.29e-16	1.54e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
LUAD	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	8.58	1.3e-16	1.55e-13	0.57	0.36	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
LUAD	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-8.58	1.3e-16	1.55e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
LUAD	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	8.58	1.31e-16	1.56e-13	0.48	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
LUAD	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	8.58	1.33e-16	1.59e-13	0.4	0.36	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
LUAD	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	8.58	1.33e-16	1.59e-13	0.44	0.36	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	8.58	1.33e-16	1.59e-13	0.44	0.36	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	8.58	1.33e-16	1.59e-13	0.44	0.36	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
LUAD	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	8.58	1.34e-16	1.6e-13	0.45	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
LUAD	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-8.58	1.35e-16	1.6e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-8.58	1.35e-16	1.61e-13	-0.29	-0.36	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
LUAD	cis	rs944289	0.646	rs8003253	ENSG00000257826.1	RP11-116N8.4	-8.58	1.35e-16	1.61e-13	-0.38	-0.36	Thyroid cancer;	chr14:36088485	chr14:36061026~36067190:-
LUAD	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-8.58	1.36e-16	1.62e-13	-0.4	-0.36	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
LUAD	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-8.58	1.36e-16	1.62e-13	-0.49	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-8.58	1.36e-16	1.62e-13	-0.49	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000223648.3	IGHV3-64	8.57	1.37e-16	1.63e-13	0.37	0.36	Kawasaki disease;	chr14:106708947	chr14:106643132~106658258:-
LUAD	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
LUAD	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	8.57	1.38e-16	1.64e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	8.57	1.38e-16	1.64e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	8.57	1.38e-16	1.64e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
LUAD	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	8.57	1.38e-16	1.64e-13	0.48	0.36	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
LUAD	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-8.57	1.38e-16	1.65e-13	-0.4	-0.36	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
LUAD	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-8.57	1.39e-16	1.66e-13	-0.38	-0.36	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
LUAD	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-8.57	1.4e-16	1.66e-13	-0.44	-0.36	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
LUAD	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-8.57	1.4e-16	1.66e-13	-0.57	-0.36	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
LUAD	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	8.57	1.4e-16	1.66e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
LUAD	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	8.57	1.41e-16	1.67e-13	0.42	0.36	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
LUAD	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-8.57	1.41e-16	1.68e-13	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000254174.1	IGHV1-12	8.57	1.42e-16	1.69e-13	0.32	0.36	Alzheimer's disease (late onset);	chr14:106781132	chr14:106122420~106122709:-
LUAD	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-8.57	1.42e-16	1.69e-13	-0.48	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
LUAD	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	8.57	1.43e-16	1.69e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.502	rs12784355	ENSG00000213731.2	RAB5CP1	-8.57	1.44e-16	1.71e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74423435~74424014:-
LUAD	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	8.57	1.44e-16	1.71e-13	0.55	0.36	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
LUAD	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	8.57	1.45e-16	1.72e-13	0.42	0.36	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	8.57	1.45e-16	1.72e-13	0.42	0.36	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
LUAD	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	8.57	1.45e-16	1.72e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
LUAD	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	8.57	1.45e-16	1.72e-13	0.43	0.36	Height;	chr11:118749988	chr11:118688039~118690600:-
LUAD	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	8.57	1.45e-16	1.72e-13	0.37	0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
LUAD	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	8.57	1.45e-16	1.72e-13	0.4	0.36	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
LUAD	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	8.57	1.46e-16	1.73e-13	0.42	0.36	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
LUAD	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	8.57	1.47e-16	1.74e-13	0.43	0.36	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
LUAD	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	8.57	1.47e-16	1.74e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	8.57	1.47e-16	1.74e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	8.57	1.47e-16	1.74e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
LUAD	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	8.56	1.48e-16	1.75e-13	0.38	0.36	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	8.56	1.48e-16	1.75e-13	0.38	0.36	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000254174.1	IGHV1-12	8.56	1.49e-16	1.77e-13	0.34	0.36	Alzheimer's disease (late onset);	chr14:106680831	chr14:106122420~106122709:-
LUAD	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
LUAD	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
LUAD	cis	rs13423976	0.546	rs10184164	ENSG00000231367.4	AC016995.3	8.56	1.51e-16	1.78e-13	0.47	0.36	Gut microbiome composition (summer);	chr2:38514411	chr2:38406719~38515740:-
LUAD	cis	rs13423976	0.586	rs12617556	ENSG00000231367.4	AC016995.3	8.56	1.51e-16	1.78e-13	0.47	0.36	Gut microbiome composition (summer);	chr2:38514972	chr2:38406719~38515740:-
LUAD	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	8.56	1.51e-16	1.78e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
LUAD	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-8.56	1.51e-16	1.79e-13	-0.42	-0.36	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
LUAD	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-8.56	1.51e-16	1.79e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
LUAD	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	8.56	1.52e-16	1.79e-13	0.48	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
LUAD	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	8.56	1.54e-16	1.82e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
LUAD	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-8.56	1.55e-16	1.83e-13	-0.35	-0.36	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
LUAD	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-8.56	1.55e-16	1.84e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
LUAD	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-8.56	1.55e-16	1.84e-13	-0.5	-0.36	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
LUAD	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	8.56	1.56e-16	1.84e-13	0.69	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
LUAD	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-8.56	1.56e-16	1.84e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-8.56	1.56e-16	1.84e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
LUAD	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-8.56	1.56e-16	1.85e-13	-0.44	-0.36	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-8.56	1.57e-16	1.85e-13	-0.29	-0.36	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
LUAD	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	8.56	1.57e-16	1.85e-13	0.36	0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-8.56	1.57e-16	1.86e-13	-0.38	-0.36	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
LUAD	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	8.56	1.58e-16	1.86e-13	0.44	0.36	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
LUAD	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-8.55	1.6e-16	1.89e-13	-0.53	-0.36	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
LUAD	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	8.55	1.61e-16	1.9e-13	0.49	0.36	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.601	rs10824073	ENSG00000213731.2	RAB5CP1	-8.55	1.62e-16	1.91e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74423435~74424014:-
LUAD	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-8.55	1.63e-16	1.92e-13	-0.43	-0.36	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
LUAD	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-8.55	1.63e-16	1.92e-13	-0.43	-0.36	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
LUAD	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-8.55	1.63e-16	1.93e-13	-0.47	-0.36	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
LUAD	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-8.55	1.64e-16	1.93e-13	-0.56	-0.36	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
LUAD	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-8.55	1.64e-16	1.94e-13	-0.42	-0.36	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
LUAD	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-8.55	1.64e-16	1.94e-13	-0.53	-0.36	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
LUAD	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-8.55	1.65e-16	1.94e-13	-0.44	-0.36	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
LUAD	cis	rs4908760	0.773	rs301805	ENSG00000232912.4	RP5-1115A15.1	8.55	1.65e-16	1.95e-13	0.33	0.36	Vitiligo;	chr1:8420956	chr1:8424645~8434838:+
LUAD	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	8.55	1.65e-16	1.95e-13	0.4	0.36	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	8.55	1.65e-16	1.95e-13	0.4	0.36	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
LUAD	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-8.55	1.67e-16	1.97e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
LUAD	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-8.55	1.67e-16	1.97e-13	-0.36	-0.36	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
LUAD	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-8.55	1.67e-16	1.97e-13	-0.48	-0.36	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
LUAD	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	8.55	1.68e-16	1.97e-13	0.42	0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
LUAD	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	8.55	1.68e-16	1.98e-13	0.42	0.36	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
LUAD	cis	rs944289	0.615	rs1333312	ENSG00000257826.1	RP11-116N8.4	-8.55	1.68e-16	1.98e-13	-0.38	-0.36	Thyroid cancer;	chr14:36093396	chr14:36061026~36067190:-
LUAD	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-8.55	1.69e-16	1.98e-13	-0.38	-0.36	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
LUAD	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-8.55	1.71e-16	2.01e-13	-0.39	-0.36	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
LUAD	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-8.54	1.71e-16	2.02e-13	-0.42	-0.36	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
LUAD	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	8.54	1.72e-16	2.02e-13	0.48	0.36	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
LUAD	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	8.54	1.73e-16	2.03e-13	0.4	0.36	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
LUAD	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	8.54	1.73e-16	2.03e-13	0.43	0.36	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	8.54	1.73e-16	2.03e-13	0.43	0.36	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	8.54	1.73e-16	2.03e-13	0.43	0.36	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
LUAD	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-8.54	1.74e-16	2.05e-13	-0.39	-0.36	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
LUAD	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-8.54	1.75e-16	2.06e-13	-0.37	-0.36	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
LUAD	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	8.54	1.75e-16	2.06e-13	0.43	0.36	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	8.54	1.75e-16	2.06e-13	0.43	0.36	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
LUAD	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-8.54	1.76e-16	2.07e-13	-0.33	-0.36	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
LUAD	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-8.54	1.76e-16	2.07e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
LUAD	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	8.54	1.78e-16	2.09e-13	0.41	0.36	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	8.54	1.78e-16	2.1e-13	0.37	0.36	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
LUAD	cis	rs944289	0.646	rs8008989	ENSG00000257826.1	RP11-116N8.4	-8.54	1.79e-16	2.1e-13	-0.38	-0.36	Thyroid cancer;	chr14:36088871	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs404131	ENSG00000257826.1	RP11-116N8.4	8.54	1.8e-16	2.12e-13	0.38	0.36	Thyroid cancer;	chr14:36075287	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000280411.1	IGHV1-69-2	-8.54	1.82e-16	2.14e-13	-0.28	-0.36	Kawasaki disease;	chr14:106649820	chr14:106762092~106762588:-
LUAD	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	8.54	1.83e-16	2.15e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
LUAD	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	8.54	1.84e-16	2.16e-13	0.46	0.36	Height;	chr6:109407238	chr6:109382795~109383666:+
LUAD	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.16e-13	0.38	0.36	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
LUAD	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	8.54	1.84e-16	2.16e-13	0.43	0.36	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.617	rs11156905	ENSG00000257826.1	RP11-116N8.4	-8.54	1.84e-16	2.16e-13	-0.38	-0.36	Thyroid cancer;	chr14:36100314	chr14:36061026~36067190:-
LUAD	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	8.54	1.85e-16	2.17e-13	0.39	0.36	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	8.53	1.85e-16	2.17e-13	0.39	0.36	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
LUAD	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-8.53	1.85e-16	2.17e-13	-0.36	-0.36	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
LUAD	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	8.53	1.86e-16	2.18e-13	0.54	0.36	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
LUAD	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	8.53	1.86e-16	2.18e-13	0.54	0.36	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-8.53	1.86e-16	2.18e-13	-0.29	-0.36	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
LUAD	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-8.53	1.87e-16	2.19e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-8.53	1.88e-16	2.2e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
LUAD	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-8.53	1.89e-16	2.22e-13	-0.46	-0.36	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
LUAD	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	8.53	1.9e-16	2.22e-13	0.33	0.36	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
LUAD	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-8.53	1.9e-16	2.23e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
LUAD	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	8.53	1.9e-16	2.23e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
LUAD	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	8.53	1.92e-16	2.25e-13	0.33	0.36	Asthma;	chr2:102399227	chr2:102438713~102440475:+
LUAD	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	8.53	1.92e-16	2.25e-13	0.42	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
LUAD	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-8.53	1.92e-16	2.25e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-8.53	1.92e-16	2.25e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-8.53	1.92e-16	2.25e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
LUAD	cis	rs7924176	0.601	rs17676126	ENSG00000213731.2	RAB5CP1	-8.53	1.93e-16	2.26e-13	-0.39	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74145440	chr10:74423435~74424014:-
LUAD	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	8.53	1.93e-16	2.26e-13	0.33	0.36	Asthma;	chr2:102402540	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	8.53	1.93e-16	2.26e-13	0.33	0.36	Asthma;	chr2:102402571	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	8.53	1.93e-16	2.26e-13	0.33	0.36	Asthma;	chr2:102403325	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	8.53	1.93e-16	2.26e-13	0.33	0.36	Asthma;	chr2:102403679	chr2:102438713~102440475:+
LUAD	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-8.53	1.93e-16	2.26e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
LUAD	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	8.53	1.94e-16	2.27e-13	0.55	0.36	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
LUAD	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-8.53	1.96e-16	2.29e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	8.53	1.96e-16	2.29e-13	0.37	0.36	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
LUAD	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-8.53	1.96e-16	2.29e-13	-0.4	-0.36	Temperament;	chr17:14046511	chr17:14024514~14025488:+
LUAD	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-8.53	1.96e-16	2.29e-13	-0.4	-0.36	Temperament;	chr17:14048649	chr17:14024514~14025488:+
LUAD	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-8.53	1.96e-16	2.3e-13	-0.37	-0.36	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
LUAD	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	8.53	1.97e-16	2.3e-13	0.5	0.36	QT interval;	chr16:28860645	chr16:28700294~28701540:-
LUAD	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	8.52	2e-16	2.34e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-8.52	2.01e-16	2.35e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
LUAD	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	8.52	2.02e-16	2.36e-13	0.4	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
LUAD	cis	rs4908760	0.783	rs301799	ENSG00000232912.4	RP5-1115A15.1	8.52	2.03e-16	2.37e-13	0.33	0.36	Vitiligo;	chr1:8429242	chr1:8424645~8434838:+
LUAD	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-8.52	2.03e-16	2.37e-13	-0.42	-0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
LUAD	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-8.52	2.05e-16	2.4e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
LUAD	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	8.52	2.06e-16	2.41e-13	0.33	0.36	Asthma;	chr2:102446466	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	8.52	2.06e-16	2.41e-13	0.33	0.36	Asthma;	chr2:102446780	chr2:102438713~102440475:+
LUAD	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-8.52	2.07e-16	2.42e-13	-0.44	-0.36	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
LUAD	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-8.52	2.07e-16	2.42e-13	-0.46	-0.36	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
LUAD	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-8.52	2.11e-16	2.46e-13	-0.44	-0.36	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	8.52	2.12e-16	2.47e-13	0.51	0.36	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
LUAD	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-8.52	2.12e-16	2.47e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
LUAD	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-8.52	2.13e-16	2.49e-13	-0.33	-0.36	Asthma;	chr2:102377873	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-8.52	2.14e-16	2.5e-13	-0.45	-0.36	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
LUAD	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	8.51	2.15e-16	2.5e-13	0.4	0.36	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
LUAD	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	8.51	2.16e-16	2.52e-13	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
LUAD	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-8.51	2.16e-16	2.52e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
LUAD	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	8.51	2.17e-16	2.53e-13	0.38	0.36	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-8.51	2.17e-16	2.53e-13	-0.48	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
LUAD	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	8.51	2.17e-16	2.53e-13	0.37	0.36	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000223648.3	IGHV3-64	8.51	2.18e-16	2.54e-13	0.37	0.36	Kawasaki disease;	chr14:106705382	chr14:106643132~106658258:-
LUAD	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-8.51	2.18e-16	2.54e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
LUAD	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	8.51	2.19e-16	2.55e-13	0.55	0.36	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	8.51	2.2e-16	2.56e-13	0.42	0.36	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-8.51	2.2e-16	2.57e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
LUAD	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-8.51	2.21e-16	2.57e-13	-0.43	-0.36	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
LUAD	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	8.51	2.22e-16	2.59e-13	0.52	0.36	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-8.51	2.22e-16	2.59e-13	-0.29	-0.36	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
LUAD	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	8.51	2.24e-16	2.61e-13	0.43	0.36	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
LUAD	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	8.51	2.25e-16	2.62e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
LUAD	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-8.51	2.25e-16	2.62e-13	-0.32	-0.36	Asthma;	chr2:102438096	chr2:102438713~102440475:+
LUAD	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	8.51	2.25e-16	2.62e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
LUAD	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-8.51	2.26e-16	2.63e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-8.51	2.26e-16	2.63e-13	-0.28	-0.36	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
LUAD	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-8.51	2.26e-16	2.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
LUAD	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	8.51	2.27e-16	2.64e-13	0.42	0.36	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
LUAD	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-8.51	2.28e-16	2.66e-13	-0.39	-0.36	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
LUAD	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	8.51	2.29e-16	2.66e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
LUAD	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	8.5	2.32e-16	2.7e-13	0.42	0.36	Height;	chr11:118760944	chr11:118688039~118690600:-
LUAD	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	8.5	2.32e-16	2.7e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
LUAD	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	8.5	2.35e-16	2.73e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	8.5	2.35e-16	2.73e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	8.5	2.35e-16	2.73e-13	0.52	0.36	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
LUAD	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	8.5	2.38e-16	2.76e-13	0.33	0.36	Asthma;	chr2:102418659	chr2:102438713~102440475:+
LUAD	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-8.5	2.38e-16	2.76e-13	-0.38	-0.36	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
LUAD	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-8.5	2.38e-16	2.76e-13	-0.45	-0.36	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
LUAD	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-8.5	2.4e-16	2.79e-13	-0.54	-0.36	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
LUAD	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	8.5	2.4e-16	2.79e-13	0.55	0.36	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
LUAD	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	8.5	2.41e-16	2.8e-13	0.46	0.36	Height;	chr6:109374782	chr6:109382795~109383666:+
LUAD	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-8.5	2.42e-16	2.81e-13	-0.85	-0.36	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
LUAD	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	8.5	2.42e-16	2.81e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	8.5	2.42e-16	2.81e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
LUAD	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	8.5	2.42e-16	2.81e-13	0.39	0.36	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
LUAD	cis	rs13423976	0.6	rs2373404	ENSG00000231367.4	AC016995.3	8.5	2.42e-16	2.81e-13	0.47	0.36	Gut microbiome composition (summer);	chr2:38512959	chr2:38406719~38515740:-
LUAD	cis	rs13423976	0.631	rs2373405	ENSG00000231367.4	AC016995.3	8.5	2.42e-16	2.81e-13	0.47	0.36	Gut microbiome composition (summer);	chr2:38513072	chr2:38406719~38515740:-
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-8.5	2.43e-16	2.82e-13	-0.28	-0.36	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
LUAD	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-8.5	2.43e-16	2.82e-13	-0.54	-0.36	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000223648.3	IGHV3-64	8.5	2.44e-16	2.83e-13	0.37	0.36	Kawasaki disease;	chr14:106704386	chr14:106643132~106658258:-
LUAD	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-8.5	2.44e-16	2.83e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
LUAD	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-8.5	2.46e-16	2.85e-13	-0.46	-0.36	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
LUAD	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	8.5	2.49e-16	2.88e-13	0.33	0.36	Asthma;	chr2:102404807	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	8.5	2.49e-16	2.88e-13	0.33	0.36	Asthma;	chr2:102407218	chr2:102438713~102440475:+
LUAD	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-8.49	2.5e-16	2.89e-13	-0.48	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
LUAD	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-8.49	2.5e-16	2.89e-13	-0.39	-0.36	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
LUAD	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-8.49	2.5e-16	2.89e-13	-0.44	-0.36	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
LUAD	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	8.49	2.5e-16	2.89e-13	0.33	0.36	Asthma;	chr2:102394452	chr2:102438713~102440475:+
LUAD	cis	rs7924176	0.601	rs767809	ENSG00000213731.2	RAB5CP1	-8.49	2.52e-16	2.91e-13	-0.39	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74105307	chr10:74423435~74424014:-
LUAD	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	8.49	2.53e-16	2.93e-13	0.46	0.36	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	8.49	2.53e-16	2.93e-13	0.46	0.36	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
LUAD	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	8.49	2.53e-16	2.93e-13	0.34	0.36	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-8.49	2.54e-16	2.94e-13	-0.28	-0.36	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
LUAD	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-8.49	2.56e-16	2.96e-13	-0.28	-0.36	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-8.49	2.56e-16	2.96e-13	-0.28	-0.36	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
LUAD	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	8.49	2.56e-16	2.96e-13	0.52	0.36	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
LUAD	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	8.49	2.57e-16	2.97e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	8.49	2.57e-16	2.97e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	8.49	2.57e-16	2.97e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
LUAD	cis	rs10129255	1	rs10137758	ENSG00000223648.3	IGHV3-64	8.49	2.58e-16	2.98e-13	0.37	0.36	Kawasaki disease;	chr14:106697673	chr14:106643132~106658258:-
LUAD	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	8.49	2.58e-16	2.98e-13	0.4	0.36	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	8.49	2.58e-16	2.98e-13	0.4	0.36	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
LUAD	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	8.49	2.6e-16	3.01e-13	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
LUAD	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-8.49	2.61e-16	3.02e-13	-0.42	-0.36	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
LUAD	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-8.49	2.62e-16	3.03e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	8.49	2.64e-16	3.05e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
LUAD	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	8.48	2.7e-16	3.12e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	8.48	2.7e-16	3.12e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	8.48	2.7e-16	3.12e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	8.48	2.7e-16	3.12e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
LUAD	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-8.48	2.7e-16	3.12e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
LUAD	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	8.48	2.7e-16	3.12e-13	0.42	0.36	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	8.48	2.7e-16	3.12e-13	0.42	0.36	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	8.48	2.7e-16	3.12e-13	0.42	0.36	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	8.48	2.7e-16	3.12e-13	0.42	0.36	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
LUAD	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-8.48	2.72e-16	3.13e-13	-0.31	-0.36	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
LUAD	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	8.48	2.72e-16	3.14e-13	0.41	0.36	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
LUAD	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-8.48	2.72e-16	3.14e-13	-0.37	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
LUAD	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-8.48	2.72e-16	3.14e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
LUAD	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-8.48	2.75e-16	3.17e-13	-0.5	-0.36	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	8.48	2.76e-16	3.18e-13	0.42	0.36	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	8.48	2.76e-16	3.18e-13	0.42	0.36	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
LUAD	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	8.48	2.77e-16	3.19e-13	0.44	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
LUAD	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	8.48	2.77e-16	3.2e-13	0.47	0.36	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
LUAD	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-8.48	2.78e-16	3.2e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
LUAD	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-8.48	2.79e-16	3.21e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
LUAD	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-8.48	2.79e-16	3.22e-13	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	8.48	2.8e-16	3.22e-13	0.35	0.36	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
LUAD	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-8.48	2.81e-16	3.23e-13	-0.4	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-8.48	2.81e-16	3.23e-13	-0.43	-0.36	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-8.48	2.81e-16	3.23e-13	-0.42	-0.36	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
LUAD	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-8.48	2.81e-16	3.24e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
LUAD	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	8.48	2.84e-16	3.26e-13	0.42	0.36	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
LUAD	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.27e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
LUAD	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-8.48	2.86e-16	3.29e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
LUAD	cis	rs11098499	0.913	rs12186259	ENSG00000245958.5	RP11-33B1.1	-8.48	2.89e-16	3.32e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119230884	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-8.48	2.89e-16	3.32e-13	-0.43	-0.36	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
LUAD	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	8.47	2.92e-16	3.35e-13	0.49	0.36	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
LUAD	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	8.47	2.95e-16	3.39e-13	0.43	0.36	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
LUAD	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	8.47	2.98e-16	3.42e-13	0.42	0.36	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	8.47	2.98e-16	3.42e-13	0.42	0.36	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
LUAD	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
LUAD	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
LUAD	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-8.47	3e-16	3.44e-13	-0.5	-0.36	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
LUAD	cis	rs2337406	0.925	rs76288499	ENSG00000254174.1	IGHV1-12	8.47	3.01e-16	3.45e-13	0.34	0.36	Alzheimer's disease (late onset);	chr14:106686309	chr14:106122420~106122709:-
LUAD	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	8.47	3.02e-16	3.46e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
LUAD	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	8.47	3.08e-16	3.53e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
LUAD	cis	rs7924176	0.601	rs7896660	ENSG00000213731.2	RAB5CP1	-8.47	3.09e-16	3.54e-13	-0.39	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74170399	chr10:74423435~74424014:-
LUAD	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-8.47	3.11e-16	3.56e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
LUAD	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	8.46	3.16e-16	3.62e-13	0.53	0.36	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
LUAD	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-8.46	3.16e-16	3.62e-13	-0.47	-0.36	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
LUAD	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.16e-16	3.62e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.16e-16	3.62e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.16e-16	3.62e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.16e-16	3.62e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
LUAD	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-8.46	3.17e-16	3.63e-13	-0.4	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
LUAD	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-8.46	3.18e-16	3.64e-13	-0.54	-0.36	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
LUAD	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-8.46	3.18e-16	3.64e-13	-0.45	-0.36	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
LUAD	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	8.46	3.18e-16	3.64e-13	0.42	0.36	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
LUAD	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-8.46	3.18e-16	3.64e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
LUAD	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	8.46	3.19e-16	3.65e-13	0.54	0.36	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	8.46	3.2e-16	3.66e-13	0.36	0.36	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
LUAD	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	8.46	3.2e-16	3.66e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
LUAD	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	8.46	3.2e-16	3.66e-13	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
LUAD	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-8.46	3.21e-16	3.68e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-8.46	3.21e-16	3.68e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	8.46	3.22e-16	3.68e-13	0.36	0.36	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
LUAD	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	8.46	3.24e-16	3.7e-13	0.62	0.36	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	8.46	3.24e-16	3.7e-13	0.62	0.36	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
LUAD	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-8.46	3.24e-16	3.7e-13	-0.4	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
LUAD	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-8.46	3.25e-16	3.71e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
LUAD	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-8.46	3.28e-16	3.75e-13	-0.4	-0.36	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
LUAD	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-8.46	3.29e-16	3.76e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	8.46	3.3e-16	3.76e-13	0.49	0.36	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.601	rs10824091	ENSG00000213731.2	RAB5CP1	-8.46	3.31e-16	3.78e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74169750	chr10:74423435~74424014:-
LUAD	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-8.46	3.32e-16	3.78e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
LUAD	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-8.45	3.4e-16	3.87e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000223648.3	IGHV3-64	8.45	3.4e-16	3.88e-13	0.36	0.36	Kawasaki disease;	chr14:106716993	chr14:106643132~106658258:-
LUAD	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	8.45	3.44e-16	3.91e-13	0.42	0.36	Height;	chr11:118781100	chr11:118688039~118690600:-
LUAD	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-8.45	3.45e-16	3.93e-13	-0.39	-0.36	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
LUAD	cis	rs2337406	1	rs17095456	ENSG00000254174.1	IGHV1-12	8.45	3.47e-16	3.95e-13	0.34	0.36	Alzheimer's disease (late onset);	chr14:106676559	chr14:106122420~106122709:-
LUAD	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-8.45	3.48e-16	3.96e-13	-0.39	-0.36	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
LUAD	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-8.45	3.48e-16	3.96e-13	-0.39	-0.36	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
LUAD	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-8.45	3.5e-16	3.98e-13	-0.39	-0.36	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
LUAD	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	8.45	3.5e-16	3.99e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
LUAD	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-8.45	3.5e-16	3.99e-13	-0.5	-0.36	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
LUAD	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-8.45	3.55e-16	4.03e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
LUAD	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	8.45	3.56e-16	4.05e-13	0.42	0.36	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
LUAD	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-8.45	3.57e-16	4.06e-13	-0.33	-0.36	Asthma;	chr2:102374909	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	8.45	3.58e-16	4.07e-13	0.32	0.36	Asthma;	chr2:102437614	chr2:102438713~102440475:+
LUAD	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	8.45	3.58e-16	4.07e-13	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
LUAD	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	8.45	3.58e-16	4.07e-13	0.42	0.36	Height;	chr11:118764443	chr11:118688039~118690600:-
LUAD	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-8.45	3.6e-16	4.09e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
LUAD	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-8.45	3.62e-16	4.11e-13	-0.6	-0.36	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000211970.3	IGHV4-61	-8.44	3.63e-16	4.13e-13	-0.29	-0.36	Kawasaki disease;	chr14:106708947	chr14:106639119~106639657:-
LUAD	cis	rs7924176	0.601	rs4638254	ENSG00000213731.2	RAB5CP1	-8.44	3.65e-16	4.15e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74423435~74424014:-
LUAD	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-8.44	3.66e-16	4.16e-13	-0.39	-0.36	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-8.44	3.66e-16	4.16e-13	-0.39	-0.36	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	8.44	3.66e-16	4.16e-13	0.42	0.36	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
LUAD	cis	rs2337406	1	rs3858878	ENSG00000254174.1	IGHV1-12	8.44	3.68e-16	4.18e-13	0.33	0.36	Alzheimer's disease (late onset);	chr14:106688061	chr14:106122420~106122709:-
LUAD	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	8.44	3.69e-16	4.19e-13	0.51	0.36	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000206090.4	AP000350.7	8.44	3.71e-16	4.21e-13	0.4	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23939998~23942798:+
LUAD	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	8.44	3.72e-16	4.22e-13	0.33	0.36	Asthma;	chr2:102374753	chr2:102438713~102440475:+
LUAD	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	8.44	3.72e-16	4.23e-13	0.45	0.36	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
LUAD	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	8.44	3.73e-16	4.24e-13	0.41	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
LUAD	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	8.44	3.77e-16	4.28e-13	0.49	0.36	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-8.44	3.8e-16	4.31e-13	-0.39	-0.36	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
LUAD	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	8.44	3.8e-16	4.32e-13	0.39	0.36	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
LUAD	cis	rs944289	0.74	rs2780302	ENSG00000257826.1	RP11-116N8.4	-8.44	3.81e-16	4.32e-13	-0.38	-0.36	Thyroid cancer;	chr14:36079456	chr14:36061026~36067190:-
LUAD	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	8.44	3.82e-16	4.33e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
LUAD	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-8.44	3.84e-16	4.35e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
LUAD	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	8.44	3.84e-16	4.36e-13	0.34	0.36	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-8.44	3.86e-16	4.37e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
LUAD	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	8.44	3.86e-16	4.38e-13	0.36	0.36	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
LUAD	cis	rs13423976	0.631	rs7582463	ENSG00000231367.4	AC016995.3	-8.44	3.87e-16	4.39e-13	-0.46	-0.36	Gut microbiome composition (summer);	chr2:38511226	chr2:38406719~38515740:-
LUAD	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	8.44	3.88e-16	4.39e-13	0.5	0.36	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	8.44	3.88e-16	4.39e-13	0.5	0.36	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
LUAD	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	8.44	3.88e-16	4.4e-13	0.39	0.36	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	8.44	3.88e-16	4.4e-13	0.39	0.36	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	8.44	3.89e-16	4.4e-13	0.42	0.36	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
LUAD	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	8.43	3.9e-16	4.42e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
LUAD	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	8.43	3.93e-16	4.46e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-8.43	3.94e-16	4.46e-13	-0.28	-0.36	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
LUAD	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-8.43	3.94e-16	4.47e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
LUAD	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-8.43	3.96e-16	4.49e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-8.43	3.96e-16	4.49e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
LUAD	cis	rs9326248	0.861	rs11216172	ENSG00000280143.1	AP000892.6	8.43	3.96e-16	4.49e-13	0.45	0.36	Blood protein levels;	chr11:116879162	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	8.43	3.99e-16	4.51e-13	0.42	0.36	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
LUAD	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
LUAD	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-8.43	4.03e-16	4.56e-13	-0.47	-0.36	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
LUAD	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	8.43	4.04e-16	4.58e-13	0.42	0.36	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	8.43	4.04e-16	4.58e-13	0.42	0.36	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
LUAD	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	8.43	4.05e-16	4.59e-13	0.45	0.36	Height;	chr6:109367528	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	8.43	4.05e-16	4.59e-13	0.45	0.36	Height;	chr6:109368704	chr6:109382795~109383666:+
LUAD	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-8.43	4.06e-16	4.59e-13	-0.51	-0.36	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
LUAD	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	8.43	4.06e-16	4.6e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
LUAD	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	8.43	4.06e-16	4.6e-13	0.54	0.36	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
LUAD	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-8.43	4.07e-16	4.6e-13	-0.47	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
LUAD	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	8.43	4.1e-16	4.63e-13	0.49	0.36	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
LUAD	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-8.43	4.11e-16	4.64e-13	-0.36	-0.36	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
LUAD	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	8.43	4.14e-16	4.68e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
LUAD	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
LUAD	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	8.43	4.16e-16	4.7e-13	0.32	0.36	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
LUAD	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-8.43	4.18e-16	4.72e-13	-0.5	-0.36	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	8.43	4.18e-16	4.72e-13	0.52	0.36	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
LUAD	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-8.43	4.18e-16	4.72e-13	-0.32	-0.36	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
LUAD	cis	rs7924176	0.601	rs11000882	ENSG00000213731.2	RAB5CP1	-8.42	4.22e-16	4.77e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74130145	chr10:74423435~74424014:-
LUAD	cis	rs13423976	0.631	rs4670876	ENSG00000231367.4	AC016995.3	8.42	4.26e-16	4.81e-13	0.46	0.36	Gut microbiome composition (summer);	chr2:38508948	chr2:38406719~38515740:-
LUAD	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	8.42	4.28e-16	4.83e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
LUAD	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
LUAD	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	8.42	4.3e-16	4.85e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
LUAD	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	8.42	4.32e-16	4.88e-13	0.39	0.36	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
LUAD	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	8.42	4.33e-16	4.88e-13	0.59	0.36	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
LUAD	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	8.42	4.33e-16	4.88e-13	0.47	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
LUAD	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	8.42	4.35e-16	4.91e-13	0.5	0.36	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-8.42	4.36e-16	4.91e-13	-0.28	-0.36	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
LUAD	cis	rs7924176	0.601	rs10824071	ENSG00000213731.2	RAB5CP1	-8.42	4.39e-16	4.95e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74113881	chr10:74423435~74424014:-
LUAD	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-8.42	4.43e-16	4.99e-13	-0.37	-0.36	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-8.42	4.43e-16	4.99e-13	-0.37	-0.36	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
LUAD	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	8.42	4.44e-16	5e-13	0.42	0.36	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-8.42	4.44e-16	5e-13	-0.39	-0.36	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	8.42	4.44e-16	5.01e-13	0.42	0.36	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-8.42	4.45e-16	5.02e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-8.42	4.45e-16	5.02e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
LUAD	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	8.42	4.46e-16	5.02e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
LUAD	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	8.42	4.48e-16	5.05e-13	0.37	0.36	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
LUAD	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	8.41	4.56e-16	5.13e-13	0.4	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-8.41	4.56e-16	5.13e-13	-0.28	-0.36	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
LUAD	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-8.41	4.57e-16	5.14e-13	-0.54	-0.36	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-8.41	4.57e-16	5.14e-13	-0.54	-0.36	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-8.41	4.57e-16	5.14e-13	-0.54	-0.36	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
LUAD	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-8.41	4.58e-16	5.15e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
LUAD	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	8.41	4.62e-16	5.19e-13	0.41	0.36	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
LUAD	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-8.41	4.65e-16	5.22e-13	-0.4	-0.36	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	8.41	4.67e-16	5.24e-13	0.42	0.36	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
LUAD	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	8.41	4.67e-16	5.25e-13	0.54	0.36	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
LUAD	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	8.41	4.75e-16	5.33e-13	0.42	0.36	Height;	chr11:118773873	chr11:118688039~118690600:-
LUAD	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	8.41	4.76e-16	5.34e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
LUAD	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	8.41	4.78e-16	5.37e-13	0.56	0.36	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
LUAD	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-8.41	4.79e-16	5.37e-13	-0.44	-0.36	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
LUAD	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	8.41	4.83e-16	5.42e-13	0.45	0.36	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
LUAD	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	8.41	4.85e-16	5.43e-13	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
LUAD	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	8.41	4.85e-16	5.44e-13	0.39	0.36	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	8.41	4.87e-16	5.46e-13	0.42	0.36	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	8.41	4.87e-16	5.46e-13	0.42	0.36	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	8.41	4.87e-16	5.46e-13	0.42	0.36	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
LUAD	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-8.4	4.9e-16	5.49e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
LUAD	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-8.4	4.9e-16	5.49e-13	-0.44	-0.36	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
LUAD	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	8.4	4.99e-16	5.59e-13	0.41	0.36	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
LUAD	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-8.4	5.02e-16	5.62e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000280411.1	IGHV1-69-2	-8.4	5.03e-16	5.63e-13	-0.27	-0.36	Kawasaki disease;	chr14:106637576	chr14:106762092~106762588:-
LUAD	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	8.4	5.05e-16	5.65e-13	0.4	0.36	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
LUAD	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-8.4	5.05e-16	5.65e-13	-0.47	-0.36	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
LUAD	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	8.4	5.06e-16	5.66e-13	0.41	0.36	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
LUAD	cis	rs1322639	0.571	rs13204417	ENSG00000261039.2	RP11-417E7.2	8.4	5.1e-16	5.71e-13	0.46	0.36	Pulse pressure;	chr6:169175260	chr6:169175304~169182740:-
LUAD	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-8.4	5.11e-16	5.71e-13	-0.39	-0.36	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
LUAD	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	8.4	5.11e-16	5.72e-13	0.71	0.36	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000223648.3	IGHV3-64	8.4	5.14e-16	5.75e-13	0.36	0.36	Kawasaki disease;	chr14:106704323	chr14:106643132~106658258:-
LUAD	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-8.4	5.14e-16	5.75e-13	-0.49	-0.36	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-8.4	5.14e-16	5.75e-13	-0.49	-0.36	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
LUAD	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-8.4	5.15e-16	5.75e-13	-0.38	-0.36	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
LUAD	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-8.4	5.16e-16	5.76e-13	-0.49	-0.36	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
LUAD	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	8.4	5.17e-16	5.77e-13	0.41	0.36	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
LUAD	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	8.4	5.17e-16	5.77e-13	0.48	0.36	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
LUAD	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-8.4	5.19e-16	5.79e-13	-0.52	-0.36	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
LUAD	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	8.4	5.22e-16	5.82e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
LUAD	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-8.4	5.23e-16	5.83e-13	-0.39	-0.36	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
LUAD	cis	rs2280018	0.609	rs2941253	ENSG00000260735.1	RP11-72I8.1	-8.39	5.28e-16	5.89e-13	-0.39	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15094411~15109197:+
LUAD	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	8.39	5.31e-16	5.92e-13	0.49	0.36	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
LUAD	cis	rs7924176	0.601	rs3750862	ENSG00000213731.2	RAB5CP1	-8.39	5.33e-16	5.95e-13	-0.39	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74091491	chr10:74423435~74424014:-
LUAD	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	8.39	5.35e-16	5.97e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	8.39	5.35e-16	5.97e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
LUAD	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	8.39	5.36e-16	5.98e-13	0.49	0.36	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
LUAD	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-8.39	5.37e-16	5.99e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
LUAD	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	8.39	5.44e-16	6.06e-13	0.38	0.36	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
LUAD	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	8.39	5.49e-16	6.12e-13	0.37	0.36	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
LUAD	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-8.39	5.51e-16	6.14e-13	-0.39	-0.36	Temperament;	chr17:14013482	chr17:14024514~14025488:+
LUAD	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	8.39	5.54e-16	6.17e-13	0.42	0.36	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
LUAD	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-8.39	5.64e-16	6.28e-13	-0.42	-0.36	Height;	chr11:118758322	chr11:118688039~118690600:-
LUAD	cis	rs35955747	0.633	rs7287937	ENSG00000236132.1	CTA-440B3.1	8.38	5.68e-16	6.32e-13	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31624759	chr22:31816379~31817491:-
LUAD	cis	rs7924176	0.601	rs3180427	ENSG00000213731.2	RAB5CP1	-8.38	5.68e-16	6.32e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74121589	chr10:74423435~74424014:-
LUAD	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-8.38	5.7e-16	6.34e-13	-0.33	-0.36	Asthma;	chr2:102392894	chr2:102438713~102440475:+
LUAD	cis	rs944289	0.74	rs1742869	ENSG00000257826.1	RP11-116N8.4	8.38	5.72e-16	6.36e-13	0.38	0.36	Thyroid cancer;	chr14:36067601	chr14:36061026~36067190:-
LUAD	cis	rs7429990	0.813	rs7627568	ENSG00000229759.1	MRPS18AP1	-8.38	5.73e-16	6.38e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48051562	chr3:48256350~48256938:-
LUAD	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	8.38	5.74e-16	6.38e-13	0.42	0.36	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	8.38	5.76e-16	6.41e-13	0.42	0.36	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
LUAD	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	8.38	5.79e-16	6.44e-13	0.41	0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
LUAD	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	8.38	5.84e-16	6.49e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
LUAD	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-8.38	5.85e-16	6.51e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
LUAD	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-8.38	5.9e-16	6.56e-13	-0.54	-0.36	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
LUAD	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	8.38	5.93e-16	6.59e-13	0.61	0.36	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
LUAD	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-8.38	5.94e-16	6.6e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
LUAD	cis	rs4853012	0.752	rs13413795	ENSG00000257800.1	FNBP1P1	8.38	5.96e-16	6.63e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74120680~74123218:+
LUAD	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	8.38	5.97e-16	6.63e-13	0.45	0.36	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
LUAD	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	8.38	5.97e-16	6.63e-13	0.5	0.36	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
LUAD	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	8.38	5.98e-16	6.64e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
LUAD	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	8.38	5.99e-16	6.65e-13	0.37	0.36	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
LUAD	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	8.38	6.02e-16	6.69e-13	0.48	0.36	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
LUAD	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	8.38	6.03e-16	6.69e-13	0.43	0.36	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	8.38	6.03e-16	6.69e-13	0.43	0.36	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	8.38	6.03e-16	6.69e-13	0.43	0.36	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	8.38	6.03e-16	6.69e-13	0.43	0.36	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
LUAD	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	8.38	6.04e-16	6.7e-13	0.42	0.36	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
LUAD	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	8.37	6.14e-16	6.81e-13	0.39	0.36	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
LUAD	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	8.37	6.25e-16	6.93e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
LUAD	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-8.37	6.29e-16	6.97e-13	-0.43	-0.36	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
LUAD	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	8.37	6.29e-16	6.97e-13	0.51	0.36	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
LUAD	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	8.37	6.3e-16	6.98e-13	0.39	0.36	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
LUAD	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-8.37	6.31e-16	7e-13	-0.47	-0.36	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
LUAD	cis	rs35955747	0.659	rs11704494	ENSG00000236132.1	CTA-440B3.1	8.37	6.35e-16	7.04e-13	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31517285	chr22:31816379~31817491:-
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-8.37	6.35e-16	7.04e-13	-0.42	-0.36	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
LUAD	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-8.37	6.35e-16	7.04e-13	-0.42	-0.36	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
LUAD	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	8.37	6.38e-16	7.07e-13	0.47	0.36	Myopia;	chr6:28302807	chr6:28943877~28944537:+
LUAD	cis	rs4273100	1	rs16960499	ENSG00000262319.1	CTC-457L16.2	-8.37	6.39e-16	7.08e-13	-0.5	-0.36	Schizophrenia;	chr17:19299719	chr17:19141017~19143689:-
LUAD	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-8.37	6.41e-16	7.1e-13	-0.39	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
LUAD	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-8.37	6.42e-16	7.11e-13	-0.32	-0.36	Asthma;	chr2:102401592	chr2:102438713~102440475:+
LUAD	cis	rs944289	0.718	rs12878623	ENSG00000257826.1	RP11-116N8.4	-8.37	6.43e-16	7.12e-13	-0.38	-0.36	Thyroid cancer;	chr14:36081499	chr14:36061026~36067190:-
LUAD	cis	rs2337406	1	rs4774173	ENSG00000254174.1	IGHV1-12	8.37	6.43e-16	7.12e-13	0.32	0.36	Alzheimer's disease (late onset);	chr14:106682029	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-8.37	6.43e-16	7.12e-13	-0.28	-0.36	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
LUAD	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	8.37	6.46e-16	7.15e-13	0.82	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
LUAD	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	8.37	6.48e-16	7.18e-13	0.4	0.36	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
LUAD	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	8.37	6.49e-16	7.18e-13	0.47	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
LUAD	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	8.37	6.5e-16	7.2e-13	0.6	0.36	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
LUAD	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	8.37	6.5e-16	7.2e-13	0.42	0.36	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
LUAD	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-8.36	6.56e-16	7.26e-13	-0.47	-0.36	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
LUAD	cis	rs35955747	0.633	rs4541328	ENSG00000236132.1	CTA-440B3.1	8.36	6.59e-16	7.29e-13	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31500186	chr22:31816379~31817491:-
LUAD	cis	rs13423976	0.572	rs11893988	ENSG00000231367.4	AC016995.3	8.36	6.66e-16	7.36e-13	0.46	0.36	Gut microbiome composition (summer);	chr2:38515630	chr2:38406719~38515740:-
LUAD	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-8.36	6.68e-16	7.38e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
LUAD	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	8.36	6.77e-16	7.48e-13	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
LUAD	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-8.36	6.78e-16	7.49e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-8.36	6.78e-16	7.49e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
LUAD	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	8.36	6.82e-16	7.54e-13	0.45	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
LUAD	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-8.36	6.88e-16	7.6e-13	-0.54	-0.36	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-8.36	6.9e-16	7.62e-13	-0.54	-0.36	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
LUAD	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	8.36	6.95e-16	7.68e-13	0.56	0.36	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
LUAD	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-8.36	6.97e-16	7.7e-13	-0.54	-0.36	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-8.36	6.97e-16	7.7e-13	-0.54	-0.36	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
LUAD	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	8.36	7.03e-16	7.76e-13	0.4	0.36	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
LUAD	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-8.36	7.05e-16	7.79e-13	-0.36	-0.36	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	8.35	7.08e-16	7.82e-13	0.37	0.36	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-8.35	7.09e-16	7.82e-13	-0.36	-0.36	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-8.35	7.11e-16	7.85e-13	-0.36	-0.36	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-8.35	7.11e-16	7.85e-13	-0.36	-0.36	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	8.35	7.18e-16	7.92e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	8.35	7.19e-16	7.94e-13	0.51	0.36	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
LUAD	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	8.35	7.25e-16	7.99e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
LUAD	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	8.35	7.27e-16	8.01e-13	0.53	0.36	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
LUAD	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-8.35	7.31e-16	8.06e-13	-0.39	-0.36	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
LUAD	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-8.35	7.31e-16	8.06e-13	-0.39	-0.36	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
LUAD	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-8.35	7.35e-16	8.1e-13	-0.36	-0.36	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
LUAD	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-8.35	7.4e-16	8.15e-13	-0.38	-0.36	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
LUAD	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
LUAD	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	8.35	7.41e-16	8.17e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
LUAD	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	8.35	7.51e-16	8.27e-13	0.44	0.36	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	8.35	7.51e-16	8.27e-13	0.44	0.36	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
LUAD	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	8.35	7.53e-16	8.29e-13	0.45	0.36	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
LUAD	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	8.35	7.55e-16	8.32e-13	0.49	0.36	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
LUAD	cis	rs35955747	0.633	rs5998012	ENSG00000236132.1	CTA-440B3.1	8.35	7.58e-16	8.35e-13	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31493858	chr22:31816379~31817491:-
LUAD	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	8.34	7.64e-16	8.41e-13	0.32	0.36	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	8.34	7.64e-16	8.41e-13	0.32	0.36	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	8.34	7.64e-16	8.41e-13	0.32	0.36	Asthma;	chr2:102423587	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	8.34	7.64e-16	8.41e-13	0.32	0.36	Asthma;	chr2:102423717	chr2:102438713~102440475:+
LUAD	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-8.34	7.71e-16	8.48e-13	-0.39	-0.36	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
LUAD	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-8.34	7.77e-16	8.55e-13	-0.46	-0.36	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
LUAD	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-8.34	7.77e-16	8.55e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	8.34	7.85e-16	8.63e-13	0.51	0.36	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	8.34	7.85e-16	8.63e-13	0.51	0.36	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	8.34	7.85e-16	8.63e-13	0.51	0.36	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
LUAD	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-8.34	7.94e-16	8.72e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
LUAD	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-8.34	8e-16	8.77e-13	-0.39	-0.36	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
LUAD	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	8.34	8.04e-16	8.81e-13	0.62	0.36	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000223648.3	IGHV3-64	8.34	8.04e-16	8.82e-13	0.36	0.36	Kawasaki disease;	chr14:106711377	chr14:106643132~106658258:-
LUAD	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	8.34	8.16e-16	8.94e-13	0.5	0.36	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
LUAD	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	8.33	8.32e-16	9.11e-13	0.48	0.36	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
LUAD	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	8.33	8.41e-16	9.2e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
LUAD	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	8.33	8.42e-16	9.21e-13	0.41	0.36	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
LUAD	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	8.33	8.42e-16	9.21e-13	0.36	0.36	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
LUAD	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	8.33	8.43e-16	9.22e-13	0.32	0.36	Asthma;	chr2:102410644	chr2:102438713~102440475:+
LUAD	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-8.33	8.52e-16	9.32e-13	-0.36	-0.36	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
LUAD	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-8.33	8.55e-16	9.35e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
LUAD	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-8.33	8.57e-16	9.37e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	8.33	8.64e-16	9.44e-13	0.41	0.35	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	8.33	8.64e-16	9.44e-13	0.41	0.35	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
LUAD	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-8.33	8.67e-16	9.47e-13	-0.48	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
LUAD	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-8.33	8.75e-16	9.56e-13	-0.36	-0.35	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
LUAD	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-8.33	8.79e-16	9.6e-13	-0.36	-0.35	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	8.33	8.79e-16	9.61e-13	0.5	0.35	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
LUAD	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-8.33	8.81e-16	9.62e-13	-0.36	-0.35	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
LUAD	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-8.32	8.86e-16	9.68e-13	-0.37	-0.35	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
LUAD	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-8.32	8.87e-16	9.69e-13	-0.38	-0.35	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
LUAD	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	8.32	8.94e-16	9.76e-13	0.37	0.35	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
LUAD	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	8.32	8.99e-16	9.81e-13	0.42	0.35	Height;	chr11:118761813	chr11:118688039~118690600:-
LUAD	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-8.32	9.06e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-8.32	9.07e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-8.32	9.07e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-8.32	9.07e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-8.32	9.07e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
LUAD	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-8.32	9.19e-16	1e-12	-0.32	-0.35	Asthma;	chr2:102393077	chr2:102438713~102440475:+
LUAD	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-8.32	9.24e-16	1.01e-12	-0.47	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
LUAD	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	8.32	9.25e-16	1.01e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	8.32	9.25e-16	1.01e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	8.32	9.3e-16	1.01e-12	0.41	0.35	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	8.32	9.3e-16	1.01e-12	0.41	0.35	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
LUAD	cis	rs2337406	0.538	rs10141701	ENSG00000274576.2	IGHV2-70	-8.32	9.31e-16	1.01e-12	-0.36	-0.35	Alzheimer's disease (late onset);	chr14:106633467	chr14:106770577~106771020:-
LUAD	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-8.32	9.37e-16	1.02e-12	-0.38	-0.35	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
LUAD	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	8.32	9.39e-16	1.02e-12	0.39	0.35	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
LUAD	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-8.32	9.42e-16	1.03e-12	-0.48	-0.35	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	8.32	9.47e-16	1.03e-12	0.42	0.35	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
LUAD	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-8.32	9.48e-16	1.03e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
LUAD	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	8.31	9.51e-16	1.04e-12	0.52	0.35	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
LUAD	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-8.31	9.61e-16	1.05e-12	-0.44	-0.35	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
LUAD	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	8.31	9.66e-16	1.05e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	8.31	9.66e-16	1.05e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
LUAD	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	8.31	9.68e-16	1.05e-12	0.43	0.35	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
LUAD	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-8.31	9.98e-16	1.08e-12	-0.35	-0.35	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
LUAD	cis	rs13423976	0.631	rs11888984	ENSG00000231367.4	AC016995.3	-8.31	1.01e-15	1.09e-12	-0.45	-0.35	Gut microbiome composition (summer);	chr2:38517250	chr2:38406719~38515740:-
LUAD	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	8.31	1.01e-15	1.1e-12	0.45	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	8.31	1.01e-15	1.1e-12	0.43	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
LUAD	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-8.31	1.01e-15	1.1e-12	-0.48	-0.35	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
LUAD	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-8.31	1.01e-15	1.1e-12	-0.37	-0.35	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
LUAD	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-8.31	1.02e-15	1.1e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-8.31	1.02e-15	1.1e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
LUAD	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-8.31	1.02e-15	1.11e-12	-0.42	-0.35	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
LUAD	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-8.3	1.02e-15	1.11e-12	-0.4	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
LUAD	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-8.3	1.03e-15	1.12e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
LUAD	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	8.3	1.05e-15	1.13e-12	0.42	0.35	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
LUAD	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-8.3	1.06e-15	1.15e-12	-0.38	-0.35	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
LUAD	cis	rs944289	0.74	rs368187	ENSG00000257826.1	RP11-116N8.4	8.3	1.06e-15	1.15e-12	0.37	0.35	Thyroid cancer;	chr14:36063370	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	8.3	1.08e-15	1.17e-12	0.41	0.35	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	8.3	1.09e-15	1.18e-12	0.51	0.35	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
LUAD	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	8.3	1.09e-15	1.18e-12	0.45	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
LUAD	cis	rs10129255	1	rs10137758	ENSG00000211970.3	IGHV4-61	-8.3	1.09e-15	1.18e-12	-0.28	-0.35	Kawasaki disease;	chr14:106697673	chr14:106639119~106639657:-
LUAD	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-8.3	1.09e-15	1.18e-12	-0.49	-0.35	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
LUAD	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-8.3	1.09e-15	1.18e-12	-0.38	-0.35	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
LUAD	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-8.29	1.1e-15	1.19e-12	-0.53	-0.35	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
LUAD	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	8.29	1.11e-15	1.2e-12	0.48	0.35	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
LUAD	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	8.29	1.11e-15	1.2e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
LUAD	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma;	chr2:102415109	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma;	chr2:102415289	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma;	chr2:102417501	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma;	chr2:102418383	chr2:102438713~102440475:+
LUAD	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	8.29	1.11e-15	1.2e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
LUAD	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	8.29	1.12e-15	1.21e-12	0.51	0.35	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
LUAD	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	8.29	1.12e-15	1.21e-12	0.37	0.35	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
LUAD	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	8.29	1.12e-15	1.22e-12	0.39	0.35	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
LUAD	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-8.29	1.13e-15	1.22e-12	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
LUAD	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	8.29	1.13e-15	1.22e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-8.29	1.14e-15	1.23e-12	-0.47	-0.35	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
LUAD	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-8.29	1.14e-15	1.23e-12	-0.56	-0.35	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
LUAD	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-8.29	1.14e-15	1.23e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
LUAD	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	8.29	1.15e-15	1.24e-12	0.45	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
LUAD	cis	rs4273100	0.834	rs59415593	ENSG00000262319.1	CTC-457L16.2	-8.29	1.15e-15	1.25e-12	-0.5	-0.35	Schizophrenia;	chr17:19319911	chr17:19141017~19143689:-
LUAD	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-8.29	1.15e-15	1.25e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-8.29	1.15e-15	1.25e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
LUAD	cis	rs7688540	0.771	rs2353605	ENSG00000275426.1	CH17-262A2.1	8.29	1.16e-15	1.25e-12	0.49	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:149738~150317:+
LUAD	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	8.29	1.16e-15	1.26e-12	0.43	0.35	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
LUAD	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	8.29	1.17e-15	1.26e-12	0.82	0.35	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
LUAD	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	8.29	1.18e-15	1.27e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
LUAD	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-8.28	1.19e-15	1.28e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
LUAD	cis	rs12439619	0.508	rs8042665	ENSG00000255769.6	GOLGA2P10	-8.28	1.19e-15	1.29e-12	-0.37	-0.35	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472993~82513950:-
LUAD	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	8.28	1.2e-15	1.29e-12	0.37	0.35	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	8.28	1.2e-15	1.29e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
LUAD	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-8.28	1.21e-15	1.31e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-8.28	1.21e-15	1.31e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
LUAD	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-8.28	1.21e-15	1.31e-12	-0.49	-0.35	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
LUAD	cis	rs944289	0.74	rs414755	ENSG00000257826.1	RP11-116N8.4	8.28	1.22e-15	1.31e-12	0.37	0.35	Thyroid cancer;	chr14:36073387	chr14:36061026~36067190:-
LUAD	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-8.28	1.22e-15	1.31e-12	-0.54	-0.35	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
LUAD	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-8.28	1.23e-15	1.32e-12	-0.32	-0.35	Asthma;	chr2:102374328	chr2:102438713~102440475:+
LUAD	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-8.28	1.25e-15	1.34e-12	-0.44	-0.35	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
LUAD	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-8.28	1.25e-15	1.35e-12	-0.49	-0.35	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
LUAD	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	8.28	1.26e-15	1.35e-12	0.42	0.35	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
LUAD	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	8.28	1.27e-15	1.37e-12	0.41	0.35	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	8.28	1.27e-15	1.37e-12	0.41	0.35	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
LUAD	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	8.28	1.27e-15	1.37e-12	0.44	0.35	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
LUAD	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	8.27	1.28e-15	1.37e-12	0.46	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
LUAD	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	8.27	1.28e-15	1.37e-12	0.32	0.35	Asthma;	chr2:102412435	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	8.27	1.28e-15	1.37e-12	0.32	0.35	Asthma;	chr2:102412461	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	8.27	1.28e-15	1.37e-12	0.32	0.35	Asthma;	chr2:102412524	chr2:102438713~102440475:+
LUAD	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-8.27	1.28e-15	1.38e-12	-0.38	-0.35	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
LUAD	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-8.27	1.28e-15	1.38e-12	-0.47	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
LUAD	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-8.27	1.28e-15	1.38e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
LUAD	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	8.27	1.29e-15	1.38e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	8.27	1.29e-15	1.38e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	8.27	1.29e-15	1.38e-12	0.51	0.35	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	8.27	1.31e-15	1.4e-12	0.49	0.35	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
LUAD	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-8.27	1.31e-15	1.41e-12	-0.41	-0.35	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
LUAD	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	8.27	1.31e-15	1.41e-12	0.38	0.35	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
LUAD	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-8.27	1.31e-15	1.41e-12	-0.57	-0.35	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
LUAD	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	8.27	1.31e-15	1.41e-12	0.37	0.35	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
LUAD	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	8.27	1.34e-15	1.44e-12	0.54	0.35	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
LUAD	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	8.27	1.35e-15	1.44e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
LUAD	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-8.27	1.35e-15	1.44e-12	-0.5	-0.35	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
LUAD	cis	rs10463554	0.892	rs1438687	ENSG00000175749.11	EIF3KP1	8.27	1.35e-15	1.45e-12	0.49	0.35	Parkinson's disease;	chr5:102968792	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	8.27	1.35e-15	1.45e-12	0.48	0.35	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
LUAD	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-8.27	1.36e-15	1.46e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
LUAD	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-8.27	1.37e-15	1.46e-12	-0.57	-0.35	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
LUAD	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	8.26	1.38e-15	1.48e-12	0.54	0.35	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
LUAD	cis	rs944289	0.774	rs34081947	ENSG00000257826.1	RP11-116N8.4	-8.26	1.41e-15	1.5e-12	-0.37	-0.35	Thyroid cancer;	chr14:36090325	chr14:36061026~36067190:-
LUAD	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	8.26	1.42e-15	1.52e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	8.26	1.42e-15	1.52e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
LUAD	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	8.26	1.42e-15	1.52e-12	0.71	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
LUAD	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-8.26	1.43e-15	1.53e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-8.26	1.43e-15	1.53e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	8.26	1.43e-15	1.53e-12	0.3	0.35	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
LUAD	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.26	1.44e-15	1.54e-12	0.49	0.35	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	8.26	1.45e-15	1.55e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
LUAD	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	8.26	1.46e-15	1.56e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
LUAD	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-8.26	1.47e-15	1.57e-12	-0.4	-0.35	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
LUAD	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	8.25	1.48e-15	1.57e-12	0.42	0.35	Height;	chr11:118791319	chr11:118688039~118690600:-
LUAD	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	8.25	1.49e-15	1.59e-12	0.42	0.35	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
LUAD	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-8.25	1.49e-15	1.59e-12	-0.31	-0.35	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
LUAD	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-8.25	1.49e-15	1.59e-12	-0.41	-0.35	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
LUAD	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	8.25	1.49e-15	1.59e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	8.25	1.49e-15	1.59e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
LUAD	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	8.25	1.49e-15	1.59e-12	0.32	0.35	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
LUAD	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	8.25	1.5e-15	1.6e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	8.25	1.5e-15	1.6e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
LUAD	cis	rs11089937	0.626	rs5757056	ENSG00000211639.2	IGLV4-60	8.25	1.51e-15	1.61e-12	0.4	0.35	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22162199~22162681:+
LUAD	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	8.25	1.51e-15	1.61e-12	0.36	0.35	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
LUAD	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	8.25	1.51e-15	1.61e-12	0.68	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
LUAD	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-8.25	1.52e-15	1.62e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
LUAD	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	8.25	1.52e-15	1.62e-12	0.42	0.35	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	8.25	1.52e-15	1.62e-12	0.42	0.35	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
LUAD	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	8.25	1.56e-15	1.67e-12	0.44	0.35	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
LUAD	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-8.25	1.57e-15	1.67e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-8.25	1.57e-15	1.67e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-8.25	1.57e-15	1.67e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
LUAD	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	8.25	1.58e-15	1.68e-12	0.51	0.35	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
LUAD	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-8.25	1.58e-15	1.68e-12	-0.49	-0.35	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
LUAD	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	8.24	1.61e-15	1.71e-12	0.39	0.35	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	8.24	1.61e-15	1.71e-12	0.39	0.35	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	8.24	1.61e-15	1.71e-12	0.41	0.35	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	8.24	1.61e-15	1.71e-12	0.39	0.35	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000211970.3	IGHV4-61	-8.24	1.62e-15	1.72e-12	-0.28	-0.35	Kawasaki disease;	chr14:106711377	chr14:106639119~106639657:-
LUAD	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	8.24	1.62e-15	1.72e-12	0.41	0.35	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
LUAD	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-8.24	1.62e-15	1.73e-12	-0.39	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
LUAD	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	8.24	1.63e-15	1.73e-12	0.51	0.35	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	8.24	1.63e-15	1.73e-12	0.51	0.35	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
LUAD	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	8.24	1.63e-15	1.74e-12	0.42	0.35	Height;	chr11:118786602	chr11:118688039~118690600:-
LUAD	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-8.24	1.63e-15	1.74e-12	-0.66	-0.35	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
LUAD	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-8.24	1.64e-15	1.74e-12	-0.4	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000206090.4	AP000350.7	-8.24	1.64e-15	1.74e-12	-0.4	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23939998~23942798:+
LUAD	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-8.24	1.65e-15	1.75e-12	-0.41	-0.35	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
LUAD	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	8.24	1.65e-15	1.76e-12	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	8.24	1.66e-15	1.76e-12	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
LUAD	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	8.24	1.66e-15	1.76e-12	0.64	0.35	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
LUAD	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	8.24	1.66e-15	1.76e-12	0.32	0.35	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
LUAD	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	8.24	1.66e-15	1.76e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
LUAD	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	8.24	1.66e-15	1.77e-12	0.32	0.35	Asthma;	chr2:102411180	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	8.24	1.66e-15	1.77e-12	0.32	0.35	Asthma;	chr2:102411191	chr2:102438713~102440475:+
LUAD	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	8.24	1.67e-15	1.77e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	8.24	1.67e-15	1.77e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
LUAD	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	8.24	1.67e-15	1.77e-12	0.32	0.35	Asthma;	chr2:102419319	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	8.24	1.67e-15	1.77e-12	0.32	0.35	Asthma;	chr2:102419875	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	8.24	1.67e-15	1.77e-12	0.32	0.35	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	8.24	1.67e-15	1.77e-12	0.32	0.35	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
LUAD	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-8.24	1.67e-15	1.78e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-8.24	1.67e-15	1.78e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	8.24	1.68e-15	1.78e-12	0.3	0.35	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
LUAD	cis	rs11846409	0.86	rs17112419	ENSG00000274576.2	IGHV2-70	-8.24	1.68e-15	1.78e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106633260	chr14:106770577~106771020:-
LUAD	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	8.24	1.69e-15	1.79e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.24	1.69e-15	1.79e-12	0.48	0.35	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
LUAD	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-8.24	1.69e-15	1.8e-12	-0.44	-0.35	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
LUAD	cis	rs2729354	0.729	rs2258835	ENSG00000265566.2	RN7SL605P	-8.24	1.7e-15	1.8e-12	-0.52	-0.35	Blood protein levels;	chr11:57476115	chr11:57528085~57528365:-
LUAD	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	8.24	1.7e-15	1.81e-12	0.3	0.35	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	8.23	1.71e-15	1.81e-12	0.41	0.35	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
LUAD	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-8.23	1.72e-15	1.82e-12	-0.39	-0.35	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	8.23	1.72e-15	1.82e-12	0.49	0.35	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
LUAD	cis	rs1322639	0.614	rs9689800	ENSG00000261039.2	RP11-417E7.2	8.23	1.72e-15	1.82e-12	0.44	0.35	Pulse pressure;	chr6:169172850	chr6:169175304~169182740:-
LUAD	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	8.23	1.72e-15	1.82e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
LUAD	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-8.23	1.73e-15	1.83e-12	-0.43	-0.35	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
LUAD	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-8.23	1.73e-15	1.83e-12	-0.46	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
LUAD	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	8.23	1.73e-15	1.84e-12	0.41	0.35	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
LUAD	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	8.23	1.73e-15	1.84e-12	0.39	0.35	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
LUAD	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	8.23	1.74e-15	1.84e-12	0.48	0.35	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
LUAD	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-8.23	1.74e-15	1.84e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
LUAD	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-8.23	1.74e-15	1.85e-12	-0.43	-0.35	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-8.23	1.75e-15	1.85e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
LUAD	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
LUAD	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	8.23	1.76e-15	1.86e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	8.23	1.76e-15	1.86e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
LUAD	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-8.23	1.76e-15	1.86e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	8.23	1.77e-15	1.87e-12	0.3	0.35	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
LUAD	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-8.23	1.79e-15	1.89e-12	-0.4	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
LUAD	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-8.23	1.81e-15	1.91e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
LUAD	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	8.23	1.82e-15	1.92e-12	0.51	0.35	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
LUAD	cis	rs944289	0.774	rs7147401	ENSG00000257826.1	RP11-116N8.4	-8.23	1.83e-15	1.94e-12	-0.37	-0.35	Thyroid cancer;	chr14:36089461	chr14:36061026~36067190:-
LUAD	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
LUAD	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	8.23	1.84e-15	1.94e-12	0.48	0.35	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
LUAD	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	8.22	1.84e-15	1.94e-12	0.38	0.35	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
LUAD	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	8.22	1.85e-15	1.95e-12	0.42	0.35	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
LUAD	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	8.22	1.86e-15	1.96e-12	0.39	0.35	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
LUAD	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-8.22	1.87e-15	1.98e-12	-0.39	-0.35	Temperament;	chr17:14033087	chr17:14024514~14025488:+
LUAD	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-8.22	1.89e-15	1.99e-12	-0.46	-0.35	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
LUAD	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-8.22	1.89e-15	1.99e-12	-0.46	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
LUAD	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-8.22	1.9e-15	2e-12	-0.49	-0.35	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
LUAD	cis	rs944289	0.774	rs12589124	ENSG00000257826.1	RP11-116N8.4	-8.22	1.91e-15	2.01e-12	-0.37	-0.35	Thyroid cancer;	chr14:36094718	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs2183451	ENSG00000257826.1	RP11-116N8.4	-8.22	1.91e-15	2.01e-12	-0.37	-0.35	Thyroid cancer;	chr14:36095227	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.774	rs884090	ENSG00000257826.1	RP11-116N8.4	-8.22	1.91e-15	2.01e-12	-0.37	-0.35	Thyroid cancer;	chr14:36095741	chr14:36061026~36067190:-
LUAD	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	8.22	1.92e-15	2.02e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
LUAD	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	8.22	1.93e-15	2.04e-12	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
LUAD	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	8.22	1.96e-15	2.06e-12	0.46	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
LUAD	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	8.22	1.97e-15	2.07e-12	0.39	0.35	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
LUAD	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-8.22	1.98e-15	2.08e-12	-0.55	-0.35	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
LUAD	cis	rs904251	0.62	rs883372	ENSG00000279942.1	RP1-153P14.7	-8.21	1.98e-15	2.08e-12	-0.39	-0.35	Cognitive performance;	chr6:37509829	chr6:37567716~37571460:+
LUAD	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	8.21	2e-15	2.1e-12	0.49	0.35	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
LUAD	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-8.21	2e-15	2.1e-12	-0.39	-0.35	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-8.21	2e-15	2.1e-12	-0.39	-0.35	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
LUAD	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
LUAD	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	8.21	2.02e-15	2.13e-12	0.42	0.35	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
LUAD	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	8.21	2.03e-15	2.14e-12	0.4	0.35	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
LUAD	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	8.21	2.03e-15	2.14e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	8.21	2.03e-15	2.14e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
LUAD	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-8.21	2.05e-15	2.16e-12	-0.46	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
LUAD	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	8.21	2.05e-15	2.16e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
LUAD	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-8.21	2.06e-15	2.16e-12	-0.38	-0.35	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
LUAD	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-8.21	2.06e-15	2.16e-12	-0.39	-0.35	Temperament;	chr17:14003617	chr17:14024514~14025488:+
LUAD	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	8.21	2.06e-15	2.17e-12	0.42	0.35	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
LUAD	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	8.21	2.06e-15	2.17e-12	0.42	0.35	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
LUAD	cis	rs11846409	0.932	rs2015469	ENSG00000274576.2	IGHV2-70	-8.21	2.07e-15	2.17e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106631857	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.932	rs56167903	ENSG00000274576.2	IGHV2-70	-8.21	2.07e-15	2.17e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106632070	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000223648.3	IGHV3-64	8.21	2.07e-15	2.18e-12	0.35	0.35	Kawasaki disease;	chr14:106718572	chr14:106643132~106658258:-
LUAD	cis	rs75045569	1	rs75045569	ENSG00000229153.4	EPHA1-AS1	8.21	2.07e-15	2.18e-12	0.6	0.35	Alzheimer's disease in APOE e4- carriers;	chr7:143412115	chr7:143407813~143523449:+
LUAD	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-8.21	2.09e-15	2.19e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
LUAD	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-8.21	2.1e-15	2.21e-12	-0.53	-0.35	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
LUAD	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-8.21	2.11e-15	2.21e-12	-0.39	-0.35	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
LUAD	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-8.21	2.11e-15	2.21e-12	-0.36	-0.35	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
LUAD	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	8.2	2.13e-15	2.24e-12	0.42	0.35	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
LUAD	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	8.2	2.14e-15	2.24e-12	0.66	0.35	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-8.2	2.15e-15	2.25e-12	-0.28	-0.35	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
LUAD	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	8.2	2.17e-15	2.28e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
LUAD	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	8.2	2.18e-15	2.28e-12	0.39	0.35	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
LUAD	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-8.2	2.18e-15	2.28e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
LUAD	cis	rs11846409	0.86	rs10150951	ENSG00000274576.2	IGHV2-70	-8.2	2.2e-15	2.31e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106632988	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.932	rs2583329	ENSG00000274576.2	IGHV2-70	8.2	2.2e-15	2.31e-12	0.36	0.35	Rheumatic heart disease;	chr14:106632971	chr14:106770577~106771020:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000206090.4	AP000350.7	8.2	2.2e-15	2.31e-12	0.41	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23939998~23942798:+
LUAD	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	8.2	2.22e-15	2.32e-12	0.38	0.35	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
LUAD	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-8.2	2.22e-15	2.32e-12	-0.49	-0.35	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	8.2	2.23e-15	2.33e-12	0.48	0.35	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	8.2	2.25e-15	2.35e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
LUAD	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	8.2	2.25e-15	2.35e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
LUAD	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-8.2	2.27e-15	2.37e-12	-0.6	-0.35	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
LUAD	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-8.2	2.27e-15	2.38e-12	-0.49	-0.35	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
LUAD	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	8.2	2.28e-15	2.38e-12	0.3	0.35	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
LUAD	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-8.2	2.28e-15	2.38e-12	-0.44	-0.35	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
LUAD	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	8.19	2.3e-15	2.4e-12	0.38	0.35	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
LUAD	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	8.19	2.31e-15	2.41e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-8.19	2.31e-15	2.42e-12	-0.38	-0.35	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
LUAD	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-8.19	2.32e-15	2.42e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
LUAD	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
LUAD	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-8.19	2.33e-15	2.43e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
LUAD	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	8.19	2.33e-15	2.44e-12	0.43	0.35	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
LUAD	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-8.19	2.33e-15	2.44e-12	-0.49	-0.35	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
LUAD	cis	rs13423976	0.631	rs4566347	ENSG00000231367.4	AC016995.3	8.19	2.33e-15	2.44e-12	0.45	0.35	Gut microbiome composition (summer);	chr2:38515498	chr2:38406719~38515740:-
LUAD	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-8.19	2.35e-15	2.46e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-8.19	2.35e-15	2.46e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
LUAD	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	8.19	2.36e-15	2.46e-12	0.43	0.35	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
LUAD	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	8.19	2.36e-15	2.46e-12	0.52	0.35	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	8.19	2.36e-15	2.46e-12	0.52	0.35	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
LUAD	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	8.19	2.36e-15	2.46e-12	0.36	0.35	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
LUAD	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	8.19	2.37e-15	2.47e-12	0.41	0.35	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
LUAD	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-8.19	2.37e-15	2.47e-12	-0.53	-0.35	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-8.19	2.37e-15	2.47e-12	-0.53	-0.35	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
LUAD	cis	rs2337406	1	rs11845269	ENSG00000254174.1	IGHV1-12	8.19	2.38e-15	2.48e-12	0.32	0.35	Alzheimer's disease (late onset);	chr14:106683851	chr14:106122420~106122709:-
LUAD	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	8.19	2.38e-15	2.48e-12	0.48	0.35	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
LUAD	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	8.19	2.39e-15	2.48e-12	0.58	0.35	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
LUAD	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	8.19	2.39e-15	2.49e-12	0.48	0.35	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
LUAD	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102426252	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102427407	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102427715	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102431747	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102432120	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102432614	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102433405	chr2:102438713~102440475:+
LUAD	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-8.19	2.41e-15	2.51e-12	-0.49	-0.35	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
LUAD	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	8.19	2.41e-15	2.51e-12	0.36	0.35	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
LUAD	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	8.19	2.42e-15	2.52e-12	0.4	0.35	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
LUAD	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-8.19	2.42e-15	2.52e-12	-0.7	-0.35	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
LUAD	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	8.19	2.43e-15	2.53e-12	0.37	0.35	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	8.19	2.43e-15	2.53e-12	0.42	0.35	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-8.19	2.44e-15	2.54e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
LUAD	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	8.19	2.45e-15	2.54e-12	0.45	0.35	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
LUAD	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	8.19	2.45e-15	2.55e-12	0.38	0.35	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
LUAD	cis	rs35955747	0.533	rs5998004	ENSG00000236132.1	CTA-440B3.1	8.18	2.47e-15	2.57e-12	0.4	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485843	chr22:31816379~31817491:-
LUAD	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	8.18	2.48e-15	2.57e-12	0.43	0.35	Height;	chr6:109405536	chr6:109382795~109383666:+
LUAD	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-8.18	2.48e-15	2.58e-12	-0.27	-0.35	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
LUAD	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-8.18	2.49e-15	2.58e-12	-0.43	-0.35	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
LUAD	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-8.18	2.49e-15	2.59e-12	-0.38	-0.35	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
LUAD	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-8.18	2.53e-15	2.62e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
LUAD	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	8.18	2.53e-15	2.62e-12	0.47	0.35	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.626	rs4820337	ENSG00000211639.2	IGLV4-60	-8.18	2.54e-15	2.64e-12	-0.41	-0.35	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22162199~22162681:+
LUAD	cis	rs6504622	0.721	rs11079748	ENSG00000262879.4	RP11-156P1.3	-8.18	2.55e-15	2.65e-12	-0.4	-0.35	Orofacial clefts;	chr17:47055097	chr17:46984045~47100323:-
LUAD	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	8.18	2.55e-15	2.65e-12	0.49	0.35	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	8.18	2.57e-15	2.66e-12	0.31	0.35	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
LUAD	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	8.18	2.57e-15	2.66e-12	0.4	0.35	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
LUAD	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-8.18	2.57e-15	2.67e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
LUAD	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-8.18	2.58e-15	2.68e-12	-0.48	-0.35	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
LUAD	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	8.18	2.59e-15	2.69e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	8.18	2.59e-15	2.69e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
LUAD	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	8.18	2.6e-15	2.69e-12	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
LUAD	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	8.18	2.6e-15	2.69e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-8.18	2.61e-15	2.7e-12	-0.42	-0.35	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
LUAD	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-8.18	2.61e-15	2.7e-12	-0.31	-0.35	Asthma;	chr2:102399682	chr2:102438713~102440475:+
LUAD	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-8.18	2.63e-15	2.73e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
LUAD	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-8.18	2.64e-15	2.74e-12	-0.37	-0.35	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
LUAD	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	8.17	2.65e-15	2.74e-12	0.58	0.35	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
LUAD	cis	rs944289	0.745	rs1537427	ENSG00000257826.1	RP11-116N8.4	8.17	2.66e-15	2.75e-12	0.37	0.35	Thyroid cancer;	chr14:36117640	chr14:36061026~36067190:-
LUAD	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	8.17	2.67e-15	2.76e-12	0.44	0.35	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
LUAD	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	8.17	2.67e-15	2.76e-12	0.44	0.35	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
LUAD	cis	rs944289	0.774	rs7150539	ENSG00000257826.1	RP11-116N8.4	-8.17	2.67e-15	2.76e-12	-0.37	-0.35	Thyroid cancer;	chr14:36086408	chr14:36061026~36067190:-
LUAD	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	8.17	2.67e-15	2.76e-12	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
LUAD	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-8.17	2.69e-15	2.78e-12	-0.31	-0.35	Asthma;	chr2:102394777	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-8.17	2.71e-15	2.8e-12	-0.27	-0.35	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
LUAD	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	8.17	2.71e-15	2.8e-12	0.41	0.35	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
LUAD	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	8.17	2.72e-15	2.8e-12	0.44	0.35	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
LUAD	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-8.17	2.73e-15	2.81e-12	-0.7	-0.35	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
LUAD	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	8.17	2.75e-15	2.83e-12	0.37	0.35	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	8.17	2.76e-15	2.84e-12	0.42	0.35	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
LUAD	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-8.17	2.76e-15	2.85e-12	-0.4	-0.35	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
LUAD	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	8.17	2.77e-15	2.85e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.17	2.78e-15	2.86e-12	0.48	0.35	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
LUAD	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	8.17	2.78e-15	2.86e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
LUAD	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	8.17	2.78e-15	2.87e-12	0.48	0.35	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
LUAD	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-8.17	2.8e-15	2.88e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-8.17	2.8e-15	2.88e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
LUAD	cis	rs1322639	0.531	rs11751421	ENSG00000261039.2	RP11-417E7.2	8.17	2.82e-15	2.9e-12	0.43	0.35	Pulse pressure;	chr6:169174898	chr6:169175304~169182740:-
LUAD	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-8.17	2.82e-15	2.9e-12	-0.56	-0.35	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
LUAD	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	8.17	2.83e-15	2.91e-12	0.38	0.35	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
LUAD	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	8.17	2.83e-15	2.91e-12	0.43	0.35	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
LUAD	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	8.16	2.86e-15	2.94e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	8.16	2.86e-15	2.94e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	8.16	2.86e-15	2.94e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
LUAD	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-8.16	2.87e-15	2.95e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
LUAD	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-8.16	2.87e-15	2.95e-12	-0.45	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
LUAD	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-8.16	2.91e-15	2.99e-12	-0.33	-0.35	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
LUAD	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	8.16	2.92e-15	3e-12	0.41	0.35	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	8.16	2.92e-15	3e-12	0.41	0.35	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
LUAD	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	8.16	2.93e-15	3.01e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
LUAD	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	8.16	2.94e-15	3.02e-12	0.48	0.35	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	8.16	2.96e-15	3.04e-12	0.42	0.35	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
LUAD	cis	rs11089937	0.54	rs9622920	ENSG00000211639.2	IGLV4-60	-8.16	2.97e-15	3.04e-12	-0.4	-0.35	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22162199~22162681:+
LUAD	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-8.16	2.97e-15	3.05e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
LUAD	cis	rs7188445	0.898	rs11644758	ENSG00000261390.4	RP11-345M22.2	-8.16	2.98e-15	3.06e-12	-0.46	-0.35	Urate levels;	chr16:79675094	chr16:79715232~79770563:-
LUAD	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	8.16	2.98e-15	3.06e-12	0.46	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
LUAD	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-8.16	2.98e-15	3.06e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-8.16	2.98e-15	3.06e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
LUAD	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	8.16	3e-15	3.08e-12	0.38	0.35	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
LUAD	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	8.16	3.01e-15	3.09e-12	0.49	0.35	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	8.16	3.04e-15	3.12e-12	0.27	0.35	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
LUAD	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	8.16	3.05e-15	3.12e-12	0.38	0.35	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
LUAD	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
LUAD	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	8.16	3.06e-15	3.13e-12	0.41	0.35	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
LUAD	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-8.16	3.06e-15	3.13e-12	-0.5	-0.35	QT interval;	chr16:28884339	chr16:28700294~28701540:-
LUAD	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	8.15	3.08e-15	3.15e-12	0.44	0.35	Height;	chr6:109391084	chr6:109382795~109383666:+
LUAD	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-8.15	3.08e-15	3.15e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
LUAD	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-8.15	3.08e-15	3.16e-12	-0.46	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
LUAD	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	8.15	3.1e-15	3.17e-12	0.42	0.35	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
LUAD	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-8.15	3.11e-15	3.18e-12	-0.71	-0.35	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
LUAD	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	8.15	3.13e-15	3.2e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
LUAD	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-8.15	3.15e-15	3.22e-12	-0.43	-0.35	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	8.15	3.15e-15	3.22e-12	0.43	0.35	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
LUAD	cis	rs2337406	1	rs17113276	ENSG00000254174.1	IGHV1-12	-8.15	3.17e-15	3.24e-12	-0.31	-0.35	Alzheimer's disease (late onset);	chr14:106683485	chr14:106122420~106122709:-
LUAD	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-8.15	3.17e-15	3.25e-12	-0.38	-0.35	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
LUAD	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	8.15	3.19e-15	3.26e-12	0.65	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-8.15	3.2e-15	3.27e-12	-0.27	-0.35	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
LUAD	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-8.15	3.23e-15	3.31e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	8.15	3.24e-15	3.31e-12	0.4	0.35	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
LUAD	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	8.15	3.24e-15	3.31e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
LUAD	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	8.15	3.25e-15	3.32e-12	0.44	0.35	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
LUAD	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-8.15	3.25e-15	3.32e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
LUAD	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-8.15	3.26e-15	3.33e-12	-0.38	-0.35	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	8.15	3.27e-15	3.34e-12	0.38	0.35	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	8.15	3.29e-15	3.36e-12	0.41	0.35	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
LUAD	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	8.15	3.29e-15	3.36e-12	0.66	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
LUAD	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	8.15	3.29e-15	3.36e-12	0.49	0.35	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000280411.1	IGHV1-69-2	-8.14	3.33e-15	3.39e-12	-0.26	-0.35	Kawasaki disease;	chr14:106673171	chr14:106762092~106762588:-
LUAD	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-8.14	3.33e-15	3.4e-12	-0.49	-0.35	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
LUAD	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	8.14	3.34e-15	3.41e-12	0.47	0.35	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
LUAD	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	8.14	3.37e-15	3.43e-12	0.48	0.35	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.589	rs4239891	ENSG00000211639.2	IGLV4-60	8.14	3.38e-15	3.45e-12	0.39	0.35	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22162199~22162681:+
LUAD	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	8.14	3.38e-15	3.45e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
LUAD	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-8.14	3.39e-15	3.46e-12	-0.47	-0.35	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
LUAD	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	8.14	3.39e-15	3.46e-12	0.56	0.35	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	8.14	3.4e-15	3.47e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
LUAD	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-8.14	3.4e-15	3.47e-12	-0.49	-0.35	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
LUAD	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	8.14	3.42e-15	3.49e-12	0.44	0.35	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
LUAD	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	8.14	3.42e-15	3.49e-12	0.43	0.35	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
LUAD	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	8.14	3.43e-15	3.49e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
LUAD	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	8.14	3.44e-15	3.51e-12	0.38	0.35	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	8.14	3.44e-15	3.51e-12	0.38	0.35	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
LUAD	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	8.14	3.45e-15	3.52e-12	0.48	0.35	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
LUAD	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-8.14	3.45e-15	3.52e-12	-0.45	-0.35	Height;	chr6:109531713	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-8.14	3.46e-15	3.53e-12	-0.27	-0.35	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
LUAD	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	8.14	3.47e-15	3.53e-12	0.43	0.35	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
LUAD	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-8.14	3.47e-15	3.53e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
LUAD	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-8.14	3.48e-15	3.54e-12	-0.51	-0.35	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
LUAD	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	8.14	3.48e-15	3.55e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
LUAD	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	8.14	3.49e-15	3.55e-12	0.42	0.35	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
LUAD	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	8.14	3.49e-15	3.55e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
LUAD	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	8.14	3.5e-15	3.57e-12	0.44	0.35	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
LUAD	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	8.14	3.5e-15	3.57e-12	0.4	0.35	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
LUAD	cis	rs10129255	1	rs8010605	ENSG00000211972.2	IGHV3-66	8.14	3.51e-15	3.57e-12	0.3	0.35	Kawasaki disease;	chr14:106678742	chr14:106675017~106675544:-
LUAD	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	8.14	3.52e-15	3.58e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
LUAD	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-8.14	3.52e-15	3.58e-12	-0.32	-0.35	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
LUAD	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-8.14	3.53e-15	3.59e-12	-0.49	-0.35	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-8.13	3.55e-15	3.61e-12	-0.42	-0.35	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
LUAD	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	8.13	3.55e-15	3.61e-12	0.36	0.35	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
LUAD	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-8.13	3.55e-15	3.61e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-8.13	3.61e-15	3.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-8.13	3.61e-15	3.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
LUAD	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-8.13	3.62e-15	3.68e-12	-0.42	-0.35	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
LUAD	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-8.13	3.63e-15	3.68e-12	-0.36	-0.35	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
LUAD	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	8.13	3.63e-15	3.69e-12	0.38	0.35	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
LUAD	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-8.13	3.64e-15	3.7e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
LUAD	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-8.13	3.64e-15	3.7e-12	-0.7	-0.35	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
LUAD	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	8.13	3.65e-15	3.7e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
LUAD	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	8.13	3.67e-15	3.73e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
LUAD	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	8.13	3.69e-15	3.75e-12	0.39	0.35	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
LUAD	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	8.13	3.73e-15	3.78e-12	0.36	0.35	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	8.13	3.73e-15	3.78e-12	0.36	0.35	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
LUAD	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-8.13	3.77e-15	3.82e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
LUAD	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	8.13	3.78e-15	3.83e-12	0.61	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
LUAD	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	8.13	3.79e-15	3.84e-12	0.43	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
LUAD	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	8.13	3.79e-15	3.84e-12	0.55	0.35	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
LUAD	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	8.13	3.79e-15	3.85e-12	0.47	0.35	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
LUAD	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	8.13	3.8e-15	3.85e-12	0.59	0.35	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
LUAD	cis	rs11089937	0.597	rs4145535	ENSG00000211639.2	IGLV4-60	8.12	3.81e-15	3.86e-12	0.42	0.35	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22162199~22162681:+
LUAD	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	8.12	3.83e-15	3.88e-12	0.65	0.35	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
LUAD	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	8.12	3.83e-15	3.88e-12	0.65	0.35	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
LUAD	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	8.12	3.88e-15	3.93e-12	0.43	0.35	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
LUAD	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-8.12	3.88e-15	3.93e-12	-0.45	-0.35	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-8.12	3.89e-15	3.94e-12	-0.27	-0.35	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
LUAD	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	8.12	3.91e-15	3.96e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-8.12	3.91e-15	3.96e-12	-0.32	-0.35	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
LUAD	cis	rs944289	0.774	rs12050449	ENSG00000257826.1	RP11-116N8.4	-8.12	3.92e-15	3.97e-12	-0.37	-0.35	Thyroid cancer;	chr14:36101949	chr14:36061026~36067190:-
LUAD	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	8.12	3.93e-15	3.98e-12	0.48	0.35	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
LUAD	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	8.12	3.93e-15	3.98e-12	0.42	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
LUAD	cis	rs10853057	0.717	rs62062479	ENSG00000214174.7	AMZ2P1	8.12	3.94e-15	3.98e-12	0.77	0.35	White matter microstructure (global fractional anisotropy);	chr17:65060017	chr17:64966550~64975576:-
LUAD	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
LUAD	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	8.12	3.96e-15	4e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
LUAD	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
LUAD	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	8.12	3.99e-15	4.04e-12	0.8	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
LUAD	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-8.12	4e-15	4.04e-12	-0.45	-0.35	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
LUAD	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	8.12	4e-15	4.04e-12	0.45	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	8.12	4.02e-15	4.07e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	8.12	4.02e-15	4.07e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
LUAD	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	8.12	4.06e-15	4.1e-12	0.41	0.35	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000206090.4	AP000350.7	8.12	4.06e-15	4.11e-12	0.39	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23939998~23942798:+
LUAD	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	8.12	4.08e-15	4.12e-12	0.49	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
LUAD	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	8.11	4.11e-15	4.15e-12	0.52	0.35	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
LUAD	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-8.11	4.12e-15	4.16e-12	-0.41	-0.35	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
LUAD	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-8.11	4.15e-15	4.19e-12	-0.4	-0.35	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
LUAD	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	8.11	4.16e-15	4.2e-12	0.48	0.35	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
LUAD	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-8.11	4.18e-15	4.22e-12	-0.41	-0.35	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
LUAD	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-8.11	4.21e-15	4.25e-12	-0.49	-0.35	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-8.11	4.23e-15	4.27e-12	-0.48	-0.35	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
LUAD	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-8.11	4.23e-15	4.27e-12	-0.38	-0.35	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-8.11	4.29e-15	4.33e-12	-0.4	-0.35	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000211972.2	IGHV3-66	8.11	4.31e-15	4.34e-12	0.3	0.35	Kawasaki disease;	chr14:106690981	chr14:106675017~106675544:-
LUAD	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	8.11	4.32e-15	4.35e-12	0.3	0.35	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
LUAD	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	8.11	4.34e-15	4.38e-12	0.41	0.35	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
LUAD	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	8.11	4.37e-15	4.4e-12	0.8	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
LUAD	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	8.11	4.39e-15	4.42e-12	0.43	0.35	Height;	chr6:109358652	chr6:109382795~109383666:+
LUAD	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	8.11	4.4e-15	4.43e-12	0.43	0.35	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
LUAD	cis	rs35955747	0.633	rs2006771	ENSG00000236132.1	CTA-440B3.1	8.1	4.4e-15	4.43e-12	0.39	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31602626	chr22:31816379~31817491:-
LUAD	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-8.1	4.41e-15	4.44e-12	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
LUAD	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-8.1	4.42e-15	4.45e-12	-0.49	-0.35	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
LUAD	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	8.1	4.44e-15	4.47e-12	0.41	0.35	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
LUAD	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	8.1	4.46e-15	4.49e-12	0.43	0.35	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
LUAD	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	8.1	4.46e-15	4.49e-12	0.35	0.35	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
LUAD	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-8.1	4.48e-15	4.5e-12	-0.32	-0.35	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-8.1	4.51e-15	4.54e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
LUAD	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	8.1	4.57e-15	4.59e-12	0.3	0.35	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	8.1	4.57e-15	4.59e-12	0.3	0.35	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-8.1	4.57e-15	4.59e-12	-0.49	-0.35	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
LUAD	cis	rs944289	0.51	rs2780314	ENSG00000257826.1	RP11-116N8.4	-8.1	4.59e-15	4.62e-12	-0.36	-0.35	Thyroid cancer;	chr14:36059286	chr14:36061026~36067190:-
LUAD	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-8.1	4.61e-15	4.63e-12	-0.38	-0.35	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
LUAD	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-8.1	4.61e-15	4.63e-12	-0.41	-0.35	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
LUAD	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-8.1	4.66e-15	4.68e-12	-0.38	-0.35	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-8.1	4.66e-15	4.68e-12	-0.38	-0.35	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-8.1	4.69e-15	4.71e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
LUAD	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-8.1	4.71e-15	4.73e-12	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
LUAD	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	8.1	4.72e-15	4.74e-12	0.43	0.35	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
LUAD	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-8.1	4.73e-15	4.75e-12	-0.45	-0.35	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
LUAD	cis	rs35955747	0.633	rs5998002	ENSG00000236132.1	CTA-440B3.1	8.1	4.73e-15	4.75e-12	0.4	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485183	chr22:31816379~31817491:-
LUAD	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	8.09	4.73e-15	4.75e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
LUAD	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-8.09	4.73e-15	4.75e-12	-0.43	-0.35	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
LUAD	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	8.09	4.73e-15	4.75e-12	0.39	0.35	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000254174.1	IGHV1-12	-8.09	4.78e-15	4.79e-12	-0.3	-0.35	Alzheimer's disease (late onset);	chr14:106780476	chr14:106122420~106122709:-
LUAD	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	8.09	4.79e-15	4.8e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
LUAD	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-8.09	4.8e-15	4.82e-12	-0.49	-0.35	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-8.09	4.8e-15	4.82e-12	-0.49	-0.35	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-8.09	4.8e-15	4.82e-12	-0.49	-0.35	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-8.09	4.8e-15	4.82e-12	-0.49	-0.35	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-8.09	4.83e-15	4.84e-12	-0.48	-0.35	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	8.09	4.84e-15	4.86e-12	0.4	0.35	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
LUAD	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	8.09	4.84e-15	4.86e-12	0.82	0.35	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
LUAD	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	8.09	4.88e-15	4.89e-12	0.41	0.35	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	8.09	4.88e-15	4.89e-12	0.41	0.35	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	8.09	4.88e-15	4.89e-12	0.41	0.35	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
LUAD	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	8.09	4.88e-15	4.89e-12	0.41	0.35	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
LUAD	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-8.09	4.88e-15	4.89e-12	-0.41	-0.35	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
LUAD	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-8.09	4.88e-15	4.89e-12	-0.45	-0.35	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
LUAD	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	8.09	4.9e-15	4.92e-12	0.37	0.35	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	8.09	4.9e-15	4.92e-12	0.37	0.35	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
LUAD	cis	rs10853057	0.717	rs62062478	ENSG00000214174.7	AMZ2P1	8.09	4.95e-15	4.96e-12	0.75	0.35	White matter microstructure (global fractional anisotropy);	chr17:65059458	chr17:64966550~64975576:-
LUAD	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-8.09	5.01e-15	5.02e-12	-0.43	-0.35	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-8.09	5.01e-15	5.02e-12	-0.43	-0.35	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-8.09	5.01e-15	5.02e-12	-0.43	-0.35	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	8.09	5.01e-15	5.02e-12	0.43	0.35	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	8.09	5.01e-15	5.02e-12	0.43	0.35	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	8.09	5.01e-15	5.02e-12	0.43	0.35	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
LUAD	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-8.09	5.01e-15	5.02e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
LUAD	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-8.09	5.01e-15	5.02e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
LUAD	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-8.09	5.04e-15	5.04e-12	-0.41	-0.35	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000206090.4	AP000350.7	8.09	5.04e-15	5.05e-12	0.39	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23939998~23942798:+
LUAD	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-8.09	5.05e-15	5.05e-12	-0.41	-0.35	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
LUAD	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-8.09	5.06e-15	5.07e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
LUAD	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	8.09	5.07e-15	5.08e-12	0.4	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	8.09	5.07e-15	5.08e-12	0.4	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	8.09	5.07e-15	5.08e-12	0.4	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
LUAD	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	8.09	5.07e-15	5.08e-12	0.4	0.35	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	8.09	5.07e-15	5.08e-12	0.4	0.35	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000211972.2	IGHV3-66	8.09	5.08e-15	5.08e-12	0.3	0.35	Kawasaki disease;	chr14:106686431	chr14:106675017~106675544:-
LUAD	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-8.08	5.13e-15	5.13e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	8.08	5.16e-15	5.16e-12	0.43	0.35	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-8.08	5.17e-15	5.17e-12	-0.38	-0.35	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
LUAD	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	8.08	5.19e-15	5.19e-12	0.46	0.35	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
LUAD	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-8.08	5.2e-15	5.2e-12	-0.51	-0.35	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	8.08	5.22e-15	5.22e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
LUAD	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	8.08	5.23e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	8.08	5.23e-15	5.23e-12	0.43	0.35	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
LUAD	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-8.08	5.25e-15	5.24e-12	-0.48	-0.35	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	8.08	5.27e-15	5.26e-12	0.4	0.35	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	8.08	5.27e-15	5.26e-12	0.4	0.35	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	8.08	5.27e-15	5.26e-12	0.4	0.35	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
LUAD	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-8.08	5.27e-15	5.26e-12	-0.38	-0.35	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
LUAD	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	8.08	5.29e-15	5.29e-12	0.47	0.35	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-8.08	5.3e-15	5.29e-12	-0.45	-0.35	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
LUAD	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	8.08	5.32e-15	5.31e-12	0.41	0.35	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	8.08	5.32e-15	5.31e-12	0.41	0.35	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
LUAD	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-8.08	5.35e-15	5.35e-12	-0.39	-0.35	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
LUAD	cis	rs11846409	0.932	rs61233250	ENSG00000274576.2	IGHV2-70	-8.08	5.36e-15	5.35e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106634072	chr14:106770577~106771020:-
LUAD	cis	rs11089937	0.597	rs4821770	ENSG00000211639.2	IGLV4-60	8.08	5.38e-15	5.37e-12	0.41	0.35	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs4821771	ENSG00000211639.2	IGLV4-60	8.08	5.38e-15	5.37e-12	0.41	0.35	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22162199~22162681:+
LUAD	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	8.08	5.42e-15	5.41e-12	0.42	0.35	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
LUAD	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-8.08	5.43e-15	5.42e-12	-0.57	-0.35	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
LUAD	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-8.08	5.44e-15	5.43e-12	-0.68	-0.35	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
LUAD	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	8.08	5.45e-15	5.44e-12	0.42	0.35	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
LUAD	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-8.08	5.46e-15	5.45e-12	-0.39	-0.35	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
LUAD	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-8.08	5.46e-15	5.45e-12	-0.39	-0.35	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
LUAD	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-8.07	5.47e-15	5.46e-12	-0.7	-0.35	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-8.07	5.47e-15	5.46e-12	-0.7	-0.35	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
LUAD	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-8.07	5.49e-15	5.47e-12	-0.42	-0.35	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
LUAD	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	8.07	5.51e-15	5.49e-12	0.42	0.35	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
LUAD	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-8.07	5.53e-15	5.51e-12	-0.45	-0.35	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
LUAD	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	8.07	5.54e-15	5.52e-12	0.42	0.35	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
LUAD	cis	rs11089937	0.626	rs5757051	ENSG00000211639.2	IGLV4-60	-8.07	5.55e-15	5.53e-12	-0.4	-0.35	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22162199~22162681:+
LUAD	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-8.07	5.56e-15	5.54e-12	-0.38	-0.35	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
LUAD	cis	rs904251	0.772	rs1224127	ENSG00000279942.1	RP1-153P14.7	-8.07	5.6e-15	5.58e-12	-0.36	-0.35	Cognitive performance;	chr6:37449780	chr6:37567716~37571460:+
LUAD	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	8.07	5.63e-15	5.61e-12	0.45	0.35	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
LUAD	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-8.07	5.63e-15	5.61e-12	-0.46	-0.35	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
LUAD	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-8.07	5.64e-15	5.61e-12	-0.49	-0.35	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
LUAD	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-8.07	5.65e-15	5.63e-12	-0.42	-0.35	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
LUAD	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	8.07	5.68e-15	5.65e-12	0.43	0.35	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	8.07	5.68e-15	5.65e-12	0.43	0.35	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	8.07	5.69e-15	5.66e-12	0.43	0.35	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
LUAD	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	8.07	5.69e-15	5.67e-12	0.47	0.35	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
LUAD	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-8.07	5.69e-15	5.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-8.07	5.69e-15	5.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-8.07	5.69e-15	5.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-8.07	5.7e-15	5.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
LUAD	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	8.07	5.7e-15	5.68e-12	0.47	0.35	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	8.07	5.72e-15	5.69e-12	0.3	0.35	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
LUAD	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	8.07	5.75e-15	5.72e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	8.07	5.75e-15	5.72e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	8.07	5.75e-15	5.72e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	8.07	5.75e-15	5.72e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
LUAD	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-8.07	5.76e-15	5.73e-12	-0.45	-0.35	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
LUAD	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-8.07	5.78e-15	5.75e-12	-0.39	-0.35	Temperament;	chr17:14015466	chr17:14024514~14025488:+
LUAD	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	8.07	5.79e-15	5.76e-12	0.47	0.35	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
LUAD	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	8.07	5.79e-15	5.76e-12	0.46	0.35	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
LUAD	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-8.07	5.82e-15	5.79e-12	-0.68	-0.35	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-8.07	5.82e-15	5.79e-12	-0.68	-0.35	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-8.07	5.82e-15	5.79e-12	-0.68	-0.35	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
LUAD	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-8.07	5.82e-15	5.79e-12	-0.7	-0.35	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
LUAD	cis	rs944289	0.74	rs1537425	ENSG00000257826.1	RP11-116N8.4	8.07	5.83e-15	5.79e-12	0.36	0.35	Thyroid cancer;	chr14:36098954	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	8.06	5.9e-15	5.86e-12	0.4	0.35	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	8.06	5.9e-15	5.86e-12	0.4	0.35	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	8.06	5.9e-15	5.86e-12	0.4	0.35	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	8.06	5.9e-15	5.86e-12	0.47	0.35	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	8.06	5.91e-15	5.87e-12	0.4	0.35	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
LUAD	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-8.06	5.92e-15	5.88e-12	-0.42	-0.35	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
LUAD	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	8.06	5.93e-15	5.89e-12	0.4	0.35	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	8.06	5.94e-15	5.9e-12	0.38	0.35	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
LUAD	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	8.06	5.94e-15	5.9e-12	0.47	0.35	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
LUAD	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
LUAD	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-8.06	6.04e-15	5.98e-12	-0.34	-0.34	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
LUAD	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-8.06	6.09e-15	6.04e-12	-0.48	-0.34	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
LUAD	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	8.06	6.11e-15	6.05e-12	0.5	0.34	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.568	rs35626600	ENSG00000211639.2	IGLV4-60	8.06	6.13e-15	6.07e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.539	rs34228957	ENSG00000211639.2	IGLV4-60	8.06	6.13e-15	6.07e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.512	rs13054756	ENSG00000211639.2	IGLV4-60	8.06	6.13e-15	6.07e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs4821768	ENSG00000211639.2	IGLV4-60	8.06	6.13e-15	6.07e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22162199~22162681:+
LUAD	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-8.06	6.13e-15	6.07e-12	-0.45	-0.34	Height;	chr6:109636120	chr6:109382795~109383666:+
LUAD	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-8.06	6.15e-15	6.09e-12	-0.38	-0.34	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
LUAD	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-8.06	6.16e-15	6.1e-12	-0.47	-0.34	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-8.06	6.16e-15	6.1e-12	-0.47	-0.34	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
LUAD	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-8.06	6.16e-15	6.1e-12	-0.37	-0.34	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
LUAD	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	8.06	6.16e-15	6.1e-12	0.3	0.34	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	8.06	6.16e-15	6.11e-12	0.4	0.34	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	8.06	6.19e-15	6.13e-12	0.38	0.34	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	8.06	6.19e-15	6.13e-12	0.4	0.34	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	8.06	6.19e-15	6.13e-12	0.4	0.34	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
LUAD	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	8.06	6.24e-15	6.18e-12	0.42	0.34	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
LUAD	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-8.06	6.29e-15	6.23e-12	-0.37	-0.34	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
LUAD	cis	rs8177876	0.749	rs12444969	ENSG00000261838.4	RP11-303E16.6	8.05	6.34e-15	6.27e-12	0.82	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81069854~81076598:+
LUAD	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-8.05	6.34e-15	6.27e-12	-0.39	-0.34	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
LUAD	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	8.05	6.37e-15	6.3e-12	0.4	0.34	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	8.05	6.37e-15	6.3e-12	0.4	0.34	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	8.05	6.37e-15	6.3e-12	0.4	0.34	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	8.05	6.37e-15	6.3e-12	0.4	0.34	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	8.05	6.37e-15	6.3e-12	0.41	0.34	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	8.05	6.37e-15	6.3e-12	0.41	0.34	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	8.05	6.37e-15	6.3e-12	0.41	0.34	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	8.05	6.37e-15	6.3e-12	0.41	0.34	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
LUAD	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	8.05	6.42e-15	6.35e-12	0.41	0.34	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
LUAD	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-8.05	6.49e-15	6.41e-12	-0.44	-0.34	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	8.05	6.54e-15	6.46e-12	0.35	0.34	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000211972.2	IGHV3-66	8.05	6.55e-15	6.48e-12	0.3	0.34	Kawasaki disease;	chr14:106691290	chr14:106675017~106675544:-
LUAD	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-8.05	6.6e-15	6.53e-12	-0.47	-0.34	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
LUAD	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	8.05	6.61e-15	6.53e-12	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
LUAD	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	8.05	6.61e-15	6.53e-12	0.43	0.34	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
LUAD	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	8.05	6.62e-15	6.54e-12	0.41	0.34	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
LUAD	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-8.05	6.62e-15	6.54e-12	-0.36	-0.34	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-8.05	6.62e-15	6.54e-12	-0.36	-0.34	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
LUAD	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	8.05	6.62e-15	6.54e-12	0.67	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
LUAD	cis	rs11089937	0.597	rs4821773	ENSG00000211639.2	IGLV4-60	8.05	6.69e-15	6.6e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-8.05	6.7e-15	6.62e-12	-0.27	-0.34	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
LUAD	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	8.05	6.7e-15	6.62e-12	0.4	0.34	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
LUAD	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-8.04	6.79e-15	6.7e-12	-0.36	-0.34	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-8.04	6.8e-15	6.71e-12	-0.35	-0.34	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
LUAD	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-8.04	6.84e-15	6.74e-12	-0.39	-0.34	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
LUAD	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	8.04	6.85e-15	6.75e-12	0.43	0.34	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	8.04	6.85e-15	6.75e-12	0.43	0.34	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
LUAD	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	8.04	6.85e-15	6.76e-12	0.56	0.34	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
LUAD	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	8.04	6.86e-15	6.77e-12	0.4	0.34	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	8.04	6.86e-15	6.77e-12	0.4	0.34	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	8.04	6.87e-15	6.78e-12	0.4	0.34	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
LUAD	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-8.04	6.91e-15	6.81e-12	-0.37	-0.34	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
LUAD	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-8.04	6.92e-15	6.82e-12	-0.45	-0.34	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
LUAD	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-8.04	6.92e-15	6.82e-12	-0.27	-0.34	Breast cancer;	chr11:743813	chr11:781645~782105:+
LUAD	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	8.04	6.93e-15	6.83e-12	0.46	0.34	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
LUAD	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-8.04	6.94e-15	6.84e-12	-0.38	-0.34	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
LUAD	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	8.04	6.94e-15	6.84e-12	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
LUAD	cis	rs11089937	0.626	rs5757017	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs59356111	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs5757019	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs5750579	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs11089925	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs5757024	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs5757026	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs2213156	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs9622955	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs4821781	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs5750589	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs5757038	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22162199~22162681:+
LUAD	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	8.04	6.98e-15	6.87e-12	0.59	0.34	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
LUAD	cis	rs2337406	1	rs10459466	ENSG00000254174.1	IGHV1-12	8.04	7e-15	6.89e-12	0.35	0.34	Alzheimer's disease (late onset);	chr14:106689255	chr14:106122420~106122709:-
LUAD	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
LUAD	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	8.04	7.03e-15	6.91e-12	0.43	0.34	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	8.04	7.03e-15	6.91e-12	0.43	0.34	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	8.04	7.09e-15	6.97e-12	0.4	0.34	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
LUAD	cis	rs34081947	0.5	rs1930766	ENSG00000257826.1	RP11-116N8.4	-8.04	7.16e-15	7.03e-12	-0.37	-0.34	Papillary thyroid cancer;Differentiated thyroid cancer;	chr14:36081037	chr14:36061026~36067190:-
LUAD	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-8.04	7.16e-15	7.04e-12	-0.56	-0.34	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
LUAD	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	8.04	7.19e-15	7.06e-12	0.49	0.34	Migraine;	chr16:75350086	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.686	rs2776911	ENSG00000279942.1	RP1-153P14.7	-8.04	7.23e-15	7.1e-12	-0.37	-0.34	Cognitive performance;	chr6:37472174	chr6:37567716~37571460:+
LUAD	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
LUAD	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	8.03	7.34e-15	7.2e-12	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
LUAD	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	8.03	7.34e-15	7.21e-12	0.48	0.34	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
LUAD	cis	rs8177876	0.822	rs56166222	ENSG00000261838.4	RP11-303E16.6	8.03	7.34e-15	7.21e-12	0.78	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81069854~81076598:+
LUAD	cis	rs11089937	0.597	rs9619812	ENSG00000211639.2	IGLV4-60	8.03	7.41e-15	7.27e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22162199~22162681:+
LUAD	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-8.03	7.42e-15	7.28e-12	-0.33	-0.34	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
LUAD	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	8.03	7.42e-15	7.28e-12	0.6	0.34	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
LUAD	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	8.03	7.45e-15	7.3e-12	0.52	0.34	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	8.03	7.45e-15	7.31e-12	0.41	0.34	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	8.03	7.48e-15	7.33e-12	0.47	0.34	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
LUAD	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	8.03	7.49e-15	7.35e-12	0.45	0.34	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
LUAD	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	8.03	7.5e-15	7.35e-12	0.4	0.34	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
LUAD	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-8.03	7.52e-15	7.37e-12	-0.34	-0.34	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
LUAD	cis	rs904251	0.714	rs2776910	ENSG00000279942.1	RP1-153P14.7	-8.03	7.57e-15	7.41e-12	-0.37	-0.34	Cognitive performance;	chr6:37468508	chr6:37567716~37571460:+
LUAD	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-8.03	7.58e-15	7.42e-12	-0.45	-0.34	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
LUAD	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	8.03	7.6e-15	7.44e-12	0.43	0.34	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
LUAD	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	8.03	7.62e-15	7.46e-12	0.42	0.34	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	8.03	7.62e-15	7.46e-12	0.42	0.34	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
LUAD	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	8.03	7.66e-15	7.5e-12	0.47	0.34	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	8.03	7.7e-15	7.54e-12	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
LUAD	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	8.03	7.7e-15	7.54e-12	0.43	0.34	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	8.03	7.76e-15	7.59e-12	0.52	0.34	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.605	rs4257849	ENSG00000204110.6	RP1-153P14.8	-8.03	7.76e-15	7.59e-12	-0.41	-0.34	Cognitive performance;	chr6:37443193	chr6:37507348~37535616:+
LUAD	cis	rs11089937	0.597	rs4821774	ENSG00000211639.2	IGLV4-60	8.02	7.84e-15	7.67e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22162199~22162681:+
LUAD	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-8.02	7.88e-15	7.71e-12	-0.42	-0.34	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
LUAD	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	8.02	7.91e-15	7.73e-12	0.59	0.34	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
LUAD	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-8.02	7.92e-15	7.74e-12	-0.38	-0.34	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
LUAD	cis	rs11089937	0.597	rs5757027	ENSG00000211639.2	IGLV4-60	8.02	7.95e-15	7.78e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22162199~22162681:+
LUAD	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-8.02	7.95e-15	7.78e-12	-0.52	-0.34	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
LUAD	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	8.02	7.96e-15	7.78e-12	0.54	0.34	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
LUAD	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	8.02	7.96e-15	7.78e-12	0.45	0.34	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
LUAD	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-8.02	7.97e-15	7.79e-12	-0.5	-0.34	QT interval;	chr16:28857143	chr16:28700294~28701540:-
LUAD	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-8.02	7.97e-15	7.79e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
LUAD	cis	rs8177876	0.822	rs77475047	ENSG00000261838.4	RP11-303E16.6	8.02	7.98e-15	7.79e-12	0.8	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81069854~81076598:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000224373.3	IGHV4-59	8.02	8.01e-15	7.82e-12	0.23	0.34	Kawasaki disease;	chr14:106637576	chr14:106627249~106627825:-
LUAD	cis	rs34976449	1	rs34976449	ENSG00000232912.4	RP5-1115A15.1	8.02	8.01e-15	7.83e-12	0.31	0.34	Lymphocyte counts;	chr1:8438266	chr1:8424645~8434838:+
LUAD	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-8.02	8.01e-15	7.83e-12	-0.34	-0.34	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-8.02	8.01e-15	7.83e-12	-0.34	-0.34	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-8.02	8.01e-15	7.83e-12	-0.34	-0.34	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
LUAD	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	8.02	8.04e-15	7.86e-12	0.47	0.34	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
LUAD	cis	rs8177876	0.749	rs79834398	ENSG00000261838.4	RP11-303E16.6	8.02	8.05e-15	7.86e-12	0.77	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81069854~81076598:+
LUAD	cis	rs1537424	0.513	rs944845	ENSG00000257826.1	RP11-116N8.4	-8.02	8.06e-15	7.87e-12	-0.37	-0.34	Thyroid hormone levels;	chr14:36081480	chr14:36061026~36067190:-
LUAD	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	8.02	8.07e-15	7.88e-12	0.41	0.34	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
LUAD	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	8.02	8.1e-15	7.91e-12	0.42	0.34	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	8.02	8.14e-15	7.95e-12	0.42	0.34	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	8.02	8.14e-15	7.95e-12	0.42	0.34	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
LUAD	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-8.02	8.15e-15	7.95e-12	-0.39	-0.34	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
LUAD	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	8.02	8.2e-15	8e-12	0.42	0.34	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	8.02	8.2e-15	8e-12	0.42	0.34	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
LUAD	cis	rs12468226	1	rs111542497	ENSG00000273456.1	RP11-686O6.2	8.02	8.25e-15	8.05e-12	0.47	0.34	Urate levels;	chr2:202330369	chr2:202374932~202375604:-
LUAD	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	8.02	8.27e-15	8.06e-12	0.4	0.34	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	8.02	8.27e-15	8.06e-12	0.4	0.34	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	8.02	8.27e-15	8.06e-12	0.4	0.34	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
LUAD	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	8.01	8.46e-15	8.25e-12	0.4	0.34	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
LUAD	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-8.01	8.5e-15	8.28e-12	-0.46	-0.34	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
LUAD	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	8.01	8.51e-15	8.29e-12	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
LUAD	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-8.01	8.54e-15	8.32e-12	-0.65	-0.34	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
LUAD	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	8.01	8.57e-15	8.35e-12	0.42	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
LUAD	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-8.01	8.58e-15	8.36e-12	-0.41	-0.34	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
LUAD	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	8.01	8.6e-15	8.38e-12	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
LUAD	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-8.01	8.63e-15	8.4e-12	-0.39	-0.34	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
LUAD	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-8.01	8.65e-15	8.42e-12	-0.41	-0.34	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-8.01	8.67e-15	8.44e-12	-0.27	-0.34	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
LUAD	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-8.01	8.71e-15	8.48e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-8.01	8.71e-15	8.48e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	8.01	8.72e-15	8.49e-12	0.42	0.34	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
LUAD	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	8.01	8.75e-15	8.52e-12	0.45	0.34	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	8.01	8.75e-15	8.52e-12	0.45	0.34	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
LUAD	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-8.01	8.76e-15	8.52e-12	-0.47	-0.34	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
LUAD	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-8.01	8.8e-15	8.56e-12	-0.45	-0.34	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
LUAD	cis	rs11089937	0.597	rs9619794	ENSG00000211639.2	IGLV4-60	8.01	8.88e-15	8.63e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs9619800	ENSG00000211639.2	IGLV4-60	8.01	8.9e-15	8.65e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22162199~22162681:+
LUAD	cis	rs8177876	0.749	rs76892049	ENSG00000261838.4	RP11-303E16.6	8.01	8.9e-15	8.66e-12	0.77	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81069854~81076598:+
LUAD	cis	rs944289	0.868	rs2415316	ENSG00000257826.1	RP11-116N8.4	-8.01	8.91e-15	8.66e-12	-0.37	-0.34	Thyroid cancer;	chr14:36139806	chr14:36061026~36067190:-
LUAD	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-8.01	8.92e-15	8.67e-12	-0.39	-0.34	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
LUAD	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	8.01	8.95e-15	8.7e-12	0.46	0.34	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-8.01	8.95e-15	8.7e-12	-0.27	-0.34	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
LUAD	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-8.01	8.96e-15	8.71e-12	-0.5	-0.34	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
LUAD	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	8.01	8.98e-15	8.72e-12	0.41	0.34	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
LUAD	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	8.01	8.99e-15	8.74e-12	0.42	0.34	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.774	rs2415313	ENSG00000257826.1	RP11-116N8.4	-8.01	9.01e-15	8.76e-12	-0.36	-0.34	Thyroid cancer;	chr14:36115246	chr14:36061026~36067190:-
LUAD	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-8.01	9.03e-15	8.77e-12	-0.5	-0.34	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
LUAD	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-8	9.11e-15	8.84e-12	-0.41	-0.34	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
LUAD	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-8	9.11e-15	8.84e-12	-0.35	-0.34	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
LUAD	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	8	9.15e-15	8.88e-12	0.42	0.34	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	8	9.15e-15	8.88e-12	0.42	0.34	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	8	9.15e-15	8.88e-12	0.42	0.34	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
LUAD	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-8	9.16e-15	8.9e-12	-0.49	-0.34	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
LUAD	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	8	9.28e-15	9e-12	0.47	0.34	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
LUAD	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	8	9.35e-15	9.07e-12	0.45	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
LUAD	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	8	9.37e-15	9.09e-12	0.37	0.34	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	8	9.37e-15	9.09e-12	0.37	0.34	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	8	9.37e-15	9.09e-12	0.37	0.34	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
LUAD	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-8	9.4e-15	9.11e-12	-0.39	-0.34	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
LUAD	cis	rs8177876	0.749	rs78707250	ENSG00000261838.4	RP11-303E16.6	8	9.4e-15	9.12e-12	0.79	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81069854~81076598:+
LUAD	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-8	9.44e-15	9.15e-12	-0.49	-0.34	QT interval;	chr16:28877088	chr16:28700294~28701540:-
LUAD	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	8	9.47e-15	9.18e-12	0.41	0.34	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
LUAD	cis	rs2337406	1	rs74090714	ENSG00000254174.1	IGHV1-12	8	9.47e-15	9.18e-12	0.32	0.34	Alzheimer's disease (late onset);	chr14:106691225	chr14:106122420~106122709:-
LUAD	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-8	9.47e-15	9.18e-12	-0.46	-0.34	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
LUAD	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-8	9.5e-15	9.21e-12	-0.35	-0.34	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
LUAD	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	8	9.52e-15	9.23e-12	0.4	0.34	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
LUAD	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-8	9.6e-15	9.3e-12	-0.44	-0.34	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
LUAD	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-8	9.63e-15	9.33e-12	-0.4	-0.34	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
LUAD	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-8	9.68e-15	9.37e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
LUAD	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-8	9.71e-15	9.4e-12	-0.38	-0.34	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
LUAD	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	7.99	9.78e-15	9.46e-12	0.41	0.34	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
LUAD	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	7.99	9.78e-15	9.47e-12	0.56	0.34	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
LUAD	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	7.99	9.78e-15	9.47e-12	0.56	0.34	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
LUAD	cis	rs7924176	0.564	rs2270551	ENSG00000213731.2	RAB5CP1	-7.99	9.84e-15	9.52e-12	-0.37	-0.34	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74109307	chr10:74423435~74424014:-
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000211972.2	IGHV3-66	7.99	9.85e-15	9.53e-12	0.3	0.34	Kawasaki disease;	chr14:106692376	chr14:106675017~106675544:-
LUAD	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	7.99	9.85e-15	9.54e-12	0.47	0.34	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
LUAD	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-7.99	9.87e-15	9.55e-12	-0.65	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
LUAD	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-7.99	9.97e-15	9.64e-12	-0.48	-0.34	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
LUAD	cis	rs12468226	1	rs77435512	ENSG00000273456.1	RP11-686O6.2	7.99	9.97e-15	9.64e-12	0.47	0.34	Urate levels;	chr2:202334165	chr2:202374932~202375604:-
LUAD	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	7.99	1e-14	9.67e-12	0.41	0.34	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	7.99	1e-14	9.67e-12	0.41	0.34	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	7.99	1e-14	9.67e-12	0.41	0.34	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
LUAD	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-7.99	1.01e-14	9.72e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-7.99	1.01e-14	9.72e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-7.99	1.01e-14	9.72e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
LUAD	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-7.99	1.01e-14	9.72e-12	-0.41	-0.34	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
LUAD	cis	rs7688540	0.68	rs77762064	ENSG00000275426.1	CH17-262A2.1	7.99	1.01e-14	9.74e-12	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:281154	chr4:149738~150317:+
LUAD	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	7.99	1.01e-14	9.76e-12	0.52	0.34	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	7.99	1.01e-14	9.77e-12	0.39	0.34	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
LUAD	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-7.99	1.01e-14	9.79e-12	-0.38	-0.34	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000280411.1	IGHV1-69-2	-7.99	1.01e-14	9.8e-12	-0.26	-0.34	Kawasaki disease;	chr14:106776558	chr14:106762092~106762588:-
LUAD	cis	rs8177876	0.822	rs55939311	ENSG00000261838.4	RP11-303E16.6	7.99	1.02e-14	9.81e-12	0.79	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs12444137	ENSG00000261838.4	RP11-303E16.6	7.99	1.02e-14	9.81e-12	0.79	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81069854~81076598:+
LUAD	cis	rs11089937	0.568	rs5756989	ENSG00000211639.2	IGLV4-60	7.99	1.02e-14	9.82e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22162199~22162681:+
LUAD	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-7.99	1.02e-14	9.84e-12	-0.45	-0.34	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
LUAD	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-7.99	1.02e-14	9.84e-12	-0.45	-0.34	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
LUAD	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
LUAD	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
LUAD	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-7.99	1.03e-14	9.91e-12	-0.47	-0.34	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
LUAD	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-7.99	1.03e-14	9.94e-12	-0.47	-0.34	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
LUAD	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-7.99	1.04e-14	1e-11	-0.45	-0.34	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
LUAD	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	7.98	1.05e-14	1.01e-11	0.41	0.34	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
LUAD	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-7.98	1.05e-14	1.01e-11	-0.44	-0.34	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
LUAD	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.48	-0.34	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.49	-0.34	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.48	-0.34	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.48	-0.34	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.48	-0.34	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	7.98	1.07e-14	1.03e-11	0.39	0.34	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000211972.2	IGHV3-66	7.98	1.07e-14	1.03e-11	0.3	0.34	Kawasaki disease;	chr14:106690675	chr14:106675017~106675544:-
LUAD	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	7.98	1.07e-14	1.03e-11	0.41	0.34	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	7.98	1.07e-14	1.03e-11	0.41	0.34	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
LUAD	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	7.98	1.08e-14	1.04e-11	0.4	0.34	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
LUAD	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	7.98	1.08e-14	1.04e-11	0.39	0.34	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
LUAD	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	7.98	1.09e-14	1.05e-11	0.37	0.34	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
LUAD	cis	rs944289	0.708	rs2755194	ENSG00000257826.1	RP11-116N8.4	-7.98	1.09e-14	1.05e-11	-0.36	-0.34	Thyroid cancer;	chr14:36079176	chr14:36061026~36067190:-
LUAD	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-7.98	1.1e-14	1.06e-11	-0.35	-0.34	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
LUAD	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	7.98	1.11e-14	1.07e-11	0.27	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
LUAD	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-7.98	1.11e-14	1.07e-11	-0.48	-0.34	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
LUAD	cis	rs11089937	0.512	rs34963809	ENSG00000211639.2	IGLV4-60	7.98	1.11e-14	1.07e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000224373.3	IGHV4-59	7.98	1.11e-14	1.07e-11	0.22	0.34	Kawasaki disease;	chr14:106649820	chr14:106627249~106627825:-
LUAD	cis	rs944289	0.74	rs11156902	ENSG00000257826.1	RP11-116N8.4	-7.98	1.11e-14	1.07e-11	-0.36	-0.34	Thyroid cancer;	chr14:36080016	chr14:36061026~36067190:-
LUAD	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	7.98	1.12e-14	1.07e-11	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	7.98	1.12e-14	1.07e-11	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
LUAD	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	7.98	1.12e-14	1.07e-11	0.43	0.34	Height;	chr6:109357369	chr6:109382795~109383666:+
LUAD	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	7.98	1.12e-14	1.07e-11	0.46	0.34	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
LUAD	cis	rs944289	0.74	rs1617130	ENSG00000257826.1	RP11-116N8.4	7.97	1.12e-14	1.08e-11	0.36	0.34	Thyroid cancer;	chr14:36077059	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	7.97	1.12e-14	1.08e-11	0.41	0.34	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	7.97	1.12e-14	1.08e-11	0.4	0.34	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
LUAD	cis	rs904251	0.772	rs10692	ENSG00000279942.1	RP1-153P14.7	-7.97	1.12e-14	1.08e-11	-0.35	-0.34	Cognitive performance;	chr6:37483138	chr6:37567716~37571460:+
LUAD	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-7.97	1.13e-14	1.08e-11	-0.41	-0.34	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
LUAD	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	7.97	1.13e-14	1.08e-11	0.42	0.34	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
LUAD	cis	rs11089937	0.597	rs5756991	ENSG00000211639.2	IGLV4-60	7.97	1.13e-14	1.08e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.54	rs5756992	ENSG00000211639.2	IGLV4-60	7.97	1.13e-14	1.08e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs9622919	ENSG00000211639.2	IGLV4-60	7.97	1.13e-14	1.08e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs9619793	ENSG00000211639.2	IGLV4-60	7.97	1.13e-14	1.08e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22162199~22162681:+
LUAD	cis	rs944289	0.74	rs56400346	ENSG00000257826.1	RP11-116N8.4	-7.97	1.13e-14	1.08e-11	-0.36	-0.34	Thyroid cancer;	chr14:36114681	chr14:36061026~36067190:-
LUAD	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-7.97	1.14e-14	1.09e-11	-0.39	-0.34	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
LUAD	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-7.97	1.14e-14	1.09e-11	-0.37	-0.34	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
LUAD	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	7.97	1.15e-14	1.1e-11	0.4	0.34	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
LUAD	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	7.97	1.15e-14	1.1e-11	0.42	0.34	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	7.97	1.15e-14	1.1e-11	0.42	0.34	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
LUAD	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-7.97	1.16e-14	1.11e-11	-0.39	-0.34	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
LUAD	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-7.97	1.17e-14	1.12e-11	-0.49	-0.34	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
LUAD	cis	rs11846409	0.932	rs60659763	ENSG00000274576.2	IGHV2-70	-7.97	1.17e-14	1.12e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106634172	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.932	rs57080270	ENSG00000274576.2	IGHV2-70	-7.97	1.17e-14	1.12e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106634215	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.932	rs60917084	ENSG00000274576.2	IGHV2-70	-7.97	1.17e-14	1.12e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106634621	chr14:106770577~106771020:-
LUAD	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	7.97	1.17e-14	1.12e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
LUAD	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	7.97	1.17e-14	1.12e-11	0.5	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
LUAD	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	7.97	1.18e-14	1.13e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
LUAD	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-7.97	1.18e-14	1.13e-11	-0.48	-0.34	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-7.97	1.18e-14	1.13e-11	-0.48	-0.34	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	7.97	1.18e-14	1.13e-11	0.4	0.34	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000280411.1	IGHV1-69-2	-7.97	1.19e-14	1.14e-11	-0.26	-0.34	Kawasaki disease;	chr14:106777278	chr14:106762092~106762588:-
LUAD	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	7.97	1.19e-14	1.14e-11	0.5	0.34	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
LUAD	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-7.97	1.2e-14	1.15e-11	-0.35	-0.34	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
LUAD	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	7.96	1.22e-14	1.16e-11	0.42	0.34	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
LUAD	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	7.96	1.22e-14	1.17e-11	0.43	0.34	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
LUAD	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	7.96	1.23e-14	1.18e-11	0.42	0.34	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000254174.1	IGHV1-12	-7.96	1.23e-14	1.18e-11	-0.29	-0.34	Alzheimer's disease (late onset);	chr14:106808070	chr14:106122420~106122709:-
LUAD	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	7.96	1.24e-14	1.18e-11	0.54	0.34	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
LUAD	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-7.96	1.26e-14	1.2e-11	-0.32	-0.34	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
LUAD	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-7.96	1.26e-14	1.2e-11	-0.39	-0.34	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
LUAD	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-7.96	1.26e-14	1.21e-11	-0.39	-0.34	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
LUAD	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-7.96	1.26e-14	1.21e-11	-0.45	-0.34	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
LUAD	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-7.96	1.27e-14	1.21e-11	-0.46	-0.34	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
LUAD	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	1.22e-11	-0.49	-0.34	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
LUAD	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	7.96	1.28e-14	1.22e-11	0.48	0.34	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
LUAD	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-7.96	1.28e-14	1.22e-11	-0.47	-0.34	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000211972.2	IGHV3-66	7.96	1.28e-14	1.23e-11	0.3	0.34	Kawasaki disease;	chr14:106680324	chr14:106675017~106675544:-
LUAD	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-7.96	1.29e-14	1.23e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
LUAD	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	7.95	1.3e-14	1.24e-11	0.37	0.34	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
LUAD	cis	rs11089937	0.553	rs35336247	ENSG00000211639.2	IGLV4-60	7.95	1.31e-14	1.25e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.553	rs34088081	ENSG00000211639.2	IGLV4-60	7.95	1.31e-14	1.25e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22162199~22162681:+
LUAD	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-7.95	1.32e-14	1.26e-11	-0.55	-0.34	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
LUAD	cis	rs8059260	0.541	rs16958028	ENSG00000274038.1	RP11-66H6.4	-7.95	1.32e-14	1.26e-11	-0.78	-0.34	Alcohol consumption over the past year;	chr16:11082811	chr16:11056556~11057034:+
LUAD	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-7.95	1.32e-14	1.26e-11	-0.42	-0.34	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-7.95	1.33e-14	1.27e-11	-0.51	-0.34	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-7.95	1.33e-14	1.27e-11	-0.51	-0.34	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
LUAD	cis	rs11089937	0.626	rs9619811	ENSG00000211639.2	IGLV4-60	7.95	1.34e-14	1.28e-11	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22162199~22162681:+
LUAD	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	7.95	1.34e-14	1.28e-11	0.42	0.34	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
LUAD	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-7.95	1.35e-14	1.29e-11	-0.68	-0.34	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
LUAD	cis	rs944289	0.74	rs1623766	ENSG00000257826.1	RP11-116N8.4	7.95	1.37e-14	1.3e-11	0.36	0.34	Thyroid cancer;	chr14:36075632	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs416664	ENSG00000257826.1	RP11-116N8.4	7.95	1.37e-14	1.3e-11	0.36	0.34	Thyroid cancer;	chr14:36076319	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	7.95	1.37e-14	1.3e-11	0.4	0.34	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
LUAD	cis	rs944289	0.74	rs1467794	ENSG00000257826.1	RP11-116N8.4	7.95	1.37e-14	1.3e-11	0.36	0.34	Thyroid cancer;	chr14:36097617	chr14:36061026~36067190:-
LUAD	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	7.95	1.37e-14	1.3e-11	0.47	0.34	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
LUAD	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	7.95	1.38e-14	1.31e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
LUAD	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	7.95	1.38e-14	1.32e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
LUAD	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	7.95	1.38e-14	1.32e-11	0.4	0.34	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
LUAD	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	7.95	1.39e-14	1.32e-11	0.41	0.34	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
LUAD	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	7.94	1.39e-14	1.32e-11	0.44	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
LUAD	cis	rs944289	0.74	rs414155	ENSG00000257826.1	RP11-116N8.4	7.94	1.39e-14	1.32e-11	0.36	0.34	Thyroid cancer;	chr14:36076300	chr14:36061026~36067190:-
LUAD	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	7.94	1.4e-14	1.33e-11	0.6	0.34	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
LUAD	cis	rs11089937	0.597	rs6001072	ENSG00000211639.2	IGLV4-60	7.94	1.41e-14	1.34e-11	0.39	0.34	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22162199~22162681:+
LUAD	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-7.94	1.41e-14	1.35e-11	-0.51	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
LUAD	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	7.94	1.41e-14	1.35e-11	0.48	0.34	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
LUAD	cis	rs4141404	0.582	rs5753630	ENSG00000236132.1	CTA-440B3.1	-7.94	1.42e-14	1.35e-11	-0.39	-0.34	Paclitaxel-induced neuropathy;	chr22:31465964	chr22:31816379~31817491:-
LUAD	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-7.94	1.43e-14	1.36e-11	-0.41	-0.34	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000280411.1	IGHV1-69-2	-7.94	1.43e-14	1.36e-11	-0.25	-0.34	Kawasaki disease;	chr14:106676288	chr14:106762092~106762588:-
LUAD	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	7.94	1.44e-14	1.36e-11	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	7.94	1.44e-14	1.36e-11	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
LUAD	cis	rs1537424	0.513	rs1615453	ENSG00000257826.1	RP11-116N8.4	7.94	1.44e-14	1.37e-11	0.37	0.34	Thyroid hormone levels;	chr14:36077246	chr14:36061026~36067190:-
LUAD	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-7.94	1.44e-14	1.37e-11	-0.43	-0.34	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
LUAD	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	7.94	1.44e-14	1.37e-11	0.41	0.34	Height;	chr11:118809363	chr11:118688039~118690600:-
LUAD	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	7.94	1.45e-14	1.38e-11	0.44	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
LUAD	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	7.94	1.45e-14	1.38e-11	0.36	0.34	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
LUAD	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	7.94	1.45e-14	1.38e-11	0.3	0.34	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
LUAD	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	7.94	1.46e-14	1.38e-11	0.37	0.34	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
LUAD	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-7.94	1.46e-14	1.39e-11	-0.7	-0.34	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
LUAD	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-7.94	1.46e-14	1.39e-11	-0.43	-0.34	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
LUAD	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-7.94	1.46e-14	1.39e-11	-0.56	-0.34	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
LUAD	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-7.94	1.46e-14	1.39e-11	-0.45	-0.34	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
LUAD	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	7.94	1.46e-14	1.39e-11	0.5	0.34	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
LUAD	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	7.94	1.47e-14	1.4e-11	0.45	0.34	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	7.94	1.47e-14	1.4e-11	0.45	0.34	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
LUAD	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-7.94	1.48e-14	1.4e-11	-0.38	-0.34	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
LUAD	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-7.94	1.48e-14	1.4e-11	-0.43	-0.34	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
LUAD	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	7.94	1.48e-14	1.4e-11	0.4	0.34	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	7.94	1.48e-14	1.4e-11	0.47	0.34	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	7.94	1.48e-14	1.4e-11	0.47	0.34	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
LUAD	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-7.94	1.48e-14	1.41e-11	-0.38	-0.34	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
LUAD	cis	rs11089937	0.626	rs2213157	ENSG00000211639.2	IGLV4-60	7.94	1.48e-14	1.41e-11	0.39	0.34	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22162199~22162681:+
LUAD	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	7.93	1.49e-14	1.42e-11	0.5	0.34	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
LUAD	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	7.93	1.49e-14	1.42e-11	0.37	0.34	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
LUAD	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-7.93	1.49e-14	1.42e-11	-0.48	-0.34	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
LUAD	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	7.93	1.5e-14	1.42e-11	0.4	0.34	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	7.93	1.5e-14	1.42e-11	0.4	0.34	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	7.93	1.51e-14	1.43e-11	0.47	0.34	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	7.93	1.51e-14	1.43e-11	0.47	0.34	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	7.93	1.51e-14	1.43e-11	0.47	0.34	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
LUAD	cis	rs944289	0.774	rs1537423	ENSG00000257826.1	RP11-116N8.4	7.93	1.52e-14	1.44e-11	0.36	0.34	Thyroid cancer;	chr14:36104863	chr14:36061026~36067190:-
LUAD	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	7.93	1.53e-14	1.45e-11	0.44	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
LUAD	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	7.93	1.53e-14	1.45e-11	0.49	0.34	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
LUAD	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	7.93	1.54e-14	1.46e-11	0.42	0.34	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
LUAD	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	7.93	1.55e-14	1.47e-11	0.44	0.34	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
LUAD	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-7.93	1.56e-14	1.47e-11	-0.39	-0.34	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
LUAD	cis	rs944289	0.712	rs35736442	ENSG00000257826.1	RP11-116N8.4	-7.93	1.56e-14	1.47e-11	-0.36	-0.34	Thyroid cancer;	chr14:36081119	chr14:36061026~36067190:-
LUAD	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	7.93	1.56e-14	1.48e-11	0.41	0.34	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
LUAD	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-7.93	1.56e-14	1.48e-11	-0.39	-0.34	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
LUAD	cis	rs944289	0.74	rs884384	ENSG00000257826.1	RP11-116N8.4	-7.93	1.56e-14	1.48e-11	-0.36	-0.34	Thyroid cancer;	chr14:36081801	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs884383	ENSG00000257826.1	RP11-116N8.4	-7.93	1.56e-14	1.48e-11	-0.36	-0.34	Thyroid cancer;	chr14:36081936	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	7.93	1.59e-14	1.5e-11	0.4	0.34	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
LUAD	cis	rs904251	0.686	rs1224128	ENSG00000204110.6	RP1-153P14.8	-7.93	1.59e-14	1.51e-11	-0.4	-0.34	Cognitive performance;	chr6:37447900	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	7.93	1.6e-14	1.51e-11	0.4	0.34	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
LUAD	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-7.92	1.6e-14	1.52e-11	-0.38	-0.34	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
LUAD	cis	rs10899021	1	rs11236190	ENSG00000279353.1	RP11-864N7.4	7.92	1.6e-14	1.52e-11	0.69	0.34	Response to metformin (IC50);	chr11:74655710	chr11:74698231~74699658:-
LUAD	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	7.92	1.61e-14	1.52e-11	0.4	0.34	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
LUAD	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	7.92	1.62e-14	1.53e-11	0.37	0.34	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
LUAD	cis	rs944289	0.74	rs398501	ENSG00000257826.1	RP11-116N8.4	-7.92	1.62e-14	1.53e-11	-0.36	-0.34	Thyroid cancer;	chr14:36078452	chr14:36061026~36067190:-
LUAD	cis	rs904251	0.714	rs2776910	ENSG00000204110.6	RP1-153P14.8	-7.92	1.63e-14	1.54e-11	-0.4	-0.34	Cognitive performance;	chr6:37468508	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	7.92	1.63e-14	1.54e-11	0.51	0.34	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
LUAD	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	7.92	1.63e-14	1.54e-11	0.37	0.34	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
LUAD	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-7.92	1.63e-14	1.54e-11	-0.41	-0.34	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
LUAD	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-7.92	1.64e-14	1.55e-11	-0.4	-0.34	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	7.92	1.64e-14	1.55e-11	0.37	0.34	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000211972.2	IGHV3-66	7.92	1.64e-14	1.55e-11	0.3	0.34	Kawasaki disease;	chr14:106689997	chr14:106675017~106675544:-
LUAD	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	7.92	1.65e-14	1.56e-11	0.41	0.34	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
LUAD	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-7.92	1.67e-14	1.57e-11	-0.35	-0.34	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
LUAD	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	7.92	1.67e-14	1.58e-11	0.42	0.34	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
LUAD	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	7.92	1.68e-14	1.58e-11	0.46	0.34	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
LUAD	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	7.92	1.68e-14	1.58e-11	0.46	0.34	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	7.92	1.68e-14	1.59e-11	0.5	0.34	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
LUAD	cis	rs10200159	0.793	rs13383352	ENSG00000272606.1	RP11-554J4.1	7.92	1.68e-14	1.59e-11	0.57	0.34	Vitiligo;	chr2:55643692	chr2:55617909~55618373:+
LUAD	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	7.92	1.69e-14	1.59e-11	0.58	0.34	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-7.92	1.69e-14	1.6e-11	-0.56	-0.34	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
LUAD	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	7.92	1.69e-14	1.6e-11	0.37	0.34	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
LUAD	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	7.92	1.69e-14	1.6e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
LUAD	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-7.92	1.69e-14	1.6e-11	-0.39	-0.34	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
LUAD	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	7.92	1.69e-14	1.6e-11	0.41	0.34	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
LUAD	cis	rs1167827	0.805	rs809439	ENSG00000127957.15	PMS2P3	7.92	1.71e-14	1.61e-11	0.32	0.34	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75502930~75528148:-
LUAD	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	7.92	1.71e-14	1.61e-11	0.41	0.34	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	7.92	1.71e-14	1.61e-11	0.41	0.34	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
LUAD	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	7.91	1.73e-14	1.63e-11	0.59	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
LUAD	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	7.91	1.73e-14	1.64e-11	0.47	0.34	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
LUAD	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	7.91	1.74e-14	1.64e-11	0.54	0.34	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
LUAD	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-7.91	1.74e-14	1.64e-11	-0.49	-0.34	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
LUAD	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	7.91	1.75e-14	1.65e-11	0.34	0.34	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
LUAD	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-7.91	1.75e-14	1.65e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
LUAD	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-7.91	1.75e-14	1.65e-11	-0.45	-0.34	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
LUAD	cis	rs10899021	1	rs11236201	ENSG00000279353.1	RP11-864N7.4	7.91	1.76e-14	1.66e-11	0.7	0.34	Response to metformin (IC50);	chr11:74664588	chr11:74698231~74699658:-
LUAD	cis	rs10899021	1	rs11236202	ENSG00000279353.1	RP11-864N7.4	7.91	1.76e-14	1.66e-11	0.7	0.34	Response to metformin (IC50);	chr11:74665647	chr11:74698231~74699658:-
LUAD	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	7.91	1.77e-14	1.67e-11	0.37	0.34	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
LUAD	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-7.91	1.77e-14	1.67e-11	-0.39	-0.34	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
LUAD	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-7.91	1.77e-14	1.67e-11	-0.56	-0.34	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
LUAD	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	7.91	1.77e-14	1.67e-11	0.39	0.34	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
LUAD	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-7.91	1.78e-14	1.67e-11	-0.33	-0.34	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
LUAD	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	7.91	1.78e-14	1.68e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
LUAD	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-7.91	1.79e-14	1.68e-11	-0.48	-0.34	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
LUAD	cis	rs9287719	0.649	rs58633964	ENSG00000234818.1	AC092687.5	7.91	1.79e-14	1.69e-11	0.41	0.34	Prostate cancer;	chr2:10596256	chr2:10589166~10604830:+
LUAD	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-7.91	1.79e-14	1.69e-11	-0.77	-0.34	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
LUAD	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-7.91	1.8e-14	1.69e-11	-0.38	-0.34	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
LUAD	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	7.91	1.8e-14	1.7e-11	0.41	0.34	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
LUAD	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-7.91	1.81e-14	1.7e-11	-0.63	-0.34	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
LUAD	cis	rs944289	0.74	rs12891345	ENSG00000257826.1	RP11-116N8.4	-7.91	1.82e-14	1.71e-11	-0.36	-0.34	Thyroid cancer;	chr14:36126977	chr14:36061026~36067190:-
LUAD	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	7.91	1.82e-14	1.72e-11	0.4	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
LUAD	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	7.91	1.83e-14	1.72e-11	0.4	0.34	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	7.91	1.83e-14	1.72e-11	0.4	0.34	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	7.91	1.84e-14	1.73e-11	0.41	0.34	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	7.91	1.84e-14	1.73e-11	0.41	0.34	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	7.91	1.84e-14	1.73e-11	0.41	0.34	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
LUAD	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-7.91	1.84e-14	1.73e-11	-0.46	-0.34	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
LUAD	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	7.9	1.87e-14	1.75e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
LUAD	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	7.9	1.87e-14	1.75e-11	0.47	0.34	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
LUAD	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	7.9	1.87e-14	1.76e-11	0.6	0.34	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
LUAD	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	7.9	1.88e-14	1.77e-11	0.44	0.34	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
LUAD	cis	rs10200159	1	rs13430684	ENSG00000272606.1	RP11-554J4.1	7.9	1.88e-14	1.77e-11	0.57	0.34	Vitiligo;	chr2:55642709	chr2:55617909~55618373:+
LUAD	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	7.9	1.89e-14	1.77e-11	0.44	0.34	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
LUAD	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-7.9	1.89e-14	1.77e-11	-0.44	-0.34	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
LUAD	cis	rs904251	0.605	rs4257849	ENSG00000279942.1	RP1-153P14.7	-7.9	1.89e-14	1.77e-11	-0.37	-0.34	Cognitive performance;	chr6:37443193	chr6:37567716~37571460:+
LUAD	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	7.9	1.89e-14	1.78e-11	0.76	0.34	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
LUAD	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	7.9	1.89e-14	1.78e-11	0.76	0.34	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
LUAD	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-7.9	1.89e-14	1.78e-11	-0.47	-0.34	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
LUAD	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-7.9	1.9e-14	1.79e-11	-0.4	-0.34	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
LUAD	cis	rs10200159	1	rs7558127	ENSG00000272606.1	RP11-554J4.1	7.9	1.91e-14	1.79e-11	0.56	0.34	Vitiligo;	chr2:55639470	chr2:55617909~55618373:+
LUAD	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	7.9	1.91e-14	1.79e-11	0.38	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
LUAD	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	7.9	1.92e-14	1.8e-11	0.41	0.34	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
LUAD	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	7.9	1.94e-14	1.82e-11	0.44	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
LUAD	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-7.9	1.95e-14	1.83e-11	-0.44	-0.34	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-7.9	1.95e-14	1.83e-11	-0.44	-0.34	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-7.9	1.95e-14	1.83e-11	-0.44	-0.34	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
LUAD	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	7.9	1.95e-14	1.83e-11	0.6	0.34	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
LUAD	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-7.9	1.95e-14	1.83e-11	-0.46	-0.34	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-7.9	1.95e-14	1.83e-11	-0.46	-0.34	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
LUAD	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	7.9	1.96e-14	1.83e-11	0.43	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
LUAD	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-7.9	1.97e-14	1.85e-11	-0.48	-0.34	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
LUAD	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	7.9	1.97e-14	1.85e-11	0.4	0.34	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
LUAD	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-7.9	1.97e-14	1.85e-11	-0.47	-0.34	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
LUAD	cis	rs35955747	0.714	rs5997989	ENSG00000236132.1	CTA-440B3.1	7.89	1.98e-14	1.86e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31443964	chr22:31816379~31817491:-
LUAD	cis	rs944289	0.74	rs379426	ENSG00000257826.1	RP11-116N8.4	7.89	1.99e-14	1.86e-11	0.36	0.34	Thyroid cancer;	chr14:36075253	chr14:36061026~36067190:-
LUAD	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-7.89	1.99e-14	1.86e-11	-0.43	-0.34	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
LUAD	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-7.89	1.99e-14	1.87e-11	-0.35	-0.34	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
LUAD	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-7.89	1.99e-14	1.87e-11	-0.47	-0.34	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
LUAD	cis	rs11089937	0.597	rs5750582	ENSG00000211639.2	IGLV4-60	7.89	1.99e-14	1.87e-11	0.39	0.34	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs5757028	ENSG00000211639.2	IGLV4-60	7.89	1.99e-14	1.87e-11	0.39	0.34	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.54	rs2329931	ENSG00000211639.2	IGLV4-60	7.89	2e-14	1.87e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs2876996	ENSG00000211639.2	IGLV4-60	7.89	2e-14	1.87e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22162199~22162681:+
LUAD	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-7.89	2e-14	1.88e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
LUAD	cis	rs8031584	0.651	rs28664821	ENSG00000260382.1	RP11-540B6.2	-7.89	2.02e-14	1.89e-11	-0.41	-0.34	Huntington's disease progression;	chr15:30880120	chr15:30882267~30883231:-
LUAD	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-7.89	2.02e-14	1.89e-11	-0.41	-0.34	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	7.89	2.02e-14	1.89e-11	0.41	0.34	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	7.89	2.02e-14	1.89e-11	0.4	0.34	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
LUAD	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
LUAD	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	7.89	2.05e-14	1.92e-11	0.39	0.34	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
LUAD	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-7.89	2.05e-14	1.92e-11	-0.39	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
LUAD	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	7.89	2.06e-14	1.92e-11	0.4	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
LUAD	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	7.89	2.06e-14	1.92e-11	0.4	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
LUAD	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-7.89	2.06e-14	1.93e-11	-0.5	-0.34	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
LUAD	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	7.89	2.07e-14	1.94e-11	0.42	0.34	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	7.89	2.08e-14	1.94e-11	0.39	0.34	Depression;	chr6:28327262	chr6:28176188~28176674:+
LUAD	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	7.89	2.09e-14	1.96e-11	0.41	0.34	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
LUAD	cis	rs904251	0.686	rs931649	ENSG00000204110.6	RP1-153P14.8	-7.89	2.1e-14	1.96e-11	-0.4	-0.34	Cognitive performance;	chr6:37498303	chr6:37507348~37535616:+
LUAD	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-7.89	2.1e-14	1.96e-11	-0.4	-0.34	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
LUAD	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	7.89	2.1e-14	1.96e-11	0.37	0.34	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
LUAD	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	7.89	2.11e-14	1.97e-11	0.55	0.34	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
LUAD	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	7.89	2.11e-14	1.97e-11	0.37	0.34	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
LUAD	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	7.89	2.12e-14	1.98e-11	0.46	0.34	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
LUAD	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	7.89	2.12e-14	1.98e-11	0.5	0.34	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
LUAD	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	7.89	2.12e-14	1.98e-11	0.41	0.34	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
LUAD	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-7.88	2.14e-14	1.99e-11	-0.43	-0.34	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
LUAD	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-7.88	2.14e-14	2e-11	-0.43	-0.34	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
LUAD	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	7.88	2.15e-14	2.01e-11	0.52	0.34	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
LUAD	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	7.88	2.15e-14	2.01e-11	0.59	0.34	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
LUAD	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-7.88	2.16e-14	2.02e-11	-0.34	-0.34	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
LUAD	cis	rs11089937	0.626	rs2213161	ENSG00000211639.2	IGLV4-60	7.88	2.16e-14	2.02e-11	0.42	0.34	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22162199~22162681:+
LUAD	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-7.88	2.17e-14	2.02e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-7.88	2.17e-14	2.02e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-7.88	2.17e-14	2.02e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
LUAD	cis	rs11089937	0.568	rs12160318	ENSG00000211639.2	IGLV4-60	7.88	2.17e-14	2.02e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs12159174	ENSG00000211639.2	IGLV4-60	7.88	2.17e-14	2.02e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs11089919	ENSG00000211639.2	IGLV4-60	7.88	2.17e-14	2.02e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22162199~22162681:+
LUAD	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	7.88	2.17e-14	2.03e-11	0.45	0.34	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
LUAD	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-7.88	2.2e-14	2.05e-11	-0.46	-0.34	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
LUAD	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-7.88	2.21e-14	2.06e-11	-0.41	-0.34	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
LUAD	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	7.88	2.22e-14	2.07e-11	0.47	0.34	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
LUAD	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-7.88	2.23e-14	2.08e-11	-0.44	-0.34	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
LUAD	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-7.88	2.23e-14	2.08e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	7.88	2.24e-14	2.09e-11	0.41	0.34	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
LUAD	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-7.88	2.24e-14	2.09e-11	-0.47	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
LUAD	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	7.87	2.28e-14	2.13e-11	0.44	0.34	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	7.87	2.28e-14	2.13e-11	0.44	0.34	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	7.87	2.28e-14	2.13e-11	0.44	0.34	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
LUAD	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	7.87	2.29e-14	2.13e-11	0.42	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
LUAD	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-7.87	2.29e-14	2.13e-11	-0.47	-0.34	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
LUAD	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
LUAD	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	7.87	2.32e-14	2.15e-11	0.79	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
LUAD	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-7.87	2.32e-14	2.16e-11	-0.39	-0.34	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
LUAD	cis	rs8031584	0.678	rs4779790	ENSG00000260382.1	RP11-540B6.2	7.87	2.33e-14	2.17e-11	0.42	0.34	Huntington's disease progression;	chr15:30872392	chr15:30882267~30883231:-
LUAD	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-7.87	2.33e-14	2.17e-11	-0.45	-0.34	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
LUAD	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	7.87	2.33e-14	2.17e-11	0.38	0.34	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
LUAD	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-7.87	2.34e-14	2.18e-11	-0.41	-0.34	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
LUAD	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-7.87	2.34e-14	2.18e-11	-0.58	-0.34	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
LUAD	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-7.87	2.35e-14	2.18e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
LUAD	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	7.87	2.35e-14	2.18e-11	0.38	0.34	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
LUAD	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	7.87	2.35e-14	2.19e-11	0.51	0.34	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
LUAD	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-7.87	2.35e-14	2.19e-11	-0.42	-0.34	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
LUAD	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-7.87	2.36e-14	2.19e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
LUAD	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	7.87	2.36e-14	2.19e-11	0.38	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
LUAD	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	7.87	2.37e-14	2.2e-11	0.44	0.34	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	7.87	2.37e-14	2.2e-11	0.44	0.34	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	7.87	2.37e-14	2.2e-11	0.44	0.34	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
LUAD	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-7.87	2.37e-14	2.2e-11	-0.39	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000274576.2	IGHV2-70	-7.87	2.37e-14	2.2e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106637262	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000274576.2	IGHV2-70	-7.87	2.37e-14	2.2e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106638192	chr14:106770577~106771020:-
LUAD	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-7.87	2.38e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-7.87	2.38e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
LUAD	cis	rs11089937	0.568	rs12160317	ENSG00000211639.2	IGLV4-60	7.87	2.38e-14	2.21e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22162199~22162681:+
LUAD	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	7.87	2.39e-14	2.22e-11	0.4	0.34	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	7.87	2.4e-14	2.23e-11	0.37	0.34	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	7.87	2.4e-14	2.23e-11	0.37	0.34	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	7.87	2.4e-14	2.23e-11	0.37	0.34	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-7.87	2.41e-14	2.24e-11	-0.26	-0.34	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
LUAD	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	7.87	2.41e-14	2.24e-11	0.37	0.34	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
LUAD	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-7.87	2.42e-14	2.25e-11	-0.42	-0.34	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	7.87	2.44e-14	2.27e-11	0.41	0.34	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
LUAD	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	7.87	2.44e-14	2.27e-11	0.57	0.34	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
LUAD	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	7.87	2.45e-14	2.27e-11	0.41	0.34	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
LUAD	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	7.86	2.45e-14	2.28e-11	0.73	0.34	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
LUAD	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	7.86	2.45e-14	2.28e-11	0.4	0.34	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
LUAD	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	7.86	2.46e-14	2.28e-11	0.41	0.34	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
LUAD	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	7.86	2.46e-14	2.28e-11	0.41	0.34	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
LUAD	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-7.86	2.47e-14	2.29e-11	-0.37	-0.34	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
LUAD	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-7.86	2.47e-14	2.29e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
LUAD	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	7.86	2.48e-14	2.3e-11	0.47	0.34	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
LUAD	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	7.86	2.48e-14	2.3e-11	0.46	0.34	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
LUAD	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	7.86	2.49e-14	2.31e-11	0.4	0.34	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
LUAD	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
LUAD	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	7.86	2.49e-14	2.31e-11	0.39	0.34	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
LUAD	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	7.86	2.51e-14	2.33e-11	0.4	0.34	Height;	chr11:118808920	chr11:118688039~118690600:-
LUAD	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
LUAD	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	7.86	2.56e-14	2.37e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
LUAD	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	7.86	2.56e-14	2.37e-11	0.41	0.34	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
LUAD	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	7.86	2.56e-14	2.37e-11	0.39	0.34	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	7.86	2.57e-14	2.37e-11	0.4	0.34	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
LUAD	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	7.86	2.57e-14	2.38e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
LUAD	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-7.86	2.57e-14	2.38e-11	-0.4	-0.34	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
LUAD	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	7.86	2.58e-14	2.39e-11	0.36	0.34	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
LUAD	cis	rs10200159	1	rs6739788	ENSG00000272606.1	RP11-554J4.1	7.86	2.61e-14	2.42e-11	0.56	0.34	Vitiligo;	chr2:55635220	chr2:55617909~55618373:+
LUAD	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	7.86	2.62e-14	2.42e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	7.86	2.62e-14	2.42e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	7.86	2.62e-14	2.42e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	7.86	2.62e-14	2.42e-11	0.4	0.34	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
LUAD	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-7.86	2.62e-14	2.42e-11	-0.42	-0.34	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.648	rs11216257	ENSG00000280143.1	AP000892.6	7.86	2.62e-14	2.43e-11	0.44	0.34	Blood protein levels;	chr11:117061845	chr11:117204967~117210292:+
LUAD	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	7.86	2.63e-14	2.43e-11	0.41	0.34	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
LUAD	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	7.86	2.63e-14	2.43e-11	0.43	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
LUAD	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	7.86	2.63e-14	2.43e-11	0.4	0.34	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
LUAD	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	7.85	2.63e-14	2.43e-11	0.44	0.34	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
LUAD	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	7.85	2.64e-14	2.44e-11	0.37	0.34	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
LUAD	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	7.85	2.64e-14	2.44e-11	0.4	0.34	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
LUAD	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	7.85	2.65e-14	2.44e-11	0.39	0.34	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	7.85	2.65e-14	2.44e-11	0.39	0.34	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	7.85	2.65e-14	2.44e-11	0.39	0.34	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	7.85	2.65e-14	2.44e-11	0.39	0.34	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
LUAD	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	7.85	2.65e-14	2.45e-11	0.4	0.34	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	7.85	2.65e-14	2.45e-11	0.4	0.34	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	7.85	2.65e-14	2.45e-11	0.4	0.34	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	7.85	2.65e-14	2.45e-11	0.4	0.34	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
LUAD	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	7.85	2.66e-14	2.46e-11	0.51	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
LUAD	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-7.85	2.67e-14	2.46e-11	-0.37	-0.34	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
LUAD	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	7.85	2.67e-14	2.46e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	7.85	2.68e-14	2.47e-11	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-7.85	2.69e-14	2.48e-11	-0.41	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
LUAD	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
LUAD	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
LUAD	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	7.85	2.71e-14	2.49e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	7.85	2.71e-14	2.5e-11	0.38	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
LUAD	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
LUAD	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	7.85	2.73e-14	2.51e-11	0.39	0.34	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	7.85	2.74e-14	2.52e-11	0.39	0.34	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
LUAD	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	7.85	2.74e-14	2.52e-11	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	7.85	2.74e-14	2.52e-11	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
LUAD	cis	rs8177876	0.658	rs2278022	ENSG00000261838.4	RP11-303E16.6	7.85	2.74e-14	2.52e-11	0.77	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81069854~81076598:+
LUAD	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	7.85	2.74e-14	2.53e-11	0.41	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
LUAD	cis	rs944289	0.74	rs376927	ENSG00000257826.1	RP11-116N8.4	-7.85	2.76e-14	2.54e-11	-0.36	-0.34	Thyroid cancer;	chr14:36078725	chr14:36061026~36067190:-
LUAD	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	7.85	2.77e-14	2.55e-11	0.41	0.34	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
LUAD	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	7.85	2.77e-14	2.55e-11	0.4	0.34	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	7.85	2.77e-14	2.55e-11	0.4	0.34	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	7.85	2.78e-14	2.56e-11	0.27	0.34	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
LUAD	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-7.85	2.78e-14	2.56e-11	-0.46	-0.34	Depression;	chr6:28096845	chr6:28115628~28116551:+
LUAD	cis	rs944289	0.708	rs2899845	ENSG00000257826.1	RP11-116N8.4	-7.85	2.81e-14	2.58e-11	-0.36	-0.34	Thyroid cancer;	chr14:36116632	chr14:36061026~36067190:-
LUAD	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	7.85	2.82e-14	2.59e-11	0.58	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
LUAD	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-7.85	2.82e-14	2.59e-11	-0.58	-0.34	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
LUAD	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	7.84	2.83e-14	2.6e-11	0.5	0.34	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	7.84	2.83e-14	2.6e-11	0.5	0.34	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
LUAD	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
LUAD	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	7.84	2.83e-14	2.6e-11	0.39	0.34	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
LUAD	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-7.84	2.83e-14	2.6e-11	-0.48	-0.34	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
LUAD	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	7.84	2.84e-14	2.61e-11	0.4	0.34	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
LUAD	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-7.84	2.84e-14	2.61e-11	-0.36	-0.34	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
LUAD	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-7.84	2.85e-14	2.61e-11	-0.37	-0.34	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
LUAD	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	7.84	2.85e-14	2.62e-11	0.5	0.34	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
LUAD	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	7.84	2.86e-14	2.63e-11	0.37	0.34	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	7.84	2.88e-14	2.65e-11	0.37	0.34	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
LUAD	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	7.84	2.88e-14	2.65e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
LUAD	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	7.84	2.9e-14	2.66e-11	0.38	0.34	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
LUAD	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-7.84	2.91e-14	2.68e-11	-0.49	-0.34	QT interval;	chr16:28845498	chr16:28700294~28701540:-
LUAD	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	7.84	2.92e-14	2.68e-11	0.4	0.34	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
LUAD	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	7.84	2.93e-14	2.69e-11	0.42	0.34	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
LUAD	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	7.84	2.93e-14	2.69e-11	0.38	0.34	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
LUAD	cis	rs1537424	0.513	rs1953119	ENSG00000257826.1	RP11-116N8.4	-7.84	2.94e-14	2.7e-11	-0.37	-0.34	Thyroid hormone levels;	chr14:36091618	chr14:36061026~36067190:-
LUAD	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-7.84	2.94e-14	2.7e-11	-0.44	-0.34	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
LUAD	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-7.84	2.94e-14	2.7e-11	-0.29	-0.34	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
LUAD	cis	rs10200159	1	rs10172506	ENSG00000272606.1	RP11-554J4.1	7.84	2.94e-14	2.7e-11	0.57	0.34	Vitiligo;	chr2:55638334	chr2:55617909~55618373:+
LUAD	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	7.84	2.96e-14	2.72e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	7.84	2.96e-14	2.72e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
LUAD	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	7.84	2.97e-14	2.73e-11	0.39	0.34	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
LUAD	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	7.84	2.99e-14	2.74e-11	0.35	0.34	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
LUAD	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	7.84	2.99e-14	2.74e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
LUAD	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	7.84	2.99e-14	2.74e-11	0.47	0.34	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
LUAD	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	7.84	2.99e-14	2.74e-11	0.44	0.34	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
LUAD	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-7.84	3e-14	2.75e-11	-0.59	-0.34	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
LUAD	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	7.84	3e-14	2.75e-11	0.43	0.34	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	7.84	3e-14	2.75e-11	0.43	0.34	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	7.84	3e-14	2.75e-11	0.43	0.34	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
LUAD	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-7.84	3e-14	2.75e-11	-0.54	-0.34	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
LUAD	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-7.84	3.01e-14	2.76e-11	-0.46	-0.34	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-7.84	3.01e-14	2.76e-11	-0.46	-0.34	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
LUAD	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-7.84	3.02e-14	2.77e-11	-0.37	-0.34	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
LUAD	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
LUAD	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	7.83	3.04e-14	2.78e-11	0.4	0.34	Temperament;	chr17:13996939	chr17:14024514~14025488:+
LUAD	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-7.83	3.04e-14	2.79e-11	-0.57	-0.34	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
LUAD	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-7.83	3.05e-14	2.79e-11	-0.42	-0.34	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
LUAD	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
LUAD	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	7.83	3.06e-14	2.8e-11	0.37	0.34	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
LUAD	cis	rs1789	0.558	rs10021522	ENSG00000273133.1	RP11-799M12.2	-7.83	3.06e-14	2.8e-11	-0.46	-0.34	Blood protein levels;	chr4:15522985	chr4:15563698~15564253:-
LUAD	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-7.83	3.08e-14	2.82e-11	-0.39	-0.34	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
LUAD	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	7.83	3.08e-14	2.82e-11	0.4	0.34	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	7.83	3.08e-14	2.82e-11	0.4	0.34	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	7.83	3.08e-14	2.82e-11	0.4	0.34	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	7.83	3.08e-14	2.82e-11	0.4	0.34	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
LUAD	cis	rs11089937	0.667	rs9622981	ENSG00000211639.2	IGLV4-60	7.83	3.11e-14	2.84e-11	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22162199~22162681:+
LUAD	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-7.83	3.12e-14	2.85e-11	-0.34	-0.34	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
LUAD	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	7.83	3.15e-14	2.88e-11	0.4	0.34	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	7.83	3.15e-14	2.88e-11	0.4	0.34	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
LUAD	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	7.83	3.15e-14	2.88e-11	0.42	0.34	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
LUAD	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	7.83	3.16e-14	2.89e-11	0.51	0.34	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
LUAD	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-7.83	3.16e-14	2.89e-11	-0.38	-0.34	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-7.83	3.17e-14	2.9e-11	-0.48	-0.34	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
LUAD	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	7.83	3.19e-14	2.91e-11	0.39	0.34	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
LUAD	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	7.83	3.2e-14	2.93e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
LUAD	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	7.83	3.22e-14	2.94e-11	0.5	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
LUAD	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	7.83	3.23e-14	2.95e-11	0.44	0.34	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
LUAD	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-7.83	3.23e-14	2.95e-11	-0.37	-0.34	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-7.83	3.23e-14	2.95e-11	-0.37	-0.34	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-7.83	3.23e-14	2.95e-11	-0.49	-0.34	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	7.83	3.24e-14	2.96e-11	0.47	0.34	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.626	rs4821784	ENSG00000211639.2	IGLV4-60	7.83	3.24e-14	2.96e-11	0.42	0.34	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22162199~22162681:+
LUAD	cis	rs2337406	1	rs17112416	ENSG00000254174.1	IGHV1-12	-7.83	3.25e-14	2.96e-11	-0.31	-0.34	Alzheimer's disease (late onset);	chr14:106686773	chr14:106122420~106122709:-
LUAD	cis	rs904251	0.647	rs2776908	ENSG00000279942.1	RP1-153P14.7	-7.83	3.25e-14	2.97e-11	-0.37	-0.34	Cognitive performance;	chr6:37467081	chr6:37567716~37571460:+
LUAD	cis	rs11089937	0.667	rs10483108	ENSG00000211639.2	IGLV4-60	7.83	3.25e-14	2.97e-11	0.42	0.34	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22162199~22162681:+
LUAD	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	7.83	3.25e-14	2.97e-11	0.42	0.34	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
LUAD	cis	rs9326248	0.53	rs7940310	ENSG00000280143.1	AP000892.6	7.82	3.27e-14	2.98e-11	0.53	0.34	Blood protein levels;	chr11:117153765	chr11:117204967~117210292:+
LUAD	cis	rs34779708	0.832	rs6481946	ENSG00000230534.5	RP11-297A16.2	7.82	3.27e-14	2.98e-11	0.41	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35098006~35127020:-
LUAD	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-7.82	3.27e-14	2.99e-11	-0.32	-0.34	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
LUAD	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-7.82	3.28e-14	2.99e-11	-0.48	-0.34	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
LUAD	cis	rs904251	0.772	rs2252920	ENSG00000279942.1	RP1-153P14.7	-7.82	3.28e-14	2.99e-11	-0.35	-0.34	Cognitive performance;	chr6:37450551	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-7.82	3.29e-14	3e-11	-0.47	-0.34	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
LUAD	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.31e-14	3.02e-11	-0.37	-0.34	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.31e-14	3.02e-11	-0.37	-0.34	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.31e-14	3.02e-11	-0.37	-0.34	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
LUAD	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	7.82	3.34e-14	3.04e-11	0.46	0.34	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.637	rs988200	ENSG00000211639.2	IGLV4-60	7.82	3.35e-14	3.06e-11	0.42	0.34	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22162199~22162681:+
LUAD	cis	rs10740039	0.583	rs9415613	ENSG00000254271.1	RP11-131N11.4	-7.82	3.37e-14	3.07e-11	-0.4	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60747636	chr10:60734342~60741828:+
LUAD	cis	rs944289	0.774	rs1958623	ENSG00000257826.1	RP11-116N8.4	-7.82	3.37e-14	3.08e-11	-0.35	-0.34	Thyroid cancer;	chr14:36128417	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-7.82	3.39e-14	3.09e-11	-0.3	-0.34	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
LUAD	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	7.82	3.4e-14	3.1e-11	0.44	0.34	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	7.82	3.4e-14	3.1e-11	0.44	0.34	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
LUAD	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	7.82	3.4e-14	3.1e-11	0.4	0.34	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
LUAD	cis	rs35955747	0.633	rs5998021	ENSG00000236132.1	CTA-440B3.1	7.82	3.41e-14	3.11e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31511441	chr22:31816379~31817491:-
LUAD	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-7.82	3.41e-14	3.11e-11	-0.38	-0.34	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	7.82	3.43e-14	3.12e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	7.82	3.43e-14	3.12e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	7.82	3.43e-14	3.12e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
LUAD	cis	rs944289	0.774	rs8013429	ENSG00000257826.1	RP11-116N8.4	-7.82	3.43e-14	3.12e-11	-0.35	-0.34	Thyroid cancer;	chr14:36131855	chr14:36061026~36067190:-
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000206090.4	AP000350.7	7.82	3.44e-14	3.14e-11	0.38	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23939998~23942798:+
LUAD	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	7.82	3.46e-14	3.15e-11	0.58	0.34	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
LUAD	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	7.82	3.46e-14	3.15e-11	0.58	0.34	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
LUAD	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	7.82	3.47e-14	3.16e-11	0.42	0.34	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-7.81	3.49e-14	3.18e-11	-0.47	-0.34	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
LUAD	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-7.81	3.5e-14	3.18e-11	-0.48	-0.34	QT interval;	chr16:28824579	chr16:28700294~28701540:-
LUAD	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	7.81	3.5e-14	3.18e-11	0.38	0.34	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
LUAD	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	7.81	3.52e-14	3.2e-11	0.45	0.34	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
LUAD	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
LUAD	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-7.81	3.52e-14	3.21e-11	-0.45	-0.34	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
LUAD	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	7.81	3.53e-14	3.21e-11	0.39	0.34	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	7.81	3.53e-14	3.21e-11	0.39	0.34	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
LUAD	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-7.81	3.54e-14	3.22e-11	-0.45	-0.34	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
LUAD	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	7.81	3.54e-14	3.22e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
LUAD	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-7.81	3.55e-14	3.22e-11	-0.42	-0.34	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
LUAD	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	7.81	3.55e-14	3.22e-11	0.46	0.34	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
LUAD	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-7.81	3.57e-14	3.24e-11	-0.46	-0.34	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
LUAD	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-7.81	3.57e-14	3.24e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
LUAD	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
LUAD	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	7.81	3.6e-14	3.27e-11	0.39	0.34	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-7.81	3.6e-14	3.27e-11	-0.42	-0.34	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
LUAD	cis	rs35955747	0.689	rs5997988	ENSG00000236132.1	CTA-440B3.1	7.81	3.62e-14	3.29e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31442099	chr22:31816379~31817491:-
LUAD	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	7.81	3.63e-14	3.3e-11	0.37	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
LUAD	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	7.81	3.65e-14	3.31e-11	0.39	0.34	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-7.81	3.65e-14	3.31e-11	-0.39	-0.34	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
LUAD	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	7.81	3.65e-14	3.31e-11	0.36	0.34	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
LUAD	cis	rs11089937	0.597	rs4821772	ENSG00000211639.2	IGLV4-60	-7.81	3.66e-14	3.32e-11	-0.39	-0.34	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22162199~22162681:+
LUAD	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-7.81	3.67e-14	3.33e-11	-0.39	-0.34	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
LUAD	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-7.81	3.67e-14	3.33e-11	-0.46	-0.34	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
LUAD	cis	rs944289	0.74	rs950319	ENSG00000257826.1	RP11-116N8.4	-7.81	3.68e-14	3.33e-11	-0.35	-0.34	Thyroid cancer;	chr14:36096786	chr14:36061026~36067190:-
LUAD	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	7.81	3.68e-14	3.34e-11	0.58	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	7.81	3.68e-14	3.34e-11	0.58	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
LUAD	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	7.81	3.69e-14	3.34e-11	0.39	0.34	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
LUAD	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	7.81	3.7e-14	3.36e-11	0.51	0.34	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
LUAD	cis	rs35955747	0.714	rs4820048	ENSG00000236132.1	CTA-440B3.1	7.81	3.7e-14	3.36e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31458384	chr22:31816379~31817491:-
LUAD	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	7.81	3.71e-14	3.36e-11	0.46	0.34	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
LUAD	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	7.81	3.71e-14	3.36e-11	0.39	0.34	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	7.81	3.71e-14	3.36e-11	0.39	0.34	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	7.81	3.71e-14	3.36e-11	0.39	0.34	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	7.81	3.71e-14	3.36e-11	0.39	0.34	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000206090.4	AP000350.7	-7.81	3.71e-14	3.37e-11	-0.38	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23939998~23942798:+
LUAD	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-7.81	3.71e-14	3.37e-11	-0.37	-0.34	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
LUAD	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-7.81	3.71e-14	3.37e-11	-0.37	-0.34	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	7.81	3.72e-14	3.37e-11	0.4	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
LUAD	cis	rs11089937	0.626	rs11704092	ENSG00000211639.2	IGLV4-60	7.81	3.72e-14	3.37e-11	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.667	rs78549985	ENSG00000211639.2	IGLV4-60	7.81	3.72e-14	3.37e-11	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000211972.2	IGHV3-66	7.81	3.73e-14	3.38e-11	0.3	0.34	Kawasaki disease;	chr14:106697402	chr14:106675017~106675544:-
LUAD	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	7.81	3.73e-14	3.38e-11	0.78	0.34	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
LUAD	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-7.8	3.77e-14	3.42e-11	-0.4	-0.34	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
LUAD	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-7.8	3.78e-14	3.43e-11	-0.46	-0.34	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
LUAD	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-7.8	3.81e-14	3.45e-11	-0.41	-0.34	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
LUAD	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-7.8	3.81e-14	3.45e-11	-0.5	-0.34	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
LUAD	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-7.8	3.82e-14	3.45e-11	-0.37	-0.34	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
LUAD	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	7.8	3.82e-14	3.46e-11	0.45	0.34	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	7.8	3.82e-14	3.46e-11	0.5	0.34	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-7.8	3.84e-14	3.47e-11	-0.48	-0.34	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
LUAD	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-7.8	3.87e-14	3.5e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-7.8	3.87e-14	3.5e-11	-0.39	-0.34	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	7.8	3.88e-14	3.51e-11	0.39	0.34	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
LUAD	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	7.8	3.9e-14	3.52e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
LUAD	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	7.8	3.9e-14	3.53e-11	0.41	0.34	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
LUAD	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	7.8	3.9e-14	3.53e-11	0.39	0.34	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.708	rs1958615	ENSG00000257826.1	RP11-116N8.4	-7.8	3.91e-14	3.53e-11	-0.35	-0.34	Thyroid cancer;	chr14:36118282	chr14:36061026~36067190:-
LUAD	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-7.8	3.91e-14	3.54e-11	-0.39	-0.34	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-7.8	3.93e-14	3.55e-11	-0.48	-0.34	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-7.8	3.93e-14	3.55e-11	-0.48	-0.34	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
LUAD	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	7.8	3.95e-14	3.57e-11	0.44	0.33	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
LUAD	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	7.8	3.96e-14	3.58e-11	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
LUAD	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	7.8	3.98e-14	3.6e-11	0.35	0.33	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	7.8	3.98e-14	3.6e-11	0.35	0.33	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
LUAD	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	7.8	3.99e-14	3.6e-11	0.46	0.33	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	7.8	3.99e-14	3.6e-11	0.46	0.33	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
LUAD	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	7.8	3.99e-14	3.6e-11	0.4	0.33	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
LUAD	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	7.8	3.99e-14	3.6e-11	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
LUAD	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-7.8	4e-14	3.61e-11	-0.48	-0.33	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
LUAD	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-7.79	4.04e-14	3.65e-11	-0.36	-0.33	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
LUAD	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	7.79	4.05e-14	3.66e-11	0.43	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
LUAD	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	7.79	4.06e-14	3.66e-11	0.46	0.33	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
LUAD	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	7.79	4.07e-14	3.68e-11	0.44	0.33	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
LUAD	cis	rs2581828	0.618	rs6777975	ENSG00000242142.1	SERBP1P3	-7.79	4.08e-14	3.68e-11	-0.38	-0.33	Crohn's disease;	chr3:53132119	chr3:53064283~53065091:-
LUAD	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	7.79	4.09e-14	3.69e-11	0.46	0.33	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
LUAD	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-7.79	4.1e-14	3.7e-11	-0.38	-0.33	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
LUAD	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	7.79	4.11e-14	3.71e-11	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
LUAD	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-7.79	4.13e-14	3.72e-11	-0.41	-0.33	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
LUAD	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	7.79	4.14e-14	3.73e-11	0.44	0.33	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
LUAD	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-7.79	4.15e-14	3.74e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-7.79	4.15e-14	3.74e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-7.79	4.16e-14	3.75e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
LUAD	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	7.79	4.17e-14	3.76e-11	0.43	0.33	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
LUAD	cis	rs944289	0.684	rs8016315	ENSG00000257826.1	RP11-116N8.4	-7.79	4.18e-14	3.76e-11	-0.35	-0.33	Thyroid cancer;	chr14:36101158	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs4982334	ENSG00000257826.1	RP11-116N8.4	-7.79	4.18e-14	3.76e-11	-0.35	-0.33	Thyroid cancer;	chr14:36101396	chr14:36061026~36067190:-
LUAD	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-7.79	4.19e-14	3.77e-11	-0.63	-0.33	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
LUAD	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-7.79	4.2e-14	3.78e-11	-0.4	-0.33	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
LUAD	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	7.79	4.2e-14	3.78e-11	0.44	0.33	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-7.79	4.21e-14	3.79e-11	-0.39	-0.33	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	7.79	4.21e-14	3.79e-11	0.39	0.33	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
LUAD	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-7.79	4.21e-14	3.79e-11	-0.47	-0.33	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
LUAD	cis	rs12439619	0.53	rs7162177	ENSG00000255769.6	GOLGA2P10	-7.79	4.21e-14	3.8e-11	-0.35	-0.33	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472993~82513950:-
LUAD	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	7.79	4.23e-14	3.8e-11	0.35	0.33	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	7.79	4.23e-14	3.8e-11	0.35	0.33	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	7.79	4.23e-14	3.8e-11	0.35	0.33	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
LUAD	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	7.79	4.23e-14	3.81e-11	0.47	0.33	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
LUAD	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	7.79	4.25e-14	3.82e-11	0.5	0.33	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
LUAD	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-7.79	4.25e-14	3.82e-11	-0.6	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
LUAD	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-7.79	4.25e-14	3.82e-11	-0.4	-0.33	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
LUAD	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-7.79	4.28e-14	3.85e-11	-0.39	-0.33	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	7.79	4.28e-14	3.85e-11	0.4	0.33	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
LUAD	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-7.78	4.32e-14	3.89e-11	-0.29	-0.33	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
LUAD	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-7.78	4.34e-14	3.9e-11	-0.39	-0.33	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
LUAD	cis	rs11089937	0.512	rs6001073	ENSG00000211639.2	IGLV4-60	7.78	4.35e-14	3.91e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22162199~22162681:+
LUAD	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	7.78	4.35e-14	3.91e-11	0.39	0.33	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	7.78	4.35e-14	3.91e-11	0.39	0.33	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	7.78	4.35e-14	3.91e-11	0.39	0.33	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
LUAD	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-7.78	4.38e-14	3.94e-11	-0.45	-0.33	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
LUAD	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	7.78	4.39e-14	3.94e-11	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
LUAD	cis	rs8177876	0.749	rs2278024	ENSG00000261838.4	RP11-303E16.6	7.78	4.41e-14	3.97e-11	0.73	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81069854~81076598:+
LUAD	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-7.78	4.43e-14	3.98e-11	-0.45	-0.33	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
LUAD	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-7.78	4.43e-14	3.98e-11	-0.45	-0.33	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
LUAD	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	7.78	4.44e-14	3.99e-11	0.32	0.33	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
LUAD	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-7.78	4.46e-14	4.01e-11	-0.41	-0.33	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
LUAD	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	7.78	4.49e-14	4.03e-11	0.57	0.33	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
LUAD	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-7.78	4.51e-14	4.05e-11	-0.46	-0.33	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
LUAD	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	7.78	4.53e-14	4.06e-11	0.39	0.33	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	7.78	4.53e-14	4.07e-11	0.29	0.33	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
LUAD	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	7.78	4.59e-14	4.11e-11	0.4	0.33	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
LUAD	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	7.78	4.59e-14	4.11e-11	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
LUAD	cis	rs8031584	0.678	rs8035703	ENSG00000260382.1	RP11-540B6.2	7.78	4.6e-14	4.13e-11	0.41	0.33	Huntington's disease progression;	chr15:30876269	chr15:30882267~30883231:-
LUAD	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-7.78	4.6e-14	4.13e-11	-0.43	-0.33	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
LUAD	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-7.78	4.61e-14	4.14e-11	-0.46	-0.33	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
LUAD	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	7.77	4.63e-14	4.15e-11	0.39	0.33	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	7.77	4.63e-14	4.15e-11	0.39	0.33	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
LUAD	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	7.77	4.63e-14	4.15e-11	0.46	0.33	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
LUAD	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	7.77	4.64e-14	4.16e-11	0.4	0.33	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
LUAD	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-7.77	4.64e-14	4.16e-11	-0.46	-0.33	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
LUAD	cis	rs1537424	0.513	rs944290	ENSG00000257826.1	RP11-116N8.4	-7.77	4.65e-14	4.17e-11	-0.36	-0.33	Thyroid hormone levels;	chr14:36095493	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	7.77	4.66e-14	4.18e-11	0.4	0.33	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	7.77	4.66e-14	4.18e-11	0.4	0.33	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-7.77	4.66e-14	4.18e-11	-0.39	-0.33	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
LUAD	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	7.77	4.67e-14	4.18e-11	0.43	0.33	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
LUAD	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-7.77	4.68e-14	4.2e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
LUAD	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-7.77	4.69e-14	4.2e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
LUAD	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	7.77	4.69e-14	4.2e-11	0.36	0.33	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-7.77	4.69e-14	4.21e-11	-0.48	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
LUAD	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-7.77	4.72e-14	4.22e-11	-0.39	-0.33	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
LUAD	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	7.77	4.74e-14	4.25e-11	0.47	0.33	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	7.77	4.74e-14	4.25e-11	0.47	0.33	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
LUAD	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	7.77	4.75e-14	4.25e-11	0.47	0.33	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
LUAD	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	7.77	4.75e-14	4.25e-11	0.39	0.33	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	7.77	4.76e-14	4.26e-11	0.5	0.33	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
LUAD	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	7.77	4.76e-14	4.27e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
LUAD	cis	rs9595908	0.9	rs9591137	ENSG00000212293.1	SNORA16	7.77	4.78e-14	4.28e-11	0.37	0.33	Body mass index;	chr13:32578345	chr13:32420390~32420516:-
LUAD	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	7.77	4.78e-14	4.28e-11	0.44	0.33	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	7.77	4.8e-14	4.3e-11	0.47	0.33	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
LUAD	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-7.77	4.81e-14	4.3e-11	-0.38	-0.33	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
LUAD	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	7.77	4.81e-14	4.31e-11	0.55	0.33	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
LUAD	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	7.77	4.86e-14	4.35e-11	0.41	0.33	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
LUAD	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	7.77	4.9e-14	4.38e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
LUAD	cis	rs944289	0.774	rs1958624	ENSG00000257826.1	RP11-116N8.4	7.77	4.91e-14	4.4e-11	0.35	0.33	Thyroid cancer;	chr14:36128692	chr14:36061026~36067190:-
LUAD	cis	rs8177876	0.658	rs77874075	ENSG00000261838.4	RP11-303E16.6	7.77	4.92e-14	4.4e-11	0.77	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81069854~81076598:+
LUAD	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-7.77	4.92e-14	4.4e-11	-0.47	-0.33	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
LUAD	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-7.77	4.94e-14	4.42e-11	-0.5	-0.33	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
LUAD	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-7.77	4.95e-14	4.43e-11	-0.37	-0.33	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-7.77	4.95e-14	4.43e-11	-0.37	-0.33	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-7.77	4.95e-14	4.43e-11	-0.37	-0.33	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
LUAD	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-7.76	4.96e-14	4.44e-11	-0.36	-0.33	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
LUAD	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	7.76	4.98e-14	4.45e-11	0.39	0.33	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
LUAD	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	7.76	5e-14	4.47e-11	0.38	0.33	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
LUAD	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-7.76	5.01e-14	4.48e-11	-0.46	-0.33	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
LUAD	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	7.76	5.01e-14	4.48e-11	0.39	0.33	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	7.76	5.01e-14	4.48e-11	0.39	0.33	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	7.76	5.01e-14	4.48e-11	0.39	0.33	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-7.76	5.05e-14	4.51e-11	-0.35	-0.33	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
LUAD	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	7.76	5.06e-14	4.52e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	7.76	5.08e-14	4.53e-11	0.4	0.33	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
LUAD	cis	rs904251	0.686	rs1224128	ENSG00000279942.1	RP1-153P14.7	-7.76	5.09e-14	4.54e-11	-0.36	-0.33	Cognitive performance;	chr6:37447900	chr6:37567716~37571460:+
LUAD	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	7.76	5.11e-14	4.56e-11	0.78	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
LUAD	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	7.76	5.11e-14	4.56e-11	0.78	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
LUAD	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-7.76	5.12e-14	4.57e-11	-0.32	-0.33	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
LUAD	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	7.76	5.15e-14	4.59e-11	0.47	0.33	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
LUAD	cis	rs944289	0.74	rs7145145	ENSG00000257826.1	RP11-116N8.4	-7.76	5.15e-14	4.6e-11	-0.35	-0.33	Thyroid cancer;	chr14:36110724	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.708	rs7145311	ENSG00000257826.1	RP11-116N8.4	-7.76	5.15e-14	4.6e-11	-0.35	-0.33	Thyroid cancer;	chr14:36110738	chr14:36061026~36067190:-
LUAD	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-7.76	5.15e-14	4.6e-11	-0.47	-0.33	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-7.76	5.15e-14	4.6e-11	-0.48	-0.33	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-7.76	5.15e-14	4.6e-11	-0.48	-0.33	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-7.76	5.15e-14	4.6e-11	-0.48	-0.33	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
LUAD	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	7.76	5.18e-14	4.62e-11	0.36	0.33	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
LUAD	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	7.76	5.18e-14	4.62e-11	0.65	0.33	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
LUAD	cis	rs904251	0.772	rs2776906	ENSG00000279942.1	RP1-153P14.7	-7.76	5.18e-14	4.62e-11	-0.34	-0.33	Cognitive performance;	chr6:37463981	chr6:37567716~37571460:+
LUAD	cis	rs6844153	0.823	rs12642922	ENSG00000240005.4	RP11-293A21.1	-7.76	5.23e-14	4.67e-11	-0.53	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:27025996	chr4:26859806~26860599:-
LUAD	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-7.76	5.24e-14	4.67e-11	-0.39	-0.33	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
LUAD	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-7.76	5.25e-14	4.68e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-7.76	5.25e-14	4.68e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
LUAD	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	7.76	5.26e-14	4.69e-11	0.39	0.33	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	7.76	5.26e-14	4.69e-11	0.39	0.33	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
LUAD	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	7.76	5.26e-14	4.69e-11	0.36	0.33	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
LUAD	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	7.76	5.27e-14	4.69e-11	0.39	0.33	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
LUAD	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-7.76	5.27e-14	4.7e-11	-0.35	-0.33	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-7.76	5.28e-14	4.7e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
LUAD	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	7.76	5.3e-14	4.72e-11	0.39	0.33	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
LUAD	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	7.76	5.31e-14	4.73e-11	0.51	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
LUAD	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-7.75	5.32e-14	4.73e-11	-0.45	-0.33	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
LUAD	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-7.75	5.32e-14	4.73e-11	-0.45	-0.33	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
LUAD	cis	rs11089937	0.626	rs737840	ENSG00000211639.2	IGLV4-60	7.75	5.39e-14	4.79e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22162199~22162681:+
LUAD	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	7.75	5.4e-14	4.8e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
LUAD	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	7.75	5.46e-14	4.85e-11	0.61	0.33	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
LUAD	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-7.75	5.51e-14	4.9e-11	-0.45	-0.33	Migraine;	chr4:56879297	chr4:56960927~56961373:-
LUAD	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-7.75	5.52e-14	4.9e-11	-0.34	-0.33	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
LUAD	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-7.75	5.53e-14	4.91e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-7.75	5.53e-14	4.91e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-7.75	5.53e-14	4.91e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-7.75	5.53e-14	4.91e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-7.75	5.57e-14	4.94e-11	-0.39	-0.33	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
LUAD	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	7.75	5.58e-14	4.95e-11	0.39	0.33	Depression;	chr6:28301886	chr6:28176188~28176674:+
LUAD	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-7.75	5.59e-14	4.96e-11	-0.31	-0.33	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
LUAD	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-7.75	5.59e-14	4.97e-11	-0.41	-0.33	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
LUAD	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-7.75	5.6e-14	4.97e-11	-0.45	-0.33	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
LUAD	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-7.75	5.61e-14	4.98e-11	-0.36	-0.33	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
LUAD	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-7.75	5.62e-14	4.99e-11	-0.37	-0.33	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
LUAD	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-7.75	5.62e-14	4.99e-11	-0.37	-0.33	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
LUAD	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-7.75	5.64e-14	5.01e-11	-0.35	-0.33	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
LUAD	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-7.75	5.69e-14	5.05e-11	-0.36	-0.33	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
LUAD	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	7.75	5.69e-14	5.05e-11	0.4	0.33	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
LUAD	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-7.75	5.7e-14	5.06e-11	-0.34	-0.33	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
LUAD	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	7.74	5.71e-14	5.06e-11	0.4	0.33	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-7.74	5.72e-14	5.07e-11	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
LUAD	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-7.74	5.73e-14	5.09e-11	-0.63	-0.33	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
LUAD	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	7.74	5.76e-14	5.1e-11	0.43	0.33	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
LUAD	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	7.74	5.77e-14	5.12e-11	0.45	0.33	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	7.74	5.77e-14	5.12e-11	0.45	0.33	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
LUAD	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	7.74	5.85e-14	5.18e-11	0.47	0.33	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
LUAD	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-7.74	5.85e-14	5.19e-11	-0.32	-0.33	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
LUAD	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-7.74	5.86e-14	5.19e-11	-0.46	-0.33	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
LUAD	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	7.74	5.86e-14	5.19e-11	0.39	0.33	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
LUAD	cis	rs8177876	0.749	rs1035541	ENSG00000261838.4	RP11-303E16.6	7.74	5.86e-14	5.19e-11	0.76	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81069854~81076598:+
LUAD	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	7.74	5.87e-14	5.2e-11	0.46	0.33	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	7.74	5.87e-14	5.2e-11	0.46	0.33	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
LUAD	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
LUAD	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-7.74	5.88e-14	5.21e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-7.74	5.88e-14	5.21e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
LUAD	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-7.74	5.88e-14	5.21e-11	-0.45	-0.33	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
LUAD	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	7.74	5.89e-14	5.22e-11	0.38	0.33	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
LUAD	cis	rs465969	1	rs1407644	ENSG00000255389.1	C6orf3	7.74	5.9e-14	5.22e-11	0.67	0.33	Psoriasis;	chr6:111480895	chr6:111599875~111602295:+
LUAD	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	7.74	5.91e-14	5.23e-11	0.35	0.33	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
LUAD	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-7.74	5.94e-14	5.25e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
LUAD	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	7.74	5.94e-14	5.26e-11	0.42	0.33	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	7.74	5.95e-14	5.27e-11	0.42	0.33	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
LUAD	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-7.74	5.96e-14	5.27e-11	-0.37	-0.33	Temperament;	chr17:14007198	chr17:14024514~14025488:+
LUAD	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	7.74	5.96e-14	5.27e-11	0.34	0.33	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
LUAD	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-7.74	5.96e-14	5.28e-11	-0.41	-0.33	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-7.74	5.96e-14	5.28e-11	-0.41	-0.33	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
LUAD	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-7.74	5.99e-14	5.29e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
LUAD	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	7.74	6.01e-14	5.31e-11	0.39	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
LUAD	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-7.74	6.01e-14	5.31e-11	-0.42	-0.33	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	7.74	6.02e-14	5.32e-11	0.39	0.33	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
LUAD	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-7.74	6.04e-14	5.34e-11	-0.37	-0.33	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
LUAD	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-7.74	6.07e-14	5.36e-11	-0.39	-0.33	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-7.74	6.07e-14	5.36e-11	-0.39	-0.33	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
LUAD	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	7.74	6.08e-14	5.37e-11	0.39	0.33	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
LUAD	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	7.74	6.08e-14	5.37e-11	0.39	0.33	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
LUAD	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-7.74	6.09e-14	5.38e-11	-0.47	-0.33	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
LUAD	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-7.74	6.09e-14	5.38e-11	-0.35	-0.33	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-7.74	6.09e-14	5.38e-11	-0.35	-0.33	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-7.74	6.11e-14	5.39e-11	-0.39	-0.33	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
LUAD	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	7.73	6.14e-14	5.42e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	7.73	6.14e-14	5.42e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
LUAD	cis	rs944289	0.712	rs12050121	ENSG00000257826.1	RP11-116N8.4	-7.73	6.18e-14	5.45e-11	-0.35	-0.33	Thyroid cancer;	chr14:36103742	chr14:36061026~36067190:-
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	7.73	6.18e-14	5.46e-11	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
LUAD	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	7.73	6.19e-14	5.47e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
LUAD	cis	rs8177876	0.731	rs74878296	ENSG00000261838.4	RP11-303E16.6	7.73	6.25e-14	5.51e-11	0.85	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81069854~81076598:+
LUAD	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	7.73	6.25e-14	5.52e-11	0.4	0.33	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
LUAD	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-7.73	6.25e-14	5.52e-11	-0.37	-0.33	Temperament;	chr17:14007316	chr17:14024514~14025488:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000211970.3	IGHV4-61	-7.73	6.28e-14	5.54e-11	-0.27	-0.33	Kawasaki disease;	chr14:106813798	chr14:106639119~106639657:-
LUAD	cis	rs8177876	0.658	rs75422577	ENSG00000261838.4	RP11-303E16.6	7.73	6.31e-14	5.56e-11	0.76	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81069854~81076598:+
LUAD	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-7.73	6.32e-14	5.58e-11	-0.47	-0.33	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	7.73	6.36e-14	5.6e-11	0.38	0.33	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	7.73	6.36e-14	5.6e-11	0.38	0.33	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
LUAD	cis	rs2439831	0.681	rs1095386	ENSG00000205771.5	CATSPER2P1	-7.73	6.36e-14	5.61e-11	-0.56	-0.33	Lung cancer in ever smokers;	chr15:43317311	chr15:43726918~43747094:-
LUAD	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	7.73	6.37e-14	5.62e-11	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	7.73	6.37e-14	5.62e-11	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	7.73	6.37e-14	5.62e-11	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
LUAD	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-7.73	6.37e-14	5.62e-11	-0.61	-0.33	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
LUAD	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	7.73	6.43e-14	5.67e-11	0.42	0.33	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
LUAD	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	7.73	6.45e-14	5.68e-11	0.55	0.33	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
LUAD	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	7.73	6.49e-14	5.71e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	7.73	6.49e-14	5.71e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	7.73	6.49e-14	5.71e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
LUAD	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-7.73	6.52e-14	5.74e-11	-0.38	-0.33	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-7.73	6.54e-14	5.76e-11	-0.26	-0.33	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
LUAD	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-7.73	6.55e-14	5.77e-11	-0.34	-0.33	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
LUAD	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	7.72	6.56e-14	5.78e-11	0.38	0.33	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	7.72	6.56e-14	5.78e-11	0.38	0.33	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
LUAD	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	7.72	6.56e-14	5.78e-11	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
LUAD	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	7.72	6.57e-14	5.78e-11	0.58	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	7.72	6.57e-14	5.78e-11	0.58	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
LUAD	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-7.72	6.65e-14	5.85e-11	-0.39	-0.33	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-7.72	6.65e-14	5.85e-11	-0.39	-0.33	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
LUAD	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-7.72	6.67e-14	5.87e-11	-0.45	-0.33	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
LUAD	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	7.72	6.69e-14	5.89e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
LUAD	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	7.72	6.73e-14	5.92e-11	0.38	0.33	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
LUAD	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	7.72	6.74e-14	5.93e-11	0.49	0.33	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
LUAD	cis	rs904251	0.772	rs1812186	ENSG00000279942.1	RP1-153P14.7	-7.72	6.75e-14	5.94e-11	-0.34	-0.33	Cognitive performance;	chr6:37498140	chr6:37567716~37571460:+
LUAD	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	7.72	6.77e-14	5.95e-11	0.36	0.33	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
LUAD	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	7.72	6.81e-14	5.98e-11	0.38	0.33	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
LUAD	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-7.72	6.83e-14	6e-11	-0.35	-0.33	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
LUAD	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	7.72	6.83e-14	6.01e-11	0.42	0.33	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
LUAD	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-7.72	6.85e-14	6.02e-11	-0.36	-0.33	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
LUAD	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	7.72	6.86e-14	6.03e-11	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
LUAD	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-7.72	6.88e-14	6.04e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
LUAD	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-7.72	6.9e-14	6.06e-11	-0.47	-0.33	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	7.72	6.9e-14	6.06e-11	0.4	0.33	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	7.72	6.9e-14	6.06e-11	0.4	0.33	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
LUAD	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-7.72	6.9e-14	6.06e-11	-0.36	-0.33	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
LUAD	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	7.72	6.91e-14	6.07e-11	0.45	0.33	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
LUAD	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	7.72	6.92e-14	6.07e-11	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
LUAD	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-7.72	6.93e-14	6.08e-11	-0.47	-0.33	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	7.72	6.99e-14	6.13e-11	0.38	0.33	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-7.72	7e-14	6.14e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000280411.1	IGHV1-69-2	-7.72	7.03e-14	6.17e-11	-0.25	-0.33	Kawasaki disease;	chr14:106675823	chr14:106762092~106762588:-
LUAD	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	7.71	7.04e-14	6.17e-11	0.44	0.33	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
LUAD	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-7.71	7.04e-14	6.18e-11	-0.31	-0.33	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
LUAD	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	7.71	7.06e-14	6.2e-11	0.38	0.33	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
LUAD	cis	rs11089937	0.626	rs5757014	ENSG00000211639.2	IGLV4-60	7.71	7.09e-14	6.22e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22162199~22162681:+
LUAD	cis	rs904251	0.772	rs756202	ENSG00000279942.1	RP1-153P14.7	-7.71	7.12e-14	6.24e-11	-0.34	-0.33	Cognitive performance;	chr6:37492574	chr6:37567716~37571460:+
LUAD	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-7.71	7.12e-14	6.25e-11	-0.5	-0.33	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
LUAD	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-7.71	7.14e-14	6.26e-11	-0.49	-0.33	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
LUAD	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-7.71	7.15e-14	6.27e-11	-0.62	-0.33	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
LUAD	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-7.71	7.17e-14	6.29e-11	-0.43	-0.33	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	7.71	7.18e-14	6.3e-11	0.39	0.33	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	7.71	7.18e-14	6.3e-11	0.39	0.33	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
LUAD	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-7.71	7.21e-14	6.32e-11	-0.38	-0.33	Temperament;	chr17:14042870	chr17:14024514~14025488:+
LUAD	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	7.71	7.22e-14	6.32e-11	0.36	0.33	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
LUAD	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	7.71	7.23e-14	6.33e-11	0.4	0.33	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
LUAD	cis	rs1537424	0.513	rs1333313	ENSG00000257826.1	RP11-116N8.4	-7.71	7.28e-14	6.38e-11	-0.36	-0.33	Thyroid hormone levels;	chr14:36093440	chr14:36061026~36067190:-
LUAD	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-7.71	7.29e-14	6.38e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
LUAD	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	7.71	7.29e-14	6.39e-11	0.44	0.33	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
LUAD	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	7.71	7.34e-14	6.42e-11	0.58	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
LUAD	cis	rs10899021	0.92	rs76121309	ENSG00000279353.1	RP11-864N7.4	7.71	7.35e-14	6.43e-11	0.65	0.33	Response to metformin (IC50);	chr11:74632876	chr11:74698231~74699658:-
LUAD	cis	rs944289	0.708	rs2415315	ENSG00000257826.1	RP11-116N8.4	-7.71	7.4e-14	6.47e-11	-0.35	-0.33	Thyroid cancer;	chr14:36115338	chr14:36061026~36067190:-
LUAD	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-7.71	7.4e-14	6.48e-11	-0.45	-0.33	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
LUAD	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	7.71	7.43e-14	6.49e-11	0.41	0.33	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	7.71	7.45e-14	6.52e-11	0.4	0.33	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
LUAD	cis	rs11089937	0.597	rs11704434	ENSG00000211639.2	IGLV4-60	7.71	7.5e-14	6.56e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22162199~22162681:+
LUAD	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-7.71	7.53e-14	6.58e-11	-0.39	-0.33	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
LUAD	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	7.7	7.56e-14	6.6e-11	0.39	0.33	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	7.7	7.56e-14	6.6e-11	0.39	0.33	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
LUAD	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-7.7	7.57e-14	6.61e-11	-0.74	-0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
LUAD	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-7.7	7.58e-14	6.62e-11	-0.35	-0.33	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
LUAD	cis	rs9326248	0.53	rs7123517	ENSG00000280143.1	AP000892.6	7.7	7.61e-14	6.64e-11	0.53	0.33	Blood protein levels;	chr11:117157039	chr11:117204967~117210292:+
LUAD	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	7.7	7.62e-14	6.65e-11	0.42	0.33	Height;	chr6:109634847	chr6:109382795~109383666:+
LUAD	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-7.7	7.63e-14	6.66e-11	-0.44	-0.33	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
LUAD	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-7.7	7.66e-14	6.69e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-7.7	7.72e-14	6.73e-11	-0.48	-0.33	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
LUAD	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	7.7	7.78e-14	6.79e-11	0.4	0.33	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
LUAD	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-7.7	7.79e-14	6.79e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
LUAD	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	7.7	7.81e-14	6.81e-11	0.43	0.33	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	7.7	7.81e-14	6.81e-11	0.43	0.33	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
LUAD	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	7.7	7.81e-14	6.81e-11	0.76	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
LUAD	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	7.7	7.85e-14	6.84e-11	0.34	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
LUAD	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	7.7	7.87e-14	6.86e-11	0.48	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
LUAD	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	7.7	7.87e-14	6.86e-11	0.4	0.33	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	7.7	7.88e-14	6.87e-11	0.39	0.33	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	7.7	7.88e-14	6.87e-11	0.39	0.33	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
LUAD	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-7.7	7.91e-14	6.89e-11	-0.37	-0.33	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
LUAD	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	7.7	7.98e-14	6.95e-11	0.46	0.33	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
LUAD	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-7.7	7.99e-14	6.96e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
LUAD	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
LUAD	cis	rs944289	0.74	rs7150440	ENSG00000257826.1	RP11-116N8.4	-7.7	8.01e-14	6.97e-11	-0.35	-0.33	Thyroid cancer;	chr14:36114691	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs7150768	ENSG00000257826.1	RP11-116N8.4	-7.7	8.01e-14	6.97e-11	-0.35	-0.33	Thyroid cancer;	chr14:36114699	chr14:36061026~36067190:-
LUAD	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	7.7	8.03e-14	6.99e-11	0.4	0.33	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	7.7	8.07e-14	7.03e-11	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
LUAD	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	7.7	8.08e-14	7.03e-11	0.39	0.33	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
LUAD	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-7.69	8.2e-14	7.13e-11	-0.38	-0.33	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
LUAD	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	7.69	8.21e-14	7.14e-11	0.73	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
LUAD	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-7.69	8.22e-14	7.15e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-7.69	8.26e-14	7.18e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
LUAD	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	7.69	8.28e-14	7.2e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000211972.2	IGHV3-66	7.69	8.29e-14	7.21e-11	0.29	0.33	Kawasaki disease;	chr14:106670217	chr14:106675017~106675544:-
LUAD	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	7.69	8.33e-14	7.24e-11	0.26	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
LUAD	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-7.69	8.34e-14	7.25e-11	-0.46	-0.33	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
LUAD	cis	rs9595908	0.965	rs7335710	ENSG00000212293.1	SNORA16	7.69	8.36e-14	7.27e-11	0.37	0.33	Body mass index;	chr13:32561287	chr13:32420390~32420516:-
LUAD	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	7.69	8.4e-14	7.3e-11	0.39	0.33	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
LUAD	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-7.69	8.4e-14	7.3e-11	-0.38	-0.33	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
LUAD	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-7.69	8.42e-14	7.32e-11	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
LUAD	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	7.69	8.52e-14	7.4e-11	0.46	0.33	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
LUAD	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	7.69	8.53e-14	7.41e-11	0.47	0.33	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
LUAD	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	7.69	8.56e-14	7.44e-11	0.42	0.33	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
LUAD	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-7.69	8.57e-14	7.44e-11	-0.42	-0.33	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
LUAD	cis	rs9326248	0.689	rs236916	ENSG00000280143.1	AP000892.6	-7.69	8.59e-14	7.46e-11	-0.5	-0.33	Blood protein levels;	chr11:117218912	chr11:117204967~117210292:+
LUAD	cis	rs11089937	0.568	rs6001078	ENSG00000211639.2	IGLV4-60	7.69	8.63e-14	7.49e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22162199~22162681:+
LUAD	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	7.68	8.67e-14	7.53e-11	0.36	0.33	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
LUAD	cis	rs730566	0.64	rs6442112	ENSG00000229759.1	MRPS18AP1	7.68	8.68e-14	7.54e-11	0.35	0.33	Prion diseases;	chr3:48274544	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-7.68	8.69e-14	7.54e-11	-0.26	-0.33	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
LUAD	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	7.68	8.72e-14	7.56e-11	0.39	0.33	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	7.68	8.73e-14	7.58e-11	0.39	0.33	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	7.68	8.79e-14	7.62e-11	0.4	0.33	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
LUAD	cis	rs944289	0.708	rs1475716	ENSG00000257826.1	RP11-116N8.4	-7.68	8.84e-14	7.67e-11	-0.35	-0.33	Thyroid cancer;	chr14:36116033	chr14:36061026~36067190:-
LUAD	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-7.68	8.84e-14	7.67e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-7.68	8.84e-14	7.67e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-7.68	8.84e-14	7.67e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-7.68	8.84e-14	7.67e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
LUAD	cis	rs904251	0.686	rs931649	ENSG00000279942.1	RP1-153P14.7	-7.68	8.85e-14	7.67e-11	-0.36	-0.33	Cognitive performance;	chr6:37498303	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	7.68	8.86e-14	7.68e-11	0.4	0.33	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	7.68	8.87e-14	7.69e-11	0.43	0.33	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
LUAD	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	7.68	8.9e-14	7.71e-11	0.41	0.33	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
LUAD	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-7.68	8.9e-14	7.72e-11	-0.39	-0.33	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
LUAD	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-7.68	8.91e-14	7.72e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-7.68	8.91e-14	7.72e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
LUAD	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-7.68	8.93e-14	7.74e-11	-0.49	-0.33	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
LUAD	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	7.68	8.94e-14	7.74e-11	0.76	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
LUAD	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	7.68	8.94e-14	7.74e-11	0.76	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
LUAD	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-7.68	8.94e-14	7.74e-11	-0.46	-0.33	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
LUAD	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-7.68	8.97e-14	7.77e-11	-0.37	-0.33	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
LUAD	cis	rs237743	1	rs238200	ENSG00000222365.1	SNORD12B	-7.68	8.99e-14	7.78e-11	-0.37	-0.33	Height;	chr20:49283115	chr20:49280319~49280409:+
LUAD	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-7.68	8.99e-14	7.79e-11	-0.31	-0.33	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
LUAD	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	7.68	9.06e-14	7.84e-11	0.36	0.33	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
LUAD	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	7.68	9.07e-14	7.85e-11	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	7.68	9.07e-14	7.85e-11	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
LUAD	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-7.68	9.1e-14	7.88e-11	-0.48	-0.33	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
LUAD	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-7.68	9.11e-14	7.89e-11	-0.34	-0.33	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
LUAD	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	7.68	9.13e-14	7.9e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	7.68	9.13e-14	7.9e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	7.68	9.13e-14	7.9e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
LUAD	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	7.68	9.13e-14	7.9e-11	0.46	0.33	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
LUAD	cis	rs9595908	0.965	rs11840502	ENSG00000212293.1	SNORA16	7.68	9.16e-14	7.93e-11	0.36	0.33	Body mass index;	chr13:32624572	chr13:32420390~32420516:-
LUAD	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	7.68	9.18e-14	7.94e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	7.68	9.18e-14	7.94e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	7.68	9.18e-14	7.94e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	7.68	9.18e-14	7.94e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000211972.2	IGHV3-66	7.68	9.23e-14	7.98e-11	0.29	0.33	Kawasaki disease;	chr14:106705382	chr14:106675017~106675544:-
LUAD	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	7.68	9.26e-14	8.01e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
LUAD	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	7.68	9.27e-14	8.01e-11	0.45	0.33	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.609	rs9622980	ENSG00000211639.2	IGLV4-60	7.68	9.27e-14	8.01e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000211972.2	IGHV3-66	7.67	9.32e-14	8.06e-11	0.29	0.33	Kawasaki disease;	chr14:106777278	chr14:106675017~106675544:-
LUAD	cis	rs944289	0.708	rs1958622	ENSG00000257826.1	RP11-116N8.4	-7.67	9.34e-14	8.07e-11	-0.35	-0.33	Thyroid cancer;	chr14:36127289	chr14:36061026~36067190:-
LUAD	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-7.67	9.43e-14	8.14e-11	-0.61	-0.33	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
LUAD	cis	rs11089937	0.626	rs737841	ENSG00000211639.2	IGLV4-60	7.67	9.45e-14	8.17e-11	0.4	0.33	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22162199~22162681:+
LUAD	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	7.67	9.46e-14	8.17e-11	0.37	0.33	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
LUAD	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-7.67	9.47e-14	8.18e-11	-0.52	-0.33	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
LUAD	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-7.67	9.47e-14	8.18e-11	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
LUAD	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-7.67	9.53e-14	8.24e-11	-0.42	-0.33	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
LUAD	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	7.67	9.56e-14	8.26e-11	0.26	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
LUAD	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-7.67	9.58e-14	8.28e-11	-0.44	-0.33	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
LUAD	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-7.67	9.69e-14	8.37e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000280411.1	IGHV1-69-2	-7.67	9.76e-14	8.43e-11	-0.25	-0.33	Kawasaki disease;	chr14:106670217	chr14:106762092~106762588:-
LUAD	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-7.67	9.8e-14	8.45e-11	-0.68	-0.33	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
LUAD	cis	rs11089937	0.597	rs5757005	ENSG00000211639.2	IGLV4-60	7.67	9.82e-14	8.47e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22162199~22162681:+
LUAD	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-7.67	9.87e-14	8.51e-11	-0.45	-0.33	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
LUAD	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	7.67	9.87e-14	8.52e-11	0.37	0.33	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
LUAD	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-7.67	9.88e-14	8.52e-11	-0.33	-0.33	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
LUAD	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	7.67	9.9e-14	8.54e-11	0.37	0.33	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
LUAD	cis	rs11089937	0.667	rs10483107	ENSG00000211639.2	IGLV4-60	7.67	9.91e-14	8.55e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22162199~22162681:+
LUAD	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	7.67	9.93e-14	8.56e-11	0.37	0.33	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
LUAD	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	7.67	9.93e-14	8.56e-11	0.4	0.33	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000280411.1	IGHV1-69-2	-7.67	9.93e-14	8.56e-11	-0.25	-0.33	Kawasaki disease;	chr14:106779116	chr14:106762092~106762588:-
LUAD	cis	rs11089937	0.667	rs11704024	ENSG00000211639.2	IGLV4-60	7.67	9.95e-14	8.58e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22162199~22162681:+
LUAD	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	7.66	9.96e-14	8.58e-11	0.43	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	7.66	9.96e-14	8.58e-11	0.43	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
LUAD	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	7.66	9.97e-14	8.59e-11	0.36	0.33	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
LUAD	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-7.66	9.97e-14	8.59e-11	-0.34	-0.33	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
LUAD	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-7.66	1e-13	8.61e-11	-0.38	-0.33	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
LUAD	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	7.66	1.01e-13	8.72e-11	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	7.66	1.01e-13	8.72e-11	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
LUAD	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	7.66	1.01e-13	8.74e-11	0.55	0.33	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
LUAD	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	7.66	1.02e-13	8.76e-11	0.37	0.33	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
LUAD	cis	rs11089937	0.626	rs5757013	ENSG00000211639.2	IGLV4-60	7.66	1.02e-13	8.76e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22162199~22162681:+
LUAD	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-7.66	1.02e-13	8.8e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
LUAD	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	7.66	1.03e-13	8.87e-11	0.59	0.33	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	7.66	1.03e-13	8.87e-11	0.59	0.33	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
LUAD	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-7.66	1.04e-13	8.93e-11	-0.45	-0.33	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
LUAD	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	7.66	1.04e-13	8.93e-11	0.41	0.33	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
LUAD	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	7.66	1.04e-13	8.95e-11	0.42	0.33	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
LUAD	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-7.66	1.04e-13	8.96e-11	-0.47	-0.33	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
LUAD	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	7.66	1.05e-13	9.01e-11	0.45	0.33	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
LUAD	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-7.66	1.05e-13	9.02e-11	-0.67	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
LUAD	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-7.66	1.05e-13	9.05e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
LUAD	cis	rs7182621	0.639	rs12906068	ENSG00000182397.13	DNM1P46	7.66	1.05e-13	9.06e-11	0.46	0.33	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99790156~99806927:-
LUAD	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	7.66	1.05e-13	9.07e-11	0.45	0.33	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	7.66	1.05e-13	9.07e-11	0.45	0.33	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.626	rs5757011	ENSG00000211639.2	IGLV4-60	7.66	1.06e-13	9.09e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22162199~22162681:+
LUAD	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-7.65	1.07e-13	9.18e-11	-0.31	-0.33	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
LUAD	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-7.65	1.07e-13	9.21e-11	-0.36	-0.33	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
LUAD	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	7.65	1.08e-13	9.25e-11	0.55	0.33	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
LUAD	cis	rs7182621	0.639	rs35049216	ENSG00000182397.13	DNM1P46	7.65	1.08e-13	9.31e-11	0.46	0.33	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99790156~99806927:-
LUAD	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	7.65	1.09e-13	9.36e-11	0.32	0.33	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
LUAD	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-7.65	1.09e-13	9.37e-11	-0.38	-0.33	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
LUAD	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-7.65	1.1e-13	9.48e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
LUAD	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-7.65	1.11e-13	9.53e-11	-0.46	-0.33	Depression;	chr6:28131566	chr6:28115628~28116551:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000280411.1	IGHV1-69-2	-7.65	1.11e-13	9.53e-11	-0.25	-0.33	Kawasaki disease;	chr14:106676625	chr14:106762092~106762588:-
LUAD	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-7.65	1.12e-13	9.6e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
LUAD	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	7.65	1.12e-13	9.61e-11	0.36	0.33	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
LUAD	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	7.65	1.12e-13	9.64e-11	0.49	0.33	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	7.65	1.12e-13	9.64e-11	0.49	0.33	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
LUAD	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-7.65	1.12e-13	9.64e-11	-0.29	-0.33	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
LUAD	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-7.65	1.13e-13	9.7e-11	-0.37	-0.33	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
LUAD	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-7.65	1.13e-13	9.73e-11	-0.61	-0.33	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
LUAD	cis	rs904251	0.686	rs2776911	ENSG00000204110.6	RP1-153P14.8	-7.65	1.14e-13	9.75e-11	-0.39	-0.33	Cognitive performance;	chr6:37472174	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	7.65	1.14e-13	9.78e-11	0.38	0.33	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
LUAD	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	7.64	1.15e-13	9.81e-11	0.36	0.33	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
LUAD	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-7.64	1.15e-13	9.82e-11	-0.42	-0.33	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-7.64	1.15e-13	9.82e-11	-0.42	-0.33	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
LUAD	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	7.64	1.15e-13	9.82e-11	0.45	0.33	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
LUAD	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-7.64	1.15e-13	9.84e-11	-0.37	-0.33	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
LUAD	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-7.64	1.15e-13	9.86e-11	-0.43	-0.33	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
LUAD	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	7.64	1.15e-13	9.86e-11	0.31	0.33	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
LUAD	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	7.64	1.15e-13	9.88e-11	0.42	0.33	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
LUAD	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	7.64	1.16e-13	9.89e-11	0.41	0.33	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
LUAD	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	7.64	1.16e-13	9.91e-11	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	7.64	1.16e-13	9.92e-11	0.23	0.33	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
LUAD	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-7.64	1.16e-13	9.93e-11	-0.38	-0.33	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-7.64	1.16e-13	9.95e-11	-0.38	-0.33	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
LUAD	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	7.64	1.17e-13	9.97e-11	0.43	0.33	Height;	chr6:109571489	chr6:109382795~109383666:+
LUAD	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	7.64	1.17e-13	9.97e-11	0.39	0.33	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
LUAD	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	7.64	1.17e-13	9.99e-11	0.43	0.33	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
LUAD	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-7.64	1.17e-13	9.99e-11	-0.44	-0.33	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
LUAD	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-7.64	1.17e-13	1e-10	-0.45	-0.33	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-7.64	1.17e-13	1e-10	-0.45	-0.33	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
LUAD	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	7.64	1.17e-13	1e-10	0.57	0.33	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
LUAD	cis	rs10740039	0.729	rs6479728	ENSG00000254271.1	RP11-131N11.4	-7.64	1.17e-13	1e-10	-0.35	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:60734342~60741828:+
LUAD	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-7.64	1.18e-13	1.01e-10	-0.45	-0.33	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
LUAD	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-7.64	1.18e-13	1.01e-10	-0.37	-0.33	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
LUAD	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	7.64	1.18e-13	1.01e-10	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	7.64	1.18e-13	1.01e-10	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
LUAD	cis	rs56205728	0.601	rs3784399	ENSG00000273855.1	RP11-133K1.12	-7.64	1.18e-13	1.01e-10	-0.43	-0.33	Schizophrenia;	chr15:40306093	chr15:40285468~40285909:-
LUAD	cis	rs9595908	0.9	rs9595850	ENSG00000212293.1	SNORA16	7.64	1.19e-13	1.02e-10	0.35	0.33	Body mass index;	chr13:32579773	chr13:32420390~32420516:-
LUAD	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-7.64	1.19e-13	1.02e-10	-0.62	-0.33	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
LUAD	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-7.64	1.19e-13	1.02e-10	-0.35	-0.33	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
LUAD	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
LUAD	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-7.64	1.2e-13	1.03e-10	-0.3	-0.33	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
LUAD	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-7.64	1.2e-13	1.03e-10	-0.3	-0.33	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
LUAD	cis	rs11089937	0.609	rs2213158	ENSG00000211639.2	IGLV4-60	7.64	1.2e-13	1.03e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.637	rs2213159	ENSG00000211639.2	IGLV4-60	7.64	1.2e-13	1.03e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22162199~22162681:+
LUAD	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-7.64	1.2e-13	1.03e-10	-0.33	-0.33	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
LUAD	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-7.64	1.21e-13	1.03e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
LUAD	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-7.64	1.21e-13	1.03e-10	-0.48	-0.33	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-7.64	1.21e-13	1.03e-10	-0.48	-0.33	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
LUAD	cis	rs35955747	0.677	rs4820974	ENSG00000236132.1	CTA-440B3.1	7.64	1.22e-13	1.04e-10	0.38	0.33	Neutrophil count;Sum basophil neutrophil counts;	chr22:31473481	chr22:31816379~31817491:-
LUAD	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-7.64	1.22e-13	1.04e-10	-0.49	-0.33	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
LUAD	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	7.63	1.24e-13	1.06e-10	0.42	0.33	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
LUAD	cis	rs904251	0.647	rs2776908	ENSG00000204110.6	RP1-153P14.8	-7.63	1.25e-13	1.07e-10	-0.39	-0.33	Cognitive performance;	chr6:37467081	chr6:37507348~37535616:+
LUAD	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-7.63	1.26e-13	1.07e-10	-0.53	-0.33	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
LUAD	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	7.63	1.26e-13	1.07e-10	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
LUAD	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-7.63	1.26e-13	1.07e-10	-0.45	-0.33	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
LUAD	cis	rs2946504	0.705	rs1879487	ENSG00000251468.2	RP11-369K16.1	-7.63	1.27e-13	1.08e-10	-0.4	-0.33	Type 2 diabetes;	chr8:12947413	chr8:12958387~12962200:+
LUAD	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	7.63	1.27e-13	1.08e-10	0.43	0.33	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
LUAD	cis	rs7646881	1	rs61558956	ENSG00000240207.5	RP11-379F4.4	-7.63	1.27e-13	1.08e-10	-0.39	-0.33	Tetralogy of Fallot;	chr3:158734866	chr3:158732263~158784070:+
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	7.63	1.27e-13	1.09e-10	0.41	0.33	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
LUAD	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-7.63	1.28e-13	1.09e-10	-0.32	-0.33	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000280411.1	IGHV1-69-2	-7.63	1.28e-13	1.09e-10	-0.25	-0.33	Kawasaki disease;	chr14:106678896	chr14:106762092~106762588:-
LUAD	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	7.63	1.28e-13	1.09e-10	0.38	0.33	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
LUAD	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-7.63	1.28e-13	1.09e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
LUAD	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-7.63	1.28e-13	1.09e-10	-0.42	-0.33	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	7.63	1.29e-13	1.1e-10	0.38	0.33	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	7.63	1.29e-13	1.1e-10	0.39	0.33	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
LUAD	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	7.63	1.3e-13	1.1e-10	0.45	0.33	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
LUAD	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-7.63	1.3e-13	1.11e-10	-0.45	-0.33	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
LUAD	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-7.63	1.3e-13	1.11e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
LUAD	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	7.63	1.31e-13	1.11e-10	0.43	0.33	Height;	chr6:109546439	chr6:109382795~109383666:+
LUAD	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	7.63	1.31e-13	1.11e-10	0.43	0.33	Height;	chr6:109551060	chr6:109382795~109383666:+
LUAD	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	7.63	1.31e-13	1.12e-10	0.43	0.33	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
LUAD	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-7.62	1.32e-13	1.12e-10	-0.41	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
LUAD	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-7.62	1.33e-13	1.13e-10	-0.4	-0.33	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
LUAD	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-7.62	1.33e-13	1.13e-10	-0.59	-0.33	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
LUAD	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-7.62	1.33e-13	1.13e-10	-0.37	-0.33	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
LUAD	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	7.62	1.33e-13	1.13e-10	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
LUAD	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	7.62	1.33e-13	1.13e-10	0.43	0.33	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
LUAD	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-7.62	1.35e-13	1.14e-10	-0.39	-0.33	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-7.62	1.35e-13	1.14e-10	-0.39	-0.33	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-7.62	1.35e-13	1.14e-10	-0.39	-0.33	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-7.62	1.35e-13	1.14e-10	-0.39	-0.33	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
LUAD	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	7.62	1.35e-13	1.15e-10	0.44	0.33	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
LUAD	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-7.62	1.35e-13	1.15e-10	-0.34	-0.33	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
LUAD	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	7.62	1.36e-13	1.15e-10	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
LUAD	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-7.62	1.36e-13	1.15e-10	-0.47	-0.33	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000211972.2	IGHV3-66	7.62	1.36e-13	1.15e-10	0.29	0.33	Kawasaki disease;	chr14:106704386	chr14:106675017~106675544:-
LUAD	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	7.62	1.36e-13	1.16e-10	0.39	0.33	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
LUAD	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-7.62	1.36e-13	1.16e-10	-0.39	-0.33	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
LUAD	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-7.62	1.37e-13	1.16e-10	-0.44	-0.33	Migraine;	chr4:56940917	chr4:56960927~56961373:-
LUAD	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-7.62	1.37e-13	1.17e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
LUAD	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	7.62	1.38e-13	1.17e-10	0.46	0.33	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
LUAD	cis	rs11089937	0.539	rs6001075	ENSG00000211639.2	IGLV4-60	7.62	1.38e-13	1.17e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs6001076	ENSG00000211639.2	IGLV4-60	7.62	1.38e-13	1.17e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs5995560	ENSG00000211639.2	IGLV4-60	7.62	1.38e-13	1.17e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22162199~22162681:+
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	7.62	1.39e-13	1.18e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
LUAD	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	7.62	1.39e-13	1.18e-10	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
LUAD	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	7.62	1.39e-13	1.18e-10	0.43	0.33	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
LUAD	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	7.62	1.39e-13	1.18e-10	0.51	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
LUAD	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	7.62	1.39e-13	1.18e-10	0.39	0.33	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
LUAD	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	7.62	1.4e-13	1.18e-10	0.49	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
LUAD	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	7.62	1.4e-13	1.19e-10	0.38	0.33	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
LUAD	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	7.62	1.41e-13	1.19e-10	0.48	0.33	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
LUAD	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	7.62	1.41e-13	1.19e-10	0.36	0.33	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
LUAD	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-7.62	1.41e-13	1.19e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
LUAD	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	7.62	1.41e-13	1.19e-10	0.48	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
LUAD	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-7.61	1.42e-13	1.2e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
LUAD	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-7.61	1.42e-13	1.2e-10	-0.33	-0.33	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
LUAD	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-7.61	1.42e-13	1.2e-10	-0.42	-0.33	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
LUAD	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-7.61	1.42e-13	1.2e-10	-0.42	-0.33	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
LUAD	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-7.61	1.43e-13	1.21e-10	-0.35	-0.33	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
LUAD	cis	rs237743	1	rs6648	ENSG00000222365.1	SNORD12B	-7.61	1.43e-13	1.21e-10	-0.37	-0.33	Height;	chr20:49278705	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs238198	ENSG00000222365.1	SNORD12B	-7.61	1.43e-13	1.21e-10	-0.37	-0.33	Height;	chr20:49282523	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs237741	ENSG00000222365.1	SNORD12B	-7.61	1.43e-13	1.21e-10	-0.37	-0.33	Height;	chr20:49287143	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs13038621	ENSG00000222365.1	SNORD12B	-7.61	1.43e-13	1.21e-10	-0.37	-0.33	Height;	chr20:49291523	chr20:49280319~49280409:+
LUAD	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	7.61	1.43e-13	1.21e-10	0.41	0.33	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
LUAD	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	7.61	1.44e-13	1.21e-10	0.43	0.33	Height;	chr6:109533040	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	7.61	1.44e-13	1.21e-10	0.43	0.33	Height;	chr6:109534269	chr6:109382795~109383666:+
LUAD	cis	rs10129255	1	rs61997605	ENSG00000280411.1	IGHV1-69-2	-7.61	1.44e-13	1.22e-10	-0.25	-0.33	Kawasaki disease;	chr14:106678368	chr14:106762092~106762588:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000280411.1	IGHV1-69-2	-7.61	1.44e-13	1.22e-10	-0.25	-0.33	Kawasaki disease;	chr14:106678854	chr14:106762092~106762588:-
LUAD	cis	rs9595908	1	rs718444	ENSG00000212293.1	SNORA16	7.61	1.44e-13	1.22e-10	0.37	0.33	Body mass index;	chr13:32572915	chr13:32420390~32420516:-
LUAD	cis	rs9595908	1	rs7332115	ENSG00000212293.1	SNORA16	7.61	1.44e-13	1.22e-10	0.37	0.33	Body mass index;	chr13:32573411	chr13:32420390~32420516:-
LUAD	cis	rs9595908	1	rs7332763	ENSG00000212293.1	SNORA16	7.61	1.44e-13	1.22e-10	0.37	0.33	Body mass index;	chr13:32573751	chr13:32420390~32420516:-
LUAD	cis	rs9595908	1	rs9591134	ENSG00000212293.1	SNORA16	7.61	1.44e-13	1.22e-10	0.37	0.33	Body mass index;	chr13:32574079	chr13:32420390~32420516:-
LUAD	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	7.61	1.45e-13	1.22e-10	0.4	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
LUAD	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
LUAD	cis	rs7646881	0.812	rs75267618	ENSG00000240207.5	RP11-379F4.4	-7.61	1.45e-13	1.22e-10	-0.42	-0.33	Tetralogy of Fallot;	chr3:158726027	chr3:158732263~158784070:+
LUAD	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	7.61	1.46e-13	1.24e-10	0.42	0.33	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
LUAD	cis	rs8177876	0.749	rs10459872	ENSG00000261838.4	RP11-303E16.6	-7.61	1.47e-13	1.24e-10	-0.68	-0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81069854~81076598:+
LUAD	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	7.61	1.48e-13	1.25e-10	0.45	0.33	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
LUAD	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	7.61	1.48e-13	1.25e-10	0.45	0.33	Depression;	chr6:28110525	chr6:28115628~28116551:+
LUAD	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	7.61	1.48e-13	1.25e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
LUAD	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-7.61	1.48e-13	1.25e-10	-0.44	-0.33	Migraine;	chr4:56950140	chr4:56960927~56961373:-
LUAD	cis	rs944289	0.74	rs4982333	ENSG00000257826.1	RP11-116N8.4	-7.61	1.48e-13	1.25e-10	-0.35	-0.33	Thyroid cancer;	chr14:36100842	chr14:36061026~36067190:-
LUAD	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	7.61	1.48e-13	1.25e-10	0.45	0.33	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
LUAD	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-7.61	1.49e-13	1.26e-10	-0.33	-0.33	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
LUAD	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-7.61	1.5e-13	1.27e-10	-0.35	-0.33	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
LUAD	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	7.6	1.51e-13	1.27e-10	0.43	0.33	Height;	chr6:109558247	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	7.6	1.51e-13	1.27e-10	0.43	0.33	Height;	chr6:109564443	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	7.6	1.51e-13	1.27e-10	0.43	0.33	Height;	chr6:109576414	chr6:109382795~109383666:+
LUAD	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	7.6	1.51e-13	1.27e-10	0.35	0.33	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
LUAD	cis	rs8031584	0.678	rs3122	ENSG00000260382.1	RP11-540B6.2	-7.6	1.51e-13	1.28e-10	-0.4	-0.33	Huntington's disease progression;	chr15:30878087	chr15:30882267~30883231:-
LUAD	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	7.6	1.51e-13	1.28e-10	0.41	0.33	Height;	chr6:109506513	chr6:109382795~109383666:+
LUAD	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-7.6	1.52e-13	1.28e-10	-0.39	-0.33	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
LUAD	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	7.6	1.52e-13	1.28e-10	0.43	0.33	Height;	chr6:109526846	chr6:109382795~109383666:+
LUAD	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-7.6	1.52e-13	1.28e-10	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
LUAD	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-7.6	1.52e-13	1.29e-10	-0.39	-0.33	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-7.6	1.53e-13	1.29e-10	-0.39	-0.33	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
LUAD	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	7.6	1.53e-13	1.29e-10	0.39	0.33	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
LUAD	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	7.6	1.53e-13	1.29e-10	0.5	0.33	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
LUAD	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-7.6	1.54e-13	1.3e-10	-0.36	-0.33	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	7.6	1.54e-13	1.3e-10	0.38	0.33	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	7.6	1.54e-13	1.3e-10	0.38	0.33	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
LUAD	cis	rs13423976	1	rs13423976	ENSG00000231367.4	AC016995.3	-7.6	1.54e-13	1.3e-10	-0.43	-0.33	Gut microbiome composition (summer);	chr2:38518482	chr2:38406719~38515740:-
LUAD	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	7.6	1.54e-13	1.3e-10	0.35	0.33	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	7.6	1.54e-13	1.3e-10	0.35	0.33	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
LUAD	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	7.6	1.54e-13	1.3e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
LUAD	cis	rs944289	0.708	rs1953120	ENSG00000257826.1	RP11-116N8.4	-7.6	1.56e-13	1.31e-10	-0.34	-0.33	Thyroid cancer;	chr14:36105724	chr14:36061026~36067190:-
LUAD	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	7.6	1.57e-13	1.32e-10	0.39	0.33	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
LUAD	cis	rs9326248	0.53	rs2127905	ENSG00000280143.1	AP000892.6	7.6	1.57e-13	1.32e-10	0.52	0.33	Blood protein levels;	chr11:117155658	chr11:117204967~117210292:+
LUAD	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	7.6	1.57e-13	1.32e-10	0.43	0.33	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	7.6	1.57e-13	1.32e-10	0.39	0.33	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
LUAD	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	7.6	1.57e-13	1.33e-10	0.37	0.33	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
LUAD	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	7.6	1.58e-13	1.33e-10	0.39	0.33	Depression;	chr6:28317705	chr6:28176188~28176674:+
LUAD	cis	rs10200159	1	rs12616982	ENSG00000272606.1	RP11-554J4.1	7.6	1.59e-13	1.34e-10	0.54	0.33	Vitiligo;	chr2:55647676	chr2:55617909~55618373:+
LUAD	cis	rs10200159	1	rs13407344	ENSG00000272606.1	RP11-554J4.1	7.6	1.59e-13	1.34e-10	0.54	0.33	Vitiligo;	chr2:55648233	chr2:55617909~55618373:+
LUAD	cis	rs10200159	1	rs13382187	ENSG00000272606.1	RP11-554J4.1	7.6	1.59e-13	1.34e-10	0.54	0.33	Vitiligo;	chr2:55648611	chr2:55617909~55618373:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000280411.1	IGHV1-69-2	-7.6	1.59e-13	1.34e-10	-0.26	-0.33	Kawasaki disease;	chr14:106813798	chr14:106762092~106762588:-
LUAD	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-7.6	1.6e-13	1.35e-10	-0.39	-0.33	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
LUAD	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	7.6	1.61e-13	1.35e-10	0.39	0.33	Depression;	chr6:28323463	chr6:28176188~28176674:+
LUAD	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-7.6	1.62e-13	1.36e-10	-0.36	-0.33	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
LUAD	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-7.6	1.62e-13	1.36e-10	-0.44	-0.33	Migraine;	chr4:56956882	chr4:56960927~56961373:-
LUAD	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-7.59	1.62e-13	1.36e-10	-0.44	-0.33	Migraine;	chr4:56957291	chr4:56960927~56961373:-
LUAD	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	7.59	1.62e-13	1.36e-10	0.42	0.33	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
LUAD	cis	rs9326248	0.53	rs7112513	ENSG00000280143.1	AP000892.6	7.59	1.62e-13	1.36e-10	0.52	0.33	Blood protein levels;	chr11:117166645	chr11:117204967~117210292:+
LUAD	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	7.59	1.62e-13	1.36e-10	0.36	0.33	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
LUAD	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	7.59	1.63e-13	1.37e-10	0.39	0.33	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
LUAD	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-7.59	1.64e-13	1.38e-10	-0.5	-0.33	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
LUAD	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	7.59	1.64e-13	1.38e-10	0.31	0.33	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
LUAD	cis	rs944289	0.774	rs1958625	ENSG00000257826.1	RP11-116N8.4	-7.59	1.66e-13	1.39e-10	-0.34	-0.33	Thyroid cancer;	chr14:36133470	chr14:36061026~36067190:-
LUAD	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	7.59	1.66e-13	1.39e-10	0.38	0.33	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	7.59	1.66e-13	1.4e-10	0.39	0.33	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.837	rs4331474	ENSG00000234818.1	AC092687.5	7.59	1.66e-13	1.4e-10	0.39	0.33	Prostate cancer;	chr2:10615457	chr2:10589166~10604830:+
LUAD	cis	rs17608059	0.611	rs2108591	ENSG00000141028.6	CDRT15P1	-7.59	1.67e-13	1.4e-10	-0.37	-0.33	Temperament;	chr17:14019308	chr17:14024514~14025488:+
LUAD	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-7.59	1.67e-13	1.4e-10	-0.47	-0.33	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
LUAD	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-7.59	1.68e-13	1.41e-10	-0.39	-0.33	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
LUAD	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28123153	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28124529	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28126588	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28126953	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28127577	chr6:28115628~28116551:+
LUAD	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-7.59	1.69e-13	1.42e-10	-0.37	-0.33	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
LUAD	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	7.59	1.69e-13	1.42e-10	0.31	0.33	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
LUAD	cis	rs944289	0.708	rs11622885	ENSG00000257826.1	RP11-116N8.4	-7.59	1.69e-13	1.42e-10	-0.35	-0.33	Thyroid cancer;	chr14:36095036	chr14:36061026~36067190:-
LUAD	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	7.59	1.69e-13	1.42e-10	0.46	0.33	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
LUAD	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	7.59	1.7e-13	1.42e-10	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
LUAD	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	7.59	1.7e-13	1.42e-10	0.45	0.33	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
LUAD	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.71e-13	1.43e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
LUAD	cis	rs1322639	0.614	rs4708414	ENSG00000261039.2	RP11-417E7.2	-7.59	1.71e-13	1.43e-10	-0.41	-0.33	Pulse pressure;	chr6:169174049	chr6:169175304~169182740:-
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000206090.4	AP000350.7	7.59	1.71e-13	1.44e-10	0.37	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23939998~23942798:+
LUAD	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	7.59	1.71e-13	1.44e-10	0.49	0.33	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
LUAD	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	7.59	1.72e-13	1.44e-10	0.45	0.33	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	7.59	1.72e-13	1.44e-10	0.45	0.33	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
LUAD	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	7.59	1.72e-13	1.44e-10	0.44	0.33	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
LUAD	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	7.59	1.72e-13	1.44e-10	0.41	0.33	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
LUAD	cis	rs4927850	0.521	rs4927679	ENSG00000231464.1	AC024937.4	-7.59	1.73e-13	1.44e-10	-0.34	-0.33	Pancreatic cancer;	chr3:195931489	chr3:195996738~195998233:+
LUAD	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-7.59	1.73e-13	1.45e-10	-0.41	-0.33	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
LUAD	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.73e-13	1.45e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
LUAD	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.73e-13	1.45e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
LUAD	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.73e-13	1.45e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
LUAD	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.73e-13	1.45e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
LUAD	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	7.58	1.74e-13	1.45e-10	0.44	0.33	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
LUAD	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-7.58	1.74e-13	1.46e-10	-0.46	-0.33	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
LUAD	cis	rs9595908	1	rs9595905	ENSG00000212293.1	SNORA16	7.58	1.74e-13	1.46e-10	0.35	0.33	Body mass index;	chr13:32609266	chr13:32420390~32420516:-
LUAD	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-7.58	1.74e-13	1.46e-10	-0.4	-0.33	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
LUAD	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-7.58	1.77e-13	1.48e-10	-0.26	-0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
LUAD	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	7.58	1.77e-13	1.48e-10	0.39	0.33	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
LUAD	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	7.58	1.78e-13	1.49e-10	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	7.58	1.78e-13	1.49e-10	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	7.58	1.79e-13	1.5e-10	0.38	0.33	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
LUAD	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-7.58	1.79e-13	1.5e-10	-0.45	-0.33	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
LUAD	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	7.58	1.8e-13	1.5e-10	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
LUAD	cis	rs8177876	0.749	rs2287995	ENSG00000261838.4	RP11-303E16.6	7.58	1.81e-13	1.51e-10	0.72	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81069854~81076598:+
LUAD	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-7.58	1.81e-13	1.51e-10	-0.33	-0.33	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
LUAD	cis	rs9595908	0.865	rs2761365	ENSG00000212293.1	SNORA16	-7.58	1.82e-13	1.52e-10	-0.38	-0.33	Body mass index;	chr13:32437687	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.827	rs2761366	ENSG00000212293.1	SNORA16	-7.58	1.82e-13	1.52e-10	-0.38	-0.33	Body mass index;	chr13:32437735	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.66	rs2191268	ENSG00000226824.5	RP4-756H11.3	-7.58	1.83e-13	1.53e-10	-0.38	-0.33	Aortic root size;	chr7:66645237	chr7:66654538~66669855:+
LUAD	cis	rs8177876	0.658	rs12444747	ENSG00000261838.4	RP11-303E16.6	7.58	1.83e-13	1.53e-10	0.77	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041299	chr16:81069854~81076598:+
LUAD	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-7.58	1.84e-13	1.53e-10	-0.46	-0.33	Depression;	chr6:28137418	chr6:28115628~28116551:+
LUAD	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-7.58	1.84e-13	1.53e-10	-0.35	-0.33	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
LUAD	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-7.58	1.85e-13	1.55e-10	-0.36	-0.33	Height;	chr3:52819385	chr3:53064283~53065091:-
LUAD	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	7.58	1.86e-13	1.55e-10	0.34	0.33	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
LUAD	cis	rs35955747	0.601	rs7289941	ENSG00000236132.1	CTA-440B3.1	-7.57	1.87e-13	1.56e-10	-0.38	-0.33	Neutrophil count;Sum basophil neutrophil counts;	chr22:31488419	chr22:31816379~31817491:-
LUAD	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-7.57	1.87e-13	1.56e-10	-0.42	-0.33	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	7.57	1.88e-13	1.57e-10	0.42	0.33	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-7.57	1.88e-13	1.57e-10	-0.39	-0.33	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
LUAD	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-7.57	1.9e-13	1.58e-10	-0.4	-0.33	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
LUAD	cis	rs944289	0.74	rs885535	ENSG00000257826.1	RP11-116N8.4	-7.57	1.9e-13	1.58e-10	-0.34	-0.33	Thyroid cancer;	chr14:36082574	chr14:36061026~36067190:-
LUAD	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-7.57	1.9e-13	1.58e-10	-0.33	-0.33	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
LUAD	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-7.57	1.9e-13	1.58e-10	-0.42	-0.33	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
LUAD	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	7.57	1.9e-13	1.58e-10	0.36	0.33	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
LUAD	cis	rs35955747	0.738	rs2012451	ENSG00000236132.1	CTA-440B3.1	7.57	1.9e-13	1.58e-10	0.36	0.33	Neutrophil count;Sum basophil neutrophil counts;	chr22:31448387	chr22:31816379~31817491:-
LUAD	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	7.57	1.91e-13	1.59e-10	0.39	0.33	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
LUAD	cis	rs8177876	0.749	rs58144189	ENSG00000261838.4	RP11-303E16.6	7.57	1.91e-13	1.59e-10	0.73	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81069854~81076598:+
LUAD	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	7.57	1.92e-13	1.6e-10	0.34	0.33	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
LUAD	cis	rs950880	0.71	rs12469506	ENSG00000234389.1	AC007278.3	-7.57	1.92e-13	1.6e-10	-0.34	-0.33	Serum protein levels (sST2);	chr2:102349411	chr2:102438713~102440475:+
LUAD	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-7.57	1.93e-13	1.61e-10	-0.34	-0.33	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
LUAD	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-7.57	1.93e-13	1.61e-10	-0.46	-0.33	Depression;	chr6:28139049	chr6:28115628~28116551:+
LUAD	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	7.57	1.93e-13	1.61e-10	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
LUAD	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	7.57	1.94e-13	1.62e-10	0.42	0.33	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
LUAD	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	7.57	1.96e-13	1.64e-10	0.56	0.33	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
LUAD	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	7.57	1.96e-13	1.64e-10	0.56	0.33	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
LUAD	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	7.57	1.97e-13	1.64e-10	0.38	0.33	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-7.57	1.97e-13	1.64e-10	-0.44	-0.33	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-7.57	1.97e-13	1.64e-10	-0.44	-0.33	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
LUAD	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	7.57	1.98e-13	1.65e-10	0.37	0.33	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
LUAD	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-7.57	1.98e-13	1.65e-10	-0.45	-0.33	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
LUAD	cis	rs62229266	0.682	rs2835224	ENSG00000214914.3	RPL23AP3	7.57	1.98e-13	1.65e-10	0.42	0.33	Mitral valve prolapse;	chr21:35997732	chr21:36016079~36016546:-
LUAD	cis	rs944289	0.708	rs1537426	ENSG00000257826.1	RP11-116N8.4	7.56	2.01e-13	1.67e-10	0.34	0.33	Thyroid cancer;	chr14:36117961	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	7.56	2.01e-13	1.67e-10	0.41	0.33	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.774	rs4997811	ENSG00000234818.1	AC092687.5	7.56	2.01e-13	1.67e-10	0.39	0.33	Prostate cancer;	chr2:10615412	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.745	rs4997810	ENSG00000234818.1	AC092687.5	7.56	2.01e-13	1.67e-10	0.39	0.33	Prostate cancer;	chr2:10615414	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.745	rs4997809	ENSG00000234818.1	AC092687.5	7.56	2.01e-13	1.67e-10	0.39	0.33	Prostate cancer;	chr2:10615416	chr2:10589166~10604830:+
LUAD	cis	rs237743	1	rs238174	ENSG00000222365.1	SNORD12B	-7.56	2.02e-13	1.68e-10	-0.37	-0.33	Height;	chr20:49262572	chr20:49280319~49280409:+
LUAD	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	7.56	2.02e-13	1.68e-10	0.45	0.33	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
LUAD	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	7.56	2.03e-13	1.69e-10	0.38	0.33	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	7.56	2.04e-13	1.7e-10	0.43	0.33	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	7.56	2.04e-13	1.7e-10	0.38	0.33	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
LUAD	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	7.56	2.04e-13	1.7e-10	0.44	0.33	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
LUAD	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	7.56	2.05e-13	1.71e-10	0.39	0.33	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	7.56	2.05e-13	1.71e-10	0.39	0.33	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	7.56	2.05e-13	1.71e-10	0.39	0.33	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
LUAD	cis	rs62229266	0.647	rs59397717	ENSG00000231106.2	LINC01436	7.56	2.07e-13	1.72e-10	0.43	0.33	Mitral valve prolapse;	chr21:36079427	chr21:36005338~36007838:+
LUAD	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	7.56	2.07e-13	1.72e-10	0.4	0.33	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	7.56	2.08e-13	1.73e-10	0.4	0.33	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
LUAD	cis	rs8059260	0.524	rs1122185	ENSG00000274038.1	RP11-66H6.4	-7.56	2.08e-13	1.73e-10	-0.48	-0.33	Alcohol consumption over the past year;	chr16:11104119	chr16:11056556~11057034:+
LUAD	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	7.56	2.09e-13	1.74e-10	0.34	0.33	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
LUAD	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	7.56	2.1e-13	1.74e-10	0.43	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
LUAD	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-7.56	2.1e-13	1.74e-10	-0.4	-0.33	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-7.56	2.1e-13	1.74e-10	-0.4	-0.33	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
LUAD	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
LUAD	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	7.56	2.1e-13	1.74e-10	0.32	0.33	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
LUAD	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	7.56	2.11e-13	1.75e-10	0.38	0.33	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
LUAD	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-7.56	2.12e-13	1.76e-10	-0.41	-0.33	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
LUAD	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	7.56	2.13e-13	1.77e-10	0.38	0.33	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
LUAD	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-7.56	2.13e-13	1.77e-10	-0.38	-0.33	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
LUAD	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	7.55	2.13e-13	1.77e-10	0.37	0.33	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
LUAD	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	7.55	2.14e-13	1.78e-10	0.42	0.33	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
LUAD	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-7.55	2.15e-13	1.78e-10	-0.46	-0.33	Depression;	chr6:28135913	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	7.55	2.15e-13	1.78e-10	0.68	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
LUAD	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-7.55	2.15e-13	1.79e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
LUAD	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-7.55	2.16e-13	1.79e-10	-0.37	-0.33	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
LUAD	cis	rs8177876	0.822	rs56198248	ENSG00000261838.4	RP11-303E16.6	7.55	2.17e-13	1.8e-10	0.81	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074869	chr16:81069854~81076598:+
LUAD	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	7.55	2.17e-13	1.8e-10	0.38	0.33	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
LUAD	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	7.55	2.17e-13	1.8e-10	0.42	0.33	Height;	chr6:109507364	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	7.55	2.17e-13	1.8e-10	0.42	0.33	Height;	chr6:109507366	chr6:109382795~109383666:+
LUAD	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	7.55	2.17e-13	1.8e-10	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
LUAD	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	7.55	2.17e-13	1.8e-10	0.59	0.33	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
LUAD	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	7.55	2.18e-13	1.81e-10	0.3	0.33	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
LUAD	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	7.55	2.19e-13	1.81e-10	0.45	0.33	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
LUAD	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	7.55	2.19e-13	1.81e-10	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
LUAD	cis	rs237743	1	rs34580798	ENSG00000222365.1	SNORD12B	-7.55	2.19e-13	1.81e-10	-0.38	-0.33	Height;	chr20:49283420	chr20:49280319~49280409:+
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000280411.1	IGHV1-69-2	-7.55	2.19e-13	1.81e-10	-0.25	-0.33	Kawasaki disease;	chr14:106692376	chr14:106762092~106762588:-
LUAD	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.19e-13	1.82e-10	-0.33	-0.33	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
LUAD	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-7.55	2.21e-13	1.83e-10	-0.36	-0.33	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
LUAD	cis	rs944289	0.708	rs34613409	ENSG00000257826.1	RP11-116N8.4	-7.55	2.21e-13	1.83e-10	-0.34	-0.33	Thyroid cancer;	chr14:36096489	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.774	rs2415312	ENSG00000257826.1	RP11-116N8.4	-7.55	2.21e-13	1.83e-10	-0.34	-0.33	Thyroid cancer;	chr14:36097145	chr14:36061026~36067190:-
LUAD	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-7.55	2.21e-13	1.83e-10	-0.4	-0.33	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
LUAD	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	7.55	2.22e-13	1.84e-10	0.43	0.33	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	7.55	2.22e-13	1.84e-10	0.4	0.33	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
LUAD	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-7.55	2.22e-13	1.84e-10	-0.35	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
LUAD	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-7.55	2.24e-13	1.85e-10	-0.44	-0.33	Migraine;	chr4:56937339	chr4:56960927~56961373:-
LUAD	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.24e-13	1.86e-10	-0.33	-0.33	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
LUAD	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-7.55	2.24e-13	1.86e-10	-0.4	-0.33	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-7.55	2.24e-13	1.86e-10	-0.4	-0.33	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28136698	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28136856	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28138363	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28138981	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28139012	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-7.55	2.25e-13	1.86e-10	-0.45	-0.33	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
LUAD	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	7.55	2.27e-13	1.88e-10	0.5	0.33	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
LUAD	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.28e-13	1.88e-10	-0.33	-0.33	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000280411.1	IGHV1-69-2	-7.55	2.28e-13	1.89e-10	-0.25	-0.33	Kawasaki disease;	chr14:106670611	chr14:106762092~106762588:-
LUAD	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	7.54	2.28e-13	1.89e-10	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
LUAD	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	7.54	2.29e-13	1.89e-10	0.34	0.33	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	7.54	2.29e-13	1.89e-10	0.34	0.33	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	7.54	2.29e-13	1.89e-10	0.34	0.33	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
LUAD	cis	rs9595908	1	rs9591165	ENSG00000212293.1	SNORA16	7.54	2.29e-13	1.89e-10	0.35	0.33	Body mass index;	chr13:32611016	chr13:32420390~32420516:-
LUAD	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	7.54	2.3e-13	1.9e-10	0.43	0.33	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
LUAD	cis	rs10129255	1	rs11621409	ENSG00000280411.1	IGHV1-69-2	-7.54	2.3e-13	1.91e-10	-0.25	-0.33	Kawasaki disease;	chr14:106695603	chr14:106762092~106762588:-
LUAD	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-7.54	2.33e-13	1.92e-10	-0.41	-0.33	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	7.54	2.33e-13	1.92e-10	0.37	0.33	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
LUAD	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	7.54	2.33e-13	1.93e-10	0.42	0.33	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	7.54	2.34e-13	1.93e-10	0.38	0.33	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-7.54	2.35e-13	1.94e-10	-0.47	-0.33	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
LUAD	cis	rs7688540	0.713	rs12511388	ENSG00000275426.1	CH17-262A2.1	7.54	2.35e-13	1.94e-10	0.45	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:149738~150317:+
LUAD	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	7.54	2.36e-13	1.95e-10	0.38	0.33	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	7.54	2.36e-13	1.95e-10	0.34	0.33	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
LUAD	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	7.54	2.37e-13	1.96e-10	0.56	0.33	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
LUAD	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-7.54	2.38e-13	1.96e-10	-0.47	-0.33	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-7.54	2.38e-13	1.96e-10	-0.47	-0.33	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
LUAD	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-7.54	2.38e-13	1.96e-10	-0.4	-0.33	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
LUAD	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-7.54	2.39e-13	1.97e-10	-0.34	-0.33	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
LUAD	cis	rs7182621	0.639	rs12906050	ENSG00000182397.13	DNM1P46	7.54	2.4e-13	1.98e-10	0.44	0.33	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99790156~99806927:-
LUAD	cis	rs7182621	0.639	rs35248328	ENSG00000182397.13	DNM1P46	7.54	2.4e-13	1.98e-10	0.44	0.33	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99790156~99806927:-
LUAD	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	7.54	2.41e-13	1.99e-10	0.38	0.32	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	7.54	2.42e-13	2e-10	0.38	0.32	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
LUAD	cis	rs34779708	0.801	rs12242110	ENSG00000230534.5	RP11-297A16.2	7.54	2.43e-13	2e-10	0.39	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35098006~35127020:-
LUAD	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	7.54	2.43e-13	2.01e-10	0.4	0.32	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
LUAD	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	7.54	2.44e-13	2.01e-10	0.4	0.32	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
LUAD	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	7.53	2.44e-13	2.01e-10	0.45	0.32	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	7.53	2.44e-13	2.01e-10	0.45	0.32	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
LUAD	cis	rs7182621	0.639	rs34701806	ENSG00000182397.13	DNM1P46	7.53	2.45e-13	2.02e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99790156~99806927:-
LUAD	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	7.53	2.45e-13	2.02e-10	0.54	0.32	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
LUAD	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-7.53	2.47e-13	2.03e-10	-0.57	-0.32	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
LUAD	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	7.53	2.47e-13	2.04e-10	0.54	0.32	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
LUAD	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	7.53	2.47e-13	2.04e-10	0.36	0.32	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
LUAD	cis	rs9326248	0.569	rs10892082	ENSG00000280143.1	AP000892.6	7.53	2.49e-13	2.05e-10	0.49	0.32	Blood protein levels;	chr11:117168609	chr11:117204967~117210292:+
LUAD	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	7.53	2.5e-13	2.06e-10	0.45	0.32	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000211970.3	IGHV4-61	-7.53	2.5e-13	2.06e-10	-0.23	-0.32	Kawasaki disease;	chr14:106686149	chr14:106639119~106639657:-
LUAD	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-7.53	2.53e-13	2.08e-10	-0.5	-0.32	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
LUAD	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-7.53	2.53e-13	2.08e-10	-0.46	-0.32	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
LUAD	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	7.53	2.54e-13	2.09e-10	0.38	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
LUAD	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	7.53	2.54e-13	2.09e-10	0.42	0.32	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
LUAD	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	7.53	2.54e-13	2.09e-10	0.42	0.32	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
LUAD	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-7.53	2.55e-13	2.09e-10	-0.38	-0.32	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	7.53	2.56e-13	2.1e-10	0.44	0.32	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
LUAD	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	7.53	2.56e-13	2.1e-10	0.44	0.32	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-7.53	2.56e-13	2.11e-10	-0.41	-0.32	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
LUAD	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	7.53	2.57e-13	2.11e-10	0.39	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
LUAD	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	7.53	2.57e-13	2.11e-10	0.58	0.32	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
LUAD	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	7.53	2.58e-13	2.12e-10	0.43	0.32	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
LUAD	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	7.53	2.58e-13	2.12e-10	0.39	0.32	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-7.53	2.58e-13	2.12e-10	-0.45	-0.32	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
LUAD	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-7.53	2.58e-13	2.12e-10	-0.46	-0.32	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
LUAD	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-7.53	2.6e-13	2.14e-10	-0.35	-0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
LUAD	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	7.53	2.6e-13	2.14e-10	0.41	0.32	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
LUAD	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	7.52	2.63e-13	2.16e-10	0.39	0.32	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
LUAD	cis	rs10129255	1	rs10137758	ENSG00000211972.2	IGHV3-66	7.52	2.63e-13	2.16e-10	0.29	0.32	Kawasaki disease;	chr14:106697673	chr14:106675017~106675544:-
LUAD	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
LUAD	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	7.52	2.63e-13	2.16e-10	0.36	0.32	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
LUAD	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
LUAD	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-7.52	2.65e-13	2.17e-10	-0.36	-0.32	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
LUAD	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-7.52	2.66e-13	2.18e-10	-0.42	-0.32	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
LUAD	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-7.52	2.68e-13	2.19e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
LUAD	cis	rs904251	0.802	rs2646933	ENSG00000279942.1	RP1-153P14.7	-7.52	2.68e-13	2.2e-10	-0.34	-0.32	Cognitive performance;	chr6:37434294	chr6:37567716~37571460:+
LUAD	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	7.52	2.73e-13	2.24e-10	0.27	0.32	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
LUAD	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	7.52	2.73e-13	2.24e-10	0.37	0.32	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
LUAD	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	7.52	2.74e-13	2.25e-10	0.75	0.32	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
LUAD	cis	rs9595908	0.9	rs731413	ENSG00000212293.1	SNORA16	7.52	2.74e-13	2.25e-10	0.34	0.32	Body mass index;	chr13:32601519	chr13:32420390~32420516:-
LUAD	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	7.52	2.75e-13	2.25e-10	0.36	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
LUAD	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	7.52	2.75e-13	2.25e-10	0.44	0.32	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
LUAD	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-7.52	2.75e-13	2.25e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
LUAD	cis	rs8177876	0.597	rs1048194	ENSG00000261838.4	RP11-303E16.6	-7.52	2.75e-13	2.25e-10	-0.76	-0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81069854~81076598:+
LUAD	cis	rs10129255	1	rs11621409	ENSG00000211972.2	IGHV3-66	7.52	2.76e-13	2.26e-10	0.29	0.32	Kawasaki disease;	chr14:106695603	chr14:106675017~106675544:-
LUAD	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-7.52	2.76e-13	2.26e-10	-0.4	-0.32	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
LUAD	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-7.52	2.78e-13	2.28e-10	-0.43	-0.32	Migraine;	chr4:56943905	chr4:56960927~56961373:-
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000280411.1	IGHV1-69-2	-7.52	2.79e-13	2.28e-10	-0.24	-0.32	Kawasaki disease;	chr14:106815190	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000211972.2	IGHV3-66	7.52	2.79e-13	2.28e-10	0.29	0.32	Kawasaki disease;	chr14:106805607	chr14:106675017~106675544:-
LUAD	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-7.52	2.79e-13	2.28e-10	-0.4	-0.32	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
LUAD	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	7.52	2.79e-13	2.28e-10	0.42	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
LUAD	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	7.52	2.79e-13	2.29e-10	0.29	0.32	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	7.51	2.83e-13	2.32e-10	0.27	0.32	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
LUAD	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	7.51	2.84e-13	2.32e-10	0.36	0.32	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
LUAD	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-7.51	2.85e-13	2.33e-10	-0.38	-0.32	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-7.51	2.87e-13	2.35e-10	-0.37	-0.32	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
LUAD	cis	rs8177876	0.749	rs754429	ENSG00000261838.4	RP11-303E16.6	7.51	2.89e-13	2.36e-10	0.72	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81069854~81076598:+
LUAD	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	7.51	2.89e-13	2.36e-10	0.44	0.32	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
LUAD	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-7.51	2.9e-13	2.37e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
LUAD	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-7.51	2.92e-13	2.38e-10	-0.44	-0.32	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
LUAD	cis	rs8177876	0.554	rs56286107	ENSG00000261838.4	RP11-303E16.6	7.51	2.93e-13	2.39e-10	0.84	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084227	chr16:81069854~81076598:+
LUAD	cis	rs4273100	1	rs4924986	ENSG00000262319.1	CTC-457L16.2	7.51	2.93e-13	2.39e-10	0.43	0.32	Schizophrenia;	chr17:19339154	chr17:19141017~19143689:-
LUAD	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-7.51	2.93e-13	2.39e-10	-0.48	-0.32	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
LUAD	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	7.51	2.94e-13	2.4e-10	0.27	0.32	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	7.51	2.94e-13	2.4e-10	0.27	0.32	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	7.51	2.94e-13	2.4e-10	0.27	0.32	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
LUAD	cis	rs6844153	0.938	rs77926313	ENSG00000240005.4	RP11-293A21.1	-7.51	2.94e-13	2.4e-10	-0.55	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26965420	chr4:26859806~26860599:-
LUAD	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-7.51	2.94e-13	2.4e-10	-0.46	-0.32	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000211972.2	IGHV3-66	7.51	2.96e-13	2.41e-10	0.29	0.32	Kawasaki disease;	chr14:106705441	chr14:106675017~106675544:-
LUAD	cis	rs9549367	0.673	rs575453	ENSG00000269125.1	RP11-98F14.11	7.51	2.96e-13	2.42e-10	0.41	0.32	Platelet distribution width;	chr13:113183557	chr13:113165002~113165183:-
LUAD	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	7.51	2.97e-13	2.42e-10	0.38	0.32	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-7.51	2.97e-13	2.42e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-7.51	2.97e-13	2.42e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
LUAD	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-7.51	2.97e-13	2.42e-10	-0.47	-0.32	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
LUAD	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-7.51	2.98e-13	2.43e-10	-0.46	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
LUAD	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-7.51	2.98e-13	2.43e-10	-0.61	-0.32	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-7.51	2.98e-13	2.43e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
LUAD	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	7.51	2.99e-13	2.43e-10	0.47	0.32	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
LUAD	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-7.51	2.99e-13	2.44e-10	-0.44	-0.32	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
LUAD	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	7.51	2.99e-13	2.44e-10	0.48	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	7.51	3e-13	2.44e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	7.51	3e-13	2.44e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
LUAD	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	7.51	3e-13	2.44e-10	0.38	0.32	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
LUAD	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	7.5	3e-13	2.44e-10	0.42	0.32	Height;	chr6:109589051	chr6:109382795~109383666:+
LUAD	cis	rs7646881	1	rs7646881	ENSG00000240207.5	RP11-379F4.4	-7.5	3e-13	2.44e-10	-0.39	-0.32	Tetralogy of Fallot;	chr3:158735490	chr3:158732263~158784070:+
LUAD	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	7.5	3.01e-13	2.45e-10	0.35	0.32	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
LUAD	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	7.5	3.01e-13	2.45e-10	0.35	0.32	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
LUAD	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-7.5	3.01e-13	2.45e-10	-0.39	-0.32	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-7.5	3.01e-13	2.45e-10	-0.39	-0.32	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-7.5	3.02e-13	2.46e-10	-0.39	-0.32	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
LUAD	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-7.5	3.03e-13	2.47e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
LUAD	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	7.5	3.05e-13	2.48e-10	0.29	0.32	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
LUAD	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-7.5	3.05e-13	2.48e-10	-0.42	-0.32	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
LUAD	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	7.5	3.05e-13	2.49e-10	0.36	0.32	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
LUAD	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	7.5	3.06e-13	2.49e-10	0.44	0.32	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
LUAD	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-7.5	3.07e-13	2.5e-10	-0.4	-0.32	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
LUAD	cis	rs9326248	0.53	rs2471884	ENSG00000280143.1	AP000892.6	7.5	3.07e-13	2.5e-10	0.51	0.32	Blood protein levels;	chr11:117139604	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	7.5	3.09e-13	2.51e-10	0.38	0.32	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	7.5	3.09e-13	2.51e-10	0.38	0.32	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
LUAD	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	7.5	3.09e-13	2.51e-10	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
LUAD	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-7.5	3.1e-13	2.52e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-7.5	3.1e-13	2.52e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
LUAD	cis	rs7646881	1	rs73015655	ENSG00000240207.5	RP11-379F4.4	-7.5	3.1e-13	2.53e-10	-0.39	-0.32	Tetralogy of Fallot;	chr3:158734093	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.904	rs112493023	ENSG00000240207.5	RP11-379F4.4	-7.5	3.11e-13	2.53e-10	-0.38	-0.32	Tetralogy of Fallot;	chr3:158730487	chr3:158732263~158784070:+
LUAD	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	7.5	3.11e-13	2.53e-10	0.47	0.32	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
LUAD	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-7.5	3.12e-13	2.54e-10	-0.34	-0.32	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
LUAD	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-7.5	3.13e-13	2.54e-10	-0.39	-0.32	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000280411.1	IGHV1-69-2	-7.5	3.13e-13	2.55e-10	-0.25	-0.32	Kawasaki disease;	chr14:106668657	chr14:106762092~106762588:-
LUAD	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-7.5	3.14e-13	2.55e-10	-0.45	-0.32	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
LUAD	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-7.5	3.14e-13	2.56e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
LUAD	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-7.5	3.16e-13	2.56e-10	-0.31	-0.32	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
LUAD	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-7.5	3.16e-13	2.57e-10	-0.35	-0.32	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
LUAD	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	7.5	3.18e-13	2.58e-10	0.42	0.32	Height;	chr6:109618620	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	7.5	3.18e-13	2.58e-10	0.42	0.32	Height;	chr6:109620772	chr6:109382795~109383666:+
LUAD	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-7.5	3.2e-13	2.6e-10	-0.5	-0.32	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	7.49	3.21e-13	2.61e-10	0.38	0.32	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
LUAD	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	7.49	3.25e-13	2.63e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
LUAD	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	7.49	3.25e-13	2.63e-10	0.38	0.32	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
LUAD	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	7.49	3.27e-13	2.65e-10	0.42	0.32	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
LUAD	cis	rs10200159	0.744	rs6725101	ENSG00000272606.1	RP11-554J4.1	7.49	3.27e-13	2.65e-10	0.53	0.32	Vitiligo;	chr2:55659736	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.744	rs10496044	ENSG00000272606.1	RP11-554J4.1	7.49	3.27e-13	2.65e-10	0.53	0.32	Vitiligo;	chr2:55660614	chr2:55617909~55618373:+
LUAD	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	7.49	3.28e-13	2.66e-10	0.39	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
LUAD	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-7.49	3.32e-13	2.68e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-7.49	3.32e-13	2.69e-10	-0.39	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
LUAD	cis	rs237743	1	rs67733885	ENSG00000222365.1	SNORD12B	-7.49	3.32e-13	2.69e-10	-0.37	-0.32	Height;	chr20:49280020	chr20:49280319~49280409:+
LUAD	cis	rs237743	0.963	rs35772539	ENSG00000222365.1	SNORD12B	-7.49	3.32e-13	2.69e-10	-0.37	-0.32	Height;	chr20:49282748	chr20:49280319~49280409:+
LUAD	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	7.49	3.34e-13	2.7e-10	0.37	0.32	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
LUAD	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-7.49	3.34e-13	2.7e-10	-0.42	-0.32	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
LUAD	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-7.49	3.34e-13	2.7e-10	-0.34	-0.32	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
LUAD	cis	rs7044106	0.791	rs12554440	ENSG00000238181.2	AHCYP2	-7.49	3.34e-13	2.7e-10	-0.43	-0.32	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120720673~120721972:+
LUAD	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-7.49	3.35e-13	2.71e-10	-0.46	-0.32	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
LUAD	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-7.49	3.35e-13	2.71e-10	-0.46	-0.32	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
LUAD	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-7.49	3.37e-13	2.72e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
LUAD	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	7.49	3.39e-13	2.74e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
LUAD	cis	rs944289	0.708	rs7158599	ENSG00000257826.1	RP11-116N8.4	-7.49	3.39e-13	2.74e-10	-0.34	-0.32	Thyroid cancer;	chr14:36111976	chr14:36061026~36067190:-
LUAD	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	7.49	3.39e-13	2.75e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
LUAD	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	7.49	3.41e-13	2.75e-10	0.48	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	7.49	3.41e-13	2.75e-10	0.48	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
LUAD	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	7.49	3.42e-13	2.77e-10	0.5	0.32	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
LUAD	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-7.49	3.44e-13	2.78e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
LUAD	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	7.48	3.46e-13	2.79e-10	0.39	0.32	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	7.48	3.46e-13	2.79e-10	0.39	0.32	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
LUAD	cis	rs10200159	1	rs7594497	ENSG00000272606.1	RP11-554J4.1	7.48	3.46e-13	2.8e-10	0.52	0.32	Vitiligo;	chr2:55645403	chr2:55617909~55618373:+
LUAD	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	7.48	3.48e-13	2.81e-10	0.38	0.32	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	7.48	3.48e-13	2.81e-10	0.4	0.32	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
LUAD	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-7.48	3.49e-13	2.82e-10	-0.47	-0.32	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-7.48	3.49e-13	2.82e-10	-0.47	-0.32	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
LUAD	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	7.48	3.51e-13	2.83e-10	0.39	0.32	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
LUAD	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	7.48	3.53e-13	2.85e-10	0.31	0.32	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
LUAD	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-7.48	3.54e-13	2.86e-10	-0.3	-0.32	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
LUAD	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	7.48	3.54e-13	2.86e-10	0.38	0.32	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
LUAD	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.54e-13	2.86e-10	-0.33	-0.32	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.54e-13	2.86e-10	-0.33	-0.32	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
LUAD	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	7.48	3.58e-13	2.89e-10	0.58	0.32	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	7.48	3.58e-13	2.89e-10	0.58	0.32	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
LUAD	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-7.48	3.58e-13	2.89e-10	-0.45	-0.32	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000211972.2	IGHV3-66	7.48	3.6e-13	2.9e-10	0.29	0.32	Kawasaki disease;	chr14:106711377	chr14:106675017~106675544:-
LUAD	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-7.48	3.6e-13	2.91e-10	-0.44	-0.32	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
LUAD	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	7.48	3.62e-13	2.92e-10	0.38	0.32	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
LUAD	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	7.48	3.62e-13	2.92e-10	0.31	0.32	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
LUAD	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-7.48	3.64e-13	2.93e-10	-0.42	-0.32	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
LUAD	cis	rs6095360	0.517	rs237700	ENSG00000222365.1	SNORD12B	-7.48	3.65e-13	2.94e-10	-0.36	-0.32	Intelligence (multi-trait analysis);	chr20:49293285	chr20:49280319~49280409:+
LUAD	cis	rs2439831	0.717	rs2470132	ENSG00000205771.5	CATSPER2P1	-7.48	3.67e-13	2.96e-10	-0.56	-0.32	Lung cancer in ever smokers;	chr15:43543283	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2255051	ENSG00000205771.5	CATSPER2P1	-7.48	3.67e-13	2.96e-10	-0.56	-0.32	Lung cancer in ever smokers;	chr15:43553963	chr15:43726918~43747094:-
LUAD	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	7.47	3.7e-13	2.98e-10	0.36	0.32	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
LUAD	cis	rs9595908	1	rs7992980	ENSG00000212293.1	SNORA16	7.47	3.7e-13	2.98e-10	0.35	0.32	Body mass index;	chr13:32607005	chr13:32420390~32420516:-
LUAD	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	7.47	3.7e-13	2.98e-10	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
LUAD	cis	rs7688540	0.723	rs7687112	ENSG00000275426.1	CH17-262A2.1	7.47	3.72e-13	2.99e-10	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:149738~150317:+
LUAD	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	7.47	3.72e-13	3e-10	0.54	0.32	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
LUAD	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-7.47	3.75e-13	3.02e-10	-0.46	-0.32	Depression;	chr6:28133900	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-7.47	3.75e-13	3.02e-10	-0.46	-0.32	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
LUAD	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-7.47	3.75e-13	3.02e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
LUAD	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-7.47	3.76e-13	3.03e-10	-0.46	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
LUAD	cis	rs944289	0.708	rs34232378	ENSG00000257826.1	RP11-116N8.4	-7.47	3.76e-13	3.03e-10	-0.34	-0.32	Thyroid cancer;	chr14:36102879	chr14:36061026~36067190:-
LUAD	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-7.47	3.77e-13	3.03e-10	-0.46	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-7.47	3.78e-13	3.04e-10	-0.4	-0.32	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000280411.1	IGHV1-69-2	-7.47	3.78e-13	3.04e-10	-0.25	-0.32	Kawasaki disease;	chr14:106785589	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000280411.1	IGHV1-69-2	-7.47	3.79e-13	3.05e-10	-0.24	-0.32	Kawasaki disease;	chr14:106782206	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-7.47	3.8e-13	3.05e-10	-0.43	-0.32	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
LUAD	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	7.47	3.81e-13	3.06e-10	0.48	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
LUAD	cis	rs6844153	0.938	rs111946747	ENSG00000240005.4	RP11-293A21.1	-7.47	3.82e-13	3.07e-10	-0.56	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26988996	chr4:26859806~26860599:-
LUAD	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	7.47	3.82e-13	3.07e-10	0.38	0.32	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000280411.1	IGHV1-69-2	-7.47	3.85e-13	3.09e-10	-0.25	-0.32	Kawasaki disease;	chr14:106680324	chr14:106762092~106762588:-
LUAD	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-7.47	3.86e-13	3.1e-10	-0.47	-0.32	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
LUAD	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	7.47	3.86e-13	3.1e-10	0.4	0.32	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
LUAD	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-7.47	3.88e-13	3.12e-10	-0.44	-0.32	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000280411.1	IGHV1-69-2	-7.47	3.88e-13	3.12e-10	-0.24	-0.32	Kawasaki disease;	chr14:106816039	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000280411.1	IGHV1-69-2	-7.47	3.89e-13	3.13e-10	-0.25	-0.32	Kawasaki disease;	chr14:106779660	chr14:106762092~106762588:-
LUAD	cis	rs944289	0.708	rs6571736	ENSG00000257826.1	RP11-116N8.4	-7.47	3.92e-13	3.15e-10	-0.34	-0.32	Thyroid cancer;	chr14:36111271	chr14:36061026~36067190:-
LUAD	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-7.47	3.92e-13	3.15e-10	-0.41	-0.32	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
LUAD	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	7.47	3.92e-13	3.15e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
LUAD	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	7.47	3.94e-13	3.16e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	7.47	3.94e-13	3.16e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
LUAD	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	7.47	3.94e-13	3.16e-10	0.42	0.32	Height;	chr6:109642186	chr6:109382795~109383666:+
LUAD	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-7.47	3.94e-13	3.16e-10	-0.4	-0.32	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
LUAD	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-7.46	3.94e-13	3.17e-10	-0.37	-0.32	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
LUAD	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-7.46	3.96e-13	3.18e-10	-0.4	-0.32	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
LUAD	cis	rs240993	0.809	rs11153277	ENSG00000230177.1	RP5-1112D6.4	-7.46	3.96e-13	3.18e-10	-0.31	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111277932~111278742:+
LUAD	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-7.46	3.97e-13	3.19e-10	-0.39	-0.32	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
LUAD	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-7.46	3.98e-13	3.2e-10	-0.47	-0.32	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
LUAD	cis	rs10200159	1	rs3748955	ENSG00000272606.1	RP11-554J4.1	7.46	3.99e-13	3.2e-10	0.56	0.32	Vitiligo;	chr2:55626335	chr2:55617909~55618373:+
LUAD	cis	rs944289	0.679	rs8016148	ENSG00000257826.1	RP11-116N8.4	-7.46	3.99e-13	3.2e-10	-0.34	-0.32	Thyroid cancer;	chr14:36111688	chr14:36061026~36067190:-
LUAD	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	7.46	3.99e-13	3.2e-10	0.37	0.32	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
LUAD	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	7.46	4e-13	3.21e-10	0.42	0.32	Height;	chr6:109584789	chr6:109382795~109383666:+
LUAD	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	7.46	4e-13	3.21e-10	0.36	0.32	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
LUAD	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-7.46	4.01e-13	3.22e-10	-0.35	-0.32	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
LUAD	cis	rs11089937	0.597	rs5757007	ENSG00000211639.2	IGLV4-60	7.46	4.02e-13	3.22e-10	0.39	0.32	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22162199~22162681:+
LUAD	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-7.46	4.03e-13	3.23e-10	-0.49	-0.32	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
LUAD	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	7.46	4.03e-13	3.23e-10	0.38	0.32	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
LUAD	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	7.46	4.04e-13	3.24e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
LUAD	cis	rs11089937	0.524	rs2877021	ENSG00000211639.2	IGLV4-60	7.46	4.04e-13	3.24e-10	0.36	0.32	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22162199~22162681:+
LUAD	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-7.46	4.05e-13	3.25e-10	-0.56	-0.32	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
LUAD	cis	rs237743	1	rs238217	ENSG00000222365.1	SNORD12B	-7.46	4.05e-13	3.25e-10	-0.36	-0.32	Height;	chr20:49254902	chr20:49280319~49280409:+
LUAD	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	7.46	4.07e-13	3.26e-10	0.27	0.32	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	7.46	4.07e-13	3.26e-10	0.27	0.32	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	7.46	4.07e-13	3.26e-10	0.27	0.32	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	7.46	4.07e-13	3.26e-10	0.27	0.32	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
LUAD	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-7.46	4.07e-13	3.26e-10	-0.47	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
LUAD	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-7.46	4.08e-13	3.27e-10	-0.46	-0.32	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000211972.2	IGHV3-66	7.46	4.08e-13	3.27e-10	0.28	0.32	Kawasaki disease;	chr14:106668657	chr14:106675017~106675544:-
LUAD	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-7.46	4.08e-13	3.27e-10	-0.52	-0.32	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
LUAD	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	7.46	4.08e-13	3.27e-10	0.38	0.32	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	7.46	4.08e-13	3.27e-10	0.38	0.32	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	7.46	4.08e-13	3.27e-10	0.38	0.32	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	7.46	4.08e-13	3.27e-10	0.38	0.32	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
LUAD	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	7.46	4.11e-13	3.29e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	7.46	4.11e-13	3.29e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
LUAD	cis	rs7115242	0.8	rs7131536	ENSG00000280143.1	AP000892.6	7.46	4.11e-13	3.29e-10	0.51	0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	7.46	4.12e-13	3.3e-10	0.39	0.32	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
LUAD	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	7.46	4.13e-13	3.3e-10	0.7	0.32	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	7.46	4.13e-13	3.3e-10	0.7	0.32	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	7.46	4.13e-13	3.3e-10	0.7	0.32	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	7.46	4.13e-13	3.3e-10	0.7	0.32	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
LUAD	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-7.46	4.13e-13	3.31e-10	-0.47	-0.32	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
LUAD	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000280411.1	IGHV1-69-2	-7.46	4.16e-13	3.33e-10	-0.24	-0.32	Kawasaki disease;	chr14:106782238	chr14:106762092~106762588:-
LUAD	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-7.46	4.17e-13	3.33e-10	-0.37	-0.32	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-7.46	4.17e-13	3.33e-10	-0.37	-0.32	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-7.46	4.17e-13	3.33e-10	-0.37	-0.32	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
LUAD	cis	rs62229266	0.839	rs11088335	ENSG00000214914.3	RPL23AP3	7.46	4.18e-13	3.34e-10	0.38	0.32	Mitral valve prolapse;	chr21:36098037	chr21:36016079~36016546:-
LUAD	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	7.46	4.18e-13	3.34e-10	0.59	0.32	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
LUAD	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-7.46	4.19e-13	3.35e-10	-0.39	-0.32	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
LUAD	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000211972.2	IGHV3-66	7.46	4.21e-13	3.36e-10	0.29	0.32	Kawasaki disease;	chr14:106708947	chr14:106675017~106675544:-
LUAD	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-7.46	4.21e-13	3.36e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
LUAD	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	7.45	4.24e-13	3.38e-10	0.37	0.32	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
LUAD	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	7.45	4.25e-13	3.39e-10	0.4	0.32	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
LUAD	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-7.45	4.26e-13	3.4e-10	-0.38	-0.32	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000211972.2	IGHV3-66	7.45	4.27e-13	3.41e-10	0.29	0.32	Kawasaki disease;	chr14:106705271	chr14:106675017~106675544:-
LUAD	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	7.45	4.27e-13	3.41e-10	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	7.45	4.27e-13	3.41e-10	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
LUAD	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	7.45	4.28e-13	3.41e-10	0.46	0.32	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
LUAD	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	7.45	4.28e-13	3.42e-10	0.41	0.32	Height;	chr6:109424139	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-7.45	4.29e-13	3.42e-10	-0.23	-0.32	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-7.45	4.29e-13	3.42e-10	-0.23	-0.32	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
LUAD	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	7.45	4.29e-13	3.42e-10	0.38	0.32	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
LUAD	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-7.45	4.29e-13	3.42e-10	-0.34	-0.32	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	7.45	4.29e-13	3.42e-10	0.38	0.32	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
LUAD	cis	rs2439831	0.681	rs526450	ENSG00000205771.5	CATSPER2P1	-7.45	4.3e-13	3.43e-10	-0.54	-0.32	Lung cancer in ever smokers;	chr15:43307127	chr15:43726918~43747094:-
LUAD	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
LUAD	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	7.45	4.31e-13	3.43e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	7.45	4.31e-13	3.43e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
LUAD	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	7.45	4.31e-13	3.44e-10	0.46	0.32	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
LUAD	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-7.45	4.32e-13	3.45e-10	-0.46	-0.32	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
LUAD	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-7.45	4.32e-13	3.45e-10	-0.46	-0.32	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
LUAD	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	7.45	4.34e-13	3.46e-10	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
LUAD	cis	rs7182621	0.546	rs11632596	ENSG00000182397.13	DNM1P46	7.45	4.35e-13	3.47e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99790156~99806927:-
LUAD	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-7.45	4.4e-13	3.5e-10	-0.38	-0.32	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
LUAD	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	7.45	4.42e-13	3.52e-10	0.39	0.32	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	7.45	4.42e-13	3.52e-10	0.39	0.32	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
LUAD	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-7.45	4.47e-13	3.55e-10	-0.35	-0.32	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
LUAD	cis	rs2439831	0.681	rs11858152	ENSG00000205771.5	CATSPER2P1	-7.45	4.48e-13	3.56e-10	-0.53	-0.32	Lung cancer in ever smokers;	chr15:43341998	chr15:43726918~43747094:-
LUAD	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	7.45	4.48e-13	3.57e-10	0.47	0.32	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
LUAD	cis	rs10200159	1	rs6712314	ENSG00000272606.1	RP11-554J4.1	7.45	4.49e-13	3.57e-10	0.55	0.32	Vitiligo;	chr2:55626901	chr2:55617909~55618373:+
LUAD	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-7.45	4.51e-13	3.58e-10	-0.4	-0.32	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
LUAD	cis	rs944289	0.74	rs10498332	ENSG00000257826.1	RP11-116N8.4	-7.44	4.52e-13	3.6e-10	-0.33	-0.32	Thyroid cancer;	chr14:36102348	chr14:36061026~36067190:-
LUAD	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-7.44	4.53e-13	3.6e-10	-0.39	-0.32	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-7.44	4.53e-13	3.6e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
LUAD	cis	rs11089937	0.568	rs5756988	ENSG00000211639.2	IGLV4-60	-7.44	4.53e-13	3.6e-10	-0.37	-0.32	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22162199~22162681:+
LUAD	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	7.44	4.54e-13	3.61e-10	0.5	0.32	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-7.44	4.55e-13	3.62e-10	-0.25	-0.32	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
LUAD	cis	rs9595908	0.965	rs8000071	ENSG00000212293.1	SNORA16	7.44	4.56e-13	3.62e-10	0.37	0.32	Body mass index;	chr13:32551236	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs7984903	ENSG00000212293.1	SNORA16	7.44	4.56e-13	3.62e-10	0.37	0.32	Body mass index;	chr13:32552002	chr13:32420390~32420516:-
LUAD	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	7.44	4.58e-13	3.64e-10	0.38	0.32	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
LUAD	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	7.44	4.58e-13	3.64e-10	0.4	0.32	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	7.44	4.59e-13	3.64e-10	0.4	0.32	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
LUAD	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-7.44	4.59e-13	3.65e-10	-0.65	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
LUAD	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000280411.1	IGHV1-69-2	-7.44	4.61e-13	3.66e-10	-0.24	-0.32	Kawasaki disease;	chr14:106689997	chr14:106762092~106762588:-
LUAD	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-7.44	4.63e-13	3.67e-10	-0.3	-0.32	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
LUAD	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	7.44	4.65e-13	3.69e-10	0.27	0.32	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
LUAD	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-7.44	4.67e-13	3.7e-10	-0.37	-0.32	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
LUAD	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-7.44	4.67e-13	3.7e-10	-0.4	-0.32	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
LUAD	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	7.44	4.68e-13	3.71e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
LUAD	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	7.44	4.68e-13	3.72e-10	0.45	0.32	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
LUAD	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-7.44	4.7e-13	3.73e-10	-0.38	-0.32	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-7.44	4.7e-13	3.73e-10	-0.38	-0.32	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-7.44	4.7e-13	3.73e-10	-0.38	-0.32	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
LUAD	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	7.44	4.7e-13	3.73e-10	0.45	0.32	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
LUAD	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-7.44	4.73e-13	3.75e-10	-0.34	-0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
LUAD	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	7.44	4.73e-13	3.76e-10	0.36	0.32	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
LUAD	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	7.44	4.75e-13	3.77e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	7.44	4.75e-13	3.77e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
LUAD	cis	rs9595908	0.931	rs55645971	ENSG00000212293.1	SNORA16	7.44	4.8e-13	3.81e-10	0.35	0.32	Body mass index;	chr13:32615452	chr13:32420390~32420516:-
LUAD	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-7.44	4.8e-13	3.81e-10	-0.45	-0.32	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
LUAD	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-7.44	4.81e-13	3.81e-10	-0.48	-0.32	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
LUAD	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
LUAD	cis	rs8040855	0.559	rs6496801	ENSG00000259774.1	RP11-182J1.13	-7.43	4.84e-13	3.83e-10	-0.39	-0.32	Bulimia nervosa;	chr15:85185168	chr15:84422618~84425882:+
LUAD	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	7.43	4.85e-13	3.84e-10	0.46	0.32	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
LUAD	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	7.43	4.86e-13	3.85e-10	0.38	0.32	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
LUAD	cis	rs56046484	0.75	rs12900078	ENSG00000259295.5	CSPG4P12	7.43	4.87e-13	3.85e-10	0.54	0.32	Testicular germ cell tumor;	chr15:84980738	chr15:85191438~85213905:+
LUAD	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
LUAD	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-7.43	4.93e-13	3.9e-10	-0.38	-0.32	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.746	rs7145546	ENSG00000257826.1	RP11-116N8.4	-7.43	4.94e-13	3.91e-10	-0.35	-0.32	Thyroid cancer;	chr14:36089040	chr14:36061026~36067190:-
LUAD	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	7.43	4.97e-13	3.93e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	7.43	4.97e-13	3.93e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
LUAD	cis	rs944289	0.746	rs7145211	ENSG00000257826.1	RP11-116N8.4	-7.43	4.97e-13	3.93e-10	-0.35	-0.32	Thyroid cancer;	chr14:36089060	chr14:36061026~36067190:-
LUAD	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-7.43	4.98e-13	3.94e-10	-0.38	-0.32	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
LUAD	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	7.43	4.99e-13	3.94e-10	0.54	0.32	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
LUAD	cis	rs9326248	0.53	rs7122944	ENSG00000280143.1	AP000892.6	7.43	4.99e-13	3.94e-10	0.51	0.32	Blood protein levels;	chr11:117163903	chr11:117204967~117210292:+
LUAD	cis	rs7115242	0.514	rs4936367	ENSG00000280143.1	AP000892.6	7.43	4.99e-13	3.94e-10	0.51	0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.53	rs4604928	ENSG00000280143.1	AP000892.6	7.43	4.99e-13	3.94e-10	0.51	0.32	Blood protein levels;	chr11:117173487	chr11:117204967~117210292:+
LUAD	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	7.43	5.01e-13	3.96e-10	0.4	0.32	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
LUAD	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	7.43	5.01e-13	3.96e-10	0.37	0.32	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	7.43	5.01e-13	3.96e-10	0.37	0.32	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
LUAD	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-7.43	5.02e-13	3.96e-10	-0.34	-0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
LUAD	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-7.43	5.03e-13	3.97e-10	-0.48	-0.32	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
LUAD	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	7.43	5.04e-13	3.98e-10	0.46	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	7.43	5.04e-13	3.98e-10	0.46	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
LUAD	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-7.43	5.06e-13	3.99e-10	-0.33	-0.32	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
LUAD	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-7.43	5.06e-13	3.99e-10	-0.45	-0.32	Depression;	chr6:28111382	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-7.43	5.06e-13	3.99e-10	-0.45	-0.32	Depression;	chr6:28111650	chr6:28115628~28116551:+
LUAD	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	7.43	5.07e-13	4e-10	0.36	0.32	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	7.43	5.07e-13	4e-10	0.38	0.32	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	7.43	5.07e-13	4e-10	0.38	0.32	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	7.43	5.07e-13	4e-10	0.38	0.32	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
LUAD	cis	rs9595908	0.897	rs10083285	ENSG00000212293.1	SNORA16	7.43	5.07e-13	4e-10	0.35	0.32	Body mass index;	chr13:32557205	chr13:32420390~32420516:-
LUAD	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	7.43	5.09e-13	4.01e-10	0.42	0.32	Migraine;	chr4:56881468	chr4:56960927~56961373:-
LUAD	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	7.43	5.09e-13	4.02e-10	0.39	0.32	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
LUAD	cis	rs7301826	0.627	rs7315707	ENSG00000256299.1	RP11-989F5.3	7.43	5.11e-13	4.03e-10	0.41	0.32	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810821~130812622:-
LUAD	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-7.43	5.11e-13	4.03e-10	-0.28	-0.32	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
LUAD	cis	rs4591358	0.648	rs7557471	ENSG00000223466.1	AC064834.2	-7.43	5.13e-13	4.05e-10	-0.45	-0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520713	chr2:195533035~195538681:+
LUAD	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	7.43	5.13e-13	4.05e-10	0.37	0.32	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
LUAD	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	7.43	5.13e-13	4.05e-10	0.36	0.32	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
LUAD	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-7.43	5.14e-13	4.05e-10	-0.38	-0.32	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
LUAD	cis	rs75422866	0.867	rs73104163	ENSG00000274902.1	RP1-197B17.4	7.43	5.14e-13	4.05e-10	0.75	0.32	Pneumonia;	chr12:47706187	chr12:47731908~47732351:+
LUAD	cis	rs75422866	1	rs12423045	ENSG00000274902.1	RP1-197B17.4	7.43	5.14e-13	4.05e-10	0.75	0.32	Pneumonia;	chr12:47706275	chr12:47731908~47732351:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000280411.1	IGHV1-69-2	-7.43	5.14e-13	4.06e-10	-0.24	-0.32	Kawasaki disease;	chr14:106690675	chr14:106762092~106762588:-
LUAD	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	7.42	5.19e-13	4.09e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
LUAD	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	7.42	5.19e-13	4.09e-10	0.38	0.32	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
LUAD	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-7.42	5.22e-13	4.11e-10	-0.33	-0.32	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	7.42	5.23e-13	4.11e-10	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
LUAD	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	7.42	5.23e-13	4.12e-10	0.41	0.32	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
LUAD	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-7.42	5.25e-13	4.13e-10	-0.43	-0.32	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
LUAD	cis	rs7646881	0.767	rs58152433	ENSG00000240207.5	RP11-379F4.4	-7.42	5.25e-13	4.14e-10	-0.42	-0.32	Tetralogy of Fallot;	chr3:158738851	chr3:158732263~158784070:+
LUAD	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-7.42	5.28e-13	4.16e-10	-0.43	-0.32	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
LUAD	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-7.42	5.29e-13	4.16e-10	-0.57	-0.32	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-7.42	5.29e-13	4.17e-10	-0.23	-0.32	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
LUAD	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-7.42	5.33e-13	4.19e-10	-0.45	-0.32	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
LUAD	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-7.42	5.34e-13	4.2e-10	-0.39	-0.32	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-7.42	5.34e-13	4.2e-10	-0.39	-0.32	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
LUAD	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	7.42	5.35e-13	4.21e-10	0.38	0.32	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
LUAD	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	7.42	5.35e-13	4.21e-10	0.42	0.32	Height;	chr6:109586733	chr6:109382795~109383666:+
LUAD	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	7.42	5.35e-13	4.21e-10	0.38	0.32	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000211970.3	IGHV4-61	-7.42	5.38e-13	4.23e-10	-0.23	-0.32	Kawasaki disease;	chr14:106776758	chr14:106639119~106639657:-
LUAD	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-7.42	5.39e-13	4.24e-10	-0.44	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
LUAD	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	7.42	5.42e-13	4.27e-10	0.41	0.32	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
LUAD	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-7.42	5.43e-13	4.27e-10	-0.46	-0.32	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	7.42	5.45e-13	4.28e-10	0.37	0.32	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	7.42	5.45e-13	4.28e-10	0.37	0.32	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
LUAD	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-7.42	5.45e-13	4.29e-10	-0.46	-0.32	Depression;	chr6:28159925	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-7.42	5.45e-13	4.29e-10	-0.46	-0.32	Depression;	chr6:28159932	chr6:28115628~28116551:+
LUAD	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	7.42	5.46e-13	4.29e-10	0.44	0.32	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
LUAD	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28112175	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28113851	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28114487	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28114933	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28115743	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28116411	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
LUAD	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	7.42	5.5e-13	4.32e-10	0.37	0.32	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
LUAD	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-7.42	5.51e-13	4.33e-10	-0.45	-0.32	Depression;	chr6:28104824	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-7.42	5.52e-13	4.33e-10	-0.45	-0.32	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
LUAD	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	7.42	5.52e-13	4.33e-10	0.32	0.32	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
LUAD	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-7.41	5.54e-13	4.35e-10	-0.38	-0.32	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
LUAD	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-7.41	5.56e-13	4.36e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
LUAD	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	7.41	5.58e-13	4.38e-10	0.42	0.32	Height;	chr6:109640141	chr6:109382795~109383666:+
LUAD	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	7.41	5.58e-13	4.38e-10	0.36	0.32	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
LUAD	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	7.41	5.59e-13	4.38e-10	0.28	0.32	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
LUAD	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
LUAD	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	7.41	5.6e-13	4.39e-10	0.39	0.32	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
LUAD	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	7.41	5.61e-13	4.4e-10	0.41	0.32	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
LUAD	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	7.41	5.61e-13	4.4e-10	0.41	0.32	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-7.41	5.61e-13	4.4e-10	-0.43	-0.32	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
LUAD	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	7.41	5.63e-13	4.41e-10	0.43	0.32	Height;	chr6:109690255	chr6:109382795~109383666:+
LUAD	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-7.41	5.65e-13	4.43e-10	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
LUAD	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-7.41	5.68e-13	4.45e-10	-0.31	-0.32	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
LUAD	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	7.41	5.69e-13	4.45e-10	0.37	0.32	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
LUAD	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	7.41	5.69e-13	4.46e-10	0.38	0.32	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	7.41	5.69e-13	4.46e-10	0.38	0.32	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
LUAD	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-7.41	5.74e-13	4.49e-10	-0.37	-0.32	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
LUAD	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	7.41	5.74e-13	4.5e-10	0.73	0.32	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	7.41	5.74e-13	4.5e-10	0.73	0.32	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	7.41	5.74e-13	4.5e-10	0.73	0.32	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
LUAD	cis	rs8031584	0.736	rs11635775	ENSG00000260382.1	RP11-540B6.2	7.41	5.77e-13	4.52e-10	0.41	0.32	Huntington's disease progression;	chr15:30868437	chr15:30882267~30883231:-
LUAD	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	7.41	5.8e-13	4.54e-10	0.41	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
LUAD	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	7.41	5.8e-13	4.54e-10	0.28	0.32	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
LUAD	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-7.41	5.84e-13	4.57e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
LUAD	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-7.41	5.84e-13	4.57e-10	-0.39	-0.32	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-7.41	5.84e-13	4.57e-10	-0.39	-0.32	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
LUAD	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	7.41	5.86e-13	4.58e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	7.41	5.86e-13	4.58e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	7.41	5.86e-13	4.58e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
LUAD	cis	rs62229266	0.654	rs62230787	ENSG00000214914.3	RPL23AP3	7.41	5.88e-13	4.6e-10	0.41	0.32	Mitral valve prolapse;	chr21:36004182	chr21:36016079~36016546:-
LUAD	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	7.41	5.88e-13	4.6e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
LUAD	cis	rs9595908	0.965	rs2239748	ENSG00000212293.1	SNORA16	7.41	5.91e-13	4.62e-10	0.38	0.32	Body mass index;	chr13:32527680	chr13:32420390~32420516:-
LUAD	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	7.41	5.92e-13	4.63e-10	0.41	0.32	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
LUAD	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-7.4	5.92e-13	4.63e-10	-0.56	-0.32	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
LUAD	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	7.4	5.93e-13	4.64e-10	0.42	0.32	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
LUAD	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-7.4	5.97e-13	4.66e-10	-0.38	-0.32	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	7.4	5.97e-13	4.67e-10	0.44	0.32	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
LUAD	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-7.4	5.99e-13	4.68e-10	-0.41	-0.32	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
LUAD	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	7.4	5.99e-13	4.68e-10	0.38	0.32	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
LUAD	cis	rs237743	1	rs68014903	ENSG00000222365.1	SNORD12B	-7.4	6.02e-13	4.7e-10	-0.37	-0.32	Height;	chr20:49295502	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs67375757	ENSG00000222365.1	SNORD12B	-7.4	6.02e-13	4.7e-10	-0.37	-0.32	Height;	chr20:49299758	chr20:49280319~49280409:+
LUAD	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-7.4	6.02e-13	4.7e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
LUAD	cis	rs9595908	0.965	rs9595893	ENSG00000212293.1	SNORA16	7.4	6.04e-13	4.71e-10	0.35	0.32	Body mass index;	chr13:32601656	chr13:32420390~32420516:-
LUAD	cis	rs944289	0.708	rs1537424	ENSG00000257826.1	RP11-116N8.4	-7.4	6.06e-13	4.73e-10	-0.34	-0.32	Thyroid cancer;	chr14:36104812	chr14:36061026~36067190:-
LUAD	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-7.4	6.07e-13	4.74e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
LUAD	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	7.4	6.08e-13	4.75e-10	0.41	0.32	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
LUAD	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-7.4	6.09e-13	4.75e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
LUAD	cis	rs944289	0.679	rs12050116	ENSG00000257826.1	RP11-116N8.4	-7.4	6.11e-13	4.77e-10	-0.34	-0.32	Thyroid cancer;	chr14:36103725	chr14:36061026~36067190:-
LUAD	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
LUAD	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	7.4	6.16e-13	4.8e-10	0.41	0.32	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
LUAD	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-7.4	6.16e-13	4.8e-10	-0.45	-0.32	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
LUAD	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	7.4	6.2e-13	4.84e-10	0.41	0.32	Height;	chr6:109500687	chr6:109382795~109383666:+
LUAD	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-7.4	6.22e-13	4.85e-10	-0.38	-0.32	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-7.4	6.22e-13	4.85e-10	-0.38	-0.32	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	7.4	6.25e-13	4.87e-10	0.4	0.32	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	7.4	6.25e-13	4.87e-10	0.42	0.32	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
LUAD	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	7.4	6.27e-13	4.88e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000211972.2	IGHV3-66	7.4	6.27e-13	4.89e-10	0.28	0.32	Kawasaki disease;	chr14:106815190	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-7.4	6.28e-13	4.89e-10	-0.46	-0.32	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
LUAD	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-7.4	6.29e-13	4.9e-10	-0.35	-0.32	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
LUAD	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	7.4	6.3e-13	4.91e-10	0.48	0.32	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
LUAD	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	7.4	6.31e-13	4.92e-10	0.72	0.32	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
LUAD	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-7.4	6.33e-13	4.93e-10	-0.3	-0.32	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
LUAD	cis	rs9595908	1	rs9591143	ENSG00000212293.1	SNORA16	7.39	6.34e-13	4.94e-10	0.35	0.32	Body mass index;	chr13:32585301	chr13:32420390~32420516:-
LUAD	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	7.39	6.35e-13	4.95e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
LUAD	cis	rs7646881	1	rs59918529	ENSG00000240207.5	RP11-379F4.4	-7.39	6.36e-13	4.96e-10	-0.37	-0.32	Tetralogy of Fallot;	chr3:158734916	chr3:158732263~158784070:+
LUAD	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	7.39	6.37e-13	4.96e-10	0.72	0.32	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	7.39	6.37e-13	4.96e-10	0.72	0.32	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	7.39	6.37e-13	4.96e-10	0.72	0.32	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	7.39	6.37e-13	4.96e-10	0.72	0.32	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
LUAD	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	7.39	6.37e-13	4.96e-10	0.37	0.32	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
LUAD	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-7.39	6.4e-13	4.98e-10	-0.36	-0.32	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
LUAD	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	7.39	6.41e-13	4.99e-10	0.42	0.32	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
LUAD	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	7.39	6.43e-13	5.01e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
LUAD	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	7.39	6.43e-13	5.01e-10	0.28	0.32	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
LUAD	cis	rs9549367	0.601	rs558869	ENSG00000269125.1	RP11-98F14.11	7.39	6.45e-13	5.02e-10	0.4	0.32	Platelet distribution width;	chr13:113195618	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs2480949	ENSG00000269125.1	RP11-98F14.11	7.39	6.45e-13	5.02e-10	0.4	0.32	Platelet distribution width;	chr13:113198835	chr13:113165002~113165183:-
LUAD	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-7.39	6.45e-13	5.02e-10	-0.41	-0.32	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
LUAD	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-7.39	6.46e-13	5.03e-10	-0.38	-0.32	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
LUAD	cis	rs2337406	0.714	rs2337463	ENSG00000254174.1	IGHV1-12	7.39	6.49e-13	5.05e-10	0.3	0.32	Alzheimer's disease (late onset);	chr14:106816066	chr14:106122420~106122709:-
LUAD	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-7.39	6.49e-13	5.05e-10	-0.46	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
LUAD	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	7.39	6.51e-13	5.06e-10	0.34	0.32	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
LUAD	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-7.39	6.51e-13	5.07e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
LUAD	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-7.39	6.51e-13	5.07e-10	-0.42	-0.32	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
LUAD	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	7.39	6.53e-13	5.08e-10	0.45	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000211972.2	IGHV3-66	7.39	6.55e-13	5.09e-10	0.28	0.32	Kawasaki disease;	chr14:106779116	chr14:106675017~106675544:-
LUAD	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	7.39	6.56e-13	5.1e-10	0.42	0.32	Height;	chr6:109507271	chr6:109382795~109383666:+
LUAD	cis	rs2439831	0.867	rs2255042	ENSG00000205771.5	CATSPER2P1	7.39	6.56e-13	5.1e-10	0.55	0.32	Lung cancer in ever smokers;	chr15:43542120	chr15:43726918~43747094:-
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-7.39	6.57e-13	5.11e-10	-0.23	-0.32	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
LUAD	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-7.39	6.58e-13	5.12e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
LUAD	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-7.39	6.6e-13	5.13e-10	-0.42	-0.32	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
LUAD	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	7.39	6.61e-13	5.14e-10	0.28	0.32	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
LUAD	cis	rs35955747	0.902	rs7288735	ENSG00000236132.1	CTA-440B3.1	7.39	6.61e-13	5.14e-10	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283560	chr22:31816379~31817491:-
LUAD	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-7.39	6.61e-13	5.14e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-7.39	6.61e-13	5.14e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-7.39	6.61e-13	5.14e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
LUAD	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-7.39	6.61e-13	5.14e-10	-0.43	-0.32	Height;	chr6:109497253	chr6:109382795~109383666:+
LUAD	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-7.39	6.65e-13	5.17e-10	-0.35	-0.32	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
LUAD	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
LUAD	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	7.39	6.68e-13	5.19e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
LUAD	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-7.39	6.68e-13	5.19e-10	-0.43	-0.32	Migraine;	chr4:56879851	chr4:56960927~56961373:-
LUAD	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-7.39	6.68e-13	5.19e-10	-0.43	-0.32	Migraine;	chr4:56880007	chr4:56960927~56961373:-
LUAD	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-7.39	6.68e-13	5.19e-10	-0.43	-0.32	Migraine;	chr4:56880190	chr4:56960927~56961373:-
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000211970.3	IGHV4-61	-7.39	6.69e-13	5.2e-10	-0.23	-0.32	Kawasaki disease;	chr14:106768275	chr14:106639119~106639657:-
LUAD	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	7.39	6.7e-13	5.2e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
LUAD	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-7.39	6.71e-13	5.21e-10	-0.36	-0.32	Height;	chr2:46617930	chr2:46668870~46670778:+
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000211972.2	IGHV3-66	7.39	6.72e-13	5.22e-10	0.28	0.32	Kawasaki disease;	chr14:106785589	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-7.39	6.72e-13	5.22e-10	-0.23	-0.32	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
LUAD	cis	rs9549367	0.713	rs553316	ENSG00000269125.1	RP11-98F14.11	7.39	6.73e-13	5.22e-10	0.4	0.32	Platelet distribution width;	chr13:113183701	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	7.39	6.73e-13	5.22e-10	0.4	0.32	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	7.39	6.73e-13	5.22e-10	0.4	0.32	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
LUAD	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	7.39	6.73e-13	5.22e-10	0.42	0.32	Height;	chr6:109588639	chr6:109382795~109383666:+
LUAD	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-7.39	6.75e-13	5.24e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
LUAD	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	7.39	6.75e-13	5.24e-10	0.39	0.32	Depression;	chr6:28327262	chr6:28943877~28944537:+
LUAD	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	7.38	6.78e-13	5.26e-10	0.74	0.32	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
LUAD	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	7.38	6.78e-13	5.26e-10	0.42	0.32	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
LUAD	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-7.38	6.81e-13	5.28e-10	-0.3	-0.32	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
LUAD	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	7.38	6.81e-13	5.28e-10	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	7.38	6.82e-13	5.29e-10	0.39	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
LUAD	cis	rs75422866	0.867	rs73104163	ENSG00000280054.1	RP1-197B17.7	7.38	6.83e-13	5.3e-10	0.76	0.32	Pneumonia;	chr12:47706187	chr12:47728151~47730598:-
LUAD	cis	rs75422866	1	rs12423045	ENSG00000280054.1	RP1-197B17.7	7.38	6.83e-13	5.3e-10	0.76	0.32	Pneumonia;	chr12:47706275	chr12:47728151~47730598:-
LUAD	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	7.38	6.83e-13	5.3e-10	0.39	0.32	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
LUAD	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-7.38	6.83e-13	5.3e-10	-0.45	-0.32	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
LUAD	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-7.38	6.84e-13	5.3e-10	-0.43	-0.32	Migraine;	chr4:56880659	chr4:56960927~56961373:-
LUAD	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	7.38	6.84e-13	5.3e-10	0.42	0.32	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
LUAD	cis	rs35955747	0.902	rs7287402	ENSG00000236132.1	CTA-440B3.1	-7.38	6.85e-13	5.31e-10	-0.35	-0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31258837	chr22:31816379~31817491:-
LUAD	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	7.38	6.89e-13	5.34e-10	0.41	0.32	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-7.38	6.91e-13	5.35e-10	-0.37	-0.32	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-7.38	6.91e-13	5.35e-10	-0.37	-0.32	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-7.38	6.91e-13	5.35e-10	-0.37	-0.32	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
LUAD	cis	rs9595908	0.9	rs7994229	ENSG00000212293.1	SNORA16	7.38	6.91e-13	5.36e-10	0.34	0.32	Body mass index;	chr13:32586568	chr13:32420390~32420516:-
LUAD	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	7.38	6.93e-13	5.37e-10	0.73	0.32	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	7.38	6.93e-13	5.37e-10	0.73	0.32	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	7.38	6.93e-13	5.37e-10	0.73	0.32	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	7.38	6.93e-13	5.37e-10	0.73	0.32	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
LUAD	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	7.38	6.94e-13	5.38e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	7.38	6.94e-13	5.38e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	7.38	6.94e-13	5.38e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	7.38	6.94e-13	5.38e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
LUAD	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	7.38	6.95e-13	5.38e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	7.38	6.95e-13	5.38e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	7.38	6.95e-13	5.38e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000206090.4	AP000350.7	7.38	6.95e-13	5.38e-10	0.35	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23939998~23942798:+
LUAD	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	7.38	6.96e-13	5.39e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.9	rs731414	ENSG00000212293.1	SNORA16	7.38	6.99e-13	5.41e-10	0.34	0.32	Body mass index;	chr13:32601160	chr13:32420390~32420516:-
LUAD	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	7.38	7e-13	5.42e-10	0.38	0.32	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-7.38	7e-13	5.42e-10	-0.51	-0.32	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
LUAD	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-7.38	7.01e-13	5.43e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
LUAD	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	7.38	7.1e-13	5.5e-10	0.38	0.32	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
LUAD	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	7.38	7.11e-13	5.5e-10	0.36	0.32	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
LUAD	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-7.38	7.11e-13	5.5e-10	-0.48	-0.32	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
LUAD	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-7.38	7.11e-13	5.51e-10	-0.41	-0.32	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
LUAD	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-7.38	7.12e-13	5.51e-10	-0.38	-0.32	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
LUAD	cis	rs237743	1	rs34804433	ENSG00000222365.1	SNORD12B	-7.38	7.14e-13	5.52e-10	-0.37	-0.32	Height;	chr20:49279650	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs67214274	ENSG00000222365.1	SNORD12B	-7.38	7.14e-13	5.52e-10	-0.37	-0.32	Height;	chr20:49282024	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs35387764	ENSG00000222365.1	SNORD12B	-7.38	7.14e-13	5.52e-10	-0.37	-0.32	Height;	chr20:49286304	chr20:49280319~49280409:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-7.38	7.15e-13	5.53e-10	-0.25	-0.32	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-7.38	7.15e-13	5.53e-10	-0.23	-0.32	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-7.38	7.15e-13	5.53e-10	-0.23	-0.32	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
LUAD	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
LUAD	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	7.38	7.19e-13	5.56e-10	0.41	0.32	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
LUAD	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	7.38	7.2e-13	5.57e-10	0.72	0.32	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
LUAD	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-7.38	7.2e-13	5.57e-10	-0.39	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
LUAD	cis	rs944289	0.624	rs55775461	ENSG00000257826.1	RP11-116N8.4	-7.38	7.2e-13	5.57e-10	-0.34	-0.32	Thyroid cancer;	chr14:36108166	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	7.38	7.21e-13	5.57e-10	0.38	0.32	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-7.38	7.23e-13	5.59e-10	-0.41	-0.32	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
LUAD	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	7.38	7.25e-13	5.6e-10	0.41	0.32	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
LUAD	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-7.37	7.25e-13	5.6e-10	-0.45	-0.32	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-7.37	7.25e-13	5.61e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
LUAD	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-7.37	7.26e-13	5.61e-10	-0.45	-0.32	Depression;	chr6:28113616	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	7.37	7.29e-13	5.63e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
LUAD	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	7.37	7.31e-13	5.64e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
LUAD	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	7.37	7.32e-13	5.65e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
LUAD	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	7.37	7.38e-13	5.7e-10	0.36	0.32	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
LUAD	cis	rs755249	1	rs17513135	ENSG00000228060.1	RP11-69E11.8	-7.37	7.4e-13	5.71e-10	-0.32	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39565160~39573203:+
LUAD	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	7.37	7.41e-13	5.72e-10	0.42	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
LUAD	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	7.37	7.44e-13	5.74e-10	0.4	0.32	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
LUAD	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	7.37	7.47e-13	5.76e-10	0.31	0.32	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
LUAD	cis	rs35955747	0.838	rs7285171	ENSG00000236132.1	CTA-440B3.1	7.37	7.47e-13	5.76e-10	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31202381	chr22:31816379~31817491:-
LUAD	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	7.37	7.48e-13	5.77e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
LUAD	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-7.37	7.48e-13	5.77e-10	-0.39	-0.32	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
LUAD	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	7.37	7.49e-13	5.78e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	7.37	7.49e-13	5.78e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
LUAD	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-7.37	7.49e-13	5.78e-10	-0.4	-0.32	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000280411.1	IGHV1-69-2	-7.37	7.5e-13	5.79e-10	-0.24	-0.32	Kawasaki disease;	chr14:106691290	chr14:106762092~106762588:-
LUAD	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-7.37	7.5e-13	5.79e-10	-0.44	-0.32	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
LUAD	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-7.37	7.52e-13	5.8e-10	-0.35	-0.32	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-7.37	7.52e-13	5.8e-10	-0.35	-0.32	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
LUAD	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	7.37	7.52e-13	5.8e-10	0.48	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-7.37	7.54e-13	5.81e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
LUAD	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-7.37	7.56e-13	5.83e-10	-0.34	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-7.37	7.56e-13	5.83e-10	-0.34	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-7.37	7.56e-13	5.83e-10	-0.34	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
LUAD	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	7.37	7.56e-13	5.83e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
LUAD	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-7.37	7.58e-13	5.84e-10	-0.38	-0.32	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
LUAD	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	7.37	7.58e-13	5.85e-10	0.46	0.32	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
LUAD	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	7.37	7.59e-13	5.85e-10	0.42	0.32	Height;	chr6:109518783	chr6:109382795~109383666:+
LUAD	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-7.37	7.61e-13	5.87e-10	-0.39	-0.32	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
LUAD	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-7.37	7.61e-13	5.87e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
LUAD	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-7.37	7.66e-13	5.9e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
LUAD	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-7.37	7.67e-13	5.91e-10	-0.39	-0.32	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
LUAD	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	7.37	7.68e-13	5.92e-10	0.35	0.32	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
LUAD	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-7.37	7.69e-13	5.92e-10	-0.41	-0.32	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
LUAD	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	7.37	7.69e-13	5.92e-10	0.52	0.32	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
LUAD	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	7.37	7.72e-13	5.95e-10	0.38	0.32	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
LUAD	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-7.37	7.73e-13	5.96e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
LUAD	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	7.36	7.78e-13	5.99e-10	0.37	0.32	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
LUAD	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-7.36	7.8e-13	6.01e-10	-0.41	-0.32	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000211972.2	IGHV3-66	7.36	7.81e-13	6.01e-10	0.29	0.32	Kawasaki disease;	chr14:106704323	chr14:106675017~106675544:-
LUAD	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-7.36	7.81e-13	6.01e-10	-0.39	-0.32	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
LUAD	cis	rs2337406	0.641	rs10133227	ENSG00000254174.1	IGHV1-12	-7.36	7.82e-13	6.02e-10	-0.29	-0.32	Alzheimer's disease (late onset);	chr14:106814260	chr14:106122420~106122709:-
LUAD	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-7.36	7.82e-13	6.02e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
LUAD	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	7.36	7.84e-13	6.03e-10	0.37	0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
LUAD	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	7.36	7.85e-13	6.04e-10	0.41	0.32	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
LUAD	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-7.36	7.86e-13	6.05e-10	-0.41	-0.32	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
LUAD	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	7.36	7.91e-13	6.09e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	7.36	7.91e-13	6.09e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	7.36	7.91e-13	6.09e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
LUAD	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-7.36	7.94e-13	6.11e-10	-0.39	-0.32	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-7.36	7.94e-13	6.11e-10	-0.39	-0.32	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-7.36	7.94e-13	6.11e-10	-0.39	-0.32	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
LUAD	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	7.36	7.95e-13	6.11e-10	0.46	0.32	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
LUAD	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	7.36	7.95e-13	6.12e-10	0.38	0.32	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
LUAD	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-7.36	7.97e-13	6.13e-10	-0.45	-0.32	Depression;	chr6:28168434	chr6:28115628~28116551:+
LUAD	cis	rs755249	1	rs2293476	ENSG00000228060.1	RP11-69E11.8	7.36	7.98e-13	6.14e-10	0.31	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39565160~39573203:+
LUAD	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	7.36	7.99e-13	6.14e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
LUAD	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	7.36	8.01e-13	6.16e-10	0.41	0.32	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
LUAD	cis	rs6844153	0.877	rs10939146	ENSG00000240005.4	RP11-293A21.1	-7.36	8.04e-13	6.18e-10	-0.51	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26978399	chr4:26859806~26860599:-
LUAD	cis	rs4591358	0.689	rs16837051	ENSG00000223466.1	AC064834.2	-7.36	8.07e-13	6.2e-10	-0.45	-0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195536281	chr2:195533035~195538681:+
LUAD	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	7.36	8.07e-13	6.2e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
LUAD	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-7.36	8.1e-13	6.22e-10	-0.36	-0.32	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
LUAD	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
LUAD	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
LUAD	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	7.36	8.11e-13	6.23e-10	0.4	0.32	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
LUAD	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	7.36	8.12e-13	6.23e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
LUAD	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	7.36	8.15e-13	6.26e-10	0.42	0.32	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
LUAD	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-7.36	8.15e-13	6.26e-10	-0.39	-0.32	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
LUAD	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	7.36	8.16e-13	6.26e-10	0.44	0.32	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
LUAD	cis	rs9595908	1	rs9591145	ENSG00000212293.1	SNORA16	7.36	8.17e-13	6.27e-10	0.35	0.32	Body mass index;	chr13:32587322	chr13:32420390~32420516:-
LUAD	cis	rs9595908	1	rs3742320	ENSG00000212293.1	SNORA16	7.36	8.17e-13	6.27e-10	0.35	0.32	Body mass index;	chr13:32590281	chr13:32420390~32420516:-
LUAD	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	7.36	8.18e-13	6.28e-10	0.65	0.32	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
LUAD	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	7.36	8.21e-13	6.3e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	7.36	8.21e-13	6.3e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	7.36	8.21e-13	6.3e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
LUAD	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	7.36	8.23e-13	6.31e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
LUAD	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-7.36	8.25e-13	6.33e-10	-0.46	-0.32	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	7.36	8.25e-13	6.33e-10	0.37	0.32	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
LUAD	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-7.36	8.26e-13	6.33e-10	-0.35	-0.32	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
LUAD	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-7.36	8.27e-13	6.34e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
LUAD	cis	rs9595908	0.965	rs7318297	ENSG00000212293.1	SNORA16	7.36	8.29e-13	6.36e-10	0.37	0.32	Body mass index;	chr13:32563835	chr13:32420390~32420516:-
LUAD	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	7.35	8.3e-13	6.36e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
LUAD	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	7.35	8.31e-13	6.37e-10	0.46	0.32	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
LUAD	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	7.35	8.33e-13	6.38e-10	0.38	0.32	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
LUAD	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-7.35	8.35e-13	6.4e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
LUAD	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	7.35	8.35e-13	6.4e-10	0.39	0.32	Height;	chr6:109375548	chr6:109382795~109383666:+
LUAD	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	7.35	8.38e-13	6.42e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	7.35	8.38e-13	6.42e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	7.35	8.38e-13	6.42e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	7.35	8.38e-13	6.42e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
LUAD	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	7.35	8.39e-13	6.43e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
LUAD	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	7.35	8.4e-13	6.43e-10	0.39	0.32	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
LUAD	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-7.35	8.41e-13	6.44e-10	-0.29	-0.32	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000280411.1	IGHV1-69-2	-7.35	8.42e-13	6.45e-10	-0.24	-0.32	Kawasaki disease;	chr14:106690981	chr14:106762092~106762588:-
LUAD	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	7.35	8.43e-13	6.46e-10	0.4	0.32	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
LUAD	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-7.35	8.47e-13	6.48e-10	-0.37	-0.32	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-7.35	8.47e-13	6.48e-10	-0.37	-0.32	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-7.35	8.47e-13	6.48e-10	-0.37	-0.32	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
LUAD	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	7.35	8.48e-13	6.49e-10	0.3	0.32	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	7.35	8.48e-13	6.49e-10	0.39	0.32	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
LUAD	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	7.35	8.49e-13	6.5e-10	0.47	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
LUAD	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	7.35	8.51e-13	6.52e-10	0.35	0.32	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
LUAD	cis	rs10200159	0.744	rs6545510	ENSG00000272606.1	RP11-554J4.1	7.35	8.52e-13	6.52e-10	0.54	0.32	Vitiligo;	chr2:55607591	chr2:55617909~55618373:+
LUAD	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	7.35	8.56e-13	6.55e-10	0.28	0.32	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
LUAD	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-7.35	8.58e-13	6.57e-10	-0.46	-0.32	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
LUAD	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66692349	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66693433	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66694214	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66701371	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66702658	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66706390	chr7:66902857~66906297:+
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66710076	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66715944	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66721259	chr7:66902857~66906297:+
LUAD	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-7.35	8.6e-13	6.58e-10	-0.4	-0.32	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	7.35	8.6e-13	6.58e-10	0.39	0.32	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
LUAD	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-7.35	8.62e-13	6.59e-10	-0.47	-0.32	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-7.35	8.62e-13	6.59e-10	-0.47	-0.32	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
LUAD	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	7.35	8.63e-13	6.6e-10	0.46	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
LUAD	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	7.35	8.64e-13	6.61e-10	0.3	0.32	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
LUAD	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-7.35	8.66e-13	6.62e-10	-0.39	-0.32	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
LUAD	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-7.35	8.67e-13	6.63e-10	-0.38	-0.32	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-7.35	8.67e-13	6.63e-10	-0.38	-0.32	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
LUAD	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-7.35	8.68e-13	6.64e-10	-0.37	-0.32	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
LUAD	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	7.35	8.69e-13	6.64e-10	0.33	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
LUAD	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-7.35	8.69e-13	6.65e-10	-0.46	-0.32	Depression;	chr6:28143758	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-7.35	8.69e-13	6.65e-10	-0.46	-0.32	Depression;	chr6:28144784	chr6:28115628~28116551:+
LUAD	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	7.35	8.7e-13	6.65e-10	0.41	0.32	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
LUAD	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	7.35	8.72e-13	6.66e-10	0.43	0.32	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
LUAD	cis	rs11089937	0.651	rs2330015	ENSG00000211639.2	IGLV4-60	-7.35	8.72e-13	6.67e-10	-0.33	-0.32	Periodontitis (PAL4Q3);	chr22:22182566	chr22:22162199~22162681:+
LUAD	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	7.35	8.75e-13	6.69e-10	0.36	0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
LUAD	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	7.35	8.77e-13	6.7e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
LUAD	cis	rs7044106	0.5	rs56725168	ENSG00000238181.2	AHCYP2	-7.35	8.77e-13	6.7e-10	-0.42	-0.32	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120720673~120721972:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000280411.1	IGHV1-69-2	-7.35	8.79e-13	6.71e-10	-0.25	-0.32	Kawasaki disease;	chr14:106705271	chr14:106762092~106762588:-
LUAD	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-7.35	8.79e-13	6.71e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
LUAD	cis	rs950880	0.71	rs67723747	ENSG00000234389.1	AC007278.3	-7.35	8.81e-13	6.73e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102353347	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs56386507	ENSG00000234389.1	AC007278.3	-7.35	8.81e-13	6.73e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102354705	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-7.35	8.81e-13	6.73e-10	-0.22	-0.32	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-7.35	8.81e-13	6.73e-10	-0.22	-0.32	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
LUAD	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	7.35	8.82e-13	6.74e-10	0.42	0.32	Height;	chr6:109592105	chr6:109382795~109383666:+
LUAD	cis	rs7044106	0.791	rs4836829	ENSG00000238181.2	AHCYP2	-7.35	8.82e-13	6.74e-10	-0.42	-0.32	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120720673~120721972:+
LUAD	cis	rs9595908	0.965	rs9337	ENSG00000212293.1	SNORA16	7.35	8.83e-13	6.75e-10	0.38	0.32	Body mass index;	chr13:32517104	chr13:32420390~32420516:-
LUAD	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	7.35	8.84e-13	6.75e-10	0.3	0.32	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
LUAD	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-7.35	8.85e-13	6.76e-10	-0.45	-0.32	Depression;	chr6:28071808	chr6:28115628~28116551:+
LUAD	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	7.34	8.89e-13	6.78e-10	0.73	0.32	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	7.34	8.89e-13	6.78e-10	0.73	0.32	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	7.34	8.89e-13	6.78e-10	0.73	0.32	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	7.34	8.89e-13	6.78e-10	0.73	0.32	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
LUAD	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-7.34	8.89e-13	6.79e-10	-0.45	-0.32	Depression;	chr6:28169676	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-7.34	8.9e-13	6.8e-10	-0.45	-0.32	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-7.34	8.91e-13	6.8e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
LUAD	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	7.34	8.96e-13	6.84e-10	0.28	0.32	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
LUAD	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	7.34	8.96e-13	6.84e-10	0.54	0.32	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
LUAD	cis	rs9595908	0.965	rs9595903	ENSG00000212293.1	SNORA16	7.34	8.98e-13	6.85e-10	0.36	0.32	Body mass index;	chr13:32608003	chr13:32420390~32420516:-
LUAD	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	7.34	8.98e-13	6.85e-10	0.42	0.32	Height;	chr6:109676091	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-7.34	8.98e-13	6.85e-10	-0.23	-0.32	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-7.34	8.98e-13	6.85e-10	-0.23	-0.32	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
LUAD	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-7.34	8.99e-13	6.86e-10	-0.57	-0.32	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
LUAD	cis	rs35955747	0.838	rs5997900	ENSG00000236132.1	CTA-440B3.1	7.34	9.03e-13	6.88e-10	0.35	0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31184360	chr22:31816379~31817491:-
LUAD	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-7.34	9.11e-13	6.95e-10	-0.45	-0.32	Depression;	chr6:28096077	chr6:28115628~28116551:+
LUAD	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-7.34	9.12e-13	6.95e-10	-0.48	-0.32	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
LUAD	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
LUAD	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
LUAD	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-7.34	9.16e-13	6.98e-10	-0.45	-0.32	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-7.34	9.16e-13	6.98e-10	-0.45	-0.32	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
LUAD	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	7.34	9.17e-13	6.99e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
LUAD	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	7.34	9.18e-13	6.99e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
LUAD	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	7.34	9.2e-13	7.01e-10	0.38	0.32	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
LUAD	cis	rs2439831	0.681	rs7168940	ENSG00000205771.5	CATSPER2P1	-7.34	9.22e-13	7.02e-10	-0.53	-0.32	Lung cancer in ever smokers;	chr15:43341136	chr15:43726918~43747094:-
LUAD	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	7.34	9.27e-13	7.06e-10	0.33	0.32	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	7.34	9.27e-13	7.06e-10	0.33	0.32	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-7.34	9.32e-13	7.1e-10	-0.23	-0.32	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
LUAD	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-7.34	9.32e-13	7.1e-10	-0.31	-0.32	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-7.34	9.34e-13	7.11e-10	-0.37	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
LUAD	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-7.34	9.41e-13	7.17e-10	-0.37	-0.32	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
LUAD	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28089816	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28090857	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28091242	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28091439	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28091659	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28092227	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28093966	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28094014	chr6:28115628~28116551:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-7.34	9.45e-13	7.19e-10	-0.39	-0.32	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
LUAD	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-7.33	9.49e-13	7.21e-10	-0.44	-0.32	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
LUAD	cis	rs10200159	1	rs13428382	ENSG00000272606.1	RP11-554J4.1	7.33	9.5e-13	7.22e-10	0.52	0.32	Vitiligo;	chr2:55636929	chr2:55617909~55618373:+
LUAD	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-7.33	9.51e-13	7.23e-10	-0.35	-0.32	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
LUAD	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	7.33	9.54e-13	7.24e-10	0.41	0.32	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	7.33	9.54e-13	7.24e-10	0.41	0.32	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
LUAD	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-7.33	9.55e-13	7.25e-10	-0.37	-0.32	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
LUAD	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-7.33	9.55e-13	7.25e-10	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-7.33	9.55e-13	7.25e-10	-0.22	-0.32	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
LUAD	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	7.33	9.57e-13	7.27e-10	0.39	0.32	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-7.33	9.59e-13	7.28e-10	-0.23	-0.32	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
LUAD	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-7.33	9.6e-13	7.28e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
LUAD	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	7.33	9.64e-13	7.31e-10	0.4	0.32	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	7.33	9.64e-13	7.31e-10	0.4	0.32	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	7.33	9.64e-13	7.31e-10	0.4	0.32	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	7.33	9.64e-13	7.31e-10	0.4	0.32	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
LUAD	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	7.33	9.64e-13	7.32e-10	0.37	0.32	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	7.33	9.64e-13	7.32e-10	0.37	0.32	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	7.33	9.64e-13	7.32e-10	0.37	0.32	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
LUAD	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	7.33	9.66e-13	7.33e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	7.33	9.66e-13	7.33e-10	0.64	0.32	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	7.33	9.66e-13	7.33e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
LUAD	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	7.33	9.7e-13	7.35e-10	0.4	0.32	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	7.33	9.7e-13	7.35e-10	0.4	0.32	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	7.33	9.7e-13	7.35e-10	0.4	0.32	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
LUAD	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	7.33	9.71e-13	7.36e-10	0.37	0.32	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	7.33	9.71e-13	7.36e-10	0.37	0.32	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
LUAD	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-7.33	9.72e-13	7.37e-10	-0.34	-0.32	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000211972.2	IGHV3-66	7.33	9.75e-13	7.39e-10	0.28	0.32	Kawasaki disease;	chr14:106816039	chr14:106675017~106675544:-
LUAD	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-7.33	9.76e-13	7.4e-10	-0.44	-0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
LUAD	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-7.33	9.76e-13	7.4e-10	-0.33	-0.32	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
LUAD	cis	rs10200159	0.744	rs6545513	ENSG00000272606.1	RP11-554J4.1	7.33	9.77e-13	7.41e-10	0.51	0.32	Vitiligo;	chr2:55657729	chr2:55617909~55618373:+
LUAD	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-7.33	9.85e-13	7.47e-10	-0.45	-0.32	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-7.33	9.85e-13	7.47e-10	-0.45	-0.32	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
LUAD	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-7.33	9.85e-13	7.47e-10	-0.45	-0.32	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
LUAD	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-7.33	9.88e-13	7.49e-10	-0.38	-0.32	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
LUAD	cis	rs6504622	0.728	rs7222781	ENSG00000262879.4	RP11-156P1.3	-7.33	9.88e-13	7.49e-10	-0.36	-0.32	Orofacial clefts;	chr17:47100059	chr17:46984045~47100323:-
LUAD	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-7.33	9.92e-13	7.51e-10	-0.45	-0.32	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
LUAD	cis	rs1167827	0.805	rs809439	ENSG00000278416.1	PMS2L2	-7.33	9.94e-13	7.53e-10	-0.4	-0.32	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75344015~75359550:-
LUAD	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-7.33	9.97e-13	7.55e-10	-0.32	-0.32	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	7.33	9.98e-13	7.56e-10	0.38	0.32	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
LUAD	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	7.33	9.99e-13	7.56e-10	0.36	0.32	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
LUAD	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	7.33	1e-12	7.57e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	7.33	1e-12	7.57e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
LUAD	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	7.33	1e-12	7.6e-10	0.44	0.32	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
LUAD	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	7.33	1e-12	7.61e-10	0.28	0.32	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
LUAD	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-7.33	1.01e-12	7.62e-10	-0.37	-0.32	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-7.33	1.01e-12	7.64e-10	-0.23	-0.32	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-7.33	1.01e-12	7.64e-10	-0.23	-0.32	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-7.33	1.01e-12	7.64e-10	-0.23	-0.32	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
LUAD	cis	rs944289	0.708	rs8016762	ENSG00000257826.1	RP11-116N8.4	-7.33	1.01e-12	7.64e-10	-0.33	-0.32	Thyroid cancer;	chr14:36108538	chr14:36061026~36067190:-
LUAD	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	7.33	1.01e-12	7.65e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	7.33	1.01e-12	7.65e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	7.33	1.01e-12	7.65e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	7.33	1.01e-12	7.65e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
LUAD	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	7.33	1.01e-12	7.66e-10	0.39	0.32	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
LUAD	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	7.33	1.01e-12	7.66e-10	0.46	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
LUAD	cis	rs237743	1	rs8117111	ENSG00000222365.1	SNORD12B	-7.33	1.01e-12	7.66e-10	-0.37	-0.32	Height;	chr20:49267648	chr20:49280319~49280409:+
LUAD	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	7.33	1.01e-12	7.67e-10	0.72	0.32	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
LUAD	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-7.32	1.02e-12	7.7e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
LUAD	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-7.32	1.02e-12	7.75e-10	-0.45	-0.32	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
LUAD	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-7.32	1.03e-12	7.8e-10	-0.33	-0.32	Gout;	chr7:66679692	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	7.32	1.03e-12	7.8e-10	0.33	0.32	Gout;	chr7:66682070	chr7:66902857~66906297:+
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	7.32	1.03e-12	7.8e-10	0.33	0.32	Gout;	chr7:66682162	chr7:66902857~66906297:+
LUAD	cis	rs11089937	0.559	rs2330014	ENSG00000211639.2	IGLV4-60	7.32	1.03e-12	7.8e-10	0.35	0.32	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22162199~22162681:+
LUAD	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-7.32	1.04e-12	7.83e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
LUAD	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	7.32	1.04e-12	7.83e-10	0.42	0.32	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
LUAD	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
LUAD	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-7.32	1.04e-12	7.85e-10	-0.34	-0.32	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
LUAD	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	7.32	1.04e-12	7.85e-10	0.73	0.32	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	7.32	1.04e-12	7.85e-10	0.73	0.32	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	7.32	1.04e-12	7.85e-10	0.73	0.32	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	7.32	1.04e-12	7.85e-10	0.73	0.32	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
LUAD	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-7.32	1.04e-12	7.86e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-7.32	1.04e-12	7.86e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-7.32	1.04e-12	7.86e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-7.32	1.04e-12	7.86e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-7.32	1.04e-12	7.87e-10	-0.45	-0.32	Depression;	chr6:28110254	chr6:28115628~28116551:+
LUAD	cis	rs10200159	1	rs10204169	ENSG00000272606.1	RP11-554J4.1	7.32	1.04e-12	7.88e-10	0.52	0.32	Vitiligo;	chr2:55663468	chr2:55617909~55618373:+
LUAD	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-7.32	1.05e-12	7.89e-10	-0.34	-0.32	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
LUAD	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	7.32	1.05e-12	7.9e-10	0.41	0.32	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
LUAD	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-7.32	1.05e-12	7.9e-10	-0.34	-0.32	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
LUAD	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-7.32	1.05e-12	7.91e-10	-0.6	-0.32	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
LUAD	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	7.32	1.05e-12	7.91e-10	0.41	0.32	Height;	chr6:109495102	chr6:109382795~109383666:+
LUAD	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-7.32	1.05e-12	7.92e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-7.32	1.05e-12	7.92e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
LUAD	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28074687	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28076559	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28076704	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28078391	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28079011	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28080757	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28080760	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28082231	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28082261	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28082984	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28083994	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28084025	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28085319	chr6:28115628~28116551:+
LUAD	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-7.32	1.05e-12	7.92e-10	-0.44	-0.32	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
LUAD	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-7.32	1.05e-12	7.93e-10	-0.39	-0.32	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
LUAD	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	7.32	1.05e-12	7.94e-10	0.36	0.32	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
LUAD	cis	rs10129255	1	rs8010605	ENSG00000280411.1	IGHV1-69-2	-7.32	1.05e-12	7.94e-10	-0.24	-0.32	Kawasaki disease;	chr14:106678742	chr14:106762092~106762588:-
LUAD	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-7.32	1.05e-12	7.94e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
LUAD	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-7.32	1.06e-12	7.95e-10	-0.34	-0.32	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
LUAD	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-7.32	1.06e-12	7.95e-10	-0.42	-0.32	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
LUAD	cis	rs10200159	1	rs9309267	ENSG00000272606.1	RP11-554J4.1	-7.32	1.06e-12	7.96e-10	-0.55	-0.32	Vitiligo;	chr2:55623198	chr2:55617909~55618373:+
LUAD	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-7.32	1.06e-12	7.96e-10	-0.42	-0.32	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
LUAD	cis	rs237743	1	rs36016605	ENSG00000222365.1	SNORD12B	-7.32	1.06e-12	7.98e-10	-0.37	-0.32	Height;	chr20:49279608	chr20:49280319~49280409:+
LUAD	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	7.32	1.06e-12	7.98e-10	0.56	0.32	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
LUAD	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-7.32	1.06e-12	7.99e-10	-0.41	-0.32	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
LUAD	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	7.32	1.06e-12	8e-10	0.41	0.32	Height;	chr6:109634150	chr6:109382795~109383666:+
LUAD	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-7.32	1.06e-12	8e-10	-0.34	-0.32	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
LUAD	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-7.32	1.07e-12	8.06e-10	-0.39	-0.32	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
LUAD	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-7.32	1.07e-12	8.08e-10	-0.37	-0.32	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
LUAD	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28154567	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28156691	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28158424	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28159056	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28159666	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28159843	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28162053	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28162598	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28163375	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28163759	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28164580	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28164825	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28164948	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28165025	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28165528	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28169019	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28169249	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28169755	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28169791	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28170075	chr6:28115628~28116551:+
LUAD	cis	rs748404	0.697	rs530188	ENSG00000205771.5	CATSPER2P1	-7.32	1.08e-12	8.09e-10	-0.39	-0.32	Lung cancer;	chr15:43253116	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs475227	ENSG00000205771.5	CATSPER2P1	-7.32	1.08e-12	8.09e-10	-0.39	-0.32	Lung cancer;	chr15:43254248	chr15:43726918~43747094:-
LUAD	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-7.32	1.08e-12	8.12e-10	-0.37	-0.32	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	7.32	1.08e-12	8.16e-10	0.33	0.32	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	7.32	1.08e-12	8.16e-10	0.33	0.32	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	7.32	1.08e-12	8.16e-10	0.33	0.32	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	7.32	1.08e-12	8.16e-10	0.33	0.32	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-7.32	1.08e-12	8.16e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-7.31	1.09e-12	8.16e-10	-0.38	-0.32	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-7.31	1.09e-12	8.16e-10	-0.38	-0.32	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-7.31	1.09e-12	8.16e-10	-0.38	-0.32	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
LUAD	cis	rs2439831	0.867	rs3213990	ENSG00000205771.5	CATSPER2P1	-7.31	1.09e-12	8.16e-10	-0.55	-0.32	Lung cancer in ever smokers;	chr15:43378028	chr15:43726918~43747094:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000280411.1	IGHV1-69-2	-7.31	1.09e-12	8.19e-10	-0.24	-0.32	Kawasaki disease;	chr14:106767990	chr14:106762092~106762588:-
LUAD	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	7.31	1.09e-12	8.19e-10	0.28	0.32	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
LUAD	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-7.31	1.09e-12	8.2e-10	-0.41	-0.32	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
LUAD	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-7.31	1.09e-12	8.2e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-7.31	1.09e-12	8.2e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
LUAD	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-7.31	1.09e-12	8.22e-10	-0.56	-0.32	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
LUAD	cis	rs10200159	0.793	rs6545512	ENSG00000272606.1	RP11-554J4.1	7.31	1.09e-12	8.22e-10	0.51	0.32	Vitiligo;	chr2:55656896	chr2:55617909~55618373:+
LUAD	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	7.31	1.1e-12	8.25e-10	0.39	0.32	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
LUAD	cis	rs7646881	1	rs59217052	ENSG00000240207.5	RP11-379F4.4	-7.31	1.1e-12	8.26e-10	-0.38	-0.32	Tetralogy of Fallot;	chr3:158734667	chr3:158732263~158784070:+
LUAD	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-7.31	1.1e-12	8.27e-10	-0.38	-0.32	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
LUAD	cis	rs9595908	0.965	rs9595877	ENSG00000212293.1	SNORA16	7.31	1.1e-12	8.28e-10	0.36	0.32	Body mass index;	chr13:32589512	chr13:32420390~32420516:-
LUAD	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-7.31	1.11e-12	8.31e-10	-0.4	-0.32	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
LUAD	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	7.31	1.11e-12	8.31e-10	0.44	0.32	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
LUAD	cis	rs9595908	0.929	rs34916533	ENSG00000212293.1	SNORA16	7.31	1.11e-12	8.31e-10	0.37	0.32	Body mass index;	chr13:32500537	chr13:32420390~32420516:-
LUAD	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
LUAD	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-7.31	1.11e-12	8.32e-10	-0.43	-0.32	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
LUAD	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	7.31	1.11e-12	8.33e-10	0.42	0.32	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
LUAD	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	7.31	1.12e-12	8.38e-10	0.4	0.32	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs2476319	ENSG00000269125.1	RP11-98F14.11	7.31	1.12e-12	8.38e-10	0.4	0.32	Platelet distribution width;	chr13:113182205	chr13:113165002~113165183:-
LUAD	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	7.31	1.12e-12	8.41e-10	0.4	0.32	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000280411.1	IGHV1-69-2	-7.31	1.12e-12	8.41e-10	-0.24	-0.32	Kawasaki disease;	chr14:106705382	chr14:106762092~106762588:-
LUAD	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-7.31	1.12e-12	8.42e-10	-0.35	-0.32	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
LUAD	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	7.31	1.12e-12	8.42e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
LUAD	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-7.31	1.12e-12	8.43e-10	-0.37	-0.32	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
LUAD	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	7.31	1.13e-12	8.44e-10	0.32	0.32	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-7.31	1.13e-12	8.45e-10	-0.22	-0.32	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-7.31	1.13e-12	8.45e-10	-0.22	-0.32	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
LUAD	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	7.31	1.13e-12	8.47e-10	0.41	0.32	Height;	chr6:109608105	chr6:109382795~109383666:+
LUAD	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	7.31	1.14e-12	8.52e-10	0.37	0.32	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-7.31	1.14e-12	8.52e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
LUAD	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	7.31	1.14e-12	8.52e-10	0.4	0.32	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
LUAD	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	7.31	1.14e-12	8.52e-10	0.4	0.32	Depression;	chr6:28323463	chr6:28943877~28944537:+
LUAD	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	7.31	1.14e-12	8.55e-10	0.28	0.32	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	7.31	1.14e-12	8.55e-10	0.28	0.32	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
LUAD	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-7.31	1.14e-12	8.57e-10	-0.34	-0.32	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
LUAD	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	7.31	1.14e-12	8.58e-10	0.43	0.32	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
LUAD	cis	rs3198697	1	rs3198697	ENSG00000207425.1	Y_RNA	7.31	1.15e-12	8.59e-10	0.36	0.32	Triglycerides;	chr16:15036083	chr16:14915457~14915556:-
LUAD	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-7.31	1.15e-12	8.59e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
LUAD	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
LUAD	cis	rs2439831	0.681	rs2278859	ENSG00000205771.5	CATSPER2P1	-7.31	1.15e-12	8.6e-10	-0.53	-0.32	Lung cancer in ever smokers;	chr15:43340762	chr15:43726918~43747094:-
LUAD	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-7.31	1.15e-12	8.62e-10	-0.37	-0.32	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-7.31	1.15e-12	8.63e-10	-0.22	-0.32	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
LUAD	cis	rs7646881	1	rs59313096	ENSG00000240207.5	RP11-379F4.4	-7.31	1.16e-12	8.67e-10	-0.38	-0.32	Tetralogy of Fallot;	chr3:158734453	chr3:158732263~158784070:+
LUAD	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-7.31	1.16e-12	8.67e-10	-0.38	-0.32	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-7.31	1.16e-12	8.68e-10	-0.37	-0.32	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-7.31	1.16e-12	8.68e-10	-0.37	-0.32	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-7.31	1.16e-12	8.68e-10	-0.22	-0.32	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
LUAD	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-7.3	1.17e-12	8.73e-10	-0.45	-0.32	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
LUAD	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-7.3	1.17e-12	8.73e-10	-0.38	-0.32	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-7.3	1.17e-12	8.73e-10	-0.38	-0.32	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
LUAD	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	7.3	1.17e-12	8.74e-10	0.45	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
LUAD	cis	rs8031584	0.678	rs4779496	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30858851	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.678	rs4779497	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30859162	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.678	rs8028173	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30863546	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.706	rs2177670	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30865548	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.678	rs36047941	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30867032	chr15:30882267~30883231:-
LUAD	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-7.3	1.17e-12	8.75e-10	-0.45	-0.32	Depression;	chr6:28070115	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000211972.2	IGHV3-66	7.3	1.17e-12	8.77e-10	0.28	0.32	Kawasaki disease;	chr14:106767441	chr14:106675017~106675544:-
LUAD	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-7.3	1.17e-12	8.78e-10	-0.44	-0.32	Depression;	chr6:28096855	chr6:28115628~28116551:+
LUAD	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-7.3	1.17e-12	8.79e-10	-0.38	-0.32	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
LUAD	cis	rs13056815	1	rs13056815	ENSG00000236132.1	CTA-440B3.1	7.3	1.17e-12	8.79e-10	0.35	0.32	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr22:31272264	chr22:31816379~31817491:-
LUAD	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-7.3	1.18e-12	8.84e-10	-0.38	-0.32	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
LUAD	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	7.3	1.18e-12	8.84e-10	0.41	0.32	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
LUAD	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-7.3	1.18e-12	8.85e-10	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
LUAD	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-7.3	1.18e-12	8.85e-10	-0.43	-0.32	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-7.3	1.18e-12	8.85e-10	-0.43	-0.32	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-7.3	1.18e-12	8.85e-10	-0.43	-0.32	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
LUAD	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-7.3	1.19e-12	8.87e-10	-0.44	-0.32	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
LUAD	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-7.3	1.19e-12	8.88e-10	-0.37	-0.32	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
LUAD	cis	rs35955747	0.669	rs878718	ENSG00000236132.1	CTA-440B3.1	-7.3	1.19e-12	8.88e-10	-0.35	-0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31156716	chr22:31816379~31817491:-
LUAD	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-7.3	1.19e-12	8.91e-10	-0.35	-0.32	Temperament;	chr17:14018109	chr17:14024514~14025488:+
LUAD	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-7.3	1.19e-12	8.92e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
LUAD	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	7.3	1.19e-12	8.92e-10	0.39	0.32	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Depression;	chr6:28099759	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Depression;	chr6:28100648	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Depression;	chr6:28107222	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Depression;	chr6:28108492	chr6:28115628~28116551:+
LUAD	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-7.3	1.2e-12	8.94e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
LUAD	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	7.3	1.2e-12	8.94e-10	0.37	0.32	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
LUAD	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-7.3	1.2e-12	8.94e-10	-0.37	-0.32	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
LUAD	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-7.3	1.2e-12	8.95e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
LUAD	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-7.3	1.2e-12	8.95e-10	-0.36	-0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
LUAD	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	7.3	1.21e-12	9.04e-10	0.56	0.32	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
LUAD	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	7.3	1.22e-12	9.08e-10	0.42	0.32	Height;	chr6:109501402	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	7.3	1.22e-12	9.08e-10	0.42	0.32	Height;	chr6:109501429	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000280411.1	IGHV1-69-2	-7.3	1.22e-12	9.09e-10	-0.24	-0.32	Kawasaki disease;	chr14:106705441	chr14:106762092~106762588:-
LUAD	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-7.3	1.24e-12	9.22e-10	-0.25	-0.32	Breast cancer;	chr11:825777	chr11:781645~782105:+
LUAD	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-7.29	1.24e-12	9.25e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000280411.1	IGHV1-69-2	-7.29	1.24e-12	9.26e-10	-0.24	-0.32	Kawasaki disease;	chr14:106704386	chr14:106762092~106762588:-
LUAD	cis	rs237743	1	rs8123912	ENSG00000222365.1	SNORD12B	-7.29	1.24e-12	9.27e-10	-0.37	-0.32	Height;	chr20:49246745	chr20:49280319~49280409:+
LUAD	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.24e-12	9.28e-10	-0.33	-0.32	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.25e-12	9.28e-10	-0.33	-0.32	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
LUAD	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-7.29	1.25e-12	9.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-7.29	1.25e-12	9.35e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-7.29	1.25e-12	9.35e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
LUAD	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
LUAD	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
LUAD	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	7.29	1.26e-12	9.36e-10	0.49	0.32	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
LUAD	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	7.29	1.26e-12	9.37e-10	0.37	0.32	Depression;	chr6:28303421	chr6:28176188~28176674:+
LUAD	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-7.29	1.26e-12	9.39e-10	-0.34	-0.32	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
LUAD	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-7.29	1.27e-12	9.45e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
LUAD	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	7.29	1.27e-12	9.47e-10	0.4	0.32	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
LUAD	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	7.29	1.27e-12	9.47e-10	0.4	0.32	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	7.29	1.28e-12	9.49e-10	0.33	0.32	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.28e-12	9.49e-10	-0.34	-0.32	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-7.29	1.28e-12	9.5e-10	-0.23	-0.32	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-7.29	1.28e-12	9.5e-10	-0.23	-0.32	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-7.29	1.28e-12	9.5e-10	-0.23	-0.32	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-7.29	1.28e-12	9.5e-10	-0.23	-0.32	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
LUAD	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	7.29	1.28e-12	9.5e-10	0.36	0.32	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
LUAD	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.28e-12	9.51e-10	-0.33	-0.32	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
LUAD	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-7.29	1.28e-12	9.51e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
LUAD	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-7.29	1.28e-12	9.53e-10	-0.43	-0.32	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000224373.3	IGHV4-59	-7.29	1.28e-12	9.54e-10	-0.19	-0.32	Kawasaki disease;	chr14:106683806	chr14:106627249~106627825:-
LUAD	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	7.29	1.28e-12	9.54e-10	0.37	0.32	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
LUAD	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-7.29	1.28e-12	9.56e-10	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
LUAD	cis	rs944289	0.598	rs56359141	ENSG00000257826.1	RP11-116N8.4	-7.29	1.29e-12	9.58e-10	-0.34	-0.32	Thyroid cancer;	chr14:36108167	chr14:36061026~36067190:-
LUAD	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-7.29	1.29e-12	9.61e-10	-0.39	-0.32	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-7.29	1.29e-12	9.63e-10	-0.45	-0.32	Depression;	chr6:28161802	chr6:28115628~28116551:+
LUAD	cis	rs944289	0.899	rs1169125	ENSG00000257826.1	RP11-116N8.4	-7.29	1.3e-12	9.66e-10	-0.34	-0.32	Thyroid cancer;	chr14:36150560	chr14:36061026~36067190:-
LUAD	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-7.29	1.31e-12	9.7e-10	-0.45	-0.32	Depression;	chr6:28139876	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-7.29	1.31e-12	9.7e-10	-0.45	-0.32	Depression;	chr6:28139998	chr6:28115628~28116551:+
LUAD	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-7.29	1.31e-12	9.72e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
LUAD	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	7.29	1.31e-12	9.77e-10	0.28	0.32	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	7.29	1.31e-12	9.77e-10	0.28	0.32	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
LUAD	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	7.29	1.32e-12	9.79e-10	0.41	0.32	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
LUAD	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	7.29	1.32e-12	9.79e-10	0.41	0.32	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
LUAD	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	7.29	1.32e-12	9.79e-10	0.37	0.32	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
LUAD	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-7.29	1.32e-12	9.8e-10	-0.45	-0.32	Depression;	chr6:28141484	chr6:28115628~28116551:+
LUAD	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	7.29	1.32e-12	9.81e-10	0.44	0.32	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
LUAD	cis	rs10200159	1	rs17047119	ENSG00000272606.1	RP11-554J4.1	7.29	1.32e-12	9.81e-10	0.54	0.32	Vitiligo;	chr2:55599979	chr2:55617909~55618373:+
LUAD	cis	rs1345301	1	rs1345301	ENSG00000234389.1	AC007278.3	-7.29	1.32e-12	9.82e-10	-0.29	-0.32	Waist circumference;	chr2:102259127	chr2:102438713~102440475:+
LUAD	cis	rs1345301	1	rs11686567	ENSG00000234389.1	AC007278.3	-7.29	1.32e-12	9.82e-10	-0.29	-0.32	Waist circumference;	chr2:102260149	chr2:102438713~102440475:+
LUAD	cis	rs1345301	0.935	rs11691721	ENSG00000234389.1	AC007278.3	-7.29	1.32e-12	9.82e-10	-0.29	-0.32	Waist circumference;	chr2:102260219	chr2:102438713~102440475:+
LUAD	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	7.29	1.33e-12	9.85e-10	0.42	0.32	Height;	chr6:109503623	chr6:109382795~109383666:+
LUAD	cis	rs9595908	0.965	rs35193668	ENSG00000212293.1	SNORA16	7.28	1.33e-12	9.86e-10	0.37	0.32	Body mass index;	chr13:32518792	chr13:32420390~32420516:-
LUAD	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	7.28	1.33e-12	9.86e-10	0.7	0.32	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
LUAD	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	7.28	1.33e-12	9.89e-10	0.37	0.32	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
LUAD	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-7.28	1.33e-12	9.9e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	7.28	1.34e-12	9.91e-10	0.37	0.32	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
LUAD	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	7.28	1.34e-12	9.92e-10	0.68	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
LUAD	cis	rs237743	1	rs238164	ENSG00000222365.1	SNORD12B	-7.28	1.34e-12	9.94e-10	-0.35	-0.32	Height;	chr20:49227804	chr20:49280319~49280409:+
LUAD	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-7.28	1.34e-12	9.95e-10	-0.39	-0.32	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
LUAD	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-7.28	1.34e-12	9.96e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
LUAD	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-7.28	1.34e-12	9.97e-10	-0.33	-0.32	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
LUAD	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-7.28	1.34e-12	9.98e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
LUAD	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	7.28	1.35e-12	1e-09	0.47	0.32	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
LUAD	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-7.28	1.35e-12	1e-09	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-7.28	1.35e-12	1e-09	-0.22	-0.32	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
LUAD	cis	rs237743	1	rs11905214	ENSG00000222365.1	SNORD12B	-7.28	1.35e-12	1e-09	-0.37	-0.32	Height;	chr20:49272073	chr20:49280319~49280409:+
LUAD	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	7.28	1.35e-12	1e-09	0.63	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
LUAD	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-7.28	1.36e-12	1.01e-09	-0.39	-0.32	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
LUAD	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-7.28	1.36e-12	1.01e-09	-0.49	-0.32	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
LUAD	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
LUAD	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	7.28	1.38e-12	1.02e-09	0.37	0.32	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	7.28	1.38e-12	1.02e-09	0.37	0.32	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	7.28	1.38e-12	1.02e-09	0.37	0.32	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
LUAD	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-7.28	1.38e-12	1.02e-09	-0.31	-0.32	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
LUAD	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-7.28	1.38e-12	1.02e-09	-0.5	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
LUAD	cis	rs4853012	0.887	rs7570950	ENSG00000257800.1	FNBP1P1	7.28	1.39e-12	1.03e-09	0.41	0.31	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74120680~74123218:+
LUAD	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-7.28	1.39e-12	1.03e-09	-0.35	-0.31	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
LUAD	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-7.28	1.39e-12	1.03e-09	-0.37	-0.31	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-7.28	1.39e-12	1.03e-09	-0.37	-0.31	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	7.28	1.39e-12	1.03e-09	0.38	0.31	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	7.28	1.39e-12	1.03e-09	0.38	0.31	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
LUAD	cis	rs7182621	0.546	rs11635811	ENSG00000182397.13	DNM1P46	7.28	1.39e-12	1.03e-09	0.43	0.31	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99790156~99806927:-
LUAD	cis	rs10200159	1	rs6545507	ENSG00000272606.1	RP11-554J4.1	7.28	1.39e-12	1.03e-09	0.54	0.31	Vitiligo;	chr2:55588756	chr2:55617909~55618373:+
LUAD	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-7.28	1.39e-12	1.03e-09	-0.46	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
LUAD	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	7.28	1.4e-12	1.04e-09	0.37	0.31	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
LUAD	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	7.28	1.4e-12	1.04e-09	0.72	0.31	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
LUAD	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	7.28	1.41e-12	1.04e-09	0.4	0.31	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
LUAD	cis	rs944289	0.708	rs1930765	ENSG00000257826.1	RP11-116N8.4	-7.28	1.41e-12	1.04e-09	-0.33	-0.31	Thyroid cancer;	chr14:36110053	chr14:36061026~36067190:-
LUAD	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-7.28	1.41e-12	1.04e-09	-0.45	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
LUAD	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-7.28	1.41e-12	1.05e-09	-0.38	-0.31	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
LUAD	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	7.27	1.42e-12	1.05e-09	0.4	0.31	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
LUAD	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	7.27	1.42e-12	1.05e-09	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
LUAD	cis	rs11089937	0.523	rs4821832	ENSG00000211639.2	IGLV4-60	7.27	1.43e-12	1.05e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22188499	chr22:22162199~22162681:+
LUAD	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	7.27	1.43e-12	1.06e-09	0.4	0.31	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
LUAD	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-7.27	1.43e-12	1.06e-09	-0.45	-0.31	Depression;	chr6:28180209	chr6:28115628~28116551:+
LUAD	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-7.27	1.43e-12	1.06e-09	-0.37	-0.31	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
LUAD	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-7.27	1.43e-12	1.06e-09	-0.34	-0.31	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-7.27	1.43e-12	1.06e-09	-0.34	-0.31	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
LUAD	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-7.27	1.43e-12	1.06e-09	-0.37	-0.31	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
LUAD	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-7.27	1.43e-12	1.06e-09	-0.34	-0.31	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
LUAD	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	7.27	1.43e-12	1.06e-09	0.47	0.31	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
LUAD	cis	rs748404	0.723	rs512431	ENSG00000205771.5	CATSPER2P1	7.27	1.43e-12	1.06e-09	0.39	0.31	Lung cancer;	chr15:43249741	chr15:43726918~43747094:-
LUAD	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	7.27	1.44e-12	1.06e-09	0.42	0.31	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
LUAD	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	7.27	1.44e-12	1.06e-09	0.4	0.31	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
LUAD	cis	rs944289	0.966	rs1182929	ENSG00000257826.1	RP11-116N8.4	-7.27	1.44e-12	1.06e-09	-0.34	-0.31	Thyroid cancer;	chr14:36165946	chr14:36061026~36067190:-
LUAD	cis	rs11089937	0.523	rs4820352	ENSG00000211639.2	IGLV4-60	7.27	1.44e-12	1.07e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22189203	chr22:22162199~22162681:+
LUAD	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	7.27	1.44e-12	1.07e-09	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
LUAD	cis	rs944289	0.966	rs1169124	ENSG00000257826.1	RP11-116N8.4	-7.27	1.46e-12	1.08e-09	-0.34	-0.31	Thyroid cancer;	chr14:36150082	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.966	rs1169129	ENSG00000257826.1	RP11-116N8.4	-7.27	1.46e-12	1.08e-09	-0.34	-0.31	Thyroid cancer;	chr14:36152619	chr14:36061026~36067190:-
LUAD	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	7.27	1.46e-12	1.08e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
LUAD	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-7.27	1.46e-12	1.08e-09	-0.45	-0.31	Depression;	chr6:28140307	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-7.27	1.46e-12	1.08e-09	-0.45	-0.31	Depression;	chr6:28140454	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-7.27	1.46e-12	1.08e-09	-0.45	-0.31	Depression;	chr6:28141189	chr6:28115628~28116551:+
LUAD	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-7.27	1.46e-12	1.08e-09	-0.38	-0.31	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-7.27	1.46e-12	1.08e-09	-0.38	-0.31	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-7.27	1.47e-12	1.08e-09	-0.22	-0.31	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
LUAD	cis	rs34081947	0.521	rs11623102	ENSG00000257826.1	RP11-116N8.4	-7.27	1.47e-12	1.08e-09	-0.34	-0.31	Papillary thyroid cancer;Differentiated thyroid cancer;	chr14:36130459	chr14:36061026~36067190:-
LUAD	cis	rs4591358	0.689	rs16836990	ENSG00000223466.1	AC064834.2	-7.27	1.47e-12	1.09e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195532968	chr2:195533035~195538681:+
LUAD	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-7.27	1.47e-12	1.09e-09	-0.43	-0.31	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-7.27	1.47e-12	1.09e-09	-0.43	-0.31	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-7.27	1.47e-12	1.09e-09	-0.43	-0.31	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
LUAD	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	7.27	1.47e-12	1.09e-09	0.39	0.31	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
LUAD	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-7.27	1.47e-12	1.09e-09	-0.38	-0.31	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-7.27	1.47e-12	1.09e-09	-0.38	-0.31	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-7.27	1.47e-12	1.09e-09	-0.38	-0.31	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
LUAD	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	7.27	1.47e-12	1.09e-09	0.4	0.31	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
LUAD	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	7.27	1.47e-12	1.09e-09	0.41	0.31	Height;	chr6:109498751	chr6:109382795~109383666:+
LUAD	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	7.27	1.48e-12	1.09e-09	0.37	0.31	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
LUAD	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	7.27	1.48e-12	1.09e-09	0.38	0.31	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
LUAD	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	7.27	1.48e-12	1.09e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
LUAD	cis	rs4591358	0.689	rs55876968	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549015	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs55974440	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549056	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs12471810	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549969	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs2133860	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195551243	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs6759817	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553739	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs6760142	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553911	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs6434785	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195554142	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.638	rs16837243	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195556458	chr2:195533035~195538681:+
LUAD	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-7.27	1.49e-12	1.1e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
LUAD	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	7.27	1.49e-12	1.1e-09	0.41	0.31	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
LUAD	cis	rs7646881	0.812	rs73017541	ENSG00000240207.5	RP11-379F4.4	-7.27	1.49e-12	1.1e-09	-0.42	-0.31	Tetralogy of Fallot;	chr3:158743007	chr3:158732263~158784070:+
LUAD	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-7.27	1.5e-12	1.1e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
LUAD	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	7.27	1.5e-12	1.11e-09	0.38	0.31	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
LUAD	cis	rs2712431	0.554	rs9864772	ENSG00000242551.2	POU5F1P6	-7.27	1.5e-12	1.11e-09	-0.35	-0.31	Monocyte chemoattractant protein-1 levels;	chr3:128598096	chr3:128674735~128677005:-
LUAD	cis	rs4591358	0.689	rs72927794	ENSG00000223466.1	AC064834.2	-7.27	1.5e-12	1.11e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195558607	chr2:195533035~195538681:+
LUAD	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-7.27	1.5e-12	1.11e-09	-0.45	-0.31	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
LUAD	cis	rs2337406	0.587	rs916547	ENSG00000211974.3	IGHV2-70	-7.27	1.5e-12	1.11e-09	-0.4	-0.31	Alzheimer's disease (late onset);	chr14:106646735	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	7.27	1.51e-12	1.11e-09	0.41	0.31	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
LUAD	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	7.27	1.51e-12	1.11e-09	0.39	0.31	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	7.27	1.51e-12	1.11e-09	0.41	0.31	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	7.26	1.52e-12	1.12e-09	0.42	0.31	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
LUAD	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	7.26	1.52e-12	1.12e-09	0.41	0.31	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
LUAD	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	7.26	1.52e-12	1.12e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
LUAD	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	7.26	1.52e-12	1.12e-09	0.41	0.31	Height;	chr6:109496680	chr6:109382795~109383666:+
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-7.26	1.53e-12	1.12e-09	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
LUAD	cis	rs11089937	0.651	rs6001217	ENSG00000211639.2	IGLV4-60	7.26	1.53e-12	1.13e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22183804	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.521	rs6001221	ENSG00000211639.2	IGLV4-60	7.26	1.53e-12	1.13e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22185176	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000280411.1	IGHV1-69-2	-7.26	1.53e-12	1.13e-09	-0.24	-0.31	Kawasaki disease;	chr14:106686431	chr14:106762092~106762588:-
LUAD	cis	rs11089937	0.584	rs6001213	ENSG00000211639.2	IGLV4-60	7.26	1.53e-12	1.13e-09	0.33	0.31	Periodontitis (PAL4Q3);	chr22:22182108	chr22:22162199~22162681:+
LUAD	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	7.26	1.53e-12	1.13e-09	0.47	0.31	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
LUAD	cis	rs2006771	0.818	rs8142376	ENSG00000236132.1	CTA-440B3.1	7.26	1.54e-12	1.13e-09	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr22:31605051	chr22:31816379~31817491:-
LUAD	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	7.26	1.54e-12	1.14e-09	0.39	0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
LUAD	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-7.26	1.55e-12	1.14e-09	-0.33	-0.31	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
LUAD	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	7.26	1.55e-12	1.14e-09	0.7	0.31	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	7.26	1.55e-12	1.14e-09	0.7	0.31	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	7.26	1.55e-12	1.14e-09	0.7	0.31	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	7.26	1.55e-12	1.14e-09	0.7	0.31	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
LUAD	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	7.26	1.55e-12	1.14e-09	0.36	0.31	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
LUAD	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-7.26	1.55e-12	1.14e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
LUAD	cis	rs11089937	0.651	rs6001216	ENSG00000211639.2	IGLV4-60	7.26	1.55e-12	1.14e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22183755	chr22:22162199~22162681:+
LUAD	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-7.26	1.55e-12	1.14e-09	-0.48	-0.31	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
LUAD	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	7.26	1.56e-12	1.15e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	7.26	1.56e-12	1.15e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
LUAD	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	7.26	1.56e-12	1.15e-09	0.36	0.31	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
LUAD	cis	rs4591358	0.689	rs72927705	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518341	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927707	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518526	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs16836823	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518785	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs57244991	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519331	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927708	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519789	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927711	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520309	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927717	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520887	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927725	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529140	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs7574191	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529995	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs1500605	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530584	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.648	rs1515877	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530995	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs16837006	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533245	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs16837010	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533302	chr2:195533035~195538681:+
LUAD	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-7.26	1.56e-12	1.15e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-7.26	1.56e-12	1.15e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
LUAD	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	7.26	1.57e-12	1.15e-09	0.43	0.31	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
LUAD	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
LUAD	cis	rs4591358	0.689	rs2173773	ENSG00000223466.1	AC064834.2	-7.26	1.57e-12	1.16e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549701	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927784	ENSG00000223466.1	AC064834.2	-7.26	1.57e-12	1.16e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195550329	chr2:195533035~195538681:+
LUAD	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	7.26	1.57e-12	1.16e-09	0.41	0.31	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
LUAD	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-7.26	1.58e-12	1.16e-09	-0.34	-0.31	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
LUAD	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-7.26	1.58e-12	1.16e-09	-0.45	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
LUAD	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	7.26	1.58e-12	1.16e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
LUAD	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-7.26	1.59e-12	1.17e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
LUAD	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	7.26	1.59e-12	1.17e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
LUAD	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-7.26	1.59e-12	1.17e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
LUAD	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	7.26	1.59e-12	1.17e-09	0.4	0.31	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	7.26	1.59e-12	1.17e-09	0.4	0.31	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
LUAD	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	7.26	1.59e-12	1.17e-09	0.44	0.31	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
LUAD	cis	rs11089937	0.651	rs1543779	ENSG00000211639.2	IGLV4-60	-7.26	1.59e-12	1.17e-09	-0.32	-0.31	Periodontitis (PAL4Q3);	chr22:22194092	chr22:22162199~22162681:+
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000206090.4	AP000350.7	7.26	1.6e-12	1.17e-09	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23939998~23942798:+
LUAD	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	7.26	1.6e-12	1.17e-09	0.38	0.31	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
LUAD	cis	rs7646881	0.951	rs6441222	ENSG00000240207.5	RP11-379F4.4	-7.26	1.6e-12	1.17e-09	-0.37	-0.31	Tetralogy of Fallot;	chr3:158731978	chr3:158732263~158784070:+
LUAD	cis	rs7646881	1	rs73015652	ENSG00000240207.5	RP11-379F4.4	-7.26	1.6e-12	1.17e-09	-0.37	-0.31	Tetralogy of Fallot;	chr3:158733594	chr3:158732263~158784070:+
LUAD	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-7.26	1.6e-12	1.17e-09	-0.45	-0.31	Depression;	chr6:28173770	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-7.26	1.6e-12	1.17e-09	-0.45	-0.31	Depression;	chr6:28174809	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-7.26	1.6e-12	1.17e-09	-0.45	-0.31	Depression;	chr6:28175233	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-7.26	1.6e-12	1.17e-09	-0.45	-0.31	Depression;	chr6:28176973	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-7.26	1.6e-12	1.18e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
LUAD	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-7.26	1.6e-12	1.18e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
LUAD	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-7.26	1.61e-12	1.18e-09	-0.45	-0.31	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
LUAD	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	7.26	1.61e-12	1.18e-09	0.7	0.31	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
LUAD	cis	rs237743	1	rs35759030	ENSG00000222365.1	SNORD12B	-7.26	1.61e-12	1.18e-09	-0.36	-0.31	Height;	chr20:49241753	chr20:49280319~49280409:+
LUAD	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	7.26	1.61e-12	1.18e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
LUAD	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	7.26	1.62e-12	1.19e-09	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
LUAD	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-7.26	1.62e-12	1.19e-09	-0.43	-0.31	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
LUAD	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	7.25	1.62e-12	1.19e-09	0.41	0.31	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
LUAD	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-7.25	1.62e-12	1.19e-09	-0.44	-0.31	Depression;	chr6:28071237	chr6:28115628~28116551:+
LUAD	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-7.25	1.62e-12	1.19e-09	-0.45	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
LUAD	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-7.25	1.62e-12	1.19e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
LUAD	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	1.19e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
LUAD	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-7.25	1.63e-12	1.19e-09	-0.4	-0.31	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
LUAD	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-7.25	1.63e-12	1.2e-09	-0.37	-0.31	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
LUAD	cis	rs62229266	0.682	rs11700546	ENSG00000214914.3	RPL23AP3	7.25	1.64e-12	1.2e-09	0.4	0.31	Mitral valve prolapse;	chr21:35998841	chr21:36016079~36016546:-
LUAD	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	7.25	1.64e-12	1.2e-09	0.39	0.31	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
LUAD	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	7.25	1.64e-12	1.21e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	7.25	1.64e-12	1.21e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
LUAD	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
LUAD	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	7.25	1.65e-12	1.21e-09	0.4	0.31	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
LUAD	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-7.25	1.65e-12	1.21e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
LUAD	cis	rs9595908	0.9	rs7981943	ENSG00000212293.1	SNORA16	7.25	1.65e-12	1.21e-09	0.33	0.31	Body mass index;	chr13:32593754	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.9	rs7327429	ENSG00000212293.1	SNORA16	7.25	1.65e-12	1.21e-09	0.33	0.31	Body mass index;	chr13:32595259	chr13:32420390~32420516:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-7.25	1.65e-12	1.21e-09	-0.37	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
LUAD	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-7.25	1.66e-12	1.22e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
LUAD	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	7.25	1.67e-12	1.22e-09	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-7.25	1.67e-12	1.23e-09	-0.22	-0.31	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
LUAD	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	7.25	1.68e-12	1.23e-09	0.41	0.31	Height;	chr6:109646187	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	7.25	1.68e-12	1.23e-09	0.41	0.31	Height;	chr6:109652694	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	7.25	1.68e-12	1.23e-09	0.41	0.31	Height;	chr6:109655791	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-7.25	1.69e-12	1.24e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-7.25	1.69e-12	1.24e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-7.25	1.69e-12	1.24e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
LUAD	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	7.25	1.69e-12	1.24e-09	0.36	0.31	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
LUAD	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	7.25	1.69e-12	1.24e-09	0.36	0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
LUAD	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-7.25	1.69e-12	1.24e-09	-0.52	-0.31	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
LUAD	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-7.25	1.69e-12	1.24e-09	-0.43	-0.31	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
LUAD	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-7.25	1.7e-12	1.24e-09	-0.36	-0.31	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	7.25	1.7e-12	1.24e-09	0.33	0.31	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-7.25	1.7e-12	1.25e-09	-0.45	-0.31	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
LUAD	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-7.25	1.7e-12	1.25e-09	-0.45	-0.31	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
LUAD	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	7.25	1.7e-12	1.25e-09	0.38	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
LUAD	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	7.25	1.71e-12	1.25e-09	0.37	0.31	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
LUAD	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-7.25	1.71e-12	1.25e-09	-0.28	-0.31	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
LUAD	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	7.25	1.71e-12	1.25e-09	0.4	0.31	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
LUAD	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-7.25	1.72e-12	1.26e-09	-0.33	-0.31	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
LUAD	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	7.25	1.72e-12	1.26e-09	0.41	0.31	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
LUAD	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-7.25	1.73e-12	1.26e-09	-0.39	-0.31	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
LUAD	cis	rs10200159	1	rs10172181	ENSG00000272606.1	RP11-554J4.1	7.25	1.73e-12	1.26e-09	0.54	0.31	Vitiligo;	chr2:55664005	chr2:55617909~55618373:+
LUAD	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-7.25	1.73e-12	1.26e-09	-0.32	-0.31	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
LUAD	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-7.25	1.73e-12	1.27e-09	-0.32	-0.31	Height;	chr2:46616492	chr2:46668870~46670778:+
LUAD	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-7.24	1.73e-12	1.27e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
LUAD	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-7.24	1.74e-12	1.27e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-7.24	1.74e-12	1.27e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
LUAD	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	7.24	1.74e-12	1.27e-09	0.27	0.31	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
LUAD	cis	rs10200159	1	rs6760959	ENSG00000272606.1	RP11-554J4.1	7.24	1.74e-12	1.27e-09	0.54	0.31	Vitiligo;	chr2:55594365	chr2:55617909~55618373:+
LUAD	cis	rs10200159	1	rs111707510	ENSG00000272606.1	RP11-554J4.1	7.24	1.74e-12	1.27e-09	0.54	0.31	Vitiligo;	chr2:55597100	chr2:55617909~55618373:+
LUAD	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-7.24	1.75e-12	1.28e-09	-0.38	-0.31	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
LUAD	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-7.24	1.75e-12	1.28e-09	-0.39	-0.31	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
LUAD	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	7.24	1.75e-12	1.28e-09	0.39	0.31	Depression;	chr6:28301886	chr6:28943877~28944537:+
LUAD	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	7.24	1.75e-12	1.28e-09	0.4	0.31	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	7.24	1.76e-12	1.28e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
LUAD	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-7.24	1.76e-12	1.28e-09	-0.35	-0.31	Temperament;	chr17:13999319	chr17:14024514~14025488:+
LUAD	cis	rs9595908	0.863	rs11616287	ENSG00000212293.1	SNORA16	7.24	1.76e-12	1.29e-09	0.34	0.31	Body mass index;	chr13:32580139	chr13:32420390~32420516:-
LUAD	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	7.24	1.76e-12	1.29e-09	0.37	0.31	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	7.24	1.76e-12	1.29e-09	0.37	0.31	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	7.24	1.77e-12	1.29e-09	0.4	0.31	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
LUAD	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	7.24	1.77e-12	1.29e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
LUAD	cis	rs237743	0.928	rs237714	ENSG00000222365.1	SNORD12B	-7.24	1.77e-12	1.3e-09	-0.36	-0.31	Height;	chr20:49306363	chr20:49280319~49280409:+
LUAD	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-7.24	1.78e-12	1.3e-09	-0.45	-0.31	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
LUAD	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-7.24	1.78e-12	1.3e-09	-0.43	-0.31	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
LUAD	cis	rs4591358	0.689	rs72927780	ENSG00000223466.1	AC064834.2	-7.24	1.78e-12	1.3e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548569	chr2:195533035~195538681:+
LUAD	cis	rs8031584	0.678	rs798086	ENSG00000260382.1	RP11-540B6.2	-7.24	1.78e-12	1.3e-09	-0.4	-0.31	Huntington's disease progression;	chr15:30837008	chr15:30882267~30883231:-
LUAD	cis	rs237743	1	rs6512577	ENSG00000222365.1	SNORD12B	-7.24	1.79e-12	1.3e-09	-0.36	-0.31	Height;	chr20:49249247	chr20:49280319~49280409:+
LUAD	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	7.24	1.8e-12	1.31e-09	0.33	0.31	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
LUAD	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-7.24	1.8e-12	1.31e-09	-0.35	-0.31	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
LUAD	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	7.24	1.8e-12	1.32e-09	0.37	0.31	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
LUAD	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	7.24	1.81e-12	1.32e-09	0.36	0.31	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
LUAD	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-7.24	1.81e-12	1.32e-09	-0.32	-0.31	Height;	chr2:46615271	chr2:46668870~46670778:+
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000254174.1	IGHV1-12	7.24	1.81e-12	1.32e-09	0.31	0.31	Alzheimer's disease (late onset);	chr14:106813739	chr14:106122420~106122709:-
LUAD	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	7.24	1.82e-12	1.33e-09	0.37	0.31	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
LUAD	cis	rs75422866	0.867	rs7303895	ENSG00000280054.1	RP1-197B17.7	7.24	1.82e-12	1.33e-09	0.67	0.31	Pneumonia;	chr12:47683290	chr12:47728151~47730598:-
LUAD	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	7.24	1.82e-12	1.33e-09	0.42	0.31	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
LUAD	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	7.24	1.82e-12	1.33e-09	0.41	0.31	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
LUAD	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-7.24	1.82e-12	1.33e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000211972.2	IGHV3-66	7.24	1.82e-12	1.33e-09	0.28	0.31	Kawasaki disease;	chr14:106767990	chr14:106675017~106675544:-
LUAD	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	7.24	1.83e-12	1.33e-09	0.35	0.31	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
LUAD	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	7.24	1.83e-12	1.33e-09	0.36	0.31	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
LUAD	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	7.24	1.83e-12	1.33e-09	0.7	0.31	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
LUAD	cis	rs35955747	0.902	rs5997938	ENSG00000236132.1	CTA-440B3.1	7.24	1.84e-12	1.34e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31281006	chr22:31816379~31817491:-
LUAD	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-7.24	1.85e-12	1.34e-09	-0.36	-0.31	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
LUAD	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-7.24	1.85e-12	1.35e-09	-0.33	-0.31	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
LUAD	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-7.23	1.85e-12	1.35e-09	-0.45	-0.31	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-7.23	1.85e-12	1.35e-09	-0.45	-0.31	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
LUAD	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-7.23	1.86e-12	1.35e-09	-0.39	-0.31	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
LUAD	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-7.23	1.86e-12	1.36e-09	-0.36	-0.31	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
LUAD	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-7.23	1.86e-12	1.36e-09	-0.5	-0.31	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
LUAD	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-7.23	1.86e-12	1.36e-09	-0.37	-0.31	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
LUAD	cis	rs4591358	0.648	rs6732306	ENSG00000223466.1	AC064834.2	-7.23	1.87e-12	1.36e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541396	chr2:195533035~195538681:+
LUAD	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	7.23	1.87e-12	1.36e-09	0.41	0.31	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
LUAD	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	7.23	1.88e-12	1.37e-09	0.39	0.31	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
LUAD	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-7.23	1.88e-12	1.37e-09	-0.35	-0.31	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
LUAD	cis	rs2439831	0.681	rs511673	ENSG00000205771.5	CATSPER2P1	-7.23	1.88e-12	1.37e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43326665	chr15:43726918~43747094:-
LUAD	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	7.23	1.88e-12	1.37e-09	0.53	0.31	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
LUAD	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	7.23	1.88e-12	1.37e-09	0.32	0.31	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
LUAD	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-7.23	1.89e-12	1.37e-09	-0.35	-0.31	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
LUAD	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-7.23	1.89e-12	1.38e-09	-0.49	-0.31	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
LUAD	cis	rs2439831	0.681	rs498837	ENSG00000205771.5	CATSPER2P1	-7.23	1.9e-12	1.38e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43315826	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.681	rs540031	ENSG00000205771.5	CATSPER2P1	-7.23	1.9e-12	1.38e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43316657	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-7.23	1.9e-12	1.38e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-7.23	1.9e-12	1.38e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-7.23	1.9e-12	1.38e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-7.23	1.9e-12	1.38e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
LUAD	cis	rs2439831	0.867	rs3809481	ENSG00000205771.5	CATSPER2P1	-7.23	1.9e-12	1.38e-09	-0.59	-0.31	Lung cancer in ever smokers;	chr15:43370631	chr15:43726918~43747094:-
LUAD	cis	rs35955747	0.807	rs9619169	ENSG00000236132.1	CTA-440B3.1	7.23	1.91e-12	1.39e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31141356	chr22:31816379~31817491:-
LUAD	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-7.23	1.91e-12	1.39e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
LUAD	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-7.23	1.91e-12	1.39e-09	-0.36	-0.31	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
LUAD	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-7.23	1.91e-12	1.39e-09	-0.35	-0.31	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
LUAD	cis	rs35955747	0.902	rs5997932	ENSG00000236132.1	CTA-440B3.1	7.23	1.92e-12	1.39e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31272168	chr22:31816379~31817491:-
LUAD	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	7.23	1.92e-12	1.4e-09	0.54	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
LUAD	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	7.23	1.93e-12	1.4e-09	0.39	0.31	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
LUAD	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-7.23	1.93e-12	1.4e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-7.23	1.93e-12	1.4e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
LUAD	cis	rs35955747	0.902	rs5997929	ENSG00000236132.1	CTA-440B3.1	7.23	1.94e-12	1.41e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31268046	chr22:31816379~31817491:-
LUAD	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	7.23	1.94e-12	1.41e-09	0.45	0.31	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
LUAD	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	7.23	1.94e-12	1.41e-09	0.37	0.31	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
LUAD	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	7.23	1.94e-12	1.41e-09	0.53	0.31	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	7.23	1.94e-12	1.41e-09	0.53	0.31	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
LUAD	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	7.23	1.94e-12	1.41e-09	0.37	0.31	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
LUAD	cis	rs1345301	1	rs13405355	ENSG00000234389.1	AC007278.3	-7.23	1.94e-12	1.41e-09	-0.28	-0.31	Waist circumference;	chr2:102261746	chr2:102438713~102440475:+
LUAD	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	7.23	1.94e-12	1.41e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	7.23	1.94e-12	1.41e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	7.23	1.94e-12	1.41e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
LUAD	cis	rs4141404	0.604	rs5753625	ENSG00000236132.1	CTA-440B3.1	7.23	1.94e-12	1.41e-09	0.36	0.31	Paclitaxel-induced neuropathy;	chr22:31458860	chr22:31816379~31817491:-
LUAD	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
LUAD	cis	rs9549367	0.713	rs3024743	ENSG00000269125.1	RP11-98F14.11	-7.23	1.95e-12	1.42e-09	-0.41	-0.31	Platelet distribution width;	chr13:113167116	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs3024744	ENSG00000269125.1	RP11-98F14.11	-7.23	1.95e-12	1.42e-09	-0.41	-0.31	Platelet distribution width;	chr13:113167163	chr13:113165002~113165183:-
LUAD	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-7.23	1.95e-12	1.42e-09	-0.33	-0.31	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
LUAD	cis	rs35955747	0.902	rs7288643	ENSG00000236132.1	CTA-440B3.1	7.23	1.96e-12	1.42e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283683	chr22:31816379~31817491:-
LUAD	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-7.23	1.96e-12	1.42e-09	-0.37	-0.31	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
LUAD	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	7.23	1.96e-12	1.42e-09	0.37	0.31	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
LUAD	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	7.23	1.96e-12	1.43e-09	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
LUAD	cis	rs9834970	0.566	rs4328757	ENSG00000234073.1	AC011816.1	-7.23	1.97e-12	1.43e-09	-0.34	-0.31	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36896689	chr3:36880184~36880729:-
LUAD	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	7.23	1.97e-12	1.43e-09	0.31	0.31	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
LUAD	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	7.23	1.97e-12	1.43e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-7.23	1.97e-12	1.43e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-7.23	1.97e-12	1.43e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-7.23	1.97e-12	1.43e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
LUAD	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-7.23	1.98e-12	1.43e-09	-0.31	-0.31	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
LUAD	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-7.23	1.98e-12	1.43e-09	-0.36	-0.31	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
LUAD	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.41	0.31	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.41	0.31	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.41	0.31	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.41	0.31	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
LUAD	cis	rs8177876	0.57	rs11863158	ENSG00000261838.4	RP11-303E16.6	7.22	1.98e-12	1.44e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr16:81069854~81076598:+
LUAD	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-7.22	1.98e-12	1.44e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
LUAD	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.39	0.31	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-7.22	1.98e-12	1.44e-09	-0.22	-0.31	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
LUAD	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-7.22	1.99e-12	1.45e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-7.22	1.99e-12	1.45e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-7.22	1.99e-12	1.45e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-7.22	1.99e-12	1.45e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
LUAD	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-7.22	2e-12	1.45e-09	-0.37	-0.31	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
LUAD	cis	rs35955747	0.869	rs5997909	ENSG00000236132.1	CTA-440B3.1	7.22	2e-12	1.45e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31195242	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.871	rs2013254	ENSG00000236132.1	CTA-440B3.1	7.22	2e-12	1.45e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31294817	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.902	rs12167361	ENSG00000236132.1	CTA-440B3.1	7.22	2e-12	1.45e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31300292	chr22:31816379~31817491:-
LUAD	cis	rs9595908	0.965	rs4941612	ENSG00000212293.1	SNORA16	7.22	2e-12	1.45e-09	0.36	0.31	Body mass index;	chr13:32549791	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs12323094	ENSG00000212293.1	SNORA16	7.22	2e-12	1.45e-09	0.36	0.31	Body mass index;	chr13:32569227	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs12323101	ENSG00000212293.1	SNORA16	7.22	2e-12	1.45e-09	0.36	0.31	Body mass index;	chr13:32569269	chr13:32420390~32420516:-
LUAD	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	7.22	2e-12	1.45e-09	0.41	0.31	Height;	chr6:109497088	chr6:109382795~109383666:+
LUAD	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	7.22	2e-12	1.45e-09	0.36	0.31	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
LUAD	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-7.22	2.01e-12	1.46e-09	-0.34	-0.31	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
LUAD	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-7.22	2.01e-12	1.46e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-7.22	2.01e-12	1.46e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
LUAD	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-7.22	2.01e-12	1.46e-09	-0.37	-0.31	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
LUAD	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-7.22	2.01e-12	1.46e-09	-0.39	-0.31	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
LUAD	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-7.22	2.02e-12	1.46e-09	-0.48	-0.31	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
LUAD	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	7.22	2.02e-12	1.46e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
LUAD	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-7.22	2.02e-12	1.46e-09	-0.32	-0.31	Gout;	chr7:66671562	chr7:66902857~66906297:+
LUAD	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-7.22	2.02e-12	1.46e-09	-0.49	-0.31	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000224373.3	IGHV4-59	7.22	2.02e-12	1.47e-09	0.19	0.31	Kawasaki disease;	chr14:106681814	chr14:106627249~106627825:-
LUAD	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-7.22	2.03e-12	1.47e-09	-0.38	-0.31	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
LUAD	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-7.22	2.04e-12	1.48e-09	-0.37	-0.31	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
LUAD	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	7.22	2.04e-12	1.48e-09	0.71	0.31	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
LUAD	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-7.22	2.04e-12	1.48e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
LUAD	cis	rs10899021	0.92	rs7122710	ENSG00000279353.1	RP11-864N7.4	7.22	2.05e-12	1.48e-09	0.56	0.31	Response to metformin (IC50);	chr11:74612130	chr11:74698231~74699658:-
LUAD	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	7.22	2.06e-12	1.49e-09	0.32	0.31	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
LUAD	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-7.22	2.06e-12	1.49e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
LUAD	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-7.22	2.07e-12	1.5e-09	-0.44	-0.31	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
LUAD	cis	rs2842992	0.724	rs4709368	ENSG00000237927.1	RP3-393E18.2	7.22	2.07e-12	1.5e-09	0.43	0.31	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159586955~159589169:-
LUAD	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-7.22	2.07e-12	1.5e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
LUAD	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-7.22	2.07e-12	1.5e-09	-0.43	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
LUAD	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-7.22	2.07e-12	1.5e-09	-0.39	-0.31	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	7.22	2.08e-12	1.5e-09	0.41	0.31	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
LUAD	cis	rs9595908	0.965	rs1123462	ENSG00000212293.1	SNORA16	7.22	2.08e-12	1.5e-09	0.36	0.31	Body mass index;	chr13:32571325	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.897	rs12429688	ENSG00000212293.1	SNORA16	7.22	2.08e-12	1.5e-09	0.36	0.31	Body mass index;	chr13:32572075	chr13:32420390~32420516:-
LUAD	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	7.22	2.08e-12	1.51e-09	0.4	0.31	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
LUAD	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	7.22	2.08e-12	1.51e-09	0.36	0.31	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
LUAD	cis	rs35955747	0.87	rs7289189	ENSG00000236132.1	CTA-440B3.1	7.22	2.08e-12	1.51e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31261196	chr22:31816379~31817491:-
LUAD	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-7.22	2.09e-12	1.51e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
LUAD	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-7.22	2.09e-12	1.51e-09	-0.37	-0.31	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-7.22	2.09e-12	1.51e-09	-0.37	-0.31	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-7.22	2.09e-12	1.51e-09	-0.37	-0.31	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
LUAD	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	7.22	2.09e-12	1.51e-09	0.38	0.31	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
LUAD	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-7.22	2.09e-12	1.51e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
LUAD	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-7.22	2.09e-12	1.51e-09	-0.39	-0.31	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
LUAD	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	7.22	2.09e-12	1.52e-09	0.41	0.31	Height;	chr6:109494148	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	7.22	2.09e-12	1.52e-09	0.41	0.31	Height;	chr6:109494760	chr6:109382795~109383666:+
LUAD	cis	rs5753618	0.504	rs5749295	ENSG00000236132.1	CTA-440B3.1	-7.22	2.09e-12	1.52e-09	-0.37	-0.31	Colorectal cancer;	chr22:31536909	chr22:31816379~31817491:-
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000280411.1	IGHV1-69-2	7.22	2.1e-12	1.52e-09	0.24	0.31	Kawasaki disease;	chr14:106684476	chr14:106762092~106762588:-
LUAD	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-7.22	2.1e-12	1.52e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
LUAD	cis	rs62229266	0.659	rs2026259	ENSG00000214914.3	RPL23AP3	7.22	2.11e-12	1.52e-09	0.36	0.31	Mitral valve prolapse;	chr21:36058329	chr21:36016079~36016546:-
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000280411.1	IGHV1-69-2	-7.22	2.11e-12	1.52e-09	-0.24	-0.31	Kawasaki disease;	chr14:106767441	chr14:106762092~106762588:-
LUAD	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-7.22	2.11e-12	1.53e-09	-0.33	-0.31	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-7.21	2.12e-12	1.53e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
LUAD	cis	rs10200159	1	rs10195281	ENSG00000272606.1	RP11-554J4.1	7.21	2.13e-12	1.54e-09	0.54	0.31	Vitiligo;	chr2:55620886	chr2:55617909~55618373:+
LUAD	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-7.21	2.13e-12	1.54e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
LUAD	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	7.21	2.13e-12	1.54e-09	0.41	0.31	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
LUAD	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	7.21	2.13e-12	1.54e-09	0.31	0.31	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000211970.3	IGHV4-61	-7.21	2.13e-12	1.54e-09	-0.22	-0.31	Kawasaki disease;	chr14:106781490	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000280411.1	IGHV1-69-2	-7.21	2.14e-12	1.54e-09	-0.24	-0.31	Kawasaki disease;	chr14:106787730	chr14:106762092~106762588:-
LUAD	cis	rs10200159	0.744	rs75365186	ENSG00000272606.1	RP11-554J4.1	7.21	2.14e-12	1.55e-09	0.55	0.31	Vitiligo;	chr2:55575834	chr2:55617909~55618373:+
LUAD	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-7.21	2.15e-12	1.55e-09	-0.33	-0.31	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
LUAD	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	7.21	2.16e-12	1.56e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	7.21	2.16e-12	1.56e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	7.21	2.16e-12	1.56e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	7.21	2.16e-12	1.56e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
LUAD	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-7.21	2.16e-12	1.56e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
LUAD	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-7.21	2.17e-12	1.57e-09	-0.62	-0.31	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
LUAD	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-7.21	2.17e-12	1.57e-09	-0.37	-0.31	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	7.21	2.17e-12	1.57e-09	0.41	0.31	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
LUAD	cis	rs10899021	0.92	rs11236171	ENSG00000279353.1	RP11-864N7.4	7.21	2.18e-12	1.57e-09	0.56	0.31	Response to metformin (IC50);	chr11:74606473	chr11:74698231~74699658:-
LUAD	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-7.21	2.18e-12	1.57e-09	-0.44	-0.31	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
LUAD	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	7.21	2.18e-12	1.57e-09	0.35	0.31	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
LUAD	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	7.21	2.18e-12	1.58e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
LUAD	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-7.21	2.18e-12	1.58e-09	-0.37	-0.31	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-7.21	2.18e-12	1.58e-09	-0.37	-0.31	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	7.21	2.21e-12	1.6e-09	0.41	0.31	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	7.21	2.21e-12	1.6e-09	0.41	0.31	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
LUAD	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-7.21	2.22e-12	1.6e-09	-0.46	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
LUAD	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-7.21	2.22e-12	1.6e-09	-0.49	-0.31	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
LUAD	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	7.21	2.22e-12	1.6e-09	0.37	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
LUAD	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	7.21	2.22e-12	1.6e-09	0.37	0.31	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
LUAD	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-7.21	2.22e-12	1.61e-09	-0.44	-0.31	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
LUAD	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	7.21	2.23e-12	1.61e-09	0.37	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
LUAD	cis	rs10899021	0.92	rs61901540	ENSG00000279353.1	RP11-864N7.4	7.21	2.23e-12	1.61e-09	0.56	0.31	Response to metformin (IC50);	chr11:74603820	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.92	rs61901541	ENSG00000279353.1	RP11-864N7.4	7.21	2.23e-12	1.61e-09	0.56	0.31	Response to metformin (IC50);	chr11:74606940	chr11:74698231~74699658:-
LUAD	cis	rs10200159	1	rs6717574	ENSG00000272606.1	RP11-554J4.1	7.21	2.24e-12	1.61e-09	0.54	0.31	Vitiligo;	chr2:55594710	chr2:55617909~55618373:+
LUAD	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	7.21	2.24e-12	1.62e-09	0.4	0.31	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	7.21	2.24e-12	1.62e-09	0.4	0.31	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000211970.3	IGHV4-61	-7.21	2.24e-12	1.62e-09	-0.22	-0.31	Kawasaki disease;	chr14:106782288	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000211972.2	IGHV3-66	7.21	2.24e-12	1.62e-09	0.28	0.31	Kawasaki disease;	chr14:106813798	chr14:106675017~106675544:-
LUAD	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	7.21	2.24e-12	1.62e-09	0.37	0.31	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
LUAD	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-7.21	2.24e-12	1.62e-09	-0.36	-0.31	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
LUAD	cis	rs1426063	0.8	rs28861517	ENSG00000249717.1	RP11-44F21.3	7.21	2.25e-12	1.62e-09	0.45	0.31	QT interval;	chr4:75092995	chr4:74955974~74970362:-
LUAD	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	7.21	2.25e-12	1.62e-09	0.37	0.31	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
LUAD	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	7.21	2.25e-12	1.62e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
LUAD	cis	rs62229266	0.804	rs2835263	ENSG00000214914.3	RPL23AP3	-7.2	2.26e-12	1.63e-09	-0.38	-0.31	Mitral valve prolapse;	chr21:36057947	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	7.2	2.27e-12	1.63e-09	0.4	0.31	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.27e-12	1.63e-09	-0.33	-0.31	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
LUAD	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-7.2	2.27e-12	1.64e-09	-0.36	-0.31	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
LUAD	cis	rs35955747	0.902	rs2413048	ENSG00000236132.1	CTA-440B3.1	7.2	2.28e-12	1.64e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31290116	chr22:31816379~31817491:-
LUAD	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
LUAD	cis	rs1322639	1	rs1322639	ENSG00000261039.2	RP11-417E7.2	7.2	2.29e-12	1.65e-09	0.44	0.31	Pulse pressure;	chr6:169187008	chr6:169175304~169182740:-
LUAD	cis	rs1322639	1	rs9689079	ENSG00000261039.2	RP11-417E7.2	7.2	2.29e-12	1.65e-09	0.44	0.31	Pulse pressure;	chr6:169187053	chr6:169175304~169182740:-
LUAD	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	7.2	2.3e-12	1.66e-09	0.44	0.31	Depression;	chr6:28142370	chr6:28115628~28116551:+
LUAD	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-7.2	2.3e-12	1.66e-09	-0.37	-0.31	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
LUAD	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-7.2	2.3e-12	1.66e-09	-0.42	-0.31	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
LUAD	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-7.2	2.31e-12	1.66e-09	-0.36	-0.31	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
LUAD	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-7.2	2.31e-12	1.66e-09	-0.38	-0.31	Height;	chr6:109432968	chr6:109382795~109383666:+
LUAD	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-7.2	2.31e-12	1.66e-09	-0.38	-0.31	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
LUAD	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-7.2	2.31e-12	1.66e-09	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
LUAD	cis	rs237743	1	rs237711	ENSG00000222365.1	SNORD12B	-7.2	2.32e-12	1.67e-09	-0.35	-0.31	Height;	chr20:49310319	chr20:49280319~49280409:+
LUAD	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-7.2	2.32e-12	1.67e-09	-0.54	-0.31	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
LUAD	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-7.2	2.33e-12	1.67e-09	-0.45	-0.31	Depression;	chr6:28145952	chr6:28115628~28116551:+
LUAD	cis	rs7646881	1	rs73015649	ENSG00000240207.5	RP11-379F4.4	-7.2	2.33e-12	1.67e-09	-0.38	-0.31	Tetralogy of Fallot;	chr3:158732509	chr3:158732263~158784070:+
LUAD	cis	rs2439831	0.867	rs7170489	ENSG00000205771.5	CATSPER2P1	-7.2	2.34e-12	1.68e-09	-0.55	-0.31	Lung cancer in ever smokers;	chr15:43344453	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs16957630	ENSG00000205771.5	CATSPER2P1	-7.2	2.34e-12	1.68e-09	-0.55	-0.31	Lung cancer in ever smokers;	chr15:43350582	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs16957632	ENSG00000205771.5	CATSPER2P1	-7.2	2.34e-12	1.68e-09	-0.55	-0.31	Lung cancer in ever smokers;	chr15:43350699	chr15:43726918~43747094:-
LUAD	cis	rs10200159	1	rs10200159	ENSG00000272606.1	RP11-554J4.1	7.2	2.34e-12	1.68e-09	0.53	0.31	Vitiligo;	chr2:55617974	chr2:55617909~55618373:+
LUAD	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	7.2	2.34e-12	1.68e-09	0.4	0.31	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000280411.1	IGHV1-69-2	-7.2	2.34e-12	1.69e-09	-0.24	-0.31	Kawasaki disease;	chr14:106799304	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000280411.1	IGHV1-69-2	-7.2	2.35e-12	1.69e-09	-0.24	-0.31	Kawasaki disease;	chr14:106787630	chr14:106762092~106762588:-
LUAD	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
LUAD	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-7.2	2.37e-12	1.7e-09	-0.36	-0.31	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
LUAD	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	7.2	2.37e-12	1.7e-09	0.4	0.31	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000211972.2	IGHV3-66	7.2	2.38e-12	1.71e-09	0.28	0.31	Kawasaki disease;	chr14:106718572	chr14:106675017~106675544:-
LUAD	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-7.2	2.39e-12	1.72e-09	-0.38	-0.31	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
LUAD	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-7.2	2.39e-12	1.72e-09	-0.39	-0.31	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
LUAD	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-7.2	2.39e-12	1.72e-09	-0.36	-0.31	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-7.2	2.39e-12	1.72e-09	-0.36	-0.31	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-7.2	2.39e-12	1.72e-09	-0.36	-0.31	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
LUAD	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.39e-12	1.72e-09	-0.32	-0.31	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-7.2	2.4e-12	1.72e-09	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
LUAD	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-7.2	2.4e-12	1.72e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
LUAD	cis	rs237743	1	rs3021	ENSG00000222365.1	SNORD12B	-7.2	2.4e-12	1.72e-09	-0.36	-0.31	Height;	chr20:49257468	chr20:49280319~49280409:+
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000206090.4	AP000350.7	7.2	2.4e-12	1.73e-09	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23939998~23942798:+
LUAD	cis	rs950880	0.71	rs12905	ENSG00000234389.1	AC007278.3	-7.2	2.41e-12	1.73e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102343547	chr2:102438713~102440475:+
LUAD	cis	rs4591358	0.53	rs72927723	ENSG00000223466.1	AC064834.2	-7.19	2.41e-12	1.73e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522498	chr2:195533035~195538681:+
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	7.19	2.42e-12	1.73e-09	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
LUAD	cis	rs10899021	0.92	rs10899014	ENSG00000279353.1	RP11-864N7.4	7.19	2.42e-12	1.73e-09	0.56	0.31	Response to metformin (IC50);	chr11:74614064	chr11:74698231~74699658:-
LUAD	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-7.19	2.42e-12	1.74e-09	-0.3	-0.31	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
LUAD	cis	rs9595908	0.827	rs7321262	ENSG00000212293.1	SNORA16	7.19	2.43e-12	1.74e-09	0.33	0.31	Body mass index;	chr13:32597942	chr13:32420390~32420516:-
LUAD	cis	rs62229266	0.804	rs62230788	ENSG00000214914.3	RPL23AP3	7.19	2.43e-12	1.75e-09	0.39	0.31	Mitral valve prolapse;	chr21:36008039	chr21:36016079~36016546:-
LUAD	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
LUAD	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-7.19	2.45e-12	1.75e-09	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-7.19	2.45e-12	1.75e-09	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
LUAD	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	7.19	2.46e-12	1.76e-09	0.51	0.31	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
LUAD	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	7.19	2.46e-12	1.76e-09	0.51	0.31	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
LUAD	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	7.19	2.46e-12	1.76e-09	0.51	0.31	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
LUAD	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	7.19	2.46e-12	1.76e-09	0.43	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	7.19	2.46e-12	1.76e-09	0.43	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
LUAD	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-7.19	2.46e-12	1.77e-09	-0.4	-0.31	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-7.19	2.46e-12	1.77e-09	-0.32	-0.31	Gout;	chr7:66654674	chr7:66902857~66906297:+
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-7.19	2.46e-12	1.77e-09	-0.32	-0.31	Gout;	chr7:66661502	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	7.19	2.46e-12	1.77e-09	0.37	0.31	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000280411.1	IGHV1-69-2	-7.19	2.47e-12	1.77e-09	-0.24	-0.31	Kawasaki disease;	chr14:106708947	chr14:106762092~106762588:-
LUAD	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-7.19	2.47e-12	1.77e-09	-0.37	-0.31	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-7.19	2.47e-12	1.77e-09	-0.37	-0.31	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
LUAD	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-7.19	2.48e-12	1.78e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-7.19	2.48e-12	1.78e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
LUAD	cis	rs8031584	0.678	rs798125	ENSG00000260382.1	RP11-540B6.2	-7.19	2.48e-12	1.78e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30824597	chr15:30882267~30883231:-
LUAD	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-7.19	2.48e-12	1.78e-09	-0.37	-0.31	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
LUAD	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	7.19	2.48e-12	1.78e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
LUAD	cis	rs6487679	1	rs7298108	ENSG00000111788.10	RP11-22B23.1	-7.19	2.49e-12	1.78e-09	-0.31	-0.31	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9277235~9313241:+
LUAD	cis	rs7044106	0.791	rs10985008	ENSG00000238181.2	AHCYP2	-7.19	2.49e-12	1.78e-09	-0.41	-0.31	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120720673~120721972:+
LUAD	cis	rs8177876	0.658	rs11150337	ENSG00000261838.4	RP11-303E16.6	7.19	2.49e-12	1.78e-09	0.66	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81069854~81076598:+
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-7.19	2.49e-12	1.79e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
LUAD	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-7.19	2.5e-12	1.79e-09	-0.35	-0.31	Height;	chr20:49235382	chr20:49280319~49280409:+
LUAD	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	7.19	2.5e-12	1.79e-09	0.4	0.31	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
LUAD	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	7.19	2.5e-12	1.79e-09	0.4	0.31	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-7.19	2.51e-12	1.79e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000206090.4	AP000350.7	7.19	2.51e-12	1.79e-09	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23939998~23942798:+
LUAD	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	7.19	2.51e-12	1.8e-09	0.4	0.31	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
LUAD	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	7.19	2.51e-12	1.8e-09	0.56	0.31	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
LUAD	cis	rs7646881	1	rs73015654	ENSG00000240207.5	RP11-379F4.4	-7.19	2.51e-12	1.8e-09	-0.38	-0.31	Tetralogy of Fallot;	chr3:158733865	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.953	rs73015657	ENSG00000240207.5	RP11-379F4.4	-7.19	2.51e-12	1.8e-09	-0.38	-0.31	Tetralogy of Fallot;	chr3:158734143	chr3:158732263~158784070:+
LUAD	cis	rs8040855	0.644	rs4635318	ENSG00000259774.1	RP11-182J1.13	-7.19	2.52e-12	1.8e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85183506	chr15:84422618~84425882:+
LUAD	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	7.19	2.52e-12	1.8e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
LUAD	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	7.19	2.53e-12	1.81e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
LUAD	cis	rs17684571	0.938	rs56101897	ENSG00000231441.1	RP11-472M19.2	7.19	2.54e-12	1.82e-09	0.43	0.31	Schizophrenia;	chr6:56687628	chr6:56844002~56864078:+
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000211972.2	IGHV3-66	7.19	2.55e-12	1.82e-09	0.27	0.31	Kawasaki disease;	chr14:106779660	chr14:106675017~106675544:-
LUAD	cis	rs8031584	0.578	rs1088473	ENSG00000260382.1	RP11-540B6.2	-7.19	2.55e-12	1.83e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30847095	chr15:30882267~30883231:-
LUAD	cis	rs35955747	0.869	rs9621216	ENSG00000236132.1	CTA-440B3.1	7.19	2.56e-12	1.83e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31194222	chr22:31816379~31817491:-
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000280411.1	IGHV1-69-2	-7.19	2.56e-12	1.83e-09	-0.24	-0.31	Kawasaki disease;	chr14:106803901	chr14:106762092~106762588:-
LUAD	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-7.19	2.56e-12	1.83e-09	-0.28	-0.31	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
LUAD	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.56e-12	1.83e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
LUAD	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-7.19	2.57e-12	1.83e-09	-0.28	-0.31	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
LUAD	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	7.19	2.57e-12	1.84e-09	0.4	0.31	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
LUAD	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-7.19	2.57e-12	1.84e-09	-0.34	-0.31	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
LUAD	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	7.19	2.58e-12	1.84e-09	0.27	0.31	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	7.19	2.58e-12	1.84e-09	0.27	0.31	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
LUAD	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-7.18	2.58e-12	1.85e-09	-0.42	-0.31	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000211972.2	IGHV3-66	7.18	2.59e-12	1.85e-09	0.27	0.31	Kawasaki disease;	chr14:106776558	chr14:106675017~106675544:-
LUAD	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.59e-12	1.85e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.59e-12	1.85e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
LUAD	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-7.18	2.59e-12	1.85e-09	-0.4	-0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
LUAD	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-7.18	2.59e-12	1.85e-09	-0.39	-0.31	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-7.18	2.6e-12	1.85e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
LUAD	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-7.18	2.6e-12	1.86e-09	-0.37	-0.31	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
LUAD	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-7.18	2.6e-12	1.86e-09	-0.41	-0.31	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
LUAD	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	7.18	2.6e-12	1.86e-09	0.4	0.31	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	7.18	2.6e-12	1.86e-09	0.4	0.31	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	7.18	2.6e-12	1.86e-09	0.4	0.31	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
LUAD	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-7.18	2.61e-12	1.86e-09	-0.38	-0.31	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
LUAD	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-7.18	2.61e-12	1.86e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-7.18	2.61e-12	1.86e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
LUAD	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	7.18	2.61e-12	1.86e-09	0.57	0.31	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	7.18	2.63e-12	1.88e-09	0.37	0.31	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
LUAD	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.63e-12	1.88e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.63e-12	1.88e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.63e-12	1.88e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
LUAD	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-7.18	2.64e-12	1.88e-09	-0.33	-0.31	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
LUAD	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-7.18	2.65e-12	1.89e-09	-0.41	-0.31	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
LUAD	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-7.18	2.65e-12	1.89e-09	-0.33	-0.31	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
LUAD	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	7.18	2.65e-12	1.89e-09	0.45	0.31	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
LUAD	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	7.18	2.65e-12	1.89e-09	0.44	0.31	Depression;	chr6:28086929	chr6:28115628~28116551:+
LUAD	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-7.18	2.65e-12	1.89e-09	-0.39	-0.31	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
LUAD	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	7.18	2.67e-12	1.9e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
LUAD	cis	rs9326248	0.731	rs90192	ENSG00000280143.1	AP000892.6	7.18	2.67e-12	1.9e-09	0.45	0.31	Blood protein levels;	chr11:117188631	chr11:117204967~117210292:+
LUAD	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	7.18	2.67e-12	1.91e-09	0.37	0.31	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
LUAD	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-7.18	2.67e-12	1.91e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	7.18	2.68e-12	1.91e-09	0.4	0.31	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
LUAD	cis	rs7646881	1	rs7646987	ENSG00000240207.5	RP11-379F4.4	7.18	2.68e-12	1.91e-09	0.37	0.31	Tetralogy of Fallot;	chr3:158735653	chr3:158732263~158784070:+
LUAD	cis	rs2439831	0.867	rs8039638	ENSG00000205771.5	CATSPER2P1	-7.18	2.68e-12	1.91e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43342207	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs28415933	ENSG00000205771.5	CATSPER2P1	-7.18	2.68e-12	1.91e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43343602	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs12324572	ENSG00000205771.5	CATSPER2P1	-7.18	2.68e-12	1.91e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43344002	chr15:43726918~43747094:-
LUAD	cis	rs9326248	0.53	rs900012	ENSG00000280143.1	AP000892.6	7.18	2.68e-12	1.91e-09	0.47	0.31	Blood protein levels;	chr11:117095719	chr11:117204967~117210292:+
LUAD	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.69e-12	1.92e-09	-0.32	-0.31	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.69e-12	1.92e-09	-0.32	-0.31	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
LUAD	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-7.18	2.69e-12	1.92e-09	-0.49	-0.31	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
LUAD	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	7.18	2.7e-12	1.92e-09	0.41	0.31	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
LUAD	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	7.18	2.71e-12	1.94e-09	0.27	0.31	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
LUAD	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-7.18	2.72e-12	1.94e-09	-0.41	-0.31	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
LUAD	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.72e-12	1.94e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
LUAD	cis	rs35955747	0.869	rs34873968	ENSG00000236132.1	CTA-440B3.1	7.18	2.72e-12	1.94e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31185787	chr22:31816379~31817491:-
LUAD	cis	rs4591358	0.689	rs2102745	ENSG00000223466.1	AC064834.2	-7.18	2.73e-12	1.94e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559315	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.638	rs6704955	ENSG00000223466.1	AC064834.2	-7.18	2.73e-12	1.94e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559393	chr2:195533035~195538681:+
LUAD	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-7.18	2.73e-12	1.94e-09	-0.36	-0.31	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
LUAD	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	7.18	2.73e-12	1.95e-09	0.32	0.31	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	7.18	2.73e-12	1.95e-09	0.32	0.31	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
LUAD	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	7.18	2.73e-12	1.95e-09	0.41	0.31	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
LUAD	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	7.18	2.74e-12	1.95e-09	0.33	0.31	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
LUAD	cis	rs8040855	0.644	rs7495437	ENSG00000259774.1	RP11-182J1.13	-7.18	2.74e-12	1.95e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85183059	chr15:84422618~84425882:+
LUAD	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	7.18	2.75e-12	1.96e-09	0.4	0.31	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
LUAD	cis	rs10129255	1	rs10137758	ENSG00000280411.1	IGHV1-69-2	-7.18	2.75e-12	1.96e-09	-0.24	-0.31	Kawasaki disease;	chr14:106697673	chr14:106762092~106762588:-
LUAD	cis	rs75422866	0.867	rs117388682	ENSG00000274902.1	RP1-197B17.4	7.18	2.75e-12	1.96e-09	0.7	0.31	Pneumonia;	chr12:47599713	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	7.18	2.75e-12	1.96e-09	0.7	0.31	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
LUAD	cis	rs1322639	0.806	rs1322640	ENSG00000261039.2	RP11-417E7.2	7.17	2.75e-12	1.96e-09	0.44	0.31	Pulse pressure;	chr6:169186792	chr6:169175304~169182740:-
LUAD	cis	rs950880	0.71	rs873022	ENSG00000234389.1	AC007278.3	-7.17	2.76e-12	1.97e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102339223	chr2:102438713~102440475:+
LUAD	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	7.17	2.76e-12	1.97e-09	0.4	0.31	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
LUAD	cis	rs4141404	0.757	rs5749272	ENSG00000236132.1	CTA-440B3.1	7.17	2.76e-12	1.97e-09	0.35	0.31	Paclitaxel-induced neuropathy;	chr22:31434365	chr22:31816379~31817491:-
LUAD	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	7.17	2.78e-12	1.98e-09	0.43	0.31	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	7.17	2.78e-12	1.98e-09	0.4	0.31	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
LUAD	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-7.17	2.78e-12	1.98e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
LUAD	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	7.17	2.79e-12	1.98e-09	0.31	0.31	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
LUAD	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-7.17	2.8e-12	1.99e-09	-0.33	-0.31	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000280411.1	IGHV1-69-2	-7.17	2.8e-12	1.99e-09	-0.24	-0.31	Kawasaki disease;	chr14:106711377	chr14:106762092~106762588:-
LUAD	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-7.17	2.8e-12	1.99e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-7.17	2.8e-12	1.99e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
LUAD	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-7.17	2.8e-12	1.99e-09	-0.49	-0.31	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
LUAD	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-7.17	2.81e-12	2e-09	-0.35	-0.31	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
LUAD	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-7.17	2.81e-12	2e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
LUAD	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	7.17	2.82e-12	2e-09	0.72	0.31	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	7.17	2.82e-12	2e-09	0.72	0.31	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	7.17	2.82e-12	2e-09	0.72	0.31	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	7.17	2.82e-12	2e-09	0.72	0.31	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
LUAD	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-7.17	2.82e-12	2.01e-09	-0.41	-0.31	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
LUAD	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-7.17	2.82e-12	2.01e-09	-0.38	-0.31	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
LUAD	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	7.17	2.82e-12	2.01e-09	0.43	0.31	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	7.17	2.82e-12	2.01e-09	0.43	0.31	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	7.17	2.82e-12	2.01e-09	0.43	0.31	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	7.17	2.82e-12	2.01e-09	0.43	0.31	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
LUAD	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-7.17	2.82e-12	2.01e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
LUAD	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	7.17	2.83e-12	2.02e-09	0.42	0.31	Height;	chr6:109694672	chr6:109382795~109383666:+
LUAD	cis	rs35955747	0.869	rs8143002	ENSG00000236132.1	CTA-440B3.1	7.17	2.84e-12	2.02e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191205	chr22:31816379~31817491:-
LUAD	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-7.17	2.84e-12	2.02e-09	-0.34	-0.31	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
LUAD	cis	rs9326248	0.53	rs511676	ENSG00000280143.1	AP000892.6	7.17	2.84e-12	2.02e-09	0.49	0.31	Blood protein levels;	chr11:116954168	chr11:117204967~117210292:+
LUAD	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-7.17	2.84e-12	2.02e-09	-0.37	-0.31	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
LUAD	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-7.17	2.84e-12	2.02e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
LUAD	cis	rs8031584	0.697	rs798080	ENSG00000260382.1	RP11-540B6.2	-7.17	2.85e-12	2.02e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30829966	chr15:30882267~30883231:-
LUAD	cis	rs62229266	0.839	rs11702763	ENSG00000214914.3	RPL23AP3	7.17	2.85e-12	2.02e-09	0.38	0.31	Mitral valve prolapse;	chr21:36098406	chr21:36016079~36016546:-
LUAD	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	7.17	2.85e-12	2.02e-09	0.42	0.31	Height;	chr6:109693890	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	7.17	2.85e-12	2.03e-09	0.4	0.31	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
LUAD	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	7.17	2.85e-12	2.03e-09	0.41	0.31	Height;	chr6:109706740	chr6:109382795~109383666:+
LUAD	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	7.17	2.85e-12	2.03e-09	0.3	0.31	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
LUAD	cis	rs904251	0.507	rs11756941	ENSG00000204110.6	RP1-153P14.8	-7.17	2.86e-12	2.03e-09	-0.39	-0.31	Cognitive performance;	chr6:37448443	chr6:37507348~37535616:+
LUAD	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-7.17	2.86e-12	2.03e-09	-0.44	-0.31	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
LUAD	cis	rs10899021	1	rs61900636	ENSG00000279353.1	RP11-864N7.4	7.17	2.86e-12	2.03e-09	0.57	0.31	Response to metformin (IC50);	chr11:74648546	chr11:74698231~74699658:-
LUAD	cis	rs1345301	0.905	rs2310243	ENSG00000234389.1	AC007278.3	-7.17	2.86e-12	2.03e-09	-0.28	-0.31	Waist circumference;	chr2:102261100	chr2:102438713~102440475:+
LUAD	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-7.17	2.86e-12	2.04e-09	-0.43	-0.31	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
LUAD	cis	rs35955747	0.869	rs131213	ENSG00000236132.1	CTA-440B3.1	-7.17	2.87e-12	2.04e-09	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31357863	chr22:31816379~31817491:-
LUAD	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-7.17	2.87e-12	2.04e-09	-0.37	-0.31	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-7.17	2.87e-12	2.04e-09	-0.37	-0.31	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-7.17	2.87e-12	2.04e-09	-0.37	-0.31	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-7.17	2.87e-12	2.04e-09	-0.36	-0.31	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
LUAD	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	7.17	2.87e-12	2.04e-09	0.3	0.31	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
LUAD	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	7.17	2.89e-12	2.06e-09	0.43	0.31	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
LUAD	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	7.17	2.9e-12	2.06e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
LUAD	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	7.17	2.91e-12	2.07e-09	0.36	0.31	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
LUAD	cis	rs2439831	0.867	rs2412780	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43363596	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2412779	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43363729	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2899082	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43363845	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs4583210	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43368727	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs28461955	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43369261	chr15:43726918~43747094:-
LUAD	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-7.17	2.92e-12	2.07e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
LUAD	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	7.17	2.93e-12	2.08e-09	0.29	0.31	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
LUAD	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-7.17	2.93e-12	2.08e-09	-0.32	-0.31	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
LUAD	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	7.17	2.94e-12	2.09e-09	0.4	0.31	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-7.16	2.94e-12	2.09e-09	-0.37	-0.31	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
LUAD	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	7.16	2.94e-12	2.09e-09	0.56	0.31	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
LUAD	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-7.16	2.96e-12	2.1e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
LUAD	cis	rs7246657	0.653	rs4805208	ENSG00000276846.1	CTD-3220F14.3	7.16	2.98e-12	2.11e-09	0.48	0.31	Coronary artery calcification;	chr19:37183357	chr19:37314868~37315620:-
LUAD	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-7.16	2.98e-12	2.12e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
LUAD	cis	rs2439831	0.681	rs528517	ENSG00000205771.5	CATSPER2P1	-7.16	2.99e-12	2.12e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43320727	chr15:43726918~43747094:-
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-7.16	2.99e-12	2.12e-09	-0.38	-0.31	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
LUAD	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-7.16	3e-12	2.13e-09	-0.4	-0.31	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
LUAD	cis	rs35955747	0.902	rs4820961	ENSG00000236132.1	CTA-440B3.1	7.16	3e-12	2.13e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283463	chr22:31816379~31817491:-
LUAD	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-7.16	3.02e-12	2.14e-09	-0.33	-0.31	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
LUAD	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-7.16	3.02e-12	2.14e-09	-0.4	-0.31	Height;	chr6:109501793	chr6:109382795~109383666:+
LUAD	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-7.16	3.02e-12	2.14e-09	-0.45	-0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
LUAD	cis	rs3738443	0.645	rs55768801	ENSG00000259865.1	RP11-488L18.10	7.16	3.02e-12	2.14e-09	0.28	0.31	Alcohol dependence;	chr1:247199688	chr1:247187281~247188526:-
LUAD	cis	rs10899021	0.92	rs11236172	ENSG00000279353.1	RP11-864N7.4	7.16	3.03e-12	2.15e-09	0.55	0.31	Response to metformin (IC50);	chr11:74619843	chr11:74698231~74699658:-
LUAD	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-7.16	3.03e-12	2.15e-09	-0.46	-0.31	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
LUAD	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	7.16	3.04e-12	2.15e-09	0.62	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	7.16	3.04e-12	2.15e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	7.16	3.04e-12	2.15e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
LUAD	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	7.16	3.04e-12	2.16e-09	0.37	0.31	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
LUAD	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-7.16	3.04e-12	2.16e-09	-0.35	-0.31	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
LUAD	cis	rs9595908	0.931	rs7998440	ENSG00000212293.1	SNORA16	7.16	3.05e-12	2.16e-09	0.35	0.31	Body mass index;	chr13:32551069	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs7991314	ENSG00000212293.1	SNORA16	7.16	3.05e-12	2.16e-09	0.35	0.31	Body mass index;	chr13:32551937	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs7328733	ENSG00000212293.1	SNORA16	7.16	3.05e-12	2.16e-09	0.35	0.31	Body mass index;	chr13:32552600	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.929	rs7328939	ENSG00000212293.1	SNORA16	7.16	3.05e-12	2.16e-09	0.35	0.31	Body mass index;	chr13:32552711	chr13:32420390~32420516:-
LUAD	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	7.16	3.05e-12	2.16e-09	0.37	0.31	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	7.16	3.05e-12	2.16e-09	0.37	0.31	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
LUAD	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	7.16	3.06e-12	2.17e-09	0.4	0.31	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
LUAD	cis	rs9834970	0.588	rs4296548	ENSG00000234073.1	AC011816.1	-7.16	3.06e-12	2.17e-09	-0.34	-0.31	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36874323	chr3:36880184~36880729:-
LUAD	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	7.16	3.06e-12	2.17e-09	0.37	0.31	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	7.16	3.06e-12	2.17e-09	0.37	0.31	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
LUAD	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-7.16	3.07e-12	2.17e-09	-0.33	-0.31	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
LUAD	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	7.16	3.08e-12	2.18e-09	0.5	0.31	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
LUAD	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	7.16	3.08e-12	2.18e-09	0.28	0.31	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
LUAD	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	7.16	3.1e-12	2.19e-09	0.41	0.31	Height;	chr6:109672088	chr6:109382795~109383666:+
LUAD	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-7.16	3.1e-12	2.19e-09	-0.33	-0.31	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
LUAD	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	7.16	3.1e-12	2.2e-09	0.56	0.31	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
LUAD	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	7.16	3.1e-12	2.2e-09	0.4	0.31	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	7.16	3.1e-12	2.2e-09	0.4	0.31	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
LUAD	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-7.16	3.1e-12	2.2e-09	-0.49	-0.31	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
LUAD	cis	rs1345301	1	rs12474199	ENSG00000234389.1	AC007278.3	-7.16	3.1e-12	2.2e-09	-0.28	-0.31	Waist circumference;	chr2:102252520	chr2:102438713~102440475:+
LUAD	cis	rs1345301	1	rs1420093	ENSG00000234389.1	AC007278.3	-7.16	3.1e-12	2.2e-09	-0.28	-0.31	Waist circumference;	chr2:102253998	chr2:102438713~102440475:+
LUAD	cis	rs1345301	1	rs10200410	ENSG00000234389.1	AC007278.3	-7.16	3.1e-12	2.2e-09	-0.28	-0.31	Waist circumference;	chr2:102254411	chr2:102438713~102440475:+
LUAD	cis	rs7115242	0.8	rs519794	ENSG00000280143.1	AP000892.6	7.16	3.11e-12	2.2e-09	0.47	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	7.16	3.11e-12	2.2e-09	0.4	0.31	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
LUAD	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-7.16	3.11e-12	2.2e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-7.16	3.11e-12	2.2e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
LUAD	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	7.16	3.11e-12	2.2e-09	0.4	0.31	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
LUAD	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-7.16	3.13e-12	2.22e-09	-0.43	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
LUAD	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	7.16	3.14e-12	2.22e-09	0.44	0.31	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
LUAD	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	7.16	3.14e-12	2.22e-09	0.37	0.31	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	7.15	3.15e-12	2.23e-09	0.37	0.31	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
LUAD	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	7.15	3.16e-12	2.24e-09	0.76	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
LUAD	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	7.15	3.16e-12	2.24e-09	0.41	0.31	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	7.15	3.16e-12	2.24e-09	0.41	0.31	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
LUAD	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-7.15	3.17e-12	2.24e-09	-0.33	-0.31	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-7.15	3.17e-12	2.24e-09	-0.38	-0.31	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
LUAD	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	7.15	3.18e-12	2.25e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	7.15	3.18e-12	2.25e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	7.15	3.18e-12	2.25e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-7.15	3.18e-12	2.25e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
LUAD	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-7.15	3.18e-12	2.25e-09	-0.3	-0.31	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
LUAD	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	7.15	3.19e-12	2.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-7.15	3.19e-12	2.26e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
LUAD	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	7.15	3.2e-12	2.26e-09	0.43	0.31	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
LUAD	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	7.15	3.2e-12	2.26e-09	0.46	0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
LUAD	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.21e-12	2.27e-09	-0.33	-0.31	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
LUAD	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	7.15	3.22e-12	2.28e-09	0.67	0.31	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
LUAD	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	7.15	3.22e-12	2.28e-09	0.58	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
LUAD	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	7.15	3.24e-12	2.29e-09	0.4	0.31	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	7.15	3.24e-12	2.29e-09	0.4	0.31	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	7.15	3.24e-12	2.29e-09	0.4	0.31	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
LUAD	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	7.15	3.24e-12	2.29e-09	0.33	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
LUAD	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-7.15	3.24e-12	2.29e-09	-0.35	-0.31	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
LUAD	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-7.15	3.24e-12	2.29e-09	-0.35	-0.31	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
LUAD	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-7.15	3.24e-12	2.29e-09	-0.41	-0.31	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-7.15	3.24e-12	2.29e-09	-0.41	-0.31	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
LUAD	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-7.15	3.26e-12	2.3e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000211974.3	IGHV2-70	-7.15	3.27e-12	2.31e-09	-0.41	-0.31	Alzheimer's disease (late onset);	chr14:106776118	chr14:106723574~106724093:-
LUAD	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-7.15	3.28e-12	2.32e-09	-0.41	-0.31	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
LUAD	cis	rs9595908	0.965	rs9595795	ENSG00000212293.1	SNORA16	7.15	3.3e-12	2.33e-09	0.36	0.31	Body mass index;	chr13:32548658	chr13:32420390~32420516:-
LUAD	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-7.15	3.31e-12	2.34e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
LUAD	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-7.15	3.32e-12	2.35e-09	-0.28	-0.31	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
LUAD	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	7.15	3.33e-12	2.35e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
LUAD	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	7.15	3.33e-12	2.35e-09	0.38	0.31	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
LUAD	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	7.15	3.33e-12	2.35e-09	0.37	0.31	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
LUAD	cis	rs7044106	0.791	rs4837793	ENSG00000238181.2	AHCYP2	-7.15	3.33e-12	2.35e-09	-0.41	-0.31	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120720673~120721972:+
LUAD	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	7.15	3.33e-12	2.35e-09	0.4	0.31	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	7.15	3.34e-12	2.35e-09	0.32	0.31	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
LUAD	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	7.15	3.34e-12	2.36e-09	0.46	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
LUAD	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-7.15	3.34e-12	2.36e-09	-0.41	-0.31	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
LUAD	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
LUAD	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
LUAD	cis	rs7246657	0.653	rs10414983	ENSG00000276846.1	CTD-3220F14.3	7.15	3.35e-12	2.36e-09	0.48	0.31	Coronary artery calcification;	chr19:37174830	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.598	rs10405372	ENSG00000276846.1	CTD-3220F14.3	7.15	3.35e-12	2.36e-09	0.48	0.31	Coronary artery calcification;	chr19:37177873	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.653	rs10425441	ENSG00000276846.1	CTD-3220F14.3	7.15	3.35e-12	2.36e-09	0.48	0.31	Coronary artery calcification;	chr19:37179746	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.653	rs4805207	ENSG00000276846.1	CTD-3220F14.3	7.15	3.35e-12	2.36e-09	0.48	0.31	Coronary artery calcification;	chr19:37182831	chr19:37314868~37315620:-
LUAD	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-7.14	3.35e-12	2.37e-09	-0.33	-0.31	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
LUAD	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-7.14	3.36e-12	2.37e-09	-0.4	-0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
LUAD	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-7.14	3.36e-12	2.37e-09	-0.36	-0.31	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-7.14	3.36e-12	2.37e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
LUAD	cis	rs7017914	0.967	rs13257800	ENSG00000223220.1	Y_RNA	7.14	3.36e-12	2.37e-09	0.34	0.31	Bone mineral density;	chr8:70801898	chr8:70780914~70781008:-
LUAD	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	7.14	3.37e-12	2.37e-09	0.38	0.31	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
LUAD	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	7.14	3.37e-12	2.38e-09	0.37	0.31	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
LUAD	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	7.14	3.38e-12	2.39e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
LUAD	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-7.14	3.38e-12	2.39e-09	-0.39	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
LUAD	cis	rs8031584	0.652	rs2691683	ENSG00000260382.1	RP11-540B6.2	-7.14	3.39e-12	2.39e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30842857	chr15:30882267~30883231:-
LUAD	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	7.14	3.39e-12	2.39e-09	0.4	0.31	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
LUAD	cis	rs11089937	0.651	rs928894	ENSG00000211639.2	IGLV4-60	7.14	3.4e-12	2.39e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22185882	chr22:22162199~22162681:+
LUAD	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	7.14	3.41e-12	2.4e-09	0.4	0.31	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	7.14	3.41e-12	2.41e-09	0.4	0.31	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
LUAD	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-7.14	3.42e-12	2.41e-09	-0.38	-0.31	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
LUAD	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	7.14	3.43e-12	2.42e-09	0.4	0.31	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	7.14	3.43e-12	2.42e-09	0.4	0.31	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	7.14	3.43e-12	2.42e-09	0.4	0.31	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-7.14	3.44e-12	2.42e-09	-0.37	-0.31	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-7.14	3.44e-12	2.42e-09	-0.36	-0.31	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	7.14	3.44e-12	2.43e-09	0.4	0.31	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
LUAD	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-7.14	3.45e-12	2.43e-09	-0.39	-0.31	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
LUAD	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-7.14	3.46e-12	2.43e-09	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
LUAD	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-7.14	3.46e-12	2.44e-09	-0.32	-0.31	Height;	chr2:46627569	chr2:46668870~46670778:+
LUAD	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	7.14	3.47e-12	2.44e-09	0.36	0.31	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
LUAD	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-7.14	3.48e-12	2.45e-09	-0.3	-0.31	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
LUAD	cis	rs8040855	0.542	rs2342122	ENSG00000259774.1	RP11-182J1.13	-7.14	3.49e-12	2.45e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85185304	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.644	rs2342120	ENSG00000259774.1	RP11-182J1.13	-7.14	3.49e-12	2.45e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85185589	chr15:84422618~84425882:+
LUAD	cis	rs950880	0.71	rs3821204	ENSG00000234389.1	AC007278.3	-7.14	3.49e-12	2.46e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102343821	chr2:102438713~102440475:+
LUAD	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-7.14	3.5e-12	2.46e-09	-0.39	-0.31	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
LUAD	cis	rs1345301	1	rs1345302	ENSG00000234389.1	AC007278.3	-7.14	3.5e-12	2.46e-09	-0.28	-0.31	Waist circumference;	chr2:102256909	chr2:102438713~102440475:+
LUAD	cis	rs1345301	1	rs13431601	ENSG00000234389.1	AC007278.3	-7.14	3.5e-12	2.46e-09	-0.28	-0.31	Waist circumference;	chr2:102257253	chr2:102438713~102440475:+
LUAD	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	7.14	3.51e-12	2.47e-09	0.32	0.31	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
LUAD	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	7.14	3.54e-12	2.49e-09	0.38	0.31	Height;	chr6:109409679	chr6:109382795~109383666:+
LUAD	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-7.14	3.55e-12	2.5e-09	-0.39	-0.31	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
LUAD	cis	rs944289	0.966	rs2415317	ENSG00000257826.1	RP11-116N8.4	7.14	3.55e-12	2.5e-09	0.33	0.31	Thyroid cancer;	chr14:36140472	chr14:36061026~36067190:-
LUAD	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-7.14	3.56e-12	2.5e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
LUAD	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	7.14	3.56e-12	2.5e-09	0.4	0.31	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	7.14	3.57e-12	2.51e-09	0.31	0.31	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
LUAD	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-7.14	3.58e-12	2.51e-09	-0.39	-0.31	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-7.14	3.58e-12	2.51e-09	-0.39	-0.31	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-7.14	3.58e-12	2.51e-09	-0.39	-0.31	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-7.14	3.58e-12	2.51e-09	-0.39	-0.31	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
LUAD	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-7.13	3.58e-12	2.52e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
LUAD	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-7.13	3.58e-12	2.52e-09	-0.27	-0.31	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
LUAD	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	7.13	3.59e-12	2.52e-09	0.37	0.31	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
LUAD	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-7.13	3.6e-12	2.53e-09	-0.37	-0.31	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-7.13	3.6e-12	2.53e-09	-0.37	-0.31	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-7.13	3.61e-12	2.54e-09	-0.37	-0.31	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
LUAD	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	7.13	3.62e-12	2.54e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	7.13	3.62e-12	2.54e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
LUAD	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-7.13	3.62e-12	2.55e-09	-0.36	-0.31	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-7.13	3.63e-12	2.55e-09	-0.36	-0.31	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	7.13	3.63e-12	2.55e-09	0.4	0.31	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	7.13	3.63e-12	2.55e-09	0.4	0.31	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
LUAD	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-7.13	3.64e-12	2.56e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	7.13	3.64e-12	2.56e-09	0.33	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
LUAD	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-7.13	3.64e-12	2.56e-09	-0.36	-0.31	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
LUAD	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	7.13	3.64e-12	2.56e-09	0.32	0.31	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
LUAD	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	7.13	3.65e-12	2.56e-09	0.37	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
LUAD	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	7.13	3.65e-12	2.56e-09	0.38	0.31	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
LUAD	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-7.13	3.65e-12	2.56e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	7.13	3.65e-12	2.57e-09	0.39	0.31	Depression;	chr6:28303421	chr6:28943877~28944537:+
LUAD	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	7.13	3.66e-12	2.57e-09	0.39	0.31	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
LUAD	cis	rs755249	1	rs61779359	ENSG00000228060.1	RP11-69E11.8	-7.13	3.68e-12	2.58e-09	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.959	rs61781363	ENSG00000228060.1	RP11-69E11.8	-7.13	3.68e-12	2.58e-09	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39565160~39573203:+
LUAD	cis	rs755249	1	rs4660808	ENSG00000228060.1	RP11-69E11.8	-7.13	3.68e-12	2.58e-09	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39565160~39573203:+
LUAD	cis	rs755249	1	rs61781364	ENSG00000228060.1	RP11-69E11.8	-7.13	3.68e-12	2.58e-09	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39565160~39573203:+
LUAD	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
LUAD	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-7.13	3.7e-12	2.6e-09	-0.31	-0.31	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
LUAD	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	7.13	3.72e-12	2.61e-09	0.4	0.31	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
LUAD	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	7.13	3.73e-12	2.62e-09	0.38	0.31	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
LUAD	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	7.13	3.78e-12	2.65e-09	0.43	0.31	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
LUAD	cis	rs2303759	0.918	rs4802597	ENSG00000268686.1	AC010524.2	-7.13	3.79e-12	2.66e-09	-0.42	-0.31	Multiple sclerosis;	chr19:49368828	chr19:49368705~49388081:-
LUAD	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	7.13	3.8e-12	2.66e-09	0.38	0.31	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
LUAD	cis	rs9595908	0.9	rs9595890	ENSG00000212293.1	SNORA16	7.13	3.8e-12	2.66e-09	0.33	0.31	Body mass index;	chr13:32597518	chr13:32420390~32420516:-
LUAD	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-7.13	3.8e-12	2.66e-09	-0.36	-0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
LUAD	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	7.13	3.81e-12	2.67e-09	0.42	0.31	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
LUAD	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	7.13	3.81e-12	2.67e-09	0.38	0.31	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
LUAD	cis	rs8031584	0.723	rs711224	ENSG00000260382.1	RP11-540B6.2	-7.13	3.81e-12	2.67e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30835718	chr15:30882267~30883231:-
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000280411.1	IGHV1-69-2	-7.13	3.82e-12	2.67e-09	-0.23	-0.31	Kawasaki disease;	chr14:106777611	chr14:106762092~106762588:-
LUAD	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-7.13	3.82e-12	2.67e-09	-0.39	-0.31	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
LUAD	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
LUAD	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	7.12	3.84e-12	2.69e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
LUAD	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	7.12	3.84e-12	2.69e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
LUAD	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	7.12	3.84e-12	2.69e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
LUAD	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	7.12	3.84e-12	2.69e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
LUAD	cis	rs7246657	0.598	rs28660259	ENSG00000276846.1	CTD-3220F14.3	7.12	3.84e-12	2.69e-09	0.48	0.31	Coronary artery calcification;	chr19:37167779	chr19:37314868~37315620:-
LUAD	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	7.12	3.84e-12	2.69e-09	0.37	0.31	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
LUAD	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-7.12	3.84e-12	2.69e-09	-0.39	-0.31	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-7.12	3.84e-12	2.69e-09	-0.39	-0.31	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	7.12	3.85e-12	2.69e-09	0.32	0.31	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
LUAD	cis	rs7044106	0.791	rs2416799	ENSG00000238181.2	AHCYP2	-7.12	3.85e-12	2.7e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.791	rs10984998	ENSG00000238181.2	AHCYP2	-7.12	3.85e-12	2.7e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120720673~120721972:+
LUAD	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	7.12	3.85e-12	2.7e-09	0.4	0.31	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
LUAD	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	7.12	3.87e-12	2.71e-09	0.42	0.31	Height;	chr6:109706514	chr6:109382795~109383666:+
LUAD	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	7.12	3.88e-12	2.72e-09	0.36	0.31	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
LUAD	cis	rs9595908	1	rs9595908	ENSG00000212293.1	SNORA16	7.12	3.89e-12	2.72e-09	0.34	0.31	Body mass index;	chr13:32610151	chr13:32420390~32420516:-
LUAD	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	7.12	3.9e-12	2.73e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
LUAD	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	7.12	3.92e-12	2.74e-09	0.43	0.31	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	7.12	3.92e-12	2.74e-09	0.43	0.31	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	7.12	3.92e-12	2.74e-09	0.43	0.31	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	7.12	3.92e-12	2.74e-09	0.43	0.31	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
LUAD	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	7.12	3.93e-12	2.75e-09	0.7	0.31	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	7.12	3.93e-12	2.75e-09	0.7	0.31	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
LUAD	cis	rs5753618	0.583	rs5749279	ENSG00000236132.1	CTA-440B3.1	-7.12	3.93e-12	2.75e-09	-0.36	-0.31	Colorectal cancer;	chr22:31458223	chr22:31816379~31817491:-
LUAD	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-7.12	3.93e-12	2.75e-09	-0.36	-0.31	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	7.12	3.94e-12	2.75e-09	0.4	0.31	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-7.12	3.94e-12	2.75e-09	-0.32	-0.31	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
LUAD	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-7.12	3.94e-12	2.75e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
LUAD	cis	rs8040855	0.621	rs6496796	ENSG00000259774.1	RP11-182J1.13	-7.12	3.94e-12	2.75e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85183617	chr15:84422618~84425882:+
LUAD	cis	rs9595908	1	rs7999125	ENSG00000212293.1	SNORA16	7.12	3.94e-12	2.75e-09	0.35	0.31	Body mass index;	chr13:32571858	chr13:32420390~32420516:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	7.12	3.95e-12	2.76e-09	0.32	0.31	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
LUAD	cis	rs2439831	0.867	rs2245715	ENSG00000205771.5	CATSPER2P1	-7.12	3.95e-12	2.76e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43525854	chr15:43726918~43747094:-
LUAD	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-7.12	3.96e-12	2.77e-09	-0.34	-0.31	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs3771177	ENSG00000234389.1	AC007278.3	-7.12	3.97e-12	2.78e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102339400	chr2:102438713~102440475:+
LUAD	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	7.12	3.98e-12	2.78e-09	0.44	0.31	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
LUAD	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-7.12	3.98e-12	2.78e-09	-0.4	-0.31	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
LUAD	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-7.12	3.98e-12	2.78e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
LUAD	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	7.12	3.98e-12	2.78e-09	0.27	0.31	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
LUAD	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	7.12	4e-12	2.8e-09	0.37	0.31	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
LUAD	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-7.12	4.01e-12	2.8e-09	-0.39	-0.31	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
LUAD	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	7.12	4.01e-12	2.8e-09	0.39	0.31	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-7.12	4.03e-12	2.81e-09	-0.4	-0.31	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	7.12	4.03e-12	2.81e-09	0.32	0.31	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
LUAD	cis	rs7646881	0.812	rs73015644	ENSG00000240207.5	RP11-379F4.4	-7.12	4.03e-12	2.81e-09	-0.41	-0.31	Tetralogy of Fallot;	chr3:158729955	chr3:158732263~158784070:+
LUAD	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28147378	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28147406	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28148143	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28149979	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28151096	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28152885	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28153120	chr6:28115628~28116551:+
LUAD	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-7.12	4.04e-12	2.82e-09	-0.39	-0.31	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-7.12	4.04e-12	2.82e-09	-0.39	-0.31	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
LUAD	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-7.12	4.04e-12	2.82e-09	-0.4	-0.31	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
LUAD	cis	rs8031584	0.723	rs11632229	ENSG00000260382.1	RP11-540B6.2	-7.12	4.05e-12	2.82e-09	-0.36	-0.31	Huntington's disease progression;	chr15:30887331	chr15:30882267~30883231:-
LUAD	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	7.12	4.05e-12	2.82e-09	0.37	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
LUAD	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	7.12	4.07e-12	2.84e-09	0.36	0.31	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
LUAD	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	7.12	4.08e-12	2.84e-09	0.28	0.31	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
LUAD	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	7.12	4.08e-12	2.85e-09	0.39	0.31	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
LUAD	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-7.11	4.09e-12	2.85e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
LUAD	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	7.11	4.09e-12	2.85e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
LUAD	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-7.11	4.1e-12	2.86e-09	-0.36	-0.31	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
LUAD	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	7.11	4.11e-12	2.87e-09	0.36	0.31	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	7.11	4.12e-12	2.87e-09	0.4	0.31	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	7.11	4.12e-12	2.87e-09	0.4	0.31	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	7.11	4.12e-12	2.87e-09	0.4	0.31	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000206090.4	AP000350.7	7.11	4.13e-12	2.87e-09	0.34	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23939998~23942798:+
LUAD	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-7.11	4.14e-12	2.88e-09	-0.37	-0.31	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
LUAD	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-7.11	4.15e-12	2.89e-09	-0.37	-0.31	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
LUAD	cis	rs35955747	0.84	rs9621221	ENSG00000236132.1	CTA-440B3.1	7.11	4.16e-12	2.9e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31220183	chr22:31816379~31817491:-
LUAD	cis	rs10759883	0.587	rs2405134	ENSG00000175611.10	LINC00476	-7.11	4.17e-12	2.9e-09	-0.37	-0.31	Nicotine dependence;	chr9:95795179	chr9:95759231~95875977:-
LUAD	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	7.11	4.18e-12	2.91e-09	0.47	0.31	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
LUAD	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	7.11	4.18e-12	2.91e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	7.11	4.18e-12	2.91e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	7.11	4.18e-12	2.91e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
LUAD	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	7.11	4.19e-12	2.92e-09	0.4	0.31	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
LUAD	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-7.11	4.19e-12	2.92e-09	-0.35	-0.31	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
LUAD	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	7.11	4.2e-12	2.92e-09	0.32	0.31	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
LUAD	cis	rs2337406	0.587	rs2583291	ENSG00000254174.1	IGHV1-12	-7.11	4.22e-12	2.93e-09	-0.27	-0.31	Alzheimer's disease (late onset);	chr14:106649293	chr14:106122420~106122709:-
LUAD	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-7.11	4.22e-12	2.94e-09	-0.48	-0.31	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
LUAD	cis	rs904251	0.734	rs2797790	ENSG00000204110.6	RP1-153P14.8	7.11	4.22e-12	2.94e-09	0.33	0.31	Cognitive performance;	chr6:37479299	chr6:37507348~37535616:+
LUAD	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	7.11	4.23e-12	2.94e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
LUAD	cis	rs35955747	0.902	rs5997919	ENSG00000236132.1	CTA-440B3.1	7.11	4.25e-12	2.95e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31227456	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	7.11	4.26e-12	2.96e-09	0.4	0.31	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	7.11	4.26e-12	2.96e-09	0.4	0.31	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
LUAD	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	7.11	4.27e-12	2.97e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
LUAD	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	7.11	4.27e-12	2.97e-09	0.41	0.31	Height;	chr6:109499759	chr6:109382795~109383666:+
LUAD	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	7.11	4.28e-12	2.97e-09	0.36	0.31	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
LUAD	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	7.11	4.28e-12	2.98e-09	0.37	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
LUAD	cis	rs748404	0.697	rs546722	ENSG00000205771.5	CATSPER2P1	-7.11	4.29e-12	2.98e-09	-0.39	-0.31	Lung cancer;	chr15:43288621	chr15:43726918~43747094:-
LUAD	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-7.11	4.29e-12	2.98e-09	-0.33	-0.31	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
LUAD	cis	rs7246657	0.653	rs10401525	ENSG00000276846.1	CTD-3220F14.3	7.11	4.3e-12	2.99e-09	0.48	0.31	Coronary artery calcification;	chr19:37168077	chr19:37314868~37315620:-
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-7.11	4.3e-12	2.99e-09	-0.33	-0.31	Gout;	chr7:66732812	chr7:66902857~66906297:+
LUAD	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-7.11	4.3e-12	2.99e-09	-0.39	-0.31	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
LUAD	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-7.11	4.31e-12	2.99e-09	-0.41	-0.31	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
LUAD	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	7.11	4.31e-12	2.99e-09	0.37	0.31	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
LUAD	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	7.11	4.31e-12	3e-09	0.29	0.31	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
LUAD	cis	rs2439831	0.681	rs1549523	ENSG00000205771.5	CATSPER2P1	-7.11	4.32e-12	3e-09	-0.52	-0.31	Lung cancer in ever smokers;	chr15:43331991	chr15:43726918~43747094:-
LUAD	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-7.11	4.33e-12	3.01e-09	-0.57	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
LUAD	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	7.11	4.33e-12	3.01e-09	0.36	0.31	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
LUAD	cis	rs950880	0.71	rs3732129	ENSG00000234389.1	AC007278.3	-7.11	4.34e-12	3.01e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102341072	chr2:102438713~102440475:+
LUAD	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	7.11	4.34e-12	3.02e-09	0.33	0.31	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
LUAD	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-7.11	4.35e-12	3.02e-09	-0.4	-0.31	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-7.11	4.35e-12	3.02e-09	-0.4	-0.31	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-7.11	4.35e-12	3.02e-09	-0.4	-0.31	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
LUAD	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	7.1	4.37e-12	3.03e-09	0.42	0.31	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-7.1	4.37e-12	3.03e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000280411.1	IGHV1-69-2	-7.1	4.38e-12	3.04e-09	-0.23	-0.31	Kawasaki disease;	chr14:106777570	chr14:106762092~106762588:-
LUAD	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	7.1	4.38e-12	3.04e-09	0.32	0.31	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	7.1	4.38e-12	3.04e-09	0.32	0.31	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-7.1	4.38e-12	3.04e-09	-0.4	-0.31	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	7.1	4.38e-12	3.04e-09	0.36	0.31	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
LUAD	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	7.1	4.38e-12	3.04e-09	0.34	0.31	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
LUAD	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-7.1	4.39e-12	3.04e-09	-0.37	-0.31	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
LUAD	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-7.1	4.4e-12	3.05e-09	-0.4	-0.31	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
LUAD	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	7.1	4.4e-12	3.06e-09	0.5	0.31	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
LUAD	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	7.1	4.4e-12	3.06e-09	0.36	0.31	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-7.1	4.41e-12	3.06e-09	-0.37	-0.31	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-7.1	4.41e-12	3.06e-09	-0.37	-0.31	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-7.1	4.41e-12	3.06e-09	-0.37	-0.31	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
LUAD	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	7.1	4.41e-12	3.06e-09	0.28	0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
LUAD	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-7.1	4.42e-12	3.07e-09	-0.43	-0.31	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
LUAD	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-7.1	4.45e-12	3.09e-09	-0.32	-0.31	Height;	chr2:46640019	chr2:46668870~46670778:+
LUAD	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	7.1	4.45e-12	3.09e-09	0.41	0.31	Height;	chr6:109498586	chr6:109382795~109383666:+
LUAD	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	7.1	4.46e-12	3.09e-09	0.35	0.31	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
LUAD	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	7.1	4.48e-12	3.1e-09	0.32	0.31	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
LUAD	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	7.1	4.48e-12	3.1e-09	0.44	0.31	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000280411.1	IGHV1-69-2	7.1	4.48e-12	3.11e-09	0.23	0.31	Kawasaki disease;	chr14:106769752	chr14:106762092~106762588:-
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	7.1	4.5e-12	3.12e-09	0.32	0.31	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	7.1	4.5e-12	3.12e-09	0.32	0.31	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	7.1	4.5e-12	3.12e-09	0.32	0.31	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
LUAD	cis	rs62229266	0.605	rs11701331	ENSG00000231106.2	LINC01436	7.1	4.51e-12	3.12e-09	0.41	0.31	Mitral valve prolapse;	chr21:36086094	chr21:36005338~36007838:+
LUAD	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-7.1	4.51e-12	3.12e-09	-0.37	-0.31	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
LUAD	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-7.1	4.51e-12	3.12e-09	-0.37	-0.31	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	7.1	4.51e-12	3.12e-09	0.32	0.31	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-7.1	4.51e-12	3.12e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-7.1	4.52e-12	3.13e-09	-0.33	-0.31	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
LUAD	cis	rs7017914	0.967	rs6993170	ENSG00000223220.1	Y_RNA	7.1	4.53e-12	3.14e-09	0.34	0.31	Bone mineral density;	chr8:70781284	chr8:70780914~70781008:-
LUAD	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-7.1	4.53e-12	3.14e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-7.1	4.53e-12	3.14e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
LUAD	cis	rs11123170	0.543	rs35222158	ENSG00000274877.1	RP11-65I12.1	-7.1	4.54e-12	3.14e-09	-0.47	-0.31	Renal function-related traits (BUN);	chr2:113229052	chr2:113237595~113240825:+
LUAD	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-7.1	4.54e-12	3.14e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
LUAD	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-7.1	4.56e-12	3.15e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
LUAD	cis	rs11123170	0.542	rs28522253	ENSG00000274877.1	RP11-65I12.1	-7.1	4.56e-12	3.16e-09	-0.48	-0.31	Renal function-related traits (BUN);	chr2:113209810	chr2:113237595~113240825:+
LUAD	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-7.1	4.56e-12	3.16e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
LUAD	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	7.1	4.57e-12	3.16e-09	0.36	0.31	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	7.1	4.57e-12	3.16e-09	0.36	0.31	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
LUAD	cis	rs950880	0.645	rs11679889	ENSG00000234389.1	AC007278.3	-7.1	4.58e-12	3.17e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102324549	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000211972.2	IGHV3-66	7.1	4.58e-12	3.17e-09	0.27	0.31	Kawasaki disease;	chr14:106803901	chr14:106675017~106675544:-
LUAD	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-7.1	4.59e-12	3.18e-09	-0.32	-0.31	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
LUAD	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	7.1	4.6e-12	3.18e-09	0.48	0.31	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
LUAD	cis	rs7044106	0.791	rs10818473	ENSG00000238181.2	AHCYP2	-7.1	4.6e-12	3.18e-09	-0.41	-0.31	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120720673~120721972:+
LUAD	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-7.1	4.6e-12	3.18e-09	-0.29	-0.31	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
LUAD	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	7.1	4.61e-12	3.19e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	7.1	4.61e-12	3.19e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	7.1	4.61e-12	3.19e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
LUAD	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	7.1	4.62e-12	3.2e-09	0.36	0.31	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
LUAD	cis	rs8177876	0.822	rs9925940	ENSG00000261838.4	RP11-303E16.6	7.1	4.64e-12	3.21e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9925943	ENSG00000261838.4	RP11-303E16.6	7.1	4.64e-12	3.21e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81069854~81076598:+
LUAD	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-7.1	4.64e-12	3.21e-09	-0.48	-0.31	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-7.1	4.64e-12	3.21e-09	-0.4	-0.31	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
LUAD	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	7.1	4.64e-12	3.21e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	7.1	4.64e-12	3.21e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
LUAD	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-7.1	4.64e-12	3.21e-09	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-7.1	4.64e-12	3.21e-09	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
LUAD	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	7.09	4.66e-12	3.22e-09	0.38	0.31	Height;	chr6:109392096	chr6:109382795~109383666:+
LUAD	cis	rs950169	0.96	rs12905475	ENSG00000225151.9	GOLGA2P7	-7.09	4.66e-12	3.23e-09	-0.45	-0.31	Schizophrenia;	chr15:84131743	chr15:84199311~84230136:-
LUAD	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-7.09	4.67e-12	3.23e-09	-0.32	-0.31	Height;	chr2:46636733	chr2:46668870~46670778:+
LUAD	cis	rs62229266	0.804	rs2835259	ENSG00000214914.3	RPL23AP3	7.09	4.67e-12	3.23e-09	0.37	0.31	Mitral valve prolapse;	chr21:36053004	chr21:36016079~36016546:-
LUAD	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-7.09	4.68e-12	3.23e-09	-0.35	-0.31	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
LUAD	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-7.09	4.68e-12	3.23e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
LUAD	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	7.09	4.68e-12	3.24e-09	0.4	0.31	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	7.09	4.68e-12	3.24e-09	0.4	0.31	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
LUAD	cis	rs9326248	0.53	rs562179	ENSG00000280143.1	AP000892.6	7.09	4.69e-12	3.24e-09	0.48	0.31	Blood protein levels;	chr11:116934488	chr11:117204967~117210292:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000211972.2	IGHV3-66	-7.09	4.69e-12	3.24e-09	-0.28	-0.31	Kawasaki disease;	chr14:106771605	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	7.09	4.69e-12	3.24e-09	0.4	0.31	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	7.09	4.7e-12	3.25e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
LUAD	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	7.09	4.7e-12	3.25e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-7.09	4.7e-12	3.25e-09	-0.32	-0.31	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
LUAD	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-7.09	4.73e-12	3.27e-09	-0.32	-0.31	Height;	chr2:46629946	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-7.09	4.73e-12	3.27e-09	-0.32	-0.31	Height;	chr2:46630262	chr2:46668870~46670778:+
LUAD	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	7.09	4.75e-12	3.28e-09	0.34	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
LUAD	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-7.09	4.75e-12	3.28e-09	-0.37	-0.31	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
LUAD	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-7.09	4.77e-12	3.3e-09	-0.37	-0.31	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
LUAD	cis	rs8177876	0.822	rs9923732	ENSG00000261838.4	RP11-303E16.6	7.09	4.78e-12	3.3e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9933184	ENSG00000261838.4	RP11-303E16.6	7.09	4.78e-12	3.3e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9926174	ENSG00000261838.4	RP11-303E16.6	7.09	4.78e-12	3.3e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.642	rs8052490	ENSG00000261838.4	RP11-303E16.6	7.09	4.78e-12	3.3e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81069854~81076598:+
LUAD	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	7.09	4.78e-12	3.3e-09	0.43	0.31	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	7.09	4.8e-12	3.31e-09	0.37	0.31	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
LUAD	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	7.09	4.81e-12	3.32e-09	0.31	0.31	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
LUAD	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	7.09	4.83e-12	3.33e-09	0.44	0.31	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
LUAD	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-7.09	4.83e-12	3.33e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
LUAD	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-7.09	4.84e-12	3.34e-09	-0.41	-0.31	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
LUAD	cis	rs9595908	0.965	rs9591180	ENSG00000212293.1	SNORA16	7.09	4.85e-12	3.35e-09	0.34	0.31	Body mass index;	chr13:32622864	chr13:32420390~32420516:-
LUAD	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	7.09	4.86e-12	3.35e-09	0.39	0.31	Height;	chr6:109403734	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	7.09	4.87e-12	3.36e-09	0.4	0.31	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
LUAD	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	7.09	4.88e-12	3.36e-09	0.36	0.31	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
LUAD	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-7.09	4.88e-12	3.36e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-7.09	4.89e-12	3.37e-09	-0.37	-0.31	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	7.09	4.89e-12	3.38e-09	0.4	0.31	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
LUAD	cis	rs8031584	0.678	rs798127	ENSG00000260382.1	RP11-540B6.2	-7.09	4.9e-12	3.38e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30825200	chr15:30882267~30883231:-
LUAD	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-7.09	4.93e-12	3.4e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
LUAD	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	7.09	4.93e-12	3.4e-09	0.52	0.31	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
LUAD	cis	rs7688540	0.771	rs11737268	ENSG00000275426.1	CH17-262A2.1	7.09	4.94e-12	3.41e-09	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11726829	ENSG00000275426.1	CH17-262A2.1	7.09	4.94e-12	3.41e-09	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:149738~150317:+
LUAD	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	7.09	4.95e-12	3.41e-09	0.39	0.31	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	7.09	4.95e-12	3.41e-09	0.39	0.31	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	7.09	4.95e-12	3.41e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	7.09	4.95e-12	3.41e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	7.09	4.95e-12	3.41e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
LUAD	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	7.09	4.97e-12	3.43e-09	0.34	0.31	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
LUAD	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-7.09	4.97e-12	3.43e-09	-0.56	-0.31	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	7.08	4.98e-12	3.43e-09	0.39	0.31	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
LUAD	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-7.08	4.98e-12	3.43e-09	-0.34	-0.31	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
LUAD	cis	rs17818399	0.51	rs12105801	ENSG00000279254.1	RP11-536C12.1	-7.08	4.99e-12	3.44e-09	-0.32	-0.31	Height;	chr2:46572204	chr2:46668870~46670778:+
LUAD	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-7.08	5e-12	3.44e-09	-0.39	-0.31	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-7.08	5e-12	3.44e-09	-0.39	-0.31	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
LUAD	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
LUAD	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	-7.08	5.01e-12	3.45e-09	-0.47	-0.31	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
LUAD	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-7.08	5.02e-12	3.45e-09	-0.32	-0.31	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
LUAD	cis	rs7044106	0.791	rs10985009	ENSG00000238181.2	AHCYP2	7.08	5.02e-12	3.46e-09	0.4	0.31	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120720673~120721972:+
LUAD	cis	rs2337406	0.587	rs2516889	ENSG00000254174.1	IGHV1-12	-7.08	5.02e-12	3.46e-09	-0.27	-0.31	Alzheimer's disease (late onset);	chr14:106648903	chr14:106122420~106122709:-
LUAD	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	3.47e-09	0.32	0.31	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	3.47e-09	0.32	0.31	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	3.47e-09	0.32	0.31	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-7.08	5.06e-12	3.48e-09	-0.32	-0.31	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
LUAD	cis	rs7849270	0.84	rs12346996	ENSG00000268707.1	RP11-247A12.7	-7.08	5.06e-12	3.48e-09	-0.38	-0.31	Blood metabolite ratios;	chr9:129078577	chr9:129170434~129170940:+
LUAD	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	7.08	5.06e-12	3.48e-09	0.39	0.31	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
LUAD	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-7.08	5.09e-12	3.5e-09	-0.48	-0.31	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
LUAD	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	7.08	5.09e-12	3.5e-09	0.32	0.31	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
LUAD	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	7.08	5.1e-12	3.51e-09	0.32	0.31	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
LUAD	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-7.08	5.1e-12	3.51e-09	-0.31	-0.31	Height;	chr2:46627225	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-7.08	5.1e-12	3.51e-09	-0.31	-0.31	Height;	chr2:46631182	chr2:46668870~46670778:+
LUAD	cis	rs11123170	0.543	rs12472361	ENSG00000274877.1	RP11-65I12.1	-7.08	5.1e-12	3.51e-09	-0.47	-0.31	Renal function-related traits (BUN);	chr2:113223068	chr2:113237595~113240825:+
LUAD	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-7.08	5.12e-12	3.52e-09	-0.39	-0.31	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
LUAD	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-7.08	5.12e-12	3.52e-09	-0.31	-0.31	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
LUAD	cis	rs7017914	0.902	rs1373480	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70774732	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs10448014	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70775930	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7000647	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70776173	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13254801	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70776749	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.783	rs13252584	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70776796	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.84	rs13254851	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70776799	chr8:70780914~70781008:-
LUAD	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
LUAD	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	7.08	5.14e-12	3.53e-09	0.38	0.31	Height;	chr6:109382188	chr6:109382795~109383666:+
LUAD	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-7.08	5.17e-12	3.55e-09	-0.37	-0.31	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
LUAD	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-7.08	5.17e-12	3.55e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
LUAD	cis	rs2337406	0.587	rs2516886	ENSG00000254174.1	IGHV1-12	-7.08	5.18e-12	3.56e-09	-0.27	-0.31	Alzheimer's disease (late onset);	chr14:106649674	chr14:106122420~106122709:-
LUAD	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	7.08	5.18e-12	3.56e-09	0.41	0.31	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
LUAD	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	7.08	5.18e-12	3.56e-09	0.41	0.31	Height;	chr6:109496073	chr6:109382795~109383666:+
LUAD	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-7.08	5.2e-12	3.58e-09	-0.36	-0.31	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
LUAD	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	7.08	5.22e-12	3.58e-09	0.38	0.31	Height;	chr6:109370741	chr6:109382795~109383666:+
LUAD	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-7.08	5.22e-12	3.59e-09	-0.33	-0.31	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
LUAD	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-7.08	5.22e-12	3.59e-09	-0.31	-0.31	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
LUAD	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	7.08	5.25e-12	3.6e-09	0.38	0.31	Height;	chr6:109371524	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-7.08	5.27e-12	3.62e-09	-0.22	-0.31	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
LUAD	cis	rs4713118	0.629	rs203887	ENSG00000204709.4	LINC01556	7.08	5.27e-12	3.62e-09	0.42	0.31	Parkinson's disease;	chr6:28053491	chr6:28943877~28944537:+
LUAD	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-7.08	5.27e-12	3.62e-09	-0.4	-0.31	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
LUAD	cis	rs7044106	0.791	rs7036196	ENSG00000238181.2	AHCYP2	-7.08	5.28e-12	3.63e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.791	rs7036766	ENSG00000238181.2	AHCYP2	-7.08	5.28e-12	3.63e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120720673~120721972:+
LUAD	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-7.08	5.3e-12	3.64e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-7.08	5.3e-12	3.64e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
LUAD	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-7.08	5.3e-12	3.64e-09	-0.68	-0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
LUAD	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	7.07	5.32e-12	3.65e-09	0.53	0.31	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
LUAD	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-7.07	5.32e-12	3.65e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	7.07	5.32e-12	3.65e-09	0.4	0.31	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
LUAD	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	7.07	5.32e-12	3.65e-09	0.33	0.31	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
LUAD	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-7.07	5.32e-12	3.66e-09	-0.4	-0.31	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
LUAD	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	7.07	5.33e-12	3.66e-09	0.43	0.31	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
LUAD	cis	rs62229266	0.618	rs11088334	ENSG00000214914.3	RPL23AP3	7.07	5.34e-12	3.66e-09	0.37	0.31	Mitral valve prolapse;	chr21:36094531	chr21:36016079~36016546:-
LUAD	cis	rs8059260	0.736	rs77334546	ENSG00000274038.1	RP11-66H6.4	-7.07	5.34e-12	3.66e-09	-0.65	-0.31	Alcohol consumption over the past year;	chr16:10970061	chr16:11056556~11057034:+
LUAD	cis	rs321358	0.731	rs484021	ENSG00000271584.1	RP11-89C3.4	7.07	5.34e-12	3.66e-09	0.47	0.31	Body mass index;	chr11:111136353	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs7112075	ENSG00000271584.1	RP11-89C3.4	7.07	5.34e-12	3.66e-09	0.47	0.31	Body mass index;	chr11:111136407	chr11:111091932~111097357:-
LUAD	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-7.07	5.34e-12	3.66e-09	-0.37	-0.31	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-7.07	5.34e-12	3.66e-09	-0.37	-0.31	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
LUAD	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-7.07	5.34e-12	3.66e-09	-0.39	-0.31	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
LUAD	cis	rs10200159	0.744	rs12616502	ENSG00000272606.1	RP11-554J4.1	7.07	5.34e-12	3.66e-09	0.54	0.31	Vitiligo;	chr2:55581879	chr2:55617909~55618373:+
LUAD	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-7.07	5.35e-12	3.67e-09	-0.36	-0.31	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-7.07	5.35e-12	3.67e-09	-0.36	-0.31	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
LUAD	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	7.07	5.37e-12	3.68e-09	0.38	0.31	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-7.07	5.4e-12	3.71e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
LUAD	cis	rs237743	1	rs35506374	ENSG00000222365.1	SNORD12B	-7.07	5.4e-12	3.71e-09	-0.36	-0.31	Height;	chr20:49311346	chr20:49280319~49280409:+
LUAD	cis	rs7017914	0.967	rs1838393	ENSG00000223220.1	Y_RNA	7.07	5.42e-12	3.71e-09	0.34	0.31	Bone mineral density;	chr8:70790356	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs7826483	ENSG00000223220.1	Y_RNA	7.07	5.42e-12	3.71e-09	0.34	0.31	Bone mineral density;	chr8:70790658	chr8:70780914~70781008:-
LUAD	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-7.07	5.42e-12	3.72e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
LUAD	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-7.07	5.42e-12	3.72e-09	-0.36	-0.31	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
LUAD	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-7.07	5.42e-12	3.72e-09	-0.33	-0.31	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
LUAD	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	7.07	5.44e-12	3.73e-09	0.41	0.31	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
LUAD	cis	rs10899021	1	rs61900635	ENSG00000279353.1	RP11-864N7.4	7.07	5.45e-12	3.73e-09	0.56	0.31	Response to metformin (IC50);	chr11:74647965	chr11:74698231~74699658:-
LUAD	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	7.07	5.46e-12	3.74e-09	0.44	0.31	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000206090.4	AP000350.7	-7.07	5.47e-12	3.75e-09	-0.33	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23939998~23942798:+
LUAD	cis	rs2286503	0.78	rs929464	ENSG00000228649.7	AC005682.5	7.07	5.48e-12	3.75e-09	0.39	0.31	Fibrinogen;	chr7:22835151	chr7:22854178~22861579:+
LUAD	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-7.07	5.48e-12	3.76e-09	-0.31	-0.31	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
LUAD	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-7.07	5.48e-12	3.76e-09	-0.36	-0.31	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
LUAD	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-7.07	5.48e-12	3.76e-09	-0.32	-0.31	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
LUAD	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-7.07	5.49e-12	3.76e-09	-0.36	-0.31	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
LUAD	cis	rs75422866	0.867	rs7304743	ENSG00000280054.1	RP1-197B17.7	-7.07	5.52e-12	3.78e-09	-0.63	-0.31	Pneumonia;	chr12:47683658	chr12:47728151~47730598:-
LUAD	cis	rs2439831	0.571	rs689883	ENSG00000205771.5	CATSPER2P1	-7.07	5.52e-12	3.78e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43520398	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-7.07	5.53e-12	3.79e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
LUAD	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-7.07	5.54e-12	3.8e-09	-0.36	-0.31	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
LUAD	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-7.07	5.56e-12	3.81e-09	-0.35	-0.31	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-7.07	5.56e-12	3.81e-09	-0.35	-0.31	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
LUAD	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	7.07	5.57e-12	3.81e-09	0.4	0.31	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
LUAD	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-7.07	5.57e-12	3.82e-09	-0.39	-0.31	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
LUAD	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	7.07	5.58e-12	3.82e-09	0.43	0.31	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
LUAD	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	7.07	5.58e-12	3.82e-09	0.46	0.31	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
LUAD	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-7.07	5.59e-12	3.83e-09	-0.33	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
LUAD	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	7.07	5.6e-12	3.83e-09	0.39	0.31	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
LUAD	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-7.07	5.66e-12	3.87e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
LUAD	cis	rs4591358	0.689	rs59017643	ENSG00000223466.1	AC064834.2	-7.07	5.67e-12	3.88e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546835	chr2:195533035~195538681:+
LUAD	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	7.06	5.67e-12	3.88e-09	0.4	0.31	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
LUAD	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	7.06	5.67e-12	3.88e-09	0.4	0.31	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
LUAD	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	7.06	5.67e-12	3.88e-09	0.69	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
LUAD	cis	rs8177876	1	rs8177876	ENSG00000261838.4	RP11-303E16.6	7.06	5.68e-12	3.88e-09	0.78	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81069854~81076598:+
LUAD	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-7.06	5.68e-12	3.88e-09	-0.41	-0.31	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
LUAD	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-7.06	5.7e-12	3.9e-09	-0.43	-0.31	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.653	rs28701616	ENSG00000276846.1	CTD-3220F14.3	7.06	5.72e-12	3.91e-09	0.48	0.31	Coronary artery calcification;	chr19:37190196	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	7.06	5.73e-12	3.92e-09	0.31	0.31	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	7.06	5.73e-12	3.92e-09	0.31	0.31	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	7.06	5.75e-12	3.93e-09	0.39	0.31	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
LUAD	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	7.06	5.75e-12	3.93e-09	0.36	0.31	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
LUAD	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
LUAD	cis	rs11089937	0.616	rs12484496	ENSG00000211639.2	IGLV4-60	-7.06	5.76e-12	3.93e-09	-0.32	-0.31	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22162199~22162681:+
LUAD	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	7.06	5.76e-12	3.93e-09	0.4	0.31	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	7.06	5.76e-12	3.93e-09	0.4	0.31	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	7.06	5.77e-12	3.94e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	7.06	5.77e-12	3.94e-09	0.31	0.31	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	7.06	5.77e-12	3.94e-09	0.31	0.31	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	7.06	5.77e-12	3.94e-09	0.31	0.31	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
LUAD	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-7.06	5.8e-12	3.96e-09	-0.28	-0.31	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
LUAD	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	7.06	5.8e-12	3.96e-09	0.36	0.31	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
LUAD	cis	rs7246657	0.765	rs10402455	ENSG00000276846.1	CTD-3220F14.3	7.06	5.81e-12	3.97e-09	0.47	0.31	Coronary artery calcification;	chr19:37237805	chr19:37314868~37315620:-
LUAD	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	7.06	5.82e-12	3.97e-09	0.35	0.31	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
LUAD	cis	rs944289	0.966	rs1169146	ENSG00000257826.1	RP11-116N8.4	-7.06	5.85e-12	3.99e-09	-0.32	-0.31	Thyroid cancer;	chr14:36163563	chr14:36061026~36067190:-
LUAD	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-7.06	5.86e-12	4e-09	-0.44	-0.31	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
LUAD	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	7.06	5.86e-12	4e-09	0.36	0.31	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
LUAD	cis	rs9549367	0.713	rs3024745	ENSG00000269125.1	RP11-98F14.11	-7.06	5.87e-12	4e-09	-0.41	-0.31	Platelet distribution width;	chr13:113167284	chr13:113165002~113165183:-
LUAD	cis	rs62229266	0.804	rs62230821	ENSG00000214914.3	RPL23AP3	7.06	5.9e-12	4.02e-09	0.37	0.31	Mitral valve prolapse;	chr21:36052818	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	7.06	5.9e-12	4.03e-09	0.39	0.31	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	7.06	5.91e-12	4.03e-09	0.39	0.31	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
LUAD	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-7.06	5.92e-12	4.03e-09	-0.48	-0.31	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-7.06	5.92e-12	4.03e-09	-0.48	-0.31	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
LUAD	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	7.06	5.93e-12	4.04e-09	0.39	0.31	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
LUAD	cis	rs237743	1	rs56335217	ENSG00000222365.1	SNORD12B	-7.06	5.95e-12	4.06e-09	-0.36	-0.31	Height;	chr20:49254660	chr20:49280319~49280409:+
LUAD	cis	rs1345301	1	rs12470560	ENSG00000234389.1	AC007278.3	-7.06	5.96e-12	4.06e-09	-0.28	-0.31	Waist circumference;	chr2:102252380	chr2:102438713~102440475:+
LUAD	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	7.06	5.96e-12	4.06e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
LUAD	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-7.06	5.97e-12	4.07e-09	-0.31	-0.31	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
LUAD	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-7.06	5.97e-12	4.07e-09	-0.31	-0.31	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
LUAD	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-7.06	5.98e-12	4.08e-09	-0.42	-0.31	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-7.06	5.98e-12	4.08e-09	-0.42	-0.31	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
LUAD	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	7.06	5.99e-12	4.08e-09	0.31	0.31	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
LUAD	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-7.06	6e-12	4.09e-09	-0.42	-0.31	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
LUAD	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-7.06	6e-12	4.09e-09	-0.27	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
LUAD	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	7.06	6e-12	4.09e-09	0.4	0.31	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
LUAD	cis	rs10899021	1	rs11236186	ENSG00000279353.1	RP11-864N7.4	7.05	6.07e-12	4.13e-09	0.56	0.31	Response to metformin (IC50);	chr11:74651820	chr11:74698231~74699658:-
LUAD	cis	rs10899021	1	rs7935426	ENSG00000279353.1	RP11-864N7.4	7.05	6.07e-12	4.13e-09	0.56	0.31	Response to metformin (IC50);	chr11:74652845	chr11:74698231~74699658:-
LUAD	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	7.05	6.09e-12	4.14e-09	0.36	0.31	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
LUAD	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-7.05	6.09e-12	4.14e-09	-0.39	-0.31	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
LUAD	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-7.05	6.14e-12	4.17e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-7.05	6.14e-12	4.17e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
LUAD	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-7.05	6.15e-12	4.18e-09	-0.52	-0.31	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
LUAD	cis	rs35955747	0.902	rs739427	ENSG00000236132.1	CTA-440B3.1	-7.05	6.15e-12	4.18e-09	-0.35	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31263115	chr22:31816379~31817491:-
LUAD	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-7.05	6.15e-12	4.18e-09	-0.32	-0.31	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
LUAD	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-7.05	6.17e-12	4.19e-09	-0.39	-0.31	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
LUAD	cis	rs11123170	0.543	rs2166421	ENSG00000274877.1	RP11-65I12.1	-7.05	6.17e-12	4.2e-09	-0.48	-0.31	Renal function-related traits (BUN);	chr2:113232665	chr2:113237595~113240825:+
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-7.05	6.19e-12	4.2e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-7.05	6.19e-12	4.21e-09	-0.32	-0.31	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000280411.1	IGHV1-69-2	-7.05	6.19e-12	4.21e-09	-0.24	-0.31	Kawasaki disease;	chr14:106718572	chr14:106762092~106762588:-
LUAD	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-7.05	6.21e-12	4.22e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-7.05	6.22e-12	4.23e-09	-0.36	-0.31	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-7.05	6.22e-12	4.23e-09	-0.36	-0.31	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	7.05	6.22e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
LUAD	cis	rs9326248	0.53	rs510988	ENSG00000280143.1	AP000892.6	7.05	6.23e-12	4.23e-09	0.48	0.31	Blood protein levels;	chr11:116943088	chr11:117204967~117210292:+
LUAD	cis	rs7115242	0.669	rs1241658	ENSG00000280143.1	AP000892.6	7.05	6.23e-12	4.23e-09	0.48	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117204967~117210292:+
LUAD	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	7.05	6.23e-12	4.23e-09	0.36	0.31	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
LUAD	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	7.05	6.24e-12	4.24e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
LUAD	cis	rs9326248	0.53	rs2513095	ENSG00000280143.1	AP000892.6	7.05	6.26e-12	4.24e-09	0.48	0.31	Blood protein levels;	chr11:116935553	chr11:117204967~117210292:+
LUAD	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-7.05	6.27e-12	4.25e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
LUAD	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-7.05	6.29e-12	4.26e-09	-0.3	-0.31	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
LUAD	cis	rs35955747	0.934	rs131200	ENSG00000236132.1	CTA-440B3.1	-7.05	6.31e-12	4.28e-09	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31307286	chr22:31816379~31817491:-
LUAD	cis	rs7017914	0.967	rs1348535	ENSG00000223220.1	Y_RNA	7.05	6.32e-12	4.29e-09	0.34	0.31	Bone mineral density;	chr8:70750506	chr8:70780914~70781008:-
LUAD	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	7.05	6.33e-12	4.29e-09	0.39	0.31	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
LUAD	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-7.05	6.35e-12	4.3e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
LUAD	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	7.05	6.35e-12	4.31e-09	0.43	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
LUAD	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-7.05	6.36e-12	4.31e-09	-0.4	-0.31	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
LUAD	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-7.05	6.36e-12	4.31e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
LUAD	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
LUAD	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-7.05	6.39e-12	4.33e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
LUAD	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-7.05	6.4e-12	4.34e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
LUAD	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	7.05	6.41e-12	4.34e-09	0.46	0.31	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
LUAD	cis	rs1823913	1	rs4853568	ENSG00000227542.1	AC092614.2	-7.05	6.41e-12	4.34e-09	-0.4	-0.31	Obesity-related traits;	chr2:191261464	chr2:191229165~191246172:-
LUAD	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-7.05	6.42e-12	4.35e-09	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
LUAD	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	7.05	6.42e-12	4.35e-09	0.41	0.31	Height;	chr6:109494237	chr6:109382795~109383666:+
LUAD	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-7.05	6.44e-12	4.36e-09	-0.39	-0.31	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
LUAD	cis	rs62229266	0.804	rs62230822	ENSG00000214914.3	RPL23AP3	7.05	6.44e-12	4.36e-09	0.37	0.31	Mitral valve prolapse;	chr21:36057647	chr21:36016079~36016546:-
LUAD	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-7.04	6.46e-12	4.38e-09	-0.32	-0.31	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
LUAD	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-7.04	6.47e-12	4.38e-09	-0.47	-0.31	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000280411.1	IGHV1-69-2	-7.04	6.49e-12	4.39e-09	-0.24	-0.31	Kawasaki disease;	chr14:106805607	chr14:106762092~106762588:-
LUAD	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	7.04	6.49e-12	4.4e-09	0.4	0.31	Depression;	chr6:28407125	chr6:28943877~28944537:+
LUAD	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	7.04	6.52e-12	4.41e-09	0.69	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-7.04	6.55e-12	4.43e-09	-0.35	-0.31	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
LUAD	cis	rs35955747	0.902	rs713947	ENSG00000236132.1	CTA-440B3.1	7.04	6.55e-12	4.43e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31243523	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.902	rs11703927	ENSG00000236132.1	CTA-440B3.1	7.04	6.55e-12	4.43e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31248978	chr22:31816379~31817491:-
LUAD	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	7.04	6.56e-12	4.43e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	7.04	6.56e-12	4.43e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	7.04	6.56e-12	4.43e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	7.04	6.56e-12	4.43e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
LUAD	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	7.04	6.57e-12	4.44e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
LUAD	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.57e-12	4.45e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	7.04	6.61e-12	4.47e-09	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
LUAD	cis	rs4591358	0.689	rs2889034	ENSG00000223466.1	AC064834.2	-7.04	6.61e-12	4.47e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548022	chr2:195533035~195538681:+
LUAD	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	7.04	6.64e-12	4.49e-09	0.46	0.31	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
LUAD	cis	rs62229266	0.633	rs743420	ENSG00000214914.3	RPL23AP3	7.04	6.65e-12	4.5e-09	0.37	0.31	Mitral valve prolapse;	chr21:36015104	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	7.04	6.66e-12	4.5e-09	0.39	0.31	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
LUAD	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-7.04	6.66e-12	4.5e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000211970.3	IGHV4-61	-7.04	6.67e-12	4.51e-09	-0.22	-0.31	Kawasaki disease;	chr14:106807047	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000211970.3	IGHV4-61	-7.04	6.67e-12	4.51e-09	-0.22	-0.31	Kawasaki disease;	chr14:106808609	chr14:106639119~106639657:-
LUAD	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-7.04	6.67e-12	4.51e-09	-0.36	-0.31	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
LUAD	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-7.04	6.67e-12	4.51e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
LUAD	cis	rs7044106	0.791	rs3904196	ENSG00000238181.2	AHCYP2	-7.04	6.68e-12	4.51e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120720673~120721972:+
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000206090.4	AP000350.7	7.04	6.7e-12	4.52e-09	0.34	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23939998~23942798:+
LUAD	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	7.04	6.7e-12	4.53e-09	0.38	0.31	Height;	chr6:109368228	chr6:109382795~109383666:+
LUAD	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-7.04	6.71e-12	4.53e-09	-0.4	-0.31	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
LUAD	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-7.04	6.72e-12	4.54e-09	-0.4	-0.31	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000280411.1	IGHV1-69-2	7.04	6.73e-12	4.55e-09	0.22	0.31	Kawasaki disease;	chr14:106775945	chr14:106762092~106762588:-
LUAD	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	7.04	6.73e-12	4.55e-09	0.29	0.31	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
LUAD	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	7.04	6.74e-12	4.55e-09	0.33	0.31	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
LUAD	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	7.04	6.74e-12	4.55e-09	0.34	0.31	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-7.04	6.76e-12	4.57e-09	-0.32	-0.31	Gout;	chr7:66693028	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	7.04	6.77e-12	4.57e-09	0.32	0.31	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
LUAD	cis	rs7017914	0.934	rs62508771	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70780453	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6998786	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70782395	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs12680988	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70783655	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs1596566	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70786341	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6993115	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70786948	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs6992879	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70787048	chr8:70780914~70781008:-
LUAD	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	7.04	6.8e-12	4.59e-09	0.39	0.31	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	7.04	6.8e-12	4.59e-09	0.39	0.31	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
LUAD	cis	rs8031584	0.697	rs8036176	ENSG00000260382.1	RP11-540B6.2	7.04	6.8e-12	4.59e-09	0.39	0.31	Huntington's disease progression;	chr15:30883066	chr15:30882267~30883231:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-7.04	6.8e-12	4.59e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
LUAD	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.81e-12	4.59e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.81e-12	4.59e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.81e-12	4.59e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.81e-12	4.59e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
LUAD	cis	rs62229266	0.771	rs62230790	ENSG00000214914.3	RPL23AP3	7.04	6.81e-12	4.6e-09	0.38	0.31	Mitral valve prolapse;	chr21:36016613	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	7.04	6.82e-12	4.6e-09	0.39	0.31	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-7.04	6.83e-12	4.61e-09	-0.36	-0.31	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
LUAD	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-7.04	6.84e-12	4.62e-09	-0.47	-0.31	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
LUAD	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-7.04	6.85e-12	4.62e-09	-0.39	-0.31	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
LUAD	cis	rs7017914	0.967	rs35207116	ENSG00000223220.1	Y_RNA	7.04	6.85e-12	4.62e-09	0.34	0.31	Bone mineral density;	chr8:70796736	chr8:70780914~70781008:-
LUAD	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
LUAD	cis	rs7017914	0.967	rs62508819	ENSG00000223220.1	Y_RNA	7.04	6.89e-12	4.65e-09	0.34	0.31	Bone mineral density;	chr8:70805871	chr8:70780914~70781008:-
LUAD	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-7.03	6.89e-12	4.65e-09	-0.31	-0.31	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
LUAD	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	7.03	6.91e-12	4.66e-09	0.39	0.31	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
LUAD	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	7.03	6.91e-12	4.66e-09	0.38	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
LUAD	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-7.03	6.91e-12	4.66e-09	-0.34	-0.31	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
LUAD	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-7.03	6.91e-12	4.66e-09	-0.28	-0.31	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
LUAD	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-7.03	6.91e-12	4.66e-09	-0.28	-0.31	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
LUAD	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-7.03	6.92e-12	4.67e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000211972.2	IGHV3-66	7.03	6.94e-12	4.68e-09	0.26	0.31	Kawasaki disease;	chr14:106673171	chr14:106675017~106675544:-
LUAD	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-7.03	6.95e-12	4.68e-09	-0.36	-0.31	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	7.03	6.96e-12	4.69e-09	0.39	0.31	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	7.03	6.96e-12	4.69e-09	0.39	0.31	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
LUAD	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-7.03	6.99e-12	4.71e-09	-0.54	-0.31	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
LUAD	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	7.03	6.99e-12	4.71e-09	0.29	0.31	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
LUAD	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	7.03	7e-12	4.72e-09	0.46	0.31	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
LUAD	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	7.03	7e-12	4.72e-09	0.4	0.31	Height;	chr6:109738307	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	7.03	7e-12	4.72e-09	0.4	0.31	Height;	chr6:109738751	chr6:109382795~109383666:+
LUAD	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-7.03	7.01e-12	4.72e-09	-0.36	-0.31	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
LUAD	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-7.03	7.02e-12	4.73e-09	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-7.03	7.02e-12	4.73e-09	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
LUAD	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
LUAD	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-7.03	7.04e-12	4.74e-09	-0.4	-0.31	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
LUAD	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	7.03	7.04e-12	4.74e-09	0.47	0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
LUAD	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	-7.03	7.04e-12	4.74e-09	-0.45	-0.31	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
LUAD	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-7.03	7.04e-12	4.74e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
LUAD	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-7.03	7.04e-12	4.74e-09	-0.42	-0.31	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
LUAD	cis	rs2439831	0.867	rs4075674	ENSG00000205771.5	CATSPER2P1	-7.03	7.05e-12	4.75e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43358032	chr15:43726918~43747094:-
LUAD	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-7.03	7.06e-12	4.75e-09	-0.39	-0.31	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-7.03	7.06e-12	4.75e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
LUAD	cis	rs6844153	1	rs74895929	ENSG00000240005.4	RP11-293A21.1	-7.03	7.07e-12	4.75e-09	-0.5	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26846035	chr4:26859806~26860599:-
LUAD	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-7.03	7.07e-12	4.76e-09	-0.42	-0.31	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
LUAD	cis	rs62229266	0.804	rs56279140	ENSG00000214914.3	RPL23AP3	7.03	7.08e-12	4.76e-09	0.38	0.31	Mitral valve prolapse;	chr21:36052063	chr21:36016079~36016546:-
LUAD	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-7.03	7.09e-12	4.77e-09	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
LUAD	cis	rs9549367	0.789	rs9549698	ENSG00000269125.1	RP11-98F14.11	-7.03	7.09e-12	4.77e-09	-0.38	-0.31	Platelet distribution width;	chr13:113223387	chr13:113165002~113165183:-
LUAD	cis	rs7115242	0.8	rs6589597	ENSG00000280143.1	AP000892.6	-7.03	7.09e-12	4.77e-09	-0.46	-0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
LUAD	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-7.03	7.13e-12	4.79e-09	-0.6	-0.31	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000280411.1	IGHV1-69-2	-7.03	7.13e-12	4.79e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776528	chr14:106762092~106762588:-
LUAD	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	7.03	7.18e-12	4.83e-09	0.44	0.31	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
LUAD	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-7.03	7.19e-12	4.83e-09	-0.49	-0.31	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
LUAD	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-7.03	7.19e-12	4.83e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
LUAD	cis	rs367615	0.642	rs439182	ENSG00000249476.1	CTD-2587M2.1	-7.03	7.21e-12	4.85e-09	-0.41	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109616666	chr5:109237120~109326369:-
LUAD	cis	rs10899021	1	rs10899025	ENSG00000279353.1	RP11-864N7.4	7.03	7.22e-12	4.85e-09	0.56	0.31	Response to metformin (IC50);	chr11:74655995	chr11:74698231~74699658:-
LUAD	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-7.03	7.23e-12	4.85e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
LUAD	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	7.03	7.24e-12	4.86e-09	0.37	0.31	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
LUAD	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
LUAD	cis	rs2337406	0.539	rs2583292	ENSG00000211974.3	IGHV2-70	-7.03	7.25e-12	4.87e-09	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106649040	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	7.03	7.26e-12	4.88e-09	0.39	0.31	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	7.03	7.27e-12	4.88e-09	0.39	0.31	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
LUAD	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-7.03	7.29e-12	4.89e-09	-0.41	-0.31	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-7.03	7.29e-12	4.89e-09	-0.41	-0.31	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
LUAD	cis	rs2439831	0.867	rs6493082	ENSG00000205771.5	CATSPER2P1	-7.03	7.3e-12	4.9e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43342610	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs8041132	ENSG00000205771.5	CATSPER2P1	-7.03	7.3e-12	4.9e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43342938	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs16957627	ENSG00000205771.5	CATSPER2P1	-7.03	7.3e-12	4.9e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43350459	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.717	rs7165471	ENSG00000205771.5	CATSPER2P1	-7.03	7.3e-12	4.9e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43352590	chr15:43726918~43747094:-
LUAD	cis	rs17684571	0.938	rs71564848	ENSG00000231441.1	RP11-472M19.2	7.03	7.32e-12	4.91e-09	0.43	0.31	Schizophrenia;	chr6:56684255	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs34576803	ENSG00000231441.1	RP11-472M19.2	7.03	7.32e-12	4.91e-09	0.43	0.31	Schizophrenia;	chr6:56684609	chr6:56844002~56864078:+
LUAD	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-7.03	7.32e-12	4.91e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-7.03	7.32e-12	4.91e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-7.03	7.32e-12	4.91e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
LUAD	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	7.03	7.32e-12	4.92e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
LUAD	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	7.03	7.34e-12	4.92e-09	0.39	0.31	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	7.03	7.34e-12	4.92e-09	0.39	0.31	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	7.02	7.35e-12	4.94e-09	0.33	0.31	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
LUAD	cis	rs4591358	0.689	rs34373729	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195543775	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs59639651	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544426	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927766	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545003	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs7580459	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545963	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs57555936	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546440	chr2:195533035~195538681:+
LUAD	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	7.02	7.41e-12	4.97e-09	0.43	0.31	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
LUAD	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	7.02	7.41e-12	4.97e-09	0.39	0.3	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
LUAD	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-7.02	7.41e-12	4.97e-09	-0.37	-0.3	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
LUAD	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	7.02	7.42e-12	4.97e-09	0.33	0.3	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
LUAD	cis	rs7646881	0.812	rs79303235	ENSG00000240207.5	RP11-379F4.4	-7.02	7.42e-12	4.98e-09	-0.4	-0.3	Tetralogy of Fallot;	chr3:158727004	chr3:158732263~158784070:+
LUAD	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-7.02	7.44e-12	4.99e-09	-0.48	-0.3	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-7.02	7.44e-12	4.99e-09	-0.48	-0.3	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
LUAD	cis	rs17684571	0.938	rs13192037	ENSG00000231441.1	RP11-472M19.2	7.02	7.46e-12	5e-09	0.42	0.3	Schizophrenia;	chr6:56689474	chr6:56844002~56864078:+
LUAD	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	7.02	7.47e-12	5.01e-09	0.54	0.3	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	7.02	7.49e-12	5.02e-09	0.39	0.3	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	7.02	7.49e-12	5.02e-09	0.39	0.3	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
LUAD	cis	rs7646881	0.812	rs74618709	ENSG00000240207.5	RP11-379F4.4	-7.02	7.49e-12	5.02e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158737492	chr3:158732263~158784070:+
LUAD	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-7.02	7.49e-12	5.02e-09	-0.32	-0.3	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
LUAD	cis	rs10759883	0.627	rs596413	ENSG00000175611.10	LINC00476	7.02	7.5e-12	5.03e-09	0.36	0.3	Nicotine dependence;	chr9:95871561	chr9:95759231~95875977:-
LUAD	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-7.02	7.51e-12	5.03e-09	-0.36	-0.3	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
LUAD	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-7.02	7.51e-12	5.04e-09	-0.32	-0.3	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
LUAD	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	7.02	7.54e-12	5.05e-09	0.37	0.3	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
LUAD	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	7.02	7.54e-12	5.05e-09	0.39	0.3	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-7.02	7.54e-12	5.05e-09	-0.36	-0.3	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
LUAD	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-7.02	7.55e-12	5.06e-09	-0.42	-0.3	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
LUAD	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	7.02	7.56e-12	5.07e-09	0.47	0.3	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
LUAD	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	7.02	7.57e-12	5.07e-09	0.35	0.3	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
LUAD	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-7.02	7.57e-12	5.07e-09	-0.4	-0.3	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000224373.3	IGHV4-59	7.02	7.58e-12	5.08e-09	0.18	0.3	Kawasaki disease;	chr14:106686149	chr14:106627249~106627825:-
LUAD	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-7.02	7.6e-12	5.09e-09	-0.39	-0.3	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
LUAD	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	7.02	7.6e-12	5.09e-09	0.33	0.3	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
LUAD	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-7.02	7.62e-12	5.11e-09	-0.36	-0.3	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-7.02	7.62e-12	5.11e-09	-0.36	-0.3	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-7.02	7.62e-12	5.11e-09	-0.36	-0.3	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	7.02	7.63e-12	5.11e-09	0.39	0.3	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
LUAD	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-7.02	7.63e-12	5.11e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
LUAD	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-7.02	7.63e-12	5.11e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
LUAD	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-7.02	7.63e-12	5.11e-09	-0.41	-0.3	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
LUAD	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	7.02	7.64e-12	5.12e-09	0.45	0.3	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-7.02	7.65e-12	5.12e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
LUAD	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	7.02	7.65e-12	5.12e-09	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	7.02	7.65e-12	5.12e-09	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000280411.1	IGHV1-69-2	-7.02	7.66e-12	5.13e-09	-0.22	-0.3	Kawasaki disease;	chr14:106776695	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000280411.1	IGHV1-69-2	-7.02	7.66e-12	5.13e-09	-0.22	-0.3	Kawasaki disease;	chr14:106778202	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000280411.1	IGHV1-69-2	-7.02	7.66e-12	5.13e-09	-0.22	-0.3	Kawasaki disease;	chr14:106778401	chr14:106762092~106762588:-
LUAD	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	7.02	7.69e-12	5.14e-09	0.36	0.3	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-7.02	7.69e-12	5.15e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-7.02	7.69e-12	5.15e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-7.02	7.69e-12	5.15e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-7.02	7.69e-12	5.15e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-7.02	7.72e-12	5.17e-09	-0.36	-0.3	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000211972.2	IGHV3-66	7.02	7.73e-12	5.17e-09	0.27	0.3	Kawasaki disease;	chr14:106787730	chr14:106675017~106675544:-
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	7.02	7.75e-12	5.18e-09	0.57	0.3	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	7.02	7.75e-12	5.18e-09	0.57	0.3	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	7.02	7.75e-12	5.18e-09	0.57	0.3	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
LUAD	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-7.02	7.75e-12	5.18e-09	-0.36	-0.3	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
LUAD	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	7.02	7.76e-12	5.19e-09	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	7.02	7.76e-12	5.19e-09	0.47	0.3	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
LUAD	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-7.02	7.77e-12	5.2e-09	-0.4	-0.3	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
LUAD	cis	rs9326248	0.53	rs10750101	ENSG00000280143.1	AP000892.6	7.02	7.78e-12	5.2e-09	0.47	0.3	Blood protein levels;	chr11:117108973	chr11:117204967~117210292:+
LUAD	cis	rs8177876	0.658	rs16954505	ENSG00000261838.4	RP11-303E16.6	7.02	7.78e-12	5.2e-09	0.67	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81040555	chr16:81069854~81076598:+
LUAD	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	7.02	7.79e-12	5.2e-09	0.38	0.3	Height;	chr6:109367335	chr6:109382795~109383666:+
LUAD	cis	rs904251	0.698	rs2646926	ENSG00000279942.1	RP1-153P14.7	-7.02	7.8e-12	5.21e-09	-0.3	-0.3	Cognitive performance;	chr6:37457212	chr6:37567716~37571460:+
LUAD	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	7.02	7.81e-12	5.22e-09	0.5	0.3	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
LUAD	cis	rs9326248	0.53	rs2000614	ENSG00000280143.1	AP000892.6	7.02	7.82e-12	5.23e-09	0.46	0.3	Blood protein levels;	chr11:117045026	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.53	rs2000616	ENSG00000280143.1	AP000892.6	7.02	7.82e-12	5.23e-09	0.46	0.3	Blood protein levels;	chr11:117045813	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.53	rs10750100	ENSG00000280143.1	AP000892.6	7.02	7.82e-12	5.23e-09	0.46	0.3	Blood protein levels;	chr11:117046528	chr11:117204967~117210292:+
LUAD	cis	rs1815787	1	rs1815787	ENSG00000280143.1	AP000892.6	7.02	7.82e-12	5.23e-09	0.46	0.3	Subjective well-being;	chr11:117050681	chr11:117204967~117210292:+
LUAD	cis	rs4141404	0.604	rs2103853	ENSG00000236132.1	CTA-440B3.1	-7.02	7.83e-12	5.23e-09	-0.35	-0.3	Paclitaxel-induced neuropathy;	chr22:31459489	chr22:31816379~31817491:-
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	7.02	7.84e-12	5.24e-09	0.22	0.3	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	7.01	7.85e-12	5.24e-09	0.39	0.3	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.713	rs3024746	ENSG00000269125.1	RP11-98F14.11	-7.01	7.86e-12	5.25e-09	-0.4	-0.3	Platelet distribution width;	chr13:113167463	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs3024747	ENSG00000269125.1	RP11-98F14.11	-7.01	7.86e-12	5.25e-09	-0.4	-0.3	Platelet distribution width;	chr13:113167473	chr13:113165002~113165183:-
LUAD	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	7.01	7.86e-12	5.25e-09	0.37	0.3	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
LUAD	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	7.01	7.87e-12	5.26e-09	0.32	0.3	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
LUAD	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	7.01	7.9e-12	5.28e-09	0.43	0.3	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
LUAD	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-7.01	7.92e-12	5.29e-09	-0.39	-0.3	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
LUAD	cis	rs2439831	0.867	rs6493085	ENSG00000205771.5	CATSPER2P1	-7.01	7.92e-12	5.29e-09	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43361984	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2412778	ENSG00000205771.5	CATSPER2P1	-7.01	7.92e-12	5.29e-09	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43368784	chr15:43726918~43747094:-
LUAD	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	7.01	7.94e-12	5.3e-09	0.45	0.3	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
LUAD	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	7.01	7.94e-12	5.3e-09	0.38	0.3	Height;	chr6:109393881	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	7.01	7.94e-12	5.3e-09	0.39	0.3	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	7.01	7.94e-12	5.3e-09	0.39	0.3	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
LUAD	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	7.01	7.97e-12	5.32e-09	0.35	0.3	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
LUAD	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-7.01	7.98e-12	5.33e-09	-0.32	-0.3	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
LUAD	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	7.01	7.98e-12	5.33e-09	0.39	0.3	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
LUAD	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-7.01	7.98e-12	5.33e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-7.01	7.98e-12	5.33e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
LUAD	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-7.01	8.01e-12	5.35e-09	-0.28	-0.3	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
LUAD	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	7.01	8.01e-12	5.35e-09	0.4	0.3	Height;	chr6:109732518	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	7.01	8.01e-12	5.35e-09	0.39	0.3	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
LUAD	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-7.01	8.03e-12	5.36e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
LUAD	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-7.01	8.03e-12	5.36e-09	-0.39	-0.3	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000224373.3	IGHV4-59	7.01	8.05e-12	5.37e-09	0.18	0.3	Kawasaki disease;	chr14:106673891	chr14:106627249~106627825:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-7.01	8.06e-12	5.38e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
LUAD	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	7.01	8.06e-12	5.38e-09	0.4	0.3	Height;	chr6:109740895	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	7.01	8.1e-12	5.4e-09	0.39	0.3	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
LUAD	cis	rs72772090	0.539	rs72773981	ENSG00000248734.2	CTD-2260A17.1	-7.01	8.11e-12	5.41e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96820356	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-7.01	8.12e-12	5.42e-09	-0.36	-0.3	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000280411.1	IGHV1-69-2	-7.01	8.13e-12	5.42e-09	-0.24	-0.3	Kawasaki disease;	chr14:106697402	chr14:106762092~106762588:-
LUAD	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-7.01	8.13e-12	5.42e-09	-0.4	-0.3	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
LUAD	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-7.01	8.13e-12	5.42e-09	-0.67	-0.3	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
LUAD	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	7.01	8.13e-12	5.42e-09	0.39	0.3	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-7.01	8.13e-12	5.42e-09	-0.31	-0.3	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
LUAD	cis	rs9595908	0.9	rs1324415	ENSG00000212293.1	SNORA16	7.01	8.14e-12	5.43e-09	0.32	0.3	Body mass index;	chr13:32600186	chr13:32420390~32420516:-
LUAD	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-7.01	8.16e-12	5.44e-09	-0.48	-0.3	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000280411.1	IGHV1-69-2	-7.01	8.16e-12	5.44e-09	-0.23	-0.3	Kawasaki disease;	chr14:106777528	chr14:106762092~106762588:-
LUAD	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-7.01	8.2e-12	5.47e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
LUAD	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-7.01	8.21e-12	5.48e-09	-0.46	-0.3	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
LUAD	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	7.01	8.22e-12	5.48e-09	0.35	0.3	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	7.01	8.22e-12	5.48e-09	0.35	0.3	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000280411.1	IGHV1-69-2	-7.01	8.25e-12	5.5e-09	-0.24	-0.3	Kawasaki disease;	chr14:106704323	chr14:106762092~106762588:-
LUAD	cis	rs7115242	0.8	rs1320668	ENSG00000280143.1	AP000892.6	7.01	8.25e-12	5.5e-09	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117204967~117210292:+
LUAD	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	7.01	8.26e-12	5.5e-09	0.35	0.3	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
LUAD	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-7.01	8.3e-12	5.53e-09	-0.28	-0.3	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
LUAD	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-7.01	8.31e-12	5.54e-09	-0.38	-0.3	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	7.01	8.31e-12	5.54e-09	0.37	0.3	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	7.01	8.31e-12	5.54e-09	0.37	0.3	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
LUAD	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
LUAD	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	7.01	8.32e-12	5.54e-09	0.34	0.3	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
LUAD	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-7.01	8.34e-12	5.55e-09	-0.39	-0.3	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
LUAD	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-7.01	8.35e-12	5.56e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-7.01	8.35e-12	5.56e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
LUAD	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	7.01	8.36e-12	5.56e-09	0.51	0.3	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
LUAD	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-7.01	8.36e-12	5.57e-09	-0.41	-0.3	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
LUAD	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	7.01	8.37e-12	5.57e-09	0.36	0.3	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	7.01	8.37e-12	5.57e-09	0.36	0.3	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
LUAD	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-7	8.38e-12	5.58e-09	-0.47	-0.3	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
LUAD	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-7	8.38e-12	5.58e-09	-0.42	-0.3	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
LUAD	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-7	8.41e-12	5.6e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
LUAD	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-7	8.42e-12	5.61e-09	-0.36	-0.3	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-7	8.42e-12	5.61e-09	-0.36	-0.3	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-7	8.42e-12	5.61e-09	-0.36	-0.3	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
LUAD	cis	rs10899021	0.92	rs12287097	ENSG00000279353.1	RP11-864N7.4	7	8.46e-12	5.63e-09	0.54	0.3	Response to metformin (IC50);	chr11:74621619	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.92	rs11236174	ENSG00000279353.1	RP11-864N7.4	7	8.46e-12	5.63e-09	0.54	0.3	Response to metformin (IC50);	chr11:74623156	chr11:74698231~74699658:-
LUAD	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	7	8.48e-12	5.64e-09	0.37	0.3	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
LUAD	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-7	8.48e-12	5.64e-09	-0.31	-0.3	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
LUAD	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-7	8.51e-12	5.66e-09	-0.41	-0.3	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
LUAD	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	7	8.52e-12	5.67e-09	0.39	0.3	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-7	8.53e-12	5.67e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-7	8.53e-12	5.67e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000224373.3	IGHV4-59	7	8.53e-12	5.67e-09	0.18	0.3	Kawasaki disease;	chr14:106685105	chr14:106627249~106627825:-
LUAD	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	7	8.55e-12	5.68e-09	0.39	0.3	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	7	8.55e-12	5.68e-09	0.39	0.3	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
LUAD	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	7	8.55e-12	5.69e-09	0.39	0.3	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
LUAD	cis	rs11123170	0.543	rs2863242	ENSG00000274877.1	RP11-65I12.1	-7	8.59e-12	5.71e-09	-0.47	-0.3	Renal function-related traits (BUN);	chr2:113231659	chr2:113237595~113240825:+
LUAD	cis	rs62229266	0.771	rs11701590	ENSG00000214914.3	RPL23AP3	7	8.59e-12	5.71e-09	0.38	0.3	Mitral valve prolapse;	chr21:36012432	chr21:36016079~36016546:-
LUAD	cis	rs7017914	0.967	rs12675271	ENSG00000223220.1	Y_RNA	7	8.6e-12	5.72e-09	0.34	0.3	Bone mineral density;	chr8:70689774	chr8:70780914~70781008:-
LUAD	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-7	8.63e-12	5.74e-09	-0.39	-0.3	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
LUAD	cis	rs7182621	0.774	rs12101368	ENSG00000182397.13	DNM1P46	7	8.64e-12	5.74e-09	0.37	0.3	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99790156~99806927:-
LUAD	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-7	8.65e-12	5.75e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
LUAD	cis	rs8177876	0.584	rs2549899	ENSG00000261838.4	RP11-303E16.6	-7	8.65e-12	5.75e-09	-0.54	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81069854~81076598:+
LUAD	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-7	8.66e-12	5.75e-09	-0.33	-0.3	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000224373.3	IGHV4-59	7	8.68e-12	5.77e-09	0.18	0.3	Kawasaki disease;	chr14:106681273	chr14:106627249~106627825:-
LUAD	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	7	8.7e-12	5.78e-09	0.39	0.3	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	7	8.7e-12	5.78e-09	0.39	0.3	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	7	8.7e-12	5.78e-09	0.39	0.3	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	7	8.7e-12	5.78e-09	0.39	0.3	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
LUAD	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-7	8.71e-12	5.78e-09	-0.62	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
LUAD	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-7	8.71e-12	5.79e-09	-0.52	-0.3	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
LUAD	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
LUAD	cis	rs4591358	0.689	rs72927760	ENSG00000223466.1	AC064834.2	-7	8.74e-12	5.8e-09	-0.45	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544584	chr2:195533035~195538681:+
LUAD	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-7	8.74e-12	5.8e-09	-0.51	-0.3	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000211972.2	IGHV3-66	7	8.74e-12	5.81e-09	0.26	0.3	Kawasaki disease;	chr14:106782238	chr14:106675017~106675544:-
LUAD	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	7	8.77e-12	5.83e-09	0.54	0.3	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
LUAD	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-7	8.77e-12	5.83e-09	-0.36	-0.3	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
LUAD	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	7	8.78e-12	5.83e-09	0.34	0.3	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
LUAD	cis	rs35955747	0.902	rs131202	ENSG00000236132.1	CTA-440B3.1	-7	8.78e-12	5.83e-09	-0.34	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31313323	chr22:31816379~31817491:-
LUAD	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	7	8.78e-12	5.83e-09	0.39	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
LUAD	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-7	8.79e-12	5.84e-09	-0.4	-0.3	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-7	8.79e-12	5.84e-09	-0.4	-0.3	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
LUAD	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	7	8.81e-12	5.85e-09	0.47	0.3	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
LUAD	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	7	8.82e-12	5.86e-09	0.36	0.3	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
LUAD	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	7	8.83e-12	5.86e-09	0.39	0.3	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	7	8.86e-12	5.88e-09	0.39	0.3	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
LUAD	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-7	8.86e-12	5.88e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
LUAD	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-7	8.87e-12	5.89e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
LUAD	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-7	8.87e-12	5.89e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
LUAD	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-7	8.87e-12	5.89e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
LUAD	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	7	8.88e-12	5.89e-09	0.69	0.3	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	7	8.88e-12	5.89e-09	0.69	0.3	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	7	8.88e-12	5.89e-09	0.69	0.3	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
LUAD	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-7	8.9e-12	5.9e-09	-0.46	-0.3	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
LUAD	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-7	8.9e-12	5.91e-09	-0.36	-0.3	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
LUAD	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	7	8.92e-12	5.91e-09	0.45	0.3	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
LUAD	cis	rs10200159	0.744	rs7586124	ENSG00000272606.1	RP11-554J4.1	6.99	8.93e-12	5.93e-09	0.52	0.3	Vitiligo;	chr2:55558165	chr2:55617909~55618373:+
LUAD	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	6.99	8.95e-12	5.94e-09	0.38	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
LUAD	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
LUAD	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-6.99	8.98e-12	5.95e-09	-0.39	-0.3	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-6.99	8.98e-12	5.95e-09	-0.39	-0.3	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
LUAD	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	6.99	8.98e-12	5.95e-09	0.38	0.3	Height;	chr6:109390638	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	6.99	9e-12	5.96e-09	0.57	0.3	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	6.99	9e-12	5.96e-09	0.57	0.3	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
LUAD	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	6.99	9.01e-12	5.97e-09	0.48	0.3	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
LUAD	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-6.99	9.03e-12	5.98e-09	-0.36	-0.3	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-6.99	9.03e-12	5.98e-09	-0.36	-0.3	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
LUAD	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	6.99	9.05e-12	6e-09	0.26	0.3	Breast size;	chr12:9232939	chr12:9277235~9313241:+
LUAD	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	6.99	9.05e-12	6e-09	0.39	0.3	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
LUAD	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-6.99	9.05e-12	6e-09	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
LUAD	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-6.99	9.06e-12	6e-09	-0.27	-0.3	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
LUAD	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-6.99	9.06e-12	6e-09	-0.27	-0.3	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
LUAD	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-6.99	9.06e-12	6.01e-09	-0.41	-0.3	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
LUAD	cis	rs7115242	0.8	rs4245168	ENSG00000280143.1	AP000892.6	6.99	9.07e-12	6.01e-09	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117204967~117210292:+
LUAD	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
LUAD	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	6.99	9.1e-12	6.03e-09	0.33	0.3	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
LUAD	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-6.99	9.1e-12	6.03e-09	-0.32	-0.3	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
LUAD	cis	rs11123170	0.543	rs4849180	ENSG00000274877.1	RP11-65I12.1	-6.99	9.17e-12	6.07e-09	-0.46	-0.3	Renal function-related traits (BUN);	chr2:113227609	chr2:113237595~113240825:+
LUAD	cis	rs7927592	0.789	rs2291467	ENSG00000212093.1	AP000807.1	6.99	9.18e-12	6.07e-09	0.35	0.3	Total body bone mineral density;	chr11:68449288	chr11:68506083~68506166:-
LUAD	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	6.99	9.22e-12	6.1e-09	0.4	0.3	Depression;	chr6:28386473	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	6.99	9.23e-12	6.11e-09	0.42	0.3	Depression;	chr6:28109824	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	6.99	9.23e-12	6.11e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	6.99	9.23e-12	6.11e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	6.99	9.23e-12	6.11e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
LUAD	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-6.99	9.24e-12	6.12e-09	-0.32	-0.3	Gout;	chr7:66642037	chr7:66902857~66906297:+
LUAD	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-6.99	9.26e-12	6.13e-09	-0.4	-0.3	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
LUAD	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-6.99	9.28e-12	6.14e-09	-0.61	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
LUAD	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	6.99	9.28e-12	6.14e-09	0.27	0.3	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
LUAD	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-6.99	9.29e-12	6.14e-09	-0.31	-0.3	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
LUAD	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	6.99	9.32e-12	6.17e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
LUAD	cis	rs7044106	0.791	rs735109	ENSG00000238181.2	AHCYP2	-6.99	9.33e-12	6.17e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120720673~120721972:+
LUAD	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-6.99	9.34e-12	6.18e-09	-0.39	-0.3	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
LUAD	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-6.99	9.36e-12	6.19e-09	-0.32	-0.3	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
LUAD	cis	rs7688540	0.713	rs4624608	ENSG00000275426.1	CH17-262A2.1	6.99	9.37e-12	6.2e-09	0.39	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:149738~150317:+
LUAD	cis	rs1318937	1	rs3821639	ENSG00000224660.1	SH3BP5-AS1	6.99	9.37e-12	6.2e-09	0.25	0.3	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15264159	chr3:15254184~15264493:+
LUAD	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-6.99	9.37e-12	6.2e-09	-0.36	-0.3	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
LUAD	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-6.99	9.38e-12	6.2e-09	-0.4	-0.3	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
LUAD	cis	rs17818399	0.708	rs13000706	ENSG00000279254.1	RP11-536C12.1	-6.99	9.4e-12	6.21e-09	-0.31	-0.3	Height;	chr2:46611108	chr2:46668870~46670778:+
LUAD	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
LUAD	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	6.99	9.41e-12	6.21e-09	0.39	0.3	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
LUAD	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-6.99	9.42e-12	6.22e-09	-0.36	-0.3	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
LUAD	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-6.99	9.45e-12	6.24e-09	-0.4	-0.3	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
LUAD	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	6.99	9.49e-12	6.26e-09	0.37	0.3	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
LUAD	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-6.99	9.51e-12	6.27e-09	-0.62	-0.3	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
LUAD	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-6.99	9.51e-12	6.27e-09	-0.56	-0.3	Gout;	chr7:66671562	chr7:66654538~66669855:+
LUAD	cis	rs7017914	0.934	rs7814274	ENSG00000223220.1	Y_RNA	-6.99	9.51e-12	6.28e-09	-0.34	-0.3	Bone mineral density;	chr8:70658176	chr8:70780914~70781008:-
LUAD	cis	rs9326248	0.53	rs7950364	ENSG00000280143.1	AP000892.6	6.99	9.52e-12	6.28e-09	0.47	0.3	Blood protein levels;	chr11:117028170	chr11:117204967~117210292:+
LUAD	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-6.98	9.58e-12	6.32e-09	-0.37	-0.3	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
LUAD	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	6.98	9.59e-12	6.32e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
LUAD	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-6.98	9.6e-12	6.33e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	6.98	9.6e-12	6.33e-09	0.44	0.3	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
LUAD	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	6.98	9.61e-12	6.34e-09	0.35	0.3	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
LUAD	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	6.98	9.62e-12	6.34e-09	0.36	0.3	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
LUAD	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-6.98	9.62e-12	6.34e-09	-0.36	-0.3	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
LUAD	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-6.98	9.64e-12	6.35e-09	-0.32	-0.3	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-6.98	9.65e-12	6.36e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-6.98	9.66e-12	6.36e-09	-0.39	-0.3	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
LUAD	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	6.98	9.68e-12	6.38e-09	0.48	0.3	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
LUAD	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-6.98	9.68e-12	6.38e-09	-0.56	-0.3	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-6.98	9.68e-12	6.38e-09	-0.56	-0.3	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-6.98	9.68e-12	6.38e-09	-0.56	-0.3	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-6.98	9.69e-12	6.38e-09	-0.4	-0.3	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
LUAD	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	6.98	9.69e-12	6.39e-09	0.47	0.3	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
LUAD	cis	rs9326248	0.53	rs2513093	ENSG00000280143.1	AP000892.6	6.98	9.7e-12	6.39e-09	0.48	0.3	Blood protein levels;	chr11:116935971	chr11:117204967~117210292:+
LUAD	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	6.98	9.7e-12	6.39e-09	0.39	0.3	Depression;	chr6:28402301	chr6:28943877~28944537:+
LUAD	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-6.98	9.7e-12	6.39e-09	-0.44	-0.3	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
LUAD	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	6.98	9.73e-12	6.41e-09	0.33	0.3	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
LUAD	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-6.98	9.73e-12	6.41e-09	-0.35	-0.3	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	6.98	9.73e-12	6.41e-09	0.38	0.3	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
LUAD	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	6.98	9.74e-12	6.42e-09	0.32	0.3	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
LUAD	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-6.98	9.75e-12	6.42e-09	-0.36	-0.3	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-6.98	9.75e-12	6.42e-09	-0.36	-0.3	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-6.98	9.75e-12	6.42e-09	-0.36	-0.3	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
LUAD	cis	rs2439831	0.681	rs825739	ENSG00000205771.5	CATSPER2P1	-6.98	9.76e-12	6.43e-09	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43300230	chr15:43726918~43747094:-
LUAD	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	6.98	9.76e-12	6.43e-09	0.43	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	6.98	9.76e-12	6.43e-09	0.43	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
LUAD	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	6.98	9.79e-12	6.45e-09	0.34	0.3	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
LUAD	cis	rs944289	0.746	rs34407552	ENSG00000257826.1	RP11-116N8.4	-6.98	9.8e-12	6.45e-09	-0.32	-0.3	Thyroid cancer;	chr14:36132935	chr14:36061026~36067190:-
LUAD	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	6.98	9.81e-12	6.46e-09	0.39	0.3	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-6.98	9.83e-12	6.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
LUAD	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-6.98	9.84e-12	6.48e-09	-0.33	-0.3	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-6.98	9.86e-12	6.49e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
LUAD	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-6.98	9.89e-12	6.51e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
LUAD	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	6.98	9.89e-12	6.51e-09	0.39	0.3	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	6.98	9.93e-12	6.53e-09	0.3	0.3	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
LUAD	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	6.98	9.95e-12	6.54e-09	0.66	0.3	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	6.98	9.95e-12	6.54e-09	0.66	0.3	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	6.98	9.95e-12	6.54e-09	0.66	0.3	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	6.98	9.95e-12	6.54e-09	0.66	0.3	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	6.98	9.97e-12	6.56e-09	0.35	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
LUAD	cis	rs7201929	0.959	rs35725751	ENSG00000259982.1	CDC37P1	-6.98	9.98e-12	6.56e-09	-0.46	-0.3	QT interval;	chr16:28834263	chr16:28700294~28701540:-
LUAD	cis	rs12458462	0.859	rs34242155	ENSG00000274828.1	RP11-567M16.6	6.98	9.98e-12	6.56e-09	0.31	0.3	Monocyte count;	chr18:79665192	chr18:79677287~79679358:-
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000224373.3	IGHV4-59	6.98	9.98e-12	6.56e-09	0.18	0.3	Kawasaki disease;	chr14:106687277	chr14:106627249~106627825:-
LUAD	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-6.98	1e-11	6.57e-09	-0.42	-0.3	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
LUAD	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-6.98	1e-11	6.58e-09	-0.35	-0.3	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
LUAD	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-6.98	1e-11	6.58e-09	-0.36	-0.3	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
LUAD	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.59e-09	0.39	0.3	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
LUAD	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-6.98	1e-11	6.59e-09	-0.36	-0.3	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.59e-09	0.39	0.3	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.59e-09	0.39	0.3	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.6e-09	0.39	0.3	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.6e-09	0.39	0.3	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
LUAD	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-6.98	1e-11	6.6e-09	-0.41	-0.3	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
LUAD	cis	rs9595908	0.9	rs1324414	ENSG00000212293.1	SNORA16	6.98	1.01e-11	6.62e-09	0.32	0.3	Body mass index;	chr13:32600088	chr13:32420390~32420516:-
LUAD	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-6.98	1.01e-11	6.63e-09	-0.39	-0.3	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-6.98	1.01e-11	6.64e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000211974.3	IGHV2-70	-6.98	1.01e-11	6.64e-09	-0.38	-0.3	Rheumatic heart disease;	chr14:106637262	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000211974.3	IGHV2-70	-6.98	1.01e-11	6.64e-09	-0.38	-0.3	Rheumatic heart disease;	chr14:106638192	chr14:106723574~106724093:-
LUAD	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	6.98	1.01e-11	6.65e-09	0.38	0.3	Height;	chr6:109361200	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000211972.2	IGHV3-66	6.98	1.01e-11	6.66e-09	0.26	0.3	Kawasaki disease;	chr14:106782206	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	6.97	1.02e-11	6.68e-09	0.39	0.3	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.713	rs3024764	ENSG00000269125.1	RP11-98F14.11	-6.97	1.02e-11	6.69e-09	-0.39	-0.3	Platelet distribution width;	chr13:113170000	chr13:113165002~113165183:-
LUAD	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-6.97	1.02e-11	6.69e-09	-0.37	-0.3	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
LUAD	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	6.97	1.02e-11	6.69e-09	0.38	0.3	Height;	chr6:109402736	chr6:109382795~109383666:+
LUAD	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	6.97	1.02e-11	6.7e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
LUAD	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-6.97	1.02e-11	6.71e-09	-0.56	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
LUAD	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	6.97	1.02e-11	6.71e-09	0.45	0.3	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
LUAD	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-6.97	1.02e-11	6.72e-09	-0.4	-0.3	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
LUAD	cis	rs10200159	1	rs17047094	ENSG00000272606.1	RP11-554J4.1	6.97	1.02e-11	6.72e-09	0.51	0.3	Vitiligo;	chr2:55570701	chr2:55617909~55618373:+
LUAD	cis	rs11846409	0.587	rs1806881	ENSG00000211974.3	IGHV2-70	6.97	1.02e-11	6.72e-09	0.39	0.3	Rheumatic heart disease;	chr14:106650770	chr14:106723574~106724093:-
LUAD	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-6.97	1.03e-11	6.75e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
LUAD	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	6.97	1.03e-11	6.75e-09	0.35	0.3	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
LUAD	cis	rs72772090	0.539	rs72773986	ENSG00000248734.2	CTD-2260A17.1	-6.97	1.03e-11	6.75e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96824014	chr5:96784777~96785999:+
LUAD	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	6.97	1.03e-11	6.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-6.97	1.03e-11	6.77e-09	-0.36	-0.3	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-6.97	1.03e-11	6.79e-09	-0.36	-0.3	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-6.97	1.03e-11	6.79e-09	-0.36	-0.3	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
LUAD	cis	rs9549367	0.712	rs2316443	ENSG00000269125.1	RP11-98F14.11	-6.97	1.04e-11	6.79e-09	-0.38	-0.3	Platelet distribution width;	chr13:113210523	chr13:113165002~113165183:-
LUAD	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-6.97	1.04e-11	6.8e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-6.97	1.04e-11	6.8e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
LUAD	cis	rs237743	1	rs6012617	ENSG00000222365.1	SNORD12B	6.97	1.04e-11	6.8e-09	0.35	0.3	Height;	chr20:49220589	chr20:49280319~49280409:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-6.97	1.04e-11	6.8e-09	-0.21	-0.3	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
LUAD	cis	rs2439831	0.717	rs10518820	ENSG00000205771.5	CATSPER2P1	-6.97	1.04e-11	6.82e-09	-0.61	-0.3	Lung cancer in ever smokers;	chr15:43596778	chr15:43726918~43747094:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-6.97	1.04e-11	6.83e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-6.97	1.04e-11	6.83e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	6.97	1.04e-11	6.84e-09	0.39	0.3	Depression;	chr6:28240757	chr6:28943877~28944537:+
LUAD	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	6.97	1.04e-11	6.84e-09	0.33	0.3	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
LUAD	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-6.97	1.04e-11	6.84e-09	-0.42	-0.3	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	6.97	1.05e-11	6.88e-09	0.4	0.3	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
LUAD	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	6.97	1.05e-11	6.89e-09	0.62	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
LUAD	cis	rs11089937	0.616	rs4991802	ENSG00000211639.2	IGLV4-60	6.97	1.05e-11	6.9e-09	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22179031	chr22:22162199~22162681:+
LUAD	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-6.97	1.05e-11	6.91e-09	-0.42	-0.3	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
LUAD	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-6.97	1.06e-11	6.94e-09	-0.32	-0.3	Gout;	chr7:66645053	chr7:66902857~66906297:+
LUAD	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	6.97	1.06e-11	6.94e-09	0.39	0.3	Height;	chr6:109476101	chr6:109382795~109383666:+
LUAD	cis	rs62229266	0.804	rs12483151	ENSG00000214914.3	RPL23AP3	6.97	1.06e-11	6.94e-09	0.37	0.3	Mitral valve prolapse;	chr21:36047280	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.804	rs880221	ENSG00000214914.3	RPL23AP3	6.97	1.06e-11	6.94e-09	0.37	0.3	Mitral valve prolapse;	chr21:36048487	chr21:36016079~36016546:-
LUAD	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-6.97	1.06e-11	6.95e-09	-0.36	-0.3	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	6.97	1.07e-11	6.98e-09	0.39	0.3	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
LUAD	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	6.97	1.07e-11	7e-09	0.36	0.3	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	6.97	1.07e-11	7.02e-09	0.43	0.3	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
LUAD	cis	rs950880	0.71	rs11693204	ENSG00000234389.1	AC007278.3	-6.97	1.07e-11	7.02e-09	-0.31	-0.3	Serum protein levels (sST2);	chr2:102319514	chr2:102438713~102440475:+
LUAD	cis	rs9549367	0.713	rs9577211	ENSG00000269125.1	RP11-98F14.11	-6.97	1.08e-11	7.04e-09	-0.39	-0.3	Platelet distribution width;	chr13:113176404	chr13:113165002~113165183:-
LUAD	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-6.97	1.08e-11	7.05e-09	-0.43	-0.3	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
LUAD	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	6.97	1.08e-11	7.06e-09	0.4	0.3	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
LUAD	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-6.97	1.08e-11	7.08e-09	-0.44	-0.3	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	6.97	1.08e-11	7.09e-09	0.33	0.3	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	6.97	1.08e-11	7.09e-09	0.33	0.3	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000224373.3	IGHV4-59	6.96	1.09e-11	7.11e-09	0.18	0.3	Kawasaki disease;	chr14:106682022	chr14:106627249~106627825:-
LUAD	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-6.96	1.09e-11	7.11e-09	-0.36	-0.3	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
LUAD	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	6.96	1.09e-11	7.12e-09	0.35	0.3	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	6.96	1.09e-11	7.12e-09	0.35	0.3	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
LUAD	cis	rs72772090	0.539	rs72773991	ENSG00000248734.2	CTD-2260A17.1	-6.96	1.09e-11	7.12e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96828072	chr5:96784777~96785999:+
LUAD	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	6.96	1.09e-11	7.12e-09	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
LUAD	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-6.96	1.09e-11	7.12e-09	-0.39	-0.3	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
LUAD	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-6.96	1.09e-11	7.12e-09	-0.39	-0.3	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
LUAD	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	6.96	1.09e-11	7.12e-09	0.38	0.3	Height;	chr6:109397362	chr6:109382795~109383666:+
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000206090.4	AP000350.7	6.96	1.09e-11	7.14e-09	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23939998~23942798:+
LUAD	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-6.96	1.09e-11	7.15e-09	-0.47	-0.3	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
LUAD	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	6.96	1.09e-11	7.16e-09	0.46	0.3	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	6.96	1.09e-11	7.16e-09	0.46	0.3	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
LUAD	cis	rs9326248	0.581	rs10892076	ENSG00000280143.1	AP000892.6	6.96	1.09e-11	7.16e-09	0.35	0.3	Blood protein levels;	chr11:117118220	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	6.96	1.09e-11	7.17e-09	0.39	0.3	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
LUAD	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-6.96	1.1e-11	7.17e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-6.96	1.1e-11	7.17e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-6.96	1.1e-11	7.17e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-6.96	1.1e-11	7.17e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
LUAD	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	6.96	1.1e-11	7.18e-09	0.39	0.3	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	6.96	1.1e-11	7.19e-09	0.39	0.3	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
LUAD	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-6.96	1.1e-11	7.2e-09	-0.3	-0.3	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
LUAD	cis	rs62229266	0.563	rs6517325	ENSG00000214914.3	RPL23AP3	6.96	1.1e-11	7.2e-09	0.37	0.3	Mitral valve prolapse;	chr21:36062680	chr21:36016079~36016546:-
LUAD	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-6.96	1.1e-11	7.21e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
LUAD	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	6.96	1.11e-11	7.23e-09	0.32	0.3	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-6.96	1.11e-11	7.23e-09	-0.32	-0.3	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
LUAD	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-6.96	1.11e-11	7.24e-09	-0.58	-0.3	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
LUAD	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-6.96	1.11e-11	7.24e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
LUAD	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-6.96	1.11e-11	7.25e-09	-0.27	-0.3	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
LUAD	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	6.96	1.11e-11	7.27e-09	0.39	0.3	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
LUAD	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	6.96	1.11e-11	7.28e-09	0.41	0.3	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
LUAD	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	6.96	1.12e-11	7.33e-09	0.39	0.3	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
LUAD	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
LUAD	cis	rs556990	0.76	rs3024739	ENSG00000269125.1	RP11-98F14.11	-6.96	1.12e-11	7.34e-09	-0.41	-0.3	Blood protein levels;	chr13:113165634	chr13:113165002~113165183:-
LUAD	cis	rs2842992	0.724	rs15982	ENSG00000237927.1	RP3-393E18.2	-6.96	1.12e-11	7.35e-09	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159586955~159589169:-
LUAD	cis	rs7044106	0.734	rs12553070	ENSG00000238181.2	AHCYP2	-6.96	1.13e-11	7.36e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120720673~120721972:+
LUAD	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-6.96	1.13e-11	7.37e-09	-0.32	-0.3	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
LUAD	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	6.96	1.13e-11	7.37e-09	0.38	0.3	Height;	chr6:109383239	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	6.96	1.13e-11	7.37e-09	0.38	0.3	Height;	chr6:109383248	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	6.96	1.13e-11	7.37e-09	0.38	0.3	Height;	chr6:109384807	chr6:109382795~109383666:+
LUAD	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	6.96	1.13e-11	7.38e-09	0.4	0.3	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
LUAD	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	6.96	1.13e-11	7.4e-09	0.46	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
LUAD	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	6.96	1.15e-11	7.48e-09	0.38	0.3	Height;	chr6:109470900	chr6:109382795~109383666:+
LUAD	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-6.96	1.15e-11	7.5e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
LUAD	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	6.96	1.15e-11	7.5e-09	0.39	0.3	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	6.96	1.15e-11	7.5e-09	0.39	0.3	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
LUAD	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-6.96	1.15e-11	7.52e-09	-0.36	-0.3	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
LUAD	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-6.96	1.15e-11	7.52e-09	-0.39	-0.3	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-6.96	1.15e-11	7.52e-09	-0.39	-0.3	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-6.96	1.15e-11	7.52e-09	-0.39	-0.3	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-6.96	1.15e-11	7.52e-09	-0.39	-0.3	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
LUAD	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	6.96	1.16e-11	7.54e-09	0.39	0.3	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
LUAD	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-6.96	1.16e-11	7.54e-09	-0.4	-0.3	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
LUAD	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-6.95	1.16e-11	7.54e-09	-0.46	-0.3	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
LUAD	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	6.95	1.16e-11	7.55e-09	0.39	0.3	Height;	chr6:109741670	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	6.95	1.16e-11	7.56e-09	0.38	0.3	Height;	chr6:109390116	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	6.95	1.16e-11	7.57e-09	0.4	0.3	Height;	chr6:109739615	chr6:109382795~109383666:+
LUAD	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	6.95	1.16e-11	7.57e-09	0.36	0.3	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
LUAD	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	6.95	1.16e-11	7.58e-09	0.4	0.3	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	6.95	1.16e-11	7.59e-09	0.39	0.3	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
LUAD	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	6.95	1.17e-11	7.62e-09	0.44	0.3	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
LUAD	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-6.95	1.17e-11	7.63e-09	-0.39	-0.3	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
LUAD	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-6.95	1.17e-11	7.64e-09	-0.33	-0.3	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
LUAD	cis	rs4908760	0.64	rs3795310	ENSG00000232912.4	RP5-1115A15.1	-6.95	1.18e-11	7.66e-09	-0.28	-0.3	Vitiligo;	chr1:8371547	chr1:8424645~8434838:+
LUAD	cis	rs10899021	1	rs7102084	ENSG00000279353.1	RP11-864N7.4	6.95	1.18e-11	7.67e-09	0.55	0.3	Response to metformin (IC50);	chr11:74647087	chr11:74698231~74699658:-
LUAD	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-6.95	1.18e-11	7.67e-09	-0.31	-0.3	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
LUAD	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	6.95	1.18e-11	7.67e-09	0.32	0.3	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
LUAD	cis	rs10200159	1	rs13428486	ENSG00000272606.1	RP11-554J4.1	6.95	1.18e-11	7.68e-09	0.51	0.3	Vitiligo;	chr2:55569451	chr2:55617909~55618373:+
LUAD	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	6.95	1.18e-11	7.69e-09	0.38	0.3	Height;	chr6:109470427	chr6:109382795~109383666:+
LUAD	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-6.95	1.18e-11	7.7e-09	-0.43	-0.3	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
LUAD	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.18e-11	7.7e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
LUAD	cis	rs7115242	0.8	rs7931770	ENSG00000280143.1	AP000892.6	6.95	1.18e-11	7.71e-09	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117204967~117210292:+
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000211974.3	IGHV2-70	6.95	1.18e-11	7.71e-09	0.38	0.3	Alzheimer's disease (late onset);	chr14:106780476	chr14:106723574~106724093:-
LUAD	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	6.95	1.19e-11	7.75e-09	0.45	0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
LUAD	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	6.95	1.19e-11	7.75e-09	0.38	0.3	Height;	chr6:109462738	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	6.95	1.19e-11	7.75e-09	0.32	0.3	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.76e-09	0.39	0.3	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
LUAD	cis	rs2439831	0.681	rs524527	ENSG00000205771.5	CATSPER2P1	6.95	1.19e-11	7.76e-09	0.52	0.3	Lung cancer in ever smokers;	chr15:43306918	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
LUAD	cis	rs237743	1	rs67652499	ENSG00000222365.1	SNORD12B	-6.95	1.19e-11	7.77e-09	-0.35	-0.3	Height;	chr20:49310154	chr20:49280319~49280409:+
LUAD	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-6.95	1.2e-11	7.8e-09	-0.57	-0.3	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
LUAD	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-6.95	1.2e-11	7.8e-09	-0.38	-0.3	Height;	chr6:109360458	chr6:109382795~109383666:+
LUAD	cis	rs11767557	1	rs11767557	ENSG00000229153.4	EPHA1-AS1	6.95	1.2e-11	7.8e-09	0.47	0.3	Alzheimer's disease (late onset);	chr7:143412046	chr7:143407813~143523449:+
LUAD	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-6.95	1.2e-11	7.8e-09	-0.4	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
LUAD	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	6.95	1.2e-11	7.8e-09	0.47	0.3	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
LUAD	cis	rs950880	0.553	rs3755272	ENSG00000234389.1	AC007278.3	-6.95	1.2e-11	7.82e-09	-0.34	-0.3	Serum protein levels (sST2);	chr2:102417365	chr2:102438713~102440475:+
LUAD	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	6.95	1.2e-11	7.82e-09	0.39	0.3	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	6.95	1.2e-11	7.82e-09	0.39	0.3	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
LUAD	cis	rs755249	0.959	rs72663520	ENSG00000228060.1	RP11-69E11.8	-6.95	1.21e-11	7.86e-09	-0.3	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39565160~39573203:+
LUAD	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	6.95	1.21e-11	7.87e-09	0.45	0.3	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
LUAD	cis	rs237743	1	rs237743	ENSG00000222365.1	SNORD12B	6.95	1.21e-11	7.87e-09	0.34	0.3	Height;	chr20:49286482	chr20:49280319~49280409:+
LUAD	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-6.95	1.21e-11	7.89e-09	-0.34	-0.3	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
LUAD	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	6.95	1.21e-11	7.89e-09	0.34	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
LUAD	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	6.95	1.21e-11	7.89e-09	0.38	0.3	Height;	chr6:109464011	chr6:109382795~109383666:+
LUAD	cis	rs2439831	1	rs471229	ENSG00000205771.5	CATSPER2P1	-6.95	1.22e-11	7.9e-09	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43441796	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	6.95	1.22e-11	7.92e-09	0.38	0.3	Depression;	chr6:28317705	chr6:28943877~28944537:+
LUAD	cis	rs9326248	0.581	rs10892048	ENSG00000280143.1	AP000892.6	6.95	1.22e-11	7.93e-09	0.35	0.3	Blood protein levels;	chr11:116943880	chr11:117204967~117210292:+
LUAD	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	6.95	1.22e-11	7.94e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	6.95	1.22e-11	7.95e-09	0.4	0.3	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
LUAD	cis	rs9326248	0.559	rs1269329	ENSG00000280143.1	AP000892.6	6.94	1.23e-11	8.01e-09	0.36	0.3	Blood protein levels;	chr11:116884325	chr11:117204967~117210292:+
LUAD	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	6.94	1.23e-11	8.02e-09	0.4	0.3	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
LUAD	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	6.94	1.23e-11	8.02e-09	0.4	0.3	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
LUAD	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	6.94	1.24e-11	8.03e-09	0.43	0.3	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
LUAD	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	6.94	1.24e-11	8.03e-09	0.35	0.3	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-6.94	1.24e-11	8.04e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
LUAD	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-6.94	1.24e-11	8.07e-09	-0.33	-0.3	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
LUAD	cis	rs904251	0.734	rs2797790	ENSG00000279942.1	RP1-153P14.7	6.94	1.25e-11	8.09e-09	0.3	0.3	Cognitive performance;	chr6:37479299	chr6:37567716~37571460:+
LUAD	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	6.94	1.25e-11	8.12e-09	0.39	0.3	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
LUAD	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	6.94	1.25e-11	8.12e-09	0.38	0.3	Height;	chr6:109465777	chr6:109382795~109383666:+
LUAD	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-6.94	1.25e-11	8.13e-09	-0.65	-0.3	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
LUAD	cis	rs35955747	0.902	rs12166373	ENSG00000236132.1	CTA-440B3.1	6.94	1.25e-11	8.13e-09	0.34	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31304522	chr22:31816379~31817491:-
LUAD	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	6.94	1.25e-11	8.14e-09	0.67	0.3	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	6.94	1.25e-11	8.14e-09	0.67	0.3	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	6.94	1.25e-11	8.14e-09	0.67	0.3	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	6.94	1.25e-11	8.14e-09	0.67	0.3	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000224373.3	IGHV4-59	-6.94	1.26e-11	8.15e-09	-0.18	-0.3	Kawasaki disease;	chr14:106677179	chr14:106627249~106627825:-
LUAD	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-6.94	1.26e-11	8.15e-09	-0.35	-0.3	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
LUAD	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-6.94	1.26e-11	8.16e-09	-0.3	-0.3	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
LUAD	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-6.94	1.26e-11	8.17e-09	-0.32	-0.3	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
LUAD	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	6.94	1.26e-11	8.17e-09	0.58	0.3	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
LUAD	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	6.94	1.26e-11	8.19e-09	0.25	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
LUAD	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	6.94	1.26e-11	8.19e-09	0.37	0.3	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
LUAD	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	6.94	1.26e-11	8.19e-09	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
LUAD	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	6.94	1.26e-11	8.19e-09	0.39	0.3	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	6.94	1.26e-11	8.19e-09	0.39	0.3	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
LUAD	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-6.94	1.27e-11	8.22e-09	-0.43	-0.3	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
LUAD	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	6.94	1.28e-11	8.27e-09	0.38	0.3	Height;	chr6:109391534	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	6.94	1.28e-11	8.3e-09	0.39	0.3	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-6.94	1.28e-11	8.31e-09	-0.36	-0.3	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-6.94	1.28e-11	8.31e-09	-0.36	-0.3	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
LUAD	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-6.94	1.28e-11	8.31e-09	-0.4	-0.3	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-6.94	1.28e-11	8.31e-09	-0.4	-0.3	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
LUAD	cis	rs62229266	0.804	rs11088331	ENSG00000214914.3	RPL23AP3	6.94	1.28e-11	8.31e-09	0.37	0.3	Mitral valve prolapse;	chr21:36049574	chr21:36016079~36016546:-
LUAD	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	6.94	1.29e-11	8.35e-09	0.39	0.3	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	6.94	1.29e-11	8.35e-09	0.39	0.3	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
LUAD	cis	rs8177876	0.749	rs11537	ENSG00000261838.4	RP11-303E16.6	6.94	1.29e-11	8.36e-09	0.64	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81069854~81076598:+
LUAD	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-6.94	1.3e-11	8.4e-09	-0.4	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
LUAD	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-6.94	1.3e-11	8.42e-09	-0.4	-0.3	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
LUAD	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	6.94	1.3e-11	8.43e-09	0.49	0.3	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
LUAD	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-6.94	1.3e-11	8.43e-09	-0.37	-0.3	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
LUAD	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-6.94	1.3e-11	8.44e-09	-0.6	-0.3	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
LUAD	cis	rs11089937	0.616	rs5757247	ENSG00000211639.2	IGLV4-60	6.94	1.3e-11	8.44e-09	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22177186	chr22:22162199~22162681:+
LUAD	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-6.94	1.3e-11	8.44e-09	-0.46	-0.3	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-6.94	1.3e-11	8.45e-09	-0.32	-0.3	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-6.94	1.3e-11	8.45e-09	-0.32	-0.3	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-6.94	1.3e-11	8.45e-09	-0.32	-0.3	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
LUAD	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	6.94	1.31e-11	8.46e-09	0.35	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
LUAD	cis	rs10899021	0.79	rs12296094	ENSG00000279353.1	RP11-864N7.4	6.94	1.31e-11	8.48e-09	0.54	0.3	Response to metformin (IC50);	chr11:74610655	chr11:74698231~74699658:-
LUAD	cis	rs4938303	0.671	rs2008915	ENSG00000254851.1	RP11-109L13.1	-6.94	1.31e-11	8.48e-09	-0.47	-0.3	Triglycerides;	chr11:116732418	chr11:117135528~117138582:+
LUAD	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	6.94	1.31e-11	8.51e-09	0.39	0.3	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
LUAD	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	6.93	1.32e-11	8.52e-09	0.33	0.3	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
LUAD	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-6.93	1.32e-11	8.52e-09	-0.49	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
LUAD	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	6.93	1.32e-11	8.52e-09	0.43	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
LUAD	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	6.93	1.32e-11	8.53e-09	0.39	0.3	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	6.93	1.32e-11	8.56e-09	0.39	0.3	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
LUAD	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-6.93	1.32e-11	8.56e-09	-0.47	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
LUAD	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-6.93	1.32e-11	8.57e-09	-0.32	-0.3	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
LUAD	cis	rs10740039	0.804	rs4948424	ENSG00000254271.1	RP11-131N11.4	6.93	1.33e-11	8.6e-09	0.34	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60681812	chr10:60734342~60741828:+
LUAD	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-6.93	1.34e-11	8.64e-09	-0.38	-0.3	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
LUAD	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	6.93	1.34e-11	8.65e-09	0.44	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
LUAD	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-6.93	1.34e-11	8.68e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
LUAD	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-6.93	1.34e-11	8.68e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
LUAD	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-6.93	1.34e-11	8.69e-09	-0.38	-0.3	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
LUAD	cis	rs2337406	0.538	rs10141701	ENSG00000254174.1	IGHV1-12	6.93	1.34e-11	8.69e-09	0.26	0.3	Alzheimer's disease (late onset);	chr14:106633467	chr14:106122420~106122709:-
LUAD	cis	rs9326248	0.559	rs12808524	ENSG00000280143.1	AP000892.6	6.93	1.34e-11	8.69e-09	0.35	0.3	Blood protein levels;	chr11:117020277	chr11:117204967~117210292:+
LUAD	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-6.93	1.35e-11	8.74e-09	-0.31	-0.3	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
LUAD	cis	rs8177876	0.822	rs4306521	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs4324142	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.642	rs4324143	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.818	rs59177227	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs59685942	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs10514515	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs1410	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs1412	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs1414	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs8177950	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.731	rs8177948	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs8177940	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.73	rs76656387	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81069854~81076598:+
LUAD	cis	rs9595908	0.895	rs9591012	ENSG00000212293.1	SNORA16	6.93	1.35e-11	8.74e-09	0.35	0.3	Body mass index;	chr13:32484196	chr13:32420390~32420516:-
LUAD	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	6.93	1.36e-11	8.75e-09	0.43	0.3	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
LUAD	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-6.93	1.36e-11	8.77e-09	-0.37	-0.3	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
LUAD	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	6.93	1.36e-11	8.78e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
LUAD	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-6.93	1.37e-11	8.82e-09	-0.27	-0.3	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
LUAD	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	6.93	1.37e-11	8.82e-09	0.42	0.3	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
LUAD	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-6.93	1.37e-11	8.82e-09	-0.52	-0.3	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
LUAD	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-6.93	1.37e-11	8.85e-09	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
LUAD	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	6.93	1.37e-11	8.86e-09	0.35	0.3	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	6.93	1.37e-11	8.86e-09	0.35	0.3	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
LUAD	cis	rs62229266	0.773	rs878606	ENSG00000214914.3	RPL23AP3	6.93	1.37e-11	8.87e-09	0.37	0.3	Mitral valve prolapse;	chr21:36034394	chr21:36016079~36016546:-
LUAD	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	6.93	1.38e-11	8.89e-09	0.46	0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
LUAD	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-6.93	1.38e-11	8.9e-09	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
LUAD	cis	rs17684571	0.938	rs62412528	ENSG00000231441.1	RP11-472M19.2	6.93	1.38e-11	8.9e-09	0.42	0.3	Schizophrenia;	chr6:56693587	chr6:56844002~56864078:+
LUAD	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-6.93	1.39e-11	8.95e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-6.93	1.39e-11	8.95e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
LUAD	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	6.93	1.39e-11	8.95e-09	0.37	0.3	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
LUAD	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	6.93	1.39e-11	8.95e-09	0.37	0.3	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
LUAD	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-6.93	1.39e-11	8.96e-09	-0.3	-0.3	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
LUAD	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	6.93	1.39e-11	8.97e-09	0.43	0.3	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
LUAD	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	6.93	1.39e-11	8.97e-09	0.43	0.3	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	6.93	1.39e-11	8.97e-09	0.43	0.3	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
LUAD	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	6.93	1.39e-11	8.97e-09	0.36	0.3	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
LUAD	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-6.93	1.4e-11	9e-09	-0.35	-0.3	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
LUAD	cis	rs7646881	0.812	rs7624408	ENSG00000240207.5	RP11-379F4.4	-6.93	1.4e-11	9.01e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742269	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs7636023	ENSG00000240207.5	RP11-379F4.4	-6.93	1.4e-11	9.01e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742270	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs73017536	ENSG00000240207.5	RP11-379F4.4	-6.93	1.4e-11	9.01e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742813	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs73017540	ENSG00000240207.5	RP11-379F4.4	-6.93	1.4e-11	9.01e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742999	chr3:158732263~158784070:+
LUAD	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-6.93	1.4e-11	9.03e-09	-0.36	-0.3	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
LUAD	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	6.92	1.4e-11	9.05e-09	0.35	0.3	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
LUAD	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-6.92	1.41e-11	9.06e-09	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
LUAD	cis	rs2286503	0.839	rs1054471	ENSG00000228649.7	AC005682.5	6.92	1.41e-11	9.06e-09	0.38	0.3	Fibrinogen;	chr7:22813024	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.839	rs2240726	ENSG00000228649.7	AC005682.5	6.92	1.41e-11	9.06e-09	0.38	0.3	Fibrinogen;	chr7:22813516	chr7:22854178~22861579:+
LUAD	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	6.92	1.41e-11	9.07e-09	0.36	0.3	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
LUAD	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	6.92	1.41e-11	9.08e-09	0.36	0.3	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
LUAD	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	6.92	1.41e-11	9.1e-09	0.4	0.3	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
LUAD	cis	rs9595908	0.931	rs9315167	ENSG00000212293.1	SNORA16	6.92	1.41e-11	9.1e-09	0.35	0.3	Body mass index;	chr13:32495051	chr13:32420390~32420516:-
LUAD	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	6.92	1.42e-11	9.12e-09	0.47	0.3	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	6.92	1.42e-11	9.12e-09	0.47	0.3	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
LUAD	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-6.92	1.42e-11	9.13e-09	-0.36	-0.3	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
LUAD	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.42e-11	9.14e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
LUAD	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
LUAD	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
LUAD	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	6.92	1.42e-11	9.15e-09	0.39	0.3	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	6.92	1.42e-11	9.15e-09	0.39	0.3	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
LUAD	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	6.92	1.42e-11	9.15e-09	0.37	0.3	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
LUAD	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	6.92	1.42e-11	9.16e-09	0.56	0.3	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	6.92	1.43e-11	9.19e-09	0.36	0.3	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
LUAD	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-6.92	1.43e-11	9.21e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
LUAD	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-6.92	1.43e-11	9.23e-09	-0.39	-0.3	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
LUAD	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
LUAD	cis	rs2439831	0.681	rs540388	ENSG00000205771.5	CATSPER2P1	-6.92	1.45e-11	9.29e-09	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43314296	chr15:43726918~43747094:-
LUAD	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.45e-11	9.29e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
LUAD	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-6.92	1.45e-11	9.31e-09	-0.39	-0.3	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
LUAD	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-6.92	1.45e-11	9.31e-09	-0.34	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
LUAD	cis	rs9326248	0.53	rs2000615	ENSG00000280143.1	AP000892.6	6.92	1.45e-11	9.33e-09	0.46	0.3	Blood protein levels;	chr11:117045103	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	6.92	1.45e-11	9.34e-09	0.38	0.3	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	6.92	1.46e-11	9.36e-09	0.39	0.3	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
LUAD	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-6.92	1.46e-11	9.36e-09	-0.39	-0.3	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
LUAD	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-6.92	1.46e-11	9.36e-09	-0.36	-0.3	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
LUAD	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	6.92	1.46e-11	9.37e-09	0.35	0.3	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
LUAD	cis	rs9595908	0.931	rs35555940	ENSG00000212293.1	SNORA16	6.92	1.46e-11	9.39e-09	0.34	0.3	Body mass index;	chr13:32492975	chr13:32420390~32420516:-
LUAD	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	6.92	1.46e-11	9.39e-09	0.43	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
LUAD	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	6.92	1.46e-11	9.42e-09	0.37	0.3	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
LUAD	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-6.92	1.47e-11	9.43e-09	-0.36	-0.3	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	6.92	1.47e-11	9.43e-09	0.56	0.3	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
LUAD	cis	rs7017914	0.902	rs10504481	ENSG00000223220.1	Y_RNA	6.92	1.47e-11	9.44e-09	0.34	0.3	Bone mineral density;	chr8:70787282	chr8:70780914~70781008:-
LUAD	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-6.92	1.47e-11	9.45e-09	-0.32	-0.3	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
LUAD	cis	rs944289	0.509	rs934075	ENSG00000257826.1	RP11-116N8.4	-6.92	1.47e-11	9.46e-09	-0.33	-0.3	Thyroid cancer;	chr14:36169016	chr14:36061026~36067190:-
LUAD	cis	rs9326248	0.539	rs660443	ENSG00000280143.1	AP000892.6	6.92	1.47e-11	9.46e-09	0.35	0.3	Blood protein levels;	chr11:116889977	chr11:117204967~117210292:+
LUAD	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	6.92	1.47e-11	9.47e-09	0.38	0.3	Height;	chr6:109443332	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-6.92	1.48e-11	9.48e-09	-0.38	-0.3	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
LUAD	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-6.92	1.48e-11	9.49e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
LUAD	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-6.92	1.48e-11	9.49e-09	-0.37	-0.3	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-6.92	1.48e-11	9.49e-09	-0.37	-0.3	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	6.92	1.48e-11	9.49e-09	0.35	0.3	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
LUAD	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	6.92	1.48e-11	9.49e-09	0.35	0.3	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
LUAD	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	6.92	1.48e-11	9.5e-09	0.33	0.3	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
LUAD	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	6.92	1.48e-11	9.5e-09	0.4	0.3	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
LUAD	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-6.92	1.48e-11	9.5e-09	-0.29	-0.3	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
LUAD	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	6.92	1.48e-11	9.5e-09	0.34	0.3	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
LUAD	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	6.92	1.48e-11	9.5e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
LUAD	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	6.92	1.48e-11	9.52e-09	0.67	0.3	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
LUAD	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	6.92	1.48e-11	9.52e-09	0.67	0.3	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
LUAD	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-6.92	1.49e-11	9.56e-09	-0.27	-0.3	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
LUAD	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-6.92	1.49e-11	9.57e-09	-0.5	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
LUAD	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-6.92	1.49e-11	9.57e-09	-0.39	-0.3	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
LUAD	cis	rs62229266	0.835	rs998384	ENSG00000214914.3	RPL23AP3	6.92	1.49e-11	9.57e-09	0.37	0.3	Mitral valve prolapse;	chr21:36073228	chr21:36016079~36016546:-
LUAD	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-6.92	1.49e-11	9.58e-09	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-6.92	1.49e-11	9.58e-09	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
LUAD	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.49e-11	9.59e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.49e-11	9.59e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.49e-11	9.59e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
LUAD	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	6.92	1.49e-11	9.59e-09	0.36	0.3	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
LUAD	cis	rs7017914	0.967	rs17688313	ENSG00000223220.1	Y_RNA	-6.92	1.49e-11	9.59e-09	-0.34	-0.3	Bone mineral density;	chr8:70771629	chr8:70780914~70781008:-
LUAD	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-6.92	1.5e-11	9.6e-09	-0.36	-0.3	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-6.92	1.5e-11	9.6e-09	-0.36	-0.3	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
LUAD	cis	rs7044106	0.791	rs4836830	ENSG00000238181.2	AHCYP2	-6.91	1.5e-11	9.6e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120720673~120721972:+
LUAD	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	6.91	1.5e-11	9.6e-09	0.59	0.3	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
LUAD	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	6.91	1.5e-11	9.6e-09	0.59	0.3	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
LUAD	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-6.91	1.5e-11	9.6e-09	-0.35	-0.3	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-6.91	1.5e-11	9.6e-09	-0.35	-0.3	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
LUAD	cis	rs9595908	0.931	rs9595617	ENSG00000212293.1	SNORA16	6.91	1.5e-11	9.62e-09	0.34	0.3	Body mass index;	chr13:32483208	chr13:32420390~32420516:-
LUAD	cis	rs7646881	1	rs73015651	ENSG00000240207.5	RP11-379F4.4	-6.91	1.5e-11	9.62e-09	-0.37	-0.3	Tetralogy of Fallot;	chr3:158733133	chr3:158732263~158784070:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000280411.1	IGHV1-69-2	6.91	1.51e-11	9.69e-09	0.23	0.3	Kawasaki disease;	chr14:106771605	chr14:106762092~106762588:-
LUAD	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-6.91	1.51e-11	9.71e-09	-0.4	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
LUAD	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-6.91	1.52e-11	9.72e-09	-0.39	-0.3	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-6.91	1.52e-11	9.72e-09	-0.39	-0.3	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
LUAD	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-6.91	1.52e-11	9.73e-09	-0.39	-0.3	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
LUAD	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-6.91	1.52e-11	9.73e-09	-0.38	-0.3	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
LUAD	cis	rs588177	0.613	rs3782101	ENSG00000236935.1	AP003774.1	-6.91	1.52e-11	9.73e-09	-0.29	-0.3	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64363808	chr11:64325050~64329504:-
LUAD	cis	rs7017914	1	rs13252719	ENSG00000223220.1	Y_RNA	6.91	1.52e-11	9.74e-09	0.34	0.3	Bone mineral density;	chr8:70822334	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs13274062	ENSG00000223220.1	Y_RNA	6.91	1.52e-11	9.74e-09	0.34	0.3	Bone mineral density;	chr8:70824852	chr8:70780914~70781008:-
LUAD	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-6.91	1.52e-11	9.74e-09	-0.36	-0.3	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	6.91	1.52e-11	9.74e-09	0.38	0.3	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	6.91	1.52e-11	9.76e-09	0.44	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
LUAD	cis	rs2842992	0.513	rs7759086	ENSG00000237927.1	RP3-393E18.2	-6.91	1.52e-11	9.77e-09	-0.41	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159586955~159589169:-
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-6.91	1.53e-11	9.78e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
LUAD	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-6.91	1.53e-11	9.79e-09	-0.39	-0.3	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
LUAD	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	6.91	1.53e-11	9.82e-09	0.6	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
LUAD	cis	rs9595908	0.931	rs9595595	ENSG00000212293.1	SNORA16	6.91	1.54e-11	9.84e-09	0.35	0.3	Body mass index;	chr13:32473678	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.931	rs11839309	ENSG00000212293.1	SNORA16	6.91	1.54e-11	9.84e-09	0.35	0.3	Body mass index;	chr13:32473853	chr13:32420390~32420516:-
LUAD	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-6.91	1.54e-11	9.84e-09	-0.26	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
LUAD	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	6.91	1.54e-11	9.85e-09	0.63	0.3	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	6.91	1.54e-11	9.85e-09	0.63	0.3	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	6.91	1.54e-11	9.85e-09	0.63	0.3	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	6.91	1.54e-11	9.85e-09	0.63	0.3	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
LUAD	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	6.91	1.54e-11	9.86e-09	0.4	0.3	Depression;	chr6:28391932	chr6:28943877~28944537:+
LUAD	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-6.91	1.54e-11	9.86e-09	-0.4	-0.3	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	6.91	1.54e-11	9.86e-09	0.42	0.3	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
LUAD	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	6.91	1.54e-11	9.88e-09	0.34	0.3	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
LUAD	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	6.91	1.54e-11	9.89e-09	0.33	0.3	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
LUAD	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	6.91	1.54e-11	9.89e-09	0.38	0.3	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
LUAD	cis	rs11089937	0.616	rs5757258	ENSG00000211639.2	IGLV4-60	6.91	1.55e-11	9.89e-09	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22179648	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000224373.3	IGHV4-59	6.91	1.55e-11	9.91e-09	0.18	0.3	Kawasaki disease;	chr14:106678273	chr14:106627249~106627825:-
LUAD	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	6.91	1.55e-11	9.92e-09	0.46	0.3	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
LUAD	cis	rs35955747	0.902	rs131209	ENSG00000236132.1	CTA-440B3.1	-6.91	1.55e-11	9.94e-09	-0.33	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31336475	chr22:31816379~31817491:-
LUAD	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	6.91	1.55e-11	9.95e-09	0.35	0.3	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
LUAD	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-6.91	1.56e-11	9.96e-09	-0.34	-0.3	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-6.91	1.56e-11	9.96e-09	-0.34	-0.3	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
LUAD	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	6.91	1.56e-11	9.96e-09	0.37	0.3	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
LUAD	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	6.91	1.56e-11	9.97e-09	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-6.91	1.56e-11	9.99e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
LUAD	cis	rs8177876	0.841	rs8177851	ENSG00000261838.4	RP11-303E16.6	6.91	1.56e-11	9.99e-09	0.73	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81092747	chr16:81069854~81076598:+
LUAD	cis	rs3096299	0.838	rs3096319	ENSG00000274627.1	RP11-104N10.2	6.91	1.56e-11	1e-08	0.29	0.3	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:89516797~89522217:+
LUAD	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	6.91	1.56e-11	1e-08	0.32	0.3	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
LUAD	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	6.91	1.57e-11	1e-08	0.35	0.3	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
LUAD	cis	rs8059260	0.877	rs6498146	ENSG00000274038.1	RP11-66H6.4	6.91	1.57e-11	1e-08	0.41	0.3	Alcohol consumption over the past year;	chr16:11012850	chr16:11056556~11057034:+
LUAD	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	6.91	1.57e-11	1e-08	0.39	0.3	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
LUAD	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	6.91	1.57e-11	1.01e-08	0.35	0.3	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
LUAD	cis	rs867371	1	rs867370	ENSG00000255769.6	GOLGA2P10	6.91	1.57e-11	1.01e-08	0.33	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs867371	ENSG00000255769.6	GOLGA2P10	6.91	1.57e-11	1.01e-08	0.33	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82472993~82513950:-
LUAD	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	6.91	1.57e-11	1.01e-08	0.33	0.3	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
LUAD	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	6.91	1.57e-11	1.01e-08	0.34	0.3	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	6.91	1.57e-11	1.01e-08	0.34	0.3	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	6.91	1.57e-11	1.01e-08	0.34	0.3	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	6.91	1.57e-11	1.01e-08	0.34	0.3	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
LUAD	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	6.91	1.58e-11	1.01e-08	0.39	0.3	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
LUAD	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	6.91	1.58e-11	1.01e-08	0.43	0.3	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
LUAD	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	6.91	1.58e-11	1.01e-08	0.28	0.3	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
LUAD	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	6.91	1.58e-11	1.01e-08	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
LUAD	cis	rs2439831	1	rs2439841	ENSG00000205771.5	CATSPER2P1	-6.91	1.58e-11	1.01e-08	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43442551	chr15:43726918~43747094:-
LUAD	cis	rs7017914	0.967	rs12680166	ENSG00000223220.1	Y_RNA	6.91	1.58e-11	1.01e-08	0.33	0.3	Bone mineral density;	chr8:70766403	chr8:70780914~70781008:-
LUAD	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-6.91	1.58e-11	1.01e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-6.91	1.58e-11	1.01e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-6.91	1.59e-11	1.01e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-6.91	1.59e-11	1.01e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
LUAD	cis	rs9326248	0.53	rs7121347	ENSG00000280143.1	AP000892.6	6.91	1.59e-11	1.01e-08	0.46	0.3	Blood protein levels;	chr11:116996493	chr11:117204967~117210292:+
LUAD	cis	rs2439831	0.681	rs3742971	ENSG00000205771.5	CATSPER2P1	6.91	1.59e-11	1.01e-08	0.51	0.3	Lung cancer in ever smokers;	chr15:43330718	chr15:43726918~43747094:-
LUAD	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-6.91	1.59e-11	1.02e-08	-0.49	-0.3	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
LUAD	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	6.91	1.59e-11	1.02e-08	0.51	0.3	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
LUAD	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-6.91	1.59e-11	1.02e-08	-0.38	-0.3	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
LUAD	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	6.9	1.59e-11	1.02e-08	0.65	0.3	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	6.9	1.59e-11	1.02e-08	0.65	0.3	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	6.9	1.59e-11	1.02e-08	0.65	0.3	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	6.9	1.59e-11	1.02e-08	0.65	0.3	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
LUAD	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.59e-11	1.02e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
LUAD	cis	rs34526934	0.566	rs35563571	ENSG00000226363.3	HAGLROS	6.9	1.6e-11	1.02e-08	0.42	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179731	chr2:176177717~176179008:+
LUAD	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	6.9	1.6e-11	1.02e-08	0.44	0.3	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
LUAD	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-6.9	1.6e-11	1.02e-08	-0.39	-0.3	Height;	chr6:109731677	chr6:109382795~109383666:+
LUAD	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-6.9	1.6e-11	1.02e-08	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
LUAD	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	6.9	1.61e-11	1.03e-08	0.37	0.3	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
LUAD	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-6.9	1.61e-11	1.03e-08	-0.38	-0.3	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
LUAD	cis	rs8177876	0.822	rs28672349	ENSG00000261838.4	RP11-303E16.6	6.9	1.61e-11	1.03e-08	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81069854~81076598:+
LUAD	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-6.9	1.61e-11	1.03e-08	-0.39	-0.3	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
LUAD	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.62e-11	1.03e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
LUAD	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-6.9	1.62e-11	1.04e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
LUAD	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	6.9	1.62e-11	1.04e-08	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
LUAD	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
LUAD	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	6.9	1.63e-11	1.04e-08	0.35	0.3	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
LUAD	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-6.9	1.63e-11	1.04e-08	-0.33	-0.3	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
LUAD	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-6.9	1.63e-11	1.04e-08	-0.36	-0.3	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
LUAD	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-6.9	1.64e-11	1.04e-08	-0.48	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
LUAD	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-6.9	1.64e-11	1.04e-08	-0.27	-0.3	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
LUAD	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	6.9	1.64e-11	1.04e-08	0.66	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
LUAD	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	6.9	1.64e-11	1.05e-08	0.34	0.3	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	6.9	1.64e-11	1.05e-08	0.34	0.3	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	6.9	1.64e-11	1.05e-08	0.34	0.3	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
LUAD	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-6.9	1.64e-11	1.05e-08	-0.39	-0.3	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
LUAD	cis	rs9326248	0.53	rs11216316	ENSG00000280143.1	AP000892.6	-6.9	1.64e-11	1.05e-08	-0.5	-0.3	Blood protein levels;	chr11:117210784	chr11:117204967~117210292:+
LUAD	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	6.9	1.64e-11	1.05e-08	0.39	0.3	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	6.9	1.64e-11	1.05e-08	0.39	0.3	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	6.9	1.64e-11	1.05e-08	0.39	0.3	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
LUAD	cis	rs62229266	0.74	rs4817759	ENSG00000214914.3	RPL23AP3	6.9	1.64e-11	1.05e-08	0.37	0.3	Mitral valve prolapse;	chr21:36017261	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.771	rs2835232	ENSG00000214914.3	RPL23AP3	6.9	1.64e-11	1.05e-08	0.37	0.3	Mitral valve prolapse;	chr21:36021129	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.74	rs2835233	ENSG00000214914.3	RPL23AP3	6.9	1.64e-11	1.05e-08	0.37	0.3	Mitral valve prolapse;	chr21:36021284	chr21:36016079~36016546:-
LUAD	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.64e-11	1.05e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
LUAD	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	6.9	1.64e-11	1.05e-08	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
LUAD	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	6.9	1.64e-11	1.05e-08	0.35	0.3	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
LUAD	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	6.9	1.65e-11	1.05e-08	0.38	0.3	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
LUAD	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	6.9	1.65e-11	1.05e-08	0.46	0.3	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
LUAD	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-6.9	1.65e-11	1.05e-08	-0.4	-0.3	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
LUAD	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.65e-11	1.05e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
LUAD	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-6.9	1.65e-11	1.05e-08	-0.39	-0.3	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
LUAD	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-6.9	1.65e-11	1.06e-08	-0.33	-0.3	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
LUAD	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	6.9	1.66e-11	1.06e-08	0.47	0.3	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-6.9	1.66e-11	1.06e-08	-0.37	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
LUAD	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-6.9	1.66e-11	1.06e-08	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
LUAD	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	6.9	1.66e-11	1.06e-08	0.46	0.3	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
LUAD	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-6.9	1.67e-11	1.06e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
LUAD	cis	rs8031584	0.706	rs798084	ENSG00000260382.1	RP11-540B6.2	6.9	1.67e-11	1.06e-08	0.38	0.3	Huntington's disease progression;	chr15:30834732	chr15:30882267~30883231:-
LUAD	cis	rs944289	0.966	rs34992253	ENSG00000257826.1	RP11-116N8.4	-6.9	1.67e-11	1.06e-08	-0.32	-0.3	Thyroid cancer;	chr14:36177957	chr14:36061026~36067190:-
LUAD	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	6.9	1.67e-11	1.07e-08	0.34	0.3	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
LUAD	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	6.9	1.68e-11	1.07e-08	0.37	0.3	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
LUAD	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	6.9	1.68e-11	1.07e-08	0.4	0.3	Height;	chr6:109715504	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	6.9	1.68e-11	1.07e-08	0.4	0.3	Height;	chr6:109715560	chr6:109382795~109383666:+
LUAD	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	6.9	1.69e-11	1.08e-08	0.63	0.3	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
LUAD	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-6.9	1.69e-11	1.08e-08	-0.3	-0.3	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
LUAD	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-6.9	1.69e-11	1.08e-08	-0.4	-0.3	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
LUAD	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-6.9	1.69e-11	1.08e-08	-0.33	-0.3	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
LUAD	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	6.9	1.7e-11	1.08e-08	0.39	0.3	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
LUAD	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	6.89	1.7e-11	1.08e-08	0.33	0.3	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
LUAD	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	6.89	1.7e-11	1.08e-08	0.27	0.3	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
LUAD	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-6.89	1.7e-11	1.08e-08	-0.4	-0.3	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
LUAD	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	6.89	1.71e-11	1.09e-08	0.46	0.3	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	6.89	1.71e-11	1.09e-08	0.46	0.3	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
LUAD	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	6.89	1.71e-11	1.09e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	6.89	1.71e-11	1.09e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
LUAD	cis	rs9326248	0.581	rs7120706	ENSG00000280143.1	AP000892.6	-6.89	1.71e-11	1.09e-08	-0.34	-0.3	Blood protein levels;	chr11:116959371	chr11:117204967~117210292:+
LUAD	cis	rs35955747	0.871	rs5994392	ENSG00000236132.1	CTA-440B3.1	6.89	1.71e-11	1.09e-08	0.33	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31387920	chr22:31816379~31817491:-
LUAD	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-6.89	1.71e-11	1.09e-08	-0.39	-0.3	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
LUAD	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.71e-11	1.09e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.71e-11	1.09e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.71e-11	1.09e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
LUAD	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-6.89	1.72e-11	1.09e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-6.89	1.73e-11	1.1e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
LUAD	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	6.89	1.73e-11	1.1e-08	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
LUAD	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	6.89	1.74e-11	1.1e-08	0.42	0.3	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
LUAD	cis	rs7044106	0.791	rs7043969	ENSG00000238181.2	AHCYP2	-6.89	1.74e-11	1.1e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120720673~120721972:+
LUAD	cis	rs9326248	0.53	rs7114963	ENSG00000280143.1	AP000892.6	6.89	1.74e-11	1.1e-08	0.46	0.3	Blood protein levels;	chr11:117005267	chr11:117204967~117210292:+
LUAD	cis	rs7115242	0.72	rs10790169	ENSG00000280143.1	AP000892.6	6.89	1.74e-11	1.1e-08	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117204967~117210292:+
LUAD	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-6.89	1.74e-11	1.11e-08	-0.3	-0.3	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
LUAD	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-6.89	1.74e-11	1.11e-08	-0.41	-0.3	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	6.89	1.74e-11	1.11e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
LUAD	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-6.89	1.75e-11	1.11e-08	-0.3	-0.3	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
LUAD	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	6.89	1.75e-11	1.11e-08	0.33	0.3	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
LUAD	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-6.89	1.76e-11	1.12e-08	-0.37	-0.3	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
LUAD	cis	rs7017914	0.967	rs34042354	ENSG00000223220.1	Y_RNA	6.89	1.76e-11	1.12e-08	0.34	0.3	Bone mineral density;	chr8:70818726	chr8:70780914~70781008:-
LUAD	cis	rs944289	1	rs944289	ENSG00000257826.1	RP11-116N8.4	-6.89	1.76e-11	1.12e-08	-0.32	-0.3	Thyroid cancer;	chr14:36180040	chr14:36061026~36067190:-
LUAD	cis	rs237743	0.896	rs2063710	ENSG00000222365.1	SNORD12B	6.89	1.77e-11	1.12e-08	0.34	0.3	Height;	chr20:49215517	chr20:49280319~49280409:+
LUAD	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	6.89	1.77e-11	1.12e-08	0.39	0.3	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
LUAD	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	6.89	1.77e-11	1.13e-08	0.39	0.3	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
LUAD	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-6.89	1.77e-11	1.13e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
LUAD	cis	rs11123170	0.529	rs1015753	ENSG00000274877.1	RP11-65I12.1	-6.89	1.78e-11	1.13e-08	-0.46	-0.3	Renal function-related traits (BUN);	chr2:113211226	chr2:113237595~113240825:+
LUAD	cis	rs9326248	0.581	rs6589582	ENSG00000280143.1	AP000892.6	6.89	1.78e-11	1.13e-08	0.34	0.3	Blood protein levels;	chr11:116958484	chr11:117204967~117210292:+
LUAD	cis	rs9595908	0.9	rs9595883	ENSG00000212293.1	SNORA16	6.89	1.78e-11	1.13e-08	0.32	0.3	Body mass index;	chr13:32593563	chr13:32420390~32420516:-
LUAD	cis	rs7017914	0.967	rs13261712	ENSG00000223220.1	Y_RNA	6.89	1.78e-11	1.13e-08	0.34	0.3	Bone mineral density;	chr8:70820029	chr8:70780914~70781008:-
LUAD	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	6.89	1.78e-11	1.13e-08	0.48	0.3	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
LUAD	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-6.89	1.79e-11	1.13e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
LUAD	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	6.89	1.79e-11	1.13e-08	0.46	0.3	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
LUAD	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	6.89	1.79e-11	1.13e-08	0.46	0.3	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
LUAD	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	6.89	1.79e-11	1.14e-08	0.33	0.3	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
LUAD	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	6.89	1.79e-11	1.14e-08	0.6	0.3	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
LUAD	cis	rs7017914	0.967	rs6987007	ENSG00000223220.1	Y_RNA	6.89	1.8e-11	1.14e-08	0.33	0.3	Bone mineral density;	chr8:70688707	chr8:70780914~70781008:-
LUAD	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-6.89	1.8e-11	1.14e-08	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
LUAD	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-6.89	1.8e-11	1.14e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
LUAD	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	6.89	1.8e-11	1.14e-08	0.39	0.3	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
LUAD	cis	rs8177876	0.841	rs117310590	ENSG00000261838.4	RP11-303E16.6	6.89	1.8e-11	1.14e-08	0.75	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094790	chr16:81069854~81076598:+
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-6.89	1.81e-11	1.15e-08	-0.32	-0.3	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
LUAD	cis	rs9549367	0.713	rs3024756	ENSG00000269125.1	RP11-98F14.11	-6.89	1.81e-11	1.15e-08	-0.39	-0.3	Platelet distribution width;	chr13:113168636	chr13:113165002~113165183:-
LUAD	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	6.89	1.81e-11	1.15e-08	0.35	0.3	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
LUAD	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-6.88	1.81e-11	1.15e-08	-0.35	-0.3	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
LUAD	cis	rs7017914	0.967	rs59992214	ENSG00000223220.1	Y_RNA	6.88	1.81e-11	1.15e-08	0.33	0.3	Bone mineral density;	chr8:70687310	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs35564237	ENSG00000223220.1	Y_RNA	6.88	1.81e-11	1.15e-08	0.33	0.3	Bone mineral density;	chr8:70688239	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs62530772	ENSG00000223220.1	Y_RNA	6.88	1.81e-11	1.15e-08	0.33	0.3	Bone mineral density;	chr8:70689306	chr8:70780914~70781008:-
LUAD	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	6.88	1.82e-11	1.15e-08	0.37	0.3	Height;	chr6:109424122	chr6:109382795~109383666:+
LUAD	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	6.88	1.82e-11	1.15e-08	0.41	0.3	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	6.88	1.82e-11	1.16e-08	0.38	0.3	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	6.88	1.82e-11	1.16e-08	0.38	0.3	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
LUAD	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	6.88	1.83e-11	1.16e-08	0.29	0.3	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
LUAD	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-6.88	1.83e-11	1.16e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
LUAD	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-6.88	1.83e-11	1.16e-08	-0.38	-0.3	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
LUAD	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	-6.88	1.83e-11	1.16e-08	-0.33	-0.3	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
LUAD	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-6.88	1.83e-11	1.16e-08	-0.31	-0.3	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
LUAD	cis	rs17301013	0.507	rs72713537	ENSG00000227373.4	RP11-160H22.5	6.88	1.83e-11	1.16e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174354189	chr1:174115300~174160004:-
LUAD	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-6.88	1.84e-11	1.16e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
LUAD	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	6.88	1.84e-11	1.17e-08	0.35	0.3	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
LUAD	cis	rs10129255	1	rs10129319	ENSG00000280411.1	IGHV1-69-2	-6.88	1.84e-11	1.17e-08	-0.22	-0.3	Kawasaki disease;	chr14:106767996	chr14:106762092~106762588:-
LUAD	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	6.88	1.84e-11	1.17e-08	0.4	0.3	Depression;	chr6:28430971	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	6.88	1.84e-11	1.17e-08	0.4	0.3	Depression;	chr6:28432562	chr6:28943877~28944537:+
LUAD	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-6.88	1.85e-11	1.17e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
LUAD	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-6.88	1.86e-11	1.18e-08	-0.34	-0.3	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
LUAD	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-6.88	1.86e-11	1.18e-08	-0.3	-0.3	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
LUAD	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	6.88	1.86e-11	1.18e-08	0.38	0.3	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
LUAD	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	6.88	1.86e-11	1.18e-08	0.38	0.3	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
LUAD	cis	rs9549367	0.569	rs3024738	ENSG00000269125.1	RP11-98F14.11	6.88	1.87e-11	1.18e-08	0.39	0.3	Platelet distribution width;	chr13:113165607	chr13:113165002~113165183:-
LUAD	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	6.88	1.87e-11	1.18e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000211974.3	IGHV2-70	-6.88	1.87e-11	1.19e-08	-0.38	-0.3	Alzheimer's disease (late onset);	chr14:106777623	chr14:106723574~106724093:-
LUAD	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-6.88	1.87e-11	1.19e-08	-0.33	-0.3	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
LUAD	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	6.88	1.88e-11	1.19e-08	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
LUAD	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	6.88	1.88e-11	1.19e-08	0.32	0.3	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
LUAD	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
LUAD	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-6.88	1.89e-11	1.2e-08	-0.35	-0.3	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
LUAD	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-6.88	1.89e-11	1.2e-08	-0.35	-0.3	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
LUAD	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-6.88	1.89e-11	1.2e-08	-0.48	-0.3	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
LUAD	cis	rs7044106	0.791	rs10739572	ENSG00000238181.2	AHCYP2	-6.88	1.89e-11	1.2e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120720673~120721972:+
LUAD	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	6.88	1.9e-11	1.2e-08	0.42	0.3	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
LUAD	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	6.88	1.9e-11	1.2e-08	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
LUAD	cis	rs7646881	0.812	rs61696028	ENSG00000240207.5	RP11-379F4.4	-6.88	1.9e-11	1.2e-08	-0.4	-0.3	Tetralogy of Fallot;	chr3:158737914	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs61387735	ENSG00000240207.5	RP11-379F4.4	-6.88	1.9e-11	1.2e-08	-0.4	-0.3	Tetralogy of Fallot;	chr3:158738372	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.767	rs73015669	ENSG00000240207.5	RP11-379F4.4	-6.88	1.9e-11	1.2e-08	-0.4	-0.3	Tetralogy of Fallot;	chr3:158738529	chr3:158732263~158784070:+
LUAD	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-6.88	1.91e-11	1.21e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
LUAD	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	6.88	1.92e-11	1.21e-08	0.34	0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
LUAD	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-6.88	1.92e-11	1.21e-08	-0.32	-0.3	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
LUAD	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	6.88	1.92e-11	1.21e-08	0.34	0.3	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
LUAD	cis	rs9326248	0.581	rs7120515	ENSG00000280143.1	AP000892.6	6.88	1.92e-11	1.21e-08	0.34	0.3	Blood protein levels;	chr11:117121210	chr11:117204967~117210292:+
LUAD	cis	rs75422866	0.867	rs7303895	ENSG00000274902.1	RP1-197B17.4	6.88	1.92e-11	1.22e-08	0.63	0.3	Pneumonia;	chr12:47683290	chr12:47731908~47732351:+
LUAD	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-6.88	1.93e-11	1.22e-08	-0.36	-0.3	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-6.88	1.93e-11	1.22e-08	-0.36	-0.3	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-6.88	1.93e-11	1.22e-08	-0.36	-0.3	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
LUAD	cis	rs7688540	0.8	rs11731285	ENSG00000275426.1	CH17-262A2.1	6.88	1.93e-11	1.22e-08	0.37	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:149738~150317:+
LUAD	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-6.87	1.93e-11	1.22e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
LUAD	cis	rs35955747	0.87	rs5997986	ENSG00000236132.1	CTA-440B3.1	6.87	1.93e-11	1.22e-08	0.33	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31438953	chr22:31816379~31817491:-
LUAD	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	6.87	1.94e-11	1.22e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	6.87	1.94e-11	1.22e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	6.87	1.94e-11	1.22e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	6.87	1.94e-11	1.22e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
LUAD	cis	rs7246657	0.598	rs10417545	ENSG00000276846.1	CTD-3220F14.3	6.87	1.94e-11	1.22e-08	0.47	0.3	Coronary artery calcification;	chr19:37163361	chr19:37314868~37315620:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000280411.1	IGHV1-69-2	-6.87	1.94e-11	1.23e-08	-0.22	-0.3	Kawasaki disease;	chr14:106779068	chr14:106762092~106762588:-
LUAD	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-6.87	1.94e-11	1.23e-08	-0.38	-0.3	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
LUAD	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	6.87	1.94e-11	1.23e-08	0.55	0.3	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
LUAD	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	6.87	1.95e-11	1.23e-08	0.42	0.3	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
LUAD	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-6.87	1.95e-11	1.23e-08	-0.34	-0.3	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
LUAD	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-6.87	1.95e-11	1.23e-08	-0.39	-0.3	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
LUAD	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-6.87	1.95e-11	1.23e-08	-0.33	-0.3	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
LUAD	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-6.87	1.96e-11	1.24e-08	-0.52	-0.3	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
LUAD	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	6.87	1.96e-11	1.24e-08	0.35	0.3	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	6.87	1.96e-11	1.24e-08	0.35	0.3	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	6.87	1.96e-11	1.24e-08	0.35	0.3	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
LUAD	cis	rs1167827	0.71	rs1167836	ENSG00000278416.1	PMS2L2	6.87	1.97e-11	1.24e-08	0.38	0.3	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75344015~75359550:-
LUAD	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-6.87	1.97e-11	1.25e-08	-0.45	-0.3	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
LUAD	cis	rs11846409	0.799	rs10467899	ENSG00000211974.3	IGHV2-70	-6.87	1.98e-11	1.25e-08	-0.38	-0.3	Rheumatic heart disease;	chr14:106644012	chr14:106723574~106724093:-
LUAD	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-6.87	1.98e-11	1.25e-08	-0.33	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
LUAD	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-6.87	1.98e-11	1.25e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	6.87	1.98e-11	1.25e-08	0.44	0.3	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
LUAD	cis	rs7927592	0.913	rs10047412	ENSG00000212093.1	AP000807.1	6.87	1.98e-11	1.25e-08	0.33	0.3	Total body bone mineral density;	chr11:68465444	chr11:68506083~68506166:-
LUAD	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-6.87	1.98e-11	1.25e-08	-0.37	-0.3	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
LUAD	cis	rs904251	0.507	rs11756941	ENSG00000279942.1	RP1-153P14.7	-6.87	1.98e-11	1.25e-08	-0.35	-0.3	Cognitive performance;	chr6:37448443	chr6:37567716~37571460:+
LUAD	cis	rs11846409	0.932	rs2015469	ENSG00000254174.1	IGHV1-12	6.87	1.99e-11	1.26e-08	0.26	0.3	Rheumatic heart disease;	chr14:106631857	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.932	rs56167903	ENSG00000254174.1	IGHV1-12	6.87	1.99e-11	1.26e-08	0.26	0.3	Rheumatic heart disease;	chr14:106632070	chr14:106122420~106122709:-
LUAD	cis	rs10740039	0.804	rs1837950	ENSG00000254271.1	RP11-131N11.4	-6.87	2e-11	1.26e-08	-0.34	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60685207	chr10:60734342~60741828:+
LUAD	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	6.87	2e-11	1.26e-08	0.37	0.3	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	6.87	2e-11	1.26e-08	0.37	0.3	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
LUAD	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-6.87	2e-11	1.26e-08	-0.32	-0.3	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
LUAD	cis	rs9326248	0.53	rs10732856	ENSG00000280143.1	AP000892.6	6.87	2e-11	1.26e-08	0.45	0.3	Blood protein levels;	chr11:117036397	chr11:117204967~117210292:+
LUAD	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	6.87	2e-11	1.26e-08	0.33	0.3	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
LUAD	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-6.87	2.01e-11	1.27e-08	-0.39	-0.3	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	6.87	2.01e-11	1.27e-08	0.54	0.3	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
LUAD	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-6.87	2.01e-11	1.27e-08	-0.45	-0.3	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
LUAD	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-6.87	2.02e-11	1.27e-08	-0.36	-0.3	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
LUAD	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	6.87	2.02e-11	1.27e-08	0.35	0.3	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
LUAD	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	6.87	2.02e-11	1.27e-08	0.37	0.3	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
LUAD	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-6.87	2.03e-11	1.28e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-6.87	2.03e-11	1.28e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
LUAD	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-6.87	2.03e-11	1.28e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
LUAD	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	6.87	2.03e-11	1.28e-08	0.6	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	6.87	2.03e-11	1.28e-08	0.6	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-6.87	2.04e-11	1.28e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
LUAD	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-6.87	2.04e-11	1.29e-08	-0.31	-0.3	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
LUAD	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-6.87	2.05e-11	1.29e-08	-0.35	-0.3	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
LUAD	cis	rs9584850	1	rs9584850	ENSG00000231194.1	FARP1-AS1	6.87	2.05e-11	1.29e-08	0.36	0.3	Neuroticism;	chr13:98449172	chr13:98435405~98435840:-
LUAD	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	6.87	2.05e-11	1.29e-08	0.38	0.3	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
LUAD	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	6.87	2.05e-11	1.29e-08	0.38	0.3	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
LUAD	cis	rs755249	1	rs4660293	ENSG00000228060.1	RP11-69E11.8	6.86	2.06e-11	1.3e-08	0.29	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39565160~39573203:+
LUAD	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	6.86	2.06e-11	1.3e-08	0.48	0.3	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
LUAD	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	6.86	2.06e-11	1.3e-08	0.46	0.3	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
LUAD	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	6.86	2.06e-11	1.3e-08	0.3	0.3	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
LUAD	cis	rs7646881	0.812	rs73017539	ENSG00000240207.5	RP11-379F4.4	-6.86	2.07e-11	1.3e-08	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742954	chr3:158732263~158784070:+
LUAD	cis	rs6844153	0.941	rs75656258	ENSG00000240005.4	RP11-293A21.1	-6.86	2.07e-11	1.3e-08	-0.49	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26843577	chr4:26859806~26860599:-
LUAD	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	6.86	2.07e-11	1.3e-08	0.39	0.3	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
LUAD	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	6.86	2.07e-11	1.3e-08	0.67	0.3	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs7304743	ENSG00000274902.1	RP1-197B17.4	-6.86	2.08e-11	1.31e-08	-0.61	-0.3	Pneumonia;	chr12:47683658	chr12:47731908~47732351:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-6.86	2.08e-11	1.31e-08	-0.21	-0.3	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
LUAD	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	6.86	2.08e-11	1.31e-08	0.42	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
LUAD	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	6.86	2.09e-11	1.31e-08	0.33	0.3	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
LUAD	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-6.86	2.09e-11	1.31e-08	-0.33	-0.3	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
LUAD	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-6.86	2.09e-11	1.31e-08	-0.33	-0.3	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
LUAD	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	1.32e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	1.32e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	1.32e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	1.32e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.581	rs7120963	ENSG00000280143.1	AP000892.6	-6.86	2.1e-11	1.32e-08	-0.34	-0.3	Blood protein levels;	chr11:116959545	chr11:117204967~117210292:+
LUAD	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-6.86	2.1e-11	1.32e-08	-0.27	-0.3	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
LUAD	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-6.86	2.11e-11	1.32e-08	-0.39	-0.3	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-6.86	2.11e-11	1.32e-08	-0.39	-0.3	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
LUAD	cis	rs62229266	0.804	rs2835231	ENSG00000214914.3	RPL23AP3	6.86	2.11e-11	1.33e-08	0.37	0.3	Mitral valve prolapse;	chr21:36018300	chr21:36016079~36016546:-
LUAD	cis	rs9326248	0.53	rs473188	ENSG00000280143.1	AP000892.6	6.86	2.12e-11	1.33e-08	0.46	0.3	Blood protein levels;	chr11:116941313	chr11:117204967~117210292:+
LUAD	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	6.86	2.12e-11	1.33e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
LUAD	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-6.86	2.12e-11	1.33e-08	-0.34	-0.3	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
LUAD	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	6.86	2.12e-11	1.33e-08	0.36	0.3	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
LUAD	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-6.86	2.13e-11	1.34e-08	-0.38	-0.3	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-6.86	2.13e-11	1.34e-08	-0.38	-0.3	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-6.86	2.13e-11	1.34e-08	-0.38	-0.3	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
LUAD	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-6.86	2.13e-11	1.34e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
LUAD	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-6.86	2.13e-11	1.34e-08	-0.34	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
LUAD	cis	rs8031584	0.918	rs3817498	ENSG00000260382.1	RP11-540B6.2	6.86	2.13e-11	1.34e-08	0.35	0.3	Huntington's disease progression;	chr15:30976578	chr15:30882267~30883231:-
LUAD	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-6.86	2.13e-11	1.34e-08	-0.39	-0.3	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
LUAD	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-6.86	2.14e-11	1.34e-08	-0.27	-0.3	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
LUAD	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	6.86	2.14e-11	1.34e-08	0.34	0.3	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
LUAD	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-6.86	2.15e-11	1.35e-08	-0.33	-0.3	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
LUAD	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	6.86	2.15e-11	1.35e-08	0.25	0.3	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
LUAD	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	6.86	2.15e-11	1.35e-08	0.3	0.3	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
LUAD	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-6.86	2.15e-11	1.35e-08	-0.35	-0.3	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
LUAD	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-6.86	2.15e-11	1.35e-08	-0.38	-0.3	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
LUAD	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-6.86	2.16e-11	1.36e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-6.86	2.16e-11	1.36e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-6.86	2.16e-11	1.36e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
LUAD	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-6.86	2.16e-11	1.36e-08	-0.39	-0.3	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
LUAD	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	6.86	2.16e-11	1.36e-08	0.62	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
LUAD	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
LUAD	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
LUAD	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-6.86	2.17e-11	1.36e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-6.86	2.17e-11	1.36e-08	-0.42	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
LUAD	cis	rs9549367	0.713	rs3024757	ENSG00000269125.1	RP11-98F14.11	-6.86	2.17e-11	1.36e-08	-0.4	-0.3	Platelet distribution width;	chr13:113168872	chr13:113165002~113165183:-
LUAD	cis	rs8059260	0.935	rs9928255	ENSG00000274038.1	RP11-66H6.4	-6.86	2.19e-11	1.37e-08	-0.42	-0.3	Alcohol consumption over the past year;	chr16:11027408	chr16:11056556~11057034:+
LUAD	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-6.86	2.19e-11	1.37e-08	-0.39	-0.3	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
LUAD	cis	rs10899021	0.92	rs7112384	ENSG00000279353.1	RP11-864N7.4	6.86	2.19e-11	1.37e-08	0.54	0.3	Response to metformin (IC50);	chr11:74637160	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.92	rs7112664	ENSG00000279353.1	RP11-864N7.4	6.86	2.19e-11	1.37e-08	0.54	0.3	Response to metformin (IC50);	chr11:74637381	chr11:74698231~74699658:-
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-6.86	2.19e-11	1.37e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-6.85	2.2e-11	1.38e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
LUAD	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	6.85	2.2e-11	1.38e-08	0.34	0.3	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
LUAD	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-6.85	2.2e-11	1.38e-08	-0.3	-0.3	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
LUAD	cis	rs62229266	0.693	rs2835264	ENSG00000214914.3	RPL23AP3	6.85	2.2e-11	1.38e-08	0.36	0.3	Mitral valve prolapse;	chr21:36063667	chr21:36016079~36016546:-
LUAD	cis	rs75920871	0.64	rs4938357	ENSG00000254851.1	RP11-109L13.1	-6.85	2.21e-11	1.38e-08	-0.51	-0.3	Subjective well-being;	chr11:117213324	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-6.85	2.21e-11	1.38e-08	-0.21	-0.3	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
LUAD	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-6.85	2.21e-11	1.38e-08	-0.27	-0.3	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
LUAD	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-6.85	2.21e-11	1.39e-08	-0.39	-0.3	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
LUAD	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	6.85	2.21e-11	1.39e-08	0.36	0.3	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
LUAD	cis	rs8059260	0.736	rs79361721	ENSG00000274038.1	RP11-66H6.4	-6.85	2.22e-11	1.39e-08	-0.61	-0.3	Alcohol consumption over the past year;	chr16:10968082	chr16:11056556~11057034:+
LUAD	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	6.85	2.22e-11	1.39e-08	0.35	0.3	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
LUAD	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
LUAD	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	6.85	2.22e-11	1.39e-08	0.4	0.3	Height;	chr6:109747119	chr6:109382795~109383666:+
LUAD	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
LUAD	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-6.85	2.23e-11	1.39e-08	-0.33	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
LUAD	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-6.85	2.24e-11	1.4e-08	-0.34	-0.3	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
LUAD	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-6.85	2.24e-11	1.4e-08	-0.39	-0.3	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
LUAD	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	6.85	2.25e-11	1.41e-08	0.37	0.3	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
LUAD	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-6.85	2.25e-11	1.41e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
LUAD	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-6.85	2.25e-11	1.41e-08	-0.34	-0.3	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
LUAD	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-6.85	2.26e-11	1.41e-08	-0.31	-0.3	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
LUAD	cis	rs10899021	1	rs11236193	ENSG00000279353.1	RP11-864N7.4	6.85	2.26e-11	1.41e-08	0.56	0.3	Response to metformin (IC50);	chr11:74657262	chr11:74698231~74699658:-
LUAD	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	6.85	2.26e-11	1.41e-08	0.38	0.3	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
LUAD	cis	rs6844153	0.887	rs62302474	ENSG00000240005.4	RP11-293A21.1	-6.85	2.26e-11	1.42e-08	-0.5	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26909118	chr4:26859806~26860599:-
LUAD	cis	rs2337406	0.587	rs10129888	ENSG00000254174.1	IGHV1-12	6.85	2.27e-11	1.42e-08	0.26	0.3	Alzheimer's disease (late onset);	chr14:106647421	chr14:106122420~106122709:-
LUAD	cis	rs9595908	0.931	rs9595628	ENSG00000212293.1	SNORA16	6.85	2.27e-11	1.42e-08	0.34	0.3	Body mass index;	chr13:32491021	chr13:32420390~32420516:-
LUAD	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-6.85	2.27e-11	1.42e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
LUAD	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	6.85	2.27e-11	1.42e-08	0.4	0.3	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
LUAD	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	6.85	2.27e-11	1.42e-08	0.31	0.3	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
LUAD	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-6.85	2.27e-11	1.42e-08	-0.6	-0.3	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
LUAD	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	6.85	2.28e-11	1.43e-08	0.49	0.3	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
LUAD	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	6.85	2.28e-11	1.43e-08	0.49	0.3	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
LUAD	cis	rs9326248	0.53	rs2155583	ENSG00000280143.1	AP000892.6	6.85	2.29e-11	1.43e-08	0.45	0.3	Blood protein levels;	chr11:117044501	chr11:117204967~117210292:+
LUAD	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-6.85	2.29e-11	1.43e-08	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
LUAD	cis	rs4141404	0.673	rs1968023	ENSG00000236132.1	CTA-440B3.1	6.85	2.3e-11	1.44e-08	0.41	0.3	Paclitaxel-induced neuropathy;	chr22:31546784	chr22:31816379~31817491:-
LUAD	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-6.85	2.31e-11	1.45e-08	-0.3	-0.3	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
LUAD	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	6.85	2.31e-11	1.45e-08	0.4	0.3	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
LUAD	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	6.85	2.32e-11	1.45e-08	0.35	0.3	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
LUAD	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	6.85	2.32e-11	1.45e-08	0.32	0.3	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
LUAD	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	6.85	2.32e-11	1.45e-08	0.41	0.3	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
LUAD	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-6.85	2.33e-11	1.45e-08	-0.35	-0.3	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
LUAD	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	6.85	2.33e-11	1.45e-08	0.33	0.3	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
LUAD	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-6.85	2.33e-11	1.45e-08	-0.47	-0.3	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
LUAD	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	6.85	2.33e-11	1.45e-08	0.34	0.3	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
LUAD	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-6.85	2.33e-11	1.46e-08	-0.39	-0.3	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
LUAD	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	6.85	2.33e-11	1.46e-08	0.4	0.3	Depression;	chr6:28431469	chr6:28943877~28944537:+
LUAD	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-6.85	2.33e-11	1.46e-08	-0.45	-0.3	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-6.85	2.33e-11	1.46e-08	-0.45	-0.3	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
LUAD	cis	rs2439831	0.681	rs1549525	ENSG00000205771.5	CATSPER2P1	-6.85	2.34e-11	1.46e-08	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43335657	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.681	rs7175434	ENSG00000205771.5	CATSPER2P1	-6.85	2.34e-11	1.46e-08	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43336344	chr15:43726918~43747094:-
LUAD	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	6.84	2.34e-11	1.46e-08	0.67	0.3	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
LUAD	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	6.84	2.34e-11	1.46e-08	0.38	0.3	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	6.84	2.34e-11	1.46e-08	0.38	0.3	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	6.84	2.34e-11	1.46e-08	0.38	0.3	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
LUAD	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-6.84	2.34e-11	1.46e-08	-0.28	-0.3	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
LUAD	cis	rs11846409	0.932	rs2583329	ENSG00000254174.1	IGHV1-12	-6.84	2.35e-11	1.47e-08	-0.26	-0.3	Rheumatic heart disease;	chr14:106632971	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.86	rs10150951	ENSG00000254174.1	IGHV1-12	6.84	2.35e-11	1.47e-08	0.26	0.3	Rheumatic heart disease;	chr14:106632988	chr14:106122420~106122709:-
LUAD	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	6.84	2.35e-11	1.47e-08	0.42	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
LUAD	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.36e-11	1.47e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
LUAD	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-6.84	2.37e-11	1.48e-08	-0.33	-0.3	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
LUAD	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	6.84	2.37e-11	1.48e-08	0.45	0.3	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
LUAD	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-6.84	2.38e-11	1.48e-08	-0.36	-0.3	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-6.84	2.38e-11	1.48e-08	-0.36	-0.3	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
LUAD	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	6.84	2.38e-11	1.48e-08	0.35	0.3	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
LUAD	cis	rs367615	0.842	rs2578484	ENSG00000249476.1	CTD-2587M2.1	-6.84	2.38e-11	1.48e-08	-0.37	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109615107	chr5:109237120~109326369:-
LUAD	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	6.84	2.38e-11	1.49e-08	0.38	0.3	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
LUAD	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-6.84	2.39e-11	1.49e-08	-0.32	-0.3	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
LUAD	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-6.84	2.4e-11	1.5e-08	-0.33	-0.3	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
LUAD	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	6.84	2.4e-11	1.5e-08	0.33	0.3	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
LUAD	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-6.84	2.4e-11	1.5e-08	-0.4	-0.3	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
LUAD	cis	rs7646881	0.812	rs59192661	ENSG00000240207.5	RP11-379F4.4	-6.84	2.4e-11	1.5e-08	-0.39	-0.3	Tetralogy of Fallot;	chr3:158741238	chr3:158732263~158784070:+
LUAD	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.4e-11	1.5e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
LUAD	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	6.84	2.42e-11	1.51e-08	0.25	0.3	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
LUAD	cis	rs11123170	0.529	rs35606997	ENSG00000274877.1	RP11-65I12.1	-6.84	2.42e-11	1.51e-08	-0.44	-0.3	Renal function-related traits (BUN);	chr2:113215773	chr2:113237595~113240825:+
LUAD	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	6.84	2.43e-11	1.51e-08	0.32	0.3	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
LUAD	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-6.84	2.43e-11	1.52e-08	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-6.84	2.43e-11	1.52e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
LUAD	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	6.84	2.44e-11	1.52e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
LUAD	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
LUAD	cis	rs2179367	0.959	rs4895789	ENSG00000231760.4	RP11-350J20.5	6.84	2.44e-11	1.52e-08	0.37	0.3	Dupuytren's disease;	chr6:149443518	chr6:149796151~149826294:-
LUAD	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-6.84	2.45e-11	1.52e-08	-0.54	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-6.84	2.45e-11	1.53e-08	-0.21	-0.3	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
LUAD	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-6.84	2.46e-11	1.53e-08	-0.39	-0.3	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
LUAD	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	6.84	2.46e-11	1.53e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	6.84	2.46e-11	1.53e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
LUAD	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	6.84	2.47e-11	1.54e-08	0.44	0.3	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
LUAD	cis	rs75920871	0.589	rs56081989	ENSG00000254851.1	RP11-109L13.1	-6.84	2.47e-11	1.54e-08	-0.51	-0.3	Subjective well-being;	chr11:117214589	chr11:117135528~117138582:+
LUAD	cis	rs2439831	0.681	rs825740	ENSG00000205771.5	CATSPER2P1	-6.84	2.47e-11	1.54e-08	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43300210	chr15:43726918~43747094:-
LUAD	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-6.84	2.47e-11	1.54e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-6.84	2.47e-11	1.54e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-6.84	2.47e-11	1.54e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
LUAD	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-6.84	2.47e-11	1.54e-08	-0.37	-0.3	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000224373.3	IGHV4-59	6.84	2.48e-11	1.55e-08	0.18	0.3	Kawasaki disease;	chr14:106676185	chr14:106627249~106627825:-
LUAD	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-6.84	2.48e-11	1.55e-08	-0.3	-0.3	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
LUAD	cis	rs720064	0.586	rs9958904	ENSG00000264745.1	TTC39C-AS1	-6.84	2.49e-11	1.55e-08	-0.32	-0.3	Strep throat;	chr18:23969940	chr18:23994213~24015339:-
LUAD	cis	rs75422866	0.51	rs73105829	ENSG00000280054.1	RP1-197B17.7	6.84	2.49e-11	1.55e-08	0.65	0.3	Pneumonia;	chr12:47734162	chr12:47728151~47730598:-
LUAD	cis	rs11089937	0.522	rs2005239	ENSG00000211639.2	IGLV4-60	6.84	2.49e-11	1.55e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22178083	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs743520	ENSG00000211639.2	IGLV4-60	6.84	2.49e-11	1.55e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22178249	chr22:22162199~22162681:+
LUAD	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-6.83	2.49e-11	1.55e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-6.83	2.49e-11	1.55e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-6.83	2.49e-11	1.55e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
LUAD	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	6.83	2.49e-11	1.55e-08	0.36	0.3	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
LUAD	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	6.83	2.5e-11	1.55e-08	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
LUAD	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-6.83	2.5e-11	1.55e-08	-0.33	-0.3	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-6.83	2.5e-11	1.55e-08	-0.33	-0.3	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
LUAD	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	6.83	2.5e-11	1.55e-08	0.43	0.3	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
LUAD	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-6.83	2.5e-11	1.55e-08	-0.39	-0.3	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
LUAD	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	6.83	2.5e-11	1.56e-08	0.59	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
LUAD	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	6.83	2.5e-11	1.56e-08	0.38	0.3	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
LUAD	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	6.83	2.5e-11	1.56e-08	0.37	0.3	Height;	chr6:109440234	chr6:109382795~109383666:+
LUAD	cis	rs11089937	0.522	rs5757259	ENSG00000211639.2	IGLV4-60	6.83	2.5e-11	1.56e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22179649	chr22:22162199~22162681:+
LUAD	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-6.83	2.51e-11	1.56e-08	-0.26	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
LUAD	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
LUAD	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	6.83	2.52e-11	1.56e-08	0.59	0.3	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	6.83	2.52e-11	1.56e-08	0.59	0.3	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	6.83	2.52e-11	1.56e-08	0.59	0.3	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	6.83	2.52e-11	1.56e-08	0.59	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
LUAD	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
LUAD	cis	rs62229266	0.625	rs2051395	ENSG00000214914.3	RPL23AP3	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Mitral valve prolapse;	chr21:36058967	chr21:36016079~36016546:-
LUAD	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	6.83	2.52e-11	1.57e-08	0.25	0.3	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
LUAD	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-6.83	2.52e-11	1.57e-08	-0.32	-0.3	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
LUAD	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-6.83	2.53e-11	1.57e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
LUAD	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	6.83	2.53e-11	1.57e-08	0.34	0.3	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
LUAD	cis	rs9326248	0.539	rs10892058	ENSG00000280143.1	AP000892.6	6.83	2.53e-11	1.57e-08	0.34	0.3	Blood protein levels;	chr11:117005905	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.52	rs7127881	ENSG00000280143.1	AP000892.6	6.83	2.53e-11	1.57e-08	0.34	0.3	Blood protein levels;	chr11:117010082	chr11:117204967~117210292:+
LUAD	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	6.83	2.54e-11	1.58e-08	0.35	0.3	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	6.83	2.54e-11	1.58e-08	0.35	0.3	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	6.83	2.54e-11	1.58e-08	0.35	0.3	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
LUAD	cis	rs2439831	0.681	rs484029	ENSG00000205771.5	CATSPER2P1	-6.83	2.54e-11	1.58e-08	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43327362	chr15:43726918~43747094:-
LUAD	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-6.83	2.55e-11	1.58e-08	-0.38	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-6.83	2.55e-11	1.58e-08	-0.38	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
LUAD	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	6.83	2.55e-11	1.59e-08	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	6.83	2.55e-11	1.59e-08	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	6.83	2.56e-11	1.59e-08	0.4	0.3	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
LUAD	cis	rs2842992	0.692	rs9347342	ENSG00000237927.1	RP3-393E18.2	-6.83	2.56e-11	1.59e-08	-0.41	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159586955~159589169:-
LUAD	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-6.83	2.56e-11	1.59e-08	-0.35	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
LUAD	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	6.83	2.56e-11	1.59e-08	0.37	0.3	Height;	chr6:109454233	chr6:109382795~109383666:+
LUAD	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-6.83	2.57e-11	1.59e-08	-0.38	-0.3	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
LUAD	cis	rs8177876	0.822	rs74437879	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs76948085	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs80315956	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.642	rs16954572	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9929586	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9938965	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs7204040	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.731	rs7188508	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.749	rs2549891	ENSG00000261838.4	RP11-303E16.6	-6.83	2.57e-11	1.59e-08	-0.56	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81069854~81076598:+
LUAD	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-6.83	2.57e-11	1.6e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
LUAD	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-6.83	2.58e-11	1.6e-08	-0.41	-0.3	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
LUAD	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-6.83	2.58e-11	1.6e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
LUAD	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-6.83	2.58e-11	1.6e-08	-0.28	-0.3	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
LUAD	cis	rs35955747	0.838	rs28716	ENSG00000236132.1	CTA-440B3.1	-6.83	2.59e-11	1.6e-08	-0.33	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31334203	chr22:31816379~31817491:-
LUAD	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-6.83	2.59e-11	1.61e-08	-0.39	-0.3	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-6.83	2.59e-11	1.61e-08	-0.39	-0.3	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
LUAD	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-6.83	2.59e-11	1.61e-08	-0.39	-0.3	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
LUAD	cis	rs755249	0.958	rs17264866	ENSG00000228060.1	RP11-69E11.8	-6.83	2.59e-11	1.61e-08	-0.29	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39565160~39573203:+
LUAD	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-6.83	2.6e-11	1.61e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
LUAD	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	6.83	2.6e-11	1.61e-08	0.37	0.3	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
LUAD	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-6.83	2.61e-11	1.62e-08	-0.31	-0.3	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
LUAD	cis	rs7829975	0.536	rs2980439	ENSG00000173295.6	FAM86B3P	6.83	2.61e-11	1.62e-08	0.32	0.3	Mood instability;	chr8:8237348	chr8:8228595~8244865:+
LUAD	cis	rs4591358	0.638	rs6732435	ENSG00000223466.1	AC064834.2	-6.83	2.62e-11	1.62e-08	-0.44	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541501	chr2:195533035~195538681:+
LUAD	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	6.83	2.63e-11	1.63e-08	0.62	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
LUAD	cis	rs2842992	0.672	rs7738253	ENSG00000237927.1	RP3-393E18.2	-6.83	2.63e-11	1.63e-08	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772885	chr6:159586955~159589169:-
LUAD	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.63e-11	1.63e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.63e-11	1.63e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
LUAD	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	6.83	2.63e-11	1.63e-08	0.66	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	6.83	2.63e-11	1.63e-08	0.66	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
LUAD	cis	rs75422866	0.764	rs73104177	ENSG00000280054.1	RP1-197B17.7	6.83	2.63e-11	1.63e-08	0.75	0.3	Pneumonia;	chr12:47713550	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.764	rs73104184	ENSG00000280054.1	RP1-197B17.7	6.83	2.63e-11	1.63e-08	0.75	0.3	Pneumonia;	chr12:47715623	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.764	rs73104188	ENSG00000280054.1	RP1-197B17.7	6.83	2.63e-11	1.63e-08	0.75	0.3	Pneumonia;	chr12:47715885	chr12:47728151~47730598:-
LUAD	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-6.83	2.64e-11	1.63e-08	-0.37	-0.3	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
LUAD	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.63e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
LUAD	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	6.83	2.64e-11	1.63e-08	0.39	0.3	Depression;	chr6:28379133	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	6.83	2.64e-11	1.63e-08	0.39	0.3	Depression;	chr6:28379168	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	6.83	2.64e-11	1.64e-08	0.21	0.3	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
LUAD	cis	rs2337406	0.587	rs10139664	ENSG00000254174.1	IGHV1-12	6.83	2.65e-11	1.64e-08	0.26	0.3	Alzheimer's disease (late onset);	chr14:106647254	chr14:106122420~106122709:-
LUAD	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-6.83	2.66e-11	1.64e-08	-0.4	-0.3	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
LUAD	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-6.83	2.66e-11	1.64e-08	-0.36	-0.3	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
LUAD	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-6.82	2.66e-11	1.64e-08	-0.32	-0.3	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
LUAD	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-6.82	2.66e-11	1.64e-08	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
LUAD	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-6.82	2.66e-11	1.65e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
LUAD	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	6.82	2.67e-11	1.65e-08	0.6	0.3	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
LUAD	cis	rs11089937	0.616	rs1076851	ENSG00000211639.2	IGLV4-60	6.82	2.68e-11	1.66e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22177442	chr22:22162199~22162681:+
LUAD	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-6.82	2.68e-11	1.66e-08	-0.31	-0.3	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
LUAD	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	6.82	2.68e-11	1.66e-08	0.37	0.3	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
LUAD	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.68e-11	1.66e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-6.82	2.69e-11	1.66e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
LUAD	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-6.82	2.69e-11	1.67e-08	-0.3	-0.3	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
LUAD	cis	rs950880	0.553	rs2293225	ENSG00000234389.1	AC007278.3	-6.82	2.7e-11	1.67e-08	-0.33	-0.3	Serum protein levels (sST2);	chr2:102419429	chr2:102438713~102440475:+
LUAD	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-6.82	2.71e-11	1.68e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
LUAD	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	6.82	2.71e-11	1.68e-08	0.71	0.3	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
LUAD	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	6.82	2.71e-11	1.68e-08	0.38	0.3	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
LUAD	cis	rs7017914	0.935	rs6472551	ENSG00000223220.1	Y_RNA	6.82	2.71e-11	1.68e-08	0.33	0.3	Bone mineral density;	chr8:70869614	chr8:70780914~70781008:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-6.82	2.73e-11	1.69e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-6.82	2.73e-11	1.69e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-6.82	2.73e-11	1.69e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-6.82	2.73e-11	1.69e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
LUAD	cis	rs8005677	0.611	rs11624528	ENSG00000279656.1	RP11-298I3.6	6.82	2.73e-11	1.69e-08	0.37	0.3	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:23023083~23024217:-
LUAD	cis	rs35955747	0.934	rs4820045	ENSG00000236132.1	CTA-440B3.1	6.82	2.74e-11	1.69e-08	0.32	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31389983	chr22:31816379~31817491:-
LUAD	cis	rs9595908	0.827	rs9595885	ENSG00000212293.1	SNORA16	6.82	2.74e-11	1.69e-08	0.33	0.3	Body mass index;	chr13:32593913	chr13:32420390~32420516:-
LUAD	cis	rs8177876	0.642	rs56032321	ENSG00000261838.4	RP11-303E16.6	6.82	2.74e-11	1.69e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81069854~81076598:+
LUAD	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-6.82	2.75e-11	1.69e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
LUAD	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	6.82	2.76e-11	1.7e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	6.82	2.76e-11	1.7e-08	0.38	0.3	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
LUAD	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	6.82	2.76e-11	1.7e-08	0.45	0.3	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
LUAD	cis	rs57960857	1	rs57960857	ENSG00000251022.5	THAP9-AS1	6.82	2.76e-11	1.7e-08	0.31	0.3	Neutrophil percentage of white cells;	chr4:82886057	chr4:82893009~82900960:-
LUAD	cis	rs7044106	0.791	rs4617229	ENSG00000238181.2	AHCYP2	-6.82	2.76e-11	1.71e-08	-0.38	-0.3	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120720673~120721972:+
LUAD	cis	rs11089937	0.616	rs12484472	ENSG00000211639.2	IGLV4-60	6.82	2.77e-11	1.71e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22180136	chr22:22162199~22162681:+
LUAD	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-6.82	2.78e-11	1.71e-08	-0.39	-0.3	Depression;	chr6:28422360	chr6:28943877~28944537:+
LUAD	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	6.82	2.78e-11	1.71e-08	0.32	0.3	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
LUAD	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	6.82	2.78e-11	1.71e-08	0.34	0.3	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
LUAD	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	6.82	2.78e-11	1.71e-08	0.35	0.3	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
LUAD	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	6.82	2.78e-11	1.72e-08	0.36	0.3	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000211974.3	IGHV2-70	-6.82	2.79e-11	1.72e-08	-0.38	-0.3	Alzheimer's disease (late onset);	chr14:106777154	chr14:106723574~106724093:-
LUAD	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-6.82	2.79e-11	1.72e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
LUAD	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-6.82	2.79e-11	1.72e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
LUAD	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	6.82	2.8e-11	1.73e-08	0.28	0.3	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
LUAD	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.8e-11	1.73e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
LUAD	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-6.82	2.81e-11	1.73e-08	-0.59	-0.3	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
LUAD	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
LUAD	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-6.82	2.82e-11	1.74e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
LUAD	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.82e-11	1.74e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.82e-11	1.74e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
LUAD	cis	rs62229266	0.659	rs2835258	ENSG00000214914.3	RPL23AP3	6.81	2.83e-11	1.74e-08	0.36	0.3	Mitral valve prolapse;	chr21:36052067	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.804	rs2255858	ENSG00000214914.3	RPL23AP3	6.81	2.83e-11	1.74e-08	0.36	0.3	Mitral valve prolapse;	chr21:36040454	chr21:36016079~36016546:-
LUAD	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	6.81	2.83e-11	1.74e-08	0.33	0.3	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
LUAD	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	6.81	2.83e-11	1.75e-08	0.59	0.3	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	6.81	2.83e-11	1.75e-08	0.59	0.3	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	6.81	2.83e-11	1.75e-08	0.59	0.3	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
LUAD	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	6.81	2.83e-11	1.75e-08	0.37	0.3	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
LUAD	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	6.81	2.84e-11	1.75e-08	0.38	0.3	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	6.81	2.84e-11	1.75e-08	0.38	0.3	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	6.81	2.84e-11	1.75e-08	0.38	0.3	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
LUAD	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-6.81	2.84e-11	1.75e-08	-0.3	-0.3	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
LUAD	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	6.81	2.84e-11	1.75e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
LUAD	cis	rs9525916	0.967	rs9533775	ENSG00000227258.4	SMIM2-AS1	-6.81	2.84e-11	1.75e-08	-0.35	-0.3	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44110451~44240517:+
LUAD	cis	rs10899021	0.915	rs11236198	ENSG00000279353.1	RP11-864N7.4	6.81	2.85e-11	1.75e-08	0.55	0.3	Response to metformin (IC50);	chr11:74661155	chr11:74698231~74699658:-
LUAD	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-6.81	2.86e-11	1.76e-08	-0.33	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
LUAD	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	6.81	2.86e-11	1.76e-08	0.37	0.3	Height;	chr6:109383848	chr6:109382795~109383666:+
LUAD	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	6.81	2.87e-11	1.77e-08	0.33	0.3	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
LUAD	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	6.81	2.87e-11	1.77e-08	0.34	0.3	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
LUAD	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-6.81	2.87e-11	1.77e-08	-0.32	-0.3	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
LUAD	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	6.81	2.89e-11	1.78e-08	0.37	0.3	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	6.81	2.89e-11	1.78e-08	0.37	0.3	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
LUAD	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	6.81	2.89e-11	1.78e-08	0.35	0.3	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
LUAD	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.89e-11	1.78e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
LUAD	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	6.81	2.9e-11	1.78e-08	0.34	0.3	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
LUAD	cis	rs10200159	1	rs1045920	ENSG00000272606.1	RP11-554J4.1	6.81	2.9e-11	1.78e-08	0.52	0.3	Vitiligo;	chr2:55544033	chr2:55617909~55618373:+
LUAD	cis	rs6487679	1	rs6487679	ENSG00000111788.10	RP11-22B23.1	6.81	2.9e-11	1.79e-08	0.32	0.3	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9277235~9313241:+
LUAD	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	6.81	2.9e-11	1.79e-08	0.59	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	6.81	2.9e-11	1.79e-08	0.59	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-6.81	2.91e-11	1.79e-08	-0.38	-0.3	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
LUAD	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	6.81	2.92e-11	1.79e-08	0.33	0.3	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
LUAD	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	6.81	2.92e-11	1.8e-08	0.41	0.3	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.8	rs28429717	ENSG00000275426.1	CH17-262A2.1	6.81	2.92e-11	1.8e-08	0.37	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:149738~150317:+
LUAD	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	6.81	2.92e-11	1.8e-08	0.33	0.3	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
LUAD	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-6.81	2.92e-11	1.8e-08	-0.54	-0.3	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.93e-11	1.8e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
LUAD	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	6.81	2.93e-11	1.8e-08	0.33	0.3	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
LUAD	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-6.81	2.93e-11	1.8e-08	-0.33	-0.3	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
LUAD	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-6.81	2.93e-11	1.8e-08	-0.34	-0.3	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
LUAD	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	6.81	2.93e-11	1.8e-08	0.35	0.3	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	6.81	2.94e-11	1.8e-08	0.38	0.3	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
LUAD	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-6.81	2.94e-11	1.81e-08	-0.42	-0.3	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
LUAD	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-6.81	2.94e-11	1.81e-08	-0.42	-0.3	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
LUAD	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-6.81	2.95e-11	1.81e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-6.81	2.95e-11	1.81e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-6.81	2.95e-11	1.81e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
LUAD	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	6.81	2.97e-11	1.82e-08	0.31	0.3	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
LUAD	cis	rs9326248	0.515	rs2727793	ENSG00000280143.1	AP000892.6	6.81	2.97e-11	1.82e-08	0.35	0.3	Blood protein levels;	chr11:116812658	chr11:117204967~117210292:+
LUAD	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.98e-11	1.83e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
LUAD	cis	rs75920871	0.589	rs67201490	ENSG00000254851.1	RP11-109L13.1	-6.81	2.98e-11	1.83e-08	-0.51	-0.3	Subjective well-being;	chr11:117212288	chr11:117135528~117138582:+
LUAD	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-6.81	2.99e-11	1.84e-08	-0.34	-0.3	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
LUAD	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-6.81	3.01e-11	1.85e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
LUAD	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	6.81	3.01e-11	1.85e-08	0.42	0.3	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
LUAD	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	6.81	3.01e-11	1.85e-08	0.35	0.3	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
LUAD	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	6.81	3.01e-11	1.85e-08	0.49	0.3	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
LUAD	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	6.81	3.01e-11	1.85e-08	0.37	0.3	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	6.81	3.01e-11	1.85e-08	0.37	0.3	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
LUAD	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	6.81	3.01e-11	1.85e-08	0.32	0.3	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
LUAD	cis	rs34526934	0.566	rs9141	ENSG00000226363.3	HAGLROS	6.81	3.01e-11	1.85e-08	0.41	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176173242	chr2:176177717~176179008:+
LUAD	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-6.81	3.01e-11	1.85e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-6.81	3.01e-11	1.85e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-6.81	3.01e-11	1.85e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-6.81	3.01e-11	1.85e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-6.8	3.02e-11	1.85e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.53	rs236918	ENSG00000280143.1	AP000892.6	-6.8	3.02e-11	1.85e-08	-0.49	-0.3	Blood protein levels;	chr11:117220893	chr11:117204967~117210292:+
LUAD	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-6.8	3.02e-11	1.86e-08	-0.33	-0.3	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
LUAD	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	6.8	3.03e-11	1.86e-08	0.36	0.3	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
LUAD	cis	rs2439831	0.867	rs933941	ENSG00000205771.5	CATSPER2P1	-6.8	3.03e-11	1.86e-08	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43340028	chr15:43726918~43747094:-
LUAD	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	6.8	3.03e-11	1.86e-08	0.33	0.3	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
LUAD	cis	rs17301013	0.507	rs10489255	ENSG00000227373.4	RP11-160H22.5	6.8	3.04e-11	1.86e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174341985	chr1:174115300~174160004:-
LUAD	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	6.8	3.04e-11	1.86e-08	0.36	0.3	Height;	chr6:109360263	chr6:109382795~109383666:+
LUAD	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	6.8	3.04e-11	1.87e-08	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	6.8	3.04e-11	1.87e-08	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
LUAD	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-6.8	3.05e-11	1.87e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
LUAD	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-6.8	3.05e-11	1.87e-08	-0.41	-0.3	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
LUAD	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-6.8	3.06e-11	1.87e-08	-0.35	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
LUAD	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	6.8	3.06e-11	1.87e-08	0.32	0.3	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
LUAD	cis	rs950880	0.71	rs12470867	ENSG00000234389.1	AC007278.3	-6.8	3.06e-11	1.88e-08	-0.31	-0.3	Serum protein levels (sST2);	chr2:102309906	chr2:102438713~102440475:+
LUAD	cis	rs7017914	0.967	rs2732091	ENSG00000223220.1	Y_RNA	-6.8	3.07e-11	1.88e-08	-0.32	-0.3	Bone mineral density;	chr8:71006188	chr8:70780914~70781008:-
LUAD	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	6.8	3.07e-11	1.88e-08	0.39	0.3	Depression;	chr6:28364057	chr6:28943877~28944537:+
LUAD	cis	rs2179367	0.959	rs4897125	ENSG00000231760.4	RP11-350J20.5	6.8	3.07e-11	1.88e-08	0.37	0.3	Dupuytren's disease;	chr6:149445072	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.887	rs6570965	ENSG00000231760.4	RP11-350J20.5	6.8	3.07e-11	1.88e-08	0.37	0.3	Dupuytren's disease;	chr6:149396340	chr6:149796151~149826294:-
LUAD	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-6.8	3.08e-11	1.89e-08	-0.52	-0.3	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
LUAD	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	6.8	3.08e-11	1.89e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
LUAD	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	6.8	3.09e-11	1.89e-08	0.37	0.3	Height;	chr6:109447092	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	6.8	3.09e-11	1.89e-08	0.39	0.3	Height;	chr6:109490935	chr6:109382795~109383666:+
LUAD	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-6.8	3.09e-11	1.89e-08	-0.39	-0.3	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
LUAD	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	6.8	3.1e-11	1.9e-08	0.37	0.3	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
LUAD	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	6.8	3.1e-11	1.9e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
LUAD	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	6.8	3.1e-11	1.9e-08	0.34	0.3	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
LUAD	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	6.8	3.11e-11	1.9e-08	0.31	0.3	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
LUAD	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
LUAD	cis	rs7044106	0.791	rs735110	ENSG00000238181.2	AHCYP2	-6.8	3.11e-11	1.91e-08	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.791	rs10985001	ENSG00000238181.2	AHCYP2	-6.8	3.13e-11	1.91e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120720673~120721972:+
LUAD	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-6.8	3.13e-11	1.92e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
LUAD	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	6.8	3.13e-11	1.92e-08	0.46	0.3	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
LUAD	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
LUAD	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-6.8	3.14e-11	1.92e-08	-0.31	-0.3	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
LUAD	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	6.8	3.14e-11	1.92e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
LUAD	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	6.8	3.14e-11	1.92e-08	0.33	0.3	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
LUAD	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	6.8	3.15e-11	1.93e-08	0.38	0.3	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
LUAD	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-6.8	3.16e-11	1.93e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
LUAD	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	6.8	3.16e-11	1.93e-08	0.24	0.3	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
LUAD	cis	rs2439831	0.681	rs478104	ENSG00000205771.5	CATSPER2P1	-6.8	3.16e-11	1.93e-08	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43302702	chr15:43726918~43747094:-
LUAD	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-6.8	3.17e-11	1.94e-08	-0.39	-0.3	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-6.8	3.17e-11	1.94e-08	-0.39	-0.3	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
LUAD	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	6.8	3.17e-11	1.94e-08	0.64	0.3	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	6.8	3.17e-11	1.94e-08	0.64	0.3	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	6.8	3.17e-11	1.94e-08	0.64	0.3	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
LUAD	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-6.8	3.17e-11	1.94e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-6.8	3.17e-11	1.94e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
LUAD	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-6.8	3.19e-11	1.95e-08	-0.34	-0.3	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
LUAD	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-6.8	3.2e-11	1.95e-08	-0.42	-0.3	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
LUAD	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-6.8	3.2e-11	1.95e-08	-0.6	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
LUAD	cis	rs1075232	1	rs34959140	ENSG00000270055.1	CTD-3092A11.2	-6.8	3.2e-11	1.95e-08	-0.6	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30487963~30490313:+
LUAD	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-6.8	3.21e-11	1.96e-08	-0.33	-0.3	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
LUAD	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-6.79	3.21e-11	1.96e-08	-0.53	-0.3	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
LUAD	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	6.79	3.22e-11	1.96e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	6.79	3.22e-11	1.96e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-6.79	3.22e-11	1.97e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
LUAD	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-6.79	3.23e-11	1.97e-08	-0.38	-0.3	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-6.79	3.23e-11	1.97e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
LUAD	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-6.79	3.23e-11	1.97e-08	-0.28	-0.3	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
LUAD	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	6.79	3.24e-11	1.98e-08	0.34	0.3	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	6.79	3.24e-11	1.98e-08	0.34	0.3	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
LUAD	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-6.79	3.25e-11	1.98e-08	-0.31	-0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
LUAD	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	6.79	3.26e-11	1.99e-08	0.36	0.3	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
LUAD	cis	rs2243480	1	rs10807702	ENSG00000232546.1	RP11-458F8.1	-6.79	3.26e-11	1.99e-08	-0.38	-0.3	Diabetic kidney disease;	chr7:66302856	chr7:66848496~66858136:+
LUAD	cis	rs62229266	0.804	rs998383	ENSG00000214914.3	RPL23AP3	6.79	3.27e-11	1.99e-08	0.36	0.3	Mitral valve prolapse;	chr21:36073441	chr21:36016079~36016546:-
LUAD	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	6.79	3.27e-11	1.99e-08	0.59	0.3	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
LUAD	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-6.79	3.27e-11	2e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-6.79	3.28e-11	2e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
LUAD	cis	rs10200159	0.793	rs2867964	ENSG00000272606.1	RP11-554J4.1	6.79	3.28e-11	2e-08	0.48	0.3	Vitiligo;	chr2:55698289	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.793	rs11691977	ENSG00000272606.1	RP11-554J4.1	6.79	3.28e-11	2e-08	0.48	0.3	Vitiligo;	chr2:55698753	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.793	rs12623625	ENSG00000272606.1	RP11-554J4.1	6.79	3.28e-11	2e-08	0.48	0.3	Vitiligo;	chr2:55699981	chr2:55617909~55618373:+
LUAD	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-6.79	3.28e-11	2e-08	-0.45	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
LUAD	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-6.79	3.28e-11	2e-08	-0.35	-0.3	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
LUAD	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	6.79	3.28e-11	2e-08	0.35	0.3	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
LUAD	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	6.79	3.28e-11	2e-08	0.35	0.3	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
LUAD	cis	rs35955747	0.838	rs5997887	ENSG00000236132.1	CTA-440B3.1	6.79	3.29e-11	2e-08	0.33	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31147211	chr22:31816379~31817491:-
LUAD	cis	rs1823913	0.599	rs17346475	ENSG00000280083.1	RP11-317J9.1	6.79	3.29e-11	2.01e-08	0.35	0.3	Obesity-related traits;	chr2:191288488	chr2:191154118~191156070:-
LUAD	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	6.79	3.29e-11	2.01e-08	0.38	0.3	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	6.79	3.29e-11	2.01e-08	0.38	0.3	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	6.79	3.31e-11	2.01e-08	0.34	0.3	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	6.79	3.31e-11	2.01e-08	0.34	0.3	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	6.79	3.31e-11	2.02e-08	0.34	0.3	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
LUAD	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-6.79	3.31e-11	2.02e-08	-0.53	-0.3	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
LUAD	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-6.79	3.31e-11	2.02e-08	-0.53	-0.3	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
LUAD	cis	rs9584850	0.874	rs9168	ENSG00000231194.1	FARP1-AS1	6.79	3.31e-11	2.02e-08	0.36	0.3	Neuroticism;	chr13:98449329	chr13:98435405~98435840:-
LUAD	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-6.79	3.32e-11	2.02e-08	-0.32	-0.3	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
LUAD	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	6.79	3.32e-11	2.02e-08	0.32	0.3	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
LUAD	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	6.79	3.32e-11	2.02e-08	0.31	0.3	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
LUAD	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	6.79	3.32e-11	2.03e-08	0.35	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
LUAD	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-6.79	3.33e-11	2.03e-08	-0.38	-0.3	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-6.79	3.33e-11	2.03e-08	-0.38	-0.3	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
LUAD	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	6.79	3.33e-11	2.03e-08	0.34	0.3	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
LUAD	cis	rs73219805	0.759	rs17055186	ENSG00000228451.3	SDAD1P1	-6.79	3.34e-11	2.03e-08	-0.53	-0.3	Schizophrenia;	chr8:26403394	chr8:26379259~26382953:-
LUAD	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-6.79	3.35e-11	2.04e-08	-0.31	-0.3	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
LUAD	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	6.79	3.35e-11	2.04e-08	0.32	0.3	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
LUAD	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	6.79	3.36e-11	2.04e-08	0.33	0.3	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
LUAD	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	6.79	3.36e-11	2.04e-08	0.44	0.3	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
LUAD	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	6.79	3.36e-11	2.04e-08	0.41	0.3	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	6.79	3.36e-11	2.04e-08	0.41	0.3	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	6.79	3.36e-11	2.04e-08	0.41	0.3	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
LUAD	cis	rs950880	0.677	rs56224165	ENSG00000234389.1	AC007278.3	-6.79	3.36e-11	2.04e-08	-0.31	-0.3	Serum protein levels (sST2);	chr2:102308763	chr2:102438713~102440475:+
LUAD	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	6.79	3.37e-11	2.05e-08	0.36	0.3	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
LUAD	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-6.79	3.37e-11	2.05e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
LUAD	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-6.79	3.37e-11	2.05e-08	-0.37	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
LUAD	cis	rs237743	1	rs9753608	ENSG00000222365.1	SNORD12B	-6.79	3.38e-11	2.06e-08	-0.35	-0.3	Height;	chr20:49220669	chr20:49280319~49280409:+
LUAD	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	6.79	3.38e-11	2.06e-08	0.37	0.3	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
LUAD	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-6.79	3.39e-11	2.06e-08	-0.37	-0.3	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
LUAD	cis	rs7826238	0.72	rs12546760	ENSG00000253981.4	ALG1L13P	-6.79	3.39e-11	2.06e-08	-0.34	-0.3	Systolic blood pressure;	chr8:8517326	chr8:8236003~8244667:-
LUAD	cis	rs11846409	0.86	rs17112419	ENSG00000254174.1	IGHV1-12	6.79	3.39e-11	2.06e-08	0.25	0.3	Rheumatic heart disease;	chr14:106633260	chr14:106122420~106122709:-
LUAD	cis	rs7646881	0.812	rs6788069	ENSG00000240207.5	RP11-379F4.4	6.79	3.4e-11	2.07e-08	0.35	0.3	Tetralogy of Fallot;	chr3:158741670	chr3:158732263~158784070:+
LUAD	cis	rs1874124	0.577	rs2807853	ENSG00000238078.1	LINC01352	6.79	3.4e-11	2.07e-08	0.42	0.3	Cholesterol, total;	chr1:220851011	chr1:220829255~220832429:+
LUAD	cis	rs1874124	0.504	rs2491257	ENSG00000238078.1	LINC01352	6.79	3.4e-11	2.07e-08	0.42	0.3	Cholesterol, total;	chr1:220855900	chr1:220829255~220832429:+
LUAD	cis	rs944289	0.932	rs1169151	ENSG00000257826.1	RP11-116N8.4	6.79	3.4e-11	2.07e-08	0.31	0.3	Thyroid cancer;	chr14:36171395	chr14:36061026~36067190:-
LUAD	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	6.79	3.4e-11	2.07e-08	0.33	0.3	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
LUAD	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	6.79	3.4e-11	2.07e-08	0.42	0.3	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
LUAD	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	6.79	3.4e-11	2.07e-08	0.33	0.3	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
LUAD	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	6.79	3.41e-11	2.07e-08	0.38	0.3	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
LUAD	cis	rs11123170	0.529	rs1015755	ENSG00000274877.1	RP11-65I12.1	-6.79	3.41e-11	2.07e-08	-0.46	-0.3	Renal function-related traits (BUN);	chr2:113210730	chr2:113237595~113240825:+
LUAD	cis	rs8177876	0.822	rs8056972	ENSG00000261838.4	RP11-303E16.6	6.79	3.41e-11	2.07e-08	0.64	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81069854~81076598:+
LUAD	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-6.79	3.41e-11	2.08e-08	-0.44	-0.3	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
LUAD	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	6.79	3.41e-11	2.08e-08	0.35	0.3	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
LUAD	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	6.78	3.44e-11	2.09e-08	0.32	0.3	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
LUAD	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-6.78	3.45e-11	2.1e-08	-0.41	-0.3	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
LUAD	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-6.78	3.45e-11	2.1e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
LUAD	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-6.78	3.45e-11	2.1e-08	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
LUAD	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-6.78	3.45e-11	2.1e-08	-0.31	-0.3	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
LUAD	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	6.78	3.46e-11	2.1e-08	0.36	0.3	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
LUAD	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-6.78	3.47e-11	2.11e-08	-0.44	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
LUAD	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	6.78	3.48e-11	2.11e-08	0.39	0.3	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
LUAD	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-6.78	3.48e-11	2.11e-08	-0.31	-0.3	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
LUAD	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	6.78	3.48e-11	2.11e-08	0.32	0.3	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
LUAD	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	6.78	3.48e-11	2.11e-08	0.38	0.3	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
LUAD	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-6.78	3.49e-11	2.12e-08	-0.35	-0.3	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
LUAD	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	6.78	3.5e-11	2.12e-08	0.38	0.3	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
LUAD	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-6.78	3.5e-11	2.13e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
LUAD	cis	rs35955747	0.869	rs7286648	ENSG00000236132.1	CTA-440B3.1	-6.78	3.51e-11	2.13e-08	-0.32	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31143628	chr22:31816379~31817491:-
LUAD	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-6.78	3.51e-11	2.13e-08	-0.36	-0.3	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
LUAD	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-6.78	3.51e-11	2.13e-08	-0.4	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
LUAD	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	6.78	3.52e-11	2.14e-08	0.32	0.3	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
LUAD	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	6.78	3.52e-11	2.14e-08	0.32	0.3	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
LUAD	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	6.78	3.52e-11	2.14e-08	0.32	0.3	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
LUAD	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	6.78	3.53e-11	2.14e-08	0.37	0.3	Height;	chr6:109430292	chr6:109382795~109383666:+
LUAD	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-6.78	3.55e-11	2.15e-08	-0.33	-0.3	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
LUAD	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-6.78	3.56e-11	2.16e-08	-0.31	-0.3	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
LUAD	cis	rs11089937	0.616	rs11705598	ENSG00000211639.2	IGLV4-60	6.78	3.56e-11	2.16e-08	0.3	0.3	Periodontitis (PAL4Q3);	chr22:22178837	chr22:22162199~22162681:+
LUAD	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	6.78	3.58e-11	2.17e-08	0.43	0.3	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	6.78	3.58e-11	2.17e-08	0.43	0.3	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
LUAD	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	6.78	3.58e-11	2.17e-08	0.34	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
LUAD	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	6.78	3.58e-11	2.17e-08	0.35	0.3	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	6.78	3.59e-11	2.17e-08	0.35	0.3	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-6.78	3.59e-11	2.18e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
LUAD	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-6.78	3.6e-11	2.18e-08	-0.3	-0.3	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
LUAD	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-6.78	3.6e-11	2.18e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
LUAD	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-6.78	3.61e-11	2.19e-08	-0.33	-0.3	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
LUAD	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	6.78	3.61e-11	2.19e-08	0.37	0.3	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
LUAD	cis	rs1345301	1	rs12475055	ENSG00000234389.1	AC007278.3	6.78	3.61e-11	2.19e-08	0.27	0.3	Waist circumference;	chr2:102262431	chr2:102438713~102440475:+
LUAD	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-6.78	3.61e-11	2.19e-08	-0.32	-0.3	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
LUAD	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-6.78	3.61e-11	2.19e-08	-0.44	-0.3	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	6.78	3.61e-11	2.19e-08	0.3	0.3	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-6.78	3.61e-11	2.19e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	6.78	3.61e-11	2.19e-08	0.55	0.3	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
LUAD	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-6.78	3.62e-11	2.19e-08	-0.34	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
LUAD	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	6.78	3.63e-11	2.2e-08	0.38	0.3	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-6.78	3.63e-11	2.2e-08	-0.56	-0.3	Gout;	chr7:66654674	chr7:66654538~66669855:+
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-6.78	3.63e-11	2.2e-08	-0.56	-0.3	Gout;	chr7:66661502	chr7:66654538~66669855:+
LUAD	cis	rs2286503	0.78	rs2240727	ENSG00000228649.7	AC005682.5	6.78	3.63e-11	2.2e-08	0.38	0.3	Fibrinogen;	chr7:22812893	chr7:22854178~22861579:+
LUAD	cis	rs9326248	0.53	rs6589575	ENSG00000280143.1	AP000892.6	6.78	3.63e-11	2.2e-08	0.47	0.3	Blood protein levels;	chr11:116862594	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.53	rs718847	ENSG00000280143.1	AP000892.6	6.78	3.63e-11	2.2e-08	0.47	0.3	Blood protein levels;	chr11:116863430	chr11:117204967~117210292:+
LUAD	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	6.78	3.64e-11	2.2e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
LUAD	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	6.78	3.64e-11	2.2e-08	0.24	0.3	Breast cancer;	chr11:750849	chr11:781645~782105:+
LUAD	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-6.78	3.64e-11	2.2e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
LUAD	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-6.78	3.64e-11	2.21e-08	-0.37	-0.3	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
LUAD	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-6.78	3.64e-11	2.21e-08	-0.27	-0.3	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
LUAD	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-6.77	3.65e-11	2.21e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
LUAD	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-6.77	3.66e-11	2.21e-08	-0.46	-0.3	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
LUAD	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-6.77	3.67e-11	2.22e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-6.77	3.67e-11	2.22e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-6.77	3.67e-11	2.22e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
LUAD	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-6.77	3.69e-11	2.23e-08	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
LUAD	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	6.77	3.7e-11	2.24e-08	0.39	0.3	Depression;	chr6:28428413	chr6:28943877~28944537:+
LUAD	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-6.77	3.7e-11	2.24e-08	-0.4	-0.3	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
LUAD	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	6.77	3.7e-11	2.24e-08	0.32	0.3	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
LUAD	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-6.77	3.7e-11	2.24e-08	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
LUAD	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-6.77	3.7e-11	2.24e-08	-0.54	-0.3	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
LUAD	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-6.77	3.7e-11	2.24e-08	-0.38	-0.3	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
LUAD	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	6.77	3.7e-11	2.24e-08	0.49	0.3	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
LUAD	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	6.77	3.7e-11	2.24e-08	0.4	0.3	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
LUAD	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	6.77	3.71e-11	2.24e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
LUAD	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	6.77	3.71e-11	2.24e-08	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
LUAD	cis	rs7044106	0.791	rs747819	ENSG00000238181.2	AHCYP2	-6.77	3.71e-11	2.24e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120720673~120721972:+
LUAD	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	6.77	3.72e-11	2.25e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
LUAD	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	6.77	3.73e-11	2.25e-08	0.38	0.3	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
LUAD	cis	rs7044106	0.791	rs10985000	ENSG00000238181.2	AHCYP2	-6.77	3.73e-11	2.25e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120720673~120721972:+
LUAD	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-6.77	3.73e-11	2.25e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
LUAD	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-6.77	3.73e-11	2.25e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-6.77	3.73e-11	2.25e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-6.77	3.73e-11	2.25e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
LUAD	cis	rs8177876	0.822	rs1563077	ENSG00000261838.4	RP11-303E16.6	6.77	3.74e-11	2.26e-08	0.63	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81069854~81076598:+
LUAD	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-6.77	3.74e-11	2.26e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
LUAD	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	6.77	3.76e-11	2.27e-08	0.34	0.29	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
LUAD	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	6.77	3.76e-11	2.27e-08	0.39	0.29	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
LUAD	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	6.77	3.76e-11	2.27e-08	0.35	0.29	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
LUAD	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-6.77	3.77e-11	2.28e-08	-0.34	-0.29	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
LUAD	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	6.77	3.77e-11	2.28e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
LUAD	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-6.77	3.78e-11	2.28e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
LUAD	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-6.77	3.8e-11	2.29e-08	-0.33	-0.29	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
LUAD	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
LUAD	cis	rs9326248	0.559	rs482371	ENSG00000280143.1	AP000892.6	6.77	3.8e-11	2.29e-08	0.35	0.29	Blood protein levels;	chr11:116881447	chr11:117204967~117210292:+
LUAD	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	6.77	3.8e-11	2.29e-08	0.32	0.29	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
LUAD	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	6.77	3.81e-11	2.3e-08	0.38	0.29	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
LUAD	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	6.77	3.81e-11	2.3e-08	0.29	0.29	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
LUAD	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	6.77	3.82e-11	2.3e-08	0.36	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
LUAD	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	6.77	3.82e-11	2.3e-08	0.36	0.29	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
LUAD	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	6.77	3.83e-11	2.31e-08	0.32	0.29	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
LUAD	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-6.77	3.83e-11	2.31e-08	-0.36	-0.29	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
LUAD	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	6.77	3.83e-11	2.31e-08	0.58	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
LUAD	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	6.77	3.84e-11	2.31e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	6.77	3.85e-11	2.32e-08	0.35	0.29	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-6.77	3.85e-11	2.32e-08	-0.39	-0.29	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
LUAD	cis	rs8177876	0.822	rs56119129	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.731	rs77145371	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.908	rs80187824	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.731	rs74882687	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.642	rs76909932	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs8177939	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81069854~81076598:+
LUAD	cis	rs2337406	0.539	rs2583292	ENSG00000254174.1	IGHV1-12	6.77	3.88e-11	2.34e-08	0.25	0.29	Alzheimer's disease (late onset);	chr14:106649040	chr14:106122420~106122709:-
LUAD	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-6.76	3.89e-11	2.34e-08	-0.33	-0.29	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
LUAD	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-6.76	3.9e-11	2.35e-08	-0.31	-0.29	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
LUAD	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	6.76	3.91e-11	2.35e-08	0.32	0.29	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
LUAD	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-6.76	3.91e-11	2.36e-08	-0.28	-0.29	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
LUAD	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-6.76	3.94e-11	2.37e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
LUAD	cis	rs7017914	0.967	rs1477944	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70703365	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs17760497	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70704810	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34677078	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70705480	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs62530792	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70706532	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs35893260	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70707838	chr8:70780914~70781008:-
LUAD	cis	rs7017914	1	rs13253842	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70713268	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13254908	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70713863	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13264669	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70714537	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34508469	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70716228	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6472539	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70717575	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs56043721	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70718192	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs3954897	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70723720	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.811	rs4272413	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70723952	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs6981435	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70724913	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6999739	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70724977	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7013657	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70725324	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs7006615	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70727572	chr8:70780914~70781008:-
LUAD	cis	rs7017914	1	rs7007450	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70728034	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs11989553	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70728664	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13272523	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70729237	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs62530826	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70729408	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs35295900	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70729826	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs35115527	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70730774	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs11991273	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70733625	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.869	rs11987511	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70733636	chr8:70780914~70781008:-
LUAD	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-6.76	3.94e-11	2.37e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
LUAD	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	6.76	3.94e-11	2.37e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
LUAD	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-6.76	3.95e-11	2.38e-08	-0.43	-0.29	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
LUAD	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-6.76	3.95e-11	2.38e-08	-0.36	-0.29	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
LUAD	cis	rs11846409	0.932	rs60659763	ENSG00000211974.3	IGHV2-70	-6.76	3.96e-11	2.38e-08	-0.37	-0.29	Rheumatic heart disease;	chr14:106634172	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.932	rs57080270	ENSG00000211974.3	IGHV2-70	-6.76	3.96e-11	2.38e-08	-0.37	-0.29	Rheumatic heart disease;	chr14:106634215	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.932	rs60917084	ENSG00000211974.3	IGHV2-70	-6.76	3.96e-11	2.38e-08	-0.37	-0.29	Rheumatic heart disease;	chr14:106634621	chr14:106723574~106724093:-
LUAD	cis	rs9326248	0.581	rs10892072	ENSG00000280143.1	AP000892.6	6.76	3.97e-11	2.39e-08	0.34	0.29	Blood protein levels;	chr11:117089597	chr11:117204967~117210292:+
LUAD	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-6.76	3.98e-11	2.39e-08	-0.28	-0.29	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
LUAD	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-6.76	3.99e-11	2.4e-08	-0.35	-0.29	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
LUAD	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-6.76	4.01e-11	2.41e-08	-0.38	-0.29	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
LUAD	cis	rs7017914	0.967	rs7814648	ENSG00000223220.1	Y_RNA	6.76	4.03e-11	2.42e-08	0.33	0.29	Bone mineral density;	chr8:70691749	chr8:70780914~70781008:-
LUAD	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-6.76	4.03e-11	2.42e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-6.76	4.03e-11	2.42e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
LUAD	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	6.76	4.03e-11	2.42e-08	0.43	0.29	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
LUAD	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-6.76	4.04e-11	2.43e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-6.76	4.04e-11	2.43e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
LUAD	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	6.76	4.04e-11	2.43e-08	0.38	0.29	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
LUAD	cis	rs17684571	0.938	rs35408048	ENSG00000231441.1	RP11-472M19.2	6.76	4.06e-11	2.43e-08	0.42	0.29	Schizophrenia;	chr6:56694746	chr6:56844002~56864078:+
LUAD	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	6.76	4.06e-11	2.44e-08	0.37	0.29	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
LUAD	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-6.76	4.06e-11	2.44e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106776648	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106776833	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106777009	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106777263	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106778385	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106778427	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106778702	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106779073	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106779163	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106779174	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106779234	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	6.76	4.07e-11	2.44e-08	0.38	0.29	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
LUAD	cis	rs9326248	0.581	rs12225187	ENSG00000280143.1	AP000892.6	6.76	4.08e-11	2.45e-08	0.34	0.29	Blood protein levels;	chr11:116922515	chr11:117204967~117210292:+
LUAD	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	6.76	4.08e-11	2.45e-08	0.42	0.29	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
LUAD	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-6.76	4.08e-11	2.45e-08	-0.38	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
LUAD	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	6.76	4.1e-11	2.46e-08	0.35	0.29	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
LUAD	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-6.76	4.11e-11	2.47e-08	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
LUAD	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	6.76	4.12e-11	2.47e-08	0.25	0.29	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
LUAD	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-6.76	4.12e-11	2.47e-08	-0.43	-0.29	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
LUAD	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	6.76	4.13e-11	2.47e-08	0.4	0.29	Depression;	chr6:28199145	chr6:28115628~28116551:+
LUAD	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	6.76	4.13e-11	2.47e-08	0.39	0.29	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
LUAD	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-6.76	4.13e-11	2.48e-08	-0.22	-0.29	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
LUAD	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-6.75	4.14e-11	2.48e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-6.75	4.15e-11	2.49e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-6.75	4.15e-11	2.49e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
LUAD	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
LUAD	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
LUAD	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-6.75	4.16e-11	2.49e-08	-0.22	-0.29	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
LUAD	cis	rs8177876	0.731	rs4889227	ENSG00000261838.4	RP11-303E16.6	-6.75	4.16e-11	2.49e-08	-0.57	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81069854~81076598:+
LUAD	cis	rs2734839	0.964	rs12808482	ENSG00000270179.1	RP11-159N11.4	-6.75	4.17e-11	2.5e-08	-0.3	-0.29	Information processing speed;	chr11:113424276	chr11:113368478~113369117:+
LUAD	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	6.75	4.17e-11	2.5e-08	0.62	0.29	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
LUAD	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	6.75	4.17e-11	2.5e-08	0.35	0.29	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
LUAD	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	6.75	4.18e-11	2.5e-08	0.36	0.29	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
LUAD	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	6.75	4.2e-11	2.51e-08	0.33	0.29	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
LUAD	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	6.75	4.2e-11	2.52e-08	0.36	0.29	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
LUAD	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-6.75	4.2e-11	2.52e-08	-0.34	-0.29	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	6.75	4.21e-11	2.52e-08	0.35	0.29	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
LUAD	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.21e-11	2.52e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.21e-11	2.52e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
LUAD	cis	rs6487679	1	rs1017302	ENSG00000111788.10	RP11-22B23.1	6.75	4.21e-11	2.52e-08	0.31	0.29	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9277235~9313241:+
LUAD	cis	rs6487679	1	rs10734765	ENSG00000111788.10	RP11-22B23.1	6.75	4.21e-11	2.52e-08	0.31	0.29	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9277235~9313241:+
LUAD	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	6.75	4.21e-11	2.52e-08	0.45	0.29	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	6.75	4.21e-11	2.52e-08	0.45	0.29	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
LUAD	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-6.75	4.22e-11	2.52e-08	-0.4	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
LUAD	cis	rs75422866	0.51	rs73105819	ENSG00000280054.1	RP1-197B17.7	6.75	4.22e-11	2.52e-08	0.65	0.29	Pneumonia;	chr12:47727190	chr12:47728151~47730598:-
LUAD	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	6.75	4.22e-11	2.53e-08	0.43	0.29	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
LUAD	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	6.75	4.22e-11	2.53e-08	0.43	0.29	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
LUAD	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	6.75	4.22e-11	2.53e-08	0.43	0.29	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
LUAD	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	6.75	4.22e-11	2.53e-08	0.43	0.29	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-6.75	4.22e-11	2.53e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
LUAD	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	6.75	4.23e-11	2.53e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
LUAD	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-6.75	4.23e-11	2.53e-08	-0.34	-0.29	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
LUAD	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-6.75	4.24e-11	2.53e-08	-0.47	-0.29	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
LUAD	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	6.75	4.24e-11	2.54e-08	0.33	0.29	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
LUAD	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	6.75	4.25e-11	2.54e-08	0.35	0.29	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
LUAD	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000211972.2	IGHV3-66	6.75	4.26e-11	2.55e-08	0.25	0.29	Kawasaki disease;	chr14:106676288	chr14:106675017~106675544:-
LUAD	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-6.75	4.26e-11	2.55e-08	-0.39	-0.29	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
LUAD	cis	rs1150668	0.768	rs1150709	ENSG00000204709.4	LINC01556	-6.75	4.26e-11	2.55e-08	-0.35	-0.29	Pubertal anthropometrics;	chr6:28239585	chr6:28943877~28944537:+
LUAD	cis	rs7674212	0.507	rs223317	ENSG00000251288.2	RP11-10L12.2	-6.75	4.27e-11	2.55e-08	-0.37	-0.29	Type 2 diabetes;	chr4:102881667	chr4:102751401~102752641:+
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000206090.4	AP000350.7	6.75	4.27e-11	2.55e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23939998~23942798:+
LUAD	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-6.75	4.27e-11	2.55e-08	-0.32	-0.29	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-6.75	4.27e-11	2.55e-08	-0.32	-0.29	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
LUAD	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	6.75	4.27e-11	2.55e-08	0.36	0.29	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
LUAD	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-6.75	4.28e-11	2.56e-08	-0.52	-0.29	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
LUAD	cis	rs465969	1	rs7750803	ENSG00000255389.1	C6orf3	6.75	4.28e-11	2.56e-08	0.65	0.29	Psoriasis;	chr6:111478910	chr6:111599875~111602295:+
LUAD	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	6.75	4.28e-11	2.56e-08	0.39	0.29	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
LUAD	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	6.75	4.28e-11	2.56e-08	0.43	0.29	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000224373.3	IGHV4-59	6.75	4.28e-11	2.56e-08	0.17	0.29	Kawasaki disease;	chr14:106782288	chr14:106627249~106627825:-
LUAD	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-6.75	4.29e-11	2.56e-08	-0.48	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
LUAD	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	6.75	4.29e-11	2.57e-08	0.33	0.29	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
LUAD	cis	rs7688540	0.8	rs7694325	ENSG00000275426.1	CH17-262A2.1	6.75	4.3e-11	2.57e-08	0.36	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:149738~150317:+
LUAD	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-6.75	4.31e-11	2.57e-08	-0.33	-0.29	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
LUAD	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-6.75	4.31e-11	2.57e-08	-0.29	-0.29	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
LUAD	cis	rs755249	0.958	rs61781370	ENSG00000228060.1	RP11-69E11.8	-6.75	4.32e-11	2.58e-08	-0.3	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39565160~39573203:+
LUAD	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	6.75	4.32e-11	2.58e-08	0.39	0.29	Height;	chr6:109747411	chr6:109382795~109383666:+
LUAD	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	6.75	4.32e-11	2.58e-08	0.39	0.29	Height;	chr6:109748819	chr6:109382795~109383666:+
LUAD	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	6.75	4.32e-11	2.58e-08	0.39	0.29	Height;	chr6:109749564	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000224373.3	IGHV4-59	6.75	4.32e-11	2.58e-08	0.17	0.29	Kawasaki disease;	chr14:106781490	chr14:106627249~106627825:-
LUAD	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-6.75	4.33e-11	2.59e-08	-0.38	-0.29	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
LUAD	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-6.75	4.34e-11	2.59e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
LUAD	cis	rs4141404	0.737	rs5998067	ENSG00000236132.1	CTA-440B3.1	6.75	4.34e-11	2.59e-08	0.36	0.29	Paclitaxel-induced neuropathy;	chr22:31647644	chr22:31816379~31817491:-
LUAD	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-6.75	4.35e-11	2.59e-08	-0.3	-0.29	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
LUAD	cis	rs2734839	0.929	rs2734835	ENSG00000270179.1	RP11-159N11.4	-6.75	4.35e-11	2.6e-08	-0.3	-0.29	Information processing speed;	chr11:113420621	chr11:113368478~113369117:+
LUAD	cis	rs7646881	0.812	rs75107964	ENSG00000240207.5	RP11-379F4.4	-6.75	4.35e-11	2.6e-08	-0.42	-0.29	Tetralogy of Fallot;	chr3:158740962	chr3:158732263~158784070:+
LUAD	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	6.75	4.36e-11	2.6e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
LUAD	cis	rs7017914	0.967	rs7842851	ENSG00000223220.1	Y_RNA	6.75	4.36e-11	2.6e-08	0.32	0.29	Bone mineral density;	chr8:70751570	chr8:70780914~70781008:-
LUAD	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	6.75	4.36e-11	2.6e-08	0.32	0.29	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	6.75	4.36e-11	2.6e-08	0.32	0.29	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
LUAD	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-6.75	4.38e-11	2.61e-08	-0.33	-0.29	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
LUAD	cis	rs2734839	0.964	rs1800498	ENSG00000270179.1	RP11-159N11.4	-6.75	4.38e-11	2.61e-08	-0.3	-0.29	Information processing speed;	chr11:113420866	chr11:113368478~113369117:+
LUAD	cis	rs2734839	0.964	rs2234690	ENSG00000270179.1	RP11-159N11.4	-6.75	4.38e-11	2.61e-08	-0.3	-0.29	Information processing speed;	chr11:113421026	chr11:113368478~113369117:+
LUAD	cis	rs2734839	0.964	rs2587548	ENSG00000270179.1	RP11-159N11.4	-6.75	4.38e-11	2.61e-08	-0.3	-0.29	Information processing speed;	chr11:113421490	chr11:113368478~113369117:+
LUAD	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-6.75	4.38e-11	2.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-6.75	4.38e-11	2.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
LUAD	cis	rs7044106	0.791	rs4837792	ENSG00000238181.2	AHCYP2	-6.75	4.39e-11	2.62e-08	-0.39	-0.29	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120720673~120721972:+
LUAD	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-6.75	4.4e-11	2.62e-08	-0.38	-0.29	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
LUAD	cis	rs7017914	0.967	rs1471114	ENSG00000223220.1	Y_RNA	6.74	4.41e-11	2.63e-08	0.33	0.29	Bone mineral density;	chr8:70763312	chr8:70780914~70781008:-
LUAD	cis	rs62229266	0.609	rs12482541	ENSG00000214914.3	RPL23AP3	6.74	4.41e-11	2.63e-08	0.35	0.29	Mitral valve prolapse;	chr21:36047445	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.609	rs2835253	ENSG00000214914.3	RPL23AP3	6.74	4.41e-11	2.63e-08	0.35	0.29	Mitral valve prolapse;	chr21:36047447	chr21:36016079~36016546:-
LUAD	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	6.74	4.41e-11	2.63e-08	0.39	0.29	Height;	chr6:109763331	chr6:109382795~109383666:+
LUAD	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	6.74	4.42e-11	2.63e-08	0.38	0.29	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
LUAD	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	6.74	4.42e-11	2.64e-08	0.36	0.29	Height;	chr6:109354092	chr6:109382795~109383666:+
LUAD	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	6.74	4.42e-11	2.64e-08	0.38	0.29	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
LUAD	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-6.74	4.42e-11	2.64e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-6.74	4.42e-11	2.64e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
LUAD	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-6.74	4.44e-11	2.64e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
LUAD	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	6.74	4.44e-11	2.65e-08	0.37	0.29	Height;	chr6:109427644	chr6:109382795~109383666:+
LUAD	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	6.74	4.44e-11	2.65e-08	0.34	0.29	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
LUAD	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	6.74	4.45e-11	2.65e-08	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
LUAD	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-6.74	4.45e-11	2.65e-08	-0.35	-0.29	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
LUAD	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	6.74	4.46e-11	2.66e-08	0.36	0.29	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	6.74	4.46e-11	2.66e-08	0.36	0.29	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
LUAD	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-6.74	4.47e-11	2.66e-08	-0.37	-0.29	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
LUAD	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-6.74	4.47e-11	2.66e-08	-0.38	-0.29	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
LUAD	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-6.74	4.48e-11	2.67e-08	-0.35	-0.29	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
LUAD	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-6.74	4.49e-11	2.67e-08	-0.33	-0.29	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-6.74	4.49e-11	2.67e-08	-0.33	-0.29	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
LUAD	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	6.74	4.49e-11	2.67e-08	0.39	0.29	Depression;	chr6:28399846	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-6.74	4.49e-11	2.68e-08	-0.38	-0.29	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
LUAD	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	6.74	4.5e-11	2.68e-08	0.43	0.29	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
LUAD	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-6.74	4.5e-11	2.68e-08	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
LUAD	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	6.74	4.51e-11	2.68e-08	0.36	0.29	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
LUAD	cis	rs12130219	0.543	rs11204988	ENSG00000237975.5	FLG-AS1	6.74	4.51e-11	2.68e-08	0.48	0.29	Inflammatory skin disease;	chr1:152371417	chr1:152168125~152445456:+
LUAD	cis	rs1426063	0.541	rs58959724	ENSG00000249717.1	RP11-44F21.3	6.74	4.51e-11	2.69e-08	0.59	0.29	QT interval;	chr4:75073543	chr4:74955974~74970362:-
LUAD	cis	rs9287719	0.625	rs7567304	ENSG00000234818.1	AC092687.5	-6.74	4.52e-11	2.69e-08	-0.36	-0.29	Prostate cancer;	chr2:10649903	chr2:10589166~10604830:+
LUAD	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-6.74	4.53e-11	2.7e-08	-0.35	-0.29	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
LUAD	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-6.74	4.53e-11	2.7e-08	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
LUAD	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-6.74	4.53e-11	2.7e-08	-0.4	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
LUAD	cis	rs9584850	0.794	rs9630321	ENSG00000231194.1	FARP1-AS1	6.74	4.54e-11	2.7e-08	0.35	0.29	Neuroticism;	chr13:98454725	chr13:98435405~98435840:-
LUAD	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-6.74	4.54e-11	2.7e-08	-0.52	-0.29	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
LUAD	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	6.74	4.55e-11	2.7e-08	0.47	0.29	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	6.74	4.55e-11	2.71e-08	0.49	0.29	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
LUAD	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-6.74	4.55e-11	2.71e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
LUAD	cis	rs2734839	0.964	rs1076563	ENSG00000270179.1	RP11-159N11.4	-6.74	4.55e-11	2.71e-08	-0.3	-0.29	Information processing speed;	chr11:113425187	chr11:113368478~113369117:+
LUAD	cis	rs2734839	0.964	rs1116313	ENSG00000270179.1	RP11-159N11.4	-6.74	4.55e-11	2.71e-08	-0.3	-0.29	Information processing speed;	chr11:113425385	chr11:113368478~113369117:+
LUAD	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	6.74	4.56e-11	2.71e-08	0.55	0.29	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	6.74	4.56e-11	2.71e-08	0.58	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
LUAD	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-6.74	4.56e-11	2.71e-08	-0.46	-0.29	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
LUAD	cis	rs35955747	0.87	rs4820969	ENSG00000236132.1	CTA-440B3.1	6.74	4.59e-11	2.73e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31377587	chr22:31816379~31817491:-
LUAD	cis	rs853679	0.769	rs7752448	ENSG00000204709.4	LINC01556	6.74	4.6e-11	2.74e-08	0.54	0.29	Depression;	chr6:28333322	chr6:28943877~28944537:+
LUAD	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	6.74	4.6e-11	2.74e-08	0.32	0.29	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
LUAD	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-6.74	4.6e-11	2.74e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-6.74	4.6e-11	2.74e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
LUAD	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-6.74	4.6e-11	2.74e-08	-0.46	-0.29	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
LUAD	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	6.74	4.61e-11	2.74e-08	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
LUAD	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	6.74	4.61e-11	2.74e-08	0.65	0.29	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	6.74	4.62e-11	2.75e-08	0.29	0.29	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
LUAD	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-6.74	4.63e-11	2.75e-08	-0.38	-0.29	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-6.74	4.63e-11	2.75e-08	-0.38	-0.29	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
LUAD	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	6.74	4.63e-11	2.75e-08	0.38	0.29	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-6.74	4.63e-11	2.75e-08	-0.56	-0.29	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
LUAD	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	6.74	4.64e-11	2.76e-08	0.45	0.29	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
LUAD	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	6.74	4.64e-11	2.76e-08	0.36	0.29	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
LUAD	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	6.74	4.64e-11	2.76e-08	0.47	0.29	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
LUAD	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	6.74	4.64e-11	2.76e-08	0.47	0.29	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
LUAD	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	6.74	4.65e-11	2.76e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
LUAD	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	6.74	4.66e-11	2.77e-08	0.37	0.29	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
LUAD	cis	rs34526934	0.566	rs62624470	ENSG00000226363.3	HAGLROS	6.74	4.67e-11	2.78e-08	0.41	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176176179	chr2:176177717~176179008:+
LUAD	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	6.74	4.68e-11	2.78e-08	0.3	0.29	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
LUAD	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	6.74	4.69e-11	2.78e-08	0.37	0.29	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
LUAD	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	6.74	4.69e-11	2.78e-08	0.36	0.29	Height;	chr6:109424305	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	6.74	4.69e-11	2.78e-08	0.36	0.29	Height;	chr6:109425054	chr6:109382795~109383666:+
LUAD	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	6.73	4.7e-11	2.79e-08	0.62	0.29	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
LUAD	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	6.73	4.7e-11	2.79e-08	0.55	0.29	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
LUAD	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-6.73	4.71e-11	2.8e-08	-0.38	-0.29	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
LUAD	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	6.73	4.72e-11	2.8e-08	0.36	0.29	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
LUAD	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-6.73	4.72e-11	2.8e-08	-0.34	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
LUAD	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-6.73	4.73e-11	2.81e-08	-0.32	-0.29	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.507	rs6684688	ENSG00000227373.4	RP11-160H22.5	6.73	4.75e-11	2.82e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174357180	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs28628056	ENSG00000227373.4	RP11-160H22.5	6.73	4.75e-11	2.82e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174369545	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912772	ENSG00000227373.4	RP11-160H22.5	6.73	4.75e-11	2.82e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174370832	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12073751	ENSG00000227373.4	RP11-160H22.5	6.73	4.75e-11	2.82e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174373177	chr1:174115300~174160004:-
LUAD	cis	rs1823913	1	rs4853561	ENSG00000227542.1	AC092614.2	-6.73	4.75e-11	2.82e-08	-0.38	-0.29	Obesity-related traits;	chr2:191242980	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs6704784	ENSG00000227542.1	AC092614.2	-6.73	4.75e-11	2.82e-08	-0.38	-0.29	Obesity-related traits;	chr2:191244832	chr2:191229165~191246172:-
LUAD	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-6.73	4.79e-11	2.84e-08	-0.32	-0.29	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-6.73	4.79e-11	2.84e-08	-0.32	-0.29	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-6.73	4.79e-11	2.84e-08	-0.32	-0.29	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-6.73	4.79e-11	2.84e-08	-0.32	-0.29	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
LUAD	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-6.73	4.79e-11	2.84e-08	-0.3	-0.29	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
LUAD	cis	rs9584850	0.874	rs3742137	ENSG00000231194.1	FARP1-AS1	6.73	4.79e-11	2.84e-08	0.36	0.29	Neuroticism;	chr13:98450195	chr13:98435405~98435840:-
LUAD	cis	rs6504622	0.902	rs7216991	ENSG00000262879.4	RP11-156P1.3	-6.73	4.8e-11	2.85e-08	-0.35	-0.29	Orofacial clefts;	chr17:46974887	chr17:46984045~47100323:-
LUAD	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-6.73	4.8e-11	2.85e-08	-0.3	-0.29	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
LUAD	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	6.73	4.81e-11	2.85e-08	0.36	0.29	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
LUAD	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	6.73	4.81e-11	2.85e-08	0.36	0.29	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
LUAD	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-6.73	4.81e-11	2.85e-08	-0.34	-0.29	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-6.73	4.82e-11	2.85e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
LUAD	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-6.73	4.82e-11	2.85e-08	-0.34	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000211974.3	IGHV2-70	-6.73	4.83e-11	2.86e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106781132	chr14:106723574~106724093:-
LUAD	cis	rs2439831	0.681	rs3742969	ENSG00000205771.5	CATSPER2P1	-6.73	4.83e-11	2.86e-08	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43329749	chr15:43726918~43747094:-
LUAD	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	6.73	4.83e-11	2.86e-08	0.32	0.29	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
LUAD	cis	rs9326248	0.581	rs7106437	ENSG00000280143.1	AP000892.6	6.73	4.85e-11	2.87e-08	0.33	0.29	Blood protein levels;	chr11:117121360	chr11:117204967~117210292:+
LUAD	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-6.73	4.86e-11	2.88e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-6.73	4.86e-11	2.88e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-6.73	4.86e-11	2.88e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
LUAD	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-6.73	4.87e-11	2.88e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
LUAD	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	6.73	4.87e-11	2.88e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
LUAD	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-6.73	4.87e-11	2.89e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-6.73	4.87e-11	2.89e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
LUAD	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	6.73	4.88e-11	2.89e-08	0.3	0.29	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
LUAD	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	6.73	4.9e-11	2.9e-08	0.35	0.29	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
LUAD	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-6.73	4.9e-11	2.9e-08	-0.32	-0.29	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
LUAD	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	6.73	4.91e-11	2.91e-08	0.37	0.29	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
LUAD	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-6.73	4.92e-11	2.91e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
LUAD	cis	rs9326248	0.581	rs10892053	ENSG00000280143.1	AP000892.6	6.73	4.94e-11	2.92e-08	0.34	0.29	Blood protein levels;	chr11:116986287	chr11:117204967~117210292:+
LUAD	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-6.73	4.94e-11	2.92e-08	-0.3	-0.29	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
LUAD	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-6.73	4.94e-11	2.92e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
LUAD	cis	rs10899021	0.79	rs59958321	ENSG00000279353.1	RP11-864N7.4	6.73	4.95e-11	2.93e-08	0.53	0.29	Response to metformin (IC50);	chr11:74643569	chr11:74698231~74699658:-
LUAD	cis	rs17684571	0.938	rs55742092	ENSG00000231441.1	RP11-472M19.2	6.73	4.95e-11	2.93e-08	0.4	0.29	Schizophrenia;	chr6:56708377	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs17684553	ENSG00000231441.1	RP11-472M19.2	6.73	4.95e-11	2.93e-08	0.4	0.29	Schizophrenia;	chr6:56708858	chr6:56844002~56864078:+
LUAD	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-6.73	4.96e-11	2.93e-08	-0.38	-0.29	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-6.73	4.96e-11	2.93e-08	-0.38	-0.29	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-6.73	4.96e-11	2.93e-08	-0.38	-0.29	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
LUAD	cis	rs12223324	0.654	rs10794338	ENSG00000279672.1	CMB9-55F22.1	-6.73	4.97e-11	2.94e-08	-0.36	-0.29	Fuchs's corneal dystrophy;	chr11:746992	chr11:779617~780755:+
LUAD	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	6.73	4.98e-11	2.94e-08	0.44	0.29	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
LUAD	cis	rs755249	1	rs755249	ENSG00000228060.1	RP11-69E11.8	-6.73	4.98e-11	2.94e-08	-0.29	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39565160~39573203:+
LUAD	cis	rs9326248	0.559	rs609177	ENSG00000280143.1	AP000892.6	6.73	4.99e-11	2.95e-08	0.34	0.29	Blood protein levels;	chr11:116899801	chr11:117204967~117210292:+
LUAD	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	6.72	5e-11	2.95e-08	0.33	0.29	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
LUAD	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-6.72	5.01e-11	2.96e-08	-0.33	-0.29	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-6.72	5.01e-11	2.96e-08	-0.33	-0.29	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
LUAD	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-6.72	5.01e-11	2.96e-08	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
LUAD	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	6.72	5.02e-11	2.96e-08	0.37	0.29	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
LUAD	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	6.72	5.04e-11	2.98e-08	0.44	0.29	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-6.72	5.04e-11	2.98e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
LUAD	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-6.72	5.04e-11	2.98e-08	-0.47	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-6.72	5.04e-11	2.98e-08	-0.47	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-6.72	5.04e-11	2.98e-08	-0.47	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
LUAD	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	6.72	5.05e-11	2.98e-08	0.38	0.29	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
LUAD	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-6.72	5.05e-11	2.98e-08	-0.39	-0.29	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
LUAD	cis	rs35955747	0.934	rs5997966	ENSG00000236132.1	CTA-440B3.1	6.72	5.06e-11	2.98e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31380260	chr22:31816379~31817491:-
LUAD	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-6.72	5.06e-11	2.98e-08	-0.31	-0.29	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
LUAD	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	6.72	5.06e-11	2.98e-08	0.34	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
LUAD	cis	rs75422866	0.51	rs35784744	ENSG00000280054.1	RP1-197B17.7	6.72	5.06e-11	2.99e-08	0.64	0.29	Pneumonia;	chr12:47729646	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.541	rs12425816	ENSG00000280054.1	RP1-197B17.7	6.72	5.06e-11	2.99e-08	0.64	0.29	Pneumonia;	chr12:47731419	chr12:47728151~47730598:-
LUAD	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-6.72	5.08e-11	3e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
LUAD	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.724	rs2273827	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790307	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.662	rs2273825	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790392	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.768	rs2273824	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790413	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.724	rs2273823	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790453	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.692	rs1128661	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790522	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.724	rs1128670	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790604	chr6:159586955~159589169:-
LUAD	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-6.72	5.1e-11	3.01e-08	-0.48	-0.29	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
LUAD	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-6.72	5.1e-11	3.01e-08	-0.48	-0.29	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
LUAD	cis	rs5753618	0.504	rs5753661	ENSG00000236132.1	CTA-440B3.1	-6.72	5.1e-11	3.01e-08	-0.36	-0.29	Colorectal cancer;	chr22:31503811	chr22:31816379~31817491:-
LUAD	cis	rs8177876	0.822	rs4324141	ENSG00000261838.4	RP11-303E16.6	-6.72	5.11e-11	3.01e-08	-0.63	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81069854~81076598:+
LUAD	cis	rs55720021	1	rs55720021	ENSG00000232871.7	SEC1P	6.72	5.11e-11	3.01e-08	0.36	0.29	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr19:48640984	chr19:48638071~48682245:+
LUAD	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-6.72	5.11e-11	3.01e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-6.72	5.11e-11	3.01e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-6.72	5.11e-11	3.01e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
LUAD	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	6.72	5.11e-11	3.01e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
LUAD	cis	rs10740039	0.842	rs10821819	ENSG00000254271.1	RP11-131N11.4	6.72	5.11e-11	3.01e-08	0.34	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658857	chr10:60734342~60741828:+
LUAD	cis	rs7017914	0.905	rs2732102	ENSG00000223220.1	Y_RNA	-6.72	5.11e-11	3.01e-08	-0.32	-0.29	Bone mineral density;	chr8:71010637	chr8:70780914~70781008:-
LUAD	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-6.72	5.12e-11	3.02e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
LUAD	cis	rs2179367	0.887	rs2789492	ENSG00000231760.4	RP11-350J20.5	-6.72	5.13e-11	3.02e-08	-0.36	-0.29	Dupuytren's disease;	chr6:149426243	chr6:149796151~149826294:-
LUAD	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	6.72	5.13e-11	3.02e-08	0.33	0.29	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000211972.2	IGHV3-66	6.72	5.14e-11	3.03e-08	0.26	0.29	Kawasaki disease;	chr14:106787630	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	6.72	5.15e-11	3.03e-08	0.43	0.29	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	6.72	5.15e-11	3.03e-08	0.43	0.29	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
LUAD	cis	rs9326248	0.581	rs10790167	ENSG00000280143.1	AP000892.6	6.72	5.15e-11	3.03e-08	0.34	0.29	Blood protein levels;	chr11:116930227	chr11:117204967~117210292:+
LUAD	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-6.72	5.16e-11	3.04e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
LUAD	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	6.72	5.16e-11	3.04e-08	0.33	0.29	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
LUAD	cis	rs4141404	0.64	rs9606854	ENSG00000236132.1	CTA-440B3.1	-6.72	5.2e-11	3.06e-08	-0.41	-0.29	Paclitaxel-induced neuropathy;	chr22:31534581	chr22:31816379~31817491:-
LUAD	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-6.72	5.2e-11	3.06e-08	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
LUAD	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-6.72	5.2e-11	3.06e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
LUAD	cis	rs11096990	0.855	rs1597722	ENSG00000249207.1	RP11-360F5.1	-6.72	5.21e-11	3.07e-08	-0.33	-0.29	Cognitive function;	chr4:39173255	chr4:39112677~39126818:-
LUAD	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	6.72	5.22e-11	3.07e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	6.72	5.22e-11	3.07e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	6.72	5.22e-11	3.07e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	6.72	5.23e-11	3.08e-08	0.3	0.29	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
LUAD	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	6.72	5.24e-11	3.09e-08	0.36	0.29	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	6.72	5.25e-11	3.09e-08	0.27	0.29	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
LUAD	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	6.72	5.25e-11	3.09e-08	0.36	0.29	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
LUAD	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-6.72	5.27e-11	3.1e-08	-0.3	-0.29	Height;	chr2:46641180	chr2:46668870~46670778:+
LUAD	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-6.72	5.27e-11	3.1e-08	-0.29	-0.29	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-6.72	5.27e-11	3.1e-08	-0.29	-0.29	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
LUAD	cis	rs7044106	0.791	rs10985004	ENSG00000238181.2	AHCYP2	-6.72	5.28e-11	3.1e-08	-0.39	-0.29	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120720673~120721972:+
LUAD	cis	rs7017914	0.967	rs6982406	ENSG00000223220.1	Y_RNA	6.72	5.28e-11	3.11e-08	0.32	0.29	Bone mineral density;	chr8:70742373	chr8:70780914~70781008:-
LUAD	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-6.72	5.28e-11	3.11e-08	-0.36	-0.29	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
LUAD	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-6.72	5.28e-11	3.11e-08	-0.3	-0.29	Height;	chr2:46635327	chr2:46668870~46670778:+
LUAD	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	6.72	5.29e-11	3.11e-08	0.35	0.29	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
LUAD	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-6.72	5.29e-11	3.11e-08	-0.28	-0.29	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
LUAD	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	6.72	5.29e-11	3.11e-08	0.32	0.29	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
LUAD	cis	rs35934224	0.891	rs12158214	ENSG00000232926.1	AC000078.5	6.72	5.31e-11	3.12e-08	0.32	0.29	Glaucoma (primary open-angle);	chr22:19884168	chr22:19887289~19887970:+
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	6.72	5.31e-11	3.12e-08	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
LUAD	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-6.71	5.32e-11	3.13e-08	-0.38	-0.29	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
LUAD	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
LUAD	cis	rs7017914	0.934	rs7015035	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70741366	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34905858	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70747215	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs6998024	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70748605	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs35960437	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70749725	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34409123	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70749881	chr8:70780914~70781008:-
LUAD	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-6.71	5.33e-11	3.13e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-6.71	5.33e-11	3.13e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-6.71	5.33e-11	3.13e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-6.71	5.33e-11	3.13e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
LUAD	cis	rs5753618	0.539	rs695438	ENSG00000236132.1	CTA-440B3.1	-6.71	5.33e-11	3.13e-08	-0.34	-0.29	Colorectal cancer;	chr22:31415890	chr22:31816379~31817491:-
LUAD	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-6.71	5.34e-11	3.14e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
LUAD	cis	rs1823913	1	rs1454749	ENSG00000227542.1	AC092614.2	6.71	5.34e-11	3.14e-08	0.38	0.29	Obesity-related traits;	chr2:191240909	chr2:191229165~191246172:-
LUAD	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	6.71	5.36e-11	3.15e-08	0.41	0.29	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
LUAD	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	6.71	5.36e-11	3.15e-08	0.41	0.29	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
LUAD	cis	rs2302464	1	rs4342183	ENSG00000214846.4	RP11-115L11.1	6.71	5.36e-11	3.15e-08	0.78	0.29	Cerebrospinal fluid biomarker levels;	chr4:15733817	chr4:15730962~15731627:-
LUAD	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	6.71	5.37e-11	3.15e-08	0.45	0.29	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
LUAD	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	6.71	5.38e-11	3.16e-08	0.36	0.29	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
LUAD	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-6.71	5.4e-11	3.17e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
LUAD	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	6.71	5.4e-11	3.17e-08	0.31	0.29	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
LUAD	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	6.71	5.41e-11	3.18e-08	0.4	0.29	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
LUAD	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	6.71	5.42e-11	3.18e-08	0.36	0.29	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
LUAD	cis	rs5753618	0.504	rs9606847	ENSG00000236132.1	CTA-440B3.1	-6.71	5.44e-11	3.19e-08	-0.36	-0.29	Colorectal cancer;	chr22:31505803	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.504	rs9606848	ENSG00000236132.1	CTA-440B3.1	-6.71	5.44e-11	3.19e-08	-0.36	-0.29	Colorectal cancer;	chr22:31505881	chr22:31816379~31817491:-
LUAD	cis	rs2286503	0.839	rs2240728	ENSG00000228649.7	AC005682.5	6.71	5.44e-11	3.19e-08	0.37	0.29	Fibrinogen;	chr7:22812880	chr7:22854178~22861579:+
LUAD	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	6.71	5.45e-11	3.2e-08	0.36	0.29	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
LUAD	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-6.71	5.46e-11	3.2e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
LUAD	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	6.71	5.46e-11	3.2e-08	0.44	0.29	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
LUAD	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	6.71	5.47e-11	3.21e-08	0.39	0.29	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000206090.4	AP000350.7	6.71	5.47e-11	3.21e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23939998~23942798:+
LUAD	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	6.71	5.47e-11	3.21e-08	0.38	0.29	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
LUAD	cis	rs9326248	0.581	rs11216267	ENSG00000280143.1	AP000892.6	6.71	5.48e-11	3.21e-08	0.34	0.29	Blood protein levels;	chr11:117081676	chr11:117204967~117210292:+
LUAD	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-6.71	5.48e-11	3.21e-08	-0.34	-0.29	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
LUAD	cis	rs9326248	0.52	rs10892060	ENSG00000280143.1	AP000892.6	6.71	5.48e-11	3.22e-08	0.34	0.29	Blood protein levels;	chr11:117010946	chr11:117204967~117210292:+
LUAD	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	6.71	5.48e-11	3.22e-08	0.32	0.29	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
LUAD	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	6.71	5.49e-11	3.22e-08	0.34	0.29	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
LUAD	cis	rs77204473	0.744	rs80143284	ENSG00000254851.1	RP11-109L13.1	6.71	5.5e-11	3.22e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117042854	chr11:117135528~117138582:+
LUAD	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	6.71	5.51e-11	3.23e-08	0.42	0.29	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
LUAD	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	6.71	5.53e-11	3.24e-08	0.28	0.29	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
LUAD	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-6.71	5.54e-11	3.25e-08	-0.39	-0.29	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
LUAD	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	6.71	5.54e-11	3.25e-08	0.56	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
LUAD	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-6.71	5.55e-11	3.25e-08	-0.39	-0.29	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-6.71	5.55e-11	3.25e-08	-0.39	-0.29	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-6.71	5.55e-11	3.25e-08	-0.39	-0.29	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-6.71	5.55e-11	3.25e-08	-0.39	-0.29	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
LUAD	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-6.71	5.56e-11	3.26e-08	-0.56	-0.29	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
LUAD	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-6.71	5.57e-11	3.26e-08	-0.4	-0.29	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
LUAD	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-6.71	5.57e-11	3.26e-08	-0.43	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
LUAD	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	6.71	5.57e-11	3.26e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
LUAD	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	6.71	5.57e-11	3.26e-08	0.36	0.29	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
LUAD	cis	rs73219805	0.759	rs3808578	ENSG00000228451.3	SDAD1P1	-6.71	5.57e-11	3.26e-08	-0.52	-0.29	Schizophrenia;	chr8:26393906	chr8:26379259~26382953:-
LUAD	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	6.71	5.58e-11	3.27e-08	0.34	0.29	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
LUAD	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	6.71	5.6e-11	3.28e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-6.71	5.61e-11	3.28e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
LUAD	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-6.71	5.61e-11	3.29e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
LUAD	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	6.71	5.62e-11	3.29e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	6.71	5.62e-11	3.29e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	6.71	5.63e-11	3.3e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-6.71	5.63e-11	3.3e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
LUAD	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	6.71	5.66e-11	3.31e-08	0.33	0.29	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	6.71	5.66e-11	3.31e-08	0.33	0.29	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	6.71	5.66e-11	3.31e-08	0.33	0.29	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	6.71	5.66e-11	3.31e-08	0.33	0.29	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
LUAD	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-6.71	5.66e-11	3.31e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-6.71	5.66e-11	3.31e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
LUAD	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-6.71	5.66e-11	3.31e-08	-0.38	-0.29	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
LUAD	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-6.71	5.66e-11	3.31e-08	-0.32	-0.29	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-6.71	5.66e-11	3.31e-08	-0.32	-0.29	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
LUAD	cis	rs5753618	0.583	rs5753639	ENSG00000236132.1	CTA-440B3.1	6.7	5.66e-11	3.31e-08	0.35	0.29	Colorectal cancer;	chr22:31474414	chr22:31816379~31817491:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-6.7	5.66e-11	3.31e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
LUAD	cis	rs2734839	0.929	rs11608185	ENSG00000270179.1	RP11-159N11.4	-6.7	5.66e-11	3.31e-08	-0.29	-0.29	Information processing speed;	chr11:113424254	chr11:113368478~113369117:+
LUAD	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-6.7	5.66e-11	3.31e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
LUAD	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	6.7	5.67e-11	3.31e-08	0.24	0.29	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
LUAD	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-6.7	5.67e-11	3.32e-08	-0.35	-0.29	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
LUAD	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	6.7	5.68e-11	3.32e-08	0.33	0.29	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
LUAD	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	6.7	5.69e-11	3.33e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	6.7	5.69e-11	3.33e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	6.7	5.7e-11	3.33e-08	0.44	0.29	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
LUAD	cis	rs5753618	0.529	rs5749298	ENSG00000236132.1	CTA-440B3.1	-6.7	5.71e-11	3.34e-08	-0.36	-0.29	Colorectal cancer;	chr22:31545046	chr22:31816379~31817491:-
LUAD	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-6.7	5.72e-11	3.34e-08	-0.36	-0.29	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
LUAD	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-6.7	5.72e-11	3.35e-08	-0.33	-0.29	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-6.7	5.72e-11	3.35e-08	-0.33	-0.29	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
LUAD	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-6.7	5.72e-11	3.35e-08	-0.36	-0.29	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
LUAD	cis	rs5753618	0.555	rs5749291	ENSG00000236132.1	CTA-440B3.1	-6.7	5.73e-11	3.35e-08	-0.36	-0.29	Colorectal cancer;	chr22:31511537	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.504	rs7284622	ENSG00000236132.1	CTA-440B3.1	-6.7	5.73e-11	3.35e-08	-0.36	-0.29	Colorectal cancer;	chr22:31511999	chr22:31816379~31817491:-
LUAD	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-6.7	5.74e-11	3.35e-08	-0.46	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-6.7	5.74e-11	3.35e-08	-0.46	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
LUAD	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	6.7	5.74e-11	3.36e-08	0.32	0.29	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
LUAD	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-6.7	5.75e-11	3.36e-08	-0.35	-0.29	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
LUAD	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-6.7	5.75e-11	3.36e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
LUAD	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-6.7	5.76e-11	3.36e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-6.7	5.76e-11	3.36e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-6.7	5.77e-11	3.37e-08	-0.38	-0.29	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
LUAD	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	6.7	5.77e-11	3.37e-08	0.47	0.29	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
LUAD	cis	rs8177876	0.749	rs11865207	ENSG00000261838.4	RP11-303E16.6	6.7	5.77e-11	3.37e-08	0.54	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr16:81069854~81076598:+
LUAD	cis	rs35955747	0.934	rs5997981	ENSG00000236132.1	CTA-440B3.1	6.7	5.79e-11	3.38e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31412841	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.934	rs926928	ENSG00000236132.1	CTA-440B3.1	6.7	5.79e-11	3.38e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31425733	chr22:31816379~31817491:-
LUAD	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-6.7	5.8e-11	3.38e-08	-0.38	-0.29	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
LUAD	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-6.7	5.8e-11	3.39e-08	-0.4	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
LUAD	cis	rs944289	0.531	rs1169149	ENSG00000257826.1	RP11-116N8.4	-6.7	5.81e-11	3.39e-08	-0.33	-0.29	Thyroid cancer;	chr14:36165019	chr14:36061026~36067190:-
LUAD	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	6.7	5.81e-11	3.39e-08	0.55	0.29	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	6.7	5.81e-11	3.39e-08	0.55	0.29	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
LUAD	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	6.7	5.82e-11	3.4e-08	0.65	0.29	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.546	rs7772141	ENSG00000255389.1	C6orf3	6.7	5.82e-11	3.4e-08	0.65	0.29	Psoriasis;	chr6:111472358	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.793	rs7776047	ENSG00000255389.1	C6orf3	6.7	5.82e-11	3.4e-08	0.65	0.29	Psoriasis;	chr6:111472391	chr6:111599875~111602295:+
LUAD	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	6.7	5.83e-11	3.4e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
LUAD	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-6.7	5.84e-11	3.41e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-6.7	5.84e-11	3.41e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-6.7	5.84e-11	3.41e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-6.7	5.84e-11	3.41e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
LUAD	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-6.7	5.86e-11	3.42e-08	-0.22	-0.29	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
LUAD	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	6.7	5.87e-11	3.43e-08	0.57	0.29	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
LUAD	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-6.7	5.88e-11	3.43e-08	-0.3	-0.29	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-6.7	5.88e-11	3.43e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	6.7	5.88e-11	3.43e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
LUAD	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-6.7	5.88e-11	3.43e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
LUAD	cis	rs950169	0.92	rs34672825	ENSG00000225151.9	GOLGA2P7	-6.7	5.89e-11	3.43e-08	-0.43	-0.29	Schizophrenia;	chr15:84034718	chr15:84199311~84230136:-
LUAD	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	6.7	5.89e-11	3.44e-08	0.42	0.29	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
LUAD	cis	rs1318937	0.915	rs78365740	ENSG00000224660.1	SH3BP5-AS1	6.7	5.89e-11	3.44e-08	0.24	0.29	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15258339	chr3:15254184~15264493:+
LUAD	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	6.7	5.9e-11	3.44e-08	0.32	0.29	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
LUAD	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-6.7	5.9e-11	3.44e-08	-0.48	-0.29	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
LUAD	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
LUAD	cis	rs7017914	1	rs7017914	ENSG00000223220.1	Y_RNA	6.7	5.92e-11	3.45e-08	0.33	0.29	Bone mineral density;	chr8:70678968	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13256250	ENSG00000223220.1	Y_RNA	6.7	5.92e-11	3.45e-08	0.33	0.29	Bone mineral density;	chr8:70683958	chr8:70780914~70781008:-
LUAD	cis	rs11089937	0.616	rs6001227	ENSG00000211639.2	IGLV4-60	6.7	5.95e-11	3.47e-08	0.31	0.29	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22162199~22162681:+
LUAD	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	6.7	5.95e-11	3.47e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	6.7	5.95e-11	3.47e-08	0.57	0.29	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	6.7	5.95e-11	3.47e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	6.7	5.95e-11	3.47e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
LUAD	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	6.7	5.96e-11	3.47e-08	0.31	0.29	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
LUAD	cis	rs1318937	1	rs2046725	ENSG00000224660.1	SH3BP5-AS1	6.7	5.96e-11	3.47e-08	0.24	0.29	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253651	chr3:15254184~15264493:+
LUAD	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	6.7	5.97e-11	3.48e-08	0.36	0.29	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
LUAD	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-6.7	5.98e-11	3.48e-08	-0.38	-0.29	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
LUAD	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	6.7	6e-11	3.49e-08	0.44	0.29	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	6.7	6e-11	3.49e-08	0.44	0.29	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
LUAD	cis	rs10899021	0.92	rs11236181	ENSG00000279353.1	RP11-864N7.4	6.7	6e-11	3.5e-08	0.52	0.29	Response to metformin (IC50);	chr11:74634778	chr11:74698231~74699658:-
LUAD	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	6.7	6e-11	3.5e-08	0.32	0.29	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
LUAD	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-6.7	6.02e-11	3.5e-08	-0.39	-0.29	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
LUAD	cis	rs10740039	0.671	rs7919726	ENSG00000254271.1	RP11-131N11.4	6.7	6.02e-11	3.5e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60689748	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs10821824	ENSG00000254271.1	RP11-131N11.4	6.7	6.02e-11	3.5e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60690449	chr10:60734342~60741828:+
LUAD	cis	rs9584850	0.915	rs7983438	ENSG00000231194.1	FARP1-AS1	6.7	6.02e-11	3.51e-08	0.35	0.29	Neuroticism;	chr13:98451063	chr13:98435405~98435840:-
LUAD	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-6.69	6.03e-11	3.51e-08	-0.55	-0.29	Gout;	chr7:66642037	chr7:66654538~66669855:+
LUAD	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	6.69	6.04e-11	3.52e-08	0.44	0.29	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
LUAD	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-6.69	6.07e-11	3.53e-08	-0.36	-0.29	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
LUAD	cis	rs9595908	0.931	rs9591001	ENSG00000212293.1	SNORA16	-6.69	6.07e-11	3.53e-08	-0.33	-0.29	Body mass index;	chr13:32468733	chr13:32420390~32420516:-
LUAD	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	6.69	6.07e-11	3.53e-08	0.36	0.29	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
LUAD	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	6.69	6.07e-11	3.54e-08	0.32	0.29	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
LUAD	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-6.69	6.08e-11	3.54e-08	-0.32	-0.29	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
LUAD	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-6.69	6.09e-11	3.54e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
LUAD	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-6.69	6.09e-11	3.54e-08	-0.39	-0.29	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-6.69	6.09e-11	3.54e-08	-0.39	-0.29	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
LUAD	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-6.69	6.09e-11	3.54e-08	-0.4	-0.29	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
LUAD	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	6.69	6.1e-11	3.55e-08	0.42	0.29	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs4718317	ENSG00000232546.1	RP11-458F8.1	6.69	6.1e-11	3.55e-08	0.38	0.29	Diabetic kidney disease;	chr7:66183914	chr7:66848496~66858136:+
LUAD	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
LUAD	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	6.69	6.15e-11	3.57e-08	0.36	0.29	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
LUAD	cis	rs367615	0.68	rs77013	ENSG00000249476.1	CTD-2587M2.1	6.69	6.15e-11	3.58e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109627385	chr5:109237120~109326369:-
LUAD	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-6.69	6.16e-11	3.58e-08	-0.31	-0.29	Height;	chr5:36861889	chr5:36666214~36725195:-
LUAD	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	6.69	6.16e-11	3.58e-08	0.62	0.29	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
LUAD	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	6.69	6.18e-11	3.59e-08	0.32	0.29	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
LUAD	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-6.69	6.18e-11	3.59e-08	-0.35	-0.29	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
LUAD	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	6.69	6.18e-11	3.59e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
LUAD	cis	rs2179367	0.919	rs4897124	ENSG00000231760.4	RP11-350J20.5	6.69	6.18e-11	3.59e-08	0.37	0.29	Dupuytren's disease;	chr6:149442073	chr6:149796151~149826294:-
LUAD	cis	rs948562	0.744	rs78111333	ENSG00000280010.1	AP001350.4	6.69	6.19e-11	3.6e-08	0.45	0.29	Lymphoma;	chr11:58482474	chr11:58627435~58628528:+
LUAD	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	6.69	6.19e-11	3.6e-08	0.38	0.29	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	6.69	6.19e-11	3.6e-08	0.38	0.29	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
LUAD	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	6.69	6.19e-11	3.6e-08	0.36	0.29	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
LUAD	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-6.69	6.2e-11	3.6e-08	-0.33	-0.29	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
LUAD	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	6.69	6.2e-11	3.61e-08	0.37	0.29	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
LUAD	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-6.69	6.2e-11	3.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-6.69	6.2e-11	3.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-6.69	6.2e-11	3.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
LUAD	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-6.69	6.22e-11	3.61e-08	-0.35	-0.29	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
LUAD	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-6.69	6.22e-11	3.62e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
LUAD	cis	rs2439831	0.681	rs484846	ENSG00000205771.5	CATSPER2P1	-6.69	6.26e-11	3.63e-08	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43308605	chr15:43726918~43747094:-
LUAD	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	6.69	6.26e-11	3.63e-08	0.34	0.29	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000224373.3	IGHV4-59	6.69	6.26e-11	3.64e-08	0.17	0.29	Kawasaki disease;	chr14:106807047	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000224373.3	IGHV4-59	6.69	6.26e-11	3.64e-08	0.17	0.29	Kawasaki disease;	chr14:106808609	chr14:106627249~106627825:-
LUAD	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-6.69	6.27e-11	3.64e-08	-0.38	-0.29	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-6.69	6.27e-11	3.64e-08	-0.38	-0.29	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	6.69	6.27e-11	3.64e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
LUAD	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	6.69	6.28e-11	3.65e-08	0.44	0.29	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
LUAD	cis	rs10899021	0.79	rs7932194	ENSG00000279353.1	RP11-864N7.4	6.69	6.29e-11	3.65e-08	0.51	0.29	Response to metformin (IC50);	chr11:74616333	chr11:74698231~74699658:-
LUAD	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-6.69	6.29e-11	3.65e-08	-0.35	-0.29	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
LUAD	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-6.69	6.31e-11	3.67e-08	-0.36	-0.29	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
LUAD	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	6.69	6.32e-11	3.67e-08	0.32	0.29	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
LUAD	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	6.69	6.32e-11	3.67e-08	0.31	0.29	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
LUAD	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	6.69	6.34e-11	3.68e-08	0.44	0.29	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
LUAD	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.58	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
LUAD	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
LUAD	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-6.69	6.38e-11	3.7e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-6.69	6.38e-11	3.7e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-6.69	6.4e-11	3.71e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-6.69	6.4e-11	3.71e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
LUAD	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-6.68	6.42e-11	3.72e-08	-0.52	-0.29	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
LUAD	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-6.68	6.43e-11	3.72e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
LUAD	cis	rs7017914	0.967	rs13274381	ENSG00000223220.1	Y_RNA	6.68	6.44e-11	3.73e-08	0.33	0.29	Bone mineral density;	chr8:70852859	chr8:70780914~70781008:-
LUAD	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-6.68	6.46e-11	3.74e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
LUAD	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-6.68	6.48e-11	3.75e-08	-0.37	-0.29	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
LUAD	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	6.68	6.49e-11	3.76e-08	0.38	0.29	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	6.68	6.49e-11	3.76e-08	0.38	0.29	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	6.68	6.49e-11	3.76e-08	0.38	0.29	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
LUAD	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	6.68	6.49e-11	3.76e-08	0.37	0.29	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	6.68	6.5e-11	3.76e-08	0.36	0.29	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000224373.3	IGHV4-59	6.68	6.5e-11	3.76e-08	0.17	0.29	Kawasaki disease;	chr14:106768275	chr14:106627249~106627825:-
LUAD	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	6.68	6.5e-11	3.77e-08	0.32	0.29	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
LUAD	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	6.68	6.5e-11	3.77e-08	0.34	0.29	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
LUAD	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-6.68	6.51e-11	3.77e-08	-0.41	-0.29	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
LUAD	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	6.68	6.51e-11	3.77e-08	0.32	0.29	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
LUAD	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	6.68	6.52e-11	3.78e-08	0.48	0.29	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
LUAD	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	6.68	6.53e-11	3.78e-08	0.33	0.29	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	6.68	6.53e-11	3.78e-08	0.33	0.29	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	6.68	6.53e-11	3.78e-08	0.32	0.29	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
LUAD	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-6.68	6.55e-11	3.79e-08	-0.32	-0.29	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
LUAD	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	6.68	6.55e-11	3.79e-08	0.39	0.29	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	6.68	6.55e-11	3.79e-08	0.39	0.29	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
LUAD	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	6.68	6.55e-11	3.79e-08	0.35	0.29	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
LUAD	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-6.68	6.55e-11	3.79e-08	-0.38	-0.29	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
LUAD	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-6.68	6.55e-11	3.79e-08	-0.3	-0.29	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
LUAD	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	6.68	6.56e-11	3.8e-08	0.38	0.29	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
LUAD	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-6.68	6.56e-11	3.8e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
LUAD	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	6.68	6.57e-11	3.8e-08	0.24	0.29	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	6.68	6.57e-11	3.8e-08	0.24	0.29	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
LUAD	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-6.68	6.59e-11	3.81e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	6.68	6.59e-11	3.81e-08	0.36	0.29	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
LUAD	cis	rs11089937	0.585	rs6001229	ENSG00000211639.2	IGLV4-60	-6.68	6.6e-11	3.82e-08	-0.31	-0.29	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22162199~22162681:+
LUAD	cis	rs948562	1	rs79475579	ENSG00000280010.1	AP001350.4	6.68	6.6e-11	3.82e-08	0.46	0.29	Lymphoma;	chr11:58528427	chr11:58627435~58628528:+
LUAD	cis	rs948562	1	rs111901203	ENSG00000280010.1	AP001350.4	6.68	6.6e-11	3.82e-08	0.46	0.29	Lymphoma;	chr11:58530069	chr11:58627435~58628528:+
LUAD	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	6.68	6.6e-11	3.82e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	6.68	6.62e-11	3.83e-08	0.36	0.29	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
LUAD	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	6.68	6.62e-11	3.83e-08	0.36	0.29	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
LUAD	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-6.68	6.62e-11	3.83e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
LUAD	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	6.68	6.63e-11	3.83e-08	0.36	0.29	Height;	chr6:109426518	chr6:109382795~109383666:+
LUAD	cis	rs2286503	0.752	rs59538378	ENSG00000228649.7	AC005682.5	6.68	6.64e-11	3.84e-08	0.38	0.29	Fibrinogen;	chr7:22837478	chr7:22854178~22861579:+
LUAD	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	6.68	6.64e-11	3.84e-08	0.37	0.29	Depression;	chr6:28314871	chr6:28943877~28944537:+
LUAD	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-6.68	6.65e-11	3.84e-08	-0.22	-0.29	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
LUAD	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	6.68	6.65e-11	3.84e-08	0.39	0.29	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-6.68	6.65e-11	3.84e-08	-0.48	-0.29	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
LUAD	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	6.68	6.65e-11	3.84e-08	0.31	0.29	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	6.68	6.65e-11	3.84e-08	0.31	0.29	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
LUAD	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	6.68	6.66e-11	3.85e-08	0.32	0.29	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	6.68	6.66e-11	3.85e-08	0.32	0.29	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	6.68	6.66e-11	3.85e-08	0.32	0.29	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
LUAD	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	6.68	6.67e-11	3.85e-08	0.43	0.29	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
LUAD	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-6.68	6.67e-11	3.85e-08	-0.4	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
LUAD	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-6.68	6.67e-11	3.86e-08	-0.32	-0.29	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
LUAD	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-6.68	6.67e-11	3.86e-08	-0.43	-0.29	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
LUAD	cis	rs8059260	0.736	rs76818150	ENSG00000274038.1	RP11-66H6.4	-6.68	6.68e-11	3.86e-08	-0.6	-0.29	Alcohol consumption over the past year;	chr16:10955006	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs113433437	ENSG00000274038.1	RP11-66H6.4	-6.68	6.68e-11	3.86e-08	-0.6	-0.29	Alcohol consumption over the past year;	chr16:10959438	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs8046423	ENSG00000274038.1	RP11-66H6.4	-6.68	6.68e-11	3.86e-08	-0.6	-0.29	Alcohol consumption over the past year;	chr16:10964016	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs77599345	ENSG00000274038.1	RP11-66H6.4	-6.68	6.68e-11	3.86e-08	-0.6	-0.29	Alcohol consumption over the past year;	chr16:10964707	chr16:11056556~11057034:+
LUAD	cis	rs948562	0.744	rs12361887	ENSG00000280010.1	AP001350.4	6.68	6.68e-11	3.86e-08	0.46	0.29	Lymphoma;	chr11:58488205	chr11:58627435~58628528:+
LUAD	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	6.68	6.69e-11	3.86e-08	0.32	0.29	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
LUAD	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	6.68	6.7e-11	3.87e-08	0.37	0.29	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
LUAD	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-6.68	6.71e-11	3.88e-08	-0.35	-0.29	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
LUAD	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	6.68	6.72e-11	3.88e-08	0.3	0.29	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
LUAD	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-6.68	6.73e-11	3.89e-08	-0.36	-0.29	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000211972.2	IGHV3-66	6.68	6.73e-11	3.89e-08	0.26	0.29	Kawasaki disease;	chr14:106799304	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	6.68	6.74e-11	3.89e-08	0.44	0.29	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
LUAD	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	6.68	6.74e-11	3.89e-08	0.24	0.29	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
LUAD	cis	rs9326248	0.53	rs6589589	ENSG00000280143.1	AP000892.6	6.68	6.74e-11	3.89e-08	0.44	0.29	Blood protein levels;	chr11:117061712	chr11:117204967~117210292:+
LUAD	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-6.68	6.75e-11	3.9e-08	-0.33	-0.29	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
LUAD	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-6.68	6.78e-11	3.91e-08	-0.62	-0.29	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
LUAD	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	6.68	6.78e-11	3.92e-08	0.34	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
LUAD	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-6.68	6.78e-11	3.92e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
LUAD	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-6.68	6.79e-11	3.92e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
LUAD	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	6.68	6.79e-11	3.92e-08	0.32	0.29	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	6.68	6.79e-11	3.92e-08	0.32	0.29	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
LUAD	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	6.68	6.8e-11	3.92e-08	0.35	0.29	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
LUAD	cis	rs11096990	0.892	rs11931354	ENSG00000249207.1	RP11-360F5.1	6.68	6.8e-11	3.93e-08	0.32	0.29	Cognitive function;	chr4:39229856	chr4:39112677~39126818:-
LUAD	cis	rs9928842	0.824	rs889515	ENSG00000280152.1	RP11-331F4.5	6.68	6.8e-11	3.93e-08	0.33	0.29	Alcoholic chronic pancreatitis;	chr16:75217401	chr16:75245994~75250077:-
LUAD	cis	rs720064	0.586	rs9950106	ENSG00000264745.1	TTC39C-AS1	6.68	6.81e-11	3.93e-08	0.31	0.29	Strep throat;	chr18:23967901	chr18:23994213~24015339:-
LUAD	cis	rs720064	0.586	rs9961089	ENSG00000264745.1	TTC39C-AS1	6.68	6.81e-11	3.93e-08	0.31	0.29	Strep throat;	chr18:23967999	chr18:23994213~24015339:-
LUAD	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-6.68	6.81e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
LUAD	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	6.68	6.81e-11	3.93e-08	0.32	0.29	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
LUAD	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
LUAD	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-6.68	6.82e-11	3.93e-08	-0.33	-0.29	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
LUAD	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	6.68	6.82e-11	3.94e-08	0.34	0.29	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
LUAD	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-6.68	6.82e-11	3.94e-08	-0.32	-0.29	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
LUAD	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	6.68	6.83e-11	3.94e-08	0.39	0.29	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
LUAD	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-6.68	6.83e-11	3.94e-08	-0.41	-0.29	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
LUAD	cis	rs237743	1	rs13038202	ENSG00000222365.1	SNORD12B	-6.67	6.85e-11	3.95e-08	-0.34	-0.29	Height;	chr20:49219081	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs2273145	ENSG00000222365.1	SNORD12B	-6.67	6.85e-11	3.95e-08	-0.34	-0.29	Height;	chr20:49223054	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs11553387	ENSG00000222365.1	SNORD12B	-6.67	6.85e-11	3.95e-08	-0.34	-0.29	Height;	chr20:49225123	chr20:49280319~49280409:+
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	6.67	6.85e-11	3.95e-08	0.29	0.29	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
LUAD	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-6.67	6.87e-11	3.96e-08	-0.33	-0.29	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-6.67	6.87e-11	3.96e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000224373.3	IGHV4-59	6.67	6.88e-11	3.97e-08	0.18	0.29	Kawasaki disease;	chr14:106776758	chr14:106627249~106627825:-
LUAD	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-6.67	6.89e-11	3.97e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-6.67	6.89e-11	3.97e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
LUAD	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	6.67	6.89e-11	3.97e-08	0.37	0.29	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
LUAD	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-6.67	6.89e-11	3.97e-08	-0.39	-0.29	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
LUAD	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	6.67	6.9e-11	3.98e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
LUAD	cis	rs7246657	1	rs34544865	ENSG00000276846.1	CTD-3220F14.3	6.67	6.9e-11	3.98e-08	0.45	0.29	Coronary artery calcification;	chr19:37310340	chr19:37314868~37315620:-
LUAD	cis	rs35955747	0.869	rs131219	ENSG00000236132.1	CTA-440B3.1	-6.67	6.91e-11	3.99e-08	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31364264	chr22:31816379~31817491:-
LUAD	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	6.67	6.91e-11	3.99e-08	0.35	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
LUAD	cis	rs13160562	0.623	rs26509	ENSG00000272109.1	CTD-2260A17.3	6.67	6.92e-11	3.99e-08	0.31	0.29	Alcohol dependence;	chr5:96746976	chr5:96804353~96806105:+
LUAD	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	6.67	6.92e-11	3.99e-08	0.36	0.29	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	6.67	6.92e-11	3.99e-08	0.36	0.29	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
LUAD	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	6.67	6.92e-11	3.99e-08	0.32	0.29	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
LUAD	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	6.67	6.92e-11	3.99e-08	0.44	0.29	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-6.67	6.92e-11	3.99e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
LUAD	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	6.67	6.93e-11	4e-08	0.38	0.29	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	6.67	6.93e-11	4e-08	0.38	0.29	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	6.67	6.93e-11	4e-08	0.38	0.29	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
LUAD	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	6.67	6.95e-11	4.01e-08	0.35	0.29	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
LUAD	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-6.67	6.96e-11	4.01e-08	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
LUAD	cis	rs10129255	1	rs10129407	ENSG00000280411.1	IGHV1-69-2	-6.67	6.98e-11	4.02e-08	-0.22	-0.29	Kawasaki disease;	chr14:106767956	chr14:106762092~106762588:-
LUAD	cis	rs10740039	0.883	rs10761542	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655465	chr10:60734342~60741828:+
LUAD	cis	rs10740039	1	rs10761543	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655633	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10761544	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655647	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs7900848	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655893	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7898504	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658233	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.671	rs7913549	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658474	chr10:60734342~60741828:+
LUAD	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-6.67	7e-11	4.03e-08	-0.33	-0.29	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
LUAD	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	6.67	7e-11	4.03e-08	0.44	0.29	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	6.67	7e-11	4.03e-08	0.44	0.29	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	6.67	7e-11	4.03e-08	0.44	0.29	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
LUAD	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-6.67	7.03e-11	4.05e-08	-0.38	-0.29	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
LUAD	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	6.67	7.06e-11	4.06e-08	0.43	0.29	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
LUAD	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	6.67	7.06e-11	4.06e-08	0.35	0.29	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
LUAD	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-6.67	7.06e-11	4.06e-08	-0.32	-0.29	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
LUAD	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	6.67	7.06e-11	4.06e-08	0.36	0.29	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
LUAD	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-6.67	7.08e-11	4.07e-08	-0.37	-0.29	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
LUAD	cis	rs5753618	0.504	rs5753669	ENSG00000236132.1	CTA-440B3.1	-6.67	7.09e-11	4.08e-08	-0.36	-0.29	Colorectal cancer;	chr22:31509833	chr22:31816379~31817491:-
LUAD	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	6.67	7.1e-11	4.08e-08	0.29	0.29	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
LUAD	cis	rs35955747	0.811	rs9606835	ENSG00000236132.1	CTA-440B3.1	-6.67	7.11e-11	4.09e-08	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31370974	chr22:31816379~31817491:-
LUAD	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	6.67	7.11e-11	4.09e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
LUAD	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	6.67	7.12e-11	4.09e-08	0.35	0.29	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
LUAD	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-6.67	7.13e-11	4.1e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
LUAD	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-6.67	7.14e-11	4.1e-08	-0.46	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-6.67	7.14e-11	4.1e-08	-0.46	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
LUAD	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	6.67	7.15e-11	4.11e-08	0.32	0.29	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
LUAD	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	6.67	7.16e-11	4.11e-08	0.33	0.29	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
LUAD	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-6.67	7.16e-11	4.11e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
LUAD	cis	rs12130219	0.588	rs2282302	ENSG00000237975.5	FLG-AS1	6.67	7.16e-11	4.12e-08	0.46	0.29	Inflammatory skin disease;	chr1:152356893	chr1:152168125~152445456:+
LUAD	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	6.67	7.17e-11	4.12e-08	0.43	0.29	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
LUAD	cis	rs3096299	0.781	rs2170839	ENSG00000274627.1	RP11-104N10.2	6.67	7.17e-11	4.12e-08	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89516797~89522217:+
LUAD	cis	rs7674212	0.507	rs223322	ENSG00000251288.2	RP11-10L12.2	-6.67	7.18e-11	4.13e-08	-0.37	-0.29	Type 2 diabetes;	chr4:102879037	chr4:102751401~102752641:+
LUAD	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-6.67	7.19e-11	4.13e-08	-0.43	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
LUAD	cis	rs7044106	0.791	rs2416797	ENSG00000238181.2	AHCYP2	-6.67	7.21e-11	4.14e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.791	rs2416798	ENSG00000238181.2	AHCYP2	-6.67	7.21e-11	4.14e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120720673~120721972:+
LUAD	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	6.67	7.21e-11	4.14e-08	0.57	0.29	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000280411.1	IGHV1-69-2	-6.67	7.22e-11	4.15e-08	-0.21	-0.29	Kawasaki disease;	chr14:106780451	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000280411.1	IGHV1-69-2	-6.67	7.22e-11	4.15e-08	-0.21	-0.29	Kawasaki disease;	chr14:106781682	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000280411.1	IGHV1-69-2	-6.67	7.22e-11	4.15e-08	-0.21	-0.29	Kawasaki disease;	chr14:106781820	chr14:106762092~106762588:-
LUAD	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	6.67	7.23e-11	4.15e-08	0.33	0.29	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
LUAD	cis	rs2276314	0.6	rs28729782	ENSG00000278986.1	RP11-723J4.3	-6.67	7.23e-11	4.15e-08	-0.31	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36010566	chr18:35972151~35973916:+
LUAD	cis	rs7674212	0.507	rs223361	ENSG00000251288.2	RP11-10L12.2	-6.67	7.23e-11	4.15e-08	-0.36	-0.29	Type 2 diabetes;	chr4:102848147	chr4:102751401~102752641:+
LUAD	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	6.67	7.23e-11	4.15e-08	0.42	0.29	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
LUAD	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	6.67	7.25e-11	4.16e-08	0.32	0.29	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
LUAD	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	6.67	7.26e-11	4.16e-08	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
LUAD	cis	rs3738443	0.645	rs11811599	ENSG00000259865.1	RP11-488L18.10	6.67	7.26e-11	4.17e-08	0.25	0.29	Alcohol dependence;	chr1:247203133	chr1:247187281~247188526:-
LUAD	cis	rs9326248	0.581	rs10892061	ENSG00000280143.1	AP000892.6	6.66	7.29e-11	4.18e-08	0.34	0.29	Blood protein levels;	chr11:117015398	chr11:117204967~117210292:+
LUAD	cis	rs75422866	0.51	rs73105818	ENSG00000280054.1	RP1-197B17.7	6.66	7.31e-11	4.19e-08	0.64	0.29	Pneumonia;	chr12:47726538	chr12:47728151~47730598:-
LUAD	cis	rs5753618	0.504	rs5753671	ENSG00000236132.1	CTA-440B3.1	-6.66	7.31e-11	4.19e-08	-0.36	-0.29	Colorectal cancer;	chr22:31514748	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	6.66	7.32e-11	4.2e-08	0.37	0.29	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.673	rs3024735	ENSG00000269125.1	RP11-98F14.11	-6.66	7.33e-11	4.2e-08	-0.38	-0.29	Platelet distribution width;	chr13:113165199	chr13:113165002~113165183:-
LUAD	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	6.66	7.33e-11	4.2e-08	0.45	0.29	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
LUAD	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	6.66	7.35e-11	4.22e-08	0.36	0.29	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
LUAD	cis	rs2221433	1	rs2354423	ENSG00000260310.1	RP11-27M24.2	6.66	7.36e-11	4.22e-08	0.32	0.29	Eating disorders;	chr16:10578271	chr16:10576499~10578183:-
LUAD	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-6.66	7.37e-11	4.23e-08	-0.36	-0.29	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
LUAD	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-6.66	7.38e-11	4.23e-08	-0.32	-0.29	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
LUAD	cis	rs8177876	0.822	rs1563075	ENSG00000261838.4	RP11-303E16.6	6.66	7.38e-11	4.23e-08	0.63	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81069854~81076598:+
LUAD	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	6.66	7.38e-11	4.23e-08	0.44	0.29	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
LUAD	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	6.66	7.38e-11	4.23e-08	0.33	0.29	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	6.66	7.38e-11	4.23e-08	0.33	0.29	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	6.66	7.38e-11	4.23e-08	0.33	0.29	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
LUAD	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-6.66	7.39e-11	4.24e-08	-0.41	-0.29	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
LUAD	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	6.66	7.39e-11	4.24e-08	0.31	0.29	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
LUAD	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-6.66	7.4e-11	4.24e-08	-0.32	-0.29	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-6.66	7.4e-11	4.24e-08	-0.32	-0.29	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-6.66	7.41e-11	4.24e-08	-0.32	-0.29	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
LUAD	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	6.66	7.41e-11	4.25e-08	0.36	0.29	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
LUAD	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	6.66	7.43e-11	4.25e-08	0.35	0.29	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
LUAD	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-6.66	7.44e-11	4.26e-08	-0.3	-0.29	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
LUAD	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	6.66	7.45e-11	4.27e-08	0.44	0.29	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
LUAD	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	6.66	7.46e-11	4.27e-08	0.36	0.29	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
LUAD	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-6.66	7.46e-11	4.27e-08	-0.41	-0.29	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	6.66	7.48e-11	4.28e-08	0.44	0.29	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
LUAD	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	6.66	7.49e-11	4.29e-08	0.34	0.29	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
LUAD	cis	rs17301013	0.507	rs12084291	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174395721	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2901815	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174397404	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs1883262	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174401104	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2860959	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174403704	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912779	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174404311	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12090860	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174405166	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12064126	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174405312	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10798310	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174408581	chr1:174115300~174160004:-
LUAD	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	6.66	7.51e-11	4.3e-08	0.3	0.29	Height;	chr2:46624894	chr2:46668870~46670778:+
LUAD	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	6.66	7.53e-11	4.31e-08	0.32	0.29	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
LUAD	cis	rs17301013	0.507	rs10912777	ENSG00000227373.4	RP11-160H22.5	6.66	7.54e-11	4.31e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174393764	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912778	ENSG00000227373.4	RP11-160H22.5	6.66	7.54e-11	4.31e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174393827	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2205937	ENSG00000227373.4	RP11-160H22.5	6.66	7.54e-11	4.31e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174394440	chr1:174115300~174160004:-
LUAD	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-6.66	7.56e-11	4.32e-08	-0.36	-0.29	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
LUAD	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-6.66	7.56e-11	4.33e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
LUAD	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	6.66	7.57e-11	4.33e-08	0.32	0.29	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
LUAD	cis	rs9326248	0.581	rs4938331	ENSG00000280143.1	AP000892.6	6.66	7.57e-11	4.33e-08	0.34	0.29	Blood protein levels;	chr11:117059966	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.51	rs4938332	ENSG00000280143.1	AP000892.6	6.66	7.57e-11	4.33e-08	0.34	0.29	Blood protein levels;	chr11:117060082	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.559	rs4938334	ENSG00000280143.1	AP000892.6	6.66	7.57e-11	4.33e-08	0.34	0.29	Blood protein levels;	chr11:117060326	chr11:117204967~117210292:+
LUAD	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-6.66	7.58e-11	4.34e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
LUAD	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	6.66	7.59e-11	4.34e-08	0.35	0.29	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	6.66	7.59e-11	4.34e-08	0.35	0.29	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	6.66	7.59e-11	4.34e-08	0.35	0.29	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	6.66	7.59e-11	4.34e-08	0.35	0.29	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
LUAD	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.59e-11	4.34e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.59e-11	4.34e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.59e-11	4.34e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
LUAD	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	6.66	7.59e-11	4.34e-08	0.34	0.29	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
LUAD	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	6.66	7.6e-11	4.35e-08	0.39	0.29	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
LUAD	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	6.66	7.62e-11	4.36e-08	0.33	0.29	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	6.66	7.62e-11	4.36e-08	0.33	0.29	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
LUAD	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	6.66	7.62e-11	4.36e-08	0.35	0.29	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
LUAD	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-6.66	7.63e-11	4.36e-08	-0.32	-0.29	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
LUAD	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	6.66	7.64e-11	4.37e-08	0.48	0.29	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
LUAD	cis	rs11089937	0.616	rs5757244	ENSG00000211639.2	IGLV4-60	6.66	7.64e-11	4.37e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22176637	chr22:22162199~22162681:+
LUAD	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	6.66	7.65e-11	4.37e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
LUAD	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	6.66	7.65e-11	4.37e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
LUAD	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-6.66	7.65e-11	4.38e-08	-0.32	-0.29	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-6.66	7.65e-11	4.38e-08	-0.32	-0.29	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
LUAD	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	6.66	7.66e-11	4.38e-08	0.34	0.29	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
LUAD	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	6.66	7.67e-11	4.38e-08	0.42	0.29	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
LUAD	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-6.66	7.69e-11	4.4e-08	-0.32	-0.29	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
LUAD	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	6.66	7.72e-11	4.41e-08	0.34	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
LUAD	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-6.66	7.73e-11	4.41e-08	-0.71	-0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
LUAD	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	6.66	7.73e-11	4.42e-08	0.43	0.29	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
LUAD	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-6.65	7.76e-11	4.43e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-6.65	7.76e-11	4.43e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000224373.3	IGHV4-59	6.65	7.76e-11	4.44e-08	0.17	0.29	Kawasaki disease;	chr14:106786292	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-6.65	7.8e-11	4.45e-08	-0.32	-0.29	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
LUAD	cis	rs34526934	0.566	rs1374325	ENSG00000226363.3	HAGLROS	6.65	7.82e-11	4.46e-08	0.4	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179243	chr2:176177717~176179008:+
LUAD	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	6.65	7.84e-11	4.48e-08	0.35	0.29	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
LUAD	cis	rs17301013	0.507	rs12079011	ENSG00000227373.4	RP11-160H22.5	6.65	7.85e-11	4.48e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174441055	chr1:174115300~174160004:-
LUAD	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	6.65	7.86e-11	4.48e-08	0.35	0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
LUAD	cis	rs9309711	0.961	rs11686236	ENSG00000225234.1	TRAPPC12-AS1	-6.65	7.87e-11	4.49e-08	-0.37	-0.29	Neurofibrillary tangles;	chr2:3467778	chr2:3481242~3482409:-
LUAD	cis	rs10740039	0.883	rs1442540	ENSG00000254271.1	RP11-131N11.4	-6.65	7.87e-11	4.49e-08	-0.33	-0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653548	chr10:60734342~60741828:+
LUAD	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	6.65	7.88e-11	4.5e-08	0.34	0.29	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
LUAD	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-6.65	7.89e-11	4.5e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
LUAD	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	6.65	7.89e-11	4.5e-08	0.44	0.29	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
LUAD	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-6.65	7.89e-11	4.5e-08	-0.55	-0.29	Gout;	chr7:66645053	chr7:66654538~66669855:+
LUAD	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
LUAD	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	6.65	7.9e-11	4.51e-08	0.41	0.29	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
LUAD	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-6.65	7.9e-11	4.51e-08	-0.34	-0.29	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
LUAD	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
LUAD	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	6.65	7.91e-11	4.51e-08	0.42	0.29	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
LUAD	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	6.65	7.91e-11	4.51e-08	0.36	0.29	Height;	chr6:109351795	chr6:109382795~109383666:+
LUAD	cis	rs62229266	0.625	rs62230813	ENSG00000214914.3	RPL23AP3	6.65	7.91e-11	4.51e-08	0.35	0.29	Mitral valve prolapse;	chr21:36031134	chr21:36016079~36016546:-
LUAD	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	6.65	7.93e-11	4.52e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
LUAD	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	6.65	7.96e-11	4.54e-08	0.36	0.29	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
LUAD	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	6.65	7.96e-11	4.54e-08	0.31	0.29	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
LUAD	cis	rs8177876	0.749	rs2911159	ENSG00000261838.4	RP11-303E16.6	-6.65	7.98e-11	4.55e-08	-0.52	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057653	chr16:81069854~81076598:+
LUAD	cis	rs7017914	0.934	rs17689585	ENSG00000223220.1	Y_RNA	6.65	7.98e-11	4.55e-08	0.33	0.29	Bone mineral density;	chr8:70906566	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000280411.1	IGHV1-69-2	-6.65	7.98e-11	4.55e-08	-0.21	-0.29	Kawasaki disease;	chr14:106779713	chr14:106762092~106762588:-
LUAD	cis	rs2243480	1	rs1039664	ENSG00000232546.1	RP11-458F8.1	-6.65	7.98e-11	4.55e-08	-0.37	-0.29	Diabetic kidney disease;	chr7:65984729	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.507	rs116545832	ENSG00000227373.4	RP11-160H22.5	6.65	7.99e-11	4.55e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174438725	chr1:174115300~174160004:-
LUAD	cis	rs8031584	1	rs1474380	ENSG00000260382.1	RP11-540B6.2	6.65	8.01e-11	4.56e-08	0.34	0.29	Huntington's disease progression;	chr15:30977032	chr15:30882267~30883231:-
LUAD	cis	rs9326248	0.581	rs11216242	ENSG00000280143.1	AP000892.6	6.65	8.01e-11	4.57e-08	0.34	0.29	Blood protein levels;	chr11:117030833	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.581	rs12804122	ENSG00000280143.1	AP000892.6	6.65	8.01e-11	4.57e-08	0.34	0.29	Blood protein levels;	chr11:117031900	chr11:117204967~117210292:+
LUAD	cis	rs2179367	0.887	rs2143076	ENSG00000231760.4	RP11-350J20.5	6.65	8.05e-11	4.59e-08	0.35	0.29	Dupuytren's disease;	chr6:149425315	chr6:149796151~149826294:-
LUAD	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-6.65	8.05e-11	4.59e-08	-0.35	-0.29	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000280411.1	IGHV1-69-2	-6.65	8.05e-11	4.59e-08	-0.22	-0.29	Kawasaki disease;	chr14:106775695	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000280411.1	IGHV1-69-2	-6.65	8.05e-11	4.59e-08	-0.22	-0.29	Kawasaki disease;	chr14:106775735	chr14:106762092~106762588:-
LUAD	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	6.65	8.06e-11	4.59e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
LUAD	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	6.65	8.07e-11	4.59e-08	0.32	0.29	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	6.65	8.07e-11	4.59e-08	0.32	0.29	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
LUAD	cis	rs853679	0.607	rs33932084	ENSG00000204709.4	LINC01556	6.65	8.07e-11	4.6e-08	0.62	0.29	Depression;	chr6:28301047	chr6:28943877~28944537:+
LUAD	cis	rs75422866	0.764	rs73104177	ENSG00000274902.1	RP1-197B17.4	6.65	8.08e-11	4.6e-08	0.73	0.29	Pneumonia;	chr12:47713550	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.764	rs73104184	ENSG00000274902.1	RP1-197B17.4	6.65	8.08e-11	4.6e-08	0.73	0.29	Pneumonia;	chr12:47715623	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.764	rs73104188	ENSG00000274902.1	RP1-197B17.4	6.65	8.08e-11	4.6e-08	0.73	0.29	Pneumonia;	chr12:47715885	chr12:47731908~47732351:+
LUAD	cis	rs77204473	0.744	rs12970	ENSG00000254851.1	RP11-109L13.1	6.65	8.09e-11	4.6e-08	0.69	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117203393	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	6.65	8.09e-11	4.61e-08	0.5	0.29	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
LUAD	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	6.65	8.1e-11	4.61e-08	0.25	0.29	Breast size;	chr12:9220132	chr12:9277235~9313241:+
LUAD	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-6.65	8.11e-11	4.61e-08	-0.43	-0.29	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
LUAD	cis	rs7017914	0.967	rs6991329	ENSG00000223220.1	Y_RNA	6.65	8.11e-11	4.62e-08	0.33	0.29	Bone mineral density;	chr8:70681190	chr8:70780914~70781008:-
LUAD	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	6.65	8.12e-11	4.62e-08	0.29	0.29	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
LUAD	cis	rs6844153	1	rs4557251	ENSG00000240005.4	RP11-293A21.1	-6.65	8.12e-11	4.62e-08	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26848285	chr4:26859806~26860599:-
LUAD	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-6.65	8.12e-11	4.62e-08	-0.37	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
LUAD	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	6.65	8.13e-11	4.63e-08	0.25	0.29	Breast size;	chr12:9219433	chr12:9277235~9313241:+
LUAD	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-6.65	8.16e-11	4.64e-08	-0.38	-0.29	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
LUAD	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	6.65	8.17e-11	4.65e-08	0.3	0.29	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	6.65	8.17e-11	4.65e-08	0.3	0.29	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
LUAD	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	6.65	8.19e-11	4.66e-08	0.36	0.29	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	6.65	8.19e-11	4.66e-08	0.36	0.29	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
LUAD	cis	rs10899021	0.704	rs11236177	ENSG00000279353.1	RP11-864N7.4	6.65	8.22e-11	4.68e-08	0.52	0.29	Response to metformin (IC50);	chr11:74628022	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.79	rs10899022	ENSG00000279353.1	RP11-864N7.4	6.65	8.22e-11	4.68e-08	0.52	0.29	Response to metformin (IC50);	chr11:74628341	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.79	rs11236180	ENSG00000279353.1	RP11-864N7.4	6.65	8.22e-11	4.68e-08	0.52	0.29	Response to metformin (IC50);	chr11:74631883	chr11:74698231~74699658:-
LUAD	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	6.65	8.22e-11	4.68e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	6.65	8.22e-11	4.68e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	6.65	8.22e-11	4.68e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	6.65	8.22e-11	4.68e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
LUAD	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	6.65	8.23e-11	4.68e-08	0.36	0.29	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
LUAD	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	6.64	8.25e-11	4.69e-08	0.62	0.29	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	6.64	8.25e-11	4.69e-08	0.62	0.29	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
LUAD	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-6.64	8.25e-11	4.69e-08	-0.31	-0.29	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
LUAD	cis	rs17818399	0.735	rs11894342	ENSG00000279254.1	RP11-536C12.1	-6.64	8.25e-11	4.69e-08	-0.3	-0.29	Height;	chr2:46609300	chr2:46668870~46670778:+
LUAD	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-6.64	8.26e-11	4.7e-08	-0.42	-0.29	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-6.64	8.26e-11	4.7e-08	-0.42	-0.29	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
LUAD	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	6.64	8.27e-11	4.7e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	6.64	8.27e-11	4.7e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	6.64	8.27e-11	4.7e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
LUAD	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-6.64	8.29e-11	4.71e-08	-0.3	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
LUAD	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-6.64	8.3e-11	4.72e-08	-0.38	-0.29	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000280411.1	IGHV1-69-2	-6.64	8.3e-11	4.72e-08	-0.22	-0.29	Kawasaki disease;	chr14:106783079	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000280411.1	IGHV1-69-2	-6.64	8.3e-11	4.72e-08	-0.22	-0.29	Kawasaki disease;	chr14:106783685	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000280411.1	IGHV1-69-2	-6.64	8.3e-11	4.72e-08	-0.22	-0.29	Kawasaki disease;	chr14:106784199	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000280411.1	IGHV1-69-2	-6.64	8.3e-11	4.72e-08	-0.22	-0.29	Kawasaki disease;	chr14:106784709	chr14:106762092~106762588:-
LUAD	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-6.64	8.31e-11	4.72e-08	-0.32	-0.29	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
LUAD	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-6.64	8.31e-11	4.72e-08	-0.41	-0.29	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
LUAD	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	6.64	8.31e-11	4.72e-08	0.36	0.29	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
LUAD	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	6.64	8.35e-11	4.75e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	6.64	8.35e-11	4.75e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.549	rs4516458	ENSG00000227542.1	AC092614.2	6.64	8.37e-11	4.75e-08	0.37	0.29	Obesity-related traits;	chr2:191325177	chr2:191229165~191246172:-
LUAD	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-6.64	8.37e-11	4.76e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
LUAD	cis	rs10129255	1	rs10129255	ENSG00000280411.1	IGHV1-69-2	6.64	8.37e-11	4.76e-08	0.22	0.29	Kawasaki disease;	chr14:106767970	chr14:106762092~106762588:-
LUAD	cis	rs11846409	0.932	rs61233250	ENSG00000254174.1	IGHV1-12	6.64	8.38e-11	4.76e-08	0.25	0.29	Rheumatic heart disease;	chr14:106634072	chr14:106122420~106122709:-
LUAD	cis	rs2439831	0.867	rs2278860	ENSG00000205771.5	CATSPER2P1	6.64	8.38e-11	4.76e-08	0.49	0.29	Lung cancer in ever smokers;	chr15:43366848	chr15:43726918~43747094:-
LUAD	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-6.64	8.39e-11	4.76e-08	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
LUAD	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	6.64	8.4e-11	4.77e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
LUAD	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	6.64	8.41e-11	4.77e-08	0.33	0.29	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
LUAD	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-6.64	8.41e-11	4.77e-08	-0.3	-0.29	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
LUAD	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	-6.64	8.41e-11	4.78e-08	-0.44	-0.29	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
LUAD	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-6.64	8.41e-11	4.78e-08	-0.38	-0.29	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	6.64	8.42e-11	4.78e-08	0.38	0.29	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
LUAD	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	6.64	8.43e-11	4.79e-08	0.39	0.29	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
LUAD	cis	rs6558530	0.965	rs730379	ENSG00000253982.1	CTD-2336O2.1	6.64	8.44e-11	4.79e-08	0.36	0.29	Systolic blood pressure;	chr8:1759927	chr8:1761990~1764502:-
LUAD	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	6.64	8.44e-11	4.79e-08	0.37	0.29	Height;	chr6:109358227	chr6:109382795~109383666:+
LUAD	cis	rs950169	0.544	rs12913702	ENSG00000259728.4	LINC00933	6.64	8.45e-11	4.79e-08	0.43	0.29	Schizophrenia;	chr15:84609953	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.509	rs71395455	ENSG00000259728.4	LINC00933	6.64	8.45e-11	4.79e-08	0.43	0.29	Schizophrenia;	chr15:84610573	chr15:84570649~84580175:+
LUAD	cis	rs6565180	0.963	rs4787642	ENSG00000183604.13	SMG1P5	-6.64	8.45e-11	4.8e-08	-0.31	-0.29	Tonsillectomy;	chr16:30348087	chr16:30267553~30335374:-
LUAD	cis	rs35955747	0.869	rs28715	ENSG00000236132.1	CTA-440B3.1	-6.64	8.45e-11	4.8e-08	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31334183	chr22:31816379~31817491:-
LUAD	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-6.64	8.46e-11	4.8e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-6.64	8.46e-11	4.8e-08	-0.35	-0.29	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
LUAD	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	6.64	8.47e-11	4.8e-08	0.62	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
LUAD	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	6.64	8.47e-11	4.81e-08	0.3	0.29	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
LUAD	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	6.64	8.48e-11	4.81e-08	0.36	0.29	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
LUAD	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	6.64	8.49e-11	4.81e-08	0.32	0.29	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	6.64	8.49e-11	4.81e-08	0.32	0.29	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	6.64	8.49e-11	4.81e-08	0.32	0.29	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	6.64	8.49e-11	4.81e-08	0.32	0.29	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
LUAD	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.5e-11	4.82e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.5e-11	4.82e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.5e-11	4.82e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
LUAD	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	6.64	8.5e-11	4.82e-08	0.41	0.29	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
LUAD	cis	rs8031584	0.918	rs34095794	ENSG00000260382.1	RP11-540B6.2	6.64	8.5e-11	4.82e-08	0.34	0.29	Huntington's disease progression;	chr15:30977488	chr15:30882267~30883231:-
LUAD	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-6.64	8.51e-11	4.83e-08	-0.32	-0.29	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
LUAD	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	6.64	8.53e-11	4.83e-08	0.37	0.29	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	6.64	8.53e-11	4.84e-08	0.34	0.29	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
LUAD	cis	rs9928842	1	rs9928842	ENSG00000280152.1	RP11-331F4.5	6.64	8.55e-11	4.84e-08	0.33	0.29	Alcoholic chronic pancreatitis;	chr16:75208969	chr16:75245994~75250077:-
LUAD	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	6.64	8.55e-11	4.85e-08	0.25	0.29	Breast size;	chr12:9228263	chr12:9277235~9313241:+
LUAD	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	6.64	8.56e-11	4.85e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
LUAD	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
LUAD	cis	rs4141404	0.851	rs5749222	ENSG00000236132.1	CTA-440B3.1	6.64	8.57e-11	4.85e-08	0.34	0.29	Paclitaxel-induced neuropathy;	chr22:31160773	chr22:31816379~31817491:-
LUAD	cis	rs4141404	0.851	rs8135417	ENSG00000236132.1	CTA-440B3.1	6.64	8.57e-11	4.85e-08	0.34	0.29	Paclitaxel-induced neuropathy;	chr22:31163269	chr22:31816379~31817491:-
LUAD	cis	rs2734839	0.964	rs2734838	ENSG00000270179.1	RP11-159N11.4	-6.64	8.58e-11	4.86e-08	-0.3	-0.29	Information processing speed;	chr11:113415779	chr11:113368478~113369117:+
LUAD	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	6.64	8.58e-11	4.86e-08	0.35	0.29	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-6.64	8.59e-11	4.86e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	6.64	8.59e-11	4.86e-08	0.55	0.29	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	6.64	8.59e-11	4.86e-08	0.55	0.29	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	6.64	8.59e-11	4.86e-08	0.55	0.29	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	6.64	8.59e-11	4.86e-08	0.55	0.29	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
LUAD	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-6.64	8.59e-11	4.87e-08	-0.34	-0.29	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
LUAD	cis	rs950169	0.656	rs748455	ENSG00000259728.4	LINC00933	6.64	8.6e-11	4.87e-08	0.43	0.29	Schizophrenia;	chr15:84606344	chr15:84570649~84580175:+
LUAD	cis	rs8031584	0.918	rs61997139	ENSG00000260382.1	RP11-540B6.2	6.64	8.63e-11	4.89e-08	0.34	0.29	Huntington's disease progression;	chr15:30981399	chr15:30882267~30883231:-
LUAD	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	6.64	8.64e-11	4.89e-08	0.75	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
LUAD	cis	rs516805	0.961	rs1267942	ENSG00000279453.1	RP3-425C14.4	-6.64	8.65e-11	4.9e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122472375	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.961	rs471620	ENSG00000279453.1	RP3-425C14.4	-6.64	8.65e-11	4.9e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122473532	chr6:122436789~122439223:-
LUAD	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	6.64	8.66e-11	4.9e-08	0.34	0.29	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
LUAD	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	6.64	8.67e-11	4.91e-08	0.35	0.29	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
LUAD	cis	rs7044106	0.791	rs10984994	ENSG00000238181.2	AHCYP2	6.64	8.69e-11	4.92e-08	0.38	0.29	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120720673~120721972:+
LUAD	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-6.64	8.69e-11	4.92e-08	-0.34	-0.29	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
LUAD	cis	rs755249	0.958	rs2068663	ENSG00000228060.1	RP11-69E11.8	-6.64	8.7e-11	4.92e-08	-0.29	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39565160~39573203:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-6.64	8.7e-11	4.92e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
LUAD	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	6.64	8.71e-11	4.93e-08	0.62	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	6.64	8.71e-11	4.93e-08	0.62	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	6.64	8.71e-11	4.93e-08	0.62	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-6.64	8.71e-11	4.93e-08	-0.21	-0.29	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
LUAD	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	6.64	8.71e-11	4.93e-08	0.33	0.29	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
LUAD	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-6.64	8.72e-11	4.93e-08	-0.35	-0.29	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
LUAD	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	6.64	8.72e-11	4.94e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
LUAD	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-6.64	8.73e-11	4.94e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-6.64	8.73e-11	4.94e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
LUAD	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	6.64	8.74e-11	4.95e-08	0.65	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
LUAD	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-6.64	8.75e-11	4.95e-08	-0.37	-0.29	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
LUAD	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	6.64	8.75e-11	4.95e-08	0.36	0.29	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000254174.1	IGHV1-12	6.63	8.78e-11	4.96e-08	0.25	0.29	Rheumatic heart disease;	chr14:106637262	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000254174.1	IGHV1-12	6.63	8.78e-11	4.96e-08	0.25	0.29	Rheumatic heart disease;	chr14:106638192	chr14:106122420~106122709:-
LUAD	cis	rs7115242	0.702	rs672058	ENSG00000280143.1	AP000892.6	6.63	8.78e-11	4.96e-08	0.44	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.559	rs10892064	ENSG00000280143.1	AP000892.6	6.63	8.8e-11	4.97e-08	0.33	0.29	Blood protein levels;	chr11:117025837	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.539	rs10892065	ENSG00000280143.1	AP000892.6	6.63	8.8e-11	4.97e-08	0.33	0.29	Blood protein levels;	chr11:117026308	chr11:117204967~117210292:+
LUAD	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-6.63	8.81e-11	4.98e-08	-0.45	-0.29	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
LUAD	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-6.63	8.83e-11	4.99e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-6.63	8.83e-11	4.99e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
LUAD	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	6.63	8.86e-11	5.01e-08	0.36	0.29	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000206090.4	AP000350.7	6.63	8.87e-11	5.01e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23939998~23942798:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000206090.4	AP000350.7	6.63	8.87e-11	5.01e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23939998~23942798:+
LUAD	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-6.63	8.88e-11	5.02e-08	-0.31	-0.29	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
LUAD	cis	rs62229266	0.659	rs62230814	ENSG00000214914.3	RPL23AP3	6.63	8.89e-11	5.02e-08	0.35	0.29	Mitral valve prolapse;	chr21:36031248	chr21:36016079~36016546:-
LUAD	cis	rs7044106	0.791	rs10984997	ENSG00000238181.2	AHCYP2	-6.63	8.89e-11	5.02e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120720673~120721972:+
LUAD	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-6.63	8.89e-11	5.02e-08	-0.29	-0.29	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
LUAD	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-6.63	8.89e-11	5.02e-08	-0.35	-0.29	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
LUAD	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-6.63	8.9e-11	5.03e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
LUAD	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-6.63	8.9e-11	5.03e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
LUAD	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-6.63	8.91e-11	5.03e-08	-0.42	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
LUAD	cis	rs7017914	0.967	rs1902614	ENSG00000223220.1	Y_RNA	6.63	8.92e-11	5.04e-08	0.32	0.29	Bone mineral density;	chr8:70743932	chr8:70780914~70781008:-
LUAD	cis	rs62229266	0.659	rs7275820	ENSG00000214914.3	RPL23AP3	6.63	8.92e-11	5.04e-08	0.35	0.29	Mitral valve prolapse;	chr21:36037116	chr21:36016079~36016546:-
LUAD	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	6.63	8.92e-11	5.04e-08	0.36	0.29	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
LUAD	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	6.63	8.94e-11	5.05e-08	0.36	0.29	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
LUAD	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-6.63	8.94e-11	5.05e-08	-0.34	-0.29	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-6.63	8.94e-11	5.05e-08	-0.36	-0.29	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000280411.1	IGHV1-69-2	-6.63	8.97e-11	5.06e-08	-0.22	-0.29	Kawasaki disease;	chr14:106767055	chr14:106762092~106762588:-
LUAD	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-6.63	8.97e-11	5.06e-08	-0.46	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
LUAD	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-6.63	8.98e-11	5.07e-08	-0.28	-0.29	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
LUAD	cis	rs11089937	0.584	rs5757245	ENSG00000211639.2	IGLV4-60	6.63	8.99e-11	5.07e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22176674	chr22:22162199~22162681:+
LUAD	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	6.63	9e-11	5.08e-08	0.43	0.29	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
LUAD	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-6.63	9e-11	5.08e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
LUAD	cis	rs9326248	0.581	rs10892063	ENSG00000280143.1	AP000892.6	6.63	9.01e-11	5.08e-08	0.33	0.29	Blood protein levels;	chr11:117025439	chr11:117204967~117210292:+
LUAD	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	6.63	9.02e-11	5.09e-08	0.32	0.29	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-6.63	9.05e-11	5.1e-08	-0.21	-0.29	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
LUAD	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	6.63	9.06e-11	5.11e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	6.63	9.06e-11	5.11e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	6.63	9.06e-11	5.11e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	6.63	9.06e-11	5.11e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-6.63	9.06e-11	5.11e-08	-0.29	-0.29	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
LUAD	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-6.63	9.08e-11	5.12e-08	-0.35	-0.29	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
LUAD	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	6.63	9.08e-11	5.12e-08	0.32	0.29	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	6.63	9.08e-11	5.12e-08	0.32	0.29	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
LUAD	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-6.63	9.08e-11	5.12e-08	-0.38	-0.29	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	6.63	9.08e-11	5.12e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	6.63	9.08e-11	5.12e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
LUAD	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-6.63	9.09e-11	5.12e-08	-0.33	-0.29	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
LUAD	cis	rs17684571	0.938	rs4074102	ENSG00000231441.1	RP11-472M19.2	6.63	9.1e-11	5.13e-08	0.4	0.29	Schizophrenia;	chr6:56697497	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs4074101	ENSG00000231441.1	RP11-472M19.2	6.63	9.1e-11	5.13e-08	0.4	0.29	Schizophrenia;	chr6:56697654	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs35668437	ENSG00000231441.1	RP11-472M19.2	6.63	9.1e-11	5.13e-08	0.4	0.29	Schizophrenia;	chr6:56701058	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs17684511	ENSG00000231441.1	RP11-472M19.2	6.63	9.1e-11	5.13e-08	0.4	0.29	Schizophrenia;	chr6:56701217	chr6:56844002~56864078:+
LUAD	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-6.63	9.11e-11	5.14e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
LUAD	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-6.63	9.12e-11	5.14e-08	-0.39	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
LUAD	cis	rs9326248	0.53	rs10790172	ENSG00000280143.1	AP000892.6	6.63	9.15e-11	5.16e-08	0.44	0.29	Blood protein levels;	chr11:117057024	chr11:117204967~117210292:+
LUAD	cis	rs17301013	0.507	rs12059307	ENSG00000227373.4	RP11-160H22.5	6.63	9.17e-11	5.17e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174342105	chr1:174115300~174160004:-
LUAD	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	6.63	9.18e-11	5.17e-08	0.34	0.29	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
LUAD	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	-6.63	9.18e-11	5.17e-08	-0.31	-0.29	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
LUAD	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	6.63	9.18e-11	5.17e-08	0.42	0.29	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	6.63	9.18e-11	5.17e-08	0.42	0.29	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
LUAD	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	6.63	9.19e-11	5.18e-08	0.32	0.29	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
LUAD	cis	rs9326248	0.53	rs1351452	ENSG00000280143.1	AP000892.6	-6.63	9.21e-11	5.19e-08	-0.43	-0.29	Blood protein levels;	chr11:117072638	chr11:117204967~117210292:+
LUAD	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	6.63	9.23e-11	5.2e-08	0.35	0.29	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
LUAD	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	6.63	9.25e-11	5.21e-08	0.37	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
LUAD	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	6.63	9.26e-11	5.21e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
LUAD	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-6.63	9.26e-11	5.21e-08	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-6.63	9.27e-11	5.22e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-6.63	9.27e-11	5.22e-08	-0.34	-0.29	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
LUAD	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	6.63	9.27e-11	5.22e-08	0.32	0.29	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
LUAD	cis	rs35955747	0.869	rs5997971	ENSG00000236132.1	CTA-440B3.1	6.63	9.28e-11	5.22e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31396306	chr22:31816379~31817491:-
LUAD	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-6.63	9.29e-11	5.23e-08	-0.32	-0.29	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
LUAD	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-6.63	9.31e-11	5.24e-08	-0.3	-0.29	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
LUAD	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	6.63	9.31e-11	5.24e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	6.63	9.31e-11	5.24e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	6.63	9.31e-11	5.24e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	6.63	9.31e-11	5.24e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
LUAD	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	6.62	9.32e-11	5.25e-08	0.34	0.29	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
LUAD	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	6.62	9.34e-11	5.25e-08	0.34	0.29	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
LUAD	cis	rs5753618	0.504	rs8138525	ENSG00000236132.1	CTA-440B3.1	6.62	9.35e-11	5.26e-08	0.36	0.29	Colorectal cancer;	chr22:31615943	chr22:31816379~31817491:-
LUAD	cis	rs2842992	0.662	rs2273826	ENSG00000237927.1	RP3-393E18.2	-6.62	9.36e-11	5.27e-08	-0.4	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790389	chr6:159586955~159589169:-
LUAD	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-6.62	9.38e-11	5.27e-08	-0.38	-0.29	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
LUAD	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	6.62	9.38e-11	5.28e-08	0.25	0.29	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
LUAD	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	6.62	9.4e-11	5.29e-08	0.36	0.29	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	6.62	9.4e-11	5.29e-08	0.35	0.29	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
LUAD	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	6.62	9.4e-11	5.29e-08	0.32	0.29	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	6.62	9.41e-11	5.29e-08	0.29	0.29	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
LUAD	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.42e-11	5.3e-08	-0.31	-0.29	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
LUAD	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.43e-11	5.3e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.43e-11	5.3e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.43e-11	5.3e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
LUAD	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	6.62	9.43e-11	5.3e-08	0.37	0.29	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
LUAD	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-6.62	9.44e-11	5.31e-08	-0.41	-0.29	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
LUAD	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-6.62	9.44e-11	5.31e-08	-0.35	-0.29	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
LUAD	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	6.62	9.46e-11	5.32e-08	0.4	0.29	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
LUAD	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-6.62	9.49e-11	5.33e-08	-0.3	-0.29	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
LUAD	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-6.62	9.51e-11	5.34e-08	-0.33	-0.29	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
LUAD	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	6.62	9.53e-11	5.35e-08	0.3	0.29	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
LUAD	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-6.62	9.53e-11	5.36e-08	-0.36	-0.29	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
LUAD	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-6.62	9.53e-11	5.36e-08	-0.38	-0.29	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
LUAD	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-6.62	9.54e-11	5.36e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
LUAD	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-6.62	9.55e-11	5.36e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
LUAD	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-6.62	9.58e-11	5.38e-08	-0.32	-0.29	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-6.62	9.58e-11	5.38e-08	-0.32	-0.29	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
LUAD	cis	rs755249	0.567	rs1537817	ENSG00000228060.1	RP11-69E11.8	6.62	9.59e-11	5.39e-08	0.29	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39565160~39573203:+
LUAD	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	6.62	9.59e-11	5.39e-08	0.3	0.29	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
LUAD	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-6.62	9.59e-11	5.39e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	6.62	9.6e-11	5.39e-08	0.55	0.29	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
LUAD	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	6.62	9.63e-11	5.41e-08	0.38	0.29	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
LUAD	cis	rs7017914	0.967	rs7819332	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70756030	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7012404	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70756463	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7018381	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70757882	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13258584	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70759344	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs7009297	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70760131	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7014012	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70760508	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	6.62	9.63e-11	5.41e-08	0.36	0.29	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.64e-11	5.42e-08	-0.31	-0.29	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
LUAD	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	6.62	9.65e-11	5.42e-08	0.32	0.29	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
LUAD	cis	rs1874124	0.577	rs2807872	ENSG00000238078.1	LINC01352	-6.62	9.65e-11	5.42e-08	-0.41	-0.29	Cholesterol, total;	chr1:220866908	chr1:220829255~220832429:+
LUAD	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	6.62	9.66e-11	5.42e-08	0.35	0.29	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
LUAD	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.66e-11	5.43e-08	-0.31	-0.29	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.66e-11	5.43e-08	-0.31	-0.29	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-6.62	9.67e-11	5.43e-08	-0.29	-0.29	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
LUAD	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	6.62	9.68e-11	5.43e-08	0.37	0.29	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
LUAD	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.68e-11	5.43e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
LUAD	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-6.62	9.71e-11	5.45e-08	-0.45	-0.29	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
LUAD	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-6.62	9.72e-11	5.45e-08	-0.3	-0.29	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
LUAD	cis	rs8177876	0.584	rs2602404	ENSG00000261838.4	RP11-303E16.6	-6.62	9.72e-11	5.46e-08	-0.51	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056042	chr16:81069854~81076598:+
LUAD	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	6.62	9.73e-11	5.46e-08	0.32	0.29	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	6.62	9.73e-11	5.46e-08	0.32	0.29	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
LUAD	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-6.62	9.75e-11	5.47e-08	-0.29	-0.29	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
LUAD	cis	rs4141404	0.74	rs9609301	ENSG00000236132.1	CTA-440B3.1	-6.62	9.76e-11	5.47e-08	-0.36	-0.29	Paclitaxel-induced neuropathy;	chr22:31499954	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.504	rs9609303	ENSG00000236132.1	CTA-440B3.1	-6.62	9.76e-11	5.47e-08	-0.36	-0.29	Colorectal cancer;	chr22:31500323	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.504	rs9606846	ENSG00000236132.1	CTA-440B3.1	-6.62	9.76e-11	5.47e-08	-0.36	-0.29	Colorectal cancer;	chr22:31501585	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.555	rs9609304	ENSG00000236132.1	CTA-440B3.1	-6.62	9.76e-11	5.47e-08	-0.36	-0.29	Colorectal cancer;	chr22:31501809	chr22:31816379~31817491:-
LUAD	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	6.62	9.76e-11	5.48e-08	0.36	0.29	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
LUAD	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	6.62	9.79e-11	5.49e-08	0.31	0.29	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
LUAD	cis	rs7017914	0.967	rs7825446	ENSG00000223220.1	Y_RNA	6.62	9.81e-11	5.5e-08	0.32	0.29	Bone mineral density;	chr8:70751939	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6472543	ENSG00000223220.1	Y_RNA	6.62	9.81e-11	5.5e-08	0.32	0.29	Bone mineral density;	chr8:70752173	chr8:70780914~70781008:-
LUAD	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.82e-11	5.51e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.82e-11	5.51e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.82e-11	5.51e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.82e-11	5.51e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
LUAD	cis	rs9326248	0.53	rs1242229	ENSG00000280143.1	AP000892.6	6.62	9.84e-11	5.52e-08	0.47	0.29	Blood protein levels;	chr11:117191654	chr11:117204967~117210292:+
LUAD	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-6.62	9.85e-11	5.52e-08	-0.35	-0.29	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
LUAD	cis	rs9326248	0.539	rs518181	ENSG00000280143.1	AP000892.6	6.62	9.86e-11	5.53e-08	0.34	0.29	Blood protein levels;	chr11:116902071	chr11:117204967~117210292:+
LUAD	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	6.62	9.86e-11	5.53e-08	0.31	0.29	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	6.62	9.86e-11	5.53e-08	0.31	0.29	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
LUAD	cis	rs948562	1	rs76435840	ENSG00000280010.1	AP001350.4	6.62	9.86e-11	5.53e-08	0.46	0.29	Lymphoma;	chr11:58518508	chr11:58627435~58628528:+
LUAD	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	6.62	9.87e-11	5.53e-08	0.3	0.29	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
LUAD	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	6.62	9.88e-11	5.54e-08	0.32	0.29	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
LUAD	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	6.62	9.88e-11	5.54e-08	0.39	0.29	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000206090.4	AP000350.7	-6.62	9.9e-11	5.55e-08	-0.33	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23939998~23942798:+
LUAD	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-6.62	9.9e-11	5.55e-08	-0.3	-0.29	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
LUAD	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-6.61	9.93e-11	5.57e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
LUAD	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-6.61	9.94e-11	5.57e-08	-0.33	-0.29	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
LUAD	cis	rs75422866	0.51	rs75424057	ENSG00000280054.1	RP1-197B17.7	6.61	9.94e-11	5.57e-08	0.63	0.29	Pneumonia;	chr12:47737294	chr12:47728151~47730598:-
LUAD	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	6.61	9.94e-11	5.57e-08	0.42	0.29	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
LUAD	cis	rs9584850	0.834	rs12463	ENSG00000231194.1	FARP1-AS1	6.61	9.96e-11	5.58e-08	0.35	0.29	Neuroticism;	chr13:98453048	chr13:98435405~98435840:-
LUAD	cis	rs9584850	0.834	rs8481	ENSG00000231194.1	FARP1-AS1	6.61	9.96e-11	5.58e-08	0.35	0.29	Neuroticism;	chr13:98453141	chr13:98435405~98435840:-
LUAD	cis	rs8177876	0.749	rs12927828	ENSG00000261838.4	RP11-303E16.6	6.61	9.96e-11	5.58e-08	0.53	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81069854~81076598:+
LUAD	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
LUAD	cis	rs8177876	0.749	rs935942	ENSG00000261838.4	RP11-303E16.6	-6.61	9.98e-11	5.59e-08	-0.55	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81069854~81076598:+
LUAD	cis	rs10740039	0.842	rs1442541	ENSG00000254271.1	RP11-131N11.4	6.61	1e-10	5.6e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626285	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs1867081	ENSG00000254271.1	RP11-131N11.4	6.61	1e-10	5.6e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626569	chr10:60734342~60741828:+
LUAD	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-6.61	1e-10	5.6e-08	-0.32	-0.29	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
LUAD	cis	rs7017914	0.967	rs2100908	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70671075	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34558600	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70673917	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6472538	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70674736	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7001162	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70675235	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs56112621	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70676159	chr8:70780914~70781008:-
LUAD	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	6.61	1e-10	5.62e-08	0.43	0.29	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
LUAD	cis	rs9287719	0.747	rs1534400	ENSG00000234818.1	AC092687.5	6.61	1.01e-10	5.63e-08	0.35	0.29	Prostate cancer;	chr2:10556707	chr2:10589166~10604830:+
LUAD	cis	rs7017914	0.967	rs13271442	ENSG00000223220.1	Y_RNA	6.61	1.01e-10	5.63e-08	0.32	0.29	Bone mineral density;	chr8:70672934	chr8:70780914~70781008:-
LUAD	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-6.61	1.01e-10	5.65e-08	-0.37	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
LUAD	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	6.61	1.01e-10	5.66e-08	0.36	0.29	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
LUAD	cis	rs720064	0.615	rs8095395	ENSG00000264745.1	TTC39C-AS1	6.61	1.01e-10	5.66e-08	0.31	0.29	Strep throat;	chr18:23962644	chr18:23994213~24015339:-
LUAD	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-6.61	1.01e-10	5.66e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-6.61	1.01e-10	5.66e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
LUAD	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-6.61	1.01e-10	5.66e-08	-0.35	-0.29	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
LUAD	cis	rs62229266	0.652	rs7280551	ENSG00000214914.3	RPL23AP3	6.61	1.01e-10	5.67e-08	0.34	0.29	Mitral valve prolapse;	chr21:36037311	chr21:36016079~36016546:-
LUAD	cis	rs2243480	1	rs313799	ENSG00000232546.1	RP11-458F8.1	-6.61	1.01e-10	5.68e-08	-0.37	-0.29	Diabetic kidney disease;	chr7:66029343	chr7:66848496~66858136:+
LUAD	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	6.61	1.02e-10	5.68e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
LUAD	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	6.61	1.02e-10	5.71e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	6.61	1.02e-10	5.71e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
LUAD	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	6.61	1.02e-10	5.71e-08	0.24	0.29	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
LUAD	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-6.61	1.02e-10	5.71e-08	-0.42	-0.29	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
LUAD	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-6.61	1.02e-10	5.72e-08	-0.57	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
LUAD	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-6.61	1.02e-10	5.72e-08	-0.57	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
LUAD	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	6.61	1.02e-10	5.72e-08	0.35	0.29	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
LUAD	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	6.61	1.02e-10	5.72e-08	0.32	0.29	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
LUAD	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	6.61	1.02e-10	5.73e-08	0.37	0.29	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
LUAD	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	6.61	1.03e-10	5.73e-08	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
LUAD	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	6.61	1.03e-10	5.75e-08	0.24	0.29	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
LUAD	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-6.61	1.03e-10	5.77e-08	-0.34	-0.29	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
LUAD	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	6.61	1.03e-10	5.77e-08	0.32	0.29	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
LUAD	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-6.61	1.04e-10	5.78e-08	-0.32	-0.29	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
LUAD	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	6.61	1.04e-10	5.79e-08	0.36	0.29	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.507	rs10912766	ENSG00000227373.4	RP11-160H22.5	6.61	1.04e-10	5.79e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174341129	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	6.61	1.04e-10	5.79e-08	0.44	0.29	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	6.61	1.04e-10	5.8e-08	0.43	0.29	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-10	5.8e-08	-0.37	-0.29	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
LUAD	cis	rs2221433	1	rs2221433	ENSG00000260310.1	RP11-27M24.2	-6.61	1.04e-10	5.81e-08	-0.34	-0.29	Eating disorders;	chr16:10569770	chr16:10576499~10578183:-
LUAD	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	6.61	1.04e-10	5.82e-08	0.42	0.29	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
LUAD	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	6.61	1.04e-10	5.82e-08	0.32	0.29	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
LUAD	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	6.61	1.05e-10	5.84e-08	0.32	0.29	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
LUAD	cis	rs8177876	0.822	rs4889225	ENSG00000261838.4	RP11-303E16.6	-6.61	1.05e-10	5.84e-08	-0.54	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr16:81069854~81076598:+
LUAD	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	6.61	1.05e-10	5.85e-08	0.37	0.29	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
LUAD	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	6.61	1.05e-10	5.85e-08	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	6.61	1.05e-10	5.85e-08	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
LUAD	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	6.61	1.05e-10	5.86e-08	0.37	0.29	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
LUAD	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	6.61	1.05e-10	5.88e-08	0.41	0.29	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
LUAD	cis	rs1499614	1	rs2707832	ENSG00000232546.1	RP11-458F8.1	-6.61	1.05e-10	5.88e-08	-0.37	-0.29	Gout;	chr7:66671562	chr7:66848496~66858136:+
LUAD	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-6.61	1.05e-10	5.88e-08	-0.34	-0.29	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
LUAD	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-6.6	1.06e-10	5.88e-08	-0.36	-0.29	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
LUAD	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-6.6	1.06e-10	5.88e-08	-0.36	-0.29	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.762	rs9549694	ENSG00000269125.1	RP11-98F14.11	-6.6	1.06e-10	5.88e-08	-0.36	-0.29	Platelet distribution width;	chr13:113216196	chr13:113165002~113165183:-
LUAD	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	6.6	1.06e-10	5.89e-08	0.32	0.29	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	6.6	1.06e-10	5.89e-08	0.32	0.29	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
LUAD	cis	rs6772849	0.83	rs4857917	ENSG00000242551.2	POU5F1P6	-6.6	1.06e-10	5.89e-08	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128657335	chr3:128674735~128677005:-
LUAD	cis	rs10740039	0.804	rs894383	ENSG00000254271.1	RP11-131N11.4	6.6	1.06e-10	5.9e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60683359	chr10:60734342~60741828:+
LUAD	cis	rs3002142	0.658	rs3008634	ENSG00000272750.1	RP11-378J18.8	6.6	1.06e-10	5.9e-08	0.38	0.29	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:222658867~222661512:-
LUAD	cis	rs9326248	0.574	rs1263173	ENSG00000280143.1	AP000892.6	6.6	1.06e-10	5.9e-08	0.33	0.29	Blood protein levels;	chr11:116810292	chr11:117204967~117210292:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-6.6	1.06e-10	5.91e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
LUAD	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	6.6	1.06e-10	5.91e-08	0.39	0.29	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
LUAD	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-6.6	1.06e-10	5.92e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-6.6	1.06e-10	5.92e-08	-0.32	-0.29	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
LUAD	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	6.6	1.06e-10	5.92e-08	0.41	0.29	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
LUAD	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-6.6	1.06e-10	5.92e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-6.6	1.06e-10	5.92e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
LUAD	cis	rs11098499	0.954	rs11098524	ENSG00000248280.1	RP11-33B1.2	6.6	1.06e-10	5.93e-08	0.37	0.29	Corneal astigmatism;	chr4:119468877	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	6.6	1.07e-10	5.93e-08	0.31	0.29	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
LUAD	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-6.6	1.07e-10	5.94e-08	-0.38	-0.29	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
LUAD	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-6.6	1.07e-10	5.95e-08	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
LUAD	cis	rs62229266	0.804	rs2835241	ENSG00000214914.3	RPL23AP3	-6.6	1.07e-10	5.95e-08	-0.35	-0.29	Mitral valve prolapse;	chr21:36039082	chr21:36016079~36016546:-
LUAD	cis	rs9450351	0.744	rs7764843	ENSG00000203875.9	SNHG5	-6.6	1.07e-10	5.96e-08	-0.6	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85903875	chr6:85660950~85678736:-
LUAD	cis	rs9450351	0.744	rs9351072	ENSG00000203875.9	SNHG5	-6.6	1.07e-10	5.96e-08	-0.6	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85917611	chr6:85660950~85678736:-
LUAD	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	6.6	1.07e-10	5.97e-08	0.38	0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
LUAD	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	6.6	1.07e-10	5.97e-08	0.25	0.29	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
LUAD	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	6.6	1.07e-10	5.97e-08	0.3	0.29	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
LUAD	cis	rs12439619	0.508	rs8023960	ENSG00000276710.3	CSPG4P8	-6.6	1.08e-10	5.99e-08	-0.26	-0.29	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82459472~82477258:+
LUAD	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-6.6	1.08e-10	5.99e-08	-0.35	-0.29	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
LUAD	cis	rs11428934	1	rs11428934	ENSG00000232871.7	SEC1P	6.6	1.08e-10	6e-08	0.35	0.29	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr19:48640988	chr19:48638071~48682245:+
LUAD	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	6.6	1.08e-10	6e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
LUAD	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-6.6	1.08e-10	6.01e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-6.6	1.08e-10	6.01e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
LUAD	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-6.6	1.08e-10	6.01e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
LUAD	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-6.6	1.08e-10	6.02e-08	-0.22	-0.29	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	6.6	1.08e-10	6.02e-08	0.43	0.29	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
LUAD	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	6.6	1.08e-10	6.02e-08	0.4	0.29	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
LUAD	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-6.6	1.09e-10	6.04e-08	-0.31	-0.29	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
LUAD	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	6.6	1.09e-10	6.05e-08	0.35	0.29	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
LUAD	cis	rs9326248	0.581	rs6589590	ENSG00000280143.1	AP000892.6	6.6	1.09e-10	6.05e-08	0.33	0.29	Blood protein levels;	chr11:117065365	chr11:117204967~117210292:+
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
LUAD	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	6.6	1.09e-10	6.06e-08	0.3	0.29	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
LUAD	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-6.6	1.09e-10	6.07e-08	-0.32	-0.29	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-6.6	1.09e-10	6.07e-08	-0.32	-0.29	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
LUAD	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	6.6	1.09e-10	6.08e-08	0.36	0.29	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
LUAD	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-6.6	1.09e-10	6.08e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
LUAD	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-6.6	1.09e-10	6.08e-08	-0.22	-0.29	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
LUAD	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	6.6	1.09e-10	6.09e-08	0.31	0.29	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
LUAD	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-6.6	1.1e-10	6.09e-08	-0.31	-0.29	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
LUAD	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-6.6	1.1e-10	6.1e-08	-0.42	-0.29	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-6.6	1.1e-10	6.1e-08	-0.42	-0.29	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
LUAD	cis	rs516805	0.961	rs527978	ENSG00000279453.1	RP3-425C14.4	-6.6	1.1e-10	6.1e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122475225	chr6:122436789~122439223:-
LUAD	cis	rs17301013	0.507	rs11799704	ENSG00000227373.4	RP11-160H22.5	6.6	1.1e-10	6.11e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174413640	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2901817	ENSG00000227373.4	RP11-160H22.5	6.6	1.1e-10	6.11e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174414479	chr1:174115300~174160004:-
LUAD	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	6.6	1.1e-10	6.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	6.6	1.1e-10	6.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	6.6	1.1e-10	6.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	6.6	1.1e-10	6.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
LUAD	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	6.6	1.1e-10	6.12e-08	0.65	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
LUAD	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	6.6	1.1e-10	6.13e-08	0.36	0.29	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
LUAD	cis	rs720064	0.525	rs7232062	ENSG00000264745.1	TTC39C-AS1	6.6	1.1e-10	6.14e-08	0.31	0.29	Strep throat;	chr18:23970609	chr18:23994213~24015339:-
LUAD	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-6.6	1.11e-10	6.14e-08	-0.34	-0.29	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	6.6	1.11e-10	6.15e-08	0.35	0.29	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
LUAD	cis	rs11118620	0.853	rs11118622	ENSG00000257551.1	HLX-AS1	6.6	1.11e-10	6.17e-08	0.35	0.29	Heart failure;	chr1:220868833	chr1:220832763~220880140:-
LUAD	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	6.6	1.11e-10	6.18e-08	0.34	0.29	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
LUAD	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-6.6	1.11e-10	6.19e-08	-0.34	-0.29	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
LUAD	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	6.6	1.12e-10	6.19e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000206090.4	AP000350.7	6.6	1.12e-10	6.21e-08	0.32	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23939998~23942798:+
LUAD	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	6.6	1.12e-10	6.22e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
LUAD	cis	rs8177876	0.658	rs2911158	ENSG00000261838.4	RP11-303E16.6	-6.6	1.12e-10	6.23e-08	-0.51	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057652	chr16:81069854~81076598:+
LUAD	cis	rs7188445	0.651	rs4889014	ENSG00000261390.4	RP11-345M22.2	6.59	1.12e-10	6.24e-08	0.35	0.29	Urate levels;	chr16:79684556	chr16:79715232~79770563:-
LUAD	cis	rs7188445	0.688	rs4889015	ENSG00000261390.4	RP11-345M22.2	6.59	1.12e-10	6.24e-08	0.35	0.29	Urate levels;	chr16:79684833	chr16:79715232~79770563:-
LUAD	cis	rs7044106	0.791	rs10760116	ENSG00000238181.2	AHCYP2	-6.59	1.12e-10	6.24e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120720673~120721972:+
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	6.24e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	6.24e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	6.24e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	6.24e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	6.59	1.13e-10	6.24e-08	0.35	0.29	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
LUAD	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-6.59	1.13e-10	6.25e-08	-0.35	-0.29	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-6.59	1.13e-10	6.25e-08	-0.35	-0.29	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
LUAD	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	6.59	1.13e-10	6.25e-08	0.61	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
LUAD	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	6.59	1.13e-10	6.25e-08	0.25	0.29	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
LUAD	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-6.59	1.13e-10	6.25e-08	-0.38	-0.29	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-6.59	1.13e-10	6.25e-08	-0.38	-0.29	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
LUAD	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-6.59	1.13e-10	6.26e-08	-0.38	-0.29	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-6.59	1.13e-10	6.26e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
LUAD	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-6.59	1.13e-10	6.27e-08	-0.45	-0.29	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
LUAD	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-6.59	1.14e-10	6.3e-08	-0.58	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
LUAD	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-6.59	1.14e-10	6.31e-08	-0.36	-0.29	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
LUAD	cis	rs7115242	0.8	rs10736487	ENSG00000280143.1	AP000892.6	6.59	1.14e-10	6.32e-08	0.44	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117204967~117210292:+
LUAD	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-6.59	1.14e-10	6.32e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
LUAD	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	6.59	1.14e-10	6.32e-08	0.48	0.29	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
LUAD	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-6.59	1.14e-10	6.32e-08	-0.35	-0.29	Height;	chr11:118860890	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-6.59	1.14e-10	6.32e-08	-0.35	-0.29	Height;	chr11:118861053	chr11:118704607~118750263:+
LUAD	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	6.59	1.14e-10	6.33e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
LUAD	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	6.59	1.14e-10	6.34e-08	0.42	0.29	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
LUAD	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	6.59	1.14e-10	6.35e-08	0.3	0.29	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
LUAD	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	6.59	1.14e-10	6.35e-08	0.5	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
LUAD	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	6.59	1.14e-10	6.35e-08	0.35	0.29	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	6.59	1.14e-10	6.35e-08	0.35	0.29	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	6.59	1.14e-10	6.35e-08	0.35	0.29	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	6.59	1.14e-10	6.35e-08	0.35	0.29	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
LUAD	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-6.59	1.15e-10	6.35e-08	-0.44	-0.29	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	6.59	1.15e-10	6.36e-08	0.54	0.29	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
LUAD	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-6.59	1.15e-10	6.36e-08	-0.36	-0.29	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
LUAD	cis	rs1426063	0.614	rs80030693	ENSG00000249717.1	RP11-44F21.3	6.59	1.15e-10	6.36e-08	0.58	0.29	QT interval;	chr4:75099929	chr4:74955974~74970362:-
LUAD	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	6.59	1.15e-10	6.36e-08	0.35	0.29	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
LUAD	cis	rs17684571	0.938	rs17751682	ENSG00000231441.1	RP11-472M19.2	-6.59	1.15e-10	6.38e-08	-0.39	-0.29	Schizophrenia;	chr6:56695732	chr6:56844002~56864078:+
LUAD	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-6.59	1.15e-10	6.38e-08	-0.34	-0.29	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
LUAD	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-6.59	1.15e-10	6.39e-08	-0.33	-0.29	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
LUAD	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	6.59	1.16e-10	6.42e-08	0.32	0.29	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-6.59	1.16e-10	6.43e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
LUAD	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	6.59	1.16e-10	6.44e-08	0.3	0.29	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
LUAD	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-6.59	1.16e-10	6.44e-08	-0.31	-0.29	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
LUAD	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-6.59	1.17e-10	6.46e-08	-0.38	-0.29	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
LUAD	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	6.59	1.17e-10	6.47e-08	0.35	0.29	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
LUAD	cis	rs5753618	0.504	rs8142121	ENSG00000236132.1	CTA-440B3.1	-6.59	1.17e-10	6.47e-08	-0.37	-0.29	Colorectal cancer;	chr22:31486799	chr22:31816379~31817491:-
LUAD	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-6.59	1.17e-10	6.47e-08	-0.37	-0.29	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
LUAD	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-6.59	1.17e-10	6.47e-08	-0.38	-0.29	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
LUAD	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-6.59	1.17e-10	6.47e-08	-0.35	-0.29	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-6.59	1.17e-10	6.48e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
LUAD	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-6.59	1.17e-10	6.48e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-6.59	1.17e-10	6.48e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-6.59	1.17e-10	6.48e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
LUAD	cis	rs9640161	0.711	rs10259796	ENSG00000261305.1	RP4-584D14.7	6.59	1.17e-10	6.48e-08	0.43	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150353338	chr7:150341771~150342607:+
LUAD	cis	rs853679	0.657	rs1778483	ENSG00000204709.4	LINC01556	6.59	1.17e-10	6.49e-08	0.37	0.29	Depression;	chr6:28273214	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.657	rs1778482	ENSG00000204709.4	LINC01556	6.59	1.17e-10	6.49e-08	0.37	0.29	Depression;	chr6:28273215	chr6:28943877~28944537:+
LUAD	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	6.59	1.17e-10	6.49e-08	0.44	0.29	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
LUAD	cis	rs35955747	0.934	rs13053245	ENSG00000236132.1	CTA-440B3.1	6.59	1.17e-10	6.49e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31420756	chr22:31816379~31817491:-
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	6.59	1.18e-10	6.51e-08	0.29	0.29	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
LUAD	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	6.59	1.18e-10	6.52e-08	0.32	0.29	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
LUAD	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	6.59	1.18e-10	6.52e-08	0.4	0.29	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
LUAD	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	6.59	1.18e-10	6.53e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
LUAD	cis	rs10740039	0.883	rs1561850	ENSG00000254271.1	RP11-131N11.4	6.59	1.18e-10	6.54e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60631583	chr10:60734342~60741828:+
LUAD	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	6.59	1.18e-10	6.54e-08	0.43	0.29	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	6.59	1.18e-10	6.54e-08	0.43	0.29	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	6.59	1.18e-10	6.54e-08	0.43	0.29	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	6.59	1.18e-10	6.54e-08	0.43	0.29	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
LUAD	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	6.59	1.18e-10	6.55e-08	0.3	0.29	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
LUAD	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	6.59	1.18e-10	6.55e-08	0.39	0.29	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
LUAD	cis	rs4728142	0.779	rs3778753	ENSG00000275106.1	RP11-309L24.10	-6.59	1.19e-10	6.56e-08	-0.34	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128939988	chr7:128952527~128953316:-
LUAD	cis	rs4728142	0.744	rs3778752	ENSG00000275106.1	RP11-309L24.10	-6.59	1.19e-10	6.56e-08	-0.34	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128939993	chr7:128952527~128953316:-
LUAD	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	6.59	1.19e-10	6.56e-08	0.35	0.29	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
LUAD	cis	rs2303759	0.918	rs1054770	ENSG00000268686.1	AC010524.2	-6.59	1.19e-10	6.57e-08	-0.41	-0.29	Multiple sclerosis;	chr19:49374858	chr19:49368705~49388081:-
LUAD	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-6.59	1.19e-10	6.57e-08	-0.28	-0.29	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
LUAD	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	6.59	1.19e-10	6.57e-08	0.32	0.29	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
LUAD	cis	rs853679	0.607	rs13211507	ENSG00000204709.4	LINC01556	6.59	1.19e-10	6.58e-08	0.61	0.29	Depression;	chr6:28289600	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34691223	ENSG00000204709.4	LINC01556	6.59	1.19e-10	6.58e-08	0.61	0.29	Depression;	chr6:28290431	chr6:28943877~28944537:+
LUAD	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	6.59	1.19e-10	6.58e-08	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
LUAD	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-6.59	1.19e-10	6.59e-08	-0.4	-0.29	Depression;	chr6:28206812	chr6:28115628~28116551:+
LUAD	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-6.59	1.19e-10	6.6e-08	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
LUAD	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	6.59	1.19e-10	6.6e-08	0.32	0.29	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
LUAD	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	6.58	1.2e-10	6.61e-08	0.35	0.29	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
LUAD	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.2e-10	6.63e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.2e-10	6.63e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.2e-10	6.63e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.2e-10	6.63e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
LUAD	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-6.58	1.2e-10	6.63e-08	-0.32	-0.29	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
LUAD	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	6.58	1.2e-10	6.63e-08	0.42	0.29	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
LUAD	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	6.58	1.2e-10	6.64e-08	0.35	0.29	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
LUAD	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-6.58	1.2e-10	6.65e-08	-0.35	-0.29	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
LUAD	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-6.58	1.2e-10	6.65e-08	-0.52	-0.29	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
LUAD	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	6.58	1.21e-10	6.66e-08	0.32	0.29	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
LUAD	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-6.58	1.21e-10	6.67e-08	-0.3	-0.29	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
LUAD	cis	rs227932	0.764	rs76349338	ENSG00000234286.1	AC006026.13	-6.58	1.21e-10	6.67e-08	-0.49	-0.29	Schizophrenia;	chr7:23709138	chr7:23680195~23680786:-
LUAD	cis	rs9326248	0.52	rs236919	ENSG00000280143.1	AP000892.6	6.58	1.21e-10	6.69e-08	0.33	0.29	Blood protein levels;	chr11:117224645	chr11:117204967~117210292:+
LUAD	cis	rs2303759	0.918	rs10405465	ENSG00000268686.1	AC010524.2	-6.58	1.21e-10	6.69e-08	-0.4	-0.29	Multiple sclerosis;	chr19:49366041	chr19:49368705~49388081:-
LUAD	cis	rs7176527	1	rs3762169	ENSG00000188388.10	GOLGA6L3	6.58	1.21e-10	6.69e-08	0.39	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85240472~85247170:+
LUAD	cis	rs516805	0.961	rs483933	ENSG00000279453.1	RP3-425C14.4	-6.58	1.21e-10	6.71e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122460377	chr6:122436789~122439223:-
LUAD	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.22e-10	6.72e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
LUAD	cis	rs10740039	0.81	rs4440977	ENSG00000254271.1	RP11-131N11.4	6.58	1.22e-10	6.73e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60618163	chr10:60734342~60741828:+
LUAD	cis	rs2115536	0.692	rs6495450	ENSG00000278600.1	RP11-81A1.6	-6.58	1.22e-10	6.74e-08	-0.23	-0.29	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79870157	chr15:79920195~79922455:-
LUAD	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-6.58	1.22e-10	6.75e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
LUAD	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	6.58	1.22e-10	6.76e-08	0.26	0.29	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
LUAD	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-6.58	1.22e-10	6.76e-08	-0.27	-0.29	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
LUAD	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	6.58	1.23e-10	6.77e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	6.58	1.23e-10	6.78e-08	0.63	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
LUAD	cis	rs1426063	0.614	rs78046076	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75091818	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs74670563	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75094656	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs115338890	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75094719	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.541	rs116304289	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75095072	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs76204704	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75097804	chr4:74955974~74970362:-
LUAD	cis	rs17301013	0.507	rs2760057	ENSG00000227373.4	RP11-160H22.5	6.58	1.23e-10	6.79e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174743384	chr1:174115300~174160004:-
LUAD	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-6.58	1.23e-10	6.8e-08	-0.35	-0.29	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
LUAD	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-6.58	1.23e-10	6.81e-08	-0.38	-0.29	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
LUAD	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-6.58	1.24e-10	6.81e-08	-0.3	-0.29	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-6.58	1.24e-10	6.82e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
LUAD	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-6.58	1.24e-10	6.83e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
LUAD	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-6.58	1.24e-10	6.83e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
LUAD	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-6.58	1.24e-10	6.83e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
LUAD	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	6.58	1.24e-10	6.86e-08	0.48	0.29	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
LUAD	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	6.58	1.24e-10	6.86e-08	0.43	0.29	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
LUAD	cis	rs9326248	0.53	rs2075292	ENSG00000280143.1	AP000892.6	6.58	1.25e-10	6.88e-08	0.45	0.29	Blood protein levels;	chr11:116861796	chr11:117204967~117210292:+
LUAD	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-6.58	1.25e-10	6.88e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	6.58	1.25e-10	6.88e-08	0.37	0.29	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
LUAD	cis	rs694739	0.536	rs11231740	ENSG00000236935.1	AP003774.1	-6.58	1.25e-10	6.88e-08	-0.27	-0.29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64279169	chr11:64325050~64329504:-
LUAD	cis	rs10740039	0.842	rs7069157	ENSG00000254271.1	RP11-131N11.4	6.58	1.25e-10	6.89e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60629475	chr10:60734342~60741828:+
LUAD	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-6.58	1.25e-10	6.9e-08	-0.53	-0.29	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-6.58	1.25e-10	6.91e-08	-0.57	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
LUAD	cis	rs1426063	0.614	rs76093954	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75087994	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs114977200	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75088736	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs77625282	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75089646	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs75112697	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75089725	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs7684790	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75090873	chr4:74955974~74970362:-
LUAD	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-6.58	1.26e-10	6.92e-08	-0.36	-0.29	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
LUAD	cis	rs8177876	0.822	rs804902	ENSG00000261838.4	RP11-303E16.6	6.58	1.26e-10	6.94e-08	0.52	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr16:81069854~81076598:+
LUAD	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	6.58	1.26e-10	6.96e-08	0.42	0.29	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
LUAD	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	6.58	1.26e-10	6.96e-08	0.32	0.29	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
LUAD	cis	rs131777	0.575	rs963980	ENSG00000205559.3	CHKB-AS1	-6.58	1.26e-10	6.96e-08	-0.34	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50583026~50583877:+
LUAD	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-6.58	1.27e-10	6.97e-08	-0.32	-0.29	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
LUAD	cis	rs2221433	0.961	rs6498087	ENSG00000260310.1	RP11-27M24.2	-6.58	1.27e-10	6.97e-08	-0.33	-0.29	Eating disorders;	chr16:10570402	chr16:10576499~10578183:-
LUAD	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	6.58	1.27e-10	6.98e-08	0.35	0.29	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
LUAD	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-6.58	1.27e-10	6.98e-08	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
LUAD	cis	rs720064	0.586	rs8083137	ENSG00000264745.1	TTC39C-AS1	6.57	1.27e-10	6.99e-08	0.31	0.29	Strep throat;	chr18:23962963	chr18:23994213~24015339:-
LUAD	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-6.57	1.27e-10	7.01e-08	-0.39	-0.29	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
LUAD	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	6.57	1.27e-10	7.01e-08	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
LUAD	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-6.57	1.28e-10	7.02e-08	-0.32	-0.29	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
LUAD	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	6.57	1.28e-10	7.03e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
LUAD	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-6.57	1.28e-10	7.04e-08	-0.39	-0.29	Depression;	chr6:28205175	chr6:28115628~28116551:+
LUAD	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	6.57	1.28e-10	7.04e-08	0.3	0.29	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
LUAD	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-6.57	1.28e-10	7.04e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
LUAD	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	6.57	1.28e-10	7.04e-08	0.4	0.29	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
LUAD	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	6.57	1.28e-10	7.05e-08	0.33	0.29	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
LUAD	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	6.57	1.28e-10	7.05e-08	0.33	0.29	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
LUAD	cis	rs62229266	0.633	rs34259635	ENSG00000214914.3	RPL23AP3	6.57	1.28e-10	7.05e-08	0.34	0.29	Mitral valve prolapse;	chr21:36031272	chr21:36016079~36016546:-
LUAD	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	6.57	1.28e-10	7.06e-08	0.67	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
LUAD	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	6.57	1.28e-10	7.07e-08	0.45	0.29	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
LUAD	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	6.57	1.29e-10	7.07e-08	0.32	0.29	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
LUAD	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	6.57	1.29e-10	7.08e-08	0.37	0.29	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
LUAD	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-6.57	1.29e-10	7.1e-08	-0.39	-0.29	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
LUAD	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	6.57	1.29e-10	7.11e-08	0.35	0.29	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
LUAD	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	6.57	1.29e-10	7.11e-08	0.37	0.29	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
LUAD	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	6.57	1.29e-10	7.12e-08	0.3	0.29	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
LUAD	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	6.57	1.3e-10	7.12e-08	0.37	0.29	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
LUAD	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	6.57	1.3e-10	7.12e-08	0.36	0.29	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
LUAD	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	6.57	1.3e-10	7.13e-08	0.32	0.29	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
LUAD	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	6.57	1.3e-10	7.14e-08	0.24	0.29	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000224373.3	IGHV4-59	-6.57	1.3e-10	7.15e-08	-0.17	-0.29	Kawasaki disease;	chr14:106779612	chr14:106627249~106627825:-
LUAD	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	6.57	1.3e-10	7.15e-08	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000280411.1	IGHV1-69-2	-6.57	1.3e-10	7.15e-08	-0.22	-0.29	Kawasaki disease;	chr14:106716993	chr14:106762092~106762588:-
LUAD	cis	rs10899021	0.79	rs12288525	ENSG00000279353.1	RP11-864N7.4	6.57	1.3e-10	7.16e-08	0.49	0.29	Response to metformin (IC50);	chr11:74621544	chr11:74698231~74699658:-
LUAD	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-6.57	1.3e-10	7.17e-08	-0.36	-0.29	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-6.57	1.3e-10	7.17e-08	-0.36	-0.29	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
LUAD	cis	rs2034650	0.544	rs2289330	ENSG00000223313.1	RNU6-516P	6.57	1.3e-10	7.17e-08	0.38	0.29	Interstitial lung disease;	chr15:40412906	chr15:40529570~40529673:+
LUAD	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-6.57	1.31e-10	7.17e-08	-0.34	-0.29	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000206090.4	AP000350.7	6.57	1.31e-10	7.2e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23939998~23942798:+
LUAD	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	6.57	1.31e-10	7.2e-08	0.41	0.29	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000206090.4	AP000350.7	6.57	1.31e-10	7.2e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23939998~23942798:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000224373.3	IGHV4-59	6.57	1.31e-10	7.22e-08	0.17	0.29	Kawasaki disease;	chr14:106778539	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000224373.3	IGHV4-59	6.57	1.31e-10	7.22e-08	0.17	0.29	Kawasaki disease;	chr14:106779186	chr14:106627249~106627825:-
LUAD	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	6.57	1.31e-10	7.22e-08	0.35	0.29	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000224373.3	IGHV4-59	6.57	1.31e-10	7.22e-08	0.17	0.29	Kawasaki disease;	chr14:106776698	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000224373.3	IGHV4-59	6.57	1.31e-10	7.22e-08	0.17	0.29	Kawasaki disease;	chr14:106776724	chr14:106627249~106627825:-
LUAD	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-6.57	1.32e-10	7.23e-08	-0.38	-0.29	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	6.57	1.32e-10	7.23e-08	0.36	0.29	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
LUAD	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	6.57	1.32e-10	7.23e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
LUAD	cis	rs10740039	0.804	rs1372714	ENSG00000254271.1	RP11-131N11.4	6.57	1.32e-10	7.25e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60686640	chr10:60734342~60741828:+
LUAD	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-6.57	1.32e-10	7.27e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	6.57	1.32e-10	7.27e-08	0.32	0.29	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
LUAD	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	6.57	1.32e-10	7.27e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
LUAD	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-6.57	1.33e-10	7.29e-08	-0.3	-0.29	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
LUAD	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	6.57	1.33e-10	7.29e-08	0.24	0.29	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
LUAD	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	6.57	1.33e-10	7.3e-08	0.36	0.29	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
LUAD	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	6.57	1.33e-10	7.3e-08	0.42	0.29	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
LUAD	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	6.57	1.33e-10	7.31e-08	0.3	0.29	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	6.57	1.33e-10	7.31e-08	0.3	0.29	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
LUAD	cis	rs62229266	0.659	rs2255734	ENSG00000214914.3	RPL23AP3	6.57	1.33e-10	7.31e-08	0.34	0.29	Mitral valve prolapse;	chr21:36039611	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.659	rs2835242	ENSG00000214914.3	RPL23AP3	6.57	1.33e-10	7.31e-08	0.34	0.29	Mitral valve prolapse;	chr21:36041234	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.659	rs2835243	ENSG00000214914.3	RPL23AP3	6.57	1.33e-10	7.31e-08	0.34	0.29	Mitral valve prolapse;	chr21:36041648	chr21:36016079~36016546:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-6.57	1.33e-10	7.31e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
LUAD	cis	rs12439619	0.508	rs8042665	ENSG00000276710.3	CSPG4P8	-6.57	1.33e-10	7.31e-08	-0.26	-0.29	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82459472~82477258:+
LUAD	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	6.57	1.34e-10	7.33e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	6.57	1.34e-10	7.33e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
LUAD	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	6.57	1.34e-10	7.34e-08	0.36	0.29	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
LUAD	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	6.57	1.34e-10	7.34e-08	0.32	0.29	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
LUAD	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-6.57	1.34e-10	7.36e-08	-0.36	-0.29	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
LUAD	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	6.57	1.35e-10	7.38e-08	0.25	0.29	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
LUAD	cis	rs77204473	0.744	rs12273545	ENSG00000254851.1	RP11-109L13.1	6.57	1.35e-10	7.38e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040296	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs77999164	ENSG00000254851.1	RP11-109L13.1	6.57	1.35e-10	7.38e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117041401	chr11:117135528~117138582:+
LUAD	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	6.57	1.35e-10	7.38e-08	0.37	0.29	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
LUAD	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	6.57	1.35e-10	7.4e-08	0.24	0.29	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
LUAD	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-6.57	1.35e-10	7.4e-08	-0.36	-0.29	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
LUAD	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	6.57	1.35e-10	7.4e-08	0.46	0.29	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
LUAD	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-6.56	1.35e-10	7.41e-08	-0.37	-0.29	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs73150014	ENSG00000232546.1	RP11-458F8.1	-6.56	1.35e-10	7.42e-08	-0.38	-0.29	Diabetic kidney disease;	chr7:65985932	chr7:66848496~66858136:+
LUAD	cis	rs755249	0.567	rs67408364	ENSG00000228060.1	RP11-69E11.8	-6.56	1.35e-10	7.42e-08	-0.29	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39565160~39573203:+
LUAD	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-6.56	1.36e-10	7.43e-08	-0.54	-0.29	Gout;	chr7:66693028	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-6.56	1.36e-10	7.46e-08	-0.32	-0.29	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
LUAD	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	6.56	1.36e-10	7.46e-08	0.35	0.29	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
LUAD	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	6.56	1.36e-10	7.46e-08	0.32	0.29	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
LUAD	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	6.56	1.36e-10	7.48e-08	0.35	0.29	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-6.56	1.37e-10	7.49e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	6.56	1.37e-10	7.5e-08	0.35	0.29	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	6.56	1.37e-10	7.5e-08	0.32	0.29	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
LUAD	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-6.56	1.37e-10	7.5e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
LUAD	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	6.56	1.37e-10	7.51e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
LUAD	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-6.56	1.37e-10	7.51e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
LUAD	cis	rs6772849	0.805	rs61159406	ENSG00000242551.2	POU5F1P6	-6.56	1.37e-10	7.52e-08	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.805	rs13325747	ENSG00000242551.2	POU5F1P6	-6.56	1.37e-10	7.52e-08	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:128674735~128677005:-
LUAD	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	6.56	1.37e-10	7.52e-08	0.31	0.29	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
LUAD	cis	rs75422866	0.764	rs67408202	ENSG00000280054.1	RP1-197B17.7	6.56	1.37e-10	7.53e-08	0.69	0.29	Pneumonia;	chr12:47713564	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs57848393	ENSG00000280054.1	RP1-197B17.7	6.56	1.37e-10	7.53e-08	0.69	0.29	Pneumonia;	chr12:47714734	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.764	rs67201012	ENSG00000280054.1	RP1-197B17.7	6.56	1.37e-10	7.53e-08	0.69	0.29	Pneumonia;	chr12:47715881	chr12:47728151~47730598:-
LUAD	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	6.56	1.38e-10	7.53e-08	0.31	0.29	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
LUAD	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	6.56	1.38e-10	7.54e-08	0.35	0.29	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
LUAD	cis	rs8177876	0.658	rs16954513	ENSG00000261838.4	RP11-303E16.6	6.56	1.38e-10	7.56e-08	0.74	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043599	chr16:81069854~81076598:+
LUAD	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	6.56	1.38e-10	7.57e-08	0.56	0.29	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
LUAD	cis	rs62229266	0.659	rs2835245	ENSG00000214914.3	RPL23AP3	6.56	1.38e-10	7.58e-08	0.34	0.29	Mitral valve prolapse;	chr21:36044410	chr21:36016079~36016546:-
LUAD	cis	rs10740039	0.768	rs1372710	ENSG00000254271.1	RP11-131N11.4	6.56	1.39e-10	7.59e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60603200	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.81	rs10821800	ENSG00000254271.1	RP11-131N11.4	6.56	1.39e-10	7.59e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607812	chr10:60734342~60741828:+
LUAD	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	6.56	1.39e-10	7.59e-08	0.24	0.29	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
LUAD	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	6.56	1.39e-10	7.61e-08	0.36	0.29	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.513	rs4334520	ENSG00000227542.1	AC092614.2	6.56	1.39e-10	7.61e-08	0.36	0.29	Obesity-related traits;	chr2:191329200	chr2:191229165~191246172:-
LUAD	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-6.56	1.39e-10	7.62e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
LUAD	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-6.56	1.4e-10	7.64e-08	-0.35	-0.29	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
LUAD	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	6.56	1.4e-10	7.66e-08	0.36	0.29	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
LUAD	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-6.56	1.4e-10	7.68e-08	-0.63	-0.29	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
LUAD	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-6.56	1.41e-10	7.7e-08	-0.32	-0.29	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
LUAD	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-6.56	1.41e-10	7.7e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
LUAD	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
LUAD	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	6.56	1.41e-10	7.72e-08	0.44	0.29	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
LUAD	cis	rs17684571	0.938	rs71564849	ENSG00000231441.1	RP11-472M19.2	6.56	1.41e-10	7.72e-08	0.4	0.29	Schizophrenia;	chr6:56709421	chr6:56844002~56864078:+
LUAD	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-6.56	1.41e-10	7.72e-08	-0.63	-0.29	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	6.56	1.41e-10	7.72e-08	0.63	0.29	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
LUAD	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-6.56	1.42e-10	7.74e-08	-0.54	-0.29	Gout;	chr7:66679692	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	6.56	1.42e-10	7.74e-08	0.54	0.29	Gout;	chr7:66682070	chr7:66654538~66669855:+
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	6.56	1.42e-10	7.74e-08	0.54	0.29	Gout;	chr7:66682162	chr7:66654538~66669855:+
LUAD	cis	rs11089937	0.616	rs713644	ENSG00000211639.2	IGLV4-60	6.56	1.42e-10	7.74e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs713624	ENSG00000211639.2	IGLV4-60	6.56	1.42e-10	7.74e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22162199~22162681:+
LUAD	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	6.56	1.42e-10	7.74e-08	0.31	0.29	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	6.56	1.42e-10	7.74e-08	0.31	0.29	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
LUAD	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-6.56	1.42e-10	7.75e-08	-0.29	-0.29	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
LUAD	cis	rs17301013	0.507	rs10912786	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174427609	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12074416	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174430109	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12069134	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174434287	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs6677262	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174434539	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs60409344	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174438724	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72713584	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174439129	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12077381	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174439566	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs74126805	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174440226	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12078960	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174440891	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12080407	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174441964	chr1:174115300~174160004:-
LUAD	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	6.56	1.42e-10	7.76e-08	0.3	0.29	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
LUAD	cis	rs9584850	0.874	rs3742136	ENSG00000231194.1	FARP1-AS1	6.56	1.42e-10	7.76e-08	0.35	0.29	Neuroticism;	chr13:98450353	chr13:98435405~98435840:-
LUAD	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	6.56	1.42e-10	7.78e-08	0.37	0.29	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
LUAD	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	6.56	1.42e-10	7.78e-08	0.37	0.29	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
LUAD	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	6.56	1.43e-10	7.78e-08	0.31	0.29	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
LUAD	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-6.56	1.43e-10	7.79e-08	-0.39	-0.29	Depression;	chr6:28197412	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-6.56	1.43e-10	7.79e-08	-0.39	-0.29	Depression;	chr6:28198669	chr6:28115628~28116551:+
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	6.56	1.43e-10	7.79e-08	0.36	0.29	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000224373.3	IGHV4-59	6.56	1.43e-10	7.79e-08	0.18	0.29	Kawasaki disease;	chr14:106676288	chr14:106627249~106627825:-
LUAD	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	6.56	1.43e-10	7.81e-08	0.36	0.29	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
LUAD	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	6.56	1.43e-10	7.81e-08	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
LUAD	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	6.56	1.43e-10	7.81e-08	0.34	0.29	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
LUAD	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	6.56	1.43e-10	7.82e-08	0.32	0.29	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
LUAD	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.82e-08	0.69	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
LUAD	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66692349	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66693433	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66694214	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66701371	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66702658	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66706390	chr7:66654538~66669855:+
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66710076	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66715944	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66721259	chr7:66654538~66669855:+
LUAD	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-6.55	1.44e-10	7.84e-08	-0.35	-0.29	Height;	chr11:118854014	chr11:118704607~118750263:+
LUAD	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-6.55	1.44e-10	7.85e-08	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
LUAD	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-6.55	1.44e-10	7.86e-08	-0.53	-0.29	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	6.55	1.44e-10	7.86e-08	0.37	0.29	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
LUAD	cis	rs7688540	0.8	rs12510827	ENSG00000275426.1	CH17-262A2.1	6.55	1.44e-10	7.87e-08	0.36	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:149738~150317:+
LUAD	cis	rs75920871	0.589	rs56061158	ENSG00000254851.1	RP11-109L13.1	-6.55	1.44e-10	7.87e-08	-0.51	-0.29	Subjective well-being;	chr11:117216402	chr11:117135528~117138582:+
LUAD	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	6.55	1.44e-10	7.87e-08	0.44	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
LUAD	cis	rs9326248	0.581	rs10502222	ENSG00000280143.1	AP000892.6	6.55	1.45e-10	7.88e-08	0.33	0.29	Blood protein levels;	chr11:116963014	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.559	rs10892052	ENSG00000280143.1	AP000892.6	6.55	1.45e-10	7.88e-08	0.33	0.29	Blood protein levels;	chr11:116963597	chr11:117204967~117210292:+
LUAD	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	6.55	1.45e-10	7.88e-08	0.41	0.29	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
LUAD	cis	rs1426063	0.614	rs115690958	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75078364	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs78681370	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75081556	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs17000212	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75081611	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs77018380	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75081621	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs76325897	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75084747	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs6534447	ENSG00000249717.1	RP11-44F21.3	-6.55	1.45e-10	7.89e-08	-0.58	-0.29	QT interval;	chr4:75080682	chr4:74955974~74970362:-
LUAD	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-6.55	1.45e-10	7.89e-08	-0.29	-0.29	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
LUAD	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	6.55	1.45e-10	7.89e-08	0.34	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
LUAD	cis	rs853679	0.607	rs34878803	ENSG00000204709.4	LINC01556	6.55	1.45e-10	7.9e-08	0.61	0.29	Depression;	chr6:28282402	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34396849	ENSG00000204709.4	LINC01556	6.55	1.45e-10	7.9e-08	0.61	0.29	Depression;	chr6:28283178	chr6:28943877~28944537:+
LUAD	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
LUAD	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-6.55	1.45e-10	7.92e-08	-0.36	-0.29	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
LUAD	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-6.55	1.46e-10	7.92e-08	-0.32	-0.29	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-6.55	1.46e-10	7.92e-08	-0.32	-0.29	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-6.55	1.46e-10	7.92e-08	-0.32	-0.29	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-6.55	1.46e-10	7.92e-08	-0.32	-0.29	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
LUAD	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	6.55	1.46e-10	7.93e-08	0.42	0.29	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
LUAD	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-6.55	1.46e-10	7.93e-08	-0.32	-0.29	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
LUAD	cis	rs35934224	0.891	rs33997573	ENSG00000232926.1	AC000078.5	6.55	1.46e-10	7.93e-08	0.34	0.29	Glaucoma (primary open-angle);	chr22:19881428	chr22:19887289~19887970:+
LUAD	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-6.55	1.46e-10	7.94e-08	-0.3	-0.29	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
LUAD	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
LUAD	cis	rs7017914	0.967	rs3098867	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.95e-08	0.32	0.29	Bone mineral density;	chr8:71004636	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs2639904	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.95e-08	0.32	0.29	Bone mineral density;	chr8:71004895	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs2639901	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.95e-08	0.32	0.29	Bone mineral density;	chr8:71005516	chr8:70780914~70781008:-
LUAD	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	6.55	1.46e-10	7.95e-08	0.55	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
LUAD	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	6.55	1.46e-10	7.96e-08	0.42	0.29	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	6.55	1.46e-10	7.96e-08	0.42	0.29	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
LUAD	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-6.55	1.46e-10	7.96e-08	-0.35	-0.29	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
LUAD	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	6.55	1.46e-10	7.96e-08	0.36	0.29	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
LUAD	cis	rs7017914	0.934	rs17760050	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.96e-08	0.32	0.29	Bone mineral density;	chr8:70662016	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs35214141	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.96e-08	0.32	0.29	Bone mineral density;	chr8:70662329	chr8:70780914~70781008:-
LUAD	cis	rs1823913	0.549	rs4465792	ENSG00000227542.1	AC092614.2	6.55	1.46e-10	7.97e-08	0.36	0.29	Obesity-related traits;	chr2:191328884	chr2:191229165~191246172:-
LUAD	cis	rs11089937	0.616	rs66651705	ENSG00000211639.2	IGLV4-60	6.55	1.46e-10	7.97e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22179973	chr22:22162199~22162681:+
LUAD	cis	rs7017914	0.902	rs3098866	ENSG00000223220.1	Y_RNA	6.55	1.47e-10	7.98e-08	0.32	0.29	Bone mineral density;	chr8:71004339	chr8:70780914~70781008:-
LUAD	cis	rs748404	0.723	rs11853991	ENSG00000205771.5	CATSPER2P1	-6.55	1.47e-10	7.99e-08	-0.37	-0.29	Lung cancer;	chr15:43265351	chr15:43726918~43747094:-
LUAD	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	6.55	1.47e-10	8e-08	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
LUAD	cis	rs11089937	0.616	rs5750675	ENSG00000211639.2	IGLV4-60	6.55	1.47e-10	8e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22179233	chr22:22162199~22162681:+
LUAD	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-6.55	1.47e-10	8e-08	-0.39	-0.29	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
LUAD	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-6.55	1.47e-10	8e-08	-0.39	-0.29	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000224373.3	IGHV4-59	6.55	1.47e-10	8.01e-08	0.17	0.29	Kawasaki disease;	chr14:106778016	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000224373.3	IGHV4-59	6.55	1.47e-10	8.01e-08	0.17	0.29	Kawasaki disease;	chr14:106778120	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000224373.3	IGHV4-59	6.55	1.47e-10	8.01e-08	0.17	0.29	Kawasaki disease;	chr14:106778135	chr14:106627249~106627825:-
LUAD	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	6.55	1.47e-10	8.01e-08	0.29	0.29	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
LUAD	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-6.55	1.48e-10	8.02e-08	-0.34	-0.29	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
LUAD	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-6.55	1.48e-10	8.03e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
LUAD	cis	rs7017914	0.934	rs3110239	ENSG00000223220.1	Y_RNA	6.55	1.48e-10	8.03e-08	0.32	0.29	Bone mineral density;	chr8:71004510	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs2732092	ENSG00000223220.1	Y_RNA	6.55	1.48e-10	8.03e-08	0.32	0.29	Bone mineral density;	chr8:71006364	chr8:70780914~70781008:-
LUAD	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	6.55	1.48e-10	8.04e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-6.55	1.48e-10	8.04e-08	-0.35	-0.29	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
LUAD	cis	rs7688540	0.8	rs61794998	ENSG00000275426.1	CH17-262A2.1	6.55	1.48e-10	8.06e-08	0.35	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:149738~150317:+
LUAD	cis	rs77204473	0.744	rs75890305	ENSG00000254851.1	RP11-109L13.1	6.55	1.49e-10	8.08e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117049253	chr11:117135528~117138582:+
LUAD	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-6.55	1.49e-10	8.08e-08	-0.33	-0.29	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
LUAD	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	6.55	1.49e-10	8.1e-08	0.35	0.29	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
LUAD	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	6.55	1.49e-10	8.1e-08	0.33	0.29	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
LUAD	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-6.55	1.49e-10	8.12e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
LUAD	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	6.55	1.49e-10	8.12e-08	0.42	0.29	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
LUAD	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-6.55	1.5e-10	8.14e-08	-0.36	-0.29	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
LUAD	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-6.55	1.5e-10	8.17e-08	-0.36	-0.29	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
LUAD	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-6.55	1.51e-10	8.18e-08	-0.33	-0.29	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
LUAD	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	6.55	1.51e-10	8.19e-08	0.4	0.29	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
LUAD	cis	rs150992	0.507	rs377731	ENSG00000248489.1	CTD-2007H13.3	6.55	1.51e-10	8.21e-08	0.31	0.29	Body mass index;	chr5:98996535	chr5:98929171~98995013:+
LUAD	cis	rs2734839	0.964	rs4587762	ENSG00000270179.1	RP11-159N11.4	-6.55	1.51e-10	8.22e-08	-0.3	-0.29	Information processing speed;	chr11:113436171	chr11:113368478~113369117:+
LUAD	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	6.55	1.52e-10	8.23e-08	0.38	0.29	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	6.55	1.52e-10	8.23e-08	0.38	0.29	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
LUAD	cis	rs4723738	1	rs1019180	ENSG00000227191.5	TRGC2	-6.55	1.52e-10	8.24e-08	-0.31	-0.29	Treatment response for severe sepsis;	chr7:38179410	chr7:38239580~38368091:-
LUAD	cis	rs7017914	0.934	rs1993862	ENSG00000223220.1	Y_RNA	6.55	1.52e-10	8.24e-08	0.32	0.29	Bone mineral density;	chr8:70667127	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs34282253	ENSG00000223220.1	Y_RNA	6.55	1.52e-10	8.24e-08	0.32	0.29	Bone mineral density;	chr8:70670131	chr8:70780914~70781008:-
LUAD	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-6.55	1.52e-10	8.24e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
LUAD	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-6.55	1.52e-10	8.25e-08	-0.37	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
LUAD	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	6.55	1.53e-10	8.27e-08	0.39	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
LUAD	cis	rs891378	0.785	rs7516640	ENSG00000274245.1	RP11-357P18.2	6.55	1.53e-10	8.27e-08	0.34	0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236069	chr1:207372559~207373252:+
LUAD	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	6.55	1.53e-10	8.27e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
LUAD	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	6.55	1.53e-10	8.28e-08	0.35	0.29	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
LUAD	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-6.55	1.53e-10	8.28e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
LUAD	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	6.54	1.53e-10	8.29e-08	0.42	0.29	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
LUAD	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	6.54	1.53e-10	8.29e-08	0.44	0.29	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
LUAD	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-6.54	1.53e-10	8.3e-08	-0.46	-0.29	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
LUAD	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	6.54	1.53e-10	8.3e-08	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
LUAD	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-6.54	1.53e-10	8.31e-08	-0.34	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
LUAD	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-6.54	1.53e-10	8.31e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
LUAD	cis	rs11846409	0.932	rs2015469	ENSG00000211974.3	IGHV2-70	-6.54	1.53e-10	8.31e-08	-0.35	-0.29	Rheumatic heart disease;	chr14:106631857	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.932	rs56167903	ENSG00000211974.3	IGHV2-70	-6.54	1.53e-10	8.31e-08	-0.35	-0.29	Rheumatic heart disease;	chr14:106632070	chr14:106723574~106724093:-
LUAD	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	6.54	1.53e-10	8.32e-08	0.44	0.29	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
LUAD	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-6.54	1.54e-10	8.33e-08	-0.34	-0.29	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000224373.3	IGHV4-59	6.54	1.54e-10	8.33e-08	0.17	0.29	Kawasaki disease;	chr14:106782523	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000224373.3	IGHV4-59	6.54	1.54e-10	8.33e-08	0.17	0.29	Kawasaki disease;	chr14:106782559	chr14:106627249~106627825:-
LUAD	cis	rs10740039	0.732	rs10159808	ENSG00000254271.1	RP11-131N11.4	6.54	1.54e-10	8.34e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602432	chr10:60734342~60741828:+
LUAD	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	6.54	1.54e-10	8.37e-08	0.32	0.29	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
LUAD	cis	rs4591358	0.773	rs13002794	ENSG00000223466.1	AC064834.2	-6.54	1.54e-10	8.37e-08	-0.38	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195517175	chr2:195533035~195538681:+
LUAD	cis	rs11118620	0.81	rs1603047	ENSG00000257551.1	HLX-AS1	6.54	1.55e-10	8.37e-08	0.35	0.29	Heart failure;	chr1:220849953	chr1:220832763~220880140:-
LUAD	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
LUAD	cis	rs6844153	1	rs74642474	ENSG00000240005.4	RP11-293A21.1	-6.54	1.55e-10	8.38e-08	-0.48	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26854979	chr4:26859806~26860599:-
LUAD	cis	rs891378	0.785	rs1346720	ENSG00000274245.1	RP11-357P18.2	6.54	1.56e-10	8.42e-08	0.37	0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207214421	chr1:207372559~207373252:+
LUAD	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	6.54	1.56e-10	8.44e-08	0.37	0.29	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
LUAD	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	6.54	1.56e-10	8.44e-08	0.32	0.29	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	6.54	1.56e-10	8.44e-08	0.32	0.29	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
LUAD	cis	rs7646881	0.812	rs59957986	ENSG00000240207.5	RP11-379F4.4	-6.54	1.56e-10	8.45e-08	-0.38	-0.29	Tetralogy of Fallot;	chr3:158741124	chr3:158732263~158784070:+
LUAD	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-6.54	1.56e-10	8.46e-08	-0.33	-0.29	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
LUAD	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-6.54	1.56e-10	8.47e-08	-0.35	-0.29	Height;	chr11:118855233	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-6.54	1.56e-10	8.47e-08	-0.35	-0.29	Height;	chr11:118855938	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	6.54	1.57e-10	8.47e-08	0.35	0.29	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
LUAD	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	6.54	1.57e-10	8.47e-08	0.33	0.29	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
LUAD	cis	rs9584850	0.874	rs4584	ENSG00000231194.1	FARP1-AS1	6.54	1.57e-10	8.47e-08	0.35	0.29	Neuroticism;	chr13:98449615	chr13:98435405~98435840:-
LUAD	cis	rs131777	0.547	rs131753	ENSG00000205559.3	CHKB-AS1	-6.54	1.57e-10	8.49e-08	-0.33	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50583026~50583877:+
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-6.54	1.57e-10	8.49e-08	-0.29	-0.29	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
LUAD	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	6.54	1.57e-10	8.49e-08	0.45	0.29	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
LUAD	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	6.54	1.58e-10	8.52e-08	0.35	0.29	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
LUAD	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	6.54	1.58e-10	8.54e-08	0.36	0.29	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-6.54	1.58e-10	8.54e-08	-0.32	-0.29	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-6.54	1.58e-10	8.54e-08	-0.32	-0.29	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
LUAD	cis	rs1823913	1	rs4853562	ENSG00000230611.1	HMGB1P27	6.54	1.58e-10	8.54e-08	0.34	0.29	Obesity-related traits;	chr2:191253696	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs4853461	ENSG00000230611.1	HMGB1P27	6.54	1.58e-10	8.54e-08	0.34	0.29	Obesity-related traits;	chr2:191254572	chr2:191174233~191174835:+
LUAD	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	6.54	1.58e-10	8.55e-08	0.31	0.29	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
LUAD	cis	rs9326248	0.581	rs7121898	ENSG00000280143.1	AP000892.6	6.54	1.58e-10	8.56e-08	0.33	0.29	Blood protein levels;	chr11:116926130	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.52	rs1446105	ENSG00000280143.1	AP000892.6	6.54	1.58e-10	8.56e-08	0.33	0.29	Blood protein levels;	chr11:116927828	chr11:117204967~117210292:+
LUAD	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-6.54	1.58e-10	8.56e-08	-0.43	-0.29	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
LUAD	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-6.54	1.58e-10	8.57e-08	-0.56	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
LUAD	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	6.54	1.59e-10	8.57e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
LUAD	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-6.54	1.59e-10	8.59e-08	-0.33	-0.29	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
LUAD	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-6.54	1.59e-10	8.59e-08	-0.35	-0.29	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
LUAD	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	6.54	1.59e-10	8.6e-08	0.32	0.29	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000228039.3	KB-1125A3.10	6.54	1.59e-10	8.61e-08	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23963780~23964374:+
LUAD	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	6.54	1.59e-10	8.61e-08	0.32	0.29	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
LUAD	cis	rs950169	0.959	rs12911210	ENSG00000259728.4	LINC00933	6.54	1.59e-10	8.62e-08	0.42	0.29	Schizophrenia;	chr15:84123331	chr15:84570649~84580175:+
LUAD	cis	rs75422866	0.51	rs73105803	ENSG00000280054.1	RP1-197B17.7	6.54	1.6e-10	8.64e-08	0.64	0.29	Pneumonia;	chr12:47722135	chr12:47728151~47730598:-
LUAD	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	6.54	1.6e-10	8.65e-08	0.4	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
LUAD	cis	rs10899021	0.79	rs12280434	ENSG00000279353.1	RP11-864N7.4	6.54	1.6e-10	8.65e-08	0.5	0.29	Response to metformin (IC50);	chr11:74621782	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.79	rs10899019	ENSG00000279353.1	RP11-864N7.4	6.54	1.6e-10	8.65e-08	0.5	0.29	Response to metformin (IC50);	chr11:74624117	chr11:74698231~74699658:-
LUAD	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	6.54	1.6e-10	8.66e-08	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
LUAD	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	6.54	1.6e-10	8.66e-08	0.39	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
LUAD	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	6.54	1.6e-10	8.67e-08	0.37	0.29	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
LUAD	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	6.54	1.61e-10	8.67e-08	0.43	0.29	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
LUAD	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	6.54	1.61e-10	8.68e-08	0.36	0.29	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
LUAD	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-6.54	1.61e-10	8.69e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-6.54	1.61e-10	8.69e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
LUAD	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-6.54	1.61e-10	8.69e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
LUAD	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	6.54	1.61e-10	8.72e-08	0.24	0.29	Breast size;	chr12:9220266	chr12:9277235~9313241:+
LUAD	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-6.54	1.61e-10	8.72e-08	-0.3	-0.29	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
LUAD	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-6.54	1.61e-10	8.72e-08	-0.34	-0.29	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
LUAD	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-6.54	1.62e-10	8.73e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
LUAD	cis	rs9928842	0.882	rs8048956	ENSG00000280152.1	RP11-331F4.5	-6.54	1.62e-10	8.73e-08	-0.31	-0.29	Alcoholic chronic pancreatitis;	chr16:75221068	chr16:75245994~75250077:-
LUAD	cis	rs11098499	0.69	rs7674713	ENSG00000248280.1	RP11-33B1.2	6.54	1.62e-10	8.73e-08	0.36	0.29	Corneal astigmatism;	chr4:119401102	chr4:119440561~119450157:-
LUAD	cis	rs8177876	0.822	rs7203546	ENSG00000261838.4	RP11-303E16.6	-6.54	1.62e-10	8.74e-08	-0.55	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81069854~81076598:+
LUAD	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-6.54	1.62e-10	8.74e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
LUAD	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-6.54	1.62e-10	8.74e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-6.54	1.62e-10	8.74e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
LUAD	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	6.54	1.62e-10	8.75e-08	0.32	0.29	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
LUAD	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	6.53	1.63e-10	8.77e-08	0.38	0.29	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
LUAD	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	6.53	1.63e-10	8.79e-08	0.39	0.29	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	6.53	1.63e-10	8.79e-08	0.39	0.29	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-6.53	1.63e-10	8.8e-08	-0.29	-0.29	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
LUAD	cis	rs891378	0.755	rs7411168	ENSG00000274245.1	RP11-357P18.2	-6.53	1.63e-10	8.8e-08	-0.34	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207201970	chr1:207372559~207373252:+
LUAD	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	6.53	1.63e-10	8.8e-08	0.29	0.29	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	6.53	1.63e-10	8.8e-08	0.29	0.29	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
LUAD	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-6.53	1.63e-10	8.8e-08	-0.29	-0.29	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
LUAD	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.63e-10	8.81e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
LUAD	cis	rs1823913	1	rs4853563	ENSG00000230611.1	HMGB1P27	6.53	1.63e-10	8.81e-08	0.34	0.29	Obesity-related traits;	chr2:191254808	chr2:191174233~191174835:+
LUAD	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	6.53	1.63e-10	8.81e-08	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
LUAD	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-6.53	1.64e-10	8.83e-08	-0.29	-0.29	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
LUAD	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-6.53	1.64e-10	8.85e-08	-0.38	-0.29	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
LUAD	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	6.53	1.64e-10	8.86e-08	0.34	0.29	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
LUAD	cis	rs35955747	0.869	rs8141987	ENSG00000236132.1	CTA-440B3.1	6.53	1.64e-10	8.86e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191169	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.869	rs8142988	ENSG00000236132.1	CTA-440B3.1	6.53	1.64e-10	8.86e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191172	chr22:31816379~31817491:-
LUAD	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-6.53	1.64e-10	8.86e-08	-0.34	-0.29	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
LUAD	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-6.53	1.64e-10	8.86e-08	-0.32	-0.29	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
LUAD	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-6.53	1.64e-10	8.86e-08	-0.39	-0.29	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
LUAD	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	6.53	1.65e-10	8.89e-08	0.34	0.29	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000224373.3	IGHV4-59	6.53	1.65e-10	8.89e-08	0.17	0.29	Kawasaki disease;	chr14:106807157	chr14:106627249~106627825:-
LUAD	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	6.53	1.65e-10	8.9e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
LUAD	cis	rs7017914	0.934	rs13255886	ENSG00000223220.1	Y_RNA	6.53	1.65e-10	8.9e-08	0.32	0.29	Bone mineral density;	chr8:70653719	chr8:70780914~70781008:-
LUAD	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-6.53	1.65e-10	8.91e-08	-0.36	-0.29	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
LUAD	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-6.53	1.65e-10	8.91e-08	-0.36	-0.29	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
LUAD	cis	rs11118620	0.853	rs12037861	ENSG00000257551.1	HLX-AS1	6.53	1.65e-10	8.91e-08	0.35	0.29	Heart failure;	chr1:220864835	chr1:220832763~220880140:-
LUAD	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-6.53	1.65e-10	8.92e-08	-0.3	-0.29	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-6.53	1.65e-10	8.92e-08	-0.3	-0.29	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
LUAD	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	6.53	1.65e-10	8.92e-08	0.25	0.29	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
LUAD	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	6.53	1.66e-10	8.92e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
LUAD	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-6.53	1.66e-10	8.95e-08	-0.32	-0.29	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-6.53	1.66e-10	8.95e-08	-0.32	-0.29	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
LUAD	cis	rs35934224	0.891	rs13054713	ENSG00000232926.1	AC000078.5	6.53	1.66e-10	8.96e-08	0.34	0.29	Glaucoma (primary open-angle);	chr22:19880391	chr22:19887289~19887970:+
LUAD	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	6.53	1.66e-10	8.97e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
LUAD	cis	rs61776719	0.875	rs10890238	ENSG00000212541.1	RNU6-510P	-6.53	1.67e-10	8.99e-08	-0.34	-0.29	Coronary artery disease;	chr1:37979982	chr1:37991462~37991569:+
LUAD	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	6.53	1.67e-10	9e-08	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
LUAD	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	6.53	1.67e-10	9e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
LUAD	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	6.53	1.67e-10	9.01e-08	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
LUAD	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	6.53	1.67e-10	9.01e-08	0.33	0.29	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
LUAD	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-6.53	1.67e-10	9.01e-08	-0.34	-0.29	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
LUAD	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	6.53	1.67e-10	9.01e-08	0.35	0.29	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
LUAD	cis	rs131777	0.575	rs131760	ENSG00000205559.3	CHKB-AS1	-6.53	1.68e-10	9.05e-08	-0.34	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50583026~50583877:+
LUAD	cis	rs11846409	0.86	rs10150951	ENSG00000211974.3	IGHV2-70	-6.53	1.68e-10	9.06e-08	-0.35	-0.29	Rheumatic heart disease;	chr14:106632988	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.932	rs2583329	ENSG00000211974.3	IGHV2-70	6.53	1.68e-10	9.06e-08	0.35	0.29	Rheumatic heart disease;	chr14:106632971	chr14:106723574~106724093:-
LUAD	cis	rs227932	0.614	rs4722260	ENSG00000234286.1	AC006026.13	6.53	1.68e-10	9.06e-08	0.45	0.29	Schizophrenia;	chr7:23719851	chr7:23680195~23680786:-
LUAD	cis	rs7017914	0.934	rs10504479	ENSG00000223220.1	Y_RNA	6.53	1.68e-10	9.07e-08	0.32	0.29	Bone mineral density;	chr8:70665280	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs35109143	ENSG00000223220.1	Y_RNA	6.53	1.68e-10	9.07e-08	0.32	0.29	Bone mineral density;	chr8:70665665	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs13269513	ENSG00000223220.1	Y_RNA	6.53	1.68e-10	9.07e-08	0.32	0.29	Bone mineral density;	chr8:70665844	chr8:70780914~70781008:-
LUAD	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-6.53	1.69e-10	9.07e-08	-0.3	-0.29	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
LUAD	cis	rs7688540	0.8	rs1578898	ENSG00000275426.1	CH17-262A2.1	6.53	1.69e-10	9.07e-08	0.35	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:149738~150317:+
LUAD	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	6.53	1.69e-10	9.08e-08	0.48	0.29	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
LUAD	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	6.53	1.69e-10	9.08e-08	0.48	0.29	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
LUAD	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	6.53	1.69e-10	9.08e-08	0.33	0.29	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
LUAD	cis	rs35955747	0.934	rs5994397	ENSG00000236132.1	CTA-440B3.1	6.53	1.69e-10	9.09e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31430164	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	6.53	1.69e-10	9.11e-08	0.36	0.29	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
LUAD	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-6.53	1.69e-10	9.11e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
LUAD	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-6.53	1.69e-10	9.11e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
LUAD	cis	rs8059260	0.866	rs12922318	ENSG00000274038.1	RP11-66H6.4	-6.53	1.7e-10	9.12e-08	-0.42	-0.29	Alcohol consumption over the past year;	chr16:10946769	chr16:11056556~11057034:+
LUAD	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
LUAD	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-6.53	1.7e-10	9.15e-08	-0.39	-0.29	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-6.53	1.7e-10	9.15e-08	-0.39	-0.29	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
LUAD	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	6.53	1.7e-10	9.15e-08	0.35	0.29	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
LUAD	cis	rs75422866	0.51	rs73104197	ENSG00000280054.1	RP1-197B17.7	6.53	1.7e-10	9.16e-08	0.64	0.29	Pneumonia;	chr12:47717273	chr12:47728151~47730598:-
LUAD	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
LUAD	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-6.53	1.71e-10	9.18e-08	-0.33	-0.29	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
LUAD	cis	rs2337406	0.587	rs10129888	ENSG00000211974.3	IGHV2-70	-6.53	1.71e-10	9.18e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106647421	chr14:106723574~106724093:-
LUAD	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	6.53	1.71e-10	9.19e-08	0.3	0.29	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
LUAD	cis	rs7017914	0.905	rs4434651	ENSG00000223220.1	Y_RNA	6.53	1.71e-10	9.21e-08	0.31	0.29	Bone mineral density;	chr8:71034952	chr8:70780914~70781008:-
LUAD	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-6.53	1.72e-10	9.22e-08	-0.21	-0.29	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
LUAD	cis	rs7646881	0.812	rs73015665	ENSG00000240207.5	RP11-379F4.4	-6.53	1.72e-10	9.23e-08	-0.37	-0.29	Tetralogy of Fallot;	chr3:158736145	chr3:158732263~158784070:+
LUAD	cis	rs755249	0.567	rs66531516	ENSG00000228060.1	RP11-69E11.8	-6.53	1.72e-10	9.23e-08	-0.29	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39565160~39573203:+
LUAD	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	6.53	1.72e-10	9.23e-08	0.24	0.29	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
LUAD	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	6.53	1.72e-10	9.23e-08	0.42	0.29	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
LUAD	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-6.53	1.72e-10	9.23e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
LUAD	cis	rs30380	0.69	rs2216752	ENSG00000248734.2	CTD-2260A17.1	-6.53	1.72e-10	9.24e-08	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96784777~96785999:+
LUAD	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-6.53	1.72e-10	9.25e-08	-0.29	-0.29	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
LUAD	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.25e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.25e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.25e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-6.53	1.72e-10	9.25e-08	-0.52	-0.29	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-6.53	1.72e-10	9.25e-08	-0.52	-0.29	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
LUAD	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-6.53	1.72e-10	9.26e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
LUAD	cis	rs11977715	0.538	rs10248407	ENSG00000233942.1	AC004012.1	-6.53	1.72e-10	9.26e-08	-0.35	-0.29	Middle childhood and early adolescence aggressive behavior;	chr7:95499441	chr7:95471835~95473998:+
LUAD	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	6.52	1.73e-10	9.31e-08	0.45	0.29	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
LUAD	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	6.52	1.74e-10	9.32e-08	0.34	0.29	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
LUAD	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	6.52	1.74e-10	9.33e-08	0.31	0.29	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
LUAD	cis	rs6504622	0.905	rs3851787	ENSG00000262879.4	RP11-156P1.3	6.52	1.74e-10	9.33e-08	0.34	0.29	Orofacial clefts;	chr17:46969616	chr17:46984045~47100323:-
LUAD	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	6.52	1.74e-10	9.34e-08	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
LUAD	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	6.52	1.74e-10	9.35e-08	0.34	0.29	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
LUAD	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	6.52	1.74e-10	9.35e-08	0.36	0.29	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.507	rs6701534	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174418612	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10798312	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174419089	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4652422	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174419501	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4233181	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174419697	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10489258	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174420447	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10798313	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174420995	chr1:174115300~174160004:-
LUAD	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	6.52	1.75e-10	9.37e-08	0.4	0.29	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
LUAD	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-6.52	1.75e-10	9.4e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	6.52	1.75e-10	9.4e-08	0.35	0.29	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
LUAD	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-6.52	1.75e-10	9.4e-08	-0.31	-0.29	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
LUAD	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-6.52	1.75e-10	9.4e-08	-0.33	-0.29	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
LUAD	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	6.52	1.75e-10	9.41e-08	0.33	0.29	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
LUAD	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	6.52	1.75e-10	9.41e-08	0.72	0.29	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
LUAD	cis	rs2303759	0.918	rs2288480	ENSG00000268686.1	AC010524.2	-6.52	1.76e-10	9.42e-08	-0.4	-0.29	Multiple sclerosis;	chr19:49363759	chr19:49368705~49388081:-
LUAD	cis	rs2303759	1	rs2303759	ENSG00000268686.1	AC010524.2	-6.52	1.76e-10	9.42e-08	-0.4	-0.29	Multiple sclerosis;	chr19:49365794	chr19:49368705~49388081:-
LUAD	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	6.52	1.76e-10	9.43e-08	0.36	0.29	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	6.52	1.76e-10	9.44e-08	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
LUAD	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	6.52	1.76e-10	9.45e-08	0.31	0.29	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
LUAD	cis	rs944289	0.562	rs860200	ENSG00000257826.1	RP11-116N8.4	-6.52	1.77e-10	9.47e-08	-0.3	-0.29	Thyroid cancer;	chr14:36057079	chr14:36061026~36067190:-
LUAD	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	6.52	1.77e-10	9.47e-08	0.24	0.29	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	6.52	1.77e-10	9.47e-08	0.24	0.29	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
LUAD	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
LUAD	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-6.52	1.77e-10	9.5e-08	-0.33	-0.28	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-6.52	1.77e-10	9.51e-08	-0.33	-0.28	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
LUAD	cis	rs891378	0.675	rs7543002	ENSG00000274245.1	RP11-357P18.2	-6.52	1.77e-10	9.51e-08	-0.36	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205496	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.785	rs7554219	ENSG00000274245.1	RP11-357P18.2	-6.52	1.77e-10	9.51e-08	-0.36	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205712	chr1:207372559~207373252:+
LUAD	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	6.52	1.78e-10	9.53e-08	0.36	0.28	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
LUAD	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-6.52	1.78e-10	9.55e-08	-0.36	-0.28	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
LUAD	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	6.52	1.79e-10	9.56e-08	0.31	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
LUAD	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	6.52	1.79e-10	9.58e-08	0.34	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
LUAD	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	6.52	1.79e-10	9.61e-08	0.38	0.28	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
LUAD	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-6.52	1.8e-10	9.62e-08	-0.39	-0.28	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
LUAD	cis	rs7246657	0.551	rs10419174	ENSG00000276846.1	CTD-3220F14.3	6.52	1.8e-10	9.62e-08	0.43	0.28	Coronary artery calcification;	chr19:37114439	chr19:37314868~37315620:-
LUAD	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	6.52	1.8e-10	9.62e-08	0.34	0.28	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
LUAD	cis	rs1167827	0.68	rs1167800	ENSG00000278416.1	PMS2L2	6.52	1.8e-10	9.63e-08	0.37	0.28	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75344015~75359550:-
LUAD	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-6.52	1.8e-10	9.65e-08	-0.31	-0.28	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
LUAD	cis	rs17684571	1	rs17684571	ENSG00000231441.1	RP11-472M19.2	6.52	1.8e-10	9.65e-08	0.39	0.28	Schizophrenia;	chr6:56710873	chr6:56844002~56864078:+
LUAD	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
LUAD	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
LUAD	cis	rs7115242	0.8	rs493134	ENSG00000280143.1	AP000892.6	6.52	1.81e-10	9.66e-08	0.44	0.28	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117204967~117210292:+
LUAD	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-6.52	1.81e-10	9.67e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
LUAD	cis	rs11096990	0.927	rs56009503	ENSG00000249207.1	RP11-360F5.1	6.52	1.81e-10	9.67e-08	0.32	0.28	Cognitive function;	chr4:39242642	chr4:39112677~39126818:-
LUAD	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-6.52	1.81e-10	9.67e-08	-0.39	-0.28	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	6.52	1.81e-10	9.69e-08	0.4	0.28	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
LUAD	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	6.52	1.81e-10	9.69e-08	0.37	0.28	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
LUAD	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-6.52	1.81e-10	9.69e-08	-0.33	-0.28	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
LUAD	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-6.52	1.81e-10	9.69e-08	-0.35	-0.28	Height;	chr11:118859432	chr11:118704607~118750263:+
LUAD	cis	rs11977715	0.521	rs6465466	ENSG00000233942.1	AC004012.1	-6.52	1.82e-10	9.71e-08	-0.35	-0.28	Middle childhood and early adolescence aggressive behavior;	chr7:95502275	chr7:95471835~95473998:+
LUAD	cis	rs8177876	0.915	rs1563072	ENSG00000261838.4	RP11-303E16.6	-6.52	1.82e-10	9.71e-08	-0.63	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095811	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.841	rs874437	ENSG00000261838.4	RP11-303E16.6	-6.52	1.82e-10	9.71e-08	-0.63	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095890	chr16:81069854~81076598:+
LUAD	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	6.52	1.82e-10	9.72e-08	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
LUAD	cis	rs11096990	0.964	rs7687651	ENSG00000249207.1	RP11-360F5.1	6.52	1.82e-10	9.73e-08	0.32	0.28	Cognitive function;	chr4:39243072	chr4:39112677~39126818:-
LUAD	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-6.52	1.82e-10	9.73e-08	-0.43	-0.28	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
LUAD	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-6.52	1.82e-10	9.74e-08	-0.52	-0.28	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
LUAD	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-6.52	1.83e-10	9.75e-08	-0.44	-0.28	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000206090.4	AP000350.7	6.52	1.83e-10	9.76e-08	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23939998~23942798:+
LUAD	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-6.52	1.83e-10	9.76e-08	-0.59	-0.28	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
LUAD	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-6.52	1.83e-10	9.78e-08	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
LUAD	cis	rs1823913	0.637	rs4853569	ENSG00000280083.1	RP11-317J9.1	6.52	1.83e-10	9.79e-08	0.34	0.28	Obesity-related traits;	chr2:191266970	chr2:191154118~191156070:-
LUAD	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	6.52	1.83e-10	9.8e-08	0.39	0.28	Depression;	chr6:28200948	chr6:28115628~28116551:+
LUAD	cis	rs11098499	0.566	rs17051356	ENSG00000248280.1	RP11-33B1.2	6.52	1.84e-10	9.81e-08	0.37	0.28	Corneal astigmatism;	chr4:119664153	chr4:119440561~119450157:-
LUAD	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	6.51	1.84e-10	9.81e-08	0.32	0.28	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	6.51	1.84e-10	9.81e-08	0.32	0.28	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	6.51	1.84e-10	9.81e-08	0.32	0.28	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
LUAD	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-6.51	1.84e-10	9.82e-08	-0.3	-0.28	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
LUAD	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	6.51	1.84e-10	9.82e-08	0.31	0.28	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs781156	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66848496~66858136:+
LUAD	cis	rs7017914	0.935	rs56289931	ENSG00000223220.1	Y_RNA	6.51	1.84e-10	9.83e-08	0.32	0.28	Bone mineral density;	chr8:70925519	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-6.51	1.84e-10	9.83e-08	-0.35	-0.28	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
LUAD	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-6.51	1.84e-10	9.83e-08	-0.36	-0.28	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
LUAD	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-6.51	1.84e-10	9.84e-08	-0.4	-0.28	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
LUAD	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-6.51	1.84e-10	9.85e-08	-0.35	-0.28	Height;	chr11:118856460	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-6.51	1.84e-10	9.85e-08	-0.35	-0.28	Height;	chr11:118856623	chr11:118704607~118750263:+
LUAD	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-6.51	1.84e-10	9.85e-08	-0.35	-0.28	Height;	chr11:118857611	chr11:118704607~118750263:+
LUAD	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-6.51	1.85e-10	9.85e-08	-0.32	-0.28	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
LUAD	cis	rs9595908	0.869	rs7337687	ENSG00000212293.1	SNORA16	-6.51	1.85e-10	9.86e-08	-0.3	-0.28	Body mass index;	chr13:32595560	chr13:32420390~32420516:-
LUAD	cis	rs2243480	1	rs781157	ENSG00000232546.1	RP11-458F8.1	-6.51	1.85e-10	9.86e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66013324	chr7:66848496~66858136:+
LUAD	cis	rs35955747	0.869	rs5753576	ENSG00000236132.1	CTA-440B3.1	-6.51	1.85e-10	9.87e-08	-0.31	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31361749	chr22:31816379~31817491:-
LUAD	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	6.51	1.86e-10	9.9e-08	0.64	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
LUAD	cis	rs13030978	0.505	rs72916554	ENSG00000227542.1	AC092614.2	6.51	1.86e-10	9.9e-08	0.36	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr2:191330532	chr2:191229165~191246172:-
LUAD	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-6.51	1.86e-10	9.94e-08	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
LUAD	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	6.51	1.86e-10	9.95e-08	0.5	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
LUAD	cis	rs6504622	0.818	rs28451958	ENSG00000262879.4	RP11-156P1.3	6.51	1.86e-10	9.95e-08	0.34	0.28	Orofacial clefts;	chr17:46968528	chr17:46984045~47100323:-
LUAD	cis	rs4141404	0.851	rs5997893	ENSG00000236132.1	CTA-440B3.1	6.51	1.87e-10	9.95e-08	0.34	0.28	Paclitaxel-induced neuropathy;	chr22:31160117	chr22:31816379~31817491:-
LUAD	cis	rs75422866	0.51	rs73105812	ENSG00000280054.1	RP1-197B17.7	6.51	1.87e-10	9.97e-08	0.64	0.28	Pneumonia;	chr12:47724404	chr12:47728151~47730598:-
LUAD	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-6.51	1.87e-10	9.99e-08	-0.36	-0.28	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
LUAD	cis	rs34526934	0.566	rs34028621	ENSG00000226363.3	HAGLROS	6.51	1.88e-10	1e-07	0.39	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176178051	chr2:176177717~176179008:+
LUAD	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	6.51	1.88e-10	1e-07	0.34	0.28	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
LUAD	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-6.51	1.88e-10	1e-07	-0.34	-0.28	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
LUAD	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-6.51	1.88e-10	1e-07	-0.21	-0.28	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
LUAD	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	6.51	1.88e-10	1e-07	0.36	0.28	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
LUAD	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-6.51	1.88e-10	1e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-6.51	1.88e-10	1e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
LUAD	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	6.51	1.88e-10	1e-07	0.36	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
LUAD	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	6.51	1.88e-10	1e-07	0.35	0.28	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	6.51	1.88e-10	1e-07	0.35	0.28	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
LUAD	cis	rs11118620	0.81	rs4587570	ENSG00000257551.1	HLX-AS1	6.51	1.9e-10	1.01e-07	0.35	0.28	Heart failure;	chr1:220860693	chr1:220832763~220880140:-
LUAD	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	6.51	1.9e-10	1.01e-07	0.28	0.28	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-6.51	1.9e-10	1.01e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
LUAD	cis	rs11096990	0.964	rs6831700	ENSG00000249207.1	RP11-360F5.1	-6.51	1.9e-10	1.01e-07	-0.31	-0.28	Cognitive function;	chr4:39255344	chr4:39112677~39126818:-
LUAD	cis	rs1707322	0.685	rs11211177	ENSG00000234329.1	RP11-767N6.2	6.51	1.91e-10	1.02e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45651039~45651826:-
LUAD	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	6.51	1.91e-10	1.02e-07	0.34	0.28	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
LUAD	cis	rs11846409	0.932	rs61233250	ENSG00000211974.3	IGHV2-70	-6.51	1.91e-10	1.02e-07	-0.35	-0.28	Rheumatic heart disease;	chr14:106634072	chr14:106723574~106724093:-
LUAD	cis	rs62025270	0.522	rs338519	ENSG00000202081.1	RNU6-1280P	-6.51	1.91e-10	1.02e-07	-0.35	-0.28	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85651522~85651628:-
LUAD	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
LUAD	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	6.51	1.91e-10	1.02e-07	0.32	0.28	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
LUAD	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-6.51	1.91e-10	1.02e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-6.51	1.91e-10	1.02e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
LUAD	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-6.51	1.91e-10	1.02e-07	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
LUAD	cis	rs516805	0.847	rs520867	ENSG00000279453.1	RP3-425C14.4	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122465501	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.961	rs693669	ENSG00000279453.1	RP3-425C14.4	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122465690	chr6:122436789~122439223:-
LUAD	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-6.51	1.91e-10	1.02e-07	-0.34	-0.28	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-6.51	1.91e-10	1.02e-07	-0.34	-0.28	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
LUAD	cis	rs17301013	0.507	rs926349	ENSG00000227373.4	RP11-160H22.5	6.51	1.91e-10	1.02e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174368408	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	6.51	1.91e-10	1.02e-07	0.42	0.28	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
LUAD	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-6.51	1.91e-10	1.02e-07	-0.57	-0.28	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
LUAD	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	6.51	1.92e-10	1.02e-07	0.42	0.28	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000224373.3	IGHV4-59	6.51	1.92e-10	1.02e-07	0.17	0.28	Kawasaki disease;	chr14:106682199	chr14:106627249~106627825:-
LUAD	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	6.51	1.92e-10	1.02e-07	0.32	0.28	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	6.51	1.92e-10	1.02e-07	0.54	0.28	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	6.51	1.92e-10	1.02e-07	0.54	0.28	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	6.51	1.92e-10	1.02e-07	0.54	0.28	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
LUAD	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	6.51	1.92e-10	1.02e-07	0.4	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
LUAD	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-6.51	1.92e-10	1.02e-07	-0.29	-0.28	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
LUAD	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-6.51	1.92e-10	1.02e-07	-0.29	-0.28	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-6.51	1.92e-10	1.02e-07	-0.29	-0.28	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
LUAD	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-6.51	1.92e-10	1.02e-07	-0.29	-0.28	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
LUAD	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-6.51	1.93e-10	1.03e-07	-0.58	-0.28	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
LUAD	cis	rs10740039	0.846	rs10761529	ENSG00000254271.1	RP11-131N11.4	6.51	1.93e-10	1.03e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60627052	chr10:60734342~60741828:+
LUAD	cis	rs7246657	0.524	rs28542490	ENSG00000276846.1	CTD-3220F14.3	6.51	1.93e-10	1.03e-07	0.4	0.28	Coronary artery calcification;	chr19:36965682	chr19:37314868~37315620:-
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-6.51	1.93e-10	1.03e-07	-0.36	-0.28	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
LUAD	cis	rs7246657	0.509	rs10426093	ENSG00000276846.1	CTD-3220F14.3	6.51	1.93e-10	1.03e-07	0.43	0.28	Coronary artery calcification;	chr19:37124727	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
LUAD	cis	rs73219805	0.597	rs3824232	ENSG00000228451.3	SDAD1P1	-6.51	1.93e-10	1.03e-07	-0.48	-0.28	Schizophrenia;	chr8:26370083	chr8:26379259~26382953:-
LUAD	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	6.51	1.94e-10	1.03e-07	0.42	0.28	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-6.51	1.94e-10	1.03e-07	-0.28	-0.28	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
LUAD	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-6.51	1.94e-10	1.03e-07	-0.33	-0.28	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
LUAD	cis	rs62025270	0.547	rs386346	ENSG00000202081.1	RNU6-1280P	-6.51	1.95e-10	1.04e-07	-0.34	-0.28	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85651522~85651628:-
LUAD	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	6.5	1.95e-10	1.04e-07	0.36	0.28	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
LUAD	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	6.5	1.96e-10	1.04e-07	0.3	0.28	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
LUAD	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-6.5	1.96e-10	1.04e-07	-0.34	-0.28	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
LUAD	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-6.5	1.96e-10	1.04e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
LUAD	cis	rs465969	1	rs34382476	ENSG00000255389.1	C6orf3	-6.5	1.96e-10	1.04e-07	-0.62	-0.28	Psoriasis;	chr6:111423551	chr6:111599875~111602295:+
LUAD	cis	rs9834970	0.588	rs28522146	ENSG00000234073.1	AC011816.1	-6.5	1.96e-10	1.04e-07	-0.31	-0.28	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36865331	chr3:36880184~36880729:-
LUAD	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-6.5	1.96e-10	1.04e-07	-0.38	-0.28	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
LUAD	cis	rs1823913	1	rs12623832	ENSG00000230611.1	HMGB1P27	6.5	1.96e-10	1.04e-07	0.34	0.28	Obesity-related traits;	chr2:191260918	chr2:191174233~191174835:+
LUAD	cis	rs7246657	0.525	rs10401417	ENSG00000276846.1	CTD-3220F14.3	6.5	1.97e-10	1.05e-07	0.42	0.28	Coronary artery calcification;	chr19:36976638	chr19:37314868~37315620:-
LUAD	cis	rs10740039	0.732	rs10160182	ENSG00000254271.1	RP11-131N11.4	6.5	1.97e-10	1.05e-07	0.33	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602693	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.768	rs10159993	ENSG00000254271.1	RP11-131N11.4	6.5	1.97e-10	1.05e-07	0.33	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602788	chr10:60734342~60741828:+
LUAD	cis	rs7567389	0.504	rs2069898	ENSG00000236682.1	AC068282.3	-6.5	1.97e-10	1.05e-07	-0.37	-0.28	Self-rated health;	chr2:127416651	chr2:127389130~127400580:+
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000224373.3	IGHV4-59	6.5	1.97e-10	1.05e-07	0.17	0.28	Kawasaki disease;	chr14:106782219	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000224373.3	IGHV4-59	6.5	1.97e-10	1.05e-07	0.17	0.28	Kawasaki disease;	chr14:106782337	chr14:106627249~106627825:-
LUAD	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-6.5	1.97e-10	1.05e-07	-0.42	-0.28	Depression;	chr6:27871968	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	6.5	1.97e-10	1.05e-07	0.43	0.28	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	6.5	1.97e-10	1.05e-07	0.31	0.28	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
LUAD	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-6.5	1.97e-10	1.05e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
LUAD	cis	rs7567389	0.502	rs2069919	ENSG00000236682.1	AC068282.3	-6.5	1.97e-10	1.05e-07	-0.37	-0.28	Self-rated health;	chr2:127421977	chr2:127389130~127400580:+
LUAD	cis	rs3002142	0.57	rs3008633	ENSG00000272750.1	RP11-378J18.8	-6.5	1.97e-10	1.05e-07	-0.39	-0.28	LDL peak particle diameter (total fat intake interaction);	chr1:222671498	chr1:222658867~222661512:-
LUAD	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	6.5	1.98e-10	1.05e-07	0.32	0.28	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
LUAD	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	6.5	1.98e-10	1.05e-07	0.29	0.28	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
LUAD	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	6.5	1.98e-10	1.05e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
LUAD	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-6.5	1.99e-10	1.06e-07	-0.35	-0.28	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
LUAD	cis	rs62229266	1	rs62229266	ENSG00000214914.3	RPL23AP3	6.5	1.99e-10	1.06e-07	0.35	0.28	Mitral valve prolapse;	chr21:36087973	chr21:36016079~36016546:-
LUAD	cis	rs6558530	0.965	rs7460287	ENSG00000253982.1	CTD-2336O2.1	6.5	1.99e-10	1.06e-07	0.35	0.28	Systolic blood pressure;	chr8:1760108	chr8:1761990~1764502:-
LUAD	cis	rs891378	0.755	rs1019830	ENSG00000274245.1	RP11-357P18.2	-6.5	1.99e-10	1.06e-07	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236817	chr1:207372559~207373252:+
LUAD	cis	rs17301013	0.507	rs1754352	ENSG00000227373.4	RP11-160H22.5	6.5	1.99e-10	1.06e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174835984	chr1:174115300~174160004:-
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000224373.3	IGHV4-59	6.5	1.99e-10	1.06e-07	0.17	0.28	Kawasaki disease;	chr14:106781985	chr14:106627249~106627825:-
LUAD	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	6.5	2e-10	1.06e-07	0.31	0.28	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
LUAD	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	6.5	2e-10	1.06e-07	0.36	0.28	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
LUAD	cis	rs7017914	0.967	rs2933853	ENSG00000223220.1	Y_RNA	6.5	2e-10	1.06e-07	0.32	0.28	Bone mineral density;	chr8:70996987	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	6.5	2.01e-10	1.07e-07	0.36	0.28	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	6.5	2.01e-10	1.07e-07	0.36	0.28	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	6.5	2.01e-10	1.07e-07	0.36	0.28	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000224373.3	IGHV4-59	6.5	2.02e-10	1.07e-07	0.17	0.28	Kawasaki disease;	chr14:106776119	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000224373.3	IGHV4-59	6.5	2.02e-10	1.07e-07	0.17	0.28	Kawasaki disease;	chr14:106776442	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000224373.3	IGHV4-59	6.5	2.02e-10	1.07e-07	0.17	0.28	Kawasaki disease;	chr14:106776448	chr14:106627249~106627825:-
LUAD	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	6.5	2.02e-10	1.07e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
LUAD	cis	rs11846409	0.86	rs17112419	ENSG00000211974.3	IGHV2-70	-6.5	2.02e-10	1.07e-07	-0.35	-0.28	Rheumatic heart disease;	chr14:106633260	chr14:106723574~106724093:-
LUAD	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	6.5	2.03e-10	1.07e-07	0.35	0.28	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
LUAD	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	6.5	2.03e-10	1.08e-07	0.35	0.28	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
LUAD	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-6.5	2.03e-10	1.08e-07	-0.33	-0.28	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
LUAD	cis	rs2221433	1	rs4780948	ENSG00000260310.1	RP11-27M24.2	-6.5	2.03e-10	1.08e-07	-0.32	-0.28	Eating disorders;	chr16:10571652	chr16:10576499~10578183:-
LUAD	cis	rs75422866	0.51	rs74733564	ENSG00000280054.1	RP1-197B17.7	6.5	2.04e-10	1.08e-07	0.64	0.28	Pneumonia;	chr12:47724644	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.51	rs73105814	ENSG00000280054.1	RP1-197B17.7	6.5	2.04e-10	1.08e-07	0.64	0.28	Pneumonia;	chr12:47725817	chr12:47728151~47730598:-
LUAD	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	6.5	2.04e-10	1.08e-07	0.25	0.28	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
LUAD	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	6.5	2.04e-10	1.08e-07	0.24	0.28	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	6.5	2.04e-10	1.08e-07	0.24	0.28	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
LUAD	cis	rs367615	0.68	rs385728	ENSG00000249476.1	CTD-2587M2.1	-6.5	2.04e-10	1.08e-07	-0.36	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109630308	chr5:109237120~109326369:-
LUAD	cis	rs11846409	0.932	rs60659763	ENSG00000254174.1	IGHV1-12	6.5	2.05e-10	1.09e-07	0.25	0.28	Rheumatic heart disease;	chr14:106634172	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.932	rs57080270	ENSG00000254174.1	IGHV1-12	6.5	2.05e-10	1.09e-07	0.25	0.28	Rheumatic heart disease;	chr14:106634215	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.932	rs60917084	ENSG00000254174.1	IGHV1-12	6.5	2.05e-10	1.09e-07	0.25	0.28	Rheumatic heart disease;	chr14:106634621	chr14:106122420~106122709:-
LUAD	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-6.5	2.06e-10	1.09e-07	-0.36	-0.28	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
LUAD	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-6.5	2.06e-10	1.09e-07	-0.25	-0.28	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
LUAD	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-6.5	2.06e-10	1.09e-07	-0.25	-0.28	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
LUAD	cis	rs62025270	0.547	rs416916	ENSG00000202081.1	RNU6-1280P	-6.5	2.06e-10	1.09e-07	-0.35	-0.28	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85651522~85651628:-
LUAD	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	6.5	2.07e-10	1.09e-07	0.46	0.28	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
LUAD	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	6.5	2.07e-10	1.09e-07	0.43	0.28	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
LUAD	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-6.5	2.07e-10	1.1e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
LUAD	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-6.5	2.07e-10	1.1e-07	-0.39	-0.28	Depression;	chr6:28197321	chr6:28115628~28116551:+
LUAD	cis	rs9595908	0.931	rs9595630	ENSG00000212293.1	SNORA16	-6.5	2.07e-10	1.1e-07	-0.32	-0.28	Body mass index;	chr13:32491306	chr13:32420390~32420516:-
LUAD	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	6.5	2.07e-10	1.1e-07	0.36	0.28	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
LUAD	cis	rs9532669	0.926	rs4942007	ENSG00000168852.11	TPTE2P5	6.5	2.07e-10	1.1e-07	0.27	0.28	Cervical cancer;	chr13:40871887	chr13:40822296~40921749:-
LUAD	cis	rs7567389	0.534	rs2069904	ENSG00000236682.1	AC068282.3	-6.49	2.08e-10	1.1e-07	-0.37	-0.28	Self-rated health;	chr2:127418203	chr2:127389130~127400580:+
LUAD	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	6.49	2.08e-10	1.1e-07	0.34	0.28	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
LUAD	cis	rs7246657	0.55	rs10411176	ENSG00000276846.1	CTD-3220F14.3	6.49	2.08e-10	1.1e-07	0.46	0.28	Coronary artery calcification;	chr19:37196051	chr19:37314868~37315620:-
LUAD	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-6.49	2.08e-10	1.1e-07	-0.44	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
LUAD	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-6.49	2.08e-10	1.1e-07	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
LUAD	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-6.49	2.08e-10	1.1e-07	-0.32	-0.28	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-6.49	2.09e-10	1.11e-07	-0.35	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
LUAD	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	6.49	2.09e-10	1.11e-07	0.32	0.28	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
LUAD	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	6.49	2.1e-10	1.11e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
LUAD	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
LUAD	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	6.49	2.1e-10	1.11e-07	0.4	0.28	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
LUAD	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	6.49	2.1e-10	1.11e-07	0.37	0.28	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
LUAD	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	6.49	2.1e-10	1.11e-07	0.35	0.28	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
LUAD	cis	rs35955747	0.777	rs5997895	ENSG00000236132.1	CTA-440B3.1	6.49	2.11e-10	1.11e-07	0.31	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31170187	chr22:31816379~31817491:-
LUAD	cis	rs4723738	1	rs10240479	ENSG00000227191.5	TRGC2	-6.49	2.11e-10	1.11e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38181654	chr7:38239580~38368091:-
LUAD	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-6.49	2.11e-10	1.12e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
LUAD	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	6.49	2.11e-10	1.12e-07	0.31	0.28	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
LUAD	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	6.49	2.12e-10	1.12e-07	0.33	0.28	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
LUAD	cis	rs2842992	0.958	rs2758318	ENSG00000237927.1	RP3-393E18.2	-6.49	2.13e-10	1.13e-07	-0.39	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159648605	chr6:159586955~159589169:-
LUAD	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-6.49	2.13e-10	1.13e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
LUAD	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	6.49	2.14e-10	1.13e-07	0.34	0.28	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
LUAD	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	6.49	2.14e-10	1.13e-07	0.4	0.28	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
LUAD	cis	rs17684571	0.938	rs17751695	ENSG00000231441.1	RP11-472M19.2	6.49	2.14e-10	1.13e-07	0.42	0.28	Schizophrenia;	chr6:56695966	chr6:56844002~56864078:+
LUAD	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	6.49	2.14e-10	1.13e-07	0.39	0.28	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
LUAD	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-6.49	2.14e-10	1.13e-07	-0.3	-0.28	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
LUAD	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-6.49	2.14e-10	1.13e-07	-0.32	-0.28	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
LUAD	cis	rs516805	0.923	rs487487	ENSG00000279453.1	RP3-425C14.4	-6.49	2.15e-10	1.13e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122422357	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.961	rs556439	ENSG00000279453.1	RP3-425C14.4	-6.49	2.15e-10	1.13e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122423864	chr6:122436789~122439223:-
LUAD	cis	rs7017914	0.967	rs12679261	ENSG00000223220.1	Y_RNA	6.49	2.15e-10	1.13e-07	0.32	0.28	Bone mineral density;	chr8:70932414	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs10089583	ENSG00000223220.1	Y_RNA	6.49	2.15e-10	1.13e-07	0.32	0.28	Bone mineral density;	chr8:70937249	chr8:70780914~70781008:-
LUAD	cis	rs2337406	0.587	rs10139664	ENSG00000211974.3	IGHV2-70	-6.49	2.15e-10	1.13e-07	-0.36	-0.28	Alzheimer's disease (late onset);	chr14:106647254	chr14:106723574~106724093:-
LUAD	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-6.49	2.15e-10	1.13e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
LUAD	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	6.49	2.15e-10	1.13e-07	0.37	0.28	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	6.49	2.15e-10	1.13e-07	0.37	0.28	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-6.49	2.15e-10	1.13e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
LUAD	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-6.49	2.15e-10	1.13e-07	-0.6	-0.28	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
LUAD	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	6.49	2.15e-10	1.13e-07	0.31	0.28	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
LUAD	cis	rs12439619	0.883	rs62012045	ENSG00000255769.6	GOLGA2P10	-6.49	2.15e-10	1.14e-07	-0.33	-0.28	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472993~82513950:-
LUAD	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	6.49	2.16e-10	1.14e-07	0.33	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
LUAD	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-6.49	2.17e-10	1.14e-07	-0.39	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
LUAD	cis	rs2765539	0.851	rs1409158	ENSG00000226172.2	RP4-712E4.1	6.49	2.17e-10	1.14e-07	0.36	0.28	Waist-hip ratio;	chr1:118996267	chr1:119000344~119001392:-
LUAD	cis	rs11089937	0.555	rs6001226	ENSG00000211639.2	IGLV4-60	6.49	2.17e-10	1.14e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22162199~22162681:+
LUAD	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	6.49	2.17e-10	1.15e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
LUAD	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-6.49	2.17e-10	1.15e-07	-0.34	-0.28	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
LUAD	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	6.49	2.18e-10	1.15e-07	0.25	0.28	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
LUAD	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-6.49	2.18e-10	1.15e-07	-0.3	-0.28	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
LUAD	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	6.49	2.18e-10	1.15e-07	0.29	0.28	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
LUAD	cis	rs12439619	0.921	rs56042848	ENSG00000255769.6	GOLGA2P10	-6.49	2.18e-10	1.15e-07	-0.33	-0.28	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472993~82513950:-
LUAD	cis	rs62025270	0.547	rs338536	ENSG00000202081.1	RNU6-1280P	-6.49	2.18e-10	1.15e-07	-0.34	-0.28	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85651522~85651628:-
LUAD	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	6.49	2.19e-10	1.15e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
LUAD	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-6.49	2.19e-10	1.15e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
LUAD	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	6.49	2.19e-10	1.15e-07	0.36	0.28	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
LUAD	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	6.49	2.19e-10	1.15e-07	0.43	0.28	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
LUAD	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
LUAD	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-6.49	2.19e-10	1.15e-07	-0.45	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
LUAD	cis	rs35740288	0.77	rs12906580	ENSG00000202081.1	RNU6-1280P	-6.49	2.2e-10	1.16e-07	-0.34	-0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612056	chr15:85651522~85651628:-
LUAD	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	6.49	2.2e-10	1.16e-07	0.6	0.28	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
LUAD	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-6.49	2.2e-10	1.16e-07	-0.29	-0.28	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
LUAD	cis	rs7017914	0.967	rs2732090	ENSG00000223220.1	Y_RNA	-6.49	2.2e-10	1.16e-07	-0.31	-0.28	Bone mineral density;	chr8:71006022	chr8:70780914~70781008:-
LUAD	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	6.49	2.2e-10	1.16e-07	0.35	0.28	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
LUAD	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	6.49	2.2e-10	1.16e-07	0.39	0.28	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
LUAD	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	6.49	2.2e-10	1.16e-07	0.32	0.28	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
LUAD	cis	rs6558530	0.931	rs4639549	ENSG00000253982.1	CTD-2336O2.1	6.49	2.2e-10	1.16e-07	0.35	0.28	Systolic blood pressure;	chr8:1759878	chr8:1761990~1764502:-
LUAD	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-6.48	2.21e-10	1.16e-07	-0.35	-0.28	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
LUAD	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	6.48	2.21e-10	1.16e-07	0.41	0.28	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
LUAD	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	6.48	2.21e-10	1.16e-07	0.56	0.28	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
LUAD	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	6.48	2.21e-10	1.16e-07	0.41	0.28	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
LUAD	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	6.48	2.21e-10	1.17e-07	0.35	0.28	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	6.48	2.21e-10	1.17e-07	0.35	0.28	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
LUAD	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-6.48	2.21e-10	1.17e-07	-0.31	-0.28	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
LUAD	cis	rs227932	0.764	rs6461725	ENSG00000234286.1	AC006026.13	-6.48	2.21e-10	1.17e-07	-0.48	-0.28	Schizophrenia;	chr7:23690555	chr7:23680195~23680786:-
LUAD	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-6.48	2.22e-10	1.17e-07	-0.31	-0.28	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-6.48	2.22e-10	1.17e-07	-0.31	-0.28	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
LUAD	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-6.48	2.22e-10	1.17e-07	-0.3	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
LUAD	cis	rs17301013	0.507	rs2860955	ENSG00000227373.4	RP11-160H22.5	-6.48	2.22e-10	1.17e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174391380	chr1:174115300~174160004:-
LUAD	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-6.48	2.22e-10	1.17e-07	-0.34	-0.28	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
LUAD	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	6.48	2.22e-10	1.17e-07	0.35	0.28	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs1723267	ENSG00000232546.1	RP11-458F8.1	-6.48	2.22e-10	1.17e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66008327	chr7:66848496~66858136:+
LUAD	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-6.48	2.22e-10	1.17e-07	-0.21	-0.28	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
LUAD	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-6.48	2.22e-10	1.17e-07	-0.21	-0.28	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
LUAD	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	6.48	2.23e-10	1.17e-07	0.52	0.28	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
LUAD	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-6.48	2.23e-10	1.17e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
LUAD	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-6.48	2.23e-10	1.18e-07	-0.34	-0.28	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
LUAD	cis	rs2842992	1	rs2842992	ENSG00000237927.1	RP3-393E18.2	-6.48	2.23e-10	1.18e-07	-0.39	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159650127	chr6:159586955~159589169:-
LUAD	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-6.48	2.24e-10	1.18e-07	-0.54	-0.28	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
LUAD	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	6.48	2.24e-10	1.18e-07	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
LUAD	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-6.48	2.24e-10	1.18e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
LUAD	cis	rs853679	0.599	rs13193295	ENSG00000204709.4	LINC01556	6.48	2.24e-10	1.18e-07	0.62	0.28	Depression;	chr6:28035450	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	6.48	2.25e-10	1.18e-07	0.36	0.28	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
LUAD	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-6.48	2.26e-10	1.19e-07	-0.34	-0.28	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
LUAD	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	6.48	2.26e-10	1.19e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
LUAD	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	6.48	2.26e-10	1.19e-07	0.41	0.28	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-6.48	2.27e-10	1.19e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
LUAD	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-6.48	2.27e-10	1.19e-07	-0.3	-0.28	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
LUAD	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-6.48	2.27e-10	1.19e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
LUAD	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-6.48	2.27e-10	1.2e-07	-0.58	-0.28	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000224373.3	IGHV4-59	6.48	2.28e-10	1.2e-07	0.17	0.28	Kawasaki disease;	chr14:106777494	chr14:106627249~106627825:-
LUAD	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	6.48	2.28e-10	1.2e-07	0.28	0.28	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000224373.3	IGHV4-59	6.48	2.28e-10	1.2e-07	0.17	0.28	Kawasaki disease;	chr14:106778866	chr14:106627249~106627825:-
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-6.48	2.28e-10	1.2e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
LUAD	cis	rs7017914	0.652	rs441890	ENSG00000223220.1	Y_RNA	6.48	2.28e-10	1.2e-07	0.31	0.28	Bone mineral density;	chr8:70652432	chr8:70780914~70781008:-
LUAD	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-6.48	2.29e-10	1.2e-07	-0.29	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
LUAD	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	6.48	2.29e-10	1.2e-07	0.41	0.28	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-6.48	2.29e-10	1.2e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
LUAD	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	6.48	2.29e-10	1.2e-07	0.24	0.28	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
LUAD	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	6.48	2.29e-10	1.2e-07	0.32	0.28	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	6.48	2.29e-10	1.2e-07	0.32	0.28	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
LUAD	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	6.48	2.29e-10	1.2e-07	0.62	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
LUAD	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-6.48	2.29e-10	1.21e-07	-0.36	-0.28	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
LUAD	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	6.48	2.29e-10	1.21e-07	0.32	0.28	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
LUAD	cis	rs4803480	0.542	rs7255742	ENSG00000270164.1	LINC01480	-6.48	2.3e-10	1.21e-07	-0.25	-0.28	Schizophrenia;	chr19:41543459	chr19:41535183~41536904:+
LUAD	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-6.48	2.3e-10	1.21e-07	-0.4	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000280411.1	IGHV1-69-2	-6.48	2.3e-10	1.21e-07	-0.21	-0.28	Kawasaki disease;	chr14:106787239	chr14:106762092~106762588:-
LUAD	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	6.48	2.31e-10	1.21e-07	0.31	0.28	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
LUAD	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-6.48	2.31e-10	1.21e-07	-0.3	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
LUAD	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-6.48	2.31e-10	1.21e-07	-0.3	-0.28	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
LUAD	cis	rs7674212	0.531	rs4699048	ENSG00000251288.2	RP11-10L12.2	-6.48	2.31e-10	1.21e-07	-0.36	-0.28	Type 2 diabetes;	chr4:103005570	chr4:102751401~102752641:+
LUAD	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	6.48	2.31e-10	1.21e-07	0.36	0.28	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
LUAD	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	6.48	2.31e-10	1.21e-07	0.32	0.28	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
LUAD	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-6.48	2.31e-10	1.21e-07	-0.38	-0.28	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
LUAD	cis	rs7688540	0.76	rs12506250	ENSG00000275426.1	CH17-262A2.1	6.48	2.31e-10	1.21e-07	0.35	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:149738~150317:+
LUAD	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-6.48	2.31e-10	1.22e-07	-0.38	-0.28	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
LUAD	cis	rs9928842	0.941	rs8057145	ENSG00000280152.1	RP11-331F4.5	6.48	2.32e-10	1.22e-07	0.32	0.28	Alcoholic chronic pancreatitis;	chr16:75222353	chr16:75245994~75250077:-
LUAD	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	6.48	2.32e-10	1.22e-07	0.39	0.28	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
LUAD	cis	rs7927592	0.83	rs11228240	ENSG00000212093.1	AP000807.1	6.48	2.32e-10	1.22e-07	0.32	0.28	Total body bone mineral density;	chr11:68450822	chr11:68506083~68506166:-
LUAD	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	6.48	2.32e-10	1.22e-07	0.33	0.28	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
LUAD	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	6.48	2.32e-10	1.22e-07	0.34	0.28	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
LUAD	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-6.48	2.33e-10	1.22e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
LUAD	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	6.48	2.33e-10	1.22e-07	0.42	0.28	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
LUAD	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-6.48	2.33e-10	1.22e-07	-0.45	-0.28	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
LUAD	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-6.48	2.33e-10	1.23e-07	-0.35	-0.28	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-6.48	2.33e-10	1.23e-07	-0.35	-0.28	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-6.48	2.33e-10	1.23e-07	-0.35	-0.28	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-6.48	2.33e-10	1.23e-07	-0.35	-0.28	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
LUAD	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-6.48	2.34e-10	1.23e-07	-0.54	-0.28	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
LUAD	cis	rs7626444	0.625	rs2948170	ENSG00000272359.1	U4	-6.48	2.34e-10	1.23e-07	-0.32	-0.28	Monocyte count;	chr3:196765660	chr3:196747192~196747324:-
LUAD	cis	rs7246657	0.551	rs4806413	ENSG00000276846.1	CTD-3220F14.3	6.48	2.34e-10	1.23e-07	0.43	0.28	Coronary artery calcification;	chr19:37126814	chr19:37314868~37315620:-
LUAD	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-6.48	2.34e-10	1.23e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
LUAD	cis	rs2911132	1	rs2911132	ENSG00000248734.2	CTD-2260A17.1	6.48	2.34e-10	1.23e-07	0.29	0.28	Urate levels (BMI interaction);	chr5:96851285	chr5:96784777~96785999:+
LUAD	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	6.47	2.34e-10	1.23e-07	0.35	0.28	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000224373.3	IGHV4-59	6.47	2.35e-10	1.23e-07	0.17	0.28	Kawasaki disease;	chr14:106777987	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000224373.3	IGHV4-59	6.47	2.35e-10	1.23e-07	0.17	0.28	Kawasaki disease;	chr14:106777997	chr14:106627249~106627825:-
LUAD	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-6.47	2.35e-10	1.23e-07	-0.34	-0.28	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
LUAD	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-6.47	2.36e-10	1.24e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
LUAD	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	6.47	2.36e-10	1.24e-07	0.58	0.28	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	6.47	2.36e-10	1.24e-07	0.58	0.28	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	6.47	2.36e-10	1.24e-07	0.58	0.28	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	6.47	2.36e-10	1.24e-07	0.58	0.28	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
LUAD	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	6.47	2.36e-10	1.24e-07	0.36	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	6.47	2.36e-10	1.24e-07	0.36	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	6.47	2.36e-10	1.24e-07	0.36	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
LUAD	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	6.47	2.36e-10	1.24e-07	0.41	0.28	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
LUAD	cis	rs7688540	0.8	rs11723492	ENSG00000275426.1	CH17-262A2.1	6.47	2.36e-10	1.24e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:149738~150317:+
LUAD	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	6.47	2.37e-10	1.24e-07	0.35	0.28	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	6.47	2.37e-10	1.24e-07	0.35	0.28	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
LUAD	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-6.47	2.37e-10	1.24e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
LUAD	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	6.47	2.37e-10	1.24e-07	0.4	0.28	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
LUAD	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	6.47	2.37e-10	1.24e-07	0.39	0.28	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
LUAD	cis	rs853679	0.628	rs9368560	ENSG00000204709.4	LINC01556	6.47	2.37e-10	1.24e-07	0.41	0.28	Depression;	chr6:28192182	chr6:28943877~28944537:+
LUAD	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	6.47	2.37e-10	1.24e-07	0.27	0.28	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
LUAD	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	6.47	2.37e-10	1.24e-07	0.36	0.28	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
LUAD	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	6.47	2.37e-10	1.24e-07	0.36	0.28	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
LUAD	cis	rs4723738	0.935	rs10233340	ENSG00000227191.5	TRGC2	-6.47	2.37e-10	1.24e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38183679	chr7:38239580~38368091:-
LUAD	cis	rs4723738	1	rs35997004	ENSG00000227191.5	TRGC2	-6.47	2.37e-10	1.24e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38186081	chr7:38239580~38368091:-
LUAD	cis	rs4723738	1	rs11766312	ENSG00000227191.5	TRGC2	-6.47	2.37e-10	1.24e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38187990	chr7:38239580~38368091:-
LUAD	cis	rs4723738	1	rs10951552	ENSG00000227191.5	TRGC2	-6.47	2.37e-10	1.24e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38190180	chr7:38239580~38368091:-
LUAD	cis	rs1823913	1	rs1840377	ENSG00000230611.1	HMGB1P27	6.47	2.37e-10	1.24e-07	0.34	0.28	Obesity-related traits;	chr2:191257992	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs4853564	ENSG00000230611.1	HMGB1P27	6.47	2.37e-10	1.24e-07	0.34	0.28	Obesity-related traits;	chr2:191258939	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs4853565	ENSG00000230611.1	HMGB1P27	6.47	2.37e-10	1.24e-07	0.34	0.28	Obesity-related traits;	chr2:191259020	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs4853462	ENSG00000230611.1	HMGB1P27	6.47	2.37e-10	1.24e-07	0.34	0.28	Obesity-related traits;	chr2:191259078	chr2:191174233~191174835:+
LUAD	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	6.47	2.38e-10	1.25e-07	0.32	0.28	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
LUAD	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-6.47	2.38e-10	1.25e-07	-0.29	-0.28	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
LUAD	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-6.47	2.39e-10	1.25e-07	-0.34	-0.28	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
LUAD	cis	rs2734839	0.927	rs2734837	ENSG00000270179.1	RP11-159N11.4	-6.47	2.39e-10	1.25e-07	-0.29	-0.28	Information processing speed;	chr11:113416107	chr11:113368478~113369117:+
LUAD	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.39e-10	1.25e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.39e-10	1.25e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
LUAD	cis	rs8177876	0.915	rs73597252	ENSG00000261838.4	RP11-303E16.6	6.47	2.39e-10	1.25e-07	0.68	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81069854~81076598:+
LUAD	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	6.47	2.39e-10	1.25e-07	0.42	0.28	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
LUAD	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	6.47	2.39e-10	1.25e-07	0.31	0.28	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
LUAD	cis	rs6504622	0.902	rs1052586	ENSG00000262879.4	RP11-156P1.3	-6.47	2.4e-10	1.26e-07	-0.33	-0.28	Orofacial clefts;	chr17:46941097	chr17:46984045~47100323:-
LUAD	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-6.47	2.4e-10	1.26e-07	-0.38	-0.28	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-6.47	2.4e-10	1.26e-07	-0.38	-0.28	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-6.47	2.4e-10	1.26e-07	-0.38	-0.28	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-6.47	2.4e-10	1.26e-07	-0.38	-0.28	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
LUAD	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-6.47	2.4e-10	1.26e-07	-0.44	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
LUAD	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-6.47	2.4e-10	1.26e-07	-0.32	-0.28	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
LUAD	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-6.47	2.4e-10	1.26e-07	-0.35	-0.28	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
LUAD	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-6.47	2.4e-10	1.26e-07	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
LUAD	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.41e-10	1.26e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
LUAD	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	6.47	2.41e-10	1.26e-07	0.29	0.28	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
LUAD	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-6.47	2.41e-10	1.26e-07	-0.43	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
LUAD	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	6.47	2.41e-10	1.26e-07	0.41	0.28	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
LUAD	cis	rs1707322	0.717	rs11211161	ENSG00000234329.1	RP11-767N6.2	6.47	2.41e-10	1.26e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs61784793	ENSG00000234329.1	RP11-767N6.2	6.47	2.41e-10	1.26e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45651039~45651826:-
LUAD	cis	rs7044106	0.762	rs3904197	ENSG00000238181.2	AHCYP2	-6.47	2.41e-10	1.26e-07	-0.37	-0.28	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120720673~120721972:+
LUAD	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	6.47	2.42e-10	1.27e-07	0.36	0.28	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
LUAD	cis	rs2734839	0.964	rs12798900	ENSG00000270179.1	RP11-159N11.4	-6.47	2.42e-10	1.27e-07	-0.29	-0.28	Information processing speed;	chr11:113428274	chr11:113368478~113369117:+
LUAD	cis	rs2734839	1	rs2734839	ENSG00000270179.1	RP11-159N11.4	-6.47	2.42e-10	1.27e-07	-0.29	-0.28	Information processing speed;	chr11:113415768	chr11:113368478~113369117:+
LUAD	cis	rs17301013	0.507	rs72713586	ENSG00000227373.4	RP11-160H22.5	6.47	2.42e-10	1.27e-07	0.44	0.28	Systemic lupus erythematosus;	chr1:174441265	chr1:174115300~174160004:-
LUAD	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-6.47	2.42e-10	1.27e-07	-0.27	-0.28	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
LUAD	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	6.47	2.42e-10	1.27e-07	0.41	0.28	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
LUAD	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-6.47	2.42e-10	1.27e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
LUAD	cis	rs5753618	0.555	rs9609302	ENSG00000236132.1	CTA-440B3.1	-6.47	2.42e-10	1.27e-07	-0.36	-0.28	Colorectal cancer;	chr22:31500001	chr22:31816379~31817491:-
LUAD	cis	rs7017914	0.934	rs6987313	ENSG00000223220.1	Y_RNA	6.47	2.43e-10	1.27e-07	0.32	0.28	Bone mineral density;	chr8:70658754	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs35580034	ENSG00000223220.1	Y_RNA	6.47	2.43e-10	1.27e-07	0.32	0.28	Bone mineral density;	chr8:70659838	chr8:70780914~70781008:-
LUAD	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	6.47	2.43e-10	1.27e-07	0.36	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
LUAD	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	6.47	2.43e-10	1.27e-07	0.44	0.28	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
LUAD	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	6.47	2.43e-10	1.27e-07	0.44	0.28	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
LUAD	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	6.47	2.43e-10	1.27e-07	0.32	0.28	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
LUAD	cis	rs10740039	0.81	rs10159646	ENSG00000254271.1	RP11-131N11.4	6.47	2.43e-10	1.27e-07	0.33	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60620366	chr10:60734342~60741828:+
LUAD	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	6.47	2.43e-10	1.27e-07	0.35	0.28	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
LUAD	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-6.47	2.44e-10	1.27e-07	-0.45	-0.28	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
LUAD	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	6.47	2.44e-10	1.27e-07	0.32	0.28	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	6.47	2.44e-10	1.28e-07	0.36	0.28	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	6.47	2.44e-10	1.28e-07	0.36	0.28	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000206090.4	AP000350.7	6.47	2.44e-10	1.28e-07	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23939998~23942798:+
LUAD	cis	rs2734839	0.964	rs11214605	ENSG00000270179.1	RP11-159N11.4	-6.47	2.44e-10	1.28e-07	-0.29	-0.28	Information processing speed;	chr11:113429879	chr11:113368478~113369117:+
LUAD	cis	rs516805	0.923	rs491171	ENSG00000279453.1	RP3-425C14.4	-6.47	2.45e-10	1.28e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122408021	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.923	rs556675	ENSG00000279453.1	RP3-425C14.4	-6.47	2.45e-10	1.28e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122408083	chr6:122436789~122439223:-
LUAD	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	6.47	2.45e-10	1.28e-07	0.36	0.28	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
LUAD	cis	rs7017914	0.902	rs7831792	ENSG00000223220.1	Y_RNA	6.47	2.45e-10	1.28e-07	0.32	0.28	Bone mineral density;	chr8:70653121	chr8:70780914~70781008:-
LUAD	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	6.47	2.46e-10	1.28e-07	0.47	0.28	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
LUAD	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-6.47	2.46e-10	1.29e-07	-0.36	-0.28	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
LUAD	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	6.47	2.46e-10	1.29e-07	0.41	0.28	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
LUAD	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-6.47	2.47e-10	1.29e-07	-0.33	-0.28	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
LUAD	cis	rs227932	0.618	rs3807888	ENSG00000234286.1	AC006026.13	-6.47	2.47e-10	1.29e-07	-0.49	-0.28	Schizophrenia;	chr7:23710213	chr7:23680195~23680786:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000232546.1	RP11-458F8.1	-6.47	2.47e-10	1.29e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66030474	chr7:66848496~66858136:+
LUAD	cis	rs1823913	0.637	rs6741454	ENSG00000280083.1	RP11-317J9.1	6.47	2.47e-10	1.29e-07	0.34	0.28	Obesity-related traits;	chr2:191269520	chr2:191154118~191156070:-
LUAD	cis	rs6504950	0.579	rs17712917	ENSG00000275710.1	RP11-257O5.4	6.47	2.47e-10	1.29e-07	0.4	0.28	Breast cancer;	chr17:55194004	chr17:54964474~54964679:+
LUAD	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-6.47	2.48e-10	1.29e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
LUAD	cis	rs1707322	0.752	rs6678444	ENSG00000234329.1	RP11-767N6.2	6.47	2.48e-10	1.29e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45651039~45651826:-
LUAD	cis	rs2337406	0.587	rs916547	ENSG00000254174.1	IGHV1-12	6.47	2.48e-10	1.3e-07	0.25	0.28	Alzheimer's disease (late onset);	chr14:106646735	chr14:106122420~106122709:-
LUAD	cis	rs7017914	0.902	rs34882924	ENSG00000223220.1	Y_RNA	6.47	2.48e-10	1.3e-07	0.32	0.28	Bone mineral density;	chr8:70654073	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000224373.3	IGHV4-59	6.47	2.48e-10	1.3e-07	0.17	0.28	Kawasaki disease;	chr14:106777510	chr14:106627249~106627825:-
LUAD	cis	rs5753618	0.554	rs5753648	ENSG00000236132.1	CTA-440B3.1	-6.47	2.48e-10	1.3e-07	-0.37	-0.28	Colorectal cancer;	chr22:31483479	chr22:31816379~31817491:-
LUAD	cis	rs1707322	0.721	rs10890346	ENSG00000234329.1	RP11-767N6.2	-6.47	2.48e-10	1.3e-07	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45651039~45651826:-
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000224373.3	IGHV4-59	6.47	2.49e-10	1.3e-07	0.17	0.28	Kawasaki disease;	chr14:106792798	chr14:106627249~106627825:-
LUAD	cis	rs11977715	0.521	rs1476516	ENSG00000233942.1	AC004012.1	-6.47	2.49e-10	1.3e-07	-0.35	-0.28	Middle childhood and early adolescence aggressive behavior;	chr7:95489898	chr7:95471835~95473998:+
LUAD	cis	rs853679	0.607	rs13207345	ENSG00000204709.4	LINC01556	6.47	2.49e-10	1.3e-07	0.61	0.28	Depression;	chr6:28297795	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs72854513	ENSG00000204709.4	LINC01556	6.47	2.49e-10	1.3e-07	0.61	0.28	Depression;	chr6:28298177	chr6:28943877~28944537:+
LUAD	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	6.46	2.49e-10	1.3e-07	0.31	0.28	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	6.46	2.49e-10	1.3e-07	0.31	0.28	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
LUAD	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	6.46	2.49e-10	1.3e-07	0.34	0.28	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
LUAD	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	6.46	2.49e-10	1.3e-07	0.38	0.28	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
LUAD	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	6.46	2.49e-10	1.3e-07	0.31	0.28	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
LUAD	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	6.46	2.5e-10	1.3e-07	0.32	0.28	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
LUAD	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-6.46	2.5e-10	1.3e-07	-0.37	-0.28	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
LUAD	cis	rs2243480	1	rs2462569	ENSG00000232546.1	RP11-458F8.1	6.46	2.5e-10	1.3e-07	0.36	0.28	Diabetic kidney disease;	chr7:66009859	chr7:66848496~66858136:+
LUAD	cis	rs11977715	0.538	rs43067	ENSG00000233942.1	AC004012.1	-6.46	2.5e-10	1.3e-07	-0.35	-0.28	Middle childhood and early adolescence aggressive behavior;	chr7:95485392	chr7:95471835~95473998:+
LUAD	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-6.46	2.5e-10	1.31e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
LUAD	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-6.46	2.5e-10	1.31e-07	-0.31	-0.28	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
LUAD	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	6.46	2.5e-10	1.31e-07	0.36	0.28	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
LUAD	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-6.46	2.5e-10	1.31e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
LUAD	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	6.46	2.5e-10	1.31e-07	0.31	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
LUAD	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-6.46	2.51e-10	1.31e-07	-0.36	-0.28	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-6.46	2.51e-10	1.31e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
LUAD	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	6.46	2.51e-10	1.31e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.637	rs2356354	ENSG00000280083.1	RP11-317J9.1	6.46	2.52e-10	1.31e-07	0.34	0.28	Obesity-related traits;	chr2:191270970	chr2:191154118~191156070:-
LUAD	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	6.46	2.52e-10	1.31e-07	0.38	0.28	Depression;	chr6:28205232	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	6.46	2.52e-10	1.31e-07	0.32	0.28	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
LUAD	cis	rs12468226	1	rs7587234	ENSG00000226261.1	AC064836.3	6.46	2.53e-10	1.32e-07	0.47	0.28	Urate levels;	chr2:202351699	chr2:202336024~202336727:-
LUAD	cis	rs227932	0.764	rs4722246	ENSG00000234286.1	AC006026.13	6.46	2.53e-10	1.32e-07	0.49	0.28	Schizophrenia;	chr7:23682359	chr7:23680195~23680786:-
LUAD	cis	rs227932	0.614	rs12700458	ENSG00000234286.1	AC006026.13	6.46	2.53e-10	1.32e-07	0.49	0.28	Schizophrenia;	chr7:23682525	chr7:23680195~23680786:-
LUAD	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-6.46	2.53e-10	1.32e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
LUAD	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	6.46	2.53e-10	1.32e-07	0.24	0.28	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
LUAD	cis	rs8059260	0.668	rs6498152	ENSG00000274038.1	RP11-66H6.4	-6.46	2.53e-10	1.32e-07	-0.39	-0.28	Alcohol consumption over the past year;	chr16:11030590	chr16:11056556~11057034:+
LUAD	cis	rs950169	0.544	rs12913702	ENSG00000225151.9	GOLGA2P7	-6.46	2.54e-10	1.32e-07	-0.39	-0.28	Schizophrenia;	chr15:84609953	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.509	rs71395455	ENSG00000225151.9	GOLGA2P7	-6.46	2.54e-10	1.32e-07	-0.39	-0.28	Schizophrenia;	chr15:84610573	chr15:84199311~84230136:-
LUAD	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-6.46	2.54e-10	1.32e-07	-0.29	-0.28	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
LUAD	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	6.46	2.54e-10	1.32e-07	0.32	0.28	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000224373.3	IGHV4-59	6.46	2.54e-10	1.32e-07	0.17	0.28	Kawasaki disease;	chr14:106804049	chr14:106627249~106627825:-
LUAD	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-6.46	2.54e-10	1.32e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
LUAD	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	6.46	2.54e-10	1.33e-07	0.32	0.28	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
LUAD	cis	rs8177876	0.749	rs2278025	ENSG00000261838.4	RP11-303E16.6	-6.46	2.55e-10	1.33e-07	-0.56	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045636	chr16:81069854~81076598:+
LUAD	cis	rs1707322	0.662	rs11211160	ENSG00000234329.1	RP11-767N6.2	6.46	2.55e-10	1.33e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45651039~45651826:-
LUAD	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-6.46	2.55e-10	1.33e-07	-0.33	-0.28	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
LUAD	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	6.46	2.55e-10	1.33e-07	0.31	0.28	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
LUAD	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-6.46	2.55e-10	1.33e-07	-0.33	-0.28	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
LUAD	cis	rs12699921	0.632	rs11768866	ENSG00000279048.1	RP11-511H23.2	-6.46	2.56e-10	1.33e-07	-0.23	-0.28	Fibrinogen levels;	chr7:17925956	chr7:17940503~17942922:+
LUAD	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	6.46	2.56e-10	1.33e-07	0.37	0.28	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
LUAD	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-6.46	2.56e-10	1.33e-07	-0.35	-0.28	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
LUAD	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-6.46	2.56e-10	1.33e-07	-0.3	-0.28	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
LUAD	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	6.46	2.56e-10	1.33e-07	0.35	0.28	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	6.46	2.56e-10	1.34e-07	0.53	0.28	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	6.46	2.56e-10	1.34e-07	0.53	0.28	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
LUAD	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	6.46	2.57e-10	1.34e-07	0.43	0.28	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
LUAD	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	6.46	2.57e-10	1.34e-07	0.24	0.28	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	6.46	2.57e-10	1.34e-07	0.24	0.28	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
LUAD	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-6.46	2.57e-10	1.34e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
LUAD	cis	rs9506514	0.722	rs4769124	ENSG00000222726.1	RNU2-7P	6.46	2.57e-10	1.34e-07	0.32	0.28	Coronary artery calcification;	chr13:20652706	chr13:20612161~20612338:+
LUAD	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-6.46	2.57e-10	1.34e-07	-0.35	-0.28	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
LUAD	cis	rs755249	0.833	rs61779313	ENSG00000228060.1	RP11-69E11.8	-6.46	2.57e-10	1.34e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39565160~39573203:+
LUAD	cis	rs155076	1	rs658244	ENSG00000233325.3	MIPEPP3	6.46	2.58e-10	1.34e-07	0.45	0.28	White matter hyperintensity burden;	chr13:21276837	chr13:21298139~21306373:+
LUAD	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-6.46	2.58e-10	1.34e-07	-0.28	-0.28	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
LUAD	cis	rs1707322	0.752	rs4586014	ENSG00000234329.1	RP11-767N6.2	6.46	2.58e-10	1.35e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.648	rs4439382	ENSG00000234329.1	RP11-767N6.2	6.46	2.58e-10	1.35e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45651039~45651826:-
LUAD	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-6.46	2.58e-10	1.35e-07	-0.33	-0.28	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
LUAD	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-6.46	2.59e-10	1.35e-07	-0.28	-0.28	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
LUAD	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	6.46	2.59e-10	1.35e-07	0.32	0.28	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
LUAD	cis	rs3096299	0.838	rs3102376	ENSG00000274627.1	RP11-104N10.2	6.46	2.59e-10	1.35e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89516797~89522217:+
LUAD	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-6.46	2.59e-10	1.35e-07	-0.31	-0.28	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
LUAD	cis	rs9450351	0.744	rs9359674	ENSG00000203875.9	SNHG5	6.46	2.6e-10	1.35e-07	0.59	0.28	Interferon gamma-induced protein 10 levels;	chr6:85996191	chr6:85660950~85678736:-
LUAD	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	6.46	2.6e-10	1.35e-07	0.33	0.28	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
LUAD	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	6.46	2.6e-10	1.35e-07	0.43	0.28	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
LUAD	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	6.46	2.6e-10	1.35e-07	0.3	0.28	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
LUAD	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-6.46	2.6e-10	1.35e-07	-0.35	-0.28	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
LUAD	cis	rs7567389	0.504	rs41280570	ENSG00000236682.1	AC068282.3	-6.46	2.6e-10	1.35e-07	-0.37	-0.28	Self-rated health;	chr2:127418654	chr2:127389130~127400580:+
LUAD	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-6.46	2.6e-10	1.35e-07	-0.34	-0.28	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
LUAD	cis	rs17301013	0.507	rs7414200	ENSG00000227373.4	RP11-160H22.5	6.46	2.6e-10	1.35e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174569820	chr1:174115300~174160004:-
LUAD	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-6.46	2.6e-10	1.35e-07	-0.33	-0.28	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
LUAD	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	6.46	2.61e-10	1.36e-07	0.37	0.28	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	6.46	2.61e-10	1.36e-07	0.37	0.28	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
LUAD	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-6.46	2.61e-10	1.36e-07	-0.34	-0.28	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
LUAD	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-6.46	2.61e-10	1.36e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
LUAD	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	6.46	2.61e-10	1.36e-07	0.31	0.28	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	6.46	2.61e-10	1.36e-07	0.31	0.28	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	6.46	2.61e-10	1.36e-07	0.31	0.28	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
LUAD	cis	rs5753618	0.504	rs9609329	ENSG00000236132.1	CTA-440B3.1	-6.46	2.61e-10	1.36e-07	-0.35	-0.28	Colorectal cancer;	chr22:31570327	chr22:31816379~31817491:-
LUAD	cis	rs6772849	0.896	rs4557179	ENSG00000242551.2	POU5F1P6	-6.46	2.61e-10	1.36e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128647883	chr3:128674735~128677005:-
LUAD	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-6.46	2.61e-10	1.36e-07	-0.34	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-6.46	2.61e-10	1.36e-07	-0.34	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
LUAD	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	6.46	2.61e-10	1.36e-07	0.36	0.28	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	6.46	2.61e-10	1.36e-07	0.36	0.28	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	6.46	2.62e-10	1.36e-07	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	6.46	2.62e-10	1.36e-07	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
LUAD	cis	rs1823913	1	rs6749232	ENSG00000230611.1	HMGB1P27	6.46	2.62e-10	1.36e-07	0.34	0.28	Obesity-related traits;	chr2:191250326	chr2:191174233~191174835:+
LUAD	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	6.46	2.62e-10	1.36e-07	0.43	0.28	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
LUAD	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	6.46	2.62e-10	1.36e-07	0.43	0.28	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
LUAD	cis	rs4141404	0.787	rs11913992	ENSG00000236132.1	CTA-440B3.1	6.46	2.62e-10	1.36e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31189234	chr22:31816379~31817491:-
LUAD	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.62e-10	1.36e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
LUAD	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-6.46	2.62e-10	1.36e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
LUAD	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	6.46	2.63e-10	1.36e-07	0.35	0.28	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
LUAD	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-6.46	2.63e-10	1.37e-07	-0.37	-0.28	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
LUAD	cis	rs1707322	0.752	rs6662164	ENSG00000234329.1	RP11-767N6.2	6.46	2.63e-10	1.37e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45651039~45651826:-
LUAD	cis	rs73219805	0.597	rs71517887	ENSG00000228451.3	SDAD1P1	-6.46	2.63e-10	1.37e-07	-0.49	-0.28	Schizophrenia;	chr8:26374081	chr8:26379259~26382953:-
LUAD	cis	rs17684571	0.938	rs35619924	ENSG00000231441.1	RP11-472M19.2	6.46	2.64e-10	1.37e-07	0.4	0.28	Schizophrenia;	chr6:56695868	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs10498811	ENSG00000231441.1	RP11-472M19.2	6.46	2.64e-10	1.37e-07	0.4	0.28	Schizophrenia;	chr6:56696475	chr6:56844002~56864078:+
LUAD	cis	rs891378	0.785	rs6700846	ENSG00000274245.1	RP11-357P18.2	-6.46	2.64e-10	1.37e-07	-0.36	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228799	chr1:207372559~207373252:+
LUAD	cis	rs2243480	1	rs313813	ENSG00000232546.1	RP11-458F8.1	-6.46	2.64e-10	1.37e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66038513	chr7:66848496~66858136:+
LUAD	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	6.46	2.64e-10	1.37e-07	0.38	0.28	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-6.46	2.64e-10	1.37e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
LUAD	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	6.46	2.65e-10	1.38e-07	0.35	0.28	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	6.46	2.65e-10	1.38e-07	0.35	0.28	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
LUAD	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	6.45	2.65e-10	1.38e-07	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
LUAD	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	6.45	2.65e-10	1.38e-07	0.43	0.28	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.656	rs748455	ENSG00000225151.9	GOLGA2P7	-6.45	2.65e-10	1.38e-07	-0.39	-0.28	Schizophrenia;	chr15:84606344	chr15:84199311~84230136:-
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000206090.4	AP000350.7	6.45	2.65e-10	1.38e-07	0.33	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23939998~23942798:+
LUAD	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-6.45	2.66e-10	1.38e-07	-0.34	-0.28	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
LUAD	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-6.45	2.67e-10	1.39e-07	-0.29	-0.28	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
LUAD	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-6.45	2.67e-10	1.39e-07	-0.29	-0.28	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
LUAD	cis	rs17684571	0.938	rs13196211	ENSG00000231441.1	RP11-472M19.2	6.45	2.68e-10	1.39e-07	0.4	0.28	Schizophrenia;	chr6:56697697	chr6:56844002~56864078:+
LUAD	cis	rs17684571	1	rs5024547	ENSG00000231441.1	RP11-472M19.2	6.45	2.68e-10	1.39e-07	0.4	0.28	Schizophrenia;	chr6:56698295	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs13206849	ENSG00000231441.1	RP11-472M19.2	6.45	2.68e-10	1.39e-07	0.4	0.28	Schizophrenia;	chr6:56701823	chr6:56844002~56864078:+
LUAD	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	6.45	2.68e-10	1.39e-07	0.73	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.68e-10	1.39e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
LUAD	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	6.45	2.68e-10	1.39e-07	0.37	0.28	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
LUAD	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	6.45	2.68e-10	1.39e-07	0.32	0.28	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	6.45	2.68e-10	1.39e-07	0.32	0.28	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	6.45	2.68e-10	1.39e-07	0.32	0.28	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
LUAD	cis	rs9549367	0.789	rs6577034	ENSG00000269125.1	RP11-98F14.11	-6.45	2.68e-10	1.39e-07	-0.34	-0.28	Platelet distribution width;	chr13:113225586	chr13:113165002~113165183:-
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	6.45	2.69e-10	1.39e-07	0.29	0.28	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	6.45	2.69e-10	1.39e-07	0.34	0.28	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
LUAD	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	6.45	2.69e-10	1.4e-07	0.28	0.28	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
LUAD	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	6.45	2.69e-10	1.4e-07	0.28	0.28	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
LUAD	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-6.45	2.69e-10	1.4e-07	-0.32	-0.28	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
LUAD	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	6.45	2.69e-10	1.4e-07	0.41	0.28	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
LUAD	cis	rs2337406	0.587	rs2516889	ENSG00000211974.3	IGHV2-70	6.45	2.69e-10	1.4e-07	0.35	0.28	Alzheimer's disease (late onset);	chr14:106648903	chr14:106723574~106724093:-
LUAD	cis	rs13160562	0.666	rs26481	ENSG00000272109.1	CTD-2260A17.3	-6.45	2.7e-10	1.4e-07	-0.3	-0.28	Alcohol dependence;	chr5:96767648	chr5:96804353~96806105:+
LUAD	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	6.45	2.7e-10	1.4e-07	0.43	0.28	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
LUAD	cis	rs1823913	1	rs4853568	ENSG00000230611.1	HMGB1P27	6.45	2.7e-10	1.4e-07	0.34	0.28	Obesity-related traits;	chr2:191261464	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	6.45	2.71e-10	1.4e-07	0.33	0.28	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
LUAD	cis	rs10200159	0.793	rs12615063	ENSG00000272606.1	RP11-554J4.1	6.45	2.71e-10	1.4e-07	0.47	0.28	Vitiligo;	chr2:55680347	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.793	rs13420929	ENSG00000272606.1	RP11-554J4.1	6.45	2.71e-10	1.4e-07	0.47	0.28	Vitiligo;	chr2:55692185	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.793	rs7586115	ENSG00000272606.1	RP11-554J4.1	6.45	2.71e-10	1.4e-07	0.47	0.28	Vitiligo;	chr2:55692501	chr2:55617909~55618373:+
LUAD	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	6.45	2.71e-10	1.41e-07	0.43	0.28	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
LUAD	cis	rs9640161	0.658	rs74348353	ENSG00000261305.1	RP4-584D14.7	6.45	2.71e-10	1.41e-07	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150356566	chr7:150341771~150342607:+
LUAD	cis	rs4660456	0.504	rs2744805	ENSG00000237899.1	RP4-739H11.3	6.45	2.72e-10	1.41e-07	0.4	0.28	Platelet count;	chr1:40654827	chr1:40669089~40687588:-
LUAD	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-6.45	2.72e-10	1.41e-07	-0.35	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
LUAD	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	6.45	2.73e-10	1.41e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	6.45	2.73e-10	1.41e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
LUAD	cis	rs10740039	0.883	rs7068934	ENSG00000254271.1	RP11-131N11.4	6.45	2.74e-10	1.42e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636490	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10740038	ENSG00000254271.1	RP11-131N11.4	6.45	2.74e-10	1.42e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643479	chr10:60734342~60741828:+
LUAD	cis	rs1318937	1	rs3773469	ENSG00000224660.1	SH3BP5-AS1	6.45	2.74e-10	1.42e-07	0.22	0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15266733	chr3:15254184~15264493:+
LUAD	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-6.45	2.75e-10	1.42e-07	-0.34	-0.28	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
LUAD	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-6.45	2.75e-10	1.42e-07	-0.34	-0.28	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
LUAD	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	6.45	2.75e-10	1.42e-07	0.35	0.28	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
LUAD	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	6.45	2.75e-10	1.42e-07	0.35	0.28	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	6.45	2.75e-10	1.42e-07	0.35	0.28	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
LUAD	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	6.45	2.75e-10	1.43e-07	0.24	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
LUAD	cis	rs9640161	0.789	rs34728606	ENSG00000261305.1	RP4-584D14.7	6.45	2.75e-10	1.43e-07	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150357605	chr7:150341771~150342607:+
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-6.45	2.75e-10	1.43e-07	-0.29	-0.28	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
LUAD	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	6.45	2.76e-10	1.43e-07	0.41	0.28	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
LUAD	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	6.45	2.76e-10	1.43e-07	0.41	0.28	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
LUAD	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-6.45	2.76e-10	1.43e-07	-0.33	-0.28	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
LUAD	cis	rs9326248	0.559	rs476399	ENSG00000280143.1	AP000892.6	6.45	2.76e-10	1.43e-07	0.32	0.28	Blood protein levels;	chr11:116863012	chr11:117204967~117210292:+
LUAD	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-6.45	2.76e-10	1.43e-07	-0.33	-0.28	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
LUAD	cis	rs2243480	1	rs313807	ENSG00000232546.1	RP11-458F8.1	-6.45	2.76e-10	1.43e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66034494	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	6.45	2.77e-10	1.43e-07	0.36	0.28	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
LUAD	cis	rs367615	0.68	rs253247	ENSG00000249476.1	CTD-2587M2.1	6.45	2.77e-10	1.43e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109648265	chr5:109237120~109326369:-
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	6.45	2.77e-10	1.43e-07	0.28	0.28	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
LUAD	cis	rs2911132	1	rs2549803	ENSG00000248734.2	CTD-2260A17.1	6.45	2.78e-10	1.44e-07	0.3	0.28	Urate levels (BMI interaction);	chr5:96839226	chr5:96784777~96785999:+
LUAD	cis	rs7017914	0.934	rs2639921	ENSG00000223220.1	Y_RNA	6.45	2.78e-10	1.44e-07	0.31	0.28	Bone mineral density;	chr8:70962599	chr8:70780914~70781008:-
LUAD	cis	rs11096990	0.821	rs76235093	ENSG00000249207.1	RP11-360F5.1	6.45	2.78e-10	1.44e-07	0.32	0.28	Cognitive function;	chr4:39281157	chr4:39112677~39126818:-
LUAD	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.79e-10	1.44e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
LUAD	cis	rs9834970	0.588	rs4642070	ENSG00000234073.1	AC011816.1	-6.45	2.79e-10	1.44e-07	-0.31	-0.28	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36859453	chr3:36880184~36880729:-
LUAD	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	6.45	2.79e-10	1.44e-07	0.25	0.28	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
LUAD	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	6.45	2.8e-10	1.45e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	6.45	2.8e-10	1.45e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	6.45	2.8e-10	1.45e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	6.45	2.8e-10	1.45e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
LUAD	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	6.45	2.8e-10	1.45e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
LUAD	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	6.45	2.8e-10	1.45e-07	0.32	0.28	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
LUAD	cis	rs5753618	0.504	rs5753659	ENSG00000236132.1	CTA-440B3.1	-6.45	2.81e-10	1.45e-07	-0.34	-0.28	Colorectal cancer;	chr22:31497627	chr22:31816379~31817491:-
LUAD	cis	rs2303759	0.918	rs7251704	ENSG00000268686.1	AC010524.2	-6.45	2.81e-10	1.45e-07	-0.4	-0.28	Multiple sclerosis;	chr19:49387616	chr19:49368705~49388081:-
LUAD	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-6.45	2.81e-10	1.45e-07	-0.37	-0.28	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
LUAD	cis	rs7688540	0.8	rs9328737	ENSG00000275426.1	CH17-262A2.1	6.44	2.82e-10	1.46e-07	0.35	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:149738~150317:+
LUAD	cis	rs9640161	0.789	rs66688634	ENSG00000261305.1	RP4-584D14.7	6.44	2.82e-10	1.46e-07	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150356717	chr7:150341771~150342607:+
LUAD	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	6.44	2.82e-10	1.46e-07	0.32	0.28	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	6.44	2.82e-10	1.46e-07	0.32	0.28	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
LUAD	cis	rs8031584	0.918	rs1425292	ENSG00000260382.1	RP11-540B6.2	6.44	2.82e-10	1.46e-07	0.34	0.28	Huntington's disease progression;	chr15:30993219	chr15:30882267~30883231:-
LUAD	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-6.44	2.82e-10	1.46e-07	-0.38	-0.28	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
LUAD	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	6.44	2.83e-10	1.47e-07	0.24	0.28	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
LUAD	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	6.44	2.84e-10	1.47e-07	0.54	0.28	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	6.44	2.84e-10	1.47e-07	0.54	0.28	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
LUAD	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	6.44	2.84e-10	1.47e-07	0.42	0.28	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
LUAD	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-6.44	2.84e-10	1.47e-07	-0.21	-0.28	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.556	rs13200214	ENSG00000204709.4	LINC01556	6.44	2.84e-10	1.47e-07	0.62	0.28	Depression;	chr6:28049472	chr6:28943877~28944537:+
LUAD	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	6.44	2.85e-10	1.47e-07	0.51	0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
LUAD	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-6.44	2.85e-10	1.47e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
LUAD	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	6.44	2.85e-10	1.47e-07	0.35	0.28	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	6.44	2.85e-10	1.47e-07	0.35	0.28	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	6.44	2.85e-10	1.47e-07	0.35	0.28	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	6.44	2.85e-10	1.47e-07	0.35	0.28	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
LUAD	cis	rs7017914	0.934	rs1389202	ENSG00000223220.1	Y_RNA	6.44	2.86e-10	1.48e-07	0.31	0.28	Bone mineral density;	chr8:70940050	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13255735	ENSG00000223220.1	Y_RNA	6.44	2.86e-10	1.48e-07	0.31	0.28	Bone mineral density;	chr8:70947504	chr8:70780914~70781008:-
LUAD	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
LUAD	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	6.44	2.86e-10	1.48e-07	0.32	0.28	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
LUAD	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-6.44	2.86e-10	1.48e-07	-0.33	-0.28	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
LUAD	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	6.44	2.88e-10	1.48e-07	0.42	0.28	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
LUAD	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	6.44	2.88e-10	1.49e-07	0.32	0.28	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
LUAD	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	6.44	2.88e-10	1.49e-07	0.33	0.28	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
LUAD	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	6.44	2.88e-10	1.49e-07	0.41	0.28	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
LUAD	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-6.44	2.88e-10	1.49e-07	-0.3	-0.28	Height;	chr11:118773873	chr11:118791254~118793137:+
LUAD	cis	rs9326248	0.53	rs588918	ENSG00000280143.1	AP000892.6	6.44	2.88e-10	1.49e-07	0.42	0.28	Blood protein levels;	chr11:116985926	chr11:117204967~117210292:+
LUAD	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	6.44	2.89e-10	1.49e-07	0.32	0.28	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
LUAD	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-6.44	2.89e-10	1.49e-07	-0.34	-0.28	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
LUAD	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-6.44	2.89e-10	1.49e-07	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
LUAD	cis	rs853679	0.607	rs13190888	ENSG00000204709.4	LINC01556	6.44	2.9e-10	1.49e-07	0.61	0.28	Depression;	chr6:28318208	chr6:28943877~28944537:+
LUAD	cis	rs78773383	0.505	rs13123782	ENSG00000249207.1	RP11-360F5.1	6.44	2.9e-10	1.5e-07	0.3	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39112677~39126818:-
LUAD	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	6.44	2.9e-10	1.5e-07	0.31	0.28	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
LUAD	cis	rs5753618	0.583	rs5753632	ENSG00000236132.1	CTA-440B3.1	-6.44	2.91e-10	1.5e-07	-0.34	-0.28	Colorectal cancer;	chr22:31467111	chr22:31816379~31817491:-
LUAD	cis	rs8177876	0.658	rs79603321	ENSG00000261838.4	RP11-303E16.6	6.44	2.91e-10	1.5e-07	0.59	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81039139	chr16:81069854~81076598:+
LUAD	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	6.44	2.91e-10	1.5e-07	0.41	0.28	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
LUAD	cis	rs4141404	0.818	rs6518737	ENSG00000236132.1	CTA-440B3.1	6.44	2.91e-10	1.5e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31186676	chr22:31816379~31817491:-
LUAD	cis	rs2302464	1	rs16892287	ENSG00000214846.4	RP11-115L11.1	6.44	2.91e-10	1.5e-07	0.75	0.28	Cerebrospinal fluid biomarker levels;	chr4:15730570	chr4:15730962~15731627:-
LUAD	cis	rs7657257	1	rs4321629	ENSG00000214846.4	RP11-115L11.1	6.44	2.91e-10	1.5e-07	0.75	0.28	Blood protein levels;	chr4:15730757	chr4:15730962~15731627:-
LUAD	cis	rs7657257	1	rs10516290	ENSG00000214846.4	RP11-115L11.1	6.44	2.91e-10	1.5e-07	0.75	0.28	Blood protein levels;	chr4:15730833	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs10516291	ENSG00000214846.4	RP11-115L11.1	6.44	2.91e-10	1.5e-07	0.75	0.28	Cerebrospinal fluid biomarker levels;	chr4:15731168	chr4:15730962~15731627:-
LUAD	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	6.44	2.91e-10	1.5e-07	0.3	0.28	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	6.44	2.91e-10	1.5e-07	0.34	0.28	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
LUAD	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	6.44	2.91e-10	1.5e-07	0.34	0.28	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
LUAD	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	6.44	2.91e-10	1.5e-07	0.34	0.28	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
LUAD	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-6.44	2.92e-10	1.5e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
LUAD	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-6.44	2.92e-10	1.51e-07	-0.36	-0.28	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
LUAD	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-6.44	2.92e-10	1.51e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
LUAD	cis	rs72634501	0.716	rs67062906	ENSG00000228060.1	RP11-69E11.8	-6.44	2.93e-10	1.51e-07	-0.28	-0.28	HDL cholesterol;	chr1:39151018	chr1:39565160~39573203:+
LUAD	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	6.44	2.93e-10	1.51e-07	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
LUAD	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	6.44	2.93e-10	1.51e-07	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
LUAD	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	6.44	2.93e-10	1.51e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
LUAD	cis	rs71403859	0.502	rs34380814	ENSG00000260886.1	TAT-AS1	6.44	2.94e-10	1.52e-07	0.43	0.28	Post bronchodilator FEV1;	chr16:71454272	chr16:71565789~71578187:+
LUAD	cis	rs9450351	0.744	rs6912150	ENSG00000203875.9	SNHG5	-6.44	2.95e-10	1.52e-07	-0.61	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85925291	chr6:85660950~85678736:-
LUAD	cis	rs755249	0.53	rs4660475	ENSG00000228060.1	RP11-69E11.8	-6.44	2.95e-10	1.52e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.53	rs66848709	ENSG00000228060.1	RP11-69E11.8	-6.44	2.95e-10	1.52e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39565160~39573203:+
LUAD	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	6.44	2.95e-10	1.52e-07	0.32	0.28	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
LUAD	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	6.44	2.95e-10	1.52e-07	0.36	0.28	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
LUAD	cis	rs6504950	0.579	rs8075983	ENSG00000275710.1	RP11-257O5.4	6.44	2.96e-10	1.52e-07	0.39	0.28	Breast cancer;	chr17:55194557	chr17:54964474~54964679:+
LUAD	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	6.44	2.97e-10	1.53e-07	0.52	0.28	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
LUAD	cis	rs8031584	0.872	rs11634761	ENSG00000260382.1	RP11-540B6.2	6.44	2.97e-10	1.53e-07	0.34	0.28	Huntington's disease progression;	chr15:30950970	chr15:30882267~30883231:-
LUAD	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-6.44	2.97e-10	1.53e-07	-0.45	-0.28	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
LUAD	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	6.44	2.98e-10	1.53e-07	0.42	0.28	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
LUAD	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-6.44	2.98e-10	1.54e-07	-0.42	-0.28	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
LUAD	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	6.44	2.98e-10	1.54e-07	0.33	0.28	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
LUAD	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	6.44	2.99e-10	1.54e-07	0.24	0.28	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
LUAD	cis	rs71403859	0.554	rs12373065	ENSG00000260886.1	TAT-AS1	6.43	2.99e-10	1.54e-07	0.51	0.28	Post bronchodilator FEV1;	chr16:71836129	chr16:71565789~71578187:+
LUAD	cis	rs4141404	0.706	rs5753698	ENSG00000236132.1	CTA-440B3.1	-6.43	2.99e-10	1.54e-07	-0.35	-0.28	Paclitaxel-induced neuropathy;	chr22:31574068	chr22:31816379~31817491:-
LUAD	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	6.43	2.99e-10	1.54e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
LUAD	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	6.43	2.99e-10	1.54e-07	0.35	0.28	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	6.43	2.99e-10	1.54e-07	0.35	0.28	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
LUAD	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
LUAD	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-6.43	3e-10	1.54e-07	-0.36	-0.28	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
LUAD	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	6.43	3.01e-10	1.55e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	6.43	3.01e-10	1.55e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
LUAD	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	6.43	3.01e-10	1.55e-07	0.24	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
LUAD	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	6.43	3.01e-10	1.55e-07	0.24	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
LUAD	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	6.43	3.02e-10	1.55e-07	0.39	0.28	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
LUAD	cis	rs7567389	0.504	rs2069895	ENSG00000236682.1	AC068282.3	-6.43	3.02e-10	1.55e-07	-0.37	-0.28	Self-rated health;	chr2:127416492	chr2:127389130~127400580:+
LUAD	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	6.43	3.02e-10	1.55e-07	0.35	0.28	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000232546.1	RP11-458F8.1	-6.43	3.02e-10	1.55e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66108952	chr7:66848496~66858136:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000280411.1	IGHV1-69-2	6.43	3.02e-10	1.55e-07	0.2	0.28	Kawasaki disease;	chr14:106779223	chr14:106762092~106762588:-
LUAD	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	6.43	3.03e-10	1.56e-07	0.32	0.28	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	6.43	3.03e-10	1.56e-07	0.32	0.28	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	6.43	3.03e-10	1.56e-07	0.32	0.28	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	6.43	3.03e-10	1.56e-07	0.32	0.28	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	6.43	3.03e-10	1.56e-07	0.35	0.28	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-6.43	3.03e-10	1.56e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
LUAD	cis	rs867371	0.896	rs8033831	ENSG00000255769.6	GOLGA2P10	-6.43	3.03e-10	1.56e-07	-0.3	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472993~82513950:-
LUAD	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-6.43	3.03e-10	1.56e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
LUAD	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	6.43	3.03e-10	1.56e-07	0.28	0.28	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
LUAD	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	6.43	3.04e-10	1.56e-07	0.4	0.28	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
LUAD	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	6.43	3.04e-10	1.56e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
LUAD	cis	rs516805	0.961	rs572632	ENSG00000279453.1	RP3-425C14.4	-6.43	3.04e-10	1.57e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122437753	chr6:122436789~122439223:-
LUAD	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	6.43	3.05e-10	1.57e-07	0.32	0.28	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
LUAD	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	6.43	3.06e-10	1.57e-07	0.34	0.28	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
LUAD	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-6.43	3.06e-10	1.57e-07	-0.35	-0.28	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
LUAD	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-6.43	3.06e-10	1.57e-07	-0.35	-0.28	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
LUAD	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	6.43	3.06e-10	1.58e-07	0.33	0.28	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	6.43	3.06e-10	1.58e-07	0.33	0.28	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
LUAD	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	6.43	3.07e-10	1.58e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
LUAD	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-6.43	3.07e-10	1.58e-07	-0.31	-0.28	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
LUAD	cis	rs2034650	0.544	rs8034217	ENSG00000223313.1	RNU6-516P	-6.43	3.07e-10	1.58e-07	-0.37	-0.28	Interstitial lung disease;	chr15:40429501	chr15:40529570~40529673:+
LUAD	cis	rs9595908	0.869	rs9595946	ENSG00000212293.1	SNORA16	6.43	3.08e-10	1.58e-07	0.3	0.28	Body mass index;	chr13:32628998	chr13:32420390~32420516:-
LUAD	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-6.43	3.08e-10	1.58e-07	-0.35	-0.28	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
LUAD	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
LUAD	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	6.43	3.09e-10	1.58e-07	0.24	0.28	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	6.43	3.09e-10	1.58e-07	0.24	0.28	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
LUAD	cis	rs2243480	1	rs7804223	ENSG00000232546.1	RP11-458F8.1	6.43	3.09e-10	1.59e-07	0.37	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66848496~66858136:+
LUAD	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	6.43	3.09e-10	1.59e-07	0.32	0.28	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
LUAD	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	6.43	3.09e-10	1.59e-07	0.34	0.28	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
LUAD	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	6.43	3.09e-10	1.59e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
LUAD	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-6.43	3.09e-10	1.59e-07	-0.39	-0.28	Depression;	chr6:28184805	chr6:28115628~28116551:+
LUAD	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-6.43	3.09e-10	1.59e-07	-0.32	-0.28	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
LUAD	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-6.43	3.09e-10	1.59e-07	-0.21	-0.28	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
LUAD	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-6.43	3.09e-10	1.59e-07	-0.21	-0.28	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
LUAD	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-6.43	3.1e-10	1.59e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
LUAD	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-6.43	3.1e-10	1.59e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
LUAD	cis	rs853679	0.607	rs34950484	ENSG00000204709.4	LINC01556	6.43	3.1e-10	1.59e-07	0.61	0.28	Depression;	chr6:28310911	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34661125	ENSG00000204709.4	LINC01556	6.43	3.1e-10	1.59e-07	0.61	0.28	Depression;	chr6:28314117	chr6:28943877~28944537:+
LUAD	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	6.43	3.11e-10	1.59e-07	0.32	0.28	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
LUAD	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	6.43	3.11e-10	1.6e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
LUAD	cis	rs75422866	0.558	rs73104190	ENSG00000280054.1	RP1-197B17.7	6.43	3.11e-10	1.6e-07	0.63	0.28	Pneumonia;	chr12:47716040	chr12:47728151~47730598:-
LUAD	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-6.43	3.11e-10	1.6e-07	-0.34	-0.28	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-6.43	3.11e-10	1.6e-07	-0.34	-0.28	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
LUAD	cis	rs10050311	0.858	rs1985944	ENSG00000251411.1	RP11-397E7.4	-6.43	3.12e-10	1.6e-07	-0.39	-0.28	Insulin-related traits;	chr4:86898130	chr4:86913266~86914817:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000224373.3	IGHV4-59	6.43	3.12e-10	1.6e-07	0.17	0.28	Kawasaki disease;	chr14:106800208	chr14:106627249~106627825:-
LUAD	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
LUAD	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-6.43	3.12e-10	1.6e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
LUAD	cis	rs853679	0.607	rs67998226	ENSG00000204709.4	LINC01556	6.43	3.12e-10	1.6e-07	0.6	0.28	Depression;	chr6:28270281	chr6:28943877~28944537:+
LUAD	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	6.43	3.12e-10	1.6e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
LUAD	cis	rs11089937	0.616	rs12484482	ENSG00000211639.2	IGLV4-60	6.43	3.13e-10	1.61e-07	0.29	0.28	Periodontitis (PAL4Q3);	chr22:22180158	chr22:22162199~22162681:+
LUAD	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	6.43	3.13e-10	1.61e-07	0.35	0.28	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
LUAD	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	6.43	3.14e-10	1.61e-07	0.55	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
LUAD	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	6.43	3.14e-10	1.61e-07	0.44	0.28	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
LUAD	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	6.43	3.15e-10	1.61e-07	0.24	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
LUAD	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	6.43	3.15e-10	1.61e-07	0.49	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
LUAD	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	6.43	3.15e-10	1.61e-07	0.35	0.28	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
LUAD	cis	rs13160562	0.666	rs28096	ENSG00000272109.1	CTD-2260A17.3	-6.43	3.15e-10	1.62e-07	-0.3	-0.28	Alcohol dependence;	chr5:96773540	chr5:96804353~96806105:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	6.43	3.15e-10	1.62e-07	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
LUAD	cis	rs4660456	0.504	rs2253835	ENSG00000237899.1	RP4-739H11.3	6.43	3.15e-10	1.62e-07	0.4	0.28	Platelet count;	chr1:40635900	chr1:40669089~40687588:-
LUAD	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-6.43	3.16e-10	1.62e-07	-0.44	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
LUAD	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-6.43	3.16e-10	1.62e-07	-0.44	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
LUAD	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-6.43	3.16e-10	1.62e-07	-0.34	-0.28	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
LUAD	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-6.43	3.16e-10	1.62e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-6.43	3.16e-10	1.62e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
LUAD	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	6.43	3.16e-10	1.62e-07	0.34	0.28	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
LUAD	cis	rs17301013	0.507	rs12084948	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174525776	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs11809482	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174530269	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs909533	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174531428	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12093966	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174535120	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
LUAD	cis	rs75920871	0.562	rs68137714	ENSG00000254851.1	RP11-109L13.1	-6.43	3.17e-10	1.62e-07	-0.47	-0.28	Subjective well-being;	chr11:117154641	chr11:117135528~117138582:+
LUAD	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-6.43	3.17e-10	1.62e-07	-0.33	-0.28	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
LUAD	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	6.43	3.17e-10	1.62e-07	0.41	0.28	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	6.43	3.17e-10	1.62e-07	0.41	0.28	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
LUAD	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	6.42	3.18e-10	1.63e-07	0.43	0.28	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
LUAD	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	6.42	3.18e-10	1.63e-07	0.35	0.28	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
LUAD	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-6.42	3.18e-10	1.63e-07	-0.3	-0.28	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
LUAD	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-6.42	3.19e-10	1.63e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-6.42	3.19e-10	1.63e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
LUAD	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	6.42	3.19e-10	1.63e-07	0.31	0.28	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
LUAD	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	6.42	3.19e-10	1.63e-07	0.31	0.28	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
LUAD	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-6.42	3.19e-10	1.63e-07	-0.38	-0.28	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
LUAD	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-6.42	3.2e-10	1.63e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
LUAD	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	6.42	3.2e-10	1.63e-07	0.4	0.28	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
LUAD	cis	rs5753618	0.555	rs5749286	ENSG00000236132.1	CTA-440B3.1	-6.42	3.2e-10	1.64e-07	-0.34	-0.28	Colorectal cancer;	chr22:31504373	chr22:31816379~31817491:-
LUAD	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	6.42	3.21e-10	1.64e-07	0.77	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
LUAD	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	6.42	3.21e-10	1.64e-07	0.35	0.28	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-6.42	3.21e-10	1.64e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
LUAD	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-6.42	3.22e-10	1.64e-07	-0.37	-0.28	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
LUAD	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	6.42	3.22e-10	1.64e-07	0.35	0.28	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
LUAD	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	6.42	3.22e-10	1.64e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	6.42	3.22e-10	1.64e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	6.42	3.22e-10	1.64e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	6.42	3.22e-10	1.64e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
LUAD	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	6.42	3.22e-10	1.64e-07	0.32	0.28	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
LUAD	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	6.42	3.22e-10	1.65e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
LUAD	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-6.42	3.22e-10	1.65e-07	-0.32	-0.28	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-6.42	3.22e-10	1.65e-07	-0.32	-0.28	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
LUAD	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-6.42	3.23e-10	1.65e-07	-0.31	-0.28	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
LUAD	cis	rs11089937	0.616	rs5995616	ENSG00000211639.2	IGLV4-60	-6.42	3.23e-10	1.65e-07	-0.3	-0.28	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22162199~22162681:+
LUAD	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-6.42	3.23e-10	1.65e-07	-0.65	-0.28	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	6.42	3.23e-10	1.65e-07	0.41	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
LUAD	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-6.42	3.23e-10	1.65e-07	-0.34	-0.28	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
LUAD	cis	rs516805	0.961	rs510283	ENSG00000279453.1	RP3-425C14.4	-6.42	3.24e-10	1.65e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122451547	chr6:122436789~122439223:-
LUAD	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	6.42	3.24e-10	1.65e-07	0.33	0.28	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-6.42	3.25e-10	1.66e-07	-0.34	-0.28	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-6.42	3.25e-10	1.66e-07	-0.34	-0.28	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-6.42	3.25e-10	1.66e-07	-0.34	-0.28	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
LUAD	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	6.42	3.25e-10	1.66e-07	0.33	0.28	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
LUAD	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	6.42	3.25e-10	1.66e-07	0.33	0.28	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
LUAD	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-6.42	3.25e-10	1.66e-07	-0.33	-0.28	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
LUAD	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-6.42	3.25e-10	1.66e-07	-0.37	-0.28	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000206090.4	AP000350.7	6.42	3.25e-10	1.66e-07	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23939998~23942798:+
LUAD	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	6.42	3.25e-10	1.66e-07	0.35	0.28	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
LUAD	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	6.42	3.26e-10	1.66e-07	0.3	0.28	Height;	chr11:118758322	chr11:118791254~118793137:+
LUAD	cis	rs4834770	1	rs4336213	ENSG00000245958.5	RP11-33B1.1	-6.42	3.26e-10	1.66e-07	-0.25	-0.28	Blood protein levels;	chr4:119315314	chr4:119454791~119552025:+
LUAD	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	6.42	3.26e-10	1.66e-07	0.32	0.28	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
LUAD	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-6.42	3.26e-10	1.67e-07	-0.28	-0.28	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
LUAD	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-6.42	3.27e-10	1.67e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
LUAD	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-6.42	3.27e-10	1.67e-07	-0.33	-0.28	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
LUAD	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-6.42	3.27e-10	1.67e-07	-0.38	-0.28	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
LUAD	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	6.42	3.27e-10	1.67e-07	0.33	0.28	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
LUAD	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-6.42	3.28e-10	1.67e-07	-0.36	-0.28	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
LUAD	cis	rs1823913	0.895	rs10931491	ENSG00000230611.1	HMGB1P27	6.42	3.28e-10	1.67e-07	0.34	0.28	Obesity-related traits;	chr2:191256087	chr2:191174233~191174835:+
LUAD	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-6.42	3.28e-10	1.68e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
LUAD	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	6.42	3.28e-10	1.68e-07	0.4	0.28	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
LUAD	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-6.42	3.28e-10	1.68e-07	-0.33	-0.28	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
LUAD	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-6.42	3.28e-10	1.68e-07	-0.31	-0.28	Height;	chr2:231490121	chr2:231508426~231514339:-
LUAD	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	6.42	3.29e-10	1.68e-07	0.4	0.28	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	6.42	3.29e-10	1.68e-07	0.4	0.28	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
LUAD	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	6.42	3.3e-10	1.68e-07	0.41	0.28	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
LUAD	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-6.42	3.3e-10	1.68e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
LUAD	cis	rs35934224	0.783	rs7287073	ENSG00000232926.1	AC000078.5	6.42	3.32e-10	1.69e-07	0.35	0.28	Glaucoma (primary open-angle);	chr22:19876812	chr22:19887289~19887970:+
LUAD	cis	rs7246657	0.653	rs10402050	ENSG00000276846.1	CTD-3220F14.3	6.42	3.32e-10	1.69e-07	0.46	0.28	Coronary artery calcification;	chr19:37198056	chr19:37314868~37315620:-
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-6.42	3.32e-10	1.69e-07	-0.28	-0.28	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
LUAD	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-6.42	3.33e-10	1.7e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
LUAD	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	6.42	3.34e-10	1.7e-07	0.34	0.28	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
LUAD	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-6.42	3.34e-10	1.7e-07	-0.29	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
LUAD	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	6.42	3.34e-10	1.7e-07	0.52	0.28	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	6.42	3.34e-10	1.7e-07	0.52	0.28	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	6.42	3.34e-10	1.7e-07	0.52	0.28	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-6.42	3.34e-10	1.7e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-6.42	3.34e-10	1.7e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
LUAD	cis	rs7674212	0.556	rs6533039	ENSG00000251288.2	RP11-10L12.2	-6.42	3.34e-10	1.7e-07	-0.35	-0.28	Type 2 diabetes;	chr4:102938381	chr4:102751401~102752641:+
LUAD	cis	rs755249	0.917	rs61779331	ENSG00000228060.1	RP11-69E11.8	-6.42	3.34e-10	1.7e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39565160~39573203:+
LUAD	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-6.42	3.35e-10	1.71e-07	-0.39	-0.28	Depression;	chr6:28206179	chr6:28115628~28116551:+
LUAD	cis	rs17027258	0.697	rs1468789	ENSG00000234389.1	AC007278.3	-6.42	3.35e-10	1.71e-07	-0.32	-0.28	White blood cell types;	chr2:102476044	chr2:102438713~102440475:+
LUAD	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-6.42	3.35e-10	1.71e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-6.42	3.35e-10	1.71e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-6.42	3.35e-10	1.71e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
LUAD	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	6.42	3.35e-10	1.71e-07	0.25	0.28	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
LUAD	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-6.42	3.35e-10	1.71e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-6.42	3.35e-10	1.71e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-6.42	3.35e-10	1.71e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
LUAD	cis	rs1707322	0.685	rs56177313	ENSG00000234329.1	RP11-767N6.2	6.42	3.36e-10	1.71e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45651039~45651826:-
LUAD	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	6.42	3.36e-10	1.71e-07	0.35	0.28	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
LUAD	cis	rs2911132	1	rs2617433	ENSG00000248734.2	CTD-2260A17.1	6.42	3.37e-10	1.71e-07	0.29	0.28	Urate levels (BMI interaction);	chr5:96840738	chr5:96784777~96785999:+
LUAD	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-6.42	3.37e-10	1.72e-07	-0.21	-0.28	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
LUAD	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-6.41	3.38e-10	1.72e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
LUAD	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	6.41	3.38e-10	1.72e-07	0.34	0.28	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	6.41	3.38e-10	1.72e-07	0.34	0.28	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	6.41	3.38e-10	1.72e-07	0.34	0.28	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
LUAD	cis	rs6558530	0.932	rs10102731	ENSG00000253982.1	CTD-2336O2.1	6.41	3.38e-10	1.72e-07	0.35	0.28	Systolic blood pressure;	chr8:1760854	chr8:1761990~1764502:-
LUAD	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-6.41	3.38e-10	1.72e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
LUAD	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	6.41	3.38e-10	1.72e-07	0.43	0.28	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
LUAD	cis	rs7017914	0.967	rs1493198	ENSG00000223220.1	Y_RNA	6.41	3.39e-10	1.72e-07	0.31	0.28	Bone mineral density;	chr8:70939722	chr8:70780914~70781008:-
LUAD	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-6.41	3.39e-10	1.73e-07	-0.28	-0.28	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-6.41	3.39e-10	1.73e-07	-0.28	-0.28	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-6.41	3.39e-10	1.73e-07	-0.42	-0.28	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
LUAD	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	6.41	3.4e-10	1.73e-07	0.29	0.28	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
LUAD	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	6.41	3.4e-10	1.73e-07	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
LUAD	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-6.41	3.41e-10	1.73e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
LUAD	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	6.41	3.41e-10	1.73e-07	0.31	0.28	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
LUAD	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-6.41	3.41e-10	1.73e-07	-0.55	-0.28	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
LUAD	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	6.41	3.42e-10	1.74e-07	0.41	0.28	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	6.41	3.42e-10	1.74e-07	0.41	0.28	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
LUAD	cis	rs2303759	0.918	rs8107548	ENSG00000268686.1	AC010524.2	-6.41	3.42e-10	1.74e-07	-0.41	-0.28	Multiple sclerosis;	chr19:49367386	chr19:49368705~49388081:-
LUAD	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-6.41	3.42e-10	1.74e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
LUAD	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-6.41	3.42e-10	1.74e-07	-0.31	-0.28	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
LUAD	cis	rs9326248	0.53	rs579890	ENSG00000280143.1	AP000892.6	6.41	3.43e-10	1.74e-07	0.46	0.28	Blood protein levels;	chr11:116928247	chr11:117204967~117210292:+
LUAD	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-6.41	3.43e-10	1.74e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
LUAD	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	6.41	3.43e-10	1.74e-07	0.31	0.28	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	6.41	3.43e-10	1.74e-07	0.31	0.28	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	6.41	3.43e-10	1.74e-07	0.31	0.28	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	6.41	3.43e-10	1.74e-07	0.31	0.28	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
LUAD	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	6.41	3.44e-10	1.75e-07	0.34	0.28	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	6.41	3.44e-10	1.75e-07	0.34	0.28	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	6.41	3.44e-10	1.75e-07	0.34	0.28	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
LUAD	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-6.41	3.44e-10	1.75e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
LUAD	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	6.41	3.44e-10	1.75e-07	0.29	0.28	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
LUAD	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	6.41	3.45e-10	1.75e-07	0.37	0.28	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
LUAD	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	6.41	3.45e-10	1.75e-07	0.33	0.28	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
LUAD	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	6.41	3.45e-10	1.75e-07	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
LUAD	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-6.41	3.45e-10	1.75e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
LUAD	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	6.41	3.45e-10	1.75e-07	0.36	0.28	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
LUAD	cis	rs2243480	1	rs313809	ENSG00000232546.1	RP11-458F8.1	-6.41	3.45e-10	1.75e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66034996	chr7:66848496~66858136:+
LUAD	cis	rs7615952	0.611	rs12488771	ENSG00000171084.14	FAM86JP	6.41	3.45e-10	1.75e-07	0.58	0.28	Blood pressure (smoking interaction);	chr3:125981683	chr3:125916620~125930024:+
LUAD	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-6.41	3.46e-10	1.75e-07	-0.35	-0.28	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
LUAD	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	6.41	3.46e-10	1.76e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	6.41	3.46e-10	1.76e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
LUAD	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-6.41	3.46e-10	1.76e-07	-0.27	-0.28	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.507	rs6665535	ENSG00000227373.4	RP11-160H22.5	6.41	3.46e-10	1.76e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174522480	chr1:174115300~174160004:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000224373.3	IGHV4-59	6.41	3.47e-10	1.76e-07	0.17	0.28	Kawasaki disease;	chr14:106783693	chr14:106627249~106627825:-
LUAD	cis	rs7246657	0.551	rs12972146	ENSG00000276846.1	CTD-3220F14.3	6.41	3.47e-10	1.76e-07	0.43	0.28	Coronary artery calcification;	chr19:37135193	chr19:37314868~37315620:-
LUAD	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	6.41	3.47e-10	1.76e-07	0.35	0.28	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
LUAD	cis	rs5753618	0.539	rs5753596	ENSG00000236132.1	CTA-440B3.1	6.41	3.47e-10	1.76e-07	0.32	0.28	Colorectal cancer;	chr22:31391486	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	6.41	3.47e-10	1.76e-07	0.36	0.28	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	6.41	3.47e-10	1.76e-07	0.53	0.28	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
LUAD	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	6.41	3.47e-10	1.76e-07	0.34	0.28	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
LUAD	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	6.41	3.48e-10	1.76e-07	0.4	0.28	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000224373.3	IGHV4-59	6.41	3.48e-10	1.76e-07	0.17	0.28	Kawasaki disease;	chr14:106802182	chr14:106627249~106627825:-
LUAD	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	6.41	3.48e-10	1.76e-07	0.35	0.28	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
LUAD	cis	rs496547	0.719	rs1790189	ENSG00000255422.1	AP002954.4	-6.41	3.48e-10	1.76e-07	-0.36	-0.28	Hip minimal joint space width;	chr11:118781617	chr11:118704607~118750263:+
LUAD	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-6.41	3.48e-10	1.77e-07	-0.51	-0.28	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
LUAD	cis	rs2303759	0.874	rs10411630	ENSG00000268686.1	AC010524.2	-6.41	3.48e-10	1.77e-07	-0.4	-0.28	Multiple sclerosis;	chr19:49388057	chr19:49368705~49388081:-
LUAD	cis	rs9549367	0.789	rs35569628	ENSG00000269125.1	RP11-98F14.11	-6.41	3.49e-10	1.77e-07	-0.34	-0.28	Platelet distribution width;	chr13:113218398	chr13:113165002~113165183:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-6.41	3.49e-10	1.77e-07	-0.2	-0.28	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
LUAD	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	6.41	3.5e-10	1.77e-07	0.55	0.28	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
LUAD	cis	rs35740288	0.77	rs35348278	ENSG00000202081.1	RNU6-1280P	6.41	3.5e-10	1.77e-07	0.35	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85657109	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	6.41	3.5e-10	1.77e-07	0.34	0.28	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
LUAD	cis	rs9928842	0.882	rs6564241	ENSG00000280152.1	RP11-331F4.5	6.41	3.5e-10	1.77e-07	0.32	0.28	Alcoholic chronic pancreatitis;	chr16:75230076	chr16:75245994~75250077:-
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000224373.3	IGHV4-59	6.41	3.5e-10	1.77e-07	0.17	0.28	Kawasaki disease;	chr14:106785926	chr14:106627249~106627825:-
LUAD	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.41	3.5e-10	1.78e-07	0.37	0.28	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
LUAD	cis	rs2243480	1	rs2420170	ENSG00000232546.1	RP11-458F8.1	6.41	3.51e-10	1.78e-07	0.37	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66848496~66858136:+
LUAD	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-6.41	3.51e-10	1.78e-07	-0.31	-0.28	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	6.41	3.51e-10	1.78e-07	0.35	0.28	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
LUAD	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-6.41	3.51e-10	1.78e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
LUAD	cis	rs7674212	0.507	rs223331	ENSG00000251288.2	RP11-10L12.2	-6.41	3.52e-10	1.79e-07	-0.35	-0.28	Type 2 diabetes;	chr4:102872408	chr4:102751401~102752641:+
LUAD	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-6.41	3.53e-10	1.79e-07	-0.3	-0.28	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
LUAD	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-6.41	3.53e-10	1.79e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-6.41	3.53e-10	1.79e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
LUAD	cis	rs131777	0.577	rs5770928	ENSG00000205559.3	CHKB-AS1	-6.41	3.53e-10	1.79e-07	-0.33	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50583026~50583877:+
LUAD	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-6.41	3.53e-10	1.79e-07	-0.27	-0.28	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000224373.3	IGHV4-59	6.41	3.54e-10	1.79e-07	0.17	0.28	Kawasaki disease;	chr14:106787090	chr14:106627249~106627825:-
LUAD	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	6.41	3.54e-10	1.79e-07	0.4	0.28	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
LUAD	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	6.41	3.54e-10	1.79e-07	0.66	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
LUAD	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-6.41	3.54e-10	1.8e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
LUAD	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	6.41	3.55e-10	1.8e-07	0.41	0.28	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
LUAD	cis	rs11089937	0.616	rs7286793	ENSG00000211639.2	IGLV4-60	6.41	3.55e-10	1.8e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22162199~22162681:+
LUAD	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	6.41	3.56e-10	1.8e-07	0.31	0.28	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
LUAD	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	6.41	3.56e-10	1.8e-07	0.29	0.28	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
LUAD	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	6.41	3.56e-10	1.8e-07	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-6.41	3.56e-10	1.8e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
LUAD	cis	rs8177876	0.749	rs2970076	ENSG00000261838.4	RP11-303E16.6	6.41	3.57e-10	1.81e-07	0.49	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056211	chr16:81069854~81076598:+
LUAD	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	6.41	3.57e-10	1.81e-07	0.35	0.28	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	6.41	3.57e-10	1.81e-07	0.35	0.28	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
LUAD	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-6.41	3.57e-10	1.81e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
LUAD	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	6.41	3.57e-10	1.81e-07	0.36	0.28	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
LUAD	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-6.41	3.57e-10	1.81e-07	-0.34	-0.28	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
LUAD	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-6.41	3.57e-10	1.81e-07	-0.34	-0.28	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
LUAD	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-6.41	3.58e-10	1.81e-07	-0.34	-0.28	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-6.41	3.58e-10	1.81e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-6.41	3.58e-10	1.81e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
LUAD	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	6.41	3.58e-10	1.81e-07	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
LUAD	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-6.41	3.58e-10	1.81e-07	-0.38	-0.28	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
LUAD	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	6.4	3.58e-10	1.81e-07	0.29	0.28	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
LUAD	cis	rs755249	0.567	rs16826000	ENSG00000228060.1	RP11-69E11.8	-6.4	3.59e-10	1.81e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs16826009	ENSG00000228060.1	RP11-69E11.8	-6.4	3.59e-10	1.81e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs4660208	ENSG00000228060.1	RP11-69E11.8	-6.4	3.59e-10	1.81e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39565160~39573203:+
LUAD	cis	rs1823913	1	rs11681777	ENSG00000230611.1	HMGB1P27	6.4	3.59e-10	1.81e-07	0.34	0.28	Obesity-related traits;	chr2:191256741	chr2:191174233~191174835:+
LUAD	cis	rs237743	1	rs1567865	ENSG00000222365.1	SNORD12B	-6.4	3.59e-10	1.82e-07	-0.33	-0.28	Height;	chr20:49265430	chr20:49280319~49280409:+
LUAD	cis	rs853679	0.546	rs71537572	ENSG00000204709.4	LINC01556	6.4	3.59e-10	1.82e-07	0.62	0.28	Depression;	chr6:28002937	chr6:28943877~28944537:+
LUAD	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	6.4	3.59e-10	1.82e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
LUAD	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-6.4	3.59e-10	1.82e-07	-0.42	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
LUAD	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	6.4	3.6e-10	1.82e-07	0.29	0.28	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
LUAD	cis	rs950169	0.96	rs12905475	ENSG00000259728.4	LINC00933	6.4	3.6e-10	1.82e-07	0.43	0.28	Schizophrenia;	chr15:84131743	chr15:84570649~84580175:+
LUAD	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-6.4	3.6e-10	1.82e-07	-0.31	-0.28	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-6.4	3.6e-10	1.82e-07	-0.31	-0.28	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
LUAD	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	6.4	3.6e-10	1.82e-07	0.4	0.28	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000232546.1	RP11-458F8.1	-6.4	3.6e-10	1.82e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66034886	chr7:66848496~66858136:+
LUAD	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	6.4	3.61e-10	1.82e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
LUAD	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	6.4	3.61e-10	1.83e-07	0.34	0.28	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
LUAD	cis	rs8177876	0.658	rs12456	ENSG00000261838.4	RP11-303E16.6	6.4	3.62e-10	1.83e-07	0.57	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031454	chr16:81069854~81076598:+
LUAD	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-6.4	3.62e-10	1.83e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000224373.3	IGHV4-59	6.4	3.62e-10	1.83e-07	0.17	0.28	Kawasaki disease;	chr14:106783414	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000224373.3	IGHV4-59	6.4	3.62e-10	1.83e-07	0.17	0.28	Kawasaki disease;	chr14:106784065	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000224373.3	IGHV4-59	6.4	3.62e-10	1.83e-07	0.17	0.28	Kawasaki disease;	chr14:106784149	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000224373.3	IGHV4-59	6.4	3.62e-10	1.83e-07	0.17	0.28	Kawasaki disease;	chr14:106785139	chr14:106627249~106627825:-
LUAD	cis	rs35740288	0.77	rs11631018	ENSG00000202081.1	RNU6-1280P	6.4	3.62e-10	1.83e-07	0.35	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85597303	chr15:85651522~85651628:-
LUAD	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-6.4	3.62e-10	1.83e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
LUAD	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	6.4	3.63e-10	1.83e-07	0.29	0.28	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
LUAD	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	6.4	3.63e-10	1.84e-07	0.37	0.28	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
LUAD	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	6.4	3.63e-10	1.84e-07	0.35	0.28	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
LUAD	cis	rs2442825	0.659	rs1129170	ENSG00000206573.7	THUMPD3-AS1	6.4	3.64e-10	1.84e-07	0.21	0.28	Cerebrospinal fluid clusterin levels;	chr3:9384227	chr3:9349689~9398579:-
LUAD	cis	rs891378	0.785	rs7516468	ENSG00000274245.1	RP11-357P18.2	-6.4	3.64e-10	1.84e-07	-0.33	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207235943	chr1:207372559~207373252:+
LUAD	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	6.4	3.64e-10	1.84e-07	0.33	0.28	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	6.4	3.65e-10	1.84e-07	0.31	0.28	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-6.4	3.65e-10	1.85e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-6.4	3.65e-10	1.85e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
LUAD	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	6.4	3.66e-10	1.85e-07	0.33	0.28	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
LUAD	cis	rs8177876	0.749	rs2549896	ENSG00000261838.4	RP11-303E16.6	-6.4	3.66e-10	1.85e-07	-0.51	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054334	chr16:81069854~81076598:+
LUAD	cis	rs6772849	0.93	rs4857916	ENSG00000242551.2	POU5F1P6	-6.4	3.67e-10	1.85e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128657171	chr3:128674735~128677005:-
LUAD	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-6.4	3.67e-10	1.85e-07	-0.35	-0.28	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
LUAD	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	6.4	3.67e-10	1.85e-07	0.31	0.28	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
LUAD	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	6.4	3.68e-10	1.86e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
LUAD	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	6.4	3.68e-10	1.86e-07	0.29	0.28	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
LUAD	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	6.4	3.69e-10	1.86e-07	0.31	0.28	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
LUAD	cis	rs4787484	0.593	rs12917712	ENSG00000214725.6	CDIPT-AS1	6.4	3.69e-10	1.86e-07	0.34	0.28	Response to taxane treatment (placlitaxel);	chr16:29871169	chr16:29863593~29868053:+
LUAD	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	6.4	3.69e-10	1.87e-07	0.32	0.28	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
LUAD	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	6.4	3.7e-10	1.87e-07	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
LUAD	cis	rs394563	0.602	rs409099	ENSG00000231760.4	RP11-350J20.5	6.4	3.7e-10	1.87e-07	0.34	0.28	Dupuytren's disease;	chr6:149445727	chr6:149796151~149826294:-
LUAD	cis	rs394563	0.602	rs409111	ENSG00000231760.4	RP11-350J20.5	6.4	3.7e-10	1.87e-07	0.34	0.28	Dupuytren's disease;	chr6:149445724	chr6:149796151~149826294:-
LUAD	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	6.4	3.7e-10	1.87e-07	0.49	0.28	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
LUAD	cis	rs1707322	0.752	rs11211152	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs4607935	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.681	rs12048866	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs3811436	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs12024590	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs12027622	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4415615	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs7529699	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.716	rs6699444	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs10430105	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45651039~45651826:-
LUAD	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	6.4	3.71e-10	1.87e-07	0.36	0.28	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
LUAD	cis	rs6991838	0.806	rs11781358	ENSG00000200714.1	Y_RNA	6.4	3.71e-10	1.87e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65592731~65592820:+
LUAD	cis	rs2243480	1	rs1039664	ENSG00000230295.1	RP11-458F8.2	-6.4	3.71e-10	1.87e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:65984729	chr7:66880708~66882981:+
LUAD	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-6.4	3.71e-10	1.87e-07	-0.56	-0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
LUAD	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	6.4	3.72e-10	1.87e-07	0.43	0.28	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
LUAD	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-6.4	3.72e-10	1.88e-07	-0.38	-0.28	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
LUAD	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	6.4	3.72e-10	1.88e-07	0.35	0.28	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
LUAD	cis	rs755249	0.917	rs61779330	ENSG00000228060.1	RP11-69E11.8	-6.4	3.72e-10	1.88e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.876	rs72662001	ENSG00000228060.1	RP11-69E11.8	-6.4	3.72e-10	1.88e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39565160~39573203:+
LUAD	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-6.4	3.73e-10	1.88e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
LUAD	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	6.4	3.73e-10	1.88e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
LUAD	cis	rs55726902	0.761	rs2544030	ENSG00000276691.1	RP5-1057I20.5	6.4	3.73e-10	1.88e-07	0.28	0.28	Allergic disease (asthma, hay fever or eczema);	chr12:47801668	chr12:47788426~47788971:+
LUAD	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	6.4	3.74e-10	1.88e-07	0.29	0.28	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
LUAD	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	6.4	3.74e-10	1.88e-07	0.33	0.28	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
LUAD	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	6.4	3.74e-10	1.88e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	6.4	3.74e-10	1.88e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
LUAD	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	6.4	3.74e-10	1.89e-07	0.4	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
LUAD	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-6.4	3.74e-10	1.89e-07	-0.38	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
LUAD	cis	rs3002142	0.658	rs1053316	ENSG00000272750.1	RP11-378J18.8	6.4	3.75e-10	1.89e-07	0.37	0.28	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:222658867~222661512:-
LUAD	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-6.4	3.75e-10	1.89e-07	-0.34	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
LUAD	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-6.4	3.75e-10	1.89e-07	-0.33	-0.28	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
LUAD	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-6.4	3.75e-10	1.89e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
LUAD	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	6.4	3.76e-10	1.89e-07	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs35353359	ENSG00000204709.4	LINC01556	6.4	3.76e-10	1.89e-07	0.61	0.28	Depression;	chr6:28356601	chr6:28943877~28944537:+
LUAD	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-6.4	3.76e-10	1.89e-07	-0.29	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
LUAD	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	6.4	3.76e-10	1.89e-07	0.35	0.28	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
LUAD	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-6.4	3.77e-10	1.9e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs1499614	ENSG00000232546.1	RP11-458F8.1	-6.4	3.77e-10	1.9e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66265811	chr7:66848496~66858136:+
LUAD	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-6.4	3.77e-10	1.9e-07	-0.34	-0.28	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
LUAD	cis	rs2243480	1	rs316304	ENSG00000232546.1	RP11-458F8.1	-6.4	3.77e-10	1.9e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66151907	chr7:66848496~66858136:+
LUAD	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-6.4	3.77e-10	1.9e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
LUAD	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-6.4	3.77e-10	1.9e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
LUAD	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	6.4	3.78e-10	1.9e-07	0.34	0.28	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
LUAD	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-6.4	3.78e-10	1.9e-07	-0.34	-0.28	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-6.4	3.78e-10	1.9e-07	-0.34	-0.28	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
LUAD	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	6.4	3.78e-10	1.91e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
LUAD	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	6.4	3.79e-10	1.91e-07	0.29	0.28	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
LUAD	cis	rs7567389	0.576	rs2069902	ENSG00000236682.1	AC068282.3	-6.4	3.79e-10	1.91e-07	-0.36	-0.28	Self-rated health;	chr2:127417287	chr2:127389130~127400580:+
LUAD	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	6.4	3.79e-10	1.91e-07	0.31	0.28	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
LUAD	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-6.4	3.79e-10	1.91e-07	-0.38	-0.28	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
LUAD	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	6.4	3.8e-10	1.91e-07	0.34	0.28	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
LUAD	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-6.4	3.81e-10	1.92e-07	-0.32	-0.28	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
LUAD	cis	rs2734839	0.964	rs2734831	ENSG00000270179.1	RP11-159N11.4	6.4	3.81e-10	1.92e-07	0.28	0.28	Information processing speed;	chr11:113422874	chr11:113368478~113369117:+
LUAD	cis	rs293748	0.771	rs292196	ENSG00000250155.1	CTD-2353F22.1	6.39	3.81e-10	1.92e-07	0.38	0.28	Obesity-related traits;	chr5:36914077	chr5:36666214~36725195:-
LUAD	cis	rs77204473	0.744	rs75216569	ENSG00000254851.1	RP11-109L13.1	6.39	3.81e-10	1.92e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117036999	chr11:117135528~117138582:+
LUAD	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	6.39	3.81e-10	1.92e-07	0.39	0.28	Depression;	chr6:28167882	chr6:28115628~28116551:+
LUAD	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	6.39	3.82e-10	1.92e-07	0.29	0.28	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
LUAD	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-6.39	3.82e-10	1.92e-07	-0.35	-0.28	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
LUAD	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-6.39	3.82e-10	1.92e-07	-0.38	-0.28	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
LUAD	cis	rs1707322	0.752	rs12062535	ENSG00000234329.1	RP11-767N6.2	6.39	3.82e-10	1.92e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45651039~45651826:-
LUAD	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	6.39	3.82e-10	1.92e-07	0.41	0.28	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
LUAD	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
LUAD	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-6.39	3.82e-10	1.92e-07	-0.3	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
LUAD	cis	rs9326248	0.52	rs74830	ENSG00000280143.1	AP000892.6	-6.39	3.83e-10	1.92e-07	-0.32	-0.28	Blood protein levels;	chr11:117219842	chr11:117204967~117210292:+
LUAD	cis	rs155076	1	rs58519241	ENSG00000233325.3	MIPEPP3	6.39	3.83e-10	1.93e-07	0.44	0.28	White matter hyperintensity burden;	chr13:21270867	chr13:21298139~21306373:+
LUAD	cis	rs2243480	1	rs316322	ENSG00000232546.1	RP11-458F8.1	-6.39	3.84e-10	1.93e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66146246	chr7:66848496~66858136:+
LUAD	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	6.39	3.84e-10	1.93e-07	0.4	0.28	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
LUAD	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-6.39	3.85e-10	1.93e-07	-0.32	-0.28	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
LUAD	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	6.39	3.85e-10	1.94e-07	0.35	0.28	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
LUAD	cis	rs6991838	0.778	rs11779601	ENSG00000200714.1	Y_RNA	6.39	3.87e-10	1.94e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65592731~65592820:+
LUAD	cis	rs7017914	0.902	rs6472542	ENSG00000223220.1	Y_RNA	-6.39	3.87e-10	1.94e-07	-0.3	-0.28	Bone mineral density;	chr8:70741852	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000224373.3	IGHV4-59	6.39	3.87e-10	1.94e-07	0.18	0.28	Kawasaki disease;	chr14:106673171	chr14:106627249~106627825:-
LUAD	cis	rs155076	1	rs261431	ENSG00000233325.3	MIPEPP3	-6.39	3.87e-10	1.95e-07	-0.42	-0.28	White matter hyperintensity burden;	chr13:21291599	chr13:21298139~21306373:+
LUAD	cis	rs111580313	0.792	rs79430710	ENSG00000270020.1	RP11-463O9.9	6.39	3.87e-10	1.95e-07	0.68	0.28	Systemic juvenile idiopathic arthritis;	chr16:86575505	chr16:86520383~86523897:-
LUAD	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-6.39	3.88e-10	1.95e-07	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
LUAD	cis	rs17301013	0.507	rs10912791	ENSG00000227373.4	RP11-160H22.5	6.39	3.89e-10	1.95e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174479298	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12079334	ENSG00000227373.4	RP11-160H22.5	6.39	3.89e-10	1.95e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174480815	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4652494	ENSG00000227373.4	RP11-160H22.5	6.39	3.89e-10	1.95e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174495861	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs7537823	ENSG00000227373.4	RP11-160H22.5	6.39	3.89e-10	1.95e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174502222	chr1:174115300~174160004:-
LUAD	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	6.39	3.89e-10	1.95e-07	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
LUAD	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-6.39	3.89e-10	1.95e-07	-0.31	-0.28	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-6.39	3.89e-10	1.95e-07	-0.31	-0.28	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
LUAD	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-6.39	3.9e-10	1.96e-07	-0.34	-0.28	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
LUAD	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	6.39	3.9e-10	1.96e-07	0.41	0.28	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
LUAD	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	6.39	3.91e-10	1.96e-07	0.39	0.28	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	6.39	3.91e-10	1.96e-07	0.39	0.28	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
LUAD	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	6.39	3.91e-10	1.97e-07	0.34	0.28	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
LUAD	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	6.39	3.92e-10	1.97e-07	0.31	0.28	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
LUAD	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	6.39	3.92e-10	1.97e-07	0.31	0.28	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
LUAD	cis	rs2221433	1	rs1110269	ENSG00000260310.1	RP11-27M24.2	-6.39	3.92e-10	1.97e-07	-0.31	-0.28	Eating disorders;	chr16:10578731	chr16:10576499~10578183:-
LUAD	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-6.39	3.93e-10	1.97e-07	-0.32	-0.28	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
LUAD	cis	rs6844153	1	rs74601981	ENSG00000240005.4	RP11-293A21.1	-6.39	3.93e-10	1.97e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915639	chr4:26859806~26860599:-
LUAD	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	6.39	3.93e-10	1.98e-07	0.29	0.28	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
LUAD	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	6.39	3.93e-10	1.98e-07	0.39	0.28	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	6.39	3.94e-10	1.98e-07	0.43	0.28	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
LUAD	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	6.39	3.94e-10	1.98e-07	0.35	0.28	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
LUAD	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-6.39	3.95e-10	1.98e-07	-0.33	-0.28	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
LUAD	cis	rs1707322	0.752	rs11488313	ENSG00000234329.1	RP11-767N6.2	6.39	3.96e-10	1.98e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45651039~45651826:-
LUAD	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-6.39	3.96e-10	1.98e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
LUAD	cis	rs1707322	0.752	rs11211145	ENSG00000234329.1	RP11-767N6.2	6.39	3.96e-10	1.99e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45651039~45651826:-
LUAD	cis	rs11096990	0.892	rs11932351	ENSG00000249207.1	RP11-360F5.1	6.39	3.96e-10	1.99e-07	0.31	0.28	Cognitive function;	chr4:39229837	chr4:39112677~39126818:-
LUAD	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-6.39	3.97e-10	1.99e-07	-0.3	-0.28	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
LUAD	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-6.39	3.97e-10	1.99e-07	-0.36	-0.28	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
LUAD	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	6.39	3.97e-10	1.99e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
LUAD	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	6.39	3.97e-10	1.99e-07	0.34	0.28	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
LUAD	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-6.39	3.98e-10	2e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-6.39	3.98e-10	2e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-6.39	3.98e-10	2e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
LUAD	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	6.39	3.98e-10	2e-07	0.32	0.28	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
LUAD	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	6.39	3.99e-10	2e-07	0.31	0.28	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
LUAD	cis	rs17301013	0.507	rs11810824	ENSG00000227373.4	RP11-160H22.5	-6.39	4e-10	2.01e-07	-0.4	-0.28	Systemic lupus erythematosus;	chr1:174408223	chr1:174115300~174160004:-
LUAD	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
LUAD	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	6.39	4.01e-10	2.01e-07	0.32	0.28	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
LUAD	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
LUAD	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	6.39	4.02e-10	2.01e-07	0.35	0.28	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
LUAD	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	6.39	4.02e-10	2.01e-07	0.35	0.28	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
LUAD	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	6.39	4.02e-10	2.01e-07	0.35	0.28	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
LUAD	cis	rs8031584	0.918	rs11639169	ENSG00000260382.1	RP11-540B6.2	6.39	4.03e-10	2.02e-07	0.34	0.28	Huntington's disease progression;	chr15:30963235	chr15:30882267~30883231:-
LUAD	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	6.39	4.03e-10	2.02e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
LUAD	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	6.39	4.03e-10	2.02e-07	0.41	0.28	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
LUAD	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-6.39	4.03e-10	2.02e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.686	rs8001047	ENSG00000212293.1	SNORA16	-6.39	4.04e-10	2.02e-07	-0.29	-0.28	Body mass index;	chr13:32802746	chr13:32420390~32420516:-
LUAD	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-6.39	4.04e-10	2.02e-07	-0.39	-0.28	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
LUAD	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	6.39	4.04e-10	2.02e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
LUAD	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-6.38	4.05e-10	2.03e-07	-0.38	-0.28	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-6.38	4.05e-10	2.03e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
LUAD	cis	rs6991838	0.778	rs11782837	ENSG00000200714.1	Y_RNA	6.38	4.05e-10	2.03e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65592731~65592820:+
LUAD	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	6.38	4.05e-10	2.03e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	6.38	4.05e-10	2.03e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	6.38	4.05e-10	2.03e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
LUAD	cis	rs12699921	0.632	rs12699918	ENSG00000279048.1	RP11-511H23.2	6.38	4.05e-10	2.03e-07	0.23	0.28	Fibrinogen levels;	chr7:17930277	chr7:17940503~17942922:+
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000232546.1	RP11-458F8.1	6.38	4.06e-10	2.03e-07	0.37	0.28	Diabetic kidney disease;	chr7:66170354	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2420171	ENSG00000232546.1	RP11-458F8.1	6.38	4.06e-10	2.03e-07	0.37	0.28	Diabetic kidney disease;	chr7:66172773	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6974723	ENSG00000232546.1	RP11-458F8.1	6.38	4.06e-10	2.03e-07	0.37	0.28	Diabetic kidney disease;	chr7:66172952	chr7:66848496~66858136:+
LUAD	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	6.38	4.06e-10	2.03e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
LUAD	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	6.38	4.07e-10	2.04e-07	0.39	0.28	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
LUAD	cis	rs12468226	1	rs13389798	ENSG00000226261.1	AC064836.3	6.38	4.07e-10	2.04e-07	0.46	0.28	Urate levels;	chr2:202348370	chr2:202336024~202336727:-
LUAD	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-6.38	4.09e-10	2.05e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-6.38	4.09e-10	2.05e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
LUAD	cis	rs8059260	0.799	rs7194545	ENSG00000274038.1	RP11-66H6.4	-6.38	4.09e-10	2.05e-07	-0.39	-0.28	Alcohol consumption over the past year;	chr16:11030439	chr16:11056556~11057034:+
LUAD	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-6.38	4.09e-10	2.05e-07	-0.37	-0.28	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
LUAD	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-6.38	4.09e-10	2.05e-07	-0.3	-0.28	Height;	chr11:118749988	chr11:118791254~118793137:+
LUAD	cis	rs155076	1	rs261423	ENSG00000233325.3	MIPEPP3	6.38	4.09e-10	2.05e-07	0.44	0.28	White matter hyperintensity burden;	chr13:21278192	chr13:21298139~21306373:+
LUAD	cis	rs496547	0.686	rs540180	ENSG00000255422.1	AP002954.4	-6.38	4.09e-10	2.05e-07	-0.36	-0.28	Hip minimal joint space width;	chr11:118782920	chr11:118704607~118750263:+
LUAD	cis	rs496547	0.686	rs2508916	ENSG00000255422.1	AP002954.4	-6.38	4.09e-10	2.05e-07	-0.36	-0.28	Hip minimal joint space width;	chr11:118783942	chr11:118704607~118750263:+
LUAD	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	6.38	4.09e-10	2.05e-07	0.37	0.28	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
LUAD	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	6.38	4.1e-10	2.05e-07	0.26	0.28	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
LUAD	cis	rs1707322	0.682	rs10890334	ENSG00000234329.1	RP11-767N6.2	6.38	4.1e-10	2.05e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.682	rs10890335	ENSG00000234329.1	RP11-767N6.2	6.38	4.1e-10	2.05e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45651039~45651826:-
LUAD	cis	rs56751865	1	rs56751865	ENSG00000254851.1	RP11-109L13.1	6.38	4.1e-10	2.05e-07	0.69	0.28	Lobe attachment (rater scored);	chr11:117066155	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-6.38	4.11e-10	2.05e-07	-0.31	-0.28	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
LUAD	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-6.38	4.11e-10	2.06e-07	-0.44	-0.28	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
LUAD	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	6.38	4.11e-10	2.06e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
LUAD	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	6.38	4.12e-10	2.06e-07	0.43	0.28	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
LUAD	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-6.38	4.12e-10	2.06e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000228039.3	KB-1125A3.10	6.38	4.12e-10	2.06e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23963780~23964374:+
LUAD	cis	rs1707322	0.752	rs4660313	ENSG00000234329.1	RP11-767N6.2	-6.38	4.12e-10	2.06e-07	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45651039~45651826:-
LUAD	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	6.38	4.13e-10	2.06e-07	0.31	0.28	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
LUAD	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	6.38	4.13e-10	2.06e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
LUAD	cis	rs7688540	0.8	rs61792060	ENSG00000275426.1	CH17-262A2.1	6.38	4.13e-10	2.06e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:149738~150317:+
LUAD	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	6.38	4.13e-10	2.06e-07	0.32	0.28	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
LUAD	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	6.38	4.13e-10	2.07e-07	0.29	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
LUAD	cis	rs35955747	0.902	rs140074	ENSG00000236132.1	CTA-440B3.1	-6.38	4.14e-10	2.07e-07	-0.31	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31329648	chr22:31816379~31817491:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-6.38	4.15e-10	2.07e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-6.38	4.15e-10	2.07e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-6.38	4.15e-10	2.07e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-6.38	4.15e-10	2.07e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
LUAD	cis	rs1707322	0.721	rs10890341	ENSG00000234329.1	RP11-767N6.2	6.38	4.15e-10	2.08e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45651039~45651826:-
LUAD	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	6.38	4.16e-10	2.08e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
LUAD	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-6.38	4.16e-10	2.08e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
LUAD	cis	rs9910055	0.664	rs433610	ENSG00000267080.4	ASB16-AS1	6.38	4.17e-10	2.08e-07	0.25	0.28	Total body bone mineral density;	chr17:44119913	chr17:44175973~44186717:-
LUAD	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-6.38	4.19e-10	2.09e-07	-0.28	-0.28	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
LUAD	cis	rs9595908	0.709	rs916289	ENSG00000212293.1	SNORA16	6.38	4.2e-10	2.1e-07	0.3	0.28	Body mass index;	chr13:32792110	chr13:32420390~32420516:-
LUAD	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	6.38	4.2e-10	2.1e-07	0.34	0.28	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs160639	ENSG00000232546.1	RP11-458F8.1	-6.38	4.2e-10	2.1e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66115000	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000232546.1	RP11-458F8.1	-6.38	4.2e-10	2.1e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66116220	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000232546.1	RP11-458F8.1	-6.38	4.2e-10	2.1e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66117071	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000232546.1	RP11-458F8.1	-6.38	4.2e-10	2.1e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66119331	chr7:66848496~66858136:+
LUAD	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	6.38	4.21e-10	2.1e-07	0.31	0.28	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
LUAD	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-6.38	4.22e-10	2.1e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
LUAD	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	6.38	4.22e-10	2.11e-07	0.38	0.28	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
LUAD	cis	rs1823913	0.614	rs6755243	ENSG00000280083.1	RP11-317J9.1	6.38	4.23e-10	2.11e-07	0.33	0.28	Obesity-related traits;	chr2:191269810	chr2:191154118~191156070:-
LUAD	cis	rs155076	1	rs9509638	ENSG00000233325.3	MIPEPP3	6.38	4.23e-10	2.11e-07	0.45	0.28	White matter hyperintensity burden;	chr13:21286054	chr13:21298139~21306373:+
LUAD	cis	rs5753618	0.561	rs5753543	ENSG00000236132.1	CTA-440B3.1	6.38	4.23e-10	2.11e-07	0.35	0.28	Colorectal cancer;	chr22:31289472	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs2413049	ENSG00000236132.1	CTA-440B3.1	6.38	4.23e-10	2.11e-07	0.35	0.28	Colorectal cancer;	chr22:31290158	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-6.38	4.23e-10	2.11e-07	-0.35	-0.28	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
LUAD	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-6.38	4.23e-10	2.11e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
LUAD	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-6.38	4.23e-10	2.11e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-6.38	4.23e-10	2.11e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
LUAD	cis	rs2708377	0.789	rs3911150	ENSG00000247157.5	LINC01252	-6.38	4.24e-10	2.11e-07	-0.47	-0.28	Bitter taste perception;	chr12:11049649	chr12:11548030~11590369:+
LUAD	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-6.38	4.24e-10	2.11e-07	-0.31	-0.28	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
LUAD	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-6.38	4.24e-10	2.11e-07	-0.31	-0.28	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
LUAD	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	6.38	4.25e-10	2.12e-07	0.42	0.28	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
LUAD	cis	rs10740039	0.883	rs1442545	ENSG00000254271.1	RP11-131N11.4	6.38	4.25e-10	2.12e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650268	chr10:60734342~60741828:+
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000206090.4	AP000350.7	6.38	4.26e-10	2.12e-07	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23939998~23942798:+
LUAD	cis	rs72772090	0.634	rs17401901	ENSG00000248734.2	CTD-2260A17.1	-6.38	4.27e-10	2.13e-07	-0.4	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.634	rs72773906	ENSG00000248734.2	CTD-2260A17.1	-6.38	4.27e-10	2.13e-07	-0.4	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96784777~96785999:+
LUAD	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	6.38	4.27e-10	2.13e-07	0.34	0.28	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
LUAD	cis	rs293748	0.66	rs61748200	ENSG00000250155.1	CTD-2353F22.1	-6.38	4.27e-10	2.13e-07	-0.4	-0.28	Obesity-related traits;	chr5:37036390	chr5:36666214~36725195:-
LUAD	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-6.38	4.29e-10	2.14e-07	-0.33	-0.28	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
LUAD	cis	rs7688540	0.8	rs28531997	ENSG00000275426.1	CH17-262A2.1	6.38	4.29e-10	2.14e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:149738~150317:+
LUAD	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
LUAD	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	6.38	4.29e-10	2.14e-07	0.29	0.28	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
LUAD	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-6.38	4.29e-10	2.14e-07	-0.37	-0.28	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-6.38	4.29e-10	2.14e-07	-0.37	-0.28	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
LUAD	cis	rs2243480	1	rs313820	ENSG00000232546.1	RP11-458F8.1	-6.37	4.29e-10	2.14e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66109479	chr7:66848496~66858136:+
LUAD	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-6.37	4.29e-10	2.14e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-6.37	4.29e-10	2.14e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-6.37	4.29e-10	2.14e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
LUAD	cis	rs12468226	1	rs16839090	ENSG00000226261.1	AC064836.3	6.37	4.3e-10	2.14e-07	0.46	0.28	Urate levels;	chr2:202348338	chr2:202336024~202336727:-
LUAD	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	6.37	4.3e-10	2.14e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
LUAD	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-6.37	4.3e-10	2.14e-07	-0.32	-0.28	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
LUAD	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-6.37	4.31e-10	2.15e-07	-0.38	-0.28	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
LUAD	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-6.37	4.31e-10	2.15e-07	-0.32	-0.28	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
LUAD	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-6.37	4.31e-10	2.15e-07	-0.32	-0.28	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
LUAD	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-6.37	4.31e-10	2.15e-07	-0.36	-0.28	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
LUAD	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-6.37	4.32e-10	2.15e-07	-0.35	-0.28	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
LUAD	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	6.37	4.32e-10	2.15e-07	0.52	0.28	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
LUAD	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	6.37	4.32e-10	2.15e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs34702770	ENSG00000232546.1	RP11-458F8.1	-6.37	4.32e-10	2.15e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65879836	chr7:66848496~66858136:+
LUAD	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	6.37	4.33e-10	2.15e-07	0.41	0.28	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	6.37	4.33e-10	2.15e-07	0.41	0.28	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-6.37	4.33e-10	2.15e-07	-0.48	-0.28	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
LUAD	cis	rs35740288	0.77	rs55740125	ENSG00000202081.1	RNU6-1280P	6.37	4.33e-10	2.16e-07	0.34	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612505	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs4843085	ENSG00000202081.1	RNU6-1280P	6.37	4.33e-10	2.16e-07	0.34	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85615268	chr15:85651522~85651628:-
LUAD	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	6.37	4.33e-10	2.16e-07	0.38	0.28	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
LUAD	cis	rs755249	0.917	rs72663503	ENSG00000228060.1	RP11-69E11.8	-6.37	4.34e-10	2.16e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39565160~39573203:+
LUAD	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-6.37	4.34e-10	2.16e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
LUAD	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	6.37	4.34e-10	2.16e-07	0.36	0.28	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
LUAD	cis	rs7246657	0.551	rs10404069	ENSG00000276846.1	CTD-3220F14.3	6.37	4.34e-10	2.16e-07	0.43	0.28	Coronary artery calcification;	chr19:37147502	chr19:37314868~37315620:-
LUAD	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-6.37	4.34e-10	2.16e-07	-0.33	-0.28	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
LUAD	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	6.37	4.35e-10	2.16e-07	0.33	0.28	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
LUAD	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	6.37	4.36e-10	2.17e-07	0.35	0.28	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
LUAD	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	6.37	4.36e-10	2.17e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
LUAD	cis	rs7688540	0.76	rs28460123	ENSG00000275426.1	CH17-262A2.1	6.37	4.36e-10	2.17e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:149738~150317:+
LUAD	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	6.37	4.37e-10	2.18e-07	0.34	0.28	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
LUAD	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	6.37	4.38e-10	2.18e-07	0.3	0.28	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.507	rs1474575	ENSG00000227373.4	RP11-160H22.5	-6.37	4.38e-10	2.18e-07	-0.41	-0.28	Systemic lupus erythematosus;	chr1:174569563	chr1:174115300~174160004:-
LUAD	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
LUAD	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-6.37	4.39e-10	2.18e-07	-0.37	-0.28	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-6.37	4.39e-10	2.18e-07	-0.37	-0.28	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
LUAD	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	6.37	4.4e-10	2.19e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
LUAD	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	6.37	4.4e-10	2.19e-07	0.32	0.28	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
LUAD	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	6.37	4.4e-10	2.19e-07	0.32	0.28	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
LUAD	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-6.37	4.4e-10	2.19e-07	-0.35	-0.28	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
LUAD	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-6.37	4.41e-10	2.19e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
LUAD	cis	rs465969	1	rs17510733	ENSG00000255389.1	C6orf3	-6.37	4.41e-10	2.19e-07	-0.61	-0.28	Psoriasis;	chr6:111389715	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-6.37	4.41e-10	2.19e-07	-0.61	-0.28	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-6.37	4.41e-10	2.19e-07	-0.61	-0.28	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
LUAD	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	6.37	4.41e-10	2.19e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
LUAD	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-6.37	4.42e-10	2.2e-07	-0.35	-0.28	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-6.37	4.42e-10	2.2e-07	-0.35	-0.28	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-6.37	4.42e-10	2.2e-07	-0.35	-0.28	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
LUAD	cis	rs17301013	0.507	rs2281011	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174509890	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2072759	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174510189	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4652511	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174515500	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4652513	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174515794	chr1:174115300~174160004:-
LUAD	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	6.37	4.43e-10	2.2e-07	0.31	0.28	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
LUAD	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	6.37	4.43e-10	2.2e-07	0.29	0.28	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
LUAD	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-6.37	4.43e-10	2.2e-07	-0.37	-0.28	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
LUAD	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	6.37	4.44e-10	2.2e-07	0.53	0.28	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
LUAD	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	6.37	4.44e-10	2.21e-07	0.3	0.28	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	6.37	4.45e-10	2.21e-07	0.31	0.28	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
LUAD	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-6.37	4.45e-10	2.21e-07	-0.29	-0.28	Height;	chr11:118764443	chr11:118791254~118793137:+
LUAD	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	6.37	4.45e-10	2.21e-07	0.31	0.28	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	6.37	4.45e-10	2.21e-07	0.31	0.28	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
LUAD	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs781150	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66015986	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66028044	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.531	rs332806	ENSG00000227373.4	RP11-160H22.5	6.37	4.46e-10	2.21e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174653645	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs316321	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66146626	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316318	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66147917	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316317	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66148650	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	6.37	4.46e-10	2.21e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
LUAD	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-6.37	4.48e-10	2.22e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
LUAD	cis	rs2243480	1	rs1546059	ENSG00000232546.1	RP11-458F8.1	6.37	4.48e-10	2.22e-07	0.36	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6958289	ENSG00000232546.1	RP11-458F8.1	6.37	4.48e-10	2.22e-07	0.36	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66848496~66858136:+
LUAD	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	6.37	4.48e-10	2.22e-07	0.31	0.28	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	6.37	4.48e-10	2.22e-07	0.31	0.28	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	6.37	4.48e-10	2.22e-07	0.31	0.28	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
LUAD	cis	rs2378497	0.564	rs115883774	ENSG00000232679.1	RP11-400N13.3	6.37	4.48e-10	2.23e-07	0.33	0.28	Serum thyroid-stimulating hormone levels;	chr1:221986970	chr1:222041705~222064763:-
LUAD	cis	rs1707322	0.752	rs11211146	ENSG00000234329.1	RP11-767N6.2	6.37	4.5e-10	2.23e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs11211147	ENSG00000234329.1	RP11-767N6.2	6.37	4.5e-10	2.23e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45651039~45651826:-
LUAD	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	6.37	4.52e-10	2.24e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
LUAD	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-6.37	4.52e-10	2.24e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
LUAD	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	6.37	4.52e-10	2.24e-07	0.35	0.28	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000228039.3	KB-1125A3.10	6.37	4.53e-10	2.25e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23963780~23964374:+
LUAD	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	6.37	4.53e-10	2.25e-07	0.32	0.28	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
LUAD	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	6.37	4.54e-10	2.25e-07	0.3	0.28	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
LUAD	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-6.37	4.54e-10	2.25e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
LUAD	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	6.37	4.55e-10	2.25e-07	0.37	0.28	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
LUAD	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	6.37	4.55e-10	2.25e-07	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	6.37	4.55e-10	2.25e-07	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
LUAD	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-6.37	4.55e-10	2.26e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
LUAD	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-6.37	4.55e-10	2.26e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
LUAD	cis	rs853679	0.517	rs16893666	ENSG00000204709.4	LINC01556	-6.37	4.55e-10	2.26e-07	-0.39	-0.28	Depression;	chr6:28086929	chr6:28943877~28944537:+
LUAD	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	6.37	4.55e-10	2.26e-07	0.36	0.28	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
LUAD	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-6.37	4.56e-10	2.26e-07	-0.31	-0.28	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
LUAD	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	6.36	4.56e-10	2.26e-07	0.4	0.28	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
LUAD	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	6.36	4.56e-10	2.26e-07	0.4	0.28	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
LUAD	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	6.36	4.56e-10	2.26e-07	0.47	0.28	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
LUAD	cis	rs7176527	0.784	rs62021162	ENSG00000188388.10	GOLGA6L3	6.36	4.57e-10	2.26e-07	0.37	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85240472~85247170:+
LUAD	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	6.36	4.57e-10	2.26e-07	0.32	0.28	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
LUAD	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	6.36	4.57e-10	2.26e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
LUAD	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	6.36	4.57e-10	2.26e-07	0.31	0.28	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
LUAD	cis	rs155076	1	rs155076	ENSG00000233325.3	MIPEPP3	6.36	4.57e-10	2.26e-07	0.45	0.28	White matter hyperintensity burden;	chr13:21295975	chr13:21298139~21306373:+
LUAD	cis	rs6504622	0.875	rs3851786	ENSG00000262879.4	RP11-156P1.3	6.36	4.57e-10	2.27e-07	0.33	0.28	Orofacial clefts;	chr17:46969566	chr17:46984045~47100323:-
LUAD	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	6.36	4.58e-10	2.27e-07	0.32	0.28	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
LUAD	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	6.36	4.58e-10	2.27e-07	0.32	0.28	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
LUAD	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	6.36	4.58e-10	2.27e-07	0.3	0.28	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
LUAD	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	6.36	4.58e-10	2.27e-07	0.24	0.28	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
LUAD	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-6.36	4.58e-10	2.27e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000232546.1	RP11-458F8.1	-6.36	4.59e-10	2.27e-07	-0.37	-0.28	Gout;	chr7:66654674	chr7:66848496~66858136:+
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000232546.1	RP11-458F8.1	-6.36	4.59e-10	2.27e-07	-0.37	-0.28	Gout;	chr7:66661502	chr7:66848496~66858136:+
LUAD	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-6.36	4.6e-10	2.28e-07	-0.29	-0.28	Height;	chr11:118760944	chr11:118791254~118793137:+
LUAD	cis	rs1012068	0.686	rs4820996	ENSG00000236132.1	CTA-440B3.1	-6.36	4.61e-10	2.28e-07	-0.33	-0.28	Chronic hepatitis C infection;	chr22:31928044	chr22:31816379~31817491:-
LUAD	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	6.36	4.61e-10	2.28e-07	0.34	0.28	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
LUAD	cis	rs7246657	0.551	rs10407224	ENSG00000276846.1	CTD-3220F14.3	6.36	4.61e-10	2.28e-07	0.43	0.28	Coronary artery calcification;	chr19:37160568	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	6.36	4.61e-10	2.28e-07	0.35	0.28	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	6.36	4.61e-10	2.28e-07	0.35	0.28	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
LUAD	cis	rs4141404	0.818	rs5997897	ENSG00000236132.1	CTA-440B3.1	6.36	4.61e-10	2.28e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31174450	chr22:31816379~31817491:-
LUAD	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	6.36	4.61e-10	2.28e-07	0.32	0.28	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
LUAD	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	6.36	4.62e-10	2.29e-07	0.29	0.28	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
LUAD	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-6.36	4.62e-10	2.29e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000232546.1	RP11-458F8.1	-6.36	4.63e-10	2.29e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65892097	chr7:66848496~66858136:+
LUAD	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-6.36	4.63e-10	2.29e-07	-0.41	-0.28	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
LUAD	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	6.36	4.63e-10	2.29e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
LUAD	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	6.36	4.63e-10	2.29e-07	0.37	0.28	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
LUAD	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-6.36	4.63e-10	2.29e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
LUAD	cis	rs4713118	0.621	rs9368548	ENSG00000204709.4	LINC01556	6.36	4.63e-10	2.29e-07	0.39	0.28	Parkinson's disease;	chr6:28066959	chr6:28943877~28944537:+
LUAD	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	6.36	4.63e-10	2.29e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
LUAD	cis	rs12699921	0.566	rs2723515	ENSG00000279048.1	RP11-511H23.2	-6.36	4.63e-10	2.29e-07	-0.22	-0.28	Fibrinogen levels;	chr7:17815843	chr7:17940503~17942922:+
LUAD	cis	rs7017914	0.967	rs17689955	ENSG00000223220.1	Y_RNA	6.36	4.63e-10	2.29e-07	0.31	0.28	Bone mineral density;	chr8:70936629	chr8:70780914~70781008:-
LUAD	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-6.36	4.64e-10	2.29e-07	-0.31	-0.28	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
LUAD	cis	rs6772849	0.93	rs9813197	ENSG00000242551.2	POU5F1P6	-6.36	4.64e-10	2.3e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:128674735~128677005:-
LUAD	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	6.36	4.64e-10	2.3e-07	0.32	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
LUAD	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-6.36	4.64e-10	2.3e-07	-0.35	-0.28	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
LUAD	cis	rs755249	0.567	rs1126313	ENSG00000228060.1	RP11-69E11.8	6.36	4.65e-10	2.3e-07	0.28	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39565160~39573203:+
LUAD	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	6.36	4.65e-10	2.3e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.734	rs67119537	ENSG00000225151.9	GOLGA2P7	-6.36	4.65e-10	2.3e-07	-0.36	-0.28	Schizophrenia;	chr15:84395671	chr15:84199311~84230136:-
LUAD	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-6.36	4.66e-10	2.31e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
LUAD	cis	rs35934224	0.783	rs7288061	ENSG00000232926.1	AC000078.5	6.36	4.68e-10	2.31e-07	0.35	0.28	Glaucoma (primary open-angle);	chr22:19876716	chr22:19887289~19887970:+
LUAD	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-6.36	4.68e-10	2.32e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
LUAD	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-6.36	4.69e-10	2.32e-07	-0.4	-0.28	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	6.36	4.69e-10	2.32e-07	0.39	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
LUAD	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	6.36	4.69e-10	2.32e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
LUAD	cis	rs7017914	0.905	rs2639957	ENSG00000223220.1	Y_RNA	6.36	4.71e-10	2.33e-07	0.31	0.28	Bone mineral density;	chr8:71010967	chr8:70780914~70781008:-
LUAD	cis	rs2243480	1	rs9769882	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66177938	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6966322	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66181767	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4145008	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66182524	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4718315	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66183554	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4718316	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66183744	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1873494	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6959002	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66848496~66858136:+
LUAD	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-6.36	4.71e-10	2.33e-07	-0.35	-0.28	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
LUAD	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	6.36	4.72e-10	2.33e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
LUAD	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-6.36	4.73e-10	2.34e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
LUAD	cis	rs8031584	0.918	rs61997138	ENSG00000260382.1	RP11-540B6.2	6.36	4.73e-10	2.34e-07	0.33	0.28	Huntington's disease progression;	chr15:30978573	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.918	rs61997140	ENSG00000260382.1	RP11-540B6.2	6.36	4.73e-10	2.34e-07	0.33	0.28	Huntington's disease progression;	chr15:30985109	chr15:30882267~30883231:-
LUAD	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	6.36	4.74e-10	2.34e-07	0.43	0.28	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
LUAD	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	6.36	4.74e-10	2.34e-07	0.43	0.28	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
LUAD	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	6.36	4.75e-10	2.35e-07	0.32	0.28	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	6.36	4.75e-10	2.35e-07	0.32	0.28	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
LUAD	cis	rs2911132	1	rs2911140	ENSG00000248734.2	CTD-2260A17.1	6.36	4.75e-10	2.35e-07	0.29	0.28	Urate levels (BMI interaction);	chr5:96844240	chr5:96784777~96785999:+
LUAD	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-6.36	4.76e-10	2.35e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
LUAD	cis	rs9640161	0.789	rs11767409	ENSG00000261305.1	RP4-584D14.7	6.36	4.76e-10	2.35e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150360954	chr7:150341771~150342607:+
LUAD	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	6.36	4.76e-10	2.35e-07	0.34	0.28	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
LUAD	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	6.36	4.77e-10	2.35e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	6.36	4.77e-10	2.35e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	6.36	4.77e-10	2.35e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	6.36	4.77e-10	2.35e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
LUAD	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
LUAD	cis	rs9549367	0.756	rs9549702	ENSG00000269125.1	RP11-98F14.11	-6.36	4.77e-10	2.36e-07	-0.34	-0.28	Platelet distribution width;	chr13:113227630	chr13:113165002~113165183:-
LUAD	cis	rs853679	0.517	rs9393891	ENSG00000204709.4	LINC01556	6.36	4.77e-10	2.36e-07	0.39	0.28	Depression;	chr6:28111382	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9468286	ENSG00000204709.4	LINC01556	6.36	4.77e-10	2.36e-07	0.39	0.28	Depression;	chr6:28111650	chr6:28943877~28944537:+
LUAD	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	6.36	4.78e-10	2.36e-07	0.35	0.28	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
LUAD	cis	rs2911132	1	rs2911130	ENSG00000248734.2	CTD-2260A17.1	6.36	4.78e-10	2.36e-07	0.29	0.28	Urate levels (BMI interaction);	chr5:96847724	chr5:96784777~96785999:+
LUAD	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	6.36	4.78e-10	2.36e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
LUAD	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	6.36	4.78e-10	2.36e-07	0.24	0.28	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	6.36	4.78e-10	2.36e-07	0.24	0.28	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
LUAD	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	6.36	4.8e-10	2.37e-07	0.31	0.28	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	6.36	4.8e-10	2.37e-07	0.31	0.28	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
LUAD	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-6.36	4.8e-10	2.37e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
LUAD	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	6.36	4.81e-10	2.37e-07	0.32	0.28	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
LUAD	cis	rs1707322	0.716	rs6694889	ENSG00000234329.1	RP11-767N6.2	6.36	4.81e-10	2.37e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.682	rs12041197	ENSG00000234329.1	RP11-767N6.2	6.36	4.81e-10	2.37e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-6.36	4.81e-10	2.37e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
LUAD	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	6.36	4.81e-10	2.37e-07	0.42	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
LUAD	cis	rs75422866	0.51	rs73105845	ENSG00000274902.1	RP1-197B17.4	6.36	4.82e-10	2.38e-07	0.64	0.28	Pneumonia;	chr12:47741824	chr12:47731908~47732351:+
LUAD	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	6.36	4.82e-10	2.38e-07	0.39	0.28	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
LUAD	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	6.36	4.82e-10	2.38e-07	0.39	0.28	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
LUAD	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	6.36	4.83e-10	2.38e-07	0.34	0.28	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
LUAD	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-6.36	4.83e-10	2.38e-07	-0.29	-0.28	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
LUAD	cis	rs2412819	0.571	rs4923965	ENSG00000205771.5	CATSPER2P1	6.36	4.83e-10	2.38e-07	0.43	0.28	Lung cancer;	chr15:43790232	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs4644832	ENSG00000205771.5	CATSPER2P1	6.36	4.83e-10	2.38e-07	0.43	0.28	Lung cancer;	chr15:43792507	chr15:43726918~43747094:-
LUAD	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-6.36	4.83e-10	2.38e-07	-0.53	-0.28	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
LUAD	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-6.36	4.84e-10	2.39e-07	-0.27	-0.28	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
LUAD	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-6.36	4.84e-10	2.39e-07	-0.27	-0.28	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
LUAD	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-6.36	4.84e-10	2.39e-07	-0.34	-0.28	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
LUAD	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-6.36	4.84e-10	2.39e-07	-0.38	-0.28	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
LUAD	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	6.36	4.84e-10	2.39e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
LUAD	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	6.35	4.85e-10	2.39e-07	0.31	0.28	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
LUAD	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-6.35	4.85e-10	2.39e-07	-0.29	-0.28	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
LUAD	cis	rs35955747	1	rs35955747	ENSG00000236132.1	CTA-440B3.1	6.35	4.85e-10	2.39e-07	0.31	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31417072	chr22:31816379~31817491:-
LUAD	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	6.35	4.86e-10	2.39e-07	0.31	0.28	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	6.35	4.86e-10	2.39e-07	0.31	0.28	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
LUAD	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	6.35	4.86e-10	2.4e-07	0.31	0.28	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
LUAD	cis	rs1823913	1	rs11691372	ENSG00000230611.1	HMGB1P27	6.35	4.87e-10	2.4e-07	0.33	0.28	Obesity-related traits;	chr2:191249952	chr2:191174233~191174835:+
LUAD	cis	rs17301013	0.507	rs1793292	ENSG00000227373.4	RP11-160H22.5	-6.35	4.88e-10	2.4e-07	-0.4	-0.28	Systemic lupus erythematosus;	chr1:174778185	chr1:174115300~174160004:-
LUAD	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-6.35	4.88e-10	2.41e-07	-0.33	-0.28	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
LUAD	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	6.35	4.88e-10	2.41e-07	0.41	0.28	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
LUAD	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	6.35	4.89e-10	2.41e-07	0.33	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
LUAD	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-6.35	4.89e-10	2.41e-07	-0.35	-0.28	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-6.35	4.89e-10	2.41e-07	-0.35	-0.28	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
LUAD	cis	rs11096990	0.855	rs2711935	ENSG00000249207.1	RP11-360F5.1	6.35	4.9e-10	2.41e-07	0.32	0.28	Cognitive function;	chr4:39160837	chr4:39112677~39126818:-
LUAD	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	6.35	4.9e-10	2.42e-07	0.32	0.28	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-6.35	4.9e-10	2.42e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-6.35	4.9e-10	2.42e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
LUAD	cis	rs7688540	0.8	rs73793597	ENSG00000275426.1	CH17-262A2.1	6.35	4.91e-10	2.42e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:149738~150317:+
LUAD	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	6.35	4.92e-10	2.42e-07	0.34	0.28	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-6.35	4.93e-10	2.43e-07	-0.3	-0.28	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
LUAD	cis	rs5753618	0.561	rs1858821	ENSG00000236132.1	CTA-440B3.1	6.35	4.93e-10	2.43e-07	0.35	0.28	Colorectal cancer;	chr22:31280468	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.519	rs5997939	ENSG00000236132.1	CTA-440B3.1	6.35	4.93e-10	2.43e-07	0.35	0.28	Colorectal cancer;	chr22:31281144	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs2040533	ENSG00000236132.1	CTA-440B3.1	6.35	4.93e-10	2.43e-07	0.35	0.28	Colorectal cancer;	chr22:31283124	chr22:31816379~31817491:-
LUAD	cis	rs7688540	0.76	rs2883229	ENSG00000275426.1	CH17-262A2.1	6.35	4.93e-10	2.43e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:149738~150317:+
LUAD	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	6.35	4.93e-10	2.43e-07	0.38	0.28	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
LUAD	cis	rs17301013	0.507	rs1793298	ENSG00000227373.4	RP11-160H22.5	-6.35	4.93e-10	2.43e-07	-0.4	-0.28	Systemic lupus erythematosus;	chr1:174784601	chr1:174115300~174160004:-
LUAD	cis	rs1707322	0.721	rs4660314	ENSG00000234329.1	RP11-767N6.2	6.35	4.93e-10	2.43e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12069121	ENSG00000234329.1	RP11-767N6.2	6.35	4.93e-10	2.43e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs61784833	ENSG00000234329.1	RP11-767N6.2	6.35	4.93e-10	2.43e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs35825738	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	2.43e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65853040	chr7:66848496~66858136:+
LUAD	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-6.35	4.94e-10	2.43e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
LUAD	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	6.35	4.94e-10	2.43e-07	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
LUAD	cis	rs62025270	0.547	rs338540	ENSG00000202081.1	RNU6-1280P	6.35	4.95e-10	2.44e-07	0.34	0.28	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85651522~85651628:-
LUAD	cis	rs4141404	0.923	rs2413046	ENSG00000236132.1	CTA-440B3.1	6.35	4.95e-10	2.44e-07	0.35	0.28	Paclitaxel-induced neuropathy;	chr22:31269923	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs2413047	ENSG00000236132.1	CTA-440B3.1	6.35	4.95e-10	2.44e-07	0.35	0.28	Colorectal cancer;	chr22:31270040	chr22:31816379~31817491:-
LUAD	cis	rs34526934	0.608	rs7591820	ENSG00000226363.3	HAGLROS	6.35	4.95e-10	2.44e-07	0.38	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176163416	chr2:176177717~176179008:+
LUAD	cis	rs34526934	0.608	rs7606110	ENSG00000226363.3	HAGLROS	6.35	4.95e-10	2.44e-07	0.38	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176163823	chr2:176177717~176179008:+
LUAD	cis	rs17301013	0.507	rs6689327	ENSG00000227373.4	RP11-160H22.5	6.35	4.96e-10	2.44e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174464274	chr1:174115300~174160004:-
LUAD	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	6.35	4.96e-10	2.44e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
LUAD	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	6.35	4.96e-10	2.44e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
LUAD	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-6.35	4.97e-10	2.45e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
LUAD	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-6.35	4.98e-10	2.45e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
LUAD	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-6.35	4.98e-10	2.45e-07	-0.61	-0.28	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-6.35	4.98e-10	2.45e-07	-0.61	-0.28	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
LUAD	cis	rs433852	0.898	rs376524	ENSG00000232871.7	SEC1P	-6.35	4.98e-10	2.45e-07	-0.36	-0.28	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613181	chr19:48638071~48682245:+
LUAD	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	6.35	4.98e-10	2.45e-07	0.34	0.28	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
LUAD	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-6.35	5e-10	2.46e-07	-0.32	-0.28	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
LUAD	cis	rs7615952	0.611	rs79405914	ENSG00000171084.14	FAM86JP	6.35	5e-10	2.46e-07	0.57	0.28	Blood pressure (smoking interaction);	chr3:126004780	chr3:125916620~125930024:+
LUAD	cis	rs7646881	0.767	rs73015629	ENSG00000240207.5	RP11-379F4.4	-6.35	5e-10	2.46e-07	-0.36	-0.28	Tetralogy of Fallot;	chr3:158716051	chr3:158732263~158784070:+
LUAD	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	6.35	5e-10	2.46e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	6.35	5e-10	2.46e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
LUAD	cis	rs11096990	0.855	rs1820939	ENSG00000249207.1	RP11-360F5.1	6.35	5.01e-10	2.46e-07	0.33	0.28	Cognitive function;	chr4:39170115	chr4:39112677~39126818:-
LUAD	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	6.35	5.01e-10	2.47e-07	0.42	0.28	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs59794892	ENSG00000232546.1	RP11-458F8.1	-6.35	5.02e-10	2.47e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65950886	chr7:66848496~66858136:+
LUAD	cis	rs2337406	0.587	rs10150642	ENSG00000254174.1	IGHV1-12	-6.35	5.02e-10	2.47e-07	-0.24	-0.28	Alzheimer's disease (late onset);	chr14:106647269	chr14:106122420~106122709:-
LUAD	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-6.35	5.04e-10	2.48e-07	-0.33	-0.28	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
LUAD	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	6.35	5.04e-10	2.48e-07	0.28	0.28	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	6.35	5.04e-10	2.48e-07	0.28	0.28	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
LUAD	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-6.35	5.04e-10	2.48e-07	-0.44	-0.28	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
LUAD	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-6.35	5.04e-10	2.48e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
LUAD	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	6.35	5.05e-10	2.48e-07	0.33	0.28	Height;	chr11:118856460	chr11:118688039~118690600:-
LUAD	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	6.35	5.05e-10	2.48e-07	0.33	0.28	Height;	chr11:118856623	chr11:118688039~118690600:-
LUAD	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	6.35	5.05e-10	2.48e-07	0.33	0.28	Height;	chr11:118857611	chr11:118688039~118690600:-
LUAD	cis	rs2273788	0.837	rs1053968	ENSG00000204173.9	LRRC37A5P	6.35	5.05e-10	2.48e-07	0.35	0.28	Monocyte count;	chr9:111590312	chr9:111602831~111631289:-
LUAD	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-6.35	5.06e-10	2.49e-07	-0.34	-0.28	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-6.35	5.06e-10	2.49e-07	-0.2	-0.28	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
LUAD	cis	rs4591358	0.689	rs17178460	ENSG00000223466.1	AC064834.2	-6.35	5.06e-10	2.49e-07	-0.43	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195555365	chr2:195533035~195538681:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000232546.1	RP11-458F8.1	6.35	5.06e-10	2.49e-07	0.37	0.28	Diabetic kidney disease;	chr7:66157859	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000232546.1	RP11-458F8.1	6.35	5.06e-10	2.49e-07	0.37	0.28	Diabetic kidney disease;	chr7:66162777	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000232546.1	RP11-458F8.1	6.35	5.06e-10	2.49e-07	0.37	0.28	Diabetic kidney disease;	chr7:66163497	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000232546.1	RP11-458F8.1	6.35	5.06e-10	2.49e-07	0.37	0.28	Diabetic kidney disease;	chr7:66164112	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000232546.1	RP11-458F8.1	-6.35	5.06e-10	2.49e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66155987	chr7:66848496~66858136:+
LUAD	cis	rs237743	0.786	rs34078534	ENSG00000222365.1	SNORD12B	-6.35	5.06e-10	2.49e-07	-0.33	-0.28	Height;	chr20:49208367	chr20:49280319~49280409:+
LUAD	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	6.35	5.07e-10	2.49e-07	0.34	0.28	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
LUAD	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-6.35	5.07e-10	2.49e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-6.35	5.07e-10	2.49e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
LUAD	cis	rs9640161	0.783	rs1132261	ENSG00000261305.1	RP4-584D14.7	6.35	5.08e-10	2.5e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362898	chr7:150341771~150342607:+
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-6.35	5.08e-10	2.5e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
LUAD	cis	rs433852	1	rs433852	ENSG00000232871.7	SEC1P	-6.35	5.08e-10	2.5e-07	-0.36	-0.28	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613847	chr19:48638071~48682245:+
LUAD	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	6.35	5.08e-10	2.5e-07	0.34	0.28	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	6.35	5.08e-10	2.5e-07	0.34	0.28	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	6.35	5.08e-10	2.5e-07	0.34	0.28	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
LUAD	cis	rs7246657	0.653	rs10406612	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	2.5e-07	0.45	0.28	Coronary artery calcification;	chr19:37225709	chr19:37314868~37315620:-
LUAD	cis	rs7044106	0.791	rs4836831	ENSG00000238181.2	AHCYP2	-6.35	5.09e-10	2.5e-07	-0.37	-0.28	Hip circumference adjusted for BMI;	chr9:120734292	chr9:120720673~120721972:+
LUAD	cis	rs1499614	1	rs1882655	ENSG00000232546.1	RP11-458F8.1	6.35	5.09e-10	2.5e-07	0.37	0.28	Gout;	chr7:66682070	chr7:66848496~66858136:+
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000232546.1	RP11-458F8.1	6.35	5.09e-10	2.5e-07	0.37	0.28	Gout;	chr7:66682162	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs1638731	ENSG00000232546.1	RP11-458F8.1	-6.35	5.09e-10	2.5e-07	-0.37	-0.28	Gout;	chr7:66679692	chr7:66848496~66858136:+
LUAD	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	6.35	5.1e-10	2.5e-07	0.37	0.28	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
LUAD	cis	rs2765539	0.851	rs1409159	ENSG00000226172.2	RP4-712E4.1	-6.35	5.1e-10	2.5e-07	-0.35	-0.28	Waist-hip ratio;	chr1:118995810	chr1:119000344~119001392:-
LUAD	cis	rs1707322	0.721	rs11211178	ENSG00000234329.1	RP11-767N6.2	6.35	5.1e-10	2.51e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45651039~45651826:-
LUAD	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	6.35	5.11e-10	2.51e-07	0.4	0.28	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
LUAD	cis	rs155076	1	rs261430	ENSG00000233325.3	MIPEPP3	6.35	5.11e-10	2.51e-07	0.44	0.28	White matter hyperintensity burden;	chr13:21291103	chr13:21298139~21306373:+
LUAD	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-6.35	5.11e-10	2.51e-07	-0.31	-0.28	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
LUAD	cis	rs9640161	0.783	rs35435439	ENSG00000261305.1	RP4-584D14.7	6.35	5.12e-10	2.51e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150366445	chr7:150341771~150342607:+
LUAD	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	6.35	5.12e-10	2.51e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
LUAD	cis	rs2115536	0.692	rs6495451	ENSG00000278600.1	RP11-81A1.6	-6.35	5.13e-10	2.52e-07	-0.23	-0.28	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79871711	chr15:79920195~79922455:-
LUAD	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	6.35	5.13e-10	2.52e-07	0.29	0.28	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
LUAD	cis	rs6504622	0.875	rs28553405	ENSG00000262879.4	RP11-156P1.3	6.35	5.14e-10	2.52e-07	0.33	0.28	Orofacial clefts;	chr17:46968529	chr17:46984045~47100323:-
LUAD	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-6.35	5.14e-10	2.52e-07	-0.4	-0.28	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-6.35	5.14e-10	2.52e-07	-0.34	-0.28	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
LUAD	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-6.34	5.16e-10	2.53e-07	-0.28	-0.28	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
LUAD	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	6.34	5.16e-10	2.53e-07	0.32	0.28	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
LUAD	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-6.34	5.17e-10	2.54e-07	-0.35	-0.28	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-6.34	5.17e-10	2.54e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
LUAD	cis	rs6504622	0.875	rs4968250	ENSG00000262879.4	RP11-156P1.3	6.34	5.17e-10	2.54e-07	0.33	0.28	Orofacial clefts;	chr17:46967985	chr17:46984045~47100323:-
LUAD	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	6.34	5.18e-10	2.54e-07	0.34	0.28	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
LUAD	cis	rs155076	1	rs2478824	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21270005	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.938	rs9509630	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21270175	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.938	rs9509633	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21270343	chr13:21298139~21306373:+
LUAD	cis	rs155076	1	rs598754	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21270871	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.938	rs485361	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21271687	chr13:21298139~21306373:+
LUAD	cis	rs155076	1	rs484365	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21271805	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.702	rs482731	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21271936	chr13:21298139~21306373:+
LUAD	cis	rs155076	1	rs564685	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21272740	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.938	rs536209	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21273575	chr13:21298139~21306373:+
LUAD	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-6.34	5.19e-10	2.54e-07	-0.32	-0.28	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
LUAD	cis	rs5753618	0.561	rs2073857	ENSG00000236132.1	CTA-440B3.1	6.34	5.19e-10	2.55e-07	0.35	0.28	Colorectal cancer;	chr22:31262295	chr22:31816379~31817491:-
LUAD	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-6.34	5.2e-10	2.55e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-6.34	5.2e-10	2.55e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
LUAD	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-6.34	5.2e-10	2.55e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
LUAD	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	6.34	5.2e-10	2.55e-07	0.34	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
LUAD	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
LUAD	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-6.34	5.22e-10	2.56e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
LUAD	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	6.34	5.22e-10	2.56e-07	0.42	0.28	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
LUAD	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	6.34	5.23e-10	2.56e-07	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
LUAD	cis	rs2734839	0.537	rs6277	ENSG00000270179.1	RP11-159N11.4	-6.34	5.23e-10	2.56e-07	-0.28	-0.28	Information processing speed;	chr11:113412737	chr11:113368478~113369117:+
LUAD	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-6.34	5.24e-10	2.57e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
LUAD	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-6.34	5.24e-10	2.57e-07	-0.36	-0.28	Migraine;	chr4:56852087	chr4:56960927~56961373:-
LUAD	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-6.34	5.24e-10	2.57e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
LUAD	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	6.34	5.24e-10	2.57e-07	0.34	0.28	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
LUAD	cis	rs8031584	0.918	rs34693097	ENSG00000260382.1	RP11-540B6.2	6.34	5.25e-10	2.57e-07	0.33	0.28	Huntington's disease progression;	chr15:30961781	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.918	rs35784593	ENSG00000260382.1	RP11-540B6.2	6.34	5.25e-10	2.57e-07	0.33	0.28	Huntington's disease progression;	chr15:30962385	chr15:30882267~30883231:-
LUAD	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-6.34	5.25e-10	2.57e-07	-0.34	-0.28	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
LUAD	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	6.34	5.25e-10	2.57e-07	0.29	0.28	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
LUAD	cis	rs1499614	1	rs2659913	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66692349	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2659911	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66693433	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2707838	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66694214	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs60326618	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66701371	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2707830	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66702658	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2707828	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66706390	chr7:66848496~66858136:+
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66710076	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2659903	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66715944	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2141924	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66721259	chr7:66848496~66858136:+
LUAD	cis	rs1823913	0.637	rs4853578	ENSG00000280083.1	RP11-317J9.1	-6.34	5.26e-10	2.58e-07	-0.33	-0.28	Obesity-related traits;	chr2:191297215	chr2:191154118~191156070:-
LUAD	cis	rs2842992	1	rs2758322	ENSG00000237927.1	RP3-393E18.2	-6.34	5.26e-10	2.58e-07	-0.39	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159654156	chr6:159586955~159589169:-
LUAD	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-6.34	5.27e-10	2.58e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
LUAD	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-6.34	5.27e-10	2.58e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
LUAD	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-6.34	5.28e-10	2.58e-07	-0.32	-0.28	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	6.34	5.28e-10	2.58e-07	0.52	0.28	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.29e-10	2.59e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
LUAD	cis	rs1707322	0.506	rs2991983	ENSG00000234329.1	RP11-767N6.2	-6.34	5.29e-10	2.59e-07	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs3014249	ENSG00000234329.1	RP11-767N6.2	-6.34	5.29e-10	2.59e-07	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45651039~45651826:-
LUAD	cis	rs1914816	1	rs2255408	ENSG00000196274.5	Metazoa_SRP	-6.34	5.29e-10	2.59e-07	-0.31	-0.28	Response to tocilizumab in rheumatoid arthritis;	chr15:76210954	chr15:76230048~76230390:-
LUAD	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	6.34	5.29e-10	2.59e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
LUAD	cis	rs7017914	0.967	rs2639903	ENSG00000223220.1	Y_RNA	6.34	5.29e-10	2.59e-07	0.31	0.28	Bone mineral density;	chr8:71005209	chr8:70780914~70781008:-
LUAD	cis	rs10214930	1	rs2074580	ENSG00000235574.1	AC073150.6	6.34	5.3e-10	2.59e-07	0.39	0.28	Hypospadias;	chr7:27794234	chr7:27491682~27492765:-
LUAD	cis	rs10740039	0.883	rs1837946	ENSG00000254271.1	RP11-131N11.4	6.34	5.32e-10	2.6e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633676	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7089720	ENSG00000254271.1	RP11-131N11.4	6.34	5.32e-10	2.6e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634063	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs7093882	ENSG00000254271.1	RP11-131N11.4	6.34	5.32e-10	2.6e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634863	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs2119912	ENSG00000254271.1	RP11-131N11.4	6.34	5.32e-10	2.6e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639754	chr10:60734342~60741828:+
LUAD	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-6.34	5.33e-10	2.61e-07	-0.21	-0.28	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
LUAD	cis	rs12699921	0.607	rs35819944	ENSG00000279048.1	RP11-511H23.2	6.34	5.33e-10	2.61e-07	0.23	0.28	Fibrinogen levels;	chr7:17928168	chr7:17940503~17942922:+
LUAD	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	6.34	5.33e-10	2.61e-07	0.4	0.28	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	6.34	5.33e-10	2.61e-07	0.4	0.28	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
LUAD	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	6.34	5.33e-10	2.61e-07	0.28	0.28	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
LUAD	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-6.34	5.34e-10	2.61e-07	-0.35	-0.28	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
LUAD	cis	rs10740039	0.883	rs1442546	ENSG00000254271.1	RP11-131N11.4	6.34	5.34e-10	2.61e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650240	chr10:60734342~60741828:+
LUAD	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-6.34	5.34e-10	2.61e-07	-0.56	-0.28	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000232546.1	RP11-458F8.1	-6.34	5.34e-10	2.61e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66007799	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316327	ENSG00000232546.1	RP11-458F8.1	6.34	5.34e-10	2.61e-07	0.36	0.28	Diabetic kidney disease;	chr7:66144214	chr7:66848496~66858136:+
LUAD	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	6.34	5.34e-10	2.61e-07	0.28	0.28	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
LUAD	cis	rs7945705	0.967	rs7123429	ENSG00000254860.4	TMEM9B-AS1	6.34	5.35e-10	2.61e-07	0.32	0.28	Hemoglobin concentration;	chr11:8845261	chr11:8964675~8977527:+
LUAD	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-6.34	5.35e-10	2.62e-07	-0.44	-0.28	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
LUAD	cis	rs9326248	0.559	rs573549	ENSG00000280143.1	AP000892.6	6.34	5.35e-10	2.62e-07	0.32	0.28	Blood protein levels;	chr11:116865963	chr11:117204967~117210292:+
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-6.34	5.36e-10	2.62e-07	-0.33	-0.28	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
LUAD	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	6.34	5.37e-10	2.63e-07	0.36	0.28	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
LUAD	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	6.34	5.38e-10	2.63e-07	0.27	0.28	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
LUAD	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-6.34	5.39e-10	2.63e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
LUAD	cis	rs1707322	0.686	rs1084086	ENSG00000234329.1	RP11-767N6.2	-6.34	5.39e-10	2.63e-07	-0.29	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45651039~45651826:-
LUAD	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	6.34	5.4e-10	2.64e-07	0.29	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
LUAD	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	6.34	5.4e-10	2.64e-07	0.29	0.28	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	6.34	5.41e-10	2.65e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
LUAD	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-6.34	5.42e-10	2.65e-07	-0.32	-0.28	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
LUAD	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	6.34	5.42e-10	2.65e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
LUAD	cis	rs2302464	1	rs16892289	ENSG00000214846.4	RP11-115L11.1	-6.34	5.42e-10	2.65e-07	-0.71	-0.28	Cerebrospinal fluid biomarker levels;	chr4:15730680	chr4:15730962~15731627:-
LUAD	cis	rs72772090	0.634	rs12186366	ENSG00000248734.2	CTD-2260A17.1	-6.34	5.42e-10	2.65e-07	-0.4	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96784777~96785999:+
LUAD	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.42e-10	2.65e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.42e-10	2.65e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
LUAD	cis	rs1914816	0.941	rs2456027	ENSG00000196274.5	Metazoa_SRP	6.34	5.42e-10	2.65e-07	0.31	0.28	Response to tocilizumab in rheumatoid arthritis;	chr15:76275868	chr15:76230048~76230390:-
LUAD	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-6.34	5.43e-10	2.65e-07	-0.32	-0.28	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
LUAD	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-6.34	5.43e-10	2.65e-07	-0.61	-0.28	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
LUAD	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-6.34	5.43e-10	2.65e-07	-0.31	-0.28	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
LUAD	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	6.34	5.44e-10	2.66e-07	0.27	0.28	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
LUAD	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	6.34	5.44e-10	2.66e-07	0.32	0.28	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000206090.4	AP000350.7	-6.34	5.45e-10	2.66e-07	-0.32	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23939998~23942798:+
LUAD	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-6.34	5.45e-10	2.66e-07	-0.35	-0.28	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
LUAD	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	6.33	5.46e-10	2.67e-07	0.31	0.28	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	6.33	5.46e-10	2.67e-07	0.31	0.28	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	6.33	5.46e-10	2.67e-07	0.31	0.28	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
LUAD	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-6.33	5.47e-10	2.67e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
LUAD	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	6.33	5.47e-10	2.67e-07	0.42	0.28	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
LUAD	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-6.33	5.47e-10	2.67e-07	-0.37	-0.28	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
LUAD	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	6.33	5.48e-10	2.67e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
LUAD	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.67e-07	0.33	0.28	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.67e-07	0.33	0.28	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.67e-07	0.33	0.28	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.67e-07	0.33	0.28	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.68e-07	0.33	0.28	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.68e-07	0.33	0.28	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000232546.1	RP11-458F8.1	-6.33	5.49e-10	2.68e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65953889	chr7:66848496~66858136:+
LUAD	cis	rs62025270	0.547	rs338520	ENSG00000202081.1	RNU6-1280P	6.33	5.49e-10	2.68e-07	0.33	0.28	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85651522~85651628:-
LUAD	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-6.33	5.5e-10	2.68e-07	-0.43	-0.28	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
LUAD	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	6.33	5.5e-10	2.68e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	6.33	5.5e-10	2.68e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
LUAD	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	6.33	5.5e-10	2.69e-07	0.24	0.28	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
LUAD	cis	rs9549367	0.789	rs2025247	ENSG00000269125.1	RP11-98F14.11	-6.33	5.51e-10	2.69e-07	-0.34	-0.28	Platelet distribution width;	chr13:113228250	chr13:113165002~113165183:-
LUAD	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	6.33	5.51e-10	2.69e-07	0.32	0.28	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
LUAD	cis	rs897200	0.965	rs897199	ENSG00000280083.1	RP11-317J9.1	6.33	5.51e-10	2.69e-07	0.35	0.28	Behcet's disease;	chr2:191153263	chr2:191154118~191156070:-
LUAD	cis	rs897200	1	rs897198	ENSG00000280083.1	RP11-317J9.1	6.33	5.51e-10	2.69e-07	0.35	0.28	Behcet's disease;	chr2:191153281	chr2:191154118~191156070:-
LUAD	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-6.33	5.52e-10	2.69e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
LUAD	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	6.33	5.53e-10	2.7e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
LUAD	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-6.33	5.53e-10	2.7e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-6.33	5.53e-10	2.7e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
LUAD	cis	rs17684571	0.872	rs13219942	ENSG00000231441.1	RP11-472M19.2	6.33	5.53e-10	2.7e-07	0.41	0.28	Schizophrenia;	chr6:56713977	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs35326806	ENSG00000231441.1	RP11-472M19.2	6.33	5.53e-10	2.7e-07	0.41	0.28	Schizophrenia;	chr6:56714216	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs35494794	ENSG00000231441.1	RP11-472M19.2	6.33	5.53e-10	2.7e-07	0.41	0.28	Schizophrenia;	chr6:56716124	chr6:56844002~56864078:+
LUAD	cis	rs11096990	0.892	rs11937540	ENSG00000249207.1	RP11-360F5.1	6.33	5.54e-10	2.7e-07	0.32	0.28	Cognitive function;	chr4:39179897	chr4:39112677~39126818:-
LUAD	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-6.33	5.55e-10	2.71e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
LUAD	cis	rs1914816	0.941	rs2460151	ENSG00000196274.5	Metazoa_SRP	6.33	5.58e-10	2.72e-07	0.32	0.28	Response to tocilizumab in rheumatoid arthritis;	chr15:76195166	chr15:76230048~76230390:-
LUAD	cis	rs12699921	0.632	rs2723501	ENSG00000279048.1	RP11-511H23.2	6.33	5.58e-10	2.72e-07	0.22	0.28	Fibrinogen levels;	chr7:17814909	chr7:17940503~17942922:+
LUAD	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-6.33	5.59e-10	2.72e-07	-0.29	-0.28	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
LUAD	cis	rs7688540	0.76	rs7687833	ENSG00000275426.1	CH17-262A2.1	6.33	5.59e-10	2.72e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:149738~150317:+
LUAD	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	6.33	5.59e-10	2.72e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	6.33	5.59e-10	2.72e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
LUAD	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	6.33	5.6e-10	2.73e-07	0.34	0.28	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
LUAD	cis	rs1707322	0.752	rs28545085	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28812624	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28507722	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28568986	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs28396194	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs28752166	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs10890345	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10789471	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs11211173	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45651039~45651826:-
LUAD	cis	rs5753618	0.561	rs737684	ENSG00000236132.1	CTA-440B3.1	6.33	5.62e-10	2.74e-07	0.35	0.28	Colorectal cancer;	chr22:31263841	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.539	rs2228619	ENSG00000236132.1	CTA-440B3.1	6.33	5.62e-10	2.74e-07	0.35	0.28	Colorectal cancer;	chr22:31267856	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.749	rs2027982	ENSG00000236132.1	CTA-440B3.1	6.33	5.62e-10	2.74e-07	0.32	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31197449	chr22:31816379~31817491:-
LUAD	cis	rs2243480	1	rs313799	ENSG00000230295.1	RP11-458F8.2	-6.33	5.63e-10	2.74e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66029343	chr7:66880708~66882981:+
LUAD	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	6.33	5.63e-10	2.74e-07	0.58	0.28	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
LUAD	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	6.33	5.63e-10	2.74e-07	0.31	0.28	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
LUAD	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-6.33	5.63e-10	2.74e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
LUAD	cis	rs2745572	0.515	rs2250686	ENSG00000272279.1	RP11-157J24.2	-6.33	5.64e-10	2.74e-07	-0.34	-0.28	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548909	chr6:1528364~1528911:-
LUAD	cis	rs2745572	0.557	rs2745574	ENSG00000272279.1	RP11-157J24.2	-6.33	5.64e-10	2.74e-07	-0.34	-0.28	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548990	chr6:1528364~1528911:-
LUAD	cis	rs2243480	1	rs316332	ENSG00000232546.1	RP11-458F8.1	-6.33	5.64e-10	2.74e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66139312	chr7:66848496~66858136:+
LUAD	cis	rs6504622	0.935	rs740617	ENSG00000262879.4	RP11-156P1.3	6.33	5.64e-10	2.75e-07	0.33	0.28	Orofacial clefts;	chr17:46950635	chr17:46984045~47100323:-
LUAD	cis	rs1318937	1	rs1318937	ENSG00000224660.1	SH3BP5-AS1	-6.33	5.64e-10	2.75e-07	-0.2	-0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253857	chr3:15254184~15264493:+
LUAD	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-6.33	5.64e-10	2.75e-07	-0.29	-0.28	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
LUAD	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	6.33	5.64e-10	2.75e-07	0.31	0.28	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
LUAD	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-6.33	5.65e-10	2.75e-07	-0.3	-0.28	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-6.33	5.65e-10	2.75e-07	-0.3	-0.28	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
LUAD	cis	rs9640161	0.789	rs34495356	ENSG00000261305.1	RP4-584D14.7	6.33	5.66e-10	2.75e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150360702	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.789	rs36035506	ENSG00000261305.1	RP4-584D14.7	6.33	5.66e-10	2.75e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150360754	chr7:150341771~150342607:+
LUAD	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	6.33	5.66e-10	2.76e-07	0.31	0.28	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
LUAD	cis	rs7688540	0.8	rs10028482	ENSG00000275426.1	CH17-262A2.1	6.33	5.67e-10	2.76e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:149738~150317:+
LUAD	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	6.33	5.68e-10	2.76e-07	0.38	0.28	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
LUAD	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-6.33	5.68e-10	2.76e-07	-0.32	-0.28	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
LUAD	cis	rs8177876	0.749	rs12927239	ENSG00000261838.4	RP11-303E16.6	6.33	5.69e-10	2.77e-07	0.54	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81053883	chr16:81069854~81076598:+
LUAD	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-6.33	5.69e-10	2.77e-07	-0.38	-0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
LUAD	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	6.33	5.7e-10	2.77e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	6.33	5.7e-10	2.77e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	6.33	5.7e-10	2.77e-07	0.31	0.28	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
LUAD	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	6.33	5.71e-10	2.78e-07	0.53	0.28	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-6.33	5.71e-10	2.78e-07	-0.31	-0.28	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
LUAD	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	6.33	5.71e-10	2.78e-07	0.31	0.28	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
LUAD	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	6.33	5.72e-10	2.78e-07	0.38	0.28	Systemic lupus erythematosus;	chr1:174230438	chr1:174115300~174160004:-
LUAD	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	6.33	5.72e-10	2.78e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
LUAD	cis	rs7044106	0.762	rs12003646	ENSG00000238181.2	AHCYP2	-6.33	5.72e-10	2.78e-07	-0.36	-0.28	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120720673~120721972:+
LUAD	cis	rs2243480	1	rs431076	ENSG00000232546.1	RP11-458F8.1	-6.33	5.73e-10	2.79e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66135333	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000232546.1	RP11-458F8.1	-6.33	5.73e-10	2.79e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66135463	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000232546.1	RP11-458F8.1	-6.33	5.73e-10	2.79e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66136518	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000232546.1	RP11-458F8.1	-6.33	5.73e-10	2.79e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66137139	chr7:66848496~66858136:+
LUAD	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	6.33	5.74e-10	2.79e-07	0.34	0.28	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs4149468	ENSG00000232546.1	RP11-458F8.1	-6.33	5.74e-10	2.79e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66360703	chr7:66848496~66858136:+
LUAD	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-6.33	5.74e-10	2.79e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
LUAD	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	6.33	5.75e-10	2.79e-07	0.42	0.28	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	6.33	5.75e-10	2.79e-07	0.42	0.28	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
LUAD	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	6.33	5.75e-10	2.79e-07	0.42	0.28	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
LUAD	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	6.33	5.76e-10	2.8e-07	0.37	0.28	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
LUAD	cis	rs7017914	0.905	rs10091471	ENSG00000223220.1	Y_RNA	6.33	5.76e-10	2.8e-07	0.31	0.28	Bone mineral density;	chr8:71041520	chr8:70780914~70781008:-
LUAD	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-6.33	5.76e-10	2.8e-07	-0.42	-0.28	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
LUAD	cis	rs17301013	0.507	rs3117838	ENSG00000227373.4	RP11-160H22.5	6.33	5.76e-10	2.8e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174749205	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs332801	ENSG00000227373.4	RP11-160H22.5	6.33	5.76e-10	2.8e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174753192	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs332800	ENSG00000227373.4	RP11-160H22.5	6.33	5.76e-10	2.8e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174753467	chr1:174115300~174160004:-
LUAD	cis	rs897200	1	rs6736458	ENSG00000280083.1	RP11-317J9.1	6.33	5.76e-10	2.8e-07	0.35	0.28	Behcet's disease;	chr2:191158982	chr2:191154118~191156070:-
LUAD	cis	rs948562	0.69	rs75365860	ENSG00000280010.1	AP001350.4	6.33	5.77e-10	2.8e-07	0.43	0.28	Lymphoma;	chr11:58402023	chr11:58627435~58628528:+
LUAD	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-6.33	5.78e-10	2.81e-07	-0.45	-0.28	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
LUAD	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	6.33	5.78e-10	2.81e-07	0.31	0.28	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
LUAD	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	6.33	5.78e-10	2.81e-07	0.36	0.28	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
LUAD	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	6.33	5.79e-10	2.81e-07	0.32	0.28	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs11538349	ENSG00000232546.1	RP11-458F8.1	-6.33	5.79e-10	2.81e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65956884	chr7:66848496~66858136:+
LUAD	cis	rs4141404	0.737	rs5998058	ENSG00000236132.1	CTA-440B3.1	-6.33	5.79e-10	2.81e-07	-0.34	-0.28	Paclitaxel-induced neuropathy;	chr22:31610422	chr22:31816379~31817491:-
LUAD	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-6.33	5.79e-10	2.81e-07	-0.37	-0.28	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
LUAD	cis	rs56080343	0.515	rs73222056	ENSG00000275759.1	RP11-131L12.3	-6.32	5.8e-10	2.82e-07	-0.43	-0.28	Neuroticism;	chr12:118215875	chr12:118428281~118428870:+
LUAD	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-6.32	5.8e-10	2.82e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
LUAD	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-6.32	5.8e-10	2.82e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
LUAD	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-6.32	5.8e-10	2.82e-07	-0.39	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
LUAD	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	6.32	5.81e-10	2.82e-07	0.35	0.28	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
LUAD	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	6.32	5.82e-10	2.83e-07	0.31	0.28	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	6.32	5.82e-10	2.83e-07	0.31	0.28	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	6.32	5.82e-10	2.83e-07	0.31	0.28	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
LUAD	cis	rs7182621	0.793	rs12904168	ENSG00000182397.13	DNM1P46	6.32	5.82e-10	2.83e-07	0.34	0.28	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99790156~99806927:-
LUAD	cis	rs1707322	0.752	rs28719889	ENSG00000234329.1	RP11-767N6.2	6.32	5.83e-10	2.83e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs1972410	ENSG00000234329.1	RP11-767N6.2	6.32	5.84e-10	2.84e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45651039~45651826:-
LUAD	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-6.32	5.84e-10	2.84e-07	-0.37	-0.28	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
LUAD	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-6.32	5.85e-10	2.84e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-6.32	5.85e-10	2.84e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
LUAD	cis	rs10899021	1	rs10899021	ENSG00000279353.1	RP11-864N7.4	-6.32	5.85e-10	2.84e-07	-0.48	-0.28	Response to metformin (IC50);	chr11:74627009	chr11:74698231~74699658:-
LUAD	cis	rs4713118	0.621	rs9295755	ENSG00000204709.4	LINC01556	-6.32	5.86e-10	2.84e-07	-0.38	-0.28	Parkinson's disease;	chr6:28065396	chr6:28943877~28944537:+
LUAD	cis	rs7017914	0.967	rs2639919	ENSG00000223220.1	Y_RNA	6.32	5.86e-10	2.85e-07	0.31	0.28	Bone mineral density;	chr8:70962893	chr8:70780914~70781008:-
LUAD	cis	rs17301013	0.507	rs6677243	ENSG00000227373.4	RP11-160H22.5	6.32	5.87e-10	2.85e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174339471	chr1:174115300~174160004:-
LUAD	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-6.32	5.87e-10	2.85e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
LUAD	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-6.32	5.88e-10	2.85e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
LUAD	cis	rs4713118	0.662	rs156744	ENSG00000204709.4	LINC01556	6.32	5.88e-10	2.85e-07	0.38	0.28	Parkinson's disease;	chr6:27999496	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs149947	ENSG00000204709.4	LINC01556	6.32	5.88e-10	2.85e-07	0.38	0.28	Parkinson's disease;	chr6:28004655	chr6:28943877~28944537:+
LUAD	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	6.32	5.9e-10	2.86e-07	0.39	0.28	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
LUAD	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	6.32	5.91e-10	2.87e-07	0.31	0.28	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
LUAD	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	6.32	5.92e-10	2.87e-07	0.32	0.28	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
LUAD	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	6.32	5.92e-10	2.87e-07	0.35	0.28	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
LUAD	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	6.32	5.92e-10	2.87e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	6.32	5.92e-10	2.87e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	6.32	5.92e-10	2.87e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
LUAD	cis	rs496547	0.686	rs487728	ENSG00000255422.1	AP002954.4	-6.32	5.93e-10	2.87e-07	-0.35	-0.28	Hip minimal joint space width;	chr11:118750785	chr11:118704607~118750263:+
LUAD	cis	rs10740039	0.768	rs10821801	ENSG00000254271.1	RP11-131N11.4	6.32	5.93e-10	2.88e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60612017	chr10:60734342~60741828:+
LUAD	cis	rs5753618	0.539	rs8135344	ENSG00000236132.1	CTA-440B3.1	6.32	5.93e-10	2.88e-07	0.35	0.28	Colorectal cancer;	chr22:31275946	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs4141404	ENSG00000236132.1	CTA-440B3.1	6.32	5.93e-10	2.88e-07	0.35	0.28	Colorectal cancer;	chr22:31279199	chr22:31816379~31817491:-
LUAD	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	6.32	5.94e-10	2.88e-07	0.37	0.28	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
LUAD	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	6.32	5.94e-10	2.88e-07	0.4	0.28	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
LUAD	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-6.32	5.94e-10	2.88e-07	-0.32	-0.28	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
LUAD	cis	rs4723738	1	rs10282407	ENSG00000227191.5	TRGC2	-6.32	5.94e-10	2.88e-07	-0.3	-0.28	Treatment response for severe sepsis;	chr7:38193791	chr7:38239580~38368091:-
LUAD	cis	rs7923609	0.871	rs10761787	ENSG00000232075.1	MRPL35P2	-6.32	5.94e-10	2.88e-07	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63593995	chr10:63634317~63634827:-
LUAD	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	6.32	5.95e-10	2.89e-07	0.39	0.28	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
LUAD	cis	rs10740039	0.729	rs6479721	ENSG00000254271.1	RP11-131N11.4	6.32	5.96e-10	2.89e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613364	chr10:60734342~60741828:+
LUAD	cis	rs948562	1	rs948562	ENSG00000280010.1	AP001350.4	6.32	5.96e-10	2.89e-07	0.42	0.28	Lymphoma;	chr11:58580292	chr11:58627435~58628528:+
LUAD	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	6.32	5.96e-10	2.89e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.842	rs7090892	ENSG00000254271.1	RP11-131N11.4	6.32	5.96e-10	2.89e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652093	chr10:60734342~60741828:+
LUAD	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-6.32	5.96e-10	2.89e-07	-0.3	-0.28	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000232546.1	RP11-458F8.1	-6.32	5.96e-10	2.89e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65951525	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000232546.1	RP11-458F8.1	-6.32	5.96e-10	2.89e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65951549	chr7:66848496~66858136:+
LUAD	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	6.32	5.98e-10	2.9e-07	0.35	0.28	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
LUAD	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	6.32	5.99e-10	2.9e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	6.32	5.99e-10	2.9e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
LUAD	cis	rs2034650	0.544	rs2289331	ENSG00000223313.1	RNU6-516P	6.32	6e-10	2.91e-07	0.36	0.28	Interstitial lung disease;	chr15:40407739	chr15:40529570~40529673:+
LUAD	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-6.32	6e-10	2.91e-07	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
LUAD	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	6.32	6e-10	2.91e-07	0.4	0.28	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
LUAD	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-6.32	6e-10	2.91e-07	-0.32	-0.28	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
LUAD	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	6.32	6e-10	2.91e-07	0.28	0.28	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
LUAD	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-6.32	6.01e-10	2.91e-07	-0.33	-0.28	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
LUAD	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-6.32	6.01e-10	2.91e-07	-0.45	-0.28	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
LUAD	cis	rs7017914	0.934	rs13255152	ENSG00000223220.1	Y_RNA	6.32	6.01e-10	2.91e-07	0.31	0.28	Bone mineral density;	chr8:70947384	chr8:70780914~70781008:-
LUAD	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	6.32	6.02e-10	2.92e-07	0.42	0.28	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
LUAD	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	6.32	6.02e-10	2.92e-07	0.37	0.28	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
LUAD	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	6.32	6.02e-10	2.92e-07	0.4	0.28	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
LUAD	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	6.32	6.02e-10	2.92e-07	0.4	0.28	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
LUAD	cis	rs6772849	0.93	rs13434160	ENSG00000242551.2	POU5F1P6	-6.32	6.02e-10	2.92e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128655927	chr3:128674735~128677005:-
LUAD	cis	rs9584850	0.834	rs2031239	ENSG00000231194.1	FARP1-AS1	6.32	6.03e-10	2.92e-07	0.34	0.28	Neuroticism;	chr13:98459306	chr13:98435405~98435840:-
LUAD	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-6.32	6.04e-10	2.92e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
LUAD	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	6.32	6.04e-10	2.92e-07	0.41	0.28	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-6.32	6.04e-10	2.92e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
LUAD	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-6.32	6.04e-10	2.93e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
LUAD	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	6.32	6.05e-10	2.93e-07	0.35	0.28	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
LUAD	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-6.32	6.05e-10	2.93e-07	-0.3	-0.28	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
LUAD	cis	rs7115242	0.748	rs1035237	ENSG00000280143.1	AP000892.6	6.32	6.05e-10	2.93e-07	0.42	0.28	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117204967~117210292:+
LUAD	cis	rs9640161	0.789	rs13223702	ENSG00000261305.1	RP4-584D14.7	6.32	6.07e-10	2.94e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150361879	chr7:150341771~150342607:+
LUAD	cis	rs1823913	1	rs4853561	ENSG00000230611.1	HMGB1P27	6.32	6.07e-10	2.94e-07	0.34	0.28	Obesity-related traits;	chr2:191242980	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs6704784	ENSG00000230611.1	HMGB1P27	6.32	6.07e-10	2.94e-07	0.34	0.28	Obesity-related traits;	chr2:191244832	chr2:191174233~191174835:+
LUAD	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	6.32	6.08e-10	2.94e-07	0.31	0.28	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
LUAD	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-6.32	6.09e-10	2.95e-07	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
LUAD	cis	rs1012068	0.662	rs11703779	ENSG00000236132.1	CTA-440B3.1	-6.32	6.09e-10	2.95e-07	-0.33	-0.28	Chronic hepatitis C infection;	chr22:31926398	chr22:31816379~31817491:-
LUAD	cis	rs7937890	0.9	rs7118682	ENSG00000254418.1	RP11-21L19.1	-6.32	6.09e-10	2.95e-07	-0.32	-0.28	Mitochondrial DNA levels;	chr11:14253004	chr11:14262846~14273691:-
LUAD	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-6.32	6.1e-10	2.95e-07	-0.33	-0.28	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
LUAD	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-6.32	6.1e-10	2.95e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
LUAD	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	6.32	6.1e-10	2.95e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
LUAD	cis	rs5753618	0.561	rs2283879	ENSG00000236132.1	CTA-440B3.1	6.32	6.1e-10	2.95e-07	0.35	0.28	Colorectal cancer;	chr22:31242462	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs2283881	ENSG00000236132.1	CTA-440B3.1	6.32	6.1e-10	2.95e-07	0.35	0.28	Colorectal cancer;	chr22:31242946	chr22:31816379~31817491:-
LUAD	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	6.32	6.11e-10	2.96e-07	0.4	0.28	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	6.32	6.11e-10	2.96e-07	0.4	0.28	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
LUAD	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	6.32	6.11e-10	2.96e-07	0.31	0.28	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
LUAD	cis	rs11846409	0.587	rs1806881	ENSG00000254174.1	IGHV1-12	-6.32	6.11e-10	2.96e-07	-0.25	-0.28	Rheumatic heart disease;	chr14:106650770	chr14:106122420~106122709:-
LUAD	cis	rs4820294	0.926	rs62236671	ENSG00000233360.4	Z83844.1	6.32	6.12e-10	2.96e-07	0.29	0.28	Fat distribution (HIV);	chr22:37673298	chr22:37641832~37658377:-
LUAD	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-6.32	6.12e-10	2.96e-07	-0.33	-0.28	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
LUAD	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	6.32	6.12e-10	2.96e-07	0.42	0.28	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
LUAD	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-6.32	6.12e-10	2.96e-07	-0.26	-0.28	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
LUAD	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	6.32	6.13e-10	2.96e-07	0.3	0.28	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
LUAD	cis	rs11089937	0.616	rs7291684	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs6001219	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs5995615	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs6001223	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs928895	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs928896	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs6001224	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22162199~22162681:+
LUAD	cis	rs1823913	1	rs1454749	ENSG00000230611.1	HMGB1P27	-6.32	6.13e-10	2.96e-07	-0.34	-0.28	Obesity-related traits;	chr2:191240909	chr2:191174233~191174835:+
LUAD	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	6.32	6.13e-10	2.97e-07	0.31	0.28	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
LUAD	cis	rs293748	0.882	rs158794	ENSG00000250155.1	CTD-2353F22.1	-6.32	6.14e-10	2.97e-07	-0.39	-0.28	Obesity-related traits;	chr5:36882986	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.882	rs151946	ENSG00000250155.1	CTD-2353F22.1	-6.32	6.14e-10	2.97e-07	-0.39	-0.28	Obesity-related traits;	chr5:36884064	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.882	rs158793	ENSG00000250155.1	CTD-2353F22.1	-6.32	6.14e-10	2.97e-07	-0.39	-0.28	Obesity-related traits;	chr5:36884988	chr5:36666214~36725195:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000232546.1	RP11-458F8.1	-6.31	6.16e-10	2.98e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65951319	chr7:66848496~66858136:+
LUAD	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	6.31	6.16e-10	2.98e-07	0.28	0.28	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
LUAD	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	6.31	6.17e-10	2.98e-07	0.35	0.28	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
LUAD	cis	rs853679	0.607	rs56075693	ENSG00000204709.4	LINC01556	6.31	6.19e-10	2.99e-07	0.61	0.28	Depression;	chr6:28322551	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34218844	ENSG00000204709.4	LINC01556	6.31	6.19e-10	2.99e-07	0.61	0.28	Depression;	chr6:28322870	chr6:28943877~28944537:+
LUAD	cis	rs77204473	0.744	rs11216252	ENSG00000254851.1	RP11-109L13.1	6.31	6.19e-10	2.99e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057507	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs11216253	ENSG00000254851.1	RP11-109L13.1	6.31	6.19e-10	2.99e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057509	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	6.31	6.21e-10	3e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
LUAD	cis	rs7567389	0.504	rs5937	ENSG00000236682.1	AC068282.3	-6.31	6.22e-10	3.01e-07	-0.36	-0.28	Self-rated health;	chr2:127427194	chr2:127389130~127400580:+
LUAD	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-6.31	6.22e-10	3.01e-07	-0.37	-0.28	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-6.31	6.22e-10	3.01e-07	-0.37	-0.28	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
LUAD	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-6.31	6.23e-10	3.01e-07	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
LUAD	cis	rs367615	0.68	rs1103198	ENSG00000249476.1	CTD-2587M2.1	6.31	6.23e-10	3.01e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109637882	chr5:109237120~109326369:-
LUAD	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-6.31	6.23e-10	3.01e-07	-0.29	-0.28	Height;	chr11:118747911	chr11:118791254~118793137:+
LUAD	cis	rs6964833	0.554	rs112506907	ENSG00000277053.3	GTF2IP1	-6.31	6.24e-10	3.01e-07	-0.35	-0.28	Menarche (age at onset);	chr7:74654407	chr7:75185385~75237696:-
LUAD	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-6.31	6.24e-10	3.01e-07	-0.38	-0.28	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-6.31	6.24e-10	3.01e-07	-0.38	-0.28	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-6.31	6.24e-10	3.01e-07	-0.38	-0.28	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-6.31	6.24e-10	3.01e-07	-0.38	-0.28	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
LUAD	cis	rs6772849	0.93	rs6768344	ENSG00000242551.2	POU5F1P6	-6.31	6.25e-10	3.02e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:128674735~128677005:-
LUAD	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	6.31	6.25e-10	3.02e-07	0.32	0.28	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
LUAD	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	6.31	6.25e-10	3.02e-07	0.32	0.28	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
LUAD	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-6.31	6.25e-10	3.02e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
LUAD	cis	rs2243480	1	rs427044	ENSG00000232546.1	RP11-458F8.1	-6.31	6.26e-10	3.02e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66043558	chr7:66848496~66858136:+
LUAD	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-6.31	6.26e-10	3.02e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
LUAD	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-6.31	6.26e-10	3.02e-07	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
LUAD	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-6.31	6.26e-10	3.03e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-6.31	6.26e-10	3.03e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
LUAD	cis	rs240993	0.909	rs240991	ENSG00000230177.1	RP5-1112D6.4	-6.31	6.27e-10	3.03e-07	-0.27	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111277932~111278742:+
LUAD	cis	rs240993	1	rs240993	ENSG00000230177.1	RP5-1112D6.4	-6.31	6.27e-10	3.03e-07	-0.27	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111277932~111278742:+
LUAD	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-6.31	6.27e-10	3.03e-07	-0.32	-0.28	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
LUAD	cis	rs2439831	0.681	rs2278858	ENSG00000205771.5	CATSPER2P1	-6.31	6.28e-10	3.03e-07	-0.52	-0.28	Lung cancer in ever smokers;	chr15:43340557	chr15:43726918~43747094:-
LUAD	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-6.31	6.28e-10	3.03e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-6.31	6.28e-10	3.03e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-6.31	6.28e-10	3.03e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
LUAD	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-6.31	6.28e-10	3.03e-07	-0.26	-0.28	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
LUAD	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-6.31	6.29e-10	3.03e-07	-0.35	-0.28	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
LUAD	cis	rs853679	0.542	rs9393892	ENSG00000204709.4	LINC01556	6.31	6.29e-10	3.04e-07	0.39	0.28	Depression;	chr6:28113616	chr6:28943877~28944537:+
LUAD	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	6.31	6.29e-10	3.04e-07	0.4	0.28	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
LUAD	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	6.31	6.3e-10	3.04e-07	0.39	0.28	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
LUAD	cis	rs1707322	0.716	rs10890342	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs6658700	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs12047629	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs11211169	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs11211171	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28623463	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.716	rs28370457	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28890893	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28550303	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.716	rs28375469	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45651039~45651826:-
LUAD	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	6.31	6.3e-10	3.04e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	6.31	6.3e-10	3.04e-07	0.34	0.28	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
LUAD	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	6.31	6.32e-10	3.05e-07	0.69	0.28	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
LUAD	cis	rs516805	0.847	rs520046	ENSG00000279453.1	RP3-425C14.4	-6.31	6.33e-10	3.05e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122446048	chr6:122436789~122439223:-
LUAD	cis	rs4723738	1	rs4723733	ENSG00000227191.5	TRGC2	6.31	6.35e-10	3.06e-07	0.3	0.28	Treatment response for severe sepsis;	chr7:38184011	chr7:38239580~38368091:-
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000232546.1	RP11-458F8.1	-6.31	6.37e-10	3.07e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65914813	chr7:66848496~66858136:+
LUAD	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-6.31	6.37e-10	3.07e-07	-0.33	-0.28	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
LUAD	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	6.31	6.38e-10	3.07e-07	0.29	0.28	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
LUAD	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-6.31	6.38e-10	3.08e-07	-0.37	-0.28	Depression;	chr6:28201380	chr6:28115628~28116551:+
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000232546.1	RP11-458F8.1	-6.31	6.38e-10	3.08e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65947955	chr7:66848496~66858136:+
LUAD	cis	rs75920871	0.513	rs76904522	ENSG00000254851.1	RP11-109L13.1	-6.31	6.4e-10	3.09e-07	-0.46	-0.28	Subjective well-being;	chr11:117144147	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.513	rs113560866	ENSG00000254851.1	RP11-109L13.1	-6.31	6.4e-10	3.09e-07	-0.46	-0.28	Subjective well-being;	chr11:117144473	chr11:117135528~117138582:+
LUAD	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	6.31	6.41e-10	3.09e-07	0.32	0.28	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
LUAD	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	6.31	6.41e-10	3.09e-07	0.49	0.28	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
LUAD	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-6.31	6.42e-10	3.09e-07	-0.36	-0.28	Migraine;	chr4:56852029	chr4:56960927~56961373:-
LUAD	cis	rs7688540	0.8	rs9328738	ENSG00000275426.1	CH17-262A2.1	-6.31	6.42e-10	3.09e-07	-0.34	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:149738~150317:+
LUAD	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	6.31	6.42e-10	3.09e-07	0.3	0.28	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
LUAD	cis	rs948562	0.69	rs11229391	ENSG00000280010.1	AP001350.4	6.31	6.42e-10	3.09e-07	0.43	0.28	Lymphoma;	chr11:58382503	chr11:58627435~58628528:+
LUAD	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-6.31	6.43e-10	3.1e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
LUAD	cis	rs10740039	0.81	rs6479720	ENSG00000254271.1	RP11-131N11.4	6.31	6.43e-10	3.1e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60610935	chr10:60734342~60741828:+
LUAD	cis	rs7044106	0.791	rs10984995	ENSG00000238181.2	AHCYP2	-6.31	6.43e-10	3.1e-07	-0.36	-0.28	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120720673~120721972:+
LUAD	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-6.31	6.44e-10	3.1e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
LUAD	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
LUAD	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	6.31	6.45e-10	3.11e-07	0.3	0.28	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
LUAD	cis	rs155076	1	rs261432	ENSG00000233325.3	MIPEPP3	6.31	6.45e-10	3.11e-07	0.44	0.28	White matter hyperintensity burden;	chr13:21291776	chr13:21298139~21306373:+
LUAD	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	6.31	6.46e-10	3.11e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	6.31	6.46e-10	3.11e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	6.31	6.46e-10	3.11e-07	0.26	0.28	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
LUAD	cis	rs7688540	0.76	rs4510422	ENSG00000275426.1	CH17-262A2.1	6.31	6.48e-10	3.12e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:149738~150317:+
LUAD	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	6.31	6.49e-10	3.12e-07	0.31	0.28	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	6.31	6.49e-10	3.12e-07	0.31	0.28	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
LUAD	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	6.31	6.49e-10	3.12e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
LUAD	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	6.31	6.49e-10	3.12e-07	0.33	0.28	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
LUAD	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-6.31	6.5e-10	3.13e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
LUAD	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	6.31	6.5e-10	3.13e-07	0.29	0.28	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
LUAD	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	6.31	6.5e-10	3.13e-07	0.52	0.28	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
LUAD	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	6.31	6.5e-10	3.13e-07	0.52	0.28	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
LUAD	cis	rs2337406	0.587	rs2583291	ENSG00000211974.3	IGHV2-70	6.31	6.51e-10	3.14e-07	0.34	0.28	Alzheimer's disease (late onset);	chr14:106649293	chr14:106723574~106724093:-
LUAD	cis	rs6504622	0.905	rs3809854	ENSG00000262879.4	RP11-156P1.3	6.31	6.52e-10	3.14e-07	0.32	0.28	Orofacial clefts;	chr17:46951928	chr17:46984045~47100323:-
LUAD	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-6.31	6.53e-10	3.14e-07	-0.33	-0.28	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
LUAD	cis	rs4713118	0.516	rs7739216	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Parkinson's disease;	chr6:28112168	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs35512245	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28112175	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380055	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28113851	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368553	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28114487	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368554	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28114933	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4713137	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28115743	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9348793	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28116411	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.586	rs6905516	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Parkinson's disease;	chr6:28118700	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.586	rs6905522	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Parkinson's disease;	chr6:28118701	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.586	rs9468290	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Parkinson's disease;	chr6:28119896	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.637	rs1470962	ENSG00000280083.1	RP11-317J9.1	6.3	6.54e-10	3.15e-07	0.32	0.28	Obesity-related traits;	chr2:191270271	chr2:191154118~191156070:-
LUAD	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-6.3	6.55e-10	3.15e-07	-0.31	-0.28	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
LUAD	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-6.3	6.55e-10	3.15e-07	-0.26	-0.28	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
LUAD	cis	rs8177876	0.822	rs7206814	ENSG00000261838.4	RP11-303E16.6	-6.3	6.56e-10	3.15e-07	-0.53	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81069854~81076598:+
LUAD	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-6.3	6.56e-10	3.16e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
LUAD	cis	rs77204473	0.744	rs74955808	ENSG00000254851.1	RP11-109L13.1	6.3	6.57e-10	3.16e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117121969	chr11:117135528~117138582:+
LUAD	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	6.3	6.57e-10	3.16e-07	0.31	0.28	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
LUAD	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-6.3	6.58e-10	3.16e-07	-0.37	-0.28	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
LUAD	cis	rs3096299	0.754	rs3096320	ENSG00000274627.1	RP11-104N10.2	6.3	6.58e-10	3.16e-07	0.26	0.28	Multiple myeloma (IgH translocation);	chr16:89336649	chr16:89516797~89522217:+
LUAD	cis	rs3002142	0.658	rs2291833	ENSG00000272750.1	RP11-378J18.8	-6.3	6.58e-10	3.17e-07	-0.36	-0.28	LDL peak particle diameter (total fat intake interaction);	chr1:222653505	chr1:222658867~222661512:-
LUAD	cis	rs35740288	0.77	rs11630286	ENSG00000202081.1	RNU6-1280P	6.3	6.59e-10	3.17e-07	0.34	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85659298	chr15:85651522~85651628:-
LUAD	cis	rs10740039	0.883	rs1837945	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633757	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7089287	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634006	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7093573	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634611	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7097818	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635106	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.842	rs2119913	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635631	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.586	rs7068462	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636240	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7069814	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637001	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10821809	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637612	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10740037	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637747	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs10761531	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638177	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10761533	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638573	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.846	rs2165690	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639609	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs2119911	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639808	chr10:60734342~60741828:+
LUAD	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	6.3	6.62e-10	3.18e-07	0.51	0.28	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
LUAD	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	6.3	6.62e-10	3.18e-07	0.3	0.28	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	6.3	6.62e-10	3.18e-07	0.3	0.28	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
LUAD	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	6.3	6.64e-10	3.19e-07	0.32	0.28	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
LUAD	cis	rs7688540	0.771	rs10005733	ENSG00000275426.1	CH17-262A2.1	6.3	6.64e-10	3.19e-07	0.37	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:149738~150317:+
LUAD	cis	rs853679	0.607	rs56189111	ENSG00000204709.4	LINC01556	6.3	6.64e-10	3.19e-07	0.61	0.28	Depression;	chr6:28304196	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs35072899	ENSG00000204709.4	LINC01556	6.3	6.64e-10	3.19e-07	0.61	0.28	Depression;	chr6:28313764	chr6:28943877~28944537:+
LUAD	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
LUAD	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	6.3	6.64e-10	3.19e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
LUAD	cis	rs8031584	0.958	rs35256769	ENSG00000260382.1	RP11-540B6.2	6.3	6.65e-10	3.2e-07	0.33	0.28	Huntington's disease progression;	chr15:30945573	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.958	rs11629793	ENSG00000260382.1	RP11-540B6.2	6.3	6.65e-10	3.2e-07	0.33	0.28	Huntington's disease progression;	chr15:30946220	chr15:30882267~30883231:-
LUAD	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	6.3	6.65e-10	3.2e-07	0.28	0.28	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
LUAD	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	6.3	6.67e-10	3.2e-07	0.35	0.28	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
LUAD	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-6.3	6.67e-10	3.2e-07	-0.26	-0.28	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000232546.1	RP11-458F8.1	6.3	6.7e-10	3.22e-07	0.37	0.28	Diabetic kidney disease;	chr7:66158142	chr7:66848496~66858136:+
LUAD	cis	rs5753618	0.539	rs737888	ENSG00000236132.1	CTA-440B3.1	6.3	6.71e-10	3.22e-07	0.35	0.28	Colorectal cancer;	chr22:31215563	chr22:31816379~31817491:-
LUAD	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	6.3	6.71e-10	3.22e-07	0.28	0.28	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
LUAD	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	6.3	6.72e-10	3.23e-07	0.33	0.28	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	6.3	6.72e-10	3.23e-07	0.33	0.28	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
LUAD	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-6.3	6.72e-10	3.23e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
LUAD	cis	rs12468226	0.938	rs80315897	ENSG00000226261.1	AC064836.3	6.3	6.72e-10	3.23e-07	0.47	0.28	Urate levels;	chr2:202318044	chr2:202336024~202336727:-
LUAD	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-6.3	6.73e-10	3.23e-07	-0.3	-0.28	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
LUAD	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	6.3	6.73e-10	3.23e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	6.3	6.73e-10	3.23e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs781157	ENSG00000230295.1	RP11-458F8.2	-6.3	6.74e-10	3.23e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66013324	chr7:66880708~66882981:+
LUAD	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-6.3	6.75e-10	3.24e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
LUAD	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-6.3	6.75e-10	3.24e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
LUAD	cis	rs7176527	1	rs7176527	ENSG00000188388.10	GOLGA6L3	6.3	6.76e-10	3.24e-07	0.39	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85240472~85247170:+
LUAD	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	6.3	6.77e-10	3.25e-07	0.31	0.28	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
LUAD	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	6.3	6.78e-10	3.25e-07	0.24	0.28	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
LUAD	cis	rs1823913	0.637	rs12992372	ENSG00000280083.1	RP11-317J9.1	-6.3	6.78e-10	3.25e-07	-0.33	-0.28	Obesity-related traits;	chr2:191289251	chr2:191154118~191156070:-
LUAD	cis	rs34526934	0.608	rs34720456	ENSG00000226363.3	HAGLROS	6.3	6.79e-10	3.26e-07	0.38	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176162564	chr2:176177717~176179008:+
LUAD	cis	rs7017914	0.967	rs2732087	ENSG00000223220.1	Y_RNA	6.3	6.79e-10	3.26e-07	0.31	0.28	Bone mineral density;	chr8:70948204	chr8:70780914~70781008:-
LUAD	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-6.3	6.8e-10	3.26e-07	-0.43	-0.28	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
LUAD	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	6.3	6.81e-10	3.26e-07	0.33	0.28	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
LUAD	cis	rs6772849	0.93	rs9873888	ENSG00000242551.2	POU5F1P6	-6.3	6.81e-10	3.26e-07	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:128674735~128677005:-
LUAD	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-6.3	6.82e-10	3.27e-07	-0.37	-0.28	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
LUAD	cis	rs2243480	1	rs709607	ENSG00000232546.1	RP11-458F8.1	6.3	6.82e-10	3.27e-07	0.35	0.28	Diabetic kidney disease;	chr7:65984554	chr7:66848496~66858136:+
LUAD	cis	rs2179367	0.959	rs2262617	ENSG00000231760.4	RP11-350J20.5	6.3	6.82e-10	3.27e-07	0.34	0.28	Dupuytren's disease;	chr6:149438590	chr6:149796151~149826294:-
LUAD	cis	rs8177876	0.686	rs2602402	ENSG00000261838.4	RP11-303E16.6	6.3	6.83e-10	3.27e-07	0.5	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81052725	chr16:81069854~81076598:+
LUAD	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	6.3	6.83e-10	3.28e-07	0.29	0.28	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
LUAD	cis	rs8059260	0.541	rs6498167	ENSG00000274038.1	RP11-66H6.4	-6.3	6.84e-10	3.28e-07	-0.56	-0.28	Alcohol consumption over the past year;	chr16:11127727	chr16:11056556~11057034:+
LUAD	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-6.3	6.84e-10	3.28e-07	-0.4	-0.28	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
LUAD	cis	rs4723738	1	rs2159501	ENSG00000227191.5	TRGC2	-6.3	6.84e-10	3.28e-07	-0.3	-0.28	Treatment response for severe sepsis;	chr7:38199675	chr7:38239580~38368091:-
LUAD	cis	rs4723738	0.934	rs1860522	ENSG00000227191.5	TRGC2	-6.3	6.84e-10	3.28e-07	-0.3	-0.28	Treatment response for severe sepsis;	chr7:38200439	chr7:38239580~38368091:-
LUAD	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-6.3	6.85e-10	3.28e-07	-0.31	-0.28	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-6.3	6.86e-10	3.29e-07	-0.33	-0.28	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
LUAD	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-6.3	6.86e-10	3.29e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
LUAD	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-6.3	6.86e-10	3.29e-07	-0.39	-0.28	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
LUAD	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-6.3	6.86e-10	3.29e-07	-0.29	-0.28	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
LUAD	cis	rs12220777	0.748	rs12259239	ENSG00000230091.5	TMEM254-AS1	6.3	6.87e-10	3.29e-07	0.49	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103265	chr10:80046860~80078912:-
LUAD	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-6.3	6.87e-10	3.29e-07	-0.36	-0.28	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
LUAD	cis	rs4713118	0.662	rs149969	ENSG00000204709.4	LINC01556	6.3	6.88e-10	3.3e-07	0.36	0.28	Parkinson's disease;	chr6:28009959	chr6:28943877~28944537:+
LUAD	cis	rs30380	0.69	rs2042381	ENSG00000248734.2	CTD-2260A17.1	6.3	6.89e-10	3.3e-07	0.3	0.28	Cerebrospinal fluid biomarker levels;	chr5:96852963	chr5:96784777~96785999:+
LUAD	cis	rs2842992	0.83	rs1475123	ENSG00000237927.1	RP3-393E18.2	-6.3	6.89e-10	3.3e-07	-0.39	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159586955~159589169:-
LUAD	cis	rs853679	0.607	rs71559070	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28071151	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs35902873	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28091171	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13197574	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28092461	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34166054	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28098023	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34662244	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28106103	chr6:28943877~28944537:+
LUAD	cis	rs35952432	1	rs35952432	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Lung cancer;	chr6:28107123	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13203816	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28111820	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.556	rs34588114	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28112850	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs34371502	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28113980	chr6:28943877~28944537:+
LUAD	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-6.3	6.89e-10	3.3e-07	-0.3	-0.28	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
LUAD	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-6.3	6.91e-10	3.31e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
LUAD	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	6.3	6.91e-10	3.31e-07	0.3	0.28	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
LUAD	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-6.3	6.92e-10	3.31e-07	-0.25	-0.28	Breast cancer;	chr11:743813	chr11:777578~784297:+
LUAD	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	6.3	6.92e-10	3.31e-07	0.32	0.28	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	6.3	6.92e-10	3.31e-07	0.32	0.28	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
LUAD	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-6.3	6.92e-10	3.32e-07	-0.32	-0.28	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
LUAD	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	6.3	6.92e-10	3.32e-07	0.31	0.28	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	6.3	6.92e-10	3.32e-07	0.31	0.28	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-6.3	6.92e-10	3.32e-07	-0.3	-0.28	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
LUAD	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-6.3	6.92e-10	3.32e-07	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
LUAD	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-6.3	6.93e-10	3.32e-07	-0.31	-0.28	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
LUAD	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	6.29	6.93e-10	3.32e-07	0.31	0.28	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
LUAD	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	6.29	6.94e-10	3.32e-07	0.34	0.28	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	6.29	6.94e-10	3.32e-07	0.34	0.28	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	6.29	6.94e-10	3.32e-07	0.34	0.28	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
LUAD	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	6.29	6.94e-10	3.32e-07	0.32	0.28	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
LUAD	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	6.29	6.95e-10	3.33e-07	0.24	0.28	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
LUAD	cis	rs5753618	0.539	rs2106294	ENSG00000236132.1	CTA-440B3.1	6.29	6.96e-10	3.33e-07	0.34	0.28	Colorectal cancer;	chr22:31249773	chr22:31816379~31817491:-
LUAD	cis	rs12468226	0.938	rs12464254	ENSG00000226261.1	AC064836.3	6.29	6.96e-10	3.33e-07	0.46	0.28	Urate levels;	chr2:202301641	chr2:202336024~202336727:-
LUAD	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-6.29	6.97e-10	3.34e-07	-0.29	-0.28	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
LUAD	cis	rs12468226	0.938	rs3731700	ENSG00000226261.1	AC064836.3	6.29	6.98e-10	3.34e-07	0.46	0.28	Urate levels;	chr2:202291213	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs12471060	ENSG00000226261.1	AC064836.3	6.29	6.98e-10	3.34e-07	0.46	0.28	Urate levels;	chr2:202309597	chr2:202336024~202336727:-
LUAD	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	6.29	6.99e-10	3.34e-07	0.31	0.28	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	6.29	6.99e-10	3.34e-07	0.31	0.28	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
LUAD	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-6.29	6.99e-10	3.34e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
LUAD	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-6.29	7e-10	3.35e-07	-0.37	-0.28	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
LUAD	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-6.29	7e-10	3.35e-07	-0.29	-0.28	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
LUAD	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	6.29	7.03e-10	3.36e-07	0.3	0.28	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
LUAD	cis	rs35740288	0.77	rs11634707	ENSG00000202081.1	RNU6-1280P	6.29	7.05e-10	3.37e-07	0.34	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85608636	chr15:85651522~85651628:-
LUAD	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	6.29	7.05e-10	3.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
LUAD	cis	rs227932	0.764	rs78660981	ENSG00000234286.1	AC006026.13	-6.29	7.05e-10	3.37e-07	-0.49	-0.28	Schizophrenia;	chr7:23719296	chr7:23680195~23680786:-
LUAD	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-6.29	7.06e-10	3.37e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
LUAD	cis	rs496547	0.686	rs524590	ENSG00000255422.1	AP002954.4	-6.29	7.06e-10	3.38e-07	-0.35	-0.28	Hip minimal joint space width;	chr11:118769354	chr11:118704607~118750263:+
LUAD	cis	rs1012068	0.686	rs5998176	ENSG00000236132.1	CTA-440B3.1	-6.29	7.08e-10	3.38e-07	-0.33	-0.28	Chronic hepatitis C infection;	chr22:31922107	chr22:31816379~31817491:-
LUAD	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	6.29	7.08e-10	3.38e-07	0.39	0.28	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
LUAD	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	6.29	7.08e-10	3.38e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	6.29	7.08e-10	3.38e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	6.29	7.08e-10	3.38e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
LUAD	cis	rs804292	1	rs804292	ENSG00000255046.1	RP11-297N6.4	-6.29	7.09e-10	3.39e-07	-0.4	-0.28	Nicotine use;Alcohol dependence;	chr8:11786406	chr8:11797928~11802568:-
LUAD	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-6.29	7.09e-10	3.39e-07	-0.41	-0.28	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
LUAD	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-6.29	7.09e-10	3.39e-07	-0.31	-0.28	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
LUAD	cis	rs4591358	0.773	rs35070116	ENSG00000223466.1	AC064834.2	-6.29	7.09e-10	3.39e-07	-0.37	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515729	chr2:195533035~195538681:+
LUAD	cis	rs1707322	0.717	rs1547925	ENSG00000234329.1	RP11-767N6.2	-6.29	7.09e-10	3.39e-07	-0.29	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45651039~45651826:-
LUAD	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	6.29	7.1e-10	3.39e-07	0.23	0.28	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
LUAD	cis	rs897200	1	rs55925192	ENSG00000280083.1	RP11-317J9.1	6.29	7.1e-10	3.39e-07	0.35	0.28	Behcet's disease;	chr2:191154393	chr2:191154118~191156070:-
LUAD	cis	rs1154275	0.511	rs10934187	ENSG00000242770.2	RP11-180K7.1	-6.29	7.12e-10	3.4e-07	-0.28	-0.28	Takotsubo syndrome;	chr3:112794635	chr3:112802478~112812819:+
LUAD	cis	rs853679	0.517	rs6932109	ENSG00000204709.4	LINC01556	-6.29	7.13e-10	3.41e-07	-0.38	-0.28	Depression;	chr6:28110525	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs67340775	ENSG00000204709.4	LINC01556	6.29	7.14e-10	3.41e-07	0.6	0.28	Depression;	chr6:28336607	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs781156	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66880708~66882981:+
LUAD	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-6.29	7.17e-10	3.42e-07	-0.44	-0.28	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
LUAD	cis	rs7017914	0.934	rs7830550	ENSG00000223220.1	Y_RNA	6.29	7.18e-10	3.43e-07	0.31	0.28	Bone mineral density;	chr8:70658196	chr8:70780914~70781008:-
LUAD	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	6.29	7.19e-10	3.43e-07	0.4	0.28	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
LUAD	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	6.29	7.19e-10	3.43e-07	0.42	0.28	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
LUAD	cis	rs11096990	0.964	rs3733280	ENSG00000249207.1	RP11-360F5.1	6.29	7.19e-10	3.43e-07	0.32	0.28	Cognitive function;	chr4:39269921	chr4:39112677~39126818:-
LUAD	cis	rs10740039	0.883	rs7088404	ENSG00000254271.1	RP11-131N11.4	6.29	7.19e-10	3.43e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633320	chr10:60734342~60741828:+
LUAD	cis	rs9326248	0.559	rs484646	ENSG00000280143.1	AP000892.6	6.29	7.2e-10	3.44e-07	0.32	0.28	Blood protein levels;	chr11:116862140	chr11:117204967~117210292:+
LUAD	cis	rs3738443	0.52	rs1771932	ENSG00000259865.1	RP11-488L18.10	6.29	7.2e-10	3.44e-07	0.23	0.28	Alcohol dependence;	chr1:247218747	chr1:247187281~247188526:-
LUAD	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-6.29	7.2e-10	3.44e-07	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
LUAD	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-6.29	7.2e-10	3.44e-07	-0.35	-0.28	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
LUAD	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	6.29	7.22e-10	3.45e-07	0.31	0.28	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
LUAD	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	6.29	7.22e-10	3.45e-07	0.38	0.28	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
LUAD	cis	rs9640161	0.83	rs7800196	ENSG00000261305.1	RP4-584D14.7	6.29	7.22e-10	3.45e-07	0.39	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150364445	chr7:150341771~150342607:+
LUAD	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	6.29	7.23e-10	3.45e-07	0.32	0.28	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
LUAD	cis	rs11096990	0.927	rs6845858	ENSG00000249207.1	RP11-360F5.1	6.29	7.24e-10	3.45e-07	0.31	0.28	Cognitive function;	chr4:39237099	chr4:39112677~39126818:-
LUAD	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	6.29	7.24e-10	3.46e-07	0.31	0.28	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
LUAD	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-6.29	7.25e-10	3.46e-07	-0.38	-0.28	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
LUAD	cis	rs11118620	1	rs11118620	ENSG00000257551.1	HLX-AS1	6.29	7.26e-10	3.47e-07	0.34	0.28	Heart failure;	chr1:220855166	chr1:220832763~220880140:-
LUAD	cis	rs1823913	0.562	rs17347499	ENSG00000280083.1	RP11-317J9.1	-6.29	7.26e-10	3.47e-07	-0.33	-0.28	Obesity-related traits;	chr2:191301116	chr2:191154118~191156070:-
LUAD	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-6.29	7.27e-10	3.47e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
LUAD	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	6.29	7.29e-10	3.48e-07	0.38	0.28	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-6.29	7.3e-10	3.48e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
LUAD	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-6.29	7.32e-10	3.49e-07	-0.29	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
LUAD	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-6.29	7.32e-10	3.49e-07	-0.26	-0.28	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
LUAD	cis	rs853679	0.542	rs6934769	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28123153	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs17711801	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28124529	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs6922063	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28126588	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs2275508	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28126953	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.527	rs9461433	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Parkinson's disease;	chr6:28127394	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9468292	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28127577	chr6:28943877~28944537:+
LUAD	cis	rs1707322	0.721	rs10890336	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211151	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12045096	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4609469	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12049027	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs10789467	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10890337	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs3811435	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs9793568	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211157	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211158	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs6429575	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.685	rs6690926	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs8179402	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs8179296	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45651039~45651826:-
LUAD	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-6.29	7.33e-10	3.49e-07	-0.37	-0.28	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
LUAD	cis	rs5753618	0.509	rs4820951	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Colorectal cancer;	chr22:31190262	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.509	rs5749229	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Colorectal cancer;	chr22:31191232	chr22:31816379~31817491:-
LUAD	cis	rs4141404	0.787	rs4820042	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Paclitaxel-induced neuropathy;	chr22:31193070	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.509	rs5997912	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Colorectal cancer;	chr22:31197875	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.509	rs5997913	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Colorectal cancer;	chr22:31197973	chr22:31816379~31817491:-
LUAD	cis	rs293748	0.882	rs16903459	ENSG00000250155.1	CTD-2353F22.1	-6.29	7.34e-10	3.5e-07	-0.39	-0.28	Obesity-related traits;	chr5:37031314	chr5:36666214~36725195:-
LUAD	cis	rs1707322	0.721	rs11211149	ENSG00000234329.1	RP11-767N6.2	6.29	7.34e-10	3.5e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-6.29	7.34e-10	3.5e-07	-0.33	-0.28	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
LUAD	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	6.29	7.34e-10	3.5e-07	0.26	0.28	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
LUAD	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	6.29	7.35e-10	3.5e-07	0.27	0.28	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
LUAD	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	6.28	7.37e-10	3.51e-07	0.4	0.28	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-6.28	7.38e-10	3.51e-07	-0.34	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
LUAD	cis	rs948562	1	rs3829218	ENSG00000280010.1	AP001350.4	6.28	7.38e-10	3.52e-07	0.43	0.28	Lymphoma;	chr11:58563836	chr11:58627435~58628528:+
LUAD	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	6.28	7.39e-10	3.52e-07	0.3	0.28	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
LUAD	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-6.28	7.39e-10	3.52e-07	-0.33	-0.28	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-6.28	7.4e-10	3.53e-07	-0.4	-0.28	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-6.28	7.41e-10	3.53e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
LUAD	cis	rs2034650	0.544	rs661488	ENSG00000223313.1	RNU6-516P	6.28	7.41e-10	3.53e-07	0.36	0.28	Interstitial lung disease;	chr15:40429221	chr15:40529570~40529673:+
LUAD	cis	rs113835537	0.597	rs3737525	ENSG00000255517.5	CTD-3074O7.5	-6.28	7.41e-10	3.53e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66538884	chr11:66473490~66480233:-
LUAD	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	6.28	7.42e-10	3.53e-07	0.34	0.28	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000224373.3	IGHV4-59	-6.28	7.42e-10	3.53e-07	-0.18	-0.28	Kawasaki disease;	chr14:106771605	chr14:106627249~106627825:-
LUAD	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	6.28	7.42e-10	3.53e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	6.28	7.42e-10	3.53e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	6.28	7.42e-10	3.53e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	6.28	7.42e-10	3.53e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
LUAD	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	6.28	7.42e-10	3.53e-07	0.24	0.28	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
LUAD	cis	rs897200	1	rs16833453	ENSG00000280083.1	RP11-317J9.1	6.28	7.43e-10	3.54e-07	0.35	0.28	Behcet's disease;	chr2:191159824	chr2:191154118~191156070:-
LUAD	cis	rs897200	0.965	rs57081321	ENSG00000280083.1	RP11-317J9.1	6.28	7.43e-10	3.54e-07	0.35	0.28	Behcet's disease;	chr2:191160259	chr2:191154118~191156070:-
LUAD	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	6.28	7.44e-10	3.54e-07	0.31	0.28	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
LUAD	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	6.28	7.48e-10	3.56e-07	0.31	0.28	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
LUAD	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	6.28	7.48e-10	3.56e-07	0.33	0.28	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
LUAD	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	6.28	7.49e-10	3.56e-07	0.28	0.28	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
LUAD	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	6.28	7.5e-10	3.57e-07	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
LUAD	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-6.28	7.5e-10	3.57e-07	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
LUAD	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	6.28	7.5e-10	3.57e-07	0.41	0.28	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
LUAD	cis	rs11089937	0.554	rs5995628	ENSG00000211639.2	IGLV4-60	6.28	7.5e-10	3.57e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22194768	chr22:22162199~22162681:+
LUAD	cis	rs4591358	0.773	rs16836736	ENSG00000223466.1	AC064834.2	-6.28	7.51e-10	3.57e-07	-0.37	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511283	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.773	rs13035516	ENSG00000223466.1	AC064834.2	-6.28	7.51e-10	3.57e-07	-0.37	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195513234	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.773	rs34475459	ENSG00000223466.1	AC064834.2	-6.28	7.51e-10	3.57e-07	-0.37	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515682	chr2:195533035~195538681:+
LUAD	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
LUAD	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-6.28	7.52e-10	3.58e-07	-0.3	-0.28	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
LUAD	cis	rs2034650	0.544	rs11070272	ENSG00000223313.1	RNU6-516P	6.28	7.52e-10	3.58e-07	0.36	0.28	Interstitial lung disease;	chr15:40433064	chr15:40529570~40529673:+
LUAD	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	6.28	7.52e-10	3.58e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
LUAD	cis	rs4723738	0.967	rs10480164	ENSG00000227191.5	TRGC2	-6.28	7.52e-10	3.58e-07	-0.3	-0.28	Treatment response for severe sepsis;	chr7:38206281	chr7:38239580~38368091:-
LUAD	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	6.28	7.53e-10	3.58e-07	0.33	0.28	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
LUAD	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	6.28	7.54e-10	3.59e-07	0.33	0.28	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
LUAD	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	6.28	7.55e-10	3.59e-07	0.31	0.28	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
LUAD	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-6.28	7.55e-10	3.59e-07	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
LUAD	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-6.28	7.55e-10	3.59e-07	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
LUAD	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	6.28	7.56e-10	3.6e-07	0.31	0.28	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
LUAD	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-6.28	7.57e-10	3.6e-07	-0.29	-0.28	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
LUAD	cis	rs293748	0.571	rs10042473	ENSG00000250155.1	CTD-2353F22.1	-6.28	7.59e-10	3.61e-07	-0.33	-0.28	Obesity-related traits;	chr5:37243651	chr5:36666214~36725195:-
LUAD	cis	rs9640161	0.83	rs35840727	ENSG00000261305.1	RP4-584D14.7	6.28	7.6e-10	3.61e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150366115	chr7:150341771~150342607:+
LUAD	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-6.28	7.6e-10	3.61e-07	-0.29	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
LUAD	cis	rs948562	0.895	rs11229537	ENSG00000280010.1	AP001350.4	6.28	7.6e-10	3.61e-07	0.43	0.28	Lymphoma;	chr11:58585392	chr11:58627435~58628528:+
LUAD	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-6.28	7.64e-10	3.63e-07	-0.21	-0.28	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
LUAD	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-6.28	7.65e-10	3.63e-07	-0.31	-0.28	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
LUAD	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	6.28	7.65e-10	3.63e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
LUAD	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	6.28	7.66e-10	3.64e-07	0.28	0.28	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
LUAD	cis	rs75920871	0.589	rs7941150	ENSG00000254851.1	RP11-109L13.1	-6.28	7.67e-10	3.64e-07	-0.47	-0.28	Subjective well-being;	chr11:117221105	chr11:117135528~117138582:+
LUAD	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-6.28	7.67e-10	3.64e-07	-0.29	-0.28	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
LUAD	cis	rs12699921	0.632	rs2691594	ENSG00000279048.1	RP11-511H23.2	-6.28	7.67e-10	3.64e-07	-0.22	-0.28	Fibrinogen levels;	chr7:17825193	chr7:17940503~17942922:+
LUAD	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	6.28	7.68e-10	3.65e-07	0.4	0.28	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
LUAD	cis	rs30380	0.632	rs27045	ENSG00000272109.1	CTD-2260A17.3	-6.28	7.68e-10	3.65e-07	-0.33	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96803158	chr5:96804353~96806105:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000224373.3	IGHV4-59	6.28	7.68e-10	3.65e-07	0.18	0.28	Kawasaki disease;	chr14:106816039	chr14:106627249~106627825:-
LUAD	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
LUAD	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-6.28	7.69e-10	3.65e-07	-0.29	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
LUAD	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	6.28	7.69e-10	3.65e-07	0.36	0.28	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
LUAD	cis	rs3738443	0.599	rs6693807	ENSG00000259865.1	RP11-488L18.10	-6.28	7.69e-10	3.65e-07	-0.24	-0.28	Alcohol dependence;	chr1:247230353	chr1:247187281~247188526:-
LUAD	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-6.28	7.7e-10	3.66e-07	-0.3	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
LUAD	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-6.28	7.7e-10	3.66e-07	-0.34	-0.28	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
LUAD	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-6.28	7.7e-10	3.66e-07	-0.34	-0.28	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
LUAD	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-6.28	7.71e-10	3.66e-07	-0.31	-0.28	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
LUAD	cis	rs5753618	0.561	rs2078803	ENSG00000236132.1	CTA-440B3.1	6.28	7.71e-10	3.66e-07	0.35	0.28	Colorectal cancer;	chr22:31256866	chr22:31816379~31817491:-
LUAD	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-6.28	7.71e-10	3.66e-07	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
LUAD	cis	rs155076	1	rs261407	ENSG00000233325.3	MIPEPP3	6.28	7.72e-10	3.66e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21281074	chr13:21298139~21306373:+
LUAD	cis	rs155076	1	rs261406	ENSG00000233325.3	MIPEPP3	6.28	7.72e-10	3.66e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21281715	chr13:21298139~21306373:+
LUAD	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-6.28	7.72e-10	3.66e-07	-0.44	-0.28	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
LUAD	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	6.28	7.72e-10	3.67e-07	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
LUAD	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-6.28	7.73e-10	3.67e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
LUAD	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	6.28	7.73e-10	3.67e-07	0.42	0.28	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
LUAD	cis	rs1823913	0.637	rs1378162	ENSG00000280083.1	RP11-317J9.1	-6.28	7.73e-10	3.67e-07	-0.33	-0.28	Obesity-related traits;	chr2:191298523	chr2:191154118~191156070:-
LUAD	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
LUAD	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.28	7.74e-10	3.68e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
LUAD	cis	rs496547	0.719	rs472641	ENSG00000255422.1	AP002954.4	-6.28	7.75e-10	3.68e-07	-0.35	-0.28	Hip minimal joint space width;	chr11:118746835	chr11:118704607~118750263:+
LUAD	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	6.28	7.76e-10	3.68e-07	0.32	0.28	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000232546.1	RP11-458F8.1	-6.28	7.76e-10	3.68e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66136229	chr7:66848496~66858136:+
LUAD	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-6.28	7.79e-10	3.7e-07	-0.34	-0.28	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
LUAD	cis	rs2243480	1	rs383402	ENSG00000232546.1	RP11-458F8.1	6.28	7.79e-10	3.7e-07	0.35	0.28	Diabetic kidney disease;	chr7:66121666	chr7:66848496~66858136:+
LUAD	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	6.27	7.82e-10	3.71e-07	0.34	0.28	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
LUAD	cis	rs5753618	0.504	rs9609297	ENSG00000236132.1	CTA-440B3.1	-6.27	7.82e-10	3.71e-07	-0.36	-0.28	Colorectal cancer;	chr22:31497745	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	6.27	7.82e-10	3.71e-07	0.34	0.28	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
LUAD	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-6.27	7.83e-10	3.71e-07	-0.32	-0.28	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
LUAD	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	6.27	7.84e-10	3.72e-07	0.3	0.28	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
LUAD	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	6.27	7.84e-10	3.72e-07	0.37	0.28	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
LUAD	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	6.27	7.85e-10	3.72e-07	0.28	0.28	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
LUAD	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	6.27	7.86e-10	3.72e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
LUAD	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	6.27	7.86e-10	3.73e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
LUAD	cis	rs11096990	0.855	rs11737290	ENSG00000249207.1	RP11-360F5.1	6.27	7.86e-10	3.73e-07	0.32	0.28	Cognitive function;	chr4:39192318	chr4:39112677~39126818:-
LUAD	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	6.27	7.86e-10	3.73e-07	0.28	0.28	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
LUAD	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	6.27	7.87e-10	3.73e-07	0.32	0.28	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
LUAD	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	6.27	7.88e-10	3.73e-07	0.3	0.28	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
LUAD	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	6.27	7.88e-10	3.73e-07	0.28	0.28	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs2243480	ENSG00000232546.1	RP11-458F8.1	-6.27	7.88e-10	3.73e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66134209	chr7:66848496~66858136:+
LUAD	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	6.27	7.89e-10	3.74e-07	0.3	0.28	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
LUAD	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	6.27	7.9e-10	3.75e-07	0.28	0.27	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	6.27	7.9e-10	3.75e-07	0.28	0.27	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
LUAD	cis	rs293748	0.882	rs13177875	ENSG00000250155.1	CTD-2353F22.1	-6.27	7.91e-10	3.75e-07	-0.38	-0.27	Obesity-related traits;	chr5:37078226	chr5:36666214~36725195:-
LUAD	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-6.27	7.91e-10	3.75e-07	-0.35	-0.27	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-6.27	7.91e-10	3.75e-07	-0.35	-0.27	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
LUAD	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	6.27	7.91e-10	3.75e-07	0.34	0.27	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
LUAD	cis	rs2295359	0.637	rs12044149	ENSG00000275678.1	RP4-547N15.3	-6.27	7.91e-10	3.75e-07	-0.31	-0.27	Psoriasis;	chr1:67135003	chr1:67121605~67123956:-
LUAD	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	6.27	7.91e-10	3.75e-07	0.31	0.27	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
LUAD	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	6.27	7.91e-10	3.75e-07	0.27	0.27	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
LUAD	cis	rs3738443	0.594	rs6664697	ENSG00000259865.1	RP11-488L18.10	-6.27	7.92e-10	3.75e-07	-0.23	-0.27	Alcohol dependence;	chr1:247217308	chr1:247187281~247188526:-
LUAD	cis	rs8177876	0.822	rs4889231	ENSG00000261838.4	RP11-303E16.6	-6.27	7.93e-10	3.76e-07	-0.55	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81069854~81076598:+
LUAD	cis	rs10740039	0.516	rs10740034	ENSG00000254271.1	RP11-131N11.4	6.27	7.93e-10	3.76e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60592624	chr10:60734342~60741828:+
LUAD	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-6.27	7.95e-10	3.76e-07	-0.28	-0.27	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
LUAD	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-6.27	7.97e-10	3.78e-07	-0.34	-0.27	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
LUAD	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	6.27	7.98e-10	3.78e-07	0.34	0.27	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
LUAD	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	6.27	7.98e-10	3.78e-07	0.31	0.27	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
LUAD	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-6.27	8.01e-10	3.79e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
LUAD	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-6.27	8.02e-10	3.8e-07	-0.43	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
LUAD	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	6.27	8.02e-10	3.8e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
LUAD	cis	rs4591358	0.773	rs13008940	ENSG00000223466.1	AC064834.2	-6.27	8.02e-10	3.8e-07	-0.37	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509828	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs7578371	ENSG00000223466.1	AC064834.2	-6.27	8.02e-10	3.8e-07	-0.37	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510222	chr2:195533035~195538681:+
LUAD	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	6.27	8.04e-10	3.8e-07	0.31	0.27	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
LUAD	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	6.27	8.04e-10	3.81e-07	0.38	0.27	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000232546.1	RP11-458F8.1	-6.27	8.04e-10	3.81e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66375924	chr7:66848496~66858136:+
LUAD	cis	rs853679	0.517	rs1947863	ENSG00000204709.4	LINC01556	6.27	8.05e-10	3.81e-07	0.38	0.27	Depression;	chr6:28131566	chr6:28943877~28944537:+
LUAD	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-6.27	8.07e-10	3.82e-07	-0.29	-0.27	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	6.27	8.08e-10	3.82e-07	0.34	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
LUAD	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-6.27	8.08e-10	3.82e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs1723267	ENSG00000230295.1	RP11-458F8.2	-6.27	8.08e-10	3.82e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66008327	chr7:66880708~66882981:+
LUAD	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	6.27	8.09e-10	3.83e-07	0.63	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
LUAD	cis	rs948562	0.627	rs11229387	ENSG00000280010.1	AP001350.4	6.27	8.1e-10	3.83e-07	0.38	0.27	Lymphoma;	chr11:58373645	chr11:58627435~58628528:+
LUAD	cis	rs17818399	1	rs62136864	ENSG00000279254.1	RP11-536C12.1	-6.27	8.1e-10	3.83e-07	-0.3	-0.27	Height;	chr2:46601985	chr2:46668870~46670778:+
LUAD	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-6.27	8.1e-10	3.83e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
LUAD	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	6.27	8.11e-10	3.83e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
LUAD	cis	rs72772090	0.634	rs17402639	ENSG00000248734.2	CTD-2260A17.1	-6.27	8.12e-10	3.84e-07	-0.41	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96771301	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.634	rs72773912	ENSG00000248734.2	CTD-2260A17.1	-6.27	8.12e-10	3.84e-07	-0.41	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96772097	chr5:96784777~96785999:+
LUAD	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	6.27	8.12e-10	3.84e-07	0.39	0.27	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
LUAD	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	6.27	8.12e-10	3.84e-07	0.31	0.27	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
LUAD	cis	rs2337406	0.587	rs2516886	ENSG00000211974.3	IGHV2-70	6.27	8.13e-10	3.84e-07	0.34	0.27	Alzheimer's disease (late onset);	chr14:106649674	chr14:106723574~106724093:-
LUAD	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	6.27	8.14e-10	3.85e-07	0.28	0.27	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
LUAD	cis	rs9549367	0.789	rs34448227	ENSG00000269125.1	RP11-98F14.11	-6.27	8.15e-10	3.85e-07	-0.34	-0.27	Platelet distribution width;	chr13:113230440	chr13:113165002~113165183:-
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000224373.3	IGHV4-59	6.27	8.15e-10	3.85e-07	0.16	0.27	Kawasaki disease;	chr14:106685899	chr14:106627249~106627825:-
LUAD	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	6.27	8.16e-10	3.86e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	6.27	8.16e-10	3.86e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
LUAD	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-6.27	8.16e-10	3.86e-07	-0.32	-0.27	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
LUAD	cis	rs4273100	0.526	rs2074280	ENSG00000262319.1	CTC-457L16.2	-6.27	8.16e-10	3.86e-07	-0.36	-0.27	Schizophrenia;	chr17:19014602	chr17:19141017~19143689:-
LUAD	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-6.27	8.19e-10	3.87e-07	-0.26	-0.27	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
LUAD	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-6.27	8.19e-10	3.87e-07	-0.24	-0.27	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	6.27	8.2e-10	3.87e-07	0.4	0.27	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-6.27	8.2e-10	3.87e-07	-0.34	-0.27	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
LUAD	cis	rs853679	0.607	rs35030260	ENSG00000204709.4	LINC01556	6.27	8.2e-10	3.88e-07	0.61	0.27	Depression;	chr6:28337731	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13217619	ENSG00000204709.4	LINC01556	6.27	8.2e-10	3.88e-07	0.61	0.27	Depression;	chr6:28338894	chr6:28943877~28944537:+
LUAD	cis	rs237743	1	rs381262	ENSG00000222365.1	SNORD12B	-6.27	8.21e-10	3.88e-07	-0.3	-0.27	Height;	chr20:49316942	chr20:49280319~49280409:+
LUAD	cis	rs7688540	0.74	rs28784663	ENSG00000275426.1	CH17-262A2.1	6.27	8.22e-10	3.88e-07	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:149738~150317:+
LUAD	cis	rs12468226	0.938	rs6435139	ENSG00000226261.1	AC064836.3	-6.27	8.22e-10	3.88e-07	-0.45	-0.27	Urate levels;	chr2:202255145	chr2:202336024~202336727:-
LUAD	cis	rs2243480	1	rs1964692	ENSG00000232546.1	RP11-458F8.1	-6.27	8.23e-10	3.89e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65989196	chr7:66848496~66858136:+
LUAD	cis	rs7246657	0.524	rs10411251	ENSG00000276846.1	CTD-3220F14.3	6.27	8.24e-10	3.89e-07	0.38	0.27	Coronary artery calcification;	chr19:36937853	chr19:37314868~37315620:-
LUAD	cis	rs7044106	0.762	rs1530370	ENSG00000238181.2	AHCYP2	-6.27	8.25e-10	3.9e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120720673~120721972:+
LUAD	cis	rs496547	0.719	rs598373	ENSG00000255422.1	AP002954.4	-6.27	8.25e-10	3.9e-07	-0.35	-0.27	Hip minimal joint space width;	chr11:118793668	chr11:118704607~118750263:+
LUAD	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	6.27	8.26e-10	3.9e-07	0.23	0.27	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
LUAD	cis	rs1106529	0.528	rs1779445	ENSG00000226172.2	RP4-712E4.1	-6.27	8.26e-10	3.9e-07	-0.39	-0.27	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118965789	chr1:119000344~119001392:-
LUAD	cis	rs9595908	0.9	rs61947058	ENSG00000212293.1	SNORA16	6.26	8.29e-10	3.91e-07	0.29	0.27	Body mass index;	chr13:32617419	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	6.26	8.29e-10	3.91e-07	0.35	0.27	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	6.26	8.3e-10	3.92e-07	0.35	0.27	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
LUAD	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-6.26	8.3e-10	3.92e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
LUAD	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	6.26	8.3e-10	3.92e-07	0.31	0.27	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
LUAD	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	6.26	8.32e-10	3.92e-07	0.49	0.27	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
LUAD	cis	rs948562	0.69	rs7342155	ENSG00000280010.1	AP001350.4	6.26	8.32e-10	3.93e-07	0.43	0.27	Lymphoma;	chr11:58348171	chr11:58627435~58628528:+
LUAD	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	6.26	8.33e-10	3.93e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000232546.1	RP11-458F8.1	-6.26	8.34e-10	3.93e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65996588	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000232546.1	RP11-458F8.1	-6.26	8.34e-10	3.93e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66002158	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000232546.1	RP11-458F8.1	-6.26	8.34e-10	3.93e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66005214	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000232546.1	RP11-458F8.1	-6.26	8.34e-10	3.93e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66005945	chr7:66848496~66858136:+
LUAD	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	6.26	8.34e-10	3.94e-07	0.32	0.27	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
LUAD	cis	rs3738443	0.594	rs60050650	ENSG00000259865.1	RP11-488L18.10	6.26	8.35e-10	3.94e-07	0.23	0.27	Alcohol dependence;	chr1:247213474	chr1:247187281~247188526:-
LUAD	cis	rs9549367	0.789	rs9549699	ENSG00000269125.1	RP11-98F14.11	-6.26	8.36e-10	3.94e-07	-0.34	-0.27	Platelet distribution width;	chr13:113223949	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs7999579	ENSG00000269125.1	RP11-98F14.11	-6.26	8.36e-10	3.94e-07	-0.34	-0.27	Platelet distribution width;	chr13:113225043	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs6577035	ENSG00000269125.1	RP11-98F14.11	-6.26	8.36e-10	3.94e-07	-0.34	-0.27	Platelet distribution width;	chr13:113225683	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs12584981	ENSG00000269125.1	RP11-98F14.11	-6.26	8.36e-10	3.94e-07	-0.34	-0.27	Platelet distribution width;	chr13:113226871	chr13:113165002~113165183:-
LUAD	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-6.26	8.36e-10	3.94e-07	-0.21	-0.27	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
LUAD	cis	rs948562	1	rs12365551	ENSG00000280010.1	AP001350.4	6.26	8.36e-10	3.94e-07	0.43	0.27	Lymphoma;	chr11:58590895	chr11:58627435~58628528:+
LUAD	cis	rs7246657	0.551	rs62108899	ENSG00000276846.1	CTD-3220F14.3	6.26	8.36e-10	3.94e-07	0.45	0.27	Coronary artery calcification;	chr19:37104281	chr19:37314868~37315620:-
LUAD	cis	rs75920871	0.589	rs4938342	ENSG00000254851.1	RP11-109L13.1	-6.26	8.36e-10	3.95e-07	-0.47	-0.27	Subjective well-being;	chr11:117132704	chr11:117135528~117138582:+
LUAD	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	6.26	8.38e-10	3.95e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
LUAD	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-6.26	8.38e-10	3.95e-07	-0.34	-0.27	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
LUAD	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-6.26	8.38e-10	3.95e-07	-0.38	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
LUAD	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	6.26	8.38e-10	3.95e-07	0.29	0.27	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.721	rs56255771	ENSG00000234329.1	RP11-767N6.2	6.26	8.39e-10	3.96e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs34136756	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65916269	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65917585	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65918212	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65920739	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65922114	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65922691	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65923503	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65924743	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65925107	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65925372	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65925938	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65926730	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65928032	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000232546.1	RP11-458F8.1	6.26	8.39e-10	3.96e-07	0.36	0.27	Diabetic kidney disease;	chr7:65928187	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65929575	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65929781	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65929865	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65938222	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65940221	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65943626	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65944004	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65944182	chr7:66848496~66858136:+
LUAD	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-6.26	8.39e-10	3.96e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
LUAD	cis	rs948562	1	rs11229535	ENSG00000280010.1	AP001350.4	6.26	8.4e-10	3.96e-07	0.43	0.27	Lymphoma;	chr11:58580913	chr11:58627435~58628528:+
LUAD	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-6.26	8.43e-10	3.97e-07	-0.28	-0.27	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
LUAD	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	6.26	8.43e-10	3.97e-07	0.33	0.27	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
LUAD	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs333454	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174653939	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs333452	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174654718	chr1:174115300~174160004:-
LUAD	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-6.26	8.44e-10	3.97e-07	-0.32	-0.27	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
LUAD	cis	rs11096990	0.892	rs28639548	ENSG00000249207.1	RP11-360F5.1	6.26	8.44e-10	3.97e-07	0.32	0.27	Cognitive function;	chr4:39185530	chr4:39112677~39126818:-
LUAD	cis	rs3738443	0.569	rs6704060	ENSG00000259865.1	RP11-488L18.10	6.26	8.45e-10	3.98e-07	0.23	0.27	Alcohol dependence;	chr1:247218222	chr1:247187281~247188526:-
LUAD	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	6.26	8.46e-10	3.99e-07	0.45	0.27	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
LUAD	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-6.26	8.48e-10	3.99e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-6.26	8.48e-10	3.99e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
LUAD	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	6.26	8.49e-10	4e-07	0.28	0.27	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
LUAD	cis	rs9880192	0.516	rs2713575	ENSG00000242551.2	POU5F1P6	-6.26	8.5e-10	4e-07	-0.31	-0.27	White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts;	chr3:128575512	chr3:128674735~128677005:-
LUAD	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	6.26	8.5e-10	4.01e-07	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
LUAD	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	6.26	8.52e-10	4.01e-07	0.27	0.27	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
LUAD	cis	rs6840258	0.547	rs72667727	ENSG00000251411.1	RP11-397E7.4	-6.26	8.52e-10	4.01e-07	-0.39	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86936370	chr4:86913266~86914817:-
LUAD	cis	rs2243480	1	rs464895	ENSG00000232546.1	RP11-458F8.1	-6.26	8.52e-10	4.01e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66062119	chr7:66848496~66858136:+
LUAD	cis	rs1707322	0.752	rs6703748	ENSG00000234329.1	RP11-767N6.2	6.26	8.53e-10	4.02e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45651039~45651826:-
LUAD	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-6.26	8.54e-10	4.02e-07	-0.43	-0.27	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
LUAD	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	6.26	8.57e-10	4.03e-07	0.41	0.27	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
LUAD	cis	rs12468226	1	rs58288071	ENSG00000226261.1	AC064836.3	6.26	8.57e-10	4.04e-07	0.46	0.27	Urate levels;	chr2:202350016	chr2:202336024~202336727:-
LUAD	cis	rs17301013	0.507	rs10912789	ENSG00000227373.4	RP11-160H22.5	6.26	8.59e-10	4.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174465616	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs6684141	ENSG00000227373.4	RP11-160H22.5	6.26	8.59e-10	4.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174467305	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12058377	ENSG00000227373.4	RP11-160H22.5	6.26	8.59e-10	4.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174470971	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs6656925	ENSG00000227373.4	RP11-160H22.5	6.26	8.59e-10	4.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174474161	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2987872	ENSG00000227373.4	RP11-160H22.5	-6.26	8.6e-10	4.05e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174840935	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs1793305	ENSG00000227373.4	RP11-160H22.5	-6.26	8.6e-10	4.05e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174841124	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs1894201	ENSG00000227373.4	RP11-160H22.5	-6.26	8.6e-10	4.05e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174841452	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs2961102	ENSG00000232546.1	RP11-458F8.1	-6.26	8.62e-10	4.05e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65959671	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-6.26	8.62e-10	4.05e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
LUAD	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	6.26	8.62e-10	4.06e-07	0.28	0.27	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
LUAD	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	6.26	8.63e-10	4.06e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	6.26	8.63e-10	4.06e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-6.26	8.63e-10	4.06e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-6.26	8.65e-10	4.07e-07	-0.39	-0.27	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000224373.3	IGHV4-59	6.26	8.65e-10	4.07e-07	0.18	0.27	Kawasaki disease;	chr14:106815190	chr14:106627249~106627825:-
LUAD	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	6.26	8.66e-10	4.07e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-6.26	8.66e-10	4.07e-07	-0.19	-0.27	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
LUAD	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-6.26	8.69e-10	4.09e-07	-0.29	-0.27	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000232546.1	RP11-458F8.1	-6.26	8.7e-10	4.09e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65946971	chr7:66848496~66858136:+
LUAD	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	6.26	8.71e-10	4.09e-07	0.32	0.27	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
LUAD	cis	rs755249	0.567	rs16825887	ENSG00000228060.1	RP11-69E11.8	6.26	8.71e-10	4.09e-07	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39565160~39573203:+
LUAD	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	6.26	8.71e-10	4.1e-07	0.28	0.27	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
LUAD	cis	rs720064	0.586	rs12957815	ENSG00000264745.1	TTC39C-AS1	6.26	8.72e-10	4.1e-07	0.29	0.27	Strep throat;	chr18:23976626	chr18:23994213~24015339:-
LUAD	cis	rs2243480	1	rs316326	ENSG00000232546.1	RP11-458F8.1	-6.26	8.73e-10	4.1e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66144466	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316325	ENSG00000232546.1	RP11-458F8.1	-6.26	8.73e-10	4.1e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66144531	chr7:66848496~66858136:+
LUAD	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	6.26	8.73e-10	4.1e-07	0.32	0.27	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
LUAD	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-6.26	8.73e-10	4.1e-07	-0.33	-0.27	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-6.26	8.73e-10	4.1e-07	-0.33	-0.27	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
LUAD	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-6.26	8.75e-10	4.11e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
LUAD	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	6.26	8.75e-10	4.11e-07	0.31	0.27	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
LUAD	cis	rs1012068	0.686	rs5994451	ENSG00000236132.1	CTA-440B3.1	-6.26	8.76e-10	4.11e-07	-0.33	-0.27	Chronic hepatitis C infection;	chr22:31927525	chr22:31816379~31817491:-
LUAD	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	6.26	8.77e-10	4.12e-07	0.38	0.27	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
LUAD	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	6.26	8.78e-10	4.12e-07	0.34	0.27	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
LUAD	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	6.26	8.78e-10	4.13e-07	0.31	0.27	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
LUAD	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	6.25	8.8e-10	4.13e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	6.25	8.8e-10	4.13e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	6.25	8.8e-10	4.13e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
LUAD	cis	rs755249	0.567	rs112672438	ENSG00000228060.1	RP11-69E11.8	-6.25	8.81e-10	4.14e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs16825921	ENSG00000228060.1	RP11-69E11.8	-6.25	8.81e-10	4.14e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39565160~39573203:+
LUAD	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-6.25	8.82e-10	4.14e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-6.25	8.82e-10	4.14e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-6.25	8.82e-10	4.14e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-6.25	8.82e-10	4.14e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
LUAD	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-6.25	8.82e-10	4.14e-07	-0.29	-0.27	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
LUAD	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	6.25	8.84e-10	4.15e-07	0.27	0.27	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
LUAD	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-6.25	8.85e-10	4.15e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
LUAD	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-6.25	8.86e-10	4.16e-07	-0.35	-0.27	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
LUAD	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs34637256	ENSG00000232546.1	RP11-458F8.1	-6.25	8.86e-10	4.16e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65895144	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35391607	ENSG00000232546.1	RP11-458F8.1	-6.25	8.86e-10	4.16e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65895842	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs13220979	ENSG00000232546.1	RP11-458F8.1	-6.25	8.86e-10	4.16e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65898217	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34974928	ENSG00000232546.1	RP11-458F8.1	-6.25	8.86e-10	4.16e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65899019	chr7:66848496~66858136:+
LUAD	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	6.25	8.87e-10	4.16e-07	0.46	0.27	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
LUAD	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	6.25	8.87e-10	4.16e-07	0.29	0.27	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	6.25	8.87e-10	4.17e-07	0.33	0.27	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
LUAD	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	6.25	8.89e-10	4.17e-07	0.32	0.27	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000232546.1	RP11-458F8.1	6.25	8.9e-10	4.18e-07	0.37	0.27	Diabetic kidney disease;	chr7:66219914	chr7:66848496~66858136:+
LUAD	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-6.25	8.9e-10	4.18e-07	-0.37	-0.27	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
LUAD	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-6.25	8.9e-10	4.18e-07	-0.37	-0.27	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
LUAD	cis	rs7923609	0.841	rs10822186	ENSG00000232075.1	MRPL35P2	-6.25	8.91e-10	4.18e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63590623	chr10:63634317~63634827:-
LUAD	cis	rs2243480	1	rs4718334	ENSG00000232546.1	RP11-458F8.1	6.25	8.91e-10	4.18e-07	0.36	0.27	Diabetic kidney disease;	chr7:66324467	chr7:66848496~66858136:+
LUAD	cis	rs4723738	1	rs7788819	ENSG00000227191.5	TRGC2	-6.25	8.92e-10	4.18e-07	-0.3	-0.27	Treatment response for severe sepsis;	chr7:38187056	chr7:38239580~38368091:-
LUAD	cis	rs4723738	1	rs17171307	ENSG00000227191.5	TRGC2	-6.25	8.92e-10	4.18e-07	-0.3	-0.27	Treatment response for severe sepsis;	chr7:38188976	chr7:38239580~38368091:-
LUAD	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-6.25	8.92e-10	4.19e-07	-0.35	-0.27	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
LUAD	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	6.25	8.93e-10	4.19e-07	0.28	0.27	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
LUAD	cis	rs6772849	0.93	rs9868579	ENSG00000242551.2	POU5F1P6	6.25	8.94e-10	4.19e-07	0.32	0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:128674735~128677005:-
LUAD	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-6.25	8.94e-10	4.19e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
LUAD	cis	rs35934224	0.831	rs13057374	ENSG00000232926.1	AC000078.5	6.25	8.95e-10	4.2e-07	0.3	0.27	Glaucoma (primary open-angle);	chr22:19883574	chr22:19887289~19887970:+
LUAD	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	6.25	8.95e-10	4.2e-07	0.41	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
LUAD	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-6.25	8.95e-10	4.2e-07	-0.2	-0.27	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
LUAD	cis	rs8177876	0.822	rs7185637	ENSG00000261838.4	RP11-303E16.6	-6.25	8.96e-10	4.2e-07	-0.52	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81089551	chr16:81069854~81076598:+
LUAD	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-6.25	8.96e-10	4.2e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
LUAD	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-6.25	8.97e-10	4.21e-07	-0.34	-0.27	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
LUAD	cis	rs7044106	0.762	rs1158553	ENSG00000238181.2	AHCYP2	-6.25	8.97e-10	4.21e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120720673~120721972:+
LUAD	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-6.25	8.98e-10	4.21e-07	-0.34	-0.27	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
LUAD	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	6.25	8.98e-10	4.21e-07	0.39	0.27	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
LUAD	cis	rs5753618	0.509	rs5753500	ENSG00000236132.1	CTA-440B3.1	6.25	8.99e-10	4.21e-07	0.35	0.27	Colorectal cancer;	chr22:31182893	chr22:31816379~31817491:-
LUAD	cis	rs728616	0.614	rs2181204	ENSG00000225484.5	NUTM2B-AS1	-6.25	8.99e-10	4.21e-07	-0.44	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79663088~79826594:-
LUAD	cis	rs3738443	0.678	rs61636449	ENSG00000259865.1	RP11-488L18.10	6.25	8.99e-10	4.22e-07	0.25	0.27	Alcohol dependence;	chr1:247213758	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.678	rs57861883	ENSG00000259865.1	RP11-488L18.10	6.25	8.99e-10	4.22e-07	0.25	0.27	Alcohol dependence;	chr1:247214089	chr1:247187281~247188526:-
LUAD	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	6.25	8.99e-10	4.22e-07	0.48	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	6.25	8.99e-10	4.22e-07	0.48	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
LUAD	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
LUAD	cis	rs9595908	0.537	rs7993153	ENSG00000212293.1	SNORA16	6.25	9.02e-10	4.23e-07	0.29	0.27	Body mass index;	chr13:32804647	chr13:32420390~32420516:-
LUAD	cis	rs10740039	0.516	rs1348281	ENSG00000254271.1	RP11-131N11.4	-6.25	9.02e-10	4.23e-07	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60596475	chr10:60734342~60741828:+
LUAD	cis	rs4713118	0.662	rs149946	ENSG00000204709.4	LINC01556	-6.25	9.02e-10	4.23e-07	-0.37	-0.27	Parkinson's disease;	chr6:28002253	chr6:28943877~28944537:+
LUAD	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-6.25	9.04e-10	4.23e-07	-0.3	-0.27	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
LUAD	cis	rs1707322	0.721	rs10890333	ENSG00000234329.1	RP11-767N6.2	6.25	9.04e-10	4.24e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45651039~45651826:-
LUAD	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-6.25	9.05e-10	4.24e-07	-0.38	-0.27	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
LUAD	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-6.25	9.06e-10	4.24e-07	-0.34	-0.27	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
LUAD	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	6.25	9.06e-10	4.25e-07	0.26	0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
LUAD	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-6.25	9.06e-10	4.25e-07	-0.31	-0.27	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
LUAD	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-6.25	9.06e-10	4.25e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
LUAD	cis	rs13230714	1	rs13230714	ENSG00000204959.4	ARHGEF34P	-6.25	9.07e-10	4.25e-07	-0.37	-0.27	Breast cancer;	chr7:144477198	chr7:144272445~144286966:-
LUAD	cis	rs7727544	0.507	rs11741341	ENSG00000233006.5	AC034220.3	6.25	9.08e-10	4.25e-07	0.25	0.27	Blood metabolite levels;	chr5:132234525	chr5:132311285~132369916:-
LUAD	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-6.25	9.08e-10	4.25e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-6.25	9.1e-10	4.26e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
LUAD	cis	rs948562	0.69	rs17473544	ENSG00000280010.1	AP001350.4	6.25	9.12e-10	4.27e-07	0.42	0.27	Lymphoma;	chr11:58388994	chr11:58627435~58628528:+
LUAD	cis	rs75422866	0.764	rs67408202	ENSG00000274902.1	RP1-197B17.4	6.25	9.13e-10	4.28e-07	0.65	0.27	Pneumonia;	chr12:47713564	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs57848393	ENSG00000274902.1	RP1-197B17.4	6.25	9.13e-10	4.28e-07	0.65	0.27	Pneumonia;	chr12:47714734	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.764	rs67201012	ENSG00000274902.1	RP1-197B17.4	6.25	9.13e-10	4.28e-07	0.65	0.27	Pneumonia;	chr12:47715881	chr12:47731908~47732351:+
LUAD	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-6.25	9.13e-10	4.28e-07	-0.34	-0.27	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
LUAD	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-6.25	9.13e-10	4.28e-07	-0.31	-0.27	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
LUAD	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	6.25	9.14e-10	4.28e-07	0.38	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
LUAD	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	6.25	9.15e-10	4.28e-07	0.39	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
LUAD	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-6.25	9.16e-10	4.29e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-6.25	9.16e-10	4.29e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000232546.1	RP11-458F8.1	-6.25	9.17e-10	4.29e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66038306	chr7:66848496~66858136:+
LUAD	cis	rs227932	0.681	rs7776862	ENSG00000234286.1	AC006026.13	6.25	9.17e-10	4.29e-07	0.44	0.27	Schizophrenia;	chr7:23736607	chr7:23680195~23680786:-
LUAD	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-6.25	9.18e-10	4.29e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-6.25	9.18e-10	4.29e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-6.25	9.18e-10	4.29e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
LUAD	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-6.25	9.19e-10	4.3e-07	-0.2	-0.27	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
LUAD	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	6.25	9.2e-10	4.3e-07	0.35	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
LUAD	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	6.25	9.2e-10	4.31e-07	0.39	0.27	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	6.25	9.2e-10	4.31e-07	0.39	0.27	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
LUAD	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	6.25	9.21e-10	4.31e-07	0.35	0.27	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
LUAD	cis	rs17684571	0.872	rs34566275	ENSG00000231441.1	RP11-472M19.2	6.25	9.23e-10	4.31e-07	0.4	0.27	Schizophrenia;	chr6:56740130	chr6:56844002~56864078:+
LUAD	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-6.25	9.23e-10	4.32e-07	-0.31	-0.27	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
LUAD	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	6.25	9.24e-10	4.32e-07	0.27	0.27	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
LUAD	cis	rs10214930	0.624	rs6949496	ENSG00000235574.1	AC073150.6	-6.25	9.25e-10	4.33e-07	-0.35	-0.27	Hypospadias;	chr7:27520075	chr7:27491682~27492765:-
LUAD	cis	rs12468226	0.938	rs116109808	ENSG00000226261.1	AC064836.3	6.25	9.25e-10	4.33e-07	0.46	0.27	Urate levels;	chr2:202287356	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.873	rs78175596	ENSG00000226261.1	AC064836.3	6.25	9.25e-10	4.33e-07	0.46	0.27	Urate levels;	chr2:202287993	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs74454549	ENSG00000226261.1	AC064836.3	6.25	9.25e-10	4.33e-07	0.46	0.27	Urate levels;	chr2:202288044	chr2:202336024~202336727:-
LUAD	cis	rs9928842	0.882	rs9927264	ENSG00000280152.1	RP11-331F4.5	6.25	9.26e-10	4.33e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75226343	chr16:75245994~75250077:-
LUAD	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	6.25	9.26e-10	4.33e-07	0.31	0.27	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
LUAD	cis	rs10740039	0.883	rs7918897	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643754	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7902632	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643811	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.96	rs10443928	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645718	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10443929	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645852	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.842	rs7915540	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60646538	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7905018	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647585	chr10:60734342~60741828:+
LUAD	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	6.25	9.27e-10	4.33e-07	0.32	0.27	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
LUAD	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	6.25	9.27e-10	4.33e-07	0.32	0.27	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
LUAD	cis	rs948562	0.744	rs11229440	ENSG00000280010.1	AP001350.4	6.25	9.27e-10	4.33e-07	0.42	0.27	Lymphoma;	chr11:58426719	chr11:58627435~58628528:+
LUAD	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	6.25	9.29e-10	4.34e-07	0.3	0.27	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	6.25	9.29e-10	4.34e-07	0.3	0.27	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
LUAD	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-6.25	9.29e-10	4.34e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
LUAD	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-6.25	9.3e-10	4.35e-07	-0.33	-0.27	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
LUAD	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	6.25	9.31e-10	4.35e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
LUAD	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	6.24	9.34e-10	4.36e-07	0.36	0.27	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
LUAD	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	6.24	9.34e-10	4.37e-07	0.3	0.27	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
LUAD	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	6.24	9.35e-10	4.37e-07	0.41	0.27	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
LUAD	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	6.24	9.36e-10	4.37e-07	0.24	0.27	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
LUAD	cis	rs4723738	1	rs2159499	ENSG00000227191.5	TRGC2	-6.24	9.37e-10	4.38e-07	-0.3	-0.27	Treatment response for severe sepsis;	chr7:38189300	chr7:38239580~38368091:-
LUAD	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-6.24	9.37e-10	4.38e-07	-0.33	-0.27	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-6.24	9.37e-10	4.38e-07	-0.33	-0.27	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-6.24	9.37e-10	4.38e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
LUAD	cis	rs2276314	0.512	rs1789506	ENSG00000278986.1	RP11-723J4.3	6.24	9.38e-10	4.38e-07	0.28	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36045407	chr18:35972151~35973916:+
LUAD	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-6.24	9.38e-10	4.38e-07	-0.25	-0.27	Breast cancer;	chr11:825777	chr11:777578~784297:+
LUAD	cis	rs7246657	0.525	rs10405238	ENSG00000276846.1	CTD-3220F14.3	6.24	9.4e-10	4.39e-07	0.41	0.27	Coronary artery calcification;	chr19:36997153	chr19:37314868~37315620:-
LUAD	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-6.24	9.4e-10	4.39e-07	-0.29	-0.27	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
LUAD	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	6.24	9.4e-10	4.39e-07	0.4	0.27	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	6.24	9.4e-10	4.39e-07	0.34	0.27	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	6.24	9.4e-10	4.39e-07	0.34	0.27	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	6.24	9.4e-10	4.39e-07	0.34	0.27	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	6.24	9.4e-10	4.39e-07	0.34	0.27	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
LUAD	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-6.24	9.42e-10	4.4e-07	-0.32	-0.27	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
LUAD	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	6.24	9.43e-10	4.4e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	6.24	9.43e-10	4.4e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
LUAD	cis	rs4723738	1	rs11766341	ENSG00000227191.5	TRGC2	-6.24	9.43e-10	4.4e-07	-0.3	-0.27	Treatment response for severe sepsis;	chr7:38188147	chr7:38239580~38368091:-
LUAD	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-6.24	9.44e-10	4.41e-07	-0.32	-0.27	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
LUAD	cis	rs8031584	0.918	rs34331396	ENSG00000260382.1	RP11-540B6.2	6.24	9.45e-10	4.41e-07	0.33	0.27	Huntington's disease progression;	chr15:30956533	chr15:30882267~30883231:-
LUAD	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	6.24	9.45e-10	4.41e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
LUAD	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	6.24	9.45e-10	4.41e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
LUAD	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	6.24	9.46e-10	4.42e-07	0.34	0.27	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
LUAD	cis	rs1707322	0.721	rs12043945	ENSG00000234329.1	RP11-767N6.2	6.24	9.47e-10	4.42e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12091503	ENSG00000234329.1	RP11-767N6.2	6.24	9.47e-10	4.42e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45651039~45651826:-
LUAD	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-6.24	9.47e-10	4.42e-07	-0.32	-0.27	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
LUAD	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-6.24	9.47e-10	4.42e-07	-0.32	-0.27	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
LUAD	cis	rs9928842	0.941	rs1808427	ENSG00000280152.1	RP11-331F4.5	6.24	9.48e-10	4.42e-07	0.31	0.27	Alcoholic chronic pancreatitis;	chr16:75207496	chr16:75245994~75250077:-
LUAD	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-6.24	9.49e-10	4.43e-07	-0.31	-0.27	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
LUAD	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	6.24	9.5e-10	4.43e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
LUAD	cis	rs35740288	0.688	rs12904047	ENSG00000202081.1	RNU6-1280P	6.24	9.52e-10	4.44e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85669635	chr15:85651522~85651628:-
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000232546.1	RP11-458F8.1	-6.24	9.52e-10	4.44e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65999249	chr7:66848496~66858136:+
LUAD	cis	rs7017914	0.905	rs2639898	ENSG00000223220.1	Y_RNA	6.24	9.55e-10	4.45e-07	0.3	0.27	Bone mineral density;	chr8:71008075	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.84	rs2732099	ENSG00000223220.1	Y_RNA	6.24	9.55e-10	4.45e-07	0.3	0.27	Bone mineral density;	chr8:71008815	chr8:70780914~70781008:-
LUAD	cis	rs10214930	1	rs10241783	ENSG00000235574.1	AC073150.6	6.24	9.55e-10	4.45e-07	0.39	0.27	Hypospadias;	chr7:27817901	chr7:27491682~27492765:-
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	6.24	9.56e-10	4.46e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
LUAD	cis	rs728616	0.614	rs58606426	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.56e-10	4.46e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs57966752	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.56e-10	4.46e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61860413	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.56e-10	4.46e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61860414	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.56e-10	4.46e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:79663088~79826594:-
LUAD	cis	rs35740288	0.77	rs11638278	ENSG00000202081.1	RNU6-1280P	6.24	9.57e-10	4.46e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85668173	chr15:85651522~85651628:-
LUAD	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-6.24	9.57e-10	4.46e-07	-0.36	-0.27	Migraine;	chr4:56850720	chr4:56960927~56961373:-
LUAD	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	6.24	9.59e-10	4.47e-07	0.3	0.27	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
LUAD	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-6.24	9.62e-10	4.48e-07	-0.4	-0.27	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
LUAD	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-6.24	9.62e-10	4.48e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
LUAD	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	6.24	9.62e-10	4.48e-07	0.24	0.27	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
LUAD	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	6.24	9.62e-10	4.48e-07	0.32	0.27	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
LUAD	cis	rs9640161	0.789	rs10248490	ENSG00000261305.1	RP4-584D14.7	6.24	9.63e-10	4.49e-07	0.4	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150354329	chr7:150341771~150342607:+
LUAD	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-6.24	9.64e-10	4.49e-07	-0.31	-0.27	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
LUAD	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	6.24	9.64e-10	4.49e-07	0.35	0.27	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
LUAD	cis	rs7937890	0.904	rs67623158	ENSG00000254418.1	RP11-21L19.1	-6.24	9.65e-10	4.5e-07	-0.31	-0.27	Mitochondrial DNA levels;	chr11:14273650	chr11:14262846~14273691:-
LUAD	cis	rs75920871	0.589	rs115787357	ENSG00000254851.1	RP11-109L13.1	-6.24	9.65e-10	4.5e-07	-0.49	-0.27	Subjective well-being;	chr11:117193790	chr11:117135528~117138582:+
LUAD	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	6.24	9.65e-10	4.5e-07	0.35	0.27	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
LUAD	cis	rs948562	0.69	rs11229393	ENSG00000280010.1	AP001350.4	-6.24	9.66e-10	4.5e-07	-0.42	-0.27	Lymphoma;	chr11:58385132	chr11:58627435~58628528:+
LUAD	cis	rs7017914	0.905	rs1908033	ENSG00000223220.1	Y_RNA	6.24	9.66e-10	4.5e-07	0.3	0.27	Bone mineral density;	chr8:71010564	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732103	ENSG00000223220.1	Y_RNA	6.24	9.66e-10	4.5e-07	0.3	0.27	Bone mineral density;	chr8:71011261	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.837	rs2732105	ENSG00000223220.1	Y_RNA	6.24	9.67e-10	4.5e-07	0.3	0.27	Bone mineral density;	chr8:71011410	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	6.24	9.67e-10	4.5e-07	0.39	0.27	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	6.24	9.67e-10	4.5e-07	0.39	0.27	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	6.24	9.67e-10	4.5e-07	0.39	0.27	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
LUAD	cis	rs4591358	0.773	rs34480328	ENSG00000223466.1	AC064834.2	-6.24	9.68e-10	4.51e-07	-0.37	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510684	chr2:195533035~195538681:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000228039.3	KB-1125A3.10	-6.24	9.69e-10	4.51e-07	-0.38	-0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23963780~23964374:+
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000232546.1	RP11-458F8.1	-6.24	9.69e-10	4.51e-07	-0.32	-0.27	Diabetic kidney disease;	chr7:65988305	chr7:66848496~66858136:+
LUAD	cis	rs17684571	0.81	rs41267675	ENSG00000231441.1	RP11-472M19.2	6.24	9.72e-10	4.52e-07	0.4	0.27	Schizophrenia;	chr6:56735323	chr6:56844002~56864078:+
LUAD	cis	rs2243480	1	rs937108	ENSG00000232546.1	RP11-458F8.1	-6.24	9.73e-10	4.53e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65963465	chr7:66848496~66858136:+
LUAD	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	6.24	9.74e-10	4.54e-07	0.41	0.27	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
LUAD	cis	rs12468226	1	rs16824599	ENSG00000226261.1	AC064836.3	6.24	9.74e-10	4.54e-07	0.46	0.27	Urate levels;	chr2:202358243	chr2:202336024~202336727:-
LUAD	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	6.24	9.75e-10	4.54e-07	0.41	0.27	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
LUAD	cis	rs728616	0.541	rs61860401	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.75e-10	4.54e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:79663088~79826594:-
LUAD	cis	rs755249	0.567	rs16825939	ENSG00000228060.1	RP11-69E11.8	-6.24	9.77e-10	4.55e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs67020650	ENSG00000228060.1	RP11-69E11.8	-6.24	9.77e-10	4.55e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs72661925	ENSG00000228060.1	RP11-69E11.8	-6.24	9.77e-10	4.55e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39565160~39573203:+
LUAD	cis	rs11089937	0.616	rs4991801	ENSG00000211639.2	IGLV4-60	6.24	9.77e-10	4.55e-07	0.28	0.27	Periodontitis (PAL4Q3);	chr22:22178958	chr22:22162199~22162681:+
LUAD	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	6.24	9.77e-10	4.55e-07	0.29	0.27	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
LUAD	cis	rs10214930	1	rs7800116	ENSG00000235574.1	AC073150.6	6.24	9.77e-10	4.55e-07	0.38	0.27	Hypospadias;	chr7:27782565	chr7:27491682~27492765:-
LUAD	cis	rs17301013	0.507	rs1653630	ENSG00000227373.4	RP11-160H22.5	-6.24	9.79e-10	4.56e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174791810	chr1:174115300~174160004:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000206090.4	AP000350.7	6.24	9.8e-10	4.56e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23939998~23942798:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000206090.4	AP000350.7	6.24	9.8e-10	4.56e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23939998~23942798:+
LUAD	cis	rs7937890	0.904	rs11023169	ENSG00000254418.1	RP11-21L19.1	-6.24	9.81e-10	4.56e-07	-0.32	-0.27	Mitochondrial DNA levels;	chr11:14269439	chr11:14262846~14273691:-
LUAD	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	6.24	9.82e-10	4.57e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	6.24	9.82e-10	4.57e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	6.24	9.82e-10	4.57e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
LUAD	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-6.24	9.83e-10	4.57e-07	-0.31	-0.27	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
LUAD	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-6.24	9.83e-10	4.57e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
LUAD	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-6.24	9.84e-10	4.57e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
LUAD	cis	rs7727544	0.507	rs10051679	ENSG00000233006.5	AC034220.3	6.24	9.84e-10	4.58e-07	0.25	0.27	Blood metabolite levels;	chr5:132235238	chr5:132311285~132369916:-
LUAD	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-6.24	9.86e-10	4.58e-07	-0.34	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
LUAD	cis	rs2337406	0.538	rs10141701	ENSG00000211974.3	IGHV2-70	-6.24	9.86e-10	4.58e-07	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106633467	chr14:106723574~106724093:-
LUAD	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	6.24	9.87e-10	4.59e-07	0.33	0.27	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
LUAD	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-6.24	9.87e-10	4.59e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
LUAD	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-6.24	9.87e-10	4.59e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
LUAD	cis	rs6772849	0.93	rs4467479	ENSG00000242551.2	POU5F1P6	-6.24	9.88e-10	4.59e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128650212	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.93	rs12630379	ENSG00000242551.2	POU5F1P6	-6.24	9.88e-10	4.59e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128651361	chr3:128674735~128677005:-
LUAD	cis	rs11096990	0.855	rs75746161	ENSG00000249207.1	RP11-360F5.1	6.24	9.89e-10	4.6e-07	0.32	0.27	Cognitive function;	chr4:39167481	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs6855008	ENSG00000249207.1	RP11-360F5.1	6.24	9.89e-10	4.6e-07	0.32	0.27	Cognitive function;	chr4:39172006	chr4:39112677~39126818:-
LUAD	cis	rs2034650	0.563	rs2412523	ENSG00000223313.1	RNU6-516P	6.23	9.9e-10	4.6e-07	0.35	0.27	Interstitial lung disease;	chr15:40417487	chr15:40529570~40529673:+
LUAD	cis	rs2243480	1	rs1618893	ENSG00000232546.1	RP11-458F8.1	-6.23	9.91e-10	4.61e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66631132	chr7:66848496~66858136:+
LUAD	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	6.23	9.91e-10	4.61e-07	0.3	0.27	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	6.23	9.91e-10	4.61e-07	0.3	0.27	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
LUAD	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-6.23	9.92e-10	4.61e-07	-0.42	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
LUAD	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	6.23	9.92e-10	4.61e-07	0.33	0.27	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
LUAD	cis	rs728616	0.614	rs10887218	ENSG00000225484.5	NUTM2B-AS1	-6.23	9.94e-10	4.62e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951268	chr10:79663088~79826594:-
LUAD	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-6.23	9.94e-10	4.62e-07	-0.27	-0.27	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
LUAD	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	6.23	9.95e-10	4.62e-07	0.34	0.27	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
LUAD	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.95e-10	4.62e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.95e-10	4.62e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.95e-10	4.62e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.95e-10	4.62e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
LUAD	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-6.23	9.95e-10	4.62e-07	-0.23	-0.27	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
LUAD	cis	rs5753618	0.561	rs5753609	ENSG00000236132.1	CTA-440B3.1	-6.23	9.96e-10	4.63e-07	-0.33	-0.27	Colorectal cancer;	chr22:31423226	chr22:31816379~31817491:-
LUAD	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.96e-10	4.63e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
LUAD	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	6.23	9.96e-10	4.63e-07	0.28	0.27	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
LUAD	cis	rs113835537	0.529	rs17495838	ENSG00000255517.5	CTD-3074O7.5	-6.23	9.98e-10	4.63e-07	-0.34	-0.27	Airway imaging phenotypes;	chr11:66428794	chr11:66473490~66480233:-
LUAD	cis	rs35740288	0.731	rs12898964	ENSG00000202081.1	RNU6-1280P	6.23	1e-09	4.65e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618046	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.731	rs2344440	ENSG00000202081.1	RNU6-1280P	6.23	1e-09	4.65e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618334	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs1157519	ENSG00000202081.1	RNU6-1280P	6.23	1e-09	4.65e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618427	chr15:85651522~85651628:-
LUAD	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	6.23	1e-09	4.66e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
LUAD	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	6.23	1e-09	4.66e-07	0.35	0.27	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000224373.3	IGHV4-59	6.23	1.01e-09	4.67e-07	0.16	0.27	Kawasaki disease;	chr14:106682286	chr14:106627249~106627825:-
LUAD	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	6.23	1.01e-09	4.67e-07	0.43	0.27	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	6.23	1.01e-09	4.68e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
LUAD	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	6.23	1.01e-09	4.68e-07	0.35	0.27	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
LUAD	cis	rs17301013	0.507	rs1923818	ENSG00000227373.4	RP11-160H22.5	6.23	1.01e-09	4.68e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174749737	chr1:174115300~174160004:-
LUAD	cis	rs7017914	0.905	rs2732104	ENSG00000223220.1	Y_RNA	6.23	1.01e-09	4.68e-07	0.3	0.27	Bone mineral density;	chr8:71011284	chr8:70780914~70781008:-
LUAD	cis	rs7221109	0.56	rs2429549	ENSG00000278834.1	RP11-458J1.1	-6.23	1.01e-09	4.68e-07	-0.32	-0.27	Type 1 diabetes;	chr17:40698154	chr17:40648300~40649718:+
LUAD	cis	rs155076	1	rs261427	ENSG00000233325.3	MIPEPP3	6.23	1.01e-09	4.69e-07	0.43	0.27	White matter hyperintensity burden;	chr13:21286859	chr13:21298139~21306373:+
LUAD	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-6.23	1.01e-09	4.69e-07	-0.36	-0.27	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-6.23	1.01e-09	4.69e-07	-0.36	-0.27	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-6.23	1.01e-09	4.69e-07	-0.31	-0.27	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-6.23	1.01e-09	4.69e-07	-0.31	-0.27	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
LUAD	cis	rs293748	0.825	rs468022	ENSG00000250155.1	CTD-2353F22.1	-6.23	1.01e-09	4.7e-07	-0.39	-0.27	Obesity-related traits;	chr5:36988150	chr5:36666214~36725195:-
LUAD	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-6.23	1.02e-09	4.71e-07	-0.41	-0.27	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
LUAD	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	6.23	1.02e-09	4.71e-07	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
LUAD	cis	rs2243480	1	rs437889	ENSG00000232546.1	RP11-458F8.1	-6.23	1.02e-09	4.71e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66044247	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000232546.1	RP11-458F8.1	-6.23	1.02e-09	4.71e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66044482	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000232546.1	RP11-458F8.1	-6.23	1.02e-09	4.71e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66044512	chr7:66848496~66858136:+
LUAD	cis	rs8059260	0.541	rs8046052	ENSG00000274038.1	RP11-66H6.4	-6.23	1.02e-09	4.71e-07	-0.54	-0.27	Alcohol consumption over the past year;	chr16:11129464	chr16:11056556~11057034:+
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-6.23	1.02e-09	4.71e-07	-0.31	-0.27	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
LUAD	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-6.23	1.02e-09	4.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-6.23	1.02e-09	4.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000206090.4	AP000350.7	-6.23	1.02e-09	4.72e-07	-0.31	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23939998~23942798:+
LUAD	cis	rs4820294	1	rs41280035	ENSG00000233360.4	Z83844.1	6.23	1.02e-09	4.72e-07	0.29	0.27	Fat distribution (HIV);	chr22:37658031	chr22:37641832~37658377:-
LUAD	cis	rs4713118	0.621	rs9295756	ENSG00000204709.4	LINC01556	6.23	1.02e-09	4.73e-07	0.38	0.27	Parkinson's disease;	chr6:28065618	chr6:28943877~28944537:+
LUAD	cis	rs11096990	0.964	rs4974999	ENSG00000249207.1	RP11-360F5.1	-6.23	1.02e-09	4.73e-07	-0.3	-0.27	Cognitive function;	chr4:39262294	chr4:39112677~39126818:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000232546.1	RP11-458F8.1	-6.23	1.02e-09	4.73e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66359432	chr7:66848496~66858136:+
LUAD	cis	rs17666538	0.591	rs1669716	ENSG00000254207.1	RP11-43A14.1	6.23	1.02e-09	4.73e-07	0.51	0.27	IgG glycosylation;	chr8:643707	chr8:725188~725877:-
LUAD	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	6.23	1.02e-09	4.73e-07	0.39	0.27	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
LUAD	cis	rs8177876	0.642	rs12445303	ENSG00000261838.4	RP11-303E16.6	-6.23	1.02e-09	4.73e-07	-0.56	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81069854~81076598:+
LUAD	cis	rs948562	0.69	rs12361133	ENSG00000280010.1	AP001350.4	6.23	1.02e-09	4.73e-07	0.43	0.27	Lymphoma;	chr11:58357532	chr11:58627435~58628528:+
LUAD	cis	rs5753618	0.561	rs715510	ENSG00000236132.1	CTA-440B3.1	6.23	1.02e-09	4.74e-07	0.34	0.27	Colorectal cancer;	chr22:31294542	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs737887	ENSG00000236132.1	CTA-440B3.1	6.23	1.02e-09	4.74e-07	0.34	0.27	Colorectal cancer;	chr22:31300629	chr22:31816379~31817491:-
LUAD	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	6.23	1.02e-09	4.74e-07	0.34	0.27	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
LUAD	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	6.23	1.02e-09	4.75e-07	0.33	0.27	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
LUAD	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	6.23	1.02e-09	4.75e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
LUAD	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	6.23	1.03e-09	4.76e-07	0.34	0.27	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	6.23	1.03e-09	4.76e-07	0.34	0.27	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000206090.4	AP000350.7	6.23	1.03e-09	4.77e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23939998~23942798:+
LUAD	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	6.23	1.03e-09	4.77e-07	0.28	0.27	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
LUAD	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-6.23	1.03e-09	4.77e-07	-0.31	-0.27	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
LUAD	cis	rs11157436	1	rs11157440	ENSG00000211812.1	TRAV26-2	-6.23	1.03e-09	4.77e-07	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22202583~22203368:+
LUAD	cis	rs1318937	0.764	rs60977744	ENSG00000224660.1	SH3BP5-AS1	6.23	1.03e-09	4.77e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15198464	chr3:15254184~15264493:+
LUAD	cis	rs1318937	0.764	rs58837640	ENSG00000224660.1	SH3BP5-AS1	6.23	1.03e-09	4.77e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15199139	chr3:15254184~15264493:+
LUAD	cis	rs1318937	0.516	rs73023424	ENSG00000224660.1	SH3BP5-AS1	6.23	1.03e-09	4.77e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15201995	chr3:15254184~15264493:+
LUAD	cis	rs1318937	0.764	rs66813829	ENSG00000224660.1	SH3BP5-AS1	6.23	1.03e-09	4.77e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15202214	chr3:15254184~15264493:+
LUAD	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-6.23	1.03e-09	4.77e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
LUAD	cis	rs7044106	0.762	rs10760115	ENSG00000238181.2	AHCYP2	-6.23	1.03e-09	4.77e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120720673~120721972:+
LUAD	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-6.23	1.03e-09	4.78e-07	-0.37	-0.27	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
LUAD	cis	rs6772849	0.83	rs7633674	ENSG00000242551.2	POU5F1P6	-6.23	1.03e-09	4.78e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:128674735~128677005:-
LUAD	cis	rs4713118	0.587	rs61471148	ENSG00000204709.4	LINC01556	6.23	1.03e-09	4.79e-07	0.38	0.27	Parkinson's disease;	chr6:28069254	chr6:28943877~28944537:+
LUAD	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-6.23	1.03e-09	4.79e-07	-0.43	-0.27	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
LUAD	cis	rs9928842	0.722	rs1035540	ENSG00000280152.1	RP11-331F4.5	6.23	1.03e-09	4.79e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75245994~75250077:-
LUAD	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	6.23	1.04e-09	4.79e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	6.23	1.04e-09	4.79e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
LUAD	cis	rs11079757	0.681	rs34811916	ENSG00000262879.4	RP11-156P1.3	6.23	1.04e-09	4.79e-07	0.37	0.27	Erythema nodosum in inflammatory bowel disease;	chr17:47111431	chr17:46984045~47100323:-
LUAD	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-6.23	1.04e-09	4.8e-07	-0.31	-0.27	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
LUAD	cis	rs9595908	0.544	rs7328213	ENSG00000212293.1	SNORA16	6.23	1.04e-09	4.8e-07	0.3	0.27	Body mass index;	chr13:32803692	chr13:32420390~32420516:-
LUAD	cis	rs17684571	0.872	rs34587484	ENSG00000231441.1	RP11-472M19.2	6.23	1.04e-09	4.8e-07	0.4	0.27	Schizophrenia;	chr6:56742926	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs34465210	ENSG00000231441.1	RP11-472M19.2	6.23	1.04e-09	4.8e-07	0.4	0.27	Schizophrenia;	chr6:56742930	chr6:56844002~56864078:+
LUAD	cis	rs1707322	0.686	rs2050376	ENSG00000234329.1	RP11-767N6.2	6.23	1.04e-09	4.81e-07	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45651039~45651826:-
LUAD	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	6.23	1.04e-09	4.81e-07	0.35	0.27	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
LUAD	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	6.23	1.04e-09	4.81e-07	0.3	0.27	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
LUAD	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	6.23	1.04e-09	4.82e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	6.23	1.04e-09	4.82e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	6.23	1.04e-09	4.82e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
LUAD	cis	rs755249	0.567	rs72637906	ENSG00000228060.1	RP11-69E11.8	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs67886352	ENSG00000228060.1	RP11-69E11.8	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs60323161	ENSG00000228060.1	RP11-69E11.8	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs66727439	ENSG00000228060.1	RP11-69E11.8	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39565160~39573203:+
LUAD	cis	rs2734839	0.929	rs7131627	ENSG00000270179.1	RP11-159N11.4	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Information processing speed;	chr11:113429107	chr11:113368478~113369117:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000211974.3	IGHV2-70	6.23	1.04e-09	4.82e-07	0.28	0.27	Kawasaki disease;	chr14:106779713	chr14:106723574~106724093:-
LUAD	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	6.23	1.04e-09	4.82e-07	0.35	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000206090.4	AP000350.7	6.23	1.04e-09	4.83e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23939998~23942798:+
LUAD	cis	rs496547	0.557	rs516719	ENSG00000255422.1	AP002954.4	-6.23	1.04e-09	4.83e-07	-0.35	-0.27	Hip minimal joint space width;	chr11:118808736	chr11:118704607~118750263:+
LUAD	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.04e-09	4.83e-07	-0.29	-0.27	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.04e-09	4.83e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.04e-09	4.83e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.04e-09	4.83e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
LUAD	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	6.23	1.05e-09	4.83e-07	0.49	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66521515	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs13237037	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66532895	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66557269	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1796228	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66568097	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1267820	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66585308	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2533288	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66591724	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2707844	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66594522	chr7:66848496~66858136:+
LUAD	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	6.23	1.05e-09	4.83e-07	0.41	0.27	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
LUAD	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-6.23	1.05e-09	4.84e-07	-0.44	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
LUAD	cis	rs853679	1	rs853694	ENSG00000204709.4	LINC01556	6.23	1.05e-09	4.84e-07	0.43	0.27	Depression;	chr6:28311323	chr6:28943877~28944537:+
LUAD	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-6.23	1.05e-09	4.84e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
LUAD	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-6.23	1.05e-09	4.84e-07	-0.29	-0.27	Height;	chr11:118761813	chr11:118791254~118793137:+
LUAD	cis	rs10214930	0.671	rs6957674	ENSG00000235574.1	AC073150.6	-6.23	1.05e-09	4.85e-07	-0.35	-0.27	Hypospadias;	chr7:27518691	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2091171	ENSG00000235574.1	AC073150.6	-6.23	1.05e-09	4.85e-07	-0.35	-0.27	Hypospadias;	chr7:27519599	chr7:27491682~27492765:-
LUAD	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-6.23	1.05e-09	4.85e-07	-0.31	-0.27	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
LUAD	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.05e-09	4.86e-07	-0.31	-0.27	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.05e-09	4.86e-07	-0.31	-0.27	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
LUAD	cis	rs1707322	0.686	rs11211179	ENSG00000234329.1	RP11-767N6.2	6.22	1.05e-09	4.86e-07	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10157795	ENSG00000234329.1	RP11-767N6.2	6.22	1.05e-09	4.86e-07	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45651039~45651826:-
LUAD	cis	rs7176527	0.848	rs3748374	ENSG00000188388.10	GOLGA6L3	6.22	1.05e-09	4.86e-07	0.39	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85240472~85247170:+
LUAD	cis	rs1061377	0.862	rs12508577	ENSG00000249685.1	RP11-360F5.3	6.22	1.05e-09	4.87e-07	0.33	0.27	Uric acid levels;	chr4:39107779	chr4:39133913~39135608:+
LUAD	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-6.22	1.05e-09	4.87e-07	-0.27	-0.27	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
LUAD	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-6.22	1.06e-09	4.88e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
LUAD	cis	rs12468226	1	rs16839077	ENSG00000226261.1	AC064836.3	6.22	1.06e-09	4.88e-07	0.46	0.27	Urate levels;	chr2:202343970	chr2:202336024~202336727:-
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66370832	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66398480	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66407358	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66408105	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66418618	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66422670	chr7:66848496~66858136:+
LUAD	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	6.22	1.06e-09	4.89e-07	0.27	0.27	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
LUAD	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	6.22	1.06e-09	4.89e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	6.22	1.06e-09	4.89e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
LUAD	cis	rs728616	0.614	rs11200859	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.06e-09	4.89e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953805	chr10:79663088~79826594:-
LUAD	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	6.22	1.06e-09	4.89e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
LUAD	cis	rs10129255	1	rs10134517	ENSG00000280411.1	IGHV1-69-2	-6.22	1.06e-09	4.89e-07	-0.2	-0.27	Kawasaki disease;	chr14:106718498	chr14:106762092~106762588:-
LUAD	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	6.22	1.06e-09	4.9e-07	0.34	0.27	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
LUAD	cis	rs4713118	0.621	rs4713132	ENSG00000204709.4	LINC01556	6.22	1.06e-09	4.9e-07	0.37	0.27	Parkinson's disease;	chr6:28066257	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.621	rs4713133	ENSG00000204709.4	LINC01556	6.22	1.06e-09	4.9e-07	0.37	0.27	Parkinson's disease;	chr6:28066263	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.621	rs4713134	ENSG00000204709.4	LINC01556	6.22	1.06e-09	4.9e-07	0.37	0.27	Parkinson's disease;	chr6:28066343	chr6:28943877~28944537:+
LUAD	cis	rs7937890	0.904	rs7484197	ENSG00000254418.1	RP11-21L19.1	6.22	1.06e-09	4.91e-07	0.32	0.27	Mitochondrial DNA levels;	chr11:14262108	chr11:14262846~14273691:-
LUAD	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	6.22	1.07e-09	4.92e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	6.22	1.07e-09	4.92e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
LUAD	cis	rs5753618	0.539	rs4820962	ENSG00000236132.1	CTA-440B3.1	6.22	1.07e-09	4.92e-07	0.34	0.27	Colorectal cancer;	chr22:31293965	chr22:31816379~31817491:-
LUAD	cis	rs1318937	0.764	rs9853971	ENSG00000224660.1	SH3BP5-AS1	6.22	1.07e-09	4.92e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15183840	chr3:15254184~15264493:+
LUAD	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	6.22	1.07e-09	4.92e-07	0.46	0.27	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	6.22	1.07e-09	4.92e-07	0.46	0.27	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	6.22	1.07e-09	4.92e-07	0.46	0.27	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
LUAD	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-6.22	1.07e-09	4.92e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.94e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65909309	chr7:66848496~66858136:+
LUAD	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	6.22	1.07e-09	4.94e-07	0.33	0.27	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
LUAD	cis	rs1823913	0.637	rs4853465	ENSG00000280083.1	RP11-317J9.1	6.22	1.07e-09	4.95e-07	0.32	0.27	Obesity-related traits;	chr2:191294768	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs4853573	ENSG00000280083.1	RP11-317J9.1	6.22	1.07e-09	4.95e-07	0.32	0.27	Obesity-related traits;	chr2:191295866	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs4853466	ENSG00000280083.1	RP11-317J9.1	6.22	1.07e-09	4.95e-07	0.32	0.27	Obesity-related traits;	chr2:191295943	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs4853574	ENSG00000280083.1	RP11-317J9.1	6.22	1.07e-09	4.95e-07	0.32	0.27	Obesity-related traits;	chr2:191296113	chr2:191154118~191156070:-
LUAD	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	6.22	1.07e-09	4.95e-07	0.31	0.27	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs316313	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66128561	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66131504	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66132354	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66133233	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66133553	chr7:66848496~66858136:+
LUAD	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-6.22	1.08e-09	4.96e-07	-0.32	-0.27	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
LUAD	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	6.22	1.08e-09	4.96e-07	0.47	0.27	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
LUAD	cis	rs728616	0.614	rs59169164	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.08e-09	4.97e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952159	chr10:79663088~79826594:-
LUAD	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	6.22	1.08e-09	4.97e-07	0.31	0.27	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
LUAD	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	6.22	1.08e-09	4.98e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
LUAD	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	6.22	1.08e-09	4.98e-07	0.32	0.27	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	6.22	1.08e-09	4.98e-07	0.32	0.27	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
LUAD	cis	rs4947019	0.534	rs13437492	ENSG00000260273.1	RP11-425D10.10	-6.22	1.08e-09	4.99e-07	-0.57	-0.27	Hematological parameters;	chr6:109365424	chr6:109382795~109383666:+
LUAD	cis	rs496547	0.588	rs473298	ENSG00000255422.1	AP002954.4	-6.22	1.08e-09	4.99e-07	-0.35	-0.27	Hip minimal joint space width;	chr11:118808678	chr11:118704607~118750263:+
LUAD	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-6.22	1.08e-09	4.99e-07	-0.43	-0.27	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
LUAD	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	6.22	1.08e-09	4.99e-07	0.27	0.27	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
LUAD	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	6.22	1.08e-09	4.99e-07	0.32	0.27	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
LUAD	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	6.22	1.08e-09	4.99e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
LUAD	cis	rs9928842	1	rs7202566	ENSG00000280152.1	RP11-331F4.5	6.22	1.08e-09	4.99e-07	0.31	0.27	Alcoholic chronic pancreatitis;	chr16:75213746	chr16:75245994~75250077:-
LUAD	cis	rs7657257	1	rs12643722	ENSG00000214846.4	RP11-115L11.1	6.22	1.08e-09	5e-07	0.72	0.27	Blood protein levels;	chr4:15728480	chr4:15730962~15731627:-
LUAD	cis	rs7657257	1	rs12640554	ENSG00000214846.4	RP11-115L11.1	6.22	1.08e-09	5e-07	0.72	0.27	Blood protein levels;	chr4:15728484	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs111541714	ENSG00000214846.4	RP11-115L11.1	6.22	1.08e-09	5e-07	0.72	0.27	Cerebrospinal fluid biomarker levels;	chr4:15728782	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs73125993	ENSG00000214846.4	RP11-115L11.1	6.22	1.08e-09	5e-07	0.72	0.27	Cerebrospinal fluid biomarker levels;	chr4:15728890	chr4:15730962~15731627:-
LUAD	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	6.22	1.08e-09	5e-07	0.27	0.27	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
LUAD	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.09e-09	5.01e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
LUAD	cis	rs1823913	0.637	rs979967	ENSG00000280083.1	RP11-317J9.1	-6.22	1.09e-09	5.01e-07	-0.32	-0.27	Obesity-related traits;	chr2:191304695	chr2:191154118~191156070:-
LUAD	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-6.22	1.09e-09	5.03e-07	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
LUAD	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-6.22	1.09e-09	5.03e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
LUAD	cis	rs6687821	0.637	rs548440	ENSG00000267734.1	RP4-604K5.3	6.22	1.09e-09	5.03e-07	0.36	0.27	Yeast infection;	chr1:86846948	chr1:86932199~86934891:-
LUAD	cis	rs728616	0.614	rs1885552	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952336	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs1885551	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952597	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs12253608	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952727	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.764	rs1885549	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952794	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs12245076	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953675	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887229	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954018	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10788321	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954039	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61858839	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954162	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61858841	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954420	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61858842	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955283	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887233	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955596	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887234	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955666	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887235	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955890	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs2146192	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955982	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs2146191	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955998	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887243	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957339	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887244	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957352	chr10:79663088~79826594:-
LUAD	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	6.22	1.09e-09	5.03e-07	0.28	0.27	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.65	rs4553239	ENSG00000234329.1	RP11-767N6.2	6.22	1.09e-09	5.03e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45651039~45651826:-
LUAD	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	6.22	1.1e-09	5.05e-07	0.34	0.27	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
LUAD	cis	rs1823913	1	rs1823913	ENSG00000230611.1	HMGB1P27	-6.22	1.1e-09	5.05e-07	-0.32	-0.27	Obesity-related traits;	chr2:191253321	chr2:191174233~191174835:+
LUAD	cis	rs5753618	0.509	rs1034589	ENSG00000236132.1	CTA-440B3.1	6.22	1.1e-09	5.05e-07	0.34	0.27	Colorectal cancer;	chr22:31183247	chr22:31816379~31817491:-
LUAD	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-6.22	1.1e-09	5.05e-07	-0.27	-0.27	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000228039.3	KB-1125A3.10	6.22	1.1e-09	5.06e-07	0.34	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23963780~23964374:+
LUAD	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	6.22	1.1e-09	5.07e-07	0.31	0.27	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
LUAD	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	6.22	1.1e-09	5.07e-07	0.34	0.27	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
LUAD	cis	rs112990264	0.568	rs3006239	ENSG00000236317.1	RP11-348H3.5	6.22	1.1e-09	5.08e-07	0.44	0.27	Itch intensity from mosquito bite;	chr1:212812498	chr1:212855175~212855366:-
LUAD	cis	rs155076	1	rs195570	ENSG00000233325.3	MIPEPP3	6.22	1.1e-09	5.08e-07	0.44	0.27	White matter hyperintensity burden;	chr13:21293441	chr13:21298139~21306373:+
LUAD	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-6.22	1.1e-09	5.08e-07	-0.4	-0.27	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
LUAD	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	6.22	1.11e-09	5.08e-07	0.28	0.27	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
LUAD	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	6.22	1.11e-09	5.09e-07	0.28	0.27	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	6.22	1.11e-09	5.09e-07	0.28	0.27	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.682	rs28490344	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs28501477	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs28641748	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs6697821	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4330955	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.691	rs12031182	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10430123	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45651039~45651826:-
LUAD	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-6.22	1.11e-09	5.09e-07	-0.29	-0.27	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000230295.1	RP11-458F8.2	-6.22	1.11e-09	5.1e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65953889	chr7:66880708~66882981:+
LUAD	cis	rs853679	0.517	rs36078605	ENSG00000204709.4	LINC01556	6.22	1.11e-09	5.1e-07	0.38	0.27	Depression;	chr6:28110254	chr6:28943877~28944537:+
LUAD	cis	rs1318937	0.764	rs2129947	ENSG00000224660.1	SH3BP5-AS1	6.22	1.11e-09	5.1e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15180755	chr3:15254184~15264493:+
LUAD	cis	rs11089937	0.616	rs4145537	ENSG00000211639.2	IGLV4-60	-6.22	1.11e-09	5.1e-07	-0.3	-0.27	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22162199~22162681:+
LUAD	cis	rs755249	1	rs4660303	ENSG00000228060.1	RP11-69E11.8	-6.22	1.11e-09	5.11e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594801	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-6.22	1.11e-09	5.12e-07	-0.3	-0.27	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
LUAD	cis	rs948562	0.69	rs79894420	ENSG00000280010.1	AP001350.4	6.21	1.11e-09	5.12e-07	0.43	0.27	Lymphoma;	chr11:58349359	chr11:58627435~58628528:+
LUAD	cis	rs6504622	0.905	rs2317997	ENSG00000262879.4	RP11-156P1.3	6.21	1.11e-09	5.12e-07	0.32	0.27	Orofacial clefts;	chr17:46950282	chr17:46984045~47100323:-
LUAD	cis	rs9640161	0.83	rs36069544	ENSG00000261305.1	RP4-584D14.7	6.21	1.11e-09	5.12e-07	0.4	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150364449	chr7:150341771~150342607:+
LUAD	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-6.21	1.12e-09	5.13e-07	-0.42	-0.27	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	6.21	1.12e-09	5.13e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
LUAD	cis	rs7044106	0.762	rs10760110	ENSG00000238181.2	AHCYP2	6.21	1.12e-09	5.13e-07	0.35	0.27	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120720673~120721972:+
LUAD	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	6.21	1.12e-09	5.13e-07	0.31	0.27	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
LUAD	cis	rs9640161	0.83	rs17173702	ENSG00000261305.1	RP4-584D14.7	6.21	1.12e-09	5.14e-07	0.41	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150371516	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.83	rs17173703	ENSG00000261305.1	RP4-584D14.7	6.21	1.12e-09	5.14e-07	0.41	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150371531	chr7:150341771~150342607:+
LUAD	cis	rs12468226	0.938	rs116601501	ENSG00000226261.1	AC064836.3	6.21	1.12e-09	5.14e-07	0.46	0.27	Urate levels;	chr2:202274567	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	6.21	1.12e-09	5.14e-07	0.46	0.27	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	6.21	1.12e-09	5.14e-07	0.46	0.27	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs78928733	ENSG00000226261.1	AC064836.3	6.21	1.12e-09	5.14e-07	0.46	0.27	Urate levels;	chr2:202283787	chr2:202336024~202336727:-
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000232546.1	RP11-458F8.1	-6.21	1.12e-09	5.15e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66528779	chr7:66848496~66858136:+
LUAD	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	6.21	1.12e-09	5.15e-07	0.38	0.27	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	6.21	1.12e-09	5.15e-07	0.38	0.27	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
LUAD	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	6.21	1.12e-09	5.15e-07	0.34	0.27	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
LUAD	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	6.21	1.12e-09	5.15e-07	0.38	0.27	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	6.21	1.12e-09	5.15e-07	0.38	0.27	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
LUAD	cis	rs4141404	0.828	rs2413043	ENSG00000236132.1	CTA-440B3.1	6.21	1.12e-09	5.15e-07	0.34	0.27	Paclitaxel-induced neuropathy;	chr22:31252590	chr22:31816379~31817491:-
LUAD	cis	rs4591358	0.689	rs72925794	ENSG00000223466.1	AC064834.2	-6.21	1.12e-09	5.15e-07	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511813	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.773	rs72925795	ENSG00000223466.1	AC064834.2	-6.21	1.12e-09	5.15e-07	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511814	chr2:195533035~195538681:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000232546.1	RP11-458F8.1	6.21	1.12e-09	5.15e-07	0.36	0.27	Diabetic kidney disease;	chr7:66139635	chr7:66848496~66858136:+
LUAD	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	6.21	1.12e-09	5.16e-07	0.35	0.27	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
LUAD	cis	rs113835537	0.597	rs7939759	ENSG00000255517.5	CTD-3074O7.5	-6.21	1.12e-09	5.17e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66570493	chr11:66473490~66480233:-
LUAD	cis	rs10740039	0.81	rs7098097	ENSG00000254271.1	RP11-131N11.4	6.21	1.13e-09	5.17e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60605233	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.81	rs10740036	ENSG00000254271.1	RP11-131N11.4	6.21	1.13e-09	5.17e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60606216	chr10:60734342~60741828:+
LUAD	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	6.21	1.13e-09	5.17e-07	0.3	0.27	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
LUAD	cis	rs7017914	0.87	rs3098883	ENSG00000223220.1	Y_RNA	6.21	1.13e-09	5.17e-07	0.3	0.27	Bone mineral density;	chr8:71031332	chr8:70780914~70781008:-
LUAD	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	6.21	1.13e-09	5.18e-07	0.29	0.27	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	6.21	1.13e-09	5.18e-07	0.29	0.27	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
LUAD	cis	rs7017914	0.905	rs3110255	ENSG00000223220.1	Y_RNA	6.21	1.13e-09	5.18e-07	0.3	0.27	Bone mineral density;	chr8:71025815	chr8:70780914~70781008:-
LUAD	cis	rs867371	0.929	rs1045508	ENSG00000255769.6	GOLGA2P10	6.21	1.13e-09	5.18e-07	0.29	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472993~82513950:-
LUAD	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	6.21	1.13e-09	5.18e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
LUAD	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	6.21	1.13e-09	5.19e-07	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000232546.1	RP11-458F8.1	6.21	1.13e-09	5.19e-07	0.36	0.27	Diabetic kidney disease;	chr7:66333815	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000232546.1	RP11-458F8.1	-6.21	1.13e-09	5.19e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66121618	chr7:66848496~66858136:+
LUAD	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-6.21	1.13e-09	5.19e-07	-0.6	-0.27	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-6.21	1.13e-09	5.19e-07	-0.6	-0.27	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-6.21	1.13e-09	5.19e-07	-0.6	-0.27	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-6.21	1.13e-09	5.19e-07	-0.6	-0.27	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
LUAD	cis	rs6772849	0.896	rs9816260	ENSG00000242551.2	POU5F1P6	-6.21	1.13e-09	5.19e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:128674735~128677005:-
LUAD	cis	rs3738443	0.678	rs6680707	ENSG00000259865.1	RP11-488L18.10	6.21	1.13e-09	5.2e-07	0.24	0.27	Alcohol dependence;	chr1:247213648	chr1:247187281~247188526:-
LUAD	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-6.21	1.14e-09	5.21e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
LUAD	cis	rs1707322	0.691	rs11211174	ENSG00000234329.1	RP11-767N6.2	6.21	1.14e-09	5.21e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45651039~45651826:-
LUAD	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-6.21	1.14e-09	5.21e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-6.21	1.14e-09	5.21e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-6.21	1.14e-09	5.22e-07	-0.31	-0.27	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-6.21	1.14e-09	5.22e-07	-0.31	-0.27	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-6.21	1.14e-09	5.22e-07	-0.31	-0.27	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs67728539	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	5.22e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4718333	ENSG00000232546.1	RP11-458F8.1	6.21	1.14e-09	5.22e-07	0.36	0.27	Diabetic kidney disease;	chr7:66307771	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7792391	ENSG00000232546.1	RP11-458F8.1	6.21	1.14e-09	5.22e-07	0.36	0.27	Diabetic kidney disease;	chr7:66308442	chr7:66848496~66858136:+
LUAD	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
LUAD	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-6.21	1.14e-09	5.23e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
LUAD	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-6.21	1.14e-09	5.24e-07	-0.44	-0.27	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
LUAD	cis	rs9918079	1	rs9918079	ENSG00000273133.1	RP11-799M12.2	6.21	1.14e-09	5.24e-07	0.47	0.27	Obesity-related traits;	chr4:15543787	chr4:15563698~15564253:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000206090.4	AP000350.7	6.21	1.14e-09	5.24e-07	0.31	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23939998~23942798:+
LUAD	cis	rs5753618	0.561	rs4820963	ENSG00000236132.1	CTA-440B3.1	6.21	1.14e-09	5.25e-07	0.34	0.27	Colorectal cancer;	chr22:31302180	chr22:31816379~31817491:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	5.25e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66358338	chr7:66848496~66858136:+
LUAD	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	6.21	1.15e-09	5.26e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
LUAD	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-6.21	1.15e-09	5.26e-07	-0.31	-0.27	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
LUAD	cis	rs2337406	0.587	rs10150642	ENSG00000211974.3	IGHV2-70	6.21	1.15e-09	5.26e-07	0.33	0.27	Alzheimer's disease (late onset);	chr14:106647269	chr14:106723574~106724093:-
LUAD	cis	rs755249	0.567	rs16825942	ENSG00000228060.1	RP11-69E11.8	-6.21	1.15e-09	5.26e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39565160~39573203:+
LUAD	cis	rs10740039	0.883	rs10994446	ENSG00000254271.1	RP11-131N11.4	6.21	1.15e-09	5.27e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639433	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs7902456	ENSG00000254271.1	RP11-131N11.4	6.21	1.15e-09	5.27e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643937	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.96	rs10761536	ENSG00000254271.1	RP11-131N11.4	6.21	1.15e-09	5.27e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644657	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10994455	ENSG00000254271.1	RP11-131N11.4	6.21	1.15e-09	5.27e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645589	chr10:60734342~60741828:+
LUAD	cis	rs853679	0.55	rs1237875	ENSG00000204709.4	LINC01556	-6.21	1.15e-09	5.27e-07	-0.37	-0.27	Depression;	chr6:28205232	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	6.21	1.15e-09	5.28e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.28e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65878455	chr7:66848496~66858136:+
LUAD	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-6.21	1.15e-09	5.28e-07	-0.33	-0.27	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
LUAD	cis	rs2243480	1	rs56016656	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65918494	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65924813	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65925352	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65925571	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65928123	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65939105	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65940751	chr7:66848496~66858136:+
LUAD	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-6.21	1.16e-09	5.31e-07	-0.31	-0.27	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
LUAD	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	6.21	1.16e-09	5.31e-07	0.24	0.27	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs10247526	ENSG00000232546.1	RP11-458F8.1	6.21	1.16e-09	5.32e-07	0.36	0.27	Diabetic kidney disease;	chr7:66315709	chr7:66848496~66858136:+
LUAD	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	6.21	1.16e-09	5.32e-07	0.29	0.27	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
LUAD	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-6.21	1.16e-09	5.33e-07	-0.37	-0.27	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
LUAD	cis	rs56114371	0.53	rs9348774	ENSG00000219392.1	RP1-265C24.5	-6.21	1.16e-09	5.33e-07	-0.39	-0.27	Breast cancer;	chr6:27721151	chr6:28115628~28116551:+
LUAD	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	6.21	1.16e-09	5.33e-07	0.32	0.27	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
LUAD	cis	rs720064	0.555	rs7244601	ENSG00000264745.1	TTC39C-AS1	6.21	1.16e-09	5.33e-07	0.29	0.27	Strep throat;	chr18:23929704	chr18:23994213~24015339:-
LUAD	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-6.21	1.17e-09	5.34e-07	-0.29	-0.27	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
LUAD	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	6.21	1.17e-09	5.35e-07	0.2	0.27	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
LUAD	cis	rs10740039	0.883	rs34168977	ENSG00000254271.1	RP11-131N11.4	6.21	1.17e-09	5.35e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632916	chr10:60734342~60741828:+
LUAD	cis	rs17301013	0.507	rs333438	ENSG00000227373.4	RP11-160H22.5	6.21	1.17e-09	5.36e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174672782	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2771401	ENSG00000227373.4	RP11-160H22.5	6.21	1.17e-09	5.36e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174678302	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs464540	ENSG00000227373.4	RP11-160H22.5	6.21	1.17e-09	5.36e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174679250	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs467437	ENSG00000227373.4	RP11-160H22.5	6.21	1.17e-09	5.36e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174679861	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-6.21	1.17e-09	5.36e-07	-0.35	-0.27	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
LUAD	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-6.21	1.17e-09	5.36e-07	-0.36	-0.27	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
LUAD	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	6.21	1.17e-09	5.37e-07	0.33	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
LUAD	cis	rs1113500	0.565	rs11185226	ENSG00000226822.1	RP11-356N1.2	6.21	1.17e-09	5.37e-07	0.37	0.27	Growth-regulated protein alpha levels;	chr1:108005429	chr1:108071482~108074519:+
LUAD	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-6.21	1.17e-09	5.38e-07	-0.35	-0.27	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
LUAD	cis	rs75422866	0.51	rs73105829	ENSG00000274902.1	RP1-197B17.4	6.21	1.18e-09	5.38e-07	0.59	0.27	Pneumonia;	chr12:47734162	chr12:47731908~47732351:+
LUAD	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-6.21	1.18e-09	5.38e-07	-0.26	-0.27	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
LUAD	cis	rs35934224	0.891	rs34249993	ENSG00000232926.1	AC000078.5	6.21	1.18e-09	5.39e-07	0.33	0.27	Glaucoma (primary open-angle);	chr22:19884647	chr22:19887289~19887970:+
LUAD	cis	rs7246657	0.551	rs12978093	ENSG00000276846.1	CTD-3220F14.3	6.21	1.18e-09	5.39e-07	0.4	0.27	Coronary artery calcification;	chr19:37093514	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs937108	ENSG00000230295.1	RP11-458F8.2	-6.21	1.18e-09	5.4e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65963465	chr7:66880708~66882981:+
LUAD	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-6.2	1.18e-09	5.41e-07	-0.29	-0.27	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
LUAD	cis	rs948562	0.744	rs60998298	ENSG00000280010.1	AP001350.4	6.2	1.18e-09	5.42e-07	0.46	0.27	Lymphoma;	chr11:58534382	chr11:58627435~58628528:+
LUAD	cis	rs2243480	1	rs316307	ENSG00000232546.1	RP11-458F8.1	-6.2	1.18e-09	5.42e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:66105184	chr7:66848496~66858136:+
LUAD	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	6.2	1.18e-09	5.42e-07	0.4	0.27	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
LUAD	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-6.2	1.19e-09	5.43e-07	-0.32	-0.27	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
LUAD	cis	rs11096990	0.793	rs9997050	ENSG00000249207.1	RP11-360F5.1	6.2	1.19e-09	5.43e-07	0.33	0.27	Cognitive function;	chr4:39301045	chr4:39112677~39126818:-
LUAD	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-6.2	1.19e-09	5.44e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
LUAD	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	6.2	1.19e-09	5.44e-07	0.33	0.27	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
LUAD	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-6.2	1.19e-09	5.45e-07	-0.27	-0.27	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
LUAD	cis	rs853679	0.517	rs2281588	ENSG00000204709.4	LINC01556	6.2	1.19e-09	5.46e-07	0.38	0.27	Depression;	chr6:28104824	chr6:28943877~28944537:+
LUAD	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	6.2	1.19e-09	5.46e-07	0.3	0.27	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
LUAD	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-6.2	1.2e-09	5.47e-07	-0.3	-0.27	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
LUAD	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	6.2	1.2e-09	5.47e-07	0.43	0.27	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
LUAD	cis	rs9353324	1	rs9444356	ENSG00000203875.9	SNHG5	-6.2	1.2e-09	5.48e-07	-0.59	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85651200	chr6:85660950~85678736:-
LUAD	cis	rs12468226	0.938	rs12463937	ENSG00000226261.1	AC064836.3	6.2	1.2e-09	5.48e-07	0.46	0.27	Urate levels;	chr2:202246543	chr2:202336024~202336727:-
LUAD	cis	rs1707322	0.721	rs4559551	ENSG00000234329.1	RP11-767N6.2	6.2	1.2e-09	5.49e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45651039~45651826:-
LUAD	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-6.2	1.2e-09	5.49e-07	-0.43	-0.27	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
LUAD	cis	rs10740039	0.734	rs10821815	ENSG00000254271.1	RP11-131N11.4	6.2	1.2e-09	5.5e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644843	chr10:60734342~60741828:+
LUAD	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-6.2	1.2e-09	5.5e-07	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
LUAD	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-6.2	1.2e-09	5.5e-07	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
LUAD	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-6.2	1.2e-09	5.5e-07	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
LUAD	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-6.2	1.2e-09	5.5e-07	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
LUAD	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-6.2	1.21e-09	5.51e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000211974.3	IGHV2-70	6.2	1.21e-09	5.51e-07	0.28	0.27	Kawasaki disease;	chr14:106777570	chr14:106723574~106724093:-
LUAD	cis	rs7017914	0.935	rs2732093	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71006844	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639899	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71007227	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.875	rs2639897	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71008441	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639896	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71008548	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs1353057	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71009862	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639960	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71009904	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639958	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71009915	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs1908036	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71010089	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs1908035	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71010173	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs1908034	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71010319	chr8:70780914~70781008:-
LUAD	cis	rs10740039	0.842	rs7080024	ENSG00000254271.1	RP11-131N11.4	-6.2	1.21e-09	5.54e-07	-0.31	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632033	chr10:60734342~60741828:+
LUAD	cis	rs7246657	0.525	rs10410594	ENSG00000276846.1	CTD-3220F14.3	6.2	1.21e-09	5.54e-07	0.41	0.27	Coronary artery calcification;	chr19:36986856	chr19:37314868~37315620:-
LUAD	cis	rs17818399	0.926	rs7590693	ENSG00000279254.1	RP11-536C12.1	-6.2	1.21e-09	5.54e-07	-0.31	-0.27	Height;	chr2:46596853	chr2:46668870~46670778:+
LUAD	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	6.2	1.21e-09	5.54e-07	0.3	0.27	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
LUAD	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	6.2	1.21e-09	5.54e-07	0.33	0.27	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
LUAD	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	6.2	1.21e-09	5.54e-07	0.3	0.27	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
LUAD	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	6.2	1.21e-09	5.55e-07	0.26	0.27	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
LUAD	cis	rs1914816	1	rs2456072	ENSG00000196274.5	Metazoa_SRP	6.2	1.21e-09	5.55e-07	0.31	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76253503	chr15:76230048~76230390:-
LUAD	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	6.2	1.21e-09	5.55e-07	0.24	0.27	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
LUAD	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	6.2	1.22e-09	5.55e-07	0.35	0.27	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
LUAD	cis	rs2412819	0.571	rs6493090	ENSG00000205771.5	CATSPER2P1	6.2	1.22e-09	5.55e-07	0.42	0.27	Lung cancer;	chr15:43792084	chr15:43726918~43747094:-
LUAD	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-6.2	1.22e-09	5.57e-07	-0.29	-0.27	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
LUAD	cis	rs948562	0.744	rs12363774	ENSG00000280010.1	AP001350.4	6.2	1.22e-09	5.57e-07	0.42	0.27	Lymphoma;	chr11:58457562	chr11:58627435~58628528:+
LUAD	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	6.2	1.22e-09	5.57e-07	0.33	0.27	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
LUAD	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-6.2	1.22e-09	5.58e-07	-0.28	-0.27	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
LUAD	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	6.2	1.22e-09	5.58e-07	0.41	0.27	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
LUAD	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	6.2	1.22e-09	5.58e-07	0.34	0.27	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs13247184	ENSG00000232546.1	RP11-458F8.1	-6.2	1.22e-09	5.59e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65893941	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35283677	ENSG00000232546.1	RP11-458F8.1	-6.2	1.22e-09	5.59e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65894246	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35421653	ENSG00000232546.1	RP11-458F8.1	-6.2	1.22e-09	5.59e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65898442	chr7:66848496~66858136:+
LUAD	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	6.2	1.22e-09	5.59e-07	0.34	0.27	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
LUAD	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.23e-09	5.59e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.23e-09	5.59e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.23e-09	5.59e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
LUAD	cis	rs6840258	0.547	rs17012170	ENSG00000251411.1	RP11-397E7.4	-6.2	1.23e-09	5.59e-07	-0.38	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86939692	chr4:86913266~86914817:-
LUAD	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	6.2	1.23e-09	5.59e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
LUAD	cis	rs2179367	0.959	rs564961	ENSG00000231760.4	RP11-350J20.5	6.2	1.23e-09	5.6e-07	0.34	0.27	Dupuytren's disease;	chr6:149336091	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.959	rs504985	ENSG00000231760.4	RP11-350J20.5	6.2	1.23e-09	5.6e-07	0.34	0.27	Dupuytren's disease;	chr6:149337842	chr6:149796151~149826294:-
LUAD	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-6.2	1.23e-09	5.6e-07	-0.29	-0.27	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
LUAD	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	6.2	1.23e-09	5.6e-07	0.34	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
LUAD	cis	rs9595908	0.568	rs4942926	ENSG00000212293.1	SNORA16	6.2	1.23e-09	5.61e-07	0.29	0.27	Body mass index;	chr13:32807204	chr13:32420390~32420516:-
LUAD	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	6.2	1.23e-09	5.63e-07	0.28	0.27	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
LUAD	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	6.2	1.24e-09	5.63e-07	0.28	0.27	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	6.2	1.24e-09	5.64e-07	0.28	0.27	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.721	rs11211163	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12037803	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10789470	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs61784796	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10749856	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10890344	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4564187	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28438704	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs28442079	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs28817701	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.691	rs28495425	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.685	rs28617418	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.691	rs61784803	ENSG00000234329.1	RP11-767N6.2	-6.2	1.24e-09	5.64e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.663	rs3935296	ENSG00000234329.1	RP11-767N6.2	-6.2	1.24e-09	5.64e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45651039~45651826:-
LUAD	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	6.2	1.24e-09	5.64e-07	0.31	0.27	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000211972.2	IGHV3-66	6.2	1.24e-09	5.64e-07	0.24	0.27	Kawasaki disease;	chr14:106716993	chr14:106675017~106675544:-
LUAD	cis	rs2179367	0.6	rs58747890	ENSG00000231760.4	RP11-350J20.5	6.2	1.24e-09	5.64e-07	0.42	0.27	Dupuytren's disease;	chr6:149459369	chr6:149796151~149826294:-
LUAD	cis	rs74233809	1	rs11191560	ENSG00000213277.3	MARCKSL1P1	6.2	1.24e-09	5.64e-07	0.45	0.27	Birth weight;	chr10:103109281	chr10:103175554~103176094:+
LUAD	cis	rs2006771	0.765	rs6518752	ENSG00000236132.1	CTA-440B3.1	-6.2	1.24e-09	5.65e-07	-0.3	-0.27	Nonsyndromic cleft lip with cleft palate;	chr22:31603141	chr22:31816379~31817491:-
LUAD	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	6.2	1.24e-09	5.65e-07	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
LUAD	cis	rs853679	0.546	rs35016036	ENSG00000204709.4	LINC01556	6.2	1.24e-09	5.65e-07	0.61	0.27	Depression;	chr6:28347103	chr6:28943877~28944537:+
LUAD	cis	rs948562	0.744	rs11229444	ENSG00000280010.1	AP001350.4	6.2	1.24e-09	5.65e-07	0.42	0.27	Lymphoma;	chr11:58430400	chr11:58627435~58628528:+
LUAD	cis	rs853679	0.517	rs4713135	ENSG00000204709.4	LINC01556	6.2	1.24e-09	5.65e-07	0.38	0.27	Depression;	chr6:28071808	chr6:28943877~28944537:+
LUAD	cis	rs2734839	0.896	rs11608109	ENSG00000270179.1	RP11-159N11.4	-6.2	1.24e-09	5.66e-07	-0.28	-0.27	Information processing speed;	chr11:113432726	chr11:113368478~113369117:+
LUAD	cis	rs1707322	0.691	rs61784799	ENSG00000234329.1	RP11-767N6.2	-6.2	1.24e-09	5.66e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45651039~45651826:-
LUAD	cis	rs4908768	0.501	rs6577492	ENSG00000232912.4	RP5-1115A15.1	6.2	1.24e-09	5.67e-07	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8515005	chr1:8424645~8434838:+
LUAD	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-6.2	1.24e-09	5.67e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-6.2	1.24e-09	5.67e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
LUAD	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	6.2	1.25e-09	5.68e-07	0.31	0.27	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
LUAD	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-6.2	1.25e-09	5.68e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
LUAD	cis	rs2243480	1	rs160633	ENSG00000232546.1	RP11-458F8.1	-6.2	1.25e-09	5.69e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66063241	chr7:66848496~66858136:+
LUAD	cis	rs6687821	0.681	rs526985	ENSG00000267734.1	RP4-604K5.3	6.2	1.25e-09	5.69e-07	0.36	0.27	Yeast infection;	chr1:86850735	chr1:86932199~86934891:-
LUAD	cis	rs293748	0.882	rs293774	ENSG00000250155.1	CTD-2353F22.1	-6.19	1.25e-09	5.71e-07	-0.38	-0.27	Obesity-related traits;	chr5:36943166	chr5:36666214~36725195:-
LUAD	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-6.19	1.25e-09	5.71e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
LUAD	cis	rs11096990	0.929	rs55976583	ENSG00000249207.1	RP11-360F5.1	6.19	1.25e-09	5.72e-07	0.31	0.27	Cognitive function;	chr4:39222871	chr4:39112677~39126818:-
LUAD	cis	rs35740288	0.77	rs11632750	ENSG00000202081.1	RNU6-1280P	6.19	1.26e-09	5.72e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672383	chr15:85651522~85651628:-
LUAD	cis	rs7017914	0.967	rs4628281	ENSG00000223220.1	Y_RNA	6.19	1.26e-09	5.73e-07	0.31	0.27	Bone mineral density;	chr8:70926929	chr8:70780914~70781008:-
LUAD	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-6.19	1.26e-09	5.73e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-6.19	1.26e-09	5.73e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-6.19	1.26e-09	5.73e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-6.19	1.26e-09	5.73e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
LUAD	cis	rs5753618	0.509	rs2079431	ENSG00000236132.1	CTA-440B3.1	6.19	1.26e-09	5.73e-07	0.34	0.27	Colorectal cancer;	chr22:31168348	chr22:31816379~31817491:-
LUAD	cis	rs2034650	0.525	rs11790	ENSG00000223313.1	RNU6-516P	6.19	1.26e-09	5.74e-07	0.35	0.27	Interstitial lung disease;	chr15:40420538	chr15:40529570~40529673:+
LUAD	cis	rs9595908	0.869	rs7998956	ENSG00000212293.1	SNORA16	6.19	1.26e-09	5.74e-07	0.29	0.27	Body mass index;	chr13:32622239	chr13:32420390~32420516:-
LUAD	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-6.19	1.26e-09	5.74e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
LUAD	cis	rs9928842	0.882	rs9319481	ENSG00000280152.1	RP11-331F4.5	6.19	1.26e-09	5.74e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75225580	chr16:75245994~75250077:-
LUAD	cis	rs9928842	0.882	rs1107593	ENSG00000280152.1	RP11-331F4.5	6.19	1.26e-09	5.74e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75227431	chr16:75245994~75250077:-
LUAD	cis	rs720064	0.586	rs12956330	ENSG00000264745.1	TTC39C-AS1	6.19	1.26e-09	5.74e-07	0.29	0.27	Strep throat;	chr18:23981536	chr18:23994213~24015339:-
LUAD	cis	rs2745572	0.557	rs2816299	ENSG00000272279.1	RP11-157J24.2	-6.19	1.26e-09	5.74e-07	-0.34	-0.27	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548451	chr6:1528364~1528911:-
LUAD	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-6.19	1.26e-09	5.74e-07	-0.3	-0.27	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
LUAD	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	6.19	1.26e-09	5.75e-07	0.28	0.27	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.686	rs2230658	ENSG00000234329.1	RP11-767N6.2	-6.19	1.26e-09	5.75e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs2230659	ENSG00000234329.1	RP11-767N6.2	-6.19	1.26e-09	5.75e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45651039~45651826:-
LUAD	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-6.19	1.26e-09	5.75e-07	-0.28	-0.27	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
LUAD	cis	rs1823913	0.637	rs2883912	ENSG00000280083.1	RP11-317J9.1	6.19	1.27e-09	5.77e-07	0.32	0.27	Obesity-related traits;	chr2:191284290	chr2:191154118~191156070:-
LUAD	cis	rs9928842	0.824	rs12924999	ENSG00000280152.1	RP11-331F4.5	6.19	1.27e-09	5.77e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75228527	chr16:75245994~75250077:-
LUAD	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	6.19	1.27e-09	5.77e-07	0.34	0.27	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
LUAD	cis	rs948562	0.744	rs11229438	ENSG00000280010.1	AP001350.4	6.19	1.27e-09	5.77e-07	0.42	0.27	Lymphoma;	chr11:58423730	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229449	ENSG00000280010.1	AP001350.4	6.19	1.27e-09	5.77e-07	0.42	0.27	Lymphoma;	chr11:58434155	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs111377246	ENSG00000280010.1	AP001350.4	6.19	1.27e-09	5.77e-07	0.42	0.27	Lymphoma;	chr11:58436505	chr11:58627435~58628528:+
LUAD	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-6.19	1.27e-09	5.78e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
LUAD	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	6.19	1.27e-09	5.78e-07	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
LUAD	cis	rs12220777	0.748	rs11201633	ENSG00000230091.5	TMEM254-AS1	6.19	1.27e-09	5.78e-07	0.48	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090068	chr10:80046860~80078912:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000211974.3	IGHV2-70	6.19	1.27e-09	5.79e-07	0.28	0.27	Kawasaki disease;	chr14:106780451	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000211974.3	IGHV2-70	6.19	1.27e-09	5.79e-07	0.28	0.27	Kawasaki disease;	chr14:106781682	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000211974.3	IGHV2-70	6.19	1.27e-09	5.79e-07	0.28	0.27	Kawasaki disease;	chr14:106781820	chr14:106723574~106724093:-
LUAD	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	6.19	1.27e-09	5.79e-07	0.23	0.27	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
LUAD	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-6.19	1.27e-09	5.8e-07	-0.41	-0.27	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
LUAD	cis	rs755249	0.761	rs3768321	ENSG00000228060.1	RP11-69E11.8	-6.19	1.27e-09	5.8e-07	-0.29	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39565160~39573203:+
LUAD	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-6.19	1.28e-09	5.8e-07	-0.35	-0.27	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
LUAD	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	6.19	1.28e-09	5.8e-07	0.4	0.27	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
LUAD	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	6.19	1.28e-09	5.81e-07	0.61	0.27	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000211974.3	IGHV2-70	6.19	1.28e-09	5.82e-07	0.29	0.27	Kawasaki disease;	chr14:106775695	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000211974.3	IGHV2-70	6.19	1.28e-09	5.82e-07	0.29	0.27	Kawasaki disease;	chr14:106775735	chr14:106723574~106724093:-
LUAD	cis	rs7017914	0.905	rs4571761	ENSG00000223220.1	Y_RNA	-6.19	1.28e-09	5.82e-07	-0.31	-0.27	Bone mineral density;	chr8:71044938	chr8:70780914~70781008:-
LUAD	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	6.19	1.28e-09	5.82e-07	0.38	0.27	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
LUAD	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	6.19	1.28e-09	5.83e-07	0.4	0.27	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
LUAD	cis	rs853679	0.607	rs13205911	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28156336	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13197176	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28161454	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13201308	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28162311	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34765154	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28162672	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34505829	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28165461	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs35098436	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28166443	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs72846794	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28169721	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13217984	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28171932	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.556	rs67297533	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28173475	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.505	rs35781323	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28177054	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	6.19	1.28e-09	5.84e-07	0.36	0.27	Depression;	chr6:28187640	chr6:28115628~28116551:+
LUAD	cis	rs9879311	0.866	rs775017	ENSG00000240288.6	GHRLOS	6.19	1.28e-09	5.84e-07	0.26	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10357280	chr3:10285754~10293449:+
LUAD	cis	rs944289	0.562	rs2780310	ENSG00000257826.1	RP11-116N8.4	6.19	1.28e-09	5.84e-07	0.29	0.27	Thyroid cancer;	chr14:36050852	chr14:36061026~36067190:-
LUAD	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	6.19	1.29e-09	5.84e-07	0.46	0.27	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
LUAD	cis	rs755249	0.567	rs4660543	ENSG00000228060.1	RP11-69E11.8	-6.19	1.29e-09	5.84e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39565160~39573203:+
LUAD	cis	rs238295	0.628	rs6133219	ENSG00000230563.2	RP5-828H9.1	6.19	1.29e-09	5.85e-07	0.36	0.27	Occipital cortical area (total cortical area interaction);	chr20:5514423	chr20:5471207~5475182:+
LUAD	cis	rs2765539	1	rs7525637	ENSG00000226172.2	RP4-712E4.1	-6.19	1.29e-09	5.86e-07	-0.34	-0.27	Waist-hip ratio;	chr1:119000848	chr1:119000344~119001392:-
LUAD	cis	rs2006771	0.74	rs8140312	ENSG00000236132.1	CTA-440B3.1	-6.19	1.29e-09	5.86e-07	-0.31	-0.27	Nonsyndromic cleft lip with cleft palate;	chr22:31609608	chr22:31816379~31817491:-
LUAD	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	6.19	1.29e-09	5.87e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
LUAD	cis	rs948562	0.69	rs11229425	ENSG00000280010.1	AP001350.4	-6.19	1.29e-09	5.87e-07	-0.42	-0.27	Lymphoma;	chr11:58411114	chr11:58627435~58628528:+
LUAD	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	6.19	1.29e-09	5.87e-07	0.34	0.27	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	6.19	1.29e-09	5.87e-07	0.34	0.27	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
LUAD	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-6.19	1.29e-09	5.88e-07	-0.35	-0.27	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
LUAD	cis	rs7017914	0.846	rs6472561	ENSG00000223220.1	Y_RNA	-6.19	1.29e-09	5.88e-07	-0.31	-0.27	Bone mineral density;	chr8:71042948	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs4074909	ENSG00000223220.1	Y_RNA	-6.19	1.29e-09	5.88e-07	-0.31	-0.27	Bone mineral density;	chr8:71043592	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs4078067	ENSG00000223220.1	Y_RNA	-6.19	1.29e-09	5.88e-07	-0.31	-0.27	Bone mineral density;	chr8:71044236	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs4504667	ENSG00000223220.1	Y_RNA	-6.19	1.29e-09	5.88e-07	-0.31	-0.27	Bone mineral density;	chr8:71044557	chr8:70780914~70781008:-
LUAD	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	6.19	1.29e-09	5.88e-07	0.34	0.27	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
LUAD	cis	rs11096990	0.892	rs2381349	ENSG00000249207.1	RP11-360F5.1	6.19	1.3e-09	5.89e-07	0.3	0.27	Cognitive function;	chr4:39210390	chr4:39112677~39126818:-
LUAD	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-6.19	1.3e-09	5.89e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-6.19	1.3e-09	5.89e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
LUAD	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-6.19	1.3e-09	5.89e-07	-0.37	-0.27	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	6.19	1.3e-09	5.9e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
LUAD	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	6.19	1.3e-09	5.9e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
LUAD	cis	rs6687821	0.681	rs481583	ENSG00000267734.1	RP4-604K5.3	6.19	1.3e-09	5.9e-07	0.35	0.27	Yeast infection;	chr1:86849596	chr1:86932199~86934891:-
LUAD	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-6.19	1.3e-09	5.91e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
LUAD	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-6.19	1.3e-09	5.91e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	6.19	1.3e-09	5.92e-07	0.33	0.27	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
LUAD	cis	rs293748	0.882	rs158802	ENSG00000250155.1	CTD-2353F22.1	-6.19	1.31e-09	5.93e-07	-0.38	-0.27	Obesity-related traits;	chr5:36941446	chr5:36666214~36725195:-
LUAD	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-6.19	1.31e-09	5.93e-07	-0.37	-0.27	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	6.19	1.31e-09	5.93e-07	0.39	0.27	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	6.19	1.31e-09	5.93e-07	0.39	0.27	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	6.19	1.31e-09	5.93e-07	0.39	0.27	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	6.19	1.31e-09	5.93e-07	0.39	0.27	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000211974.3	IGHV2-70	-6.19	1.31e-09	5.93e-07	-0.28	-0.27	Kawasaki disease;	chr14:106775945	chr14:106723574~106724093:-
LUAD	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	6.19	1.31e-09	5.93e-07	0.33	0.27	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
LUAD	cis	rs10214930	1	rs17155876	ENSG00000235574.1	AC073150.6	6.19	1.31e-09	5.94e-07	0.38	0.27	Hypospadias;	chr7:27811436	chr7:27491682~27492765:-
LUAD	cis	rs4723738	0.967	rs12531618	ENSG00000227191.5	TRGC2	-6.19	1.31e-09	5.94e-07	-0.29	-0.27	Treatment response for severe sepsis;	chr7:38213263	chr7:38239580~38368091:-
LUAD	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-6.19	1.31e-09	5.95e-07	-0.28	-0.27	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
LUAD	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	6.19	1.31e-09	5.95e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	6.19	1.31e-09	5.95e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
LUAD	cis	rs35740288	0.77	rs11635190	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605300	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11631449	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605422	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs1871285	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609256	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs4843081	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609813	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs4843082	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85610159	chr15:85651522~85651628:-
LUAD	cis	rs6772849	0.896	rs35535737	ENSG00000242551.2	POU5F1P6	-6.19	1.32e-09	5.98e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128674735~128677005:-
LUAD	cis	rs11846409	0.799	rs10467899	ENSG00000254174.1	IGHV1-12	6.19	1.32e-09	5.98e-07	0.24	0.27	Rheumatic heart disease;	chr14:106644012	chr14:106122420~106122709:-
LUAD	cis	rs5753618	0.561	rs5753521	ENSG00000236132.1	CTA-440B3.1	6.19	1.32e-09	5.98e-07	0.34	0.27	Colorectal cancer;	chr22:31242041	chr22:31816379~31817491:-
LUAD	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	6.19	1.32e-09	5.98e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
LUAD	cis	rs853679	0.517	rs4713145	ENSG00000204709.4	LINC01556	6.19	1.32e-09	5.99e-07	0.38	0.27	Depression;	chr6:28139049	chr6:28943877~28944537:+
LUAD	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	6.19	1.32e-09	5.99e-07	0.34	0.27	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
LUAD	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	6.19	1.32e-09	5.99e-07	0.33	0.27	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
LUAD	cis	rs7688540	0.8	rs6837796	ENSG00000275426.1	CH17-262A2.1	6.19	1.32e-09	5.99e-07	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:149738~150317:+
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-6.19	1.32e-09	6e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
LUAD	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	6.19	1.32e-09	6e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
LUAD	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	6.19	1.32e-09	6.01e-07	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
LUAD	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-6.19	1.33e-09	6.02e-07	-0.37	-0.27	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
LUAD	cis	rs867371	0.929	rs7173852	ENSG00000255769.6	GOLGA2P10	-6.18	1.33e-09	6.02e-07	-0.29	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472993~82513950:-
LUAD	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-6.18	1.33e-09	6.03e-07	-0.29	-0.27	Height;	chr11:118737823	chr11:118791254~118793137:+
LUAD	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	6.18	1.33e-09	6.03e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	6.18	1.33e-09	6.03e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs969472	ENSG00000227373.4	RP11-160H22.5	6.18	1.33e-09	6.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174458562	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10798314	ENSG00000227373.4	RP11-160H22.5	6.18	1.33e-09	6.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174458958	chr1:174115300~174160004:-
LUAD	cis	rs10740039	0.842	rs10761537	ENSG00000254271.1	RP11-131N11.4	6.18	1.34e-09	6.05e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649263	chr10:60734342~60741828:+
LUAD	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	6.18	1.34e-09	6.05e-07	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
LUAD	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	6.18	1.34e-09	6.05e-07	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
LUAD	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-6.18	1.34e-09	6.05e-07	-0.32	-0.27	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
LUAD	cis	rs9584850	0.874	rs7988959	ENSG00000231194.1	FARP1-AS1	6.18	1.34e-09	6.06e-07	0.33	0.27	Neuroticism;	chr13:98451750	chr13:98435405~98435840:-
LUAD	cis	rs8031584	0.958	rs7168641	ENSG00000260382.1	RP11-540B6.2	6.18	1.34e-09	6.07e-07	0.32	0.27	Huntington's disease progression;	chr15:30943249	chr15:30882267~30883231:-
LUAD	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	6.18	1.34e-09	6.07e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
LUAD	cis	rs155076	1	rs261404	ENSG00000233325.3	MIPEPP3	6.18	1.34e-09	6.07e-07	0.41	0.27	White matter hyperintensity burden;	chr13:21284023	chr13:21298139~21306373:+
LUAD	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-6.18	1.34e-09	6.07e-07	-0.3	-0.27	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-6.18	1.34e-09	6.07e-07	-0.3	-0.27	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
LUAD	cis	rs7044106	0.762	rs1547268	ENSG00000238181.2	AHCYP2	-6.18	1.34e-09	6.07e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.762	rs1547267	ENSG00000238181.2	AHCYP2	-6.18	1.34e-09	6.07e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.762	rs4142158	ENSG00000238181.2	AHCYP2	-6.18	1.34e-09	6.07e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120720673~120721972:+
LUAD	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-6.18	1.34e-09	6.08e-07	-0.34	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
LUAD	cis	rs9652601	0.622	rs3901386	ENSG00000274038.1	RP11-66H6.4	-6.18	1.34e-09	6.08e-07	-0.32	-0.27	Systemic lupus erythematosus;	chr16:11048863	chr16:11056556~11057034:+
LUAD	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-6.18	1.34e-09	6.08e-07	-0.37	-0.27	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
LUAD	cis	rs748404	0.666	rs12906017	ENSG00000205771.5	CATSPER2P1	-6.18	1.34e-09	6.08e-07	-0.42	-0.27	Lung cancer;	chr15:43504710	chr15:43726918~43747094:-
LUAD	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	6.18	1.35e-09	6.09e-07	0.29	0.27	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
LUAD	cis	rs10740039	0.516	rs7477771	ENSG00000254271.1	RP11-131N11.4	6.18	1.35e-09	6.09e-07	0.3	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60595970	chr10:60734342~60741828:+
LUAD	cis	rs1823913	0.526	rs36028476	ENSG00000280083.1	RP11-317J9.1	-6.18	1.35e-09	6.09e-07	-0.33	-0.27	Obesity-related traits;	chr2:191300595	chr2:191154118~191156070:-
LUAD	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-6.18	1.35e-09	6.09e-07	-0.41	-0.27	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
LUAD	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6.18	1.35e-09	6.1e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-6.18	1.35e-09	6.1e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	6.18	1.35e-09	6.1e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
LUAD	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-6.18	1.35e-09	6.11e-07	-0.26	-0.27	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
LUAD	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-6.18	1.35e-09	6.12e-07	-0.34	-0.27	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
LUAD	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	6.18	1.35e-09	6.12e-07	0.3	0.27	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	6.18	1.35e-09	6.12e-07	0.3	0.27	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	6.18	1.35e-09	6.12e-07	0.3	0.27	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	6.18	1.35e-09	6.12e-07	0.3	0.27	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
LUAD	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-6.18	1.35e-09	6.12e-07	-0.3	-0.27	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-6.18	1.35e-09	6.12e-07	-0.3	-0.27	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-6.18	1.35e-09	6.12e-07	-0.3	-0.27	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
LUAD	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-6.18	1.35e-09	6.12e-07	-0.38	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
LUAD	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	6.18	1.35e-09	6.13e-07	0.4	0.27	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
LUAD	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	6.18	1.36e-09	6.14e-07	0.24	0.27	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
LUAD	cis	rs35740288	0.77	rs11633893	ENSG00000202081.1	RNU6-1280P	-6.18	1.36e-09	6.14e-07	-0.33	-0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605207	chr15:85651522~85651628:-
LUAD	cis	rs8177876	0.596	rs2317087	ENSG00000261838.4	RP11-303E16.6	-6.18	1.36e-09	6.14e-07	-0.66	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104753	chr16:81069854~81076598:+
LUAD	cis	rs897200	1	rs897200	ENSG00000280083.1	RP11-317J9.1	6.18	1.36e-09	6.14e-07	0.34	0.27	Behcet's disease;	chr2:191153045	chr2:191154118~191156070:-
LUAD	cis	rs755249	1	rs76841360	ENSG00000228060.1	RP11-69E11.8	-6.18	1.36e-09	6.15e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594353	chr1:39565160~39573203:+
LUAD	cis	rs1167827	0.71	rs1167836	ENSG00000127957.15	PMS2P3	-6.18	1.36e-09	6.15e-07	-0.26	-0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75502930~75528148:-
LUAD	cis	rs2412819	0.545	rs35822148	ENSG00000205771.5	CATSPER2P1	-6.18	1.36e-09	6.15e-07	-0.46	-0.27	Lung cancer;	chr15:43808084	chr15:43726918~43747094:-
LUAD	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	6.18	1.36e-09	6.15e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
LUAD	cis	rs1707322	0.721	rs11211165	ENSG00000234329.1	RP11-767N6.2	6.18	1.36e-09	6.16e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211166	ENSG00000234329.1	RP11-767N6.2	6.18	1.36e-09	6.16e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45651039~45651826:-
LUAD	cis	rs755249	0.756	rs72637908	ENSG00000228060.1	RP11-69E11.8	-6.18	1.36e-09	6.16e-07	-0.25	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39565160~39573203:+
LUAD	cis	rs2276314	0.532	rs11081927	ENSG00000278986.1	RP11-723J4.3	-6.18	1.36e-09	6.16e-07	-0.28	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36034319	chr18:35972151~35973916:+
LUAD	cis	rs7688540	0.8	rs10003142	ENSG00000275426.1	CH17-262A2.1	6.18	1.36e-09	6.16e-07	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11723803	ENSG00000275426.1	CH17-262A2.1	6.18	1.36e-09	6.16e-07	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:149738~150317:+
LUAD	cis	rs113835537	0.597	rs10896129	ENSG00000255517.5	CTD-3074O7.5	-6.18	1.37e-09	6.19e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66570829	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.559	rs57045447	ENSG00000255517.5	CTD-3074O7.5	-6.18	1.37e-09	6.19e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66572212	chr11:66473490~66480233:-
LUAD	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	6.18	1.37e-09	6.19e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
LUAD	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	6.18	1.37e-09	6.19e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
LUAD	cis	rs6504622	0.905	rs736603	ENSG00000262879.4	RP11-156P1.3	6.18	1.38e-09	6.22e-07	0.31	0.27	Orofacial clefts;	chr17:46947379	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.905	rs736604	ENSG00000262879.4	RP11-156P1.3	6.18	1.38e-09	6.22e-07	0.31	0.27	Orofacial clefts;	chr17:46947443	chr17:46984045~47100323:-
LUAD	cis	rs17301013	0.531	rs1793318	ENSG00000227373.4	RP11-160H22.5	-6.18	1.38e-09	6.22e-07	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174824678	chr1:174115300~174160004:-
LUAD	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-6.18	1.38e-09	6.23e-07	-0.34	-0.27	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
LUAD	cis	rs8031584	0.958	rs8034856	ENSG00000260382.1	RP11-540B6.2	6.18	1.38e-09	6.23e-07	0.33	0.27	Huntington's disease progression;	chr15:30948754	chr15:30882267~30883231:-
LUAD	cis	rs1823913	0.637	rs4853575	ENSG00000280083.1	RP11-317J9.1	6.18	1.38e-09	6.24e-07	0.32	0.27	Obesity-related traits;	chr2:191296149	chr2:191154118~191156070:-
LUAD	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-6.18	1.38e-09	6.24e-07	-0.3	-0.27	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
LUAD	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-6.18	1.38e-09	6.25e-07	-0.32	-0.27	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
LUAD	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-6.18	1.38e-09	6.25e-07	-0.26	-0.27	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
LUAD	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	6.26e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	6.26e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	6.26e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
LUAD	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-6.18	1.39e-09	6.27e-07	-0.34	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
LUAD	cis	rs9450351	0.744	rs9444371	ENSG00000203875.9	SNHG5	-6.18	1.39e-09	6.28e-07	-0.56	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85950676	chr6:85660950~85678736:-
LUAD	cis	rs853679	0.517	rs9380047	ENSG00000204709.4	LINC01556	6.18	1.39e-09	6.28e-07	0.38	0.27	Depression;	chr6:28070115	chr6:28943877~28944537:+
LUAD	cis	rs8177376	0.681	rs240548	ENSG00000254905.1	RP11-712L6.7	6.18	1.39e-09	6.28e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126335072	chr11:126292922~126294254:-
LUAD	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	6.18	1.39e-09	6.29e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	6.18	1.39e-09	6.29e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	6.18	1.39e-09	6.29e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	6.18	1.39e-09	6.29e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
LUAD	cis	rs948562	0.744	rs113707421	ENSG00000280010.1	AP001350.4	6.18	1.39e-09	6.29e-07	0.42	0.27	Lymphoma;	chr11:58449669	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229468	ENSG00000280010.1	AP001350.4	6.18	1.39e-09	6.29e-07	0.42	0.27	Lymphoma;	chr11:58451300	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs113392266	ENSG00000280010.1	AP001350.4	6.18	1.39e-09	6.29e-07	0.42	0.27	Lymphoma;	chr11:58452278	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs74406537	ENSG00000280010.1	AP001350.4	6.18	1.39e-09	6.29e-07	0.42	0.27	Lymphoma;	chr11:58452887	chr11:58627435~58628528:+
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000230295.1	RP11-458F8.2	-6.18	1.39e-09	6.29e-07	-0.34	-0.27	Diabetic kidney disease;	chr7:65892097	chr7:66880708~66882981:+
LUAD	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	6.18	1.4e-09	6.31e-07	0.3	0.27	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	6.18	1.4e-09	6.31e-07	0.3	0.27	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
LUAD	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-6.18	1.4e-09	6.31e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000211974.3	IGHV2-70	6.18	1.4e-09	6.33e-07	0.33	0.27	Alzheimer's disease (late onset);	chr14:106808070	chr14:106723574~106724093:-
LUAD	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	6.18	1.4e-09	6.33e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
LUAD	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	6.18	1.4e-09	6.33e-07	0.34	0.27	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
LUAD	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	6.18	1.4e-09	6.33e-07	0.34	0.27	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
LUAD	cis	rs74233809	1	rs77420391	ENSG00000213277.3	MARCKSL1P1	6.18	1.4e-09	6.33e-07	0.46	0.27	Birth weight;	chr10:103186066	chr10:103175554~103176094:+
LUAD	cis	rs17301013	0.507	rs12065454	ENSG00000227373.4	RP11-160H22.5	6.18	1.41e-09	6.34e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174492226	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-6.18	1.41e-09	6.35e-07	-0.39	-0.27	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
LUAD	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-6.18	1.41e-09	6.35e-07	-0.43	-0.27	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
LUAD	cis	rs1012068	0.662	rs5753816	ENSG00000236132.1	CTA-440B3.1	-6.18	1.41e-09	6.35e-07	-0.32	-0.27	Chronic hepatitis C infection;	chr22:31916856	chr22:31816379~31817491:-
LUAD	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	6.18	1.41e-09	6.35e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
LUAD	cis	rs9595908	0.686	rs1015364	ENSG00000212293.1	SNORA16	6.18	1.41e-09	6.35e-07	0.29	0.27	Body mass index;	chr13:32784455	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7983889	ENSG00000212293.1	SNORA16	6.18	1.41e-09	6.35e-07	0.29	0.27	Body mass index;	chr13:32785441	chr13:32420390~32420516:-
LUAD	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	6.17	1.41e-09	6.36e-07	0.29	0.27	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
LUAD	cis	rs6921919	0.562	rs13198809	ENSG00000204709.4	LINC01556	6.17	1.41e-09	6.36e-07	0.6	0.27	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28943877~28944537:+
LUAD	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	6.17	1.41e-09	6.36e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
LUAD	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	6.17	1.41e-09	6.37e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
LUAD	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	6.17	1.41e-09	6.37e-07	0.41	0.27	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	6.17	1.41e-09	6.38e-07	0.39	0.27	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	6.17	1.41e-09	6.38e-07	0.39	0.27	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
LUAD	cis	rs853679	0.546	rs35744819	ENSG00000204709.4	LINC01556	6.17	1.41e-09	6.38e-07	0.6	0.27	Depression;	chr6:28350554	chr6:28943877~28944537:+
LUAD	cis	rs6504622	0.875	rs2316330	ENSG00000262879.4	RP11-156P1.3	6.17	1.42e-09	6.38e-07	0.32	0.27	Orofacial clefts;	chr17:46962666	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.905	rs3851785	ENSG00000262879.4	RP11-156P1.3	6.17	1.42e-09	6.38e-07	0.32	0.27	Orofacial clefts;	chr17:46962781	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.875	rs11652318	ENSG00000262879.4	RP11-156P1.3	6.17	1.42e-09	6.38e-07	0.32	0.27	Orofacial clefts;	chr17:46963728	chr17:46984045~47100323:-
LUAD	cis	rs72634501	0.642	rs67452844	ENSG00000228060.1	RP11-69E11.8	-6.17	1.42e-09	6.39e-07	-0.26	-0.27	HDL cholesterol;	chr1:39150610	chr1:39565160~39573203:+
LUAD	cis	rs35934224	0.891	rs5993850	ENSG00000232926.1	AC000078.5	6.17	1.42e-09	6.39e-07	0.29	0.27	Glaucoma (primary open-angle);	chr22:19882180	chr22:19887289~19887970:+
LUAD	cis	rs35934224	0.891	rs8141451	ENSG00000232926.1	AC000078.5	6.17	1.42e-09	6.39e-07	0.29	0.27	Glaucoma (primary open-angle);	chr22:19882513	chr22:19887289~19887970:+
LUAD	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	6.17	1.42e-09	6.4e-07	0.29	0.27	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	6.17	1.42e-09	6.4e-07	0.29	0.27	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	6.17	1.42e-09	6.4e-07	0.29	0.27	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
LUAD	cis	rs8177876	0.915	rs12444974	ENSG00000261838.4	RP11-303E16.6	6.17	1.42e-09	6.41e-07	0.62	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094625	chr16:81069854~81076598:+
LUAD	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-6.17	1.42e-09	6.41e-07	-0.32	-0.27	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
LUAD	cis	rs2179367	0.959	rs9285519	ENSG00000231760.4	RP11-350J20.5	6.17	1.43e-09	6.43e-07	0.34	0.27	Dupuytren's disease;	chr6:149371799	chr6:149796151~149826294:-
LUAD	cis	rs367615	0.918	rs115145487	ENSG00000249476.1	CTD-2587M2.1	6.17	1.43e-09	6.43e-07	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109552445	chr5:109237120~109326369:-
LUAD	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-6.17	1.43e-09	6.43e-07	-0.35	-0.27	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
LUAD	cis	rs10740039	0.81	rs1372709	ENSG00000254271.1	RP11-131N11.4	6.17	1.43e-09	6.44e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60621666	chr10:60734342~60741828:+
LUAD	cis	rs2243480	1	rs11538349	ENSG00000230295.1	RP11-458F8.2	-6.17	1.43e-09	6.44e-07	-0.32	-0.27	Diabetic kidney disease;	chr7:65956884	chr7:66880708~66882981:+
LUAD	cis	rs17301013	0.507	rs1793316	ENSG00000227373.4	RP11-160H22.5	6.17	1.43e-09	6.45e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174825006	chr1:174115300~174160004:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	6.17	1.44e-09	6.47e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
LUAD	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-6.17	1.44e-09	6.47e-07	-0.33	-0.27	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
LUAD	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	6.17	1.44e-09	6.49e-07	0.34	0.27	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
LUAD	cis	rs71403859	0.504	rs12926413	ENSG00000260886.1	TAT-AS1	6.17	1.44e-09	6.49e-07	0.49	0.27	Post bronchodilator FEV1;	chr16:71938422	chr16:71565789~71578187:+
LUAD	cis	rs77204473	0.744	rs116861530	ENSG00000254851.1	RP11-109L13.1	6.17	1.44e-09	6.5e-07	0.69	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117091945	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs74420345	ENSG00000254851.1	RP11-109L13.1	6.17	1.44e-09	6.5e-07	0.69	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117092561	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	6.17	1.44e-09	6.5e-07	0.33	0.27	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
LUAD	cis	rs6504622	0.818	rs9910899	ENSG00000262879.4	RP11-156P1.3	6.17	1.44e-09	6.5e-07	0.32	0.27	Orofacial clefts;	chr17:46956976	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.818	rs9912794	ENSG00000262879.4	RP11-156P1.3	6.17	1.44e-09	6.5e-07	0.32	0.27	Orofacial clefts;	chr17:46957075	chr17:46984045~47100323:-
LUAD	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	6.17	1.44e-09	6.5e-07	0.36	0.27	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000232546.1	RP11-458F8.1	6.17	1.44e-09	6.5e-07	0.36	0.27	Diabetic kidney disease;	chr7:66226660	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7778911	ENSG00000232546.1	RP11-458F8.1	6.17	1.44e-09	6.5e-07	0.36	0.27	Diabetic kidney disease;	chr7:66229519	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1979823	ENSG00000232546.1	RP11-458F8.1	6.17	1.44e-09	6.5e-07	0.36	0.27	Diabetic kidney disease;	chr7:66239626	chr7:66848496~66858136:+
LUAD	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	6.17	1.44e-09	6.5e-07	0.35	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
LUAD	cis	rs7176527	0.796	rs1057946	ENSG00000188388.10	GOLGA6L3	6.17	1.45e-09	6.52e-07	0.39	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85240472~85247170:+
LUAD	cis	rs9928842	0.823	rs6564243	ENSG00000280152.1	RP11-331F4.5	6.17	1.45e-09	6.52e-07	0.31	0.27	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75245994~75250077:-
LUAD	cis	rs755249	0.567	rs4660214	ENSG00000228060.1	RP11-69E11.8	-6.17	1.45e-09	6.52e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39565160~39573203:+
LUAD	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-6.17	1.45e-09	6.52e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
LUAD	cis	rs6687821	0.637	rs493341	ENSG00000267734.1	RP4-604K5.3	6.17	1.45e-09	6.53e-07	0.35	0.27	Yeast infection;	chr1:86845499	chr1:86932199~86934891:-
LUAD	cis	rs4591358	0.648	rs56906982	ENSG00000223466.1	AC064834.2	-6.17	1.45e-09	6.53e-07	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512939	chr2:195533035~195538681:+
LUAD	cis	rs4723738	1	rs4723734	ENSG00000227191.5	TRGC2	-6.17	1.45e-09	6.54e-07	-0.29	-0.27	Treatment response for severe sepsis;	chr7:38192459	chr7:38239580~38368091:-
LUAD	cis	rs7829975	0.633	rs2979181	ENSG00000253981.4	ALG1L13P	6.17	1.45e-09	6.54e-07	0.31	0.27	Mood instability;	chr8:8465578	chr8:8236003~8244667:-
LUAD	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-6.17	1.45e-09	6.54e-07	-0.34	-0.27	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
LUAD	cis	rs9326248	0.603	rs7396061	ENSG00000280143.1	AP000892.6	6.17	1.46e-09	6.55e-07	0.31	0.27	Blood protein levels;	chr11:116880158	chr11:117204967~117210292:+
LUAD	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-6.17	1.46e-09	6.55e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
LUAD	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-6.17	1.46e-09	6.55e-07	-0.37	-0.27	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
LUAD	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	6.17	1.46e-09	6.56e-07	0.28	0.27	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
LUAD	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	6.17	1.46e-09	6.57e-07	0.3	0.27	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
LUAD	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-6.17	1.46e-09	6.57e-07	-0.28	-0.27	Height;	chr11:118703207	chr11:118791254~118793137:+
LUAD	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	6.17	1.46e-09	6.57e-07	0.29	0.27	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
LUAD	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	6.17	1.46e-09	6.57e-07	0.32	0.27	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
LUAD	cis	rs496547	0.686	rs477014	ENSG00000255422.1	AP002954.4	-6.17	1.46e-09	6.58e-07	-0.35	-0.27	Hip minimal joint space width;	chr11:118808277	chr11:118704607~118750263:+
LUAD	cis	rs74233809	1	rs11191587	ENSG00000213277.3	MARCKSL1P1	6.17	1.46e-09	6.58e-07	0.45	0.27	Birth weight;	chr10:103169959	chr10:103175554~103176094:+
LUAD	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	6.17	1.46e-09	6.58e-07	0.34	0.27	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
LUAD	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	6.17	1.46e-09	6.58e-07	0.38	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
LUAD	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-6.17	1.46e-09	6.59e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
LUAD	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-6.17	1.47e-09	6.59e-07	-0.41	-0.27	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
LUAD	cis	rs2115536	0.64	rs934134	ENSG00000278600.1	RP11-81A1.6	-6.17	1.47e-09	6.59e-07	-0.22	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79875876	chr15:79920195~79922455:-
LUAD	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-6.17	1.47e-09	6.6e-07	-0.26	-0.27	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
LUAD	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-6.17	1.47e-09	6.6e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
LUAD	cis	rs1823913	0.637	rs921737	ENSG00000280083.1	RP11-317J9.1	6.17	1.47e-09	6.6e-07	0.32	0.27	Obesity-related traits;	chr2:191286097	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs6736071	ENSG00000280083.1	RP11-317J9.1	6.17	1.47e-09	6.6e-07	0.32	0.27	Obesity-related traits;	chr2:191287265	chr2:191154118~191156070:-
LUAD	cis	rs17818399	0.712	rs13008088	ENSG00000279254.1	RP11-536C12.1	-6.17	1.47e-09	6.61e-07	-0.31	-0.27	Height;	chr2:46554441	chr2:46668870~46670778:+
LUAD	cis	rs2765539	0.515	rs2788183	ENSG00000226172.2	RP4-712E4.1	-6.17	1.47e-09	6.61e-07	-0.34	-0.27	Waist-hip ratio;	chr1:118929322	chr1:119000344~119001392:-
LUAD	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-6.17	1.47e-09	6.62e-07	-0.37	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
LUAD	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	6.17	1.47e-09	6.62e-07	0.28	0.27	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
LUAD	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-6.17	1.47e-09	6.62e-07	-0.31	-0.27	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-6.17	1.47e-09	6.62e-07	-0.31	-0.27	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-6.17	1.47e-09	6.62e-07	-0.31	-0.27	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-6.17	1.47e-09	6.62e-07	-0.31	-0.27	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
LUAD	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-6.17	1.47e-09	6.63e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
LUAD	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	6.17	1.47e-09	6.63e-07	0.3	0.27	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
LUAD	cis	rs12468226	0.938	rs3843338	ENSG00000226261.1	AC064836.3	-6.17	1.47e-09	6.63e-07	-0.44	-0.27	Urate levels;	chr2:202246102	chr2:202336024~202336727:-
LUAD	cis	rs875971	1	rs2220626	ENSG00000222364.1	RNU6-96P	6.17	1.47e-09	6.63e-07	0.3	0.27	Aortic root size;	chr7:66081075	chr7:66395191~66395286:+
LUAD	cis	rs7727544	0.507	rs9791170	ENSG00000233006.5	AC034220.3	6.17	1.48e-09	6.63e-07	0.24	0.27	Blood metabolite levels;	chr5:132233934	chr5:132311285~132369916:-
LUAD	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-6.17	1.48e-09	6.64e-07	-0.35	-0.27	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
LUAD	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-6.17	1.48e-09	6.65e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
LUAD	cis	rs1914816	0.941	rs2469544	ENSG00000196274.5	Metazoa_SRP	6.17	1.48e-09	6.66e-07	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76192606	chr15:76230048~76230390:-
LUAD	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-6.17	1.48e-09	6.67e-07	-0.38	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
LUAD	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-6.17	1.48e-09	6.67e-07	-0.28	-0.27	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
LUAD	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	6.17	1.48e-09	6.67e-07	0.33	0.27	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
LUAD	cis	rs8031584	0.958	rs61997079	ENSG00000260382.1	RP11-540B6.2	6.17	1.49e-09	6.68e-07	0.32	0.27	Huntington's disease progression;	chr15:30946068	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.958	rs11637469	ENSG00000260382.1	RP11-540B6.2	6.17	1.49e-09	6.68e-07	0.32	0.27	Huntington's disease progression;	chr15:30946580	chr15:30882267~30883231:-
LUAD	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-6.17	1.49e-09	6.68e-07	-0.35	-0.27	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
LUAD	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	6.17	1.49e-09	6.69e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
LUAD	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	6.17	1.49e-09	6.7e-07	0.35	0.27	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
LUAD	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	6.17	1.49e-09	6.7e-07	0.35	0.27	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
LUAD	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	6.16	1.49e-09	6.71e-07	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
LUAD	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-6.16	1.5e-09	6.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-6.16	1.5e-09	6.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-6.16	1.5e-09	6.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
LUAD	cis	rs11096990	0.964	rs11096987	ENSG00000249207.1	RP11-360F5.1	6.16	1.5e-09	6.72e-07	0.31	0.27	Cognitive function;	chr4:39257570	chr4:39112677~39126818:-
LUAD	cis	rs17684571	0.938	rs62412526	ENSG00000231441.1	RP11-472M19.2	6.16	1.5e-09	6.72e-07	0.37	0.27	Schizophrenia;	chr6:56689171	chr6:56844002~56864078:+
LUAD	cis	rs35740288	0.77	rs36044792	ENSG00000202081.1	RNU6-1280P	6.16	1.5e-09	6.73e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85603320	chr15:85651522~85651628:-
LUAD	cis	rs1823913	0.614	rs4853463	ENSG00000280083.1	RP11-317J9.1	6.16	1.5e-09	6.73e-07	0.32	0.27	Obesity-related traits;	chr2:191278699	chr2:191154118~191156070:-
LUAD	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-6.16	1.5e-09	6.73e-07	-0.34	-0.27	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
LUAD	cis	rs6504622	0.818	rs9898527	ENSG00000262879.4	RP11-156P1.3	6.16	1.5e-09	6.74e-07	0.32	0.27	Orofacial clefts;	chr17:46958844	chr17:46984045~47100323:-
LUAD	cis	rs17301013	0.556	rs1754353	ENSG00000227373.4	RP11-160H22.5	-6.16	1.5e-09	6.74e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174822229	chr1:174115300~174160004:-
LUAD	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-6.16	1.5e-09	6.76e-07	-0.29	-0.27	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
LUAD	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-6.16	1.51e-09	6.77e-07	-0.34	-0.27	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
LUAD	cis	rs12699921	0.632	rs2723552	ENSG00000279048.1	RP11-511H23.2	-6.16	1.51e-09	6.77e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17821038	chr7:17940503~17942922:+
LUAD	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	6.16	1.51e-09	6.78e-07	0.36	0.27	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
LUAD	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	6.16	1.51e-09	6.79e-07	0.31	0.27	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
LUAD	cis	rs17301013	0.507	rs1793320	ENSG00000227373.4	RP11-160H22.5	6.16	1.51e-09	6.79e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174796308	chr1:174115300~174160004:-
LUAD	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	6.16	1.52e-09	6.81e-07	0.28	0.27	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	6.16	1.52e-09	6.81e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
LUAD	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	6.16	1.52e-09	6.81e-07	0.31	0.27	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
LUAD	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-6.16	1.52e-09	6.81e-07	-0.32	-0.27	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
LUAD	cis	rs2980439	0.807	rs2980438	ENSG00000253981.4	ALG1L13P	6.16	1.52e-09	6.82e-07	0.31	0.27	Neuroticism;	chr8:8237303	chr8:8236003~8244667:-
LUAD	cis	rs12699921	0.572	rs2030725	ENSG00000279048.1	RP11-511H23.2	-6.16	1.52e-09	6.82e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17828708	chr7:17940503~17942922:+
LUAD	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	6.16	1.52e-09	6.82e-07	0.31	0.27	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	6.16	1.52e-09	6.82e-07	0.31	0.27	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
LUAD	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	6.16	1.52e-09	6.83e-07	0.34	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
LUAD	cis	rs1823913	0.637	rs12624271	ENSG00000280083.1	RP11-317J9.1	6.16	1.52e-09	6.84e-07	0.32	0.27	Obesity-related traits;	chr2:191288586	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	6.16	1.52e-09	6.84e-07	0.33	0.27	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.637	rs11686185	ENSG00000280083.1	RP11-317J9.1	6.16	1.53e-09	6.84e-07	0.32	0.27	Obesity-related traits;	chr2:191289282	chr2:191154118~191156070:-
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	6.16	1.53e-09	6.84e-07	0.27	0.27	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
LUAD	cis	rs2243480	1	rs427044	ENSG00000230295.1	RP11-458F8.2	-6.16	1.53e-09	6.85e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66043558	chr7:66880708~66882981:+
LUAD	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
LUAD	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-6.16	1.53e-09	6.87e-07	-0.3	-0.27	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
LUAD	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-6.16	1.53e-09	6.88e-07	-0.34	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
LUAD	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-6.16	1.53e-09	6.88e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
LUAD	cis	rs1318937	0.764	rs58768954	ENSG00000224660.1	SH3BP5-AS1	6.16	1.54e-09	6.88e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15198798	chr3:15254184~15264493:+
LUAD	cis	rs1707322	0.752	rs11211168	ENSG00000234329.1	RP11-767N6.2	6.16	1.54e-09	6.89e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-6.16	1.54e-09	6.89e-07	-0.33	-0.27	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
LUAD	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-6.16	1.54e-09	6.89e-07	-0.35	-0.27	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
LUAD	cis	rs75920871	0.589	rs73008568	ENSG00000254851.1	RP11-109L13.1	-6.16	1.54e-09	6.89e-07	-0.48	-0.27	Subjective well-being;	chr11:117194291	chr11:117135528~117138582:+
LUAD	cis	rs1318937	1	rs3773471	ENSG00000224660.1	SH3BP5-AS1	-6.16	1.54e-09	6.9e-07	-0.2	-0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15261540	chr3:15254184~15264493:+
LUAD	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	6.16	1.54e-09	6.9e-07	0.31	0.27	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	6.16	1.54e-09	6.9e-07	0.31	0.27	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	6.16	1.54e-09	6.9e-07	0.31	0.27	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	6.16	1.54e-09	6.9e-07	0.31	0.27	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
LUAD	cis	rs7396835	0.5	rs5092	ENSG00000280143.1	AP000892.6	6.16	1.54e-09	6.91e-07	0.38	0.27	Quantitative traits;	chr11:116822748	chr11:117204967~117210292:+
LUAD	cis	rs7017914	0.905	rs1353058	ENSG00000223220.1	Y_RNA	6.16	1.54e-09	6.92e-07	0.3	0.27	Bone mineral density;	chr8:71009783	chr8:70780914~70781008:-
LUAD	cis	rs9326248	0.52	rs2735183	ENSG00000280143.1	AP000892.6	6.16	1.54e-09	6.92e-07	0.31	0.27	Blood protein levels;	chr11:117144479	chr11:117204967~117210292:+
LUAD	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	6.16	1.55e-09	6.94e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
LUAD	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-6.16	1.55e-09	6.94e-07	-0.29	-0.27	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
LUAD	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	6.16	1.55e-09	6.94e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
LUAD	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
LUAD	cis	rs75422866	0.51	rs73105845	ENSG00000280054.1	RP1-197B17.7	6.16	1.55e-09	6.95e-07	0.63	0.27	Pneumonia;	chr12:47741824	chr12:47728151~47730598:-
LUAD	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	6.16	1.55e-09	6.95e-07	0.34	0.27	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
LUAD	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-6.16	1.55e-09	6.95e-07	-0.29	-0.27	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
LUAD	cis	rs4835473	0.932	rs9997931	ENSG00000251600.4	RP11-673E1.1	6.16	1.55e-09	6.96e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143904601	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs2036880	ENSG00000251600.4	RP11-673E1.1	6.16	1.55e-09	6.96e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143907834	chr4:143912331~143982454:+
LUAD	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
LUAD	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	6.16	1.56e-09	6.97e-07	0.24	0.27	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
LUAD	cis	rs11157436	0.918	rs1983519	ENSG00000211812.1	TRAV26-2	-6.16	1.56e-09	6.98e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22202583~22203368:+
LUAD	cis	rs111580313	0.685	rs79088793	ENSG00000270020.1	RP11-463O9.9	6.16	1.56e-09	6.98e-07	0.65	0.27	Systemic juvenile idiopathic arthritis;	chr16:86573421	chr16:86520383~86523897:-
LUAD	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	6.16	1.56e-09	6.98e-07	0.4	0.27	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
LUAD	cis	rs4273100	0.834	rs59415593	ENSG00000279825.1	CTC-457L16.1	6.16	1.56e-09	6.99e-07	0.36	0.27	Schizophrenia;	chr17:19319911	chr17:19030857~19033529:+
LUAD	cis	rs12699921	0.632	rs1524777	ENSG00000279048.1	RP11-511H23.2	-6.16	1.56e-09	6.99e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17799986	chr7:17940503~17942922:+
LUAD	cis	rs10214930	0.651	rs42085	ENSG00000235574.1	AC073150.6	6.16	1.56e-09	7e-07	0.34	0.27	Hypospadias;	chr7:27658320	chr7:27491682~27492765:-
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-6.16	1.56e-09	7e-07	-0.52	-0.27	Gout;	chr7:66732812	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs73142166	ENSG00000232546.1	RP11-458F8.1	-6.16	1.56e-09	7e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65910845	chr7:66848496~66858136:+
LUAD	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	6.16	1.57e-09	7.01e-07	0.34	0.27	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
LUAD	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	6.16	1.57e-09	7.01e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	6.16	1.57e-09	7.01e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-6.16	1.57e-09	7.02e-07	-0.34	-0.27	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
LUAD	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	6.16	1.57e-09	7.02e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	6.16	1.57e-09	7.02e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	6.16	1.57e-09	7.02e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
LUAD	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-6.16	1.57e-09	7.03e-07	-0.32	-0.27	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
LUAD	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-6.16	1.57e-09	7.03e-07	-0.32	-0.27	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
LUAD	cis	rs1816752	1	rs1816752	ENSG00000273628.1	RP11-756A22.7	6.16	1.57e-09	7.04e-07	0.32	0.27	Obesity-related traits;	chr13:24406811	chr13:24933006~24936796:+
LUAD	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-6.16	1.57e-09	7.04e-07	-0.3	-0.27	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
LUAD	cis	rs12468226	0.938	rs79117531	ENSG00000272966.1	RP11-686O6.1	6.16	1.57e-09	7.04e-07	0.47	0.27	Urate levels;	chr2:202307690	chr2:202336739~202337200:+
LUAD	cis	rs1499614	1	rs1267818	ENSG00000232546.1	RP11-458F8.1	-6.16	1.57e-09	7.04e-07	-0.36	-0.27	Gout;	chr7:66642037	chr7:66848496~66858136:+
LUAD	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	6.16	1.58e-09	7.05e-07	0.3	0.27	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	6.16	1.58e-09	7.05e-07	0.3	0.27	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	6.16	1.58e-09	7.05e-07	0.3	0.27	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
LUAD	cis	rs9910055	0.762	rs1135215	ENSG00000267080.4	ASB16-AS1	-6.16	1.58e-09	7.06e-07	-0.25	-0.27	Total body bone mineral density;	chr17:44176151	chr17:44175973~44186717:-
LUAD	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-6.16	1.58e-09	7.06e-07	-0.32	-0.27	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
LUAD	cis	rs853679	0.598	rs9380054	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Depression;	chr6:28099759	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.547	rs2116981	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Parkinson's disease;	chr6:28100173	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368552	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Depression;	chr6:28100648	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.542	rs34131763	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Depression;	chr6:28107222	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs35193936	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Depression;	chr6:28108492	chr6:28943877~28944537:+
LUAD	cis	rs17301013	0.507	rs12085652	ENSG00000227373.4	RP11-160H22.5	6.16	1.58e-09	7.07e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174588864	chr1:174115300~174160004:-
LUAD	cis	rs12699921	0.632	rs2691621	ENSG00000279048.1	RP11-511H23.2	-6.16	1.58e-09	7.07e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17782826	chr7:17940503~17942922:+
LUAD	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	6.16	1.58e-09	7.08e-07	0.28	0.27	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
LUAD	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-6.16	1.58e-09	7.08e-07	-0.39	-0.27	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs316330	ENSG00000232546.1	RP11-458F8.1	-6.15	1.59e-09	7.1e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66140385	chr7:66848496~66858136:+
LUAD	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-6.15	1.59e-09	7.1e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-6.15	1.59e-09	7.1e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-6.15	1.59e-09	7.1e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-6.15	1.59e-09	7.1e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
LUAD	cis	rs9532669	0.89	rs9532627	ENSG00000168852.11	TPTE2P5	6.15	1.59e-09	7.11e-07	0.26	0.27	Cervical cancer;	chr13:40874811	chr13:40822296~40921749:-
LUAD	cis	rs9928842	0.77	rs4888364	ENSG00000280152.1	RP11-331F4.5	6.15	1.59e-09	7.11e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75245612	chr16:75245994~75250077:-
LUAD	cis	rs7246657	0.525	rs1667357	ENSG00000276846.1	CTD-3220F14.3	6.15	1.59e-09	7.11e-07	0.4	0.27	Coronary artery calcification;	chr19:36993450	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.525	rs1667359	ENSG00000276846.1	CTD-3220F14.3	6.15	1.59e-09	7.11e-07	0.4	0.27	Coronary artery calcification;	chr19:36995270	chr19:37314868~37315620:-
LUAD	cis	rs12699921	0.599	rs2723554	ENSG00000279048.1	RP11-511H23.2	-6.15	1.59e-09	7.12e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17802029	chr7:17940503~17942922:+
LUAD	cis	rs4713118	0.869	rs6456802	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27730576	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9393851	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27731802	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9461400	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27732780	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9295742	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27735053	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9461401	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27735512	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
LUAD	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	6.15	1.59e-09	7.12e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
LUAD	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	6.15	1.59e-09	7.13e-07	0.37	0.27	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
LUAD	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-6.15	1.6e-09	7.13e-07	-0.28	-0.27	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
LUAD	cis	rs12468226	1	rs7597469	ENSG00000226261.1	AC064836.3	6.15	1.6e-09	7.13e-07	0.45	0.27	Urate levels;	chr2:202329547	chr2:202336024~202336727:-
LUAD	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-6.15	1.6e-09	7.13e-07	-0.36	-0.27	Migraine;	chr4:56853383	chr4:56960927~56961373:-
LUAD	cis	rs9467773	0.511	rs11755443	ENSG00000241549.7	GUSBP2	6.15	1.6e-09	7.14e-07	0.29	0.27	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26871484~26956554:-
LUAD	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-6.15	1.6e-09	7.14e-07	-0.28	-0.27	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
LUAD	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	6.15	1.6e-09	7.14e-07	0.31	0.27	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
LUAD	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	6.15	1.6e-09	7.14e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
LUAD	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	6.15	1.6e-09	7.14e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
LUAD	cis	rs516805	0.748	rs572261	ENSG00000279453.1	RP3-425C14.4	-6.15	1.6e-09	7.15e-07	-0.37	-0.27	Lymphocyte counts;	chr6:122408877	chr6:122436789~122439223:-
LUAD	cis	rs2179367	0.568	rs9498358	ENSG00000231760.4	RP11-350J20.5	6.15	1.6e-09	7.16e-07	0.42	0.27	Dupuytren's disease;	chr6:149458529	chr6:149796151~149826294:-
LUAD	cis	rs853679	0.517	rs1947862	ENSG00000204709.4	LINC01556	6.15	1.6e-09	7.16e-07	0.38	0.27	Depression;	chr6:28137418	chr6:28943877~28944537:+
LUAD	cis	rs11098499	0.532	rs12512646	ENSG00000248280.1	RP11-33B1.2	6.15	1.6e-09	7.16e-07	0.34	0.27	Corneal astigmatism;	chr4:119664578	chr4:119440561~119450157:-
LUAD	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	6.15	1.6e-09	7.16e-07	0.34	0.27	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
LUAD	cis	rs7674212	0.531	rs2866416	ENSG00000251288.2	RP11-10L12.2	-6.15	1.6e-09	7.16e-07	-0.35	-0.27	Type 2 diabetes;	chr4:102959554	chr4:102751401~102752641:+
LUAD	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	6.15	1.61e-09	7.18e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
LUAD	cis	rs55665837	0.524	rs61884009	ENSG00000251991.1	RNU7-49P	6.15	1.61e-09	7.19e-07	0.31	0.27	Vitamin D levels;	chr11:14404916	chr11:14478892~14478953:+
LUAD	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	6.15	1.61e-09	7.2e-07	0.32	0.27	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
LUAD	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	6.15	1.61e-09	7.21e-07	0.25	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
LUAD	cis	rs7618501	0.633	rs9866695	ENSG00000234667.1	ACTBP13	6.15	1.61e-09	7.21e-07	0.3	0.27	Intelligence (multi-trait analysis);	chr3:50032019	chr3:49873347~49877980:-
LUAD	cis	rs74233809	1	rs11191593	ENSG00000213277.3	MARCKSL1P1	6.15	1.62e-09	7.21e-07	0.45	0.27	Birth weight;	chr10:103179458	chr10:103175554~103176094:+
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000206090.4	AP000350.7	6.15	1.62e-09	7.21e-07	0.31	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23939998~23942798:+
LUAD	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	6.15	1.62e-09	7.22e-07	0.34	0.27	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
LUAD	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	6.15	1.62e-09	7.23e-07	0.34	0.27	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
LUAD	cis	rs7017914	0.905	rs12542300	ENSG00000223220.1	Y_RNA	-6.15	1.62e-09	7.23e-07	-0.3	-0.27	Bone mineral density;	chr8:71039160	chr8:70780914~70781008:-
LUAD	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	6.15	1.62e-09	7.23e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
LUAD	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-6.15	1.62e-09	7.23e-07	-0.34	-0.27	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
LUAD	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	6.15	1.62e-09	7.23e-07	0.33	0.27	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
LUAD	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	6.15	1.62e-09	7.23e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-6.15	1.62e-09	7.24e-07	-0.3	-0.27	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
LUAD	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	6.15	1.62e-09	7.24e-07	0.34	0.27	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
LUAD	cis	rs4713118	0.869	rs6930992	ENSG00000219392.1	RP1-265C24.5	-6.15	1.62e-09	7.24e-07	-0.36	-0.27	Parkinson's disease;	chr6:27744341	chr6:28115628~28116551:+
LUAD	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-6.15	1.62e-09	7.24e-07	-0.32	-0.27	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
LUAD	cis	rs1707322	0.752	rs7541962	ENSG00000234329.1	RP11-767N6.2	6.15	1.63e-09	7.26e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	6.15	1.63e-09	7.26e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
LUAD	cis	rs1499614	1	rs2659913	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66692349	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2659911	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66693433	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2707838	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66694214	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs60326618	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66701371	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2707830	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66702658	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2707828	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66706390	chr7:66880708~66882981:+
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66710076	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2659903	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66715944	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2141924	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66721259	chr7:66880708~66882981:+
LUAD	cis	rs853679	0.607	rs35001169	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28219854	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs35656932	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28223510	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34243448	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28225324	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13204012	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28233753	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13205211	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28235278	chr6:28943877~28944537:+
LUAD	cis	rs10214930	0.697	rs12665991	ENSG00000235574.1	AC073150.6	-6.15	1.63e-09	7.28e-07	-0.34	-0.27	Hypospadias;	chr7:27620152	chr7:27491682~27492765:-
LUAD	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	6.15	1.63e-09	7.28e-07	0.41	0.27	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
LUAD	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	6.15	1.63e-09	7.29e-07	0.32	0.27	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
LUAD	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-6.15	1.63e-09	7.29e-07	-0.41	-0.27	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
LUAD	cis	rs17684571	0.872	rs34803237	ENSG00000231441.1	RP11-472M19.2	6.15	1.63e-09	7.29e-07	0.4	0.27	Schizophrenia;	chr6:56759620	chr6:56844002~56864078:+
LUAD	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-6.15	1.64e-09	7.32e-07	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
LUAD	cis	rs35740288	0.77	rs745191	ENSG00000202081.1	RNU6-1280P	6.15	1.64e-09	7.32e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85579939	chr15:85651522~85651628:-
LUAD	cis	rs71403859	0.504	rs35203704	ENSG00000260886.1	TAT-AS1	6.15	1.64e-09	7.32e-07	0.49	0.27	Post bronchodilator FEV1;	chr16:71925758	chr16:71565789~71578187:+
LUAD	cis	rs1823913	0.599	rs55685315	ENSG00000280083.1	RP11-317J9.1	-6.15	1.64e-09	7.33e-07	-0.32	-0.27	Obesity-related traits;	chr2:191306451	chr2:191154118~191156070:-
LUAD	cis	rs17684571	0.872	rs34455199	ENSG00000231441.1	RP11-472M19.2	6.15	1.64e-09	7.33e-07	0.4	0.27	Schizophrenia;	chr6:56759780	chr6:56844002~56864078:+
LUAD	cis	rs1499614	1	rs1638731	ENSG00000230295.1	RP11-458F8.2	-6.15	1.65e-09	7.34e-07	-0.33	-0.27	Gout;	chr7:66679692	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs1882655	ENSG00000230295.1	RP11-458F8.2	6.15	1.65e-09	7.34e-07	0.33	0.27	Gout;	chr7:66682070	chr7:66880708~66882981:+
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000230295.1	RP11-458F8.2	6.15	1.65e-09	7.34e-07	0.33	0.27	Gout;	chr7:66682162	chr7:66880708~66882981:+
LUAD	cis	rs1707322	0.686	rs2152078	ENSG00000234329.1	RP11-767N6.2	-6.15	1.65e-09	7.35e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs2991979	ENSG00000234329.1	RP11-767N6.2	-6.15	1.65e-09	7.35e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45651039~45651826:-
LUAD	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	6.15	1.65e-09	7.35e-07	0.27	0.27	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
LUAD	cis	rs2115536	1	rs11072871	ENSG00000278600.1	RP11-81A1.6	-6.15	1.65e-09	7.36e-07	-0.22	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79905589	chr15:79920195~79922455:-
LUAD	cis	rs10740039	0.883	rs7920170	ENSG00000254271.1	RP11-131N11.4	6.15	1.65e-09	7.37e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647766	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10761538	ENSG00000254271.1	RP11-131N11.4	6.15	1.65e-09	7.37e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649463	chr10:60734342~60741828:+
LUAD	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-6.15	1.66e-09	7.38e-07	-0.36	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
LUAD	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-6.15	1.66e-09	7.38e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
LUAD	cis	rs10740039	0.516	rs7072678	ENSG00000254271.1	RP11-131N11.4	-6.15	1.66e-09	7.38e-07	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60585011	chr10:60734342~60741828:+
LUAD	cis	rs10214930	0.767	rs42087	ENSG00000235574.1	AC073150.6	6.15	1.66e-09	7.4e-07	0.36	0.27	Hypospadias;	chr7:27660863	chr7:27491682~27492765:-
LUAD	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-6.15	1.66e-09	7.4e-07	-0.29	-0.27	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-6.15	1.66e-09	7.4e-07	-0.29	-0.27	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
LUAD	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	6.15	1.66e-09	7.4e-07	0.41	0.27	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
LUAD	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-6.15	1.66e-09	7.4e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-6.15	1.66e-09	7.4e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
LUAD	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	6.15	1.66e-09	7.4e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
LUAD	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	6.15	1.66e-09	7.41e-07	0.37	0.27	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
LUAD	cis	rs11157436	0.958	rs3811277	ENSG00000211812.1	TRAV26-2	-6.15	1.66e-09	7.42e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22202583~22203368:+
LUAD	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	6.15	1.67e-09	7.42e-07	0.31	0.27	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
LUAD	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	6.15	1.67e-09	7.42e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
LUAD	cis	rs853679	0.607	rs35749575	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.42e-07	0.6	0.27	Depression;	chr6:28147040	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs72846780	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.42e-07	0.6	0.27	Depression;	chr6:28151277	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380056	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28136698	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380057	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28136856	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs6941992	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28138363	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.516	rs4713142	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Parkinson's disease;	chr6:28138569	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4713143	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28138981	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4713144	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28139012	chr6:28943877~28944537:+
LUAD	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-6.15	1.67e-09	7.45e-07	-0.32	-0.27	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
LUAD	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-6.15	1.67e-09	7.45e-07	-0.32	-0.27	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
LUAD	cis	rs35740288	0.77	rs17570529	ENSG00000202081.1	RNU6-1280P	6.15	1.68e-09	7.47e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85582376	chr15:85651522~85651628:-
LUAD	cis	rs2765539	0.59	rs912960	ENSG00000226172.2	RP4-712E4.1	-6.15	1.68e-09	7.47e-07	-0.34	-0.27	Waist-hip ratio;	chr1:118935879	chr1:119000344~119001392:-
LUAD	cis	rs7017914	0.87	rs2639953	ENSG00000223220.1	Y_RNA	6.15	1.68e-09	7.48e-07	0.3	0.27	Bone mineral density;	chr8:71013425	chr8:70780914~70781008:-
LUAD	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-6.15	1.68e-09	7.48e-07	-0.43	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
LUAD	cis	rs11096990	0.892	rs11729098	ENSG00000249207.1	RP11-360F5.1	6.14	1.68e-09	7.48e-07	0.31	0.27	Cognitive function;	chr4:39232357	chr4:39112677~39126818:-
LUAD	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-6.14	1.68e-09	7.48e-07	-0.33	-0.27	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-6.14	1.69e-09	7.52e-07	-0.31	-0.27	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-6.14	1.69e-09	7.52e-07	-0.31	-0.27	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
LUAD	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	6.14	1.69e-09	7.52e-07	0.26	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
LUAD	cis	rs9595908	0.709	rs55797910	ENSG00000212293.1	SNORA16	6.14	1.69e-09	7.52e-07	0.29	0.27	Body mass index;	chr13:32787154	chr13:32420390~32420516:-
LUAD	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-6.14	1.69e-09	7.53e-07	-0.3	-0.27	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
LUAD	cis	rs17818399	0.89	rs34544165	ENSG00000279254.1	RP11-536C12.1	-6.14	1.69e-09	7.54e-07	-0.3	-0.27	Height;	chr2:46609767	chr2:46668870~46670778:+
LUAD	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	6.14	1.69e-09	7.54e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	6.14	1.69e-09	7.54e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
LUAD	cis	rs516805	0.961	rs573709	ENSG00000279453.1	RP3-425C14.4	6.14	1.69e-09	7.54e-07	0.31	0.27	Lymphocyte counts;	chr6:122457673	chr6:122436789~122439223:-
LUAD	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	6.14	1.7e-09	7.54e-07	0.43	0.27	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
LUAD	cis	rs2034650	0.563	rs12914710	ENSG00000223313.1	RNU6-516P	6.14	1.7e-09	7.54e-07	0.34	0.27	Interstitial lung disease;	chr15:40421650	chr15:40529570~40529673:+
LUAD	cis	rs2303759	0.918	rs9749416	ENSG00000268686.1	AC010524.2	-6.14	1.7e-09	7.56e-07	-0.38	-0.27	Multiple sclerosis;	chr19:49381748	chr19:49368705~49388081:-
LUAD	cis	rs35740288	0.77	rs62023931	ENSG00000202081.1	RNU6-1280P	6.14	1.7e-09	7.56e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85589521	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs1382534	ENSG00000202081.1	RNU6-1280P	6.14	1.7e-09	7.56e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85598939	chr15:85651522~85651628:-
LUAD	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-6.14	1.7e-09	7.56e-07	-0.35	-0.27	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	6.14	1.7e-09	7.56e-07	0.51	0.27	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	6.14	1.7e-09	7.56e-07	0.34	0.27	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000211974.3	IGHV2-70	6.14	1.7e-09	7.56e-07	0.28	0.27	Kawasaki disease;	chr14:106779068	chr14:106723574~106724093:-
LUAD	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	6.14	1.7e-09	7.56e-07	0.39	0.27	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
LUAD	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-6.14	1.7e-09	7.57e-07	-0.36	-0.27	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
LUAD	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-6.14	1.7e-09	7.58e-07	-0.36	-0.27	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
LUAD	cis	rs948562	0.744	rs11229485	ENSG00000280010.1	AP001350.4	6.14	1.7e-09	7.58e-07	0.41	0.27	Lymphoma;	chr11:58465381	chr11:58627435~58628528:+
LUAD	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-6.14	1.71e-09	7.59e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs10807702	ENSG00000230295.1	RP11-458F8.2	-6.14	1.71e-09	7.6e-07	-0.32	-0.27	Diabetic kidney disease;	chr7:66302856	chr7:66880708~66882981:+
LUAD	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-6.14	1.71e-09	7.61e-07	-0.45	-0.27	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
LUAD	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	6.14	1.71e-09	7.61e-07	0.37	0.27	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
LUAD	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-6.14	1.71e-09	7.61e-07	-0.39	-0.27	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
LUAD	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-6.14	1.71e-09	7.62e-07	-0.3	-0.27	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
LUAD	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	6.14	1.72e-09	7.63e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
LUAD	cis	rs227932	0.51	rs10950957	ENSG00000234286.1	AC006026.13	6.14	1.72e-09	7.63e-07	0.39	0.27	Schizophrenia;	chr7:23723661	chr7:23680195~23680786:-
LUAD	cis	rs17301013	0.507	rs1754354	ENSG00000227373.4	RP11-160H22.5	-6.14	1.72e-09	7.64e-07	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174817196	chr1:174115300~174160004:-
LUAD	cis	rs367615	0.68	rs31595	ENSG00000249476.1	CTD-2587M2.1	6.14	1.72e-09	7.64e-07	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109643617	chr5:109237120~109326369:-
LUAD	cis	rs853679	0.607	rs68188794	ENSG00000204709.4	LINC01556	6.14	1.72e-09	7.65e-07	0.62	0.27	Depression;	chr6:28112999	chr6:28943877~28944537:+
LUAD	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	6.14	1.72e-09	7.65e-07	0.28	0.27	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
LUAD	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	6.14	1.72e-09	7.65e-07	0.32	0.27	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
LUAD	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-6.14	1.72e-09	7.65e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-6.14	1.72e-09	7.65e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-6.14	1.72e-09	7.65e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	6.14	1.73e-09	7.67e-07	0.33	0.27	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
LUAD	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-6.14	1.73e-09	7.68e-07	-0.36	-0.27	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
LUAD	cis	rs7176527	0.8	rs56747535	ENSG00000188388.10	GOLGA6L3	6.14	1.73e-09	7.69e-07	0.39	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85240472~85247170:+
LUAD	cis	rs74233809	1	rs732998	ENSG00000213277.3	MARCKSL1P1	-6.14	1.73e-09	7.7e-07	-0.43	-0.27	Birth weight;	chr10:103138144	chr10:103175554~103176094:+
LUAD	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-6.14	1.73e-09	7.7e-07	-0.29	-0.27	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-6.14	1.73e-09	7.7e-07	-0.29	-0.27	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-6.14	1.73e-09	7.7e-07	-0.29	-0.27	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
LUAD	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	6.14	1.73e-09	7.7e-07	0.26	0.27	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
LUAD	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	6.14	1.73e-09	7.7e-07	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
LUAD	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	6.14	1.73e-09	7.7e-07	0.33	0.27	Depression;	chr6:28399886	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	6.14	1.73e-09	7.7e-07	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
LUAD	cis	rs7044106	0.762	rs7357638	ENSG00000238181.2	AHCYP2	-6.14	1.74e-09	7.71e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.718	rs1960421	ENSG00000238181.2	AHCYP2	-6.14	1.74e-09	7.71e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120720673~120721972:+
LUAD	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	6.14	1.74e-09	7.72e-07	0.31	0.27	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	6.14	1.74e-09	7.72e-07	0.31	0.27	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
LUAD	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-6.14	1.74e-09	7.72e-07	-0.35	-0.27	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
LUAD	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	6.14	1.74e-09	7.72e-07	0.27	0.27	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
LUAD	cis	rs12699921	0.632	rs2691581	ENSG00000279048.1	RP11-511H23.2	-6.14	1.74e-09	7.72e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17789568	chr7:17940503~17942922:+
LUAD	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	6.14	1.74e-09	7.72e-07	0.35	0.27	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
LUAD	cis	rs948562	0.793	rs79869893	ENSG00000280010.1	AP001350.4	6.14	1.74e-09	7.73e-07	0.46	0.27	Lymphoma;	chr11:58514409	chr11:58627435~58628528:+
LUAD	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	6.14	1.74e-09	7.73e-07	0.39	0.27	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
LUAD	cis	rs4141404	0.923	rs2413035	ENSG00000236132.1	CTA-440B3.1	6.14	1.74e-09	7.73e-07	0.34	0.27	Paclitaxel-induced neuropathy;	chr22:31204474	chr22:31816379~31817491:-
LUAD	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-6.14	1.74e-09	7.74e-07	-0.28	-0.27	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
LUAD	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	6.14	1.74e-09	7.74e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
LUAD	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	6.14	1.74e-09	7.75e-07	0.64	0.27	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	6.14	1.74e-09	7.75e-07	0.64	0.27	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	6.14	1.74e-09	7.75e-07	0.64	0.27	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
LUAD	cis	rs2243480	1	rs34136756	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65916269	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65917585	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65918212	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65920739	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65922114	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65922691	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65923503	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65924743	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65925107	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65925372	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65925938	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65926730	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65928032	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65929575	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65929781	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65929865	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65938222	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65940221	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65943626	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65944004	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65944182	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000230295.1	RP11-458F8.2	6.14	1.75e-09	7.76e-07	0.33	0.27	Diabetic kidney disease;	chr7:65928187	chr7:66880708~66882981:+
LUAD	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	6.14	1.75e-09	7.76e-07	0.37	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
LUAD	cis	rs7017914	0.905	rs3110244	ENSG00000223220.1	Y_RNA	-6.14	1.75e-09	7.76e-07	-0.3	-0.27	Bone mineral density;	chr8:71020962	chr8:70780914~70781008:-
LUAD	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	6.14	1.75e-09	7.76e-07	0.32	0.27	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
LUAD	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-6.14	1.75e-09	7.77e-07	-0.34	-0.27	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
LUAD	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	6.14	1.75e-09	7.77e-07	0.3	0.27	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
LUAD	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-6.14	1.75e-09	7.77e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
LUAD	cis	rs1707322	0.627	rs3014213	ENSG00000234329.1	RP11-767N6.2	-6.14	1.75e-09	7.78e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45651039~45651826:-
LUAD	cis	rs2179367	0.959	rs4895788	ENSG00000231760.4	RP11-350J20.5	6.14	1.75e-09	7.78e-07	0.33	0.27	Dupuytren's disease;	chr6:149426955	chr6:149796151~149826294:-
LUAD	cis	rs12699921	0.568	rs2691605	ENSG00000279048.1	RP11-511H23.2	-6.14	1.76e-09	7.8e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17837825	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	6.14	1.76e-09	7.81e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
LUAD	cis	rs4713118	0.869	rs9468214	ENSG00000219392.1	RP1-265C24.5	-6.14	1.76e-09	7.81e-07	-0.36	-0.27	Parkinson's disease;	chr6:27745520	chr6:28115628~28116551:+
LUAD	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	6.14	1.76e-09	7.82e-07	0.34	0.27	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
LUAD	cis	rs12439619	0.508	rs11856561	ENSG00000276710.3	CSPG4P8	-6.14	1.76e-09	7.82e-07	-0.25	-0.27	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82459472~82477258:+
LUAD	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-6.14	1.77e-09	7.83e-07	-0.33	-0.27	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
LUAD	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	6.14	1.77e-09	7.83e-07	0.28	0.27	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
LUAD	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-6.14	1.77e-09	7.84e-07	-0.33	-0.27	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
LUAD	cis	rs12699921	0.558	rs2691559	ENSG00000279048.1	RP11-511H23.2	-6.14	1.77e-09	7.84e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17905636	chr7:17940503~17942922:+
LUAD	cis	rs7182621	0.846	rs12915935	ENSG00000182397.13	DNM1P46	6.14	1.77e-09	7.84e-07	0.32	0.27	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99790156~99806927:-
LUAD	cis	rs1823913	0.637	rs897197	ENSG00000280083.1	RP11-317J9.1	6.14	1.77e-09	7.86e-07	0.32	0.27	Obesity-related traits;	chr2:191281456	chr2:191154118~191156070:-
LUAD	cis	rs3738443	0.868	rs7546908	ENSG00000259865.1	RP11-488L18.10	-6.14	1.77e-09	7.87e-07	-0.27	-0.27	Alcohol dependence;	chr1:247200531	chr1:247187281~247188526:-
LUAD	cis	rs10214930	0.671	rs6959495	ENSG00000235574.1	AC073150.6	-6.14	1.78e-09	7.87e-07	-0.34	-0.27	Hypospadias;	chr7:27652673	chr7:27491682~27492765:-
LUAD	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	6.14	1.78e-09	7.88e-07	0.33	0.27	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	6.14	1.78e-09	7.88e-07	0.33	0.27	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
LUAD	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	6.14	1.78e-09	7.88e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	6.14	1.78e-09	7.88e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
LUAD	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	6.14	1.78e-09	7.88e-07	0.36	0.27	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
LUAD	cis	rs2179367	0.959	rs9377212	ENSG00000231760.4	RP11-350J20.5	6.14	1.78e-09	7.88e-07	0.33	0.27	Dupuytren's disease;	chr6:149383765	chr6:149796151~149826294:-
LUAD	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	6.13	1.78e-09	7.89e-07	0.32	0.27	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
LUAD	cis	rs155076	1	rs261369	ENSG00000233325.3	MIPEPP3	6.13	1.79e-09	7.92e-07	0.43	0.27	White matter hyperintensity burden;	chr13:21294281	chr13:21298139~21306373:+
LUAD	cis	rs113835537	0.569	rs17496586	ENSG00000255517.5	CTD-3074O7.5	-6.13	1.79e-09	7.92e-07	-0.34	-0.27	Airway imaging phenotypes;	chr11:66548041	chr11:66473490~66480233:-
LUAD	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	6.13	1.79e-09	7.93e-07	0.32	0.27	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
LUAD	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	6.13	1.79e-09	7.94e-07	0.31	0.27	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
LUAD	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	6.13	1.79e-09	7.95e-07	0.36	0.27	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
LUAD	cis	rs10214930	0.957	rs7786569	ENSG00000235574.1	AC073150.6	6.13	1.8e-09	7.96e-07	0.39	0.27	Hypospadias;	chr7:27682832	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.957	rs42113	ENSG00000235574.1	AC073150.6	6.13	1.8e-09	7.96e-07	0.39	0.27	Hypospadias;	chr7:27682977	chr7:27491682~27492765:-
LUAD	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	6.13	1.8e-09	7.96e-07	0.31	0.27	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
LUAD	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-6.13	1.8e-09	7.97e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
LUAD	cis	rs9595908	0.869	rs55880225	ENSG00000212293.1	SNORA16	6.13	1.8e-09	7.98e-07	0.29	0.27	Body mass index;	chr13:32616733	chr13:32420390~32420516:-
LUAD	cis	rs853679	0.55	rs1150689	ENSG00000204709.4	LINC01556	6.13	1.8e-09	7.98e-07	0.37	0.27	Depression;	chr6:28197321	chr6:28943877~28944537:+
LUAD	cis	rs6504622	0.791	rs61671555	ENSG00000262879.4	RP11-156P1.3	6.13	1.8e-09	7.99e-07	0.32	0.27	Orofacial clefts;	chr17:46960491	chr17:46984045~47100323:-
LUAD	cis	rs2115630	0.645	rs1107179	ENSG00000229212.6	RP11-561C5.4	-6.13	1.8e-09	7.99e-07	-0.32	-0.27	P wave terminal force;	chr15:84655131	chr15:85205440~85234795:-
LUAD	cis	rs10214930	0.697	rs12670771	ENSG00000235574.1	AC073150.6	-6.13	1.81e-09	8.01e-07	-0.34	-0.27	Hypospadias;	chr7:27616971	chr7:27491682~27492765:-
LUAD	cis	rs853679	0.546	rs13213986	ENSG00000204709.4	LINC01556	6.13	1.81e-09	8.01e-07	0.61	0.27	Depression;	chr6:28390232	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	6.13	1.81e-09	8.02e-07	0.33	0.27	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
LUAD	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	6.13	1.81e-09	8.02e-07	0.3	0.27	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
LUAD	cis	rs12468226	0.873	rs79071680	ENSG00000226261.1	AC064836.3	6.13	1.81e-09	8.02e-07	0.46	0.27	Urate levels;	chr2:202191520	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.873	rs79860867	ENSG00000226261.1	AC064836.3	6.13	1.81e-09	8.02e-07	0.46	0.27	Urate levels;	chr2:202192397	chr2:202336024~202336727:-
LUAD	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-6.13	1.81e-09	8.02e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-6.13	1.81e-09	8.03e-07	-0.39	-0.27	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs73150014	ENSG00000230295.1	RP11-458F8.2	-6.13	1.82e-09	8.04e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65985932	chr7:66880708~66882981:+
LUAD	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	6.13	1.82e-09	8.05e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	6.13	1.82e-09	8.05e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
LUAD	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-6.13	1.82e-09	8.05e-07	-0.38	-0.27	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
LUAD	cis	rs3762637	0.769	rs13317855	ENSG00000272758.4	RP11-299J3.8	-6.13	1.82e-09	8.05e-07	-0.48	-0.27	LDL cholesterol levels;	chr3:122385387	chr3:122416207~122443180:+
LUAD	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-6.13	1.82e-09	8.05e-07	-0.29	-0.27	Height;	chr11:118746590	chr11:118791254~118793137:+
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000232546.1	RP11-458F8.1	-6.13	1.82e-09	8.05e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65970805	chr7:66848496~66858136:+
LUAD	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	6.13	1.82e-09	8.06e-07	0.34	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
LUAD	cis	rs7646881	0.812	rs9864589	ENSG00000240207.5	RP11-379F4.4	-6.13	1.82e-09	8.06e-07	-0.33	-0.27	Tetralogy of Fallot;	chr3:158712917	chr3:158732263~158784070:+
LUAD	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-6.13	1.82e-09	8.06e-07	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
LUAD	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	6.13	1.82e-09	8.07e-07	0.32	0.27	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
LUAD	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	6.13	1.83e-09	8.08e-07	0.32	0.27	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
LUAD	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	6.13	1.83e-09	8.08e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
LUAD	cis	rs11157436	0.915	rs11622938	ENSG00000211812.1	TRAV26-2	-6.13	1.83e-09	8.08e-07	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22202583~22203368:+
LUAD	cis	rs1729407	0.774	rs2849167	ENSG00000280143.1	AP000892.6	-6.13	1.83e-09	8.08e-07	-0.3	-0.27	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117204967~117210292:+
LUAD	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-6.13	1.83e-09	8.1e-07	-0.4	-0.27	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
LUAD	cis	rs1707322	0.686	rs3014251	ENSG00000234329.1	RP11-767N6.2	-6.13	1.83e-09	8.11e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45651039~45651826:-
LUAD	cis	rs270601	0.633	rs733300	ENSG00000233006.5	AC034220.3	6.13	1.84e-09	8.12e-07	0.25	0.27	Acylcarnitine levels;	chr5:132236550	chr5:132311285~132369916:-
LUAD	cis	rs270601	0.633	rs4535443	ENSG00000233006.5	AC034220.3	6.13	1.84e-09	8.12e-07	0.25	0.27	Acylcarnitine levels;	chr5:132236868	chr5:132311285~132369916:-
LUAD	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-6.13	1.84e-09	8.14e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
LUAD	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-6.13	1.84e-09	8.15e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
LUAD	cis	rs853679	0.55	rs1233707	ENSG00000204709.4	LINC01556	6.13	1.84e-09	8.15e-07	0.37	0.27	Depression;	chr6:28205175	chr6:28943877~28944537:+
LUAD	cis	rs6772849	0.93	rs4857914	ENSG00000242551.2	POU5F1P6	-6.13	1.85e-09	8.17e-07	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128631841	chr3:128674735~128677005:-
LUAD	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-6.13	1.85e-09	8.18e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
LUAD	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-6.13	1.86e-09	8.2e-07	-0.28	-0.27	Height;	chr11:118703185	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-6.13	1.86e-09	8.2e-07	-0.28	-0.27	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
LUAD	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	6.13	1.86e-09	8.2e-07	0.33	0.27	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
LUAD	cis	rs853679	0.546	rs36092177	ENSG00000204709.4	LINC01556	6.13	1.86e-09	8.21e-07	0.6	0.27	Depression;	chr6:28390030	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs2232429	ENSG00000204709.4	LINC01556	6.13	1.86e-09	8.21e-07	0.6	0.27	Depression;	chr6:28391855	chr6:28943877~28944537:+
LUAD	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-6.13	1.86e-09	8.21e-07	-0.29	-0.27	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
LUAD	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	6.13	1.86e-09	8.22e-07	0.28	0.27	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
LUAD	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	6.13	1.86e-09	8.22e-07	0.28	0.27	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
LUAD	cis	rs1499614	1	rs1267817	ENSG00000232546.1	RP11-458F8.1	-6.13	1.86e-09	8.22e-07	-0.36	-0.27	Gout;	chr7:66645053	chr7:66848496~66858136:+
LUAD	cis	rs293748	0.882	rs245588	ENSG00000250155.1	CTD-2353F22.1	-6.13	1.86e-09	8.23e-07	-0.38	-0.27	Obesity-related traits;	chr5:36923108	chr5:36666214~36725195:-
LUAD	cis	rs1707322	0.717	rs12023439	ENSG00000234329.1	RP11-767N6.2	6.13	1.86e-09	8.23e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45651039~45651826:-
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	6.13	1.86e-09	8.24e-07	0.27	0.27	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000224373.3	IGHV4-59	6.13	1.86e-09	8.24e-07	0.16	0.27	Kawasaki disease;	chr14:106680002	chr14:106627249~106627825:-
LUAD	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	6.13	1.86e-09	8.24e-07	0.2	0.27	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
LUAD	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	6.13	1.87e-09	8.24e-07	0.3	0.27	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
LUAD	cis	rs11157436	0.914	rs7142794	ENSG00000211812.1	TRAV26-2	-6.13	1.87e-09	8.25e-07	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22202583~22203368:+
LUAD	cis	rs10050311	0.858	rs72667703	ENSG00000251411.1	RP11-397E7.4	-6.13	1.87e-09	8.25e-07	-0.38	-0.27	Insulin-related traits;	chr4:86891825	chr4:86913266~86914817:-
LUAD	cis	rs4654783	1	rs4654783	ENSG00000228397.1	RP1-224A6.3	6.13	1.87e-09	8.26e-07	0.36	0.27	Endometriosis;	chr1:22113027	chr1:22023994~22024968:-
LUAD	cis	rs1930961	0.558	rs5996951	ENSG00000272977.1	CTA-390C10.10	-6.13	1.87e-09	8.26e-07	-0.39	-0.27	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25476218~25479971:+
LUAD	cis	rs853679	0.55	rs1225599	ENSG00000204709.4	LINC01556	6.13	1.87e-09	8.26e-07	0.37	0.27	Depression;	chr6:28197412	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.574	rs1233705	ENSG00000204709.4	LINC01556	6.13	1.87e-09	8.26e-07	0.37	0.27	Depression;	chr6:28198669	chr6:28943877~28944537:+
LUAD	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	6.13	1.87e-09	8.27e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
LUAD	cis	rs12699921	0.599	rs9942602	ENSG00000279048.1	RP11-511H23.2	6.13	1.87e-09	8.27e-07	0.22	0.27	Fibrinogen levels;	chr7:17937431	chr7:17940503~17942922:+
LUAD	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	6.13	1.87e-09	8.27e-07	0.34	0.27	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-6.13	1.87e-09	8.28e-07	-0.34	-0.27	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
LUAD	cis	rs7945705	1	rs7937298	ENSG00000254860.4	TMEM9B-AS1	-6.13	1.88e-09	8.29e-07	-0.32	-0.27	Hemoglobin concentration;	chr11:8845962	chr11:8964675~8977527:+
LUAD	cis	rs8177876	0.749	rs79834398	ENSG00000261061.1	RP11-303E16.2	-6.13	1.88e-09	8.29e-07	-0.46	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81030770~81031485:+
LUAD	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	6.13	1.88e-09	8.29e-07	0.45	0.27	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
LUAD	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	6.13	1.88e-09	8.29e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
LUAD	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	6.13	1.88e-09	8.3e-07	0.38	0.27	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
LUAD	cis	rs74233809	0.901	rs12416331	ENSG00000213277.3	MARCKSL1P1	6.13	1.88e-09	8.3e-07	0.46	0.27	Birth weight;	chr10:103169157	chr10:103175554~103176094:+
LUAD	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-6.13	1.88e-09	8.3e-07	-0.32	-0.27	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-6.13	1.88e-09	8.3e-07	-0.32	-0.27	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-6.13	1.88e-09	8.3e-07	-0.32	-0.27	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-6.13	1.88e-09	8.3e-07	-0.32	-0.27	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
LUAD	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	6.13	1.88e-09	8.31e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
LUAD	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	6.13	1.88e-09	8.31e-07	0.3	0.27	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
LUAD	cis	rs9595908	0.709	rs7318563	ENSG00000212293.1	SNORA16	6.13	1.88e-09	8.32e-07	0.29	0.27	Body mass index;	chr13:32749348	chr13:32420390~32420516:-
LUAD	cis	rs4713118	0.869	rs9366700	ENSG00000219392.1	RP1-265C24.5	-6.13	1.88e-09	8.32e-07	-0.36	-0.27	Parkinson's disease;	chr6:27729172	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	6.13	1.89e-09	8.32e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
LUAD	cis	rs12439619	0.53	rs7162177	ENSG00000276710.3	CSPG4P8	-6.13	1.89e-09	8.32e-07	-0.25	-0.27	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82459472~82477258:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000211974.3	IGHV2-70	6.12	1.89e-09	8.33e-07	0.28	0.27	Kawasaki disease;	chr14:106777611	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	6.12	1.89e-09	8.33e-07	0.31	0.27	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
LUAD	cis	rs948562	0.69	rs60200286	ENSG00000280010.1	AP001350.4	6.12	1.89e-09	8.33e-07	0.42	0.27	Lymphoma;	chr11:58347242	chr11:58627435~58628528:+
LUAD	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-6.12	1.89e-09	8.34e-07	-0.28	-0.27	Height;	chr11:118742526	chr11:118791254~118793137:+
LUAD	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-6.12	1.89e-09	8.34e-07	-0.29	-0.27	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-6.12	1.89e-09	8.34e-07	-0.29	-0.27	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-6.12	1.89e-09	8.34e-07	-0.29	-0.27	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-6.12	1.89e-09	8.34e-07	-0.29	-0.27	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
LUAD	cis	rs853679	0.546	rs13195291	ENSG00000204709.4	LINC01556	6.12	1.89e-09	8.34e-07	0.59	0.27	Depression;	chr6:28201463	chr6:28943877~28944537:+
LUAD	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-6.12	1.89e-09	8.35e-07	-0.36	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
LUAD	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-6.12	1.89e-09	8.36e-07	-0.39	-0.27	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-6.12	1.89e-09	8.36e-07	-0.39	-0.27	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-6.12	1.89e-09	8.36e-07	-0.39	-0.27	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
LUAD	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	6.12	1.9e-09	8.36e-07	0.32	0.27	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
LUAD	cis	rs10214930	0.697	rs12537499	ENSG00000235574.1	AC073150.6	6.12	1.9e-09	8.37e-07	0.34	0.27	Hypospadias;	chr7:27551976	chr7:27491682~27492765:-
LUAD	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-6.12	1.9e-09	8.39e-07	-0.39	-0.27	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
LUAD	cis	rs694739	0.536	rs671976	ENSG00000236935.1	AP003774.1	6.12	1.9e-09	8.39e-07	0.25	0.27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64278557	chr11:64325050~64329504:-
LUAD	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	6.12	1.9e-09	8.39e-07	0.3	0.27	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000224373.3	IGHV4-59	6.12	1.9e-09	8.39e-07	0.16	0.27	Kawasaki disease;	chr14:106686361	chr14:106627249~106627825:-
LUAD	cis	rs1426063	0.614	rs76087197	ENSG00000249717.1	RP11-44F21.3	6.12	1.91e-09	8.4e-07	0.5	0.27	QT interval;	chr4:75134108	chr4:74955974~74970362:-
LUAD	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	6.12	1.91e-09	8.41e-07	0.31	0.27	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
LUAD	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	6.12	1.91e-09	8.41e-07	0.31	0.27	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
LUAD	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	6.12	1.91e-09	8.42e-07	0.31	0.27	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
LUAD	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	6.12	1.91e-09	8.43e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
LUAD	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	6.12	1.91e-09	8.43e-07	0.37	0.27	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
LUAD	cis	rs9910055	0.718	rs7212854	ENSG00000267080.4	ASB16-AS1	-6.12	1.91e-09	8.44e-07	-0.25	-0.27	Total body bone mineral density;	chr17:44177049	chr17:44175973~44186717:-
LUAD	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	6.12	1.92e-09	8.46e-07	0.3	0.27	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
LUAD	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-6.12	1.92e-09	8.48e-07	-0.29	-0.27	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
LUAD	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-6.12	1.93e-09	8.49e-07	-0.26	-0.27	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
LUAD	cis	rs7176527	1	rs3762168	ENSG00000188388.10	GOLGA6L3	6.12	1.93e-09	8.49e-07	0.37	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85240472~85247170:+
LUAD	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-6.12	1.93e-09	8.5e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
LUAD	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-6.12	1.93e-09	8.51e-07	-0.35	-0.27	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
LUAD	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-6.12	1.93e-09	8.51e-07	-0.34	-0.27	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
LUAD	cis	rs2115630	0.645	rs2292463	ENSG00000229212.6	RP11-561C5.4	6.12	1.93e-09	8.52e-07	0.31	0.27	P wave terminal force;	chr15:84632519	chr15:85205440~85234795:-
LUAD	cis	rs944289	0.504	rs107196	ENSG00000257826.1	RP11-116N8.4	6.12	1.93e-09	8.52e-07	0.28	0.27	Thyroid cancer;	chr14:36054892	chr14:36061026~36067190:-
LUAD	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	6.12	1.93e-09	8.52e-07	0.32	0.27	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
LUAD	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	6.12	1.94e-09	8.52e-07	0.39	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
LUAD	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-6.12	1.94e-09	8.53e-07	-0.32	-0.27	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
LUAD	cis	rs7017914	0.905	rs1389206	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71012627	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639955	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013107	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.869	rs2639954	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013340	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.837	rs2639952	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013495	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732108	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013864	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732109	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013988	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs1493203	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71014272	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732110	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71014576	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639951	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71014990	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732112	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71015606	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.811	rs1389204	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71016063	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732113	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71016314	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732114	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71016477	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732116	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017092	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2956610	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017298	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098868	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017457	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098870	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017700	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110240	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017869	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.875	rs3098871	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71018180	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098873	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71020351	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110241	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71020729	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110242	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71020732	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110243	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71020834	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs3098874	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71022103	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110247	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71022652	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110248	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71022700	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110249	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71023310	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098876	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71024009	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs3098877	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71024211	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.875	rs3110251	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71024739	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110252	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71024985	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110253	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71025318	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110254	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71025627	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs3110256	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71025901	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110257	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71025916	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098879	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71026225	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs3110258	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71026297	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs3098880	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71026686	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098881	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71027455	chr8:70780914~70781008:-
LUAD	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-6.12	1.94e-09	8.54e-07	-0.47	-0.27	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000211970.3	IGHV4-61	-6.12	1.94e-09	8.55e-07	-0.19	-0.27	Kawasaki disease;	chr14:106686361	chr14:106639119~106639657:-
LUAD	cis	rs36093844	0.66	rs12274717	ENSG00000279742.1	RP11-700A24.1	-6.12	1.94e-09	8.55e-07	-0.36	-0.27	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866671	chr11:85852557~85854943:-
LUAD	cis	rs853679	0.517	rs9380052	ENSG00000204709.4	LINC01556	6.12	1.94e-09	8.55e-07	0.37	0.27	Depression;	chr6:28096845	chr6:28943877~28944537:+
LUAD	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-6.12	1.95e-09	8.57e-07	-0.28	-0.27	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
LUAD	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-6.12	1.95e-09	8.58e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
LUAD	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	6.12	1.95e-09	8.58e-07	0.34	0.27	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	6.12	1.95e-09	8.58e-07	0.34	0.27	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
LUAD	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-6.12	1.95e-09	8.59e-07	-0.32	-0.27	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
LUAD	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	6.12	1.96e-09	8.6e-07	0.28	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
LUAD	cis	rs10214930	0.752	rs2391448	ENSG00000235574.1	AC073150.6	-6.12	1.96e-09	8.61e-07	-0.36	-0.27	Hypospadias;	chr7:27638566	chr7:27491682~27492765:-
LUAD	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-6.12	1.96e-09	8.61e-07	-0.59	-0.27	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
LUAD	cis	rs7567389	0.504	rs1568278	ENSG00000236682.1	AC068282.3	-6.12	1.96e-09	8.61e-07	-0.35	-0.27	Self-rated health;	chr2:127432619	chr2:127389130~127400580:+
LUAD	cis	rs10214930	0.706	rs4722726	ENSG00000235574.1	AC073150.6	-6.12	1.96e-09	8.61e-07	-0.36	-0.27	Hypospadias;	chr7:27654589	chr7:27491682~27492765:-
LUAD	cis	rs7626444	0.584	rs11711813	ENSG00000272359.1	U4	-6.12	1.96e-09	8.61e-07	-0.3	-0.27	Monocyte count;	chr3:196740467	chr3:196747192~196747324:-
LUAD	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	6.12	1.96e-09	8.62e-07	0.3	0.27	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	6.12	1.96e-09	8.62e-07	0.3	0.27	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
LUAD	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-6.12	1.96e-09	8.63e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
LUAD	cis	rs7246657	0.551	rs4806414	ENSG00000276846.1	CTD-3220F14.3	6.12	1.96e-09	8.63e-07	0.42	0.27	Coronary artery calcification;	chr19:37147886	chr19:37314868~37315620:-
LUAD	cis	rs4908768	0.539	rs7537982	ENSG00000232912.4	RP5-1115A15.1	6.12	1.96e-09	8.64e-07	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8424645~8434838:+
LUAD	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-6.12	1.96e-09	8.64e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
LUAD	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	6.12	1.97e-09	8.64e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
LUAD	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	6.12	1.97e-09	8.64e-07	0.31	0.27	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
LUAD	cis	rs7017914	0.905	rs2732094	ENSG00000223220.1	Y_RNA	6.12	1.97e-09	8.65e-07	0.3	0.27	Bone mineral density;	chr8:71007683	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732095	ENSG00000223220.1	Y_RNA	6.12	1.97e-09	8.65e-07	0.3	0.27	Bone mineral density;	chr8:71007711	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs2732096	ENSG00000223220.1	Y_RNA	6.12	1.97e-09	8.65e-07	0.3	0.27	Bone mineral density;	chr8:71007745	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs2732097	ENSG00000223220.1	Y_RNA	6.12	1.97e-09	8.65e-07	0.3	0.27	Bone mineral density;	chr8:71007778	chr8:70780914~70781008:-
LUAD	cis	rs10214930	0.697	rs1052741	ENSG00000235574.1	AC073150.6	-6.12	1.97e-09	8.65e-07	-0.34	-0.27	Hypospadias;	chr7:27525542	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1052724	ENSG00000235574.1	AC073150.6	-6.12	1.97e-09	8.65e-07	-0.34	-0.27	Hypospadias;	chr7:27525587	chr7:27491682~27492765:-
LUAD	cis	rs2034650	0.544	rs600791	ENSG00000223313.1	RNU6-516P	6.12	1.97e-09	8.65e-07	0.35	0.27	Interstitial lung disease;	chr15:40428868	chr15:40529570~40529673:+
LUAD	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-6.12	1.97e-09	8.65e-07	-0.32	-0.27	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
LUAD	cis	rs2243480	1	rs67728539	ENSG00000230295.1	RP11-458F8.2	-6.12	1.97e-09	8.66e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66880708~66882981:+
LUAD	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	6.12	1.97e-09	8.66e-07	0.31	0.27	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
LUAD	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-6.12	1.97e-09	8.67e-07	-0.35	-0.27	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
LUAD	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	6.12	1.97e-09	8.67e-07	0.33	0.27	Depression;	chr6:28273214	chr6:28176188~28176674:+
LUAD	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	6.12	1.97e-09	8.67e-07	0.33	0.27	Depression;	chr6:28273215	chr6:28176188~28176674:+
LUAD	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	6.12	1.98e-09	8.68e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
LUAD	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	6.12	1.98e-09	8.7e-07	0.32	0.27	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
LUAD	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-6.12	1.98e-09	8.7e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-6.12	1.98e-09	8.7e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
LUAD	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-6.12	1.98e-09	8.7e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
LUAD	cis	rs7044106	0.762	rs10818471	ENSG00000238181.2	AHCYP2	-6.12	1.98e-09	8.71e-07	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120720673~120721972:+
LUAD	cis	rs1823913	0.622	rs55787447	ENSG00000280083.1	RP11-317J9.1	-6.12	1.98e-09	8.72e-07	-0.32	-0.27	Obesity-related traits;	chr2:191288596	chr2:191154118~191156070:-
LUAD	cis	rs10214930	0.697	rs6963421	ENSG00000235574.1	AC073150.6	-6.12	1.98e-09	8.72e-07	-0.34	-0.27	Hypospadias;	chr7:27652809	chr7:27491682~27492765:-
LUAD	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	6.12	1.98e-09	8.72e-07	0.34	0.27	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
LUAD	cis	rs12699921	0.598	rs2723504	ENSG00000279048.1	RP11-511H23.2	-6.12	1.99e-09	8.73e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17815210	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.598	rs2723505	ENSG00000279048.1	RP11-511H23.2	-6.12	1.99e-09	8.73e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17815226	chr7:17940503~17942922:+
LUAD	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-6.12	1.99e-09	8.74e-07	-0.32	-0.27	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
LUAD	cis	rs11157436	0.958	rs1041859	ENSG00000211812.1	TRAV26-2	-6.12	1.99e-09	8.74e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.958	rs1041860	ENSG00000211812.1	TRAV26-2	-6.12	1.99e-09	8.74e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22202583~22203368:+
LUAD	cis	rs74233809	1	rs74233809	ENSG00000213277.3	MARCKSL1P1	6.12	1.99e-09	8.75e-07	0.45	0.27	Birth weight;	chr10:103154183	chr10:103175554~103176094:+
LUAD	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-6.12	1.99e-09	8.75e-07	-0.36	-0.27	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
LUAD	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-6.12	1.99e-09	8.75e-07	-0.36	-0.27	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
LUAD	cis	rs6772849	0.93	rs68090762	ENSG00000242551.2	POU5F1P6	-6.12	1.99e-09	8.76e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128625064	chr3:128674735~128677005:-
LUAD	cis	rs11157436	1	rs3811278	ENSG00000211812.1	TRAV26-2	-6.12	1.99e-09	8.76e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22202583~22203368:+
LUAD	cis	rs30380	0.632	rs26498	ENSG00000272109.1	CTD-2260A17.3	6.12	1.99e-09	8.76e-07	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr5:96803109	chr5:96804353~96806105:+
LUAD	cis	rs4713118	0.629	rs203888	ENSG00000204709.4	LINC01556	6.12	2e-09	8.76e-07	0.35	0.27	Parkinson's disease;	chr6:28053811	chr6:28943877~28944537:+
LUAD	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-6.12	2e-09	8.76e-07	-0.28	-0.27	Height;	chr11:118737916	chr11:118791254~118793137:+
LUAD	cis	rs7688540	0.8	rs2353599	ENSG00000275426.1	CH17-262A2.1	6.12	2e-09	8.77e-07	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:149738~150317:+
LUAD	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	6.12	2e-09	8.77e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	6.12	2e-09	8.77e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	6.12	2e-09	8.77e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	6.12	2e-09	8.77e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
LUAD	cis	rs6772849	0.896	rs61112519	ENSG00000242551.2	POU5F1P6	-6.11	2e-09	8.78e-07	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128619333	chr3:128674735~128677005:-
LUAD	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-6.11	2e-09	8.79e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
LUAD	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	6.11	2e-09	8.79e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	6.11	2e-09	8.79e-07	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
LUAD	cis	rs77204473	0.744	rs76567973	ENSG00000254851.1	RP11-109L13.1	6.11	2e-09	8.8e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100045	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs78135964	ENSG00000254851.1	RP11-109L13.1	6.11	2e-09	8.8e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100961	chr11:117135528~117138582:+
LUAD	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	6.11	2.01e-09	8.81e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
LUAD	cis	rs4591358	0.648	rs17177798	ENSG00000223466.1	AC064834.2	-6.11	2.01e-09	8.81e-07	-0.39	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195521352	chr2:195533035~195538681:+
LUAD	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-6.11	2.01e-09	8.82e-07	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
LUAD	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-6.11	2.01e-09	8.83e-07	-0.26	-0.27	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000230295.1	RP11-458F8.2	-6.11	2.01e-09	8.83e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65996588	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000230295.1	RP11-458F8.2	-6.11	2.01e-09	8.83e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66002158	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000230295.1	RP11-458F8.2	-6.11	2.01e-09	8.83e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66005214	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000230295.1	RP11-458F8.2	-6.11	2.01e-09	8.83e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66005945	chr7:66880708~66882981:+
LUAD	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	6.11	2.01e-09	8.83e-07	0.27	0.27	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
LUAD	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-6.11	2.01e-09	8.84e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
LUAD	cis	rs6504622	0.905	rs197926	ENSG00000262879.4	RP11-156P1.3	6.11	2.02e-09	8.85e-07	0.31	0.27	Orofacial clefts;	chr17:46934721	chr17:46984045~47100323:-
LUAD	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-6.11	2.02e-09	8.85e-07	-0.39	-0.27	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs2462569	ENSG00000230295.1	RP11-458F8.2	6.11	2.02e-09	8.85e-07	0.31	0.27	Diabetic kidney disease;	chr7:66009859	chr7:66880708~66882981:+
LUAD	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	6.11	2.02e-09	8.87e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
LUAD	cis	rs74233809	1	rs12219304	ENSG00000213277.3	MARCKSL1P1	6.11	2.02e-09	8.88e-07	0.45	0.27	Birth weight;	chr10:103171827	chr10:103175554~103176094:+
LUAD	cis	rs9595908	0.792	rs61947055	ENSG00000212293.1	SNORA16	6.11	2.02e-09	8.88e-07	0.29	0.27	Body mass index;	chr13:32614414	chr13:32420390~32420516:-
LUAD	cis	rs8177376	0.727	rs240555	ENSG00000254905.1	RP11-712L6.7	6.11	2.03e-09	8.88e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126332190	chr11:126292922~126294254:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000232546.1	RP11-458F8.1	-6.11	2.03e-09	8.89e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66004843	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs958550	ENSG00000232546.1	RP11-458F8.1	6.11	2.03e-09	8.89e-07	0.32	0.27	Diabetic kidney disease;	chr7:66170692	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-6.11	2.03e-09	8.91e-07	-0.39	-0.27	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
LUAD	cis	rs9834970	0.588	rs4441609	ENSG00000234073.1	AC011816.1	-6.11	2.04e-09	8.94e-07	-0.29	-0.27	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36851226	chr3:36880184~36880729:-
LUAD	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-6.11	2.04e-09	8.94e-07	-0.29	-0.27	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-6.11	2.04e-09	8.94e-07	-0.29	-0.27	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
LUAD	cis	rs5753618	0.509	rs2413033	ENSG00000236132.1	CTA-440B3.1	6.11	2.04e-09	8.94e-07	0.34	0.27	Colorectal cancer;	chr22:31178227	chr22:31816379~31817491:-
LUAD	cis	rs1426063	0.614	rs74949513	ENSG00000249717.1	RP11-44F21.3	6.11	2.04e-09	8.96e-07	0.5	0.27	QT interval;	chr4:75124631	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs77982391	ENSG00000249717.1	RP11-44F21.3	6.11	2.04e-09	8.96e-07	0.5	0.27	QT interval;	chr4:75125224	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.541	rs116664844	ENSG00000249717.1	RP11-44F21.3	6.11	2.04e-09	8.96e-07	0.5	0.27	QT interval;	chr4:75125677	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.541	rs114162294	ENSG00000249717.1	RP11-44F21.3	6.11	2.04e-09	8.96e-07	0.5	0.27	QT interval;	chr4:75125682	chr4:74955974~74970362:-
LUAD	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	6.11	2.04e-09	8.96e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
LUAD	cis	rs2302464	1	rs12651052	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15726813	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs56381553	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15726824	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs12645513	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15727155	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs58335439	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15727183	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs73123625	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15727550	chr4:15730962~15731627:-
LUAD	cis	rs10050311	0.858	rs1010903	ENSG00000251411.1	RP11-397E7.4	-6.11	2.05e-09	8.97e-07	-0.36	-0.27	Insulin-related traits;	chr4:86898040	chr4:86913266~86914817:-
LUAD	cis	rs948562	0.74	rs12361770	ENSG00000280010.1	AP001350.4	6.11	2.05e-09	8.99e-07	0.43	0.27	Lymphoma;	chr11:58666759	chr11:58627435~58628528:+
LUAD	cis	rs4273100	1	rs16960499	ENSG00000279825.1	CTC-457L16.1	6.11	2.05e-09	9e-07	0.36	0.27	Schizophrenia;	chr17:19299719	chr17:19030857~19033529:+
LUAD	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-6.11	2.06e-09	9.01e-07	-0.39	-0.27	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-6.11	2.06e-09	9.01e-07	-0.39	-0.27	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
LUAD	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	6.11	2.06e-09	9.03e-07	0.3	0.27	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
LUAD	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	6.11	2.06e-09	9.04e-07	0.28	0.27	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
LUAD	cis	rs12699921	0.632	rs2723572	ENSG00000279048.1	RP11-511H23.2	-6.11	2.07e-09	9.05e-07	-0.21	-0.27	Fibrinogen levels;	chr7:17848964	chr7:17940503~17942922:+
LUAD	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.07e-09	9.05e-07	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
LUAD	cis	rs720064	0.586	rs9963697	ENSG00000264745.1	TTC39C-AS1	6.11	2.07e-09	9.05e-07	0.28	0.27	Strep throat;	chr18:23944796	chr18:23994213~24015339:-
LUAD	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	6.11	2.07e-09	9.05e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	6.11	2.07e-09	9.05e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	6.11	2.07e-09	9.05e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
LUAD	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-6.11	2.07e-09	9.06e-07	-0.36	-0.27	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
LUAD	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	6.11	2.07e-09	9.07e-07	0.46	0.27	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
LUAD	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	6.11	2.07e-09	9.07e-07	0.34	0.27	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
LUAD	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-6.11	2.08e-09	9.09e-07	-0.36	-0.27	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
LUAD	cis	rs8031584	0.958	rs1043742	ENSG00000260382.1	RP11-540B6.2	6.11	2.08e-09	9.1e-07	0.32	0.27	Huntington's disease progression;	chr15:30940378	chr15:30882267~30883231:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000232546.1	RP11-458F8.1	6.11	2.08e-09	9.1e-07	0.35	0.27	Diabetic kidney disease;	chr7:66259699	chr7:66848496~66858136:+
LUAD	cis	rs4908768	0.501	rs7520617	ENSG00000232912.4	RP5-1115A15.1	6.11	2.08e-09	9.1e-07	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8424645~8434838:+
LUAD	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-6.11	2.08e-09	9.11e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.597	rs11227523	ENSG00000255517.5	CTD-3074O7.5	-6.11	2.08e-09	9.11e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66538467	chr11:66473490~66480233:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000230295.1	RP11-458F8.2	-6.11	2.08e-09	9.11e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65951319	chr7:66880708~66882981:+
LUAD	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	6.11	2.08e-09	9.12e-07	0.41	0.27	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
LUAD	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	6.11	2.09e-09	9.13e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
LUAD	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	6.11	2.09e-09	9.13e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
LUAD	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	6.11	2.09e-09	9.13e-07	0.34	0.27	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
LUAD	cis	rs2276314	0.512	rs1789515	ENSG00000278986.1	RP11-723J4.3	6.11	2.09e-09	9.14e-07	0.28	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36055930	chr18:35972151~35973916:+
LUAD	cis	rs12439619	0.921	rs4778672	ENSG00000255769.6	GOLGA2P10	6.11	2.09e-09	9.14e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472993~82513950:-
LUAD	cis	rs5753618	0.504	rs9609296	ENSG00000236132.1	CTA-440B3.1	-6.11	2.09e-09	9.15e-07	-0.33	-0.27	Colorectal cancer;	chr22:31495798	chr22:31816379~31817491:-
LUAD	cis	rs4591358	0.773	rs17781737	ENSG00000223466.1	AC064834.2	-6.11	2.09e-09	9.15e-07	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508251	chr2:195533035~195538681:+
LUAD	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	6.11	2.1e-09	9.16e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	6.11	2.1e-09	9.16e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
LUAD	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	6.11	2.1e-09	9.17e-07	0.43	0.27	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
LUAD	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-6.11	2.1e-09	9.17e-07	-0.31	-0.27	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
LUAD	cis	rs728616	0.614	rs10788319	ENSG00000225484.5	NUTM2B-AS1	-6.11	2.1e-09	9.18e-07	-0.46	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953754	chr10:79663088~79826594:-
LUAD	cis	rs10214930	0.813	rs6462027	ENSG00000235574.1	AC073150.6	-6.11	2.1e-09	9.18e-07	-0.36	-0.27	Hypospadias;	chr7:27523619	chr7:27491682~27492765:-
LUAD	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	6.11	2.1e-09	9.2e-07	0.37	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
LUAD	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	6.11	2.11e-09	9.22e-07	0.35	0.27	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
LUAD	cis	rs35740288	0.77	rs34048547	ENSG00000202081.1	RNU6-1280P	6.11	2.11e-09	9.23e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85637836	chr15:85651522~85651628:-
LUAD	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	6.11	2.11e-09	9.24e-07	0.32	0.27	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000211970.3	IGHV4-61	-6.11	2.11e-09	9.24e-07	-0.19	-0.27	Kawasaki disease;	chr14:106683893	chr14:106639119~106639657:-
LUAD	cis	rs6772849	0.93	rs55987729	ENSG00000242551.2	POU5F1P6	-6.11	2.11e-09	9.24e-07	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128621267	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	6.11	2.12e-09	9.24e-07	0.3	0.27	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
LUAD	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-6.11	2.12e-09	9.26e-07	-0.33	-0.27	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
LUAD	cis	rs74233809	1	rs11191575	ENSG00000213277.3	MARCKSL1P1	6.1	2.13e-09	9.29e-07	0.45	0.27	Birth weight;	chr10:103138580	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs79993475	ENSG00000213277.3	MARCKSL1P1	6.1	2.13e-09	9.29e-07	0.45	0.27	Birth weight;	chr10:103141274	chr10:103175554~103176094:+
LUAD	cis	rs30380	0.587	rs151940	ENSG00000272109.1	CTD-2260A17.3	-6.1	2.13e-09	9.3e-07	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96812074	chr5:96804353~96806105:+
LUAD	cis	rs10214930	0.697	rs13242248	ENSG00000235574.1	AC073150.6	-6.1	2.13e-09	9.31e-07	-0.33	-0.27	Hypospadias;	chr7:27643252	chr7:27491682~27492765:-
LUAD	cis	rs10759883	0.539	rs689744	ENSG00000175611.10	LINC00476	6.1	2.13e-09	9.31e-07	0.32	0.27	Nicotine dependence;	chr9:96040417	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.539	rs2296858	ENSG00000175611.10	LINC00476	6.1	2.13e-09	9.31e-07	0.32	0.27	Nicotine dependence;	chr9:96041126	chr9:95759231~95875977:-
LUAD	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	6.1	2.14e-09	9.33e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	6.1	2.14e-09	9.33e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
LUAD	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-6.1	2.14e-09	9.35e-07	-0.27	-0.27	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
LUAD	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-6.1	2.14e-09	9.35e-07	-0.32	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-6.1	2.14e-09	9.35e-07	-0.32	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
LUAD	cis	rs7182621	0.622	rs12904160	ENSG00000182397.13	DNM1P46	6.1	2.14e-09	9.35e-07	0.32	0.27	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99790156~99806927:-
LUAD	cis	rs7017914	0.902	rs6472562	ENSG00000223220.1	Y_RNA	6.1	2.14e-09	9.36e-07	0.3	0.27	Bone mineral density;	chr8:71057643	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs6472563	ENSG00000223220.1	Y_RNA	6.1	2.14e-09	9.36e-07	0.3	0.27	Bone mineral density;	chr8:71057672	chr8:70780914~70781008:-
LUAD	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	6.1	2.15e-09	9.37e-07	0.32	0.27	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
LUAD	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-6.1	2.15e-09	9.39e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-6.1	2.15e-09	9.39e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
LUAD	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-6.1	2.15e-09	9.39e-07	-0.27	-0.27	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
LUAD	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	6.1	2.15e-09	9.39e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
LUAD	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	6.1	2.15e-09	9.4e-07	0.29	0.27	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
LUAD	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	6.1	2.15e-09	9.4e-07	0.29	0.27	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	6.1	2.15e-09	9.4e-07	0.29	0.27	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
LUAD	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	6.1	2.15e-09	9.4e-07	0.47	0.27	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
LUAD	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	6.1	2.15e-09	9.4e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000224373.3	IGHV4-59	-6.1	2.16e-09	9.41e-07	-0.16	-0.27	Kawasaki disease;	chr14:106683696	chr14:106627249~106627825:-
LUAD	cis	rs2243480	1	rs59794892	ENSG00000230295.1	RP11-458F8.2	-6.1	2.16e-09	9.41e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65950886	chr7:66880708~66882981:+
LUAD	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	6.1	2.16e-09	9.41e-07	0.34	0.27	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
LUAD	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-6.1	2.16e-09	9.42e-07	-0.27	-0.27	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
LUAD	cis	rs35740288	0.77	rs12898597	ENSG00000202081.1	RNU6-1280P	6.1	2.16e-09	9.43e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85646688	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11631386	ENSG00000202081.1	RNU6-1280P	6.1	2.16e-09	9.43e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85648764	chr15:85651522~85651628:-
LUAD	cis	rs8177876	0.749	rs76892049	ENSG00000261061.1	RP11-303E16.2	-6.1	2.16e-09	9.44e-07	-0.46	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81030770~81031485:+
LUAD	cis	rs853679	0.607	rs67662114	ENSG00000204709.4	LINC01556	6.1	2.16e-09	9.44e-07	0.6	0.27	Depression;	chr6:27964523	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13216117	ENSG00000204709.4	LINC01556	6.1	2.16e-09	9.44e-07	0.6	0.27	Depression;	chr6:27970706	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs36101351	ENSG00000204709.4	LINC01556	6.1	2.16e-09	9.44e-07	0.6	0.27	Depression;	chr6:27975591	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs28360499	ENSG00000204709.4	LINC01556	6.1	2.16e-09	9.44e-07	0.6	0.27	Depression;	chr6:27977618	chr6:28943877~28944537:+
LUAD	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-6.1	2.17e-09	9.46e-07	-0.29	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
LUAD	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	6.1	2.17e-09	9.46e-07	0.29	0.27	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
LUAD	cis	rs2243480	1	rs431318	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66046610	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66049744	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66051386	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66052736	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66055492	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66055509	chr7:66848496~66858136:+
LUAD	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	6.1	2.17e-09	9.47e-07	0.4	0.27	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
LUAD	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	6.1	2.17e-09	9.47e-07	0.4	0.27	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
LUAD	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.48e-07	-0.25	-0.27	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
LUAD	cis	rs1823913	0.637	rs2067610	ENSG00000280083.1	RP11-317J9.1	-6.1	2.17e-09	9.48e-07	-0.32	-0.27	Obesity-related traits;	chr2:191299251	chr2:191154118~191156070:-
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000230295.1	RP11-458F8.2	-6.1	2.17e-09	9.48e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65999249	chr7:66880708~66882981:+
LUAD	cis	rs1551277	0.538	rs55652830	ENSG00000146666.5	LINC00525	6.1	2.18e-09	9.49e-07	0.33	0.27	Anxiety disorder;	chr7:47805887	chr7:47761476~47766772:+
LUAD	cis	rs2243480	1	rs35542501	ENSG00000232546.1	RP11-458F8.1	-6.1	2.18e-09	9.49e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65966228	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000232546.1	RP11-458F8.1	-6.1	2.18e-09	9.49e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65973566	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000232546.1	RP11-458F8.1	-6.1	2.18e-09	9.49e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65973791	chr7:66848496~66858136:+
LUAD	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-6.1	2.18e-09	9.5e-07	-0.28	-0.27	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
LUAD	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-6.1	2.18e-09	9.5e-07	-0.3	-0.27	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
LUAD	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-6.1	2.18e-09	9.5e-07	-0.28	-0.27	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
LUAD	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-6.1	2.18e-09	9.51e-07	-0.34	-0.27	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
LUAD	cis	rs4803480	1	rs11882144	ENSG00000270164.1	LINC01480	-6.1	2.18e-09	9.51e-07	-0.26	-0.27	Schizophrenia;	chr19:41566244	chr19:41535183~41536904:+
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000230295.1	RP11-458F8.2	-6.1	2.18e-09	9.52e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65951525	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000230295.1	RP11-458F8.2	-6.1	2.18e-09	9.52e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65951549	chr7:66880708~66882981:+
LUAD	cis	rs853679	0.517	rs9366715	ENSG00000204709.4	LINC01556	6.1	2.18e-09	9.52e-07	0.37	0.27	Depression;	chr6:28096855	chr6:28943877~28944537:+
LUAD	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	6.1	2.19e-09	9.52e-07	0.29	0.27	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
LUAD	cis	rs853679	0.607	rs13208096	ENSG00000204709.4	LINC01556	6.1	2.19e-09	9.55e-07	0.6	0.27	Depression;	chr6:28257533	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-6.1	2.19e-09	9.55e-07	-0.39	-0.27	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
LUAD	cis	rs10214930	0.723	rs56139857	ENSG00000235574.1	AC073150.6	-6.1	2.19e-09	9.56e-07	-0.34	-0.27	Hypospadias;	chr7:27639352	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs11973492	ENSG00000235574.1	AC073150.6	-6.1	2.19e-09	9.56e-07	-0.34	-0.27	Hypospadias;	chr7:27640770	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs6945993	ENSG00000235574.1	AC073150.6	-6.1	2.19e-09	9.56e-07	-0.34	-0.27	Hypospadias;	chr7:27641391	chr7:27491682~27492765:-
LUAD	cis	rs2115536	0.692	rs8036559	ENSG00000278600.1	RP11-81A1.6	-6.1	2.2e-09	9.56e-07	-0.22	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79878221	chr15:79920195~79922455:-
LUAD	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
LUAD	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	6.1	2.2e-09	9.57e-07	0.32	0.27	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
LUAD	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-6.1	2.2e-09	9.58e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
LUAD	cis	rs7044106	0.762	rs7044226	ENSG00000238181.2	AHCYP2	-6.1	2.21e-09	9.61e-07	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120720673~120721972:+
LUAD	cis	rs12699921	0.632	rs2723494	ENSG00000279048.1	RP11-511H23.2	-6.1	2.21e-09	9.61e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17814360	chr7:17940503~17942922:+
LUAD	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-6.1	2.21e-09	9.61e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
LUAD	cis	rs7246657	0.551	rs11084873	ENSG00000276846.1	CTD-3220F14.3	6.1	2.21e-09	9.62e-07	0.4	0.27	Coronary artery calcification;	chr19:37093008	chr19:37314868~37315620:-
LUAD	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-6.1	2.21e-09	9.62e-07	-0.29	-0.27	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
LUAD	cis	rs9584850	0.834	rs3783005	ENSG00000231194.1	FARP1-AS1	-6.1	2.21e-09	9.62e-07	-0.32	-0.27	Neuroticism;	chr13:98459083	chr13:98435405~98435840:-
LUAD	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	6.1	2.21e-09	9.62e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
LUAD	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	6.1	2.21e-09	9.62e-07	0.27	0.27	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
LUAD	cis	rs720064	0.558	rs7245197	ENSG00000264745.1	TTC39C-AS1	6.1	2.21e-09	9.63e-07	0.29	0.27	Strep throat;	chr18:23926339	chr18:23994213~24015339:-
LUAD	cis	rs720064	0.586	rs12958287	ENSG00000264745.1	TTC39C-AS1	6.1	2.21e-09	9.63e-07	0.29	0.27	Strep throat;	chr18:23927465	chr18:23994213~24015339:-
LUAD	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	6.1	2.21e-09	9.64e-07	0.32	0.27	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
LUAD	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-6.1	2.22e-09	9.65e-07	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
LUAD	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	6.1	2.22e-09	9.67e-07	0.31	0.27	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
LUAD	cis	rs11157436	0.918	rs7159024	ENSG00000211812.1	TRAV26-2	-6.1	2.22e-09	9.67e-07	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22202583~22203368:+
LUAD	cis	rs172166	0.694	rs536704	ENSG00000204709.4	LINC01556	6.1	2.23e-09	9.69e-07	0.35	0.27	Cardiac Troponin-T levels;	chr6:28124825	chr6:28943877~28944537:+
LUAD	cis	rs10740039	0.81	rs9415605	ENSG00000254271.1	RP11-131N11.4	-6.1	2.23e-09	9.7e-07	-0.32	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60616809	chr10:60734342~60741828:+
LUAD	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-6.1	2.24e-09	9.73e-07	-0.27	-0.27	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
LUAD	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	6.1	2.24e-09	9.73e-07	0.38	0.27	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000211972.2	IGHV3-66	-6.1	2.24e-09	9.73e-07	-0.23	-0.27	Kawasaki disease;	chr14:106769752	chr14:106675017~106675544:-
LUAD	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	6.1	2.24e-09	9.74e-07	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
LUAD	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	6.1	2.24e-09	9.74e-07	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
LUAD	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-6.1	2.24e-09	9.75e-07	-0.3	-0.27	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000232546.1	RP11-458F8.1	-6.1	2.25e-09	9.77e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66433290	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs67536397	ENSG00000232546.1	RP11-458F8.1	-6.1	2.25e-09	9.77e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66482930	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs58669269	ENSG00000232546.1	RP11-458F8.1	-6.1	2.25e-09	9.77e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66486966	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000232546.1	RP11-458F8.1	-6.1	2.25e-09	9.77e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66500146	chr7:66848496~66858136:+
LUAD	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-6.1	2.25e-09	9.77e-07	-0.45	-0.27	Depression;	chr6:28129415	chr6:28115628~28116551:+
LUAD	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	6.09	2.25e-09	9.78e-07	0.33	0.27	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	6.09	2.25e-09	9.78e-07	0.33	0.27	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	6.09	2.25e-09	9.78e-07	0.33	0.27	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
LUAD	cis	rs35740288	0.77	rs56092539	ENSG00000202081.1	RNU6-1280P	6.09	2.25e-09	9.79e-07	0.32	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85639281	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11636185	ENSG00000202081.1	RNU6-1280P	6.09	2.25e-09	9.79e-07	0.32	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85639887	chr15:85651522~85651628:-
LUAD	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	6.09	2.25e-09	9.8e-07	0.42	0.27	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
LUAD	cis	rs10214930	0.697	rs6462024	ENSG00000235574.1	AC073150.6	-6.09	2.25e-09	9.8e-07	-0.34	-0.27	Hypospadias;	chr7:27522721	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6462025	ENSG00000235574.1	AC073150.6	-6.09	2.25e-09	9.8e-07	-0.34	-0.27	Hypospadias;	chr7:27522722	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6462026	ENSG00000235574.1	AC073150.6	-6.09	2.25e-09	9.8e-07	-0.34	-0.27	Hypospadias;	chr7:27522749	chr7:27491682~27492765:-
LUAD	cis	rs11977715	0.538	rs3801916	ENSG00000233942.1	AC004012.1	6.09	2.26e-09	9.8e-07	0.33	0.27	Middle childhood and early adolescence aggressive behavior;	chr7:95491707	chr7:95471835~95473998:+
LUAD	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	6.09	2.26e-09	9.81e-07	0.34	0.27	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.81e-07	-0.29	-0.27	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.81e-07	-0.29	-0.27	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.81e-07	-0.29	-0.27	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.81e-07	-0.29	-0.27	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000230295.1	RP11-458F8.2	6.09	2.26e-09	9.82e-07	0.33	0.27	Diabetic kidney disease;	chr7:66157859	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000230295.1	RP11-458F8.2	6.09	2.26e-09	9.82e-07	0.33	0.27	Diabetic kidney disease;	chr7:66162777	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000230295.1	RP11-458F8.2	6.09	2.26e-09	9.82e-07	0.33	0.27	Diabetic kidney disease;	chr7:66163497	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000230295.1	RP11-458F8.2	6.09	2.26e-09	9.82e-07	0.33	0.27	Diabetic kidney disease;	chr7:66164112	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000230295.1	RP11-458F8.2	-6.09	2.26e-09	9.82e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66155987	chr7:66880708~66882981:+
LUAD	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	6.09	2.26e-09	9.82e-07	0.34	0.27	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.83e-07	-0.29	-0.27	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
LUAD	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	6.09	2.26e-09	9.83e-07	0.35	0.27	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
LUAD	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	6.09	2.26e-09	9.83e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
LUAD	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	6.09	2.26e-09	9.83e-07	0.31	0.27	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
LUAD	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	6.09	2.26e-09	9.83e-07	0.37	0.27	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
LUAD	cis	rs10214930	0.697	rs6974052	ENSG00000235574.1	AC073150.6	-6.09	2.26e-09	9.84e-07	-0.34	-0.27	Hypospadias;	chr7:27515978	chr7:27491682~27492765:-
LUAD	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-6.09	2.26e-09	9.84e-07	-0.3	-0.27	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
LUAD	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-6.09	2.27e-09	9.84e-07	-0.33	-0.27	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
LUAD	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	6.09	2.27e-09	9.84e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.522	rs1638736	ENSG00000273142.1	RP11-458F8.4	-6.09	2.27e-09	9.84e-07	-0.31	-0.27	Diabetic kidney disease;	chr7:66627321	chr7:66902857~66906297:+
LUAD	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	6.09	2.27e-09	9.84e-07	0.31	0.27	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
LUAD	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	6.09	2.27e-09	9.84e-07	0.28	0.27	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
LUAD	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	6.09	2.27e-09	9.84e-07	0.28	0.27	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
LUAD	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-6.09	2.27e-09	9.85e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
LUAD	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-6.09	2.27e-09	9.85e-07	-0.37	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000211974.3	IGHV2-70	6.09	2.27e-09	9.86e-07	0.28	0.27	Kawasaki disease;	chr14:106776695	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000211974.3	IGHV2-70	6.09	2.27e-09	9.86e-07	0.28	0.27	Kawasaki disease;	chr14:106778202	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000211974.3	IGHV2-70	6.09	2.27e-09	9.86e-07	0.28	0.27	Kawasaki disease;	chr14:106778401	chr14:106723574~106724093:-
LUAD	cis	rs9450351	0.744	rs9353339	ENSG00000203875.9	SNHG5	6.09	2.27e-09	9.86e-07	0.55	0.27	Interferon gamma-induced protein 10 levels;	chr6:85794480	chr6:85660950~85678736:-
LUAD	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	6.09	2.27e-09	9.86e-07	0.43	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
LUAD	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-6.09	2.27e-09	9.87e-07	-0.33	-0.27	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
LUAD	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	6.09	2.27e-09	9.87e-07	0.34	0.27	Height;	chr6:109471826	chr6:109382795~109383666:+
LUAD	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-6.09	2.28e-09	9.88e-07	-0.28	-0.27	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
LUAD	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-6.09	2.28e-09	9.88e-07	-0.27	-0.27	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
LUAD	cis	rs10214930	0.781	rs6943883	ENSG00000235574.1	AC073150.6	-6.09	2.28e-09	9.88e-07	-0.36	-0.27	Hypospadias;	chr7:27653274	chr7:27491682~27492765:-
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-6.09	2.28e-09	9.89e-07	-0.3	-0.27	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
LUAD	cis	rs2404602	0.692	rs4886503	ENSG00000259422.1	RP11-593F23.1	-6.09	2.28e-09	9.91e-07	-0.31	-0.27	Blood metabolite levels;	chr15:76816533	chr15:76174891~76181486:-
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000230295.1	RP11-458F8.2	-6.09	2.29e-09	9.92e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65947955	chr7:66880708~66882981:+
LUAD	cis	rs10740039	0.768	rs10994432	ENSG00000254271.1	RP11-131N11.4	6.09	2.29e-09	9.92e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60623831	chr10:60734342~60741828:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000232546.1	RP11-458F8.1	-6.09	2.29e-09	9.92e-07	-0.35	-0.27	Gout;	chr7:66693028	chr7:66848496~66858136:+
LUAD	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-6.09	2.29e-09	9.92e-07	-0.35	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
LUAD	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.556	rs13197633	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.59	0.27	Depression;	chr6:28206979	chr6:28943877~28944537:+
LUAD	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	6.09	2.29e-09	9.94e-07	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-6.09	2.29e-09	9.94e-07	-0.3	-0.27	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
LUAD	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-6.09	2.29e-09	9.95e-07	-0.32	-0.27	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
LUAD	cis	rs55665837	0.701	rs12286408	ENSG00000251991.1	RNU7-49P	6.09	2.29e-09	9.95e-07	0.31	0.27	Vitamin D levels;	chr11:14557830	chr11:14478892~14478953:+
LUAD	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	6.09	2.3e-09	9.96e-07	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
LUAD	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
LUAD	cis	rs7017914	0.902	rs34856835	ENSG00000223220.1	Y_RNA	6.09	2.3e-09	9.98e-07	0.3	0.27	Bone mineral density;	chr8:71058376	chr8:70780914~70781008:-
LUAD	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-6.09	2.3e-09	9.98e-07	-0.36	-0.27	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
LUAD	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	6.09	2.3e-09	9.98e-07	0.31	0.27	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
LUAD	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	6.09	2.3e-09	9.98e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
LUAD	cis	rs4787484	0.964	rs7498372	ENSG00000214725.6	CDIPT-AS1	-6.09	2.3e-09	9.99e-07	-0.34	-0.27	Response to taxane treatment (placlitaxel);	chr16:29899404	chr16:29863593~29868053:+
LUAD	cis	rs7044106	0.762	rs4837789	ENSG00000238181.2	AHCYP2	-6.09	2.3e-09	9.99e-07	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120720673~120721972:+
LUAD	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	6.09	2.3e-09	9.99e-07	0.38	0.27	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
LUAD	cis	rs875971	0.895	rs4145009	ENSG00000222364.1	RNU6-96P	6.09	2.31e-09	9.99e-07	0.31	0.27	Aortic root size;	chr7:66261628	chr7:66395191~66395286:+
LUAD	cis	rs755249	0.567	rs3818806	ENSG00000228060.1	RP11-69E11.8	-6.09	2.31e-09	1e-06	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39565160~39573203:+
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000224373.3	IGHV4-59	6.09	2.31e-09	1e-06	0.16	0.27	Kawasaki disease;	chr14:106683893	chr14:106627249~106627825:-
LUAD	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	6.09	2.31e-09	1e-06	0.53	0.27	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs6964245	ENSG00000232546.1	RP11-458F8.1	6.09	2.31e-09	1e-06	0.35	0.27	Diabetic kidney disease;	chr7:66253730	chr7:66848496~66858136:+
LUAD	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-6.09	2.32e-09	1e-06	-0.32	-0.27	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-6.09	2.32e-09	1e-06	-0.29	-0.27	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1167411	ENSG00000222364.1	RNU6-96P	6.09	2.32e-09	1.01e-06	0.3	0.27	Aortic root size;	chr7:66074277	chr7:66395191~66395286:+
LUAD	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	6.09	2.32e-09	1.01e-06	0.34	0.27	Depression;	chr6:28363475	chr6:28943877~28944537:+
LUAD	cis	rs8031584	0.958	rs3512	ENSG00000260382.1	RP11-540B6.2	6.09	2.33e-09	1.01e-06	0.32	0.27	Huntington's disease progression;	chr15:30942802	chr15:30882267~30883231:-
LUAD	cis	rs853679	0.546	rs13213152	ENSG00000204709.4	LINC01556	6.09	2.33e-09	1.01e-06	0.6	0.27	Depression;	chr6:28381921	chr6:28943877~28944537:+
LUAD	cis	rs1874124	0.836	rs17596947	ENSG00000238078.1	LINC01352	6.09	2.33e-09	1.01e-06	0.38	0.27	Cholesterol, total;	chr1:220820122	chr1:220829255~220832429:+
LUAD	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	6.09	2.33e-09	1.01e-06	0.32	0.27	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
LUAD	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-6.09	2.33e-09	1.01e-06	-0.37	-0.27	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	6.09	2.33e-09	1.01e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
LUAD	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-6.09	2.34e-09	1.01e-06	-0.27	-0.27	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
LUAD	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	6.09	2.34e-09	1.01e-06	0.32	0.27	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
LUAD	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.01e-06	0.32	0.27	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
LUAD	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	6.09	2.34e-09	1.01e-06	0.29	0.27	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
LUAD	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	6.09	2.34e-09	1.01e-06	0.3	0.27	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
LUAD	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	6.09	2.35e-09	1.02e-06	0.37	0.27	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12082012	ENSG00000227373.4	RP11-160H22.5	6.09	2.35e-09	1.02e-06	0.4	0.27	Systemic lupus erythematosus;	chr1:174588729	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4451598	ENSG00000227373.4	RP11-160H22.5	6.09	2.35e-09	1.02e-06	0.4	0.27	Systemic lupus erythematosus;	chr1:174606576	chr1:174115300~174160004:-
LUAD	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	6.09	2.35e-09	1.02e-06	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
LUAD	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	6.09	2.35e-09	1.02e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
LUAD	cis	rs17818399	1	rs17818399	ENSG00000279254.1	RP11-536C12.1	-6.09	2.35e-09	1.02e-06	-0.3	-0.27	Height;	chr2:46598887	chr2:46668870~46670778:+
LUAD	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	6.09	2.36e-09	1.02e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
LUAD	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	6.09	2.36e-09	1.02e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
LUAD	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	6.09	2.36e-09	1.02e-06	0.33	0.27	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
LUAD	cis	rs5753618	0.539	rs5997933	ENSG00000236132.1	CTA-440B3.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Colorectal cancer;	chr22:31276766	chr22:31816379~31817491:-
LUAD	cis	rs56114371	0.53	rs9357045	ENSG00000219392.1	RP1-265C24.5	-6.09	2.36e-09	1.02e-06	-0.39	-0.27	Breast cancer;	chr6:27721148	chr6:28115628~28116551:+
LUAD	cis	rs10740039	0.516	rs10740035	ENSG00000254271.1	RP11-131N11.4	-6.09	2.36e-09	1.02e-06	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60592848	chr10:60734342~60741828:+
LUAD	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-6.09	2.36e-09	1.02e-06	-0.35	-0.27	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-6.09	2.36e-09	1.02e-06	-0.35	-0.27	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
LUAD	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
LUAD	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	6.09	2.37e-09	1.02e-06	0.28	0.27	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
LUAD	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-6.09	2.37e-09	1.02e-06	-0.43	-0.27	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
LUAD	cis	rs7017914	0.905	rs3110246	ENSG00000223220.1	Y_RNA	6.09	2.37e-09	1.03e-06	0.3	0.27	Bone mineral density;	chr8:71022378	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110250	ENSG00000223220.1	Y_RNA	6.09	2.37e-09	1.03e-06	0.3	0.27	Bone mineral density;	chr8:71024149	chr8:70780914~70781008:-
LUAD	cis	rs7044106	0.762	rs7024046	ENSG00000238181.2	AHCYP2	-6.09	2.37e-09	1.03e-06	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120720673~120721972:+
LUAD	cis	rs1707322	0.721	rs10789468	ENSG00000234329.1	RP11-767N6.2	6.09	2.37e-09	1.03e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs6429574	ENSG00000234329.1	RP11-767N6.2	6.09	2.37e-09	1.03e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45651039~45651826:-
LUAD	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-6.09	2.37e-09	1.03e-06	-0.32	-0.27	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
LUAD	cis	rs10214930	0.697	rs1880370	ENSG00000235574.1	AC073150.6	-6.09	2.38e-09	1.03e-06	-0.34	-0.27	Hypospadias;	chr7:27543693	chr7:27491682~27492765:-
LUAD	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-6.08	2.38e-09	1.03e-06	-0.32	-0.27	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
LUAD	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	6.08	2.38e-09	1.03e-06	0.33	0.27	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
LUAD	cis	rs1874124	0.778	rs1335920	ENSG00000238078.1	LINC01352	-6.08	2.38e-09	1.03e-06	-0.4	-0.27	Cholesterol, total;	chr1:220844946	chr1:220829255~220832429:+
LUAD	cis	rs1823913	0.637	rs4853579	ENSG00000280083.1	RP11-317J9.1	6.08	2.38e-09	1.03e-06	0.32	0.27	Obesity-related traits;	chr2:191297413	chr2:191154118~191156070:-
LUAD	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-6.08	2.38e-09	1.03e-06	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000211972.2	IGHV3-66	6.08	2.38e-09	1.03e-06	0.23	0.27	Kawasaki disease;	chr14:106718498	chr14:106675017~106675544:-
LUAD	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-6.08	2.38e-09	1.03e-06	-0.33	-0.27	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-6.08	2.38e-09	1.03e-06	-0.33	-0.27	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-6.08	2.38e-09	1.03e-06	-0.33	-0.27	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
LUAD	cis	rs12699921	0.632	rs1404424	ENSG00000279048.1	RP11-511H23.2	-6.08	2.38e-09	1.03e-06	-0.22	-0.27	Fibrinogen levels;	chr7:17906981	chr7:17940503~17942922:+
LUAD	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	6.08	2.39e-09	1.03e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
LUAD	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	6.08	2.39e-09	1.03e-06	0.36	0.27	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
LUAD	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	6.08	2.39e-09	1.03e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
LUAD	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	6.08	2.39e-09	1.03e-06	0.33	0.27	Height;	chr6:109370985	chr6:109382795~109383666:+
LUAD	cis	rs4908768	0.501	rs11121186	ENSG00000232912.4	RP5-1115A15.1	6.08	2.39e-09	1.03e-06	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8424645~8434838:+
LUAD	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	6.08	2.39e-09	1.03e-06	0.29	0.27	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	6.08	2.39e-09	1.03e-06	0.29	0.27	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
LUAD	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	6.08	2.39e-09	1.03e-06	0.39	0.27	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
LUAD	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	6.08	2.39e-09	1.03e-06	0.28	0.27	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs1796220	ENSG00000232546.1	RP11-458F8.1	-6.08	2.4e-09	1.04e-06	-0.36	-0.27	Diabetic kidney disease;	chr7:66597113	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2707831	ENSG00000232546.1	RP11-458F8.1	-6.08	2.4e-09	1.04e-06	-0.36	-0.27	Diabetic kidney disease;	chr7:66597524	chr7:66848496~66858136:+
LUAD	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	6.08	2.4e-09	1.04e-06	0.39	0.27	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
LUAD	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	6.08	2.4e-09	1.04e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	6.08	2.4e-09	1.04e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	6.08	2.4e-09	1.04e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	6.08	2.4e-09	1.04e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-6.08	2.4e-09	1.04e-06	-0.36	-0.27	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
LUAD	cis	rs35740288	0.77	rs11638379	ENSG00000202081.1	RNU6-1280P	6.08	2.4e-09	1.04e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85568059	chr15:85651522~85651628:-
LUAD	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	6.08	2.4e-09	1.04e-06	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
LUAD	cis	rs853679	0.546	rs35017208	ENSG00000204709.4	LINC01556	6.08	2.41e-09	1.04e-06	0.6	0.27	Depression;	chr6:28377505	chr6:28943877~28944537:+
LUAD	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	6.08	2.41e-09	1.04e-06	0.32	0.27	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.532	rs4833624	ENSG00000248280.1	RP11-33B1.2	6.08	2.41e-09	1.04e-06	0.34	0.27	Corneal astigmatism;	chr4:119664342	chr4:119440561~119450157:-
LUAD	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-6.08	2.41e-09	1.04e-06	-0.3	-0.27	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
LUAD	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-6.08	2.41e-09	1.04e-06	-0.32	-0.27	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-6.08	2.41e-09	1.04e-06	-0.49	-0.27	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
LUAD	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-6.08	2.41e-09	1.04e-06	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-6.08	2.42e-09	1.04e-06	-0.29	-0.27	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
LUAD	cis	rs10214930	0.671	rs6963585	ENSG00000235574.1	AC073150.6	-6.08	2.42e-09	1.04e-06	-0.34	-0.27	Hypospadias;	chr7:27544204	chr7:27491682~27492765:-
LUAD	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	6.08	2.42e-09	1.04e-06	0.43	0.27	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
LUAD	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	6.08	2.42e-09	1.04e-06	0.32	0.27	Depression;	chr6:28363475	chr6:28176188~28176674:+
LUAD	cis	rs1823913	0.599	rs1454754	ENSG00000280083.1	RP11-317J9.1	-6.08	2.42e-09	1.05e-06	-0.32	-0.27	Obesity-related traits;	chr2:191303562	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs13010441	ENSG00000280083.1	RP11-317J9.1	-6.08	2.42e-09	1.05e-06	-0.32	-0.27	Obesity-related traits;	chr2:191303903	chr2:191154118~191156070:-
LUAD	cis	rs9595908	0.645	rs4942924	ENSG00000212293.1	SNORA16	6.08	2.42e-09	1.05e-06	0.28	0.27	Body mass index;	chr13:32806987	chr13:32420390~32420516:-
LUAD	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	6.08	2.42e-09	1.05e-06	0.34	0.27	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
LUAD	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	6.08	2.42e-09	1.05e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
LUAD	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	6.08	2.42e-09	1.05e-06	0.37	0.27	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
LUAD	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	6.08	2.43e-09	1.05e-06	0.3	0.27	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
LUAD	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	6.08	2.43e-09	1.05e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
LUAD	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	6.08	2.43e-09	1.05e-06	0.29	0.27	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
LUAD	cis	rs11157436	1	rs12587157	ENSG00000211812.1	TRAV26-2	-6.08	2.43e-09	1.05e-06	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22202583~22203368:+
LUAD	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	6.08	2.43e-09	1.05e-06	0.37	0.27	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
LUAD	cis	rs12468226	0.938	rs80282360	ENSG00000226261.1	AC064836.3	6.08	2.43e-09	1.05e-06	0.45	0.27	Urate levels;	chr2:202275121	chr2:202336024~202336727:-
LUAD	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	6.08	2.43e-09	1.05e-06	0.41	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
LUAD	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-6.08	2.43e-09	1.05e-06	-0.25	-0.27	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
LUAD	cis	rs55665837	0.559	rs11023209	ENSG00000251991.1	RNU7-49P	6.08	2.43e-09	1.05e-06	0.3	0.27	Vitamin D levels;	chr11:14401054	chr11:14478892~14478953:+
LUAD	cis	rs11157436	1	rs61972228	ENSG00000211812.1	TRAV26-2	-6.08	2.43e-09	1.05e-06	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22202583~22203368:+
LUAD	cis	rs853679	0.517	rs3757187	ENSG00000204709.4	LINC01556	6.08	2.43e-09	1.05e-06	0.38	0.27	Depression;	chr6:28139876	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs3757185	ENSG00000204709.4	LINC01556	6.08	2.43e-09	1.05e-06	0.38	0.27	Depression;	chr6:28139998	chr6:28943877~28944537:+
LUAD	cis	rs6772849	0.896	rs4857859	ENSG00000242551.2	POU5F1P6	-6.08	2.43e-09	1.05e-06	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:128674735~128677005:-
LUAD	cis	rs10740039	0.883	rs2393676	ENSG00000254271.1	RP11-131N11.4	6.08	2.44e-09	1.05e-06	0.3	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60630500	chr10:60734342~60741828:+
LUAD	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-6.08	2.44e-09	1.05e-06	-0.35	-0.27	Migraine;	chr4:56851192	chr4:56960927~56961373:-
LUAD	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	6.08	2.44e-09	1.05e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
LUAD	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	6.08	2.44e-09	1.05e-06	0.39	0.27	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000230295.1	RP11-458F8.2	-6.08	2.44e-09	1.05e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:66108952	chr7:66880708~66882981:+
LUAD	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	6.08	2.44e-09	1.05e-06	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
LUAD	cis	rs7618501	0.633	rs6772095	ENSG00000234667.1	ACTBP13	-6.08	2.44e-09	1.05e-06	-0.3	-0.27	Intelligence (multi-trait analysis);	chr3:49940636	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.603	rs72942333	ENSG00000234667.1	ACTBP13	-6.08	2.44e-09	1.05e-06	-0.3	-0.27	Intelligence (multi-trait analysis);	chr3:49948685	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs6792892	ENSG00000234667.1	ACTBP13	-6.08	2.44e-09	1.05e-06	-0.3	-0.27	Intelligence (multi-trait analysis);	chr3:49958085	chr3:49873347~49877980:-
LUAD	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	6.08	2.44e-09	1.05e-06	0.31	0.27	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
LUAD	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-6.08	2.45e-09	1.06e-06	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000228039.3	KB-1125A3.10	6.08	2.45e-09	1.06e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23963780~23964374:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000228039.3	KB-1125A3.10	6.08	2.45e-09	1.06e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23963780~23964374:+
LUAD	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	6.08	2.45e-09	1.06e-06	0.32	0.27	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
LUAD	cis	rs7246657	0.891	rs2279149	ENSG00000276846.1	CTD-3220F14.3	6.08	2.45e-09	1.06e-06	0.37	0.27	Coronary artery calcification;	chr19:37533465	chr19:37314868~37315620:-
LUAD	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-6.08	2.45e-09	1.06e-06	-0.31	-0.27	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
LUAD	cis	rs948562	0.744	rs11229484	ENSG00000280010.1	AP001350.4	6.08	2.45e-09	1.06e-06	0.4	0.27	Lymphoma;	chr11:58464724	chr11:58627435~58628528:+
LUAD	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	6.08	2.45e-09	1.06e-06	0.37	0.27	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
LUAD	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	6.08	2.45e-09	1.06e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
LUAD	cis	rs2243480	1	rs1964692	ENSG00000230295.1	RP11-458F8.2	-6.08	2.46e-09	1.06e-06	-0.32	-0.27	Diabetic kidney disease;	chr7:65989196	chr7:66880708~66882981:+
LUAD	cis	rs4591358	0.773	rs17781713	ENSG00000223466.1	AC064834.2	-6.08	2.46e-09	1.06e-06	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506827	chr2:195533035~195538681:+
LUAD	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	6.08	2.46e-09	1.06e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
LUAD	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	6.08	2.46e-09	1.06e-06	0.32	0.27	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
LUAD	cis	rs17684571	0.751	rs1610157	ENSG00000231441.1	RP11-472M19.2	6.08	2.46e-09	1.06e-06	0.41	0.27	Schizophrenia;	chr6:56844035	chr6:56844002~56864078:+
LUAD	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	6.08	2.46e-09	1.06e-06	0.28	0.27	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
LUAD	cis	rs7688540	0.515	rs28415975	ENSG00000275426.1	CH17-262A2.1	6.08	2.46e-09	1.06e-06	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:149738~150317:+
LUAD	cis	rs1823913	0.599	rs13427761	ENSG00000280083.1	RP11-317J9.1	6.08	2.46e-09	1.06e-06	0.32	0.27	Obesity-related traits;	chr2:191269256	chr2:191154118~191156070:-
LUAD	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-6.08	2.46e-09	1.06e-06	-0.37	-0.27	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-6.08	2.46e-09	1.06e-06	-0.37	-0.27	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
LUAD	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	6.08	2.47e-09	1.06e-06	0.31	0.27	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	6.08	2.47e-09	1.06e-06	0.31	0.27	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
LUAD	cis	rs9467773	0.511	rs17278688	ENSG00000241549.7	GUSBP2	6.08	2.47e-09	1.06e-06	0.29	0.27	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26871484~26956554:-
LUAD	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-6.08	2.47e-09	1.06e-06	-0.4	-0.27	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
LUAD	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	6.08	2.47e-09	1.07e-06	0.3	0.27	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
LUAD	cis	rs853679	0.517	rs7755442	ENSG00000204709.4	LINC01556	6.08	2.47e-09	1.07e-06	0.37	0.27	Depression;	chr6:28071237	chr6:28943877~28944537:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	6.08	2.47e-09	1.07e-06	0.39	0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
LUAD	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	6.08	2.48e-09	1.07e-06	0.39	0.27	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
LUAD	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	6.08	2.48e-09	1.07e-06	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
LUAD	cis	rs2243480	1	rs6958420	ENSG00000232546.1	RP11-458F8.1	6.08	2.48e-09	1.07e-06	0.35	0.27	Diabetic kidney disease;	chr7:66286184	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1392104	ENSG00000232546.1	RP11-458F8.1	6.08	2.48e-09	1.07e-06	0.35	0.27	Diabetic kidney disease;	chr7:66294120	chr7:66848496~66858136:+
LUAD	cis	rs1914816	0.941	rs2957037	ENSG00000196274.5	Metazoa_SRP	6.08	2.48e-09	1.07e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76193195	chr15:76230048~76230390:-
LUAD	cis	rs4723738	1	rs4723738	ENSG00000227191.5	TRGC2	-6.08	2.48e-09	1.07e-06	-0.29	-0.27	Treatment response for severe sepsis;	chr7:38201307	chr7:38239580~38368091:-
LUAD	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	6.08	2.48e-09	1.07e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
LUAD	cis	rs9910055	0.762	rs7213436	ENSG00000267080.4	ASB16-AS1	6.08	2.48e-09	1.07e-06	0.24	0.27	Total body bone mineral density;	chr17:44174795	chr17:44175973~44186717:-
LUAD	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	6.08	2.49e-09	1.07e-06	0.3	0.27	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
LUAD	cis	rs1275468	1	rs3858534	ENSG00000257497.2	RP11-585P4.5	-6.08	2.49e-09	1.07e-06	-0.37	-0.27	Polycystic ovary syndrome;	chr12:75553304	chr12:75483454~75489820:-
LUAD	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-6.08	2.49e-09	1.07e-06	-0.33	-0.27	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
LUAD	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-6.08	2.49e-09	1.07e-06	-0.26	-0.27	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
LUAD	cis	rs9652601	0.691	rs9941107	ENSG00000274038.1	RP11-66H6.4	-6.08	2.49e-09	1.07e-06	-0.32	-0.27	Systemic lupus erythematosus;	chr16:11102184	chr16:11056556~11057034:+
LUAD	cis	rs30380	0.632	rs149189	ENSG00000272109.1	CTD-2260A17.3	-6.08	2.5e-09	1.08e-06	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96802101	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.632	rs26495	ENSG00000272109.1	CTD-2260A17.3	-6.08	2.5e-09	1.08e-06	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96802137	chr5:96804353~96806105:+
LUAD	cis	rs10129255	1	rs10129255	ENSG00000211972.2	IGHV3-66	-6.08	2.5e-09	1.08e-06	-0.23	-0.27	Kawasaki disease;	chr14:106767970	chr14:106675017~106675544:-
LUAD	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	6.08	2.5e-09	1.08e-06	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
LUAD	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-6.08	2.5e-09	1.08e-06	-0.31	-0.27	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
LUAD	cis	rs4591358	0.773	rs13035226	ENSG00000223466.1	AC064834.2	-6.08	2.51e-09	1.08e-06	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512957	chr2:195533035~195538681:+
LUAD	cis	rs9879311	1	rs9879311	ENSG00000240288.6	GHRLOS	6.08	2.51e-09	1.08e-06	0.25	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373659	chr3:10285754~10293449:+
LUAD	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-6.08	2.51e-09	1.08e-06	-0.37	-0.27	Depression;	chr6:28193021	chr6:28115628~28116551:+
LUAD	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-6.08	2.51e-09	1.08e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
LUAD	cis	rs7246657	0.678	rs2927740	ENSG00000276846.1	CTD-3220F14.3	-6.08	2.52e-09	1.08e-06	-0.35	-0.27	Coronary artery calcification;	chr19:37650065	chr19:37314868~37315620:-
LUAD	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	6.08	2.52e-09	1.09e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	6.08	2.52e-09	1.09e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	6.08	2.52e-09	1.09e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000232546.1	RP11-458F8.1	-6.07	2.52e-09	1.09e-06	-0.36	-0.27	Diabetic kidney disease;	chr7:65977771	chr7:66848496~66858136:+
LUAD	cis	rs1345301	0.514	rs57738191	ENSG00000234389.1	AC007278.3	-6.07	2.52e-09	1.09e-06	-0.24	-0.27	Waist circumference;	chr2:102251899	chr2:102438713~102440475:+
LUAD	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	6.07	2.53e-09	1.09e-06	0.37	0.27	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	6.07	2.53e-09	1.09e-06	0.37	0.27	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
LUAD	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	6.07	2.53e-09	1.09e-06	0.29	0.27	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	6.07	2.53e-09	1.09e-06	0.29	0.27	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
LUAD	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-6.07	2.53e-09	1.09e-06	-0.29	-0.27	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
LUAD	cis	rs1914816	0.941	rs2460146	ENSG00000196274.5	Metazoa_SRP	6.07	2.53e-09	1.09e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76262414	chr15:76230048~76230390:-
LUAD	cis	rs1914816	1	rs2456075	ENSG00000196274.5	Metazoa_SRP	6.07	2.53e-09	1.09e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76263645	chr15:76230048~76230390:-
LUAD	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-6.07	2.53e-09	1.09e-06	-0.34	-0.27	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
LUAD	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	6.07	2.53e-09	1.09e-06	0.32	0.27	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
LUAD	cis	rs8031584	0.958	rs34294266	ENSG00000260382.1	RP11-540B6.2	6.07	2.53e-09	1.09e-06	0.32	0.27	Huntington's disease progression;	chr15:30954637	chr15:30882267~30883231:-
LUAD	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-6.07	2.53e-09	1.09e-06	-0.25	-0.27	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
LUAD	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-6.07	2.53e-09	1.09e-06	-0.25	-0.27	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
LUAD	cis	rs875971	1	rs1183245	ENSG00000222364.1	RNU6-96P	6.07	2.53e-09	1.09e-06	0.3	0.27	Aortic root size;	chr7:66076198	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1144895	ENSG00000222364.1	RNU6-96P	6.07	2.53e-09	1.09e-06	0.3	0.27	Aortic root size;	chr7:66076320	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1144894	ENSG00000222364.1	RNU6-96P	6.07	2.53e-09	1.09e-06	0.3	0.27	Aortic root size;	chr7:66077907	chr7:66395191~66395286:+
LUAD	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-6.07	2.54e-09	1.09e-06	-0.28	-0.27	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
LUAD	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	6.07	2.54e-09	1.09e-06	0.27	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
LUAD	cis	rs12699921	0.599	rs2462512	ENSG00000279048.1	RP11-511H23.2	-6.07	2.54e-09	1.09e-06	-0.21	-0.27	Fibrinogen levels;	chr7:17808215	chr7:17940503~17942922:+
LUAD	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	6.07	2.55e-09	1.1e-06	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
LUAD	cis	rs4713118	0.662	rs149900	ENSG00000204709.4	LINC01556	6.07	2.55e-09	1.1e-06	0.36	0.27	Parkinson's disease;	chr6:28046819	chr6:28943877~28944537:+
LUAD	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	6.07	2.55e-09	1.1e-06	0.3	0.27	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
LUAD	cis	rs62229266	0.557	rs4817761	ENSG00000214914.3	RPL23AP3	6.07	2.55e-09	1.1e-06	0.33	0.27	Mitral valve prolapse;	chr21:36023258	chr21:36016079~36016546:-
LUAD	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	6.07	2.56e-09	1.1e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	6.07	2.56e-09	1.1e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
LUAD	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	6.07	2.56e-09	1.1e-06	0.3	0.27	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
LUAD	cis	rs755249	0.874	rs61779310	ENSG00000228060.1	RP11-69E11.8	-6.07	2.56e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39565160~39573203:+
LUAD	cis	rs10050311	0.858	rs76283582	ENSG00000251411.1	RP11-397E7.4	-6.07	2.57e-09	1.1e-06	-0.37	-0.27	Insulin-related traits;	chr4:86878202	chr4:86913266~86914817:-
LUAD	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	6.07	2.57e-09	1.1e-06	0.32	0.27	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	6.07	2.57e-09	1.1e-06	0.32	0.27	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
LUAD	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	6.07	2.57e-09	1.1e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
LUAD	cis	rs1874124	0.577	rs2807880	ENSG00000238078.1	LINC01352	6.07	2.57e-09	1.1e-06	0.39	0.27	Cholesterol, total;	chr1:220869661	chr1:220829255~220832429:+
LUAD	cis	rs755249	0.567	rs4660546	ENSG00000228060.1	RP11-69E11.8	-6.07	2.57e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs2036463	ENSG00000228060.1	RP11-69E11.8	-6.07	2.57e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs2036464	ENSG00000228060.1	RP11-69E11.8	-6.07	2.57e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs905381	ENSG00000228060.1	RP11-69E11.8	-6.07	2.57e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39565160~39573203:+
LUAD	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-6.07	2.57e-09	1.11e-06	-0.37	-0.27	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000211974.3	IGHV2-70	6.07	2.58e-09	1.11e-06	0.27	0.27	Kawasaki disease;	chr14:106776528	chr14:106723574~106724093:-
LUAD	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	6.07	2.58e-09	1.11e-06	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000232546.1	RP11-458F8.1	-6.07	2.58e-09	1.11e-06	-0.36	-0.27	Gout;	chr7:66732812	chr7:66848496~66858136:+
LUAD	cis	rs270601	0.661	rs10036208	ENSG00000233006.5	AC034220.3	6.07	2.58e-09	1.11e-06	0.25	0.27	Acylcarnitine levels;	chr5:132235630	chr5:132311285~132369916:-
LUAD	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-6.07	2.58e-09	1.11e-06	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-6.07	2.58e-09	1.11e-06	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
LUAD	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-6.07	2.58e-09	1.11e-06	-0.35	-0.27	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
LUAD	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-6.07	2.58e-09	1.11e-06	-0.28	-0.27	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
LUAD	cis	rs496547	0.756	rs562059	ENSG00000255422.1	AP002954.4	-6.07	2.58e-09	1.11e-06	-0.34	-0.27	Hip minimal joint space width;	chr11:118731349	chr11:118704607~118750263:+
LUAD	cis	rs853679	1	rs1936365	ENSG00000204709.4	LINC01556	-6.07	2.58e-09	1.11e-06	-0.4	-0.27	Depression;	chr6:28300675	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-6.07	2.58e-09	1.11e-06	-0.29	-0.27	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-6.07	2.58e-09	1.11e-06	-0.28	-0.27	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
LUAD	cis	rs321358	0.731	rs516110	ENSG00000271584.1	RP11-89C3.4	6.07	2.59e-09	1.11e-06	0.4	0.27	Body mass index;	chr11:111166525	chr11:111091932~111097357:-
LUAD	cis	rs853679	0.517	rs9393890	ENSG00000204709.4	LINC01556	6.07	2.59e-09	1.11e-06	0.37	0.27	Depression;	chr6:28096077	chr6:28943877~28944537:+
LUAD	cis	rs496547	0.719	rs476246	ENSG00000255422.1	AP002954.4	6.07	2.59e-09	1.11e-06	0.34	0.27	Hip minimal joint space width;	chr11:118747211	chr11:118704607~118750263:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000206090.4	AP000350.7	-6.07	2.59e-09	1.11e-06	-0.35	-0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23939998~23942798:+
LUAD	cis	rs1499614	1	rs2707832	ENSG00000230295.1	RP11-458F8.2	-6.07	2.59e-09	1.11e-06	-0.32	-0.27	Gout;	chr7:66671562	chr7:66880708~66882981:+
LUAD	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	6.07	2.6e-09	1.12e-06	0.37	0.27	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
LUAD	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-6.07	2.6e-09	1.12e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
LUAD	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-6.07	2.6e-09	1.12e-06	-0.34	-0.27	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
LUAD	cis	rs35740288	0.703	rs10520598	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630150	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11635587	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630402	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs35447727	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631168	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs34058174	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631231	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.587	rs4843089	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85632905	chr15:85651522~85651628:-
LUAD	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	6.07	2.6e-09	1.12e-06	0.29	0.27	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
LUAD	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	6.07	2.6e-09	1.12e-06	0.32	0.27	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
LUAD	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-6.07	2.61e-09	1.12e-06	-0.38	-0.27	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
LUAD	cis	rs755249	0.567	rs72661927	ENSG00000228060.1	RP11-69E11.8	-6.07	2.61e-09	1.12e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39565160~39573203:+
LUAD	cis	rs9506514	0.722	rs10400670	ENSG00000222726.1	RNU2-7P	6.07	2.61e-09	1.12e-06	0.3	0.27	Coronary artery calcification;	chr13:20679350	chr13:20612161~20612338:+
LUAD	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	6.07	2.62e-09	1.12e-06	0.3	0.27	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
LUAD	cis	rs10129255	1	rs10129407	ENSG00000211972.2	IGHV3-66	6.07	2.62e-09	1.12e-06	0.23	0.27	Kawasaki disease;	chr14:106767956	chr14:106675017~106675544:-
LUAD	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	6.07	2.62e-09	1.12e-06	0.3	0.27	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
LUAD	cis	rs9326248	0.501	rs4938351	ENSG00000280143.1	AP000892.6	6.07	2.62e-09	1.13e-06	0.31	0.27	Blood protein levels;	chr11:117151636	chr11:117204967~117210292:+
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000230295.1	RP11-458F8.2	-6.07	2.62e-09	1.13e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:66034886	chr7:66880708~66882981:+
LUAD	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	6.07	2.63e-09	1.13e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
LUAD	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-6.07	2.63e-09	1.13e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
LUAD	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-6.07	2.63e-09	1.13e-06	-0.33	-0.27	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
LUAD	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	6.07	2.63e-09	1.13e-06	0.32	0.27	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
LUAD	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	6.07	2.63e-09	1.13e-06	0.37	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
LUAD	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	6.07	2.63e-09	1.13e-06	0.24	0.27	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
LUAD	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-6.07	2.64e-09	1.13e-06	-0.28	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
LUAD	cis	rs7923837	0.634	rs61862780	ENSG00000236493.2	EIF2S2P3	-6.07	2.64e-09	1.13e-06	-0.3	-0.27	Multiple sclerosis;Body mass index;	chr10:92708886	chr10:92668745~92669743:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000211974.3	IGHV2-70	6.07	2.64e-09	1.13e-06	0.28	0.27	Kawasaki disease;	chr14:106777528	chr14:106723574~106724093:-
LUAD	cis	rs1823913	0.599	rs12988037	ENSG00000280083.1	RP11-317J9.1	-6.07	2.64e-09	1.13e-06	-0.32	-0.27	Obesity-related traits;	chr2:191306419	chr2:191154118~191156070:-
LUAD	cis	rs5753618	0.509	rs5749224	ENSG00000236132.1	CTA-440B3.1	6.07	2.64e-09	1.13e-06	0.34	0.27	Colorectal cancer;	chr22:31162563	chr22:31816379~31817491:-
LUAD	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	6.07	2.64e-09	1.13e-06	0.43	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
LUAD	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
LUAD	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	6.07	2.65e-09	1.14e-06	0.37	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
LUAD	cis	rs7688540	0.8	rs12506277	ENSG00000275426.1	CH17-262A2.1	6.07	2.65e-09	1.14e-06	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:149738~150317:+
LUAD	cis	rs7688540	0.8	rs12501727	ENSG00000275426.1	CH17-262A2.1	6.07	2.65e-09	1.14e-06	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:149738~150317:+
LUAD	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	6.07	2.65e-09	1.14e-06	0.33	0.27	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
LUAD	cis	rs2243480	1	rs313807	ENSG00000230295.1	RP11-458F8.2	-6.07	2.65e-09	1.14e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:66034494	chr7:66880708~66882981:+
LUAD	cis	rs1914816	1	rs1914816	ENSG00000196274.5	Metazoa_SRP	6.07	2.65e-09	1.14e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76254592	chr15:76230048~76230390:-
LUAD	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-6.07	2.66e-09	1.14e-06	-0.32	-0.27	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
LUAD	cis	rs1914816	0.887	rs2460155	ENSG00000196274.5	Metazoa_SRP	6.07	2.66e-09	1.14e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76186584	chr15:76230048~76230390:-
LUAD	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-6.07	2.66e-09	1.14e-06	-0.36	-0.27	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-6.07	2.66e-09	1.14e-06	-0.36	-0.27	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
LUAD	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-6.07	2.66e-09	1.14e-06	-0.33	-0.27	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
LUAD	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-6.07	2.66e-09	1.14e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
LUAD	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-6.07	2.66e-09	1.14e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
LUAD	cis	rs17301013	0.507	rs1622802	ENSG00000227373.4	RP11-160H22.5	-6.07	2.66e-09	1.14e-06	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174766066	chr1:174115300~174160004:-
LUAD	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	6.07	2.66e-09	1.14e-06	0.33	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
LUAD	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-6.07	2.66e-09	1.14e-06	-0.35	-0.27	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-6.07	2.67e-09	1.14e-06	-0.38	-0.27	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
LUAD	cis	rs10214930	0.697	rs12672811	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27645264	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs2391449	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27645527	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs2391452	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27646533	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.624	rs13244903	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27649292	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs12530626	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650189	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12535844	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650205	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs6948460	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650619	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.647	rs6966587	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650744	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.625	rs2391453	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650968	chr7:27491682~27492765:-
LUAD	cis	rs9595908	0.869	rs2320301	ENSG00000212293.1	SNORA16	6.07	2.67e-09	1.14e-06	0.29	0.27	Body mass index;	chr13:32635067	chr13:32420390~32420516:-
LUAD	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-6.07	2.67e-09	1.14e-06	-0.38	-0.27	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
LUAD	cis	rs9879311	0.932	rs7427473	ENSG00000240288.6	GHRLOS	6.06	2.67e-09	1.15e-06	0.25	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10371513	chr3:10285754~10293449:+
LUAD	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	6.06	2.67e-09	1.15e-06	0.28	0.27	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
LUAD	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	6.06	2.68e-09	1.15e-06	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000224373.3	IGHV4-59	6.06	2.68e-09	1.15e-06	0.17	0.27	Kawasaki disease;	chr14:106779116	chr14:106627249~106627825:-
LUAD	cis	rs4820294	1	rs929039	ENSG00000233360.4	Z83844.1	6.06	2.68e-09	1.15e-06	0.28	0.27	Fat distribution (HIV);	chr22:37675504	chr22:37641832~37658377:-
LUAD	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-6.06	2.68e-09	1.15e-06	-0.36	-0.27	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
LUAD	cis	rs720064	0.555	rs11873358	ENSG00000264745.1	TTC39C-AS1	6.06	2.68e-09	1.15e-06	0.28	0.27	Strep throat;	chr18:23951942	chr18:23994213~24015339:-
LUAD	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-6.06	2.68e-09	1.15e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
LUAD	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	6.06	2.69e-09	1.15e-06	0.33	0.27	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
LUAD	cis	rs9595908	0.606	rs4942922	ENSG00000212293.1	SNORA16	6.06	2.69e-09	1.15e-06	0.29	0.27	Body mass index;	chr13:32806832	chr13:32420390~32420516:-
LUAD	cis	rs12699921	0.599	rs6955984	ENSG00000279048.1	RP11-511H23.2	6.06	2.69e-09	1.15e-06	0.22	0.27	Fibrinogen levels;	chr7:17938589	chr7:17940503~17942922:+
LUAD	cis	rs7618501	0.633	rs2883057	ENSG00000234667.1	ACTBP13	-6.06	2.69e-09	1.15e-06	-0.3	-0.27	Intelligence (multi-trait analysis);	chr3:49960849	chr3:49873347~49877980:-
LUAD	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	6.06	2.7e-09	1.15e-06	0.29	0.27	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
LUAD	cis	rs9928842	0.77	rs8048371	ENSG00000280152.1	RP11-331F4.5	6.06	2.7e-09	1.16e-06	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75245994~75250077:-
LUAD	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-6.06	2.7e-09	1.16e-06	-0.22	-0.27	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
LUAD	cis	rs9506514	0.712	rs11838795	ENSG00000222726.1	RNU2-7P	6.06	2.7e-09	1.16e-06	0.3	0.27	Coronary artery calcification;	chr13:20684189	chr13:20612161~20612338:+
LUAD	cis	rs11096990	0.964	rs6828598	ENSG00000249207.1	RP11-360F5.1	6.06	2.7e-09	1.16e-06	0.3	0.27	Cognitive function;	chr4:39259850	chr4:39112677~39126818:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000228039.3	KB-1125A3.10	6.06	2.7e-09	1.16e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23963780~23964374:+
LUAD	cis	rs853679	0.517	rs4713141	ENSG00000204709.4	LINC01556	6.06	2.7e-09	1.16e-06	0.37	0.27	Depression;	chr6:28133900	chr6:28943877~28944537:+
LUAD	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	6.06	2.71e-09	1.16e-06	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
LUAD	cis	rs6504622	0.818	rs758391	ENSG00000262879.4	RP11-156P1.3	6.06	2.71e-09	1.16e-06	0.31	0.27	Orofacial clefts;	chr17:46939875	chr17:46984045~47100323:-
LUAD	cis	rs12468226	0.938	rs114177656	ENSG00000272966.1	RP11-686O6.1	6.06	2.71e-09	1.16e-06	0.46	0.27	Urate levels;	chr2:202291596	chr2:202336739~202337200:+
LUAD	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	6.06	2.71e-09	1.16e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	6.06	2.71e-09	1.16e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	6.06	2.71e-09	1.16e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
LUAD	cis	rs755249	0.567	rs41270799	ENSG00000228060.1	RP11-69E11.8	-6.06	2.71e-09	1.16e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39565160~39573203:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000230295.1	RP11-458F8.2	6.06	2.71e-09	1.16e-06	0.33	0.27	Diabetic kidney disease;	chr7:66158142	chr7:66880708~66882981:+
LUAD	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	6.06	2.71e-09	1.16e-06	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-6.06	2.72e-09	1.16e-06	-0.29	-0.27	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-6.06	2.72e-09	1.16e-06	-0.29	-0.27	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
LUAD	cis	rs7688540	0.8	rs10023604	ENSG00000275426.1	CH17-262A2.1	6.06	2.72e-09	1.16e-06	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:149738~150317:+
LUAD	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-6.06	2.72e-09	1.16e-06	-0.35	-0.27	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
LUAD	cis	rs7044106	0.708	rs10760113	ENSG00000238181.2	AHCYP2	-6.06	2.72e-09	1.16e-06	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120720673~120721972:+
LUAD	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-6.06	2.72e-09	1.16e-06	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-6.06	2.72e-09	1.16e-06	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
LUAD	cis	rs17684571	0.751	rs34896026	ENSG00000231441.1	RP11-472M19.2	6.06	2.72e-09	1.16e-06	0.41	0.27	Schizophrenia;	chr6:56829383	chr6:56844002~56864078:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000228039.3	KB-1125A3.10	6.06	2.72e-09	1.16e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23963780~23964374:+
LUAD	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-6.06	2.73e-09	1.17e-06	-0.3	-0.27	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
LUAD	cis	rs755249	1	rs12037222	ENSG00000228060.1	RP11-69E11.8	-6.06	2.73e-09	1.17e-06	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39599289	chr1:39565160~39573203:+
LUAD	cis	rs12699921	0.632	rs2691627	ENSG00000279048.1	RP11-511H23.2	-6.06	2.73e-09	1.17e-06	-0.21	-0.27	Fibrinogen levels;	chr7:17784627	chr7:17940503~17942922:+
LUAD	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	6.06	2.73e-09	1.17e-06	0.33	0.27	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	6.06	2.73e-09	1.17e-06	0.33	0.27	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
LUAD	cis	rs853679	0.517	rs12174753	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28074687	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs55747925	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28076559	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs56310871	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28076704	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs34716816	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28078391	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393884	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28079011	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380049	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28080757	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380050	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28080760	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393885	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28082231	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393886	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28082261	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.515	rs9368549	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Parkinson's disease;	chr6:28082269	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs56364346	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28082984	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9357061	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28083994	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368550	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28084025	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.542	rs2295594	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28085319	chr6:28943877~28944537:+
LUAD	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	6.06	2.74e-09	1.17e-06	0.3	0.27	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
LUAD	cis	rs9834970	0.566	rs4327336	ENSG00000234073.1	AC011816.1	-6.06	2.75e-09	1.17e-06	-0.29	-0.27	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36854779	chr3:36880184~36880729:-
LUAD	cis	rs17684571	0.751	rs71564863	ENSG00000231441.1	RP11-472M19.2	6.06	2.75e-09	1.17e-06	0.41	0.27	Schizophrenia;	chr6:56840372	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs13192540	ENSG00000231441.1	RP11-472M19.2	6.06	2.75e-09	1.17e-06	0.41	0.27	Schizophrenia;	chr6:56842637	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs13192931	ENSG00000231441.1	RP11-472M19.2	6.06	2.75e-09	1.17e-06	0.41	0.27	Schizophrenia;	chr6:56842921	chr6:56844002~56864078:+
LUAD	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-6.06	2.75e-09	1.17e-06	-0.29	-0.27	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
LUAD	cis	rs1012068	0.686	rs5753818	ENSG00000236132.1	CTA-440B3.1	6.06	2.75e-09	1.18e-06	0.31	0.27	Chronic hepatitis C infection;	chr22:31917947	chr22:31816379~31817491:-
LUAD	cis	rs9595908	0.568	rs4942923	ENSG00000212293.1	SNORA16	6.06	2.75e-09	1.18e-06	0.28	0.27	Body mass index;	chr13:32806887	chr13:32420390~32420516:-
LUAD	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-6.06	2.76e-09	1.18e-06	-0.29	-0.27	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
LUAD	cis	rs1707322	0.717	rs2253862	ENSG00000234329.1	RP11-767N6.2	-6.06	2.76e-09	1.18e-06	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs2991988	ENSG00000234329.1	RP11-767N6.2	-6.06	2.76e-09	1.18e-06	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs2991989	ENSG00000234329.1	RP11-767N6.2	-6.06	2.76e-09	1.18e-06	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45651039~45651826:-
LUAD	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-6.06	2.76e-09	1.18e-06	-0.37	-0.27	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
LUAD	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-6.06	2.77e-09	1.18e-06	-0.39	-0.27	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
LUAD	cis	rs748404	0.666	rs12906481	ENSG00000205771.5	CATSPER2P1	-6.06	2.77e-09	1.18e-06	-0.41	-0.27	Lung cancer;	chr15:43467356	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs35958032	ENSG00000205771.5	CATSPER2P1	-6.06	2.77e-09	1.18e-06	-0.41	-0.27	Lung cancer;	chr15:43494397	chr15:43726918~43747094:-
LUAD	cis	rs1914816	0.878	rs2456078	ENSG00000196274.5	Metazoa_SRP	6.06	2.77e-09	1.18e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76266529	chr15:76230048~76230390:-
LUAD	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-6.06	2.77e-09	1.18e-06	-0.26	-0.27	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
LUAD	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	6.06	2.77e-09	1.18e-06	0.33	0.27	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
LUAD	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-6.06	2.78e-09	1.19e-06	-0.42	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
LUAD	cis	rs1154275	0.537	rs6800648	ENSG00000242770.2	RP11-180K7.1	6.06	2.78e-09	1.19e-06	0.28	0.27	Takotsubo syndrome;	chr3:112797586	chr3:112802478~112812819:+
LUAD	cis	rs7044106	0.708	rs10984992	ENSG00000238181.2	AHCYP2	-6.06	2.78e-09	1.19e-06	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120720673~120721972:+
LUAD	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-6.06	2.79e-09	1.19e-06	-0.31	-0.27	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
LUAD	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	6.06	2.79e-09	1.19e-06	0.38	0.27	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
LUAD	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-6.06	2.79e-09	1.19e-06	-0.35	-0.27	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
LUAD	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-6.06	2.79e-09	1.19e-06	-0.33	-0.27	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
LUAD	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-6.06	2.79e-09	1.19e-06	-0.28	-0.27	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
LUAD	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
LUAD	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	6.06	2.8e-09	1.19e-06	0.38	0.27	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000232546.1	RP11-458F8.1	-6.06	2.8e-09	1.19e-06	-0.35	-0.27	Diabetic kidney disease;	chr7:66500834	chr7:66848496~66858136:+
LUAD	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	6.06	2.8e-09	1.19e-06	0.39	0.27	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
LUAD	cis	rs6687821	0.515	rs523679	ENSG00000267734.1	RP4-604K5.3	6.06	2.8e-09	1.19e-06	0.33	0.27	Yeast infection;	chr1:86902412	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs525519	ENSG00000267734.1	RP4-604K5.3	6.06	2.8e-09	1.19e-06	0.33	0.27	Yeast infection;	chr1:86902611	chr1:86932199~86934891:-
LUAD	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	6.06	2.8e-09	1.2e-06	0.38	0.27	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
LUAD	cis	rs10200159	1	rs6705295	ENSG00000272606.1	RP11-554J4.1	6.06	2.81e-09	1.2e-06	0.43	0.27	Vitiligo;	chr2:55686874	chr2:55617909~55618373:+
LUAD	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-6.06	2.81e-09	1.2e-06	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
LUAD	cis	rs7246657	0.551	rs28462002	ENSG00000276846.1	CTD-3220F14.3	6.06	2.81e-09	1.2e-06	0.41	0.27	Coronary artery calcification;	chr19:37143560	chr19:37314868~37315620:-
LUAD	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-6.06	2.81e-09	1.2e-06	-0.38	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
LUAD	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-6.06	2.81e-09	1.2e-06	-0.36	-0.27	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-6.06	2.82e-09	1.2e-06	-0.27	-0.27	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-6.06	2.82e-09	1.2e-06	-0.27	-0.27	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
LUAD	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	6.06	2.82e-09	1.2e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	6.06	2.82e-09	1.2e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
LUAD	cis	rs1426063	0.614	rs7671634	ENSG00000249717.1	RP11-44F21.3	6.06	2.82e-09	1.2e-06	0.54	0.27	QT interval;	chr4:75090883	chr4:74955974~74970362:-
LUAD	cis	rs1823913	0.637	rs4853577	ENSG00000280083.1	RP11-317J9.1	6.06	2.82e-09	1.2e-06	0.32	0.27	Obesity-related traits;	chr2:191297118	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
LUAD	cis	rs10214930	1	rs6462050	ENSG00000235574.1	AC073150.6	6.06	2.83e-09	1.21e-06	0.37	0.27	Hypospadias;	chr7:27804884	chr7:27491682~27492765:-
LUAD	cis	rs10214930	1	rs6462051	ENSG00000235574.1	AC073150.6	6.06	2.83e-09	1.21e-06	0.37	0.27	Hypospadias;	chr7:27805042	chr7:27491682~27492765:-
LUAD	cis	rs6504622	1	rs6504622	ENSG00000262879.4	RP11-156P1.3	6.06	2.83e-09	1.21e-06	0.31	0.27	Orofacial clefts;	chr17:46942365	chr17:46984045~47100323:-
LUAD	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-6.05	2.83e-09	1.21e-06	-0.24	-0.27	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
LUAD	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-6.05	2.83e-09	1.21e-06	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
LUAD	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	6.05	2.84e-09	1.21e-06	0.28	0.27	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
LUAD	cis	rs453301	0.606	rs7462373	ENSG00000253981.4	ALG1L13P	-6.05	2.84e-09	1.21e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9041808	chr8:8236003~8244667:-
LUAD	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-6.05	2.84e-09	1.21e-06	-0.3	-0.27	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
LUAD	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-6.05	2.84e-09	1.21e-06	-0.37	-0.27	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
LUAD	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-6.05	2.85e-09	1.21e-06	-0.32	-0.27	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
LUAD	cis	rs1113500	0.548	rs7541433	ENSG00000226822.1	RP11-356N1.2	6.05	2.85e-09	1.21e-06	0.36	0.27	Growth-regulated protein alpha levels;	chr1:108103019	chr1:108071482~108074519:+
LUAD	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	6.05	2.85e-09	1.21e-06	0.35	0.27	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
LUAD	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-6.05	2.85e-09	1.22e-06	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
LUAD	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	6.05	2.86e-09	1.22e-06	0.33	0.27	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
LUAD	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-6.05	2.86e-09	1.22e-06	-0.28	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-6.05	2.86e-09	1.22e-06	-0.28	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
LUAD	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	6.05	2.86e-09	1.22e-06	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
LUAD	cis	rs62025270	0.547	rs8035496	ENSG00000202081.1	RNU6-1280P	-6.05	2.86e-09	1.22e-06	-0.34	-0.27	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85651522~85651628:-
LUAD	cis	rs11096990	0.892	rs11930865	ENSG00000249207.1	RP11-360F5.1	6.05	2.86e-09	1.22e-06	0.3	0.27	Cognitive function;	chr4:39218711	chr4:39112677~39126818:-
LUAD	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	6.05	2.87e-09	1.22e-06	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
LUAD	cis	rs30380	0.632	rs26497	ENSG00000272109.1	CTD-2260A17.3	-6.05	2.87e-09	1.22e-06	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96803064	chr5:96804353~96806105:+
LUAD	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-6.05	2.87e-09	1.22e-06	-0.36	-0.27	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
LUAD	cis	rs74233809	1	rs9633712	ENSG00000213277.3	MARCKSL1P1	6.05	2.87e-09	1.22e-06	0.44	0.27	Birth weight;	chr10:103114004	chr10:103175554~103176094:+
LUAD	cis	rs74233809	0.786	rs11191564	ENSG00000213277.3	MARCKSL1P1	6.05	2.87e-09	1.22e-06	0.44	0.27	Birth weight;	chr10:103118786	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs1060240	ENSG00000213277.3	MARCKSL1P1	6.05	2.87e-09	1.22e-06	0.44	0.27	Birth weight;	chr10:103123580	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs10883835	ENSG00000213277.3	MARCKSL1P1	6.05	2.87e-09	1.22e-06	0.44	0.27	Birth weight;	chr10:103124451	chr10:103175554~103176094:+
LUAD	cis	rs7044106	0.762	rs1867254	ENSG00000238181.2	AHCYP2	-6.05	2.88e-09	1.23e-06	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120720673~120721972:+
LUAD	cis	rs9450351	0.744	rs6902904	ENSG00000203875.9	SNHG5	-6.05	2.88e-09	1.23e-06	-0.58	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85492985	chr6:85660950~85678736:-
LUAD	cis	rs477895	1	rs34292685	ENSG00000236935.1	AP003774.1	-6.05	2.88e-09	1.23e-06	-0.34	-0.27	Mean platelet volume;	chr11:64281549	chr11:64325050~64329504:-
LUAD	cis	rs30380	0.587	rs469674	ENSG00000272109.1	CTD-2260A17.3	-6.05	2.88e-09	1.23e-06	-0.32	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96794312	chr5:96804353~96806105:+
LUAD	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	6.05	2.89e-09	1.23e-06	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
LUAD	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-6.05	2.89e-09	1.23e-06	-0.38	-0.27	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
LUAD	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-6.05	2.89e-09	1.23e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
LUAD	cis	rs2765539	0.59	rs1325942	ENSG00000226172.2	RP4-712E4.1	-6.05	2.89e-09	1.23e-06	-0.34	-0.27	Waist-hip ratio;	chr1:118941210	chr1:119000344~119001392:-
LUAD	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-6.05	2.89e-09	1.23e-06	-0.29	-0.27	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
LUAD	cis	rs11096990	0.855	rs2566170	ENSG00000249207.1	RP11-360F5.1	6.05	2.9e-09	1.23e-06	0.31	0.27	Cognitive function;	chr4:39150757	chr4:39112677~39126818:-
LUAD	cis	rs4908768	0.501	rs6669503	ENSG00000232912.4	RP5-1115A15.1	6.05	2.9e-09	1.23e-06	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8424645~8434838:+
LUAD	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	6.05	2.9e-09	1.23e-06	0.31	0.27	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
LUAD	cis	rs394563	0.69	rs237009	ENSG00000231760.4	RP11-350J20.5	6.05	2.91e-09	1.24e-06	0.33	0.27	Dupuytren's disease;	chr6:149438416	chr6:149796151~149826294:-
LUAD	cis	rs113835537	0.597	rs3825065	ENSG00000255517.5	CTD-3074O7.5	-6.05	2.91e-09	1.24e-06	-0.32	-0.27	Airway imaging phenotypes;	chr11:66543540	chr11:66473490~66480233:-
LUAD	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-6.05	2.91e-09	1.24e-06	-0.3	-0.27	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-6.05	2.91e-09	1.24e-06	-0.3	-0.27	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	6.05	2.91e-09	1.24e-06	0.3	0.27	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
LUAD	cis	rs7120173	1	rs7120173	ENSG00000254851.1	RP11-109L13.1	6.05	2.92e-09	1.24e-06	0.41	0.27	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117135528~117138582:+
LUAD	cis	rs4834770	1	rs878374	ENSG00000245958.5	RP11-33B1.1	-6.05	2.92e-09	1.24e-06	-0.24	-0.27	Blood protein levels;	chr4:119316409	chr4:119454791~119552025:+
LUAD	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-6.05	2.92e-09	1.24e-06	-0.36	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
LUAD	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-6.05	2.92e-09	1.24e-06	-0.51	-0.27	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
LUAD	cis	rs17684571	0.872	rs34832779	ENSG00000231441.1	RP11-472M19.2	6.05	2.92e-09	1.24e-06	0.39	0.27	Schizophrenia;	chr6:56758350	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs13203000	ENSG00000231441.1	RP11-472M19.2	6.05	2.92e-09	1.24e-06	0.39	0.27	Schizophrenia;	chr6:56758921	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs13217390	ENSG00000231441.1	RP11-472M19.2	6.05	2.92e-09	1.24e-06	0.39	0.27	Schizophrenia;	chr6:56758953	chr6:56844002~56864078:+
LUAD	cis	rs2243480	1	rs410128	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	1.24e-06	-0.36	-0.27	Diabetic kidney disease;	chr7:66138186	chr7:66848496~66858136:+
LUAD	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-6.05	2.93e-09	1.24e-06	-0.3	-0.27	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-6.05	2.93e-09	1.24e-06	-0.3	-0.27	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
LUAD	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	6.05	2.93e-09	1.24e-06	0.31	0.27	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
LUAD	cis	rs9595908	0.686	rs7988353	ENSG00000212293.1	SNORA16	6.05	2.93e-09	1.24e-06	0.29	0.27	Body mass index;	chr13:32760250	chr13:32420390~32420516:-
LUAD	cis	rs17684571	0.751	rs35242294	ENSG00000231441.1	RP11-472M19.2	6.05	2.93e-09	1.25e-06	0.41	0.27	Schizophrenia;	chr6:56846131	chr6:56844002~56864078:+
LUAD	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	6.05	2.94e-09	1.25e-06	0.37	0.27	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	6.05	2.94e-09	1.25e-06	0.37	0.27	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
LUAD	cis	rs7017914	0.905	rs2639956	ENSG00000223220.1	Y_RNA	6.05	2.94e-09	1.25e-06	0.3	0.27	Bone mineral density;	chr8:71011856	chr8:70780914~70781008:-
LUAD	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	6.05	2.94e-09	1.25e-06	0.3	0.27	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs1499613	ENSG00000232546.1	RP11-458F8.1	6.05	2.94e-09	1.25e-06	0.35	0.27	Diabetic kidney disease;	chr7:66265873	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1553174	ENSG00000232546.1	RP11-458F8.1	6.05	2.94e-09	1.25e-06	0.35	0.27	Diabetic kidney disease;	chr7:66266207	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs10950032	ENSG00000232546.1	RP11-458F8.1	6.05	2.94e-09	1.25e-06	0.35	0.27	Diabetic kidney disease;	chr7:66273604	chr7:66848496~66858136:+
LUAD	cis	rs2439831	1	rs9920763	ENSG00000205771.5	CATSPER2P1	-6.05	2.94e-09	1.25e-06	-0.56	-0.27	Lung cancer in ever smokers;	chr15:43468310	chr15:43726918~43747094:-
LUAD	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	6.05	2.94e-09	1.25e-06	0.24	0.27	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	6.05	2.94e-09	1.25e-06	0.24	0.27	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	6.05	2.94e-09	1.25e-06	0.24	0.27	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	6.05	2.95e-09	1.25e-06	0.24	0.27	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
LUAD	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-6.05	2.95e-09	1.25e-06	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
LUAD	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	6.05	2.95e-09	1.25e-06	0.31	0.27	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-6.05	2.95e-09	1.25e-06	-0.38	-0.27	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
LUAD	cis	rs2276314	0.553	rs12964535	ENSG00000278986.1	RP11-723J4.3	6.05	2.95e-09	1.25e-06	0.28	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36031728	chr18:35972151~35973916:+
LUAD	cis	rs227932	0.681	rs79586340	ENSG00000234286.1	AC006026.13	-6.05	2.96e-09	1.26e-06	-0.46	-0.27	Schizophrenia;	chr7:23746122	chr7:23680195~23680786:-
LUAD	cis	rs227932	0.681	rs75405201	ENSG00000234286.1	AC006026.13	-6.05	2.96e-09	1.26e-06	-0.46	-0.27	Schizophrenia;	chr7:23746123	chr7:23680195~23680786:-
LUAD	cis	rs35740288	0.742	rs4843087	ENSG00000202081.1	RNU6-1280P	6.05	2.96e-09	1.26e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85629624	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs62022867	ENSG00000202081.1	RNU6-1280P	6.05	2.96e-09	1.26e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630050	chr15:85651522~85651628:-
LUAD	cis	rs172166	0.611	rs203882	ENSG00000204709.4	LINC01556	6.05	2.97e-09	1.26e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28110724	chr6:28943877~28944537:+
LUAD	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-6.05	2.98e-09	1.26e-06	-0.32	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
LUAD	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	6.05	2.98e-09	1.26e-06	0.29	0.27	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
LUAD	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-6.05	2.98e-09	1.26e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
LUAD	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.98e-09	1.26e-06	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.98e-09	1.26e-06	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.98e-09	1.26e-06	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.98e-09	1.26e-06	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
LUAD	cis	rs8031584	0.958	rs11293	ENSG00000260382.1	RP11-540B6.2	6.05	2.98e-09	1.27e-06	0.32	0.27	Huntington's disease progression;	chr15:30942778	chr15:30882267~30883231:-
LUAD	cis	rs1707322	0.721	rs10890343	ENSG00000234329.1	RP11-767N6.2	6.05	2.99e-09	1.27e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45651039~45651826:-
LUAD	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	6.05	2.99e-09	1.27e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	6.05	2.99e-09	1.27e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
LUAD	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-6.05	2.99e-09	1.27e-06	-0.29	-0.27	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
LUAD	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	6.05	3e-09	1.27e-06	0.25	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
LUAD	cis	rs1707322	0.721	rs61784800	ENSG00000234329.1	RP11-767N6.2	-6.04	3e-09	1.27e-06	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs6665808	ENSG00000234329.1	RP11-767N6.2	6.04	3e-09	1.27e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.682	rs28508523	ENSG00000234329.1	RP11-767N6.2	6.04	3e-09	1.27e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45651039~45651826:-
LUAD	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	6.04	3e-09	1.27e-06	0.32	0.27	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
LUAD	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	6.04	3.01e-09	1.27e-06	0.28	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
LUAD	cis	rs453301	0.562	rs1038248	ENSG00000253893.2	FAM85B	6.04	3.01e-09	1.27e-06	0.33	0.27	Joint mobility (Beighton score);	chr8:9183348	chr8:8167819~8226614:-
LUAD	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	6.04	3.01e-09	1.28e-06	0.29	0.27	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
LUAD	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	6.04	3.01e-09	1.28e-06	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
LUAD	cis	rs17301013	0.507	rs11802092	ENSG00000227373.4	RP11-160H22.5	6.04	3.02e-09	1.28e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174601773	chr1:174115300~174160004:-
LUAD	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-6.04	3.02e-09	1.28e-06	-0.29	-0.27	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
LUAD	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-6.04	3.02e-09	1.28e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-6.04	3.02e-09	1.28e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-6.04	3.02e-09	1.28e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
LUAD	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	6.04	3.02e-09	1.28e-06	0.3	0.27	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
LUAD	cis	rs853679	0.55	rs1233699	ENSG00000204709.4	LINC01556	6.04	3.02e-09	1.28e-06	0.36	0.27	Depression;	chr6:28201380	chr6:28943877~28944537:+
LUAD	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	6.04	3.02e-09	1.28e-06	0.31	0.27	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
LUAD	cis	rs1823913	0.614	rs4853576	ENSG00000280083.1	RP11-317J9.1	6.04	3.02e-09	1.28e-06	0.32	0.27	Obesity-related traits;	chr2:191296618	chr2:191154118~191156070:-
LUAD	cis	rs9595908	0.869	rs9595949	ENSG00000212293.1	SNORA16	6.04	3.03e-09	1.28e-06	0.28	0.27	Body mass index;	chr13:32629939	chr13:32420390~32420516:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000228039.3	KB-1125A3.10	6.04	3.03e-09	1.28e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23963780~23964374:+
LUAD	cis	rs17684571	0.751	rs35225175	ENSG00000231441.1	RP11-472M19.2	6.04	3.03e-09	1.28e-06	0.41	0.27	Schizophrenia;	chr6:56822783	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs34866877	ENSG00000231441.1	RP11-472M19.2	6.04	3.03e-09	1.28e-06	0.41	0.27	Schizophrenia;	chr6:56829507	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs35407078	ENSG00000231441.1	RP11-472M19.2	6.04	3.03e-09	1.28e-06	0.41	0.27	Schizophrenia;	chr6:56830216	chr6:56844002~56864078:+
LUAD	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-6.04	3.03e-09	1.28e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	6.04	3.03e-09	1.28e-06	0.3	0.27	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
LUAD	cis	rs853679	0.517	rs2273564	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28089816	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs1853097	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28090857	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393887	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28091242	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393888	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28091439	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs3734573	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28091659	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9357063	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28092227	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs3823180	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28093966	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368551	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28094014	chr6:28943877~28944537:+
LUAD	cis	rs4820294	1	rs4820294	ENSG00000233360.4	Z83844.1	6.04	3.03e-09	1.29e-06	0.28	0.27	Fat distribution (HIV);	chr22:37675036	chr22:37641832~37658377:-
LUAD	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	6.04	3.03e-09	1.29e-06	0.32	0.27	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
LUAD	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	6.04	3.04e-09	1.29e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
LUAD	cis	rs1707322	0.721	rs6699418	ENSG00000234329.1	RP11-767N6.2	6.04	3.04e-09	1.29e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4431884	ENSG00000234329.1	RP11-767N6.2	6.04	3.04e-09	1.29e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.65	rs4660879	ENSG00000234329.1	RP11-767N6.2	6.04	3.04e-09	1.29e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45651039~45651826:-
LUAD	cis	rs8177876	0.642	rs4454990	ENSG00000261061.1	RP11-303E16.2	6.04	3.04e-09	1.29e-06	0.39	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81030770~81031485:+
LUAD	cis	rs17666538	0.585	rs336444	ENSG00000254207.1	RP11-43A14.1	-6.04	3.04e-09	1.29e-06	-0.48	-0.27	IgG glycosylation;	chr8:683123	chr8:725188~725877:-
LUAD	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	6.04	3.05e-09	1.29e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
LUAD	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	6.04	3.05e-09	1.29e-06	0.34	0.27	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
LUAD	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-6.04	3.06e-09	1.29e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-6.04	3.06e-09	1.29e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
LUAD	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
LUAD	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
LUAD	cis	rs17666538	0.585	rs6559063	ENSG00000254207.1	RP11-43A14.1	6.04	3.06e-09	1.3e-06	0.54	0.27	IgG glycosylation;	chr8:673051	chr8:725188~725877:-
LUAD	cis	rs12699921	0.632	rs2723553	ENSG00000279048.1	RP11-511H23.2	-6.04	3.06e-09	1.3e-06	-0.22	-0.27	Fibrinogen levels;	chr7:17799715	chr7:17940503~17942922:+
LUAD	cis	rs6504622	0.905	rs9898981	ENSG00000262879.4	RP11-156P1.3	6.04	3.07e-09	1.3e-06	0.31	0.27	Orofacial clefts;	chr17:46949349	chr17:46984045~47100323:-
LUAD	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	6.04	3.07e-09	1.3e-06	0.39	0.27	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
LUAD	cis	rs150992	0.631	rs79399563	ENSG00000248489.1	CTD-2007H13.3	6.04	3.07e-09	1.3e-06	0.31	0.27	Body mass index;	chr5:98993275	chr5:98929171~98995013:+
LUAD	cis	rs4713118	0.869	rs6901520	ENSG00000219392.1	RP1-265C24.5	-6.04	3.07e-09	1.3e-06	-0.36	-0.27	Parkinson's disease;	chr6:27746796	chr6:28115628~28116551:+
LUAD	cis	rs71636778	0.509	rs35583548	ENSG00000260063.1	RP5-968P14.2	-6.04	3.07e-09	1.3e-06	-0.46	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813658	chr1:26692132~26694131:-
LUAD	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	6.04	3.07e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	6.04	3.07e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	6.04	3.07e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	6.04	3.07e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
LUAD	cis	rs10050311	0.858	rs55698195	ENSG00000251411.1	RP11-397E7.4	-6.04	3.07e-09	1.3e-06	-0.37	-0.27	Insulin-related traits;	chr4:86872297	chr4:86913266~86914817:-
LUAD	cis	rs8177376	0.727	rs4937121	ENSG00000254905.1	RP11-712L6.7	6.04	3.08e-09	1.3e-06	0.36	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330659	chr11:126292922~126294254:-
LUAD	cis	rs55823223	0.646	rs55868394	ENSG00000267801.1	RP11-552F3.9	6.04	3.08e-09	1.3e-06	0.4	0.27	Psoriasis;	chr17:75855032	chr17:75876372~75879546:+
LUAD	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	6.04	3.08e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
LUAD	cis	rs35934224	0.771	rs34820460	ENSG00000232926.1	AC000078.5	6.04	3.08e-09	1.3e-06	0.29	0.27	Glaucoma (primary open-angle);	chr22:19881687	chr22:19887289~19887970:+
LUAD	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-6.04	3.08e-09	1.3e-06	-0.37	-0.27	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
LUAD	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-6.04	3.09e-09	1.31e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
LUAD	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	6.04	3.09e-09	1.31e-06	0.3	0.27	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
LUAD	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-6.04	3.09e-09	1.31e-06	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs313813	ENSG00000230295.1	RP11-458F8.2	-6.04	3.1e-09	1.31e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:66038513	chr7:66880708~66882981:+
LUAD	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	6.04	3.1e-09	1.31e-06	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
LUAD	cis	rs7246657	0.525	rs997516	ENSG00000276846.1	CTD-3220F14.3	6.04	3.1e-09	1.31e-06	0.4	0.27	Coronary artery calcification;	chr19:36983362	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	6.04	3.1e-09	1.31e-06	0.33	0.27	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	6.04	3.1e-09	1.31e-06	0.33	0.27	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
LUAD	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	6.04	3.1e-09	1.31e-06	0.27	0.27	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
LUAD	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-6.04	3.11e-09	1.31e-06	-0.37	-0.27	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
LUAD	cis	rs1707322	0.721	rs7519900	ENSG00000234329.1	RP11-767N6.2	6.04	3.11e-09	1.31e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45651039~45651826:-
LUAD	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	6.04	3.11e-09	1.31e-06	0.33	0.27	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
LUAD	cis	rs1823913	0.549	rs4465792	ENSG00000280083.1	RP11-317J9.1	-6.04	3.12e-09	1.32e-06	-0.33	-0.27	Obesity-related traits;	chr2:191328884	chr2:191154118~191156070:-
LUAD	cis	rs3738443	0.672	rs6691539	ENSG00000259865.1	RP11-488L18.10	6.04	3.12e-09	1.32e-06	0.23	0.27	Alcohol dependence;	chr1:247209370	chr1:247187281~247188526:-
LUAD	cis	rs10214930	0.697	rs978447	ENSG00000235574.1	AC073150.6	-6.04	3.12e-09	1.32e-06	-0.34	-0.27	Hypospadias;	chr7:27543164	chr7:27491682~27492765:-
LUAD	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-6.04	3.13e-09	1.32e-06	-0.32	-0.27	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
LUAD	cis	rs293748	0.571	rs13171061	ENSG00000250155.1	CTD-2353F22.1	-6.04	3.13e-09	1.32e-06	-0.34	-0.27	Obesity-related traits;	chr5:37154591	chr5:36666214~36725195:-
LUAD	cis	rs4834770	1	rs878375	ENSG00000245958.5	RP11-33B1.1	-6.04	3.13e-09	1.32e-06	-0.23	-0.27	Blood protein levels;	chr4:119316419	chr4:119454791~119552025:+
LUAD	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	6.04	3.13e-09	1.32e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
LUAD	cis	rs6991838	0.806	rs4285523	ENSG00000200714.1	Y_RNA	6.04	3.13e-09	1.32e-06	0.31	0.27	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65592731~65592820:+
LUAD	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	6.04	3.14e-09	1.32e-06	0.32	0.27	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	6.04	3.14e-09	1.32e-06	0.32	0.27	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
LUAD	cis	rs2243480	1	rs34637256	ENSG00000230295.1	RP11-458F8.2	-6.04	3.14e-09	1.33e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:65895144	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35391607	ENSG00000230295.1	RP11-458F8.2	-6.04	3.14e-09	1.33e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:65895842	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs13220979	ENSG00000230295.1	RP11-458F8.2	-6.04	3.14e-09	1.33e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:65898217	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34974928	ENSG00000230295.1	RP11-458F8.2	-6.04	3.14e-09	1.33e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:65899019	chr7:66880708~66882981:+
LUAD	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-6.04	3.14e-09	1.33e-06	-0.28	-0.27	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
LUAD	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	6.04	3.14e-09	1.33e-06	0.33	0.27	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
LUAD	cis	rs11096990	0.964	rs56284364	ENSG00000249207.1	RP11-360F5.1	6.04	3.14e-09	1.33e-06	0.3	0.27	Cognitive function;	chr4:39255028	chr4:39112677~39126818:-
LUAD	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-6.04	3.14e-09	1.33e-06	-0.31	-0.27	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
LUAD	cis	rs4713118	0.621	rs10484403	ENSG00000204709.4	LINC01556	6.04	3.15e-09	1.33e-06	0.37	0.27	Parkinson's disease;	chr6:28065745	chr6:28943877~28944537:+
LUAD	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	6.04	3.15e-09	1.33e-06	0.28	0.27	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
LUAD	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	6.04	3.15e-09	1.33e-06	0.28	0.27	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
LUAD	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	6.04	3.15e-09	1.33e-06	0.28	0.27	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
LUAD	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-6.04	3.15e-09	1.33e-06	-0.28	-0.27	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
LUAD	cis	rs78579487	1	rs78579487	ENSG00000240875.4	LINC00886	-6.04	3.15e-09	1.33e-06	-0.29	-0.27	Breast cancer;	chr3:156800879	chr3:156747346~156817062:-
LUAD	cis	rs987724	0.551	rs1835372	ENSG00000240875.4	LINC00886	-6.04	3.15e-09	1.33e-06	-0.29	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156801238	chr3:156747346~156817062:-
LUAD	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-6.04	3.15e-09	1.33e-06	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
LUAD	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-6.04	3.16e-09	1.33e-06	-0.29	-0.27	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
LUAD	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	6.04	3.16e-09	1.33e-06	0.32	0.27	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	6.04	3.16e-09	1.33e-06	0.32	0.27	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
LUAD	cis	rs367615	0.68	rs253246	ENSG00000249476.1	CTD-2587M2.1	6.04	3.16e-09	1.34e-06	0.35	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109648317	chr5:109237120~109326369:-
LUAD	cis	rs12699921	0.632	rs4316058	ENSG00000279048.1	RP11-511H23.2	-6.04	3.17e-09	1.34e-06	-0.21	-0.27	Fibrinogen levels;	chr7:17795103	chr7:17940503~17942922:+
LUAD	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-6.04	3.17e-09	1.34e-06	-0.39	-0.27	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
LUAD	cis	rs13030978	0.505	rs72916554	ENSG00000280083.1	RP11-317J9.1	-6.04	3.17e-09	1.34e-06	-0.33	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr2:191330532	chr2:191154118~191156070:-
LUAD	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	6.04	3.17e-09	1.34e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
LUAD	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	6.04	3.18e-09	1.34e-06	0.29	0.27	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
LUAD	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-6.03	3.18e-09	1.34e-06	-0.32	-0.27	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
LUAD	cis	rs10214930	0.697	rs1851913	ENSG00000235574.1	AC073150.6	-6.03	3.18e-09	1.34e-06	-0.34	-0.27	Hypospadias;	chr7:27545457	chr7:27491682~27492765:-
LUAD	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-6.03	3.18e-09	1.34e-06	-0.29	-0.27	Height;	chr11:118786602	chr11:118791254~118793137:+
LUAD	cis	rs11096990	0.964	rs11096986	ENSG00000249207.1	RP11-360F5.1	6.03	3.18e-09	1.34e-06	0.3	0.27	Cognitive function;	chr4:39257122	chr4:39112677~39126818:-
LUAD	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-6.03	3.18e-09	1.34e-06	-0.33	-0.27	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
LUAD	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-6.03	3.19e-09	1.34e-06	-0.25	-0.27	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
LUAD	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-6.03	3.19e-09	1.34e-06	-0.25	-0.27	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
LUAD	cis	rs748404	0.666	rs8027748	ENSG00000205771.5	CATSPER2P1	-6.03	3.19e-09	1.35e-06	-0.41	-0.27	Lung cancer;	chr15:43447622	chr15:43726918~43747094:-
LUAD	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	6.03	3.19e-09	1.35e-06	0.35	0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
LUAD	cis	rs36093844	0.8	rs112468922	ENSG00000279742.1	RP11-700A24.1	-6.03	3.19e-09	1.35e-06	-0.35	-0.27	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865651	chr11:85852557~85854943:-
LUAD	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-6.03	3.2e-09	1.35e-06	-0.37	-0.27	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-6.03	3.2e-09	1.35e-06	-0.37	-0.27	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-6.03	3.2e-09	1.35e-06	-0.37	-0.27	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
LUAD	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	6.03	3.2e-09	1.35e-06	0.24	0.27	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	6.03	3.2e-09	1.35e-06	0.24	0.27	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
LUAD	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-6.03	3.2e-09	1.35e-06	-0.34	-0.27	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
LUAD	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-6.03	3.2e-09	1.35e-06	-0.39	-0.27	Pain;	chr19:21475141	chr19:21554640~21569237:-
LUAD	cis	rs1426063	0.614	rs75846524	ENSG00000249717.1	RP11-44F21.3	6.03	3.21e-09	1.35e-06	0.54	0.27	QT interval;	chr4:75083172	chr4:74955974~74970362:-
LUAD	cis	rs8177876	0.658	rs75422577	ENSG00000261061.1	RP11-303E16.2	-6.03	3.21e-09	1.35e-06	-0.47	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81030770~81031485:+
LUAD	cis	rs897200	0.898	rs1031507	ENSG00000280083.1	RP11-317J9.1	6.03	3.21e-09	1.35e-06	0.34	0.27	Behcet's disease;	chr2:191155892	chr2:191154118~191156070:-
LUAD	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	6.03	3.21e-09	1.36e-06	0.31	0.27	Height;	chr11:118854014	chr11:118688039~118690600:-
LUAD	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	6.03	3.22e-09	1.36e-06	0.36	0.27	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
LUAD	cis	rs7618501	0.602	rs9311446	ENSG00000234667.1	ACTBP13	6.03	3.22e-09	1.36e-06	0.3	0.27	Intelligence (multi-trait analysis);	chr3:50054793	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.602	rs2245365	ENSG00000234667.1	ACTBP13	6.03	3.22e-09	1.36e-06	0.3	0.27	Intelligence (multi-trait analysis);	chr3:50059886	chr3:49873347~49877980:-
LUAD	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-6.03	3.22e-09	1.36e-06	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
LUAD	cis	rs12699921	0.632	rs2691625	ENSG00000279048.1	RP11-511H23.2	-6.03	3.22e-09	1.36e-06	-0.21	-0.27	Fibrinogen levels;	chr7:17784000	chr7:17940503~17942922:+
LUAD	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	6.03	3.22e-09	1.36e-06	0.27	0.27	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
LUAD	cis	rs9595908	0.709	rs9596222	ENSG00000212293.1	SNORA16	6.03	3.23e-09	1.36e-06	0.28	0.27	Body mass index;	chr13:32767679	chr13:32420390~32420516:-
LUAD	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	6.03	3.23e-09	1.36e-06	0.32	0.27	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
LUAD	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	6.03	3.23e-09	1.36e-06	0.39	0.27	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	6.03	3.23e-09	1.36e-06	0.39	0.27	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
LUAD	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-6.03	3.23e-09	1.36e-06	-0.54	-0.27	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
LUAD	cis	rs853679	0.55	rs1233704	ENSG00000204709.4	LINC01556	-6.03	3.23e-09	1.36e-06	-0.36	-0.27	Depression;	chr6:28199145	chr6:28943877~28944537:+
LUAD	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-6.03	3.23e-09	1.36e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
LUAD	cis	rs948562	0.69	rs734777	ENSG00000280010.1	AP001350.4	6.03	3.23e-09	1.36e-06	0.42	0.27	Lymphoma;	chr11:58343636	chr11:58627435~58628528:+
LUAD	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	6.03	3.23e-09	1.36e-06	0.33	0.27	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
LUAD	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	6.03	3.23e-09	1.36e-06	0.31	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
LUAD	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-6.03	3.23e-09	1.36e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
LUAD	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	6.03	3.23e-09	1.36e-06	0.36	0.27	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
LUAD	cis	rs9311474	1	rs6445358	ENSG00000243224.1	RP5-1157M23.2	-6.03	3.24e-09	1.37e-06	-0.27	-0.27	Electroencephalogram traits;	chr3:52274829	chr3:52239258~52241097:+
LUAD	cis	rs5753618	0.539	rs1034588	ENSG00000236132.1	CTA-440B3.1	6.03	3.24e-09	1.37e-06	0.33	0.27	Colorectal cancer;	chr22:31220315	chr22:31816379~31817491:-
LUAD	cis	rs4723738	1	rs6462817	ENSG00000227191.5	TRGC2	-6.03	3.24e-09	1.37e-06	-0.29	-0.27	Treatment response for severe sepsis;	chr7:38211264	chr7:38239580~38368091:-
LUAD	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	6.03	3.24e-09	1.37e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
LUAD	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-6.03	3.25e-09	1.37e-06	-0.22	-0.27	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
LUAD	cis	rs8177876	0.749	rs754429	ENSG00000261061.1	RP11-303E16.2	-6.03	3.25e-09	1.37e-06	-0.45	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81030770~81031485:+
LUAD	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	6.03	3.25e-09	1.37e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
LUAD	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-6.03	3.26e-09	1.37e-06	-0.32	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
LUAD	cis	rs4908768	0.501	rs4908760	ENSG00000232912.4	RP5-1115A15.1	6.03	3.26e-09	1.37e-06	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8466082	chr1:8424645~8434838:+
LUAD	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	6.03	3.26e-09	1.37e-06	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
LUAD	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	6.03	3.27e-09	1.37e-06	0.3	0.27	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
LUAD	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-6.03	3.27e-09	1.38e-06	-0.34	-0.27	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
LUAD	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-6.03	3.27e-09	1.38e-06	-0.33	-0.27	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
LUAD	cis	rs9928842	0.823	rs2870472	ENSG00000280152.1	RP11-331F4.5	6.03	3.27e-09	1.38e-06	0.29	0.27	Alcoholic chronic pancreatitis;	chr16:75244943	chr16:75245994~75250077:-
LUAD	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	6.03	3.27e-09	1.38e-06	0.34	0.27	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
LUAD	cis	rs755249	0.53	rs112205225	ENSG00000228060.1	RP11-69E11.8	-6.03	3.27e-09	1.38e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39121716	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-6.03	3.27e-09	1.38e-06	-0.29	-0.27	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
LUAD	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-6.03	3.28e-09	1.38e-06	-0.22	-0.27	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
LUAD	cis	rs11096990	0.855	rs4974986	ENSG00000249207.1	RP11-360F5.1	6.03	3.28e-09	1.38e-06	0.31	0.27	Cognitive function;	chr4:39165308	chr4:39112677~39126818:-
LUAD	cis	rs7017914	0.905	rs2732106	ENSG00000223220.1	Y_RNA	6.03	3.28e-09	1.38e-06	0.3	0.27	Bone mineral density;	chr8:71011604	chr8:70780914~70781008:-
LUAD	cis	rs2562456	0.72	rs6511250	ENSG00000268081.1	RP11-678G14.2	-6.03	3.28e-09	1.38e-06	-0.4	-0.27	Pain;	chr19:21473244	chr19:21554640~21569237:-
LUAD	cis	rs11742741	0.579	rs4701424	ENSG00000248874.4	C5orf17	-6.03	3.28e-09	1.38e-06	-0.33	-0.27	Educational attainment;	chr5:24108437	chr5:23951348~24178263:+
LUAD	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-6.03	3.28e-09	1.38e-06	-0.35	-0.27	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
LUAD	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	6.03	3.28e-09	1.38e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-6.03	3.28e-09	1.38e-06	-0.3	-0.27	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.793	rs460678	ENSG00000222364.1	RNU6-96P	-6.03	3.29e-09	1.38e-06	-0.3	-0.27	Aortic root size;	chr7:66062213	chr7:66395191~66395286:+
LUAD	cis	rs6504622	0.791	rs758392	ENSG00000262879.4	RP11-156P1.3	-6.03	3.29e-09	1.39e-06	-0.31	-0.27	Orofacial clefts;	chr17:46940493	chr17:46984045~47100323:-
LUAD	cis	rs2243480	1	rs906134	ENSG00000232546.1	RP11-458F8.1	-6.03	3.3e-09	1.39e-06	-0.35	-0.27	Diabetic kidney disease;	chr7:65979301	chr7:66848496~66858136:+
LUAD	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	6.03	3.3e-09	1.39e-06	0.39	0.27	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
LUAD	cis	rs75920871	0.528	rs4388921	ENSG00000254851.1	RP11-109L13.1	6.03	3.3e-09	1.39e-06	0.38	0.27	Subjective well-being;	chr11:117106062	chr11:117135528~117138582:+
LUAD	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	6.03	3.31e-09	1.39e-06	0.32	0.27	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
LUAD	cis	rs55665837	0.559	rs9667144	ENSG00000251991.1	RNU7-49P	-6.03	3.31e-09	1.39e-06	-0.3	-0.27	Vitamin D levels;	chr11:14399555	chr11:14478892~14478953:+
LUAD	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	6.03	3.31e-09	1.39e-06	0.39	0.27	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
LUAD	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-6.03	3.31e-09	1.39e-06	-0.26	-0.27	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
LUAD	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	6.03	3.31e-09	1.39e-06	0.3	0.27	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	6.03	3.31e-09	1.39e-06	0.3	0.27	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	6.03	3.31e-09	1.39e-06	0.3	0.27	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
LUAD	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-6.03	3.31e-09	1.39e-06	-0.46	-0.27	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
LUAD	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	6.03	3.31e-09	1.39e-06	0.29	0.27	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
LUAD	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-6.03	3.32e-09	1.4e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
LUAD	cis	rs1707322	0.717	rs3014237	ENSG00000234329.1	RP11-767N6.2	-6.03	3.32e-09	1.4e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45651039~45651826:-
LUAD	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	6.03	3.32e-09	1.4e-06	0.27	0.26	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-6.03	3.32e-09	1.4e-06	-0.39	-0.26	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
LUAD	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	6.03	3.33e-09	1.4e-06	0.32	0.26	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
LUAD	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	6.03	3.33e-09	1.4e-06	0.29	0.26	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	6.03	3.33e-09	1.4e-06	0.29	0.26	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
LUAD	cis	rs9595908	0.622	rs7983267	ENSG00000212293.1	SNORA16	6.03	3.34e-09	1.4e-06	0.28	0.26	Body mass index;	chr13:32806767	chr13:32420390~32420516:-
LUAD	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-6.03	3.34e-09	1.4e-06	-0.29	-0.26	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
LUAD	cis	rs2243480	1	rs34970380	ENSG00000232546.1	RP11-458F8.1	-6.03	3.34e-09	1.4e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:65966506	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000232546.1	RP11-458F8.1	-6.03	3.34e-09	1.4e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:65966800	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.862	rs2460432	ENSG00000222364.1	RNU6-96P	6.03	3.34e-09	1.4e-06	0.3	0.26	Aortic root size;	chr7:66089398	chr7:66395191~66395286:+
LUAD	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	6.03	3.34e-09	1.4e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
LUAD	cis	rs720064	0.586	rs2288592	ENSG00000264745.1	TTC39C-AS1	6.03	3.35e-09	1.41e-06	0.28	0.26	Strep throat;	chr18:23946123	chr18:23994213~24015339:-
LUAD	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	6.03	3.35e-09	1.41e-06	0.34	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
LUAD	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	6.03	3.36e-09	1.41e-06	0.33	0.26	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
LUAD	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	6.03	3.36e-09	1.41e-06	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
LUAD	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	6.03	3.36e-09	1.41e-06	0.28	0.26	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
LUAD	cis	rs12699921	0.566	rs1997019	ENSG00000279048.1	RP11-511H23.2	-6.03	3.36e-09	1.41e-06	-0.22	-0.26	Fibrinogen levels;	chr7:17787856	chr7:17940503~17942922:+
LUAD	cis	rs6991838	0.778	rs11779602	ENSG00000200714.1	Y_RNA	6.03	3.36e-09	1.41e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65592731~65592820:+
LUAD	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-6.03	3.37e-09	1.41e-06	-0.42	-0.26	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
LUAD	cis	rs4908768	0.501	rs4908761	ENSG00000232912.4	RP5-1115A15.1	6.02	3.37e-09	1.42e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8424645~8434838:+
LUAD	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-6.02	3.38e-09	1.42e-06	-0.29	-0.26	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
LUAD	cis	rs10740039	0.516	rs2393675	ENSG00000254271.1	RP11-131N11.4	6.02	3.38e-09	1.42e-06	0.3	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60590990	chr10:60734342~60741828:+
LUAD	cis	rs12699921	0.632	rs2691601	ENSG00000279048.1	RP11-511H23.2	-6.02	3.38e-09	1.42e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17835808	chr7:17940503~17942922:+
LUAD	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	6.02	3.38e-09	1.42e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
LUAD	cis	rs74233809	1	rs79237883	ENSG00000213277.3	MARCKSL1P1	6.02	3.38e-09	1.42e-06	0.45	0.26	Birth weight;	chr10:103181189	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs34747231	ENSG00000213277.3	MARCKSL1P1	6.02	3.38e-09	1.42e-06	0.45	0.26	Birth weight;	chr10:103182487	chr10:103175554~103176094:+
LUAD	cis	rs5753618	0.509	rs5997902	ENSG00000236132.1	CTA-440B3.1	6.02	3.38e-09	1.42e-06	0.33	0.26	Colorectal cancer;	chr22:31187021	chr22:31816379~31817491:-
LUAD	cis	rs3096299	0.629	rs12929744	ENSG00000274627.1	RP11-104N10.2	6.02	3.39e-09	1.42e-06	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89427172	chr16:89516797~89522217:+
LUAD	cis	rs4591358	0.731	rs34634374	ENSG00000223466.1	AC064834.2	-6.02	3.39e-09	1.42e-06	-0.36	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509437	chr2:195533035~195538681:+
LUAD	cis	rs9595908	0.693	rs4942911	ENSG00000212293.1	SNORA16	6.02	3.39e-09	1.42e-06	0.29	0.26	Body mass index;	chr13:32793038	chr13:32420390~32420516:-
LUAD	cis	rs2243480	1	rs6964530	ENSG00000232546.1	RP11-458F8.1	6.02	3.39e-09	1.42e-06	0.35	0.26	Diabetic kidney disease;	chr7:66253864	chr7:66848496~66858136:+
LUAD	cis	rs8177376	0.727	rs586566	ENSG00000254905.1	RP11-712L6.7	6.02	3.39e-09	1.42e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126329723	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs667469	ENSG00000254905.1	RP11-712L6.7	6.02	3.39e-09	1.42e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330171	chr11:126292922~126294254:-
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000211970.3	IGHV4-61	-6.02	3.39e-09	1.42e-06	-0.19	-0.26	Kawasaki disease;	chr14:106680002	chr14:106639119~106639657:-
LUAD	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	6.02	3.4e-09	1.42e-06	0.38	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	6.02	3.4e-09	1.42e-06	0.38	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
LUAD	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-6.02	3.4e-09	1.42e-06	-0.29	-0.26	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
LUAD	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-6.02	3.4e-09	1.42e-06	-0.33	-0.26	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
LUAD	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-6.02	3.4e-09	1.43e-06	-0.3	-0.26	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
LUAD	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-6.02	3.4e-09	1.43e-06	-0.33	-0.26	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
LUAD	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-6.02	3.4e-09	1.43e-06	-0.34	-0.26	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
LUAD	cis	rs11096990	0.892	rs7680520	ENSG00000249207.1	RP11-360F5.1	6.02	3.41e-09	1.43e-06	0.3	0.26	Cognitive function;	chr4:39219013	chr4:39112677~39126818:-
LUAD	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	6.02	3.41e-09	1.43e-06	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
LUAD	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	6.02	3.41e-09	1.43e-06	0.34	0.26	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
LUAD	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	6.02	3.41e-09	1.43e-06	0.34	0.26	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
LUAD	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-6.02	3.42e-09	1.43e-06	-0.31	-0.26	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
LUAD	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-6.02	3.42e-09	1.43e-06	-0.28	-0.26	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
LUAD	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
LUAD	cis	rs853679	0.607	rs66886492	ENSG00000204709.4	LINC01556	6.02	3.42e-09	1.43e-06	0.59	0.26	Depression;	chr6:28121953	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs35345226	ENSG00000204709.4	LINC01556	6.02	3.42e-09	1.43e-06	0.59	0.26	Depression;	chr6:28123802	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.769	rs7752608	ENSG00000204709.4	LINC01556	6.02	3.42e-09	1.44e-06	0.53	0.26	Depression;	chr6:28333418	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-6.02	3.42e-09	1.44e-06	-0.32	-0.26	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
LUAD	cis	rs7937890	0.874	rs2303972	ENSG00000254418.1	RP11-21L19.1	-6.02	3.42e-09	1.44e-06	-0.31	-0.26	Mitochondrial DNA levels;	chr11:14281736	chr11:14262846~14273691:-
LUAD	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	6.02	3.42e-09	1.44e-06	0.33	0.26	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
LUAD	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	6.02	3.43e-09	1.44e-06	0.3	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
LUAD	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-6.02	3.43e-09	1.44e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
LUAD	cis	rs6504622	0.905	rs9889741	ENSG00000262879.4	RP11-156P1.3	6.02	3.44e-09	1.44e-06	0.31	0.26	Orofacial clefts;	chr17:46948967	chr17:46984045~47100323:-
LUAD	cis	rs2404602	0.655	rs10444809	ENSG00000259422.1	RP11-593F23.1	-6.02	3.44e-09	1.44e-06	-0.31	-0.26	Blood metabolite levels;	chr15:76832195	chr15:76174891~76181486:-
LUAD	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-6.02	3.44e-09	1.44e-06	-0.29	-0.26	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
LUAD	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.44e-09	1.44e-06	-0.29	-0.26	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
LUAD	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	6.02	3.44e-09	1.44e-06	0.31	0.26	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
LUAD	cis	rs35740288	0.731	rs11634651	ENSG00000202081.1	RNU6-1280P	6.02	3.44e-09	1.44e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85550695	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	6.02	3.44e-09	1.44e-06	0.3	0.26	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	6.02	3.44e-09	1.44e-06	0.3	0.26	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	6.02	3.44e-09	1.44e-06	0.3	0.26	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	6.02	3.44e-09	1.44e-06	0.3	0.26	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-6.02	3.44e-09	1.44e-06	-0.3	-0.26	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
LUAD	cis	rs11051970	0.513	rs2892655	ENSG00000274964.1	RP11-817I4.1	-6.02	3.44e-09	1.44e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337295	chr12:32339368~32340724:+
LUAD	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-6.02	3.45e-09	1.44e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
LUAD	cis	rs496547	0.686	rs591756	ENSG00000255422.1	AP002954.4	-6.02	3.45e-09	1.44e-06	-0.34	-0.26	Hip minimal joint space width;	chr11:118808172	chr11:118704607~118750263:+
LUAD	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-6.02	3.45e-09	1.44e-06	-0.23	-0.26	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
LUAD	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	6.02	3.45e-09	1.45e-06	0.3	0.26	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
LUAD	cis	rs4713118	0.662	rs9380045	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28057501	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.616	rs9348789	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28057708	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468274	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28058299	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468275	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28058358	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468276	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28059910	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468277	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28060612	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468278	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28060704	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs13218430	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28062059	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	6.02	3.45e-09	1.45e-06	0.33	0.26	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
LUAD	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	6.02	3.45e-09	1.45e-06	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
LUAD	cis	rs10214930	0.697	rs3847001	ENSG00000235574.1	AC073150.6	-6.02	3.46e-09	1.45e-06	-0.33	-0.26	Hypospadias;	chr7:27524686	chr7:27491682~27492765:-
LUAD	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	6.02	3.46e-09	1.45e-06	0.28	0.26	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
LUAD	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	6.02	3.46e-09	1.45e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
LUAD	cis	rs293748	0.771	rs158792	ENSG00000250155.1	CTD-2353F22.1	-6.02	3.46e-09	1.45e-06	-0.37	-0.26	Obesity-related traits;	chr5:36889068	chr5:36666214~36725195:-
LUAD	cis	rs853679	0.517	rs4713146	ENSG00000204709.4	LINC01556	6.02	3.46e-09	1.45e-06	0.38	0.26	Depression;	chr6:28143758	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393894	ENSG00000204709.4	LINC01556	6.02	3.46e-09	1.45e-06	0.38	0.26	Depression;	chr6:28144784	chr6:28943877~28944537:+
LUAD	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	6.02	3.46e-09	1.45e-06	0.42	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
LUAD	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	6.02	3.47e-09	1.45e-06	0.38	0.26	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
LUAD	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-6.02	3.47e-09	1.45e-06	-0.3	-0.26	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
LUAD	cis	rs11096990	0.855	rs2566184	ENSG00000249207.1	RP11-360F5.1	6.02	3.47e-09	1.45e-06	0.31	0.26	Cognitive function;	chr4:39162700	chr4:39112677~39126818:-
LUAD	cis	rs8177376	0.727	rs651983	ENSG00000254905.1	RP11-712L6.7	6.02	3.47e-09	1.45e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331343	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs651922	ENSG00000254905.1	RP11-712L6.7	6.02	3.47e-09	1.45e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331395	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs616360	ENSG00000254905.1	RP11-712L6.7	6.02	3.47e-09	1.45e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331508	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs651034	ENSG00000254905.1	RP11-712L6.7	6.02	3.47e-09	1.45e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331563	chr11:126292922~126294254:-
LUAD	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-6.02	3.47e-09	1.45e-06	-0.3	-0.26	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
LUAD	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-6.02	3.47e-09	1.45e-06	-0.32	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
LUAD	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	6.02	3.48e-09	1.46e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
LUAD	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-6.02	3.48e-09	1.46e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-6.02	3.48e-09	1.46e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
LUAD	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-6.02	3.48e-09	1.46e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
LUAD	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.48e-09	1.46e-06	-0.29	-0.26	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
LUAD	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-6.02	3.48e-09	1.46e-06	-0.26	-0.26	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
LUAD	cis	rs4908768	0.501	rs1024197	ENSG00000232912.4	RP5-1115A15.1	6.02	3.48e-09	1.46e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8476998	chr1:8424645~8434838:+
LUAD	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
LUAD	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
LUAD	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
LUAD	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
LUAD	cis	rs516805	0.683	rs115988443	ENSG00000279453.1	RP3-425C14.4	6.02	3.48e-09	1.46e-06	0.37	0.26	Lymphocyte counts;	chr6:122383201	chr6:122436789~122439223:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000211972.2	IGHV3-66	6.02	3.49e-09	1.46e-06	0.23	0.26	Kawasaki disease;	chr14:106767055	chr14:106675017~106675544:-
LUAD	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-6.02	3.49e-09	1.46e-06	-0.29	-0.26	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
LUAD	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	6.02	3.49e-09	1.46e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	6.02	3.49e-09	1.46e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
LUAD	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	6.02	3.49e-09	1.46e-06	0.38	0.26	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
LUAD	cis	rs2439831	0.681	rs28578454	ENSG00000205771.5	CATSPER2P1	-6.02	3.49e-09	1.46e-06	-0.5	-0.26	Lung cancer in ever smokers;	chr15:43310834	chr15:43726918~43747094:-
LUAD	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-6.02	3.5e-09	1.46e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
LUAD	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-6.02	3.5e-09	1.47e-06	-0.24	-0.26	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
LUAD	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	6.02	3.51e-09	1.47e-06	0.31	0.26	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
LUAD	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	6.02	3.51e-09	1.47e-06	0.32	0.26	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
LUAD	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	6.02	3.51e-09	1.47e-06	0.32	0.26	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
LUAD	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	6.02	3.51e-09	1.47e-06	0.3	0.26	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
LUAD	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-6.02	3.51e-09	1.47e-06	-0.37	-0.26	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
LUAD	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-6.02	3.52e-09	1.47e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	6.02	3.52e-09	1.47e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
LUAD	cis	rs2115630	0.691	rs61322921	ENSG00000229212.6	RP11-561C5.4	6.02	3.53e-09	1.47e-06	0.32	0.26	P wave terminal force;	chr15:84620407	chr15:85205440~85234795:-
LUAD	cis	rs853679	0.55	rs6901017	ENSG00000204709.4	LINC01556	6.02	3.53e-09	1.47e-06	0.36	0.26	Depression;	chr6:28184805	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.611	rs203883	ENSG00000204709.4	LINC01556	6.02	3.53e-09	1.47e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28110578	chr6:28943877~28944537:+
LUAD	cis	rs7246657	0.507	rs8107654	ENSG00000276846.1	CTD-3220F14.3	6.02	3.53e-09	1.47e-06	0.41	0.26	Coronary artery calcification;	chr19:36962632	chr19:37314868~37315620:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-6.02	3.53e-09	1.48e-06	-0.33	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
LUAD	cis	rs62432291	0.681	rs378547	ENSG00000235086.1	FNDC1-IT1	6.02	3.53e-09	1.48e-06	0.44	0.26	Joint mobility (Beighton score);	chr6:159241493	chr6:159240786~159243329:+
LUAD	cis	rs12699921	0.632	rs10249221	ENSG00000279048.1	RP11-511H23.2	6.02	3.53e-09	1.48e-06	0.21	0.26	Fibrinogen levels;	chr7:17782436	chr7:17940503~17942922:+
LUAD	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-6.02	3.54e-09	1.48e-06	-0.29	-0.26	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.54e-09	1.48e-06	-0.29	-0.26	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.54e-09	1.48e-06	-0.29	-0.26	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
LUAD	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	6.02	3.54e-09	1.48e-06	0.24	0.26	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.964	rs160635	ENSG00000222364.1	RNU6-96P	-6.02	3.54e-09	1.48e-06	-0.3	-0.26	Aortic root size;	chr7:66063931	chr7:66395191~66395286:+
LUAD	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
LUAD	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	6.02	3.55e-09	1.48e-06	0.29	0.26	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
LUAD	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
LUAD	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	6.02	3.56e-09	1.49e-06	0.38	0.26	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
LUAD	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-6.02	3.56e-09	1.49e-06	-0.37	-0.26	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
LUAD	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-6.02	3.56e-09	1.49e-06	-0.26	-0.26	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
LUAD	cis	rs3096299	0.589	rs3114898	ENSG00000274627.1	RP11-104N10.2	6.01	3.57e-09	1.49e-06	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89325907	chr16:89516797~89522217:+
LUAD	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	6.01	3.57e-09	1.49e-06	0.33	0.26	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
LUAD	cis	rs9595908	0.869	rs9591185	ENSG00000212293.1	SNORA16	6.01	3.57e-09	1.49e-06	0.28	0.26	Body mass index;	chr13:32627829	chr13:32420390~32420516:-
LUAD	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-6.01	3.57e-09	1.49e-06	-0.39	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
LUAD	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-6.01	3.57e-09	1.49e-06	-0.22	-0.26	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
LUAD	cis	rs17301013	0.507	rs333422	ENSG00000227373.4	RP11-160H22.5	-6.01	3.57e-09	1.49e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174664167	chr1:174115300~174160004:-
LUAD	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-6.01	3.57e-09	1.49e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
LUAD	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-6.01	3.57e-09	1.49e-06	-0.33	-0.26	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
LUAD	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-6.01	3.57e-09	1.49e-06	-0.33	-0.26	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
LUAD	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-6.01	3.58e-09	1.49e-06	-0.3	-0.26	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
LUAD	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-6.01	3.58e-09	1.49e-06	-0.32	-0.26	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
LUAD	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-6.01	3.58e-09	1.5e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-6.01	3.59e-09	1.5e-06	-0.29	-0.26	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-6.01	3.59e-09	1.5e-06	-0.29	-0.26	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-6.01	3.59e-09	1.5e-06	-0.29	-0.26	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-6.01	3.59e-09	1.5e-06	-0.29	-0.26	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	6.01	3.59e-09	1.5e-06	0.33	0.26	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
LUAD	cis	rs1707322	0.717	rs1135812	ENSG00000234329.1	RP11-767N6.2	6.01	3.59e-09	1.5e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45651039~45651826:-
LUAD	cis	rs7044106	0.762	rs13291660	ENSG00000238181.2	AHCYP2	-6.01	3.59e-09	1.5e-06	-0.34	-0.26	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120720673~120721972:+
LUAD	cis	rs11096990	0.891	rs61691409	ENSG00000249207.1	RP11-360F5.1	6.01	3.59e-09	1.5e-06	0.3	0.26	Cognitive function;	chr4:39243801	chr4:39112677~39126818:-
LUAD	cis	rs9309711	0.813	rs11690865	ENSG00000225234.1	TRAPPC12-AS1	-6.01	3.59e-09	1.5e-06	-0.34	-0.26	Neurofibrillary tangles;	chr2:3468179	chr2:3481242~3482409:-
LUAD	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-6.01	3.59e-09	1.5e-06	-0.38	-0.26	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
LUAD	cis	rs11157436	1	rs2293731	ENSG00000211812.1	TRAV26-2	-6.01	3.59e-09	1.5e-06	-0.31	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22202583~22203368:+
LUAD	cis	rs8177376	0.727	rs240552	ENSG00000254905.1	RP11-712L6.7	6.01	3.6e-09	1.5e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126333818	chr11:126292922~126294254:-
LUAD	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-6.01	3.6e-09	1.5e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-6.01	3.6e-09	1.5e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
LUAD	cis	rs728616	0.614	rs3934643	ENSG00000225484.5	NUTM2B-AS1	-6.01	3.6e-09	1.5e-06	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79663088~79826594:-
LUAD	cis	rs1707322	0.691	rs11211175	ENSG00000234329.1	RP11-767N6.2	6.01	3.61e-09	1.5e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45651039~45651826:-
LUAD	cis	rs6991838	0.778	rs13261559	ENSG00000272010.1	CTD-3025N20.3	6.01	3.61e-09	1.51e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.778	rs7843697	ENSG00000272010.1	CTD-3025N20.3	6.01	3.61e-09	1.51e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.778	rs7843724	ENSG00000272010.1	CTD-3025N20.3	6.01	3.61e-09	1.51e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65591850~65592472:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000232546.1	RP11-458F8.1	-6.01	3.61e-09	1.51e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66073444	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	6.01	3.61e-09	1.51e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.709	rs4942897	ENSG00000212293.1	SNORA16	6.01	3.61e-09	1.51e-06	0.28	0.26	Body mass index;	chr13:32757615	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.694	rs3752474	ENSG00000212293.1	SNORA16	6.01	3.61e-09	1.51e-06	0.28	0.26	Body mass index;	chr13:32758510	chr13:32420390~32420516:-
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
LUAD	cis	rs293748	0.571	rs13171414	ENSG00000250155.1	CTD-2353F22.1	-6.01	3.62e-09	1.51e-06	-0.33	-0.26	Obesity-related traits;	chr5:37231977	chr5:36666214~36725195:-
LUAD	cis	rs11096990	0.964	rs35494908	ENSG00000249207.1	RP11-360F5.1	6.01	3.62e-09	1.51e-06	0.3	0.26	Cognitive function;	chr4:39252574	chr4:39112677~39126818:-
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000230295.1	RP11-458F8.2	6.01	3.62e-09	1.51e-06	0.33	0.26	Diabetic kidney disease;	chr7:66219914	chr7:66880708~66882981:+
LUAD	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-6.01	3.62e-09	1.51e-06	-0.28	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
LUAD	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	6.01	3.62e-09	1.51e-06	0.38	0.26	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
LUAD	cis	rs11096990	0.964	rs9998591	ENSG00000249207.1	RP11-360F5.1	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Cognitive function;	chr4:39240491	chr4:39112677~39126818:-
LUAD	cis	rs755249	0.567	rs4660603	ENSG00000228060.1	RP11-69E11.8	6.01	3.62e-09	1.51e-06	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39565160~39573203:+
LUAD	cis	rs1729407	0.647	rs2727791	ENSG00000280143.1	AP000892.6	6.01	3.62e-09	1.51e-06	0.3	0.26	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117204967~117210292:+
LUAD	cis	rs56145559	1	rs56145559	ENSG00000163016.8	ALMS1P	6.01	3.63e-09	1.51e-06	0.33	0.26	Schizophrenia;	chr2:73396311	chr2:73644919~73685576:+
LUAD	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	6.01	3.63e-09	1.52e-06	0.3	0.26	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	6.01	3.63e-09	1.52e-06	0.3	0.26	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	6.01	3.63e-09	1.52e-06	0.3	0.26	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
LUAD	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	6.01	3.64e-09	1.52e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
LUAD	cis	rs11157436	1	rs75648426	ENSG00000211812.1	TRAV26-2	-6.01	3.64e-09	1.52e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22202583~22203368:+
LUAD	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	6.01	3.64e-09	1.52e-06	0.58	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
LUAD	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	6.01	3.64e-09	1.52e-06	0.29	0.26	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
LUAD	cis	rs12699921	0.589	rs2723556	ENSG00000279048.1	RP11-511H23.2	-6.01	3.64e-09	1.52e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17827972	chr7:17940503~17942922:+
LUAD	cis	rs4591358	0.689	rs1913894	ENSG00000223466.1	AC064834.2	-6.01	3.64e-09	1.52e-06	-0.41	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195534032	chr2:195533035~195538681:+
LUAD	cis	rs17684571	0.751	rs13207768	ENSG00000231441.1	RP11-472M19.2	6.01	3.64e-09	1.52e-06	0.4	0.26	Schizophrenia;	chr6:56851277	chr6:56844002~56864078:+
LUAD	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-6.01	3.65e-09	1.52e-06	-0.3	-0.26	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-6.01	3.65e-09	1.52e-06	-0.3	-0.26	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
LUAD	cis	rs1113500	0.933	rs1414674	ENSG00000226822.1	RP11-356N1.2	6.01	3.65e-09	1.52e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108083325	chr1:108071482~108074519:+
LUAD	cis	rs1823913	0.513	rs4334520	ENSG00000280083.1	RP11-317J9.1	-6.01	3.65e-09	1.52e-06	-0.33	-0.26	Obesity-related traits;	chr2:191329200	chr2:191154118~191156070:-
LUAD	cis	rs7246657	0.722	rs2972438	ENSG00000276846.1	CTD-3220F14.3	6.01	3.65e-09	1.52e-06	0.35	0.26	Coronary artery calcification;	chr19:37719946	chr19:37314868~37315620:-
LUAD	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-6.01	3.65e-09	1.52e-06	-0.3	-0.26	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
LUAD	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	6.01	3.65e-09	1.52e-06	0.38	0.26	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
LUAD	cis	rs72634501	0.54	rs16826036	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	HDL cholesterol;	chr1:39292127	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs16826038	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61782157	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs41270803	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61783376	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs4660636	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39565160~39573203:+
LUAD	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-6.01	3.66e-09	1.52e-06	-0.3	-0.26	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
LUAD	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	6.01	3.66e-09	1.53e-06	0.3	0.26	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-6.01	3.66e-09	1.53e-06	-0.39	-0.26	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
LUAD	cis	rs2286503	0.533	rs1880239	ENSG00000228649.7	AC005682.5	6.01	3.66e-09	1.53e-06	0.37	0.26	Fibrinogen;	chr7:22832065	chr7:22854178~22861579:+
LUAD	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	6.01	3.67e-09	1.53e-06	0.33	0.26	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
LUAD	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	6.01	3.67e-09	1.53e-06	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000230295.1	RP11-458F8.2	-6.01	3.67e-09	1.53e-06	-0.28	-0.26	Diabetic kidney disease;	chr7:65988305	chr7:66880708~66882981:+
LUAD	cis	rs30380	0.632	rs26496	ENSG00000272109.1	CTD-2260A17.3	-6.01	3.67e-09	1.53e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96802179	chr5:96804353~96806105:+
LUAD	cis	rs172166	0.694	rs1770131	ENSG00000204709.4	LINC01556	6.01	3.68e-09	1.53e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28118635	chr6:28943877~28944537:+
LUAD	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-6.01	3.68e-09	1.53e-06	-0.27	-0.26	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
LUAD	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	6.01	3.68e-09	1.53e-06	0.32	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000224373.3	IGHV4-59	6.01	3.69e-09	1.54e-06	0.17	0.26	Kawasaki disease;	chr14:106670611	chr14:106627249~106627825:-
LUAD	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
LUAD	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	6.01	3.69e-09	1.54e-06	0.33	0.26	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
LUAD	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-6.01	3.69e-09	1.54e-06	-0.36	-0.26	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
LUAD	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-6.01	3.7e-09	1.54e-06	-0.34	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
LUAD	cis	rs9595908	0.669	rs17594908	ENSG00000212293.1	SNORA16	6.01	3.7e-09	1.54e-06	0.29	0.26	Body mass index;	chr13:32789427	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs2025474	ENSG00000212293.1	SNORA16	6.01	3.7e-09	1.54e-06	0.29	0.26	Body mass index;	chr13:32792319	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs4941669	ENSG00000212293.1	SNORA16	6.01	3.7e-09	1.54e-06	0.29	0.26	Body mass index;	chr13:32793045	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	6.01	3.7e-09	1.54e-06	0.31	0.26	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
LUAD	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	6.01	3.7e-09	1.54e-06	0.3	0.26	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
LUAD	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	6.01	3.71e-09	1.54e-06	0.32	0.26	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
LUAD	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	6.01	3.71e-09	1.54e-06	0.39	0.26	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
LUAD	cis	rs853679	0.513	rs13437444	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.4	0.26	Depression;	chr6:28103220	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
LUAD	cis	rs227932	0.571	rs3801898	ENSG00000234286.1	AC006026.13	-6.01	3.72e-09	1.55e-06	-0.46	-0.26	Schizophrenia;	chr7:23762526	chr7:23680195~23680786:-
LUAD	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-6.01	3.72e-09	1.55e-06	-0.35	-0.26	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
LUAD	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	6.01	3.72e-09	1.55e-06	0.3	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
LUAD	cis	rs36093844	1	rs36093844	ENSG00000279742.1	RP11-700A24.1	6.01	3.72e-09	1.55e-06	0.3	0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865084	chr11:85852557~85854943:-
LUAD	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	6.01	3.72e-09	1.55e-06	0.3	0.26	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
LUAD	cis	rs10214930	0.697	rs12700822	ENSG00000235574.1	AC073150.6	-6.01	3.73e-09	1.55e-06	-0.33	-0.26	Hypospadias;	chr7:27605807	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs13308974	ENSG00000235574.1	AC073150.6	-6.01	3.73e-09	1.55e-06	-0.33	-0.26	Hypospadias;	chr7:27612719	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs12534603	ENSG00000235574.1	AC073150.6	-6.01	3.73e-09	1.55e-06	-0.33	-0.26	Hypospadias;	chr7:27613034	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.647	rs7790498	ENSG00000235574.1	AC073150.6	-6.01	3.73e-09	1.55e-06	-0.33	-0.26	Hypospadias;	chr7:27613588	chr7:27491682~27492765:-
LUAD	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	6.01	3.73e-09	1.55e-06	0.39	0.26	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
LUAD	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	6.01	3.74e-09	1.55e-06	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
LUAD	cis	rs9595908	0.869	rs9595962	ENSG00000212293.1	SNORA16	6.01	3.74e-09	1.55e-06	0.28	0.26	Body mass index;	chr13:32634429	chr13:32420390~32420516:-
LUAD	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-6.01	3.74e-09	1.56e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-6.01	3.74e-09	1.56e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
LUAD	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6.01	3.75e-09	1.56e-06	-0.39	-0.26	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
LUAD	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-6.01	3.75e-09	1.56e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
LUAD	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	6.01	3.75e-09	1.56e-06	0.29	0.26	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
LUAD	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-6.01	3.75e-09	1.56e-06	-0.39	-0.26	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
LUAD	cis	rs2734839	0.964	rs12800853	ENSG00000270179.1	RP11-159N11.4	-6.01	3.75e-09	1.56e-06	-0.27	-0.26	Information processing speed;	chr11:113431792	chr11:113368478~113369117:+
LUAD	cis	rs12699921	0.632	rs2691555	ENSG00000279048.1	RP11-511H23.2	-6.01	3.76e-09	1.56e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17898660	chr7:17940503~17942922:+
LUAD	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-6.01	3.76e-09	1.56e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
LUAD	cis	rs10214930	0.671	rs10951172	ENSG00000235574.1	AC073150.6	-6.01	3.76e-09	1.56e-06	-0.33	-0.26	Hypospadias;	chr7:27574492	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs4719898	ENSG00000235574.1	AC073150.6	-6.01	3.77e-09	1.57e-06	-0.33	-0.26	Hypospadias;	chr7:27524042	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6462029	ENSG00000235574.1	AC073150.6	-6.01	3.77e-09	1.57e-06	-0.33	-0.26	Hypospadias;	chr7:27541876	chr7:27491682~27492765:-
LUAD	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	6	3.78e-09	1.57e-06	0.3	0.26	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
LUAD	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-6	3.78e-09	1.57e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
LUAD	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-6	3.78e-09	1.57e-06	-0.29	-0.26	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000232546.1	RP11-458F8.1	-6	3.78e-09	1.57e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66100518	chr7:66848496~66858136:+
LUAD	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
LUAD	cis	rs1707322	0.686	rs1547924	ENSG00000234329.1	RP11-767N6.2	6	3.79e-09	1.57e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45651039~45651826:-
LUAD	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	6	3.79e-09	1.58e-06	0.31	0.26	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
LUAD	cis	rs2276314	0.512	rs4393644	ENSG00000278986.1	RP11-723J4.3	-6	3.79e-09	1.58e-06	-0.29	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35878684	chr18:35972151~35973916:+
LUAD	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-6	3.79e-09	1.58e-06	-0.29	-0.26	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-6	3.79e-09	1.58e-06	-0.34	-0.26	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
LUAD	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	6	3.8e-09	1.58e-06	0.22	0.26	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
LUAD	cis	rs1113500	0.524	rs11185270	ENSG00000226822.1	RP11-356N1.2	6	3.8e-09	1.58e-06	0.35	0.26	Growth-regulated protein alpha levels;	chr1:108111740	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.548	rs17020971	ENSG00000226822.1	RP11-356N1.2	6	3.8e-09	1.58e-06	0.35	0.26	Growth-regulated protein alpha levels;	chr1:108112666	chr1:108071482~108074519:+
LUAD	cis	rs11096990	0.855	rs2711989	ENSG00000249207.1	RP11-360F5.1	6	3.8e-09	1.58e-06	0.31	0.26	Cognitive function;	chr4:39150416	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566169	ENSG00000249207.1	RP11-360F5.1	6	3.8e-09	1.58e-06	0.31	0.26	Cognitive function;	chr4:39150420	chr4:39112677~39126818:-
LUAD	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-6	3.81e-09	1.58e-06	-0.3	-0.26	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
LUAD	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-6	3.81e-09	1.58e-06	-0.29	-0.26	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
LUAD	cis	rs11096990	0.855	rs2566177	ENSG00000249207.1	RP11-360F5.1	6	3.81e-09	1.58e-06	0.31	0.26	Cognitive function;	chr4:39154558	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2711934	ENSG00000249207.1	RP11-360F5.1	6	3.81e-09	1.58e-06	0.31	0.26	Cognitive function;	chr4:39156254	chr4:39112677~39126818:-
LUAD	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	6	3.82e-09	1.59e-06	0.43	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
LUAD	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-6	3.82e-09	1.59e-06	-0.29	-0.26	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-6	3.82e-09	1.59e-06	-0.29	-0.26	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
LUAD	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	6	3.82e-09	1.59e-06	0.28	0.26	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	6	3.82e-09	1.59e-06	0.28	0.26	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
LUAD	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-6	3.82e-09	1.59e-06	-0.24	-0.26	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000211970.3	IGHV4-61	-6	3.82e-09	1.59e-06	-0.19	-0.26	Kawasaki disease;	chr14:106682286	chr14:106639119~106639657:-
LUAD	cis	rs12699921	0.632	rs2691615	ENSG00000279048.1	RP11-511H23.2	-6	3.83e-09	1.59e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17847557	chr7:17940503~17942922:+
LUAD	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-6	3.83e-09	1.59e-06	-0.38	-0.26	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.869	rs2056925	ENSG00000219392.1	RP1-265C24.5	-6	3.84e-09	1.59e-06	-0.36	-0.26	Parkinson's disease;	chr6:27723126	chr6:28115628~28116551:+
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000230295.1	RP11-458F8.2	-6	3.84e-09	1.59e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65970805	chr7:66880708~66882981:+
LUAD	cis	rs2034650	0.544	rs8034416	ENSG00000223313.1	RNU6-516P	6	3.84e-09	1.59e-06	0.35	0.26	Interstitial lung disease;	chr15:40411140	chr15:40529570~40529673:+
LUAD	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	6	3.84e-09	1.59e-06	0.29	0.26	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	6	3.84e-09	1.59e-06	0.29	0.26	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
LUAD	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-6	3.84e-09	1.6e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	6	3.84e-09	1.6e-06	0.29	0.26	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
LUAD	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-6	3.85e-09	1.6e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
LUAD	cis	rs1816752	1	rs7999554	ENSG00000273628.1	RP11-756A22.7	6	3.85e-09	1.6e-06	0.31	0.26	Obesity-related traits;	chr13:24435631	chr13:24933006~24936796:+
LUAD	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-6	3.85e-09	1.6e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
LUAD	cis	rs7044106	0.762	rs10760107	ENSG00000238181.2	AHCYP2	-6	3.85e-09	1.6e-06	-0.34	-0.26	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120720673~120721972:+
LUAD	cis	rs62158211	0.955	rs7556815	ENSG00000234997.1	AC016745.3	-6	3.85e-09	1.6e-06	-0.33	-0.26	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr2:113424495~113425324:+
LUAD	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-6	3.85e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
LUAD	cis	rs8031584	0.541	rs1983459	ENSG00000270015.1	RP11-540B6.6	-6	3.86e-09	1.6e-06	-0.18	-0.26	Huntington's disease progression;	chr15:30916546	chr15:30926514~30928407:+
LUAD	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-6	3.86e-09	1.6e-06	-0.38	-0.26	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
LUAD	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-6	3.86e-09	1.6e-06	-0.24	-0.26	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
LUAD	cis	rs12699921	0.537	rs2691582	ENSG00000279048.1	RP11-511H23.2	-6	3.86e-09	1.6e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17789623	chr7:17940503~17942922:+
LUAD	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	6	3.86e-09	1.6e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
LUAD	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	6	3.86e-09	1.6e-06	0.29	0.26	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-6	3.86e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-6	3.86e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-6	3.86e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-6	3.86e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.824	rs9468223	ENSG00000219392.1	RP1-265C24.5	-6	3.86e-09	1.6e-06	-0.36	-0.26	Parkinson's disease;	chr6:27772887	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-6	3.86e-09	1.6e-06	-0.38	-0.26	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
LUAD	cis	rs17684571	0.751	rs35080938	ENSG00000231441.1	RP11-472M19.2	6	3.86e-09	1.6e-06	0.4	0.26	Schizophrenia;	chr6:56847992	chr6:56844002~56864078:+
LUAD	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	6	3.87e-09	1.6e-06	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
LUAD	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-6	3.87e-09	1.6e-06	-0.37	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
LUAD	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	6	3.87e-09	1.61e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
LUAD	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-6	3.88e-09	1.61e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
LUAD	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	6	3.88e-09	1.61e-06	0.37	0.26	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
LUAD	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	6	3.89e-09	1.61e-06	0.27	0.26	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	6	3.89e-09	1.61e-06	0.27	0.26	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
LUAD	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	6	3.89e-09	1.61e-06	0.47	0.26	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
LUAD	cis	rs36093844	0.948	rs11234451	ENSG00000279742.1	RP11-700A24.1	-6	3.9e-09	1.62e-06	-0.3	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85862659	chr11:85852557~85854943:-
LUAD	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	6	3.9e-09	1.62e-06	0.33	0.26	Height;	chr6:109458989	chr6:109382795~109383666:+
LUAD	cis	rs7017914	0.905	rs2732115	ENSG00000223220.1	Y_RNA	6	3.9e-09	1.62e-06	0.3	0.26	Bone mineral density;	chr8:71016619	chr8:70780914~70781008:-
LUAD	cis	rs5753618	0.583	rs738657	ENSG00000236132.1	CTA-440B3.1	-6	3.9e-09	1.62e-06	-0.31	-0.26	Colorectal cancer;	chr22:31445763	chr22:31816379~31817491:-
LUAD	cis	rs35740288	0.77	rs11631660	ENSG00000202081.1	RNU6-1280P	-6	3.9e-09	1.62e-06	-0.32	-0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672181	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	6	3.9e-09	1.62e-06	0.29	0.26	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
LUAD	cis	rs897200	1	rs7561569	ENSG00000280083.1	RP11-317J9.1	6	3.91e-09	1.62e-06	0.33	0.26	Behcet's disease;	chr2:191154820	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs10931497	ENSG00000280083.1	RP11-317J9.1	6	3.92e-09	1.62e-06	0.31	0.26	Obesity-related traits;	chr2:191306254	chr2:191154118~191156070:-
LUAD	cis	rs4908768	0.501	rs910581	ENSG00000232912.4	RP5-1115A15.1	6	3.92e-09	1.62e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469464	chr1:8424645~8434838:+
LUAD	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	6	3.92e-09	1.63e-06	0.64	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
LUAD	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-6	3.92e-09	1.63e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000230295.1	RP11-458F8.2	-6	3.93e-09	1.63e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66030474	chr7:66880708~66882981:+
LUAD	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	6	3.93e-09	1.63e-06	0.34	0.26	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
LUAD	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	6	3.94e-09	1.63e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
LUAD	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-6	3.94e-09	1.63e-06	-0.28	-0.26	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
LUAD	cis	rs12468226	0.873	rs76552560	ENSG00000226261.1	AC064836.3	6	3.94e-09	1.63e-06	0.44	0.26	Urate levels;	chr2:202173123	chr2:202336024~202336727:-
LUAD	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-6	3.94e-09	1.63e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
LUAD	cis	rs1707322	0.821	rs11211182	ENSG00000234329.1	RP11-767N6.2	6	3.94e-09	1.63e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45651039~45651826:-
LUAD	cis	rs17666538	0.539	rs1703925	ENSG00000254207.1	RP11-43A14.1	6	3.95e-09	1.64e-06	0.53	0.26	IgG glycosylation;	chr8:658279	chr8:725188~725877:-
LUAD	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-6	3.95e-09	1.64e-06	-0.63	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
LUAD	cis	rs10214930	0.957	rs2057998	ENSG00000235574.1	AC073150.6	6	3.95e-09	1.64e-06	0.37	0.26	Hypospadias;	chr7:27756902	chr7:27491682~27492765:-
LUAD	cis	rs2404602	0.583	rs3759853	ENSG00000259422.1	RP11-593F23.1	6	3.95e-09	1.64e-06	0.3	0.26	Blood metabolite levels;	chr15:76295436	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.583	rs4381566	ENSG00000259422.1	RP11-593F23.1	6	3.95e-09	1.64e-06	0.3	0.26	Blood metabolite levels;	chr15:76296921	chr15:76174891~76181486:-
LUAD	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-6	3.95e-09	1.64e-06	-0.28	-0.26	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
LUAD	cis	rs1816752	1	rs7326932	ENSG00000273628.1	RP11-756A22.7	6	3.95e-09	1.64e-06	0.31	0.26	Obesity-related traits;	chr13:24430355	chr13:24933006~24936796:+
LUAD	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-6	3.95e-09	1.64e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-6	3.95e-09	1.64e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
LUAD	cis	rs12699921	0.632	rs2691628	ENSG00000279048.1	RP11-511H23.2	-6	3.95e-09	1.64e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17784732	chr7:17940503~17942922:+
LUAD	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	6	3.96e-09	1.64e-06	0.29	0.26	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
LUAD	cis	rs453301	0.653	rs7016139	ENSG00000173295.6	FAM86B3P	-6	3.96e-09	1.64e-06	-0.29	-0.26	Joint mobility (Beighton score);	chr8:9037960	chr8:8228595~8244865:+
LUAD	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-6	3.96e-09	1.64e-06	-0.35	-0.26	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
LUAD	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-6	3.96e-09	1.64e-06	-0.28	-0.26	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
LUAD	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-6	3.96e-09	1.64e-06	-0.36	-0.26	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
LUAD	cis	rs9928842	0.823	rs4888365	ENSG00000280152.1	RP11-331F4.5	6	3.96e-09	1.64e-06	0.3	0.26	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75245994~75250077:-
LUAD	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	6	3.97e-09	1.64e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
LUAD	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	6	3.98e-09	1.65e-06	0.4	0.26	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
LUAD	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	6	3.98e-09	1.65e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-6	3.98e-09	1.65e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
LUAD	cis	rs4713118	0.662	rs149961	ENSG00000204709.4	LINC01556	6	3.99e-09	1.65e-06	0.35	0.26	Parkinson's disease;	chr6:28047791	chr6:28943877~28944537:+
LUAD	cis	rs8031584	0.781	rs4779498	ENSG00000270015.1	RP11-540B6.6	-6	3.99e-09	1.65e-06	-0.19	-0.26	Huntington's disease progression;	chr15:30885273	chr15:30926514~30928407:+
LUAD	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	6	3.99e-09	1.65e-06	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
LUAD	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-6	3.99e-09	1.65e-06	-0.26	-0.26	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
LUAD	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-6	4e-09	1.65e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000211970.3	IGHV4-61	-5.99	4e-09	1.66e-06	-0.19	-0.26	Kawasaki disease;	chr14:106685899	chr14:106639119~106639657:-
LUAD	cis	rs11157436	0.958	rs17255537	ENSG00000211812.1	TRAV26-2	-5.99	4e-09	1.66e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22202583~22203368:+
LUAD	cis	rs293748	0.771	rs158797	ENSG00000250155.1	CTD-2353F22.1	-5.99	4e-09	1.66e-06	-0.37	-0.26	Obesity-related traits;	chr5:36870318	chr5:36666214~36725195:-
LUAD	cis	rs11157436	0.846	rs12435431	ENSG00000211812.1	TRAV26-2	-5.99	4e-09	1.66e-06	-0.29	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22202583~22203368:+
LUAD	cis	rs755249	0.53	rs4660443	ENSG00000228060.1	RP11-69E11.8	-5.99	4e-09	1.66e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39126107	chr1:39565160~39573203:+
LUAD	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
LUAD	cis	rs12908161	0.683	rs12903256	ENSG00000259728.4	LINC00933	5.99	4.01e-09	1.66e-06	0.34	0.26	Schizophrenia;	chr15:84764910	chr15:84570649~84580175:+
LUAD	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-5.99	4.02e-09	1.66e-06	-0.67	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
LUAD	cis	rs516805	0.748	rs12211888	ENSG00000279453.1	RP3-425C14.4	5.99	4.02e-09	1.66e-06	0.36	0.26	Lymphocyte counts;	chr6:122384621	chr6:122436789~122439223:-
LUAD	cis	rs55665837	0.559	rs11023210	ENSG00000251991.1	RNU7-49P	-5.99	4.02e-09	1.66e-06	-0.29	-0.26	Vitamin D levels;	chr11:14401216	chr11:14478892~14478953:+
LUAD	cis	rs224090	0.54	rs11592442	ENSG00000238280.1	RP11-436D10.3	-5.99	4.02e-09	1.66e-06	-0.33	-0.26	Crohn's disease;	chr10:62774144	chr10:62793562~62805887:-
LUAD	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-5.99	4.03e-09	1.66e-06	-0.29	-0.26	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
LUAD	cis	rs6772849	0.796	rs9841521	ENSG00000242551.2	POU5F1P6	-5.99	4.03e-09	1.67e-06	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128674735~128677005:-
LUAD	cis	rs11096990	0.821	rs2711991	ENSG00000249207.1	RP11-360F5.1	5.99	4.03e-09	1.67e-06	0.3	0.26	Cognitive function;	chr4:39149733	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566168	ENSG00000249207.1	RP11-360F5.1	5.99	4.03e-09	1.67e-06	0.3	0.26	Cognitive function;	chr4:39150053	chr4:39112677~39126818:-
LUAD	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	5.99	4.04e-09	1.67e-06	0.33	0.26	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
LUAD	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	5.99	4.04e-09	1.67e-06	0.39	0.26	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
LUAD	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-5.99	4.04e-09	1.67e-06	-0.3	-0.26	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
LUAD	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-5.99	4.05e-09	1.67e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-5.99	4.05e-09	1.67e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-5.99	4.05e-09	1.67e-06	-0.38	-0.26	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
LUAD	cis	rs3738443	0.523	rs56338561	ENSG00000259865.1	RP11-488L18.10	5.99	4.05e-09	1.68e-06	0.23	0.26	Alcohol dependence;	chr1:247210592	chr1:247187281~247188526:-
LUAD	cis	rs9494145	0.68	rs4895441	ENSG00000232876.1	CTA-212D2.2	5.99	4.06e-09	1.68e-06	0.35	0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135055033~135060550:+
LUAD	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-5.99	4.06e-09	1.68e-06	-0.26	-0.26	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
LUAD	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-5.99	4.07e-09	1.68e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
LUAD	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-5.99	4.07e-09	1.68e-06	-0.32	-0.26	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
LUAD	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-5.99	4.07e-09	1.68e-06	-0.22	-0.26	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
LUAD	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-5.99	4.08e-09	1.68e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
LUAD	cis	rs853679	0.55	rs9295762	ENSG00000204709.4	LINC01556	-5.99	4.08e-09	1.68e-06	-0.35	-0.26	Depression;	chr6:28187640	chr6:28943877~28944537:+
LUAD	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	5.99	4.08e-09	1.68e-06	0.28	0.26	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
LUAD	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	5.99	4.08e-09	1.69e-06	0.35	0.26	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
LUAD	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	5.99	4.09e-09	1.69e-06	0.27	0.26	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
LUAD	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-5.99	4.09e-09	1.69e-06	-0.38	-0.26	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
LUAD	cis	rs948562	0.947	rs1938601	ENSG00000280010.1	AP001350.4	5.99	4.1e-09	1.69e-06	0.42	0.26	Lymphoma;	chr11:58646988	chr11:58627435~58628528:+
LUAD	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	5.99	4.1e-09	1.69e-06	0.33	0.26	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
LUAD	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	5.99	4.1e-09	1.69e-06	0.33	0.26	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs316307	ENSG00000230295.1	RP11-458F8.2	-5.99	4.1e-09	1.69e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66105184	chr7:66880708~66882981:+
LUAD	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-5.99	4.1e-09	1.69e-06	-0.35	-0.26	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
LUAD	cis	rs9813712	0.571	rs9836814	ENSG00000249846.5	RP11-77P16.4	5.99	4.1e-09	1.7e-06	0.31	0.26	Response to amphetamines;	chr3:130216054	chr3:130112550~130120579:+
LUAD	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	5.99	4.1e-09	1.7e-06	0.31	0.26	Height;	chr11:118860890	chr11:118688039~118690600:-
LUAD	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	5.99	4.1e-09	1.7e-06	0.31	0.26	Height;	chr11:118861053	chr11:118688039~118690600:-
LUAD	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	5.99	4.11e-09	1.7e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	5.99	4.11e-09	1.7e-06	0.34	0.26	Depression;	chr6:28399886	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	5.99	4.11e-09	1.7e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-5.99	4.11e-09	1.7e-06	-0.31	-0.26	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
LUAD	cis	rs10214930	0.697	rs986706	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27573133	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7806605	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27573966	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs4722719	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27575303	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs5009225	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27577166	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs10807841	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27580132	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs1009252	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27582054	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7789788	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27582992	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1608664	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27584309	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs4140899	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27585408	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1524532	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27586067	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2391443	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27586310	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12539707	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27586546	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7783447	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27587236	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.65	rs4348389	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27589331	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1980329	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27590681	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12667235	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27592012	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.723	rs6948814	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27593782	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12668430	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27593899	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs28416309	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27594123	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs28429439	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27594180	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1404278	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27595107	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.723	rs6960834	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27596367	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6980382	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27598043	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6947731	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27599076	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1030003	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27600240	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6462036	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27601444	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.625	rs6462037	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27601481	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7811436	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27601667	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2110528	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27603400	chr7:27491682~27492765:-
LUAD	cis	rs7181230	0.885	rs35781999	ENSG00000275636.1	RP11-521C20.5	5.99	4.11e-09	1.7e-06	0.36	0.26	Dehydroepiandrosterone sulphate levels;	chr15:40063205	chr15:40078892~40079347:+
LUAD	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	5.99	4.12e-09	1.7e-06	0.31	0.26	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
LUAD	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-5.99	4.12e-09	1.7e-06	-0.32	-0.26	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
LUAD	cis	rs897200	1	rs11684030	ENSG00000280083.1	RP11-317J9.1	5.99	4.12e-09	1.7e-06	0.33	0.26	Behcet's disease;	chr2:191152153	chr2:191154118~191156070:-
LUAD	cis	rs11157436	0.958	rs764161	ENSG00000211812.1	TRAV26-2	-5.99	4.13e-09	1.7e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22202583~22203368:+
LUAD	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	5.99	4.13e-09	1.7e-06	0.34	0.26	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
LUAD	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	5.99	4.13e-09	1.7e-06	0.34	0.26	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
LUAD	cis	rs10740039	0.81	rs1006956	ENSG00000254271.1	RP11-131N11.4	-5.99	4.13e-09	1.7e-06	-0.3	-0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60608218	chr10:60734342~60741828:+
LUAD	cis	rs2034650	0.506	rs1984793	ENSG00000223313.1	RNU6-516P	5.99	4.13e-09	1.71e-06	0.34	0.26	Interstitial lung disease;	chr15:40407172	chr15:40529570~40529673:+
LUAD	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-5.99	4.13e-09	1.71e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
LUAD	cis	rs11977715	0.538	rs43063	ENSG00000233942.1	AC004012.1	-5.99	4.13e-09	1.71e-06	-0.31	-0.26	Middle childhood and early adolescence aggressive behavior;	chr7:95480475	chr7:95471835~95473998:+
LUAD	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	5.99	4.15e-09	1.71e-06	0.29	0.26	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs160646	ENSG00000232546.1	RP11-458F8.1	-5.99	4.15e-09	1.71e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66091293	chr7:66848496~66858136:+
LUAD	cis	rs6991838	0.806	rs35284121	ENSG00000272010.1	CTD-3025N20.3	5.99	4.15e-09	1.71e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	5.99	4.15e-09	1.71e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	5.99	4.15e-09	1.71e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
LUAD	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	5.99	4.16e-09	1.71e-06	0.3	0.26	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
LUAD	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-5.99	4.16e-09	1.71e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
LUAD	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-5.99	4.16e-09	1.72e-06	-0.33	-0.26	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
LUAD	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	5.99	4.16e-09	1.72e-06	0.29	0.26	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
LUAD	cis	rs11157436	0.958	rs61972229	ENSG00000211812.1	TRAV26-2	-5.99	4.16e-09	1.72e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.958	rs17183301	ENSG00000211812.1	TRAV26-2	-5.99	4.16e-09	1.72e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22202583~22203368:+
LUAD	cis	rs67311347	1	rs67311347	ENSG00000223797.4	ENTPD3-AS1	5.99	4.16e-09	1.72e-06	0.29	0.26	Renal cell carcinoma;	chr3:40491752	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	5.99	4.16e-09	1.72e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
LUAD	cis	rs748404	0.666	rs7177146	ENSG00000205771.5	CATSPER2P1	-5.99	4.17e-09	1.72e-06	-0.4	-0.26	Lung cancer;	chr15:43506110	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-5.99	4.17e-09	1.72e-06	-0.39	-0.26	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
LUAD	cis	rs897200	1	rs16833437	ENSG00000280083.1	RP11-317J9.1	5.99	4.18e-09	1.72e-06	0.33	0.26	Behcet's disease;	chr2:191154646	chr2:191154118~191156070:-
LUAD	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	5.99	4.18e-09	1.72e-06	0.23	0.26	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
LUAD	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	5.99	4.18e-09	1.72e-06	0.3	0.26	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
LUAD	cis	rs4713118	0.662	rs464312	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.72e-06	0.36	0.26	Parkinson's disease;	chr6:27999813	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs469228	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.72e-06	0.36	0.26	Parkinson's disease;	chr6:28002926	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.54	rs469227	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.72e-06	0.36	0.26	Parkinson's disease;	chr6:28002927	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs149948	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.72e-06	0.36	0.26	Parkinson's disease;	chr6:28007039	chr6:28943877~28944537:+
LUAD	cis	rs7246657	0.943	rs2279148	ENSG00000276846.1	CTD-3220F14.3	5.99	4.19e-09	1.73e-06	0.36	0.26	Coronary artery calcification;	chr19:37533781	chr19:37314868~37315620:-
LUAD	cis	rs293748	0.54	rs12652735	ENSG00000250155.1	CTD-2353F22.1	-5.99	4.19e-09	1.73e-06	-0.33	-0.26	Obesity-related traits;	chr5:37230629	chr5:36666214~36725195:-
LUAD	cis	rs2243480	1	rs316322	ENSG00000230295.1	RP11-458F8.2	-5.99	4.19e-09	1.73e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66146246	chr7:66880708~66882981:+
LUAD	cis	rs6772849	0.931	rs60825080	ENSG00000242551.2	POU5F1P6	-5.99	4.2e-09	1.73e-06	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128665991	chr3:128674735~128677005:-
LUAD	cis	rs8031584	0.958	rs34909055	ENSG00000260382.1	RP11-540B6.2	5.99	4.2e-09	1.73e-06	0.31	0.26	Huntington's disease progression;	chr15:30991967	chr15:30882267~30883231:-
LUAD	cis	rs1823913	0.599	rs4146103	ENSG00000280083.1	RP11-317J9.1	-5.99	4.2e-09	1.73e-06	-0.31	-0.26	Obesity-related traits;	chr2:191272000	chr2:191154118~191156070:-
LUAD	cis	rs11651753	0.613	rs4793732	ENSG00000264920.1	RP11-6N17.4	-5.99	4.2e-09	1.73e-06	-0.34	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:47891255~47895812:-
LUAD	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-5.99	4.2e-09	1.73e-06	-0.32	-0.26	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
LUAD	cis	rs2098713	0.512	rs13166974	ENSG00000250155.1	CTD-2353F22.1	-5.99	4.2e-09	1.73e-06	-0.33	-0.26	Telomere length;	chr5:37171263	chr5:36666214~36725195:-
LUAD	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-5.99	4.21e-09	1.73e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-5.99	4.21e-09	1.74e-06	-0.34	-0.26	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
LUAD	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	5.99	4.21e-09	1.74e-06	0.33	0.26	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
LUAD	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-5.99	4.21e-09	1.74e-06	-0.23	-0.26	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
LUAD	cis	rs10740039	0.81	rs2165691	ENSG00000254271.1	RP11-131N11.4	5.99	4.22e-09	1.74e-06	0.3	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60611891	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.81	rs1442543	ENSG00000254271.1	RP11-131N11.4	5.99	4.22e-09	1.74e-06	0.3	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613704	chr10:60734342~60741828:+
LUAD	cis	rs4713118	0.866	rs2179094	ENSG00000219392.1	RP1-265C24.5	-5.99	4.22e-09	1.74e-06	-0.35	-0.26	Parkinson's disease;	chr6:27774046	chr6:28115628~28116551:+
LUAD	cis	rs35934224	0.783	rs16984299	ENSG00000232926.1	AC000078.5	-5.99	4.22e-09	1.74e-06	-0.28	-0.26	Glaucoma (primary open-angle);	chr22:19876070	chr22:19887289~19887970:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000211967.3	IGHV3-53	-5.99	4.22e-09	1.74e-06	-0.19	-0.26	Kawasaki disease;	chr14:106685105	chr14:106592676~106593347:-
LUAD	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	5.99	4.22e-09	1.74e-06	0.49	0.26	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
LUAD	cis	rs12468226	0.938	rs4675274	ENSG00000226261.1	AC064836.3	-5.99	4.22e-09	1.74e-06	-0.43	-0.26	Urate levels;	chr2:202243145	chr2:202336024~202336727:-
LUAD	cis	rs1275468	1	rs3847669	ENSG00000257497.2	RP11-585P4.5	-5.99	4.22e-09	1.74e-06	-0.36	-0.26	Polycystic ovary syndrome;	chr12:75555378	chr12:75483454~75489820:-
LUAD	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	5.99	4.23e-09	1.74e-06	0.32	0.26	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
LUAD	cis	rs2243480	1	rs465359	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66093177	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66093180	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66093199	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66093386	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66100154	chr7:66848496~66858136:+
LUAD	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-5.99	4.23e-09	1.74e-06	-0.28	-0.26	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
LUAD	cis	rs293748	0.771	rs35011787	ENSG00000250155.1	CTD-2353F22.1	-5.99	4.23e-09	1.74e-06	-0.37	-0.26	Obesity-related traits;	chr5:37010302	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs35701604	ENSG00000250155.1	CTD-2353F22.1	-5.99	4.23e-09	1.74e-06	-0.37	-0.26	Obesity-related traits;	chr5:37021831	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
LUAD	cis	rs2288884	1	rs2043298	ENSG00000275055.1	CTC-471J1.11	5.98	4.24e-09	1.74e-06	0.39	0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069814	chr19:52049007~52049754:+
LUAD	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-5.98	4.24e-09	1.75e-06	-0.3	-0.26	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
LUAD	cis	rs12699921	0.658	rs1404422	ENSG00000279048.1	RP11-511H23.2	-5.98	4.24e-09	1.75e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17795362	chr7:17940503~17942922:+
LUAD	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-5.98	4.25e-09	1.75e-06	-0.31	-0.26	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
LUAD	cis	rs11742741	0.539	rs13164843	ENSG00000248874.4	C5orf17	-5.98	4.26e-09	1.75e-06	-0.33	-0.26	Educational attainment;	chr5:24102085	chr5:23951348~24178263:+
LUAD	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-5.98	4.26e-09	1.75e-06	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
LUAD	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-5.98	4.26e-09	1.75e-06	-0.28	-0.26	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
LUAD	cis	rs1707322	0.682	rs12037459	ENSG00000234329.1	RP11-767N6.2	5.98	4.26e-09	1.75e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45651039~45651826:-
LUAD	cis	rs10740039	0.516	rs7072017	ENSG00000254271.1	RP11-131N11.4	5.98	4.26e-09	1.75e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60584568	chr10:60734342~60741828:+
LUAD	cis	rs875971	0.965	rs697968	ENSG00000222364.1	RNU6-96P	5.98	4.27e-09	1.76e-06	0.3	0.26	Aortic root size;	chr7:66070046	chr7:66395191~66395286:+
LUAD	cis	rs17301013	0.507	rs1329281	ENSG00000227373.4	RP11-160H22.5	-5.98	4.27e-09	1.76e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174766432	chr1:174115300~174160004:-
LUAD	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	5.98	4.27e-09	1.76e-06	0.34	0.26	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	5.98	4.28e-09	1.76e-06	0.3	0.26	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
LUAD	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	5.98	4.28e-09	1.76e-06	0.34	0.26	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
LUAD	cis	rs1707322	0.686	rs2991987	ENSG00000234329.1	RP11-767N6.2	-5.98	4.29e-09	1.76e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45651039~45651826:-
LUAD	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	5.98	4.3e-09	1.77e-06	0.31	0.26	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	5.98	4.3e-09	1.77e-06	0.31	0.26	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	5.98	4.3e-09	1.77e-06	0.31	0.26	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
LUAD	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-5.98	4.3e-09	1.77e-06	-0.39	-0.26	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
LUAD	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	5.98	4.3e-09	1.77e-06	0.41	0.26	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
LUAD	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	5.98	4.31e-09	1.77e-06	0.32	0.26	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
LUAD	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	5.98	4.31e-09	1.77e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-5.98	4.31e-09	1.77e-06	-0.32	-0.26	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-5.98	4.31e-09	1.77e-06	-0.32	-0.26	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-5.98	4.31e-09	1.77e-06	-0.32	-0.26	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-5.98	4.31e-09	1.77e-06	-0.32	-0.26	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
LUAD	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-5.98	4.31e-09	1.77e-06	-0.35	-0.26	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
LUAD	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-5.98	4.32e-09	1.78e-06	-0.32	-0.26	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs35542501	ENSG00000230295.1	RP11-458F8.2	-5.98	4.32e-09	1.78e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65966228	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000230295.1	RP11-458F8.2	-5.98	4.32e-09	1.78e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65973566	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000230295.1	RP11-458F8.2	-5.98	4.32e-09	1.78e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65973791	chr7:66880708~66882981:+
LUAD	cis	rs496547	0.721	rs2508570	ENSG00000255422.1	AP002954.4	-5.98	4.32e-09	1.78e-06	-0.33	-0.26	Hip minimal joint space width;	chr11:118807900	chr11:118704607~118750263:+
LUAD	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-5.98	4.32e-09	1.78e-06	-0.36	-0.26	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
LUAD	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-5.98	4.33e-09	1.78e-06	-0.29	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
LUAD	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	5.98	4.33e-09	1.78e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
LUAD	cis	rs12699921	0.632	rs2140710	ENSG00000279048.1	RP11-511H23.2	-5.98	4.33e-09	1.78e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17855952	chr7:17940503~17942922:+
LUAD	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
LUAD	cis	rs17666538	0.585	rs1669733	ENSG00000254207.1	RP11-43A14.1	-5.98	4.34e-09	1.78e-06	-0.5	-0.26	IgG glycosylation;	chr8:656696	chr8:725188~725877:-
LUAD	cis	rs75422866	0.51	rs35784744	ENSG00000274902.1	RP1-197B17.4	5.98	4.35e-09	1.79e-06	0.57	0.26	Pneumonia;	chr12:47729646	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.541	rs12425816	ENSG00000274902.1	RP1-197B17.4	5.98	4.35e-09	1.79e-06	0.57	0.26	Pneumonia;	chr12:47731419	chr12:47731908~47732351:+
LUAD	cis	rs897984	0.647	rs7203999	ENSG00000260911.2	RP11-196G11.2	-5.98	4.35e-09	1.79e-06	-0.24	-0.26	Dementia with Lewy bodies;	chr16:31006233	chr16:31043150~31049868:+
LUAD	cis	rs1167827	0.68	rs1167800	ENSG00000127957.15	PMS2P3	-5.98	4.35e-09	1.79e-06	-0.26	-0.26	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75502930~75528148:-
LUAD	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	5.98	4.36e-09	1.79e-06	0.29	0.26	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	5.98	4.36e-09	1.79e-06	0.29	0.26	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
LUAD	cis	rs8031584	0.781	rs4779498	ENSG00000260382.1	RP11-540B6.2	5.98	4.36e-09	1.79e-06	0.32	0.26	Huntington's disease progression;	chr15:30885273	chr15:30882267~30883231:-
LUAD	cis	rs10740039	0.516	rs9731224	ENSG00000254271.1	RP11-131N11.4	5.98	4.37e-09	1.79e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60583390	chr10:60734342~60741828:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000211967.3	IGHV3-53	-5.98	4.37e-09	1.79e-06	-0.19	-0.26	Kawasaki disease;	chr14:106678273	chr14:106592676~106593347:-
LUAD	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	5.98	4.37e-09	1.8e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
LUAD	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-5.98	4.37e-09	1.8e-06	-0.34	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
LUAD	cis	rs11096990	0.964	rs16995206	ENSG00000249207.1	RP11-360F5.1	5.98	4.37e-09	1.8e-06	0.3	0.26	Cognitive function;	chr4:39262887	chr4:39112677~39126818:-
LUAD	cis	rs7430456	1	rs7430456	ENSG00000228221.4	LINC00578	-5.98	4.38e-09	1.8e-06	-0.31	-0.26	Breast cancer;	chr3:177768082	chr3:177441921~177752305:+
LUAD	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	5.98	4.38e-09	1.8e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
LUAD	cis	rs10214930	0.767	rs56282178	ENSG00000235574.1	AC073150.6	5.98	4.39e-09	1.8e-06	0.35	0.26	Hypospadias;	chr7:27658973	chr7:27491682~27492765:-
LUAD	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	5.98	4.39e-09	1.8e-06	0.33	0.26	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
LUAD	cis	rs12699921	0.632	rs2691600	ENSG00000279048.1	RP11-511H23.2	-5.98	4.4e-09	1.81e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17833542	chr7:17940503~17942922:+
LUAD	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	5.98	4.4e-09	1.81e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-5.98	4.4e-09	1.81e-06	-0.34	-0.26	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
LUAD	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	5.98	4.4e-09	1.81e-06	0.29	0.26	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
LUAD	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-5.98	4.41e-09	1.81e-06	-0.42	-0.26	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
LUAD	cis	rs12468226	0.938	rs56684065	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202289528	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs1474001	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202290230	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs76664732	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202296298	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs16841867	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202303512	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs16839065	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202308774	chr2:202336739~202337200:+
LUAD	cis	rs853679	1	rs853676	ENSG00000204709.4	LINC01556	5.98	4.42e-09	1.81e-06	0.42	0.26	Depression;	chr6:28331910	chr6:28943877~28944537:+
LUAD	cis	rs11157436	0.958	rs12433649	ENSG00000211812.1	TRAV26-2	-5.98	4.42e-09	1.81e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22202583~22203368:+
LUAD	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	5.98	4.42e-09	1.82e-06	0.32	0.26	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
LUAD	cis	rs12291225	0.535	rs16930126	ENSG00000251991.1	RNU7-49P	-5.98	4.43e-09	1.82e-06	-0.29	-0.26	Sense of smell;	chr11:14383437	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	5.98	4.43e-09	1.82e-06	0.3	0.26	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	5.98	4.43e-09	1.82e-06	0.3	0.26	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	5.98	4.43e-09	1.82e-06	0.3	0.26	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
LUAD	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	5.98	4.43e-09	1.82e-06	0.32	0.26	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
LUAD	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	5.98	4.43e-09	1.82e-06	0.35	0.26	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
LUAD	cis	rs11051970	0.527	rs2388989	ENSG00000274964.1	RP11-817I4.1	-5.98	4.43e-09	1.82e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337341	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs2388988	ENSG00000274964.1	RP11-817I4.1	-5.98	4.43e-09	1.82e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337414	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs4604975	ENSG00000274964.1	RP11-817I4.1	-5.98	4.43e-09	1.82e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337441	chr12:32339368~32340724:+
LUAD	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	5.98	4.43e-09	1.82e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
LUAD	cis	rs516805	0.748	rs11154077	ENSG00000279453.1	RP3-425C14.4	5.98	4.44e-09	1.82e-06	0.36	0.26	Lymphocyte counts;	chr6:122386994	chr6:122436789~122439223:-
LUAD	cis	rs2439831	0.867	rs935901	ENSG00000205771.5	CATSPER2P1	-5.98	4.44e-09	1.82e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43359058	chr15:43726918~43747094:-
LUAD	cis	rs755249	0.567	rs72661940	ENSG00000228060.1	RP11-69E11.8	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39262975	chr1:39565160~39573203:+
LUAD	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-5.98	4.44e-09	1.82e-06	-0.31	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
LUAD	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
LUAD	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	5.98	4.44e-09	1.82e-06	0.33	0.26	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
LUAD	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	5.98	4.44e-09	1.82e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
LUAD	cis	rs12468226	0.938	rs115418918	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202315145	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs114922024	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202315958	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs77261109	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202316233	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs12466003	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202317317	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs76501067	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202318042	chr2:202336739~202337200:+
LUAD	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-5.98	4.44e-09	1.82e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
LUAD	cis	rs5753618	0.561	rs13054220	ENSG00000236132.1	CTA-440B3.1	-5.98	4.44e-09	1.82e-06	-0.33	-0.26	Colorectal cancer;	chr22:31308506	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs9609254	ENSG00000236132.1	CTA-440B3.1	-5.98	4.44e-09	1.82e-06	-0.33	-0.26	Colorectal cancer;	chr22:31309956	chr22:31816379~31817491:-
LUAD	cis	rs8177876	0.749	rs58144189	ENSG00000261061.1	RP11-303E16.2	-5.98	4.44e-09	1.82e-06	-0.45	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81030770~81031485:+
LUAD	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	5.98	4.45e-09	1.82e-06	0.31	0.26	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
LUAD	cis	rs17301013	0.507	rs6696465	ENSG00000227373.4	RP11-160H22.5	-5.98	4.45e-09	1.82e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174769700	chr1:174115300~174160004:-
LUAD	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-5.98	4.45e-09	1.82e-06	-0.23	-0.26	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
LUAD	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-5.98	4.45e-09	1.83e-06	-0.32	-0.26	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-5.98	4.45e-09	1.83e-06	-0.32	-0.26	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
LUAD	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
LUAD	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-5.98	4.46e-09	1.83e-06	-0.33	-0.26	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
LUAD	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
LUAD	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	5.98	4.46e-09	1.83e-06	0.62	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
LUAD	cis	rs270601	0.69	rs162907	ENSG00000233006.5	AC034220.3	-5.98	4.46e-09	1.83e-06	-0.24	-0.26	Acylcarnitine levels;	chr5:132244459	chr5:132311285~132369916:-
LUAD	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
LUAD	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-5.98	4.47e-09	1.83e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
LUAD	cis	rs853679	0.517	rs4713150	ENSG00000204709.4	LINC01556	5.98	4.47e-09	1.83e-06	0.37	0.26	Depression;	chr6:28168434	chr6:28943877~28944537:+
LUAD	cis	rs5753618	0.561	rs4820043	ENSG00000236132.1	CTA-440B3.1	5.98	4.47e-09	1.83e-06	0.33	0.26	Colorectal cancer;	chr22:31251108	chr22:31816379~31817491:-
LUAD	cis	rs17301013	0.531	rs1653634	ENSG00000227373.4	RP11-160H22.5	-5.98	4.47e-09	1.83e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174783348	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.599	rs13020656	ENSG00000280083.1	RP11-317J9.1	-5.98	4.47e-09	1.83e-06	-0.31	-0.26	Obesity-related traits;	chr2:191314197	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-5.98	4.47e-09	1.83e-06	-0.39	-0.26	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
LUAD	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	5.98	4.47e-09	1.83e-06	0.22	0.26	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
LUAD	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-5.98	4.48e-09	1.83e-06	-0.45	-0.26	Depression;	chr6:28124907	chr6:28115628~28116551:+
LUAD	cis	rs8177376	0.681	rs678422	ENSG00000254905.1	RP11-712L6.7	5.98	4.48e-09	1.84e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330009	chr11:126292922~126294254:-
LUAD	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	5.98	4.48e-09	1.84e-06	0.68	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs313809	ENSG00000230295.1	RP11-458F8.2	-5.97	4.48e-09	1.84e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66034996	chr7:66880708~66882981:+
LUAD	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	5.97	4.49e-09	1.84e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	5.97	4.49e-09	1.84e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
LUAD	cis	rs1707322	0.821	rs10749857	ENSG00000234329.1	RP11-767N6.2	5.97	4.49e-09	1.84e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45651039~45651826:-
LUAD	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-5.97	4.49e-09	1.84e-06	-0.36	-0.26	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
LUAD	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	5.97	4.49e-09	1.84e-06	0.3	0.26	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
LUAD	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.49e-09	1.84e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
LUAD	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	5.97	4.49e-09	1.84e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	5.97	4.49e-09	1.84e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
LUAD	cis	rs74233809	1	rs12220375	ENSG00000213277.3	MARCKSL1P1	5.97	4.5e-09	1.84e-06	0.44	0.26	Birth weight;	chr10:103141734	chr10:103175554~103176094:+
LUAD	cis	rs6687821	0.681	rs517395	ENSG00000267734.1	RP4-604K5.3	5.97	4.5e-09	1.84e-06	0.35	0.26	Yeast infection;	chr1:86854562	chr1:86932199~86934891:-
LUAD	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	5.97	4.5e-09	1.84e-06	0.32	0.26	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
LUAD	cis	rs7017914	0.905	rs4738105	ENSG00000223220.1	Y_RNA	-5.97	4.51e-09	1.85e-06	-0.3	-0.26	Bone mineral density;	chr8:71046683	chr8:70780914~70781008:-
LUAD	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-5.97	4.51e-09	1.85e-06	-0.33	-0.26	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
LUAD	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
LUAD	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-5.97	4.51e-09	1.85e-06	-0.45	-0.26	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
LUAD	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-5.97	4.51e-09	1.85e-06	-0.25	-0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
LUAD	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-5.97	4.51e-09	1.85e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
LUAD	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-5.97	4.51e-09	1.85e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
LUAD	cis	rs5753618	0.561	rs9606830	ENSG00000236132.1	CTA-440B3.1	-5.97	4.51e-09	1.85e-06	-0.33	-0.26	Colorectal cancer;	chr22:31321813	chr22:31816379~31817491:-
LUAD	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-5.97	4.52e-09	1.85e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000230295.1	RP11-458F8.2	-5.97	4.52e-09	1.85e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:65914813	chr7:66880708~66882981:+
LUAD	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-5.97	4.53e-09	1.85e-06	-0.27	-0.26	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
LUAD	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-5.97	4.53e-09	1.85e-06	-0.33	-0.26	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
LUAD	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-5.97	4.53e-09	1.85e-06	-0.64	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
LUAD	cis	rs1823913	0.599	rs2124093	ENSG00000280083.1	RP11-317J9.1	-5.97	4.53e-09	1.85e-06	-0.31	-0.26	Obesity-related traits;	chr2:191288280	chr2:191154118~191156070:-
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000211967.3	IGHV3-53	5.97	4.53e-09	1.86e-06	0.19	0.26	Kawasaki disease;	chr14:106677179	chr14:106592676~106593347:-
LUAD	cis	rs227932	0.541	rs78177212	ENSG00000234286.1	AC006026.13	-5.97	4.55e-09	1.86e-06	-0.44	-0.26	Schizophrenia;	chr7:23770500	chr7:23680195~23680786:-
LUAD	cis	rs4713118	0.629	rs203890	ENSG00000204709.4	LINC01556	5.97	4.55e-09	1.86e-06	0.36	0.26	Parkinson's disease;	chr6:28054470	chr6:28943877~28944537:+
LUAD	cis	rs62432291	0.681	rs2932987	ENSG00000235086.1	FNDC1-IT1	5.97	4.55e-09	1.86e-06	0.45	0.26	Joint mobility (Beighton score);	chr6:159234641	chr6:159240786~159243329:+
LUAD	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	5.97	4.55e-09	1.86e-06	0.27	0.26	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
LUAD	cis	rs11157436	0.958	rs764160	ENSG00000211812.1	TRAV26-2	-5.97	4.55e-09	1.86e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22202583~22203368:+
LUAD	cis	rs2765539	0.561	rs2645290	ENSG00000226172.2	RP4-712E4.1	5.97	4.55e-09	1.86e-06	0.33	0.26	Waist-hip ratio;	chr1:118929285	chr1:119000344~119001392:-
LUAD	cis	rs1426063	0.614	rs79750906	ENSG00000249717.1	RP11-44F21.3	5.97	4.56e-09	1.86e-06	0.48	0.26	QT interval;	chr4:75139193	chr4:74955974~74970362:-
LUAD	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-5.97	4.56e-09	1.86e-06	-0.31	-0.26	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
LUAD	cis	rs11157436	1	rs12587166	ENSG00000211812.1	TRAV26-2	-5.97	4.56e-09	1.86e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22202583~22203368:+
LUAD	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-5.97	4.56e-09	1.87e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-5.97	4.56e-09	1.87e-06	-0.38	-0.26	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
LUAD	cis	rs3738443	0.868	rs60698393	ENSG00000259865.1	RP11-488L18.10	5.97	4.56e-09	1.87e-06	0.27	0.26	Alcohol dependence;	chr1:247198135	chr1:247187281~247188526:-
LUAD	cis	rs1426063	0.668	rs6534595	ENSG00000249717.1	RP11-44F21.3	5.97	4.57e-09	1.87e-06	0.36	0.26	QT interval;	chr4:75104432	chr4:74955974~74970362:-
LUAD	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-5.97	4.58e-09	1.87e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
LUAD	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-5.97	4.58e-09	1.87e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-5.97	4.58e-09	1.87e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
LUAD	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-5.97	4.58e-09	1.87e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
LUAD	cis	rs17301013	0.507	rs3118990	ENSG00000227373.4	RP11-160H22.5	-5.97	4.58e-09	1.87e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174818586	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	5.97	4.58e-09	1.87e-06	0.39	0.26	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
LUAD	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-5.97	4.59e-09	1.88e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
LUAD	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	5.97	4.59e-09	1.88e-06	0.3	0.26	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	5.97	4.59e-09	1.88e-06	0.3	0.26	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
LUAD	cis	rs1816752	0.935	rs4770676	ENSG00000273628.1	RP11-756A22.7	5.97	4.59e-09	1.88e-06	0.31	0.26	Obesity-related traits;	chr13:24429745	chr13:24933006~24936796:+
LUAD	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	5.97	4.59e-09	1.88e-06	0.3	0.26	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
LUAD	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-5.97	4.59e-09	1.88e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
LUAD	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-5.97	4.6e-09	1.88e-06	-0.29	-0.26	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-5.97	4.6e-09	1.88e-06	-0.29	-0.26	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-5.97	4.6e-09	1.88e-06	-0.29	-0.26	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
LUAD	cis	rs10214930	1	rs1859328	ENSG00000235574.1	AC073150.6	-5.97	4.6e-09	1.88e-06	-0.38	-0.26	Hypospadias;	chr7:27838458	chr7:27491682~27492765:-
LUAD	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	5.97	4.6e-09	1.88e-06	0.4	0.26	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
LUAD	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
LUAD	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-5.97	4.61e-09	1.89e-06	-0.33	-0.26	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
LUAD	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-5.97	4.61e-09	1.89e-06	-0.28	-0.26	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
LUAD	cis	rs1823913	0.637	rs1947456	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191298759	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs11693878	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191299399	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs10931494	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191299442	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs10931495	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191299447	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs12623156	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191299661	chr2:191154118~191156070:-
LUAD	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	5.97	4.62e-09	1.89e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
LUAD	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	5.97	4.62e-09	1.89e-06	0.3	0.26	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
LUAD	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-5.97	4.62e-09	1.89e-06	-0.3	-0.26	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
LUAD	cis	rs3738443	0.52	rs6699577	ENSG00000259865.1	RP11-488L18.10	5.97	4.62e-09	1.89e-06	0.23	0.26	Alcohol dependence;	chr1:247224152	chr1:247187281~247188526:-
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000211967.3	IGHV3-53	-5.97	4.62e-09	1.89e-06	-0.19	-0.26	Kawasaki disease;	chr14:106687277	chr14:106592676~106593347:-
LUAD	cis	rs367615	0.68	rs816542	ENSG00000249476.1	CTD-2587M2.1	5.97	4.62e-09	1.89e-06	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109646923	chr5:109237120~109326369:-
LUAD	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	5.97	4.63e-09	1.89e-06	0.34	0.26	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	5.97	4.63e-09	1.89e-06	0.34	0.26	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	5.97	4.63e-09	1.89e-06	0.34	0.26	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
LUAD	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	5.97	4.63e-09	1.89e-06	0.29	0.26	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
LUAD	cis	rs1823913	0.599	rs13027086	ENSG00000280083.1	RP11-317J9.1	-5.97	4.63e-09	1.89e-06	-0.32	-0.26	Obesity-related traits;	chr2:191294058	chr2:191154118~191156070:-
LUAD	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	5.97	4.63e-09	1.89e-06	0.38	0.26	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
LUAD	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-5.97	4.63e-09	1.89e-06	-0.28	-0.26	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-5.97	4.63e-09	1.89e-06	-0.28	-0.26	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-5.97	4.63e-09	1.89e-06	-0.28	-0.26	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
LUAD	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-5.97	4.63e-09	1.89e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
LUAD	cis	rs1707322	0.721	rs10430124	ENSG00000234329.1	RP11-767N6.2	5.97	4.64e-09	1.89e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45651039~45651826:-
LUAD	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-5.97	4.64e-09	1.9e-06	-0.33	-0.26	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-5.97	4.64e-09	1.9e-06	-0.38	-0.26	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
LUAD	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	5.97	4.65e-09	1.9e-06	0.29	0.26	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
LUAD	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	5.97	4.67e-09	1.91e-06	0.4	0.26	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
LUAD	cis	rs853679	0.55	rs1150692	ENSG00000204709.4	LINC01556	5.97	4.67e-09	1.91e-06	0.36	0.26	Depression;	chr6:28206179	chr6:28943877~28944537:+
LUAD	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	5.97	4.67e-09	1.91e-06	0.4	0.26	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
LUAD	cis	rs728616	0.764	rs11201025	ENSG00000225484.5	NUTM2B-AS1	-5.97	4.67e-09	1.91e-06	-0.47	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79663088~79826594:-
LUAD	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-5.97	4.67e-09	1.91e-06	-0.27	-0.26	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
LUAD	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-5.97	4.68e-09	1.91e-06	-0.51	-0.26	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	5.97	4.68e-09	1.91e-06	0.26	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
LUAD	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-5.97	4.68e-09	1.91e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
LUAD	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-5.97	4.68e-09	1.91e-06	-0.37	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
LUAD	cis	rs17482078	0.885	rs10045403	ENSG00000248734.2	CTD-2260A17.1	5.97	4.69e-09	1.91e-06	0.31	0.26	Behcet's disease;Blood protein levels;	chr5:96812030	chr5:96784777~96785999:+
LUAD	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-5.97	4.69e-09	1.92e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	5.97	4.7e-09	1.92e-06	0.3	0.26	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	5.97	4.7e-09	1.92e-06	0.3	0.26	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	5.97	4.7e-09	1.92e-06	0.3	0.26	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	5.97	4.7e-09	1.92e-06	0.3	0.26	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
LUAD	cis	rs2212361	0.558	rs11020815	ENSG00000255893.1	RP11-685N10.1	-5.97	4.7e-09	1.92e-06	-0.34	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535890	chr11:94472908~94473570:-
LUAD	cis	rs62025270	0.547	rs1026722	ENSG00000202081.1	RNU6-1280P	5.97	4.71e-09	1.92e-06	0.33	0.26	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85651522~85651628:-
LUAD	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-5.97	4.71e-09	1.92e-06	-0.32	-0.26	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
LUAD	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-5.97	4.71e-09	1.92e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
LUAD	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	5.97	4.71e-09	1.92e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
LUAD	cis	rs6687821	0.515	rs61800752	ENSG00000267734.1	RP4-604K5.3	5.97	4.71e-09	1.92e-06	0.33	0.26	Yeast infection;	chr1:86932001	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs56291917	ENSG00000267734.1	RP4-604K5.3	5.97	4.71e-09	1.92e-06	0.33	0.26	Yeast infection;	chr1:86934926	chr1:86932199~86934891:-
LUAD	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	5.97	4.72e-09	1.92e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
LUAD	cis	rs853679	0.517	rs1340004	ENSG00000204709.4	LINC01556	5.97	4.72e-09	1.93e-06	0.37	0.26	Depression;	chr6:28135913	chr6:28943877~28944537:+
LUAD	cis	rs1816752	1	rs9511265	ENSG00000273628.1	RP11-756A22.7	5.97	4.73e-09	1.93e-06	0.31	0.26	Obesity-related traits;	chr13:24438221	chr13:24933006~24936796:+
LUAD	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	5.97	4.73e-09	1.93e-06	0.7	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
LUAD	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	5.97	4.73e-09	1.93e-06	0.37	0.26	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
LUAD	cis	rs293748	0.571	rs13181187	ENSG00000250155.1	CTD-2353F22.1	-5.97	4.73e-09	1.93e-06	-0.33	-0.26	Obesity-related traits;	chr5:37239275	chr5:36666214~36725195:-
LUAD	cis	rs9640161	0.83	rs12703061	ENSG00000261305.1	RP4-584D14.7	5.97	4.73e-09	1.93e-06	0.39	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150365456	chr7:150341771~150342607:+
LUAD	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	5.97	4.73e-09	1.93e-06	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	5.97	4.73e-09	1.93e-06	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
LUAD	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	5.97	4.74e-09	1.93e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
LUAD	cis	rs9595908	0.869	rs7983457	ENSG00000212293.1	SNORA16	-5.97	4.74e-09	1.93e-06	-0.28	-0.26	Body mass index;	chr13:32631797	chr13:32420390~32420516:-
LUAD	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-5.96	4.75e-09	1.94e-06	-0.33	-0.26	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
LUAD	cis	rs8062405	0.931	rs12928404	ENSG00000251417.2	RP11-1348G14.4	-5.96	4.76e-09	1.94e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28802743~28817828:+
LUAD	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-5.96	4.76e-09	1.94e-06	-0.38	-0.26	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
LUAD	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-5.96	4.76e-09	1.94e-06	-0.33	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	5.96	4.76e-09	1.94e-06	0.34	0.26	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
LUAD	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-5.96	4.76e-09	1.94e-06	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
LUAD	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-5.96	4.76e-09	1.94e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
LUAD	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	5.96	4.77e-09	1.94e-06	0.23	0.26	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
LUAD	cis	rs11157436	1	rs72638482	ENSG00000211812.1	TRAV26-2	-5.96	4.77e-09	1.94e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22202583~22203368:+
LUAD	cis	rs1823913	0.637	rs1349938	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191299970	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.592	rs1349939	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191300079	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs4853581	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191301533	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs7565987	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191301815	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs1973067	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302021	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs1973068	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302227	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs7569231	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302373	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs6434461	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302661	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs6434462	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302705	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs6750360	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303089	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs11677694	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303203	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.571	rs6737307	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303247	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs4853582	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303483	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs35200176	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303534	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs17348013	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303726	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-5.96	4.77e-09	1.94e-06	-0.32	-0.26	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
LUAD	cis	rs293748	0.771	rs293746	ENSG00000250155.1	CTD-2353F22.1	-5.96	4.77e-09	1.95e-06	-0.37	-0.26	Obesity-related traits;	chr5:36895168	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs292160	ENSG00000250155.1	CTD-2353F22.1	-5.96	4.77e-09	1.95e-06	-0.37	-0.26	Obesity-related traits;	chr5:36895971	chr5:36666214~36725195:-
LUAD	cis	rs11096990	0.855	rs2566183	ENSG00000249207.1	RP11-360F5.1	5.96	4.78e-09	1.95e-06	0.31	0.26	Cognitive function;	chr4:39162288	chr4:39112677~39126818:-
LUAD	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	5.96	4.78e-09	1.95e-06	0.2	0.26	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
LUAD	cis	rs4713118	0.662	rs9380046	ENSG00000204709.4	LINC01556	5.96	4.78e-09	1.95e-06	0.36	0.26	Parkinson's disease;	chr6:28062721	chr6:28943877~28944537:+
LUAD	cis	rs293748	0.515	rs12658479	ENSG00000250155.1	CTD-2353F22.1	5.96	4.78e-09	1.95e-06	0.32	0.26	Obesity-related traits;	chr5:37206519	chr5:36666214~36725195:-
LUAD	cis	rs2255336	0.938	rs61917750	ENSG00000245648.1	RP11-277P12.20	-5.96	4.8e-09	1.95e-06	-0.41	-0.26	Blood protein levels;	chr12:10480824	chr12:10363769~10398506:+
LUAD	cis	rs4142995	0.586	rs2389858	ENSG00000279048.1	RP11-511H23.2	-5.96	4.8e-09	1.95e-06	-0.21	-0.26	HDL cholesterol;HDL cholesterol levels;	chr7:17868507	chr7:17940503~17942922:+
LUAD	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-5.96	4.8e-09	1.95e-06	-0.51	-0.26	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-5.96	4.8e-09	1.95e-06	-0.33	-0.26	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
LUAD	cis	rs11157436	0.958	rs61972231	ENSG00000211812.1	TRAV26-2	-5.96	4.81e-09	1.96e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22202583~22203368:+
LUAD	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-5.96	4.81e-09	1.96e-06	-0.28	-0.26	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
LUAD	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-5.96	4.82e-09	1.96e-06	-0.31	-0.26	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
LUAD	cis	rs172166	0.694	rs1631552	ENSG00000204709.4	LINC01556	5.96	4.82e-09	1.96e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28121921	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-5.96	4.82e-09	1.96e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
LUAD	cis	rs10214930	0.767	rs6957378	ENSG00000235574.1	AC073150.6	5.96	4.82e-09	1.96e-06	0.35	0.26	Hypospadias;	chr7:27657330	chr7:27491682~27492765:-
LUAD	cis	rs6687821	0.515	rs512912	ENSG00000267734.1	RP4-604K5.3	5.96	4.83e-09	1.96e-06	0.32	0.26	Yeast infection;	chr1:86898359	chr1:86932199~86934891:-
LUAD	cis	rs4664293	0.51	rs2042776	ENSG00000226266.5	AC009961.3	5.96	4.83e-09	1.96e-06	0.43	0.26	Monocyte percentage of white cells;	chr2:159653793	chr2:159670708~159712435:-
LUAD	cis	rs227932	0.571	rs12536173	ENSG00000234286.1	AC006026.13	-5.96	4.83e-09	1.97e-06	-0.45	-0.26	Schizophrenia;	chr7:23834413	chr7:23680195~23680786:-
LUAD	cis	rs4713118	0.869	rs9283880	ENSG00000219392.1	RP1-265C24.5	-5.96	4.84e-09	1.97e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747464	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9283881	ENSG00000219392.1	RP1-265C24.5	-5.96	4.84e-09	1.97e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747476	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9283882	ENSG00000219392.1	RP1-265C24.5	-5.96	4.84e-09	1.97e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747479	chr6:28115628~28116551:+
LUAD	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-5.96	4.85e-09	1.97e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
LUAD	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	5.96	4.85e-09	1.97e-06	0.27	0.26	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
LUAD	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	5.96	4.85e-09	1.97e-06	0.31	0.26	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
LUAD	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	5.96	4.85e-09	1.97e-06	0.33	0.26	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
LUAD	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	5.96	4.85e-09	1.97e-06	0.27	0.26	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
LUAD	cis	rs2337406	1	rs17112416	ENSG00000211974.3	IGHV2-70	5.96	4.85e-09	1.97e-06	0.35	0.26	Alzheimer's disease (late onset);	chr14:106686773	chr14:106723574~106724093:-
LUAD	cis	rs4803480	0.935	rs1476769	ENSG00000270164.1	LINC01480	-5.96	4.85e-09	1.97e-06	-0.26	-0.26	Schizophrenia;	chr19:41577925	chr19:41535183~41536904:+
LUAD	cis	rs4803480	0.873	rs1476770	ENSG00000270164.1	LINC01480	-5.96	4.85e-09	1.97e-06	-0.26	-0.26	Schizophrenia;	chr19:41578033	chr19:41535183~41536904:+
LUAD	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	5.96	4.86e-09	1.98e-06	0.33	0.26	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
LUAD	cis	rs12699921	0.598	rs2723567	ENSG00000279048.1	RP11-511H23.2	-5.96	4.86e-09	1.98e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17858856	chr7:17940503~17942922:+
LUAD	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-5.96	4.87e-09	1.98e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-5.96	4.87e-09	1.98e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-5.96	4.87e-09	1.98e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
LUAD	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	5.96	4.87e-09	1.98e-06	0.3	0.26	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
LUAD	cis	rs6687821	0.515	rs507966	ENSG00000267734.1	RP4-604K5.3	5.96	4.87e-09	1.98e-06	0.32	0.26	Yeast infection;	chr1:86904391	chr1:86932199~86934891:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000232546.1	RP11-458F8.1	-5.96	4.87e-09	1.98e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66357373	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
LUAD	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-5.96	4.89e-09	1.99e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-5.96	4.89e-09	1.99e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
LUAD	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	5.96	4.89e-09	1.99e-06	0.49	0.26	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
LUAD	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	5.96	4.89e-09	1.99e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
LUAD	cis	rs11051970	0.559	rs11051945	ENSG00000274964.1	RP11-817I4.1	-5.96	4.89e-09	1.99e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32336191	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs11051946	ENSG00000274964.1	RP11-817I4.1	-5.96	4.89e-09	1.99e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32336335	chr12:32339368~32340724:+
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000230295.1	RP11-458F8.2	-5.96	4.89e-09	1.99e-06	-0.32	-0.26	Gout;	chr7:66654674	chr7:66880708~66882981:+
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000230295.1	RP11-458F8.2	-5.96	4.89e-09	1.99e-06	-0.32	-0.26	Gout;	chr7:66661502	chr7:66880708~66882981:+
LUAD	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-5.96	4.89e-09	1.99e-06	-0.37	-0.26	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	5.96	4.89e-09	1.99e-06	0.3	0.26	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	5.96	4.89e-09	1.99e-06	0.3	0.26	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
LUAD	cis	rs948562	0.523	rs12362065	ENSG00000280010.1	AP001350.4	5.96	4.9e-09	1.99e-06	0.41	0.26	Lymphoma;	chr11:58287727	chr11:58627435~58628528:+
LUAD	cis	rs1823913	0.637	rs12622194	ENSG00000280083.1	RP11-317J9.1	5.96	4.9e-09	1.99e-06	0.31	0.26	Obesity-related traits;	chr2:191298680	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs13019567	ENSG00000280083.1	RP11-317J9.1	5.96	4.9e-09	1.99e-06	0.31	0.26	Obesity-related traits;	chr2:191298736	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs316304	ENSG00000230295.1	RP11-458F8.2	-5.96	4.9e-09	1.99e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66151907	chr7:66880708~66882981:+
LUAD	cis	rs6687821	0.548	rs539915	ENSG00000267734.1	RP4-604K5.3	5.96	4.9e-09	1.99e-06	0.35	0.26	Yeast infection;	chr1:86856101	chr1:86932199~86934891:-
LUAD	cis	rs8040855	0.599	rs2342123	ENSG00000259774.1	RP11-182J1.13	5.96	4.91e-09	2e-06	0.3	0.26	Bulimia nervosa;	chr15:85181918	chr15:84422618~84425882:+
LUAD	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-5.96	4.91e-09	2e-06	-0.29	-0.26	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
LUAD	cis	rs9595908	0.709	rs7988089	ENSG00000212293.1	SNORA16	5.96	4.92e-09	2e-06	0.28	0.26	Body mass index;	chr13:32759738	chr13:32420390~32420516:-
LUAD	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	5.96	4.92e-09	2e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
LUAD	cis	rs11157436	0.958	rs2075494	ENSG00000211812.1	TRAV26-2	-5.96	4.93e-09	2e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.958	rs2242542	ENSG00000211812.1	TRAV26-2	-5.96	4.93e-09	2e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22202583~22203368:+
LUAD	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	5.96	4.93e-09	2e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	5.96	4.93e-09	2e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
LUAD	cis	rs853679	0.517	rs12332979	ENSG00000204709.4	LINC01556	5.96	4.93e-09	2e-06	0.37	0.26	Depression;	chr6:28173770	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs67878650	ENSG00000204709.4	LINC01556	5.96	4.93e-09	2e-06	0.37	0.26	Depression;	chr6:28174809	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.569	rs9348798	ENSG00000204709.4	LINC01556	5.96	4.93e-09	2e-06	0.37	0.26	Depression;	chr6:28175233	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380065	ENSG00000204709.4	LINC01556	5.96	4.93e-09	2e-06	0.37	0.26	Depression;	chr6:28176973	chr6:28943877~28944537:+
LUAD	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-5.96	4.93e-09	2e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
LUAD	cis	rs7181230	0.885	rs28444847	ENSG00000275636.1	RP11-521C20.5	5.96	4.95e-09	2.01e-06	0.35	0.26	Dehydroepiandrosterone sulphate levels;	chr15:40064403	chr15:40078892~40079347:+
LUAD	cis	rs2280018	0.609	rs2941253	ENSG00000188599.16	NPIPP1	-5.96	4.95e-09	2.01e-06	-0.23	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15104312~15123498:-
LUAD	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-5.96	4.95e-09	2.01e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
LUAD	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-5.96	4.95e-09	2.01e-06	-0.33	-0.26	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
LUAD	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-5.96	4.95e-09	2.01e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-5.96	4.95e-09	2.01e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
LUAD	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
LUAD	cis	rs1707322	0.647	rs6686944	ENSG00000234329.1	RP11-767N6.2	5.96	4.95e-09	2.01e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
LUAD	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-5.96	4.95e-09	2.01e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
LUAD	cis	rs2243480	1	rs316321	ENSG00000230295.1	RP11-458F8.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66146626	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316318	ENSG00000230295.1	RP11-458F8.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66147917	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316317	ENSG00000230295.1	RP11-458F8.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66148650	chr7:66880708~66882981:+
LUAD	cis	rs17684571	0.751	rs35828379	ENSG00000231441.1	RP11-472M19.2	5.96	4.95e-09	2.01e-06	0.4	0.26	Schizophrenia;	chr6:56839003	chr6:56844002~56864078:+
LUAD	cis	rs897200	0.898	rs7572482	ENSG00000280083.1	RP11-317J9.1	-5.96	4.96e-09	2.02e-06	-0.33	-0.26	Behcet's disease;	chr2:191150346	chr2:191154118~191156070:-
LUAD	cis	rs72615157	0.716	rs75779608	ENSG00000242294.5	STAG3L5P	5.96	4.97e-09	2.02e-06	0.23	0.26	Lung function (FEV1/FVC);	chr7:100171334	chr7:100336079~100351900:+
LUAD	cis	rs853679	0.713	rs200991	ENSG00000219392.1	RP1-265C24.5	5.96	4.97e-09	2.02e-06	0.4	0.26	Depression;	chr6:27847716	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs781150	ENSG00000230295.1	RP11-458F8.2	-5.96	4.97e-09	2.02e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66015986	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000230295.1	RP11-458F8.2	-5.96	4.97e-09	2.02e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66028044	chr7:66880708~66882981:+
LUAD	cis	rs1707322	0.752	rs4660880	ENSG00000234329.1	RP11-767N6.2	5.96	4.97e-09	2.02e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45651039~45651826:-
LUAD	cis	rs9532669	0.926	rs4254182	ENSG00000168852.11	TPTE2P5	5.96	4.98e-09	2.02e-06	0.25	0.26	Cervical cancer;	chr13:40879120	chr13:40822296~40921749:-
LUAD	cis	rs1823913	0.599	rs17511445	ENSG00000280083.1	RP11-317J9.1	5.96	4.99e-09	2.03e-06	0.31	0.26	Obesity-related traits;	chr2:191279831	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-5.96	4.99e-09	2.03e-06	-0.3	-0.26	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
LUAD	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	5.96	4.99e-09	2.03e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
LUAD	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-5.96	5e-09	2.03e-06	-0.35	-0.26	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
LUAD	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-5.96	5e-09	2.03e-06	-0.36	-0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
LUAD	cis	rs4591358	0.773	rs35785148	ENSG00000223466.1	AC064834.2	-5.96	5.01e-09	2.03e-06	-0.36	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195516751	chr2:195533035~195538681:+
LUAD	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-5.96	5.01e-09	2.04e-06	-0.22	-0.26	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
LUAD	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-5.96	5.01e-09	2.04e-06	-0.24	-0.26	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
LUAD	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	5.96	5.02e-09	2.04e-06	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-5.96	5.02e-09	2.04e-06	-0.29	-0.26	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
LUAD	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-5.96	5.02e-09	2.04e-06	-0.31	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
LUAD	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-5.96	5.02e-09	2.04e-06	-0.31	-0.26	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
LUAD	cis	rs71636778	0.509	rs35021342	ENSG00000260063.1	RP5-968P14.2	-5.95	5.03e-09	2.04e-06	-0.46	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759736	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs34201939	ENSG00000260063.1	RP5-968P14.2	-5.95	5.03e-09	2.04e-06	-0.46	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767220	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs35615194	ENSG00000260063.1	RP5-968P14.2	-5.95	5.03e-09	2.04e-06	-0.46	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26791680	chr1:26692132~26694131:-
LUAD	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-5.95	5.03e-09	2.04e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
LUAD	cis	rs2239547	0.603	rs12489490	ENSG00000242142.1	SERBP1P3	5.95	5.03e-09	2.04e-06	0.33	0.26	Schizophrenia;	chr3:53030006	chr3:53064283~53065091:-
LUAD	cis	rs10214930	0.697	rs10447552	ENSG00000235574.1	AC073150.6	5.95	5.03e-09	2.04e-06	0.33	0.26	Hypospadias;	chr7:27643679	chr7:27491682~27492765:-
LUAD	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-5.95	5.04e-09	2.04e-06	-0.29	-0.26	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
LUAD	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	5.95	5.04e-09	2.04e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
LUAD	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-5.95	5.04e-09	2.05e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
LUAD	cis	rs7208859	0.673	rs1347360	ENSG00000263603.1	CTD-2349P21.5	-5.95	5.04e-09	2.05e-06	-0.44	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30729469~30731202:+
LUAD	cis	rs7804306	0.826	rs73053556	ENSG00000233264.2	AC006042.8	5.95	5.05e-09	2.05e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8066180	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73053562	ENSG00000233264.2	AC006042.8	5.95	5.05e-09	2.05e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8068527	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs55746128	ENSG00000233264.2	AC006042.8	5.95	5.05e-09	2.05e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8070757	chr7:7980312~7982228:+
LUAD	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	5.95	5.05e-09	2.05e-06	0.32	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	5.95	5.06e-09	2.05e-06	0.29	0.26	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	5.95	5.06e-09	2.05e-06	0.29	0.26	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	5.95	5.06e-09	2.05e-06	0.29	0.26	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	5.95	5.06e-09	2.05e-06	0.29	0.26	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs316327	ENSG00000230295.1	RP11-458F8.2	5.95	5.06e-09	2.05e-06	0.31	0.26	Diabetic kidney disease;	chr7:66144214	chr7:66880708~66882981:+
LUAD	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	5.95	5.07e-09	2.06e-06	0.38	0.26	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
LUAD	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	5.95	5.07e-09	2.06e-06	0.26	0.26	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
LUAD	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-5.95	5.07e-09	2.06e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
LUAD	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-5.95	5.07e-09	2.06e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
LUAD	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-5.95	5.07e-09	2.06e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
LUAD	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-5.95	5.07e-09	2.06e-06	-0.28	-0.26	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
LUAD	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	5.95	5.07e-09	2.06e-06	0.25	0.26	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
LUAD	cis	rs10214930	0.697	rs6462034	ENSG00000235574.1	AC073150.6	-5.95	5.08e-09	2.06e-06	-0.33	-0.26	Hypospadias;	chr7:27588965	chr7:27491682~27492765:-
LUAD	cis	rs720064	0.586	rs2241643	ENSG00000264745.1	TTC39C-AS1	5.95	5.08e-09	2.06e-06	0.28	0.26	Strep throat;	chr18:23949758	chr18:23994213~24015339:-
LUAD	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	5.95	5.08e-09	2.06e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	5.95	5.08e-09	2.06e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	5.95	5.08e-09	2.06e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	5.95	5.08e-09	2.06e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
LUAD	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	5.95	5.08e-09	2.06e-06	0.32	0.26	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
LUAD	cis	rs4273100	1	rs4924986	ENSG00000279825.1	CTC-457L16.1	-5.95	5.08e-09	2.06e-06	-0.33	-0.26	Schizophrenia;	chr17:19339154	chr17:19030857~19033529:+
LUAD	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	5.95	5.08e-09	2.06e-06	0.28	0.26	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-5.95	5.09e-09	2.06e-06	-0.28	-0.26	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-5.95	5.09e-09	2.06e-06	-0.29	-0.26	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
LUAD	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	5.95	5.1e-09	2.07e-06	0.32	0.26	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	5.95	5.1e-09	2.07e-06	0.32	0.26	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
LUAD	cis	rs897200	0.898	rs7574070	ENSG00000280083.1	RP11-317J9.1	-5.95	5.1e-09	2.07e-06	-0.33	-0.26	Behcet's disease;	chr2:191145762	chr2:191154118~191156070:-
LUAD	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	5.95	5.1e-09	2.07e-06	0.23	0.26	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
LUAD	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-5.95	5.11e-09	2.07e-06	-0.32	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
LUAD	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-5.95	5.11e-09	2.07e-06	-0.32	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
LUAD	cis	rs7804306	0.826	rs74761423	ENSG00000233264.2	AC006042.8	5.95	5.11e-09	2.07e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8059693	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.655	rs73053544	ENSG00000233264.2	AC006042.8	5.95	5.11e-09	2.07e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8059883	chr7:7980312~7982228:+
LUAD	cis	rs10740039	0.516	rs10761526	ENSG00000254271.1	RP11-131N11.4	5.95	5.11e-09	2.07e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60594661	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs1009410	ENSG00000254271.1	RP11-131N11.4	5.95	5.11e-09	2.07e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60595039	chr10:60734342~60741828:+
LUAD	cis	rs2243480	1	rs1638734	ENSG00000232546.1	RP11-458F8.1	-5.95	5.12e-09	2.07e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66632552	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	5.95	5.12e-09	2.07e-06	0.3	0.26	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs313831	ENSG00000232546.1	RP11-458F8.1	-5.95	5.12e-09	2.08e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66086239	chr7:66848496~66858136:+
LUAD	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-5.95	5.13e-09	2.08e-06	-0.31	-0.26	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
LUAD	cis	rs1874124	0.577	rs2807872	ENSG00000272823.1	RP11-295M18.6	-5.95	5.13e-09	2.08e-06	-0.38	-0.26	Cholesterol, total;	chr1:220866908	chr1:220828676~220829211:-
LUAD	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-5.95	5.13e-09	2.08e-06	-0.32	-0.26	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
LUAD	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	5.95	5.13e-09	2.08e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	5.95	5.13e-09	2.08e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	5.95	5.13e-09	2.08e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	5.95	5.13e-09	2.08e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
LUAD	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	5.95	5.14e-09	2.08e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	5.95	5.14e-09	2.08e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000224373.3	IGHV4-59	5.95	5.15e-09	2.08e-06	0.18	0.26	Kawasaki disease;	chr14:106813798	chr14:106627249~106627825:-
LUAD	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-5.95	5.15e-09	2.08e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-5.95	5.15e-09	2.08e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-5.95	5.15e-09	2.08e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-5.95	5.15e-09	2.08e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
LUAD	cis	rs1707322	0.717	rs1135850	ENSG00000234329.1	RP11-767N6.2	5.95	5.15e-09	2.09e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs3014246	ENSG00000234329.1	RP11-767N6.2	-5.95	5.15e-09	2.09e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.655	rs3014240	ENSG00000234329.1	RP11-767N6.2	-5.95	5.15e-09	2.09e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs3014235	ENSG00000234329.1	RP11-767N6.2	-5.95	5.15e-09	2.09e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45651039~45651826:-
LUAD	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-5.95	5.15e-09	2.09e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs431076	ENSG00000230295.1	RP11-458F8.2	-5.95	5.15e-09	2.09e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66135333	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000230295.1	RP11-458F8.2	-5.95	5.15e-09	2.09e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66135463	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000230295.1	RP11-458F8.2	-5.95	5.15e-09	2.09e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66136518	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000230295.1	RP11-458F8.2	-5.95	5.15e-09	2.09e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66137139	chr7:66880708~66882981:+
LUAD	cis	rs12699921	0.632	rs2723570	ENSG00000279048.1	RP11-511H23.2	-5.95	5.16e-09	2.09e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17853533	chr7:17940503~17942922:+
LUAD	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-5.95	5.16e-09	2.09e-06	-0.28	-0.26	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
LUAD	cis	rs30380	0.666	rs26512	ENSG00000272109.1	CTD-2260A17.3	-5.95	5.16e-09	2.09e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96792697	chr5:96804353~96806105:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000230295.1	RP11-458F8.2	-5.95	5.16e-09	2.09e-06	-0.32	-0.26	Gout;	chr7:66693028	chr7:66880708~66882981:+
LUAD	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-5.95	5.17e-09	2.09e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	5.95	5.17e-09	2.09e-06	0.32	0.26	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	5.95	5.17e-09	2.09e-06	0.32	0.26	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
LUAD	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	5.95	5.17e-09	2.09e-06	0.32	0.26	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
LUAD	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-5.95	5.18e-09	2.1e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
LUAD	cis	rs853679	1	rs853679	ENSG00000204709.4	LINC01556	5.95	5.19e-09	2.1e-06	0.41	0.26	Depression;	chr6:28329086	chr6:28943877~28944537:+
LUAD	cis	rs853679	1	rs853678	ENSG00000204709.4	LINC01556	5.95	5.19e-09	2.1e-06	0.41	0.26	Depression;	chr6:28329536	chr6:28943877~28944537:+
LUAD	cis	rs1914816	0.941	rs2938691	ENSG00000196274.5	Metazoa_SRP	5.95	5.19e-09	2.1e-06	0.3	0.26	Response to tocilizumab in rheumatoid arthritis;	chr15:76214865	chr15:76230048~76230390:-
LUAD	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-5.95	5.19e-09	2.1e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
LUAD	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	5.95	5.2e-09	2.1e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
LUAD	cis	rs6772849	0.93	rs1962040	ENSG00000242551.2	POU5F1P6	-5.95	5.2e-09	2.1e-06	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128605318	chr3:128674735~128677005:-
LUAD	cis	rs9910055	0.762	rs227579	ENSG00000267080.4	ASB16-AS1	5.95	5.2e-09	2.1e-06	0.24	0.26	Total body bone mineral density;	chr17:44145766	chr17:44175973~44186717:-
LUAD	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-5.95	5.2e-09	2.1e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-5.95	5.2e-09	2.1e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-5.95	5.2e-09	2.1e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
LUAD	cis	rs3738443	0.545	rs12566906	ENSG00000259865.1	RP11-488L18.10	5.95	5.2e-09	2.1e-06	0.23	0.26	Alcohol dependence;	chr1:247224904	chr1:247187281~247188526:-
LUAD	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	5.95	5.21e-09	2.11e-06	0.32	0.26	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
LUAD	cis	rs10740039	0.516	rs1442549	ENSG00000254271.1	RP11-131N11.4	5.95	5.21e-09	2.11e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60574542	chr10:60734342~60741828:+
LUAD	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	5.95	5.21e-09	2.11e-06	0.32	0.26	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
LUAD	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	5.95	5.21e-09	2.11e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
LUAD	cis	rs12699921	0.632	rs2691585	ENSG00000279048.1	RP11-511H23.2	-5.95	5.21e-09	2.11e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17798064	chr7:17940503~17942922:+
LUAD	cis	rs4713118	0.869	rs9283883	ENSG00000219392.1	RP1-265C24.5	-5.95	5.22e-09	2.11e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747691	chr6:28115628~28116551:+
LUAD	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-5.95	5.22e-09	2.11e-06	-0.28	-0.26	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-5.95	5.22e-09	2.11e-06	-0.28	-0.26	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
LUAD	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	5.95	5.22e-09	2.11e-06	0.23	0.26	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
LUAD	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	5.95	5.24e-09	2.12e-06	0.38	0.26	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
LUAD	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	5.95	5.24e-09	2.12e-06	0.38	0.26	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
LUAD	cis	rs2404602	0.574	rs4886795	ENSG00000259422.1	RP11-593F23.1	-5.95	5.24e-09	2.12e-06	-0.37	-0.26	Blood metabolite levels;	chr15:76349877	chr15:76174891~76181486:-
LUAD	cis	rs4713118	0.513	rs149972	ENSG00000204709.4	LINC01556	5.95	5.24e-09	2.12e-06	0.33	0.26	Parkinson's disease;	chr6:28015449	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs149975	ENSG00000204709.4	LINC01556	5.95	5.24e-09	2.12e-06	0.33	0.26	Parkinson's disease;	chr6:28018562	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-5.95	5.24e-09	2.12e-06	-0.35	-0.26	Depression;	chr6:28229408	chr6:28115628~28116551:+
LUAD	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-5.95	5.25e-09	2.12e-06	-0.32	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
LUAD	cis	rs9910055	0.762	rs2240226	ENSG00000267080.4	ASB16-AS1	-5.95	5.25e-09	2.12e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44188850	chr17:44175973~44186717:-
LUAD	cis	rs9595908	0.581	rs2032507	ENSG00000212293.1	SNORA16	5.95	5.25e-09	2.12e-06	0.27	0.26	Body mass index;	chr13:32779298	chr13:32420390~32420516:-
LUAD	cis	rs516805	0.748	rs6912610	ENSG00000279453.1	RP3-425C14.4	5.95	5.26e-09	2.12e-06	0.35	0.26	Lymphocyte counts;	chr6:122379961	chr6:122436789~122439223:-
LUAD	cis	rs10129255	1	rs8010605	ENSG00000224373.3	IGHV4-59	5.95	5.27e-09	2.13e-06	0.17	0.26	Kawasaki disease;	chr14:106678742	chr14:106627249~106627825:-
LUAD	cis	rs9595908	0.645	rs7983065	ENSG00000212293.1	SNORA16	5.95	5.28e-09	2.13e-06	0.28	0.26	Body mass index;	chr13:32806648	chr13:32420390~32420516:-
LUAD	cis	rs6504622	0.818	rs9303532	ENSG00000262879.4	RP11-156P1.3	-5.95	5.29e-09	2.14e-06	-0.31	-0.26	Orofacial clefts;	chr17:46956636	chr17:46984045~47100323:-
LUAD	cis	rs35740288	0.694	rs17618909	ENSG00000202081.1	RNU6-1280P	5.95	5.29e-09	2.14e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85552231	chr15:85651522~85651628:-
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000211970.3	IGHV4-61	5.95	5.29e-09	2.14e-06	0.18	0.26	Kawasaki disease;	chr14:106683696	chr14:106639119~106639657:-
LUAD	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	5.95	5.29e-09	2.14e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
LUAD	cis	rs755249	0.883	rs12035330	ENSG00000228060.1	RP11-69E11.8	-5.95	5.3e-09	2.14e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39565160~39573203:+
LUAD	cis	rs6687821	0.515	rs502404	ENSG00000267734.1	RP4-604K5.3	5.95	5.31e-09	2.14e-06	0.32	0.26	Yeast infection;	chr1:86878204	chr1:86932199~86934891:-
LUAD	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-5.95	5.31e-09	2.15e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
LUAD	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	5.94	5.32e-09	2.15e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	5.94	5.32e-09	2.15e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	5.94	5.32e-09	2.15e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
LUAD	cis	rs270601	0.77	rs10463891	ENSG00000233006.5	AC034220.3	-5.94	5.33e-09	2.15e-06	-0.24	-0.26	Acylcarnitine levels;	chr5:132261699	chr5:132311285~132369916:-
LUAD	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	5.94	5.33e-09	2.15e-06	0.33	0.26	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
LUAD	cis	rs4908768	0.539	rs1061039	ENSG00000232912.4	RP5-1115A15.1	5.94	5.34e-09	2.15e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8424645~8434838:+
LUAD	cis	rs948562	0.744	rs4313600	ENSG00000280010.1	AP001350.4	5.94	5.34e-09	2.16e-06	0.39	0.26	Lymphoma;	chr11:58463748	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.69	rs11229480	ENSG00000280010.1	AP001350.4	5.94	5.34e-09	2.16e-06	0.39	0.26	Lymphoma;	chr11:58464209	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229481	ENSG00000280010.1	AP001350.4	5.94	5.34e-09	2.16e-06	0.39	0.26	Lymphoma;	chr11:58464426	chr11:58627435~58628528:+
LUAD	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-5.94	5.34e-09	2.16e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
LUAD	cis	rs9595908	0.709	rs2025473	ENSG00000212293.1	SNORA16	5.94	5.34e-09	2.16e-06	0.28	0.26	Body mass index;	chr13:32791632	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-5.94	5.34e-09	2.16e-06	-0.39	-0.26	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	5.94	5.34e-09	2.16e-06	0.29	0.26	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
LUAD	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-5.94	5.35e-09	2.16e-06	-0.27	-0.26	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
LUAD	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	5.94	5.35e-09	2.16e-06	0.29	0.26	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
LUAD	cis	rs10214930	0.697	rs10951171	ENSG00000235574.1	AC073150.6	-5.94	5.35e-09	2.16e-06	-0.33	-0.26	Hypospadias;	chr7:27571988	chr7:27491682~27492765:-
LUAD	cis	rs2115630	0.645	rs3825877	ENSG00000229212.6	RP11-561C5.4	5.94	5.35e-09	2.16e-06	0.31	0.26	P wave terminal force;	chr15:84631400	chr15:85205440~85234795:-
LUAD	cis	rs2115630	0.645	rs3825878	ENSG00000229212.6	RP11-561C5.4	5.94	5.35e-09	2.16e-06	0.31	0.26	P wave terminal force;	chr15:84631524	chr15:85205440~85234795:-
LUAD	cis	rs9595908	0.669	rs2032508	ENSG00000212293.1	SNORA16	5.94	5.35e-09	2.16e-06	0.29	0.26	Body mass index;	chr13:32779332	chr13:32420390~32420516:-
LUAD	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-5.94	5.35e-09	2.16e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
LUAD	cis	rs9595908	0.709	rs17516498	ENSG00000212293.1	SNORA16	5.94	5.36e-09	2.16e-06	0.27	0.26	Body mass index;	chr13:32750477	chr13:32420390~32420516:-
LUAD	cis	rs7618501	0.665	rs7621352	ENSG00000234667.1	ACTBP13	5.94	5.36e-09	2.16e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50033330	chr3:49873347~49877980:-
LUAD	cis	rs10214930	0.706	rs10081338	ENSG00000235574.1	AC073150.6	5.94	5.36e-09	2.16e-06	0.35	0.26	Hypospadias;	chr7:27658969	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.767	rs10081339	ENSG00000235574.1	AC073150.6	5.94	5.36e-09	2.16e-06	0.35	0.26	Hypospadias;	chr7:27658975	chr7:27491682~27492765:-
LUAD	cis	rs7208859	0.673	rs216409	ENSG00000263603.1	CTD-2349P21.5	5.94	5.36e-09	2.17e-06	0.4	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30729469~30731202:+
LUAD	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-5.94	5.36e-09	2.17e-06	-0.29	-0.26	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
LUAD	cis	rs720064	0.586	rs8099403	ENSG00000264745.1	TTC39C-AS1	-5.94	5.37e-09	2.17e-06	-0.27	-0.26	Strep throat;	chr18:23933031	chr18:23994213~24015339:-
LUAD	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-5.94	5.37e-09	2.17e-06	-0.34	-0.26	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
LUAD	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-5.94	5.38e-09	2.17e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
LUAD	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	5.94	5.39e-09	2.18e-06	0.64	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
LUAD	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	5.94	5.41e-09	2.18e-06	0.23	0.26	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-5.94	5.41e-09	2.18e-06	-0.3	-0.26	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
LUAD	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-5.94	5.42e-09	2.18e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-5.94	5.42e-09	2.18e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
LUAD	cis	rs853679	0.517	rs9468298	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28154567	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9295759	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28156691	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9348796	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28158424	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs11552219	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28159056	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380058	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28159666	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393895	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28159843	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9357066	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28162053	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393898	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28162598	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368556	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28163375	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368557	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28163759	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380059	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28164580	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380060	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28164825	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs35227624	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28164948	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380061	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28165025	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368558	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28165528	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.587	rs9393899	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Parkinson's disease;	chr6:28165750	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.527	rs4713151	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Parkinson's disease;	chr6:28168578	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393901	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28169019	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs3173443	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28169249	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9348797	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28169755	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380062	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28169791	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.542	rs9380063	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28170075	chr6:28943877~28944537:+
LUAD	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	5.94	5.42e-09	2.18e-06	0.32	0.26	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
LUAD	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	5.94	5.42e-09	2.18e-06	0.29	0.26	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
LUAD	cis	rs12468226	0.873	rs60722019	ENSG00000226261.1	AC064836.3	5.94	5.42e-09	2.18e-06	0.44	0.26	Urate levels;	chr2:202282060	chr2:202336024~202336727:-
LUAD	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-5.94	5.42e-09	2.19e-06	-0.32	-0.26	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
LUAD	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-5.94	5.42e-09	2.19e-06	-0.29	-0.26	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.662	rs175954	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.19e-06	0.35	0.26	Parkinson's disease;	chr6:28043807	chr6:28943877~28944537:+
LUAD	cis	rs6504622	0.935	rs62075889	ENSG00000262879.4	RP11-156P1.3	-5.94	5.43e-09	2.19e-06	-0.31	-0.26	Orofacial clefts;	chr17:46950671	chr17:46984045~47100323:-
LUAD	cis	rs6504622	1	rs12940071	ENSG00000262879.4	RP11-156P1.3	-5.94	5.43e-09	2.19e-06	-0.31	-0.26	Orofacial clefts;	chr17:46950686	chr17:46984045~47100323:-
LUAD	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-5.94	5.44e-09	2.19e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
LUAD	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	5.94	5.44e-09	2.19e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	5.94	5.44e-09	2.19e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
LUAD	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	5.94	5.44e-09	2.19e-06	0.31	0.26	Height;	chr11:118855233	chr11:118688039~118690600:-
LUAD	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	5.94	5.44e-09	2.19e-06	0.31	0.26	Height;	chr11:118855938	chr11:118688039~118690600:-
LUAD	cis	rs10214930	1	rs4719906	ENSG00000235574.1	AC073150.6	5.94	5.44e-09	2.19e-06	0.37	0.26	Hypospadias;	chr7:27733233	chr7:27491682~27492765:-
LUAD	cis	rs4713118	0.662	rs9357060	ENSG00000204709.4	LINC01556	5.94	5.45e-09	2.2e-06	0.36	0.26	Parkinson's disease;	chr6:28056708	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468271	ENSG00000204709.4	LINC01556	5.94	5.45e-09	2.2e-06	0.36	0.26	Parkinson's disease;	chr6:28056792	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-5.94	5.46e-09	2.2e-06	-0.36	-0.26	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
LUAD	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-5.94	5.46e-09	2.2e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
LUAD	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	5.94	5.46e-09	2.2e-06	0.31	0.26	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
LUAD	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-5.94	5.46e-09	2.2e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
LUAD	cis	rs11742741	0.539	rs6880304	ENSG00000248874.4	C5orf17	-5.94	5.46e-09	2.2e-06	-0.33	-0.26	Educational attainment;	chr5:24113952	chr5:23951348~24178263:+
LUAD	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-5.94	5.47e-09	2.2e-06	-0.31	-0.26	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
LUAD	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	5.94	5.48e-09	2.21e-06	0.45	0.26	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
LUAD	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-5.94	5.48e-09	2.21e-06	-0.33	-0.26	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
LUAD	cis	rs2255336	0.938	rs61917723	ENSG00000245648.1	RP11-277P12.20	-5.94	5.49e-09	2.21e-06	-0.41	-0.26	Blood protein levels;	chr12:10472728	chr12:10363769~10398506:+
LUAD	cis	rs7246657	0.722	rs8103647	ENSG00000276846.1	CTD-3220F14.3	5.94	5.49e-09	2.21e-06	0.35	0.26	Coronary artery calcification;	chr19:37609551	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs8100646	ENSG00000276846.1	CTD-3220F14.3	5.94	5.49e-09	2.21e-06	0.35	0.26	Coronary artery calcification;	chr19:37617042	chr19:37314868~37315620:-
LUAD	cis	rs293748	0.54	rs10461978	ENSG00000250155.1	CTD-2353F22.1	-5.94	5.49e-09	2.21e-06	-0.33	-0.26	Obesity-related traits;	chr5:37274810	chr5:36666214~36725195:-
LUAD	cis	rs11971779	0.666	rs6467847	ENSG00000273391.1	RP11-634H22.1	5.94	5.5e-09	2.21e-06	0.28	0.26	Diisocyanate-induced asthma;	chr7:139394690	chr7:139359032~139359566:-
LUAD	cis	rs7208859	0.562	rs216408	ENSG00000263603.1	CTD-2349P21.5	5.94	5.5e-09	2.22e-06	0.39	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30729469~30731202:+
LUAD	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-5.94	5.5e-09	2.22e-06	-0.36	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
LUAD	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-5.94	5.51e-09	2.22e-06	-0.34	-0.26	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
LUAD	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	5.94	5.51e-09	2.22e-06	0.29	0.26	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
LUAD	cis	rs17666538	0.585	rs4735812	ENSG00000254207.1	RP11-43A14.1	5.94	5.52e-09	2.22e-06	0.53	0.26	IgG glycosylation;	chr8:657766	chr8:725188~725877:-
LUAD	cis	rs2255336	0.938	rs7298494	ENSG00000245648.1	RP11-277P12.20	-5.94	5.52e-09	2.22e-06	-0.41	-0.26	Blood protein levels;	chr12:10460666	chr12:10363769~10398506:+
LUAD	cis	rs35934224	0.831	rs8141610	ENSG00000232926.1	AC000078.5	-5.94	5.52e-09	2.22e-06	-0.31	-0.26	Glaucoma (primary open-angle);	chr22:19882624	chr22:19887289~19887970:+
LUAD	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-5.94	5.52e-09	2.22e-06	-0.2	-0.26	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
LUAD	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-5.94	5.52e-09	2.22e-06	-0.29	-0.26	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	5.94	5.52e-09	2.22e-06	0.29	0.26	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
LUAD	cis	rs4713118	0.629	rs203889	ENSG00000204709.4	LINC01556	5.94	5.53e-09	2.23e-06	0.35	0.26	Parkinson's disease;	chr6:28053997	chr6:28943877~28944537:+
LUAD	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	5.94	5.53e-09	2.23e-06	0.56	0.26	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
LUAD	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-5.94	5.53e-09	2.23e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
LUAD	cis	rs1707322	0.717	rs3014245	ENSG00000234329.1	RP11-767N6.2	-5.94	5.54e-09	2.23e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45651039~45651826:-
LUAD	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-5.94	5.54e-09	2.23e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
LUAD	cis	rs10214930	0.697	rs6958467	ENSG00000235574.1	AC073150.6	-5.94	5.55e-09	2.23e-06	-0.32	-0.26	Hypospadias;	chr7:27564193	chr7:27491682~27492765:-
LUAD	cis	rs1823913	0.549	rs4516458	ENSG00000280083.1	RP11-317J9.1	-5.94	5.56e-09	2.24e-06	-0.32	-0.26	Obesity-related traits;	chr2:191325177	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000230295.1	RP11-458F8.2	-5.94	5.57e-09	2.24e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66007799	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160655	ENSG00000232546.1	RP11-458F8.1	-5.94	5.57e-09	2.24e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66068227	chr7:66848496~66858136:+
LUAD	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	5.94	5.58e-09	2.24e-06	0.29	0.26	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
LUAD	cis	rs1426063	0.748	rs7654088	ENSG00000249717.1	RP11-44F21.3	-5.94	5.59e-09	2.25e-06	-0.34	-0.26	QT interval;	chr4:75107103	chr4:74955974~74970362:-
LUAD	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
LUAD	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-5.94	5.6e-09	2.25e-06	-0.34	-0.26	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
LUAD	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-5.94	5.6e-09	2.25e-06	-0.38	-0.26	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
LUAD	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-5.94	5.6e-09	2.25e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
LUAD	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-5.94	5.61e-09	2.26e-06	-0.37	-0.26	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
LUAD	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	5.94	5.61e-09	2.26e-06	0.32	0.26	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
LUAD	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	5.94	5.62e-09	2.26e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
LUAD	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-5.94	5.63e-09	2.26e-06	-0.32	-0.26	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
LUAD	cis	rs10214930	0.697	rs12700817	ENSG00000235574.1	AC073150.6	-5.94	5.63e-09	2.26e-06	-0.33	-0.26	Hypospadias;	chr7:27551474	chr7:27491682~27492765:-
LUAD	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	5.93	5.63e-09	2.26e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
LUAD	cis	rs12699921	0.632	rs2691597	ENSG00000279048.1	RP11-511H23.2	-5.93	5.64e-09	2.27e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17830717	chr7:17940503~17942922:+
LUAD	cis	rs13230714	0.858	rs714429	ENSG00000204959.4	ARHGEF34P	-5.93	5.64e-09	2.27e-06	-0.34	-0.26	Breast cancer;	chr7:144456641	chr7:144272445~144286966:-
LUAD	cis	rs9318086	1	rs9318086	ENSG00000205861.10	C1QTNF9B-AS1	5.93	5.64e-09	2.27e-06	0.31	0.26	Myopia (pathological);	chr13:23858328	chr13:23888889~23897263:+
LUAD	cis	rs516805	0.596	rs1531186	ENSG00000279453.1	RP3-425C14.4	-5.93	5.64e-09	2.27e-06	-0.35	-0.26	Lymphocyte counts;	chr6:122208219	chr6:122436789~122439223:-
LUAD	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-5.93	5.64e-09	2.27e-06	-0.37	-0.26	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
LUAD	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	5.93	5.65e-09	2.27e-06	0.3	0.26	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
LUAD	cis	rs1707322	0.682	rs3014241	ENSG00000234329.1	RP11-767N6.2	-5.93	5.65e-09	2.27e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45651039~45651826:-
LUAD	cis	rs293748	0.54	rs13163937	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.65e-09	2.27e-06	-0.33	-0.26	Obesity-related traits;	chr5:37253547	chr5:36666214~36725195:-
LUAD	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-5.93	5.66e-09	2.27e-06	-0.29	-0.26	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
LUAD	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	5.93	5.66e-09	2.28e-06	0.31	0.26	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
LUAD	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-5.93	5.67e-09	2.28e-06	-0.3	-0.26	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
LUAD	cis	rs7044106	0.762	rs966396	ENSG00000238181.2	AHCYP2	-5.93	5.67e-09	2.28e-06	-0.34	-0.26	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120720673~120721972:+
LUAD	cis	rs11089937	0.568	rs5756988	ENSG00000211638.2	IGLV8-61	5.93	5.67e-09	2.28e-06	0.3	0.26	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22098700~22099212:+
LUAD	cis	rs6504622	0.967	rs11869840	ENSG00000262879.4	RP11-156P1.3	-5.93	5.67e-09	2.28e-06	-0.3	-0.26	Orofacial clefts;	chr17:46918734	chr17:46984045~47100323:-
LUAD	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	5.93	5.68e-09	2.28e-06	0.32	0.26	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000230295.1	RP11-458F8.2	-5.93	5.69e-09	2.29e-06	-0.33	-0.26	Gout;	chr7:66732812	chr7:66880708~66882981:+
LUAD	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-5.93	5.69e-09	2.29e-06	-0.3	-0.26	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
LUAD	cis	rs9326248	0.539	rs7120565	ENSG00000280143.1	AP000892.6	5.93	5.69e-09	2.29e-06	0.3	0.26	Blood protein levels;	chr11:117172233	chr11:117204967~117210292:+
LUAD	cis	rs2404602	0.583	rs12907668	ENSG00000259422.1	RP11-593F23.1	5.93	5.7e-09	2.29e-06	0.29	0.26	Blood metabolite levels;	chr15:76297426	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.632	rs1404414	ENSG00000279048.1	RP11-511H23.2	5.93	5.7e-09	2.29e-06	0.21	0.26	Fibrinogen levels;	chr7:17826764	chr7:17940503~17942922:+
LUAD	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-5.93	5.72e-09	2.3e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-5.93	5.72e-09	2.3e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
LUAD	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	5.93	5.72e-09	2.3e-06	0.37	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
LUAD	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-5.93	5.72e-09	2.3e-06	-0.4	-0.26	Pain;	chr19:21513185	chr19:21554640~21569237:-
LUAD	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-5.93	5.73e-09	2.3e-06	-0.32	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
LUAD	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-5.93	5.73e-09	2.3e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
LUAD	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-5.93	5.73e-09	2.3e-06	-0.25	-0.26	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
LUAD	cis	rs1499614	0.522	rs13247442	ENSG00000273142.1	RP11-458F8.4	-5.93	5.73e-09	2.3e-06	-0.32	-0.26	Gout;	chr7:66723871	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.517	rs9357065	ENSG00000204709.4	LINC01556	5.93	5.74e-09	2.3e-06	0.37	0.26	Depression;	chr6:28161802	chr6:28943877~28944537:+
LUAD	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-5.93	5.74e-09	2.3e-06	-0.3	-0.26	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
LUAD	cis	rs7911264	0.967	rs2497318	ENSG00000236493.2	EIF2S2P3	-5.93	5.74e-09	2.3e-06	-0.3	-0.26	Inflammatory bowel disease;	chr10:92672243	chr10:92668745~92669743:-
LUAD	cis	rs12699921	0.632	rs2691609	ENSG00000279048.1	RP11-511H23.2	-5.93	5.74e-09	2.31e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17841539	chr7:17940503~17942922:+
LUAD	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	5.93	5.74e-09	2.31e-06	0.3	0.26	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	5.93	5.74e-09	2.31e-06	0.3	0.26	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	5.93	5.74e-09	2.31e-06	0.3	0.26	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
LUAD	cis	rs2303759	0.83	rs7257053	ENSG00000268686.1	AC010524.2	-5.93	5.75e-09	2.31e-06	-0.37	-0.26	Multiple sclerosis;	chr19:49391199	chr19:49368705~49388081:-
LUAD	cis	rs75422866	0.51	rs75424057	ENSG00000274902.1	RP1-197B17.4	5.93	5.75e-09	2.31e-06	0.57	0.26	Pneumonia;	chr12:47737294	chr12:47731908~47732351:+
LUAD	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	5.93	5.75e-09	2.31e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
LUAD	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	5.93	5.75e-09	2.31e-06	0.33	0.26	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
LUAD	cis	rs12699921	0.632	rs2691613	ENSG00000279048.1	RP11-511H23.2	-5.93	5.76e-09	2.31e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17844358	chr7:17940503~17942922:+
LUAD	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	5.93	5.76e-09	2.31e-06	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	5.93	5.76e-09	2.31e-06	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
LUAD	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	5.93	5.76e-09	2.31e-06	0.28	0.26	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	5.93	5.76e-09	2.31e-06	0.28	0.26	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	5.93	5.76e-09	2.31e-06	0.28	0.26	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	5.93	5.76e-09	2.31e-06	0.28	0.26	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
LUAD	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-5.93	5.76e-09	2.31e-06	-0.28	-0.26	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
LUAD	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	5.93	5.77e-09	2.31e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
LUAD	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	5.93	5.77e-09	2.32e-06	0.29	0.26	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
LUAD	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	5.93	5.77e-09	2.32e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	5.93	5.77e-09	2.32e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	5.93	5.77e-09	2.32e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
LUAD	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-5.93	5.78e-09	2.32e-06	-0.32	-0.26	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
LUAD	cis	rs2243480	1	rs316329	ENSG00000232546.1	RP11-458F8.1	-5.93	5.78e-09	2.32e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66143429	chr7:66848496~66858136:+
LUAD	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
LUAD	cis	rs9494145	0.68	rs9389269	ENSG00000232876.1	CTA-212D2.2	-5.93	5.79e-09	2.32e-06	-0.36	-0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106021	chr6:135055033~135060550:+
LUAD	cis	rs293748	0.771	rs292181	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.8e-09	2.33e-06	-0.37	-0.26	Obesity-related traits;	chr5:36952474	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs292186	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.8e-09	2.33e-06	-0.37	-0.26	Obesity-related traits;	chr5:36967320	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs294695	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.8e-09	2.33e-06	-0.37	-0.26	Obesity-related traits;	chr5:36986586	chr5:36666214~36725195:-
LUAD	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-5.93	5.8e-09	2.33e-06	-0.45	-0.26	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
LUAD	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-5.93	5.8e-09	2.33e-06	-0.33	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
LUAD	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	5.93	5.8e-09	2.33e-06	0.29	0.26	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
LUAD	cis	rs2276314	0.512	rs7234973	ENSG00000278986.1	RP11-723J4.3	-5.93	5.81e-09	2.33e-06	-0.28	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35870373	chr18:35972151~35973916:+
LUAD	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	5.93	5.81e-09	2.33e-06	0.32	0.26	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
LUAD	cis	rs9494145	0.68	rs9402686	ENSG00000232876.1	CTA-212D2.2	-5.93	5.81e-09	2.33e-06	-0.36	-0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106679	chr6:135055033~135060550:+
LUAD	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	5.93	5.82e-09	2.33e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
LUAD	cis	rs3738443	0.817	rs6698690	ENSG00000259865.1	RP11-488L18.10	5.93	5.83e-09	2.34e-06	0.27	0.26	Alcohol dependence;	chr1:247199176	chr1:247187281~247188526:-
LUAD	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	5.93	5.83e-09	2.34e-06	0.29	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
LUAD	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	5.93	5.83e-09	2.34e-06	0.29	0.26	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
LUAD	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	5.93	5.83e-09	2.34e-06	0.27	0.26	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
LUAD	cis	rs9450351	0.744	rs9353348	ENSG00000203875.9	SNHG5	-5.93	5.84e-09	2.34e-06	-0.53	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85981635	chr6:85660950~85678736:-
LUAD	cis	rs7618501	0.635	rs7635002	ENSG00000234667.1	ACTBP13	-5.93	5.84e-09	2.34e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49951722	chr3:49873347~49877980:-
LUAD	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	5.93	5.85e-09	2.34e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	5.93	5.85e-09	2.34e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	5.93	5.85e-09	2.34e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
LUAD	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-5.93	5.85e-09	2.34e-06	-0.32	-0.26	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
LUAD	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	5.93	5.85e-09	2.35e-06	0.3	0.26	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
LUAD	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	5.93	5.85e-09	2.35e-06	0.32	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
LUAD	cis	rs783540	0.681	rs1259178	ENSG00000278603.1	RP13-608F4.5	-5.93	5.86e-09	2.35e-06	-0.32	-0.26	Schizophrenia;	chr15:82603127	chr15:82472203~82472426:+
LUAD	cis	rs853679	0.517	rs4713152	ENSG00000204709.4	LINC01556	5.93	5.86e-09	2.35e-06	0.37	0.26	Depression;	chr6:28169676	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.583	rs12898415	ENSG00000259422.1	RP11-593F23.1	5.93	5.86e-09	2.35e-06	0.29	0.26	Blood metabolite levels;	chr15:76281891	chr15:76174891~76181486:-
LUAD	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-5.93	5.86e-09	2.35e-06	-0.28	-0.26	Height;	chr11:118791319	chr11:118791254~118793137:+
LUAD	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
LUAD	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	5.93	5.87e-09	2.35e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
LUAD	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-5.93	5.87e-09	2.35e-06	-0.28	-0.26	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
LUAD	cis	rs2734839	0.964	rs7131440	ENSG00000270179.1	RP11-159N11.4	5.93	5.87e-09	2.35e-06	0.27	0.26	Information processing speed;	chr11:113429188	chr11:113368478~113369117:+
LUAD	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-5.93	5.88e-09	2.35e-06	-0.3	-0.26	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
LUAD	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	5.93	5.89e-09	2.36e-06	0.35	0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
LUAD	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-5.93	5.89e-09	2.36e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
LUAD	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-5.93	5.89e-09	2.36e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
LUAD	cis	rs17684571	0.751	rs13195601	ENSG00000231441.1	RP11-472M19.2	5.93	5.89e-09	2.36e-06	0.4	0.26	Schizophrenia;	chr6:56836186	chr6:56844002~56864078:+
LUAD	cis	rs4713118	0.869	rs9295743	ENSG00000219392.1	RP1-265C24.5	-5.93	5.89e-09	2.36e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747323	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-5.93	5.9e-09	2.36e-06	-0.29	-0.26	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
LUAD	cis	rs7618501	0.633	rs6446189	ENSG00000234667.1	ACTBP13	-5.93	5.9e-09	2.36e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49971133	chr3:49873347~49877980:-
LUAD	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	5.93	5.9e-09	2.36e-06	0.38	0.26	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
LUAD	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-5.93	5.9e-09	2.36e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
LUAD	cis	rs10129255	1	rs10129319	ENSG00000211972.2	IGHV3-66	5.93	5.91e-09	2.37e-06	0.22	0.26	Kawasaki disease;	chr14:106767996	chr14:106675017~106675544:-
LUAD	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
LUAD	cis	rs55823223	0.702	rs3785437	ENSG00000267801.1	RP11-552F3.9	5.93	5.92e-09	2.37e-06	0.4	0.26	Psoriasis;	chr17:75910141	chr17:75876372~75879546:+
LUAD	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-5.93	5.92e-09	2.37e-06	-0.29	-0.26	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-5.93	5.92e-09	2.37e-06	-0.29	-0.26	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-5.93	5.92e-09	2.37e-06	-0.29	-0.26	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
LUAD	cis	rs3738443	0.817	rs61839996	ENSG00000259865.1	RP11-488L18.10	5.93	5.92e-09	2.37e-06	0.27	0.26	Alcohol dependence;	chr1:247197571	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.83	rs58405512	ENSG00000259865.1	RP11-488L18.10	5.93	5.92e-09	2.37e-06	0.27	0.26	Alcohol dependence;	chr1:247198454	chr1:247187281~247188526:-
LUAD	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	5.93	5.92e-09	2.37e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	5.93	5.92e-09	2.37e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
LUAD	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	5.93	5.92e-09	2.37e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
LUAD	cis	rs293748	0.771	rs16903490	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.93e-09	2.37e-06	-0.37	-0.26	Obesity-related traits;	chr5:37067944	chr5:36666214~36725195:-
LUAD	cis	rs2288884	1	rs72483951	ENSG00000275055.1	CTC-471J1.11	-5.93	5.93e-09	2.37e-06	-0.41	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52070429	chr19:52049007~52049754:+
LUAD	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	5.93	5.94e-09	2.38e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
LUAD	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-5.93	5.94e-09	2.38e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
LUAD	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-5.93	5.94e-09	2.38e-06	-0.33	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
LUAD	cis	rs74233809	1	rs11191580	ENSG00000213277.3	MARCKSL1P1	-5.93	5.94e-09	2.38e-06	-0.44	-0.26	Birth weight;	chr10:103146454	chr10:103175554~103176094:+
LUAD	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-5.93	5.95e-09	2.38e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
LUAD	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-5.93	5.95e-09	2.38e-06	-0.35	-0.26	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	5.93	5.95e-09	2.38e-06	0.29	0.26	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs313832	ENSG00000232546.1	RP11-458F8.1	-5.93	5.95e-09	2.38e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66085904	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	5.93	5.95e-09	2.38e-06	0.28	0.26	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
LUAD	cis	rs293748	0.571	rs16903531	ENSG00000250155.1	CTD-2353F22.1	-5.92	5.96e-09	2.39e-06	-0.33	-0.26	Obesity-related traits;	chr5:37197058	chr5:36666214~36725195:-
LUAD	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	5.92	5.97e-09	2.39e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
LUAD	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	5.92	5.97e-09	2.39e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
LUAD	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-5.92	5.98e-09	2.39e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
LUAD	cis	rs9326248	0.52	rs6589602	ENSG00000280143.1	AP000892.6	5.92	5.98e-09	2.39e-06	0.3	0.26	Blood protein levels;	chr11:117166349	chr11:117204967~117210292:+
LUAD	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-5.92	5.99e-09	2.4e-06	-0.31	-0.26	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
LUAD	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-5.92	6e-09	2.4e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-5.92	6e-09	2.4e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-5.92	6e-09	2.4e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
LUAD	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-5.92	6e-09	2.4e-06	-0.3	-0.26	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
LUAD	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-5.92	6e-09	2.4e-06	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
LUAD	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-5.92	6e-09	2.4e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
LUAD	cis	rs453301	0.686	rs11787026	ENSG00000253981.4	ALG1L13P	5.92	6.01e-09	2.4e-06	0.3	0.26	Joint mobility (Beighton score);	chr8:9044861	chr8:8236003~8244667:-
LUAD	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-5.92	6.02e-09	2.41e-06	-0.31	-0.26	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-5.92	6.02e-09	2.41e-06	-0.31	-0.26	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-5.92	6.02e-09	2.41e-06	-0.31	-0.26	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs34262638	ENSG00000280083.1	RP11-317J9.1	-5.92	6.02e-09	2.41e-06	-0.31	-0.26	Obesity-related traits;	chr2:191279442	chr2:191154118~191156070:-
LUAD	cis	rs9543976	0.623	rs974373	ENSG00000261553.4	RP11-29G8.3	5.92	6.02e-09	2.41e-06	0.34	0.26	Diabetic retinopathy;	chr13:75589660	chr13:75549773~75807120:+
LUAD	cis	rs9595908	0.669	rs9285094	ENSG00000212293.1	SNORA16	5.92	6.02e-09	2.41e-06	0.28	0.26	Body mass index;	chr13:32761453	chr13:32420390~32420516:-
LUAD	cis	rs7246657	0.722	rs16958863	ENSG00000276846.1	CTD-3220F14.3	5.92	6.03e-09	2.41e-06	0.34	0.26	Coronary artery calcification;	chr19:37633334	chr19:37314868~37315620:-
LUAD	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-5.92	6.03e-09	2.41e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
LUAD	cis	rs17818399	0.962	rs2122715	ENSG00000279254.1	RP11-536C12.1	-5.92	6.04e-09	2.41e-06	-0.29	-0.26	Height;	chr2:46618710	chr2:46668870~46670778:+
LUAD	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	5.92	6.04e-09	2.42e-06	0.34	0.26	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	5.92	6.04e-09	2.42e-06	0.34	0.26	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
LUAD	cis	rs30380	0.688	rs27524	ENSG00000272109.1	CTD-2260A17.3	-5.92	6.05e-09	2.42e-06	-0.27	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96766240	chr5:96804353~96806105:+
LUAD	cis	rs9595908	0.568	rs61945198	ENSG00000212293.1	SNORA16	5.92	6.05e-09	2.42e-06	0.28	0.26	Body mass index;	chr13:32797780	chr13:32420390~32420516:-
LUAD	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-5.92	6.05e-09	2.42e-06	-0.29	-0.26	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
LUAD	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	5.92	6.06e-09	2.42e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
LUAD	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	5.92	6.06e-09	2.42e-06	0.37	0.26	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
LUAD	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	5.92	6.06e-09	2.42e-06	0.31	0.26	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
LUAD	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	5.92	6.06e-09	2.42e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
LUAD	cis	rs62445005	1	rs62445005	ENSG00000211698.2	TRGV4	5.92	6.07e-09	2.42e-06	0.31	0.26	Shingles;	chr7:38346957	chr7:38353715~38354517:-
LUAD	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-5.92	6.07e-09	2.43e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000230295.1	RP11-458F8.2	-5.92	6.07e-09	2.43e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66136229	chr7:66880708~66882981:+
LUAD	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	5.92	6.08e-09	2.43e-06	0.3	0.26	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
LUAD	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-5.92	6.08e-09	2.43e-06	-0.3	-0.26	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
LUAD	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-5.92	6.08e-09	2.43e-06	-0.41	-0.26	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
LUAD	cis	rs1707322	0.686	rs1250	ENSG00000234329.1	RP11-767N6.2	5.92	6.09e-09	2.43e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-5.92	6.1e-09	2.44e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-5.92	6.1e-09	2.44e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-5.92	6.1e-09	2.44e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
LUAD	cis	rs35934224	0.831	rs1044732	ENSG00000232926.1	AC000078.5	5.92	6.1e-09	2.44e-06	0.31	0.26	Glaucoma (primary open-angle);	chr22:19875619	chr22:19887289~19887970:+
LUAD	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	5.92	6.11e-09	2.44e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000232546.1	RP11-458F8.1	-5.92	6.11e-09	2.44e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66474549	chr7:66848496~66858136:+
LUAD	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-5.92	6.12e-09	2.44e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-5.92	6.12e-09	2.44e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
LUAD	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-5.92	6.12e-09	2.44e-06	-0.32	-0.26	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
LUAD	cis	rs74233809	1	rs79082900	ENSG00000213277.3	MARCKSL1P1	5.92	6.12e-09	2.44e-06	0.44	0.26	Birth weight;	chr10:103117545	chr10:103175554~103176094:+
LUAD	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-5.92	6.13e-09	2.45e-06	-0.32	-0.26	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
LUAD	cis	rs17684571	1	rs16888128	ENSG00000231441.1	RP11-472M19.2	5.92	6.13e-09	2.45e-06	0.35	0.26	Schizophrenia;	chr6:56704306	chr6:56844002~56864078:+
LUAD	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-5.92	6.13e-09	2.45e-06	-0.35	-0.26	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-5.92	6.13e-09	2.45e-06	-0.35	-0.26	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
LUAD	cis	rs10214930	0.624	rs4719902	ENSG00000235574.1	AC073150.6	-5.92	6.13e-09	2.45e-06	-0.33	-0.26	Hypospadias;	chr7:27548723	chr7:27491682~27492765:-
LUAD	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	5.92	6.14e-09	2.45e-06	0.3	0.26	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
LUAD	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-5.92	6.15e-09	2.45e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
LUAD	cis	rs17301013	0.507	rs10798324	ENSG00000227373.4	RP11-160H22.5	-5.92	6.16e-09	2.46e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174787485	chr1:174115300~174160004:-
LUAD	cis	rs12935418	1	rs62054589	ENSG00000261838.4	RP11-303E16.6	5.92	6.16e-09	2.46e-06	0.47	0.26	Mean corpuscular volume;	chr16:81035143	chr16:81069854~81076598:+
LUAD	cis	rs2404602	0.716	rs12917430	ENSG00000259422.1	RP11-593F23.1	5.92	6.16e-09	2.46e-06	0.3	0.26	Blood metabolite levels;	chr15:76382019	chr15:76174891~76181486:-
LUAD	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	5.92	6.17e-09	2.46e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	5.92	6.17e-09	2.46e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
LUAD	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-5.92	6.18e-09	2.47e-06	-0.38	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
LUAD	cis	rs1874124	0.577	rs2807853	ENSG00000272823.1	RP11-295M18.6	5.92	6.18e-09	2.47e-06	0.38	0.26	Cholesterol, total;	chr1:220851011	chr1:220828676~220829211:-
LUAD	cis	rs1874124	0.504	rs2491257	ENSG00000272823.1	RP11-295M18.6	5.92	6.18e-09	2.47e-06	0.38	0.26	Cholesterol, total;	chr1:220855900	chr1:220828676~220829211:-
LUAD	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-5.92	6.19e-09	2.47e-06	-0.32	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
LUAD	cis	rs6687821	0.515	rs496675	ENSG00000267734.1	RP4-604K5.3	5.92	6.19e-09	2.47e-06	0.32	0.26	Yeast infection;	chr1:86858756	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs552483	ENSG00000267734.1	RP4-604K5.3	5.92	6.19e-09	2.47e-06	0.32	0.26	Yeast infection;	chr1:86860335	chr1:86932199~86934891:-
LUAD	cis	rs9652601	0.691	rs12924985	ENSG00000274038.1	RP11-66H6.4	-5.92	6.19e-09	2.47e-06	-0.32	-0.26	Systemic lupus erythematosus;	chr16:11114465	chr16:11056556~11057034:+
LUAD	cis	rs7618501	0.633	rs12485600	ENSG00000234667.1	ACTBP13	-5.92	6.2e-09	2.47e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49988097	chr3:49873347~49877980:-
LUAD	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-5.92	6.2e-09	2.47e-06	-0.37	-0.26	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
LUAD	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
LUAD	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	5.92	6.2e-09	2.47e-06	0.32	0.26	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
LUAD	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-5.92	6.2e-09	2.47e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	5.92	6.22e-09	2.48e-06	0.28	0.26	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-5.92	6.22e-09	2.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
LUAD	cis	rs2243480	1	rs316332	ENSG00000230295.1	RP11-458F8.2	-5.92	6.23e-09	2.48e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66139312	chr7:66880708~66882981:+
LUAD	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	5.92	6.24e-09	2.49e-06	0.29	0.26	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
LUAD	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-5.92	6.25e-09	2.49e-06	-0.28	-0.26	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-5.92	6.25e-09	2.49e-06	-0.28	-0.26	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-5.92	6.25e-09	2.49e-06	-0.28	-0.26	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-5.92	6.25e-09	2.49e-06	-0.28	-0.26	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
LUAD	cis	rs9450351	0.744	rs9450313	ENSG00000203875.9	SNHG5	-5.92	6.25e-09	2.49e-06	-0.56	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85684419	chr6:85660950~85678736:-
LUAD	cis	rs7618501	0.633	rs9853222	ENSG00000234667.1	ACTBP13	-5.92	6.25e-09	2.49e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49985493	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.635	rs34080578	ENSG00000234667.1	ACTBP13	-5.92	6.25e-09	2.49e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49988596	chr3:49873347~49877980:-
LUAD	cis	rs9928842	0.823	rs11149811	ENSG00000280152.1	RP11-331F4.5	5.92	6.25e-09	2.49e-06	0.3	0.26	Alcoholic chronic pancreatitis;	chr16:75266810	chr16:75245994~75250077:-
LUAD	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	5.92	6.25e-09	2.49e-06	0.41	0.26	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
LUAD	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-5.92	6.25e-09	2.49e-06	-0.39	-0.26	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-5.92	6.25e-09	2.49e-06	-0.39	-0.26	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
LUAD	cis	rs9928842	0.882	rs11641896	ENSG00000280152.1	RP11-331F4.5	5.92	6.26e-09	2.5e-06	0.3	0.26	Alcoholic chronic pancreatitis;	chr16:75266281	chr16:75245994~75250077:-
LUAD	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	5.92	6.27e-09	2.5e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
LUAD	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-5.92	6.27e-09	2.5e-06	-0.57	-0.26	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
LUAD	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	5.92	6.27e-09	2.5e-06	0.3	0.26	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
LUAD	cis	rs5753618	0.583	rs5753628	ENSG00000236132.1	CTA-440B3.1	-5.92	6.27e-09	2.5e-06	-0.32	-0.26	Colorectal cancer;	chr22:31464336	chr22:31816379~31817491:-
LUAD	cis	rs7246657	0.722	rs3101746	ENSG00000276846.1	CTD-3220F14.3	-5.92	6.28e-09	2.5e-06	-0.36	-0.26	Coronary artery calcification;	chr19:37655499	chr19:37314868~37315620:-
LUAD	cis	rs7044106	0.762	rs10984972	ENSG00000238181.2	AHCYP2	-5.92	6.28e-09	2.5e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120720673~120721972:+
LUAD	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-5.92	6.28e-09	2.5e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000211974.3	IGHV2-70	5.92	6.28e-09	2.5e-06	0.27	0.26	Kawasaki disease;	chr14:106787239	chr14:106723574~106724093:-
LUAD	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-5.92	6.28e-09	2.5e-06	-0.31	-0.26	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
LUAD	cis	rs4908760	0.965	rs10864354	ENSG00000232912.4	RP5-1115A15.1	5.92	6.29e-09	2.5e-06	0.25	0.26	Vitiligo;	chr1:8489681	chr1:8424645~8434838:+
LUAD	cis	rs7618501	0.633	rs4688755	ENSG00000234667.1	ACTBP13	5.92	6.29e-09	2.51e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50026991	chr3:49873347~49877980:-
LUAD	cis	rs1501911	0.509	rs34487	ENSG00000248489.1	CTD-2007H13.3	5.91	6.31e-09	2.51e-06	0.28	0.26	Lung function (FEV1/FVC);	chr5:98872725	chr5:98929171~98995013:+
LUAD	cis	rs1501911	0.509	rs327786	ENSG00000248489.1	CTD-2007H13.3	5.91	6.31e-09	2.51e-06	0.28	0.26	Lung function (FEV1/FVC);	chr5:98878301	chr5:98929171~98995013:+
LUAD	cis	rs2034650	0.563	rs11070270	ENSG00000223313.1	RNU6-516P	-5.91	6.31e-09	2.51e-06	-0.33	-0.26	Interstitial lung disease;	chr15:40416223	chr15:40529570~40529673:+
LUAD	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	5.91	6.31e-09	2.51e-06	0.3	0.26	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
LUAD	cis	rs1426063	0.748	rs10005117	ENSG00000249717.1	RP11-44F21.3	5.91	6.31e-09	2.51e-06	0.35	0.26	QT interval;	chr4:75108281	chr4:74955974~74970362:-
LUAD	cis	rs2115536	0.73	rs12898642	ENSG00000278600.1	RP11-81A1.6	-5.91	6.31e-09	2.52e-06	-0.21	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79889708	chr15:79920195~79922455:-
LUAD	cis	rs7618501	0.633	rs6771546	ENSG00000234667.1	ACTBP13	-5.91	6.32e-09	2.52e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49931139	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs55751738	ENSG00000234667.1	ACTBP13	-5.91	6.32e-09	2.52e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49934668	chr3:49873347~49877980:-
LUAD	cis	rs1823913	0.637	rs4853583	ENSG00000280083.1	RP11-317J9.1	5.91	6.32e-09	2.52e-06	0.31	0.26	Obesity-related traits;	chr2:191304648	chr2:191154118~191156070:-
LUAD	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-5.91	6.33e-09	2.52e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
LUAD	cis	rs9879311	0.966	rs4684684	ENSG00000240288.6	GHRLOS	5.91	6.34e-09	2.52e-06	0.24	0.26	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369660	chr3:10285754~10293449:+
LUAD	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-5.91	6.35e-09	2.53e-06	-0.35	-0.26	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
LUAD	cis	rs853679	0.546	rs34546986	ENSG00000204709.4	LINC01556	5.91	6.35e-09	2.53e-06	0.59	0.26	Depression;	chr6:28394532	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs34871267	ENSG00000204709.4	LINC01556	5.91	6.35e-09	2.53e-06	0.59	0.26	Depression;	chr6:28396455	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs35883476	ENSG00000204709.4	LINC01556	5.91	6.35e-09	2.53e-06	0.59	0.26	Depression;	chr6:28400731	chr6:28943877~28944537:+
LUAD	cis	rs948562	0.793	rs11229552	ENSG00000280010.1	AP001350.4	5.91	6.35e-09	2.53e-06	0.43	0.26	Lymphoma;	chr11:58633441	chr11:58627435~58628528:+
LUAD	cis	rs7044106	0.762	rs1158554	ENSG00000238181.2	AHCYP2	-5.91	6.35e-09	2.53e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120720673~120721972:+
LUAD	cis	rs8177376	0.727	rs658614	ENSG00000254905.1	RP11-712L6.7	5.91	6.36e-09	2.53e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328096	chr11:126292922~126294254:-
LUAD	cis	rs293748	0.571	rs13169211	ENSG00000250155.1	CTD-2353F22.1	-5.91	6.37e-09	2.53e-06	-0.33	-0.26	Obesity-related traits;	chr5:37131567	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.571	rs9632396	ENSG00000250155.1	CTD-2353F22.1	-5.91	6.37e-09	2.53e-06	-0.33	-0.26	Obesity-related traits;	chr5:37140229	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.571	rs10512664	ENSG00000250155.1	CTD-2353F22.1	-5.91	6.37e-09	2.53e-06	-0.33	-0.26	Obesity-related traits;	chr5:37158021	chr5:36666214~36725195:-
LUAD	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	5.91	6.37e-09	2.54e-06	0.36	0.26	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-5.91	6.38e-09	2.54e-06	-0.29	-0.26	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
LUAD	cis	rs17138358	0.515	rs1357796	ENSG00000279048.1	RP11-511H23.2	-5.91	6.38e-09	2.54e-06	-0.21	-0.26	HDL cholesterol levels;	chr7:17833852	chr7:17940503~17942922:+
LUAD	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	5.91	6.4e-09	2.55e-06	0.34	0.26	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
LUAD	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	5.91	6.4e-09	2.55e-06	0.29	0.26	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
LUAD	cis	rs12699921	0.632	rs4543433	ENSG00000279048.1	RP11-511H23.2	-5.91	6.41e-09	2.55e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17926529	chr7:17940503~17942922:+
LUAD	cis	rs853679	0.546	rs2232426	ENSG00000204709.4	LINC01556	5.91	6.41e-09	2.55e-06	0.58	0.26	Depression;	chr6:28392882	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs2232423	ENSG00000204709.4	LINC01556	5.91	6.41e-09	2.55e-06	0.58	0.26	Depression;	chr6:28398374	chr6:28943877~28944537:+
LUAD	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-5.91	6.41e-09	2.55e-06	-0.35	-0.26	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
LUAD	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-5.91	6.42e-09	2.55e-06	-0.28	-0.26	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
LUAD	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.606	rs4942925	ENSG00000212293.1	SNORA16	5.91	6.43e-09	2.56e-06	0.28	0.26	Body mass index;	chr13:32807106	chr13:32420390~32420516:-
LUAD	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	5.91	6.43e-09	2.56e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
LUAD	cis	rs11122895	0.61	rs13397902	ENSG00000236307.2	EEF1E1P1	5.91	6.43e-09	2.56e-06	0.28	0.26	Allergic sensitization;	chr2:111849928	chr2:111887914~111888741:+
LUAD	cis	rs293748	0.771	rs159140	ENSG00000250155.1	CTD-2353F22.1	-5.91	6.44e-09	2.56e-06	-0.37	-0.26	Obesity-related traits;	chr5:36925903	chr5:36666214~36725195:-
LUAD	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-5.91	6.44e-09	2.56e-06	-0.32	-0.26	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
LUAD	cis	rs7246657	0.722	rs2927742	ENSG00000276846.1	CTD-3220F14.3	-5.91	6.45e-09	2.56e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37642717	chr19:37314868~37315620:-
LUAD	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	5.91	6.45e-09	2.56e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	5.91	6.45e-09	2.56e-06	0.3	0.26	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-5.91	6.45e-09	2.56e-06	-0.29	-0.26	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-5.91	6.45e-09	2.56e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
LUAD	cis	rs10214930	0.697	rs12155430	ENSG00000235574.1	AC073150.6	-5.91	6.47e-09	2.57e-06	-0.32	-0.26	Hypospadias;	chr7:27631677	chr7:27491682~27492765:-
LUAD	cis	rs2562456	0.874	rs9304986	ENSG00000268081.1	RP11-678G14.2	-5.91	6.48e-09	2.57e-06	-0.4	-0.26	Pain;	chr19:21499260	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs2650805	ENSG00000268081.1	RP11-678G14.2	-5.91	6.48e-09	2.57e-06	-0.4	-0.26	Pain;	chr19:21505137	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-5.91	6.48e-09	2.57e-06	-0.4	-0.26	Pain;	chr19:21510513	chr19:21554640~21569237:-
LUAD	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-5.91	6.48e-09	2.57e-06	-0.33	-0.26	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
LUAD	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-5.91	6.48e-09	2.58e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
LUAD	cis	rs755249	0.53	rs1472662	ENSG00000228060.1	RP11-69E11.8	-5.91	6.49e-09	2.58e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39124737	chr1:39565160~39573203:+
LUAD	cis	rs11051970	0.527	rs7309590	ENSG00000274964.1	RP11-817I4.1	-5.91	6.5e-09	2.58e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337915	chr12:32339368~32340724:+
LUAD	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-5.91	6.5e-09	2.58e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
LUAD	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-5.91	6.5e-09	2.58e-06	-0.43	-0.26	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
LUAD	cis	rs12699921	0.632	rs2723502	ENSG00000279048.1	RP11-511H23.2	-5.91	6.51e-09	2.59e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17814993	chr7:17940503~17942922:+
LUAD	cis	rs948562	0.947	rs11541682	ENSG00000280010.1	AP001350.4	5.91	6.53e-09	2.59e-06	0.42	0.26	Lymphoma;	chr11:58618279	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.947	rs17489568	ENSG00000280010.1	AP001350.4	5.91	6.53e-09	2.59e-06	0.42	0.26	Lymphoma;	chr11:58622534	chr11:58627435~58628528:+
LUAD	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	5.91	6.53e-09	2.59e-06	0.34	0.26	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
LUAD	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	5.91	6.54e-09	2.6e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
LUAD	cis	rs9595908	0.709	rs7322668	ENSG00000212293.1	SNORA16	5.91	6.55e-09	2.6e-06	0.28	0.26	Body mass index;	chr13:32780298	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7318610	ENSG00000212293.1	SNORA16	5.91	6.55e-09	2.6e-06	0.28	0.26	Body mass index;	chr13:32781912	chr13:32420390~32420516:-
LUAD	cis	rs853679	0.517	rs9393896	ENSG00000204709.4	LINC01556	5.91	6.55e-09	2.6e-06	0.37	0.26	Depression;	chr6:28159925	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393897	ENSG00000204709.4	LINC01556	5.91	6.55e-09	2.6e-06	0.37	0.26	Depression;	chr6:28159932	chr6:28943877~28944537:+
LUAD	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	5.91	6.55e-09	2.6e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
LUAD	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	5.91	6.56e-09	2.61e-06	0.31	0.26	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	5.91	6.57e-09	2.61e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
LUAD	cis	rs12699921	0.598	rs1524774	ENSG00000279048.1	RP11-511H23.2	-5.91	6.58e-09	2.61e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17827352	chr7:17940503~17942922:+
LUAD	cis	rs7804306	0.826	rs55832940	ENSG00000233264.2	AC006042.8	5.91	6.58e-09	2.61e-06	0.53	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8054449	chr7:7980312~7982228:+
LUAD	cis	rs2115630	0.691	rs8040066	ENSG00000229212.6	RP11-561C5.4	5.91	6.59e-09	2.62e-06	0.31	0.26	P wave terminal force;	chr15:84633234	chr15:85205440~85234795:-
LUAD	cis	rs12699921	0.598	rs2691607	ENSG00000279048.1	RP11-511H23.2	-5.91	6.59e-09	2.62e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17839480	chr7:17940503~17942922:+
LUAD	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-5.91	6.59e-09	2.62e-06	-0.32	-0.26	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
LUAD	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	5.91	6.59e-09	2.62e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
LUAD	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	5.91	6.6e-09	2.62e-06	0.29	0.26	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
LUAD	cis	rs11096990	0.819	rs2711992	ENSG00000249207.1	RP11-360F5.1	5.91	6.6e-09	2.62e-06	0.3	0.26	Cognitive function;	chr4:39148651	chr4:39112677~39126818:-
LUAD	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-5.91	6.61e-09	2.62e-06	-0.28	-0.26	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
LUAD	cis	rs9910055	0.762	rs6503489	ENSG00000267080.4	ASB16-AS1	-5.91	6.61e-09	2.62e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44168921	chr17:44175973~44186717:-
LUAD	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-5.91	6.62e-09	2.63e-06	-0.28	-0.26	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
LUAD	cis	rs74233809	1	rs12219901	ENSG00000213277.3	MARCKSL1P1	5.91	6.62e-09	2.63e-06	0.45	0.26	Birth weight;	chr10:103081210	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs10458729	ENSG00000213277.3	MARCKSL1P1	5.91	6.62e-09	2.63e-06	0.45	0.26	Birth weight;	chr10:103081722	chr10:103175554~103176094:+
LUAD	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	5.91	6.63e-09	2.63e-06	0.32	0.26	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	5.91	6.63e-09	2.63e-06	0.32	0.26	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	5.91	6.63e-09	2.63e-06	0.32	0.26	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
LUAD	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	5.91	6.63e-09	2.63e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
LUAD	cis	rs9353324	1	rs9353324	ENSG00000203875.9	SNHG5	-5.91	6.64e-09	2.63e-06	-0.56	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85653156	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-5.91	6.64e-09	2.63e-06	-0.33	-0.26	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-5.91	6.64e-09	2.63e-06	-0.38	-0.26	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
LUAD	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-5.91	6.64e-09	2.64e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-5.91	6.64e-09	2.64e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
LUAD	cis	rs4713118	0.513	rs149942	ENSG00000204709.4	LINC01556	5.91	6.65e-09	2.64e-06	0.33	0.26	Parkinson's disease;	chr6:28033832	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs149944	ENSG00000204709.4	LINC01556	5.91	6.65e-09	2.64e-06	0.33	0.26	Parkinson's disease;	chr6:28035040	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs149945	ENSG00000204709.4	LINC01556	5.91	6.65e-09	2.64e-06	0.33	0.26	Parkinson's disease;	chr6:28035075	chr6:28943877~28944537:+
LUAD	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	5.91	6.65e-09	2.64e-06	0.38	0.26	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
LUAD	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	5.91	6.66e-09	2.64e-06	0.29	0.26	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
LUAD	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-5.91	6.67e-09	2.64e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
LUAD	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-5.9	6.67e-09	2.65e-06	-0.35	-0.26	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
LUAD	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-5.9	6.67e-09	2.65e-06	-0.35	-0.26	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
LUAD	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	5.9	6.67e-09	2.65e-06	0.32	0.26	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	5.9	6.68e-09	2.65e-06	0.33	0.26	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
LUAD	cis	rs74233809	1	rs11191555	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103097766	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs11191557	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103104857	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs11191558	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103104921	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs12413046	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103111447	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs10883832	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103111522	chr10:103175554~103176094:+
LUAD	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	5.9	6.69e-09	2.65e-06	0.37	0.26	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
LUAD	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	5.9	6.69e-09	2.65e-06	0.27	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
LUAD	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	5.9	6.7e-09	2.66e-06	0.38	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
LUAD	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-5.9	6.7e-09	2.66e-06	-0.28	-0.26	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
LUAD	cis	rs853679	0.517	rs868987	ENSG00000204709.4	LINC01556	-5.9	6.7e-09	2.66e-06	-0.37	-0.26	Depression;	chr6:28142370	chr6:28943877~28944537:+
LUAD	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	5.9	6.71e-09	2.66e-06	0.3	0.26	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	5.9	6.71e-09	2.66e-06	0.3	0.26	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
LUAD	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-5.9	6.71e-09	2.66e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	5.9	6.71e-09	2.66e-06	0.28	0.26	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	5.9	6.71e-09	2.66e-06	0.28	0.26	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
LUAD	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-5.9	6.72e-09	2.66e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
LUAD	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	5.9	6.72e-09	2.66e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
LUAD	cis	rs12468226	0.873	rs59293950	ENSG00000226261.1	AC064836.3	5.9	6.72e-09	2.66e-06	0.44	0.26	Urate levels;	chr2:202214069	chr2:202336024~202336727:-
LUAD	cis	rs17301013	0.507	rs332767	ENSG00000227373.4	RP11-160H22.5	5.9	6.73e-09	2.67e-06	0.37	0.26	Systemic lupus erythematosus;	chr1:174686386	chr1:174115300~174160004:-
LUAD	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-5.9	6.74e-09	2.67e-06	-0.38	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
LUAD	cis	rs2115630	0.653	rs61394864	ENSG00000229212.6	RP11-561C5.4	5.9	6.74e-09	2.67e-06	0.31	0.26	P wave terminal force;	chr15:84626943	chr15:85205440~85234795:-
LUAD	cis	rs293748	0.571	rs13177573	ENSG00000250155.1	CTD-2353F22.1	5.9	6.74e-09	2.67e-06	0.32	0.26	Obesity-related traits;	chr5:37233335	chr5:36666214~36725195:-
LUAD	cis	rs10214930	1	rs6970578	ENSG00000235574.1	AC073150.6	5.9	6.74e-09	2.67e-06	0.35	0.26	Hypospadias;	chr7:27804419	chr7:27491682~27492765:-
LUAD	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	5.9	6.74e-09	2.67e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
LUAD	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	5.9	6.75e-09	2.67e-06	0.27	0.26	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
LUAD	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-5.9	6.75e-09	2.67e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
LUAD	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	5.9	6.75e-09	2.68e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
LUAD	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	5.9	6.76e-09	2.68e-06	0.22	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
LUAD	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-5.9	6.77e-09	2.68e-06	-0.37	-0.26	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
LUAD	cis	rs8177876	0.822	rs56166222	ENSG00000261061.1	RP11-303E16.2	-5.9	6.78e-09	2.68e-06	-0.45	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81030770~81031485:+
LUAD	cis	rs1387259	0.839	rs7486941	ENSG00000240399.1	RP1-228P16.1	-5.9	6.78e-09	2.68e-06	-0.24	-0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48054813~48055591:-
LUAD	cis	rs72634501	0.531	rs67758468	ENSG00000228060.1	RP11-69E11.8	-5.9	6.78e-09	2.68e-06	-0.25	-0.26	HDL cholesterol;	chr1:39156916	chr1:39565160~39573203:+
LUAD	cis	rs10214930	0.671	rs1005128	ENSG00000235574.1	AC073150.6	-5.9	6.79e-09	2.69e-06	-0.33	-0.26	Hypospadias;	chr7:27569057	chr7:27491682~27492765:-
LUAD	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	5.9	6.79e-09	2.69e-06	0.28	0.26	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
LUAD	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-5.9	6.8e-09	2.69e-06	-0.29	-0.26	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-5.9	6.8e-09	2.69e-06	-0.29	-0.26	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-5.9	6.8e-09	2.69e-06	-0.29	-0.26	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
LUAD	cis	rs4803480	0.935	rs758349	ENSG00000270164.1	LINC01480	-5.9	6.8e-09	2.69e-06	-0.26	-0.26	Schizophrenia;	chr19:41578753	chr19:41535183~41536904:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000230295.1	RP11-458F8.2	-5.9	6.81e-09	2.7e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66375924	chr7:66880708~66882981:+
LUAD	cis	rs7246657	0.722	rs1531549	ENSG00000276846.1	CTD-3220F14.3	5.9	6.83e-09	2.7e-06	0.34	0.26	Coronary artery calcification;	chr19:37597108	chr19:37314868~37315620:-
LUAD	cis	rs12699921	0.632	rs2723571	ENSG00000279048.1	RP11-511H23.2	-5.9	6.83e-09	2.7e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17851591	chr7:17940503~17942922:+
LUAD	cis	rs9595908	0.709	rs4942880	ENSG00000212293.1	SNORA16	5.9	6.83e-09	2.7e-06	0.28	0.26	Body mass index;	chr13:32751641	chr13:32420390~32420516:-
LUAD	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-5.9	6.84e-09	2.71e-06	-0.4	-0.26	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
LUAD	cis	rs11089937	0.616	rs4991798	ENSG00000211639.2	IGLV4-60	5.9	6.85e-09	2.71e-06	0.27	0.26	Periodontitis (PAL4Q3);	chr22:22178915	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs4991799	ENSG00000211639.2	IGLV4-60	5.9	6.85e-09	2.71e-06	0.27	0.26	Periodontitis (PAL4Q3);	chr22:22178938	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs4991800	ENSG00000211639.2	IGLV4-60	5.9	6.85e-09	2.71e-06	0.27	0.26	Periodontitis (PAL4Q3);	chr22:22178942	chr22:22162199~22162681:+
LUAD	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-5.9	6.85e-09	2.71e-06	-0.29	-0.26	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
LUAD	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	5.9	6.86e-09	2.71e-06	0.32	0.26	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
LUAD	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	5.9	6.86e-09	2.71e-06	0.28	0.26	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
LUAD	cis	rs2243480	1	rs56016656	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65918494	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65924813	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65925352	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65925571	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65928123	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65939105	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65940751	chr7:66880708~66882981:+
LUAD	cis	rs7618501	0.633	rs4688690	ENSG00000234667.1	ACTBP13	-5.9	6.87e-09	2.72e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49984859	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs11130234	ENSG00000234667.1	ACTBP13	-5.9	6.87e-09	2.72e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49987325	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs4688758	ENSG00000234667.1	ACTBP13	-5.9	6.87e-09	2.72e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49990952	chr3:49873347~49877980:-
LUAD	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	5.9	6.87e-09	2.72e-06	0.32	0.26	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
LUAD	cis	rs7246657	0.722	rs1975937	ENSG00000276846.1	CTD-3220F14.3	5.9	6.88e-09	2.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37601031	chr19:37314868~37315620:-
LUAD	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	5.9	6.88e-09	2.72e-06	0.29	0.26	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
LUAD	cis	rs8031584	1	rs35607976	ENSG00000260382.1	RP11-540B6.2	5.9	6.88e-09	2.72e-06	0.34	0.26	Huntington's disease progression;	chr15:30985585	chr15:30882267~30883231:-
LUAD	cis	rs755249	0.567	rs41270821	ENSG00000228060.1	RP11-69E11.8	-5.9	6.88e-09	2.72e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs2296175	ENSG00000228060.1	RP11-69E11.8	-5.9	6.88e-09	2.72e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39565160~39573203:+
LUAD	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-5.9	6.88e-09	2.72e-06	-0.27	-0.26	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
LUAD	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	5.9	6.89e-09	2.72e-06	0.33	0.26	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	5.9	6.89e-09	2.72e-06	0.33	0.26	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
LUAD	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	5.9	6.9e-09	2.73e-06	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
LUAD	cis	rs1823913	0.927	rs13013390	ENSG00000230611.1	HMGB1P27	-5.9	6.9e-09	2.73e-06	-0.3	-0.26	Obesity-related traits;	chr2:191262001	chr2:191174233~191174835:+
LUAD	cis	rs35955747	0.778	rs9609263	ENSG00000236132.1	CTA-440B3.1	5.9	6.91e-09	2.73e-06	0.29	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31349288	chr22:31816379~31817491:-
LUAD	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-5.9	6.91e-09	2.73e-06	-0.38	-0.26	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000211974.3	IGHV2-70	5.9	6.92e-09	2.73e-06	0.27	0.26	Kawasaki disease;	chr14:106783079	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000211974.3	IGHV2-70	5.9	6.92e-09	2.73e-06	0.27	0.26	Kawasaki disease;	chr14:106783685	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000211974.3	IGHV2-70	5.9	6.92e-09	2.73e-06	0.27	0.26	Kawasaki disease;	chr14:106784199	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000211974.3	IGHV2-70	5.9	6.92e-09	2.73e-06	0.27	0.26	Kawasaki disease;	chr14:106784709	chr14:106723574~106724093:-
LUAD	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.92e-09	2.73e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
LUAD	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	5.9	6.93e-09	2.74e-06	0.24	0.26	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
LUAD	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-5.9	6.93e-09	2.74e-06	-0.29	-0.26	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
LUAD	cis	rs11838725	1	rs11838725	ENSG00000176268.5	CYCSP34	5.9	6.94e-09	2.74e-06	0.25	0.26	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40863599~40863902:-
LUAD	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-5.9	6.94e-09	2.74e-06	-0.46	-0.26	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
LUAD	cis	rs875971	0.825	rs59466412	ENSG00000222364.1	RNU6-96P	5.9	6.94e-09	2.74e-06	0.3	0.26	Aortic root size;	chr7:66100371	chr7:66395191~66395286:+
LUAD	cis	rs9595908	0.709	rs7318510	ENSG00000212293.1	SNORA16	5.9	6.96e-09	2.75e-06	0.28	0.26	Body mass index;	chr13:32752122	chr13:32420390~32420516:-
LUAD	cis	rs7044106	0.664	rs7861679	ENSG00000238181.2	AHCYP2	5.9	6.97e-09	2.75e-06	0.33	0.26	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120720673~120721972:+
LUAD	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-5.9	6.98e-09	2.76e-06	-0.36	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
LUAD	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-5.9	6.98e-09	2.76e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
LUAD	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	5.9	6.98e-09	2.76e-06	0.36	0.26	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
LUAD	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-5.9	6.99e-09	2.76e-06	-0.38	-0.26	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
LUAD	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-5.9	6.99e-09	2.76e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000224373.3	IGHV4-59	5.9	7e-09	2.76e-06	0.17	0.26	Kawasaki disease;	chr14:106668657	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-5.9	7e-09	2.77e-06	-0.28	-0.26	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
LUAD	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-5.9	7.01e-09	2.77e-06	-0.35	-0.26	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-5.9	7.01e-09	2.77e-06	-0.35	-0.26	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
LUAD	cis	rs4972806	0.814	rs966801	ENSG00000226363.3	HAGLROS	-5.9	7.01e-09	2.77e-06	-0.33	-0.26	IgG glycosylation;	chr2:176173099	chr2:176177717~176179008:+
LUAD	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	5.9	7.01e-09	2.77e-06	0.31	0.26	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
LUAD	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-5.9	7.02e-09	2.77e-06	-0.41	-0.26	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
LUAD	cis	rs516805	0.886	rs557528	ENSG00000279453.1	RP3-425C14.4	-5.9	7.02e-09	2.77e-06	-0.3	-0.26	Lymphocyte counts;	chr6:122482793	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.961	rs559721	ENSG00000279453.1	RP3-425C14.4	-5.9	7.02e-09	2.77e-06	-0.3	-0.26	Lymphocyte counts;	chr6:122482796	chr6:122436789~122439223:-
LUAD	cis	rs9910055	0.762	rs2526020	ENSG00000267080.4	ASB16-AS1	-5.9	7.02e-09	2.77e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44139220	chr17:44175973~44186717:-
LUAD	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	5.9	7.02e-09	2.77e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
LUAD	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	5.9	7.02e-09	2.77e-06	0.37	0.26	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
LUAD	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	5.9	7.02e-09	2.77e-06	0.36	0.26	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
LUAD	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
LUAD	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
LUAD	cis	rs8031584	0.958	rs7176569	ENSG00000260382.1	RP11-540B6.2	-5.9	7.05e-09	2.78e-06	-0.31	-0.26	Huntington's disease progression;	chr15:30952292	chr15:30882267~30883231:-
LUAD	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	5.9	7.06e-09	2.78e-06	0.26	0.26	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
LUAD	cis	rs6504622	0.935	rs17608961	ENSG00000262879.4	RP11-156P1.3	-5.89	7.06e-09	2.79e-06	-0.3	-0.26	Orofacial clefts;	chr17:46952302	chr17:46984045~47100323:-
LUAD	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	5.89	7.07e-09	2.79e-06	0.29	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	5.89	7.07e-09	2.79e-06	0.29	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
LUAD	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	5.89	7.07e-09	2.79e-06	0.29	0.26	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
LUAD	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-5.89	7.07e-09	2.79e-06	-0.53	-0.26	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
LUAD	cis	rs17711722	0.583	rs10085415	ENSG00000164669.11	INTS4P1	5.89	7.08e-09	2.79e-06	0.32	0.26	Calcium levels;	chr7:65628655	chr7:65141225~65234216:+
LUAD	cis	rs853679	0.517	rs9295761	ENSG00000204709.4	LINC01556	5.89	7.09e-09	2.8e-06	0.37	0.26	Depression;	chr6:28180209	chr6:28943877~28944537:+
LUAD	cis	rs2412819	0.571	rs678084	ENSG00000249839.1	AC011330.5	5.89	7.09e-09	2.8e-06	0.4	0.26	Lung cancer;	chr15:43828361	chr15:43663654~43684339:-
LUAD	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	5.89	7.09e-09	2.8e-06	0.3	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
LUAD	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-5.89	7.09e-09	2.8e-06	-0.39	-0.26	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316326	ENSG00000230295.1	RP11-458F8.2	-5.89	7.1e-09	2.8e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66144466	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316325	ENSG00000230295.1	RP11-458F8.2	-5.89	7.1e-09	2.8e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66144531	chr7:66880708~66882981:+
LUAD	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-5.89	7.1e-09	2.8e-06	-0.28	-0.26	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
LUAD	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-5.89	7.1e-09	2.8e-06	-0.33	-0.26	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-5.89	7.1e-09	2.8e-06	-0.33	-0.26	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
LUAD	cis	rs1707322	0.686	rs2991986	ENSG00000234329.1	RP11-767N6.2	-5.89	7.12e-09	2.81e-06	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45651039~45651826:-
LUAD	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-5.89	7.13e-09	2.81e-06	-0.38	-0.26	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
LUAD	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	5.89	7.14e-09	2.81e-06	0.34	0.26	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
LUAD	cis	rs950169	0.526	rs698620	ENSG00000229212.6	RP11-561C5.4	5.89	7.14e-09	2.82e-06	0.31	0.26	Schizophrenia;	chr15:84633977	chr15:85205440~85234795:-
LUAD	cis	rs2562456	0.833	rs2562487	ENSG00000268081.1	RP11-678G14.2	5.89	7.15e-09	2.82e-06	0.4	0.26	Pain;	chr19:21468580	chr19:21554640~21569237:-
LUAD	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	5.89	7.15e-09	2.82e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
LUAD	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-5.89	7.15e-09	2.82e-06	-0.28	-0.26	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
LUAD	cis	rs2243480	0.522	rs778717	ENSG00000273142.1	RP11-458F8.4	-5.89	7.15e-09	2.82e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66383164	chr7:66902857~66906297:+
LUAD	cis	rs2599510	0.744	rs4952212	ENSG00000276334.1	AL133243.1	-5.89	7.15e-09	2.82e-06	-0.3	-0.26	Interleukin-18 levels;	chr2:32393425	chr2:32521927~32523547:+
LUAD	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-5.89	7.15e-09	2.82e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
LUAD	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	5.89	7.15e-09	2.82e-06	0.32	0.26	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
LUAD	cis	rs8177876	0.658	rs2970077	ENSG00000261838.4	RP11-303E16.6	5.89	7.16e-09	2.82e-06	0.47	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041195	chr16:81069854~81076598:+
LUAD	cis	rs7618501	0.602	rs6780731	ENSG00000234667.1	ACTBP13	-5.89	7.16e-09	2.82e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49980045	chr3:49873347~49877980:-
LUAD	cis	rs10214930	0.697	rs1404276	ENSG00000235574.1	AC073150.6	-5.89	7.17e-09	2.82e-06	-0.33	-0.26	Hypospadias;	chr7:27551228	chr7:27491682~27492765:-
LUAD	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-5.89	7.17e-09	2.83e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
LUAD	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	5.89	7.17e-09	2.83e-06	0.32	0.26	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
LUAD	cis	rs853679	0.599	rs202906	ENSG00000204709.4	LINC01556	-5.89	7.18e-09	2.83e-06	-0.42	-0.26	Depression;	chr6:28043874	chr6:28943877~28944537:+
LUAD	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-5.89	7.18e-09	2.83e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
LUAD	cis	rs2404602	0.716	rs56216512	ENSG00000259422.1	RP11-593F23.1	5.89	7.19e-09	2.83e-06	0.3	0.26	Blood metabolite levels;	chr15:76394595	chr15:76174891~76181486:-
LUAD	cis	rs12468226	1	rs7597469	ENSG00000272966.1	RP11-686O6.1	5.89	7.19e-09	2.83e-06	0.45	0.26	Urate levels;	chr2:202329547	chr2:202336739~202337200:+
LUAD	cis	rs9595908	0.629	rs962454	ENSG00000212293.1	SNORA16	5.89	7.19e-09	2.83e-06	0.28	0.26	Body mass index;	chr13:32719131	chr13:32420390~32420516:-
LUAD	cis	rs4908768	0.501	rs1922983	ENSG00000232912.4	RP5-1115A15.1	5.89	7.21e-09	2.84e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8424645~8434838:+
LUAD	cis	rs9595066	0.627	rs4432167	ENSG00000227258.4	SMIM2-AS1	-5.89	7.21e-09	2.84e-06	-0.39	-0.26	Schizophrenia;	chr13:44178225	chr13:44110451~44240517:+
LUAD	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	5.89	7.21e-09	2.84e-06	0.32	0.26	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
LUAD	cis	rs853679	0.506	rs1150693	ENSG00000204709.4	LINC01556	5.89	7.21e-09	2.84e-06	0.36	0.26	Depression;	chr6:28206812	chr6:28943877~28944537:+
LUAD	cis	rs35740288	0.77	rs1382538	ENSG00000202081.1	RNU6-1280P	5.89	7.22e-09	2.84e-06	0.33	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85622665	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	5.89	7.22e-09	2.84e-06	0.29	0.26	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	5.89	7.22e-09	2.84e-06	0.29	0.26	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	5.89	7.22e-09	2.84e-06	0.29	0.26	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	5.89	7.22e-09	2.84e-06	0.29	0.26	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
LUAD	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-5.89	7.23e-09	2.85e-06	-0.33	-0.26	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
LUAD	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	5.89	7.23e-09	2.85e-06	0.24	0.26	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
LUAD	cis	rs7299940	0.694	rs12296337	ENSG00000256299.1	RP11-989F5.3	5.89	7.24e-09	2.85e-06	0.29	0.26	Panic disorder;	chr12:130891406	chr12:130810821~130812622:-
LUAD	cis	rs8040855	0.579	rs28521166	ENSG00000259774.1	RP11-182J1.13	-5.89	7.24e-09	2.85e-06	-0.3	-0.26	Bulimia nervosa;	chr15:85184801	chr15:84422618~84425882:+
LUAD	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-5.89	7.24e-09	2.85e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
LUAD	cis	rs783540	0.632	rs17356528	ENSG00000278603.1	RP13-608F4.5	-5.89	7.24e-09	2.85e-06	-0.33	-0.26	Schizophrenia;	chr15:82636799	chr15:82472203~82472426:+
LUAD	cis	rs948562	0.947	rs7482383	ENSG00000280010.1	AP001350.4	5.89	7.25e-09	2.86e-06	0.42	0.26	Lymphoma;	chr11:58602225	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.947	rs76985515	ENSG00000280010.1	AP001350.4	5.89	7.25e-09	2.86e-06	0.42	0.26	Lymphoma;	chr11:58604321	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.947	rs78176302	ENSG00000280010.1	AP001350.4	5.89	7.25e-09	2.86e-06	0.42	0.26	Lymphoma;	chr11:58615176	chr11:58627435~58628528:+
LUAD	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	5.89	7.26e-09	2.86e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
LUAD	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	5.89	7.26e-09	2.86e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
LUAD	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-5.89	7.27e-09	2.86e-06	-0.33	-0.26	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-5.89	7.27e-09	2.86e-06	-0.33	-0.26	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
LUAD	cis	rs7618501	0.633	rs2856234	ENSG00000234667.1	ACTBP13	5.89	7.29e-09	2.87e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50101709	chr3:49873347~49877980:-
LUAD	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-5.89	7.29e-09	2.87e-06	-0.49	-0.26	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-5.89	7.29e-09	2.87e-06	-0.49	-0.26	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
LUAD	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-5.89	7.31e-09	2.88e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
LUAD	cis	rs17666538	0.585	rs10090260	ENSG00000254207.1	RP11-43A14.1	5.89	7.32e-09	2.88e-06	0.51	0.26	IgG glycosylation;	chr8:658034	chr8:725188~725877:-
LUAD	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-5.89	7.32e-09	2.88e-06	-0.28	-0.26	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000224373.3	IGHV4-59	5.89	7.33e-09	2.88e-06	0.17	0.26	Kawasaki disease;	chr14:106767441	chr14:106627249~106627825:-
LUAD	cis	rs2115536	0.967	rs4778734	ENSG00000278600.1	RP11-81A1.6	-5.89	7.33e-09	2.88e-06	-0.21	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79918509	chr15:79920195~79922455:-
LUAD	cis	rs2288884	1	rs17779301	ENSG00000275055.1	CTC-471J1.11	5.89	7.33e-09	2.88e-06	0.4	0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035990	chr19:52049007~52049754:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000211974.3	IGHV2-70	5.89	7.34e-09	2.89e-06	0.27	0.26	Kawasaki disease;	chr14:106718498	chr14:106723574~106724093:-
LUAD	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-5.89	7.36e-09	2.89e-06	-0.48	-0.26	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
LUAD	cis	rs2243480	1	rs4149468	ENSG00000230295.1	RP11-458F8.2	-5.89	7.36e-09	2.89e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66360703	chr7:66880708~66882981:+
LUAD	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	5.89	7.37e-09	2.9e-06	0.31	0.26	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
LUAD	cis	rs755249	0.567	rs2018212	ENSG00000228060.1	RP11-69E11.8	-5.89	7.37e-09	2.9e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs4660751	ENSG00000228060.1	RP11-69E11.8	-5.89	7.37e-09	2.9e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39565160~39573203:+
LUAD	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	5.89	7.38e-09	2.9e-06	0.29	0.26	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	5.89	7.38e-09	2.9e-06	0.29	0.26	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
LUAD	cis	rs4908768	0.539	rs11121204	ENSG00000232912.4	RP5-1115A15.1	-5.89	7.38e-09	2.9e-06	-0.24	-0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8424645~8434838:+
LUAD	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	5.89	7.39e-09	2.9e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	5.89	7.39e-09	2.9e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
LUAD	cis	rs10214930	0.697	rs759269	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.9e-06	-0.33	-0.26	Hypospadias;	chr7:27552728	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.56	rs1015750	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.9e-06	-0.33	-0.26	Hypospadias;	chr7:27553600	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7780431	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.9e-06	-0.33	-0.26	Hypospadias;	chr7:27553749	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1554641	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.9e-06	-0.33	-0.26	Hypospadias;	chr7:27555068	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs2391451	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27646203	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs12700829	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27647483	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs2160125	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27648667	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs12700830	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27649240	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs2391454	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27651005	chr7:27491682~27492765:-
LUAD	cis	rs12699921	0.599	rs2691583	ENSG00000279048.1	RP11-511H23.2	-5.89	7.39e-09	2.91e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17792182	chr7:17940503~17942922:+
LUAD	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-5.89	7.42e-09	2.91e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
LUAD	cis	rs6687821	0.593	rs797947	ENSG00000267734.1	RP4-604K5.3	5.89	7.42e-09	2.91e-06	0.34	0.26	Yeast infection;	chr1:86844606	chr1:86932199~86934891:-
LUAD	cis	rs62432291	0.681	rs404461	ENSG00000235086.1	FNDC1-IT1	5.89	7.43e-09	2.92e-06	0.44	0.26	Joint mobility (Beighton score);	chr6:159219677	chr6:159240786~159243329:+
LUAD	cis	rs394563	0.622	rs237024	ENSG00000231760.4	RP11-350J20.5	5.89	7.43e-09	2.92e-06	0.31	0.26	Dupuytren's disease;	chr6:149400829	chr6:149796151~149826294:-
LUAD	cis	rs7618501	0.633	rs9814664	ENSG00000234667.1	ACTBP13	5.89	7.43e-09	2.92e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50041108	chr3:49873347~49877980:-
LUAD	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	5.89	7.44e-09	2.92e-06	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
LUAD	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	5.89	7.44e-09	2.92e-06	0.34	0.26	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
LUAD	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	5.89	7.44e-09	2.92e-06	0.34	0.26	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
LUAD	cis	rs9595908	0.869	rs9591191	ENSG00000212293.1	SNORA16	5.89	7.44e-09	2.92e-06	0.28	0.26	Body mass index;	chr13:32633397	chr13:32420390~32420516:-
LUAD	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-5.89	7.44e-09	2.92e-06	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
LUAD	cis	rs5753618	0.583	rs9606843	ENSG00000236132.1	CTA-440B3.1	-5.89	7.44e-09	2.92e-06	-0.32	-0.26	Colorectal cancer;	chr22:31457385	chr22:31816379~31817491:-
LUAD	cis	rs10214930	0.697	rs2110526	ENSG00000235574.1	AC073150.6	-5.89	7.46e-09	2.93e-06	-0.33	-0.26	Hypospadias;	chr7:27596061	chr7:27491682~27492765:-
LUAD	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	5.89	7.47e-09	2.93e-06	0.42	0.26	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
LUAD	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-5.88	7.49e-09	2.94e-06	-0.35	-0.26	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
LUAD	cis	rs1707322	0.721	rs7520123	ENSG00000234329.1	RP11-767N6.2	5.88	7.49e-09	2.94e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45651039~45651826:-
LUAD	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-5.88	7.5e-09	2.94e-06	-0.32	-0.26	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
LUAD	cis	rs853679	0.513	rs9468296	ENSG00000204709.4	LINC01556	5.88	7.5e-09	2.94e-06	0.37	0.26	Depression;	chr6:28145952	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.824	rs742046	ENSG00000219392.1	RP1-265C24.5	-5.88	7.5e-09	2.95e-06	-0.35	-0.26	Parkinson's disease;	chr6:27771475	chr6:28115628~28116551:+
LUAD	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-5.88	7.51e-09	2.95e-06	-0.28	-0.26	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000224373.3	IGHV4-59	5.88	7.51e-09	2.95e-06	0.17	0.26	Kawasaki disease;	chr14:106670217	chr14:106627249~106627825:-
LUAD	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	5.88	7.51e-09	2.95e-06	0.33	0.26	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
LUAD	cis	rs7618501	0.571	rs2240329	ENSG00000234667.1	ACTBP13	5.88	7.52e-09	2.95e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50070079	chr3:49873347~49877980:-
LUAD	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-5.88	7.52e-09	2.95e-06	-0.31	-0.26	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
LUAD	cis	rs4908768	0.539	rs6670508	ENSG00000232912.4	RP5-1115A15.1	5.88	7.53e-09	2.95e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8424645~8434838:+
LUAD	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	5.88	7.53e-09	2.95e-06	0.23	0.26	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
LUAD	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	5.88	7.53e-09	2.96e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
LUAD	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-5.88	7.53e-09	2.96e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
LUAD	cis	rs12699921	0.594	rs2691620	ENSG00000279048.1	RP11-511H23.2	-5.88	7.54e-09	2.96e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17851213	chr7:17940503~17942922:+
LUAD	cis	rs36093844	1	rs11234452	ENSG00000279742.1	RP11-700A24.1	-5.88	7.54e-09	2.96e-06	-0.29	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865758	chr11:85852557~85854943:-
LUAD	cis	rs2404602	0.716	rs117129193	ENSG00000259422.1	RP11-593F23.1	5.88	7.54e-09	2.96e-06	0.3	0.26	Blood metabolite levels;	chr15:76364462	chr15:76174891~76181486:-
LUAD	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	5.88	7.55e-09	2.96e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
LUAD	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-5.88	7.56e-09	2.97e-06	-0.24	-0.26	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
LUAD	cis	rs2243480	1	rs160639	ENSG00000230295.1	RP11-458F8.2	-5.88	7.56e-09	2.97e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66115000	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000230295.1	RP11-458F8.2	-5.88	7.56e-09	2.97e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66116220	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000230295.1	RP11-458F8.2	-5.88	7.56e-09	2.97e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66117071	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000230295.1	RP11-458F8.2	-5.88	7.56e-09	2.97e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66119331	chr7:66880708~66882981:+
LUAD	cis	rs35740288	0.752	rs11636138	ENSG00000202081.1	RNU6-1280P	5.88	7.56e-09	2.97e-06	0.33	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744316	chr15:85651522~85651628:-
LUAD	cis	rs12699921	0.607	rs1404425	ENSG00000279048.1	RP11-511H23.2	-5.88	7.57e-09	2.97e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17788034	chr7:17940503~17942922:+
LUAD	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-5.88	7.57e-09	2.97e-06	-0.31	-0.26	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-5.88	7.57e-09	2.97e-06	-0.31	-0.26	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
LUAD	cis	rs4947019	0.609	rs9487109	ENSG00000260273.1	RP11-425D10.10	5.88	7.58e-09	2.97e-06	0.59	0.26	Hematological parameters;	chr6:109436323	chr6:109382795~109383666:+
LUAD	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	5.88	7.58e-09	2.97e-06	0.28	0.26	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
LUAD	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-5.88	7.59e-09	2.98e-06	-0.39	-0.26	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-5.88	7.59e-09	2.98e-06	-0.39	-0.26	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
LUAD	cis	rs9860428	0.711	rs9810246	ENSG00000242770.2	RP11-180K7.1	5.88	7.59e-09	2.98e-06	0.28	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112807706	chr3:112802478~112812819:+
LUAD	cis	rs12699921	0.632	rs2691618	ENSG00000279048.1	RP11-511H23.2	-5.88	7.59e-09	2.98e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17850572	chr7:17940503~17942922:+
LUAD	cis	rs394563	0.591	rs237026	ENSG00000231760.4	RP11-350J20.5	5.88	7.59e-09	2.98e-06	0.31	0.26	Dupuytren's disease;	chr6:149399545	chr6:149796151~149826294:-
LUAD	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-5.88	7.59e-09	2.98e-06	-0.32	-0.26	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
LUAD	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-5.88	7.6e-09	2.98e-06	-0.31	-0.26	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
LUAD	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-5.88	7.61e-09	2.99e-06	-0.28	-0.26	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
LUAD	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-5.88	7.62e-09	2.99e-06	-0.32	-0.26	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
LUAD	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	5.88	7.62e-09	2.99e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000211967.3	IGHV3-53	-5.88	7.63e-09	2.99e-06	-0.19	-0.26	Kawasaki disease;	chr14:106676185	chr14:106592676~106593347:-
LUAD	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-5.88	7.64e-09	3e-06	-0.28	-0.26	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-5.88	7.64e-09	3e-06	-0.28	-0.26	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
LUAD	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-5.88	7.65e-09	3e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
LUAD	cis	rs293748	0.771	rs159141	ENSG00000250155.1	CTD-2353F22.1	-5.88	7.65e-09	3e-06	-0.36	-0.26	Obesity-related traits;	chr5:36925544	chr5:36666214~36725195:-
LUAD	cis	rs12188164	0.502	rs55929184	ENSG00000225138.6	CTD-2228K2.7	5.88	7.65e-09	3e-06	0.25	0.26	Cystic fibrosis severity;	chr5:405461	chr5:473236~480884:+
LUAD	cis	rs10214930	1	rs10214930	ENSG00000235574.1	AC073150.6	5.88	7.65e-09	3e-06	0.36	0.26	Hypospadias;	chr7:27745330	chr7:27491682~27492765:-
LUAD	cis	rs10214930	1	rs4722740	ENSG00000235574.1	AC073150.6	5.88	7.65e-09	3e-06	0.36	0.26	Hypospadias;	chr7:27747390	chr7:27491682~27492765:-
LUAD	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-5.88	7.65e-09	3e-06	-0.28	-0.26	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
LUAD	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-5.88	7.67e-09	3.01e-06	-0.45	-0.26	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
LUAD	cis	rs8177376	0.727	rs589442	ENSG00000254905.1	RP11-712L6.7	5.88	7.68e-09	3.01e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328101	chr11:126292922~126294254:-
LUAD	cis	rs30380	0.632	rs27640	ENSG00000272109.1	CTD-2260A17.3	-5.88	7.68e-09	3.01e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96792202	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.632	rs27434	ENSG00000272109.1	CTD-2260A17.3	-5.88	7.68e-09	3.01e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96793809	chr5:96804353~96806105:+
LUAD	cis	rs2255336	0.938	rs73070926	ENSG00000245648.1	RP11-277P12.20	-5.88	7.68e-09	3.01e-06	-0.41	-0.26	Blood protein levels;	chr12:10459717	chr12:10363769~10398506:+
LUAD	cis	rs9595908	0.709	rs9315179	ENSG00000212293.1	SNORA16	5.88	7.68e-09	3.01e-06	0.28	0.26	Body mass index;	chr13:32773889	chr13:32420390~32420516:-
LUAD	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	5.88	7.69e-09	3.01e-06	0.29	0.26	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
LUAD	cis	rs11051970	0.559	rs7300646	ENSG00000274964.1	RP11-817I4.1	-5.88	7.7e-09	3.01e-06	-0.33	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32335695	chr12:32339368~32340724:+
LUAD	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-5.88	7.71e-09	3.02e-06	-0.29	-0.26	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
LUAD	cis	rs9595908	0.694	rs9596233	ENSG00000212293.1	SNORA16	5.88	7.71e-09	3.02e-06	0.27	0.26	Body mass index;	chr13:32776878	chr13:32420390~32420516:-
LUAD	cis	rs11971779	0.68	rs6947215	ENSG00000273391.1	RP11-634H22.1	5.88	7.72e-09	3.02e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139341892	chr7:139359032~139359566:-
LUAD	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	5.88	7.72e-09	3.02e-06	0.39	0.26	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
LUAD	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-5.88	7.73e-09	3.03e-06	-0.33	-0.26	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
LUAD	cis	rs1707322	0.721	rs11211181	ENSG00000234329.1	RP11-767N6.2	5.88	7.73e-09	3.03e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45651039~45651826:-
LUAD	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	5.88	7.73e-09	3.03e-06	0.48	0.26	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
LUAD	cis	rs4538475	0.556	rs4613561	ENSG00000214846.4	RP11-115L11.1	5.88	7.73e-09	3.03e-06	0.37	0.26	Parkinson's disease;	chr4:15736267	chr4:15730962~15731627:-
LUAD	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-5.88	7.73e-09	3.03e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
LUAD	cis	rs11157436	0.958	rs2204963	ENSG00000211812.1	TRAV26-2	-5.88	7.74e-09	3.03e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22202583~22203368:+
LUAD	cis	rs7044106	0.762	rs3903886	ENSG00000238181.2	AHCYP2	5.88	7.74e-09	3.03e-06	0.32	0.26	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120720673~120721972:+
LUAD	cis	rs9287719	0.601	rs12996735	ENSG00000243819.4	RN7SL832P	5.88	7.74e-09	3.03e-06	0.28	0.26	Prostate cancer;	chr2:10576590	chr2:10690344~10692099:+
LUAD	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	5.88	7.74e-09	3.03e-06	0.31	0.26	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
LUAD	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-5.88	7.74e-09	3.03e-06	-0.23	-0.26	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs73142166	ENSG00000230295.1	RP11-458F8.2	-5.88	7.75e-09	3.03e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65910845	chr7:66880708~66882981:+
LUAD	cis	rs2880765	0.506	rs719138	ENSG00000259295.5	CSPG4P12	5.88	7.75e-09	3.03e-06	0.32	0.26	Coronary artery disease;	chr15:85511831	chr15:85191438~85213905:+
LUAD	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-5.88	7.77e-09	3.04e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
LUAD	cis	rs2243480	1	rs313814	ENSG00000230295.1	RP11-458F8.2	-5.88	7.79e-09	3.05e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66038306	chr7:66880708~66882981:+
LUAD	cis	rs12468226	1	rs113877751	ENSG00000272966.1	RP11-686O6.1	5.88	7.79e-09	3.05e-06	0.45	0.26	Urate levels;	chr2:202329998	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.935	rs113021930	ENSG00000272966.1	RP11-686O6.1	5.88	7.79e-09	3.05e-06	0.45	0.26	Urate levels;	chr2:202330448	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs113491584	ENSG00000272966.1	RP11-686O6.1	5.88	7.79e-09	3.05e-06	0.45	0.26	Urate levels;	chr2:202331724	chr2:202336739~202337200:+
LUAD	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	5.88	7.79e-09	3.05e-06	0.4	0.26	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
LUAD	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-5.88	7.79e-09	3.05e-06	-0.37	-0.26	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
LUAD	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	5.88	7.79e-09	3.05e-06	0.32	0.26	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
LUAD	cis	rs7246657	0.524	rs35080624	ENSG00000276846.1	CTD-3220F14.3	5.88	7.8e-09	3.05e-06	0.41	0.26	Coronary artery calcification;	chr19:36965680	chr19:37314868~37315620:-
LUAD	cis	rs5753618	0.607	rs5753621	ENSG00000236132.1	CTA-440B3.1	-5.88	7.8e-09	3.05e-06	-0.32	-0.26	Colorectal cancer;	chr22:31451661	chr22:31816379~31817491:-
LUAD	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-5.88	7.8e-09	3.05e-06	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
LUAD	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	5.88	7.81e-09	3.06e-06	0.29	0.26	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	5.88	7.81e-09	3.06e-06	0.29	0.26	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
LUAD	cis	rs4908768	0.501	rs12756257	ENSG00000232912.4	RP5-1115A15.1	5.88	7.82e-09	3.06e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8424645~8434838:+
LUAD	cis	rs2243480	1	rs313820	ENSG00000230295.1	RP11-458F8.2	-5.88	7.83e-09	3.06e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66109479	chr7:66880708~66882981:+
LUAD	cis	rs10200159	1	rs6545509	ENSG00000272606.1	RP11-554J4.1	5.88	7.83e-09	3.06e-06	0.53	0.26	Vitiligo;	chr2:55607461	chr2:55617909~55618373:+
LUAD	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-5.88	7.83e-09	3.07e-06	-0.33	-0.26	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-5.88	7.83e-09	3.07e-06	-0.33	-0.26	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-5.88	7.83e-09	3.07e-06	-0.33	-0.26	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
LUAD	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	5.88	7.84e-09	3.07e-06	0.31	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
LUAD	cis	rs7618501	0.633	rs4688757	ENSG00000234667.1	ACTBP13	-5.88	7.84e-09	3.07e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49997890	chr3:49873347~49877980:-
LUAD	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-5.88	7.84e-09	3.07e-06	-0.29	-0.26	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
LUAD	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	5.88	7.84e-09	3.07e-06	0.35	0.26	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
LUAD	cis	rs8031584	0.918	rs35396566	ENSG00000260382.1	RP11-540B6.2	5.88	7.85e-09	3.07e-06	0.34	0.26	Huntington's disease progression;	chr15:30970854	chr15:30882267~30883231:-
LUAD	cis	rs9910055	0.676	rs11079983	ENSG00000267080.4	ASB16-AS1	-5.88	7.85e-09	3.07e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44120802	chr17:44175973~44186717:-
LUAD	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	5.88	7.86e-09	3.07e-06	0.31	0.26	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
LUAD	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-5.88	7.86e-09	3.08e-06	-0.3	-0.26	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
LUAD	cis	rs3738443	0.678	rs4314914	ENSG00000259865.1	RP11-488L18.10	5.88	7.86e-09	3.08e-06	0.24	0.26	Alcohol dependence;	chr1:247210326	chr1:247187281~247188526:-
LUAD	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	5.88	7.86e-09	3.08e-06	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
LUAD	cis	rs238295	0.696	rs6038189	ENSG00000230563.2	RP5-828H9.1	5.88	7.88e-09	3.08e-06	0.36	0.26	Occipital cortical area (total cortical area interaction);	chr20:5513196	chr20:5471207~5475182:+
LUAD	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-5.88	7.89e-09	3.09e-06	-0.28	-0.26	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
LUAD	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-5.88	7.9e-09	3.09e-06	-0.42	-0.26	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-5.88	7.9e-09	3.09e-06	-0.42	-0.26	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-5.87	7.91e-09	3.09e-06	-0.37	-0.26	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
LUAD	cis	rs26528	0.584	rs153103	ENSG00000259982.1	CDC37P1	-5.87	7.92e-09	3.09e-06	-0.32	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28700294~28701540:-
LUAD	cis	rs11096990	0.855	rs2566173	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39151111	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2043102	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39151292	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2711986	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39152258	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.75	rs2465242	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39153796	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2465243	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39154036	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566176	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39154373	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566178	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39155194	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.819	rs2435528	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39155916	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2711933	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39156090	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566179	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39156413	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566180	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39157381	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566181	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39157987	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.819	rs2381225	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39158915	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.819	rs1367297	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39159614	chr4:39112677~39126818:-
LUAD	cis	rs10214930	0.813	rs6946305	ENSG00000235574.1	AC073150.6	-5.87	7.93e-09	3.1e-06	-0.35	-0.26	Hypospadias;	chr7:27641576	chr7:27491682~27492765:-
LUAD	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-5.87	7.93e-09	3.1e-06	-0.38	-0.26	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
LUAD	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-5.87	7.93e-09	3.1e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
LUAD	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	5.87	7.93e-09	3.1e-06	0.28	0.26	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
LUAD	cis	rs10214930	0.697	rs6462031	ENSG00000235574.1	AC073150.6	-5.87	7.94e-09	3.1e-06	-0.33	-0.26	Hypospadias;	chr7:27549871	chr7:27491682~27492765:-
LUAD	cis	rs997295	0.535	rs11630854	ENSG00000270964.1	RP11-502I4.3	-5.87	7.95e-09	3.11e-06	-0.27	-0.26	Motion sickness;	chr15:67565778	chr15:67541072~67542604:-
LUAD	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-5.87	7.96e-09	3.11e-06	-0.27	-0.26	Height;	chr11:118781100	chr11:118791254~118793137:+
LUAD	cis	rs30380	0.506	rs469735	ENSG00000272109.1	CTD-2260A17.3	-5.87	7.96e-09	3.11e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96794311	chr5:96804353~96806105:+
LUAD	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-5.87	7.96e-09	3.11e-06	-0.28	-0.26	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-5.87	7.96e-09	3.11e-06	-0.28	-0.26	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
LUAD	cis	rs149313	1	rs149313	ENSG00000248734.2	CTD-2260A17.1	-5.87	7.97e-09	3.11e-06	-0.24	-0.26	Blood protein levels;	chr5:96734501	chr5:96784777~96785999:+
LUAD	cis	rs17684571	0.938	rs34724718	ENSG00000231441.1	RP11-472M19.2	5.87	7.97e-09	3.11e-06	0.35	0.26	Schizophrenia;	chr6:56693024	chr6:56844002~56864078:+
LUAD	cis	rs9860428	0.682	rs9809444	ENSG00000242770.2	RP11-180K7.1	5.87	7.99e-09	3.12e-06	0.28	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112807206	chr3:112802478~112812819:+
LUAD	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	5.87	7.99e-09	3.12e-06	0.25	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
LUAD	cis	rs293748	0.515	rs13179402	ENSG00000250155.1	CTD-2353F22.1	-5.87	7.99e-09	3.12e-06	-0.33	-0.26	Obesity-related traits;	chr5:37256242	chr5:36666214~36725195:-
LUAD	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	5.87	8e-09	3.12e-06	0.32	0.26	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
LUAD	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	5.87	8.01e-09	3.13e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
LUAD	cis	rs8177876	0.658	rs77874075	ENSG00000261061.1	RP11-303E16.2	-5.87	8.01e-09	3.13e-06	-0.46	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81030770~81031485:+
LUAD	cis	rs9595908	0.694	rs2224883	ENSG00000212293.1	SNORA16	5.87	8.01e-09	3.13e-06	0.28	0.26	Body mass index;	chr13:32763753	chr13:32420390~32420516:-
LUAD	cis	rs11157436	0.958	rs17183308	ENSG00000211812.1	TRAV26-2	-5.87	8.01e-09	3.13e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22202583~22203368:+
LUAD	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-5.87	8.01e-09	3.13e-06	-0.28	-0.26	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
LUAD	cis	rs2115630	0.645	rs6496284	ENSG00000229212.6	RP11-561C5.4	5.87	8.02e-09	3.13e-06	0.31	0.26	P wave terminal force;	chr15:84635039	chr15:85205440~85234795:-
LUAD	cis	rs853679	0.55	rs1225598	ENSG00000204709.4	LINC01556	5.87	8.03e-09	3.13e-06	0.36	0.26	Depression;	chr6:28193021	chr6:28943877~28944537:+
LUAD	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	5.87	8.03e-09	3.14e-06	0.33	0.26	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	5.87	8.03e-09	3.14e-06	0.33	0.26	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
LUAD	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-5.87	8.03e-09	3.14e-06	-0.32	-0.26	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
LUAD	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-5.87	8.04e-09	3.14e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-5.87	8.04e-09	3.14e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
LUAD	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	5.87	8.04e-09	3.14e-06	0.29	0.26	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
LUAD	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-5.87	8.04e-09	3.14e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
LUAD	cis	rs2212361	0.527	rs7931179	ENSG00000255893.1	RP11-685N10.1	-5.87	8.04e-09	3.14e-06	-0.34	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531037	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.558	rs7934286	ENSG00000255893.1	RP11-685N10.1	-5.87	8.04e-09	3.14e-06	-0.34	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531347	chr11:94472908~94473570:-
LUAD	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-5.87	8.04e-09	3.14e-06	-0.33	-0.26	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
LUAD	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-5.87	8.04e-09	3.14e-06	-0.29	-0.26	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-5.87	8.04e-09	3.14e-06	-0.29	-0.26	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
LUAD	cis	rs10129255	1	rs10129319	ENSG00000211974.3	IGHV2-70	5.87	8.05e-09	3.14e-06	0.27	0.26	Kawasaki disease;	chr14:106767996	chr14:106723574~106724093:-
LUAD	cis	rs7246657	0.508	rs1628959	ENSG00000276846.1	CTD-3220F14.3	5.87	8.05e-09	3.14e-06	0.4	0.26	Coronary artery calcification;	chr19:36999474	chr19:37314868~37315620:-
LUAD	cis	rs9368481	0.594	rs2636425	ENSG00000241549.7	GUSBP2	5.87	8.05e-09	3.14e-06	0.29	0.26	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26871484~26956554:-
LUAD	cis	rs9928842	0.882	rs3169330	ENSG00000280152.1	RP11-331F4.5	5.87	8.05e-09	3.14e-06	0.29	0.26	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75245994~75250077:-
LUAD	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-5.87	8.06e-09	3.15e-06	-0.37	-0.26	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.628	rs9295740	ENSG00000219392.1	RP1-265C24.5	-5.87	8.06e-09	3.15e-06	-0.37	-0.26	Parkinson's disease;	chr6:27721723	chr6:28115628~28116551:+
LUAD	cis	rs368187	0.721	rs1759760	ENSG00000257826.1	RP11-116N8.4	5.87	8.06e-09	3.15e-06	0.27	0.26	Thyroid cancer;	chr14:36052560	chr14:36061026~36067190:-
LUAD	cis	rs9494145	0.68	rs9376092	ENSG00000232876.1	CTA-212D2.2	5.87	8.07e-09	3.15e-06	0.35	0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106006	chr6:135055033~135060550:+
LUAD	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	5.87	8.07e-09	3.15e-06	0.29	0.26	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
LUAD	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-5.87	8.07e-09	3.15e-06	-0.34	-0.26	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
LUAD	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	5.87	8.08e-09	3.15e-06	0.3	0.26	Height;	chr11:118859432	chr11:118688039~118690600:-
LUAD	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-5.87	8.08e-09	3.15e-06	-0.3	-0.26	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
LUAD	cis	rs9595908	0.832	rs13378546	ENSG00000212293.1	SNORA16	5.87	8.08e-09	3.15e-06	0.28	0.26	Body mass index;	chr13:32631522	chr13:32420390~32420516:-
LUAD	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-5.87	8.09e-09	3.15e-06	-0.26	-0.26	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
LUAD	cis	rs516805	0.667	rs2816139	ENSG00000279453.1	RP3-425C14.4	-5.87	8.09e-09	3.16e-06	-0.36	-0.26	Lymphocyte counts;	chr6:122182267	chr6:122436789~122439223:-
LUAD	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	5.87	8.09e-09	3.16e-06	0.23	0.26	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
LUAD	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	5.87	8.09e-09	3.16e-06	0.27	0.26	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
LUAD	cis	rs4713118	0.629	rs149899	ENSG00000204709.4	LINC01556	5.87	8.1e-09	3.16e-06	0.35	0.26	Parkinson's disease;	chr6:28052201	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.629	rs172165	ENSG00000204709.4	LINC01556	5.87	8.1e-09	3.16e-06	0.35	0.26	Parkinson's disease;	chr6:28053036	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.597	rs172166	ENSG00000204709.4	LINC01556	5.87	8.1e-09	3.16e-06	0.35	0.26	Parkinson's disease;	chr6:28053042	chr6:28943877~28944537:+
LUAD	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	5.87	8.1e-09	3.16e-06	0.32	0.26	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
LUAD	cis	rs35740288	0.77	rs10520592	ENSG00000202081.1	RNU6-1280P	5.87	8.11e-09	3.16e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85570911	chr15:85651522~85651628:-
LUAD	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	5.87	8.11e-09	3.16e-06	0.25	0.26	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	5.87	8.11e-09	3.16e-06	0.25	0.26	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	5.87	8.11e-09	3.16e-06	0.25	0.26	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	5.87	8.11e-09	3.16e-06	0.25	0.26	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
LUAD	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-5.87	8.12e-09	3.17e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
LUAD	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-5.87	8.12e-09	3.17e-06	-0.32	-0.26	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
LUAD	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	5.87	8.13e-09	3.17e-06	0.31	0.26	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
LUAD	cis	rs755249	0.53	rs16826087	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs3754346	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs16826093	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs41270811	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61779274	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39565160~39573203:+
LUAD	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	5.87	8.14e-09	3.17e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
LUAD	cis	rs2288884	1	rs11673286	ENSG00000275055.1	CTC-471J1.11	-5.87	8.14e-09	3.17e-06	-0.4	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037065	chr19:52049007~52049754:+
LUAD	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	5.87	8.15e-09	3.17e-06	0.29	0.26	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	5.87	8.15e-09	3.17e-06	0.29	0.26	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
LUAD	cis	rs9890032	0.509	rs11656986	ENSG00000266490.1	CTD-2349P21.9	5.87	8.15e-09	3.18e-06	0.25	0.26	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30792372~30792833:+
LUAD	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	5.87	8.15e-09	3.18e-06	0.31	0.26	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
LUAD	cis	rs755249	0.567	rs61779275	ENSG00000228060.1	RP11-69E11.8	-5.87	8.15e-09	3.18e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39565160~39573203:+
LUAD	cis	rs897200	1	rs1598253	ENSG00000280083.1	RP11-317J9.1	5.87	8.15e-09	3.18e-06	0.32	0.26	Behcet's disease;	chr2:191153691	chr2:191154118~191156070:-
LUAD	cis	rs2303759	0.515	rs2334867	ENSG00000268686.1	AC010524.2	5.87	8.16e-09	3.18e-06	0.39	0.26	Multiple sclerosis;	chr19:49284948	chr19:49368705~49388081:-
LUAD	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-5.87	8.17e-09	3.18e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
LUAD	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-5.87	8.17e-09	3.18e-06	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
LUAD	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	5.87	8.17e-09	3.18e-06	0.29	0.26	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	5.87	8.17e-09	3.18e-06	0.29	0.26	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
LUAD	cis	rs516805	0.748	rs55863504	ENSG00000279453.1	RP3-425C14.4	5.87	8.18e-09	3.19e-06	0.35	0.26	Lymphocyte counts;	chr6:122376339	chr6:122436789~122439223:-
LUAD	cis	rs7017914	0.84	rs1481804	ENSG00000223220.1	Y_RNA	5.87	8.2e-09	3.19e-06	0.29	0.26	Bone mineral density;	chr8:71057195	chr8:70780914~70781008:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000230295.1	RP11-458F8.2	-5.87	8.2e-09	3.19e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66358338	chr7:66880708~66882981:+
LUAD	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	5.87	8.2e-09	3.19e-06	0.37	0.26	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
LUAD	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-5.87	8.21e-09	3.2e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-5.87	8.21e-09	3.2e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
LUAD	cis	rs2243480	1	rs1499614	ENSG00000230295.1	RP11-458F8.2	-5.87	8.21e-09	3.2e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66265811	chr7:66880708~66882981:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000211972.2	IGHV3-66	-5.87	8.21e-09	3.2e-06	-0.22	-0.26	Kawasaki disease;	chr14:106779223	chr14:106675017~106675544:-
LUAD	cis	rs9595908	0.709	rs7319275	ENSG00000212293.1	SNORA16	5.87	8.22e-09	3.2e-06	0.27	0.26	Body mass index;	chr13:32733280	chr13:32420390~32420516:-
LUAD	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	5.87	8.22e-09	3.2e-06	0.31	0.26	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
LUAD	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	5.87	8.22e-09	3.2e-06	0.31	0.26	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
LUAD	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-5.87	8.22e-09	3.2e-06	-0.31	-0.26	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
LUAD	cis	rs2562456	0.917	rs2650825	ENSG00000268081.1	RP11-678G14.2	5.87	8.22e-09	3.2e-06	0.41	0.26	Pain;	chr19:21516423	chr19:21554640~21569237:-
LUAD	cis	rs10129255	1	rs11627342	ENSG00000224373.3	IGHV4-59	5.87	8.22e-09	3.2e-06	0.17	0.26	Kawasaki disease;	chr14:106675823	chr14:106627249~106627825:-
LUAD	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	5.87	8.22e-09	3.2e-06	0.29	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
LUAD	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	5.87	8.23e-09	3.2e-06	0.29	0.26	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
LUAD	cis	rs35740288	0.77	rs11630112	ENSG00000202081.1	RNU6-1280P	5.87	8.23e-09	3.21e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85577015	chr15:85651522~85651628:-
LUAD	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
LUAD	cis	rs496547	0.654	rs688161	ENSG00000255422.1	AP002954.4	-5.87	8.24e-09	3.21e-06	-0.33	-0.26	Hip minimal joint space width;	chr11:118807001	chr11:118704607~118750263:+
LUAD	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
LUAD	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	5.87	8.25e-09	3.21e-06	0.4	0.26	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
LUAD	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	5.87	8.26e-09	3.21e-06	0.34	0.26	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	5.87	8.26e-09	3.21e-06	0.34	0.26	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	5.87	8.26e-09	3.21e-06	0.34	0.26	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
LUAD	cis	rs2243480	0.522	rs73150635	ENSG00000273142.1	RP11-458F8.4	-5.87	8.27e-09	3.22e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66507503	chr7:66902857~66906297:+
LUAD	cis	rs2115630	0.645	rs4842978	ENSG00000229212.6	RP11-561C5.4	5.87	8.27e-09	3.22e-06	0.31	0.26	P wave terminal force;	chr15:84654022	chr15:85205440~85234795:-
LUAD	cis	rs4908760	0.931	rs1463049	ENSG00000232912.4	RP5-1115A15.1	5.87	8.28e-09	3.22e-06	0.24	0.26	Vitiligo;	chr1:8537049	chr1:8424645~8434838:+
LUAD	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	5.87	8.29e-09	3.23e-06	0.28	0.26	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
LUAD	cis	rs1876905	0.569	rs354523	ENSG00000272356.1	RP5-1112D6.8	-5.87	8.3e-09	3.23e-06	-0.28	-0.26	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111309203~111313517:+
LUAD	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-5.87	8.32e-09	3.24e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
LUAD	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-5.87	8.32e-09	3.24e-06	-0.32	-0.26	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
LUAD	cis	rs2998286	0.541	rs332180	ENSG00000254635.4	WAC-AS1	-5.87	8.32e-09	3.24e-06	-0.38	-0.26	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621166	chr10:28522652~28532743:-
LUAD	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-5.87	8.32e-09	3.24e-06	-0.38	-0.26	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-5.87	8.32e-09	3.24e-06	-0.38	-0.26	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
LUAD	cis	rs1707322	0.789	rs10789473	ENSG00000234329.1	RP11-767N6.2	5.87	8.33e-09	3.24e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45651039~45651826:-
LUAD	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	5.87	8.34e-09	3.24e-06	0.29	0.26	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000211974.3	IGHV2-70	-5.87	8.35e-09	3.25e-06	-0.26	-0.26	Kawasaki disease;	chr14:106779223	chr14:106723574~106724093:-
LUAD	cis	rs853679	1	rs853685	ENSG00000204709.4	LINC01556	5.87	8.35e-09	3.25e-06	0.4	0.26	Depression;	chr6:28321008	chr6:28943877~28944537:+
LUAD	cis	rs5753618	0.561	rs4603880	ENSG00000236132.1	CTA-440B3.1	-5.87	8.35e-09	3.25e-06	-0.32	-0.26	Colorectal cancer;	chr22:31348735	chr22:31816379~31817491:-
LUAD	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-5.87	8.35e-09	3.25e-06	-0.37	-0.26	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
LUAD	cis	rs3095008	0.603	rs2190434	ENSG00000243004.4	AC005062.2	5.87	8.36e-09	3.25e-06	0.29	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);	chr7:20212410	chr7:19918981~20140453:-
LUAD	cis	rs2946504	0.861	rs2946494	ENSG00000251468.2	RP11-369K16.1	-5.87	8.36e-09	3.25e-06	-0.34	-0.26	Type 2 diabetes;	chr8:12962601	chr8:12958387~12962200:+
LUAD	cis	rs62229266	0.771	rs7280136	ENSG00000214914.3	RPL23AP3	-5.86	8.36e-09	3.25e-06	-0.32	-0.26	Mitral valve prolapse;	chr21:36060612	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	5.86	8.36e-09	3.25e-06	0.32	0.26	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	5.86	8.36e-09	3.25e-06	0.32	0.26	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
LUAD	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
LUAD	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-5.86	8.38e-09	3.26e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
LUAD	cis	rs2243480	1	rs2961102	ENSG00000230295.1	RP11-458F8.2	-5.86	8.38e-09	3.26e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65959671	chr7:66880708~66882981:+
LUAD	cis	rs2404602	0.669	rs1875885	ENSG00000259422.1	RP11-593F23.1	5.86	8.39e-09	3.26e-06	0.3	0.26	Blood metabolite levels;	chr15:76345740	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.669	rs1875884	ENSG00000259422.1	RP11-593F23.1	5.86	8.39e-09	3.26e-06	0.3	0.26	Blood metabolite levels;	chr15:76345820	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-5.86	8.4e-09	3.27e-06	-0.33	-0.26	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
LUAD	cis	rs848490	0.656	rs55714086	ENSG00000214293.7	APTR	5.86	8.41e-09	3.27e-06	0.29	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77807168	chr7:77657660~77696265:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000230295.1	RP11-458F8.2	-5.86	8.41e-09	3.27e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66357373	chr7:66880708~66882981:+
LUAD	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	5.86	8.42e-09	3.27e-06	0.32	0.26	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
LUAD	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-5.86	8.42e-09	3.27e-06	-0.3	-0.26	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
LUAD	cis	rs7618501	0.573	rs7634917	ENSG00000234667.1	ACTBP13	5.86	8.42e-09	3.27e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50011866	chr3:49873347~49877980:-
LUAD	cis	rs12291225	0.535	rs11023203	ENSG00000251991.1	RNU7-49P	5.86	8.42e-09	3.27e-06	0.29	0.26	Sense of smell;	chr11:14388269	chr11:14478892~14478953:+
LUAD	cis	rs293748	0.571	rs13184464	ENSG00000250155.1	CTD-2353F22.1	-5.86	8.42e-09	3.27e-06	-0.33	-0.26	Obesity-related traits;	chr5:37191983	chr5:36666214~36725195:-
LUAD	cis	rs9326248	0.569	rs4938315	ENSG00000280143.1	AP000892.6	5.86	8.43e-09	3.28e-06	0.39	0.26	Blood protein levels;	chr11:116860489	chr11:117204967~117210292:+
LUAD	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-5.86	8.43e-09	3.28e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-5.86	8.46e-09	3.29e-06	-0.28	-0.26	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000211974.3	IGHV2-70	-5.86	8.48e-09	3.29e-06	-0.27	-0.26	Kawasaki disease;	chr14:106769752	chr14:106723574~106724093:-
LUAD	cis	rs1930961	0.558	rs12160908	ENSG00000272977.1	CTA-390C10.10	-5.86	8.48e-09	3.3e-06	-0.38	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25476218~25479971:+
LUAD	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-5.86	8.49e-09	3.3e-06	-0.48	-0.26	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
LUAD	cis	rs1823913	0.927	rs13025919	ENSG00000230611.1	HMGB1P27	-5.86	8.49e-09	3.3e-06	-0.32	-0.26	Obesity-related traits;	chr2:191260175	chr2:191174233~191174835:+
LUAD	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-5.86	8.5e-09	3.3e-06	-0.38	-0.26	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-5.86	8.5e-09	3.3e-06	-0.38	-0.26	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-5.86	8.5e-09	3.3e-06	-0.38	-0.26	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
LUAD	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-5.86	8.5e-09	3.3e-06	-0.23	-0.26	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
LUAD	cis	rs10214930	0.697	rs6974932	ENSG00000235574.1	AC073150.6	5.86	8.5e-09	3.3e-06	0.33	0.26	Hypospadias;	chr7:27657211	chr7:27491682~27492765:-
LUAD	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	5.86	8.51e-09	3.3e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	5.86	8.51e-09	3.3e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	5.86	8.51e-09	3.3e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.669	rs9596218	ENSG00000212293.1	SNORA16	5.86	8.52e-09	3.31e-06	0.28	0.26	Body mass index;	chr13:32764222	chr13:32420390~32420516:-
LUAD	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	5.86	8.53e-09	3.31e-06	0.36	0.26	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
LUAD	cis	rs4767841	0.552	rs12827937	ENSG00000248636.5	RP11-768F21.1	-5.86	8.54e-09	3.31e-06	-0.3	-0.26	Urgency urinary incontinence;	chr12:119612444	chr12:119387987~119668079:-
LUAD	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-5.86	8.55e-09	3.32e-06	-0.32	-0.26	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
LUAD	cis	rs4713118	0.824	rs9468225	ENSG00000219392.1	RP1-265C24.5	-5.86	8.55e-09	3.32e-06	-0.34	-0.26	Parkinson's disease;	chr6:27777940	chr6:28115628~28116551:+
LUAD	cis	rs4908768	0.501	rs11121199	ENSG00000232912.4	RP5-1115A15.1	5.86	8.56e-09	3.32e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8424645~8434838:+
LUAD	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-5.86	8.56e-09	3.32e-06	-0.35	-0.26	Depression;	chr6:28226851	chr6:28115628~28116551:+
LUAD	cis	rs9595908	0.832	rs9315172	ENSG00000212293.1	SNORA16	5.86	8.56e-09	3.32e-06	0.28	0.26	Body mass index;	chr13:32634035	chr13:32420390~32420516:-
LUAD	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-5.86	8.56e-09	3.32e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
LUAD	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	5.86	8.57e-09	3.33e-06	0.36	0.26	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
LUAD	cis	rs55665837	0.701	rs2007361	ENSG00000251991.1	RNU7-49P	5.86	8.59e-09	3.33e-06	0.31	0.26	Vitamin D levels;	chr11:14641176	chr11:14478892~14478953:+
LUAD	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-5.86	8.6e-09	3.34e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
LUAD	cis	rs2115536	1	rs7163338	ENSG00000278600.1	RP11-81A1.6	-5.86	8.6e-09	3.34e-06	-0.21	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79906066	chr15:79920195~79922455:-
LUAD	cis	rs12291225	0.535	rs10832248	ENSG00000251991.1	RNU7-49P	5.86	8.6e-09	3.34e-06	0.29	0.26	Sense of smell;	chr11:14391541	chr11:14478892~14478953:+
LUAD	cis	rs1707322	0.827	rs6683274	ENSG00000234329.1	RP11-767N6.2	5.86	8.61e-09	3.34e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45651039~45651826:-
LUAD	cis	rs11742741	0.539	rs12153459	ENSG00000248874.4	C5orf17	-5.86	8.62e-09	3.35e-06	-0.32	-0.26	Educational attainment;	chr5:24105812	chr5:23951348~24178263:+
LUAD	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	5.86	8.62e-09	3.35e-06	0.31	0.26	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
LUAD	cis	rs172166	0.694	rs188105	ENSG00000204709.4	LINC01556	5.86	8.62e-09	3.35e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28103615	chr6:28943877~28944537:+
LUAD	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	5.86	8.63e-09	3.35e-06	0.32	0.26	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	5.86	8.63e-09	3.35e-06	0.29	0.26	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
LUAD	cis	rs7618501	0.633	rs7621026	ENSG00000234667.1	ACTBP13	-5.86	8.64e-09	3.35e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49937901	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs3774733	ENSG00000234667.1	ACTBP13	-5.86	8.65e-09	3.35e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49999690	chr3:49873347~49877980:-
LUAD	cis	rs9928842	0.823	rs8061356	ENSG00000280152.1	RP11-331F4.5	5.86	8.65e-09	3.36e-06	0.28	0.26	Alcoholic chronic pancreatitis;	chr16:75260334	chr16:75245994~75250077:-
LUAD	cis	rs4908768	0.501	rs2016084	ENSG00000232912.4	RP5-1115A15.1	5.86	8.66e-09	3.36e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8424645~8434838:+
LUAD	cis	rs7246657	0.722	rs2909105	ENSG00000276846.1	CTD-3220F14.3	-5.86	8.68e-09	3.37e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37677005	chr19:37314868~37315620:-
LUAD	cis	rs2153535	1	rs11243251	ENSG00000230939.1	RP11-314C16.1	5.86	8.69e-09	3.37e-06	0.29	0.26	Motion sickness;	chr6:8367974	chr6:8784178~8785445:+
LUAD	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	5.86	8.7e-09	3.37e-06	0.45	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
LUAD	cis	rs17818399	0.781	rs12105006	ENSG00000279254.1	RP11-536C12.1	5.86	8.7e-09	3.38e-06	0.29	0.26	Height;	chr2:46635447	chr2:46668870~46670778:+
LUAD	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	5.86	8.71e-09	3.38e-06	0.29	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
LUAD	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-5.86	8.72e-09	3.38e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
LUAD	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	5.86	8.72e-09	3.38e-06	0.36	0.26	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
LUAD	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-5.86	8.72e-09	3.38e-06	-0.32	-0.26	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
LUAD	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-5.86	8.73e-09	3.39e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-5.86	8.73e-09	3.39e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-5.86	8.73e-09	3.39e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
LUAD	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	5.86	8.75e-09	3.39e-06	0.29	0.26	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
LUAD	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	5.86	8.75e-09	3.39e-06	0.49	0.26	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
LUAD	cis	rs10214930	0.813	rs2391447	ENSG00000235574.1	AC073150.6	-5.86	8.75e-09	3.39e-06	-0.34	-0.26	Hypospadias;	chr7:27634945	chr7:27491682~27492765:-
LUAD	cis	rs36093844	0.898	rs12361800	ENSG00000279742.1	RP11-700A24.1	-5.86	8.76e-09	3.39e-06	-0.3	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85854821	chr11:85852557~85854943:-
LUAD	cis	rs2288884	1	rs58817690	ENSG00000275055.1	CTC-471J1.11	-5.86	8.76e-09	3.4e-06	-0.4	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52033439	chr19:52049007~52049754:+
LUAD	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	5.86	8.76e-09	3.4e-06	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
LUAD	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	5.86	8.79e-09	3.41e-06	0.32	0.26	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
LUAD	cis	rs2243480	1	rs410128	ENSG00000230295.1	RP11-458F8.2	-5.86	8.79e-09	3.41e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66138186	chr7:66880708~66882981:+
LUAD	cis	rs6772849	0.93	rs7639400	ENSG00000242551.2	POU5F1P6	-5.86	8.8e-09	3.41e-06	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128604513	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-5.86	8.8e-09	3.41e-06	-0.37	-0.26	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
LUAD	cis	rs6991838	0.806	rs17302392	ENSG00000200714.1	Y_RNA	5.86	8.8e-09	3.41e-06	0.3	0.26	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65592731~65592820:+
LUAD	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-5.86	8.81e-09	3.41e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
LUAD	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-5.86	8.82e-09	3.42e-06	-0.31	-0.26	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
LUAD	cis	rs7176527	0.519	rs12148368	ENSG00000230373.7	GOLGA6L5P	5.86	8.82e-09	3.42e-06	0.27	0.26	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84507885~84516814:-
LUAD	cis	rs1876905	0.597	rs354551	ENSG00000272356.1	RP5-1112D6.8	-5.86	8.83e-09	3.42e-06	-0.29	-0.26	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111309203~111313517:+
LUAD	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-5.85	8.85e-09	3.43e-06	-0.32	-0.26	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
LUAD	cis	rs12468226	0.938	rs77062060	ENSG00000272966.1	RP11-686O6.1	5.85	8.86e-09	3.43e-06	0.45	0.26	Urate levels;	chr2:202285639	chr2:202336739~202337200:+
LUAD	cis	rs10740039	0.516	rs7088259	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559094	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs2393646	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559676	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs2068042	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60560535	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs10740032	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60562627	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs958852	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60562860	chr10:60734342~60741828:+
LUAD	cis	rs755249	0.567	rs41270807	ENSG00000228060.1	RP11-69E11.8	-5.85	8.86e-09	3.43e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39565160~39573203:+
LUAD	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	5.85	8.87e-09	3.43e-06	0.33	0.26	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
LUAD	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-5.85	8.87e-09	3.43e-06	-0.36	-0.26	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000230295.1	RP11-458F8.2	-5.85	8.87e-09	3.43e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65946971	chr7:66880708~66882981:+
LUAD	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	5.85	8.87e-09	3.43e-06	0.3	0.26	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
LUAD	cis	rs62229266	0.557	rs4817760	ENSG00000214914.3	RPL23AP3	5.85	8.88e-09	3.44e-06	0.32	0.26	Mitral valve prolapse;	chr21:36023003	chr21:36016079~36016546:-
LUAD	cis	rs12468226	0.873	rs60722019	ENSG00000272966.1	RP11-686O6.1	5.85	8.89e-09	3.44e-06	0.45	0.26	Urate levels;	chr2:202282060	chr2:202336739~202337200:+
LUAD	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	5.85	8.89e-09	3.44e-06	0.33	0.26	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000211967.3	IGHV3-53	-5.85	8.89e-09	3.44e-06	-0.18	-0.26	Kawasaki disease;	chr14:106682022	chr14:106592676~106593347:-
LUAD	cis	rs2404602	0.583	rs12913096	ENSG00000259422.1	RP11-593F23.1	5.85	8.9e-09	3.44e-06	0.29	0.26	Blood metabolite levels;	chr15:76259511	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.632	rs949451	ENSG00000279048.1	RP11-511H23.2	-5.85	8.9e-09	3.45e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17818931	chr7:17940503~17942922:+
LUAD	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	5.85	8.92e-09	3.45e-06	0.38	0.26	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
LUAD	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	5.85	8.92e-09	3.45e-06	0.27	0.26	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
LUAD	cis	rs4803480	0.935	rs9304595	ENSG00000270164.1	LINC01480	5.85	8.93e-09	3.46e-06	0.25	0.26	Schizophrenia;	chr19:41571639	chr19:41535183~41536904:+
LUAD	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	5.85	8.93e-09	3.46e-06	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
LUAD	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	5.85	8.93e-09	3.46e-06	0.33	0.26	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
LUAD	cis	rs9506514	0.722	rs11147813	ENSG00000222726.1	RNU2-7P	5.85	8.94e-09	3.46e-06	0.3	0.26	Coronary artery calcification;	chr13:20684419	chr13:20612161~20612338:+
LUAD	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	5.85	8.94e-09	3.46e-06	0.4	0.26	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
LUAD	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-5.85	8.97e-09	3.47e-06	-0.31	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
LUAD	cis	rs11157436	0.871	rs8003190	ENSG00000211812.1	TRAV26-2	-5.85	8.97e-09	3.47e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22202583~22203368:+
LUAD	cis	rs7246657	0.722	rs2909098	ENSG00000276846.1	CTD-3220F14.3	-5.85	8.98e-09	3.47e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37713347	chr19:37314868~37315620:-
LUAD	cis	rs9311474	1	rs7614727	ENSG00000243224.1	RP5-1157M23.2	-5.85	8.98e-09	3.47e-06	-0.26	-0.26	Electroencephalogram traits;	chr3:52261879	chr3:52239258~52241097:+
LUAD	cis	rs748404	0.55	rs12912505	ENSG00000205771.5	CATSPER2P1	-5.85	8.99e-09	3.48e-06	-0.4	-0.26	Lung cancer;	chr15:43525206	chr15:43726918~43747094:-
LUAD	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
LUAD	cis	rs10214930	0.697	rs12670415	ENSG00000235574.1	AC073150.6	-5.85	9.01e-09	3.48e-06	-0.32	-0.26	Hypospadias;	chr7:27562604	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.624	rs6959126	ENSG00000235574.1	AC073150.6	-5.85	9.01e-09	3.48e-06	-0.32	-0.26	Hypospadias;	chr7:27564631	chr7:27491682~27492765:-
LUAD	cis	rs4908760	0.965	rs12080583	ENSG00000232912.4	RP5-1115A15.1	5.85	9.02e-09	3.49e-06	0.24	0.26	Vitiligo;	chr1:8464817	chr1:8424645~8434838:+
LUAD	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	5.85	9.03e-09	3.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
LUAD	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	5.85	9.04e-09	3.49e-06	0.32	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
LUAD	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-5.85	9.06e-09	3.5e-06	-0.33	-0.26	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
LUAD	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-5.85	9.06e-09	3.5e-06	-0.23	-0.26	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs2243480	ENSG00000230295.1	RP11-458F8.2	-5.85	9.07e-09	3.5e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66134209	chr7:66880708~66882981:+
LUAD	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-5.85	9.07e-09	3.5e-06	-0.29	-0.26	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
LUAD	cis	rs35740288	0.77	rs11630968	ENSG00000202081.1	RNU6-1280P	5.85	9.07e-09	3.5e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85574770	chr15:85651522~85651628:-
LUAD	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	5.85	9.07e-09	3.5e-06	0.32	0.26	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
LUAD	cis	rs293748	0.771	rs292179	ENSG00000250155.1	CTD-2353F22.1	-5.85	9.07e-09	3.51e-06	-0.36	-0.26	Obesity-related traits;	chr5:36947511	chr5:36666214~36725195:-
LUAD	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	5.85	9.08e-09	3.51e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000224373.3	IGHV4-59	5.85	9.08e-09	3.51e-06	0.17	0.26	Kawasaki disease;	chr14:106803901	chr14:106627249~106627825:-
LUAD	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-5.85	9.09e-09	3.51e-06	-0.28	-0.26	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
LUAD	cis	rs853679	0.517	rs1904841	ENSG00000204709.4	LINC01556	5.85	9.09e-09	3.51e-06	0.37	0.26	Depression;	chr6:28140307	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs1904840	ENSG00000204709.4	LINC01556	5.85	9.09e-09	3.51e-06	0.37	0.26	Depression;	chr6:28140454	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368555	ENSG00000204709.4	LINC01556	5.85	9.09e-09	3.51e-06	0.37	0.26	Depression;	chr6:28141189	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	5.85	9.09e-09	3.51e-06	0.29	0.26	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
LUAD	cis	rs9595908	0.709	rs7327412	ENSG00000212293.1	SNORA16	-5.85	9.09e-09	3.51e-06	-0.27	-0.26	Body mass index;	chr13:32774430	chr13:32420390~32420516:-
LUAD	cis	rs1823913	0.66	rs1454752	ENSG00000280083.1	RP11-317J9.1	5.85	9.11e-09	3.52e-06	0.31	0.26	Obesity-related traits;	chr2:191298668	chr2:191154118~191156070:-
LUAD	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-5.85	9.11e-09	3.52e-06	-0.39	-0.26	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
LUAD	cis	rs73219805	1	rs1042992	ENSG00000228451.3	SDAD1P1	5.85	9.12e-09	3.52e-06	0.38	0.26	Schizophrenia;	chr8:26411675	chr8:26379259~26382953:-
LUAD	cis	rs720064	0.555	rs9956312	ENSG00000264745.1	TTC39C-AS1	5.85	9.12e-09	3.52e-06	0.27	0.26	Strep throat;	chr18:23969713	chr18:23994213~24015339:-
LUAD	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	5.85	9.13e-09	3.52e-06	0.29	0.26	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
LUAD	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	5.85	9.13e-09	3.53e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
LUAD	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.13e-09	3.53e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
LUAD	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	5.85	9.14e-09	3.53e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000224373.3	IGHV4-59	5.85	9.15e-09	3.53e-06	0.17	0.26	Kawasaki disease;	chr14:106777278	chr14:106627249~106627825:-
LUAD	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	5.85	9.15e-09	3.53e-06	0.29	0.26	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
LUAD	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	5.85	9.16e-09	3.54e-06	0.31	0.26	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
LUAD	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	5.85	9.16e-09	3.54e-06	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
LUAD	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	5.85	9.17e-09	3.54e-06	0.34	0.26	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
LUAD	cis	rs4908760	0.899	rs61783642	ENSG00000232912.4	RP5-1115A15.1	5.85	9.17e-09	3.54e-06	0.24	0.26	Vitiligo;	chr1:8531338	chr1:8424645~8434838:+
LUAD	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-5.85	9.18e-09	3.55e-06	-0.32	-0.26	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
LUAD	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	5.85	9.19e-09	3.55e-06	0.38	0.26	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs316330	ENSG00000230295.1	RP11-458F8.2	-5.85	9.19e-09	3.55e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66140385	chr7:66880708~66882981:+
LUAD	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-5.85	9.2e-09	3.55e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
LUAD	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-5.85	9.2e-09	3.55e-06	-0.28	-0.26	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	5.85	9.21e-09	3.55e-06	0.29	0.26	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-5.85	9.21e-09	3.55e-06	-0.29	-0.26	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-5.85	9.21e-09	3.55e-06	-0.29	-0.26	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
LUAD	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	5.85	9.21e-09	3.56e-06	0.29	0.26	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
LUAD	cis	rs6504622	1	rs4968285	ENSG00000262879.4	RP11-156P1.3	-5.85	9.24e-09	3.56e-06	-0.29	-0.26	Orofacial clefts;	chr17:46938266	chr17:46984045~47100323:-
LUAD	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-5.85	9.24e-09	3.57e-06	-0.44	-0.26	Depression;	chr6:28223052	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-5.85	9.24e-09	3.57e-06	-0.44	-0.26	Depression;	chr6:28223279	chr6:28115628~28116551:+
LUAD	cis	rs9353324	1	rs7745560	ENSG00000203875.9	SNHG5	5.85	9.27e-09	3.58e-06	0.52	0.26	Interferon gamma-induced protein 10 levels;	chr6:85579203	chr6:85660950~85678736:-
LUAD	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-5.85	9.27e-09	3.58e-06	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
LUAD	cis	rs8177876	0.749	rs1035541	ENSG00000261061.1	RP11-303E16.2	-5.85	9.27e-09	3.58e-06	-0.45	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81030770~81031485:+
LUAD	cis	rs948562	0.569	rs74810062	ENSG00000280010.1	AP001350.4	5.85	9.27e-09	3.58e-06	0.42	0.26	Lymphoma;	chr11:58446218	chr11:58627435~58628528:+
LUAD	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-5.85	9.28e-09	3.58e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
LUAD	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	5.85	9.28e-09	3.58e-06	0.47	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	5.85	9.28e-09	3.58e-06	0.47	0.26	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
LUAD	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	5.85	9.28e-09	3.58e-06	0.35	0.26	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
LUAD	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-5.85	9.29e-09	3.58e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
LUAD	cis	rs4908760	0.965	rs7542312	ENSG00000232912.4	RP5-1115A15.1	5.85	9.3e-09	3.59e-06	0.24	0.26	Vitiligo;	chr1:8513412	chr1:8424645~8434838:+
LUAD	cis	rs62246343	0.786	rs11547584	ENSG00000254485.4	RP11-380O24.1	5.85	9.3e-09	3.59e-06	0.37	0.26	Fibrinogen levels;	chr3:9365020	chr3:9292588~9363303:-
LUAD	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-5.85	9.31e-09	3.59e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
LUAD	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	5.85	9.31e-09	3.59e-06	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
LUAD	cis	rs1823913	0.927	rs35339956	ENSG00000230611.1	HMGB1P27	-5.85	9.32e-09	3.59e-06	-0.32	-0.26	Obesity-related traits;	chr2:191261668	chr2:191174233~191174835:+
LUAD	cis	rs755249	0.567	rs16826069	ENSG00000228060.1	RP11-69E11.8	-5.85	9.33e-09	3.6e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39565160~39573203:+
LUAD	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	5.85	9.33e-09	3.6e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
LUAD	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	5.85	9.34e-09	3.6e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
LUAD	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-5.85	9.34e-09	3.6e-06	-0.32	-0.26	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
LUAD	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	5.84	9.36e-09	3.61e-06	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
LUAD	cis	rs1823913	0.614	rs6434459	ENSG00000280083.1	RP11-317J9.1	5.84	9.36e-09	3.61e-06	0.31	0.26	Obesity-related traits;	chr2:191300886	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.592	rs7588555	ENSG00000280083.1	RP11-317J9.1	5.84	9.36e-09	3.61e-06	0.31	0.26	Obesity-related traits;	chr2:191300912	chr2:191154118~191156070:-
LUAD	cis	rs853679	0.517	rs9393893	ENSG00000204709.4	LINC01556	5.84	9.36e-09	3.61e-06	0.37	0.26	Depression;	chr6:28141484	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.501	rs12061328	ENSG00000232912.4	RP5-1115A15.1	5.84	9.36e-09	3.61e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8424645~8434838:+
LUAD	cis	rs4604732	0.631	rs4436425	ENSG00000227135.1	GCSAML-AS1	-5.84	9.37e-09	3.61e-06	-0.39	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469021	chr1:247524679~247526752:-
LUAD	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	5.84	9.37e-09	3.61e-06	0.52	0.26	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
LUAD	cis	rs12699921	0.599	rs4721665	ENSG00000279048.1	RP11-511H23.2	-5.84	9.38e-09	3.61e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17876696	chr7:17940503~17942922:+
LUAD	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	5.84	9.38e-09	3.61e-06	0.32	0.26	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
LUAD	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-5.84	9.38e-09	3.61e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
LUAD	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	5.84	9.38e-09	3.61e-06	0.37	0.26	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	5.84	9.38e-09	3.61e-06	0.37	0.26	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
LUAD	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-5.84	9.38e-09	3.62e-06	-0.31	-0.26	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
LUAD	cis	rs516805	0.748	rs510471	ENSG00000279453.1	RP3-425C14.4	-5.84	9.38e-09	3.62e-06	-0.34	-0.26	Lymphocyte counts;	chr6:122391714	chr6:122436789~122439223:-
LUAD	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	5.84	9.39e-09	3.62e-06	0.27	0.26	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
LUAD	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	5.84	9.39e-09	3.62e-06	0.35	0.26	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
LUAD	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	5.84	9.4e-09	3.62e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
LUAD	cis	rs17301013	0.507	rs3118988	ENSG00000227373.4	RP11-160H22.5	-5.84	9.41e-09	3.63e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174819245	chr1:174115300~174160004:-
LUAD	cis	rs7208859	0.573	rs79505916	ENSG00000263603.1	CTD-2349P21.5	-5.84	9.43e-09	3.63e-06	-0.46	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30729469~30731202:+
LUAD	cis	rs7181230	0.885	rs4497657	ENSG00000275636.1	RP11-521C20.5	5.84	9.43e-09	3.63e-06	0.34	0.26	Dehydroepiandrosterone sulphate levels;	chr15:40067232	chr15:40078892~40079347:+
LUAD	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	5.84	9.44e-09	3.64e-06	0.37	0.26	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
LUAD	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-5.84	9.44e-09	3.64e-06	-0.31	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
LUAD	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-5.84	9.44e-09	3.64e-06	-0.35	-0.26	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
LUAD	cis	rs4713118	0.662	rs149901	ENSG00000204709.4	LINC01556	5.84	9.44e-09	3.64e-06	0.35	0.26	Parkinson's disease;	chr6:27997725	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	5.84	9.44e-09	3.64e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
LUAD	cis	rs12468226	0.938	rs3731700	ENSG00000272966.1	RP11-686O6.1	5.84	9.45e-09	3.64e-06	0.45	0.26	Urate levels;	chr2:202291213	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs12471060	ENSG00000272966.1	RP11-686O6.1	5.84	9.45e-09	3.64e-06	0.45	0.26	Urate levels;	chr2:202309597	chr2:202336739~202337200:+
LUAD	cis	rs8177876	0.658	rs2278022	ENSG00000261061.1	RP11-303E16.2	-5.84	9.45e-09	3.64e-06	-0.45	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81030770~81031485:+
LUAD	cis	rs2911132	0.967	rs2042380	ENSG00000248734.2	CTD-2260A17.1	5.84	9.45e-09	3.64e-06	0.26	0.26	Urate levels (BMI interaction);	chr5:96851563	chr5:96784777~96785999:+
LUAD	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-5.84	9.46e-09	3.64e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
LUAD	cis	rs2898681	0.618	rs116241740	ENSG00000248375.1	RP11-177B4.1	-5.84	9.46e-09	3.64e-06	-0.47	-0.26	Optic nerve measurement (cup area);	chr4:52867356	chr4:52720081~52720831:-
LUAD	cis	rs748404	0.666	rs12905220	ENSG00000205771.5	CATSPER2P1	-5.84	9.48e-09	3.65e-06	-0.39	-0.26	Lung cancer;	chr15:43465641	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.55	rs1233701	ENSG00000204709.4	LINC01556	-5.84	9.48e-09	3.65e-06	-0.35	-0.26	Depression;	chr6:28200948	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.539	rs1809332	ENSG00000232912.4	RP5-1115A15.1	5.84	9.49e-09	3.65e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8424645~8434838:+
LUAD	cis	rs7246657	0.722	rs2972458	ENSG00000276846.1	CTD-3220F14.3	-5.84	9.5e-09	3.66e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37644502	chr19:37314868~37315620:-
LUAD	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	5.84	9.5e-09	3.66e-06	0.37	0.26	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
LUAD	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-5.84	9.51e-09	3.66e-06	-0.21	-0.26	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
LUAD	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	5.84	9.51e-09	3.66e-06	0.33	0.26	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
LUAD	cis	rs12468226	0.938	rs80315897	ENSG00000272966.1	RP11-686O6.1	5.84	9.51e-09	3.66e-06	0.45	0.26	Urate levels;	chr2:202318044	chr2:202336739~202337200:+
LUAD	cis	rs9595908	0.709	rs9591311	ENSG00000212293.1	SNORA16	5.84	9.52e-09	3.66e-06	0.27	0.26	Body mass index;	chr13:32757339	chr13:32420390~32420516:-
LUAD	cis	rs10214930	0.697	rs2041714	ENSG00000235574.1	AC073150.6	-5.84	9.53e-09	3.67e-06	-0.32	-0.26	Hypospadias;	chr7:27559228	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12700819	ENSG00000235574.1	AC073150.6	-5.84	9.53e-09	3.67e-06	-0.32	-0.26	Hypospadias;	chr7:27560271	chr7:27491682~27492765:-
LUAD	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	5.84	9.54e-09	3.67e-06	0.28	0.26	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
LUAD	cis	rs12699921	0.565	rs2714876	ENSG00000279048.1	RP11-511H23.2	-5.84	9.54e-09	3.67e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17887983	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2714877	ENSG00000279048.1	RP11-511H23.2	-5.84	9.54e-09	3.67e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17888027	chr7:17940503~17942922:+
LUAD	cis	rs2255336	0.938	rs9651850	ENSG00000245648.1	RP11-277P12.20	-5.84	9.55e-09	3.67e-06	-0.41	-0.26	Blood protein levels;	chr12:10490533	chr12:10363769~10398506:+
LUAD	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	5.84	9.55e-09	3.68e-06	0.36	0.26	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000230295.1	RP11-458F8.2	-5.84	9.55e-09	3.68e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66359432	chr7:66880708~66882981:+
LUAD	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	5.84	9.56e-09	3.68e-06	0.52	0.26	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
LUAD	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	5.84	9.57e-09	3.68e-06	0.31	0.26	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
LUAD	cis	rs7044106	0.718	rs1981021	ENSG00000238181.2	AHCYP2	-5.84	9.57e-09	3.68e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.734	rs1981020	ENSG00000238181.2	AHCYP2	-5.84	9.57e-09	3.68e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120720673~120721972:+
LUAD	cis	rs7115242	0.92	rs6589574	ENSG00000280143.1	AP000892.6	5.84	9.57e-09	3.68e-06	0.46	0.26	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117204967~117210292:+
LUAD	cis	rs516805	0.667	rs2606608	ENSG00000279453.1	RP3-425C14.4	-5.84	9.57e-09	3.68e-06	-0.35	-0.26	Lymphocyte counts;	chr6:122195051	chr6:122436789~122439223:-
LUAD	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-5.84	9.58e-09	3.68e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
LUAD	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-5.84	9.59e-09	3.69e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-5.84	9.6e-09	3.69e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-5.84	9.6e-09	3.69e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-5.84	9.6e-09	3.69e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
LUAD	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	5.84	9.61e-09	3.7e-06	0.4	0.26	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
LUAD	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-5.84	9.61e-09	3.7e-06	-0.31	-0.26	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
LUAD	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
LUAD	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-5.84	9.63e-09	3.7e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-5.84	9.63e-09	3.7e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-5.84	9.63e-09	3.7e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
LUAD	cis	rs4947019	0.534	rs75527655	ENSG00000260273.1	RP11-425D10.10	5.84	9.63e-09	3.7e-06	0.57	0.26	Hematological parameters;	chr6:109392693	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000211967.3	IGHV3-53	-5.84	9.64e-09	3.7e-06	-0.18	-0.26	Kawasaki disease;	chr14:106681273	chr14:106592676~106593347:-
LUAD	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-5.84	9.64e-09	3.71e-06	-0.31	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
LUAD	cis	rs2734839	0.964	rs4938017	ENSG00000270179.1	RP11-159N11.4	5.84	9.65e-09	3.71e-06	0.27	0.26	Information processing speed;	chr11:113433207	chr11:113368478~113369117:+
LUAD	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	5.84	9.65e-09	3.71e-06	0.32	0.26	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
LUAD	cis	rs1707322	0.686	rs3014242	ENSG00000234329.1	RP11-767N6.2	-5.84	9.66e-09	3.71e-06	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs3014239	ENSG00000234329.1	RP11-767N6.2	-5.84	9.66e-09	3.71e-06	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs3014236	ENSG00000234329.1	RP11-767N6.2	-5.84	9.66e-09	3.71e-06	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45651039~45651826:-
LUAD	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-5.84	9.67e-09	3.72e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
LUAD	cis	rs10214930	0.697	rs9639552	ENSG00000235574.1	AC073150.6	-5.84	9.68e-09	3.72e-06	-0.32	-0.26	Hypospadias;	chr7:27535904	chr7:27491682~27492765:-
LUAD	cis	rs944289	0.53	rs2755193	ENSG00000257826.1	RP11-116N8.4	5.84	9.68e-09	3.72e-06	0.27	0.26	Thyroid cancer;	chr14:36049416	chr14:36061026~36067190:-
LUAD	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-5.84	9.68e-09	3.72e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
LUAD	cis	rs755249	0.567	rs61783378	ENSG00000228060.1	RP11-69E11.8	-5.84	9.7e-09	3.73e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39565160~39573203:+
LUAD	cis	rs6921919	0.673	rs13201681	ENSG00000204709.4	LINC01556	5.84	9.71e-09	3.73e-06	0.58	0.26	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28943877~28944537:+
LUAD	cis	rs7618501	0.633	rs2526751	ENSG00000234667.1	ACTBP13	5.84	9.72e-09	3.73e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50027434	chr3:49873347~49877980:-
LUAD	cis	rs12468226	0.938	rs116601501	ENSG00000272966.1	RP11-686O6.1	5.84	9.72e-09	3.73e-06	0.45	0.26	Urate levels;	chr2:202274567	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs76658848	ENSG00000272966.1	RP11-686O6.1	5.84	9.72e-09	3.73e-06	0.45	0.26	Urate levels;	chr2:202275548	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs57571703	ENSG00000272966.1	RP11-686O6.1	5.84	9.72e-09	3.73e-06	0.45	0.26	Urate levels;	chr2:202281997	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs78928733	ENSG00000272966.1	RP11-686O6.1	5.84	9.72e-09	3.73e-06	0.45	0.26	Urate levels;	chr2:202283787	chr2:202336739~202337200:+
LUAD	cis	rs11742741	0.539	rs12152823	ENSG00000248874.4	C5orf17	-5.84	9.73e-09	3.74e-06	-0.32	-0.26	Educational attainment;	chr5:24105632	chr5:23951348~24178263:+
LUAD	cis	rs2255336	0.873	rs12301897	ENSG00000245648.1	RP11-277P12.20	-5.84	9.76e-09	3.75e-06	-0.41	-0.26	Blood protein levels;	chr12:10491974	chr12:10363769~10398506:+
LUAD	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-5.84	9.78e-09	3.75e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66370832	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66398480	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66407358	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66408105	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66418618	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66422670	chr7:66880708~66882981:+
LUAD	cis	rs853679	0.517	rs4711164	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28147378	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4711165	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28147406	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4713148	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28148143	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9348794	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28149979	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9468297	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28151096	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9295758	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28152885	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs17774663	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28153120	chr6:28943877~28944537:+
LUAD	cis	rs944289	0.53	rs2780308	ENSG00000257826.1	RP11-116N8.4	5.84	9.79e-09	3.76e-06	0.27	0.26	Thyroid cancer;	chr14:36050062	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.53	rs2780309	ENSG00000257826.1	RP11-116N8.4	5.84	9.79e-09	3.76e-06	0.27	0.26	Thyroid cancer;	chr14:36050646	chr14:36061026~36067190:-
LUAD	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-5.84	9.8e-09	3.76e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
LUAD	cis	rs8177876	0.749	rs10459872	ENSG00000261061.1	RP11-303E16.2	5.84	9.8e-09	3.76e-06	0.41	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81030770~81031485:+
LUAD	cis	rs9595908	0.63	rs4057297	ENSG00000212293.1	SNORA16	5.84	9.8e-09	3.76e-06	0.27	0.26	Body mass index;	chr13:32731612	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.63	rs1929939	ENSG00000212293.1	SNORA16	5.84	9.8e-09	3.76e-06	0.27	0.26	Body mass index;	chr13:32733547	chr13:32420390~32420516:-
LUAD	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	5.84	9.81e-09	3.77e-06	0.28	0.26	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.656	rs9429172	ENSG00000234329.1	RP11-767N6.2	-5.84	9.82e-09	3.77e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45651039~45651826:-
LUAD	cis	rs896854	0.624	rs9297949	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94957217	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs10429443	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94958936	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs896846	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94960225	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs896847	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94960323	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs13281625	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94960510	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.625	rs13281709	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94960591	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.625	rs4735335	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94961099	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs4735337	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94961237	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
LUAD	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	5.84	9.83e-09	3.77e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
LUAD	cis	rs61776719	0.738	rs7555461	ENSG00000212541.1	RNU6-510P	5.84	9.84e-09	3.77e-06	0.31	0.26	Coronary artery disease;	chr1:37979077	chr1:37991462~37991569:+
LUAD	cis	rs12468226	0.938	rs116109808	ENSG00000272966.1	RP11-686O6.1	5.84	9.85e-09	3.78e-06	0.45	0.26	Urate levels;	chr2:202287356	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.873	rs78175596	ENSG00000272966.1	RP11-686O6.1	5.84	9.85e-09	3.78e-06	0.45	0.26	Urate levels;	chr2:202287993	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs74454549	ENSG00000272966.1	RP11-686O6.1	5.84	9.85e-09	3.78e-06	0.45	0.26	Urate levels;	chr2:202288044	chr2:202336739~202337200:+
LUAD	cis	rs36093844	0.752	rs57534090	ENSG00000279742.1	RP11-700A24.1	-5.84	9.85e-09	3.78e-06	-0.34	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85861977	chr11:85852557~85854943:-
LUAD	cis	rs27434	0.821	rs28337	ENSG00000272109.1	CTD-2260A17.3	-5.84	9.85e-09	3.78e-06	-0.31	-0.26	Ankylosing spondylitis;	chr5:96789611	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.587	rs30185	ENSG00000272109.1	CTD-2260A17.3	-5.84	9.85e-09	3.78e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96789762	chr5:96804353~96806105:+
LUAD	cis	rs12468226	0.873	rs78798541	ENSG00000226261.1	AC064836.3	5.84	9.86e-09	3.78e-06	0.44	0.26	Urate levels;	chr2:202194708	chr2:202336024~202336727:-
LUAD	cis	rs1816752	0.935	rs3816219	ENSG00000273628.1	RP11-756A22.7	5.84	9.86e-09	3.78e-06	0.3	0.26	Obesity-related traits;	chr13:24442995	chr13:24933006~24936796:+
LUAD	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-5.84	9.86e-09	3.78e-06	-0.38	-0.26	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
LUAD	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-5.84	9.87e-09	3.78e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
LUAD	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-5.84	9.87e-09	3.78e-06	-0.32	-0.26	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
LUAD	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	5.84	9.88e-09	3.79e-06	0.38	0.26	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
LUAD	cis	rs62432291	0.681	rs431205	ENSG00000235086.1	FNDC1-IT1	-5.84	9.88e-09	3.79e-06	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159241467	chr6:159240786~159243329:+
LUAD	cis	rs4713118	0.513	rs1225591	ENSG00000204709.4	LINC01556	5.83	9.9e-09	3.8e-06	0.35	0.26	Parkinson's disease;	chr6:28180974	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.501	rs1463051	ENSG00000232912.4	RP5-1115A15.1	-5.83	9.93e-09	3.81e-06	-0.24	-0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8424645~8434838:+
LUAD	cis	rs944289	0.561	rs1169122	ENSG00000257826.1	RP11-116N8.4	-5.83	9.93e-09	3.81e-06	-0.28	-0.26	Thyroid cancer;	chr14:36148896	chr14:36061026~36067190:-
LUAD	cis	rs9652601	0.622	rs1003603	ENSG00000274038.1	RP11-66H6.4	-5.83	9.94e-09	3.81e-06	-0.3	-0.26	Systemic lupus erythematosus;	chr16:11020766	chr16:11056556~11057034:+
LUAD	cis	rs12699921	0.598	rs1965534	ENSG00000279048.1	RP11-511H23.2	-5.83	9.95e-09	3.81e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17790488	chr7:17940503~17942922:+
LUAD	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-5.83	9.96e-09	3.82e-06	-0.31	-0.26	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
LUAD	cis	rs948562	0.793	rs79170562	ENSG00000280010.1	AP001350.4	5.83	9.96e-09	3.82e-06	0.43	0.26	Lymphoma;	chr11:58604081	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.793	rs1944051	ENSG00000280010.1	AP001350.4	5.83	9.96e-09	3.82e-06	0.43	0.26	Lymphoma;	chr11:58607820	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.696	rs17568220	ENSG00000280010.1	AP001350.4	5.83	9.96e-09	3.82e-06	0.43	0.26	Lymphoma;	chr11:58627550	chr11:58627435~58628528:+
LUAD	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	5.83	9.96e-09	3.82e-06	0.29	0.26	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
LUAD	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	5.83	9.96e-09	3.82e-06	0.4	0.26	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
LUAD	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-5.83	9.98e-09	3.82e-06	-0.34	-0.26	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
LUAD	cis	rs10050311	0.858	rs72667705	ENSG00000251411.1	RP11-397E7.4	-5.83	9.99e-09	3.83e-06	-0.36	-0.26	Insulin-related traits;	chr4:86892986	chr4:86913266~86914817:-
LUAD	cis	rs7246657	0.722	rs2075284	ENSG00000276846.1	CTD-3220F14.3	-5.83	9.99e-09	3.83e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37698715	chr19:37314868~37315620:-
LUAD	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	5.83	9.99e-09	3.83e-06	0.33	0.26	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	5.83	9.99e-09	3.83e-06	0.33	0.26	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
LUAD	cis	rs62246343	0.786	rs73126664	ENSG00000254485.4	RP11-380O24.1	5.83	1e-08	3.83e-06	0.37	0.26	Fibrinogen levels;	chr3:9362966	chr3:9292588~9363303:-
LUAD	cis	rs7618501	0.601	rs2624825	ENSG00000234667.1	ACTBP13	5.83	1e-08	3.84e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50117556	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.602	rs2071206	ENSG00000234667.1	ACTBP13	5.83	1e-08	3.84e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50122676	chr3:49873347~49877980:-
LUAD	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-5.83	1.01e-08	3.85e-06	-0.28	-0.26	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-5.83	1.01e-08	3.85e-06	-0.36	-0.26	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
LUAD	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-5.83	1.01e-08	3.85e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
LUAD	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	5.83	1.01e-08	3.86e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	5.83	1.01e-08	3.86e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
LUAD	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	5.83	1.01e-08	3.86e-06	0.42	0.26	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
LUAD	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	5.83	1.01e-08	3.86e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
LUAD	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	5.83	1.01e-08	3.86e-06	0.45	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
LUAD	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	5.83	1.01e-08	3.87e-06	0.31	0.26	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
LUAD	cis	rs7804306	0.826	rs77672302	ENSG00000233264.2	AC006042.8	5.83	1.01e-08	3.87e-06	0.51	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8048681	chr7:7980312~7982228:+
LUAD	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-5.83	1.01e-08	3.87e-06	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
LUAD	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	5.83	1.01e-08	3.87e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
LUAD	cis	rs10214930	0.647	rs11767188	ENSG00000235574.1	AC073150.6	-5.83	1.01e-08	3.87e-06	-0.32	-0.26	Hypospadias;	chr7:27532326	chr7:27491682~27492765:-
LUAD	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-5.83	1.01e-08	3.87e-06	-0.32	-0.26	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
LUAD	cis	rs8177876	0.915	rs8059692	ENSG00000261838.4	RP11-303E16.6	5.83	1.01e-08	3.87e-06	0.54	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81069854~81076598:+
LUAD	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	5.83	1.01e-08	3.87e-06	0.31	0.26	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs160643	ENSG00000232546.1	RP11-458F8.1	-5.83	1.01e-08	3.88e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66093235	chr7:66848496~66858136:+
LUAD	cis	rs8081395	0.58	rs180515	ENSG00000266992.1	DHX40P1	5.83	1.01e-08	3.88e-06	0.32	0.26	White blood cell count;	chr17:59946914	chr17:59976009~60002384:-
LUAD	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-5.83	1.01e-08	3.88e-06	-0.37	-0.26	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
LUAD	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-5.83	1.01e-08	3.88e-06	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
LUAD	cis	rs7246657	0.722	rs10410588	ENSG00000276846.1	CTD-3220F14.3	5.83	1.01e-08	3.88e-06	0.34	0.26	Coronary artery calcification;	chr19:37551508	chr19:37314868~37315620:-
LUAD	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-5.83	1.01e-08	3.88e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
LUAD	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	5.83	1.01e-08	3.88e-06	0.22	0.26	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
LUAD	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	5.83	1.01e-08	3.88e-06	0.32	0.26	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
LUAD	cis	rs9652601	0.691	rs9921287	ENSG00000274038.1	RP11-66H6.4	-5.83	1.02e-08	3.89e-06	-0.31	-0.26	Systemic lupus erythematosus;	chr16:11115882	chr16:11056556~11057034:+
LUAD	cis	rs55665837	0.701	rs10160597	ENSG00000251991.1	RNU7-49P	5.83	1.02e-08	3.89e-06	0.3	0.26	Vitamin D levels;	chr11:14582446	chr11:14478892~14478953:+
LUAD	cis	rs293748	0.54	rs6879284	ENSG00000250155.1	CTD-2353F22.1	-5.83	1.02e-08	3.89e-06	-0.31	-0.26	Obesity-related traits;	chr5:37230185	chr5:36666214~36725195:-
LUAD	cis	rs7246657	0.722	rs16958861	ENSG00000276846.1	CTD-3220F14.3	5.83	1.02e-08	3.89e-06	0.34	0.26	Coronary artery calcification;	chr19:37633278	chr19:37314868~37315620:-
LUAD	cis	rs36423	0.528	rs1205066	ENSG00000266869.1	RP6-114E22.1	5.83	1.02e-08	3.89e-06	0.38	0.26	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71880340	chr14:71848606~71908430:+
LUAD	cis	rs2243480	1	rs4718334	ENSG00000230295.1	RP11-458F8.2	5.83	1.02e-08	3.89e-06	0.31	0.26	Diabetic kidney disease;	chr7:66324467	chr7:66880708~66882981:+
LUAD	cis	rs172166	0.652	rs476167	ENSG00000204709.4	LINC01556	5.83	1.02e-08	3.9e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28098110	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.694	rs203892	ENSG00000204709.4	LINC01556	5.83	1.02e-08	3.9e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28099418	chr6:28943877~28944537:+
LUAD	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-5.83	1.02e-08	3.9e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-5.83	1.02e-08	3.9e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
LUAD	cis	rs12699921	0.632	rs2723496	ENSG00000279048.1	RP11-511H23.2	-5.83	1.02e-08	3.9e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17786367	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2691553	ENSG00000279048.1	RP11-511H23.2	-5.83	1.02e-08	3.9e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17786658	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.598	rs1852010	ENSG00000279048.1	RP11-511H23.2	-5.83	1.02e-08	3.9e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17786744	chr7:17940503~17942922:+
LUAD	cis	rs2212361	0.558	rs12294732	ENSG00000255893.1	RP11-685N10.1	-5.83	1.02e-08	3.9e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531716	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.527	rs12282965	ENSG00000255893.1	RP11-685N10.1	-5.83	1.02e-08	3.9e-06	-0.34	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94528348	chr11:94472908~94473570:-
LUAD	cis	rs367615	0.68	rs166181	ENSG00000249476.1	CTD-2587M2.1	5.83	1.02e-08	3.91e-06	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109648392	chr5:109237120~109326369:-
LUAD	cis	rs944289	0.6	rs2415320	ENSG00000257826.1	RP11-116N8.4	-5.83	1.02e-08	3.91e-06	-0.29	-0.26	Thyroid cancer;	chr14:36148733	chr14:36061026~36067190:-
LUAD	cis	rs11020821	0.884	rs12286498	ENSG00000255893.1	RP11-685N10.1	-5.83	1.02e-08	3.91e-06	-0.34	-0.26	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94529857	chr11:94472908~94473570:-
LUAD	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	5.83	1.02e-08	3.91e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-5.83	1.02e-08	3.91e-06	-0.29	-0.26	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
LUAD	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	5.83	1.02e-08	3.92e-06	0.38	0.26	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-5.83	1.02e-08	3.92e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
LUAD	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	5.83	1.03e-08	3.92e-06	0.28	0.26	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
LUAD	cis	rs12699921	0.568	rs67452591	ENSG00000279048.1	RP11-511H23.2	-5.83	1.03e-08	3.92e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17876573	chr7:17940503~17942922:+
LUAD	cis	rs17214007	0.735	rs2075513	ENSG00000263335.1	AF001548.5	-5.83	1.03e-08	3.93e-06	-0.37	-0.26	Cognitive function;	chr16:15782614	chr16:15726674~15732993:+
LUAD	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-5.83	1.03e-08	3.93e-06	-0.32	-0.26	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
LUAD	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-5.83	1.03e-08	3.93e-06	-0.53	-0.26	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
LUAD	cis	rs10214930	0.647	rs2098316	ENSG00000235574.1	AC073150.6	-5.83	1.03e-08	3.93e-06	-0.32	-0.26	Hypospadias;	chr7:27529018	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2080246	ENSG00000235574.1	AC073150.6	-5.83	1.03e-08	3.93e-06	-0.32	-0.26	Hypospadias;	chr7:27530085	chr7:27491682~27492765:-
LUAD	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-5.83	1.03e-08	3.93e-06	-0.35	-0.26	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-5.83	1.03e-08	3.93e-06	-0.28	-0.26	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
LUAD	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-5.83	1.03e-08	3.94e-06	-0.32	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
LUAD	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	5.83	1.03e-08	3.94e-06	0.37	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
LUAD	cis	rs12188164	0.515	rs11742006	ENSG00000225138.6	CTD-2228K2.7	5.83	1.03e-08	3.94e-06	0.25	0.26	Cystic fibrosis severity;	chr5:408414	chr5:473236~480884:+
LUAD	cis	rs4713118	0.513	rs149954	ENSG00000204709.4	LINC01556	5.83	1.03e-08	3.94e-06	0.33	0.26	Parkinson's disease;	chr6:28067468	chr6:28943877~28944537:+
LUAD	cis	rs9860428	0.774	rs9814008	ENSG00000242770.2	RP11-180K7.1	5.83	1.03e-08	3.95e-06	0.27	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112845336	chr3:112802478~112812819:+
LUAD	cis	rs11651753	0.689	rs2525107	ENSG00000264920.1	RP11-6N17.4	5.83	1.03e-08	3.95e-06	0.32	0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964038	chr17:47891255~47895812:-
LUAD	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	5.83	1.03e-08	3.95e-06	0.28	0.26	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
LUAD	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	5.83	1.03e-08	3.95e-06	0.48	0.26	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
LUAD	cis	rs1707322	0.827	rs6694302	ENSG00000234329.1	RP11-767N6.2	5.83	1.03e-08	3.95e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-5.83	1.03e-08	3.95e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
LUAD	cis	rs12468226	0.938	rs6435139	ENSG00000272966.1	RP11-686O6.1	-5.83	1.04e-08	3.96e-06	-0.43	-0.26	Urate levels;	chr2:202255145	chr2:202336739~202337200:+
LUAD	cis	rs3096299	0.754	rs3102382	ENSG00000274627.1	RP11-104N10.2	5.83	1.04e-08	3.96e-06	0.24	0.26	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89516797~89522217:+
LUAD	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-5.83	1.04e-08	3.96e-06	-0.32	-0.26	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
LUAD	cis	rs2255336	0.938	rs12298043	ENSG00000245648.1	RP11-277P12.20	-5.83	1.04e-08	3.96e-06	-0.41	-0.26	Blood protein levels;	chr12:10456883	chr12:10363769~10398506:+
LUAD	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	5.83	1.04e-08	3.96e-06	0.31	0.26	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
LUAD	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-5.83	1.04e-08	3.97e-06	-0.32	-0.26	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
LUAD	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	5.83	1.04e-08	3.97e-06	0.37	0.26	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
LUAD	cis	rs5753618	0.561	rs9609264	ENSG00000236132.1	CTA-440B3.1	-5.83	1.04e-08	3.97e-06	-0.32	-0.26	Colorectal cancer;	chr22:31350733	chr22:31816379~31817491:-
LUAD	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	5.83	1.04e-08	3.98e-06	0.33	0.26	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
LUAD	cis	rs12468226	0.938	rs12464254	ENSG00000272966.1	RP11-686O6.1	5.83	1.04e-08	3.98e-06	0.45	0.26	Urate levels;	chr2:202301641	chr2:202336739~202337200:+
LUAD	cis	rs12439619	0.705	rs4778665	ENSG00000255769.6	GOLGA2P10	-5.83	1.04e-08	3.98e-06	-0.34	-0.26	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472993~82513950:-
LUAD	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-5.83	1.04e-08	3.98e-06	-0.28	-0.26	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
LUAD	cis	rs9813712	0.548	rs9880123	ENSG00000249846.5	RP11-77P16.4	-5.83	1.05e-08	3.99e-06	-0.3	-0.26	Response to amphetamines;	chr3:130215275	chr3:130112550~130120579:+
LUAD	cis	rs35955747	0.722	rs5997898	ENSG00000236132.1	CTA-440B3.1	5.83	1.05e-08	3.99e-06	0.29	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31176977	chr22:31816379~31817491:-
LUAD	cis	rs7044106	0.762	rs7849566	ENSG00000238181.2	AHCYP2	-5.82	1.05e-08	3.99e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120720673~120721972:+
LUAD	cis	rs8177876	0.749	rs75923695	ENSG00000261061.1	RP11-303E16.2	-5.82	1.05e-08	4e-06	-0.44	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81030770~81031485:+
LUAD	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-5.82	1.05e-08	4e-06	-0.37	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
LUAD	cis	rs11096990	0.855	rs2711988	ENSG00000249207.1	RP11-360F5.1	5.82	1.05e-08	4e-06	0.3	0.26	Cognitive function;	chr4:39151128	chr4:39112677~39126818:-
LUAD	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-5.82	1.05e-08	4.01e-06	-0.54	-0.26	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
LUAD	cis	rs7246657	0.722	rs35863684	ENSG00000276846.1	CTD-3220F14.3	5.82	1.05e-08	4.01e-06	0.34	0.26	Coronary artery calcification;	chr19:37618876	chr19:37314868~37315620:-
LUAD	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-5.82	1.05e-08	4.01e-06	-0.29	-0.26	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
LUAD	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	5.82	1.05e-08	4.01e-06	0.21	0.26	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
LUAD	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-5.82	1.05e-08	4.02e-06	-0.35	-0.26	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
LUAD	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-5.82	1.05e-08	4.02e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
LUAD	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-5.82	1.05e-08	4.02e-06	-0.53	-0.26	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
LUAD	cis	rs3096299	0.702	rs2086825	ENSG00000274627.1	RP11-104N10.2	5.82	1.05e-08	4.02e-06	0.24	0.26	Multiple myeloma (IgH translocation);	chr16:89405134	chr16:89516797~89522217:+
LUAD	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	5.82	1.05e-08	4.02e-06	0.29	0.26	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
LUAD	cis	rs6687821	0.515	rs10489917	ENSG00000267734.1	RP4-604K5.3	5.82	1.05e-08	4.02e-06	0.31	0.26	Yeast infection;	chr1:86932105	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs12072434	ENSG00000267734.1	RP4-604K5.3	5.82	1.05e-08	4.02e-06	0.31	0.26	Yeast infection;	chr1:86935026	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs1923144	ENSG00000267734.1	RP4-604K5.3	5.82	1.05e-08	4.02e-06	0.31	0.26	Yeast infection;	chr1:86938548	chr1:86932199~86934891:-
LUAD	cis	rs5753618	0.583	rs5753631	ENSG00000236132.1	CTA-440B3.1	-5.82	1.06e-08	4.03e-06	-0.32	-0.26	Colorectal cancer;	chr22:31467036	chr22:31816379~31817491:-
LUAD	cis	rs2562456	0.917	rs10420016	ENSG00000268081.1	RP11-678G14.2	-5.82	1.06e-08	4.04e-06	-0.39	-0.26	Pain;	chr19:21505800	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-5.82	1.06e-08	4.04e-06	-0.39	-0.26	Pain;	chr19:21509773	chr19:21554640~21569237:-
LUAD	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-5.82	1.06e-08	4.04e-06	-0.28	-0.26	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
LUAD	cis	rs62432291	0.681	rs294912	ENSG00000235086.1	FNDC1-IT1	-5.82	1.06e-08	4.04e-06	-0.45	-0.26	Joint mobility (Beighton score);	chr6:159246305	chr6:159240786~159243329:+
LUAD	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-5.82	1.06e-08	4.04e-06	-0.35	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
LUAD	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-5.82	1.06e-08	4.04e-06	-0.31	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
LUAD	cis	rs12468226	0.574	rs4675271	ENSG00000273456.1	RP11-686O6.2	-5.82	1.06e-08	4.04e-06	-0.35	-0.26	Urate levels;	chr2:202170967	chr2:202374932~202375604:-
LUAD	cis	rs1707322	0.785	rs10890348	ENSG00000234329.1	RP11-767N6.2	5.82	1.06e-08	4.04e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45651039~45651826:-
LUAD	cis	rs897984	0.542	rs4468641	ENSG00000260911.2	RP11-196G11.2	5.82	1.06e-08	4.04e-06	0.23	0.26	Dementia with Lewy bodies;	chr16:31085555	chr16:31043150~31049868:+
LUAD	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	5.82	1.06e-08	4.05e-06	0.36	0.26	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
LUAD	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-5.82	1.06e-08	4.05e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
LUAD	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-5.82	1.06e-08	4.05e-06	-0.35	-0.26	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-5.82	1.06e-08	4.05e-06	-0.35	-0.26	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
LUAD	cis	rs17684571	0.751	rs17684941	ENSG00000231441.1	RP11-472M19.2	-5.82	1.06e-08	4.05e-06	-0.39	-0.26	Schizophrenia;	chr6:56862636	chr6:56844002~56864078:+
LUAD	cis	rs9595908	0.655	rs56080053	ENSG00000212293.1	SNORA16	5.82	1.06e-08	4.05e-06	0.28	0.26	Body mass index;	chr13:32720045	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-5.82	1.06e-08	4.06e-06	-0.34	-0.26	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000211967.3	IGHV3-53	-5.82	1.06e-08	4.06e-06	-0.2	-0.26	Kawasaki disease;	chr14:106637576	chr14:106592676~106593347:-
LUAD	cis	rs12699921	0.599	rs998342	ENSG00000279048.1	RP11-511H23.2	-5.82	1.07e-08	4.06e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17785965	chr7:17940503~17942922:+
LUAD	cis	rs755249	0.532	rs2296173	ENSG00000228060.1	RP11-69E11.8	-5.82	1.07e-08	4.07e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs3118014	ENSG00000228060.1	RP11-69E11.8	-5.82	1.07e-08	4.07e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-5.82	1.07e-08	4.07e-06	-0.29	-0.26	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-5.82	1.07e-08	4.07e-06	-0.28	-0.26	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-5.82	1.07e-08	4.07e-06	-0.28	-0.26	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
LUAD	cis	rs8177876	0.658	rs2316730	ENSG00000261838.4	RP11-303E16.6	5.82	1.07e-08	4.08e-06	0.57	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.915	rs6420421	ENSG00000261838.4	RP11-303E16.6	-5.82	1.07e-08	4.08e-06	-0.54	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094601	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.749	rs5023849	ENSG00000261838.4	RP11-303E16.6	-5.82	1.07e-08	4.08e-06	-0.54	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094694	chr16:81069854~81076598:+
LUAD	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-5.82	1.07e-08	4.08e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
LUAD	cis	rs2412819	0.571	rs4923964	ENSG00000249839.1	AC011330.5	5.82	1.07e-08	4.09e-06	0.41	0.26	Lung cancer;	chr15:43722882	chr15:43663654~43684339:-
LUAD	cis	rs755249	0.567	rs17264671	ENSG00000228060.1	RP11-69E11.8	-5.82	1.07e-08	4.09e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs4660690	ENSG00000228060.1	RP11-69E11.8	-5.82	1.07e-08	4.09e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39565160~39573203:+
LUAD	cis	rs6687821	0.515	rs496588	ENSG00000267734.1	RP4-604K5.3	5.82	1.07e-08	4.09e-06	0.32	0.26	Yeast infection;	chr1:86858728	chr1:86932199~86934891:-
LUAD	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	5.82	1.07e-08	4.09e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	5.82	1.07e-08	4.09e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	5.82	1.07e-08	4.09e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	5.82	1.07e-08	4.09e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
LUAD	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	5.82	1.08e-08	4.1e-06	0.23	0.26	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
LUAD	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-5.82	1.08e-08	4.1e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-5.82	1.08e-08	4.1e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
LUAD	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-5.82	1.08e-08	4.1e-06	-0.36	-0.26	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
LUAD	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	5.82	1.08e-08	4.1e-06	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
LUAD	cis	rs516805	0.748	rs11154078	ENSG00000279453.1	RP3-425C14.4	5.82	1.08e-08	4.11e-06	0.35	0.26	Lymphocyte counts;	chr6:122387058	chr6:122436789~122439223:-
LUAD	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	5.82	1.08e-08	4.11e-06	0.38	0.26	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
LUAD	cis	rs1707322	0.827	rs12125508	ENSG00000234329.1	RP11-767N6.2	5.82	1.08e-08	4.11e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs422164	ENSG00000230295.1	RP11-458F8.2	-5.82	1.08e-08	4.11e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66121618	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000230295.1	RP11-458F8.2	5.82	1.08e-08	4.11e-06	0.31	0.26	Diabetic kidney disease;	chr7:66333815	chr7:66880708~66882981:+
LUAD	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-5.82	1.08e-08	4.12e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
LUAD	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-5.82	1.08e-08	4.12e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
LUAD	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-5.82	1.09e-08	4.13e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-5.82	1.09e-08	4.13e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
LUAD	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-5.82	1.09e-08	4.13e-06	-0.31	-0.26	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
LUAD	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-5.82	1.09e-08	4.13e-06	-0.29	-0.26	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
LUAD	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-5.82	1.09e-08	4.14e-06	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
LUAD	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	5.82	1.09e-08	4.14e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	5.82	1.09e-08	4.14e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
LUAD	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-5.82	1.09e-08	4.14e-06	-0.27	-0.26	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
LUAD	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	5.82	1.09e-08	4.14e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
LUAD	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	5.82	1.09e-08	4.15e-06	0.31	0.26	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
LUAD	cis	rs12699921	0.632	rs2723503	ENSG00000279048.1	RP11-511H23.2	-5.82	1.09e-08	4.15e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17782012	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs10264355	ENSG00000279048.1	RP11-511H23.2	5.82	1.09e-08	4.15e-06	0.21	0.26	Fibrinogen levels;	chr7:17782391	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs10264445	ENSG00000279048.1	RP11-511H23.2	5.82	1.09e-08	4.15e-06	0.21	0.26	Fibrinogen levels;	chr7:17782425	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.607	rs10264447	ENSG00000279048.1	RP11-511H23.2	5.82	1.09e-08	4.15e-06	0.21	0.26	Fibrinogen levels;	chr7:17782430	chr7:17940503~17942922:+
LUAD	cis	rs4908768	0.501	rs6577491	ENSG00000232912.4	RP5-1115A15.1	5.82	1.09e-08	4.15e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8424645~8434838:+
LUAD	cis	rs4713118	0.513	rs149897	ENSG00000204709.4	LINC01556	5.82	1.09e-08	4.15e-06	0.33	0.26	Parkinson's disease;	chr6:28038872	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs156734	ENSG00000204709.4	LINC01556	5.82	1.09e-08	4.15e-06	0.33	0.26	Parkinson's disease;	chr6:28039579	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.501	rs11121201	ENSG00000232912.4	RP5-1115A15.1	5.82	1.09e-08	4.16e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8424645~8434838:+
LUAD	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	5.82	1.09e-08	4.16e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
LUAD	cis	rs9595908	0.686	rs9591314	ENSG00000212293.1	SNORA16	5.82	1.09e-08	4.16e-06	0.28	0.26	Body mass index;	chr13:32760248	chr13:32420390~32420516:-
LUAD	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-5.82	1.09e-08	4.16e-06	-0.36	-0.26	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000211967.3	IGHV3-53	-5.82	1.1e-08	4.17e-06	-0.18	-0.26	Kawasaki disease;	chr14:106673891	chr14:106592676~106593347:-
LUAD	cis	rs293748	0.771	rs167146	ENSG00000250155.1	CTD-2353F22.1	-5.82	1.1e-08	4.17e-06	-0.36	-0.26	Obesity-related traits;	chr5:36922204	chr5:36666214~36725195:-
LUAD	cis	rs12699921	0.598	rs2691602	ENSG00000279048.1	RP11-511H23.2	-5.82	1.1e-08	4.17e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17836153	chr7:17940503~17942922:+
LUAD	cis	rs72615157	0.634	rs79986079	ENSG00000242294.5	STAG3L5P	5.82	1.1e-08	4.18e-06	0.22	0.26	Lung function (FEV1/FVC);	chr7:100204421	chr7:100336079~100351900:+
LUAD	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-5.82	1.1e-08	4.18e-06	-0.29	-0.26	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-5.82	1.1e-08	4.18e-06	-0.29	-0.26	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs316313	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66128561	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66131504	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66132354	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66133233	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66133553	chr7:66880708~66882981:+
LUAD	cis	rs12699921	0.632	rs1524776	ENSG00000279048.1	RP11-511H23.2	-5.82	1.1e-08	4.18e-06	-0.2	-0.26	Fibrinogen levels;	chr7:17832470	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-5.82	1.1e-08	4.19e-06	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
LUAD	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-5.82	1.1e-08	4.19e-06	-0.32	-0.26	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-5.82	1.1e-08	4.19e-06	-0.32	-0.26	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
LUAD	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	5.82	1.1e-08	4.19e-06	0.34	0.26	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
LUAD	cis	rs2919009	0.537	rs11199650	ENSG00000271670.1	RP11-95I16.4	5.82	1.1e-08	4.19e-06	0.31	0.26	Obesity-related traits;	chr10:120923297	chr10:120879256~120880667:-
LUAD	cis	rs66887589	0.87	rs10518336	ENSG00000245958.5	RP11-33B1.1	-5.82	1.1e-08	4.19e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119601779	chr4:119454791~119552025:+
LUAD	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	5.82	1.1e-08	4.2e-06	0.38	0.26	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
LUAD	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	5.82	1.11e-08	4.2e-06	0.28	0.26	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
LUAD	cis	rs7044106	0.762	rs1324473	ENSG00000238181.2	AHCYP2	5.81	1.11e-08	4.2e-06	0.32	0.26	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120720673~120721972:+
LUAD	cis	rs12699921	0.632	rs2723545	ENSG00000279048.1	RP11-511H23.2	-5.81	1.11e-08	4.2e-06	-0.2	-0.26	Fibrinogen levels;	chr7:17820068	chr7:17940503~17942922:+
LUAD	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	5.81	1.11e-08	4.21e-06	0.27	0.26	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
LUAD	cis	rs7044106	0.762	rs10739570	ENSG00000238181.2	AHCYP2	-5.81	1.11e-08	4.21e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120720673~120721972:+
LUAD	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	5.81	1.11e-08	4.21e-06	0.31	0.26	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
LUAD	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-5.81	1.11e-08	4.22e-06	-0.31	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
LUAD	cis	rs1874124	0.836	rs7549963	ENSG00000238078.1	LINC01352	-5.81	1.11e-08	4.22e-06	-0.37	-0.26	Cholesterol, total;	chr1:220814918	chr1:220829255~220832429:+
LUAD	cis	rs35740288	0.857	rs11632034	ENSG00000202081.1	RNU6-1280P	5.81	1.11e-08	4.23e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85740841	chr15:85651522~85651628:-
LUAD	cis	rs7618501	0.633	rs4688689	ENSG00000234667.1	ACTBP13	-5.81	1.11e-08	4.23e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr3:49998109	chr3:49873347~49877980:-
LUAD	cis	rs185968827	1	rs185968827	ENSG00000231441.1	RP11-472M19.2	5.81	1.12e-08	4.24e-06	0.39	0.26	Alzheimer disease and age of onset;	chr6:56843712	chr6:56844002~56864078:+
LUAD	cis	rs10214930	0.781	rs12700823	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27619602	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs6966091	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27620394	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs12531518	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27621520	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs7808275	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27621885	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs12540063	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27621926	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.705	rs12700824	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27622135	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs7782422	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27623884	chr7:27491682~27492765:-
LUAD	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-5.81	1.12e-08	4.25e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
LUAD	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-5.81	1.12e-08	4.25e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
LUAD	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	5.81	1.12e-08	4.26e-06	0.29	0.26	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
LUAD	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	5.81	1.12e-08	4.26e-06	0.35	0.26	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
LUAD	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	5.81	1.12e-08	4.26e-06	0.31	0.26	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
LUAD	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-5.81	1.12e-08	4.26e-06	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
LUAD	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-5.81	1.12e-08	4.27e-06	-0.28	-0.26	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
LUAD	cis	rs11651753	0.636	rs4793731	ENSG00000264920.1	RP11-6N17.4	-5.81	1.12e-08	4.27e-06	-0.32	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956327	chr17:47891255~47895812:-
LUAD	cis	rs11651753	0.636	rs4793733	ENSG00000264920.1	RP11-6N17.4	-5.81	1.12e-08	4.27e-06	-0.32	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956616	chr17:47891255~47895812:-
LUAD	cis	rs11651753	0.636	rs35280206	ENSG00000264920.1	RP11-6N17.4	-5.81	1.12e-08	4.27e-06	-0.32	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47957645	chr17:47891255~47895812:-
LUAD	cis	rs2898681	0.58	rs41279517	ENSG00000248375.1	RP11-177B4.1	-5.81	1.12e-08	4.27e-06	-0.47	-0.26	Optic nerve measurement (cup area);	chr4:52863604	chr4:52720081~52720831:-
LUAD	cis	rs2898681	0.567	rs77657787	ENSG00000248375.1	RP11-177B4.1	-5.81	1.12e-08	4.27e-06	-0.47	-0.26	Optic nerve measurement (cup area);	chr4:52863814	chr4:52720081~52720831:-
LUAD	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-5.81	1.13e-08	4.27e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-5.81	1.13e-08	4.27e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
LUAD	cis	rs896854	0.54	rs2011567	ENSG00000253528.2	RP11-347C18.4	5.81	1.13e-08	4.27e-06	0.25	0.26	Type 2 diabetes;	chr8:94959692	chr8:94974573~94974853:-
LUAD	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-5.81	1.13e-08	4.28e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	5.81	1.13e-08	4.28e-06	0.29	0.26	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
LUAD	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	5.81	1.13e-08	4.28e-06	0.26	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000230295.1	RP11-458F8.2	-5.81	1.13e-08	4.28e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65909309	chr7:66880708~66882981:+
LUAD	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-5.81	1.13e-08	4.28e-06	-0.27	-0.26	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
LUAD	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	5.81	1.13e-08	4.29e-06	0.33	0.26	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
LUAD	cis	rs755249	0.567	rs61779306	ENSG00000228060.1	RP11-69E11.8	-5.81	1.13e-08	4.29e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39565160~39573203:+
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	5.81	1.13e-08	4.29e-06	0.26	0.26	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
LUAD	cis	rs9595908	0.709	rs1929937	ENSG00000212293.1	SNORA16	5.81	1.13e-08	4.29e-06	0.27	0.26	Body mass index;	chr13:32722907	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7325016	ENSG00000212293.1	SNORA16	5.81	1.13e-08	4.29e-06	0.27	0.26	Body mass index;	chr13:32728681	chr13:32420390~32420516:-
LUAD	cis	rs17684571	0.872	rs35206656	ENSG00000231441.1	RP11-472M19.2	5.81	1.13e-08	4.3e-06	0.34	0.26	Schizophrenia;	chr6:56706662	chr6:56844002~56864078:+
LUAD	cis	rs755249	0.917	rs61781392	ENSG00000228060.1	RP11-69E11.8	-5.81	1.13e-08	4.3e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39565160~39573203:+
LUAD	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-5.81	1.13e-08	4.3e-06	-0.31	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
LUAD	cis	rs4908768	0.501	rs6702060	ENSG00000232912.4	RP5-1115A15.1	5.81	1.13e-08	4.3e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs6577502	ENSG00000232912.4	RP5-1115A15.1	5.81	1.13e-08	4.3e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs1473420	ENSG00000232912.4	RP5-1115A15.1	5.81	1.13e-08	4.3e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8424645~8434838:+
LUAD	cis	rs10740039	0.516	rs1442551	ENSG00000254271.1	RP11-131N11.4	5.81	1.13e-08	4.3e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60564733	chr10:60734342~60741828:+
LUAD	cis	rs4723738	1	rs7795499	ENSG00000227191.5	TRGC2	-5.81	1.13e-08	4.3e-06	-0.27	-0.26	Treatment response for severe sepsis;	chr7:38228794	chr7:38239580~38368091:-
LUAD	cis	rs7246657	0.722	rs2287229	ENSG00000276846.1	CTD-3220F14.3	-5.81	1.13e-08	4.3e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37697751	chr19:37314868~37315620:-
LUAD	cis	rs2832077	1	rs2832077	ENSG00000232855.5	AF131217.1	5.81	1.14e-08	4.31e-06	0.29	0.26	Cognitive test performance;	chr21:28768699	chr21:28439346~28674848:-
LUAD	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-5.81	1.14e-08	4.31e-06	-0.35	-0.26	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
LUAD	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	5.81	1.14e-08	4.31e-06	0.31	0.26	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	5.81	1.14e-08	4.31e-06	0.31	0.26	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
LUAD	cis	rs755249	0.917	rs61232586	ENSG00000228060.1	RP11-69E11.8	-5.81	1.14e-08	4.32e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39565160~39573203:+
LUAD	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-5.81	1.14e-08	4.32e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-5.81	1.14e-08	4.32e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-5.81	1.14e-08	4.32e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
LUAD	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-5.81	1.14e-08	4.33e-06	-0.31	-0.26	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
LUAD	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-5.81	1.15e-08	4.34e-06	-0.35	-0.26	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
LUAD	cis	rs394563	0.69	rs237010	ENSG00000231760.4	RP11-350J20.5	5.81	1.15e-08	4.34e-06	0.31	0.26	Dupuytren's disease;	chr6:149437614	chr6:149796151~149826294:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000224373.3	IGHV4-59	5.81	1.15e-08	4.34e-06	0.17	0.26	Kawasaki disease;	chr14:106776558	chr14:106627249~106627825:-
LUAD	cis	rs7044106	0.762	rs10984974	ENSG00000238181.2	AHCYP2	-5.81	1.15e-08	4.34e-06	-0.32	-0.26	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120720673~120721972:+
LUAD	cis	rs10214930	0.781	rs961723	ENSG00000235574.1	AC073150.6	-5.81	1.15e-08	4.34e-06	-0.34	-0.26	Hypospadias;	chr7:27618354	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs961724	ENSG00000235574.1	AC073150.6	-5.81	1.15e-08	4.34e-06	-0.34	-0.26	Hypospadias;	chr7:27618416	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs961725	ENSG00000235574.1	AC073150.6	-5.81	1.15e-08	4.34e-06	-0.34	-0.26	Hypospadias;	chr7:27618451	chr7:27491682~27492765:-
LUAD	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-5.81	1.15e-08	4.34e-06	-0.31	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
LUAD	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	5.81	1.15e-08	4.35e-06	0.26	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
LUAD	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-5.81	1.15e-08	4.35e-06	-0.35	-0.26	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-5.81	1.15e-08	4.35e-06	-0.35	-0.26	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
LUAD	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	5.81	1.15e-08	4.35e-06	0.35	0.26	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
LUAD	cis	rs36423	0.528	rs1205063	ENSG00000266869.1	RP6-114E22.1	5.81	1.15e-08	4.36e-06	0.37	0.26	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71881828	chr14:71848606~71908430:+
LUAD	cis	rs4591358	0.773	rs35261538	ENSG00000223466.1	AC064834.2	-5.81	1.15e-08	4.37e-06	-0.35	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509681	chr2:195533035~195538681:+
LUAD	cis	rs7246657	0.722	rs12979640	ENSG00000276846.1	CTD-3220F14.3	-5.81	1.15e-08	4.37e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37688255	chr19:37314868~37315620:-
LUAD	cis	rs36093844	0.8	rs59179556	ENSG00000279742.1	RP11-700A24.1	-5.81	1.15e-08	4.37e-06	-0.33	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85862854	chr11:85852557~85854943:-
LUAD	cis	rs237743	0.963	rs73611371	ENSG00000222365.1	SNORD12B	-5.81	1.16e-08	4.37e-06	-0.3	-0.26	Height;	chr20:49218618	chr20:49280319~49280409:+
LUAD	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-5.81	1.16e-08	4.37e-06	-0.31	-0.26	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
LUAD	cis	rs9923856	0.519	rs7197754	ENSG00000274038.1	RP11-66H6.4	-5.81	1.16e-08	4.38e-06	-0.31	-0.26	Atopic dermatitis;Adult asthma;	chr16:11036522	chr16:11056556~11057034:+
LUAD	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-5.81	1.16e-08	4.39e-06	-0.27	-0.26	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
LUAD	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-5.81	1.16e-08	4.39e-06	-0.29	-0.26	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
LUAD	cis	rs4713118	0.513	rs149941	ENSG00000204709.4	LINC01556	5.81	1.16e-08	4.39e-06	0.32	0.26	Parkinson's disease;	chr6:28033255	chr6:28943877~28944537:+
LUAD	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	5.81	1.16e-08	4.39e-06	0.4	0.26	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-5.81	1.16e-08	4.4e-06	-0.28	-0.26	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
LUAD	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	5.81	1.16e-08	4.41e-06	0.49	0.26	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
LUAD	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	5.81	1.17e-08	4.41e-06	0.32	0.26	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
LUAD	cis	rs8177376	0.834	rs12287976	ENSG00000254905.1	RP11-712L6.7	5.81	1.17e-08	4.41e-06	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126302693	chr11:126292922~126294254:-
LUAD	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	5.81	1.17e-08	4.41e-06	0.27	0.26	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-5.81	1.17e-08	4.42e-06	-0.28	-0.26	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
LUAD	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	5.81	1.17e-08	4.42e-06	0.35	0.26	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
LUAD	cis	rs7246657	0.722	rs968073	ENSG00000276846.1	CTD-3220F14.3	-5.81	1.17e-08	4.42e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37701120	chr19:37314868~37315620:-
LUAD	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	5.81	1.17e-08	4.42e-06	0.4	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
LUAD	cis	rs9910055	0.762	rs4239142	ENSG00000267080.4	ASB16-AS1	5.8	1.17e-08	4.42e-06	0.23	0.26	Total body bone mineral density;	chr17:44128508	chr17:44175973~44186717:-
LUAD	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-5.8	1.17e-08	4.42e-06	-0.35	-0.26	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
LUAD	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	5.8	1.17e-08	4.43e-06	0.38	0.26	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
LUAD	cis	rs4908768	0.501	rs35865480	ENSG00000232912.4	RP5-1115A15.1	5.8	1.17e-08	4.43e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8424645~8434838:+
LUAD	cis	rs30380	0.632	rs30186	ENSG00000272109.1	CTD-2260A17.3	-5.8	1.17e-08	4.43e-06	-0.3	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96788744	chr5:96804353~96806105:+
LUAD	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-5.8	1.17e-08	4.44e-06	-0.26	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
LUAD	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-5.8	1.18e-08	4.44e-06	-0.27	-0.26	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-5.8	1.18e-08	4.44e-06	-0.27	-0.26	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	5.8	1.18e-08	4.45e-06	0.29	0.26	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
LUAD	cis	rs9860428	0.774	rs10934188	ENSG00000242770.2	RP11-180K7.1	5.8	1.18e-08	4.45e-06	0.27	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112821421	chr3:112802478~112812819:+
LUAD	cis	rs7246657	0.722	rs2927746	ENSG00000276846.1	CTD-3220F14.3	-5.8	1.18e-08	4.45e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37665669	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs2927747	ENSG00000276846.1	CTD-3220F14.3	-5.8	1.18e-08	4.45e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37668629	chr19:37314868~37315620:-
LUAD	cis	rs1426063	0.748	rs6534607	ENSG00000249717.1	RP11-44F21.3	5.8	1.18e-08	4.45e-06	0.34	0.26	QT interval;	chr4:75106366	chr4:74955974~74970362:-
LUAD	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-5.8	1.18e-08	4.45e-06	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
LUAD	cis	rs4908768	0.501	rs6577488	ENSG00000232912.4	RP5-1115A15.1	5.8	1.18e-08	4.45e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs4351668	ENSG00000232912.4	RP5-1115A15.1	5.8	1.18e-08	4.45e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs7551849	ENSG00000232912.4	RP5-1115A15.1	5.8	1.18e-08	4.45e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8424645~8434838:+
LUAD	cis	rs17138358	0.506	rs2691623	ENSG00000279048.1	RP11-511H23.2	-5.8	1.18e-08	4.45e-06	-0.21	-0.26	HDL cholesterol levels;	chr7:17853953	chr7:17940503~17942922:+
LUAD	cis	rs2243480	1	rs10247526	ENSG00000230295.1	RP11-458F8.2	5.8	1.18e-08	4.45e-06	0.31	0.26	Diabetic kidney disease;	chr7:66315709	chr7:66880708~66882981:+
LUAD	cis	rs2276314	0.512	rs9949178	ENSG00000278986.1	RP11-723J4.3	5.8	1.18e-08	4.46e-06	0.27	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35870612	chr18:35972151~35973916:+
LUAD	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-5.8	1.18e-08	4.46e-06	-0.27	-0.26	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
LUAD	cis	rs367615	0.55	rs10060801	ENSG00000249476.1	CTD-2587M2.1	5.8	1.18e-08	4.46e-06	0.27	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109546081	chr5:109237120~109326369:-
LUAD	cis	rs4908760	0.731	rs12075458	ENSG00000232912.4	RP5-1115A15.1	5.8	1.18e-08	4.46e-06	0.24	0.26	Vitiligo;	chr1:8698735	chr1:8424645~8434838:+
LUAD	cis	rs74233809	1	rs11191548	ENSG00000213277.3	MARCKSL1P1	-5.8	1.18e-08	4.47e-06	-0.44	-0.26	Birth weight;	chr10:103086421	chr10:103175554~103176094:+
LUAD	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	5.8	1.18e-08	4.47e-06	0.28	0.26	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
LUAD	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-5.8	1.18e-08	4.47e-06	-0.34	-0.26	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
LUAD	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	5.8	1.18e-08	4.48e-06	0.36	0.26	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
LUAD	cis	rs1823913	0.927	rs56209234	ENSG00000230611.1	HMGB1P27	-5.8	1.19e-08	4.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191261748	chr2:191174233~191174835:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000230295.1	RP11-458F8.2	5.8	1.19e-08	4.48e-06	0.32	0.26	Diabetic kidney disease;	chr7:66139635	chr7:66880708~66882981:+
LUAD	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-5.8	1.19e-08	4.48e-06	-0.6	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-5.8	1.19e-08	4.49e-06	-0.28	-0.26	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
LUAD	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	5.8	1.19e-08	4.49e-06	0.38	0.26	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
LUAD	cis	rs7688540	0.771	rs7669892	ENSG00000275426.1	CH17-262A2.1	-5.8	1.19e-08	4.49e-06	-0.3	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:315464	chr4:149738~150317:+
LUAD	cis	rs12468226	1	rs112306637	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202334195	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs111252524	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202334465	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs112753638	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202334496	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.935	rs113188021	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202336237	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs6731027	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202337443	chr2:202336739~202337200:+
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66521515	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs13237037	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66532895	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66557269	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1796228	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66568097	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1267820	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66585308	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2533288	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66591724	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2707844	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66594522	chr7:66880708~66882981:+
LUAD	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-5.8	1.19e-08	4.5e-06	-0.31	-0.26	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
LUAD	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	5.8	1.19e-08	4.51e-06	0.2	0.26	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
LUAD	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-5.8	1.19e-08	4.51e-06	-0.27	-0.26	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-5.8	1.19e-08	4.51e-06	-0.27	-0.26	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
LUAD	cis	rs36093844	0.8	rs2044390	ENSG00000279742.1	RP11-700A24.1	-5.8	1.19e-08	4.51e-06	-0.33	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85858791	chr11:85852557~85854943:-
LUAD	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-5.8	1.2e-08	4.52e-06	-0.32	-0.26	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
LUAD	cis	rs9652601	0.691	rs9939397	ENSG00000274038.1	RP11-66H6.4	-5.8	1.2e-08	4.52e-06	-0.31	-0.26	Systemic lupus erythematosus;	chr16:11115907	chr16:11056556~11057034:+
LUAD	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-5.8	1.2e-08	4.52e-06	-0.36	-0.26	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
LUAD	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	5.8	1.2e-08	4.53e-06	0.3	0.26	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
LUAD	cis	rs2243480	0.522	rs12698511	ENSG00000273142.1	RP11-458F8.4	-5.8	1.2e-08	4.53e-06	-0.3	-0.26	Diabetic kidney disease;	chr7:66009932	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-5.8	1.2e-08	4.54e-06	-0.28	-0.26	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
LUAD	cis	rs9595066	0.627	rs4394973	ENSG00000227258.4	SMIM2-AS1	-5.8	1.2e-08	4.54e-06	-0.39	-0.26	Schizophrenia;	chr13:44179173	chr13:44110451~44240517:+
LUAD	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	5.8	1.2e-08	4.54e-06	0.32	0.26	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
LUAD	cis	rs10214930	0.813	rs2391444	ENSG00000235574.1	AC073150.6	-5.8	1.2e-08	4.54e-06	-0.34	-0.26	Hypospadias;	chr7:27602801	chr7:27491682~27492765:-
LUAD	cis	rs4908768	0.501	rs1463050	ENSG00000232912.4	RP5-1115A15.1	5.8	1.2e-08	4.55e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8424645~8434838:+
LUAD	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-5.8	1.21e-08	4.55e-06	-0.33	-0.26	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
LUAD	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-5.8	1.21e-08	4.55e-06	-0.37	-0.26	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
LUAD	cis	rs293748	0.54	rs13166829	ENSG00000250155.1	CTD-2353F22.1	-5.8	1.21e-08	4.55e-06	-0.32	-0.26	Obesity-related traits;	chr5:37222124	chr5:36666214~36725195:-
LUAD	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-5.8	1.21e-08	4.56e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
LUAD	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	5.8	1.21e-08	4.56e-06	0.57	0.26	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	5.8	1.21e-08	4.56e-06	0.57	0.26	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	5.8	1.21e-08	4.56e-06	0.57	0.26	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
LUAD	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-5.8	1.21e-08	4.56e-06	-0.28	-0.26	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
LUAD	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	5.8	1.21e-08	4.56e-06	0.26	0.26	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
LUAD	cis	rs6921919	0.583	rs9468355	ENSG00000204709.4	LINC01556	5.8	1.21e-08	4.56e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28943877~28944537:+
LUAD	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-5.8	1.21e-08	4.57e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
LUAD	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-5.8	1.21e-08	4.57e-06	-0.3	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
LUAD	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-5.8	1.21e-08	4.57e-06	-0.35	-0.26	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-5.8	1.21e-08	4.57e-06	-0.35	-0.26	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
LUAD	cis	rs17684571	0.872	rs13198938	ENSG00000231441.1	RP11-472M19.2	5.8	1.21e-08	4.57e-06	0.37	0.26	Schizophrenia;	chr6:56733628	chr6:56844002~56864078:+
LUAD	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-5.8	1.21e-08	4.58e-06	-0.32	-0.26	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-5.8	1.21e-08	4.58e-06	-0.32	-0.26	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
LUAD	cis	rs4713118	0.513	rs183244	ENSG00000204709.4	LINC01556	5.8	1.21e-08	4.58e-06	0.33	0.26	Parkinson's disease;	chr6:28064060	chr6:28943877~28944537:+
LUAD	cis	rs13230714	0.858	rs2888075	ENSG00000204959.4	ARHGEF34P	5.8	1.22e-08	4.58e-06	0.33	0.26	Breast cancer;	chr7:144456786	chr7:144272445~144286966:-
LUAD	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-5.8	1.22e-08	4.59e-06	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
LUAD	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-5.8	1.22e-08	4.59e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
LUAD	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	5.8	1.22e-08	4.59e-06	0.29	0.26	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
LUAD	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	5.8	1.22e-08	4.59e-06	0.35	0.26	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
LUAD	cis	rs2212361	0.6	rs34185869	ENSG00000255893.1	RP11-685N10.1	-5.8	1.22e-08	4.59e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535430	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.593	rs34288874	ENSG00000255893.1	RP11-685N10.1	-5.8	1.22e-08	4.59e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535484	chr11:94472908~94473570:-
LUAD	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-5.8	1.22e-08	4.59e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
LUAD	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	5.8	1.22e-08	4.6e-06	0.31	0.26	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
LUAD	cis	rs9595908	0.832	rs2032495	ENSG00000212293.1	SNORA16	5.8	1.22e-08	4.6e-06	0.27	0.26	Body mass index;	chr13:32630605	chr13:32420390~32420516:-
LUAD	cis	rs7017914	0.875	rs2732107	ENSG00000223220.1	Y_RNA	5.8	1.22e-08	4.61e-06	0.29	0.26	Bone mineral density;	chr8:71013073	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000224373.3	IGHV4-59	-5.8	1.22e-08	4.61e-06	-0.16	-0.26	Kawasaki disease;	chr14:106775945	chr14:106627249~106627825:-
LUAD	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-5.8	1.22e-08	4.61e-06	-0.35	-0.26	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
LUAD	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-5.8	1.22e-08	4.61e-06	-0.5	-0.26	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
LUAD	cis	rs17666538	0.535	rs896522	ENSG00000254207.1	RP11-43A14.1	5.8	1.23e-08	4.62e-06	0.51	0.26	IgG glycosylation;	chr8:666991	chr8:725188~725877:-
LUAD	cis	rs17666538	0.535	rs1669613	ENSG00000254207.1	RP11-43A14.1	5.8	1.23e-08	4.62e-06	0.51	0.26	IgG glycosylation;	chr8:667565	chr8:725188~725877:-
LUAD	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	5.8	1.23e-08	4.62e-06	0.58	0.26	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
LUAD	cis	rs4947019	0.534	rs9487087	ENSG00000260273.1	RP11-425D10.10	5.8	1.23e-08	4.62e-06	0.56	0.26	Hematological parameters;	chr6:109401184	chr6:109382795~109383666:+
LUAD	cis	rs394563	0.591	rs237035	ENSG00000231760.4	RP11-350J20.5	5.8	1.23e-08	4.62e-06	0.31	0.26	Dupuytren's disease;	chr6:149389712	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	5.8	1.23e-08	4.62e-06	0.29	0.26	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
LUAD	cis	rs763567	0.9	rs525489	ENSG00000271811.1	RP1-79C4.4	5.8	1.23e-08	4.62e-06	0.31	0.26	Tonsillectomy;	chr1:170665861	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.835	rs503706	ENSG00000271811.1	RP1-79C4.4	5.8	1.23e-08	4.62e-06	0.31	0.26	Tonsillectomy;	chr1:170665943	chr1:170667381~170669425:+
LUAD	cis	rs948562	0.793	rs1800169	ENSG00000280010.1	AP001350.4	5.8	1.23e-08	4.62e-06	0.43	0.26	Lymphoma;	chr11:58624028	chr11:58627435~58628528:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000211967.3	IGHV3-53	-5.8	1.23e-08	4.62e-06	-0.19	-0.26	Kawasaki disease;	chr14:106776758	chr14:106592676~106593347:-
LUAD	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-5.8	1.23e-08	4.62e-06	-0.35	-0.26	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
LUAD	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-5.8	1.23e-08	4.62e-06	-0.28	-0.26	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
LUAD	cis	rs2765539	0.851	rs1325939	ENSG00000226172.2	RP4-712E4.1	5.8	1.23e-08	4.62e-06	0.31	0.26	Waist-hip ratio;	chr1:119041345	chr1:119000344~119001392:-
LUAD	cis	rs8177376	0.727	rs601985	ENSG00000254905.1	RP11-712L6.7	5.8	1.23e-08	4.63e-06	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327662	chr11:126292922~126294254:-
LUAD	cis	rs2243480	1	rs13247184	ENSG00000230295.1	RP11-458F8.2	-5.8	1.23e-08	4.63e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65893941	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35283677	ENSG00000230295.1	RP11-458F8.2	-5.8	1.23e-08	4.63e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65894246	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35421653	ENSG00000230295.1	RP11-458F8.2	-5.8	1.23e-08	4.63e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65898442	chr7:66880708~66882981:+
LUAD	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	5.8	1.23e-08	4.63e-06	0.32	0.26	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	5.8	1.23e-08	4.63e-06	0.29	0.26	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
LUAD	cis	rs7246657	0.722	rs2972430	ENSG00000276846.1	CTD-3220F14.3	-5.8	1.23e-08	4.63e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37691210	chr19:37314868~37315620:-
LUAD	cis	rs4835473	0.932	rs9308176	ENSG00000251600.4	RP11-673E1.1	-5.8	1.23e-08	4.63e-06	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:144072718	chr4:143912331~143982454:+
LUAD	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	5.8	1.23e-08	4.64e-06	0.31	0.26	Depression;	chr6:28314871	chr6:28176188~28176674:+
LUAD	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-5.8	1.23e-08	4.64e-06	-0.3	-0.26	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
LUAD	cis	rs7246657	0.722	rs2909093	ENSG00000276846.1	CTD-3220F14.3	-5.8	1.23e-08	4.64e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37708561	chr19:37314868~37315620:-
LUAD	cis	rs2288884	1	rs2288884	ENSG00000275055.1	CTC-471J1.11	-5.8	1.23e-08	4.65e-06	-0.39	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52029018	chr19:52049007~52049754:+
LUAD	cis	rs9595908	0.709	rs56347753	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32721685	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs9596149	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32722533	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs4281583	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32722781	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7322827	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32724396	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.629	rs9596156	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32724977	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.733	rs9591282	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32725844	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs7319787	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32728320	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs7331529	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32728409	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-5.8	1.24e-08	4.65e-06	-0.33	-0.26	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
LUAD	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-5.79	1.24e-08	4.66e-06	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
LUAD	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	5.79	1.24e-08	4.66e-06	0.38	0.26	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
LUAD	cis	rs12291225	0.535	rs12806025	ENSG00000251991.1	RNU7-49P	5.79	1.24e-08	4.66e-06	0.28	0.26	Sense of smell;	chr11:14392271	chr11:14478892~14478953:+
LUAD	cis	rs3738443	0.868	rs61840048	ENSG00000259865.1	RP11-488L18.10	5.79	1.24e-08	4.67e-06	0.26	0.26	Alcohol dependence;	chr1:247199829	chr1:247187281~247188526:-
LUAD	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-5.79	1.24e-08	4.67e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
LUAD	cis	rs6772849	0.775	rs67105978	ENSG00000242551.2	POU5F1P6	-5.79	1.24e-08	4.67e-06	-0.3	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128696337	chr3:128674735~128677005:-
LUAD	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	5.79	1.24e-08	4.67e-06	0.28	0.26	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
LUAD	cis	rs35740288	0.77	rs12907126	ENSG00000202081.1	RNU6-1280P	5.79	1.24e-08	4.67e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85628126	chr15:85651522~85651628:-
LUAD	cis	rs10740039	0.81	rs10761528	ENSG00000254271.1	RP11-131N11.4	5.79	1.24e-08	4.68e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607902	chr10:60734342~60741828:+
LUAD	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-5.79	1.24e-08	4.68e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
LUAD	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-5.79	1.24e-08	4.68e-06	-0.35	-0.26	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
LUAD	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	5.79	1.25e-08	4.69e-06	0.28	0.26	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
LUAD	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-5.79	1.25e-08	4.69e-06	-0.3	-0.26	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
LUAD	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-5.79	1.25e-08	4.69e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
LUAD	cis	rs10214930	0.606	rs4719900	ENSG00000235574.1	AC073150.6	-5.79	1.25e-08	4.69e-06	-0.32	-0.26	Hypospadias;	chr7:27528502	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2080245	ENSG00000235574.1	AC073150.6	-5.79	1.25e-08	4.69e-06	-0.32	-0.26	Hypospadias;	chr7:27529911	chr7:27491682~27492765:-
LUAD	cis	rs293748	0.771	rs158410	ENSG00000250155.1	CTD-2353F22.1	-5.79	1.25e-08	4.7e-06	-0.36	-0.26	Obesity-related traits;	chr5:36858559	chr5:36666214~36725195:-
LUAD	cis	rs17666538	0.585	rs4448252	ENSG00000254207.1	RP11-43A14.1	5.79	1.25e-08	4.7e-06	0.51	0.26	IgG glycosylation;	chr8:665597	chr8:725188~725877:-
LUAD	cis	rs17666538	0.535	rs4338080	ENSG00000254207.1	RP11-43A14.1	5.79	1.25e-08	4.7e-06	0.51	0.26	IgG glycosylation;	chr8:665598	chr8:725188~725877:-
LUAD	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-5.79	1.25e-08	4.71e-06	-0.33	-0.26	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
LUAD	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	5.79	1.25e-08	4.71e-06	0.31	0.26	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	5.79	1.25e-08	4.71e-06	0.31	0.26	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
LUAD	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-5.79	1.25e-08	4.71e-06	-0.33	-0.26	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.632	rs4532510	ENSG00000279048.1	RP11-511H23.2	5.79	1.25e-08	4.71e-06	0.21	0.26	Fibrinogen levels;	chr7:17931601	chr7:17940503~17942922:+
LUAD	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	5.79	1.26e-08	4.72e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
LUAD	cis	rs755249	0.876	rs61781391	ENSG00000228060.1	RP11-69E11.8	-5.79	1.26e-08	4.73e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39565160~39573203:+
LUAD	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	5.79	1.26e-08	4.74e-06	0.31	0.26	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
LUAD	cis	rs10214930	0.697	rs1524533	ENSG00000235574.1	AC073150.6	-5.79	1.26e-08	4.74e-06	-0.32	-0.26	Hypospadias;	chr7:27586177	chr7:27491682~27492765:-
LUAD	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-5.79	1.26e-08	4.74e-06	-0.29	-0.26	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-5.79	1.26e-08	4.74e-06	-0.29	-0.26	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-5.79	1.26e-08	4.74e-06	-0.29	-0.26	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
LUAD	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	5.79	1.26e-08	4.75e-06	0.31	0.26	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
LUAD	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-5.79	1.26e-08	4.75e-06	-0.3	-0.26	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
LUAD	cis	rs755249	0.567	rs61779308	ENSG00000228060.1	RP11-69E11.8	-5.79	1.26e-08	4.75e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39565160~39573203:+
LUAD	cis	rs17214007	0.877	rs7201553	ENSG00000263335.1	AF001548.5	-5.79	1.26e-08	4.75e-06	-0.36	-0.26	Cognitive function;	chr16:15781186	chr16:15726674~15732993:+
LUAD	cis	rs9595908	0.709	rs1924606	ENSG00000212293.1	SNORA16	5.79	1.27e-08	4.75e-06	0.27	0.26	Body mass index;	chr13:32759230	chr13:32420390~32420516:-
LUAD	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	5.79	1.27e-08	4.75e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	5.79	1.27e-08	4.75e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
LUAD	cis	rs55665837	0.701	rs11023265	ENSG00000251991.1	RNU7-49P	5.79	1.27e-08	4.75e-06	0.3	0.26	Vitamin D levels;	chr11:14594492	chr11:14478892~14478953:+
LUAD	cis	rs997295	0.57	rs28730805	ENSG00000270964.1	RP11-502I4.3	-5.79	1.27e-08	4.75e-06	-0.27	-0.26	Motion sickness;	chr15:67587080	chr15:67541072~67542604:-
LUAD	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-5.79	1.27e-08	4.76e-06	-0.28	-0.26	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
LUAD	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-5.79	1.27e-08	4.76e-06	-0.26	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
LUAD	cis	rs4803480	0.543	rs7257282	ENSG00000270164.1	LINC01480	-5.79	1.27e-08	4.76e-06	-0.23	-0.26	Schizophrenia;	chr19:41536585	chr19:41535183~41536904:+
LUAD	cis	rs2998286	0.678	rs332184	ENSG00000254635.4	WAC-AS1	-5.79	1.27e-08	4.76e-06	-0.37	-0.26	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624042	chr10:28522652~28532743:-
LUAD	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	5.79	1.27e-08	4.76e-06	0.29	0.26	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
LUAD	cis	rs7181230	0.885	rs3923235	ENSG00000275636.1	RP11-521C20.5	5.79	1.27e-08	4.76e-06	0.35	0.26	Dehydroepiandrosterone sulphate levels;	chr15:40078920	chr15:40078892~40079347:+
LUAD	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	5.79	1.27e-08	4.76e-06	0.29	0.26	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
LUAD	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-5.79	1.27e-08	4.77e-06	-0.37	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
LUAD	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	5.79	1.27e-08	4.77e-06	0.28	0.26	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	5.79	1.27e-08	4.77e-06	0.28	0.26	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	5.79	1.27e-08	4.77e-06	0.28	0.26	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	5.79	1.27e-08	4.77e-06	0.36	0.26	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-5.79	1.27e-08	4.77e-06	-0.33	-0.26	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.632	rs2723569	ENSG00000279048.1	RP11-511H23.2	-5.79	1.27e-08	4.78e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17854048	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-5.79	1.27e-08	4.78e-06	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-5.79	1.27e-08	4.78e-06	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
LUAD	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	5.79	1.27e-08	4.78e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
LUAD	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-5.79	1.27e-08	4.78e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
LUAD	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	5.79	1.28e-08	4.79e-06	0.29	0.26	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
LUAD	cis	rs4713118	0.513	rs149950	ENSG00000204709.4	LINC01556	5.79	1.28e-08	4.79e-06	0.32	0.26	Parkinson's disease;	chr6:28065261	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs149951	ENSG00000204709.4	LINC01556	5.79	1.28e-08	4.79e-06	0.32	0.26	Parkinson's disease;	chr6:28065309	chr6:28943877~28944537:+
LUAD	cis	rs9601248	0.627	rs9545151	ENSG00000227354.5	RBM26-AS1	-5.79	1.28e-08	4.79e-06	-0.29	-0.26	Major depressive disorder;	chr13:79608400	chr13:79406309~79424328:+
LUAD	cis	rs7246657	0.638	rs7246461	ENSG00000276846.1	CTD-3220F14.3	-5.79	1.28e-08	4.8e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37705680	chr19:37314868~37315620:-
LUAD	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-5.79	1.28e-08	4.8e-06	-0.35	-0.26	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
LUAD	cis	rs2212361	0.558	rs7934178	ENSG00000255893.1	RP11-685N10.1	-5.79	1.28e-08	4.8e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531307	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.558	rs7934183	ENSG00000255893.1	RP11-685N10.1	-5.79	1.28e-08	4.8e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531321	chr11:94472908~94473570:-
LUAD	cis	rs6772849	0.768	rs9820741	ENSG00000242551.2	POU5F1P6	-5.79	1.28e-08	4.82e-06	-0.3	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128697237	chr3:128674735~128677005:-
LUAD	cis	rs1707322	0.826	rs10890349	ENSG00000234329.1	RP11-767N6.2	5.79	1.28e-08	4.82e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.758	rs10789474	ENSG00000234329.1	RP11-767N6.2	5.79	1.28e-08	4.82e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45651039~45651826:-
LUAD	cis	rs1322639	0.614	rs9364361	ENSG00000261039.2	RP11-417E7.2	-5.79	1.28e-08	4.82e-06	-0.41	-0.26	Pulse pressure;	chr6:169180404	chr6:169175304~169182740:-
LUAD	cis	rs2404602	0.716	rs4886813	ENSG00000259422.1	RP11-593F23.1	-5.79	1.28e-08	4.82e-06	-0.29	-0.26	Blood metabolite levels;	chr15:76545880	chr15:76174891~76181486:-
LUAD	cis	rs155076	1	rs12870992	ENSG00000233325.3	MIPEPP3	-5.79	1.29e-08	4.83e-06	-0.41	-0.26	White matter hyperintensity burden;	chr13:21271880	chr13:21298139~21306373:+
LUAD	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-5.79	1.29e-08	4.83e-06	-0.35	-0.26	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-5.79	1.29e-08	4.83e-06	-0.35	-0.26	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
LUAD	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-5.79	1.29e-08	4.83e-06	-0.26	-0.26	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
LUAD	cis	rs2255336	0.938	rs7953692	ENSG00000245648.1	RP11-277P12.20	-5.79	1.29e-08	4.83e-06	-0.41	-0.26	Blood protein levels;	chr12:10482432	chr12:10363769~10398506:+
LUAD	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	5.79	1.29e-08	4.83e-06	0.3	0.26	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
LUAD	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	5.79	1.29e-08	4.84e-06	0.28	0.26	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-5.79	1.29e-08	4.84e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
LUAD	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	5.79	1.29e-08	4.84e-06	0.32	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	5.79	1.29e-08	4.84e-06	0.32	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
LUAD	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	5.79	1.29e-08	4.85e-06	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
LUAD	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-5.79	1.3e-08	4.86e-06	-0.35	-0.26	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-5.79	1.3e-08	4.86e-06	-0.35	-0.26	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
LUAD	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	5.79	1.3e-08	4.86e-06	0.31	0.26	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
LUAD	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-5.79	1.3e-08	4.87e-06	-0.31	-0.26	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
LUAD	cis	rs2243480	1	rs160643	ENSG00000230295.1	RP11-458F8.2	-5.79	1.3e-08	4.87e-06	-0.29	-0.26	Diabetic kidney disease;	chr7:66093235	chr7:66880708~66882981:+
LUAD	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	5.79	1.3e-08	4.87e-06	0.31	0.26	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
LUAD	cis	rs7688540	0.8	rs6857106	ENSG00000275426.1	CH17-262A2.1	-5.79	1.3e-08	4.88e-06	-0.3	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:149738~150317:+
LUAD	cis	rs9326246	0.556	rs662799	ENSG00000254851.1	RP11-109L13.1	-5.79	1.3e-08	4.88e-06	-0.53	-0.26	Coronary artery disease;	chr11:116792991	chr11:117135528~117138582:+
LUAD	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	5.79	1.3e-08	4.88e-06	0.23	0.26	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
LUAD	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	5.79	1.3e-08	4.88e-06	0.4	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	5.79	1.3e-08	4.88e-06	0.4	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
LUAD	cis	rs10214930	0.813	rs6954905	ENSG00000235574.1	AC073150.6	-5.79	1.3e-08	4.88e-06	-0.34	-0.26	Hypospadias;	chr7:27625206	chr7:27491682~27492765:-
LUAD	cis	rs516805	0.961	rs9385248	ENSG00000279453.1	RP3-425C14.4	-5.79	1.3e-08	4.88e-06	-0.29	-0.26	Lymphocyte counts;	chr6:122490982	chr6:122436789~122439223:-
LUAD	cis	rs10214930	0.647	rs2391438	ENSG00000235574.1	AC073150.6	-5.79	1.3e-08	4.89e-06	-0.32	-0.26	Hypospadias;	chr7:27530554	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1014373	ENSG00000235574.1	AC073150.6	-5.79	1.3e-08	4.89e-06	-0.32	-0.26	Hypospadias;	chr7:27531474	chr7:27491682~27492765:-
LUAD	cis	rs914615	0.508	rs4971079	ENSG00000160766.13	GBAP1	-5.79	1.3e-08	4.89e-06	-0.26	-0.26	Urinary albumin-to-creatinine ratio;	chr1:155157915	chr1:155213821~155227422:-
LUAD	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-5.79	1.31e-08	4.89e-06	-0.22	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
LUAD	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-5.79	1.31e-08	4.9e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-5.79	1.31e-08	4.9e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
LUAD	cis	rs6687821	0.515	rs1199726	ENSG00000267734.1	RP4-604K5.3	5.78	1.31e-08	4.91e-06	0.32	0.26	Yeast infection;	chr1:86951691	chr1:86932199~86934891:-
LUAD	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-5.78	1.31e-08	4.91e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
LUAD	cis	rs9326246	0.643	rs2072560	ENSG00000254851.1	RP11-109L13.1	-5.78	1.31e-08	4.91e-06	-0.56	-0.26	Coronary artery disease;	chr11:116791110	chr11:117135528~117138582:+
LUAD	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	5.78	1.31e-08	4.92e-06	0.18	0.26	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
LUAD	cis	rs2408955	0.522	rs3997	ENSG00000240399.1	RP1-228P16.1	-5.78	1.31e-08	4.92e-06	-0.26	-0.26	Glycated hemoglobin levels;	chr12:48087804	chr12:48054813~48055591:-
LUAD	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-5.78	1.32e-08	4.94e-06	-0.26	-0.25	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
LUAD	cis	rs7246657	0.722	rs2291002	ENSG00000276846.1	CTD-3220F14.3	5.78	1.32e-08	4.94e-06	0.33	0.25	Coronary artery calcification;	chr19:37543024	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs10404031	ENSG00000276846.1	CTD-3220F14.3	5.78	1.32e-08	4.94e-06	0.33	0.25	Coronary artery calcification;	chr19:37545052	chr19:37314868~37315620:-
LUAD	cis	rs4787484	1	rs7189750	ENSG00000214725.6	CDIPT-AS1	-5.78	1.32e-08	4.94e-06	-0.32	-0.25	Response to taxane treatment (placlitaxel);	chr16:29900095	chr16:29863593~29868053:+
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000273142.1	RP11-458F8.4	-5.78	1.32e-08	4.95e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66046617	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-5.78	1.32e-08	4.95e-06	-0.29	-0.25	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
LUAD	cis	rs2765539	1	rs2765539	ENSG00000226172.2	RP4-712E4.1	-5.78	1.32e-08	4.95e-06	-0.32	-0.25	Waist-hip ratio;	chr1:119006795	chr1:119000344~119001392:-
LUAD	cis	rs2179367	0.632	rs997682	ENSG00000231760.4	RP11-350J20.5	-5.78	1.32e-08	4.96e-06	-0.36	-0.25	Dupuytren's disease;	chr6:149345484	chr6:149796151~149826294:-
LUAD	cis	rs7618501	0.602	rs2240327	ENSG00000234667.1	ACTBP13	-5.78	1.32e-08	4.96e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:50075601	chr3:49873347~49877980:-
LUAD	cis	rs72615157	0.634	rs7789890	ENSG00000242294.5	STAG3L5P	5.78	1.32e-08	4.96e-06	0.22	0.25	Lung function (FEV1/FVC);	chr7:100202936	chr7:100336079~100351900:+
LUAD	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	5.78	1.32e-08	4.96e-06	0.31	0.25	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
LUAD	cis	rs9595908	0.63	rs79837633	ENSG00000212293.1	SNORA16	5.78	1.33e-08	4.96e-06	0.27	0.25	Body mass index;	chr13:32754590	chr13:32420390~32420516:-
LUAD	cis	rs1426063	0.614	rs17000261	ENSG00000249717.1	RP11-44F21.3	5.78	1.33e-08	4.96e-06	0.47	0.25	QT interval;	chr4:75108766	chr4:74955974~74970362:-
LUAD	cis	rs55665837	0.583	rs78843135	ENSG00000251991.1	RNU7-49P	5.78	1.33e-08	4.97e-06	0.28	0.25	Vitamin D levels;	chr11:14389708	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-5.78	1.33e-08	4.97e-06	-0.38	-0.25	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
LUAD	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	5.78	1.33e-08	4.97e-06	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	5.78	1.33e-08	4.97e-06	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
LUAD	cis	rs12188164	0.686	rs72711365	ENSG00000225138.6	CTD-2228K2.7	5.78	1.33e-08	4.97e-06	0.25	0.25	Cystic fibrosis severity;	chr5:416557	chr5:473236~480884:+
LUAD	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	5.78	1.33e-08	4.97e-06	0.5	0.25	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000211967.3	IGHV3-53	-5.78	1.33e-08	4.98e-06	-0.18	-0.25	Kawasaki disease;	chr14:106686149	chr14:106592676~106593347:-
LUAD	cis	rs7246657	0.722	rs2927739	ENSG00000276846.1	CTD-3220F14.3	-5.78	1.33e-08	4.99e-06	-0.35	-0.25	Coronary artery calcification;	chr19:37658429	chr19:37314868~37315620:-
LUAD	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	5.78	1.33e-08	4.99e-06	0.3	0.25	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
LUAD	cis	rs9595908	0.709	rs7331632	ENSG00000212293.1	SNORA16	5.78	1.33e-08	4.99e-06	0.27	0.25	Body mass index;	chr13:32753864	chr13:32420390~32420516:-
LUAD	cis	rs3738443	0.868	rs4351686	ENSG00000259865.1	RP11-488L18.10	5.78	1.34e-08	4.99e-06	0.27	0.25	Alcohol dependence;	chr1:247190028	chr1:247187281~247188526:-
LUAD	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	5.78	1.34e-08	5e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
LUAD	cis	rs301901	0.729	rs125682	ENSG00000250155.1	CTD-2353F22.1	-5.78	1.34e-08	5e-06	-0.27	-0.25	Height;	chr5:37337045	chr5:36666214~36725195:-
LUAD	cis	rs304029	0.716	rs2307068	ENSG00000231249.1	ITPR1-AS1	5.78	1.34e-08	5e-06	0.27	0.25	Diabetic kidney disease;	chr3:4491276	chr3:4490891~4493163:-
LUAD	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	5.78	1.34e-08	5e-06	0.3	0.25	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
LUAD	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-5.78	1.34e-08	5e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-5.78	1.34e-08	5e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-5.78	1.34e-08	5e-06	-0.36	-0.25	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-5.78	1.34e-08	5e-06	-0.36	-0.25	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-5.78	1.34e-08	5e-06	-0.36	-0.25	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
LUAD	cis	rs9311474	0.967	rs11717383	ENSG00000243224.1	RP5-1157M23.2	-5.78	1.34e-08	5e-06	-0.25	-0.25	Electroencephalogram traits;	chr3:52253452	chr3:52239258~52241097:+
LUAD	cis	rs9311474	1	rs1060330	ENSG00000243224.1	RP5-1157M23.2	-5.78	1.34e-08	5e-06	-0.25	-0.25	Electroencephalogram traits;	chr3:52254929	chr3:52239258~52241097:+
LUAD	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	5.78	1.34e-08	5e-06	0.26	0.25	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
LUAD	cis	rs9500256	0.683	rs10458024	ENSG00000215190.7	LINC00680	-5.78	1.34e-08	5.01e-06	-0.33	-0.25	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57946074~57961501:-
LUAD	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	5.78	1.34e-08	5.01e-06	0.29	0.25	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
LUAD	cis	rs7246657	0.722	rs10406379	ENSG00000276846.1	CTD-3220F14.3	5.78	1.34e-08	5.01e-06	0.33	0.25	Coronary artery calcification;	chr19:37545823	chr19:37314868~37315620:-
LUAD	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	5.78	1.34e-08	5.01e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
LUAD	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-5.78	1.34e-08	5.01e-06	-0.34	-0.25	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-5.78	1.34e-08	5.02e-06	-0.28	-0.25	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-5.78	1.34e-08	5.02e-06	-0.28	-0.25	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
LUAD	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	5.78	1.34e-08	5.02e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
LUAD	cis	rs7246657	0.722	rs2909102	ENSG00000276846.1	CTD-3220F14.3	-5.78	1.34e-08	5.02e-06	-0.34	-0.25	Coronary artery calcification;	chr19:37676463	chr19:37314868~37315620:-
LUAD	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	5.78	1.34e-08	5.02e-06	0.32	0.25	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
LUAD	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-5.78	1.34e-08	5.02e-06	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
LUAD	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	5.78	1.34e-08	5.02e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
LUAD	cis	rs17684571	0.7	rs13208409	ENSG00000231441.1	RP11-472M19.2	5.78	1.34e-08	5.03e-06	0.37	0.25	Schizophrenia;	chr6:56763747	chr6:56844002~56864078:+
LUAD	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	5.78	1.35e-08	5.03e-06	0.4	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
LUAD	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	5.78	1.35e-08	5.04e-06	0.32	0.25	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
LUAD	cis	rs17684571	0.751	rs13194625	ENSG00000231441.1	RP11-472M19.2	5.78	1.35e-08	5.04e-06	0.38	0.25	Schizophrenia;	chr6:56820446	chr6:56844002~56864078:+
LUAD	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-5.78	1.35e-08	5.04e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000224373.3	IGHV4-59	5.78	1.35e-08	5.05e-06	0.16	0.25	Kawasaki disease;	chr14:106776695	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000224373.3	IGHV4-59	5.78	1.35e-08	5.05e-06	0.16	0.25	Kawasaki disease;	chr14:106778202	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000224373.3	IGHV4-59	5.78	1.35e-08	5.05e-06	0.16	0.25	Kawasaki disease;	chr14:106778401	chr14:106627249~106627825:-
LUAD	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-5.78	1.35e-08	5.06e-06	-0.47	-0.25	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
LUAD	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	5.78	1.35e-08	5.06e-06	0.33	0.25	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	5.78	1.35e-08	5.06e-06	0.33	0.25	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
LUAD	cis	rs9860428	0.774	rs7651207	ENSG00000242770.2	RP11-180K7.1	5.78	1.36e-08	5.07e-06	0.27	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112822625	chr3:112802478~112812819:+
LUAD	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	5.78	1.36e-08	5.07e-06	0.36	0.25	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
LUAD	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	5.78	1.36e-08	5.07e-06	0.32	0.25	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
LUAD	cis	rs1499614	1	rs1267818	ENSG00000230295.1	RP11-458F8.2	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Gout;	chr7:66642037	chr7:66880708~66882981:+
LUAD	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
LUAD	cis	rs12188164	0.686	rs56279338	ENSG00000225138.6	CTD-2228K2.7	5.78	1.36e-08	5.08e-06	0.25	0.25	Cystic fibrosis severity;	chr5:416003	chr5:473236~480884:+
LUAD	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	5.78	1.36e-08	5.09e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
LUAD	cis	rs7829975	0.511	rs2980426	ENSG00000253981.4	ALG1L13P	5.78	1.36e-08	5.09e-06	0.31	0.25	Mood instability;	chr8:8288087	chr8:8236003~8244667:-
LUAD	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-5.78	1.36e-08	5.09e-06	-0.41	-0.25	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
LUAD	cis	rs8177876	0.915	rs4889233	ENSG00000261838.4	RP11-303E16.6	-5.78	1.36e-08	5.09e-06	-0.54	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093378	chr16:81069854~81076598:+
LUAD	cis	rs2303759	0.543	rs7255778	ENSG00000268686.1	AC010524.2	-5.78	1.36e-08	5.09e-06	-0.35	-0.25	Multiple sclerosis;	chr19:49403351	chr19:49368705~49388081:-
LUAD	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-5.78	1.36e-08	5.09e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-5.78	1.36e-08	5.09e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
LUAD	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-5.78	1.37e-08	5.1e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
LUAD	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-5.78	1.37e-08	5.1e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
LUAD	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-5.78	1.37e-08	5.1e-06	-0.32	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
LUAD	cis	rs11157436	0.958	rs17255510	ENSG00000211812.1	TRAV26-2	5.78	1.37e-08	5.1e-06	0.29	0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22202583~22203368:+
LUAD	cis	rs131777	0.545	rs140514	ENSG00000205559.3	CHKB-AS1	-5.78	1.37e-08	5.11e-06	-0.29	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50580150	chr22:50583026~50583877:+
LUAD	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-5.78	1.37e-08	5.11e-06	-0.38	-0.25	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
LUAD	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	5.78	1.37e-08	5.12e-06	0.36	0.25	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
LUAD	cis	rs4908768	0.539	rs4480384	ENSG00000232912.4	RP5-1115A15.1	5.78	1.37e-08	5.12e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8424645~8434838:+
LUAD	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	5.78	1.37e-08	5.12e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000211972.2	IGHV3-66	5.78	1.37e-08	5.13e-06	0.22	0.25	Kawasaki disease;	chr14:106777611	chr14:106675017~106675544:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000230295.1	RP11-458F8.2	-5.78	1.38e-08	5.13e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66004843	chr7:66880708~66882981:+
LUAD	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	5.78	1.38e-08	5.13e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	5.78	1.38e-08	5.13e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000224373.3	IGHV4-59	5.78	1.38e-08	5.14e-06	0.16	0.25	Kawasaki disease;	chr14:106779068	chr14:106627249~106627825:-
LUAD	cis	rs36093844	0.898	rs11234446	ENSG00000279742.1	RP11-700A24.1	-5.78	1.38e-08	5.14e-06	-0.29	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85855126	chr11:85852557~85854943:-
LUAD	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-5.78	1.38e-08	5.14e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
LUAD	cis	rs12468226	0.606	rs10445793	ENSG00000226261.1	AC064836.3	5.78	1.38e-08	5.15e-06	0.39	0.25	Urate levels;	chr2:202190799	chr2:202336024~202336727:-
LUAD	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-5.78	1.38e-08	5.15e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
LUAD	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	5.78	1.38e-08	5.15e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
LUAD	cis	rs997295	0.57	rs7172298	ENSG00000270964.1	RP11-502I4.3	-5.78	1.38e-08	5.15e-06	-0.27	-0.25	Motion sickness;	chr15:67580645	chr15:67541072~67542604:-
LUAD	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-5.78	1.38e-08	5.15e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-5.78	1.38e-08	5.15e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-5.78	1.38e-08	5.15e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
LUAD	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	5.77	1.38e-08	5.16e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
LUAD	cis	rs17666538	0.535	rs1669658	ENSG00000254207.1	RP11-43A14.1	5.77	1.38e-08	5.16e-06	0.5	0.25	IgG glycosylation;	chr8:657380	chr8:725188~725877:-
LUAD	cis	rs17301013	0.507	rs1613634	ENSG00000227373.4	RP11-160H22.5	-5.77	1.38e-08	5.16e-06	-0.37	-0.25	Systemic lupus erythematosus;	chr1:174803184	chr1:174115300~174160004:-
LUAD	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	5.77	1.38e-08	5.16e-06	0.28	0.25	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
LUAD	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	5.77	1.38e-08	5.16e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
LUAD	cis	rs2998286	0.723	rs332190	ENSG00000254635.4	WAC-AS1	-5.77	1.38e-08	5.17e-06	-0.37	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28630899	chr10:28522652~28532743:-
LUAD	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-5.77	1.39e-08	5.17e-06	-0.44	-0.25	Depression;	chr6:28139579	chr6:28115628~28116551:+
LUAD	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-5.77	1.39e-08	5.17e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
LUAD	cis	rs55665837	0.524	rs2882128	ENSG00000251991.1	RNU7-49P	5.77	1.39e-08	5.17e-06	0.28	0.25	Vitamin D levels;	chr11:14393088	chr11:14478892~14478953:+
LUAD	cis	rs2765539	0.545	rs1623409	ENSG00000226172.2	RP4-712E4.1	-5.77	1.39e-08	5.18e-06	-0.33	-0.25	Waist-hip ratio;	chr1:118962218	chr1:119000344~119001392:-
LUAD	cis	rs7246657	0.722	rs10409605	ENSG00000276846.1	CTD-3220F14.3	5.77	1.39e-08	5.18e-06	0.33	0.25	Coronary artery calcification;	chr19:37632236	chr19:37314868~37315620:-
LUAD	cis	rs17684571	0.687	rs17752213	ENSG00000231441.1	RP11-472M19.2	5.77	1.39e-08	5.18e-06	0.38	0.25	Schizophrenia;	chr6:56864627	chr6:56844002~56864078:+
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000224373.3	IGHV4-59	5.77	1.39e-08	5.18e-06	0.16	0.25	Kawasaki disease;	chr14:106787239	chr14:106627249~106627825:-
LUAD	cis	rs270601	0.721	rs162894	ENSG00000233006.5	AC034220.3	5.77	1.39e-08	5.18e-06	0.24	0.25	Acylcarnitine levels;	chr5:132276179	chr5:132311285~132369916:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000211974.3	IGHV2-70	5.77	1.39e-08	5.18e-06	0.27	0.25	Kawasaki disease;	chr14:106767055	chr14:106723574~106724093:-
LUAD	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	5.77	1.39e-08	5.19e-06	0.29	0.25	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
LUAD	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	5.77	1.39e-08	5.19e-06	0.36	0.25	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
LUAD	cis	rs5753618	0.561	rs714909	ENSG00000236132.1	CTA-440B3.1	-5.77	1.39e-08	5.19e-06	-0.32	-0.25	Colorectal cancer;	chr22:31345081	chr22:31816379~31817491:-
LUAD	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	5.77	1.39e-08	5.2e-06	0.31	0.25	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
LUAD	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-5.77	1.4e-08	5.2e-06	-0.35	-0.25	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
LUAD	cis	rs11098499	0.913	rs12186259	ENSG00000248280.1	RP11-33B1.2	5.77	1.4e-08	5.2e-06	0.33	0.25	Corneal astigmatism;	chr4:119230884	chr4:119440561~119450157:-
LUAD	cis	rs516805	0.923	rs538457	ENSG00000279453.1	RP3-425C14.4	-5.77	1.4e-08	5.21e-06	-0.29	-0.25	Lymphocyte counts;	chr6:122485610	chr6:122436789~122439223:-
LUAD	cis	rs10740039	0.516	rs2154392	ENSG00000254271.1	RP11-131N11.4	5.77	1.4e-08	5.21e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60557728	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs6479717	ENSG00000254271.1	RP11-131N11.4	5.77	1.4e-08	5.21e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559530	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs2068044	ENSG00000254271.1	RP11-131N11.4	5.77	1.4e-08	5.21e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60560679	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs1975443	ENSG00000254271.1	RP11-131N11.4	5.77	1.4e-08	5.21e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60561584	chr10:60734342~60741828:+
LUAD	cis	rs4604732	0.631	rs4411161	ENSG00000227135.1	GCSAML-AS1	-5.77	1.4e-08	5.21e-06	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469072	chr1:247524679~247526752:-
LUAD	cis	rs75920871	0.589	rs2075547	ENSG00000254851.1	RP11-109L13.1	-5.77	1.4e-08	5.22e-06	-0.43	-0.25	Subjective well-being;	chr11:117197818	chr11:117135528~117138582:+
LUAD	cis	rs783540	0.656	rs783524	ENSG00000278603.1	RP13-608F4.5	-5.77	1.4e-08	5.22e-06	-0.32	-0.25	Schizophrenia;	chr15:82615393	chr15:82472203~82472426:+
LUAD	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-5.77	1.4e-08	5.23e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
LUAD	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-5.77	1.4e-08	5.23e-06	-0.35	-0.25	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
LUAD	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	5.77	1.41e-08	5.25e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
LUAD	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-5.77	1.41e-08	5.25e-06	-0.36	-0.25	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
LUAD	cis	rs1426063	0.61	rs72862239	ENSG00000249717.1	RP11-44F21.3	5.77	1.41e-08	5.25e-06	0.49	0.25	QT interval;	chr4:75071967	chr4:74955974~74970362:-
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000230295.1	RP11-458F8.2	-5.77	1.41e-08	5.25e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66500834	chr7:66880708~66882981:+
LUAD	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs4718333	ENSG00000230295.1	RP11-458F8.2	5.77	1.41e-08	5.26e-06	0.31	0.25	Diabetic kidney disease;	chr7:66307771	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7792391	ENSG00000230295.1	RP11-458F8.2	5.77	1.41e-08	5.26e-06	0.31	0.25	Diabetic kidney disease;	chr7:66308442	chr7:66880708~66882981:+
LUAD	cis	rs948562	0.573	rs7480262	ENSG00000280010.1	AP001350.4	5.77	1.41e-08	5.26e-06	0.39	0.25	Lymphoma;	chr11:58296313	chr11:58627435~58628528:+
LUAD	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.28	0.25	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
LUAD	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	5.77	1.41e-08	5.26e-06	0.28	0.25	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-5.77	1.42e-08	5.27e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-5.77	1.42e-08	5.27e-06	-0.29	-0.25	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
LUAD	cis	rs17684571	0.7	rs4299824	ENSG00000231441.1	RP11-472M19.2	5.77	1.42e-08	5.27e-06	0.37	0.25	Schizophrenia;	chr6:56815697	chr6:56844002~56864078:+
LUAD	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-5.77	1.42e-08	5.27e-06	-0.32	-0.25	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
LUAD	cis	rs2179367	0.6	rs9498356	ENSG00000231760.4	RP11-350J20.5	5.77	1.42e-08	5.28e-06	0.37	0.25	Dupuytren's disease;	chr6:149443337	chr6:149796151~149826294:-
LUAD	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	5.77	1.42e-08	5.28e-06	0.32	0.25	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	5.77	1.42e-08	5.28e-06	0.32	0.25	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
LUAD	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-5.77	1.42e-08	5.28e-06	-0.32	-0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
LUAD	cis	rs1501911	0.509	rs692759	ENSG00000248489.1	CTD-2007H13.3	-5.77	1.42e-08	5.29e-06	-0.27	-0.25	Lung function (FEV1/FVC);	chr5:98856841	chr5:98929171~98995013:+
LUAD	cis	rs35740288	0.857	rs3803506	ENSG00000202081.1	RNU6-1280P	5.77	1.42e-08	5.29e-06	0.32	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85747709	chr15:85651522~85651628:-
LUAD	cis	rs10214930	0.671	rs11762342	ENSG00000235574.1	AC073150.6	-5.77	1.42e-08	5.29e-06	-0.31	-0.25	Hypospadias;	chr7:27622314	chr7:27491682~27492765:-
LUAD	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-5.77	1.42e-08	5.29e-06	-0.3	-0.25	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000230295.1	RP11-458F8.2	-5.77	1.42e-08	5.3e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66528779	chr7:66880708~66882981:+
LUAD	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-5.77	1.42e-08	5.3e-06	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
LUAD	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	5.77	1.42e-08	5.3e-06	0.31	0.25	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	5.77	1.42e-08	5.3e-06	0.31	0.25	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
LUAD	cis	rs172166	0.694	rs203876	ENSG00000204709.4	LINC01556	5.77	1.42e-08	5.3e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28078895	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.694	rs203877	ENSG00000204709.4	LINC01556	5.77	1.42e-08	5.3e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28080846	chr6:28943877~28944537:+
LUAD	cis	rs8040855	0.599	rs8037195	ENSG00000259774.1	RP11-182J1.13	-5.77	1.42e-08	5.3e-06	-0.29	-0.25	Bulimia nervosa;	chr15:85181455	chr15:84422618~84425882:+
LUAD	cis	rs7181230	0.885	rs2412478	ENSG00000275636.1	RP11-521C20.5	5.77	1.42e-08	5.3e-06	0.34	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40078892~40079347:+
LUAD	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.31e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.31e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
LUAD	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	5.77	1.43e-08	5.31e-06	0.41	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
LUAD	cis	rs2302464	1	rs6835705	ENSG00000214846.4	RP11-115L11.1	-5.77	1.43e-08	5.31e-06	-0.67	-0.25	Cerebrospinal fluid biomarker levels;	chr4:15736747	chr4:15730962~15731627:-
LUAD	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	5.77	1.43e-08	5.31e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
LUAD	cis	rs12188164	0.515	rs11745246	ENSG00000225138.6	CTD-2228K2.7	5.77	1.43e-08	5.31e-06	0.25	0.25	Cystic fibrosis severity;	chr5:410828	chr5:473236~480884:+
LUAD	cis	rs4713118	0.513	rs149989	ENSG00000204709.4	LINC01556	5.77	1.43e-08	5.32e-06	0.32	0.25	Parkinson's disease;	chr6:28030406	chr6:28943877~28944537:+
LUAD	cis	rs8040855	0.579	rs4843029	ENSG00000259774.1	RP11-182J1.13	-5.77	1.43e-08	5.32e-06	-0.29	-0.25	Bulimia nervosa;	chr15:85182164	chr15:84422618~84425882:+
LUAD	cis	rs11098499	0.913	rs67073020	ENSG00000248280.1	RP11-33B1.2	5.77	1.43e-08	5.32e-06	0.33	0.25	Corneal astigmatism;	chr4:119231402	chr4:119440561~119450157:-
LUAD	cis	rs11096990	0.964	rs6835064	ENSG00000249207.1	RP11-360F5.1	5.77	1.43e-08	5.33e-06	0.28	0.25	Cognitive function;	chr4:39264346	chr4:39112677~39126818:-
LUAD	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-5.77	1.43e-08	5.33e-06	-0.38	-0.25	Pain;	chr19:21491155	chr19:21554640~21569237:-
LUAD	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-5.77	1.43e-08	5.33e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
LUAD	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.34e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.34e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.34e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.34e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
LUAD	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-5.77	1.43e-08	5.34e-06	-0.35	-0.25	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
LUAD	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-5.77	1.44e-08	5.34e-06	-0.37	-0.25	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
LUAD	cis	rs36093844	0.752	rs75639684	ENSG00000279742.1	RP11-700A24.1	-5.77	1.44e-08	5.34e-06	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85860533	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs79734467	ENSG00000279742.1	RP11-700A24.1	-5.77	1.44e-08	5.34e-06	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85860910	chr11:85852557~85854943:-
LUAD	cis	rs10214930	0.651	rs4722728	ENSG00000235574.1	AC073150.6	5.77	1.44e-08	5.34e-06	0.32	0.25	Hypospadias;	chr7:27654669	chr7:27491682~27492765:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000211972.2	IGHV3-66	5.77	1.44e-08	5.34e-06	0.22	0.25	Kawasaki disease;	chr14:106777528	chr14:106675017~106675544:-
LUAD	cis	rs75422866	0.51	rs73105819	ENSG00000274902.1	RP1-197B17.4	5.77	1.44e-08	5.34e-06	0.56	0.25	Pneumonia;	chr12:47727190	chr12:47731908~47732351:+
LUAD	cis	rs17666538	0.585	rs1669615	ENSG00000254207.1	RP11-43A14.1	5.77	1.44e-08	5.35e-06	0.51	0.25	IgG glycosylation;	chr8:666665	chr8:725188~725877:-
LUAD	cis	rs1031391	0.716	rs10772416	ENSG00000270863.1	DDX55P1	-5.77	1.44e-08	5.35e-06	-0.36	-0.25	Bitter taste perception;	chr12:11017488	chr12:11512723~11514136:+
LUAD	cis	rs12223324	0.654	rs10794338	ENSG00000255142.1	AP006621.6	-5.77	1.44e-08	5.36e-06	-0.24	-0.25	Fuchs's corneal dystrophy;	chr11:746992	chr11:781645~782105:+
LUAD	cis	rs755249	0.761	rs61781390	ENSG00000228060.1	RP11-69E11.8	-5.77	1.44e-08	5.36e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39565160~39573203:+
LUAD	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-5.77	1.44e-08	5.36e-06	-0.35	-0.25	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
LUAD	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	5.77	1.45e-08	5.38e-06	0.4	0.25	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
LUAD	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	5.77	1.45e-08	5.38e-06	0.4	0.25	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
LUAD	cis	rs17666538	0.585	rs6559065	ENSG00000254207.1	RP11-43A14.1	5.77	1.45e-08	5.38e-06	0.51	0.25	IgG glycosylation;	chr8:673156	chr8:725188~725877:-
LUAD	cis	rs17684571	0.683	rs13215883	ENSG00000231441.1	RP11-472M19.2	5.77	1.45e-08	5.38e-06	0.39	0.25	Schizophrenia;	chr6:56858927	chr6:56844002~56864078:+
LUAD	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-5.77	1.45e-08	5.38e-06	-0.29	-0.25	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
LUAD	cis	rs1426063	0.614	rs114761716	ENSG00000249717.1	RP11-44F21.3	5.77	1.45e-08	5.39e-06	0.47	0.25	QT interval;	chr4:75107209	chr4:74955974~74970362:-
LUAD	cis	rs3738443	0.768	rs6668154	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247187981	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.768	rs6665647	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247188127	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.817	rs1115202	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247189878	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.868	rs61839994	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247195479	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.868	rs7536883	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247196266	chr1:247187281~247188526:-
LUAD	cis	rs7804306	1	rs35641104	ENSG00000233264.2	AC006042.8	5.77	1.45e-08	5.39e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046289	chr7:7980312~7982228:+
LUAD	cis	rs7804306	1	rs12702689	ENSG00000233264.2	AC006042.8	5.77	1.45e-08	5.39e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046767	chr7:7980312~7982228:+
LUAD	cis	rs6772849	0.804	rs4857920	ENSG00000242551.2	POU5F1P6	-5.77	1.45e-08	5.39e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128688780	chr3:128674735~128677005:-
LUAD	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	5.77	1.45e-08	5.4e-06	0.37	0.25	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
LUAD	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	5.77	1.45e-08	5.4e-06	0.53	0.25	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
LUAD	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-5.77	1.46e-08	5.42e-06	-0.32	-0.25	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
LUAD	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	5.77	1.46e-08	5.42e-06	0.28	0.25	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
LUAD	cis	rs301901	0.569	rs217846	ENSG00000250155.1	CTD-2353F22.1	5.77	1.46e-08	5.42e-06	0.27	0.25	Height;	chr5:37367180	chr5:36666214~36725195:-
LUAD	cis	rs9652601	0.691	rs9926078	ENSG00000274038.1	RP11-66H6.4	-5.77	1.46e-08	5.42e-06	-0.31	-0.25	Systemic lupus erythematosus;	chr16:11109708	chr16:11056556~11057034:+
LUAD	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-5.77	1.46e-08	5.42e-06	-0.31	-0.25	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
LUAD	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	5.77	1.46e-08	5.42e-06	0.29	0.25	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
LUAD	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-5.77	1.46e-08	5.42e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
LUAD	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-5.76	1.46e-08	5.43e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
LUAD	cis	rs12439619	0.705	rs17354185	ENSG00000255769.6	GOLGA2P10	5.76	1.46e-08	5.44e-06	0.33	0.25	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472993~82513950:-
LUAD	cis	rs35740288	0.731	rs11638407	ENSG00000202081.1	RNU6-1280P	5.76	1.46e-08	5.44e-06	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85551424	chr15:85651522~85651628:-
LUAD	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-5.76	1.46e-08	5.44e-06	-0.34	-0.25	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
LUAD	cis	rs1823913	0.614	rs12616167	ENSG00000280083.1	RP11-317J9.1	5.76	1.47e-08	5.44e-06	0.3	0.25	Obesity-related traits;	chr2:191311274	chr2:191154118~191156070:-
LUAD	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	5.76	1.47e-08	5.46e-06	0.29	0.25	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
LUAD	cis	rs896854	0.654	rs1453377	ENSG00000253528.2	RP11-347C18.4	5.76	1.47e-08	5.47e-06	0.25	0.25	Type 2 diabetes;	chr8:94957719	chr8:94974573~94974853:-
LUAD	cis	rs6504622	0.934	rs3760377	ENSG00000262879.4	RP11-156P1.3	-5.76	1.47e-08	5.47e-06	-0.3	-0.25	Orofacial clefts;	chr17:46964713	chr17:46984045~47100323:-
LUAD	cis	rs6504622	1	rs11079745	ENSG00000262879.4	RP11-156P1.3	-5.76	1.47e-08	5.47e-06	-0.3	-0.25	Orofacial clefts;	chr17:46966781	chr17:46984045~47100323:-
LUAD	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-5.76	1.48e-08	5.47e-06	-0.29	-0.25	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
LUAD	cis	rs72634501	0.622	rs4660416	ENSG00000228060.1	RP11-69E11.8	-5.76	1.48e-08	5.48e-06	-0.26	-0.25	HDL cholesterol;	chr1:39113314	chr1:39565160~39573203:+
LUAD	cis	rs1426063	0.614	rs17000260	ENSG00000249717.1	RP11-44F21.3	5.76	1.48e-08	5.48e-06	0.46	0.25	QT interval;	chr4:75108576	chr4:74955974~74970362:-
LUAD	cis	rs10214930	0.602	rs2098315	ENSG00000235574.1	AC073150.6	-5.76	1.48e-08	5.48e-06	-0.32	-0.25	Hypospadias;	chr7:27541026	chr7:27491682~27492765:-
LUAD	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-5.76	1.48e-08	5.48e-06	-0.28	-0.25	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
LUAD	cis	rs10214930	1	rs10250333	ENSG00000235574.1	AC073150.6	5.76	1.48e-08	5.49e-06	0.36	0.25	Hypospadias;	chr7:27723003	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.958	rs28521509	ENSG00000235574.1	AC073150.6	5.76	1.48e-08	5.49e-06	0.36	0.25	Hypospadias;	chr7:27723008	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.958	rs10268051	ENSG00000235574.1	AC073150.6	5.76	1.48e-08	5.49e-06	0.36	0.25	Hypospadias;	chr7:27723971	chr7:27491682~27492765:-
LUAD	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	5.76	1.48e-08	5.49e-06	0.32	0.25	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	5.76	1.48e-08	5.49e-06	0.32	0.25	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
LUAD	cis	rs4787484	1	rs11344	ENSG00000214725.6	CDIPT-AS1	-5.76	1.48e-08	5.49e-06	-0.32	-0.25	Response to taxane treatment (placlitaxel);	chr16:29899197	chr16:29863593~29868053:+
LUAD	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	5.76	1.48e-08	5.5e-06	0.31	0.25	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	5.76	1.48e-08	5.5e-06	0.31	0.25	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
LUAD	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	5.76	1.48e-08	5.51e-06	0.27	0.25	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	5.76	1.48e-08	5.51e-06	0.31	0.25	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
LUAD	cis	rs1426063	0.614	rs76931926	ENSG00000249717.1	RP11-44F21.3	5.76	1.48e-08	5.51e-06	0.47	0.25	QT interval;	chr4:75106902	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs115279737	ENSG00000249717.1	RP11-44F21.3	5.76	1.48e-08	5.51e-06	0.47	0.25	QT interval;	chr4:75107557	chr4:74955974~74970362:-
LUAD	cis	rs1707322	0.686	rs2991977	ENSG00000234329.1	RP11-767N6.2	-5.76	1.48e-08	5.51e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.656	rs2991981	ENSG00000234329.1	RP11-767N6.2	-5.76	1.48e-08	5.51e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-5.76	1.49e-08	5.51e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
LUAD	cis	rs755249	0.567	rs3768301	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs113214136	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs3768302	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.532	rs17343193	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61779300	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39565160~39573203:+
LUAD	cis	rs7246657	0.678	rs4802024	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37561291	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs6508736	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37570855	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.55	rs9941475	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37573615	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.765	rs4803262	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37575858	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.712	rs4803263	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37575880	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs10412510	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37585043	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs3829688	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37586199	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs13744	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37587011	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs10403173	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37587779	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.679	rs12461113	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37592287	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.639	rs12459015	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37592288	chr19:37314868~37315620:-
LUAD	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-5.76	1.49e-08	5.52e-06	-0.36	-0.25	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
LUAD	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	5.76	1.49e-08	5.52e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000224373.3	IGHV4-59	-5.76	1.49e-08	5.52e-06	-0.17	-0.25	Kawasaki disease;	chr14:106684476	chr14:106627249~106627825:-
LUAD	cis	rs2898681	0.528	rs73814883	ENSG00000248375.1	RP11-177B4.1	-5.76	1.49e-08	5.53e-06	-0.47	-0.25	Optic nerve measurement (cup area);	chr4:52861887	chr4:52720081~52720831:-
LUAD	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-5.76	1.49e-08	5.53e-06	-0.27	-0.25	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
LUAD	cis	rs4803480	0.872	rs2058149	ENSG00000270164.1	LINC01480	-5.76	1.49e-08	5.53e-06	-0.25	-0.25	Schizophrenia;	chr19:41580312	chr19:41535183~41536904:+
LUAD	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-5.76	1.49e-08	5.53e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
LUAD	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-5.76	1.49e-08	5.53e-06	-0.34	-0.25	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-5.76	1.49e-08	5.53e-06	-0.34	-0.25	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
LUAD	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-5.76	1.49e-08	5.54e-06	-0.27	-0.25	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
LUAD	cis	rs10761482	0.5	rs1890926	ENSG00000254271.1	RP11-131N11.4	5.76	1.49e-08	5.54e-06	0.28	0.25	Schizophrenia;	chr10:60530347	chr10:60734342~60741828:+
LUAD	cis	rs17684571	0.751	rs10498812	ENSG00000231441.1	RP11-472M19.2	5.76	1.49e-08	5.54e-06	0.38	0.25	Schizophrenia;	chr6:56819412	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs13220628	ENSG00000231441.1	RP11-472M19.2	5.76	1.49e-08	5.54e-06	0.38	0.25	Schizophrenia;	chr6:56819445	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs13203148	ENSG00000231441.1	RP11-472M19.2	5.76	1.49e-08	5.54e-06	0.38	0.25	Schizophrenia;	chr6:56822235	chr6:56844002~56864078:+
LUAD	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-5.76	1.49e-08	5.54e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
LUAD	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	5.76	1.49e-08	5.54e-06	0.28	0.25	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
LUAD	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-5.76	1.49e-08	5.54e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
LUAD	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-5.76	1.5e-08	5.54e-06	-0.27	-0.25	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
LUAD	cis	rs301901	0.698	rs217845	ENSG00000250155.1	CTD-2353F22.1	5.76	1.5e-08	5.55e-06	0.27	0.25	Height;	chr5:37367360	chr5:36666214~36725195:-
LUAD	cis	rs600231	0.708	rs1784100	ENSG00000245532.5	NEAT1	5.76	1.5e-08	5.55e-06	0.2	0.25	Bone mineral density;	chr11:65481756	chr11:65422774~65445540:+
LUAD	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-5.76	1.5e-08	5.55e-06	-0.27	-0.25	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
LUAD	cis	rs6840258	0.607	rs56023922	ENSG00000251411.1	RP11-397E7.4	-5.76	1.5e-08	5.56e-06	-0.36	-0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86994934	chr4:86913266~86914817:-
LUAD	cis	rs2919009	0.602	rs7906342	ENSG00000271670.1	RP11-95I16.4	5.76	1.5e-08	5.57e-06	0.31	0.25	Obesity-related traits;	chr10:120923654	chr10:120879256~120880667:-
LUAD	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-5.76	1.5e-08	5.57e-06	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
LUAD	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-5.76	1.5e-08	5.57e-06	-0.28	-0.25	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	5.76	1.5e-08	5.57e-06	0.29	0.25	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
LUAD	cis	rs7804306	1	rs35425218	ENSG00000233264.2	AC006042.8	5.76	1.51e-08	5.58e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7977124	chr7:7980312~7982228:+
LUAD	cis	rs17684571	0.687	rs13214893	ENSG00000231441.1	RP11-472M19.2	5.76	1.51e-08	5.58e-06	0.39	0.25	Schizophrenia;	chr6:56865425	chr6:56844002~56864078:+
LUAD	cis	rs1499614	1	rs1267817	ENSG00000230295.1	RP11-458F8.2	-5.76	1.51e-08	5.58e-06	-0.31	-0.25	Gout;	chr7:66645053	chr7:66880708~66882981:+
LUAD	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	5.76	1.51e-08	5.59e-06	0.28	0.25	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	5.76	1.51e-08	5.59e-06	0.28	0.25	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
LUAD	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	5.76	1.51e-08	5.59e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.583	rs2176623	ENSG00000259422.1	RP11-593F23.1	5.76	1.51e-08	5.59e-06	0.29	0.25	Blood metabolite levels;	chr15:76276238	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-5.76	1.51e-08	5.59e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
LUAD	cis	rs6840258	0.66	rs55816619	ENSG00000251411.1	RP11-397E7.4	-5.76	1.51e-08	5.59e-06	-0.36	-0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87038653	chr4:86913266~86914817:-
LUAD	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-5.76	1.51e-08	5.6e-06	-0.32	-0.25	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
LUAD	cis	rs7208859	0.673	rs216411	ENSG00000263603.1	CTD-2349P21.5	5.76	1.51e-08	5.6e-06	0.38	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30729469~30731202:+
LUAD	cis	rs36093844	0.8	rs78356210	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85870224	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs113529766	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85872358	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs76464398	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85872855	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs116940726	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873009	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs1445505	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873679	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs1445504	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873836	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs1445503	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873968	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.698	rs79435802	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85874163	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs79814326	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85874530	chr11:85852557~85854943:-
LUAD	cis	rs7246657	0.722	rs954504	ENSG00000276846.1	CTD-3220F14.3	5.76	1.51e-08	5.6e-06	0.33	0.25	Coronary artery calcification;	chr19:37554492	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs8110865	ENSG00000276846.1	CTD-3220F14.3	5.76	1.51e-08	5.6e-06	0.33	0.25	Coronary artery calcification;	chr19:37556485	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs4802029	ENSG00000276846.1	CTD-3220F14.3	5.76	1.51e-08	5.6e-06	0.33	0.25	Coronary artery calcification;	chr19:37564710	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs28512414	ENSG00000276846.1	CTD-3220F14.3	5.76	1.51e-08	5.6e-06	0.33	0.25	Coronary artery calcification;	chr19:37565672	chr19:37314868~37315620:-
LUAD	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	5.76	1.51e-08	5.61e-06	0.28	0.25	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-5.76	1.52e-08	5.61e-06	-0.37	-0.25	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
LUAD	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	5.76	1.52e-08	5.62e-06	0.33	0.25	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
LUAD	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	5.76	1.52e-08	5.62e-06	0.37	0.25	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
LUAD	cis	rs6543140	0.964	rs2080288	ENSG00000234389.1	AC007278.3	5.76	1.52e-08	5.62e-06	0.25	0.25	Blood protein levels;	chr2:102405706	chr2:102438713~102440475:+
LUAD	cis	rs3096299	0.583	rs2965949	ENSG00000274627.1	RP11-104N10.2	5.76	1.52e-08	5.62e-06	0.27	0.25	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89516797~89522217:+
LUAD	cis	rs4908760	0.795	rs6693009	ENSG00000232912.4	RP5-1115A15.1	5.76	1.52e-08	5.63e-06	0.23	0.25	Vitiligo;	chr1:8683651	chr1:8424645~8434838:+
LUAD	cis	rs1113500	0.527	rs1777482	ENSG00000226822.1	RP11-356N1.2	-5.76	1.52e-08	5.63e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108068752	chr1:108071482~108074519:+
LUAD	cis	rs10214930	0.671	rs6462038	ENSG00000235574.1	AC073150.6	-5.76	1.52e-08	5.63e-06	-0.31	-0.25	Hypospadias;	chr7:27620831	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs1115347	ENSG00000235574.1	AC073150.6	-5.76	1.52e-08	5.63e-06	-0.31	-0.25	Hypospadias;	chr7:27622979	chr7:27491682~27492765:-
LUAD	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-5.76	1.52e-08	5.63e-06	-0.25	-0.25	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
LUAD	cis	rs12468226	0.873	rs3181153	ENSG00000226261.1	AC064836.3	-5.76	1.52e-08	5.64e-06	-0.41	-0.25	Urate levels;	chr2:202205155	chr2:202336024~202336727:-
LUAD	cis	rs1816752	0.905	rs1348110	ENSG00000273628.1	RP11-756A22.7	5.76	1.52e-08	5.64e-06	0.29	0.25	Obesity-related traits;	chr13:24406537	chr13:24933006~24936796:+
LUAD	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-5.76	1.52e-08	5.64e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-5.76	1.52e-08	5.64e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
LUAD	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	5.76	1.52e-08	5.64e-06	0.23	0.25	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
LUAD	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	5.76	1.52e-08	5.64e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
LUAD	cis	rs807029	0.758	rs807025	ENSG00000272572.1	RP11-179B2.2	-5.76	1.53e-08	5.64e-06	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101005064	chr10:100911103~100912739:-
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000224373.3	IGHV4-59	5.76	1.53e-08	5.65e-06	0.16	0.25	Kawasaki disease;	chr14:106776528	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-5.76	1.53e-08	5.66e-06	-0.28	-0.25	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-5.76	1.53e-08	5.66e-06	-0.25	-0.25	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
LUAD	cis	rs4604732	0.536	rs12037221	ENSG00000227135.1	GCSAML-AS1	-5.76	1.53e-08	5.66e-06	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247467910	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs4925551	ENSG00000227135.1	GCSAML-AS1	-5.76	1.53e-08	5.66e-06	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468422	chr1:247524679~247526752:-
LUAD	cis	rs2288884	1	rs76368799	ENSG00000275055.1	CTC-471J1.11	-5.76	1.53e-08	5.66e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058254	chr19:52049007~52049754:+
LUAD	cis	rs948562	0.535	rs11229439	ENSG00000280010.1	AP001350.4	5.76	1.53e-08	5.67e-06	0.41	0.25	Lymphoma;	chr11:58425138	chr11:58627435~58628528:+
LUAD	cis	rs8177876	0.915	rs11866124	ENSG00000261838.4	RP11-303E16.6	-5.76	1.53e-08	5.67e-06	-0.54	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093866	chr16:81069854~81076598:+
LUAD	cis	rs6687821	0.515	rs10782587	ENSG00000267734.1	RP4-604K5.3	-5.76	1.53e-08	5.67e-06	-0.31	-0.25	Yeast infection;	chr1:86962204	chr1:86932199~86934891:-
LUAD	cis	rs4789693	0.518	rs6502108	ENSG00000265458.1	RP13-20L14.6	-5.76	1.53e-08	5.67e-06	-0.33	-0.25	Glucocorticoid-induced osteonecrosis;	chr17:82417023	chr17:82454273~82458521:-
LUAD	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-5.76	1.53e-08	5.68e-06	-0.3	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
LUAD	cis	rs12699921	0.632	rs2691604	ENSG00000279048.1	RP11-511H23.2	-5.76	1.54e-08	5.68e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17781389	chr7:17940503~17942922:+
LUAD	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	5.76	1.54e-08	5.68e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
LUAD	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-5.76	1.54e-08	5.69e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
LUAD	cis	rs4908768	0.501	rs6668508	ENSG00000232912.4	RP5-1115A15.1	5.76	1.54e-08	5.69e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs6577494	ENSG00000232912.4	RP5-1115A15.1	5.76	1.54e-08	5.69e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8424645~8434838:+
LUAD	cis	rs35740288	0.857	rs11630274	ENSG00000202081.1	RNU6-1280P	5.76	1.54e-08	5.69e-06	0.32	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85745156	chr15:85651522~85651628:-
LUAD	cis	rs748404	0.666	rs12899865	ENSG00000205771.5	CATSPER2P1	-5.76	1.54e-08	5.69e-06	-0.37	-0.25	Lung cancer;	chr15:43448819	chr15:43726918~43747094:-
LUAD	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	5.76	1.54e-08	5.69e-06	0.33	0.25	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-5.76	1.54e-08	5.69e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-5.76	1.54e-08	5.69e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	5.76	1.54e-08	5.7e-06	0.29	0.25	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	5.76	1.54e-08	5.7e-06	0.29	0.25	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
LUAD	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	5.76	1.54e-08	5.7e-06	0.32	0.25	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
LUAD	cis	rs301901	0.634	rs4869429	ENSG00000250155.1	CTD-2353F22.1	5.76	1.54e-08	5.7e-06	0.27	0.25	Height;	chr5:37407777	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	5.76	1.54e-08	5.7e-06	0.27	0.25	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
LUAD	cis	rs9652601	0.622	rs8049882	ENSG00000274038.1	RP11-66H6.4	-5.76	1.54e-08	5.7e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11025629	chr16:11056556~11057034:+
LUAD	cis	rs720064	0.557	rs12969459	ENSG00000264745.1	TTC39C-AS1	5.76	1.54e-08	5.7e-06	0.27	0.25	Strep throat;	chr18:23922095	chr18:23994213~24015339:-
LUAD	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-5.76	1.54e-08	5.7e-06	-0.28	-0.25	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
LUAD	cis	rs4538475	0.556	rs4403048	ENSG00000214846.4	RP11-115L11.1	5.76	1.54e-08	5.71e-06	0.37	0.25	Parkinson's disease;	chr4:15735497	chr4:15730962~15731627:-
LUAD	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-5.75	1.55e-08	5.71e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
LUAD	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	5.75	1.55e-08	5.71e-06	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
LUAD	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-5.75	1.55e-08	5.71e-06	-0.27	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
LUAD	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	5.75	1.55e-08	5.72e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
LUAD	cis	rs1426063	0.614	rs78784058	ENSG00000249717.1	RP11-44F21.3	5.75	1.55e-08	5.72e-06	0.47	0.25	QT interval;	chr4:75108738	chr4:74955974~74970362:-
LUAD	cis	rs7246657	0.722	rs1564206	ENSG00000276846.1	CTD-3220F14.3	5.75	1.55e-08	5.72e-06	0.33	0.25	Coronary artery calcification;	chr19:37549174	chr19:37314868~37315620:-
LUAD	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-5.75	1.55e-08	5.73e-06	-0.36	-0.25	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
LUAD	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	5.75	1.55e-08	5.74e-06	0.28	0.25	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
LUAD	cis	rs12468226	0.679	rs6435133	ENSG00000226261.1	AC064836.3	-5.75	1.55e-08	5.74e-06	-0.41	-0.25	Urate levels;	chr2:202209237	chr2:202336024~202336727:-
LUAD	cis	rs948562	0.744	rs12362087	ENSG00000280010.1	AP001350.4	5.75	1.55e-08	5.74e-06	0.37	0.25	Lymphoma;	chr11:58456447	chr11:58627435~58628528:+
LUAD	cis	rs7618501	0.633	rs2526748	ENSG00000234667.1	ACTBP13	5.75	1.55e-08	5.74e-06	0.28	0.25	Intelligence (multi-trait analysis);	chr3:50043006	chr3:49873347~49877980:-
LUAD	cis	rs35740288	0.787	rs2291048	ENSG00000202081.1	RNU6-1280P	-5.75	1.55e-08	5.74e-06	-0.32	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682427	chr15:85651522~85651628:-
LUAD	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	5.75	1.56e-08	5.75e-06	0.36	0.25	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
LUAD	cis	rs2288884	1	rs80278704	ENSG00000275055.1	CTC-471J1.11	-5.75	1.56e-08	5.75e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52045930	chr19:52049007~52049754:+
LUAD	cis	rs2288884	1	rs11669540	ENSG00000275055.1	CTC-471J1.11	-5.75	1.56e-08	5.75e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52046486	chr19:52049007~52049754:+
LUAD	cis	rs2288884	1	rs78543982	ENSG00000275055.1	CTC-471J1.11	-5.75	1.56e-08	5.75e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047614	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.943	rs3752120	ENSG00000275055.1	CTC-471J1.11	-5.75	1.56e-08	5.75e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048768	chr19:52049007~52049754:+
LUAD	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	5.75	1.56e-08	5.75e-06	0.32	0.25	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
LUAD	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	5.75	1.56e-08	5.75e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	5.75	1.56e-08	5.75e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	5.75	1.56e-08	5.75e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	5.75	1.56e-08	5.75e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
LUAD	cis	rs4713118	0.513	rs149878	ENSG00000219392.1	RP1-265C24.5	-5.75	1.56e-08	5.76e-06	-0.33	-0.25	Parkinson's disease;	chr6:27910960	chr6:28115628~28116551:+
LUAD	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	5.75	1.56e-08	5.76e-06	0.29	0.25	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
LUAD	cis	rs7246657	0.722	rs10402671	ENSG00000276846.1	CTD-3220F14.3	5.75	1.56e-08	5.76e-06	0.34	0.25	Coronary artery calcification;	chr19:37626185	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs10417576	ENSG00000276846.1	CTD-3220F14.3	5.75	1.56e-08	5.76e-06	0.34	0.25	Coronary artery calcification;	chr19:37628311	chr19:37314868~37315620:-
LUAD	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	5.75	1.56e-08	5.76e-06	0.27	0.25	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
LUAD	cis	rs2115536	0.73	rs4238512	ENSG00000278600.1	RP11-81A1.6	5.75	1.56e-08	5.76e-06	0.21	0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79891556	chr15:79920195~79922455:-
LUAD	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
LUAD	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	5.75	1.56e-08	5.77e-06	0.29	0.25	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
LUAD	cis	rs9595908	0.709	rs9285093	ENSG00000212293.1	SNORA16	5.75	1.56e-08	5.78e-06	0.27	0.25	Body mass index;	chr13:32745500	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-5.75	1.56e-08	5.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
LUAD	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-5.75	1.57e-08	5.78e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
LUAD	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	5.75	1.57e-08	5.78e-06	0.28	0.25	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-5.75	1.57e-08	5.79e-06	-0.27	-0.25	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
LUAD	cis	rs3738443	0.904	rs61840000	ENSG00000259865.1	RP11-488L18.10	5.75	1.57e-08	5.79e-06	0.28	0.25	Alcohol dependence;	chr1:247199027	chr1:247187281~247188526:-
LUAD	cis	rs10740039	0.516	rs1938546	ENSG00000254271.1	RP11-131N11.4	5.75	1.57e-08	5.79e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60556228	chr10:60734342~60741828:+
LUAD	cis	rs9652601	0.719	rs12103174	ENSG00000274038.1	RP11-66H6.4	-5.75	1.57e-08	5.8e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11109873	chr16:11056556~11057034:+
LUAD	cis	rs9652601	0.649	rs767448	ENSG00000274038.1	RP11-66H6.4	-5.75	1.57e-08	5.8e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11110364	chr16:11056556~11057034:+
LUAD	cis	rs6504622	1	rs1047779	ENSG00000262879.4	RP11-156P1.3	-5.75	1.57e-08	5.8e-06	-0.29	-0.25	Orofacial clefts;	chr17:46941877	chr17:46984045~47100323:-
LUAD	cis	rs9910055	0.718	rs2526022	ENSG00000267080.4	ASB16-AS1	-5.75	1.58e-08	5.82e-06	-0.23	-0.25	Total body bone mineral density;	chr17:44135848	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.762	rs2526021	ENSG00000267080.4	ASB16-AS1	-5.75	1.58e-08	5.82e-06	-0.23	-0.25	Total body bone mineral density;	chr17:44135979	chr17:44175973~44186717:-
LUAD	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-5.75	1.58e-08	5.82e-06	-0.28	-0.25	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
LUAD	cis	rs9595908	0.869	rs9591189	ENSG00000212293.1	SNORA16	5.75	1.58e-08	5.82e-06	0.27	0.25	Body mass index;	chr13:32632514	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	5.75	1.58e-08	5.83e-06	0.31	0.25	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
LUAD	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-5.75	1.58e-08	5.83e-06	-0.24	-0.25	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
LUAD	cis	rs6543140	0.964	rs1035126	ENSG00000234389.1	AC007278.3	5.75	1.58e-08	5.84e-06	0.25	0.25	Blood protein levels;	chr2:102403521	chr2:102438713~102440475:+
LUAD	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	5.75	1.58e-08	5.84e-06	0.3	0.25	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
LUAD	cis	rs2688482	0.512	rs3103954	ENSG00000224769.1	AC069213.1	5.75	1.58e-08	5.84e-06	0.44	0.25	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195614947~195620233:+
LUAD	cis	rs4713118	0.513	rs9368547	ENSG00000204709.4	LINC01556	5.75	1.59e-08	5.85e-06	0.32	0.25	Parkinson's disease;	chr6:28060289	chr6:28943877~28944537:+
LUAD	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-5.75	1.59e-08	5.87e-06	-0.35	-0.25	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-5.75	1.59e-08	5.87e-06	-0.21	-0.25	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
LUAD	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-5.75	1.59e-08	5.88e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-5.75	1.59e-08	5.88e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-5.75	1.59e-08	5.88e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
LUAD	cis	rs8031584	0.56	rs7171208	ENSG00000270015.1	RP11-540B6.6	5.75	1.59e-08	5.88e-06	0.17	0.25	Huntington's disease progression;	chr15:30906726	chr15:30926514~30928407:+
LUAD	cis	rs1816752	1	rs7988810	ENSG00000273628.1	RP11-756A22.7	5.75	1.59e-08	5.88e-06	0.3	0.25	Obesity-related traits;	chr13:24444958	chr13:24933006~24936796:+
LUAD	cis	rs9543976	1	rs73223984	ENSG00000261553.4	RP11-29G8.3	-5.75	1.59e-08	5.88e-06	-0.41	-0.25	Diabetic retinopathy;	chr13:75607005	chr13:75549773~75807120:+
LUAD	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	5.75	1.6e-08	5.89e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	5.75	1.6e-08	5.89e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
LUAD	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	5.75	1.6e-08	5.89e-06	0.38	0.25	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
LUAD	cis	rs2280018	0.963	rs4985147	ENSG00000188599.16	NPIPP1	-5.75	1.6e-08	5.9e-06	-0.21	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15104312~15123498:-
LUAD	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-5.75	1.6e-08	5.9e-06	-0.33	-0.25	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000211972.2	IGHV3-66	-5.75	1.6e-08	5.9e-06	-0.22	-0.25	Kawasaki disease;	chr14:106775945	chr14:106675017~106675544:-
LUAD	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	5.75	1.6e-08	5.9e-06	0.29	0.25	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
LUAD	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	5.75	1.6e-08	5.9e-06	0.33	0.25	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	5.75	1.6e-08	5.9e-06	0.33	0.25	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
LUAD	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-5.75	1.6e-08	5.91e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	5.75	1.6e-08	5.91e-06	0.36	0.25	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
LUAD	cis	rs36093844	0.8	rs76663264	ENSG00000279742.1	RP11-700A24.1	-5.75	1.6e-08	5.91e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867412	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs75605851	ENSG00000279742.1	RP11-700A24.1	-5.75	1.6e-08	5.91e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85868988	chr11:85852557~85854943:-
LUAD	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-5.75	1.61e-08	5.92e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
LUAD	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	5.75	1.61e-08	5.92e-06	0.29	0.25	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
LUAD	cis	rs10761482	0.544	rs1938544	ENSG00000254271.1	RP11-131N11.4	5.75	1.61e-08	5.92e-06	0.28	0.25	Schizophrenia;	chr10:60524901	chr10:60734342~60741828:+
LUAD	cis	rs10761482	0.5	rs1938543	ENSG00000254271.1	RP11-131N11.4	5.75	1.61e-08	5.92e-06	0.28	0.25	Schizophrenia;	chr10:60524902	chr10:60734342~60741828:+
LUAD	cis	rs293748	0.571	rs12652882	ENSG00000250155.1	CTD-2353F22.1	-5.75	1.61e-08	5.92e-06	-0.32	-0.25	Obesity-related traits;	chr5:37188340	chr5:36666214~36725195:-
LUAD	cis	rs17214007	0.877	rs2075514	ENSG00000263335.1	AF001548.5	-5.75	1.61e-08	5.93e-06	-0.36	-0.25	Cognitive function;	chr16:15778752	chr16:15726674~15732993:+
LUAD	cis	rs17214007	0.877	rs11644832	ENSG00000263335.1	AF001548.5	-5.75	1.61e-08	5.93e-06	-0.36	-0.25	Cognitive function;	chr16:15778891	chr16:15726674~15732993:+
LUAD	cis	rs17214007	0.877	rs11645883	ENSG00000263335.1	AF001548.5	-5.75	1.61e-08	5.93e-06	-0.36	-0.25	Cognitive function;	chr16:15778950	chr16:15726674~15732993:+
LUAD	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	5.75	1.61e-08	5.93e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	5.75	1.61e-08	5.93e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	5.75	1.61e-08	5.93e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
LUAD	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-5.75	1.61e-08	5.94e-06	-0.34	-0.25	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
LUAD	cis	rs12468226	0.873	rs12472035	ENSG00000226261.1	AC064836.3	5.75	1.61e-08	5.94e-06	0.43	0.25	Urate levels;	chr2:202221970	chr2:202336024~202336727:-
LUAD	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-5.75	1.61e-08	5.95e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
LUAD	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-5.75	1.62e-08	5.95e-06	-0.28	-0.25	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
LUAD	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-5.75	1.62e-08	5.95e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-5.75	1.62e-08	5.95e-06	-0.25	-0.25	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
LUAD	cis	rs35934224	0.783	rs13056219	ENSG00000232926.1	AC000078.5	5.75	1.62e-08	5.96e-06	0.31	0.25	Glaucoma (primary open-angle);	chr22:19873323	chr22:19887289~19887970:+
LUAD	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	5.75	1.62e-08	5.96e-06	0.24	0.25	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
LUAD	cis	rs7618501	0.633	rs13060128	ENSG00000234667.1	ACTBP13	-5.75	1.62e-08	5.96e-06	-0.29	-0.25	Intelligence (multi-trait analysis);	chr3:49987595	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs2353579	ENSG00000234667.1	ACTBP13	-5.75	1.62e-08	5.96e-06	-0.29	-0.25	Intelligence (multi-trait analysis);	chr3:49990341	chr3:49873347~49877980:-
LUAD	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	5.75	1.62e-08	5.98e-06	0.29	0.25	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
LUAD	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-5.75	1.62e-08	5.98e-06	-0.35	-0.25	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
LUAD	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-5.75	1.63e-08	5.99e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-5.75	1.63e-08	5.99e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
LUAD	cis	rs2404602	0.569	rs283793	ENSG00000259422.1	RP11-593F23.1	5.75	1.63e-08	5.99e-06	0.33	0.25	Blood metabolite levels;	chr15:76482411	chr15:76174891~76181486:-
LUAD	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	5.75	1.63e-08	6e-06	0.23	0.25	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
LUAD	cis	rs2302464	1	rs73123607	ENSG00000214846.4	RP11-115L11.1	5.75	1.63e-08	6e-06	0.61	0.25	Cerebrospinal fluid biomarker levels;	chr4:15725058	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs6844968	ENSG00000214846.4	RP11-115L11.1	5.75	1.63e-08	6e-06	0.61	0.25	Cerebrospinal fluid biomarker levels;	chr4:15725641	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs58978163	ENSG00000214846.4	RP11-115L11.1	5.75	1.63e-08	6e-06	0.61	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726385	chr4:15730962~15731627:-
LUAD	cis	rs172166	0.694	rs203893	ENSG00000204709.4	LINC01556	5.75	1.63e-08	6e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28094288	chr6:28943877~28944537:+
LUAD	cis	rs10214930	0.697	rs6958747	ENSG00000235574.1	AC073150.6	5.75	1.63e-08	6e-06	0.31	0.25	Hypospadias;	chr7:27652244	chr7:27491682~27492765:-
LUAD	cis	rs4654783	0.627	rs66766977	ENSG00000228397.1	RP1-224A6.3	5.75	1.63e-08	6e-06	0.31	0.25	Endometriosis;	chr1:22104599	chr1:22023994~22024968:-
LUAD	cis	rs1707322	1	rs785467	ENSG00000234329.1	RP11-767N6.2	-5.75	1.63e-08	6e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45651039~45651826:-
LUAD	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	5.75	1.63e-08	6.01e-06	0.26	0.25	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
LUAD	cis	rs30380	0.632	rs26500	ENSG00000272109.1	CTD-2260A17.3	-5.74	1.63e-08	6.01e-06	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96798009	chr5:96804353~96806105:+
LUAD	cis	rs9879311	0.966	rs28113	ENSG00000240288.6	GHRLOS	5.74	1.63e-08	6.01e-06	0.24	0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358959	chr3:10285754~10293449:+
LUAD	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	5.74	1.64e-08	6.02e-06	0.37	0.25	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	5.74	1.64e-08	6.02e-06	0.37	0.25	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	5.74	1.64e-08	6.02e-06	0.37	0.25	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	5.74	1.64e-08	6.02e-06	0.37	0.25	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
LUAD	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-5.74	1.64e-08	6.02e-06	-0.29	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
LUAD	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-5.74	1.64e-08	6.02e-06	-0.29	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
LUAD	cis	rs4604732	0.631	rs12038793	ENSG00000227135.1	GCSAML-AS1	5.74	1.64e-08	6.02e-06	0.39	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460960	chr1:247524679~247526752:-
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000230295.1	RP11-458F8.2	5.74	1.64e-08	6.02e-06	0.31	0.25	Diabetic kidney disease;	chr7:66170354	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2420171	ENSG00000230295.1	RP11-458F8.2	5.74	1.64e-08	6.02e-06	0.31	0.25	Diabetic kidney disease;	chr7:66172773	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6974723	ENSG00000230295.1	RP11-458F8.2	5.74	1.64e-08	6.02e-06	0.31	0.25	Diabetic kidney disease;	chr7:66172952	chr7:66880708~66882981:+
LUAD	cis	rs453301	0.686	rs10217044	ENSG00000253981.4	ALG1L13P	-5.74	1.64e-08	6.03e-06	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9037242	chr8:8236003~8244667:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000211967.3	IGHV3-53	-5.74	1.64e-08	6.03e-06	-0.18	-0.25	Kawasaki disease;	chr14:106777510	chr14:106592676~106593347:-
LUAD	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	5.74	1.64e-08	6.04e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000211967.3	IGHV3-53	-5.74	1.64e-08	6.04e-06	-0.18	-0.25	Kawasaki disease;	chr14:106777494	chr14:106592676~106593347:-
LUAD	cis	rs10214930	0.602	rs1115346	ENSG00000235574.1	AC073150.6	-5.74	1.64e-08	6.04e-06	-0.3	-0.25	Hypospadias;	chr7:27622485	chr7:27491682~27492765:-
LUAD	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-5.74	1.64e-08	6.05e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-5.74	1.64e-08	6.05e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
LUAD	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	5.74	1.64e-08	6.05e-06	0.48	0.25	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
LUAD	cis	rs4713118	0.662	rs9393881	ENSG00000204709.4	LINC01556	5.74	1.65e-08	6.05e-06	0.34	0.25	Parkinson's disease;	chr6:28055973	chr6:28943877~28944537:+
LUAD	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	5.74	1.65e-08	6.06e-06	0.31	0.25	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
LUAD	cis	rs10214930	0.813	rs7786973	ENSG00000235574.1	AC073150.6	-5.74	1.65e-08	6.06e-06	-0.34	-0.25	Hypospadias;	chr7:27542629	chr7:27491682~27492765:-
LUAD	cis	rs10246939	0.544	rs12668089	ENSG00000228775.6	WEE2-AS1	5.74	1.65e-08	6.06e-06	0.31	0.25	Bitter taste perception;	chr7:141875111	chr7:141704338~141738346:-
LUAD	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
LUAD	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	5.74	1.65e-08	6.06e-06	0.3	0.25	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
LUAD	cis	rs17684571	0.7	rs13200768	ENSG00000231441.1	RP11-472M19.2	5.74	1.65e-08	6.06e-06	0.38	0.25	Schizophrenia;	chr6:56786828	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13204466	ENSG00000231441.1	RP11-472M19.2	5.74	1.65e-08	6.06e-06	0.38	0.25	Schizophrenia;	chr6:56787376	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs34612783	ENSG00000231441.1	RP11-472M19.2	5.74	1.65e-08	6.06e-06	0.38	0.25	Schizophrenia;	chr6:56787851	chr6:56844002~56864078:+
LUAD	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	5.74	1.65e-08	6.07e-06	0.29	0.25	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
LUAD	cis	rs8177876	0.749	rs2287995	ENSG00000261061.1	RP11-303E16.2	-5.74	1.65e-08	6.07e-06	-0.43	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81030770~81031485:+
LUAD	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-5.74	1.65e-08	6.08e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-5.74	1.65e-08	6.08e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
LUAD	cis	rs9543976	0.623	rs7986566	ENSG00000261553.4	RP11-29G8.3	5.74	1.65e-08	6.08e-06	0.34	0.25	Diabetic retinopathy;	chr13:75623795	chr13:75549773~75807120:+
LUAD	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-5.74	1.65e-08	6.08e-06	-0.31	-0.25	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
LUAD	cis	rs36093844	0.752	rs17817308	ENSG00000279742.1	RP11-700A24.1	-5.74	1.66e-08	6.08e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882486	chr11:85852557~85854943:-
LUAD	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-5.74	1.66e-08	6.09e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
LUAD	cis	rs12468226	0.938	rs10166594	ENSG00000226261.1	AC064836.3	5.74	1.66e-08	6.09e-06	0.39	0.25	Urate levels;	chr2:202250262	chr2:202336024~202336727:-
LUAD	cis	rs4713118	0.513	rs149955	ENSG00000204709.4	LINC01556	5.74	1.66e-08	6.09e-06	0.33	0.25	Parkinson's disease;	chr6:28068447	chr6:28943877~28944537:+
LUAD	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-5.74	1.66e-08	6.1e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-5.74	1.66e-08	6.1e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
LUAD	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-5.74	1.66e-08	6.1e-06	-0.31	-0.25	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
LUAD	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-5.74	1.66e-08	6.1e-06	-0.29	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
LUAD	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-5.74	1.66e-08	6.1e-06	-0.32	-0.25	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
LUAD	cis	rs17666538	0.585	rs1037393	ENSG00000254207.1	RP11-43A14.1	5.74	1.66e-08	6.11e-06	0.51	0.25	IgG glycosylation;	chr8:672634	chr8:725188~725877:-
LUAD	cis	rs17666538	0.585	rs6559064	ENSG00000254207.1	RP11-43A14.1	5.74	1.66e-08	6.11e-06	0.51	0.25	IgG glycosylation;	chr8:673061	chr8:725188~725877:-
LUAD	cis	rs9595908	0.669	rs9596205	ENSG00000212293.1	SNORA16	-5.74	1.66e-08	6.11e-06	-0.28	-0.25	Body mass index;	chr13:32754487	chr13:32420390~32420516:-
LUAD	cis	rs9652601	0.622	rs9935174	ENSG00000274038.1	RP11-66H6.4	-5.74	1.66e-08	6.11e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11017490	chr16:11056556~11057034:+
LUAD	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	5.74	1.67e-08	6.13e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
LUAD	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-5.74	1.68e-08	6.16e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
LUAD	cis	rs4835473	0.932	rs10857415	ENSG00000251600.4	RP11-673E1.1	5.74	1.68e-08	6.16e-06	0.32	0.25	Immature fraction of reticulocytes;	chr4:143908753	chr4:143912331~143982454:+
LUAD	cis	rs17684571	0.872	rs13198399	ENSG00000231441.1	RP11-472M19.2	5.74	1.68e-08	6.17e-06	0.37	0.25	Schizophrenia;	chr6:56733196	chr6:56844002~56864078:+
LUAD	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-5.74	1.68e-08	6.17e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-5.74	1.68e-08	6.17e-06	-0.34	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
LUAD	cis	rs7208859	0.623	rs59447372	ENSG00000263603.1	CTD-2349P21.5	-5.74	1.68e-08	6.17e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs8079891	ENSG00000263603.1	CTD-2349P21.5	-5.74	1.68e-08	6.17e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30729469~30731202:+
LUAD	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	5.74	1.68e-08	6.18e-06	0.32	0.25	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
LUAD	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-5.74	1.68e-08	6.18e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
LUAD	cis	rs1823913	0.637	rs4853584	ENSG00000280083.1	RP11-317J9.1	5.74	1.68e-08	6.18e-06	0.3	0.25	Obesity-related traits;	chr2:191310596	chr2:191154118~191156070:-
LUAD	cis	rs728616	0.614	rs55768100	ENSG00000225484.5	NUTM2B-AS1	-5.74	1.69e-08	6.19e-06	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:79663088~79826594:-
LUAD	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-5.74	1.69e-08	6.19e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
LUAD	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-5.74	1.69e-08	6.2e-06	-0.29	-0.25	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000224373.3	IGHV4-59	5.74	1.69e-08	6.2e-06	0.17	0.25	Kawasaki disease;	chr14:106767990	chr14:106627249~106627825:-
LUAD	cis	rs2348418	0.579	rs2126896	ENSG00000247934.4	RP11-967K21.1	-5.74	1.69e-08	6.2e-06	-0.27	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28239701	chr12:28163298~28190738:-
LUAD	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	5.74	1.69e-08	6.2e-06	0.36	0.25	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
LUAD	cis	rs6687821	0.515	rs5859	ENSG00000267734.1	RP4-604K5.3	5.74	1.69e-08	6.21e-06	0.31	0.25	Yeast infection;	chr1:86862842	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs554213	ENSG00000267734.1	RP4-604K5.3	5.74	1.69e-08	6.21e-06	0.31	0.25	Yeast infection;	chr1:86876474	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs576955	ENSG00000267734.1	RP4-604K5.3	5.74	1.69e-08	6.21e-06	0.31	0.25	Yeast infection;	chr1:86876627	chr1:86932199~86934891:-
LUAD	cis	rs293748	0.882	rs34525350	ENSG00000250155.1	CTD-2353F22.1	-5.74	1.69e-08	6.21e-06	-0.36	-0.25	Obesity-related traits;	chr5:37089535	chr5:36666214~36725195:-
LUAD	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-5.74	1.7e-08	6.22e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.517	rs17711344	ENSG00000204709.4	LINC01556	-5.74	1.7e-08	6.22e-06	-0.35	-0.25	Depression;	chr6:28109824	chr6:28943877~28944537:+
LUAD	cis	rs8177376	0.727	rs645852	ENSG00000254905.1	RP11-712L6.7	5.74	1.7e-08	6.22e-06	0.34	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327509	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs646775	ENSG00000254905.1	RP11-712L6.7	5.74	1.7e-08	6.22e-06	0.34	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327704	chr11:126292922~126294254:-
LUAD	cis	rs11651753	0.636	rs12602494	ENSG00000264920.1	RP11-6N17.4	-5.74	1.7e-08	6.23e-06	-0.32	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47960241	chr17:47891255~47895812:-
LUAD	cis	rs453301	0.606	rs6601279	ENSG00000253981.4	ALG1L13P	-5.74	1.7e-08	6.24e-06	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9050721	chr8:8236003~8244667:-
LUAD	cis	rs453301	0.606	rs6981060	ENSG00000253981.4	ALG1L13P	-5.74	1.7e-08	6.24e-06	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9050725	chr8:8236003~8244667:-
LUAD	cis	rs12468226	0.938	rs12463937	ENSG00000272966.1	RP11-686O6.1	5.74	1.7e-08	6.24e-06	0.44	0.25	Urate levels;	chr2:202246543	chr2:202336739~202337200:+
LUAD	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
LUAD	cis	rs301901	0.548	rs2366176	ENSG00000250155.1	CTD-2353F22.1	5.74	1.71e-08	6.25e-06	0.28	0.25	Height;	chr5:37439326	chr5:36666214~36725195:-
LUAD	cis	rs10761482	0.5	rs2211220	ENSG00000254271.1	RP11-131N11.4	5.74	1.71e-08	6.25e-06	0.28	0.25	Schizophrenia;	chr10:60511733	chr10:60734342~60741828:+
LUAD	cis	rs7948661	1	rs9332781	ENSG00000278376.1	RP11-158I9.8	5.74	1.71e-08	6.25e-06	0.54	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118475884	chr11:118791254~118793137:+
LUAD	cis	rs10214930	0.697	rs10951169	ENSG00000235574.1	AC073150.6	5.74	1.71e-08	6.26e-06	0.31	0.25	Hypospadias;	chr7:27516295	chr7:27491682~27492765:-
LUAD	cis	rs997295	0.57	rs737226	ENSG00000270964.1	RP11-502I4.3	-5.74	1.71e-08	6.26e-06	-0.26	-0.25	Motion sickness;	chr15:67548435	chr15:67541072~67542604:-
LUAD	cis	rs997295	0.57	rs11632574	ENSG00000270964.1	RP11-502I4.3	-5.74	1.71e-08	6.26e-06	-0.26	-0.25	Motion sickness;	chr15:67560067	chr15:67541072~67542604:-
LUAD	cis	rs3738443	0.868	rs6660351	ENSG00000259865.1	RP11-488L18.10	5.74	1.71e-08	6.26e-06	0.27	0.25	Alcohol dependence;	chr1:247184526	chr1:247187281~247188526:-
LUAD	cis	rs997295	0.57	rs72747464	ENSG00000270964.1	RP11-502I4.3	-5.74	1.71e-08	6.26e-06	-0.27	-0.25	Motion sickness;	chr15:67526202	chr15:67541072~67542604:-
LUAD	cis	rs7044106	0.537	rs10739573	ENSG00000238181.2	AHCYP2	-5.74	1.71e-08	6.27e-06	-0.36	-0.25	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120720673~120721972:+
LUAD	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	5.74	1.71e-08	6.27e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
LUAD	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	5.74	1.72e-08	6.29e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	5.74	1.72e-08	6.29e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
LUAD	cis	rs10091374	1	rs2380651	ENSG00000253967.1	RP11-333A23.4	-5.74	1.72e-08	6.29e-06	-0.28	-0.25	Cardiac Troponin-T levels;	chr8:70473322	chr8:70471134~70485687:+
LUAD	cis	rs7617773	0.851	rs13068288	ENSG00000228638.1	FCF1P2	-5.74	1.72e-08	6.29e-06	-0.32	-0.25	Coronary artery disease;	chr3:48290261	chr3:48290793~48291375:-
LUAD	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	5.74	1.72e-08	6.29e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
LUAD	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	5.74	1.72e-08	6.29e-06	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
LUAD	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	5.74	1.72e-08	6.3e-06	0.31	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
LUAD	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-5.74	1.72e-08	6.3e-06	-0.29	-0.25	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
LUAD	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-5.74	1.72e-08	6.3e-06	-0.29	-0.25	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
LUAD	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	5.74	1.72e-08	6.3e-06	0.29	0.25	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
LUAD	cis	rs896854	0.654	rs13278601	ENSG00000253528.2	RP11-347C18.4	5.74	1.72e-08	6.31e-06	0.24	0.25	Type 2 diabetes;	chr8:94960746	chr8:94974573~94974853:-
LUAD	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-5.74	1.72e-08	6.31e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
LUAD	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-5.74	1.72e-08	6.32e-06	-0.27	-0.25	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000230295.1	RP11-458F8.2	-5.74	1.72e-08	6.32e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66433290	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs67536397	ENSG00000230295.1	RP11-458F8.2	-5.74	1.72e-08	6.32e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66482930	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs58669269	ENSG00000230295.1	RP11-458F8.2	-5.74	1.72e-08	6.32e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66486966	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000230295.1	RP11-458F8.2	-5.74	1.72e-08	6.32e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66500146	chr7:66880708~66882981:+
LUAD	cis	rs9532669	0.926	rs9594450	ENSG00000168852.11	TPTE2P5	5.73	1.73e-08	6.32e-06	0.27	0.25	Cervical cancer;	chr13:40880067	chr13:40822296~40921749:-
LUAD	cis	rs783540	0.592	rs2567632	ENSG00000278603.1	RP13-608F4.5	-5.73	1.73e-08	6.32e-06	-0.32	-0.25	Schizophrenia;	chr15:82616053	chr15:82472203~82472426:+
LUAD	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-5.73	1.73e-08	6.32e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
LUAD	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	5.73	1.73e-08	6.33e-06	0.2	0.25	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
LUAD	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-5.73	1.73e-08	6.33e-06	-0.4	-0.25	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
LUAD	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	5.73	1.73e-08	6.33e-06	0.33	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	5.73	1.73e-08	6.33e-06	0.33	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	5.73	1.73e-08	6.33e-06	0.33	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
LUAD	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	5.73	1.73e-08	6.34e-06	0.33	0.25	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
LUAD	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	5.73	1.73e-08	6.34e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
LUAD	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-5.73	1.73e-08	6.34e-06	-0.28	-0.25	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
LUAD	cis	rs7246657	0.722	rs12974225	ENSG00000276846.1	CTD-3220F14.3	-5.73	1.73e-08	6.35e-06	-0.34	-0.25	Coronary artery calcification;	chr19:37749458	chr19:37314868~37315620:-
LUAD	cis	rs9652601	0.691	rs6498160	ENSG00000274038.1	RP11-66H6.4	-5.73	1.74e-08	6.36e-06	-0.31	-0.25	Systemic lupus erythematosus;	chr16:11105590	chr16:11056556~11057034:+
LUAD	cis	rs1113500	0.548	rs3853495	ENSG00000226822.1	RP11-356N1.2	5.73	1.74e-08	6.36e-06	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108100623	chr1:108071482~108074519:+
LUAD	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-5.73	1.74e-08	6.36e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
LUAD	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	5.73	1.74e-08	6.38e-06	0.33	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
LUAD	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-5.73	1.75e-08	6.39e-06	-0.33	-0.25	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
LUAD	cis	rs2302464	1	rs11944132	ENSG00000214846.4	RP11-115L11.1	5.73	1.75e-08	6.4e-06	0.61	0.25	Cerebrospinal fluid biomarker levels;	chr4:15724291	chr4:15730962~15731627:-
LUAD	cis	rs2599510	0.783	rs62136349	ENSG00000276334.1	AL133243.1	5.73	1.75e-08	6.4e-06	0.3	0.25	Interleukin-18 levels;	chr2:32602437	chr2:32521927~32523547:+
LUAD	cis	rs516805	0.634	rs2816142	ENSG00000279453.1	RP3-425C14.4	5.73	1.75e-08	6.4e-06	0.34	0.25	Lymphocyte counts;	chr6:122177653	chr6:122436789~122439223:-
LUAD	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-5.73	1.75e-08	6.41e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
LUAD	cis	rs17684571	0.938	rs4073960	ENSG00000231441.1	RP11-472M19.2	5.73	1.75e-08	6.42e-06	0.34	0.25	Schizophrenia;	chr6:56683561	chr6:56844002~56864078:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000211967.3	IGHV3-53	-5.73	1.76e-08	6.42e-06	-0.18	-0.25	Kawasaki disease;	chr14:106807047	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000211967.3	IGHV3-53	-5.73	1.76e-08	6.42e-06	-0.18	-0.25	Kawasaki disease;	chr14:106808609	chr14:106592676~106593347:-
LUAD	cis	rs1707322	0.717	rs2275086	ENSG00000234329.1	RP11-767N6.2	-5.73	1.76e-08	6.43e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45651039~45651826:-
LUAD	cis	rs62432291	0.681	rs433786	ENSG00000235086.1	FNDC1-IT1	-5.73	1.76e-08	6.44e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159244914	chr6:159240786~159243329:+
LUAD	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	5.73	1.76e-08	6.44e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
LUAD	cis	rs7044106	0.762	rs4837790	ENSG00000238181.2	AHCYP2	-5.73	1.76e-08	6.44e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120720673~120721972:+
LUAD	cis	rs2562456	0.917	rs9304987	ENSG00000268081.1	RP11-678G14.2	-5.73	1.76e-08	6.44e-06	-0.39	-0.25	Pain;	chr19:21499472	chr19:21554640~21569237:-
LUAD	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-5.73	1.76e-08	6.44e-06	-0.32	-0.25	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
LUAD	cis	rs61776719	0.81	rs34655914	ENSG00000212541.1	RNU6-510P	-5.73	1.76e-08	6.45e-06	-0.3	-0.25	Coronary artery disease;	chr1:37931669	chr1:37991462~37991569:+
LUAD	cis	rs61776719	0.84	rs35267671	ENSG00000212541.1	RNU6-510P	-5.73	1.76e-08	6.45e-06	-0.3	-0.25	Coronary artery disease;	chr1:37931697	chr1:37991462~37991569:+
LUAD	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-5.73	1.76e-08	6.45e-06	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
LUAD	cis	rs17684571	0.7	rs13205667	ENSG00000231441.1	RP11-472M19.2	5.73	1.76e-08	6.45e-06	0.38	0.25	Schizophrenia;	chr6:56775176	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13200559	ENSG00000231441.1	RP11-472M19.2	5.73	1.76e-08	6.45e-06	0.38	0.25	Schizophrenia;	chr6:56777522	chr6:56844002~56864078:+
LUAD	cis	rs9595908	0.832	rs9595976	ENSG00000212293.1	SNORA16	5.73	1.77e-08	6.45e-06	0.28	0.25	Body mass index;	chr13:32637910	chr13:32420390~32420516:-
LUAD	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	5.73	1.77e-08	6.47e-06	0.36	0.25	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	5.73	1.77e-08	6.47e-06	0.36	0.25	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	5.73	1.77e-08	6.47e-06	0.36	0.25	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
LUAD	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	5.73	1.77e-08	6.47e-06	0.26	0.25	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
LUAD	cis	rs5753618	0.583	rs71324184	ENSG00000236132.1	CTA-440B3.1	-5.73	1.77e-08	6.47e-06	-0.3	-0.25	Colorectal cancer;	chr22:31356075	chr22:31816379~31817491:-
LUAD	cis	rs997295	0.57	rs7170299	ENSG00000270964.1	RP11-502I4.3	-5.73	1.77e-08	6.48e-06	-0.26	-0.25	Motion sickness;	chr15:67580380	chr15:67541072~67542604:-
LUAD	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
LUAD	cis	rs4141404	0.816	rs5749227	ENSG00000236132.1	CTA-440B3.1	5.73	1.78e-08	6.49e-06	0.36	0.25	Paclitaxel-induced neuropathy;	chr22:31185180	chr22:31816379~31817491:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000211967.3	IGHV3-53	-5.73	1.78e-08	6.5e-06	-0.18	-0.25	Kawasaki disease;	chr14:106781490	chr14:106592676~106593347:-
LUAD	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	5.73	1.78e-08	6.5e-06	0.3	0.25	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
LUAD	cis	rs9595908	0.669	rs7983309	ENSG00000212293.1	SNORA16	5.73	1.78e-08	6.5e-06	0.27	0.25	Body mass index;	chr13:32740254	chr13:32420390~32420516:-
LUAD	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-5.73	1.78e-08	6.51e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
LUAD	cis	rs10761482	0.5	rs7072229	ENSG00000254271.1	RP11-131N11.4	5.73	1.78e-08	6.51e-06	0.28	0.25	Schizophrenia;	chr10:60524462	chr10:60734342~60741828:+
LUAD	cis	rs7618501	0.633	rs2624843	ENSG00000234667.1	ACTBP13	-5.73	1.78e-08	6.51e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49960530	chr3:49873347~49877980:-
LUAD	cis	rs516805	0.961	rs544099	ENSG00000279453.1	RP3-425C14.4	5.73	1.78e-08	6.52e-06	0.29	0.25	Lymphocyte counts;	chr6:122479837	chr6:122436789~122439223:-
LUAD	cis	rs380904	0.519	rs12541790	ENSG00000254859.1	RP11-661A12.5	-5.73	1.79e-08	6.52e-06	-0.4	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr8:143541973~143549729:-
LUAD	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	5.73	1.79e-08	6.53e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	5.73	1.79e-08	6.53e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
LUAD	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	5.73	1.79e-08	6.53e-06	0.31	0.25	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
LUAD	cis	rs301901	0.698	rs217840	ENSG00000250155.1	CTD-2353F22.1	5.73	1.79e-08	6.53e-06	0.27	0.25	Height;	chr5:37373000	chr5:36666214~36725195:-
LUAD	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	5.73	1.79e-08	6.53e-06	0.31	0.25	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
LUAD	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	5.73	1.79e-08	6.53e-06	0.38	0.25	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
LUAD	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-5.73	1.79e-08	6.54e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
LUAD	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-5.73	1.79e-08	6.54e-06	-0.39	-0.25	Depression;	chr6:28103220	chr6:28115628~28116551:+
LUAD	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	5.73	1.79e-08	6.55e-06	0.29	0.25	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
LUAD	cis	rs9595908	0.709	rs7322505	ENSG00000212293.1	SNORA16	5.73	1.79e-08	6.55e-06	0.27	0.25	Body mass index;	chr13:32756282	chr13:32420390~32420516:-
LUAD	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	5.73	1.8e-08	6.56e-06	0.27	0.25	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	5.73	1.8e-08	6.56e-06	0.27	0.25	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
LUAD	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-5.73	1.8e-08	6.56e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-5.73	1.8e-08	6.56e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-5.73	1.8e-08	6.56e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
LUAD	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	5.73	1.8e-08	6.56e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
LUAD	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-5.73	1.8e-08	6.57e-06	-0.33	-0.25	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	5.73	1.8e-08	6.57e-06	0.29	0.25	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
LUAD	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-5.73	1.8e-08	6.57e-06	-0.32	-0.25	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
LUAD	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-5.73	1.8e-08	6.57e-06	-0.31	-0.25	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
LUAD	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-5.73	1.8e-08	6.57e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
LUAD	cis	rs6504622	1	rs2003539	ENSG00000262879.4	RP11-156P1.3	-5.73	1.8e-08	6.58e-06	-0.29	-0.25	Orofacial clefts;	chr17:46947953	chr17:46984045~47100323:-
LUAD	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	5.73	1.8e-08	6.59e-06	0.36	0.25	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
LUAD	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-5.73	1.8e-08	6.59e-06	-0.31	-0.25	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
LUAD	cis	rs1707322	1	rs12403666	ENSG00000234329.1	RP11-767N6.2	5.73	1.81e-08	6.59e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45651039~45651826:-
LUAD	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-5.73	1.81e-08	6.6e-06	-0.34	-0.25	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000211967.3	IGHV3-53	-5.73	1.81e-08	6.6e-06	-0.18	-0.25	Kawasaki disease;	chr14:106782288	chr14:106592676~106593347:-
LUAD	cis	rs62432291	0.681	rs423533	ENSG00000235086.1	FNDC1-IT1	-5.73	1.81e-08	6.61e-06	-0.44	-0.25	Joint mobility (Beighton score);	chr6:159243484	chr6:159240786~159243329:+
LUAD	cis	rs910316	0.575	rs12889133	ENSG00000279594.1	RP11-950C14.10	5.73	1.81e-08	6.61e-06	0.3	0.25	Height;	chr14:74998386	chr14:75011269~75012851:-
LUAD	cis	rs35740288	0.77	rs11634177	ENSG00000202081.1	RNU6-1280P	-5.73	1.81e-08	6.61e-06	-0.31	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605159	chr15:85651522~85651628:-
LUAD	cis	rs2255336	0.938	rs2734414	ENSG00000245648.1	RP11-277P12.20	5.73	1.81e-08	6.61e-06	0.35	0.25	Blood protein levels;	chr12:10446203	chr12:10363769~10398506:+
LUAD	cis	rs4908760	0.868	rs12131864	ENSG00000232912.4	RP5-1115A15.1	5.73	1.81e-08	6.61e-06	0.23	0.25	Vitiligo;	chr1:8531103	chr1:8424645~8434838:+
LUAD	cis	rs1707322	1	rs1707303	ENSG00000234329.1	RP11-767N6.2	-5.73	1.81e-08	6.61e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45651039~45651826:-
LUAD	cis	rs7618501	0.633	rs12496973	ENSG00000234667.1	ACTBP13	-5.73	1.82e-08	6.62e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49964812	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs11130228	ENSG00000234667.1	ACTBP13	-5.73	1.82e-08	6.62e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49965813	chr3:49873347~49877980:-
LUAD	cis	rs27524	0.537	rs57889668	ENSG00000272109.1	CTD-2260A17.3	5.73	1.82e-08	6.62e-06	0.31	0.25	Hodgkin's lymphoma;Psoriasis;	chr5:96745230	chr5:96804353~96806105:+
LUAD	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-5.73	1.82e-08	6.63e-06	-0.27	-0.25	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
LUAD	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-5.73	1.82e-08	6.63e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
LUAD	cis	rs12188164	0.515	rs11744936	ENSG00000225138.6	CTD-2228K2.7	5.73	1.82e-08	6.64e-06	0.24	0.25	Cystic fibrosis severity;	chr5:411997	chr5:473236~480884:+
LUAD	cis	rs3771180	0.505	rs2160203	ENSG00000234389.1	AC007278.3	5.73	1.82e-08	6.64e-06	0.27	0.25	Asthma;	chr2:102344364	chr2:102438713~102440475:+
LUAD	cis	rs891378	1	rs925131	ENSG00000274245.1	RP11-357P18.2	-5.73	1.82e-08	6.64e-06	-0.34	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207330376	chr1:207372559~207373252:+
LUAD	cis	rs1707322	0.686	rs2275085	ENSG00000234329.1	RP11-767N6.2	-5.73	1.82e-08	6.64e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	5.72	1.82e-08	6.65e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	5.72	1.82e-08	6.65e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	5.72	1.82e-08	6.65e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-5.72	1.82e-08	6.65e-06	-0.34	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
LUAD	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	5.72	1.82e-08	6.65e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
LUAD	cis	rs7430456	0.874	rs7428501	ENSG00000228221.4	LINC00578	5.72	1.83e-08	6.67e-06	0.3	0.25	Breast cancer;	chr3:177751974	chr3:177441921~177752305:+
LUAD	cis	rs2412819	0.571	rs4923965	ENSG00000249839.1	AC011330.5	5.72	1.83e-08	6.68e-06	0.4	0.25	Lung cancer;	chr15:43790232	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs4644832	ENSG00000249839.1	AC011330.5	5.72	1.83e-08	6.68e-06	0.4	0.25	Lung cancer;	chr15:43792507	chr15:43663654~43684339:-
LUAD	cis	rs7246657	0.722	rs2972437	ENSG00000276846.1	CTD-3220F14.3	5.72	1.83e-08	6.68e-06	0.34	0.25	Coronary artery calcification;	chr19:37719610	chr19:37314868~37315620:-
LUAD	cis	rs6772849	0.775	rs9828414	ENSG00000242551.2	POU5F1P6	-5.72	1.83e-08	6.69e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128693874	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.804	rs9832430	ENSG00000242551.2	POU5F1P6	-5.72	1.83e-08	6.69e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128694054	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.775	rs66822528	ENSG00000242551.2	POU5F1P6	-5.72	1.83e-08	6.69e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128674735~128677005:-
LUAD	cis	rs1816752	1	rs9507341	ENSG00000273628.1	RP11-756A22.7	-5.72	1.84e-08	6.69e-06	-0.3	-0.25	Obesity-related traits;	chr13:24432440	chr13:24933006~24936796:+
LUAD	cis	rs516805	0.667	rs2606610	ENSG00000279453.1	RP3-425C14.4	-5.72	1.84e-08	6.69e-06	-0.34	-0.25	Lymphocyte counts;	chr6:122189959	chr6:122436789~122439223:-
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000211967.3	IGHV3-53	-5.72	1.84e-08	6.7e-06	-0.18	-0.25	Kawasaki disease;	chr14:106778016	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000211967.3	IGHV3-53	-5.72	1.84e-08	6.7e-06	-0.18	-0.25	Kawasaki disease;	chr14:106778120	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000211967.3	IGHV3-53	-5.72	1.84e-08	6.7e-06	-0.18	-0.25	Kawasaki disease;	chr14:106778135	chr14:106592676~106593347:-
LUAD	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	5.72	1.84e-08	6.7e-06	0.27	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000230295.1	RP11-458F8.2	5.72	1.84e-08	6.7e-06	0.31	0.25	Diabetic kidney disease;	chr7:66226660	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7778911	ENSG00000230295.1	RP11-458F8.2	5.72	1.84e-08	6.7e-06	0.31	0.25	Diabetic kidney disease;	chr7:66229519	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1979823	ENSG00000230295.1	RP11-458F8.2	5.72	1.84e-08	6.7e-06	0.31	0.25	Diabetic kidney disease;	chr7:66239626	chr7:66880708~66882981:+
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000211974.3	IGHV2-70	-5.72	1.84e-08	6.72e-06	-0.35	-0.25	Alzheimer's disease (late onset);	chr14:106813739	chr14:106723574~106724093:-
LUAD	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-5.72	1.84e-08	6.72e-06	-0.28	-0.25	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-5.72	1.84e-08	6.72e-06	-0.28	-0.25	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
LUAD	cis	rs9652601	0.691	rs9933507	ENSG00000274038.1	RP11-66H6.4	-5.72	1.84e-08	6.72e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11107571	chr16:11056556~11057034:+
LUAD	cis	rs7430456	0.839	rs9824506	ENSG00000228221.4	LINC00578	-5.72	1.85e-08	6.72e-06	-0.3	-0.25	Breast cancer;	chr3:177751431	chr3:177441921~177752305:+
LUAD	cis	rs35740288	0.731	rs35085180	ENSG00000202081.1	RNU6-1280P	5.72	1.85e-08	6.73e-06	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85559381	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs75039806	ENSG00000202081.1	RNU6-1280P	5.72	1.85e-08	6.73e-06	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561813	chr15:85651522~85651628:-
LUAD	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-5.72	1.85e-08	6.73e-06	-0.34	-0.25	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
LUAD	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-5.72	1.85e-08	6.73e-06	-0.28	-0.25	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
LUAD	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	5.72	1.85e-08	6.74e-06	0.32	0.25	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-5.72	1.85e-08	6.74e-06	-0.31	-0.25	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
LUAD	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	5.72	1.85e-08	6.74e-06	0.27	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
LUAD	cis	rs807029	0.533	rs67813203	ENSG00000272572.1	RP11-179B2.2	-5.72	1.85e-08	6.74e-06	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.533	rs2295716	ENSG00000272572.1	RP11-179B2.2	-5.72	1.85e-08	6.74e-06	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100911103~100912739:-
LUAD	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-5.72	1.85e-08	6.74e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
LUAD	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	5.72	1.86e-08	6.75e-06	0.31	0.25	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
LUAD	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-5.72	1.86e-08	6.76e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-5.72	1.86e-08	6.76e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-5.72	1.86e-08	6.76e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
LUAD	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	5.72	1.86e-08	6.76e-06	0.35	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
LUAD	cis	rs72634501	0.716	rs4660165	ENSG00000228060.1	RP11-69E11.8	5.72	1.86e-08	6.77e-06	0.26	0.25	HDL cholesterol;	chr1:39112860	chr1:39565160~39573203:+
LUAD	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	5.72	1.86e-08	6.77e-06	0.31	0.25	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
LUAD	cis	rs1707322	1	rs10890380	ENSG00000234329.1	RP11-767N6.2	5.72	1.86e-08	6.77e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45651039~45651826:-
LUAD	cis	rs7829975	0.511	rs1543238	ENSG00000253981.4	ALG1L13P	5.72	1.86e-08	6.77e-06	0.3	0.25	Mood instability;	chr8:8277287	chr8:8236003~8244667:-
LUAD	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-5.72	1.86e-08	6.77e-06	-0.33	-0.25	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-5.72	1.86e-08	6.77e-06	-0.33	-0.25	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
LUAD	cis	rs8031584	1	rs35811129	ENSG00000260382.1	RP11-540B6.2	5.72	1.86e-08	6.78e-06	0.33	0.25	Huntington's disease progression;	chr15:30949143	chr15:30882267~30883231:-
LUAD	cis	rs2288884	1	rs79817140	ENSG00000275055.1	CTC-471J1.11	-5.72	1.86e-08	6.78e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068404	chr19:52049007~52049754:+
LUAD	cis	rs2288884	1	rs11669385	ENSG00000275055.1	CTC-471J1.11	-5.72	1.86e-08	6.78e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068699	chr19:52049007~52049754:+
LUAD	cis	rs7246657	0.654	rs10407568	ENSG00000276846.1	CTD-3220F14.3	5.72	1.86e-08	6.78e-06	0.33	0.25	Coronary artery calcification;	chr19:37632108	chr19:37314868~37315620:-
LUAD	cis	rs1823913	0.599	rs34840299	ENSG00000280083.1	RP11-317J9.1	-5.72	1.86e-08	6.79e-06	-0.3	-0.25	Obesity-related traits;	chr2:191280379	chr2:191154118~191156070:-
LUAD	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-5.72	1.86e-08	6.79e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
LUAD	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	5.72	1.87e-08	6.79e-06	0.39	0.25	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-5.72	1.87e-08	6.79e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
LUAD	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	5.72	1.87e-08	6.79e-06	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
LUAD	cis	rs1707322	1	rs6429588	ENSG00000234329.1	RP11-767N6.2	5.72	1.87e-08	6.8e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660331	ENSG00000234329.1	RP11-767N6.2	5.72	1.87e-08	6.8e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs12097799	ENSG00000234329.1	RP11-767N6.2	5.72	1.87e-08	6.8e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45651039~45651826:-
LUAD	cis	rs6840258	0.66	rs55851914	ENSG00000251411.1	RP11-397E7.4	-5.72	1.87e-08	6.81e-06	-0.35	-0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955903	chr4:86913266~86914817:-
LUAD	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	5.72	1.87e-08	6.81e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
LUAD	cis	rs74233809	1	rs11191519	ENSG00000213277.3	MARCKSL1P1	5.72	1.87e-08	6.81e-06	0.44	0.25	Birth weight;	chr10:103025161	chr10:103175554~103176094:+
LUAD	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-5.72	1.87e-08	6.82e-06	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
LUAD	cis	rs1874124	0.577	rs2807880	ENSG00000272823.1	RP11-295M18.6	5.72	1.87e-08	6.82e-06	0.37	0.25	Cholesterol, total;	chr1:220869661	chr1:220828676~220829211:-
LUAD	cis	rs172166	0.637	rs1225597	ENSG00000204709.4	LINC01556	5.72	1.88e-08	6.83e-06	0.32	0.25	Cardiac Troponin-T levels;	chr6:28194309	chr6:28943877~28944537:+
LUAD	cis	rs12289961	0.634	rs11229378	ENSG00000280010.1	AP001350.4	5.72	1.88e-08	6.84e-06	0.41	0.25	Lymphoma;	chr11:58364344	chr11:58627435~58628528:+
LUAD	cis	rs12289961	0.634	rs77183714	ENSG00000280010.1	AP001350.4	5.72	1.88e-08	6.84e-06	0.41	0.25	Lymphoma;	chr11:58364460	chr11:58627435~58628528:+
LUAD	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-5.72	1.88e-08	6.84e-06	-0.4	-0.25	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
LUAD	cis	rs62432291	0.681	rs438853	ENSG00000235086.1	FNDC1-IT1	-5.72	1.88e-08	6.84e-06	-0.41	-0.25	Joint mobility (Beighton score);	chr6:159209320	chr6:159240786~159243329:+
LUAD	cis	rs2562456	0.917	rs2650793	ENSG00000268081.1	RP11-678G14.2	-5.72	1.88e-08	6.85e-06	-0.38	-0.25	Pain;	chr19:21493313	chr19:21554640~21569237:-
LUAD	cis	rs7208859	0.673	rs8077116	ENSG00000263603.1	CTD-2349P21.5	-5.72	1.88e-08	6.85e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30729469~30731202:+
LUAD	cis	rs1113500	0.509	rs1619485	ENSG00000226822.1	RP11-356N1.2	-5.72	1.88e-08	6.85e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108065725	chr1:108071482~108074519:+
LUAD	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	5.72	1.89e-08	6.86e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
LUAD	cis	rs7044106	0.762	rs1470307	ENSG00000238181.2	AHCYP2	-5.72	1.89e-08	6.86e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120720673~120721972:+
LUAD	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	5.72	1.89e-08	6.87e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
LUAD	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-5.72	1.89e-08	6.87e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
LUAD	cis	rs8180040	0.654	rs4682831	ENSG00000271161.1	BOLA2P2	-5.72	1.89e-08	6.87e-06	-0.24	-0.25	Colorectal cancer;	chr3:46985648	chr3:47499841~47500407:+
LUAD	cis	rs7246657	0.663	rs9304568	ENSG00000276846.1	CTD-3220F14.3	5.72	1.89e-08	6.87e-06	0.33	0.25	Coronary artery calcification;	chr19:37563606	chr19:37314868~37315620:-
LUAD	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	5.72	1.89e-08	6.87e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
LUAD	cis	rs1707322	0.827	rs10890347	ENSG00000234329.1	RP11-767N6.2	-5.72	1.89e-08	6.87e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45651039~45651826:-
LUAD	cis	rs2412819	0.571	rs8030536	ENSG00000249839.1	AC011330.5	-5.72	1.89e-08	6.89e-06	-0.42	-0.25	Lung cancer;	chr15:43627365	chr15:43663654~43684339:-
LUAD	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-5.72	1.89e-08	6.89e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.708	rs920745	ENSG00000238181.2	AHCYP2	-5.72	1.9e-08	6.89e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.734	rs10491784	ENSG00000238181.2	AHCYP2	-5.72	1.9e-08	6.89e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120720673~120721972:+
LUAD	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	5.72	1.9e-08	6.9e-06	0.31	0.25	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	5.72	1.9e-08	6.9e-06	0.31	0.25	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
LUAD	cis	rs12908161	0.853	rs12912342	ENSG00000259728.4	LINC00933	5.72	1.9e-08	6.9e-06	0.34	0.25	Schizophrenia;	chr15:84704985	chr15:84570649~84580175:+
LUAD	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	5.72	1.9e-08	6.9e-06	0.5	0.25	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
LUAD	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-5.72	1.9e-08	6.91e-06	-0.35	-0.25	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
LUAD	cis	rs9860428	0.933	rs6808135	ENSG00000242770.2	RP11-180K7.1	5.72	1.9e-08	6.91e-06	0.26	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112847301	chr3:112802478~112812819:+
LUAD	cis	rs12699921	0.632	rs2691616	ENSG00000279048.1	RP11-511H23.2	-5.72	1.91e-08	6.92e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17782557	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
LUAD	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000211967.3	IGHV3-53	-5.72	1.91e-08	6.93e-06	-0.18	-0.25	Kawasaki disease;	chr14:106776698	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000211967.3	IGHV3-53	-5.72	1.91e-08	6.93e-06	-0.18	-0.25	Kawasaki disease;	chr14:106776724	chr14:106592676~106593347:-
LUAD	cis	rs728616	0.558	rs723192	ENSG00000225484.5	NUTM2B-AS1	-5.72	1.91e-08	6.93e-06	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948257	chr10:79663088~79826594:-
LUAD	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	5.72	1.91e-08	6.94e-06	0.32	0.25	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000224373.3	IGHV4-59	5.72	1.91e-08	6.94e-06	0.17	0.25	Kawasaki disease;	chr14:106787630	chr14:106627249~106627825:-
LUAD	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-5.72	1.91e-08	6.94e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-5.72	1.91e-08	6.94e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
LUAD	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	5.72	1.91e-08	6.94e-06	0.27	0.25	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
LUAD	cis	rs948562	0.947	rs75708979	ENSG00000280010.1	AP001350.4	5.72	1.92e-08	6.96e-06	0.42	0.25	Lymphoma;	chr11:58662312	chr11:58627435~58628528:+
LUAD	cis	rs9549367	0.569	rs3024719	ENSG00000269125.1	RP11-98F14.11	-5.72	1.92e-08	6.96e-06	-0.37	-0.25	Platelet distribution width;	chr13:113159911	chr13:113165002~113165183:-
LUAD	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	5.72	1.93e-08	6.99e-06	0.29	0.25	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
LUAD	cis	rs2280018	1	rs2280017	ENSG00000188599.16	NPIPP1	5.72	1.93e-08	6.99e-06	0.21	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15104312~15123498:-
LUAD	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	5.72	1.93e-08	6.99e-06	0.33	0.25	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
LUAD	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	5.71	1.93e-08	7e-06	0.37	0.25	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	5.71	1.93e-08	7e-06	0.37	0.25	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
LUAD	cis	rs2288884	1	rs76768215	ENSG00000275055.1	CTC-471J1.11	-5.71	1.93e-08	7e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069370	chr19:52049007~52049754:+
LUAD	cis	rs7208859	0.623	rs73267858	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs56095789	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11656844	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11652533	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11652631	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30729469~30731202:+
LUAD	cis	rs2749097	1	rs12024831	ENSG00000244256.3	RN7SL130P	-5.71	1.93e-08	7.01e-06	-0.37	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63671796	chr1:63655743~63656047:+
LUAD	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-5.71	1.93e-08	7.01e-06	-0.26	-0.25	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
LUAD	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-5.71	1.94e-08	7.02e-06	-0.26	-0.25	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
LUAD	cis	rs5753618	0.561	rs9606831	ENSG00000236132.1	CTA-440B3.1	-5.71	1.94e-08	7.02e-06	-0.32	-0.25	Colorectal cancer;	chr22:31336526	chr22:31816379~31817491:-
LUAD	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-5.71	1.94e-08	7.02e-06	-0.26	-0.25	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
LUAD	cis	rs12468226	1	rs16839090	ENSG00000272966.1	RP11-686O6.1	5.71	1.94e-08	7.02e-06	0.43	0.25	Urate levels;	chr2:202348338	chr2:202336739~202337200:+
LUAD	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	5.71	1.94e-08	7.03e-06	0.3	0.25	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
LUAD	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	5.71	1.94e-08	7.04e-06	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	5.71	1.94e-08	7.04e-06	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
LUAD	cis	rs7804306	1	rs34156160	ENSG00000233264.2	AC006042.8	5.71	1.94e-08	7.04e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8043155	chr7:7980312~7982228:+
LUAD	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-5.71	1.94e-08	7.04e-06	-0.3	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
LUAD	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	5.71	1.94e-08	7.04e-06	0.31	0.25	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
LUAD	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-5.71	1.95e-08	7.06e-06	-0.43	-0.25	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
LUAD	cis	rs860295	0.541	rs11264359	ENSG00000225855.5	RUSC1-AS1	5.71	1.95e-08	7.08e-06	0.17	0.25	Body mass index;	chr1:155313038	chr1:155316863~155324176:-
LUAD	cis	rs75422866	0.51	rs73105818	ENSG00000274902.1	RP1-197B17.4	5.71	1.95e-08	7.08e-06	0.55	0.25	Pneumonia;	chr12:47726538	chr12:47731908~47732351:+
LUAD	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-5.71	1.96e-08	7.09e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
LUAD	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	5.71	1.96e-08	7.09e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
LUAD	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	5.71	1.96e-08	7.1e-06	0.3	0.25	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
LUAD	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	5.71	1.96e-08	7.1e-06	0.31	0.25	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
LUAD	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	5.71	1.96e-08	7.1e-06	0.29	0.25	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	5.71	1.96e-08	7.11e-06	0.27	0.25	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	5.71	1.96e-08	7.11e-06	0.27	0.25	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	5.71	1.96e-08	7.11e-06	0.27	0.25	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
LUAD	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	5.71	1.96e-08	7.11e-06	0.48	0.25	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
LUAD	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	5.71	1.96e-08	7.11e-06	0.29	0.25	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	5.71	1.96e-08	7.11e-06	0.29	0.25	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	5.71	1.96e-08	7.11e-06	0.29	0.25	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
LUAD	cis	rs61776719	0.905	rs17465420	ENSG00000212541.1	RNU6-510P	-5.71	1.96e-08	7.11e-06	-0.3	-0.25	Coronary artery disease;	chr1:37932916	chr1:37991462~37991569:+
LUAD	cis	rs2581794	1	rs2581794	ENSG00000242142.1	SERBP1P3	5.71	1.96e-08	7.11e-06	0.28	0.25	Schizophrenia;	chr3:53002190	chr3:53064283~53065091:-
LUAD	cis	rs30380	0.586	rs28119	ENSG00000272109.1	CTD-2260A17.3	-5.71	1.96e-08	7.11e-06	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96796030	chr5:96804353~96806105:+
LUAD	cis	rs7246657	0.722	rs4802051	ENSG00000276846.1	CTD-3220F14.3	5.71	1.97e-08	7.12e-06	0.33	0.25	Coronary artery calcification;	chr19:37581427	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.663	rs4803276	ENSG00000276846.1	CTD-3220F14.3	5.71	1.97e-08	7.12e-06	0.33	0.25	Coronary artery calcification;	chr19:37581429	chr19:37314868~37315620:-
LUAD	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	5.71	1.97e-08	7.12e-06	0.32	0.25	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
LUAD	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	5.71	1.97e-08	7.12e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	5.71	1.97e-08	7.12e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	5.71	1.97e-08	7.12e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
LUAD	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	5.71	1.97e-08	7.12e-06	0.3	0.25	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
LUAD	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	5.71	1.97e-08	7.13e-06	0.31	0.25	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-5.71	1.97e-08	7.14e-06	-0.31	-0.25	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
LUAD	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	5.71	1.97e-08	7.15e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
LUAD	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-5.71	1.97e-08	7.15e-06	-0.34	-0.25	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
LUAD	cis	rs2243480	1	rs9769882	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66177938	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6966322	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66181767	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs4145008	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66182524	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs4718315	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66183554	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs4718316	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66183744	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1873494	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66184912	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6959002	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66185509	chr7:66880708~66882981:+
LUAD	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	5.71	1.98e-08	7.16e-06	0.27	0.25	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.686	rs1541131	ENSG00000234329.1	RP11-767N6.2	-5.71	1.98e-08	7.16e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs316315	ENSG00000232546.1	RP11-458F8.1	5.71	1.98e-08	7.16e-06	0.29	0.25	Diabetic kidney disease;	chr7:66126218	chr7:66848496~66858136:+
LUAD	cis	rs9652601	0.691	rs7198004	ENSG00000274038.1	RP11-66H6.4	-5.71	1.98e-08	7.16e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11113760	chr16:11056556~11057034:+
LUAD	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	5.71	1.98e-08	7.16e-06	0.3	0.25	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
LUAD	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-5.71	1.98e-08	7.16e-06	-0.33	-0.25	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
LUAD	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-5.71	1.98e-08	7.16e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
LUAD	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-5.71	1.98e-08	7.16e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-5.71	1.98e-08	7.16e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-5.71	1.98e-08	7.16e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
LUAD	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-5.71	1.98e-08	7.16e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
LUAD	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-5.71	1.98e-08	7.17e-06	-0.31	-0.25	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
LUAD	cis	rs10129255	1	rs10129255	ENSG00000211974.3	IGHV2-70	-5.71	1.98e-08	7.17e-06	-0.26	-0.25	Kawasaki disease;	chr14:106767970	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-5.71	1.98e-08	7.18e-06	-0.32	-0.25	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
LUAD	cis	rs17818399	0.962	rs7565274	ENSG00000279254.1	RP11-536C12.1	-5.71	1.98e-08	7.18e-06	-0.28	-0.25	Height;	chr2:46614722	chr2:46668870~46670778:+
LUAD	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	5.71	1.98e-08	7.18e-06	0.51	0.25	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
LUAD	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	5.71	1.98e-08	7.18e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
LUAD	cis	rs12468226	0.873	rs12470401	ENSG00000226261.1	AC064836.3	5.71	1.98e-08	7.18e-06	0.43	0.25	Urate levels;	chr2:202236436	chr2:202336024~202336727:-
LUAD	cis	rs948562	0.585	rs11229477	ENSG00000280010.1	AP001350.4	5.71	1.99e-08	7.19e-06	0.41	0.25	Lymphoma;	chr11:58461125	chr11:58627435~58628528:+
LUAD	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	5.71	1.99e-08	7.19e-06	0.4	0.25	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
LUAD	cis	rs2243480	1	rs4718317	ENSG00000230295.1	RP11-458F8.2	5.71	1.99e-08	7.19e-06	0.3	0.25	Diabetic kidney disease;	chr7:66183914	chr7:66880708~66882981:+
LUAD	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	5.71	1.99e-08	7.19e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
LUAD	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-5.71	1.99e-08	7.19e-06	-0.32	-0.25	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
LUAD	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	5.71	1.99e-08	7.2e-06	0.29	0.25	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
LUAD	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-5.71	1.99e-08	7.2e-06	-0.29	-0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
LUAD	cis	rs2404602	0.655	rs4886507	ENSG00000259422.1	RP11-593F23.1	5.71	1.99e-08	7.2e-06	0.29	0.25	Blood metabolite levels;	chr15:76917353	chr15:76174891~76181486:-
LUAD	cis	rs7246657	0.663	rs10408619	ENSG00000276846.1	CTD-3220F14.3	5.71	1.99e-08	7.2e-06	0.33	0.25	Coronary artery calcification;	chr19:37579573	chr19:37314868~37315620:-
LUAD	cis	rs7923837	0.634	rs1544210	ENSG00000236493.2	EIF2S2P3	-5.71	1.99e-08	7.2e-06	-0.29	-0.25	Multiple sclerosis;Body mass index;	chr10:92728044	chr10:92668745~92669743:-
LUAD	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	5.71	1.99e-08	7.21e-06	0.35	0.25	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
LUAD	cis	rs17684571	0.7	rs62411366	ENSG00000231441.1	RP11-472M19.2	5.71	1.99e-08	7.21e-06	0.37	0.25	Schizophrenia;	chr6:56773015	chr6:56844002~56864078:+
LUAD	cis	rs1707322	1	rs946527	ENSG00000234329.1	RP11-767N6.2	5.71	2e-08	7.22e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45651039~45651826:-
LUAD	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	5.71	2e-08	7.23e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	5.71	2e-08	7.23e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
LUAD	cis	rs6543140	0.89	rs61122764	ENSG00000234389.1	AC007278.3	5.71	2e-08	7.23e-06	0.25	0.25	Blood protein levels;	chr2:102383060	chr2:102438713~102440475:+
LUAD	cis	rs75422866	0.51	rs73105803	ENSG00000274902.1	RP1-197B17.4	5.71	2e-08	7.23e-06	0.56	0.25	Pneumonia;	chr12:47722135	chr12:47731908~47732351:+
LUAD	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	5.71	2e-08	7.23e-06	0.35	0.25	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	5.71	2e-08	7.23e-06	0.35	0.25	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	5.71	2e-08	7.24e-06	0.38	0.25	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
LUAD	cis	rs7804306	0.826	rs35567393	ENSG00000233264.2	AC006042.8	5.71	2e-08	7.24e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8033938	chr7:7980312~7982228:+
LUAD	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	5.71	2e-08	7.24e-06	0.36	0.25	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
LUAD	cis	rs4908768	0.501	rs12046643	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8424645~8434838:+
LUAD	cis	rs4908760	0.965	rs10864353	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Vitiligo;	chr1:8489656	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs6677736	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs7527389	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs7518608	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8424645~8434838:+
LUAD	cis	rs4908760	0.965	rs10864356	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Vitiligo;	chr1:8509812	chr1:8424645~8434838:+
LUAD	cis	rs10129255	1	rs61997605	ENSG00000224373.3	IGHV4-59	5.71	2e-08	7.25e-06	0.16	0.25	Kawasaki disease;	chr14:106678368	chr14:106627249~106627825:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000224373.3	IGHV4-59	5.71	2e-08	7.25e-06	0.16	0.25	Kawasaki disease;	chr14:106678854	chr14:106627249~106627825:-
LUAD	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-5.71	2.01e-08	7.26e-06	-0.3	-0.25	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
LUAD	cis	rs2412819	0.597	rs7181912	ENSG00000249839.1	AC011330.5	5.71	2.01e-08	7.26e-06	0.4	0.25	Lung cancer;	chr15:43770676	chr15:43663654~43684339:-
LUAD	cis	rs944289	0.6	rs2899846	ENSG00000257826.1	RP11-116N8.4	-5.71	2.01e-08	7.27e-06	-0.28	-0.25	Thyroid cancer;	chr14:36140737	chr14:36061026~36067190:-
LUAD	cis	rs2243480	1	rs1546059	ENSG00000230295.1	RP11-458F8.2	5.71	2.01e-08	7.27e-06	0.3	0.25	Diabetic kidney disease;	chr7:66189722	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6958289	ENSG00000230295.1	RP11-458F8.2	5.71	2.01e-08	7.27e-06	0.3	0.25	Diabetic kidney disease;	chr7:66192124	chr7:66880708~66882981:+
LUAD	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-5.71	2.01e-08	7.27e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
LUAD	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	5.71	2.01e-08	7.28e-06	0.32	0.25	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
LUAD	cis	rs17666538	0.535	rs168062	ENSG00000254207.1	RP11-43A14.1	5.71	2.01e-08	7.28e-06	0.49	0.25	IgG glycosylation;	chr8:682444	chr8:725188~725877:-
LUAD	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	5.71	2.02e-08	7.28e-06	0.37	0.25	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
LUAD	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	5.71	2.02e-08	7.29e-06	0.37	0.25	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
LUAD	cis	rs4835473	0.742	rs7695853	ENSG00000251600.4	RP11-673E1.1	5.71	2.02e-08	7.29e-06	0.31	0.25	Immature fraction of reticulocytes;	chr4:143883243	chr4:143912331~143982454:+
LUAD	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-5.71	2.02e-08	7.29e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
LUAD	cis	rs55665837	0.665	rs11023273	ENSG00000251991.1	RNU7-49P	5.71	2.02e-08	7.3e-06	0.29	0.25	Vitamin D levels;	chr11:14609273	chr11:14478892~14478953:+
LUAD	cis	rs948562	0.947	rs78629620	ENSG00000280010.1	AP001350.4	5.71	2.02e-08	7.31e-06	0.41	0.25	Lymphoma;	chr11:58662329	chr11:58627435~58628528:+
LUAD	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	5.71	2.02e-08	7.31e-06	0.31	0.25	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
LUAD	cis	rs149313	0.901	rs697976	ENSG00000248734.2	CTD-2260A17.1	5.71	2.02e-08	7.31e-06	0.24	0.25	Blood protein levels;	chr5:96733063	chr5:96784777~96785999:+
LUAD	cis	rs172166	0.637	rs1233691	ENSG00000204709.4	LINC01556	5.71	2.03e-08	7.33e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28186119	chr6:28943877~28944537:+
LUAD	cis	rs4908760	0.899	rs6577496	ENSG00000232912.4	RP5-1115A15.1	5.71	2.03e-08	7.33e-06	0.23	0.25	Vitiligo;	chr1:8521168	chr1:8424645~8434838:+
LUAD	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	5.71	2.03e-08	7.33e-06	0.37	0.25	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
LUAD	cis	rs6558530	0.73	rs7341635	ENSG00000253982.1	CTD-2336O2.1	5.71	2.03e-08	7.34e-06	0.32	0.25	Systolic blood pressure;	chr8:1773477	chr8:1761990~1764502:-
LUAD	cis	rs7618501	0.633	rs35065728	ENSG00000234667.1	ACTBP13	-5.71	2.03e-08	7.34e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49971743	chr3:49873347~49877980:-
LUAD	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
LUAD	cis	rs2599510	0.783	rs13399071	ENSG00000276334.1	AL133243.1	5.71	2.03e-08	7.34e-06	0.29	0.25	Interleukin-18 levels;	chr2:32568716	chr2:32521927~32523547:+
LUAD	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-5.7	2.04e-08	7.35e-06	-0.36	-0.25	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
LUAD	cis	rs748404	0.666	rs72709879	ENSG00000205771.5	CATSPER2P1	-5.7	2.04e-08	7.36e-06	-0.38	-0.25	Lung cancer;	chr15:43507777	chr15:43726918~43747094:-
LUAD	cis	rs12699921	0.599	rs4721661	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.36e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17834677	chr7:17940503~17942922:+
LUAD	cis	rs9876781	0.56	rs2362451	ENSG00000229759.1	MRPS18AP1	-5.7	2.04e-08	7.36e-06	-0.25	-0.25	Longevity;	chr3:48358338	chr3:48256350~48256938:-
LUAD	cis	rs2765539	0.59	rs4659137	ENSG00000226172.2	RP4-712E4.1	-5.7	2.04e-08	7.36e-06	-0.33	-0.25	Waist-hip ratio;	chr1:118978171	chr1:119000344~119001392:-
LUAD	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-5.7	2.04e-08	7.36e-06	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
LUAD	cis	rs12468226	0.938	rs80282360	ENSG00000272966.1	RP11-686O6.1	5.7	2.04e-08	7.37e-06	0.44	0.25	Urate levels;	chr2:202275121	chr2:202336739~202337200:+
LUAD	cis	rs12699921	0.632	rs2691629	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785007	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723500	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785111	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2691630	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785163	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723499	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785261	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723498	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785362	chr7:17940503~17942922:+
LUAD	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	5.7	2.04e-08	7.37e-06	0.32	0.25	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
LUAD	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-5.7	2.04e-08	7.38e-06	-0.34	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
LUAD	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	5.7	2.05e-08	7.38e-06	0.35	0.25	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
LUAD	cis	rs7208859	0.673	rs1347359	ENSG00000263603.1	CTD-2349P21.5	-5.7	2.05e-08	7.39e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30729469~30731202:+
LUAD	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-5.7	2.05e-08	7.39e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
LUAD	cis	rs944289	0.536	rs1951375	ENSG00000257826.1	RP11-116N8.4	-5.7	2.05e-08	7.4e-06	-0.26	-0.25	Thyroid cancer;	chr14:36051569	chr14:36061026~36067190:-
LUAD	cis	rs2408955	0.522	rs4760612	ENSG00000240399.1	RP1-228P16.1	-5.7	2.05e-08	7.4e-06	-0.25	-0.25	Glycated hemoglobin levels;	chr12:48028073	chr12:48054813~48055591:-
LUAD	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-5.7	2.05e-08	7.4e-06	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
LUAD	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-5.7	2.05e-08	7.4e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
LUAD	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	5.7	2.05e-08	7.41e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	5.7	2.05e-08	7.41e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	5.7	2.05e-08	7.41e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
LUAD	cis	rs2288884	0.943	rs11671792	ENSG00000275055.1	CTC-471J1.11	-5.7	2.06e-08	7.42e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52078430	chr19:52049007~52049754:+
LUAD	cis	rs1707322	0.963	rs10890373	ENSG00000234329.1	RP11-767N6.2	5.7	2.06e-08	7.42e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45651039~45651826:-
LUAD	cis	rs35740288	0.822	rs17574774	ENSG00000202081.1	RNU6-1280P	-5.7	2.06e-08	7.43e-06	-0.31	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85690139	chr15:85651522~85651628:-
LUAD	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	5.7	2.06e-08	7.43e-06	0.4	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
LUAD	cis	rs4908760	0.965	rs1884352	ENSG00000232912.4	RP5-1115A15.1	5.7	2.06e-08	7.43e-06	0.23	0.25	Vitiligo;	chr1:8477229	chr1:8424645~8434838:+
LUAD	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	5.7	2.06e-08	7.44e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	5.7	2.06e-08	7.44e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
LUAD	cis	rs453301	0.658	rs3855900	ENSG00000253981.4	ALG1L13P	-5.7	2.07e-08	7.45e-06	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9044411	chr8:8236003~8244667:-
LUAD	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	5.7	2.07e-08	7.45e-06	0.35	0.25	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
LUAD	cis	rs7246657	0.722	rs1564208	ENSG00000276846.1	CTD-3220F14.3	5.7	2.07e-08	7.45e-06	0.33	0.25	Coronary artery calcification;	chr19:37550319	chr19:37314868~37315620:-
LUAD	cis	rs1707322	1	rs1707322	ENSG00000234329.1	RP11-767N6.2	5.7	2.07e-08	7.45e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45651039~45651826:-
LUAD	cis	rs6687821	0.515	rs12734749	ENSG00000267734.1	RP4-604K5.3	-5.7	2.07e-08	7.46e-06	-0.31	-0.25	Yeast infection;	chr1:86971063	chr1:86932199~86934891:-
LUAD	cis	rs1799949	0.602	rs8176257	ENSG00000267681.1	CTD-3199J23.6	-5.7	2.07e-08	7.46e-06	-0.32	-0.25	Menopause (age at onset);	chr17:43064188	chr17:43144956~43145255:+
LUAD	cis	rs74233809	1	rs77787671	ENSG00000213277.3	MARCKSL1P1	5.7	2.07e-08	7.47e-06	0.44	0.25	Birth weight;	chr10:103016448	chr10:103175554~103176094:+
LUAD	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-5.7	2.07e-08	7.48e-06	-0.27	-0.25	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
LUAD	cis	rs7044106	0.537	rs4434680	ENSG00000238181.2	AHCYP2	-5.7	2.08e-08	7.48e-06	-0.36	-0.25	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120720673~120721972:+
LUAD	cis	rs17138358	0.515	rs2691610	ENSG00000279048.1	RP11-511H23.2	-5.7	2.08e-08	7.49e-06	-0.2	-0.25	HDL cholesterol levels;	chr7:17781815	chr7:17940503~17942922:+
LUAD	cis	rs9807989	0.839	rs6749114	ENSG00000234389.1	AC007278.3	5.7	2.08e-08	7.49e-06	0.24	0.25	Asthma;	chr2:102351127	chr2:102438713~102440475:+
LUAD	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-5.7	2.08e-08	7.49e-06	-0.34	-0.25	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	5.7	2.09e-08	7.51e-06	0.31	0.25	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
LUAD	cis	rs6687821	0.515	rs10747338	ENSG00000267734.1	RP4-604K5.3	-5.7	2.09e-08	7.52e-06	-0.31	-0.25	Yeast infection;	chr1:87043716	chr1:86932199~86934891:-
LUAD	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	5.7	2.09e-08	7.52e-06	0.31	0.25	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
LUAD	cis	rs62432291	0.681	rs445957	ENSG00000235086.1	FNDC1-IT1	-5.7	2.09e-08	7.52e-06	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159241032	chr6:159240786~159243329:+
LUAD	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	5.7	2.09e-08	7.52e-06	0.27	0.25	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
LUAD	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	5.7	2.09e-08	7.53e-06	0.37	0.25	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
LUAD	cis	rs2408955	0.521	rs11168437	ENSG00000240399.1	RP1-228P16.1	5.7	2.09e-08	7.53e-06	0.25	0.25	Glycated hemoglobin levels;	chr12:48172373	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000224373.3	IGHV4-59	5.7	2.09e-08	7.54e-06	0.16	0.25	Kawasaki disease;	chr14:106678896	chr14:106627249~106627825:-
LUAD	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-5.7	2.09e-08	7.54e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-5.7	2.09e-08	7.54e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-5.7	2.09e-08	7.54e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
LUAD	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-5.7	2.09e-08	7.54e-06	-0.33	-0.25	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
LUAD	cis	rs2404602	0.669	rs12441484	ENSG00000259422.1	RP11-593F23.1	5.7	2.1e-08	7.55e-06	0.29	0.25	Blood metabolite levels;	chr15:76817534	chr15:76174891~76181486:-
LUAD	cis	rs4273100	1	rs12602286	ENSG00000279825.1	CTC-457L16.1	-5.7	2.1e-08	7.55e-06	-0.32	-0.25	Schizophrenia;	chr17:19333641	chr17:19030857~19033529:+
LUAD	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	5.7	2.1e-08	7.55e-06	0.36	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
LUAD	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-5.7	2.1e-08	7.58e-06	-0.38	-0.25	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
LUAD	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	5.7	2.11e-08	7.58e-06	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000224373.3	IGHV4-59	5.7	2.11e-08	7.59e-06	0.16	0.25	Kawasaki disease;	chr14:106775695	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000224373.3	IGHV4-59	5.7	2.11e-08	7.59e-06	0.16	0.25	Kawasaki disease;	chr14:106775735	chr14:106627249~106627825:-
LUAD	cis	rs12699921	0.632	rs2254176	ENSG00000279048.1	RP11-511H23.2	-5.7	2.11e-08	7.6e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785981	chr7:17940503~17942922:+
LUAD	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	5.7	2.11e-08	7.6e-06	0.37	0.25	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
LUAD	cis	rs9595908	0.785	rs4942804	ENSG00000212293.1	SNORA16	5.7	2.11e-08	7.6e-06	0.26	0.25	Body mass index;	chr13:32684365	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-5.7	2.11e-08	7.6e-06	-0.33	-0.25	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000224373.3	IGHV4-59	5.7	2.11e-08	7.61e-06	0.16	0.25	Kawasaki disease;	chr14:106676625	chr14:106627249~106627825:-
LUAD	cis	rs75422866	0.51	rs73104197	ENSG00000274902.1	RP1-197B17.4	5.7	2.12e-08	7.62e-06	0.56	0.25	Pneumonia;	chr12:47717273	chr12:47731908~47732351:+
LUAD	cis	rs9652601	0.622	rs8056098	ENSG00000274038.1	RP11-66H6.4	-5.7	2.12e-08	7.62e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11044955	chr16:11056556~11057034:+
LUAD	cis	rs172166	0.637	rs1225592	ENSG00000204709.4	LINC01556	5.7	2.12e-08	7.62e-06	0.32	0.25	Cardiac Troponin-T levels;	chr6:28182464	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.637	rs1225595	ENSG00000204709.4	LINC01556	5.7	2.12e-08	7.62e-06	0.32	0.25	Cardiac Troponin-T levels;	chr6:28183562	chr6:28943877~28944537:+
LUAD	cis	rs16863064	1	rs16863064	ENSG00000279891.1	FLJ42393	5.7	2.12e-08	7.63e-06	0.36	0.25	Schizophrenia;	chr3:188169789	chr3:188178543~188180812:+
LUAD	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	5.7	2.12e-08	7.63e-06	0.27	0.25	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
LUAD	cis	rs755249	0.567	rs61779309	ENSG00000228060.1	RP11-69E11.8	-5.7	2.12e-08	7.63e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39565160~39573203:+
LUAD	cis	rs948562	0.585	rs17472536	ENSG00000280010.1	AP001350.4	5.7	2.12e-08	7.63e-06	0.42	0.25	Lymphoma;	chr11:58346066	chr11:58627435~58628528:+
LUAD	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	5.7	2.12e-08	7.64e-06	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
LUAD	cis	rs9860428	0.868	rs9871605	ENSG00000242770.2	RP11-180K7.1	5.7	2.13e-08	7.65e-06	0.26	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112845234	chr3:112802478~112812819:+
LUAD	cis	rs7246657	0.606	rs2972439	ENSG00000276846.1	CTD-3220F14.3	-5.7	2.13e-08	7.65e-06	-0.34	-0.25	Coronary artery calcification;	chr19:37721680	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs2909100	ENSG00000276846.1	CTD-3220F14.3	-5.7	2.13e-08	7.65e-06	-0.34	-0.25	Coronary artery calcification;	chr19:37721779	chr19:37314868~37315620:-
LUAD	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	5.7	2.13e-08	7.66e-06	0.47	0.25	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	5.7	2.13e-08	7.66e-06	0.47	0.25	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
LUAD	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-5.7	2.13e-08	7.66e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
LUAD	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	5.7	2.13e-08	7.66e-06	0.28	0.25	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
LUAD	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
LUAD	cis	rs755249	0.917	rs61781393	ENSG00000228060.1	RP11-69E11.8	-5.7	2.14e-08	7.69e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39565160~39573203:+
LUAD	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	5.7	2.14e-08	7.69e-06	0.54	0.25	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
LUAD	cis	rs9652601	0.691	rs7203150	ENSG00000274038.1	RP11-66H6.4	-5.7	2.14e-08	7.7e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11113865	chr16:11056556~11057034:+
LUAD	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-5.7	2.14e-08	7.7e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-5.7	2.14e-08	7.7e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
LUAD	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-5.7	2.14e-08	7.7e-06	-0.31	-0.25	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
LUAD	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	5.7	2.14e-08	7.7e-06	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
LUAD	cis	rs12908161	0.959	rs61074241	ENSG00000225151.9	GOLGA2P7	-5.7	2.14e-08	7.7e-06	-0.36	-0.25	Schizophrenia;	chr15:84790165	chr15:84199311~84230136:-
LUAD	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-5.7	2.14e-08	7.7e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
LUAD	cis	rs62246343	0.786	rs62246267	ENSG00000254485.4	RP11-380O24.1	5.7	2.14e-08	7.71e-06	0.37	0.25	Fibrinogen levels;	chr3:9361477	chr3:9292588~9363303:-
LUAD	cis	rs35740288	0.721	rs17637276	ENSG00000202081.1	RNU6-1280P	5.7	2.14e-08	7.71e-06	0.32	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700289	chr15:85651522~85651628:-
LUAD	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	5.7	2.14e-08	7.71e-06	0.3	0.25	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	5.7	2.14e-08	7.71e-06	0.3	0.25	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
LUAD	cis	rs2288884	1	rs12609219	ENSG00000275055.1	CTC-471J1.11	-5.7	2.15e-08	7.72e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077743	chr19:52049007~52049754:+
LUAD	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	5.7	2.15e-08	7.72e-06	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
LUAD	cis	rs55665837	0.701	rs10766188	ENSG00000251991.1	RNU7-49P	5.7	2.15e-08	7.72e-06	0.3	0.25	Vitamin D levels;	chr11:14639280	chr11:14478892~14478953:+
LUAD	cis	rs9595908	0.686	rs9596155	ENSG00000212293.1	SNORA16	5.7	2.15e-08	7.72e-06	0.27	0.25	Body mass index;	chr13:32724002	chr13:32420390~32420516:-
LUAD	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	5.69	2.15e-08	7.73e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
LUAD	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	5.69	2.15e-08	7.74e-06	0.3	0.25	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
LUAD	cis	rs9435732	1	rs9435732	ENSG00000235241.1	RP11-108M9.5	5.69	2.15e-08	7.74e-06	0.29	0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16981663	chr1:16889095~16889602:+
LUAD	cis	rs10214930	0.781	rs974883	ENSG00000235574.1	AC073150.6	-5.69	2.16e-08	7.75e-06	-0.33	-0.25	Hypospadias;	chr7:27549115	chr7:27491682~27492765:-
LUAD	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-5.69	2.16e-08	7.78e-06	-0.39	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
LUAD	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
LUAD	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-5.69	2.17e-08	7.78e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
LUAD	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	5.69	2.17e-08	7.78e-06	0.31	0.25	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	5.69	2.17e-08	7.78e-06	0.31	0.25	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	5.69	2.17e-08	7.78e-06	0.31	0.25	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
LUAD	cis	rs9813712	0.571	rs11715351	ENSG00000249846.5	RP11-77P16.4	-5.69	2.17e-08	7.78e-06	-0.29	-0.25	Response to amphetamines;	chr3:130214704	chr3:130112550~130120579:+
LUAD	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-5.69	2.17e-08	7.78e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
LUAD	cis	rs10129255	1	rs10129407	ENSG00000211974.3	IGHV2-70	5.69	2.17e-08	7.79e-06	0.26	0.25	Kawasaki disease;	chr14:106767956	chr14:106723574~106724093:-
LUAD	cis	rs7804306	0.826	rs73050951	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.8e-06	0.51	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8032762	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73050956	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.8e-06	0.51	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036076	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73050958	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.8e-06	0.51	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036162	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73050959	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.8e-06	0.51	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037069	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049270	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.81e-06	0.5	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982015	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049276	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.81e-06	0.5	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982385	chr7:7980312~7982228:+
LUAD	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	5.69	2.18e-08	7.81e-06	0.27	0.25	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
LUAD	cis	rs17684571	0.7	rs35873865	ENSG00000231441.1	RP11-472M19.2	5.69	2.18e-08	7.81e-06	0.38	0.25	Schizophrenia;	chr6:56790203	chr6:56844002~56864078:+
LUAD	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	5.69	2.18e-08	7.82e-06	0.25	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
LUAD	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-5.69	2.18e-08	7.83e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-5.69	2.18e-08	7.83e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
LUAD	cis	rs12554020	0.786	rs3893381	ENSG00000227603.1	RP11-165J3.6	-5.69	2.18e-08	7.83e-06	-0.46	-0.25	Schizophrenia;	chr9:93519576	chr9:93435332~93437121:-
LUAD	cis	rs1823913	0.503	rs34716486	ENSG00000280083.1	RP11-317J9.1	-5.69	2.18e-08	7.84e-06	-0.31	-0.25	Obesity-related traits;	chr2:191343335	chr2:191154118~191156070:-
LUAD	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-5.69	2.18e-08	7.84e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
LUAD	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-5.69	2.18e-08	7.84e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
LUAD	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	5.69	2.19e-08	7.84e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000099984.9	GSTT2	5.69	2.19e-08	7.86e-06	0.34	0.25	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23980123~23983911:+
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000211967.3	IGHV3-53	-5.69	2.19e-08	7.86e-06	-0.18	-0.25	Kawasaki disease;	chr14:106768275	chr14:106592676~106593347:-
LUAD	cis	rs2243480	1	rs906134	ENSG00000230295.1	RP11-458F8.2	-5.69	2.19e-08	7.86e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:65979301	chr7:66880708~66882981:+
LUAD	cis	rs1799949	0.602	rs8176199	ENSG00000267681.1	CTD-3199J23.6	-5.69	2.19e-08	7.86e-06	-0.33	-0.25	Menopause (age at onset);	chr17:43078507	chr17:43144956~43145255:+
LUAD	cis	rs6772849	0.775	rs12486377	ENSG00000242551.2	POU5F1P6	-5.69	2.19e-08	7.86e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128696010	chr3:128674735~128677005:-
LUAD	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	5.69	2.19e-08	7.87e-06	0.36	0.25	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
LUAD	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	5.69	2.19e-08	7.88e-06	0.31	0.25	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
LUAD	cis	rs2115630	0.691	rs2292462	ENSG00000229212.6	RP11-561C5.4	5.69	2.2e-08	7.88e-06	0.3	0.25	P wave terminal force;	chr15:84657523	chr15:85205440~85234795:-
LUAD	cis	rs8031584	0.541	rs2959037	ENSG00000270015.1	RP11-540B6.6	5.69	2.2e-08	7.88e-06	0.17	0.25	Huntington's disease progression;	chr15:30925961	chr15:30926514~30928407:+
LUAD	cis	rs2832077	1	rs12329875	ENSG00000232855.5	AF131217.1	5.69	2.2e-08	7.88e-06	0.28	0.25	Cognitive test performance;	chr21:28765474	chr21:28439346~28674848:-
LUAD	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-5.69	2.2e-08	7.89e-06	-0.3	-0.25	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
LUAD	cis	rs1707322	0.927	rs6690386	ENSG00000234329.1	RP11-767N6.2	5.69	2.2e-08	7.89e-06	0.27	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45651039~45651826:-
LUAD	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	5.69	2.2e-08	7.89e-06	0.29	0.25	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
LUAD	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-5.69	2.2e-08	7.89e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
LUAD	cis	rs925255	0.817	rs7606480	ENSG00000270210.1	RP11-373D23.3	-5.69	2.2e-08	7.89e-06	-0.3	-0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28409510	chr2:28425945~28426719:+
LUAD	cis	rs10214930	0.813	rs9639559	ENSG00000235574.1	AC073150.6	-5.69	2.2e-08	7.9e-06	-0.33	-0.25	Hypospadias;	chr7:27565876	chr7:27491682~27492765:-
LUAD	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	5.69	2.2e-08	7.9e-06	0.3	0.25	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
LUAD	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	5.69	2.2e-08	7.9e-06	0.27	0.25	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
LUAD	cis	rs9652601	0.622	rs2286974	ENSG00000274038.1	RP11-66H6.4	-5.69	2.2e-08	7.9e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11020655	chr16:11056556~11057034:+
LUAD	cis	rs12468226	0.817	rs6722588	ENSG00000226261.1	AC064836.3	-5.69	2.21e-08	7.91e-06	-0.41	-0.25	Urate levels;	chr2:202187163	chr2:202336024~202336727:-
LUAD	cis	rs17684571	0.7	rs17684802	ENSG00000231441.1	RP11-472M19.2	-5.69	2.21e-08	7.91e-06	-0.36	-0.25	Schizophrenia;	chr6:56813854	chr6:56844002~56864078:+
LUAD	cis	rs1113500	0.548	rs9970655	ENSG00000226822.1	RP11-356N1.2	5.69	2.21e-08	7.92e-06	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108100915	chr1:108071482~108074519:+
LUAD	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-5.69	2.21e-08	7.92e-06	-0.28	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
LUAD	cis	rs748404	0.666	rs66629206	ENSG00000205771.5	CATSPER2P1	-5.69	2.21e-08	7.92e-06	-0.38	-0.25	Lung cancer;	chr15:43458804	chr15:43726918~43747094:-
LUAD	cis	rs944289	0.576	rs1169140	ENSG00000257826.1	RP11-116N8.4	-5.69	2.21e-08	7.93e-06	-0.28	-0.25	Thyroid cancer;	chr14:36159160	chr14:36061026~36067190:-
LUAD	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	5.69	2.21e-08	7.94e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
LUAD	cis	rs4908768	0.539	rs2100888	ENSG00000232912.4	RP5-1115A15.1	5.69	2.22e-08	7.95e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8424645~8434838:+
LUAD	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	5.69	2.22e-08	7.95e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
LUAD	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	5.69	2.22e-08	7.96e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
LUAD	cis	rs1426063	0.614	rs17000262	ENSG00000249717.1	RP11-44F21.3	5.69	2.22e-08	7.96e-06	0.45	0.25	QT interval;	chr4:75108836	chr4:74955974~74970362:-
LUAD	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	5.69	2.22e-08	7.97e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	5.69	2.22e-08	7.97e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
LUAD	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-5.69	2.22e-08	7.97e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
LUAD	cis	rs17301853	1	rs17301853	ENSG00000227373.4	RP11-160H22.5	5.69	2.22e-08	7.97e-06	0.5	0.25	Migraine without aura;Migraine - clinic-based;	chr1:174583673	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs316329	ENSG00000230295.1	RP11-458F8.2	-5.69	2.23e-08	7.98e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66143429	chr7:66880708~66882981:+
LUAD	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	5.69	2.23e-08	7.98e-06	0.45	0.25	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
LUAD	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	5.69	2.23e-08	7.99e-06	0.28	0.25	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	5.69	2.23e-08	7.99e-06	0.28	0.25	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	5.69	2.23e-08	7.99e-06	0.28	0.25	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	5.69	2.23e-08	7.99e-06	0.28	0.25	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
LUAD	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-5.69	2.23e-08	7.99e-06	-0.3	-0.25	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
LUAD	cis	rs7208859	0.623	rs8075163	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs8075107	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Body mass index;	chr17:30779631	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7223209	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7223404	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9916725	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9916727	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73269945	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9897728	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1054400	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1054397	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9890558	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs3752020	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9890855	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9893422	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9891166	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73269974	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs34756112	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs60724269	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs76633166	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1061346	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1061343	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73269988	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9899525	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9911784	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9911997	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9890862	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs78071511	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs2035494	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9915566	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs8064686	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11657369	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs8075341	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73271842	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.524	rs28760584	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7212991	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs28627615	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30729469~30731202:+
LUAD	cis	rs4908768	0.501	rs11121194	ENSG00000232912.4	RP5-1115A15.1	5.69	2.23e-08	8e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8424645~8434838:+
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000211974.3	IGHV2-70	-5.69	2.23e-08	8e-06	-0.34	-0.25	Alzheimer's disease (late onset);	chr14:106680831	chr14:106723574~106724093:-
LUAD	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-5.69	2.23e-08	8e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
LUAD	cis	rs10740039	0.516	rs2893840	ENSG00000254271.1	RP11-131N11.4	5.69	2.24e-08	8e-06	0.28	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60554257	chr10:60734342~60741828:+
LUAD	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-5.69	2.24e-08	8.02e-06	-0.27	-0.25	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
LUAD	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-5.69	2.24e-08	8.02e-06	-0.33	-0.25	Height;	chr6:109380015	chr6:109382795~109383666:+
LUAD	cis	rs16863064	0.932	rs9817667	ENSG00000279891.1	FLJ42393	5.69	2.24e-08	8.03e-06	0.36	0.25	Schizophrenia;	chr3:188169906	chr3:188178543~188180812:+
LUAD	cis	rs9928842	0.54	rs8051363	ENSG00000280152.1	RP11-331F4.5	5.69	2.24e-08	8.03e-06	0.24	0.25	Alcoholic chronic pancreatitis;	chr16:75221319	chr16:75245994~75250077:-
LUAD	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	5.69	2.24e-08	8.03e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
LUAD	cis	rs17301853	0.818	rs78923809	ENSG00000227373.4	RP11-160H22.5	5.69	2.24e-08	8.03e-06	0.5	0.25	Migraine without aura;Migraine - clinic-based;	chr1:174616446	chr1:174115300~174160004:-
LUAD	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	5.69	2.25e-08	8.05e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
LUAD	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-5.69	2.25e-08	8.05e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
LUAD	cis	rs35740288	0.731	rs12913556	ENSG00000202081.1	RNU6-1280P	5.69	2.25e-08	8.06e-06	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85558965	chr15:85651522~85651628:-
LUAD	cis	rs35934224	0.783	rs7290770	ENSG00000232926.1	AC000078.5	5.69	2.25e-08	8.06e-06	0.3	0.25	Glaucoma (primary open-angle);	chr22:19873638	chr22:19887289~19887970:+
LUAD	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	5.69	2.25e-08	8.07e-06	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
LUAD	cis	rs2749097	1	rs2749096	ENSG00000244256.3	RN7SL130P	-5.69	2.25e-08	8.07e-06	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63661991	chr1:63655743~63656047:+
LUAD	cis	rs2412819	0.545	rs35822148	ENSG00000249839.1	AC011330.5	-5.69	2.26e-08	8.09e-06	-0.44	-0.25	Lung cancer;	chr15:43808084	chr15:43663654~43684339:-
LUAD	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	5.69	2.26e-08	8.09e-06	0.47	0.25	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
LUAD	cis	rs10214930	1	rs4481475	ENSG00000235574.1	AC073150.6	-5.69	2.26e-08	8.09e-06	-0.35	-0.25	Hypospadias;	chr7:27731902	chr7:27491682~27492765:-
LUAD	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-5.69	2.26e-08	8.1e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
LUAD	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	5.69	2.27e-08	8.12e-06	0.3	0.25	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000211972.2	IGHV3-66	5.69	2.27e-08	8.12e-06	0.21	0.25	Kawasaki disease;	chr14:106776695	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000211972.2	IGHV3-66	5.69	2.27e-08	8.12e-06	0.21	0.25	Kawasaki disease;	chr14:106778202	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000211972.2	IGHV3-66	5.69	2.27e-08	8.12e-06	0.21	0.25	Kawasaki disease;	chr14:106778401	chr14:106675017~106675544:-
LUAD	cis	rs4908768	0.501	rs6577499	ENSG00000232912.4	RP5-1115A15.1	-5.69	2.27e-08	8.12e-06	-0.23	-0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8424645~8434838:+
LUAD	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	5.68	2.27e-08	8.13e-06	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	5.68	2.27e-08	8.13e-06	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
LUAD	cis	rs6687821	0.515	rs4484904	ENSG00000267734.1	RP4-604K5.3	-5.68	2.27e-08	8.14e-06	-0.31	-0.25	Yeast infection;	chr1:87048234	chr1:86932199~86934891:-
LUAD	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs7804223	ENSG00000230295.1	RP11-458F8.2	5.68	2.28e-08	8.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66199572	chr7:66880708~66882981:+
LUAD	cis	rs2562456	0.92	rs2650784	ENSG00000268081.1	RP11-678G14.2	-5.68	2.28e-08	8.16e-06	-0.37	-0.25	Pain;	chr19:21483795	chr19:21554640~21569237:-
LUAD	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-5.68	2.28e-08	8.16e-06	-0.31	-0.25	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
LUAD	cis	rs4908768	0.539	rs6663123	ENSG00000232912.4	RP5-1115A15.1	5.68	2.28e-08	8.17e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8424645~8434838:+
LUAD	cis	rs9807989	0.708	rs6543124	ENSG00000234389.1	AC007278.3	5.68	2.28e-08	8.17e-06	0.24	0.25	Asthma;	chr2:102370999	chr2:102438713~102440475:+
LUAD	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-5.68	2.28e-08	8.17e-06	-0.39	-0.25	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
LUAD	cis	rs2243480	1	rs1796220	ENSG00000230295.1	RP11-458F8.2	-5.68	2.29e-08	8.18e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66597113	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2707831	ENSG00000230295.1	RP11-458F8.2	-5.68	2.29e-08	8.18e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66597524	chr7:66880708~66882981:+
LUAD	cis	rs7208859	0.524	rs11653098	ENSG00000263603.1	CTD-2349P21.5	-5.68	2.29e-08	8.18e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30729469~30731202:+
LUAD	cis	rs55665837	0.701	rs11023272	ENSG00000251991.1	RNU7-49P	5.68	2.29e-08	8.18e-06	0.29	0.25	Vitamin D levels;	chr11:14608824	chr11:14478892~14478953:+
LUAD	cis	rs66887589	0.66	rs4833613	ENSG00000248280.1	RP11-33B1.2	-5.68	2.29e-08	8.18e-06	-0.29	-0.25	Diastolic blood pressure;	chr4:119229001	chr4:119440561~119450157:-
LUAD	cis	rs30380	0.632	rs26489	ENSG00000272109.1	CTD-2260A17.3	-5.68	2.29e-08	8.19e-06	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96797724	chr5:96804353~96806105:+
LUAD	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-5.68	2.29e-08	8.19e-06	-0.37	-0.25	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
LUAD	cis	rs1707322	1	rs3922887	ENSG00000234329.1	RP11-767N6.2	5.68	2.29e-08	8.19e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs3922886	ENSG00000234329.1	RP11-767N6.2	5.68	2.29e-08	8.19e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45651039~45651826:-
LUAD	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	5.68	2.29e-08	8.2e-06	0.25	0.25	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	5.68	2.3e-08	8.21e-06	0.28	0.25	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
LUAD	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-5.68	2.3e-08	8.22e-06	-0.32	-0.25	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
LUAD	cis	rs1318937	0.764	rs9864422	ENSG00000224660.1	SH3BP5-AS1	5.68	2.3e-08	8.23e-06	0.2	0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15185745	chr3:15254184~15264493:+
LUAD	cis	rs55665837	0.701	rs11023278	ENSG00000251991.1	RNU7-49P	5.68	2.31e-08	8.24e-06	0.29	0.25	Vitamin D levels;	chr11:14619638	chr11:14478892~14478953:+
LUAD	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	5.68	2.31e-08	8.25e-06	0.31	0.25	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	5.68	2.31e-08	8.25e-06	0.31	0.25	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	5.68	2.31e-08	8.25e-06	0.31	0.25	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	5.68	2.31e-08	8.25e-06	0.31	0.25	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
LUAD	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	5.68	2.31e-08	8.26e-06	0.27	0.25	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
LUAD	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-5.68	2.32e-08	8.28e-06	-0.36	-0.25	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
LUAD	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	5.68	2.32e-08	8.3e-06	0.27	0.25	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
LUAD	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	5.68	2.32e-08	8.3e-06	0.31	0.25	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
LUAD	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	5.68	2.32e-08	8.3e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
LUAD	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	5.68	2.33e-08	8.31e-06	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
LUAD	cis	rs2212361	0.529	rs11020821	ENSG00000255893.1	RP11-685N10.1	-5.68	2.33e-08	8.32e-06	-0.33	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94538497	chr11:94472908~94473570:-
LUAD	cis	rs9595908	0.709	rs3492	ENSG00000212293.1	SNORA16	5.68	2.33e-08	8.32e-06	0.27	0.25	Body mass index;	chr13:32775203	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7326102	ENSG00000212293.1	SNORA16	5.68	2.33e-08	8.32e-06	0.27	0.25	Body mass index;	chr13:32777857	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs17516561	ENSG00000212293.1	SNORA16	5.68	2.33e-08	8.32e-06	0.27	0.25	Body mass index;	chr13:32782063	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-5.68	2.33e-08	8.32e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
LUAD	cis	rs807029	0.533	rs722435	ENSG00000272572.1	RP11-179B2.2	-5.68	2.33e-08	8.34e-06	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100911103~100912739:-
LUAD	cis	rs748404	0.666	rs60018990	ENSG00000205771.5	CATSPER2P1	-5.68	2.34e-08	8.35e-06	-0.38	-0.25	Lung cancer;	chr15:43504606	chr15:43726918~43747094:-
LUAD	cis	rs2998286	0.774	rs2790442	ENSG00000254635.4	WAC-AS1	-5.68	2.34e-08	8.35e-06	-0.36	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28539597	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.678	rs2807758	ENSG00000254635.4	WAC-AS1	-5.68	2.34e-08	8.35e-06	-0.36	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28549643	chr10:28522652~28532743:-
LUAD	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-5.68	2.34e-08	8.36e-06	-0.29	-0.25	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
LUAD	cis	rs9807989	0.801	rs6752482	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351398	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs4988956	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351547	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10192036	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351751	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10204137	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351752	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs4988958	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351825	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10192157	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351896	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10206753	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351902	chr2:102438713~102440475:+
LUAD	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	5.68	2.35e-08	8.37e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	5.68	2.35e-08	8.37e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	5.68	2.35e-08	8.37e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
LUAD	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	5.68	2.35e-08	8.37e-06	0.27	0.25	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
LUAD	cis	rs73219805	1	rs73217798	ENSG00000228451.3	SDAD1P1	-5.68	2.35e-08	8.38e-06	-0.38	-0.25	Schizophrenia;	chr8:26406847	chr8:26379259~26382953:-
LUAD	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	5.68	2.35e-08	8.38e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
LUAD	cis	rs2919009	0.607	rs2919007	ENSG00000271670.1	RP11-95I16.4	5.68	2.35e-08	8.39e-06	0.33	0.25	Obesity-related traits;	chr10:120842499	chr10:120879256~120880667:-
LUAD	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	5.68	2.35e-08	8.4e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
LUAD	cis	rs12699921	0.632	rs2723497	ENSG00000279048.1	RP11-511H23.2	-5.68	2.35e-08	8.4e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17786204	chr7:17940503~17942922:+
LUAD	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-5.68	2.36e-08	8.4e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
LUAD	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	5.68	2.36e-08	8.41e-06	0.31	0.25	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
LUAD	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	5.68	2.36e-08	8.41e-06	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
LUAD	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	5.68	2.36e-08	8.41e-06	0.31	0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
LUAD	cis	rs7208859	0.623	rs9912283	ENSG00000263603.1	CTD-2349P21.5	-5.68	2.36e-08	8.42e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30729469~30731202:+
LUAD	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-5.68	2.36e-08	8.42e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
LUAD	cis	rs1707322	1	rs6661500	ENSG00000234329.1	RP11-767N6.2	5.68	2.36e-08	8.42e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4660883	ENSG00000234329.1	RP11-767N6.2	5.68	2.36e-08	8.42e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45651039~45651826:-
LUAD	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	5.68	2.36e-08	8.42e-06	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
LUAD	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-5.68	2.36e-08	8.42e-06	-0.36	-0.25	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
LUAD	cis	rs17214007	0.597	rs11649126	ENSG00000263335.1	AF001548.5	-5.68	2.36e-08	8.43e-06	-0.37	-0.25	Cognitive function;	chr16:15626390	chr16:15726674~15732993:+
LUAD	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	5.68	2.36e-08	8.43e-06	0.38	0.25	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
LUAD	cis	rs2832077	1	rs2832065	ENSG00000232855.5	AF131217.1	5.68	2.36e-08	8.43e-06	0.28	0.25	Cognitive test performance;	chr21:28763040	chr21:28439346~28674848:-
LUAD	cis	rs2749097	1	rs11208268	ENSG00000244256.3	RN7SL130P	-5.68	2.36e-08	8.43e-06	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63672553	chr1:63655743~63656047:+
LUAD	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	5.68	2.37e-08	8.44e-06	0.28	0.25	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	5.68	2.37e-08	8.44e-06	0.28	0.25	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
LUAD	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	5.68	2.37e-08	8.44e-06	0.41	0.25	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
LUAD	cis	rs1426063	0.614	rs75345649	ENSG00000249717.1	RP11-44F21.3	5.68	2.37e-08	8.44e-06	0.47	0.25	QT interval;	chr4:75100963	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs77333523	ENSG00000249717.1	RP11-44F21.3	5.68	2.37e-08	8.44e-06	0.47	0.25	QT interval;	chr4:75101024	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs17199632	ENSG00000249717.1	RP11-44F21.3	5.68	2.37e-08	8.44e-06	0.47	0.25	QT interval;	chr4:75103663	chr4:74955974~74970362:-
LUAD	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	5.68	2.37e-08	8.45e-06	0.35	0.25	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
LUAD	cis	rs4947019	0.609	rs79097132	ENSG00000260273.1	RP11-425D10.10	5.68	2.37e-08	8.46e-06	0.55	0.25	Hematological parameters;	chr6:109404619	chr6:109382795~109383666:+
LUAD	cis	rs7083	0.935	rs523366	ENSG00000254851.1	RP11-109L13.1	5.68	2.37e-08	8.46e-06	0.32	0.25	Blood protein levels;	chr11:117248836	chr11:117135528~117138582:+
LUAD	cis	rs944289	0.576	rs10150608	ENSG00000257826.1	RP11-116N8.4	-5.68	2.38e-08	8.47e-06	-0.28	-0.25	Thyroid cancer;	chr14:36142221	chr14:36061026~36067190:-
LUAD	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-5.68	2.38e-08	8.48e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-5.68	2.38e-08	8.48e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
LUAD	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	5.68	2.38e-08	8.48e-06	0.31	0.25	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	5.68	2.38e-08	8.48e-06	0.31	0.25	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	5.68	2.38e-08	8.48e-06	0.31	0.25	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
LUAD	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	5.68	2.38e-08	8.49e-06	0.36	0.25	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
LUAD	cis	rs6840258	0.66	rs6531941	ENSG00000251411.1	RP11-397E7.4	5.68	2.38e-08	8.5e-06	0.32	0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86974808	chr4:86913266~86914817:-
LUAD	cis	rs368187	0.71	rs2780303	ENSG00000257826.1	RP11-116N8.4	5.68	2.38e-08	8.5e-06	0.27	0.25	Thyroid cancer;	chr14:36045580	chr14:36061026~36067190:-
LUAD	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	5.68	2.39e-08	8.5e-06	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
LUAD	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	5.68	2.39e-08	8.51e-06	0.32	0.25	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
LUAD	cis	rs2404602	0.692	rs35498563	ENSG00000259422.1	RP11-593F23.1	5.68	2.39e-08	8.51e-06	0.29	0.25	Blood metabolite levels;	chr15:76666527	chr15:76174891~76181486:-
LUAD	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-5.68	2.39e-08	8.52e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-5.68	2.39e-08	8.52e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
LUAD	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-5.68	2.39e-08	8.52e-06	-0.27	-0.25	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
LUAD	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	5.68	2.39e-08	8.53e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
LUAD	cis	rs7208859	0.673	rs9907197	ENSG00000263603.1	CTD-2349P21.5	-5.68	2.4e-08	8.54e-06	-0.39	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9915963	ENSG00000263603.1	CTD-2349P21.5	-5.68	2.4e-08	8.54e-06	-0.39	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30729469~30731202:+
LUAD	cis	rs10214930	0.813	rs759270	ENSG00000235574.1	AC073150.6	-5.68	2.4e-08	8.54e-06	-0.33	-0.25	Hypospadias;	chr7:27606842	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.781	rs759271	ENSG00000235574.1	AC073150.6	-5.68	2.4e-08	8.54e-06	-0.33	-0.25	Hypospadias;	chr7:27607494	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs2391445	ENSG00000235574.1	AC073150.6	-5.68	2.4e-08	8.54e-06	-0.33	-0.25	Hypospadias;	chr7:27609252	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs2391446	ENSG00000235574.1	AC073150.6	-5.68	2.4e-08	8.54e-06	-0.33	-0.25	Hypospadias;	chr7:27609301	chr7:27491682~27492765:-
LUAD	cis	rs2749097	1	rs61765315	ENSG00000244256.3	RN7SL130P	-5.67	2.4e-08	8.55e-06	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63662638	chr1:63655743~63656047:+
LUAD	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
LUAD	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	5.67	2.4e-08	8.56e-06	0.37	0.25	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
LUAD	cis	rs848490	0.615	rs2428939	ENSG00000214293.7	APTR	-5.67	2.4e-08	8.56e-06	-0.29	-0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77932977	chr7:77657660~77696265:-
LUAD	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-5.67	2.41e-08	8.57e-06	-0.34	-0.25	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
LUAD	cis	rs948562	0.535	rs11229369	ENSG00000280010.1	AP001350.4	5.67	2.41e-08	8.57e-06	0.42	0.25	Lymphoma;	chr11:58341039	chr11:58627435~58628528:+
LUAD	cis	rs7208859	0.623	rs7208441	ENSG00000263603.1	CTD-2349P21.5	-5.67	2.41e-08	8.57e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30729469~30731202:+
LUAD	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-5.67	2.41e-08	8.57e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
LUAD	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
LUAD	cis	rs10214930	0.697	rs3925338	ENSG00000235574.1	AC073150.6	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Hypospadias;	chr7:27553820	chr7:27491682~27492765:-
LUAD	cis	rs7246657	0.722	rs11083432	ENSG00000276846.1	CTD-3220F14.3	-5.67	2.41e-08	8.58e-06	-0.33	-0.25	Coronary artery calcification;	chr19:37691732	chr19:37314868~37315620:-
LUAD	cis	rs36093844	0.605	rs79719453	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85871174	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs75334800	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85875538	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs77497327	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85875898	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs79276445	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85876784	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs78681528	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85877113	chr11:85852557~85854943:-
LUAD	cis	rs1707322	1	rs1707317	ENSG00000234329.1	RP11-767N6.2	-5.67	2.41e-08	8.59e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45651039~45651826:-
LUAD	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	5.67	2.41e-08	8.59e-06	0.37	0.25	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	5.67	2.41e-08	8.59e-06	0.37	0.25	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
LUAD	cis	rs17666538	0.71	rs11987001	ENSG00000254207.1	RP11-43A14.1	5.67	2.41e-08	8.59e-06	0.54	0.25	IgG glycosylation;	chr8:680755	chr8:725188~725877:-
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000232546.1	RP11-458F8.1	-5.67	2.42e-08	8.61e-06	-0.32	-0.25	Diabetic kidney disease;	chr7:66078212	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000232546.1	RP11-458F8.1	-5.67	2.42e-08	8.61e-06	-0.32	-0.25	Diabetic kidney disease;	chr7:66078397	chr7:66848496~66858136:+
LUAD	cis	rs516805	0.528	rs2606631	ENSG00000279453.1	RP3-425C14.4	-5.67	2.42e-08	8.61e-06	-0.34	-0.25	Lymphocyte counts;	chr6:122099510	chr6:122436789~122439223:-
LUAD	cis	rs2404602	0.655	rs3829489	ENSG00000259422.1	RP11-593F23.1	5.67	2.42e-08	8.62e-06	0.29	0.25	Blood metabolite levels;	chr15:76930915	chr15:76174891~76181486:-
LUAD	cis	rs5753618	0.583	rs2899164	ENSG00000236132.1	CTA-440B3.1	-5.67	2.42e-08	8.62e-06	-0.31	-0.25	Colorectal cancer;	chr22:31394303	chr22:31816379~31817491:-
LUAD	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-5.67	2.42e-08	8.62e-06	-0.31	-0.25	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
LUAD	cis	rs763567	0.539	rs593479	ENSG00000271811.1	RP1-79C4.4	5.67	2.43e-08	8.63e-06	0.29	0.25	Tonsillectomy;	chr1:170673758	chr1:170667381~170669425:+
LUAD	cis	rs9500256	0.655	rs12208465	ENSG00000215190.7	LINC00680	-5.67	2.43e-08	8.63e-06	-0.32	-0.25	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57946074~57961501:-
LUAD	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	5.67	2.43e-08	8.63e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
LUAD	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	5.67	2.43e-08	8.64e-06	0.29	0.25	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
LUAD	cis	rs7911264	0.905	rs7918084	ENSG00000236493.2	EIF2S2P3	5.67	2.43e-08	8.64e-06	0.28	0.25	Inflammatory bowel disease;	chr10:92669710	chr10:92668745~92669743:-
LUAD	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	5.67	2.43e-08	8.64e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
LUAD	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	5.67	2.43e-08	8.64e-06	0.2	0.25	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
LUAD	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-5.67	2.43e-08	8.65e-06	-0.24	-0.25	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
LUAD	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-5.67	2.43e-08	8.66e-06	-0.36	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
LUAD	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-5.67	2.43e-08	8.66e-06	-0.36	-0.25	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
LUAD	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-5.67	2.44e-08	8.66e-06	-0.22	-0.25	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
LUAD	cis	rs755249	0.529	rs4660732	ENSG00000228060.1	RP11-69E11.8	-5.67	2.44e-08	8.67e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61779285	ENSG00000228060.1	RP11-69E11.8	-5.67	2.44e-08	8.67e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39565160~39573203:+
LUAD	cis	rs2243480	1	rs6958420	ENSG00000230295.1	RP11-458F8.2	5.67	2.44e-08	8.67e-06	0.3	0.25	Diabetic kidney disease;	chr7:66286184	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1392104	ENSG00000230295.1	RP11-458F8.2	5.67	2.44e-08	8.67e-06	0.3	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66880708~66882981:+
LUAD	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	5.67	2.44e-08	8.67e-06	0.2	0.25	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
LUAD	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	5.67	2.44e-08	8.68e-06	0.31	0.25	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
LUAD	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-5.67	2.44e-08	8.68e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
LUAD	cis	rs9500256	0.655	rs12210275	ENSG00000215190.7	LINC00680	-5.67	2.44e-08	8.68e-06	-0.32	-0.25	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57946074~57961501:-
LUAD	cis	rs2998286	0.813	rs2790431	ENSG00000254635.4	WAC-AS1	-5.67	2.44e-08	8.69e-06	-0.36	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28500266	chr10:28522652~28532743:-
LUAD	cis	rs755249	0.567	rs61779284	ENSG00000228060.1	RP11-69E11.8	-5.67	2.45e-08	8.69e-06	-0.25	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39565160~39573203:+
LUAD	cis	rs7044106	0.762	rs10491783	ENSG00000238181.2	AHCYP2	-5.67	2.45e-08	8.69e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.762	rs966397	ENSG00000238181.2	AHCYP2	-5.67	2.45e-08	8.69e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120720673~120721972:+
LUAD	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	5.67	2.45e-08	8.7e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	5.67	2.45e-08	8.7e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	5.67	2.45e-08	8.7e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
LUAD	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-5.67	2.45e-08	8.7e-06	-0.34	-0.25	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-5.67	2.45e-08	8.7e-06	-0.34	-0.25	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-5.67	2.45e-08	8.7e-06	-0.34	-0.25	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
LUAD	cis	rs944289	0.562	rs12431566	ENSG00000257826.1	RP11-116N8.4	5.67	2.45e-08	8.7e-06	0.26	0.25	Thyroid cancer;	chr14:36051211	chr14:36061026~36067190:-
LUAD	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	5.67	2.45e-08	8.71e-06	0.31	0.25	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
LUAD	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
LUAD	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-5.67	2.45e-08	8.72e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
LUAD	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-5.67	2.45e-08	8.72e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-5.67	2.45e-08	8.72e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
LUAD	cis	rs30380	1	rs151964	ENSG00000272109.1	CTD-2260A17.3	-5.67	2.46e-08	8.73e-06	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96804353~96806105:+
LUAD	cis	rs7804306	0.826	rs73049252	ENSG00000233264.2	AC006042.8	5.67	2.46e-08	8.73e-06	0.5	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7976971	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049256	ENSG00000233264.2	AC006042.8	5.67	2.46e-08	8.73e-06	0.5	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7978858	chr7:7980312~7982228:+
LUAD	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-5.67	2.46e-08	8.73e-06	-0.32	-0.25	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
LUAD	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-5.67	2.46e-08	8.73e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
LUAD	cis	rs7181230	0.885	rs28826672	ENSG00000275636.1	RP11-521C20.5	5.67	2.46e-08	8.73e-06	0.34	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40078892~40079347:+
LUAD	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	5.67	2.46e-08	8.75e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
LUAD	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-5.67	2.46e-08	8.75e-06	-0.32	-0.25	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
LUAD	cis	rs4604732	0.536	rs7528219	ENSG00000227135.1	GCSAML-AS1	-5.67	2.46e-08	8.75e-06	-0.38	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465005	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs7549955	ENSG00000227135.1	GCSAML-AS1	-5.67	2.46e-08	8.75e-06	-0.38	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465019	chr1:247524679~247526752:-
LUAD	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	5.67	2.46e-08	8.75e-06	0.32	0.25	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
LUAD	cis	rs10050311	1	rs10050311	ENSG00000251411.1	RP11-397E7.4	-5.67	2.46e-08	8.75e-06	-0.36	-0.25	Insulin-related traits;	chr4:86833266	chr4:86913266~86914817:-
LUAD	cis	rs9652601	0.622	rs8045749	ENSG00000274038.1	RP11-66H6.4	-5.67	2.47e-08	8.76e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11025796	chr16:11056556~11057034:+
LUAD	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-5.67	2.47e-08	8.76e-06	-0.27	-0.25	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
LUAD	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-5.67	2.47e-08	8.76e-06	-0.27	-0.25	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-5.67	2.47e-08	8.76e-06	-0.27	-0.25	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
LUAD	cis	rs453301	0.606	rs6601279	ENSG00000233609.3	RP11-62H7.2	-5.67	2.47e-08	8.76e-06	-0.21	-0.25	Joint mobility (Beighton score);	chr8:9050721	chr8:8961200~8979025:+
LUAD	cis	rs453301	0.606	rs6981060	ENSG00000233609.3	RP11-62H7.2	-5.67	2.47e-08	8.76e-06	-0.21	-0.25	Joint mobility (Beighton score);	chr8:9050725	chr8:8961200~8979025:+
LUAD	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	5.67	2.47e-08	8.77e-06	0.33	0.25	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
LUAD	cis	rs7115242	0.925	rs7925256	ENSG00000280143.1	AP000892.6	5.67	2.47e-08	8.78e-06	0.45	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117204967~117210292:+
LUAD	cis	rs516805	0.667	rs9490411	ENSG00000279453.1	RP3-425C14.4	5.67	2.47e-08	8.79e-06	0.35	0.25	Lymphocyte counts;	chr6:122217270	chr6:122436789~122439223:-
LUAD	cis	rs4841134	0.625	rs12235038	ENSG00000233609.3	RP11-62H7.2	-5.67	2.48e-08	8.8e-06	-0.2	-0.25	Age-related disease endophenotypes;	chr8:9379893	chr8:8961200~8979025:+
LUAD	cis	rs4908768	0.539	rs11121205	ENSG00000232912.4	RP5-1115A15.1	5.67	2.48e-08	8.8e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8424645~8434838:+
LUAD	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	5.67	2.48e-08	8.81e-06	0.35	0.25	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	5.67	2.48e-08	8.81e-06	0.35	0.25	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	5.67	2.48e-08	8.81e-06	0.35	0.25	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	5.67	2.48e-08	8.81e-06	0.27	0.25	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-5.67	2.48e-08	8.81e-06	-0.32	-0.25	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
LUAD	cis	rs2288884	0.943	rs12611112	ENSG00000275055.1	CTC-471J1.11	-5.67	2.48e-08	8.81e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52071686	chr19:52049007~52049754:+
LUAD	cis	rs75422866	0.51	rs74733564	ENSG00000274902.1	RP1-197B17.4	5.67	2.48e-08	8.81e-06	0.56	0.25	Pneumonia;	chr12:47724644	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.51	rs73105814	ENSG00000274902.1	RP1-197B17.4	5.67	2.48e-08	8.81e-06	0.56	0.25	Pneumonia;	chr12:47725817	chr12:47731908~47732351:+
LUAD	cis	rs4591358	0.773	rs17177580	ENSG00000223466.1	AC064834.2	5.67	2.48e-08	8.81e-06	0.33	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508426	chr2:195533035~195538681:+
LUAD	cis	rs4835473	0.897	rs35140014	ENSG00000251600.4	RP11-673E1.1	5.67	2.48e-08	8.82e-06	0.31	0.25	Immature fraction of reticulocytes;	chr4:143964292	chr4:143912331~143982454:+
LUAD	cis	rs9879311	0.966	rs4684685	ENSG00000240288.6	GHRLOS	5.67	2.48e-08	8.82e-06	0.23	0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369869	chr3:10285754~10293449:+
LUAD	cis	rs2404602	0.692	rs35138393	ENSG00000259422.1	RP11-593F23.1	5.67	2.49e-08	8.82e-06	0.29	0.25	Blood metabolite levels;	chr15:76685276	chr15:76174891~76181486:-
LUAD	cis	rs10740039	0.516	rs2393645	ENSG00000254271.1	RP11-131N11.4	5.67	2.49e-08	8.82e-06	0.28	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60555269	chr10:60734342~60741828:+
LUAD	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	5.67	2.49e-08	8.83e-06	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
LUAD	cis	rs9311474	1	rs7629072	ENSG00000243224.1	RP5-1157M23.2	-5.67	2.49e-08	8.83e-06	-0.25	-0.25	Electroencephalogram traits;	chr3:52271617	chr3:52239258~52241097:+
LUAD	cis	rs9807989	0.765	rs13424006	ENSG00000234389.1	AC007278.3	5.67	2.49e-08	8.83e-06	0.24	0.25	Asthma;	chr2:102350776	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.765	rs6751967	ENSG00000234389.1	AC007278.3	5.67	2.49e-08	8.83e-06	0.24	0.25	Asthma;	chr2:102350953	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.765	rs6751977	ENSG00000234389.1	AC007278.3	5.67	2.49e-08	8.83e-06	0.24	0.25	Asthma;	chr2:102350970	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.765	rs6704565	ENSG00000234389.1	AC007278.3	5.67	2.49e-08	8.83e-06	0.24	0.25	Asthma;	chr2:102350971	chr2:102438713~102440475:+
LUAD	cis	rs6840258	0.66	rs72667736	ENSG00000251411.1	RP11-397E7.4	-5.67	2.49e-08	8.84e-06	-0.35	-0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86954803	chr4:86913266~86914817:-
LUAD	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-5.67	2.49e-08	8.84e-06	-0.29	-0.25	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-5.67	2.49e-08	8.84e-06	-0.29	-0.25	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-5.67	2.49e-08	8.84e-06	-0.29	-0.25	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
LUAD	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	5.67	2.49e-08	8.84e-06	0.28	0.25	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
LUAD	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-5.67	2.49e-08	8.84e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
LUAD	cis	rs2243480	1	rs34970380	ENSG00000230295.1	RP11-458F8.2	-5.67	2.5e-08	8.86e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:65966506	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000230295.1	RP11-458F8.2	-5.67	2.5e-08	8.86e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:65966800	chr7:66880708~66882981:+
LUAD	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-5.67	2.5e-08	8.86e-06	-0.32	-0.25	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
LUAD	cis	rs453301	0.538	rs7830804	ENSG00000173295.6	FAM86B3P	-5.67	2.5e-08	8.86e-06	-0.27	-0.25	Joint mobility (Beighton score);	chr8:9113252	chr8:8228595~8244865:+
LUAD	cis	rs4713118	0.739	rs2893931	ENSG00000219392.1	RP1-265C24.5	-5.67	2.5e-08	8.87e-06	-0.34	-0.25	Parkinson's disease;	chr6:27780231	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.824	rs2092075	ENSG00000219392.1	RP1-265C24.5	-5.67	2.5e-08	8.87e-06	-0.34	-0.25	Parkinson's disease;	chr6:27781551	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.694	rs1225716	ENSG00000204709.4	LINC01556	5.67	2.5e-08	8.88e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28145968	chr6:28943877~28944537:+
LUAD	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-5.67	2.51e-08	8.89e-06	-0.24	-0.25	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
LUAD	cis	rs1823913	0.503	rs35868016	ENSG00000280083.1	RP11-317J9.1	-5.67	2.51e-08	8.89e-06	-0.31	-0.25	Obesity-related traits;	chr2:191344082	chr2:191154118~191156070:-
LUAD	cis	rs9595908	0.709	rs4942892	ENSG00000212293.1	SNORA16	-5.67	2.51e-08	8.89e-06	-0.26	-0.25	Body mass index;	chr13:32754269	chr13:32420390~32420516:-
LUAD	cis	rs36093844	0.898	rs12361645	ENSG00000279742.1	RP11-700A24.1	-5.67	2.51e-08	8.9e-06	-0.29	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884063	chr11:85852557~85854943:-
LUAD	cis	rs7430456	0.87	rs9864169	ENSG00000228221.4	LINC00578	5.67	2.51e-08	8.9e-06	0.29	0.25	Breast cancer;	chr3:177746841	chr3:177441921~177752305:+
LUAD	cis	rs7430456	0.901	rs12696448	ENSG00000228221.4	LINC00578	5.67	2.51e-08	8.9e-06	0.29	0.25	Breast cancer;	chr3:177746860	chr3:177441921~177752305:+
LUAD	cis	rs3096299	0.617	rs2353030	ENSG00000274627.1	RP11-104N10.2	-5.67	2.51e-08	8.91e-06	-0.23	-0.25	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89516797~89522217:+
LUAD	cis	rs1322639	0.614	rs7751131	ENSG00000261039.2	RP11-417E7.2	-5.67	2.51e-08	8.91e-06	-0.4	-0.25	Pulse pressure;	chr6:169178615	chr6:169175304~169182740:-
LUAD	cis	rs1322639	0.574	rs9364360	ENSG00000261039.2	RP11-417E7.2	-5.67	2.51e-08	8.91e-06	-0.4	-0.25	Pulse pressure;	chr6:169180079	chr6:169175304~169182740:-
LUAD	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	5.67	2.51e-08	8.91e-06	0.26	0.25	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
LUAD	cis	rs11822910	0.654	rs2439450	ENSG00000265566.2	RN7SL605P	5.67	2.52e-08	8.93e-06	0.32	0.25	Platelet distribution width;	chr11:57445588	chr11:57528085~57528365:-
LUAD	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-5.67	2.52e-08	8.93e-06	-0.25	-0.25	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
LUAD	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	5.67	2.52e-08	8.93e-06	0.48	0.25	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
LUAD	cis	rs3020264	0.669	rs7005662	ENSG00000271743.1	CTD-2541M15.3	5.67	2.52e-08	8.93e-06	0.34	0.25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6619105	chr8:6615604~6617198:-
LUAD	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	5.67	2.52e-08	8.93e-06	0.28	0.25	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
LUAD	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	5.67	2.52e-08	8.93e-06	0.36	0.25	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
LUAD	cis	rs9595908	0.709	rs3213532	ENSG00000212293.1	SNORA16	5.67	2.52e-08	8.94e-06	0.27	0.25	Body mass index;	chr13:32773550	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-5.67	2.52e-08	8.94e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
LUAD	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
LUAD	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
LUAD	cis	rs897984	0.609	rs72800847	ENSG00000260911.2	RP11-196G11.2	5.67	2.52e-08	8.95e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31011318	chr16:31043150~31049868:+
LUAD	cis	rs4767841	0.552	rs11064861	ENSG00000248636.5	RP11-768F21.1	-5.67	2.53e-08	8.96e-06	-0.29	-0.25	Urgency urinary incontinence;	chr12:119633855	chr12:119387987~119668079:-
LUAD	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-5.67	2.53e-08	8.96e-06	-0.36	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
LUAD	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	5.67	2.53e-08	8.97e-06	0.25	0.25	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
LUAD	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	5.67	2.53e-08	8.97e-06	0.25	0.25	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
LUAD	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-5.67	2.53e-08	8.97e-06	-0.52	-0.25	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-5.67	2.53e-08	8.97e-06	-0.52	-0.25	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
LUAD	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	5.66	2.53e-08	8.98e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
LUAD	cis	rs9311474	1	rs2276834	ENSG00000243224.1	RP5-1157M23.2	-5.66	2.54e-08	8.99e-06	-0.26	-0.25	Electroencephalogram traits;	chr3:52291743	chr3:52239258~52241097:+
LUAD	cis	rs12468226	0.817	rs12693965	ENSG00000226261.1	AC064836.3	-5.66	2.54e-08	8.99e-06	-0.41	-0.25	Urate levels;	chr2:202210188	chr2:202336024~202336727:-
LUAD	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	5.66	2.54e-08	8.99e-06	0.32	0.25	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
LUAD	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-5.66	2.54e-08	9e-06	-0.29	-0.25	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-5.66	2.54e-08	9e-06	-0.29	-0.25	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-5.66	2.54e-08	9e-06	-0.29	-0.25	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-5.66	2.54e-08	9e-06	-0.29	-0.25	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
LUAD	cis	rs984222	0.838	rs10923724	ENSG00000226172.2	RP4-712E4.1	-5.66	2.54e-08	9.02e-06	-0.27	-0.25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119004219	chr1:119000344~119001392:-
LUAD	cis	rs7221109	0.633	rs9915135	ENSG00000278834.1	RP11-458J1.1	5.66	2.55e-08	9.02e-06	0.29	0.25	Type 1 diabetes;	chr17:40634823	chr17:40648300~40649718:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000211972.2	IGHV3-66	5.66	2.55e-08	9.03e-06	0.21	0.25	Kawasaki disease;	chr14:106776528	chr14:106675017~106675544:-
LUAD	cis	rs36093844	0.615	rs77258124	ENSG00000279742.1	RP11-700A24.1	-5.66	2.55e-08	9.05e-06	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867038	chr11:85852557~85854943:-
LUAD	cis	rs2404602	0.692	rs1116535	ENSG00000259422.1	RP11-593F23.1	-5.66	2.56e-08	9.05e-06	-0.29	-0.25	Blood metabolite levels;	chr15:76717173	chr15:76174891~76181486:-
LUAD	cis	rs12468226	0.938	rs3843338	ENSG00000272966.1	RP11-686O6.1	-5.66	2.56e-08	9.06e-06	-0.42	-0.25	Urate levels;	chr2:202246102	chr2:202336739~202337200:+
LUAD	cis	rs8031584	0.56	rs1056118	ENSG00000270015.1	RP11-540B6.6	5.66	2.56e-08	9.06e-06	0.17	0.25	Huntington's disease progression;	chr15:30911583	chr15:30926514~30928407:+
LUAD	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-5.66	2.56e-08	9.07e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
LUAD	cis	rs2404602	0.692	rs35395069	ENSG00000259422.1	RP11-593F23.1	5.66	2.57e-08	9.08e-06	0.29	0.25	Blood metabolite levels;	chr15:76693993	chr15:76174891~76181486:-
LUAD	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	5.66	2.57e-08	9.09e-06	0.25	0.25	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
LUAD	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	5.66	2.57e-08	9.11e-06	0.31	0.25	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	5.66	2.57e-08	9.11e-06	0.28	0.25	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
LUAD	cis	rs30380	1	rs26510	ENSG00000272109.1	CTD-2260A17.3	-5.66	2.57e-08	9.11e-06	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96804353~96806105:+
LUAD	cis	rs12699921	0.598	rs2691611	ENSG00000279048.1	RP11-511H23.2	-5.66	2.58e-08	9.12e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17843804	chr7:17940503~17942922:+
LUAD	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	5.66	2.58e-08	9.13e-06	0.37	0.25	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
LUAD	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-5.66	2.58e-08	9.14e-06	-0.31	-0.25	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
LUAD	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-5.66	2.59e-08	9.15e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-5.66	2.59e-08	9.15e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-5.66	2.59e-08	9.15e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-5.66	2.59e-08	9.15e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
LUAD	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	5.66	2.59e-08	9.15e-06	0.35	0.25	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
LUAD	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	5.66	2.59e-08	9.16e-06	0.31	0.25	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
LUAD	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
LUAD	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	5.66	2.6e-08	9.19e-06	0.48	0.25	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
LUAD	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	5.66	2.6e-08	9.21e-06	0.31	0.25	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
LUAD	cis	rs4604732	0.536	rs12074913	ENSG00000227135.1	GCSAML-AS1	-5.66	2.6e-08	9.21e-06	-0.38	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468305	chr1:247524679~247526752:-
LUAD	cis	rs7662987	0.793	rs28730602	ENSG00000272777.1	RP11-571L19.8	5.66	2.61e-08	9.22e-06	0.4	0.25	Smoking initiation;	chr4:99080531	chr4:99067256~99068125:-
LUAD	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-5.66	2.61e-08	9.22e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-5.66	2.61e-08	9.22e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-5.66	2.61e-08	9.22e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
LUAD	cis	rs10214930	0.813	rs6462033	ENSG00000235574.1	AC073150.6	-5.66	2.61e-08	9.23e-06	-0.33	-0.25	Hypospadias;	chr7:27579066	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.723	rs1524529	ENSG00000235574.1	AC073150.6	-5.66	2.61e-08	9.23e-06	-0.33	-0.25	Hypospadias;	chr7:27580796	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs1608663	ENSG00000235574.1	AC073150.6	-5.66	2.61e-08	9.23e-06	-0.33	-0.25	Hypospadias;	chr7:27584157	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.767	rs1980330	ENSG00000235574.1	AC073150.6	-5.66	2.61e-08	9.23e-06	-0.33	-0.25	Hypospadias;	chr7:27590704	chr7:27491682~27492765:-
LUAD	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-5.66	2.61e-08	9.23e-06	-0.37	-0.25	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000211967.3	IGHV3-53	5.66	2.61e-08	9.23e-06	0.18	0.25	Kawasaki disease;	chr14:106683806	chr14:106592676~106593347:-
LUAD	cis	rs12908161	1	rs35808647	ENSG00000225151.9	GOLGA2P7	-5.66	2.61e-08	9.24e-06	-0.35	-0.25	Schizophrenia;	chr15:84834210	chr15:84199311~84230136:-
LUAD	cis	rs2790457	0.874	rs1265840	ENSG00000254635.4	WAC-AS1	-5.66	2.61e-08	9.24e-06	-0.27	-0.25	Multiple myeloma;	chr10:28630712	chr10:28522652~28532743:-
LUAD	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-5.66	2.62e-08	9.25e-06	-0.31	-0.25	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
LUAD	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	5.66	2.62e-08	9.25e-06	0.31	0.25	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
LUAD	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-5.66	2.62e-08	9.25e-06	-0.34	-0.25	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.692	rs7350777	ENSG00000259422.1	RP11-593F23.1	5.66	2.62e-08	9.26e-06	0.29	0.25	Blood metabolite levels;	chr15:76693100	chr15:76174891~76181486:-
LUAD	cis	rs17818399	0.781	rs4952837	ENSG00000279254.1	RP11-536C12.1	-5.66	2.62e-08	9.26e-06	-0.29	-0.25	Height;	chr2:46638595	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.781	rs6746598	ENSG00000279254.1	RP11-536C12.1	-5.66	2.62e-08	9.26e-06	-0.29	-0.25	Height;	chr2:46638634	chr2:46668870~46670778:+
LUAD	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	5.66	2.62e-08	9.26e-06	0.26	0.25	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
LUAD	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-5.66	2.62e-08	9.26e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
LUAD	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	5.66	2.62e-08	9.26e-06	0.32	0.25	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
LUAD	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-5.66	2.62e-08	9.27e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-5.66	2.62e-08	9.27e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-5.66	2.62e-08	9.27e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
LUAD	cis	rs8031584	0.541	rs1983459	ENSG00000260382.1	RP11-540B6.2	5.66	2.62e-08	9.27e-06	0.28	0.25	Huntington's disease progression;	chr15:30916546	chr15:30882267~30883231:-
LUAD	cis	rs748404	0.666	rs12907870	ENSG00000205771.5	CATSPER2P1	-5.66	2.62e-08	9.27e-06	-0.37	-0.25	Lung cancer;	chr15:43453971	chr15:43726918~43747094:-
LUAD	cis	rs997295	0.713	rs10518739	ENSG00000270964.1	RP11-502I4.3	5.66	2.62e-08	9.27e-06	0.26	0.25	Motion sickness;	chr15:67722633	chr15:67541072~67542604:-
LUAD	cis	rs62432291	0.681	rs3003173	ENSG00000235086.1	FNDC1-IT1	-5.66	2.63e-08	9.29e-06	-0.44	-0.25	Joint mobility (Beighton score);	chr6:159244660	chr6:159240786~159243329:+
LUAD	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	5.66	2.63e-08	9.3e-06	0.32	0.25	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
LUAD	cis	rs6687821	0.515	rs10873806	ENSG00000267734.1	RP4-604K5.3	-5.66	2.64e-08	9.31e-06	-0.31	-0.25	Yeast infection;	chr1:86974915	chr1:86932199~86934891:-
LUAD	cis	rs10214930	0.813	rs6462039	ENSG00000235574.1	AC073150.6	5.66	2.64e-08	9.31e-06	0.33	0.25	Hypospadias;	chr7:27626763	chr7:27491682~27492765:-
LUAD	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	5.66	2.64e-08	9.31e-06	0.28	0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
LUAD	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	5.66	2.64e-08	9.33e-06	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	5.66	2.64e-08	9.33e-06	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
LUAD	cis	rs997295	0.713	rs3784695	ENSG00000270964.1	RP11-502I4.3	-5.66	2.64e-08	9.33e-06	-0.26	-0.25	Motion sickness;	chr15:67710264	chr15:67541072~67542604:-
LUAD	cis	rs9914544	0.628	rs4924924	ENSG00000273018.4	CTD-2303H24.2	-5.66	2.64e-08	9.34e-06	-0.3	-0.25	Educational attainment (years of education);	chr17:18774461	chr17:18511221~18551705:-
LUAD	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	5.66	2.64e-08	9.34e-06	0.33	0.25	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
LUAD	cis	rs2243480	1	rs709607	ENSG00000230295.1	RP11-458F8.2	5.66	2.64e-08	9.34e-06	0.3	0.25	Diabetic kidney disease;	chr7:65984554	chr7:66880708~66882981:+
LUAD	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	5.66	2.65e-08	9.34e-06	0.3	0.25	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
LUAD	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
LUAD	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	5.66	2.65e-08	9.36e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	5.66	2.65e-08	9.36e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	5.66	2.65e-08	9.36e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	5.66	2.65e-08	9.36e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
LUAD	cis	rs2412819	0.571	rs6493090	ENSG00000249839.1	AC011330.5	5.66	2.65e-08	9.36e-06	0.4	0.25	Lung cancer;	chr15:43792084	chr15:43663654~43684339:-
LUAD	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	5.66	2.65e-08	9.36e-06	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	5.66	2.65e-08	9.36e-06	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
LUAD	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-5.66	2.65e-08	9.37e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
LUAD	cis	rs10246939	0.543	rs9640357	ENSG00000270923.1	TAS2R6P	-5.66	2.65e-08	9.37e-06	-0.27	-0.25	Bitter taste perception;	chr7:141843298	chr7:141787815~141788640:+
LUAD	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-5.66	2.65e-08	9.37e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
LUAD	cis	rs477895	1	rs7939107	ENSG00000236935.1	AP003774.1	-5.66	2.66e-08	9.38e-06	-0.31	-0.25	Mean platelet volume;	chr11:64267301	chr11:64325050~64329504:-
LUAD	cis	rs477895	1	rs7938380	ENSG00000236935.1	AP003774.1	-5.66	2.66e-08	9.38e-06	-0.31	-0.25	Mean platelet volume;	chr11:64267394	chr11:64325050~64329504:-
LUAD	cis	rs71386933	0.543	rs36114735	ENSG00000260886.1	TAT-AS1	5.66	2.66e-08	9.38e-06	0.5	0.25	Post bronchodilator FEV1;	chr16:71983784	chr16:71565789~71578187:+
LUAD	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	5.66	2.66e-08	9.38e-06	0.37	0.25	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	5.66	2.66e-08	9.38e-06	0.37	0.25	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
LUAD	cis	rs7968440	0.902	rs2684901	ENSG00000200428.1	Y_RNA	-5.66	2.66e-08	9.38e-06	-0.31	-0.25	Fibrinogen;	chr12:50657985	chr12:50743568~50743684:+
LUAD	cis	rs9860428	0.935	rs1114404	ENSG00000242770.2	RP11-180K7.1	5.66	2.66e-08	9.39e-06	0.25	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112844072	chr3:112802478~112812819:+
LUAD	cis	rs12468226	0.873	rs6435138	ENSG00000226261.1	AC064836.3	-5.66	2.66e-08	9.39e-06	-0.41	-0.25	Urate levels;	chr2:202234310	chr2:202336024~202336727:-
LUAD	cis	rs10214930	0.957	rs10230973	ENSG00000235574.1	AC073150.6	5.66	2.66e-08	9.4e-06	0.36	0.25	Hypospadias;	chr7:27743305	chr7:27491682~27492765:-
LUAD	cis	rs2404602	0.692	rs12437733	ENSG00000259422.1	RP11-593F23.1	5.66	2.66e-08	9.4e-06	0.29	0.25	Blood metabolite levels;	chr15:76863221	chr15:76174891~76181486:-
LUAD	cis	rs7829975	0.564	rs2976855	ENSG00000253981.4	ALG1L13P	5.66	2.66e-08	9.4e-06	0.29	0.25	Mood instability;	chr8:8444284	chr8:8236003~8244667:-
LUAD	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-5.66	2.67e-08	9.43e-06	-0.31	-0.25	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-5.66	2.67e-08	9.43e-06	-0.31	-0.25	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
LUAD	cis	rs9595908	0.758	rs2031354	ENSG00000212293.1	SNORA16	5.66	2.68e-08	9.44e-06	0.27	0.25	Body mass index;	chr13:32641454	chr13:32420390~32420516:-
LUAD	cis	rs11742741	0.539	rs13168500	ENSG00000248874.4	C5orf17	-5.66	2.68e-08	9.44e-06	-0.31	-0.25	Educational attainment;	chr5:24094615	chr5:23951348~24178263:+
LUAD	cis	rs7246657	0.508	rs1644702	ENSG00000276846.1	CTD-3220F14.3	5.65	2.68e-08	9.46e-06	0.38	0.25	Coronary artery calcification;	chr19:37001005	chr19:37314868~37315620:-
LUAD	cis	rs2408955	0.522	rs11168408	ENSG00000240399.1	RP1-228P16.1	-5.65	2.68e-08	9.46e-06	-0.25	-0.25	Glycated hemoglobin levels;	chr12:48104544	chr12:48054813~48055591:-
LUAD	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	5.65	2.68e-08	9.46e-06	0.34	0.25	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
LUAD	cis	rs944289	0.6	rs1169123	ENSG00000257826.1	RP11-116N8.4	-5.65	2.68e-08	9.47e-06	-0.27	-0.25	Thyroid cancer;	chr14:36149287	chr14:36061026~36067190:-
LUAD	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	5.65	2.68e-08	9.47e-06	0.37	0.25	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
LUAD	cis	rs8031584	0.723	rs11632229	ENSG00000270015.1	RP11-540B6.6	5.65	2.68e-08	9.47e-06	0.18	0.25	Huntington's disease progression;	chr15:30887331	chr15:30926514~30928407:+
LUAD	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	5.65	2.69e-08	9.47e-06	0.2	0.25	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	5.65	2.69e-08	9.47e-06	0.2	0.25	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	5.65	2.69e-08	9.47e-06	0.2	0.25	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
LUAD	cis	rs2337406	0.925	rs76288499	ENSG00000211974.3	IGHV2-70	-5.65	2.69e-08	9.49e-06	-0.34	-0.25	Alzheimer's disease (late onset);	chr14:106686309	chr14:106723574~106724093:-
LUAD	cis	rs9652601	0.696	rs12917656	ENSG00000274038.1	RP11-66H6.4	-5.65	2.69e-08	9.49e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11094005	chr16:11056556~11057034:+
LUAD	cis	rs4141404	0.851	rs5749248	ENSG00000236132.1	CTA-440B3.1	5.65	2.69e-08	9.49e-06	0.35	0.25	Paclitaxel-induced neuropathy;	chr22:31287725	chr22:31816379~31817491:-
LUAD	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-5.65	2.69e-08	9.5e-06	-0.33	-0.25	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
LUAD	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	5.65	2.69e-08	9.5e-06	0.43	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000224373.3	IGHV4-59	5.65	2.7e-08	9.51e-06	0.16	0.25	Kawasaki disease;	chr14:106686431	chr14:106627249~106627825:-
LUAD	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	5.65	2.7e-08	9.52e-06	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	5.65	2.7e-08	9.52e-06	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
LUAD	cis	rs1150668	0.768	rs1233713	ENSG00000219392.1	RP1-265C24.5	-5.65	2.7e-08	9.52e-06	-0.31	-0.25	Pubertal anthropometrics;	chr6:28230503	chr6:28115628~28116551:+
LUAD	cis	rs11096990	0.892	rs3733288	ENSG00000249207.1	RP11-360F5.1	5.65	2.7e-08	9.52e-06	0.29	0.25	Cognitive function;	chr4:39216949	chr4:39112677~39126818:-
LUAD	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-5.65	2.7e-08	9.53e-06	-0.31	-0.25	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
LUAD	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-5.65	2.7e-08	9.53e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
LUAD	cis	rs17684571	1	rs16888133	ENSG00000231441.1	RP11-472M19.2	5.65	2.7e-08	9.54e-06	0.33	0.25	Schizophrenia;	chr6:56709593	chr6:56844002~56864078:+
LUAD	cis	rs9652601	0.622	rs1861548	ENSG00000274038.1	RP11-66H6.4	-5.65	2.7e-08	9.54e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11024643	chr16:11056556~11057034:+
LUAD	cis	rs9543976	0.623	rs8192764	ENSG00000261553.4	RP11-29G8.3	5.65	2.71e-08	9.54e-06	0.33	0.25	Diabetic retinopathy;	chr13:75605079	chr13:75549773~75807120:+
LUAD	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	5.65	2.71e-08	9.54e-06	0.24	0.25	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
LUAD	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-5.65	2.71e-08	9.54e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
LUAD	cis	rs2243480	1	rs1499613	ENSG00000230295.1	RP11-458F8.2	5.65	2.71e-08	9.55e-06	0.3	0.25	Diabetic kidney disease;	chr7:66265873	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1553174	ENSG00000230295.1	RP11-458F8.2	5.65	2.71e-08	9.55e-06	0.3	0.25	Diabetic kidney disease;	chr7:66266207	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs10950032	ENSG00000230295.1	RP11-458F8.2	5.65	2.71e-08	9.55e-06	0.3	0.25	Diabetic kidney disease;	chr7:66273604	chr7:66880708~66882981:+
LUAD	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	5.65	2.71e-08	9.55e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
LUAD	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	5.65	2.71e-08	9.57e-06	0.27	0.25	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
LUAD	cis	rs944289	0.576	rs1169131	ENSG00000257826.1	RP11-116N8.4	-5.65	2.71e-08	9.57e-06	-0.28	-0.25	Thyroid cancer;	chr14:36153349	chr14:36061026~36067190:-
LUAD	cis	rs17684571	0.938	rs16888130	ENSG00000231441.1	RP11-472M19.2	5.65	2.72e-08	9.59e-06	0.33	0.25	Schizophrenia;	chr6:56709382	chr6:56844002~56864078:+
LUAD	cis	rs7968440	1	rs2684898	ENSG00000200428.1	Y_RNA	-5.65	2.72e-08	9.59e-06	-0.31	-0.25	Fibrinogen;	chr12:50653042	chr12:50743568~50743684:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000230295.1	RP11-458F8.2	-5.65	2.72e-08	9.59e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66062119	chr7:66880708~66882981:+
LUAD	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	5.65	2.72e-08	9.6e-06	0.29	0.25	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
LUAD	cis	rs891378	0.874	rs59036171	ENSG00000274245.1	RP11-357P18.2	-5.65	2.73e-08	9.61e-06	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207271583	chr1:207372559~207373252:+
LUAD	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000224373.3	IGHV4-59	5.65	2.73e-08	9.61e-06	0.16	0.25	Kawasaki disease;	chr14:106777611	chr14:106627249~106627825:-
LUAD	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	5.65	2.73e-08	9.62e-06	0.3	0.25	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
LUAD	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-5.65	2.73e-08	9.62e-06	-0.29	-0.25	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
LUAD	cis	rs9595908	0.669	rs4057298	ENSG00000212293.1	SNORA16	5.65	2.73e-08	9.62e-06	0.27	0.25	Body mass index;	chr13:32734227	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs17516382	ENSG00000212293.1	SNORA16	5.65	2.73e-08	9.62e-06	0.27	0.25	Body mass index;	chr13:32735426	chr13:32420390~32420516:-
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	5.65	2.74e-08	9.64e-06	0.27	0.25	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
LUAD	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-5.65	2.74e-08	9.65e-06	-0.33	-0.25	Migraine;	chr4:56881195	chr4:56960927~56961373:-
LUAD	cis	rs948562	0.519	rs4127347	ENSG00000280010.1	AP001350.4	5.65	2.74e-08	9.65e-06	0.37	0.25	Lymphoma;	chr11:58282283	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.573	rs77894570	ENSG00000280010.1	AP001350.4	5.65	2.74e-08	9.65e-06	0.37	0.25	Lymphoma;	chr11:58283639	chr11:58627435~58628528:+
LUAD	cis	rs4604732	0.578	rs12040725	ENSG00000227135.1	GCSAML-AS1	-5.65	2.74e-08	9.65e-06	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247481395	chr1:247524679~247526752:-
LUAD	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	5.65	2.74e-08	9.66e-06	0.22	0.25	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
LUAD	cis	rs6504622	0.818	rs3851784	ENSG00000262879.4	RP11-156P1.3	5.65	2.74e-08	9.66e-06	0.29	0.25	Orofacial clefts;	chr17:46962751	chr17:46984045~47100323:-
LUAD	cis	rs2243480	1	rs2420170	ENSG00000230295.1	RP11-458F8.2	5.65	2.74e-08	9.66e-06	0.3	0.25	Diabetic kidney disease;	chr7:66191066	chr7:66880708~66882981:+
LUAD	cis	rs3738443	0.868	rs56029850	ENSG00000259865.1	RP11-488L18.10	5.65	2.74e-08	9.67e-06	0.25	0.25	Alcohol dependence;	chr1:247201027	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.868	rs55643126	ENSG00000259865.1	RP11-488L18.10	5.65	2.74e-08	9.67e-06	0.25	0.25	Alcohol dependence;	chr1:247201042	chr1:247187281~247188526:-
LUAD	cis	rs7826238	0.509	rs2948288	ENSG00000253981.4	ALG1L13P	5.65	2.75e-08	9.67e-06	0.29	0.25	Systolic blood pressure;	chr8:8257782	chr8:8236003~8244667:-
LUAD	cis	rs36093844	0.752	rs7121363	ENSG00000279742.1	RP11-700A24.1	-5.65	2.75e-08	9.68e-06	-0.32	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85864067	chr11:85852557~85854943:-
LUAD	cis	rs16863064	0.932	rs9816875	ENSG00000279891.1	FLJ42393	5.65	2.75e-08	9.68e-06	0.36	0.25	Schizophrenia;	chr3:188169404	chr3:188178543~188180812:+
LUAD	cis	rs12468226	0.873	rs6761131	ENSG00000226261.1	AC064836.3	-5.65	2.75e-08	9.69e-06	-0.41	-0.25	Urate levels;	chr2:202237675	chr2:202336024~202336727:-
LUAD	cis	rs1015362	0.54	rs2050209	ENSG00000276073.1	RP5-1125A11.7	5.65	2.75e-08	9.7e-06	0.31	0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33985617~33988989:-
LUAD	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-5.65	2.76e-08	9.71e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-5.65	2.76e-08	9.71e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-5.65	2.76e-08	9.71e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-5.65	2.76e-08	9.71e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
LUAD	cis	rs75422866	0.51	rs73105812	ENSG00000274902.1	RP1-197B17.4	5.65	2.76e-08	9.72e-06	0.56	0.25	Pneumonia;	chr12:47724404	chr12:47731908~47732351:+
LUAD	cis	rs2404602	0.692	rs55729975	ENSG00000259422.1	RP11-593F23.1	5.65	2.76e-08	9.73e-06	0.29	0.25	Blood metabolite levels;	chr15:76510885	chr15:76174891~76181486:-
LUAD	cis	rs72615157	0.634	rs74742883	ENSG00000242294.5	STAG3L5P	5.65	2.76e-08	9.73e-06	0.21	0.25	Lung function (FEV1/FVC);	chr7:100188142	chr7:100336079~100351900:+
LUAD	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	5.65	2.77e-08	9.73e-06	0.28	0.25	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
LUAD	cis	rs72615157	0.628	rs7801070	ENSG00000242294.5	STAG3L5P	5.65	2.77e-08	9.75e-06	0.21	0.25	Lung function (FEV1/FVC);	chr7:100249524	chr7:100336079~100351900:+
LUAD	cis	rs910316	1	rs12879542	ENSG00000259138.1	RP11-950C14.7	5.65	2.77e-08	9.75e-06	0.26	0.25	Height;	chr14:75040822	chr14:75127153~75136930:+
LUAD	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	5.65	2.77e-08	9.76e-06	0.28	0.25	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
LUAD	cis	rs5753618	0.561	rs5749265	ENSG00000236132.1	CTA-440B3.1	-5.65	2.78e-08	9.77e-06	-0.31	-0.25	Colorectal cancer;	chr22:31400911	chr22:31816379~31817491:-
LUAD	cis	rs7923609	1	rs7073746	ENSG00000232075.1	MRPL35P2	-5.65	2.78e-08	9.77e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63144311	chr10:63634317~63634827:-
LUAD	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-5.65	2.78e-08	9.78e-06	-0.25	-0.25	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
LUAD	cis	rs72615157	0.645	rs11771660	ENSG00000242294.5	STAG3L5P	5.65	2.79e-08	9.8e-06	0.21	0.25	Lung function (FEV1/FVC);	chr7:100253646	chr7:100336079~100351900:+
LUAD	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-5.65	2.79e-08	9.8e-06	-0.27	-0.25	Height;	chr11:118808920	chr11:118791254~118793137:+
LUAD	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	5.65	2.79e-08	9.8e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	5.65	2.79e-08	9.8e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
LUAD	cis	rs12935418	1	rs12935418	ENSG00000261838.4	RP11-303E16.6	5.65	2.79e-08	9.81e-06	0.46	0.25	Mean corpuscular volume;	chr16:81036403	chr16:81069854~81076598:+
LUAD	cis	rs7657257	1	rs11931532	ENSG00000214846.4	RP11-115L11.1	5.65	2.79e-08	9.81e-06	0.6	0.25	Blood protein levels;	chr4:15724143	chr4:15730962~15731627:-
LUAD	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
LUAD	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	5.65	2.79e-08	9.82e-06	0.32	0.25	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
LUAD	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	5.65	2.79e-08	9.82e-06	0.32	0.25	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
LUAD	cis	rs36093844	0.898	rs11234462	ENSG00000279742.1	RP11-700A24.1	-5.65	2.79e-08	9.83e-06	-0.29	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85885881	chr11:85852557~85854943:-
LUAD	cis	rs896854	0.654	rs16893776	ENSG00000253528.2	RP11-347C18.4	5.65	2.79e-08	9.83e-06	0.24	0.25	Type 2 diabetes;	chr8:94961376	chr8:94974573~94974853:-
LUAD	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-5.65	2.8e-08	9.84e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
LUAD	cis	rs2599510	0.783	rs2038534	ENSG00000276334.1	AL133243.1	5.65	2.8e-08	9.84e-06	0.29	0.25	Interleukin-18 levels;	chr2:32434421	chr2:32521927~32523547:+
LUAD	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	5.65	2.8e-08	9.85e-06	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
LUAD	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	5.65	2.8e-08	9.85e-06	0.32	0.25	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
LUAD	cis	rs5753618	0.583	rs5753601	ENSG00000236132.1	CTA-440B3.1	-5.65	2.8e-08	9.85e-06	-0.31	-0.25	Colorectal cancer;	chr22:31402273	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.583	rs8141150	ENSG00000236132.1	CTA-440B3.1	-5.65	2.8e-08	9.85e-06	-0.31	-0.25	Colorectal cancer;	chr22:31404350	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.583	rs9606839	ENSG00000236132.1	CTA-440B3.1	-5.65	2.8e-08	9.85e-06	-0.31	-0.25	Colorectal cancer;	chr22:31406724	chr22:31816379~31817491:-
LUAD	cis	rs7923837	0.574	rs2488075	ENSG00000236493.2	EIF2S2P3	-5.65	2.8e-08	9.86e-06	-0.28	-0.25	Multiple sclerosis;Body mass index;	chr10:92730417	chr10:92668745~92669743:-
LUAD	cis	rs62432291	0.681	rs7757530	ENSG00000235086.1	FNDC1-IT1	5.65	2.8e-08	9.86e-06	0.42	0.25	Joint mobility (Beighton score);	chr6:159226897	chr6:159240786~159243329:+
LUAD	cis	rs807029	0.577	rs3740488	ENSG00000272572.1	RP11-179B2.2	-5.65	2.8e-08	9.86e-06	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100911103~100912739:-
LUAD	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	5.65	2.81e-08	9.87e-06	0.22	0.25	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
LUAD	cis	rs36093844	0.752	rs80193798	ENSG00000279742.1	RP11-700A24.1	-5.65	2.81e-08	9.88e-06	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866486	chr11:85852557~85854943:-
LUAD	cis	rs1707322	1	rs4660332	ENSG00000234329.1	RP11-767N6.2	5.65	2.81e-08	9.89e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45651039~45651826:-
LUAD	cis	rs6687821	0.515	rs1970607	ENSG00000267734.1	RP4-604K5.3	5.65	2.82e-08	9.9e-06	0.3	0.25	Yeast infection;	chr1:86962619	chr1:86932199~86934891:-
LUAD	cis	rs1707322	1	rs10890375	ENSG00000234329.1	RP11-767N6.2	5.65	2.82e-08	9.9e-06	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890377	ENSG00000234329.1	RP11-767N6.2	5.65	2.82e-08	9.9e-06	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45651039~45651826:-
LUAD	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-5.65	2.82e-08	9.91e-06	-0.33	-0.25	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
LUAD	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	5.65	2.82e-08	9.91e-06	0.37	0.25	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
LUAD	cis	rs7044106	0.762	rs1886337	ENSG00000238181.2	AHCYP2	-5.65	2.82e-08	9.91e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120720673~120721972:+
LUAD	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-5.65	2.82e-08	9.91e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
LUAD	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-5.65	2.82e-08	9.91e-06	-0.33	-0.25	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
LUAD	cis	rs910316	0.783	rs11850751	ENSG00000259138.1	RP11-950C14.7	5.65	2.82e-08	9.93e-06	0.27	0.25	Height;	chr14:75123410	chr14:75127153~75136930:+
LUAD	cis	rs12699921	0.658	rs2691592	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17779817	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.598	rs2691593	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780032	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723507	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780305	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2691596	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780460	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723506	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780675	chr7:17940503~17942922:+
LUAD	cis	rs1707322	1	rs785490	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785493	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs785496	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785497	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs785499	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45651039~45651826:-
LUAD	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	5.64	2.83e-08	9.93e-06	0.32	0.25	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
LUAD	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	5.64	2.83e-08	9.94e-06	0.23	0.25	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
LUAD	cis	rs4538475	0.556	rs4266290	ENSG00000214846.4	RP11-115L11.1	5.64	2.83e-08	9.95e-06	0.36	0.25	Parkinson's disease;	chr4:15735495	chr4:15730962~15731627:-
LUAD	cis	rs1707322	0.89	rs2297883	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1707338	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs1707339	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1768818	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1768817	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785470	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785469	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785468	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45651039~45651826:-
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-5.64	2.83e-08	9.96e-06	-0.25	-0.25	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
LUAD	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	5.64	2.83e-08	9.96e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
LUAD	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	5.64	2.84e-08	9.96e-06	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
LUAD	cis	rs997295	0.57	rs17241808	ENSG00000270964.1	RP11-502I4.3	-5.64	2.84e-08	9.96e-06	-0.26	-0.25	Motion sickness;	chr15:67600454	chr15:67541072~67542604:-
LUAD	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	5.64	2.84e-08	9.96e-06	0.31	0.25	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
LUAD	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-5.64	2.84e-08	9.97e-06	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
LUAD	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	5.64	2.84e-08	9.97e-06	0.26	0.25	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	5.64	2.84e-08	9.97e-06	0.26	0.25	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
LUAD	cis	rs12699921	0.632	rs2691595	ENSG00000279048.1	RP11-511H23.2	-5.64	2.84e-08	9.98e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780421	chr7:17940503~17942922:+
LUAD	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-5.64	2.84e-08	9.99e-06	-0.29	-0.25	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
LUAD	cis	rs7044106	0.615	rs10818470	ENSG00000238181.2	AHCYP2	-5.64	2.84e-08	9.99e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120720673~120721972:+
LUAD	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-5.64	2.84e-08	9.99e-06	-0.29	-0.25	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
LUAD	cis	rs8177876	0.915	rs73597252	ENSG00000261061.1	RP11-303E16.2	-5.64	2.84e-08	9.99e-06	-0.46	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81030770~81031485:+
LUAD	cis	rs603446	0.583	rs180377	ENSG00000254851.1	RP11-109L13.1	-5.64	2.85e-08	9.99e-06	-0.32	-0.25	Triglycerides;	chr11:116718411	chr11:117135528~117138582:+
LUAD	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	5.64	2.85e-08	1e-05	0.31	0.25	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
LUAD	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	5.64	2.85e-08	1e-05	0.31	0.25	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
LUAD	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	5.64	2.85e-08	1e-05	0.31	0.25	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
LUAD	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-5.64	2.85e-08	1e-05	-0.33	-0.25	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-5.64	2.85e-08	1e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
LUAD	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	5.64	2.85e-08	1e-05	0.3	0.25	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
LUAD	cis	rs8081395	0.627	rs12952730	ENSG00000266992.1	DHX40P1	5.64	2.85e-08	1e-05	0.31	0.25	White blood cell count;	chr17:59901475	chr17:59976009~60002384:-
LUAD	cis	rs8081395	0.627	rs180536	ENSG00000266992.1	DHX40P1	5.64	2.85e-08	1e-05	0.31	0.25	White blood cell count;	chr17:59919445	chr17:59976009~60002384:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000211972.2	IGHV3-66	5.64	2.85e-08	1e-05	0.22	0.25	Kawasaki disease;	chr14:106649820	chr14:106675017~106675544:-
LUAD	cis	rs4947019	0.609	rs4946968	ENSG00000260273.1	RP11-425D10.10	5.64	2.85e-08	1e-05	0.55	0.25	Hematological parameters;	chr6:109357907	chr6:109382795~109383666:+
LUAD	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-5.64	2.86e-08	1e-05	-0.29	-0.25	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
LUAD	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-5.64	2.86e-08	1e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
LUAD	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-5.64	2.86e-08	1e-05	-0.25	-0.25	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000224373.3	IGHV4-59	5.64	2.86e-08	1e-05	0.16	0.25	Kawasaki disease;	chr14:106680324	chr14:106627249~106627825:-
LUAD	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	5.64	2.86e-08	1.01e-05	0.3	0.25	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
LUAD	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	5.64	2.86e-08	1.01e-05	0.3	0.25	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
LUAD	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	5.64	2.87e-08	1.01e-05	0.25	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
LUAD	cis	rs116139393	0.54	rs12539942	ENSG00000187953.9	PMS2CL	-5.64	2.87e-08	1.01e-05	-0.32	-0.25	Alzheimer's disease (APOE e4 interaction);	chr7:6736954	chr7:6710128~6753862:+
LUAD	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	5.64	2.87e-08	1.01e-05	0.29	0.25	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
LUAD	cis	rs74233809	1	rs76752100	ENSG00000213277.3	MARCKSL1P1	5.64	2.87e-08	1.01e-05	0.43	0.25	Birth weight;	chr10:103034329	chr10:103175554~103176094:+
LUAD	cis	rs9287719	0.649	rs6721857	ENSG00000243819.4	RN7SL832P	-5.64	2.87e-08	1.01e-05	-0.26	-0.25	Prostate cancer;	chr2:10581084	chr2:10690344~10692099:+
LUAD	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	5.64	2.87e-08	1.01e-05	0.27	0.25	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
LUAD	cis	rs4908760	0.965	rs301814	ENSG00000232912.4	RP5-1115A15.1	5.64	2.87e-08	1.01e-05	0.23	0.25	Vitiligo;	chr1:8450517	chr1:8424645~8434838:+
LUAD	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	5.64	2.87e-08	1.01e-05	0.29	0.25	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000211972.2	IGHV3-66	5.64	2.88e-08	1.01e-05	0.21	0.25	Kawasaki disease;	chr14:106777570	chr14:106675017~106675544:-
LUAD	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	5.64	2.88e-08	1.01e-05	0.32	0.25	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000224373.3	IGHV4-59	5.64	2.88e-08	1.01e-05	0.16	0.25	Kawasaki disease;	chr14:106777570	chr14:106627249~106627825:-
LUAD	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	5.64	2.88e-08	1.01e-05	0.35	0.25	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
LUAD	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-5.64	2.88e-08	1.01e-05	-0.35	-0.25	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
LUAD	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-5.64	2.88e-08	1.01e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
LUAD	cis	rs4908768	0.52	rs6695867	ENSG00000232912.4	RP5-1115A15.1	5.64	2.89e-08	1.01e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8670720	chr1:8424645~8434838:+
LUAD	cis	rs9595908	0.785	rs9315173	ENSG00000212293.1	SNORA16	5.64	2.89e-08	1.01e-05	0.26	0.25	Body mass index;	chr13:32645674	chr13:32420390~32420516:-
LUAD	cis	rs6687821	0.515	rs12025384	ENSG00000267734.1	RP4-604K5.3	-5.64	2.89e-08	1.02e-05	-0.3	-0.25	Yeast infection;	chr1:86972227	chr1:86932199~86934891:-
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	5.64	2.89e-08	1.02e-05	0.27	0.25	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-5.64	2.89e-08	1.02e-05	-0.34	-0.25	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000211974.3	IGHV2-70	5.64	2.9e-08	1.02e-05	0.27	0.25	Kawasaki disease;	chr14:106716993	chr14:106723574~106724093:-
LUAD	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-5.64	2.9e-08	1.02e-05	-0.48	-0.25	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
LUAD	cis	rs4908768	0.539	rs6666191	ENSG00000232912.4	RP5-1115A15.1	5.64	2.9e-08	1.02e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8424645~8434838:+
LUAD	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	5.64	2.9e-08	1.02e-05	0.31	0.25	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
LUAD	cis	rs12699921	0.599	rs2723540	ENSG00000279048.1	RP11-511H23.2	-5.64	2.9e-08	1.02e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17866067	chr7:17940503~17942922:+
LUAD	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	5.64	2.91e-08	1.02e-05	0.27	0.25	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
LUAD	cis	rs12699921	0.632	rs2691612	ENSG00000279048.1	RP11-511H23.2	-5.64	2.91e-08	1.02e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17844293	chr7:17940503~17942922:+
LUAD	cis	rs17826219	0.5	rs28452421	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Body mass index;	chr17:30756962	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs28779471	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.5	rs61685770	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Body mass index;	chr17:30758695	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs57486336	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs12103440	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11657777	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30729469~30731202:+
LUAD	cis	rs9652601	0.691	rs12917716	ENSG00000274038.1	RP11-66H6.4	-5.64	2.92e-08	1.02e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11095291	chr16:11056556~11057034:+
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000224373.3	IGHV4-59	5.64	2.92e-08	1.02e-05	0.16	0.25	Kawasaki disease;	chr14:106799304	chr14:106627249~106627825:-
LUAD	cis	rs6687821	0.5	rs2753270	ENSG00000267734.1	RP4-604K5.3	5.64	2.92e-08	1.02e-05	0.31	0.25	Yeast infection;	chr1:86947874	chr1:86932199~86934891:-
LUAD	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
LUAD	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	5.64	2.93e-08	1.03e-05	0.29	0.25	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
LUAD	cis	rs9910055	0.747	rs2905981	ENSG00000267080.4	ASB16-AS1	-5.64	2.93e-08	1.03e-05	-0.23	-0.25	Total body bone mineral density;	chr17:44161257	chr17:44175973~44186717:-
LUAD	cis	rs30380	0.632	rs26491	ENSG00000272109.1	CTD-2260A17.3	-5.64	2.93e-08	1.03e-05	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96798410	chr5:96804353~96806105:+
LUAD	cis	rs6840360	0.904	rs73862064	ENSG00000270265.1	RP11-731D1.4	-5.64	2.93e-08	1.03e-05	-0.25	-0.25	Intelligence (multi-trait analysis);	chr4:151581948	chr4:151333775~151353224:-
LUAD	cis	rs9910055	0.762	rs11080007	ENSG00000267080.4	ASB16-AS1	5.64	2.94e-08	1.03e-05	0.22	0.25	Total body bone mineral density;	chr17:44188074	chr17:44175973~44186717:-
LUAD	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-5.64	2.94e-08	1.03e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
LUAD	cis	rs2562456	0.516	rs56072098	ENSG00000268081.1	RP11-678G14.2	-5.64	2.94e-08	1.03e-05	-0.38	-0.25	Pain;	chr19:21469158	chr19:21554640~21569237:-
LUAD	cis	rs516805	0.748	rs12189881	ENSG00000279453.1	RP3-425C14.4	5.64	2.94e-08	1.03e-05	0.34	0.25	Lymphocyte counts;	chr6:122375109	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.748	rs72974455	ENSG00000279453.1	RP3-425C14.4	5.64	2.94e-08	1.03e-05	0.34	0.25	Lymphocyte counts;	chr6:122377134	chr6:122436789~122439223:-
LUAD	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-5.64	2.94e-08	1.03e-05	-0.37	-0.25	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
LUAD	cis	rs910316	1	rs4903275	ENSG00000259138.1	RP11-950C14.7	5.64	2.95e-08	1.03e-05	0.26	0.25	Height;	chr14:75045806	chr14:75127153~75136930:+
LUAD	cis	rs180730	0.561	rs3115313	ENSG00000251609.2	SETP12	-5.64	2.95e-08	1.03e-05	-0.32	-0.25	Fasting plasma glucose;	chr4:120887708	chr4:120895494~120897083:-
LUAD	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-5.64	2.95e-08	1.03e-05	-0.33	-0.25	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
LUAD	cis	rs3738443	0.868	rs12569042	ENSG00000259865.1	RP11-488L18.10	5.64	2.96e-08	1.03e-05	0.26	0.25	Alcohol dependence;	chr1:247203078	chr1:247187281~247188526:-
LUAD	cis	rs8031584	0.541	rs2955797	ENSG00000270015.1	RP11-540B6.6	5.64	2.96e-08	1.04e-05	0.17	0.25	Huntington's disease progression;	chr15:30918778	chr15:30926514~30928407:+
LUAD	cis	rs5753618	0.583	rs7285619	ENSG00000236132.1	CTA-440B3.1	-5.64	2.96e-08	1.04e-05	-0.31	-0.25	Colorectal cancer;	chr22:31446568	chr22:31816379~31817491:-
LUAD	cis	rs301807	0.533	rs1466654	ENSG00000232912.4	RP5-1115A15.1	5.64	2.96e-08	1.04e-05	0.23	0.25	Vitiligo;Sum eosinophil basophil counts;	chr1:8315853	chr1:8424645~8434838:+
LUAD	cis	rs1707322	1	rs7527079	ENSG00000234329.1	RP11-767N6.2	5.64	2.96e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs34446427	ENSG00000234329.1	RP11-767N6.2	5.64	2.96e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs4660900	ENSG00000234329.1	RP11-767N6.2	5.64	2.96e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4454479	ENSG00000234329.1	RP11-767N6.2	5.64	2.96e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45651039~45651826:-
LUAD	cis	rs4698412	0.531	rs6852450	ENSG00000214846.4	RP11-115L11.1	-5.64	2.96e-08	1.04e-05	-0.33	-0.25	Parkinson's disease;	chr4:15741363	chr4:15730962~15731627:-
LUAD	cis	rs10761482	0.5	rs10821790	ENSG00000254271.1	RP11-131N11.4	5.64	2.97e-08	1.04e-05	0.28	0.25	Schizophrenia;	chr10:60529009	chr10:60734342~60741828:+
LUAD	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-5.64	2.97e-08	1.04e-05	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
LUAD	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-5.64	2.97e-08	1.04e-05	-0.35	-0.25	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
LUAD	cis	rs4713118	0.513	rs149962	ENSG00000204709.4	LINC01556	5.64	2.97e-08	1.04e-05	0.31	0.25	Parkinson's disease;	chr6:28048140	chr6:28943877~28944537:+
LUAD	cis	rs1707322	1	rs4074225	ENSG00000234329.1	RP11-767N6.2	5.64	2.98e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4134387	ENSG00000234329.1	RP11-767N6.2	5.64	2.98e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45651039~45651826:-
LUAD	cis	rs516805	0.667	rs9320856	ENSG00000279453.1	RP3-425C14.4	-5.64	2.98e-08	1.04e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122219888	chr6:122436789~122439223:-
LUAD	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-5.64	2.98e-08	1.04e-05	-0.29	-0.25	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
LUAD	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-5.63	2.99e-08	1.04e-05	-0.38	-0.25	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
LUAD	cis	rs6687821	0.515	rs10493794	ENSG00000267734.1	RP4-604K5.3	-5.63	2.99e-08	1.05e-05	-0.31	-0.25	Yeast infection;	chr1:87004946	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs10747335	ENSG00000267734.1	RP4-604K5.3	-5.63	2.99e-08	1.05e-05	-0.31	-0.25	Yeast infection;	chr1:87006739	chr1:86932199~86934891:-
LUAD	cis	rs7208859	0.673	rs73263981	ENSG00000263603.1	CTD-2349P21.5	-5.63	3e-08	1.05e-05	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30729469~30731202:+
LUAD	cis	rs4604732	0.588	rs7549495	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464504	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.536	rs76191272	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464753	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs7552443	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465281	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs7552461	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465342	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs9943231	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247466527	chr1:247524679~247526752:-
LUAD	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	5.63	3e-08	1.05e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
LUAD	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-5.63	3e-08	1.05e-05	-0.43	-0.25	Depression;	chr6:28200565	chr6:28115628~28116551:+
LUAD	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	5.63	3.01e-08	1.05e-05	0.28	0.25	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
LUAD	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-5.63	3.01e-08	1.05e-05	-0.27	-0.25	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
LUAD	cis	rs2749097	1	rs8294	ENSG00000244256.3	RN7SL130P	-5.63	3.01e-08	1.05e-05	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63659697	chr1:63655743~63656047:+
LUAD	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	5.63	3.01e-08	1.05e-05	0.31	0.25	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
LUAD	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	5.63	3.01e-08	1.05e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
LUAD	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-5.63	3.01e-08	1.05e-05	-0.29	-0.25	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
LUAD	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	5.63	3.01e-08	1.05e-05	0.27	0.25	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
LUAD	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-5.63	3.01e-08	1.05e-05	-0.34	-0.25	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
LUAD	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	5.63	3.01e-08	1.05e-05	0.27	0.25	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	5.63	3.01e-08	1.05e-05	0.27	0.25	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	5.63	3.01e-08	1.05e-05	0.27	0.25	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	5.63	3.01e-08	1.05e-05	0.27	0.25	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
LUAD	cis	rs9287719	0.649	rs9973374	ENSG00000243819.4	RN7SL832P	5.63	3.01e-08	1.05e-05	0.26	0.25	Prostate cancer;	chr2:10576258	chr2:10690344~10692099:+
LUAD	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	5.63	3.02e-08	1.05e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
LUAD	cis	rs8040855	0.791	rs8042888	ENSG00000259774.1	RP11-182J1.13	-5.63	3.02e-08	1.05e-05	-0.31	-0.25	Bulimia nervosa;	chr15:85152360	chr15:84422618~84425882:+
LUAD	cis	rs4947019	0.609	rs9487099	ENSG00000260273.1	RP11-425D10.10	5.63	3.02e-08	1.05e-05	0.57	0.25	Hematological parameters;	chr6:109423803	chr6:109382795~109383666:+
LUAD	cis	rs9807989	0.801	rs6734742	ENSG00000234389.1	AC007278.3	5.63	3.02e-08	1.05e-05	0.24	0.25	Asthma;	chr2:102351397	chr2:102438713~102440475:+
LUAD	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	5.63	3.02e-08	1.06e-05	0.37	0.25	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
LUAD	cis	rs516805	0.667	rs2045354	ENSG00000279453.1	RP3-425C14.4	-5.63	3.02e-08	1.06e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122209244	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs2606596	ENSG00000279453.1	RP3-425C14.4	-5.63	3.02e-08	1.06e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122211597	chr6:122436789~122439223:-
LUAD	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	5.63	3.03e-08	1.06e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
LUAD	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	5.63	3.03e-08	1.06e-05	0.2	0.25	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
LUAD	cis	rs4713118	0.513	rs156739	ENSG00000204709.4	LINC01556	5.63	3.03e-08	1.06e-05	0.31	0.25	Parkinson's disease;	chr6:28045632	chr6:28943877~28944537:+
LUAD	cis	rs62432291	0.681	rs447637	ENSG00000235086.1	FNDC1-IT1	-5.63	3.04e-08	1.06e-05	-0.43	-0.25	Joint mobility (Beighton score);	chr6:159237694	chr6:159240786~159243329:+
LUAD	cis	rs5753618	0.583	rs5749268	ENSG00000236132.1	CTA-440B3.1	-5.63	3.04e-08	1.06e-05	-0.31	-0.25	Colorectal cancer;	chr22:31413166	chr22:31816379~31817491:-
LUAD	cis	rs7968440	1	rs2252589	ENSG00000200428.1	Y_RNA	-5.63	3.04e-08	1.06e-05	-0.31	-0.25	Fibrinogen;	chr12:50648174	chr12:50743568~50743684:+
LUAD	cis	rs1707322	0.896	rs946528	ENSG00000234329.1	RP11-767N6.2	-5.63	3.04e-08	1.06e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45651039~45651826:-
LUAD	cis	rs944289	0.553	rs1169134	ENSG00000257826.1	RP11-116N8.4	-5.63	3.04e-08	1.06e-05	-0.28	-0.25	Thyroid cancer;	chr14:36155514	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.537	rs1169137	ENSG00000257826.1	RP11-116N8.4	-5.63	3.04e-08	1.06e-05	-0.28	-0.25	Thyroid cancer;	chr14:36156548	chr14:36061026~36067190:-
LUAD	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-5.63	3.04e-08	1.06e-05	-0.27	-0.25	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
LUAD	cis	rs2286503	0.646	rs17147344	ENSG00000228649.7	AC005682.5	5.63	3.04e-08	1.06e-05	0.36	0.25	Fibrinogen;	chr7:22841237	chr7:22854178~22861579:+
LUAD	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	5.63	3.05e-08	1.06e-05	0.37	0.25	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
LUAD	cis	rs7804306	1	rs35009545	ENSG00000233264.2	AC006042.8	5.63	3.05e-08	1.06e-05	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037223	chr7:7980312~7982228:+
LUAD	cis	rs12468226	0.873	rs3769817	ENSG00000226261.1	AC064836.3	-5.63	3.05e-08	1.06e-05	-0.4	-0.25	Urate levels;	chr2:202214584	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.873	rs6435134	ENSG00000226261.1	AC064836.3	-5.63	3.05e-08	1.06e-05	-0.4	-0.25	Urate levels;	chr2:202214857	chr2:202336024~202336727:-
LUAD	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	5.63	3.05e-08	1.06e-05	0.33	0.25	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.694	rs1150666	ENSG00000204709.4	LINC01556	5.63	3.05e-08	1.06e-05	0.33	0.25	Cardiac Troponin-T levels;	chr6:28156150	chr6:28943877~28944537:+
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000224373.3	IGHV4-59	5.63	3.05e-08	1.06e-05	0.16	0.25	Kawasaki disease;	chr14:106777528	chr14:106627249~106627825:-
LUAD	cis	rs1707322	0.963	rs10789484	ENSG00000234329.1	RP11-767N6.2	5.63	3.05e-08	1.07e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45651039~45651826:-
LUAD	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	5.63	3.05e-08	1.07e-05	0.31	0.25	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
LUAD	cis	rs4713118	0.513	rs202908	ENSG00000204709.4	LINC01556	5.63	3.05e-08	1.07e-05	0.32	0.25	Parkinson's disease;	chr6:28043773	chr6:28943877~28944537:+
LUAD	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	5.63	3.06e-08	1.07e-05	0.29	0.25	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
LUAD	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-5.63	3.06e-08	1.07e-05	-0.36	-0.25	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
LUAD	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	5.63	3.06e-08	1.07e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
LUAD	cis	rs1707322	1	rs10890376	ENSG00000234329.1	RP11-767N6.2	5.63	3.06e-08	1.07e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45651039~45651826:-
LUAD	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	5.63	3.06e-08	1.07e-05	0.36	0.25	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
LUAD	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	5.63	3.06e-08	1.07e-05	0.29	0.25	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
LUAD	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	5.63	3.06e-08	1.07e-05	0.31	0.25	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
LUAD	cis	rs4654783	0.627	rs1046310	ENSG00000228397.1	RP1-224A6.3	5.63	3.06e-08	1.07e-05	0.31	0.25	Endometriosis;	chr1:22117394	chr1:22023994~22024968:-
LUAD	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-5.63	3.06e-08	1.07e-05	-0.34	-0.25	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
LUAD	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	5.63	3.07e-08	1.07e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
LUAD	cis	rs9595908	0.669	rs28637641	ENSG00000212293.1	SNORA16	5.63	3.07e-08	1.07e-05	0.27	0.25	Body mass index;	chr13:32726997	chr13:32420390~32420516:-
LUAD	cis	rs1707322	1	rs4073847	ENSG00000234329.1	RP11-767N6.2	-5.63	3.07e-08	1.07e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45651039~45651826:-
LUAD	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-5.63	3.07e-08	1.07e-05	-0.28	-0.25	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
LUAD	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	5.63	3.07e-08	1.07e-05	0.29	0.25	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
LUAD	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-5.63	3.07e-08	1.07e-05	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000224373.3	IGHV4-59	5.63	3.07e-08	1.07e-05	0.16	0.25	Kawasaki disease;	chr14:106779660	chr14:106627249~106627825:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000230295.1	RP11-458F8.2	5.63	3.07e-08	1.07e-05	0.3	0.25	Diabetic kidney disease;	chr7:66259699	chr7:66880708~66882981:+
LUAD	cis	rs1707322	0.963	rs4630155	ENSG00000234329.1	RP11-767N6.2	5.63	3.08e-08	1.07e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs4508055	ENSG00000234329.1	RP11-767N6.2	5.63	3.08e-08	1.07e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs12076580	ENSG00000234329.1	RP11-767N6.2	5.63	3.08e-08	1.07e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45651039~45651826:-
LUAD	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-5.63	3.08e-08	1.07e-05	-0.34	-0.25	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-5.63	3.08e-08	1.07e-05	-0.34	-0.25	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
LUAD	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	5.63	3.08e-08	1.07e-05	0.28	0.25	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
LUAD	cis	rs1823913	0.503	rs35282329	ENSG00000280083.1	RP11-317J9.1	-5.63	3.08e-08	1.07e-05	-0.31	-0.25	Obesity-related traits;	chr2:191343925	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs6964245	ENSG00000230295.1	RP11-458F8.2	5.63	3.08e-08	1.07e-05	0.3	0.25	Diabetic kidney disease;	chr7:66253730	chr7:66880708~66882981:+
LUAD	cis	rs10761482	0.5	rs1574466	ENSG00000254271.1	RP11-131N11.4	5.63	3.08e-08	1.07e-05	0.27	0.25	Schizophrenia;	chr10:60534634	chr10:60734342~60741828:+
LUAD	cis	rs17301853	0.908	rs3862942	ENSG00000227373.4	RP11-160H22.5	5.63	3.08e-08	1.07e-05	0.49	0.25	Migraine without aura;Migraine - clinic-based;	chr1:174724440	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	5.63	3.09e-08	1.08e-05	0.28	0.25	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
LUAD	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-5.63	3.09e-08	1.08e-05	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
LUAD	cis	rs4835473	0.932	rs1973608	ENSG00000251600.4	RP11-673E1.1	5.63	3.09e-08	1.08e-05	0.31	0.25	Immature fraction of reticulocytes;	chr4:143913057	chr4:143912331~143982454:+
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000211967.3	IGHV3-53	-5.63	3.09e-08	1.08e-05	-0.18	-0.25	Kawasaki disease;	chr14:106776119	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000211967.3	IGHV3-53	-5.63	3.09e-08	1.08e-05	-0.18	-0.25	Kawasaki disease;	chr14:106776442	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000211967.3	IGHV3-53	-5.63	3.09e-08	1.08e-05	-0.18	-0.25	Kawasaki disease;	chr14:106776448	chr14:106592676~106593347:-
LUAD	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	5.63	3.09e-08	1.08e-05	0.38	0.25	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
LUAD	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-5.63	3.09e-08	1.08e-05	-0.37	-0.25	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
LUAD	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-5.63	3.09e-08	1.08e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
LUAD	cis	rs516805	0.528	rs2679703	ENSG00000279453.1	RP3-425C14.4	-5.63	3.1e-08	1.08e-05	-0.33	-0.25	Lymphocyte counts;	chr6:122099490	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2606632	ENSG00000279453.1	RP3-425C14.4	-5.63	3.1e-08	1.08e-05	-0.33	-0.25	Lymphocyte counts;	chr6:122099728	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2606634	ENSG00000279453.1	RP3-425C14.4	-5.63	3.1e-08	1.08e-05	-0.33	-0.25	Lymphocyte counts;	chr6:122100337	chr6:122436789~122439223:-
LUAD	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	5.63	3.1e-08	1.08e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	5.63	3.1e-08	1.08e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	5.63	3.1e-08	1.08e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
LUAD	cis	rs496547	0.654	rs688161	ENSG00000255239.1	AP002954.6	5.63	3.1e-08	1.08e-05	0.3	0.25	Hip minimal joint space width;	chr11:118807001	chr11:118688039~118690600:-
LUAD	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	5.63	3.1e-08	1.08e-05	0.28	0.25	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
LUAD	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-5.63	3.1e-08	1.08e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
LUAD	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	5.63	3.11e-08	1.08e-05	0.29	0.25	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
LUAD	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	5.63	3.11e-08	1.08e-05	0.27	0.25	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	5.63	3.11e-08	1.08e-05	0.27	0.25	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-5.63	3.11e-08	1.08e-05	-0.34	-0.25	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
LUAD	cis	rs6772849	0.93	rs4857912	ENSG00000242551.2	POU5F1P6	-5.63	3.11e-08	1.08e-05	-0.29	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128610381	chr3:128674735~128677005:-
LUAD	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-5.63	3.11e-08	1.08e-05	-0.31	-0.25	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
LUAD	cis	rs7208859	0.623	rs9895785	ENSG00000263603.1	CTD-2349P21.5	5.63	3.11e-08	1.08e-05	0.44	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30729469~30731202:+
LUAD	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	5.63	3.11e-08	1.08e-05	0.25	0.25	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
LUAD	cis	rs1707322	1	rs1622208	ENSG00000234329.1	RP11-767N6.2	-5.63	3.12e-08	1.09e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45651039~45651826:-
LUAD	cis	rs11098499	0.874	rs10022508	ENSG00000248280.1	RP11-33B1.2	5.63	3.12e-08	1.09e-05	0.32	0.25	Corneal astigmatism;	chr4:119194073	chr4:119440561~119450157:-
LUAD	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-5.63	3.12e-08	1.09e-05	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
LUAD	cis	rs997295	0.513	rs11635495	ENSG00000270964.1	RP11-502I4.3	-5.63	3.12e-08	1.09e-05	-0.26	-0.25	Motion sickness;	chr15:67512344	chr15:67541072~67542604:-
LUAD	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	5.63	3.12e-08	1.09e-05	0.31	0.25	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
LUAD	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	5.63	3.12e-08	1.09e-05	0.33	0.25	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
LUAD	cis	rs1707322	1	rs10789486	ENSG00000234329.1	RP11-767N6.2	5.63	3.12e-08	1.09e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-5.63	3.13e-08	1.09e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-5.63	3.13e-08	1.09e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-5.63	3.13e-08	1.09e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
LUAD	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	5.63	3.13e-08	1.09e-05	0.29	0.25	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
LUAD	cis	rs2212361	0.615	rs6483345	ENSG00000255893.1	RP11-685N10.1	-5.63	3.13e-08	1.09e-05	-0.3	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94530983	chr11:94472908~94473570:-
LUAD	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	5.63	3.13e-08	1.09e-05	0.35	0.25	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
LUAD	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	5.63	3.14e-08	1.09e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
LUAD	cis	rs9543976	0.623	rs9318361	ENSG00000261553.4	RP11-29G8.3	5.63	3.14e-08	1.09e-05	0.33	0.25	Diabetic retinopathy;	chr13:75602944	chr13:75549773~75807120:+
LUAD	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-5.63	3.14e-08	1.09e-05	-0.38	-0.25	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
LUAD	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-5.63	3.14e-08	1.09e-05	-0.27	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
LUAD	cis	rs4787484	1	rs7189550	ENSG00000214725.6	CDIPT-AS1	5.63	3.14e-08	1.09e-05	0.31	0.25	Response to taxane treatment (placlitaxel);	chr16:29899939	chr16:29863593~29868053:+
LUAD	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-5.63	3.14e-08	1.09e-05	-0.29	-0.25	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
LUAD	cis	rs4947019	0.688	rs9480937	ENSG00000260273.1	RP11-425D10.10	-5.63	3.14e-08	1.09e-05	-0.57	-0.25	Hematological parameters;	chr6:109358629	chr6:109382795~109383666:+
LUAD	cis	rs3738443	0.868	rs7551871	ENSG00000259865.1	RP11-488L18.10	5.63	3.14e-08	1.09e-05	0.25	0.25	Alcohol dependence;	chr1:247199888	chr1:247187281~247188526:-
LUAD	cis	rs516805	0.748	rs11154072	ENSG00000279453.1	RP3-425C14.4	5.63	3.15e-08	1.1e-05	0.34	0.25	Lymphocyte counts;	chr6:122374632	chr6:122436789~122439223:-
LUAD	cis	rs5753618	0.583	rs5753615	ENSG00000236132.1	CTA-440B3.1	-5.63	3.15e-08	1.1e-05	-0.31	-0.25	Colorectal cancer;	chr22:31432041	chr22:31816379~31817491:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000230295.1	RP11-458F8.2	-5.63	3.15e-08	1.1e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66073444	chr7:66880708~66882981:+
LUAD	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-5.62	3.15e-08	1.1e-05	-0.25	-0.25	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
LUAD	cis	rs11098499	0.874	rs6851169	ENSG00000248280.1	RP11-33B1.2	5.62	3.15e-08	1.1e-05	0.32	0.25	Corneal astigmatism;	chr4:119196355	chr4:119440561~119450157:-
LUAD	cis	rs1154275	0.563	rs9859168	ENSG00000242770.2	RP11-180K7.1	5.62	3.15e-08	1.1e-05	0.26	0.25	Takotsubo syndrome;	chr3:112797059	chr3:112802478~112812819:+
LUAD	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	5.62	3.16e-08	1.1e-05	0.28	0.25	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-5.62	3.16e-08	1.1e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-5.62	3.16e-08	1.1e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-5.62	3.16e-08	1.1e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-5.62	3.16e-08	1.1e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
LUAD	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	5.62	3.16e-08	1.1e-05	0.27	0.25	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	5.62	3.16e-08	1.1e-05	0.27	0.25	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
LUAD	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	5.62	3.16e-08	1.1e-05	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
LUAD	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	5.62	3.16e-08	1.1e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
LUAD	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	5.62	3.16e-08	1.1e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000224373.3	IGHV4-59	5.62	3.16e-08	1.1e-05	0.16	0.25	Kawasaki disease;	chr14:106782238	chr14:106627249~106627825:-
LUAD	cis	rs600231	0.665	rs1621277	ENSG00000245532.5	NEAT1	-5.62	3.17e-08	1.1e-05	-0.19	-0.25	Bone mineral density;	chr11:65454483	chr11:65422774~65445540:+
LUAD	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-5.62	3.17e-08	1.1e-05	-0.33	-0.25	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
LUAD	cis	rs6687821	0.515	rs4311860	ENSG00000267734.1	RP4-604K5.3	-5.62	3.17e-08	1.1e-05	-0.3	-0.25	Yeast infection;	chr1:87031539	chr1:86932199~86934891:-
LUAD	cis	rs7017914	0.69	rs3098872	ENSG00000223220.1	Y_RNA	-5.62	3.18e-08	1.1e-05	-0.29	-0.25	Bone mineral density;	chr8:71019969	chr8:70780914~70781008:-
LUAD	cis	rs1876905	0.68	rs187130	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.18e-08	1.1e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111309203~111313517:+
LUAD	cis	rs36423	0.528	rs1205061	ENSG00000266869.1	RP6-114E22.1	5.62	3.18e-08	1.1e-05	0.37	0.25	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71882819	chr14:71848606~71908430:+
LUAD	cis	rs2790457	0.958	rs2772433	ENSG00000254635.4	WAC-AS1	5.62	3.18e-08	1.11e-05	0.27	0.25	Multiple myeloma;	chr10:28607017	chr10:28522652~28532743:-
LUAD	cis	rs11096990	0.964	rs16988409	ENSG00000249207.1	RP11-360F5.1	-5.62	3.18e-08	1.11e-05	-0.28	-0.25	Cognitive function;	chr4:39267730	chr4:39112677~39126818:-
LUAD	cis	rs1707322	1	rs4660335	ENSG00000234329.1	RP11-767N6.2	5.62	3.18e-08	1.11e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45651039~45651826:-
LUAD	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	5.62	3.18e-08	1.11e-05	0.26	0.25	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
LUAD	cis	rs783540	0.5	rs783541	ENSG00000276710.3	CSPG4P8	5.62	3.18e-08	1.11e-05	0.26	0.25	Schizophrenia;	chr15:82586310	chr15:82459472~82477258:+
LUAD	cis	rs2276314	0.512	rs9951125	ENSG00000278986.1	RP11-723J4.3	-5.62	3.18e-08	1.11e-05	-0.26	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35872841	chr18:35972151~35973916:+
LUAD	cis	rs7923609	0.875	rs10822143	ENSG00000232075.1	MRPL35P2	-5.62	3.19e-08	1.11e-05	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63128096	chr10:63634317~63634827:-
LUAD	cis	rs1426063	0.614	rs76512224	ENSG00000249717.1	RP11-44F21.3	5.62	3.19e-08	1.11e-05	0.46	0.25	QT interval;	chr4:75144808	chr4:74955974~74970362:-
LUAD	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	5.62	3.19e-08	1.11e-05	0.27	0.25	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
LUAD	cis	rs9652601	0.665	rs17805769	ENSG00000274038.1	RP11-66H6.4	-5.62	3.19e-08	1.11e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11092016	chr16:11056556~11057034:+
LUAD	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	5.62	3.19e-08	1.11e-05	0.36	0.25	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	5.62	3.19e-08	1.11e-05	0.36	0.25	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
LUAD	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	5.62	3.2e-08	1.11e-05	0.44	0.25	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
LUAD	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	5.62	3.2e-08	1.11e-05	0.35	0.25	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.524	rs8065744	ENSG00000263603.1	CTD-2349P21.5	-5.62	3.2e-08	1.11e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs8071236	ENSG00000263603.1	CTD-2349P21.5	-5.62	3.2e-08	1.11e-05	-0.44	-0.25	Body mass index;	chr17:30772984	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs56163556	ENSG00000263603.1	CTD-2349P21.5	-5.62	3.2e-08	1.11e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30729469~30731202:+
LUAD	cis	rs516805	0.748	rs155466	ENSG00000279453.1	RP3-425C14.4	-5.62	3.2e-08	1.11e-05	-0.37	-0.25	Lymphocyte counts;	chr6:122512286	chr6:122436789~122439223:-
LUAD	cis	rs9807989	0.801	rs4851566	ENSG00000234389.1	AC007278.3	5.62	3.21e-08	1.11e-05	0.24	0.25	Asthma;	chr2:102356339	chr2:102438713~102440475:+
LUAD	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	5.62	3.21e-08	1.11e-05	0.34	0.25	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
LUAD	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-5.62	3.21e-08	1.11e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-5.62	3.21e-08	1.11e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	5.62	3.21e-08	1.11e-05	0.25	0.25	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
LUAD	cis	rs17684571	0.7	rs34966024	ENSG00000231441.1	RP11-472M19.2	5.62	3.21e-08	1.11e-05	0.36	0.25	Schizophrenia;	chr6:56766213	chr6:56844002~56864078:+
LUAD	cis	rs75422866	0.558	rs73104190	ENSG00000274902.1	RP1-197B17.4	5.62	3.21e-08	1.11e-05	0.55	0.25	Pneumonia;	chr12:47716040	chr12:47731908~47732351:+
LUAD	cis	rs1816752	0.905	rs2000153	ENSG00000273628.1	RP11-756A22.7	5.62	3.21e-08	1.11e-05	0.29	0.25	Obesity-related traits;	chr13:24405752	chr13:24933006~24936796:+
LUAD	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	5.62	3.21e-08	1.11e-05	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
LUAD	cis	rs6687821	0.506	rs559491	ENSG00000267734.1	RP4-604K5.3	5.62	3.21e-08	1.11e-05	0.34	0.25	Yeast infection;	chr1:86853136	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.548	rs492624	ENSG00000267734.1	RP4-604K5.3	5.62	3.21e-08	1.11e-05	0.34	0.25	Yeast infection;	chr1:86854981	chr1:86932199~86934891:-
LUAD	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-5.62	3.21e-08	1.12e-05	-0.28	-0.25	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
LUAD	cis	rs2998286	0.813	rs2790430	ENSG00000254635.4	WAC-AS1	-5.62	3.22e-08	1.12e-05	-0.36	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28498865	chr10:28522652~28532743:-
LUAD	cis	rs5753618	0.583	rs2273251	ENSG00000236132.1	CTA-440B3.1	-5.62	3.22e-08	1.12e-05	-0.3	-0.25	Colorectal cancer;	chr22:31447581	chr22:31816379~31817491:-
LUAD	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-5.62	3.22e-08	1.12e-05	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
LUAD	cis	rs1876905	0.68	rs1215848	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.22e-08	1.12e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs402940	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.22e-08	1.12e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111309203~111313517:+
LUAD	cis	rs1234598	1	rs1234598	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.22e-08	1.12e-05	-0.27	-0.25	Mean corpuscular volume;	chr6:111208250	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs354543	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.22e-08	1.12e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111309203~111313517:+
LUAD	cis	rs62432291	0.681	rs418859	ENSG00000235086.1	FNDC1-IT1	5.62	3.22e-08	1.12e-05	0.42	0.25	Joint mobility (Beighton score);	chr6:159228663	chr6:159240786~159243329:+
LUAD	cis	rs155076	0.666	rs4638420	ENSG00000233325.3	MIPEPP3	-5.62	3.22e-08	1.12e-05	-0.38	-0.25	White matter hyperintensity burden;	chr13:21298209	chr13:21298139~21306373:+
LUAD	cis	rs8098244	0.557	rs2226835	ENSG00000264745.1	TTC39C-AS1	5.62	3.23e-08	1.12e-05	0.26	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23715912	chr18:23994213~24015339:-
LUAD	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	5.62	3.23e-08	1.12e-05	0.26	0.25	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
LUAD	cis	rs6991838	0.806	rs11777025	ENSG00000200714.1	Y_RNA	-5.62	3.23e-08	1.12e-05	-0.28	-0.25	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65592731~65592820:+
LUAD	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	5.62	3.23e-08	1.12e-05	0.37	0.25	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
LUAD	cis	rs5753618	0.583	rs7293171	ENSG00000236132.1	CTA-440B3.1	-5.62	3.23e-08	1.12e-05	-0.31	-0.25	Colorectal cancer;	chr22:31406338	chr22:31816379~31817491:-
LUAD	cis	rs4713118	0.513	rs156738	ENSG00000204709.4	LINC01556	5.62	3.24e-08	1.12e-05	0.31	0.25	Parkinson's disease;	chr6:28046247	chr6:28943877~28944537:+
LUAD	cis	rs9595908	0.785	rs9652200	ENSG00000212293.1	SNORA16	5.62	3.24e-08	1.12e-05	0.26	0.25	Body mass index;	chr13:32715613	chr13:32420390~32420516:-
LUAD	cis	rs9860428	0.774	rs13094280	ENSG00000242770.2	RP11-180K7.1	5.62	3.24e-08	1.12e-05	0.26	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112825903	chr3:112802478~112812819:+
LUAD	cis	rs9928842	0.771	rs8059190	ENSG00000280152.1	RP11-331F4.5	5.62	3.25e-08	1.13e-05	0.27	0.25	Alcoholic chronic pancreatitis;	chr16:75226899	chr16:75245994~75250077:-
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000230295.1	RP11-458F8.2	-5.62	3.25e-08	1.13e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66100518	chr7:66880708~66882981:+
LUAD	cis	rs7208859	0.614	rs216412	ENSG00000263603.1	CTD-2349P21.5	5.62	3.25e-08	1.13e-05	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30729469~30731202:+
LUAD	cis	rs10214930	0.915	rs6462042	ENSG00000235574.1	AC073150.6	5.62	3.25e-08	1.13e-05	0.34	0.25	Hypospadias;	chr7:27682833	chr7:27491682~27492765:-
LUAD	cis	rs12699921	0.632	rs1852011	ENSG00000279048.1	RP11-511H23.2	-5.62	3.25e-08	1.13e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17787004	chr7:17940503~17942922:+
LUAD	cis	rs10761482	0.5	rs1892547	ENSG00000254271.1	RP11-131N11.4	5.62	3.25e-08	1.13e-05	0.27	0.25	Schizophrenia;	chr10:60533200	chr10:60734342~60741828:+
LUAD	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-5.62	3.26e-08	1.13e-05	-0.31	-0.25	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
LUAD	cis	rs2404602	0.632	rs34338978	ENSG00000259422.1	RP11-593F23.1	5.62	3.26e-08	1.13e-05	0.29	0.25	Blood metabolite levels;	chr15:76934464	chr15:76174891~76181486:-
LUAD	cis	rs1707322	0.964	rs785516	ENSG00000234329.1	RP11-767N6.2	-5.62	3.26e-08	1.13e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785517	ENSG00000234329.1	RP11-767N6.2	-5.62	3.26e-08	1.13e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785484	ENSG00000234329.1	RP11-767N6.2	-5.62	3.26e-08	1.13e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45651039~45651826:-
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000211967.3	IGHV3-53	-5.62	3.26e-08	1.13e-05	-0.18	-0.25	Kawasaki disease;	chr14:106685899	chr14:106592676~106593347:-
LUAD	cis	rs1823913	0.503	rs35672076	ENSG00000280083.1	RP11-317J9.1	-5.62	3.26e-08	1.13e-05	-0.31	-0.25	Obesity-related traits;	chr2:191343907	chr2:191154118~191156070:-
LUAD	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	5.62	3.26e-08	1.13e-05	0.27	0.25	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
LUAD	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-5.62	3.26e-08	1.13e-05	-0.3	-0.25	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-5.62	3.26e-08	1.13e-05	-0.31	-0.25	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
LUAD	cis	rs9652601	0.691	rs11861236	ENSG00000274038.1	RP11-66H6.4	-5.62	3.27e-08	1.13e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11089769	chr16:11056556~11057034:+
LUAD	cis	rs2404602	0.655	rs34748201	ENSG00000259422.1	RP11-593F23.1	5.62	3.27e-08	1.13e-05	0.29	0.25	Blood metabolite levels;	chr15:76929189	chr15:76174891~76181486:-
LUAD	cis	rs9287719	0.649	rs2884232	ENSG00000243819.4	RN7SL832P	5.62	3.27e-08	1.13e-05	0.26	0.25	Prostate cancer;	chr2:10579553	chr2:10690344~10692099:+
LUAD	cis	rs7044106	0.762	rs10760112	ENSG00000238181.2	AHCYP2	-5.62	3.27e-08	1.13e-05	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120720673~120721972:+
LUAD	cis	rs2243480	1	rs313831	ENSG00000230295.1	RP11-458F8.2	-5.62	3.27e-08	1.14e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66086239	chr7:66880708~66882981:+
LUAD	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	5.62	3.27e-08	1.14e-05	0.36	0.25	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
LUAD	cis	rs9807989	0.773	rs72823661	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102352256	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.801	rs72823663	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102352278	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs67088699	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102352291	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.773	rs5010059	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102352366	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs11695627	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102353645	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.801	rs7558339	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102353783	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs7608638	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102353829	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs4485584	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102354290	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs4485585	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102354299	chr2:102438713~102440475:+
LUAD	cis	rs9807989	1	rs9807989	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102354740	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs9808453	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102354846	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs4851565	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102355021	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.765	rs9807962	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102355204	chr2:102438713~102440475:+
LUAD	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
LUAD	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
LUAD	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
LUAD	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
LUAD	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	5.62	3.28e-08	1.14e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
LUAD	cis	rs35740288	0.721	rs11636347	ENSG00000202081.1	RNU6-1280P	5.62	3.28e-08	1.14e-05	0.32	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85698002	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11635711	ENSG00000202081.1	RNU6-1280P	5.62	3.28e-08	1.14e-05	0.3	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85583255	chr15:85651522~85651628:-
LUAD	cis	rs4604732	0.536	rs10925056	ENSG00000227135.1	GCSAML-AS1	-5.62	3.28e-08	1.14e-05	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247487170	chr1:247524679~247526752:-
LUAD	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.33	-0.25	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
LUAD	cis	rs2337406	1	rs17095456	ENSG00000211974.3	IGHV2-70	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Alzheimer's disease (late onset);	chr14:106676559	chr14:106723574~106724093:-
LUAD	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-5.62	3.29e-08	1.14e-05	-0.31	-0.25	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
LUAD	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-5.62	3.29e-08	1.14e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
LUAD	cis	rs2243480	1	rs160646	ENSG00000230295.1	RP11-458F8.2	-5.62	3.29e-08	1.14e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66091293	chr7:66880708~66882981:+
LUAD	cis	rs12468226	0.817	rs6435135	ENSG00000226261.1	AC064836.3	-5.62	3.29e-08	1.14e-05	-0.4	-0.25	Urate levels;	chr2:202217469	chr2:202336024~202336727:-
LUAD	cis	rs4852324	0.536	rs71418714	ENSG00000217702.2	RP11-287D1.4	5.62	3.3e-08	1.14e-05	0.6	0.25	Systemic lupus erythematosus;	chr2:73992759	chr2:74130583~74135395:+
LUAD	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-5.62	3.3e-08	1.14e-05	-0.4	-0.25	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
LUAD	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	5.62	3.3e-08	1.14e-05	0.3	0.25	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
LUAD	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	5.62	3.3e-08	1.14e-05	0.26	0.25	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
LUAD	cis	rs72615157	0.697	rs2056726	ENSG00000242294.5	STAG3L5P	5.62	3.3e-08	1.14e-05	0.21	0.25	Lung function (FEV1/FVC);	chr7:100182660	chr7:100336079~100351900:+
LUAD	cis	rs2749592	0.513	rs1208708	ENSG00000263064.2	RP11-291L22.7	5.62	3.3e-08	1.14e-05	0.26	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38448689~38448949:+
LUAD	cis	rs453301	0.686	rs2409120	ENSG00000253981.4	ALG1L13P	-5.62	3.31e-08	1.15e-05	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9025061	chr8:8236003~8244667:-
LUAD	cis	rs1707322	0.964	rs785508	ENSG00000234329.1	RP11-767N6.2	-5.62	3.31e-08	1.15e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs785509	ENSG00000234329.1	RP11-767N6.2	-5.62	3.31e-08	1.15e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45651039~45651826:-
LUAD	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-5.62	3.31e-08	1.15e-05	-0.3	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
LUAD	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	5.62	3.31e-08	1.15e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	5.62	3.31e-08	1.15e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	5.62	3.31e-08	1.15e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	5.62	3.31e-08	1.15e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
LUAD	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	5.62	3.31e-08	1.15e-05	0.32	0.25	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
LUAD	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	5.62	3.31e-08	1.15e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
LUAD	cis	rs72615157	0.634	rs2272343	ENSG00000242294.5	STAG3L5P	5.62	3.32e-08	1.15e-05	0.21	0.25	Lung function (FEV1/FVC);	chr7:100180662	chr7:100336079~100351900:+
LUAD	cis	rs1707322	1	rs10789485	ENSG00000234329.1	RP11-767N6.2	5.62	3.32e-08	1.15e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45651039~45651826:-
LUAD	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-5.62	3.32e-08	1.15e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.656	rs3014210	ENSG00000234329.1	RP11-767N6.2	-5.62	3.32e-08	1.15e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45651039~45651826:-
LUAD	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	5.62	3.32e-08	1.15e-05	0.19	0.25	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	5.62	3.32e-08	1.15e-05	0.19	0.25	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
LUAD	cis	rs9652601	0.649	rs12599402	ENSG00000274038.1	RP11-66H6.4	-5.62	3.32e-08	1.15e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11096031	chr16:11056556~11057034:+
LUAD	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-5.61	3.33e-08	1.15e-05	-0.3	-0.25	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
LUAD	cis	rs1707322	1	rs10890365	ENSG00000234329.1	RP11-767N6.2	5.61	3.33e-08	1.15e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45651039~45651826:-
LUAD	cis	rs11098499	0.526	rs10026625	ENSG00000245958.5	RP11-33B1.1	-5.61	3.33e-08	1.15e-05	-0.21	-0.25	Corneal astigmatism;	chr4:119358981	chr4:119454791~119552025:+
LUAD	cis	rs496547	0.719	rs598373	ENSG00000255239.1	AP002954.6	5.61	3.33e-08	1.15e-05	0.31	0.25	Hip minimal joint space width;	chr11:118793668	chr11:118688039~118690600:-
LUAD	cis	rs11651753	0.636	rs4793737	ENSG00000264920.1	RP11-6N17.4	-5.61	3.34e-08	1.15e-05	-0.31	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964891	chr17:47891255~47895812:-
LUAD	cis	rs854462	0.925	rs712040	ENSG00000274767.1	AC131056.3	-5.61	3.34e-08	1.16e-05	-0.39	-0.25	Blood protein levels;	chr17:36058228	chr17:36183235~36196471:+
LUAD	cis	rs516805	0.667	rs2816078	ENSG00000279453.1	RP3-425C14.4	-5.61	3.34e-08	1.16e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122201755	chr6:122436789~122439223:-
LUAD	cis	rs6543140	0.964	rs4851010	ENSG00000234389.1	AC007278.3	-5.61	3.34e-08	1.16e-05	-0.25	-0.25	Blood protein levels;	chr2:102439667	chr2:102438713~102440475:+
LUAD	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-5.61	3.35e-08	1.16e-05	-0.32	-0.25	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
LUAD	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-5.61	3.35e-08	1.16e-05	-0.28	-0.25	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
LUAD	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-5.61	3.35e-08	1.16e-05	-0.22	-0.25	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
LUAD	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	5.61	3.35e-08	1.16e-05	0.28	0.25	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
LUAD	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	5.61	3.36e-08	1.16e-05	0.25	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
LUAD	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	5.61	3.36e-08	1.16e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	5.61	3.36e-08	1.16e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	5.61	3.36e-08	1.16e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
LUAD	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	5.61	3.37e-08	1.16e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
LUAD	cis	rs7182621	1	rs7182621	ENSG00000182397.13	DNM1P46	-5.61	3.37e-08	1.16e-05	-0.29	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99790156~99806927:-
LUAD	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	5.61	3.37e-08	1.17e-05	0.31	0.25	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
LUAD	cis	rs2599510	0.811	rs2583713	ENSG00000276334.1	AL133243.1	5.61	3.38e-08	1.17e-05	0.29	0.25	Interleukin-18 levels;	chr2:32597662	chr2:32521927~32523547:+
LUAD	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	5.61	3.38e-08	1.17e-05	0.27	0.25	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
LUAD	cis	rs12468226	1	rs58288071	ENSG00000272966.1	RP11-686O6.1	5.61	3.38e-08	1.17e-05	0.43	0.25	Urate levels;	chr2:202350016	chr2:202336739~202337200:+
LUAD	cis	rs155076	0.666	rs9509640	ENSG00000233325.3	MIPEPP3	-5.61	3.38e-08	1.17e-05	-0.38	-0.25	White matter hyperintensity burden;	chr13:21298741	chr13:21298139~21306373:+
LUAD	cis	rs11742741	0.539	rs11743753	ENSG00000248874.4	C5orf17	5.61	3.38e-08	1.17e-05	0.31	0.25	Educational attainment;	chr5:24093021	chr5:23951348~24178263:+
LUAD	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	5.61	3.38e-08	1.17e-05	0.36	0.25	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.863	rs274054	ENSG00000226816.2	AC005082.12	5.61	3.38e-08	1.17e-05	0.33	0.25	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23206013~23208045:+
LUAD	cis	rs891378	1	rs7543250	ENSG00000274245.1	RP11-357P18.2	5.61	3.39e-08	1.17e-05	0.3	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251698	chr1:207372559~207373252:+
LUAD	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-5.61	3.39e-08	1.17e-05	-0.33	-0.25	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
LUAD	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-5.61	3.39e-08	1.17e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-5.61	3.39e-08	1.17e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
LUAD	cis	rs4908760	0.827	rs2401138	ENSG00000232912.4	RP5-1115A15.1	-5.61	3.39e-08	1.17e-05	-0.23	-0.25	Vitiligo;	chr1:8644000	chr1:8424645~8434838:+
LUAD	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	5.61	3.39e-08	1.17e-05	0.29	0.25	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
LUAD	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	5.61	3.4e-08	1.17e-05	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
LUAD	cis	rs6558530	0.698	rs7015858	ENSG00000253982.1	CTD-2336O2.1	5.61	3.4e-08	1.17e-05	0.31	0.25	Systolic blood pressure;	chr8:1776141	chr8:1761990~1764502:-
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000224373.3	IGHV4-59	-5.61	3.4e-08	1.17e-05	-0.16	-0.25	Kawasaki disease;	chr14:106769752	chr14:106627249~106627825:-
LUAD	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	5.61	3.4e-08	1.18e-05	0.33	0.25	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
LUAD	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-5.61	3.41e-08	1.18e-05	-0.28	-0.25	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
LUAD	cis	rs2412819	0.571	rs2930529	ENSG00000249839.1	AC011330.5	5.61	3.41e-08	1.18e-05	0.38	0.25	Lung cancer;	chr15:43819467	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs2930530	ENSG00000249839.1	AC011330.5	5.61	3.41e-08	1.18e-05	0.38	0.25	Lung cancer;	chr15:43823268	chr15:43663654~43684339:-
LUAD	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-5.61	3.41e-08	1.18e-05	-0.34	-0.25	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
LUAD	cis	rs9311474	0.935	rs7622851	ENSG00000243224.1	RP5-1157M23.2	-5.61	3.41e-08	1.18e-05	-0.26	-0.25	Electroencephalogram traits;	chr3:52299655	chr3:52239258~52241097:+
LUAD	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-5.61	3.41e-08	1.18e-05	-0.36	-0.25	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-5.61	3.41e-08	1.18e-05	-0.36	-0.25	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.928	rs6681068	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211228	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs11211229	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs9803784	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs12022335	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.503	rs34689696	ENSG00000227542.1	AC092614.2	5.61	3.41e-08	1.18e-05	0.32	0.25	Obesity-related traits;	chr2:191355247	chr2:191229165~191246172:-
LUAD	cis	rs4908768	0.539	rs1934138	ENSG00000232912.4	RP5-1115A15.1	5.61	3.41e-08	1.18e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8424645~8434838:+
LUAD	cis	rs2919009	0.664	rs10510083	ENSG00000271670.1	RP11-95I16.4	5.61	3.41e-08	1.18e-05	0.32	0.25	Obesity-related traits;	chr10:120925013	chr10:120879256~120880667:-
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	5.61	3.43e-08	1.18e-05	0.27	0.25	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	5.61	3.43e-08	1.18e-05	0.27	0.25	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
LUAD	cis	rs1667284	0.935	rs1791161	ENSG00000266521.1	RP11-650P15.1	5.61	3.43e-08	1.18e-05	0.29	0.25	Problematic alcohol use in trauma-exposed individuals;	chr18:31624247	chr18:31496645~31497195:-
LUAD	cis	rs4767841	0.552	rs11064855	ENSG00000248636.5	RP11-768F21.1	-5.61	3.44e-08	1.19e-05	-0.29	-0.25	Urgency urinary incontinence;	chr12:119626986	chr12:119387987~119668079:-
LUAD	cis	rs763567	0.9	rs473133	ENSG00000271811.1	RP1-79C4.4	5.61	3.44e-08	1.19e-05	0.3	0.25	Tonsillectomy;	chr1:170666938	chr1:170667381~170669425:+
LUAD	cis	rs9287719	0.649	rs10929677	ENSG00000243819.4	RN7SL832P	5.61	3.44e-08	1.19e-05	0.26	0.25	Prostate cancer;	chr2:10577422	chr2:10690344~10692099:+
LUAD	cis	rs11051970	0.559	rs11051944	ENSG00000274964.1	RP11-817I4.1	-5.61	3.44e-08	1.19e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32332984	chr12:32339368~32340724:+
LUAD	cis	rs1876905	0.569	rs354542	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs1216020	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.569	rs354541	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs354537	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs354536	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs557028	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111309203~111313517:+
LUAD	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	5.61	3.45e-08	1.19e-05	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
LUAD	cis	rs7044106	0.762	rs1411158	ENSG00000238181.2	AHCYP2	-5.61	3.45e-08	1.19e-05	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120720673~120721972:+
LUAD	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-5.61	3.46e-08	1.19e-05	-0.42	-0.25	Depression;	chr6:28119105	chr6:28115628~28116551:+
LUAD	cis	rs2404602	0.692	rs34181263	ENSG00000259422.1	RP11-593F23.1	5.61	3.46e-08	1.2e-05	0.29	0.25	Blood metabolite levels;	chr15:76773047	chr15:76174891~76181486:-
LUAD	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-5.61	3.47e-08	1.2e-05	-0.29	-0.25	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
LUAD	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	5.61	3.47e-08	1.2e-05	0.31	0.25	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
LUAD	cis	rs10214930	0.697	rs1111647	ENSG00000235574.1	AC073150.6	-5.61	3.47e-08	1.2e-05	-0.3	-0.25	Hypospadias;	chr7:27521114	chr7:27491682~27492765:-
LUAD	cis	rs9914544	0.591	rs9900052	ENSG00000273018.4	CTD-2303H24.2	-5.61	3.47e-08	1.2e-05	-0.29	-0.25	Educational attainment (years of education);	chr17:18796085	chr17:18511221~18551705:-
LUAD	cis	rs11157436	1	rs11157436	ENSG00000211812.1	TRAV26-2	5.61	3.47e-08	1.2e-05	0.28	0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22202583~22203368:+
LUAD	cis	rs9595908	0.669	rs56291634	ENSG00000212293.1	SNORA16	5.61	3.48e-08	1.2e-05	0.27	0.25	Body mass index;	chr13:32720404	chr13:32420390~32420516:-
LUAD	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-5.61	3.48e-08	1.2e-05	-0.29	-0.25	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
LUAD	cis	rs7181230	0.885	rs749748	ENSG00000275636.1	RP11-521C20.5	5.61	3.49e-08	1.2e-05	0.33	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40078892~40079347:+
LUAD	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	5.61	3.5e-08	1.21e-05	0.28	0.25	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
LUAD	cis	rs7618501	0.633	rs7628058	ENSG00000234667.1	ACTBP13	-5.61	3.5e-08	1.21e-05	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:50002041	chr3:49873347~49877980:-
LUAD	cis	rs2243480	1	rs1618893	ENSG00000230295.1	RP11-458F8.2	-5.61	3.5e-08	1.21e-05	-0.28	-0.25	Diabetic kidney disease;	chr7:66631132	chr7:66880708~66882981:+
LUAD	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	5.61	3.5e-08	1.21e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
LUAD	cis	rs7948661	0.661	rs113028342	ENSG00000278376.1	RP11-158I9.8	5.61	3.5e-08	1.21e-05	0.53	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118462822	chr11:118791254~118793137:+
LUAD	cis	rs62432291	0.681	rs404435	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159233455	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.614	rs370434	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159233519	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs402388	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159233962	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.764	rs436743	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234070	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs3003174	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234294	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs2501176	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234351	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs2501177	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234561	chr6:159240786~159243329:+
LUAD	cis	rs293748	0.605	rs13188136	ENSG00000250155.1	CTD-2353F22.1	-5.61	3.5e-08	1.21e-05	-0.32	-0.25	Obesity-related traits;	chr5:37117132	chr5:36666214~36725195:-
LUAD	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	5.61	3.5e-08	1.21e-05	0.36	0.25	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
LUAD	cis	rs2404602	0.692	rs12910734	ENSG00000259422.1	RP11-593F23.1	5.61	3.5e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76857590	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs12594556	ENSG00000259422.1	RP11-593F23.1	5.61	3.5e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76873022	chr15:76174891~76181486:-
LUAD	cis	rs4604732	0.588	rs6677477	ENSG00000227135.1	GCSAML-AS1	-5.61	3.5e-08	1.21e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247466109	chr1:247524679~247526752:-
LUAD	cis	rs7804306	0.826	rs73049300	ENSG00000233264.2	AC006042.8	5.61	3.51e-08	1.21e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8002315	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs58348680	ENSG00000233264.2	AC006042.8	5.61	3.51e-08	1.21e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8005655	chr7:7980312~7982228:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000211967.3	IGHV3-53	-5.61	3.51e-08	1.21e-05	-0.18	-0.25	Kawasaki disease;	chr14:106777987	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000211967.3	IGHV3-53	-5.61	3.51e-08	1.21e-05	-0.18	-0.25	Kawasaki disease;	chr14:106777997	chr14:106592676~106593347:-
LUAD	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	5.61	3.51e-08	1.21e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
LUAD	cis	rs848490	0.722	rs4729772	ENSG00000214293.7	APTR	5.61	3.51e-08	1.21e-05	0.28	0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77826582	chr7:77657660~77696265:-
LUAD	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-5.61	3.51e-08	1.21e-05	-0.35	-0.25	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
LUAD	cis	rs2404602	0.74	rs34924128	ENSG00000259422.1	RP11-593F23.1	5.6	3.52e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76672828	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs67010831	ENSG00000259422.1	RP11-593F23.1	5.6	3.52e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76672967	chr15:76174891~76181486:-
LUAD	cis	rs11157436	0.958	rs17183356	ENSG00000211812.1	TRAV26-2	-5.6	3.52e-08	1.21e-05	-0.29	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22202583~22203368:+
LUAD	cis	rs2404602	0.692	rs2137307	ENSG00000259422.1	RP11-593F23.1	5.6	3.52e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76856679	chr15:76174891~76181486:-
LUAD	cis	rs2303759	0.676	rs10426452	ENSG00000268686.1	AC010524.2	-5.6	3.52e-08	1.21e-05	-0.33	-0.25	Multiple sclerosis;	chr19:49404433	chr19:49368705~49388081:-
LUAD	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-5.6	3.52e-08	1.21e-05	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
LUAD	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	5.6	3.52e-08	1.21e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
LUAD	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	5.6	3.53e-08	1.22e-05	0.27	0.25	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	5.6	3.53e-08	1.22e-05	0.26	0.25	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
LUAD	cis	rs131777	0.545	rs131759	ENSG00000205559.3	CHKB-AS1	-5.6	3.53e-08	1.22e-05	-0.28	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50577052	chr22:50583026~50583877:+
LUAD	cis	rs11098499	0.874	rs9995277	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119187448	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.874	rs6826823	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119190943	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.874	rs12509054	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119193920	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.874	rs12502503	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119195100	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.874	rs6832670	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119197637	chr4:119440561~119450157:-
LUAD	cis	rs9652601	0.691	rs9888868	ENSG00000274038.1	RP11-66H6.4	-5.6	3.54e-08	1.22e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11089706	chr16:11056556~11057034:+
LUAD	cis	rs74233809	1	rs12219027	ENSG00000213277.3	MARCKSL1P1	5.6	3.54e-08	1.22e-05	0.42	0.25	Birth weight;	chr10:103051446	chr10:103175554~103176094:+
LUAD	cis	rs12699921	0.607	rs1051603	ENSG00000279048.1	RP11-511H23.2	-5.6	3.54e-08	1.22e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17822402	chr7:17940503~17942922:+
LUAD	cis	rs2408955	0.521	rs1476607	ENSG00000240399.1	RP1-228P16.1	-5.6	3.54e-08	1.22e-05	-0.25	-0.25	Glycated hemoglobin levels;	chr12:48131021	chr12:48054813~48055591:-
LUAD	cis	rs62432291	0.614	rs420339	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159236163	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs425906	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159236543	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs388001	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159237427	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs378339	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159237820	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs419836	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159238449	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs450538	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159238491	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.764	rs433256	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159239073	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs429339	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159239116	chr6:159240786~159243329:+
LUAD	cis	rs748404	0.666	rs72709850	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43462486	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs34633582	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43462683	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs36078097	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43466209	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs7181783	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43469723	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs35903301	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43472332	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs34002293	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43472401	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs34181131	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43478527	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs7173383	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43480838	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs55801120	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43495042	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs12911740	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43498254	chr15:43726918~43747094:-
LUAD	cis	rs7911264	0.967	rs9419741	ENSG00000236493.2	EIF2S2P3	-5.6	3.54e-08	1.22e-05	-0.28	-0.25	Inflammatory bowel disease;	chr10:92670768	chr10:92668745~92669743:-
LUAD	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	5.6	3.54e-08	1.22e-05	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	5.6	3.54e-08	1.22e-05	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
LUAD	cis	rs1707322	1	rs10890381	ENSG00000234329.1	RP11-767N6.2	5.6	3.54e-08	1.22e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890378	ENSG00000234329.1	RP11-767N6.2	-5.6	3.55e-08	1.22e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45651039~45651826:-
LUAD	cis	rs1154275	0.537	rs6772960	ENSG00000242770.2	RP11-180K7.1	5.6	3.56e-08	1.22e-05	0.26	0.25	Takotsubo syndrome;	chr3:112796693	chr3:112802478~112812819:+
LUAD	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	5.6	3.56e-08	1.22e-05	0.25	0.25	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
LUAD	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-5.6	3.56e-08	1.22e-05	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
LUAD	cis	rs30380	1	rs30187	ENSG00000272109.1	CTD-2260A17.3	-5.6	3.56e-08	1.23e-05	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96804353~96806105:+
LUAD	cis	rs4947019	0.686	rs9487083	ENSG00000260273.1	RP11-425D10.10	5.6	3.56e-08	1.23e-05	0.54	0.25	Hematological parameters;	chr6:109394399	chr6:109382795~109383666:+
LUAD	cis	rs5753618	0.583	rs8138596	ENSG00000236132.1	CTA-440B3.1	-5.6	3.57e-08	1.23e-05	-0.31	-0.25	Colorectal cancer;	chr22:31390975	chr22:31816379~31817491:-
LUAD	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-5.6	3.57e-08	1.23e-05	-0.31	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
LUAD	cis	rs4948102	0.595	rs7793921	ENSG00000275875.1	RP11-613E4.5	-5.6	3.57e-08	1.23e-05	-0.27	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55741525~55741869:+
LUAD	cis	rs4948102	0.595	rs10255049	ENSG00000275875.1	RP11-613E4.5	-5.6	3.57e-08	1.23e-05	-0.27	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55741525~55741869:+
LUAD	cis	rs2404602	0.692	rs72738889	ENSG00000259422.1	RP11-593F23.1	5.6	3.57e-08	1.23e-05	0.29	0.25	Blood metabolite levels;	chr15:76699722	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs3816266	ENSG00000259422.1	RP11-593F23.1	5.6	3.57e-08	1.23e-05	0.29	0.25	Blood metabolite levels;	chr15:76701494	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs2304920	ENSG00000259422.1	RP11-593F23.1	5.6	3.57e-08	1.23e-05	0.29	0.25	Blood metabolite levels;	chr15:76701526	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.566	rs2691586	ENSG00000279048.1	RP11-511H23.2	-5.6	3.57e-08	1.23e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17798236	chr7:17940503~17942922:+
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000226002.1	RP11-460N20.5	5.6	3.57e-08	1.23e-05	0.28	0.25	Calcium levels;	chr7:65825628	chr7:65084103~65100232:+
LUAD	cis	rs1154275	0.537	rs6763014	ENSG00000242770.2	RP11-180K7.1	5.6	3.57e-08	1.23e-05	0.26	0.25	Takotsubo syndrome;	chr3:112793800	chr3:112802478~112812819:+
LUAD	cis	rs1707322	1	rs11211223	ENSG00000234329.1	RP11-767N6.2	5.6	3.57e-08	1.23e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45651039~45651826:-
LUAD	cis	rs7246657	0.508	rs10419845	ENSG00000276846.1	CTD-3220F14.3	5.6	3.58e-08	1.23e-05	0.39	0.25	Coronary artery calcification;	chr19:37000290	chr19:37314868~37315620:-
LUAD	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-5.6	3.58e-08	1.23e-05	-0.27	-0.25	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
LUAD	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	5.6	3.58e-08	1.23e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
LUAD	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-5.6	3.58e-08	1.23e-05	-0.23	-0.25	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
LUAD	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-5.6	3.58e-08	1.23e-05	-0.23	-0.25	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
LUAD	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-5.6	3.58e-08	1.23e-05	-0.31	-0.25	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
LUAD	cis	rs2404602	0.692	rs58361452	ENSG00000259422.1	RP11-593F23.1	5.6	3.58e-08	1.23e-05	0.29	0.25	Blood metabolite levels;	chr15:76681031	chr15:76174891~76181486:-
LUAD	cis	rs180730	0.561	rs343194	ENSG00000251609.2	SETP12	-5.6	3.58e-08	1.23e-05	-0.32	-0.25	Fasting plasma glucose;	chr4:120880199	chr4:120895494~120897083:-
LUAD	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	5.6	3.59e-08	1.23e-05	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
LUAD	cis	rs172166	0.769	rs149965	ENSG00000204709.4	LINC01556	5.6	3.59e-08	1.23e-05	0.31	0.25	Cardiac Troponin-T levels;	chr6:28050911	chr6:28943877~28944537:+
LUAD	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-5.6	3.59e-08	1.23e-05	-0.3	-0.25	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
LUAD	cis	rs9834970	0.588	rs9985296	ENSG00000234073.1	AC011816.1	5.6	3.59e-08	1.23e-05	0.27	0.25	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36848130	chr3:36880184~36880729:-
LUAD	cis	rs1707322	1	rs12077546	ENSG00000234329.1	RP11-767N6.2	5.6	3.59e-08	1.23e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs12124291	ENSG00000234329.1	RP11-767N6.2	5.6	3.59e-08	1.23e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45651039~45651826:-
LUAD	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	5.6	3.59e-08	1.23e-05	0.33	0.25	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	5.6	3.59e-08	1.23e-05	0.33	0.25	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
LUAD	cis	rs17684571	0.751	rs6918949	ENSG00000231441.1	RP11-472M19.2	-5.6	3.6e-08	1.24e-05	-0.37	-0.25	Schizophrenia;	chr6:56845183	chr6:56844002~56864078:+
LUAD	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	5.6	3.6e-08	1.24e-05	0.27	0.25	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
LUAD	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	5.6	3.6e-08	1.24e-05	0.35	0.25	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000224373.3	IGHV4-59	5.6	3.6e-08	1.24e-05	0.16	0.25	Kawasaki disease;	chr14:106782206	chr14:106627249~106627825:-
LUAD	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	5.6	3.6e-08	1.24e-05	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	5.6	3.6e-08	1.24e-05	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
LUAD	cis	rs11098499	0.874	rs6822498	ENSG00000248280.1	RP11-33B1.2	5.6	3.6e-08	1.24e-05	0.32	0.25	Corneal astigmatism;	chr4:119199028	chr4:119440561~119450157:-
LUAD	cis	rs2288884	0.943	rs11084131	ENSG00000275055.1	CTC-471J1.11	-5.6	3.61e-08	1.24e-05	-0.38	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011193	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.943	rs11084132	ENSG00000275055.1	CTC-471J1.11	-5.6	3.61e-08	1.24e-05	-0.38	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011327	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.655	rs4886824	ENSG00000259422.1	RP11-593F23.1	5.6	3.61e-08	1.24e-05	0.29	0.25	Blood metabolite levels;	chr15:76676915	chr15:76174891~76181486:-
LUAD	cis	rs7208859	0.623	rs426434	ENSG00000263603.1	CTD-2349P21.5	-5.6	3.61e-08	1.24e-05	-0.42	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30729469~30731202:+
LUAD	cis	rs36093844	0.8	rs17817331	ENSG00000279742.1	RP11-700A24.1	5.6	3.61e-08	1.24e-05	0.33	0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884295	chr11:85852557~85854943:-
LUAD	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-5.6	3.61e-08	1.24e-05	-0.37	-0.25	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
LUAD	cis	rs910316	1	rs7156328	ENSG00000259138.1	RP11-950C14.7	5.6	3.62e-08	1.24e-05	0.26	0.25	Height;	chr14:75066238	chr14:75127153~75136930:+
LUAD	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	5.6	3.62e-08	1.24e-05	0.47	0.25	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
LUAD	cis	rs7618501	0.602	rs10049087	ENSG00000234667.1	ACTBP13	5.6	3.62e-08	1.24e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr3:50085984	chr3:49873347~49877980:-
LUAD	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	5.6	3.62e-08	1.24e-05	0.49	0.25	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
LUAD	cis	rs7208859	0.623	rs7214570	ENSG00000263603.1	CTD-2349P21.5	-5.6	3.62e-08	1.24e-05	-0.43	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30729469~30731202:+
LUAD	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	5.6	3.63e-08	1.25e-05	0.47	0.25	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
LUAD	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	5.6	3.63e-08	1.25e-05	0.47	0.25	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
LUAD	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	5.6	3.63e-08	1.25e-05	0.29	0.25	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
LUAD	cis	rs62432291	0.681	rs420137	ENSG00000235086.1	FNDC1-IT1	-5.6	3.63e-08	1.25e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159231899	chr6:159240786~159243329:+
LUAD	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	5.6	3.63e-08	1.25e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
LUAD	cis	rs1707322	1	rs11211248	ENSG00000234329.1	RP11-767N6.2	5.6	3.64e-08	1.25e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45651039~45651826:-
LUAD	cis	rs2302464	1	rs57326588	ENSG00000214846.4	RP11-115L11.1	5.6	3.64e-08	1.25e-05	0.59	0.25	Cerebrospinal fluid biomarker levels;	chr4:15723813	chr4:15730962~15731627:-
LUAD	cis	rs712039	0.652	rs829161	ENSG00000276054.1	RP11-378E13.3	-5.6	3.64e-08	1.25e-05	-0.36	-0.25	Tuberculosis;	chr17:37403775	chr17:37386886~37387926:+
LUAD	cis	rs6991838	0.806	rs13262793	ENSG00000200714.1	Y_RNA	5.6	3.64e-08	1.25e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65592731~65592820:+
LUAD	cis	rs2765539	0.887	rs2765541	ENSG00000226172.2	RP4-712E4.1	-5.6	3.65e-08	1.25e-05	-0.3	-0.25	Waist-hip ratio;	chr1:119016034	chr1:119000344~119001392:-
LUAD	cis	rs2404602	0.692	rs8043474	ENSG00000259422.1	RP11-593F23.1	5.6	3.65e-08	1.25e-05	0.29	0.25	Blood metabolite levels;	chr15:76682382	chr15:76174891~76181486:-
LUAD	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-5.6	3.65e-08	1.25e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs160633	ENSG00000230295.1	RP11-458F8.2	-5.6	3.65e-08	1.25e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66063241	chr7:66880708~66882981:+
LUAD	cis	rs4835473	0.932	rs1375986	ENSG00000251600.4	RP11-673E1.1	-5.6	3.65e-08	1.25e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143746048	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs35420625	ENSG00000251600.4	RP11-673E1.1	-5.6	3.65e-08	1.25e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143746089	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs4835009	ENSG00000251600.4	RP11-673E1.1	-5.6	3.65e-08	1.25e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143746130	chr4:143912331~143982454:+
LUAD	cis	rs17684571	0.7	rs13203327	ENSG00000231441.1	RP11-472M19.2	5.6	3.66e-08	1.26e-05	0.37	0.25	Schizophrenia;	chr6:56792498	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs71564854	ENSG00000231441.1	RP11-472M19.2	5.6	3.66e-08	1.26e-05	0.37	0.25	Schizophrenia;	chr6:56794662	chr6:56844002~56864078:+
LUAD	cis	rs1707322	0.964	rs12067716	ENSG00000234329.1	RP11-767N6.2	5.6	3.66e-08	1.26e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45651039~45651826:-
LUAD	cis	rs2276314	0.512	rs12458709	ENSG00000278986.1	RP11-723J4.3	5.6	3.67e-08	1.26e-05	0.26	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35861928	chr18:35972151~35973916:+
LUAD	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-5.6	3.67e-08	1.26e-05	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
LUAD	cis	rs12699921	0.632	rs2723508	ENSG00000279048.1	RP11-511H23.2	-5.6	3.67e-08	1.26e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17778440	chr7:17940503~17942922:+
LUAD	cis	rs1707322	1	rs785507	ENSG00000234329.1	RP11-767N6.2	-5.6	3.67e-08	1.26e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45651039~45651826:-
LUAD	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-5.6	3.68e-08	1.26e-05	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
LUAD	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	5.6	3.68e-08	1.26e-05	0.23	0.25	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
LUAD	cis	rs11098499	0.874	rs13123591	ENSG00000248280.1	RP11-33B1.2	5.6	3.68e-08	1.26e-05	0.32	0.25	Corneal astigmatism;	chr4:119184835	chr4:119440561~119450157:-
LUAD	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	5.6	3.69e-08	1.27e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
LUAD	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-5.6	3.69e-08	1.27e-05	-0.31	-0.25	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
LUAD	cis	rs1707322	1	rs6671754	ENSG00000234329.1	RP11-767N6.2	5.6	3.69e-08	1.27e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45651039~45651826:-
LUAD	cis	rs7923837	0.656	rs2497306	ENSG00000236493.2	EIF2S2P3	-5.6	3.69e-08	1.27e-05	-0.28	-0.25	Multiple sclerosis;Body mass index;	chr10:92725454	chr10:92668745~92669743:-
LUAD	cis	rs2832077	0.943	rs2832091	ENSG00000232855.5	AF131217.1	5.6	3.69e-08	1.27e-05	0.28	0.25	Cognitive test performance;	chr21:28790533	chr21:28439346~28674848:-
LUAD	cis	rs4713118	0.824	rs7759217	ENSG00000219392.1	RP1-265C24.5	-5.6	3.7e-08	1.27e-05	-0.33	-0.25	Parkinson's disease;	chr6:27762684	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.784	rs9468219	ENSG00000219392.1	RP1-265C24.5	-5.6	3.7e-08	1.27e-05	-0.33	-0.25	Parkinson's disease;	chr6:27763976	chr6:28115628~28116551:+
LUAD	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	5.6	3.7e-08	1.27e-05	0.47	0.25	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	5.6	3.7e-08	1.27e-05	0.47	0.25	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
LUAD	cis	rs2288884	1	rs17835749	ENSG00000275055.1	CTC-471J1.11	-5.6	3.7e-08	1.27e-05	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075442	chr19:52049007~52049754:+
LUAD	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
LUAD	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	5.59	3.71e-08	1.27e-05	0.31	0.25	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
LUAD	cis	rs9543976	0.623	rs9544004	ENSG00000261553.4	RP11-29G8.3	5.59	3.71e-08	1.27e-05	0.33	0.25	Diabetic retinopathy;	chr13:75617748	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.588	rs7324195	ENSG00000261553.4	RP11-29G8.3	5.59	3.71e-08	1.27e-05	0.33	0.25	Diabetic retinopathy;	chr13:75618386	chr13:75549773~75807120:+
LUAD	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	5.59	3.71e-08	1.27e-05	0.55	0.25	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
LUAD	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-5.59	3.72e-08	1.27e-05	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
LUAD	cis	rs74233809	1	rs11191543	ENSG00000213277.3	MARCKSL1P1	5.59	3.72e-08	1.28e-05	0.42	0.25	Birth weight;	chr10:103064630	chr10:103175554~103176094:+
LUAD	cis	rs12699921	0.598	rs1404421	ENSG00000279048.1	RP11-511H23.2	-5.59	3.72e-08	1.28e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17777807	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-5.59	3.72e-08	1.28e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
LUAD	cis	rs1823913	0.637	rs6722183	ENSG00000280083.1	RP11-317J9.1	5.59	3.73e-08	1.28e-05	0.29	0.25	Obesity-related traits;	chr2:191333203	chr2:191154118~191156070:-
LUAD	cis	rs8098244	0.557	rs10853571	ENSG00000264745.1	TTC39C-AS1	5.59	3.73e-08	1.28e-05	0.26	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710723	chr18:23994213~24015339:-
LUAD	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-5.59	3.73e-08	1.28e-05	-0.3	-0.25	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
LUAD	cis	rs6687821	0.515	rs6697798	ENSG00000267734.1	RP4-604K5.3	-5.59	3.73e-08	1.28e-05	-0.3	-0.25	Yeast infection;	chr1:87020598	chr1:86932199~86934891:-
LUAD	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-5.59	3.74e-08	1.28e-05	-0.33	-0.25	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
LUAD	cis	rs2337406	1	rs11845269	ENSG00000211974.3	IGHV2-70	-5.59	3.74e-08	1.28e-05	-0.32	-0.25	Alzheimer's disease (late onset);	chr14:106683851	chr14:106723574~106724093:-
LUAD	cis	rs807029	0.533	rs67692077	ENSG00000272572.1	RP11-179B2.2	-5.59	3.74e-08	1.28e-05	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.533	rs12571302	ENSG00000272572.1	RP11-179B2.2	-5.59	3.74e-08	1.28e-05	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100911103~100912739:-
LUAD	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	5.59	3.74e-08	1.28e-05	0.29	0.25	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
LUAD	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	5.59	3.75e-08	1.28e-05	0.35	0.25	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
LUAD	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-5.59	3.75e-08	1.28e-05	-0.29	-0.25	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
LUAD	cis	rs36093844	0.8	rs11826218	ENSG00000279742.1	RP11-700A24.1	-5.59	3.75e-08	1.28e-05	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85857479	chr11:85852557~85854943:-
LUAD	cis	rs11976180	0.517	rs6949375	ENSG00000228960.5	OR2A9P	-5.59	3.75e-08	1.29e-05	-0.41	-0.25	Obesity-related traits;	chr7:144076758	chr7:144294480~144300934:+
LUAD	cis	rs10214930	0.697	rs6970104	ENSG00000235574.1	AC073150.6	5.59	3.75e-08	1.29e-05	0.29	0.25	Hypospadias;	chr7:27624575	chr7:27491682~27492765:-
LUAD	cis	rs12908161	0.853	rs11633788	ENSG00000259728.4	LINC00933	5.59	3.76e-08	1.29e-05	0.32	0.25	Schizophrenia;	chr15:84761911	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs313832	ENSG00000230295.1	RP11-458F8.2	-5.59	3.76e-08	1.29e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66085904	chr7:66880708~66882981:+
LUAD	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	5.59	3.76e-08	1.29e-05	0.3	0.25	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
LUAD	cis	rs7804306	1	rs35143180	ENSG00000233264.2	AC006042.8	5.59	3.76e-08	1.29e-05	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8017141	chr7:7980312~7982228:+
LUAD	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	5.59	3.76e-08	1.29e-05	0.31	0.25	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
LUAD	cis	rs155076	0.711	rs4770131	ENSG00000233325.3	MIPEPP3	-5.59	3.76e-08	1.29e-05	-0.36	-0.25	White matter hyperintensity burden;	chr13:21323329	chr13:21298139~21306373:+
LUAD	cis	rs11051970	0.559	rs10844188	ENSG00000274964.1	RP11-817I4.1	-5.59	3.77e-08	1.29e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32334710	chr12:32339368~32340724:+
LUAD	cis	rs9928842	0.771	rs4888363	ENSG00000280152.1	RP11-331F4.5	5.59	3.77e-08	1.29e-05	0.26	0.25	Alcoholic chronic pancreatitis;	chr16:75243446	chr16:75245994~75250077:-
LUAD	cis	rs7618501	0.669	rs7634084	ENSG00000234667.1	ACTBP13	-5.59	3.77e-08	1.29e-05	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49912401	chr3:49873347~49877980:-
LUAD	cis	rs17684571	0.751	rs13190854	ENSG00000231441.1	RP11-472M19.2	5.59	3.77e-08	1.29e-05	0.37	0.25	Schizophrenia;	chr6:56827020	chr6:56844002~56864078:+
LUAD	cis	rs1707322	0.929	rs785500	ENSG00000234329.1	RP11-767N6.2	-5.59	3.77e-08	1.29e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45651039~45651826:-
LUAD	cis	rs4713118	0.824	rs9366702	ENSG00000219392.1	RP1-265C24.5	-5.59	3.77e-08	1.29e-05	-0.33	-0.25	Parkinson's disease;	chr6:27766691	chr6:28115628~28116551:+
LUAD	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-5.59	3.78e-08	1.29e-05	-0.38	-0.25	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
LUAD	cis	rs9876781	0.507	rs1824362	ENSG00000229759.1	MRPS18AP1	-5.59	3.78e-08	1.29e-05	-0.24	-0.25	Longevity;	chr3:48360459	chr3:48256350~48256938:-
LUAD	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	5.59	3.78e-08	1.29e-05	0.31	0.25	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
LUAD	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-5.59	3.78e-08	1.3e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
LUAD	cis	rs948562	0.744	rs11229479	ENSG00000280010.1	AP001350.4	5.59	3.79e-08	1.3e-05	0.37	0.25	Lymphoma;	chr11:58463158	chr11:58627435~58628528:+
LUAD	cis	rs219780	0.687	rs219790	ENSG00000233818.1	AP000695.4	5.59	3.79e-08	1.3e-05	0.27	0.25	Kidney stones;	chr21:36456564	chr21:36445731~36532408:+
LUAD	cis	rs1150668	0.799	rs853684	ENSG00000219392.1	RP1-265C24.5	-5.59	3.79e-08	1.3e-05	-0.31	-0.25	Pubertal anthropometrics;	chr6:28326773	chr6:28115628~28116551:+
LUAD	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-5.59	3.79e-08	1.3e-05	-0.37	-0.25	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-5.59	3.79e-08	1.3e-05	-0.37	-0.25	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
LUAD	cis	rs7804306	0.826	rs73049290	ENSG00000233264.2	AC006042.8	5.59	3.79e-08	1.3e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7992584	chr7:7980312~7982228:+
LUAD	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-5.59	3.79e-08	1.3e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
LUAD	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-5.59	3.8e-08	1.3e-05	-0.31	-0.25	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
LUAD	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-5.59	3.8e-08	1.3e-05	-0.31	-0.25	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
LUAD	cis	rs2832077	0.943	rs2832094	ENSG00000232855.5	AF131217.1	5.59	3.8e-08	1.3e-05	0.28	0.25	Cognitive test performance;	chr21:28793588	chr21:28439346~28674848:-
LUAD	cis	rs6991838	0.778	rs13261559	ENSG00000200714.1	Y_RNA	5.59	3.8e-08	1.3e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.778	rs7843697	ENSG00000200714.1	Y_RNA	5.59	3.8e-08	1.3e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.778	rs7843724	ENSG00000200714.1	Y_RNA	5.59	3.8e-08	1.3e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65592731~65592820:+
LUAD	cis	rs10761482	0.515	rs2393642	ENSG00000254271.1	RP11-131N11.4	5.59	3.8e-08	1.3e-05	0.27	0.25	Schizophrenia;	chr10:60522732	chr10:60734342~60741828:+
LUAD	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-5.59	3.8e-08	1.3e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-5.59	3.8e-08	1.3e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
LUAD	cis	rs948562	0.519	rs12365107	ENSG00000280010.1	AP001350.4	5.59	3.8e-08	1.3e-05	0.35	0.25	Lymphoma;	chr11:58288226	chr11:58627435~58628528:+
LUAD	cis	rs516805	0.748	rs6908508	ENSG00000279453.1	RP3-425C14.4	5.59	3.81e-08	1.3e-05	0.33	0.25	Lymphocyte counts;	chr6:122387857	chr6:122436789~122439223:-
LUAD	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	5.59	3.81e-08	1.31e-05	0.27	0.25	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	5.59	3.82e-08	1.31e-05	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
LUAD	cis	rs9494145	0.648	rs7758845	ENSG00000232876.1	CTA-212D2.2	-5.59	3.82e-08	1.31e-05	-0.33	-0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135107399	chr6:135055033~135060550:+
LUAD	cis	rs8040855	0.557	rs9744503	ENSG00000259774.1	RP11-182J1.13	-5.59	3.82e-08	1.31e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85180986	chr15:84422618~84425882:+
LUAD	cis	rs172166	0.694	rs9295760	ENSG00000204709.4	LINC01556	5.59	3.82e-08	1.31e-05	0.33	0.25	Cardiac Troponin-T levels;	chr6:28179607	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.669	rs17367297	ENSG00000259422.1	RP11-593F23.1	5.59	3.82e-08	1.31e-05	0.28	0.25	Blood metabolite levels;	chr15:76865685	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs12913810	ENSG00000259422.1	RP11-593F23.1	5.59	3.82e-08	1.31e-05	0.28	0.25	Blood metabolite levels;	chr15:76874334	chr15:76174891~76181486:-
LUAD	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	5.59	3.83e-08	1.31e-05	0.41	0.25	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
LUAD	cis	rs948562	0.573	rs73479901	ENSG00000280010.1	AP001350.4	5.59	3.83e-08	1.31e-05	0.37	0.25	Lymphoma;	chr11:58276171	chr11:58627435~58628528:+
LUAD	cis	rs7181230	0.885	rs28736699	ENSG00000275636.1	RP11-521C20.5	5.59	3.83e-08	1.31e-05	0.33	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40078892~40079347:+
LUAD	cis	rs4604732	0.574	rs111928142	ENSG00000227135.1	GCSAML-AS1	-5.59	3.83e-08	1.31e-05	-0.38	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461927	chr1:247524679~247526752:-
LUAD	cis	rs948562	0.642	rs60483579	ENSG00000280010.1	AP001350.4	5.59	3.83e-08	1.31e-05	0.42	0.25	Lymphoma;	chr11:58660991	chr11:58627435~58628528:+
LUAD	cis	rs62432291	0.681	rs2932988	ENSG00000235086.1	FNDC1-IT1	-5.59	3.83e-08	1.31e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234370	chr6:159240786~159243329:+
LUAD	cis	rs9287719	0.593	rs13009015	ENSG00000243819.4	RN7SL832P	5.59	3.83e-08	1.31e-05	0.27	0.25	Prostate cancer;	chr2:10622992	chr2:10690344~10692099:+
LUAD	cis	rs7804306	1	rs73050929	ENSG00000233264.2	AC006042.8	5.59	3.84e-08	1.31e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8019638	chr7:7980312~7982228:+
LUAD	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-5.59	3.84e-08	1.31e-05	-0.3	-0.25	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
LUAD	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	5.59	3.84e-08	1.31e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	5.59	3.84e-08	1.31e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
LUAD	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	5.59	3.84e-08	1.31e-05	0.28	0.25	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	5.59	3.84e-08	1.32e-05	0.27	0.25	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.692	rs12904198	ENSG00000259422.1	RP11-593F23.1	5.59	3.84e-08	1.32e-05	0.28	0.25	Blood metabolite levels;	chr15:76854637	chr15:76174891~76181486:-
LUAD	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-5.59	3.84e-08	1.32e-05	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
LUAD	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-5.59	3.84e-08	1.32e-05	-0.3	-0.25	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
LUAD	cis	rs4947019	0.609	rs2177092	ENSG00000260273.1	RP11-425D10.10	5.59	3.85e-08	1.32e-05	0.55	0.25	Hematological parameters;	chr6:109365466	chr6:109382795~109383666:+
LUAD	cis	rs2302464	1	rs73123615	ENSG00000214846.4	RP11-115L11.1	5.59	3.85e-08	1.32e-05	0.6	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726553	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs16892276	ENSG00000214846.4	RP11-115L11.1	5.59	3.85e-08	1.32e-05	0.6	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726614	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs60913985	ENSG00000214846.4	RP11-115L11.1	5.59	3.85e-08	1.32e-05	0.6	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726671	chr4:15730962~15731627:-
LUAD	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	5.59	3.85e-08	1.32e-05	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
LUAD	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	5.59	3.85e-08	1.32e-05	0.37	0.25	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
LUAD	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-5.59	3.85e-08	1.32e-05	-0.34	-0.25	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
LUAD	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-5.59	3.86e-08	1.32e-05	-0.32	-0.25	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
LUAD	cis	rs2404602	0.692	rs66866130	ENSG00000259422.1	RP11-593F23.1	5.59	3.86e-08	1.32e-05	0.28	0.25	Blood metabolite levels;	chr15:76836233	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs35170561	ENSG00000259422.1	RP11-593F23.1	5.59	3.86e-08	1.32e-05	0.28	0.25	Blood metabolite levels;	chr15:76838354	chr15:76174891~76181486:-
LUAD	cis	rs12468226	1	rs16824599	ENSG00000272966.1	RP11-686O6.1	5.59	3.86e-08	1.32e-05	0.43	0.25	Urate levels;	chr2:202358243	chr2:202336739~202337200:+
LUAD	cis	rs948562	0.519	rs2096558	ENSG00000280010.1	AP001350.4	5.59	3.86e-08	1.32e-05	0.35	0.25	Lymphoma;	chr11:58286715	chr11:58627435~58628528:+
LUAD	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	5.59	3.86e-08	1.32e-05	0.29	0.25	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
LUAD	cis	rs516805	0.63	rs2606606	ENSG00000279453.1	RP3-425C14.4	-5.59	3.88e-08	1.32e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122201126	chr6:122436789~122439223:-
LUAD	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	5.59	3.88e-08	1.32e-05	0.28	0.25	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
LUAD	cis	rs2919009	0.581	rs61872768	ENSG00000271670.1	RP11-95I16.4	5.59	3.88e-08	1.33e-05	0.32	0.25	Obesity-related traits;	chr10:120934409	chr10:120879256~120880667:-
LUAD	cis	rs896854	0.812	rs4582532	ENSG00000253528.2	RP11-347C18.4	5.59	3.88e-08	1.33e-05	0.24	0.25	Type 2 diabetes;	chr8:94957029	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.812	rs2340586	ENSG00000253528.2	RP11-347C18.4	5.59	3.88e-08	1.33e-05	0.24	0.25	Type 2 diabetes;	chr8:94957033	chr8:94974573~94974853:-
LUAD	cis	rs2412819	0.52	rs17727763	ENSG00000205771.5	CATSPER2P1	-5.59	3.89e-08	1.33e-05	-0.42	-0.25	Lung cancer;	chr15:43623873	chr15:43726918~43747094:-
LUAD	cis	rs11096990	0.855	rs2711990	ENSG00000249207.1	RP11-360F5.1	5.59	3.89e-08	1.33e-05	0.28	0.25	Cognitive function;	chr4:39150116	chr4:39112677~39126818:-
LUAD	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-5.59	3.89e-08	1.33e-05	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
LUAD	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-5.59	3.89e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-5.59	3.89e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-5.59	3.89e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
LUAD	cis	rs9914544	0.628	rs67053020	ENSG00000273018.4	CTD-2303H24.2	-5.59	3.89e-08	1.33e-05	-0.3	-0.25	Educational attainment (years of education);	chr17:18776748	chr17:18511221~18551705:-
LUAD	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	5.59	3.89e-08	1.33e-05	0.25	0.25	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
LUAD	cis	rs4908768	0.539	rs922366	ENSG00000232912.4	RP5-1115A15.1	5.59	3.89e-08	1.33e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8424645~8434838:+
LUAD	cis	rs2302464	1	rs16892272	ENSG00000214846.4	RP11-115L11.1	5.59	3.89e-08	1.33e-05	0.6	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726456	chr4:15730962~15731627:-
LUAD	cis	rs9595908	0.785	rs3848085	ENSG00000212293.1	SNORA16	5.59	3.89e-08	1.33e-05	0.26	0.25	Body mass index;	chr13:32687527	chr13:32420390~32420516:-
LUAD	cis	rs807029	0.577	rs701835	ENSG00000272572.1	RP11-179B2.2	-5.59	3.9e-08	1.33e-05	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100911103~100912739:-
LUAD	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	5.59	3.9e-08	1.33e-05	0.33	0.25	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
LUAD	cis	rs9595908	0.785	rs7332884	ENSG00000212293.1	SNORA16	5.59	3.9e-08	1.33e-05	0.26	0.25	Body mass index;	chr13:32642412	chr13:32420390~32420516:-
LUAD	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	5.59	3.9e-08	1.33e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
LUAD	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-5.59	3.9e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-5.59	3.9e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
LUAD	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-5.59	3.9e-08	1.33e-05	-0.31	-0.25	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
LUAD	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-5.59	3.9e-08	1.33e-05	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-5.59	3.9e-08	1.33e-05	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-5.59	3.9e-08	1.33e-05	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
LUAD	cis	rs6687821	0.515	rs7534355	ENSG00000267734.1	RP4-604K5.3	-5.59	3.9e-08	1.33e-05	-0.3	-0.25	Yeast infection;	chr1:87015237	chr1:86932199~86934891:-
LUAD	cis	rs8177876	0.749	rs12444969	ENSG00000261061.1	RP11-303E16.2	-5.59	3.91e-08	1.33e-05	-0.45	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81030770~81031485:+
LUAD	cis	rs11098499	0.874	rs7661020	ENSG00000248280.1	RP11-33B1.2	5.59	3.91e-08	1.33e-05	0.32	0.25	Corneal astigmatism;	chr4:119185827	chr4:119440561~119450157:-
LUAD	cis	rs944289	0.553	rs1169128	ENSG00000257826.1	RP11-116N8.4	-5.59	3.91e-08	1.34e-05	-0.28	-0.25	Thyroid cancer;	chr14:36151659	chr14:36061026~36067190:-
LUAD	cis	rs6687821	0.515	rs1112998	ENSG00000267734.1	RP4-604K5.3	-5.59	3.91e-08	1.34e-05	-0.3	-0.25	Yeast infection;	chr1:86983198	chr1:86932199~86934891:-
LUAD	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-5.59	3.91e-08	1.34e-05	-0.27	-0.25	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-5.59	3.91e-08	1.34e-05	-0.27	-0.25	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
LUAD	cis	rs800160	0.777	rs2651783	ENSG00000236264.4	RPL26P30	-5.58	3.92e-08	1.34e-05	-0.33	-0.25	Bacteremia;	chr11:2324660	chr11:2335132~2335776:-
LUAD	cis	rs7208859	0.623	rs9912440	ENSG00000263603.1	CTD-2349P21.5	-5.58	3.92e-08	1.34e-05	-0.43	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30729469~30731202:+
LUAD	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	5.58	3.92e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
LUAD	cis	rs293748	0.771	rs151945	ENSG00000250155.1	CTD-2353F22.1	-5.58	3.93e-08	1.34e-05	-0.34	-0.25	Obesity-related traits;	chr5:36838494	chr5:36666214~36725195:-
LUAD	cis	rs2404602	0.692	rs55676827	ENSG00000259422.1	RP11-593F23.1	5.58	3.93e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76669375	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs10444858	ENSG00000259422.1	RP11-593F23.1	5.58	3.93e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76670163	chr15:76174891~76181486:-
LUAD	cis	rs7176527	0.579	rs366717	ENSG00000188388.10	GOLGA6L3	5.58	3.93e-08	1.34e-05	0.31	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85240472~85247170:+
LUAD	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
LUAD	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	5.58	3.93e-08	1.34e-05	0.29	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
LUAD	cis	rs11742741	0.579	rs4701422	ENSG00000248874.4	C5orf17	-5.58	3.93e-08	1.34e-05	-0.31	-0.25	Educational attainment;	chr5:24108058	chr5:23951348~24178263:+
LUAD	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	5.58	3.93e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
LUAD	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	5.58	3.93e-08	1.34e-05	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
LUAD	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-5.58	3.94e-08	1.34e-05	-0.27	-0.25	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
LUAD	cis	rs2404602	0.669	rs12595313	ENSG00000259422.1	RP11-593F23.1	5.58	3.94e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76686029	chr15:76174891~76181486:-
LUAD	cis	rs11651753	0.613	rs3096	ENSG00000264920.1	RP11-6N17.4	-5.58	3.94e-08	1.34e-05	-0.31	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47952066	chr17:47891255~47895812:-
LUAD	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	5.58	3.95e-08	1.35e-05	0.28	0.25	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
LUAD	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-5.58	3.95e-08	1.35e-05	-0.31	-0.25	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
LUAD	cis	rs891378	1	rs10864180	ENSG00000274245.1	RP11-357P18.2	-5.58	3.95e-08	1.35e-05	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272416	chr1:207372559~207373252:+
LUAD	cis	rs944289	0.553	rs1169127	ENSG00000257826.1	RP11-116N8.4	-5.58	3.95e-08	1.35e-05	-0.28	-0.25	Thyroid cancer;	chr14:36151474	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.515	rs1169130	ENSG00000257826.1	RP11-116N8.4	-5.58	3.95e-08	1.35e-05	-0.28	-0.25	Thyroid cancer;	chr14:36152701	chr14:36061026~36067190:-
LUAD	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	5.58	3.95e-08	1.35e-05	0.25	0.25	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	5.58	3.95e-08	1.35e-05	0.25	0.25	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	5.58	3.95e-08	1.35e-05	0.25	0.25	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
LUAD	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	5.58	3.95e-08	1.35e-05	0.3	0.25	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
LUAD	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	5.58	3.96e-08	1.35e-05	0.3	0.25	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
LUAD	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	5.58	3.96e-08	1.35e-05	0.32	0.25	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
LUAD	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	5.58	3.96e-08	1.35e-05	0.41	0.25	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
LUAD	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	5.58	3.96e-08	1.35e-05	0.35	0.25	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	5.58	3.96e-08	1.35e-05	0.35	0.25	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	5.58	3.96e-08	1.35e-05	0.35	0.25	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
LUAD	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-5.58	3.96e-08	1.35e-05	-0.3	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
LUAD	cis	rs7804306	0.826	rs56017154	ENSG00000233264.2	AC006042.8	5.58	3.97e-08	1.35e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7995282	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049293	ENSG00000233264.2	AC006042.8	5.58	3.97e-08	1.35e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999017	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049297	ENSG00000233264.2	AC006042.8	5.58	3.97e-08	1.35e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999429	chr7:7980312~7982228:+
LUAD	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	5.58	3.97e-08	1.35e-05	0.46	0.25	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
LUAD	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-5.58	3.97e-08	1.35e-05	-0.37	-0.25	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
LUAD	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-5.58	3.97e-08	1.35e-05	-0.31	-0.25	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
LUAD	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-5.58	3.97e-08	1.35e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
LUAD	cis	rs8040855	0.599	rs6496792	ENSG00000259774.1	RP11-182J1.13	-5.58	3.97e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85182514	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.599	rs6496793	ENSG00000259774.1	RP11-182J1.13	-5.58	3.97e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85182515	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.599	rs6496795	ENSG00000259774.1	RP11-182J1.13	-5.58	3.97e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85182622	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.599	rs4577058	ENSG00000259774.1	RP11-182J1.13	-5.58	3.97e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85183227	chr15:84422618~84425882:+
LUAD	cis	rs2412819	0.597	rs541871	ENSG00000249839.1	AC011330.5	-5.58	3.97e-08	1.35e-05	-0.38	-0.25	Lung cancer;	chr15:43868656	chr15:43663654~43684339:-
LUAD	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-5.58	3.97e-08	1.35e-05	-0.31	-0.25	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
LUAD	cis	rs2243480	1	rs465359	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66093177	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66093180	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66093199	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66093386	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66100154	chr7:66880708~66882981:+
LUAD	cis	rs8040855	0.599	rs1964724	ENSG00000259774.1	RP11-182J1.13	-5.58	3.98e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85183269	chr15:84422618~84425882:+
LUAD	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	5.58	3.98e-08	1.36e-05	0.31	0.25	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	5.58	3.98e-08	1.36e-05	0.31	0.25	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	5.58	3.98e-08	1.36e-05	0.31	0.25	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
LUAD	cis	rs2288884	1	rs56808319	ENSG00000275055.1	CTC-471J1.11	-5.58	3.99e-08	1.36e-05	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074621	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.716	rs67920045	ENSG00000259422.1	RP11-593F23.1	5.58	3.99e-08	1.36e-05	0.28	0.25	Blood metabolite levels;	chr15:76507743	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-5.58	3.99e-08	1.36e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
LUAD	cis	rs2288884	0.945	rs78336183	ENSG00000275055.1	CTC-471J1.11	-5.58	3.99e-08	1.36e-05	-0.36	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058230	chr19:52049007~52049754:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000224373.3	IGHV4-59	5.58	3.99e-08	1.36e-05	0.16	0.25	Kawasaki disease;	chr14:106787730	chr14:106627249~106627825:-
LUAD	cis	rs896854	0.654	rs2011566	ENSG00000253528.2	RP11-347C18.4	5.58	4e-08	1.36e-05	0.24	0.25	Type 2 diabetes;	chr8:94959693	chr8:94974573~94974853:-
LUAD	cis	rs516805	0.667	rs2606598	ENSG00000279453.1	RP3-425C14.4	5.58	4e-08	1.36e-05	0.33	0.25	Lymphocyte counts;	chr6:122206501	chr6:122436789~122439223:-
LUAD	cis	rs4767841	0.552	rs10849682	ENSG00000248636.5	RP11-768F21.1	-5.58	4e-08	1.36e-05	-0.29	-0.25	Urgency urinary incontinence;	chr12:119622325	chr12:119387987~119668079:-
LUAD	cis	rs2404602	0.692	rs7169663	ENSG00000259422.1	RP11-593F23.1	5.58	4e-08	1.36e-05	0.28	0.25	Blood metabolite levels;	chr15:76900502	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs35999717	ENSG00000259422.1	RP11-593F23.1	5.58	4e-08	1.36e-05	0.28	0.25	Blood metabolite levels;	chr15:76901026	chr15:76174891~76181486:-
LUAD	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-5.58	4.01e-08	1.36e-05	-0.3	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
LUAD	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	5.58	4.01e-08	1.36e-05	0.3	0.25	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
LUAD	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	5.58	4.01e-08	1.36e-05	0.35	0.25	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	5.58	4.01e-08	1.36e-05	0.35	0.25	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	5.58	4.01e-08	1.36e-05	0.35	0.25	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	5.58	4.01e-08	1.36e-05	0.35	0.25	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
LUAD	cis	rs3096299	0.702	rs2086824	ENSG00000274627.1	RP11-104N10.2	-5.58	4.01e-08	1.37e-05	-0.23	-0.25	Multiple myeloma (IgH translocation);	chr16:89404838	chr16:89516797~89522217:+
LUAD	cis	rs155076	0.711	rs9550724	ENSG00000233325.3	MIPEPP3	-5.58	4.01e-08	1.37e-05	-0.36	-0.25	White matter hyperintensity burden;	chr13:21310891	chr13:21298139~21306373:+
LUAD	cis	rs9652601	0.691	rs998592	ENSG00000274038.1	RP11-66H6.4	5.58	4.02e-08	1.37e-05	0.3	0.25	Systemic lupus erythematosus;	chr16:11105821	chr16:11056556~11057034:+
LUAD	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-5.58	4.02e-08	1.37e-05	-0.26	-0.25	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-5.58	4.02e-08	1.37e-05	-0.26	-0.25	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
LUAD	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	5.58	4.02e-08	1.37e-05	0.29	0.25	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
LUAD	cis	rs113835537	0.627	rs4630309	ENSG00000255517.5	CTD-3074O7.5	5.58	4.02e-08	1.37e-05	0.31	0.25	Airway imaging phenotypes;	chr11:66565601	chr11:66473490~66480233:-
LUAD	cis	rs11089937	0.524	rs2877021	ENSG00000211638.2	IGLV8-61	-5.58	4.02e-08	1.37e-05	-0.27	-0.25	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22098700~22099212:+
LUAD	cis	rs2749097	1	rs11208259	ENSG00000244256.3	RN7SL130P	-5.58	4.03e-08	1.37e-05	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63657549	chr1:63655743~63656047:+
LUAD	cis	rs910316	1	rs10140851	ENSG00000259138.1	RP11-950C14.7	5.58	4.03e-08	1.37e-05	0.26	0.25	Height;	chr14:75045909	chr14:75127153~75136930:+
LUAD	cis	rs36093844	0.752	rs17744675	ENSG00000279742.1	RP11-700A24.1	5.58	4.03e-08	1.37e-05	0.31	0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882863	chr11:85852557~85854943:-
LUAD	cis	rs155076	0.938	rs261375	ENSG00000233325.3	MIPEPP3	-5.58	4.03e-08	1.37e-05	-0.4	-0.25	White matter hyperintensity burden;	chr13:21297743	chr13:21298139~21306373:+
LUAD	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-5.58	4.03e-08	1.37e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-5.58	4.03e-08	1.37e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-5.58	4.03e-08	1.37e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
LUAD	cis	rs6687821	0.515	rs7552285	ENSG00000267734.1	RP4-604K5.3	-5.58	4.03e-08	1.37e-05	-0.3	-0.25	Yeast infection;	chr1:87017482	chr1:86932199~86934891:-
LUAD	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-5.58	4.04e-08	1.37e-05	-0.29	-0.25	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
LUAD	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-5.58	4.04e-08	1.37e-05	-0.34	-0.25	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
LUAD	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-5.58	4.04e-08	1.37e-05	-0.29	-0.25	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
LUAD	cis	rs9807989	0.811	rs11688559	ENSG00000234389.1	AC007278.3	5.58	4.04e-08	1.37e-05	0.24	0.25	Asthma;	chr2:102353453	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs11688568	ENSG00000234389.1	AC007278.3	5.58	4.04e-08	1.37e-05	0.24	0.25	Asthma;	chr2:102353489	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs11688573	ENSG00000234389.1	AC007278.3	5.58	4.04e-08	1.37e-05	0.24	0.25	Asthma;	chr2:102353511	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs11689730	ENSG00000234389.1	AC007278.3	5.58	4.04e-08	1.37e-05	0.24	0.25	Asthma;	chr2:102353524	chr2:102438713~102440475:+
LUAD	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	5.58	4.04e-08	1.37e-05	0.3	0.25	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	5.58	4.04e-08	1.37e-05	0.3	0.25	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
LUAD	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	5.58	4.04e-08	1.37e-05	0.27	0.25	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
LUAD	cis	rs1707322	1	rs10890382	ENSG00000234329.1	RP11-767N6.2	5.58	4.04e-08	1.38e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45651039~45651826:-
LUAD	cis	rs6687821	0.515	rs2764427	ENSG00000267734.1	RP4-604K5.3	-5.58	4.06e-08	1.38e-05	-0.3	-0.25	Yeast infection;	chr1:87076636	chr1:86932199~86934891:-
LUAD	cis	rs8031584	1	rs35239376	ENSG00000260382.1	RP11-540B6.2	5.58	4.06e-08	1.38e-05	0.32	0.25	Huntington's disease progression;	chr15:30998335	chr15:30882267~30883231:-
LUAD	cis	rs7662987	0.793	rs7669660	ENSG00000272777.1	RP11-571L19.8	5.58	4.06e-08	1.38e-05	0.39	0.25	Smoking initiation;	chr4:99071451	chr4:99067256~99068125:-
LUAD	cis	rs7662987	0.793	rs12106	ENSG00000272777.1	RP11-571L19.8	5.58	4.06e-08	1.38e-05	0.39	0.25	Smoking initiation;	chr4:99072199	chr4:99067256~99068125:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000230295.1	RP11-458F8.2	-5.58	4.06e-08	1.38e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:65977771	chr7:66880708~66882981:+
LUAD	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	5.58	4.06e-08	1.38e-05	0.37	0.25	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
LUAD	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	5.58	4.06e-08	1.38e-05	0.29	0.25	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
LUAD	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-5.58	4.06e-08	1.38e-05	-0.33	-0.25	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
LUAD	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-5.58	4.07e-08	1.38e-05	-0.29	-0.25	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
LUAD	cis	rs9910055	0.762	rs184478	ENSG00000267080.4	ASB16-AS1	5.58	4.07e-08	1.38e-05	0.22	0.25	Total body bone mineral density;	chr17:44132383	chr17:44175973~44186717:-
LUAD	cis	rs2288884	0.943	rs75722407	ENSG00000275055.1	CTC-471J1.11	-5.58	4.07e-08	1.38e-05	-0.39	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021989	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-5.58	4.08e-08	1.39e-05	-0.34	-0.25	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
LUAD	cis	rs1707322	1	rs1707337	ENSG00000234329.1	RP11-767N6.2	-5.58	4.08e-08	1.39e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1768807	ENSG00000234329.1	RP11-767N6.2	-5.58	4.08e-08	1.39e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45651039~45651826:-
LUAD	cis	rs9500256	0.655	rs12191043	ENSG00000215190.7	LINC00680	-5.58	4.08e-08	1.39e-05	-0.32	-0.25	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57946074~57961501:-
LUAD	cis	rs1799949	0.602	rs8176235	ENSG00000267681.1	CTD-3199J23.6	-5.58	4.08e-08	1.39e-05	-0.31	-0.25	Menopause (age at onset);	chr17:43067543	chr17:43144956~43145255:+
LUAD	cis	rs2404602	0.692	rs12911174	ENSG00000259422.1	RP11-593F23.1	5.58	4.08e-08	1.39e-05	0.28	0.25	Blood metabolite levels;	chr15:76857602	chr15:76174891~76181486:-
LUAD	cis	rs62158211	0.955	rs1823125	ENSG00000234997.1	AC016745.3	5.58	4.08e-08	1.39e-05	0.3	0.25	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113424495~113425324:+
LUAD	cis	rs8031584	0.541	rs2955797	ENSG00000260382.1	RP11-540B6.2	-5.58	4.08e-08	1.39e-05	-0.28	-0.25	Huntington's disease progression;	chr15:30918778	chr15:30882267~30883231:-
LUAD	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-5.58	4.08e-08	1.39e-05	-0.34	-0.25	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
LUAD	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	5.58	4.09e-08	1.39e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
LUAD	cis	rs17684571	0.7	rs13194904	ENSG00000231441.1	RP11-472M19.2	5.58	4.09e-08	1.39e-05	0.37	0.25	Schizophrenia;	chr6:56811443	chr6:56844002~56864078:+
LUAD	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	5.58	4.09e-08	1.39e-05	0.25	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
LUAD	cis	rs1874124	0.778	rs1335920	ENSG00000272823.1	RP11-295M18.6	-5.58	4.1e-08	1.39e-05	-0.37	-0.25	Cholesterol, total;	chr1:220844946	chr1:220828676~220829211:-
LUAD	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	5.58	4.1e-08	1.39e-05	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
LUAD	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-5.58	4.1e-08	1.39e-05	-0.29	-0.25	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
LUAD	cis	rs909685	1	rs2069235	ENSG00000280216.1	RP3-333H23.9	5.58	4.1e-08	1.39e-05	0.27	0.25	Rheumatoid arthritis;	chr22:39351775	chr22:39379610~39380015:+
LUAD	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-5.58	4.11e-08	1.4e-05	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-5.58	4.11e-08	1.4e-05	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
LUAD	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-5.58	4.11e-08	1.4e-05	-0.31	-0.25	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
LUAD	cis	rs4947019	0.609	rs116647873	ENSG00000260273.1	RP11-425D10.10	5.58	4.11e-08	1.4e-05	0.54	0.25	Hematological parameters;	chr6:109398216	chr6:109382795~109383666:+
LUAD	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	5.58	4.11e-08	1.4e-05	0.31	0.25	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
LUAD	cis	rs2263638	0.565	rs2488794	ENSG00000228701.1	TNKS2-AS1	-5.58	4.11e-08	1.4e-05	-0.39	-0.25	Airflow obstruction;	chr10:92408060	chr10:91782839~91798291:-
LUAD	cis	rs9287719	0.625	rs12473787	ENSG00000243819.4	RN7SL832P	5.58	4.11e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10577068	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs2160258	ENSG00000243819.4	RN7SL832P	5.58	4.11e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10577095	chr2:10690344~10692099:+
LUAD	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	5.58	4.12e-08	1.4e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
LUAD	cis	rs1154275	0.537	rs6789210	ENSG00000242770.2	RP11-180K7.1	5.58	4.12e-08	1.4e-05	0.25	0.25	Takotsubo syndrome;	chr3:112797481	chr3:112802478~112812819:+
LUAD	cis	rs9287719	0.649	rs9973456	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578004	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10175884	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578408	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10190673	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578492	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10198971	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578573	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10190774	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578620	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10188373	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578676	chr2:10690344~10692099:+
LUAD	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	5.58	4.13e-08	1.4e-05	0.31	0.25	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
LUAD	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	5.58	4.13e-08	1.4e-05	0.26	0.25	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
LUAD	cis	rs1707322	1	rs1612419	ENSG00000234329.1	RP11-767N6.2	-5.57	4.14e-08	1.4e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45651039~45651826:-
LUAD	cis	rs2404602	0.619	rs7342603	ENSG00000259422.1	RP11-593F23.1	5.57	4.14e-08	1.41e-05	0.28	0.25	Blood metabolite levels;	chr15:76690284	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs8024476	ENSG00000259422.1	RP11-593F23.1	5.57	4.14e-08	1.41e-05	0.28	0.25	Blood metabolite levels;	chr15:76691613	chr15:76174891~76181486:-
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-5.57	4.14e-08	1.41e-05	-0.53	-0.25	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
LUAD	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-5.57	4.14e-08	1.41e-05	-0.23	-0.25	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
LUAD	cis	rs10761482	0.5	rs6479716	ENSG00000254271.1	RP11-131N11.4	5.57	4.14e-08	1.41e-05	0.27	0.25	Schizophrenia;	chr10:60542800	chr10:60734342~60741828:+
LUAD	cis	rs367615	0.68	rs2256556	ENSG00000249476.1	CTD-2587M2.1	-5.57	4.15e-08	1.41e-05	-0.31	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109629206	chr5:109237120~109326369:-
LUAD	cis	rs35740288	0.862	rs11637444	ENSG00000202081.1	RNU6-1280P	5.57	4.15e-08	1.41e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85767957	chr15:85651522~85651628:-
LUAD	cis	rs8098244	0.638	rs12965685	ENSG00000264745.1	TTC39C-AS1	5.57	4.15e-08	1.41e-05	0.25	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23861753	chr18:23994213~24015339:-
LUAD	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-5.57	4.15e-08	1.41e-05	-0.29	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
LUAD	cis	rs12468226	0.873	rs79071680	ENSG00000272966.1	RP11-686O6.1	5.57	4.15e-08	1.41e-05	0.44	0.25	Urate levels;	chr2:202191520	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.873	rs79860867	ENSG00000272966.1	RP11-686O6.1	5.57	4.15e-08	1.41e-05	0.44	0.25	Urate levels;	chr2:202192397	chr2:202336739~202337200:+
LUAD	cis	rs948562	0.711	rs12361623	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58454953	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs12362108	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58456879	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229472	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58458778	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs12362953	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58459432	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229475	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58459910	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.725	rs11229476	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58461120	chr11:58627435~58628528:+
LUAD	cis	rs8103033	0.786	rs6508899	ENSG00000226025.8	LGALS17A	5.57	4.15e-08	1.41e-05	0.27	0.25	Obesity-related traits;	chr19:39661982	chr19:39679374~39686373:+
LUAD	cis	rs7044106	0.708	rs959558	ENSG00000238181.2	AHCYP2	-5.57	4.16e-08	1.41e-05	-0.31	-0.25	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120720673~120721972:+
LUAD	cis	rs6772849	0.93	rs12487604	ENSG00000242551.2	POU5F1P6	-5.57	4.16e-08	1.41e-05	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128618232	chr3:128674735~128677005:-
LUAD	cis	rs1075265	0.518	rs13414393	ENSG00000272156.1	RP11-477N3.1	-5.57	4.17e-08	1.41e-05	-0.31	-0.25	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54082554~54085066:+
LUAD	cis	rs11700536	1	rs11700536	ENSG00000236663.1	AP001631.9	-5.57	4.17e-08	1.41e-05	-0.28	-0.25	Interleukin-18 levels;	chr21:43138577	chr21:43140523~43141092:-
LUAD	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	5.57	4.17e-08	1.42e-05	0.31	0.25	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
LUAD	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-5.57	4.17e-08	1.42e-05	-0.33	-0.25	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
LUAD	cis	rs7246657	0.722	rs2972447	ENSG00000276846.1	CTD-3220F14.3	-5.57	4.17e-08	1.42e-05	-0.33	-0.25	Coronary artery calcification;	chr19:37638835	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.678	rs2972446	ENSG00000276846.1	CTD-3220F14.3	-5.57	4.17e-08	1.42e-05	-0.33	-0.25	Coronary artery calcification;	chr19:37638992	chr19:37314868~37315620:-
LUAD	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-5.57	4.17e-08	1.42e-05	-0.2	-0.25	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
LUAD	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	5.57	4.17e-08	1.42e-05	0.31	0.25	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
LUAD	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-5.57	4.18e-08	1.42e-05	-0.31	-0.25	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
LUAD	cis	rs1707322	1	rs785510	ENSG00000234329.1	RP11-767N6.2	-5.57	4.19e-08	1.42e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45651039~45651826:-
LUAD	cis	rs12188164	0.686	rs72711367	ENSG00000225138.6	CTD-2228K2.7	5.57	4.19e-08	1.42e-05	0.25	0.25	Cystic fibrosis severity;	chr5:418379	chr5:473236~480884:+
LUAD	cis	rs7937890	0.732	rs7946902	ENSG00000254418.1	RP11-21L19.1	-5.57	4.21e-08	1.43e-05	-0.29	-0.25	Mitochondrial DNA levels;	chr11:14251762	chr11:14262846~14273691:-
LUAD	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	5.57	4.21e-08	1.43e-05	0.31	0.25	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
LUAD	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	5.57	4.22e-08	1.43e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
LUAD	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	5.57	4.23e-08	1.43e-05	0.31	0.25	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
LUAD	cis	rs17684571	0.751	rs35073881	ENSG00000231441.1	RP11-472M19.2	5.57	4.23e-08	1.43e-05	0.37	0.25	Schizophrenia;	chr6:56842410	chr6:56844002~56864078:+
LUAD	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-5.57	4.24e-08	1.44e-05	-0.31	-0.25	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
LUAD	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-5.57	4.24e-08	1.44e-05	-0.35	-0.25	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-5.57	4.24e-08	1.44e-05	-0.28	-0.25	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
LUAD	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	5.57	4.24e-08	1.44e-05	0.39	0.25	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
LUAD	cis	rs2832077	0.943	rs2832084	ENSG00000232855.5	AF131217.1	5.57	4.24e-08	1.44e-05	0.28	0.25	Cognitive test performance;	chr21:28782476	chr21:28439346~28674848:-
LUAD	cis	rs1667284	1	rs1667283	ENSG00000266521.1	RP11-650P15.1	5.57	4.24e-08	1.44e-05	0.29	0.25	Problematic alcohol use in trauma-exposed individuals;	chr18:31643658	chr18:31496645~31497195:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000206090.4	AP000350.7	5.57	4.25e-08	1.44e-05	0.29	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23939998~23942798:+
LUAD	cis	rs7968440	1	rs2731442	ENSG00000200428.1	Y_RNA	-5.57	4.25e-08	1.44e-05	-0.31	-0.25	Fibrinogen;	chr12:50660872	chr12:50743568~50743684:+
LUAD	cis	rs516805	0.673	rs561953	ENSG00000279453.1	RP3-425C14.4	-5.57	4.26e-08	1.44e-05	-0.32	-0.25	Lymphocyte counts;	chr6:122440341	chr6:122436789~122439223:-
LUAD	cis	rs17684571	0.7	rs4457154	ENSG00000231441.1	RP11-472M19.2	5.57	4.26e-08	1.44e-05	0.37	0.25	Schizophrenia;	chr6:56805653	chr6:56844002~56864078:+
LUAD	cis	rs30380	1	rs246454	ENSG00000272109.1	CTD-2260A17.3	-5.57	4.26e-08	1.44e-05	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.922	rs246453	ENSG00000272109.1	CTD-2260A17.3	-5.57	4.26e-08	1.44e-05	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96804353~96806105:+
LUAD	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	5.57	4.27e-08	1.44e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	5.57	4.27e-08	1.44e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
LUAD	cis	rs2749097	1	rs4643	ENSG00000244256.3	RN7SL130P	-5.57	4.27e-08	1.45e-05	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63659768	chr1:63655743~63656047:+
LUAD	cis	rs9847710	0.901	rs2564964	ENSG00000242142.1	SERBP1P3	5.57	4.27e-08	1.45e-05	0.27	0.25	Ulcerative colitis;	chr3:53004102	chr3:53064283~53065091:-
LUAD	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	5.57	4.28e-08	1.45e-05	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
LUAD	cis	rs1707322	1	rs7517560	ENSG00000234329.1	RP11-767N6.2	5.57	4.28e-08	1.45e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45651039~45651826:-
LUAD	cis	rs1876905	0.68	rs1150082	ENSG00000272356.1	RP5-1112D6.8	-5.57	4.28e-08	1.45e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111309203~111313517:+
LUAD	cis	rs807029	0.577	rs11190787	ENSG00000272572.1	RP11-179B2.2	-5.57	4.28e-08	1.45e-05	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100911103~100912739:-
LUAD	cis	rs867371	0.896	rs8033831	ENSG00000259429.4	UBE2Q2P2	-5.57	4.28e-08	1.45e-05	-0.21	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82355142~82420075:+
LUAD	cis	rs1707322	1	rs785498	ENSG00000234329.1	RP11-767N6.2	-5.57	4.28e-08	1.45e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45651039~45651826:-
LUAD	cis	rs9595908	0.709	rs3752476	ENSG00000212293.1	SNORA16	-5.57	4.29e-08	1.45e-05	-0.25	-0.25	Body mass index;	chr13:32770965	chr13:32420390~32420516:-
LUAD	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	5.57	4.3e-08	1.45e-05	0.35	0.25	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	5.57	4.3e-08	1.46e-05	0.31	0.25	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
LUAD	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	5.57	4.3e-08	1.46e-05	0.36	0.25	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
LUAD	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-5.57	4.3e-08	1.46e-05	-0.35	-0.25	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
LUAD	cis	rs7430456	0.81	rs6443489	ENSG00000228221.4	LINC00578	5.57	4.31e-08	1.46e-05	0.29	0.25	Breast cancer;	chr3:177737489	chr3:177441921~177752305:+
LUAD	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-5.57	4.31e-08	1.46e-05	-0.34	-0.25	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
LUAD	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-5.57	4.32e-08	1.46e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
LUAD	cis	rs601999	1	rs601999	ENSG00000108785.7	HSD17B1P1	5.57	4.32e-08	1.46e-05	0.28	0.25	Parkinson's disease;	chr17:42546140	chr17:42546764~42548706:+
LUAD	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
LUAD	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	5.57	4.33e-08	1.46e-05	0.33	0.25	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
LUAD	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	5.57	4.33e-08	1.46e-05	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
LUAD	cis	rs17684571	0.938	rs16888124	ENSG00000231441.1	RP11-472M19.2	5.57	4.33e-08	1.46e-05	0.33	0.25	Schizophrenia;	chr6:56700826	chr6:56844002~56864078:+
LUAD	cis	rs6687821	0.515	rs4656139	ENSG00000267734.1	RP4-604K5.3	-5.57	4.33e-08	1.46e-05	-0.3	-0.25	Yeast infection;	chr1:87059180	chr1:86932199~86934891:-
LUAD	cis	rs6504622	0.967	rs9889762	ENSG00000262879.4	RP11-156P1.3	5.57	4.33e-08	1.46e-05	0.28	0.25	Orofacial clefts;	chr17:46949000	chr17:46984045~47100323:-
LUAD	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-5.57	4.33e-08	1.47e-05	-0.32	-0.25	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000211974.3	IGHV2-70	5.57	4.33e-08	1.47e-05	0.27	0.25	Kawasaki disease;	chr14:106718572	chr14:106723574~106724093:-
LUAD	cis	rs6772849	0.662	rs12494372	ENSG00000242551.2	POU5F1P6	-5.57	4.34e-08	1.47e-05	-0.29	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128682850	chr3:128674735~128677005:-
LUAD	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	5.57	4.34e-08	1.47e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
LUAD	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-5.57	4.35e-08	1.47e-05	-0.26	-0.25	Height;	chr11:118809363	chr11:118791254~118793137:+
LUAD	cis	rs6095360	0.727	rs13036715	ENSG00000222365.1	SNORD12B	-5.57	4.35e-08	1.47e-05	-0.28	-0.25	Intelligence (multi-trait analysis);	chr20:49201278	chr20:49280319~49280409:+
LUAD	cis	rs6687821	0.515	rs7524526	ENSG00000267734.1	RP4-604K5.3	-5.57	4.35e-08	1.47e-05	-0.3	-0.25	Yeast infection;	chr1:87027154	chr1:86932199~86934891:-
LUAD	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-5.57	4.35e-08	1.47e-05	-0.34	-0.25	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
LUAD	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	5.57	4.36e-08	1.47e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
LUAD	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	5.57	4.36e-08	1.47e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
LUAD	cis	rs12188164	0.686	rs72711369	ENSG00000225138.6	CTD-2228K2.7	5.57	4.36e-08	1.47e-05	0.25	0.25	Cystic fibrosis severity;	chr5:420402	chr5:473236~480884:+
LUAD	cis	rs12188164	0.686	rs72711370	ENSG00000225138.6	CTD-2228K2.7	5.57	4.36e-08	1.47e-05	0.25	0.25	Cystic fibrosis severity;	chr5:420942	chr5:473236~480884:+
LUAD	cis	rs12188164	0.714	rs11741954	ENSG00000225138.6	CTD-2228K2.7	5.57	4.36e-08	1.47e-05	0.25	0.25	Cystic fibrosis severity;	chr5:421340	chr5:473236~480884:+
LUAD	cis	rs17818399	0.533	rs13420857	ENSG00000279254.1	RP11-536C12.1	5.57	4.36e-08	1.47e-05	0.26	0.25	Height;	chr2:46570866	chr2:46668870~46670778:+
LUAD	cis	rs4908760	0.792	rs11121215	ENSG00000232912.4	RP5-1115A15.1	5.56	4.36e-08	1.47e-05	0.23	0.25	Vitiligo;	chr1:8673069	chr1:8424645~8434838:+
LUAD	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	5.56	4.36e-08	1.47e-05	0.24	0.25	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
LUAD	cis	rs12699921	0.632	rs2691557	ENSG00000279048.1	RP11-511H23.2	-5.56	4.37e-08	1.48e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17902974	chr7:17940503~17942922:+
LUAD	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	5.56	4.37e-08	1.48e-05	0.3	0.25	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
LUAD	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	5.56	4.37e-08	1.48e-05	0.29	0.25	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	5.56	4.37e-08	1.48e-05	0.29	0.25	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
LUAD	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	5.56	4.37e-08	1.48e-05	0.3	0.25	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
LUAD	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-5.56	4.38e-08	1.48e-05	-0.3	-0.25	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-5.56	4.38e-08	1.48e-05	-0.3	-0.25	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
LUAD	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-5.56	4.39e-08	1.49e-05	-0.26	-0.25	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-5.56	4.39e-08	1.49e-05	-0.26	-0.25	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
LUAD	cis	rs4908760	0.827	rs10864360	ENSG00000232912.4	RP5-1115A15.1	5.56	4.4e-08	1.49e-05	0.22	0.25	Vitiligo;	chr1:8664463	chr1:8424645~8434838:+
LUAD	cis	rs8103033	0.676	rs1988274	ENSG00000226025.8	LGALS17A	-5.56	4.4e-08	1.49e-05	-0.28	-0.25	Obesity-related traits;	chr19:39664258	chr19:39679374~39686373:+
LUAD	cis	rs180730	0.561	rs3099888	ENSG00000251609.2	SETP12	-5.56	4.4e-08	1.49e-05	-0.32	-0.25	Fasting plasma glucose;	chr4:120882580	chr4:120895494~120897083:-
LUAD	cis	rs7727544	0.548	rs4705938	ENSG00000233006.5	AC034220.3	5.56	4.4e-08	1.49e-05	0.22	0.25	Blood metabolite levels;	chr5:132358384	chr5:132311285~132369916:-
LUAD	cis	rs1707322	0.896	rs785512	ENSG00000234329.1	RP11-767N6.2	-5.56	4.41e-08	1.49e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45651039~45651826:-
LUAD	cis	rs7208859	0.528	rs3764416	ENSG00000263531.1	RP13-753N3.1	-5.56	4.41e-08	1.49e-05	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30863921~30864940:-
LUAD	cis	rs10050311	0.79	rs17012132	ENSG00000251411.1	RP11-397E7.4	-5.56	4.42e-08	1.49e-05	-0.38	-0.25	Insulin-related traits;	chr4:86860135	chr4:86913266~86914817:-
LUAD	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	5.56	4.42e-08	1.49e-05	0.31	0.25	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
LUAD	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	5.56	4.42e-08	1.49e-05	0.3	0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
LUAD	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	5.56	4.42e-08	1.49e-05	0.29	0.25	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
LUAD	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	5.56	4.42e-08	1.49e-05	0.28	0.25	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
LUAD	cis	rs7618501	0.633	rs6446193	ENSG00000234667.1	ACTBP13	5.56	4.42e-08	1.49e-05	0.27	0.25	Intelligence (multi-trait analysis);	chr3:50022325	chr3:49873347~49877980:-
LUAD	cis	rs66887589	0.776	rs10518337	ENSG00000248280.1	RP11-33B1.2	-5.56	4.42e-08	1.49e-05	-0.27	-0.25	Diastolic blood pressure;	chr4:119653719	chr4:119440561~119450157:-
LUAD	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-5.56	4.43e-08	1.5e-05	-0.29	-0.25	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
LUAD	cis	rs8098244	0.557	rs8089282	ENSG00000264745.1	TTC39C-AS1	5.56	4.44e-08	1.5e-05	0.26	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23708402	chr18:23994213~24015339:-
LUAD	cis	rs643506	0.845	rs762550	ENSG00000230911.1	PPIHP1	-5.56	4.44e-08	1.5e-05	-0.31	-0.25	Breast cancer;	chr11:111912376	chr11:112029858~112030367:-
LUAD	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	5.56	4.44e-08	1.5e-05	0.34	0.25	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
LUAD	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	5.56	4.44e-08	1.5e-05	0.3	0.25	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
LUAD	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	5.56	4.44e-08	1.5e-05	0.27	0.25	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
LUAD	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	5.56	4.44e-08	1.5e-05	0.35	0.25	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
LUAD	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	5.56	4.44e-08	1.5e-05	0.31	0.25	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
LUAD	cis	rs12468226	0.606	rs79092351	ENSG00000226261.1	AC064836.3	5.56	4.45e-08	1.5e-05	0.37	0.25	Urate levels;	chr2:202204388	chr2:202336024~202336727:-
LUAD	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	5.56	4.45e-08	1.5e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
LUAD	cis	rs1707322	1	rs4660906	ENSG00000234329.1	RP11-767N6.2	5.56	4.45e-08	1.5e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45651039~45651826:-
LUAD	cis	rs7826238	0.517	rs35144760	ENSG00000253893.2	FAM85B	5.56	4.45e-08	1.5e-05	0.32	0.25	Systolic blood pressure;	chr8:8504213	chr8:8167819~8226614:-
LUAD	cis	rs35740288	0.787	rs2008916	ENSG00000202081.1	RNU6-1280P	5.56	4.46e-08	1.5e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677959	chr15:85651522~85651628:-
LUAD	cis	rs72634501	0.716	rs67637163	ENSG00000228060.1	RP11-69E11.8	-5.56	4.46e-08	1.5e-05	-0.26	-0.25	HDL cholesterol;	chr1:39110949	chr1:39565160~39573203:+
LUAD	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-5.56	4.46e-08	1.51e-05	-0.27	-0.25	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
LUAD	cis	rs9952991	0.941	rs45450798	ENSG00000260302.1	RP11-973H7.1	5.56	4.46e-08	1.51e-05	0.45	0.25	Inflammatory skin disease;	chr18:12792941	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.941	rs60735058	ENSG00000260302.1	RP11-973H7.1	5.56	4.46e-08	1.51e-05	0.45	0.25	Inflammatory skin disease;	chr18:12795471	chr18:12774651~12775923:-
LUAD	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-5.56	4.46e-08	1.51e-05	-0.33	-0.25	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
LUAD	cis	rs67311347	0.955	rs73080163	ENSG00000223797.4	ENTPD3-AS1	5.56	4.47e-08	1.51e-05	0.27	0.25	Renal cell carcinoma;	chr3:40491570	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs73080165	ENSG00000223797.4	ENTPD3-AS1	5.56	4.47e-08	1.51e-05	0.27	0.25	Renal cell carcinoma;	chr3:40491571	chr3:40313802~40453329:-
LUAD	cis	rs1707322	1	rs12124847	ENSG00000234329.1	RP11-767N6.2	5.56	4.48e-08	1.51e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45651039~45651826:-
LUAD	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-5.56	4.48e-08	1.51e-05	-0.23	-0.25	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000211972.2	IGHV3-66	5.56	4.49e-08	1.51e-05	0.21	0.25	Kawasaki disease;	chr14:106779068	chr14:106675017~106675544:-
LUAD	cis	rs2404602	0.692	rs2120108	ENSG00000259422.1	RP11-593F23.1	-5.56	4.49e-08	1.51e-05	-0.28	-0.25	Blood metabolite levels;	chr15:76577588	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-5.56	4.49e-08	1.51e-05	-0.32	-0.25	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
LUAD	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	5.56	4.49e-08	1.51e-05	0.33	0.25	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	5.56	4.49e-08	1.51e-05	0.33	0.25	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
LUAD	cis	rs9847710	0.869	rs2564920	ENSG00000242142.1	SERBP1P3	5.56	4.49e-08	1.52e-05	0.27	0.25	Ulcerative colitis;	chr3:52999041	chr3:53064283~53065091:-
LUAD	cis	rs9847710	0.838	rs12635298	ENSG00000242142.1	SERBP1P3	5.56	4.49e-08	1.52e-05	0.27	0.25	Ulcerative colitis;	chr3:52999780	chr3:53064283~53065091:-
LUAD	cis	rs7618915	1	rs7618915	ENSG00000243224.1	RP5-1157M23.2	-5.56	4.5e-08	1.52e-05	-0.26	-0.25	Bipolar disorder;	chr3:52245578	chr3:52239258~52241097:+
LUAD	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-5.56	4.5e-08	1.52e-05	-0.3	-0.25	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
LUAD	cis	rs17684571	0.7	rs34805046	ENSG00000231441.1	RP11-472M19.2	5.56	4.5e-08	1.52e-05	0.37	0.25	Schizophrenia;	chr6:56815813	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.765	rs34425815	ENSG00000231441.1	RP11-472M19.2	5.56	4.5e-08	1.52e-05	0.37	0.25	Schizophrenia;	chr6:56816040	chr6:56844002~56864078:+
LUAD	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	5.56	4.5e-08	1.52e-05	0.3	0.25	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
LUAD	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	5.56	4.51e-08	1.52e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
LUAD	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	5.56	4.51e-08	1.52e-05	0.28	0.25	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
LUAD	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	5.56	4.51e-08	1.52e-05	0.19	0.25	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
LUAD	cis	rs2070074	0.591	rs41274863	ENSG00000230074.1	RP11-195F19.9	-5.56	4.51e-08	1.52e-05	-0.65	-0.25	CTACK levels;	chr9:34638348	chr9:34665665~34681298:+
LUAD	cis	rs853679	0.599	rs149990	ENSG00000204709.4	LINC01556	5.56	4.52e-08	1.52e-05	0.43	0.25	Depression;	chr6:28030480	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.599	rs149943	ENSG00000204709.4	LINC01556	5.56	4.52e-08	1.52e-05	0.43	0.25	Depression;	chr6:28034610	chr6:28943877~28944537:+
LUAD	cis	rs2919009	0.598	rs2420896	ENSG00000271670.1	RP11-95I16.4	5.56	4.52e-08	1.53e-05	0.31	0.25	Obesity-related traits;	chr10:120936893	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.581	rs2420897	ENSG00000271670.1	RP11-95I16.4	5.56	4.52e-08	1.53e-05	0.31	0.25	Obesity-related traits;	chr10:120936918	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.62	rs4437952	ENSG00000271670.1	RP11-95I16.4	5.56	4.52e-08	1.53e-05	0.31	0.25	Obesity-related traits;	chr10:120937138	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.581	rs2118962	ENSG00000271670.1	RP11-95I16.4	5.56	4.52e-08	1.53e-05	0.31	0.25	Obesity-related traits;	chr10:120937721	chr10:120879256~120880667:-
LUAD	cis	rs997295	0.57	rs60066681	ENSG00000270964.1	RP11-502I4.3	-5.56	4.53e-08	1.53e-05	-0.26	-0.25	Motion sickness;	chr15:67515738	chr15:67541072~67542604:-
LUAD	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	5.56	4.53e-08	1.53e-05	0.34	0.25	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
LUAD	cis	rs35538253	0.522	rs10492823	ENSG00000260886.1	TAT-AS1	5.56	4.53e-08	1.53e-05	0.42	0.25	Post bronchodilator FEV1;	chr16:71984961	chr16:71565789~71578187:+
LUAD	cis	rs9595908	0.709	rs17594677	ENSG00000212293.1	SNORA16	5.56	4.54e-08	1.53e-05	0.26	0.25	Body mass index;	chr13:32734875	chr13:32420390~32420516:-
LUAD	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-5.56	4.54e-08	1.53e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
LUAD	cis	rs948562	0.744	rs11229474	ENSG00000280010.1	AP001350.4	5.56	4.54e-08	1.53e-05	0.37	0.25	Lymphoma;	chr11:58459729	chr11:58627435~58628528:+
LUAD	cis	rs4908768	0.52	rs11121224	ENSG00000232912.4	RP5-1115A15.1	5.56	4.54e-08	1.53e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8713456	chr1:8424645~8434838:+
LUAD	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	5.56	4.54e-08	1.53e-05	0.3	0.25	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
LUAD	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-5.56	4.55e-08	1.53e-05	-0.29	-0.25	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
LUAD	cis	rs172166	0.516	rs1225710	ENSG00000219392.1	RP1-265C24.5	5.56	4.55e-08	1.54e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28132862	chr6:28115628~28116551:+
LUAD	cis	rs293748	0.771	rs181755	ENSG00000250155.1	CTD-2353F22.1	-5.56	4.56e-08	1.54e-05	-0.34	-0.25	Obesity-related traits;	chr5:36839162	chr5:36666214~36725195:-
LUAD	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-5.56	4.56e-08	1.54e-05	-0.35	-0.25	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
LUAD	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-5.56	4.56e-08	1.54e-05	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
LUAD	cis	rs11051970	0.559	rs4931621	ENSG00000274964.1	RP11-817I4.1	-5.56	4.56e-08	1.54e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32333569	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs3816819	ENSG00000274964.1	RP11-817I4.1	-5.56	4.56e-08	1.54e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32334123	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs2291421	ENSG00000274964.1	RP11-817I4.1	-5.56	4.56e-08	1.54e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32334173	chr12:32339368~32340724:+
LUAD	cis	rs4908768	0.539	rs7547411	ENSG00000232912.4	RP5-1115A15.1	5.56	4.56e-08	1.54e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8424645~8434838:+
LUAD	cis	rs987724	0.519	rs9818684	ENSG00000240875.4	LINC00886	5.56	4.57e-08	1.54e-05	0.27	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156806431	chr3:156747346~156817062:-
LUAD	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-5.56	4.57e-08	1.54e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
LUAD	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-5.56	4.58e-08	1.54e-05	-0.31	-0.25	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
LUAD	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-5.56	4.58e-08	1.54e-05	-0.33	-0.25	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-5.56	4.58e-08	1.54e-05	-0.33	-0.25	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-5.56	4.58e-08	1.54e-05	-0.33	-0.25	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
LUAD	cis	rs2404602	0.716	rs2404737	ENSG00000259422.1	RP11-593F23.1	5.56	4.58e-08	1.54e-05	0.28	0.25	Blood metabolite levels;	chr15:76579876	chr15:76174891~76181486:-
LUAD	cis	rs4604732	0.578	rs112449432	ENSG00000227135.1	GCSAML-AS1	-5.56	4.58e-08	1.54e-05	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460878	chr1:247524679~247526752:-
LUAD	cis	rs1061377	0.965	rs12511857	ENSG00000249685.1	RP11-360F5.3	5.56	4.58e-08	1.54e-05	0.31	0.25	Uric acid levels;	chr4:39143252	chr4:39133913~39135608:+
LUAD	cis	rs4908760	0.759	rs6577514	ENSG00000232912.4	RP5-1115A15.1	5.56	4.59e-08	1.54e-05	0.22	0.25	Vitiligo;	chr1:8652684	chr1:8424645~8434838:+
LUAD	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	5.56	4.59e-08	1.55e-05	0.25	0.25	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
LUAD	cis	rs17684571	0.7	rs1610156	ENSG00000231441.1	RP11-472M19.2	5.56	4.59e-08	1.55e-05	0.37	0.25	Schizophrenia;	chr6:56844274	chr6:56844002~56864078:+
LUAD	cis	rs755249	0.501	rs661316	ENSG00000228060.1	RP11-69E11.8	-5.56	4.59e-08	1.55e-05	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39565160~39573203:+
LUAD	cis	rs74233809	1	rs11191515	ENSG00000213277.3	MARCKSL1P1	5.56	4.59e-08	1.55e-05	0.44	0.25	Birth weight;	chr10:103016770	chr10:103175554~103176094:+
LUAD	cis	rs6687821	0.515	rs4656138	ENSG00000267734.1	RP4-604K5.3	-5.56	4.59e-08	1.55e-05	-0.3	-0.25	Yeast infection;	chr1:87045494	chr1:86932199~86934891:-
LUAD	cis	rs897984	0.762	rs2054213	ENSG00000260911.2	RP11-196G11.2	-5.56	4.6e-08	1.55e-05	-0.22	-0.25	Dementia with Lewy bodies;	chr16:30960489	chr16:31043150~31049868:+
LUAD	cis	rs896854	0.625	rs4735336	ENSG00000253528.2	RP11-347C18.4	-5.56	4.6e-08	1.55e-05	-0.23	-0.25	Type 2 diabetes;	chr8:94961182	chr8:94974573~94974853:-
LUAD	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	5.55	4.61e-08	1.55e-05	0.29	0.25	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
LUAD	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	5.55	4.61e-08	1.55e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
LUAD	cis	rs71403859	0.57	rs77809998	ENSG00000260886.1	TAT-AS1	5.55	4.61e-08	1.55e-05	0.44	0.25	Post bronchodilator FEV1;	chr16:71396784	chr16:71565789~71578187:+
LUAD	cis	rs1707322	0.928	rs7527244	ENSG00000234329.1	RP11-767N6.2	5.55	4.61e-08	1.55e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45651039~45651826:-
LUAD	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	5.55	4.61e-08	1.55e-05	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
LUAD	cis	rs7170668	0.597	rs17493093	ENSG00000259134.4	LINC00924	5.55	4.61e-08	1.55e-05	0.3	0.25	Motion sickness;	chr15:95506447	chr15:95433095~95507847:+
LUAD	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	5.55	4.61e-08	1.55e-05	0.37	0.25	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
LUAD	cis	rs80028505	1	rs2237096	ENSG00000271304.1	DPRXP2	5.55	4.61e-08	1.55e-05	0.49	0.25	Foot ulcer in diabetes and neuropathy;	chr6:36040225	chr6:35989515~35990436:-
LUAD	cis	rs12699921	0.632	rs2103144	ENSG00000279048.1	RP11-511H23.2	-5.55	4.62e-08	1.55e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17900529	chr7:17940503~17942922:+
LUAD	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-5.55	4.62e-08	1.56e-05	-0.27	-0.25	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
LUAD	cis	rs8031584	0.679	rs34017474	ENSG00000260382.1	RP11-540B6.2	5.55	4.62e-08	1.56e-05	0.28	0.25	Huntington's disease progression;	chr15:30938408	chr15:30882267~30883231:-
LUAD	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	5.55	4.62e-08	1.56e-05	0.19	0.25	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
LUAD	cis	rs720064	0.655	rs12964862	ENSG00000264745.1	TTC39C-AS1	5.55	4.62e-08	1.56e-05	0.26	0.25	Strep throat;	chr18:23700711	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.536	rs12955616	ENSG00000264745.1	TTC39C-AS1	5.55	4.62e-08	1.56e-05	0.26	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701097	chr18:23994213~24015339:-
LUAD	cis	rs1823913	0.614	rs1947457	ENSG00000227542.1	AC092614.2	5.55	4.64e-08	1.56e-05	0.53	0.25	Obesity-related traits;	chr2:191298970	chr2:191229165~191246172:-
LUAD	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	5.55	4.64e-08	1.56e-05	0.25	0.25	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
LUAD	cis	rs74233809	1	rs11191531	ENSG00000213277.3	MARCKSL1P1	5.55	4.64e-08	1.56e-05	0.42	0.25	Birth weight;	chr10:103047141	chr10:103175554~103176094:+
LUAD	cis	rs7182621	0.509	rs12917012	ENSG00000182397.13	DNM1P46	5.55	4.65e-08	1.56e-05	0.28	0.25	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99790156~99806927:-
LUAD	cis	rs516805	0.706	rs1267943	ENSG00000279453.1	RP3-425C14.4	-5.55	4.65e-08	1.56e-05	-0.32	-0.25	Lymphocyte counts;	chr6:122462498	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.706	rs541551	ENSG00000279453.1	RP3-425C14.4	-5.55	4.65e-08	1.56e-05	-0.32	-0.25	Lymphocyte counts;	chr6:122462736	chr6:122436789~122439223:-
LUAD	cis	rs74233809	1	rs943037	ENSG00000213277.3	MARCKSL1P1	5.55	4.65e-08	1.56e-05	0.43	0.25	Birth weight;	chr10:103076162	chr10:103175554~103176094:+
LUAD	cis	rs1707322	1	rs2458400	ENSG00000234329.1	RP11-767N6.2	-5.55	4.65e-08	1.56e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs9429186	ENSG00000234329.1	RP11-767N6.2	-5.55	4.65e-08	1.56e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785506	ENSG00000234329.1	RP11-767N6.2	-5.55	4.65e-08	1.56e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45651039~45651826:-
LUAD	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-5.55	4.66e-08	1.57e-05	-0.51	-0.25	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
LUAD	cis	rs10214930	0.752	rs1015265	ENSG00000235574.1	AC073150.6	-5.55	4.66e-08	1.57e-05	-0.33	-0.25	Hypospadias;	chr7:27599990	chr7:27491682~27492765:-
LUAD	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-5.55	4.66e-08	1.57e-05	-0.31	-0.25	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
LUAD	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-5.55	4.66e-08	1.57e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-5.55	4.66e-08	1.57e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
LUAD	cis	rs1154275	0.537	rs6793183	ENSG00000242770.2	RP11-180K7.1	5.55	4.66e-08	1.57e-05	0.25	0.25	Takotsubo syndrome;	chr3:112798908	chr3:112802478~112812819:+
LUAD	cis	rs17507216	0.958	rs72751643	ENSG00000255769.6	GOLGA2P10	-5.55	4.67e-08	1.57e-05	-0.31	-0.25	Excessive daytime sleepiness;	chr15:82559444	chr15:82472993~82513950:-
LUAD	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	5.55	4.67e-08	1.57e-05	0.31	0.25	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
LUAD	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-5.55	4.67e-08	1.57e-05	-0.27	-0.25	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-5.55	4.67e-08	1.57e-05	-0.27	-0.25	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-5.55	4.67e-08	1.57e-05	-0.27	-0.25	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
LUAD	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	5.55	4.68e-08	1.57e-05	0.34	0.25	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
LUAD	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-5.55	4.68e-08	1.57e-05	-0.21	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
LUAD	cis	rs8180040	0.701	rs7617689	ENSG00000271161.1	BOLA2P2	-5.55	4.68e-08	1.58e-05	-0.23	-0.25	Colorectal cancer;	chr3:46954952	chr3:47499841~47500407:+
LUAD	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	5.55	4.68e-08	1.58e-05	0.27	0.25	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
LUAD	cis	rs7804306	0.655	rs34746652	ENSG00000233264.2	AC006042.8	5.55	4.69e-08	1.58e-05	0.43	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8012957	chr7:7980312~7982228:+
LUAD	cis	rs1707322	1	rs785465	ENSG00000234329.1	RP11-767N6.2	5.55	4.69e-08	1.58e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45651039~45651826:-
LUAD	cis	rs10214930	0.697	rs6974387	ENSG00000235574.1	AC073150.6	-5.55	4.69e-08	1.58e-05	-0.3	-0.25	Hypospadias;	chr7:27626788	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7806812	ENSG00000235574.1	AC073150.6	-5.55	4.69e-08	1.58e-05	-0.3	-0.25	Hypospadias;	chr7:27626960	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12667610	ENSG00000235574.1	AC073150.6	-5.55	4.69e-08	1.58e-05	-0.3	-0.25	Hypospadias;	chr7:27627866	chr7:27491682~27492765:-
LUAD	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	5.55	4.7e-08	1.58e-05	0.37	0.25	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
LUAD	cis	rs74233809	1	rs75970938	ENSG00000213277.3	MARCKSL1P1	5.55	4.7e-08	1.58e-05	0.44	0.25	Birth weight;	chr10:103033891	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs79668541	ENSG00000213277.3	MARCKSL1P1	5.55	4.7e-08	1.58e-05	0.44	0.25	Birth weight;	chr10:103034147	chr10:103175554~103176094:+
LUAD	cis	rs7017914	0.652	rs2035929	ENSG00000223220.1	Y_RNA	-5.55	4.7e-08	1.58e-05	-0.28	-0.25	Bone mineral density;	chr8:71001137	chr8:70780914~70781008:-
LUAD	cis	rs755249	0.762	rs1775654	ENSG00000228060.1	RP11-69E11.8	-5.55	4.7e-08	1.58e-05	-0.22	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39565160~39573203:+
LUAD	cis	rs516805	0.597	rs666046	ENSG00000279453.1	RP3-425C14.4	-5.55	4.71e-08	1.58e-05	-0.33	-0.25	Lymphocyte counts;	chr6:122290427	chr6:122436789~122439223:-
LUAD	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-5.55	4.71e-08	1.58e-05	-0.3	-0.25	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
LUAD	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-5.55	4.72e-08	1.58e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
LUAD	cis	rs35740288	0.822	rs2306225	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85684721	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.822	rs11638720	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686042	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.822	rs1961601	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686375	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.822	rs2016517	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686387	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.787	rs727379	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686659	chr15:85651522~85651628:-
LUAD	cis	rs4713118	0.513	rs149959	ENSG00000204709.4	LINC01556	5.55	4.72e-08	1.59e-05	0.31	0.25	Parkinson's disease;	chr6:28046076	chr6:28943877~28944537:+
LUAD	cis	rs2070074	0.591	rs41274865	ENSG00000230074.1	RP11-195F19.9	-5.55	4.72e-08	1.59e-05	-0.65	-0.25	CTACK levels;	chr9:34647805	chr9:34665665~34681298:+
LUAD	cis	rs2070074	0.591	rs2277202	ENSG00000230074.1	RP11-195F19.9	-5.55	4.72e-08	1.59e-05	-0.65	-0.25	CTACK levels;	chr9:34648023	chr9:34665665~34681298:+
LUAD	cis	rs2070074	0.591	rs41274867	ENSG00000230074.1	RP11-195F19.9	-5.55	4.72e-08	1.59e-05	-0.65	-0.25	CTACK levels;	chr9:34648091	chr9:34665665~34681298:+
LUAD	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	5.55	4.72e-08	1.59e-05	0.24	0.25	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
LUAD	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-5.55	4.72e-08	1.59e-05	-0.26	-0.25	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
LUAD	cis	rs1345301	0.587	rs10186746	ENSG00000234389.1	AC007278.3	-5.55	4.73e-08	1.59e-05	-0.23	-0.25	Waist circumference;	chr2:102249917	chr2:102438713~102440475:+
LUAD	cis	rs17507216	0.591	rs7163848	ENSG00000255769.6	GOLGA2P10	-5.55	4.73e-08	1.59e-05	-0.32	-0.25	Excessive daytime sleepiness;	chr15:82729563	chr15:82472993~82513950:-
LUAD	cis	rs7044106	0.708	rs2416760	ENSG00000238181.2	AHCYP2	-5.55	4.73e-08	1.59e-05	-0.31	-0.25	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120720673~120721972:+
LUAD	cis	rs9595908	0.785	rs9596109	ENSG00000212293.1	SNORA16	5.55	4.74e-08	1.59e-05	0.26	0.25	Body mass index;	chr13:32712611	chr13:32420390~32420516:-
LUAD	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-5.55	4.74e-08	1.59e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
LUAD	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	5.55	4.74e-08	1.59e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
LUAD	cis	rs9287719	0.601	rs62128635	ENSG00000243819.4	RN7SL832P	5.55	4.75e-08	1.59e-05	0.27	0.25	Prostate cancer;	chr2:10585208	chr2:10690344~10692099:+
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000211967.3	IGHV3-53	-5.55	4.75e-08	1.6e-05	-0.17	-0.25	Kawasaki disease;	chr14:106681814	chr14:106592676~106593347:-
LUAD	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-5.55	4.75e-08	1.6e-05	-0.24	-0.25	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
LUAD	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-5.55	4.75e-08	1.6e-05	-0.29	-0.25	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
LUAD	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	5.55	4.75e-08	1.6e-05	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
LUAD	cis	rs2919009	0.581	rs56118695	ENSG00000271670.1	RP11-95I16.4	5.55	4.76e-08	1.6e-05	0.31	0.25	Obesity-related traits;	chr10:120938383	chr10:120879256~120880667:-
LUAD	cis	rs1876905	0.68	rs373526	ENSG00000272356.1	RP5-1112D6.8	5.55	4.76e-08	1.6e-05	0.26	0.25	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111309203~111313517:+
LUAD	cis	rs1707322	1	rs785486	ENSG00000234329.1	RP11-767N6.2	-5.55	4.76e-08	1.6e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.865	rs785501	ENSG00000234329.1	RP11-767N6.2	-5.55	4.76e-08	1.6e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785504	ENSG00000234329.1	RP11-767N6.2	-5.55	4.76e-08	1.6e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45651039~45651826:-
LUAD	cis	rs2404602	0.716	rs1125932	ENSG00000259422.1	RP11-593F23.1	5.55	4.76e-08	1.6e-05	0.28	0.25	Blood metabolite levels;	chr15:76528199	chr15:76174891~76181486:-
LUAD	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	5.55	4.77e-08	1.6e-05	0.31	0.25	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
LUAD	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	5.55	4.77e-08	1.6e-05	0.32	0.25	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
LUAD	cis	rs9652601	0.691	rs12928726	ENSG00000274038.1	RP11-66H6.4	-5.55	4.77e-08	1.6e-05	-0.29	-0.25	Systemic lupus erythematosus;	chr16:11097715	chr16:11056556~11057034:+
LUAD	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-5.55	4.77e-08	1.6e-05	-0.35	-0.25	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
LUAD	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-5.55	4.77e-08	1.6e-05	-0.31	-0.25	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
LUAD	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	5.55	4.77e-08	1.6e-05	0.31	0.25	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	5.55	4.77e-08	1.6e-05	0.31	0.25	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
LUAD	cis	rs2243480	1	rs437889	ENSG00000230295.1	RP11-458F8.2	-5.55	4.78e-08	1.61e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66044247	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000230295.1	RP11-458F8.2	-5.55	4.78e-08	1.61e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66044482	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000230295.1	RP11-458F8.2	-5.55	4.78e-08	1.61e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66044512	chr7:66880708~66882981:+
LUAD	cis	rs4568518	0.502	rs4543441	ENSG00000279048.1	RP11-511H23.2	5.55	4.78e-08	1.61e-05	0.2	0.25	Measles;	chr7:17943674	chr7:17940503~17942922:+
LUAD	cis	rs1106529	0.51	rs7526102	ENSG00000226172.2	RP4-712E4.1	-5.55	4.79e-08	1.61e-05	-0.32	-0.25	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118984604	chr1:119000344~119001392:-
LUAD	cis	rs72615157	0.634	rs74774557	ENSG00000242294.5	STAG3L5P	5.55	4.79e-08	1.61e-05	0.21	0.25	Lung function (FEV1/FVC);	chr7:100212802	chr7:100336079~100351900:+
LUAD	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	5.55	4.79e-08	1.61e-05	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
LUAD	cis	rs1876905	0.62	rs354530	ENSG00000272356.1	RP5-1112D6.8	-5.55	4.79e-08	1.61e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111309203~111313517:+
LUAD	cis	rs853679	0.585	rs201001	ENSG00000219392.1	RP1-265C24.5	-5.55	4.8e-08	1.61e-05	-0.34	-0.25	Depression;	chr6:27841121	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.585	rs201000	ENSG00000219392.1	RP1-265C24.5	-5.55	4.8e-08	1.61e-05	-0.34	-0.25	Depression;	chr6:27841381	chr6:28115628~28116551:+
LUAD	cis	rs2440129	0.611	rs11571335	ENSG00000215067.8	ALOX12-AS1	5.55	4.8e-08	1.61e-05	0.25	0.25	Tonsillectomy;	chr17:7000944	chr17:6876635~7012349:-
LUAD	cis	rs6687821	0.515	rs2390224	ENSG00000267734.1	RP4-604K5.3	-5.55	4.81e-08	1.62e-05	-0.3	-0.25	Yeast infection;	chr1:86991201	chr1:86932199~86934891:-
LUAD	cis	rs9549367	0.804	rs9549704	ENSG00000269125.1	RP11-98F14.11	-5.55	4.81e-08	1.62e-05	-0.32	-0.25	Platelet distribution width;	chr13:113230873	chr13:113165002~113165183:-
LUAD	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	5.55	4.82e-08	1.62e-05	0.3	0.25	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
LUAD	cis	rs453301	0.686	rs6601281	ENSG00000253981.4	ALG1L13P	-5.55	4.82e-08	1.62e-05	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9053494	chr8:8236003~8244667:-
LUAD	cis	rs1707322	1	rs6657720	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs7519181	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs7526369	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs10890371	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890372	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45651039~45651826:-
LUAD	cis	rs9287719	0.649	rs12473957	ENSG00000243819.4	RN7SL832P	-5.55	4.82e-08	1.62e-05	-0.26	-0.25	Prostate cancer;	chr2:10577588	chr2:10690344~10692099:+
LUAD	cis	rs997295	0.57	rs72747462	ENSG00000270964.1	RP11-502I4.3	-5.55	4.82e-08	1.62e-05	-0.26	-0.25	Motion sickness;	chr15:67526200	chr15:67541072~67542604:-
LUAD	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-5.55	4.83e-08	1.62e-05	-0.25	-0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
LUAD	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	5.55	4.84e-08	1.62e-05	0.22	0.25	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
LUAD	cis	rs12468226	0.873	rs78798541	ENSG00000272966.1	RP11-686O6.1	5.55	4.84e-08	1.62e-05	0.43	0.25	Urate levels;	chr2:202194708	chr2:202336739~202337200:+
LUAD	cis	rs4908768	0.501	rs12030885	ENSG00000232912.4	RP5-1115A15.1	5.55	4.84e-08	1.62e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8721337	chr1:8424645~8434838:+
LUAD	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	5.55	4.84e-08	1.62e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	5.55	4.84e-08	1.62e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
LUAD	cis	rs1707322	0.896	rs809774	ENSG00000234329.1	RP11-767N6.2	-5.55	4.85e-08	1.63e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45651039~45651826:-
LUAD	cis	rs17684571	0.751	rs7761729	ENSG00000231441.1	RP11-472M19.2	5.55	4.85e-08	1.63e-05	0.34	0.25	Schizophrenia;	chr6:56846478	chr6:56844002~56864078:+
LUAD	cis	rs172166	0.543	rs1150691	ENSG00000219392.1	RP1-265C24.5	-5.55	4.85e-08	1.63e-05	-0.31	-0.25	Cardiac Troponin-T levels;	chr6:28200255	chr6:28115628~28116551:+
LUAD	cis	rs4908760	0.566	rs7532459	ENSG00000232912.4	RP5-1115A15.1	5.55	4.85e-08	1.63e-05	0.23	0.25	Vitiligo;	chr1:8617714	chr1:8424645~8434838:+
LUAD	cis	rs453301	0.686	rs6601281	ENSG00000173295.6	FAM86B3P	-5.55	4.85e-08	1.63e-05	-0.26	-0.25	Joint mobility (Beighton score);	chr8:9053494	chr8:8228595~8244865:+
LUAD	cis	rs1426063	0.614	rs17199779	ENSG00000249717.1	RP11-44F21.3	-5.55	4.85e-08	1.63e-05	-0.46	-0.25	QT interval;	chr4:75105647	chr4:74955974~74970362:-
LUAD	cis	rs9847710	0.869	rs11708675	ENSG00000242142.1	SERBP1P3	5.55	4.86e-08	1.63e-05	0.27	0.25	Ulcerative colitis;	chr3:52997896	chr3:53064283~53065091:-
LUAD	cis	rs2749097	1	rs11208263	ENSG00000244256.3	RN7SL130P	-5.54	4.86e-08	1.63e-05	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63659259	chr1:63655743~63656047:+
LUAD	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	5.54	4.86e-08	1.63e-05	0.33	0.25	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
LUAD	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	5.54	4.87e-08	1.63e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
LUAD	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	5.54	4.87e-08	1.63e-05	0.26	0.25	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
LUAD	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	5.54	4.87e-08	1.63e-05	0.47	0.25	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	5.54	4.87e-08	1.63e-05	0.47	0.25	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	5.54	4.87e-08	1.63e-05	0.47	0.25	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
LUAD	cis	rs4660456	0.504	rs570671	ENSG00000237899.1	RP4-739H11.3	5.54	4.87e-08	1.63e-05	0.35	0.25	Platelet count;	chr1:40625455	chr1:40669089~40687588:-
LUAD	cis	rs944289	0.553	rs1169147	ENSG00000257826.1	RP11-116N8.4	-5.54	4.88e-08	1.63e-05	-0.28	-0.25	Thyroid cancer;	chr14:36163697	chr14:36061026~36067190:-
LUAD	cis	rs2303759	0.676	rs7248378	ENSG00000268686.1	AC010524.2	-5.54	4.88e-08	1.64e-05	-0.33	-0.25	Multiple sclerosis;	chr19:49404887	chr19:49368705~49388081:-
LUAD	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	5.54	4.88e-08	1.64e-05	0.33	0.25	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
LUAD	cis	rs4713118	0.513	rs149958	ENSG00000204709.4	LINC01556	5.54	4.88e-08	1.64e-05	0.31	0.25	Parkinson's disease;	chr6:28045839	chr6:28943877~28944537:+
LUAD	cis	rs1707322	1	rs11211243	ENSG00000234329.1	RP11-767N6.2	5.54	4.88e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211244	ENSG00000234329.1	RP11-767N6.2	5.54	4.88e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660903	ENSG00000234329.1	RP11-767N6.2	5.54	4.88e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45651039~45651826:-
LUAD	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-5.54	4.88e-08	1.64e-05	-0.27	-0.25	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
LUAD	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	5.54	4.89e-08	1.64e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	5.54	4.89e-08	1.64e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
LUAD	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	5.54	4.89e-08	1.64e-05	0.38	0.25	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	5.54	4.89e-08	1.64e-05	0.38	0.25	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
LUAD	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	5.54	4.89e-08	1.64e-05	0.29	0.25	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
LUAD	cis	rs7116495	1	rs3814721	ENSG00000254682.1	RP11-660L16.2	5.54	4.89e-08	1.64e-05	0.49	0.25	Severe influenza A (H1N1) infection;	chr11:71998226	chr11:71448674~71452157:+
LUAD	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	5.54	4.89e-08	1.64e-05	0.26	0.25	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.963	rs6666763	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4489497	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211235	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.893	rs9919275	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211236	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660328	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.928	rs61785614	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs9793167	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211237	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs11211238	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4460583	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs4459051	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211239	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45651039~45651826:-
LUAD	cis	rs9287719	0.649	rs7589694	ENSG00000243819.4	RN7SL832P	5.54	4.9e-08	1.64e-05	0.26	0.25	Prostate cancer;	chr2:10560748	chr2:10690344~10692099:+
LUAD	cis	rs180730	0.509	rs1588521	ENSG00000251609.2	SETP12	-5.54	4.91e-08	1.64e-05	-0.32	-0.25	Fasting plasma glucose;	chr4:120881202	chr4:120895494~120897083:-
LUAD	cis	rs948562	0.947	rs73470773	ENSG00000280010.1	AP001350.4	5.54	4.91e-08	1.64e-05	0.38	0.25	Lymphoma;	chr11:58648100	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.947	rs73470778	ENSG00000280010.1	AP001350.4	5.54	4.91e-08	1.64e-05	0.38	0.25	Lymphoma;	chr11:58650594	chr11:58627435~58628528:+
LUAD	cis	rs1154275	0.537	rs6797028	ENSG00000242770.2	RP11-180K7.1	5.54	4.91e-08	1.65e-05	0.26	0.25	Takotsubo syndrome;	chr3:112796340	chr3:112802478~112812819:+
LUAD	cis	rs4698412	0.646	rs4698120	ENSG00000214846.4	RP11-115L11.1	-5.54	4.91e-08	1.65e-05	-0.33	-0.25	Parkinson's disease;	chr4:15741709	chr4:15730962~15731627:-
LUAD	cis	rs7181230	0.885	rs4924413	ENSG00000275636.1	RP11-521C20.5	5.54	4.92e-08	1.65e-05	0.33	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40078892~40079347:+
LUAD	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-5.54	4.92e-08	1.65e-05	-0.24	-0.25	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
LUAD	cis	rs6558530	0.73	rs13256424	ENSG00000253982.1	CTD-2336O2.1	5.54	4.92e-08	1.65e-05	0.31	0.25	Systolic blood pressure;	chr8:1776838	chr8:1761990~1764502:-
LUAD	cis	rs17818399	0.612	rs4952834	ENSG00000279254.1	RP11-536C12.1	-5.54	4.92e-08	1.65e-05	-0.28	-0.25	Height;	chr2:46550323	chr2:46668870~46670778:+
LUAD	cis	rs477895	0.938	rs28395875	ENSG00000236935.1	AP003774.1	-5.54	4.93e-08	1.65e-05	-0.3	-0.25	Mean platelet volume;	chr11:64256576	chr11:64325050~64329504:-
LUAD	cis	rs17214007	0.877	rs11075280	ENSG00000263335.1	AF001548.5	-5.54	4.93e-08	1.65e-05	-0.35	-0.25	Cognitive function;	chr16:15776630	chr16:15726674~15732993:+
LUAD	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-5.54	4.93e-08	1.65e-05	-0.25	-0.24	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
LUAD	cis	rs12468226	0.817	rs2350360	ENSG00000272966.1	RP11-686O6.1	-5.54	4.94e-08	1.65e-05	-0.41	-0.24	Urate levels;	chr2:202222980	chr2:202336739~202337200:+
LUAD	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	5.54	4.94e-08	1.65e-05	0.28	0.24	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
LUAD	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.54	4.94e-08	1.65e-05	-0.56	-0.24	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
LUAD	cis	rs8127691	0.904	rs3804031	ENSG00000237604.1	AP001056.1	5.54	4.94e-08	1.66e-05	0.29	0.24	Inflammatory bowel disease;	chr21:44209721	chr21:44175489~44176453:+
LUAD	cis	rs9652601	0.691	rs3893660	ENSG00000274038.1	RP11-66H6.4	-5.54	4.95e-08	1.66e-05	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11100073	chr16:11056556~11057034:+
LUAD	cis	rs4713118	0.824	rs13211701	ENSG00000219392.1	RP1-265C24.5	-5.54	4.95e-08	1.66e-05	-0.33	-0.24	Parkinson's disease;	chr6:27782300	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.824	rs9468229	ENSG00000219392.1	RP1-265C24.5	-5.54	4.95e-08	1.66e-05	-0.33	-0.24	Parkinson's disease;	chr6:27782307	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
LUAD	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-5.54	4.96e-08	1.66e-05	-0.29	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
LUAD	cis	rs5753618	0.583	rs7287267	ENSG00000236132.1	CTA-440B3.1	-5.54	4.96e-08	1.66e-05	-0.3	-0.24	Colorectal cancer;	chr22:31352429	chr22:31816379~31817491:-
LUAD	cis	rs17684571	0.751	rs74777312	ENSG00000231441.1	RP11-472M19.2	5.54	4.96e-08	1.66e-05	0.37	0.24	Schizophrenia;	chr6:56845568	chr6:56844002~56864078:+
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000226002.1	RP11-460N20.5	5.54	4.97e-08	1.66e-05	0.28	0.24	Calcium levels;	chr7:65829495	chr7:65084103~65100232:+
LUAD	cis	rs453301	0.606	rs6601279	ENSG00000173295.6	FAM86B3P	-5.54	4.98e-08	1.66e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9050721	chr8:8228595~8244865:+
LUAD	cis	rs453301	0.606	rs6981060	ENSG00000173295.6	FAM86B3P	-5.54	4.98e-08	1.66e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9050725	chr8:8228595~8244865:+
LUAD	cis	rs7618501	0.602	rs2240326	ENSG00000234667.1	ACTBP13	5.54	4.98e-08	1.66e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50090953	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.54	rs11130241	ENSG00000234667.1	ACTBP13	5.54	4.98e-08	1.66e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50094026	chr3:49873347~49877980:-
LUAD	cis	rs7937890	0.681	rs4756784	ENSG00000254418.1	RP11-21L19.1	-5.54	4.98e-08	1.67e-05	-0.29	-0.24	Mitochondrial DNA levels;	chr11:14249358	chr11:14262846~14273691:-
LUAD	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-5.54	4.98e-08	1.67e-05	-0.3	-0.24	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
LUAD	cis	rs1707322	1	rs6687301	ENSG00000234329.1	RP11-767N6.2	5.54	4.99e-08	1.67e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45651039~45651826:-
LUAD	cis	rs10214930	0.671	rs6415251	ENSG00000235574.1	AC073150.6	-5.54	4.99e-08	1.67e-05	-0.3	-0.24	Hypospadias;	chr7:27629079	chr7:27491682~27492765:-
LUAD	cis	rs2070074	0.591	rs41306057	ENSG00000230074.1	RP11-195F19.9	-5.54	4.99e-08	1.67e-05	-0.65	-0.24	CTACK levels;	chr9:34636826	chr9:34665665~34681298:+
LUAD	cis	rs8040855	0.825	rs4843021	ENSG00000259774.1	RP11-182J1.13	-5.54	4.99e-08	1.67e-05	-0.31	-0.24	Bulimia nervosa;	chr15:85151317	chr15:84422618~84425882:+
LUAD	cis	rs10761482	0.5	rs1938524	ENSG00000254271.1	RP11-131N11.4	5.54	5e-08	1.67e-05	0.27	0.24	Schizophrenia;	chr10:60543815	chr10:60734342~60741828:+
LUAD	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	5.54	5e-08	1.67e-05	0.28	0.24	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
LUAD	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-5.54	5e-08	1.67e-05	-0.3	-0.24	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
LUAD	cis	rs6687821	0.515	rs524515	ENSG00000267734.1	RP4-604K5.3	5.54	5.01e-08	1.68e-05	0.3	0.24	Yeast infection;	chr1:86907736	chr1:86932199~86934891:-
LUAD	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	5.54	5.02e-08	1.68e-05	0.26	0.24	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
LUAD	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	5.54	5.02e-08	1.68e-05	0.25	0.24	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
LUAD	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	5.54	5.02e-08	1.68e-05	0.28	0.24	QT interval;	chr12:29284120	chr12:29280418~29317848:-
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-5.54	5.02e-08	1.68e-05	-0.25	-0.24	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
LUAD	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-5.54	5.02e-08	1.68e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
LUAD	cis	rs225245	0.531	rs321609	ENSG00000267592.1	CTC-507E2.2	5.54	5.03e-08	1.68e-05	0.29	0.24	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35553657	chr17:35596904~35597128:-
LUAD	cis	rs116095464	1	rs62331562	ENSG00000277812.1	AC021087.1	5.54	5.03e-08	1.68e-05	0.68	0.24	Breast cancer;	chr5:349183	chr5:262769~262881:+
LUAD	cis	rs6687821	0.515	rs1573202	ENSG00000267734.1	RP4-604K5.3	-5.54	5.03e-08	1.68e-05	-0.3	-0.24	Yeast infection;	chr1:87046037	chr1:86932199~86934891:-
LUAD	cis	rs9595908	0.655	rs2213377	ENSG00000212293.1	SNORA16	5.54	5.03e-08	1.68e-05	0.27	0.24	Body mass index;	chr13:32743076	chr13:32420390~32420516:-
LUAD	cis	rs910316	0.967	rs175505	ENSG00000259138.1	RP11-950C14.7	-5.54	5.03e-08	1.68e-05	-0.26	-0.24	Height;	chr14:75062916	chr14:75127153~75136930:+
LUAD	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-5.54	5.04e-08	1.68e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-5.54	5.04e-08	1.68e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-5.54	5.04e-08	1.68e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
LUAD	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-5.54	5.04e-08	1.68e-05	-0.33	-0.24	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-5.54	5.04e-08	1.68e-05	-0.33	-0.24	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-5.54	5.04e-08	1.68e-05	-0.33	-0.24	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
LUAD	cis	rs1318937	0.764	rs11128738	ENSG00000224660.1	SH3BP5-AS1	5.54	5.04e-08	1.68e-05	0.18	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15200989	chr3:15254184~15264493:+
LUAD	cis	rs9828933	0.832	rs3774723	ENSG00000280620.1	SCAANT1	5.54	5.04e-08	1.69e-05	0.36	0.24	Type 2 diabetes;	chr3:63976663	chr3:63911518~63911772:-
LUAD	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-5.54	5.05e-08	1.69e-05	-0.35	-0.24	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
LUAD	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	5.54	5.05e-08	1.69e-05	0.37	0.24	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
LUAD	cis	rs41307935	0.908	rs34618114	ENSG00000260063.1	RP5-968P14.2	-5.54	5.06e-08	1.69e-05	-0.44	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26771828	chr1:26692132~26694131:-
LUAD	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-5.54	5.06e-08	1.69e-05	-0.3	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
LUAD	cis	rs4767841	0.562	rs10849683	ENSG00000248636.5	RP11-768F21.1	-5.54	5.06e-08	1.69e-05	-0.29	-0.24	Urgency urinary incontinence;	chr12:119624203	chr12:119387987~119668079:-
LUAD	cis	rs394563	0.591	rs237029	ENSG00000231760.4	RP11-350J20.5	5.54	5.07e-08	1.69e-05	0.3	0.24	Dupuytren's disease;	chr6:149396289	chr6:149796151~149826294:-
LUAD	cis	rs8098244	0.557	rs11082724	ENSG00000264745.1	TTC39C-AS1	5.54	5.07e-08	1.69e-05	0.26	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732544	chr18:23994213~24015339:-
LUAD	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-5.54	5.07e-08	1.69e-05	-0.31	-0.24	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
LUAD	cis	rs10214930	0.697	rs10951175	ENSG00000235574.1	AC073150.6	-5.54	5.07e-08	1.69e-05	-0.29	-0.24	Hypospadias;	chr7:27631439	chr7:27491682~27492765:-
LUAD	cis	rs7618501	0.633	rs2252833	ENSG00000234667.1	ACTBP13	-5.54	5.07e-08	1.69e-05	-0.28	-0.24	Intelligence (multi-trait analysis);	chr3:49966776	chr3:49873347~49877980:-
LUAD	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	5.54	5.07e-08	1.69e-05	0.3	0.24	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
LUAD	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	5.54	5.07e-08	1.69e-05	0.28	0.24	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
LUAD	cis	rs10214930	0.813	rs6415252	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27629241	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs7779990	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27632280	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs12700825	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27632952	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs11764753	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27633340	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs7806415	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27633918	chr7:27491682~27492765:-
LUAD	cis	rs35740288	0.721	rs4843093	ENSG00000202081.1	RNU6-1280P	5.54	5.08e-08	1.7e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85694202	chr15:85651522~85651628:-
LUAD	cis	rs2288884	0.943	rs1433089	ENSG00000275055.1	CTC-471J1.11	-5.54	5.08e-08	1.7e-05	-0.37	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52003732	chr19:52049007~52049754:+
LUAD	cis	rs1823874	0.613	rs4608318	ENSG00000182397.13	DNM1P46	-5.54	5.09e-08	1.7e-05	-0.3	-0.24	IgG glycosylation;	chr15:99823621	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.677	rs2168069	ENSG00000182397.13	DNM1P46	-5.54	5.09e-08	1.7e-05	-0.3	-0.24	IgG glycosylation;	chr15:99823798	chr15:99790156~99806927:-
LUAD	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-5.54	5.09e-08	1.7e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
LUAD	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	5.54	5.09e-08	1.7e-05	0.3	0.24	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
LUAD	cis	rs948562	0.573	rs17471365	ENSG00000280010.1	AP001350.4	-5.54	5.09e-08	1.7e-05	-0.36	-0.24	Lymphoma;	chr11:58275959	chr11:58627435~58628528:+
LUAD	cis	rs4908768	0.501	rs7530745	ENSG00000232912.4	RP5-1115A15.1	5.54	5.1e-08	1.7e-05	0.23	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497631	chr1:8424645~8434838:+
LUAD	cis	rs9595908	0.785	rs4120131	ENSG00000212293.1	SNORA16	-5.54	5.1e-08	1.7e-05	-0.26	-0.24	Body mass index;	chr13:32702949	chr13:32420390~32420516:-
LUAD	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-5.54	5.1e-08	1.7e-05	-0.33	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
LUAD	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	5.54	5.1e-08	1.7e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	5.54	5.1e-08	1.7e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
LUAD	cis	rs9847710	0.869	rs2581793	ENSG00000242142.1	SERBP1P3	5.54	5.1e-08	1.7e-05	0.26	0.24	Ulcerative colitis;	chr3:53001639	chr3:53064283~53065091:-
LUAD	cis	rs6991838	0.806	rs35284121	ENSG00000200714.1	Y_RNA	5.54	5.1e-08	1.7e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.751	rs35553155	ENSG00000200714.1	Y_RNA	5.54	5.1e-08	1.7e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.806	rs35024820	ENSG00000200714.1	Y_RNA	5.54	5.1e-08	1.7e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65592731~65592820:+
LUAD	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	5.54	5.11e-08	1.71e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
LUAD	cis	rs948562	0.744	rs73485969	ENSG00000280010.1	AP001350.4	5.54	5.11e-08	1.71e-05	0.37	0.24	Lymphoma;	chr11:58452253	chr11:58627435~58628528:+
LUAD	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	5.54	5.11e-08	1.71e-05	0.3	0.24	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
LUAD	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-5.54	5.12e-08	1.71e-05	-0.28	-0.24	QT interval;	chr12:29287150	chr12:29280418~29317848:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000211967.3	IGHV3-53	-5.54	5.12e-08	1.71e-05	-0.17	-0.24	Kawasaki disease;	chr14:106778866	chr14:106592676~106593347:-
LUAD	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	5.53	5.13e-08	1.71e-05	0.32	0.24	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
LUAD	cis	rs9900062	0.844	rs9908143	ENSG00000270714.1	MINOS1P2	-5.53	5.13e-08	1.71e-05	-0.37	-0.24	QT interval;	chr17:64758468	chr17:64747264~64747492:-
LUAD	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	5.53	5.13e-08	1.71e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
LUAD	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	5.53	5.14e-08	1.72e-05	0.32	0.24	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000224373.3	IGHV4-59	5.53	5.15e-08	1.72e-05	0.16	0.24	Kawasaki disease;	chr14:106718572	chr14:106627249~106627825:-
LUAD	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-5.53	5.15e-08	1.72e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
LUAD	cis	rs9595908	0.785	rs9591236	ENSG00000212293.1	SNORA16	5.53	5.16e-08	1.72e-05	0.26	0.24	Body mass index;	chr13:32671667	chr13:32420390~32420516:-
LUAD	cis	rs4767841	0.552	rs4767833	ENSG00000248636.5	RP11-768F21.1	-5.53	5.16e-08	1.72e-05	-0.28	-0.24	Urgency urinary incontinence;	chr12:119613165	chr12:119387987~119668079:-
LUAD	cis	rs2404602	0.692	rs55864032	ENSG00000259422.1	RP11-593F23.1	5.53	5.16e-08	1.72e-05	0.28	0.24	Blood metabolite levels;	chr15:76830207	chr15:76174891~76181486:-
LUAD	cis	rs763567	0.585	rs553905	ENSG00000271811.1	RP1-79C4.4	-5.53	5.16e-08	1.72e-05	-0.29	-0.24	Tonsillectomy;	chr1:170611336	chr1:170667381~170669425:+
LUAD	cis	rs8180040	0.726	rs61729713	ENSG00000271161.1	BOLA2P2	-5.53	5.17e-08	1.72e-05	-0.23	-0.24	Colorectal cancer;	chr3:46985702	chr3:47499841~47500407:+
LUAD	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	5.53	5.18e-08	1.73e-05	0.24	0.24	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
LUAD	cis	rs58873874	0.522	rs6875379	ENSG00000251405.2	CTB-109A12.1	5.53	5.18e-08	1.73e-05	0.45	0.24	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157362615~157460078:-
LUAD	cis	rs1707322	1	rs4539075	ENSG00000234329.1	RP11-767N6.2	5.53	5.18e-08	1.73e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45651039~45651826:-
LUAD	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	5.53	5.18e-08	1.73e-05	0.31	0.24	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	5.53	5.18e-08	1.73e-05	0.31	0.24	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	5.53	5.18e-08	1.73e-05	0.31	0.24	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	5.53	5.18e-08	1.73e-05	0.31	0.24	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-5.53	5.19e-08	1.73e-05	-0.31	-0.24	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
LUAD	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	5.53	5.19e-08	1.73e-05	0.26	0.24	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
LUAD	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-5.53	5.2e-08	1.73e-05	-0.3	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
LUAD	cis	rs9879311	0.966	rs775018	ENSG00000240288.6	GHRLOS	5.53	5.2e-08	1.73e-05	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358461	chr3:10285754~10293449:+
LUAD	cis	rs35740288	0.929	rs1978391	ENSG00000202081.1	RNU6-1280P	-5.53	5.2e-08	1.73e-05	-0.31	-0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85768464	chr15:85651522~85651628:-
LUAD	cis	rs6543140	0.929	rs11465700	ENSG00000234389.1	AC007278.3	5.53	5.2e-08	1.73e-05	0.24	0.24	Blood protein levels;	chr2:102441208	chr2:102438713~102440475:+
LUAD	cis	rs1667284	0.967	rs1791221	ENSG00000266521.1	RP11-650P15.1	5.53	5.2e-08	1.73e-05	0.28	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31639928	chr18:31496645~31497195:-
LUAD	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	5.53	5.21e-08	1.74e-05	0.44	0.24	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
LUAD	cis	rs5753618	0.583	rs5753612	ENSG00000236132.1	CTA-440B3.1	-5.53	5.21e-08	1.74e-05	-0.3	-0.24	Colorectal cancer;	chr22:31425493	chr22:31816379~31817491:-
LUAD	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-5.53	5.21e-08	1.74e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
LUAD	cis	rs7617773	0.78	rs11706277	ENSG00000228638.1	FCF1P2	-5.53	5.21e-08	1.74e-05	-0.3	-0.24	Coronary artery disease;	chr3:48318943	chr3:48290793~48291375:-
LUAD	cis	rs9595908	0.785	rs6561500	ENSG00000212293.1	SNORA16	5.53	5.21e-08	1.74e-05	0.25	0.24	Body mass index;	chr13:32681234	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs3912038	ENSG00000212293.1	SNORA16	5.53	5.21e-08	1.74e-05	0.25	0.24	Body mass index;	chr13:32682061	chr13:32420390~32420516:-
LUAD	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-5.53	5.22e-08	1.74e-05	-0.26	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
LUAD	cis	rs17826219	0.561	rs11655876	ENSG00000263603.1	CTD-2349P21.5	-5.53	5.22e-08	1.74e-05	-0.38	-0.24	Body mass index;	chr17:30690132	chr17:30729469~30731202:+
LUAD	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-5.53	5.22e-08	1.74e-05	-0.29	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
LUAD	cis	rs30380	1	rs27710	ENSG00000272109.1	CTD-2260A17.3	5.53	5.22e-08	1.74e-05	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96804353~96806105:+
LUAD	cis	rs6565180	1	rs68051857	ENSG00000183604.13	SMG1P5	-5.53	5.22e-08	1.74e-05	-0.26	-0.24	Tonsillectomy;	chr16:30348690	chr16:30267553~30335374:-
LUAD	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
LUAD	cis	rs4654783	0.627	rs2092322	ENSG00000228397.1	RP1-224A6.3	-5.53	5.23e-08	1.74e-05	-0.29	-0.24	Endometriosis;	chr1:22109230	chr1:22023994~22024968:-
LUAD	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-5.53	5.23e-08	1.74e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
LUAD	cis	rs9952991	0.527	rs2847259	ENSG00000260302.1	RP11-973H7.1	-5.53	5.23e-08	1.74e-05	-0.36	-0.24	Inflammatory skin disease;	chr18:12775822	chr18:12774651~12775923:-
LUAD	cis	rs2440129	0.632	rs2292353	ENSG00000215067.8	ALOX12-AS1	5.53	5.24e-08	1.75e-05	0.25	0.24	Tonsillectomy;	chr17:7000218	chr17:6876635~7012349:-
LUAD	cis	rs36093844	0.948	rs56271770	ENSG00000279742.1	RP11-700A24.1	-5.53	5.25e-08	1.75e-05	-0.28	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837357	chr11:85852557~85854943:-
LUAD	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-5.53	5.25e-08	1.75e-05	-0.42	-0.24	Depression;	chr6:28111963	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.509	rs2945269	ENSG00000253981.4	ALG1L13P	5.53	5.25e-08	1.75e-05	0.29	0.24	Mood instability;	chr8:8258056	chr8:8236003~8244667:-
LUAD	cis	rs6543140	0.964	rs6748390	ENSG00000234389.1	AC007278.3	5.53	5.25e-08	1.75e-05	0.24	0.24	Blood protein levels;	chr2:102445715	chr2:102438713~102440475:+
LUAD	cis	rs8098244	0.597	rs12964391	ENSG00000264745.1	TTC39C-AS1	5.53	5.25e-08	1.75e-05	0.26	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23734541	chr18:23994213~24015339:-
LUAD	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	5.53	5.26e-08	1.75e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	5.53	5.26e-08	1.75e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
LUAD	cis	rs1707322	1	rs11211232	ENSG00000234329.1	RP11-767N6.2	5.53	5.27e-08	1.75e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45651039~45651826:-
LUAD	cis	rs17684571	0.751	rs6905603	ENSG00000231441.1	RP11-472M19.2	5.53	5.27e-08	1.75e-05	0.37	0.24	Schizophrenia;	chr6:56848145	chr6:56844002~56864078:+
LUAD	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-5.53	5.27e-08	1.75e-05	-0.26	-0.24	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
LUAD	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-5.53	5.27e-08	1.75e-05	-0.24	-0.24	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
LUAD	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	5.53	5.27e-08	1.75e-05	0.3	0.24	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
LUAD	cis	rs36423	0.702	rs1205076	ENSG00000266869.1	RP6-114E22.1	5.53	5.27e-08	1.75e-05	0.38	0.24	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71871335	chr14:71848606~71908430:+
LUAD	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-5.53	5.27e-08	1.75e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
LUAD	cis	rs9287719	0.566	rs34595606	ENSG00000243819.4	RN7SL832P	5.53	5.28e-08	1.76e-05	0.27	0.24	Prostate cancer;	chr2:10582392	chr2:10690344~10692099:+
LUAD	cis	rs1707322	1	rs7553924	ENSG00000234329.1	RP11-767N6.2	5.53	5.28e-08	1.76e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4641257	ENSG00000234329.1	RP11-767N6.2	5.53	5.28e-08	1.76e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs6693336	ENSG00000234329.1	RP11-767N6.2	5.53	5.28e-08	1.76e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45651039~45651826:-
LUAD	cis	rs9914544	0.628	rs4630608	ENSG00000273018.4	CTD-2303H24.2	-5.53	5.29e-08	1.76e-05	-0.29	-0.24	Educational attainment (years of education);	chr17:18775235	chr17:18511221~18551705:-
LUAD	cis	rs1275468	0.731	rs1627431	ENSG00000257497.2	RP11-585P4.5	-5.53	5.29e-08	1.76e-05	-0.37	-0.24	Polycystic ovary syndrome;	chr12:75569132	chr12:75483454~75489820:-
LUAD	cis	rs116095464	1	rs56700778	ENSG00000277812.1	AC021087.1	5.53	5.3e-08	1.76e-05	0.69	0.24	Breast cancer;	chr5:313071	chr5:262769~262881:+
LUAD	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-5.53	5.3e-08	1.76e-05	-0.24	-0.24	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
LUAD	cis	rs2273788	1	rs12555931	ENSG00000204173.9	LRRC37A5P	5.53	5.3e-08	1.76e-05	0.27	0.24	Monocyte count;	chr9:111581096	chr9:111602831~111631289:-
LUAD	cis	rs17684571	0.7	rs16888171	ENSG00000231441.1	RP11-472M19.2	5.53	5.3e-08	1.77e-05	0.34	0.24	Schizophrenia;	chr6:56810369	chr6:56844002~56864078:+
LUAD	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	5.53	5.31e-08	1.77e-05	0.28	0.24	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
LUAD	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	5.53	5.31e-08	1.77e-05	0.35	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
LUAD	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	5.53	5.31e-08	1.77e-05	0.3	0.24	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
LUAD	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-5.53	5.31e-08	1.77e-05	-0.31	-0.24	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
LUAD	cis	rs9595908	0.536	rs73452706	ENSG00000212293.1	SNORA16	5.53	5.31e-08	1.77e-05	0.26	0.24	Body mass index;	chr13:32718155	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-5.53	5.33e-08	1.77e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
LUAD	cis	rs6964587	0.743	rs33993294	ENSG00000188693.7	CYP51A1-AS1	-5.53	5.33e-08	1.77e-05	-0.29	-0.24	Breast cancer;	chr7:92369341	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.773	rs38793	ENSG00000188693.7	CYP51A1-AS1	5.53	5.33e-08	1.77e-05	0.29	0.24	Breast cancer;	chr7:92397873	chr7:92134604~92180725:+
LUAD	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-5.53	5.33e-08	1.77e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-5.53	5.33e-08	1.77e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
LUAD	cis	rs7665090	0.728	rs228617	ENSG00000246560.2	RP11-10L12.4	-5.53	5.33e-08	1.77e-05	-0.3	-0.24	Primary biliary cholangitis;	chr4:102659631	chr4:102828055~102844075:+
LUAD	cis	rs9847710	0.808	rs2564919	ENSG00000242142.1	SERBP1P3	5.53	5.33e-08	1.77e-05	0.27	0.24	Ulcerative colitis;	chr3:52999279	chr3:53064283~53065091:-
LUAD	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	5.53	5.35e-08	1.78e-05	0.42	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
LUAD	cis	rs2919009	0.544	rs2901280	ENSG00000271670.1	RP11-95I16.4	-5.53	5.35e-08	1.78e-05	-0.3	-0.24	Obesity-related traits;	chr10:120895865	chr10:120879256~120880667:-
LUAD	cis	rs62432291	0.681	rs294913	ENSG00000235086.1	FNDC1-IT1	-5.53	5.35e-08	1.78e-05	-0.42	-0.24	Joint mobility (Beighton score);	chr6:159246195	chr6:159240786~159243329:+
LUAD	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-5.53	5.36e-08	1.78e-05	-0.32	-0.24	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
LUAD	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	5.53	5.36e-08	1.78e-05	0.31	0.24	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
LUAD	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	5.53	5.37e-08	1.78e-05	0.3	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
LUAD	cis	rs74233809	1	rs3781285	ENSG00000213277.3	MARCKSL1P1	5.53	5.37e-08	1.79e-05	0.43	0.24	Birth weight;	chr10:103065908	chr10:103175554~103176094:+
LUAD	cis	rs35740288	0.689	rs11630688	ENSG00000202081.1	RNU6-1280P	5.53	5.38e-08	1.79e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85710048	chr15:85651522~85651628:-
LUAD	cis	rs910316	0.523	rs4026175	ENSG00000279594.1	RP11-950C14.10	5.53	5.38e-08	1.79e-05	0.29	0.24	Height;	chr14:75035537	chr14:75011269~75012851:-
LUAD	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	5.53	5.38e-08	1.79e-05	0.38	0.24	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
LUAD	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	5.53	5.38e-08	1.79e-05	0.35	0.24	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
LUAD	cis	rs1707322	0.964	rs785483	ENSG00000234329.1	RP11-767N6.2	-5.53	5.38e-08	1.79e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs796773	ENSG00000234329.1	RP11-767N6.2	-5.53	5.38e-08	1.79e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.896	rs785518	ENSG00000234329.1	RP11-767N6.2	-5.53	5.38e-08	1.79e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785519	ENSG00000234329.1	RP11-767N6.2	-5.53	5.38e-08	1.79e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45651039~45651826:-
LUAD	cis	rs6687821	0.515	rs1407132	ENSG00000267734.1	RP4-604K5.3	5.53	5.38e-08	1.79e-05	0.3	0.24	Yeast infection;	chr1:86928231	chr1:86932199~86934891:-
LUAD	cis	rs748404	0.589	rs3862138	ENSG00000205771.5	CATSPER2P1	-5.53	5.38e-08	1.79e-05	-0.37	-0.24	Lung cancer;	chr15:43523801	chr15:43726918~43747094:-
LUAD	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-5.53	5.39e-08	1.79e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
LUAD	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-5.53	5.39e-08	1.79e-05	-0.25	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
LUAD	cis	rs8098244	0.515	rs4387667	ENSG00000264745.1	TTC39C-AS1	5.53	5.39e-08	1.79e-05	0.26	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716161	chr18:23994213~24015339:-
LUAD	cis	rs394563	0.591	rs237028	ENSG00000231760.4	RP11-350J20.5	5.53	5.39e-08	1.79e-05	0.3	0.24	Dupuytren's disease;	chr6:149397514	chr6:149796151~149826294:-
LUAD	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-5.53	5.4e-08	1.79e-05	-0.27	-0.24	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
LUAD	cis	rs62432291	0.681	rs386818	ENSG00000235086.1	FNDC1-IT1	-5.53	5.4e-08	1.79e-05	-0.42	-0.24	Joint mobility (Beighton score);	chr6:159239223	chr6:159240786~159243329:+
LUAD	cis	rs9500256	0.655	rs12209098	ENSG00000215190.7	LINC00680	5.53	5.41e-08	1.8e-05	0.31	0.24	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57946074~57961501:-
LUAD	cis	rs7182621	0.639	rs36069387	ENSG00000182397.13	DNM1P46	5.52	5.41e-08	1.8e-05	0.29	0.24	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99790156~99806927:-
LUAD	cis	rs8040855	0.86	rs6496775	ENSG00000259774.1	RP11-182J1.13	-5.52	5.41e-08	1.8e-05	-0.31	-0.24	Bulimia nervosa;	chr15:85164910	chr15:84422618~84425882:+
LUAD	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	5.52	5.41e-08	1.8e-05	0.32	0.24	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
LUAD	cis	rs948562	0.947	rs7481388	ENSG00000280010.1	AP001350.4	5.52	5.41e-08	1.8e-05	0.36	0.24	Lymphoma;	chr11:58592143	chr11:58627435~58628528:+
LUAD	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-5.52	5.41e-08	1.8e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
LUAD	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	5.52	5.41e-08	1.8e-05	0.5	0.24	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
LUAD	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-5.52	5.42e-08	1.8e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
LUAD	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-5.52	5.42e-08	1.8e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-5.52	5.42e-08	1.8e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
LUAD	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	5.52	5.42e-08	1.8e-05	0.36	0.24	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
LUAD	cis	rs453301	0.686	rs1045527	ENSG00000253981.4	ALG1L13P	-5.52	5.42e-08	1.8e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9032531	chr8:8236003~8244667:-
LUAD	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-5.52	5.43e-08	1.8e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
LUAD	cis	rs6687821	0.515	rs11161914	ENSG00000267734.1	RP4-604K5.3	-5.52	5.44e-08	1.81e-05	-0.3	-0.24	Yeast infection;	chr1:86977846	chr1:86932199~86934891:-
LUAD	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	5.52	5.44e-08	1.81e-05	0.28	0.24	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
LUAD	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-5.52	5.44e-08	1.81e-05	-0.33	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
LUAD	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-5.52	5.44e-08	1.81e-05	-0.32	-0.24	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
LUAD	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-5.52	5.44e-08	1.81e-05	-0.27	-0.24	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
LUAD	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	5.52	5.45e-08	1.81e-05	0.31	0.24	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
LUAD	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	5.52	5.45e-08	1.81e-05	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
LUAD	cis	rs4713118	0.824	rs2179095	ENSG00000219392.1	RP1-265C24.5	5.52	5.45e-08	1.81e-05	0.32	0.24	Parkinson's disease;	chr6:27783079	chr6:28115628~28116551:+
LUAD	cis	rs6496044	0.507	rs7175731	ENSG00000259407.1	RP11-158M2.3	5.52	5.45e-08	1.81e-05	0.22	0.24	Interstitial lung disease;	chr15:85611115	chr15:85744109~85750281:-
LUAD	cis	rs6496044	0.507	rs1471455	ENSG00000259407.1	RP11-158M2.3	5.52	5.45e-08	1.81e-05	0.22	0.24	Interstitial lung disease;	chr15:85611496	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.787	rs35250181	ENSG00000202081.1	RNU6-1280P	5.52	5.46e-08	1.81e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85699431	chr15:85651522~85651628:-
LUAD	cis	rs10091374	0.839	rs6472533	ENSG00000253967.1	RP11-333A23.4	-5.52	5.47e-08	1.81e-05	-0.28	-0.24	Cardiac Troponin-T levels;	chr8:70482378	chr8:70471134~70485687:+
LUAD	cis	rs36093844	0.8	rs75203358	ENSG00000279742.1	RP11-700A24.1	-5.52	5.47e-08	1.82e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85856347	chr11:85852557~85854943:-
LUAD	cis	rs2880765	0.835	rs56406982	ENSG00000259295.5	CSPG4P12	5.52	5.47e-08	1.82e-05	0.28	0.24	Coronary artery disease;	chr15:85493148	chr15:85191438~85213905:+
LUAD	cis	rs9928842	0.679	rs4888361	ENSG00000280152.1	RP11-331F4.5	5.52	5.47e-08	1.82e-05	0.26	0.24	Alcoholic chronic pancreatitis;	chr16:75233778	chr16:75245994~75250077:-
LUAD	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-5.52	5.47e-08	1.82e-05	-0.28	-0.24	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
LUAD	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-5.52	5.47e-08	1.82e-05	-0.31	-0.24	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
LUAD	cis	rs12468226	1	rs16839077	ENSG00000272966.1	RP11-686O6.1	5.52	5.48e-08	1.82e-05	0.42	0.24	Urate levels;	chr2:202343970	chr2:202336739~202337200:+
LUAD	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	5.52	5.49e-08	1.82e-05	0.31	0.24	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
LUAD	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	5.52	5.49e-08	1.82e-05	0.29	0.24	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
LUAD	cis	rs71636778	0.509	rs35917448	ENSG00000260063.1	RP5-968P14.2	-5.52	5.49e-08	1.82e-05	-0.45	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26690834	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs71514277	ENSG00000260063.1	RP5-968P14.2	-5.52	5.49e-08	1.82e-05	-0.45	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26707937	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.57	rs12737407	ENSG00000260063.1	RP5-968P14.2	-5.52	5.49e-08	1.82e-05	-0.45	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26709671	chr1:26692132~26694131:-
LUAD	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-5.52	5.49e-08	1.82e-05	-0.34	-0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
LUAD	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-5.52	5.5e-08	1.82e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
LUAD	cis	rs4568518	0.53	rs4493811	ENSG00000279048.1	RP11-511H23.2	5.52	5.5e-08	1.83e-05	0.2	0.24	Measles;	chr7:17943746	chr7:17940503~17942922:+
LUAD	cis	rs2948294	0.566	rs13274039	ENSG00000173295.6	FAM86B3P	5.52	5.51e-08	1.83e-05	0.27	0.24	Red cell distribution width;	chr8:8254137	chr8:8228595~8244865:+
LUAD	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-5.52	5.51e-08	1.83e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
LUAD	cis	rs7044106	0.708	rs991121	ENSG00000238181.2	AHCYP2	-5.52	5.52e-08	1.83e-05	-0.31	-0.24	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120720673~120721972:+
LUAD	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	5.52	5.53e-08	1.83e-05	0.31	0.24	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
LUAD	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-5.52	5.53e-08	1.83e-05	-0.31	-0.24	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
LUAD	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	5.52	5.53e-08	1.83e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
LUAD	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-5.52	5.53e-08	1.84e-05	-0.32	-0.24	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
LUAD	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	5.52	5.54e-08	1.84e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
LUAD	cis	rs74233809	1	rs12220743	ENSG00000213277.3	MARCKSL1P1	5.52	5.54e-08	1.84e-05	0.43	0.24	Birth weight;	chr10:103092155	chr10:103175554~103176094:+
LUAD	cis	rs12289961	0.634	rs11229433	ENSG00000280010.1	AP001350.4	5.52	5.54e-08	1.84e-05	0.4	0.24	Lymphoma;	chr11:58417863	chr11:58627435~58628528:+
LUAD	cis	rs853679	0.546	rs175597	ENSG00000219392.1	RP1-265C24.5	-5.52	5.54e-08	1.84e-05	-0.47	-0.24	Depression;	chr6:27842848	chr6:28115628~28116551:+
LUAD	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-5.52	5.55e-08	1.84e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-5.52	5.55e-08	1.84e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
LUAD	cis	rs6687758	0.687	rs12137323	ENSG00000228437.4	RP11-400N13.2	5.52	5.56e-08	1.84e-05	0.37	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221952186	chr1:221966341~221984964:+
LUAD	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-5.52	5.56e-08	1.84e-05	-0.28	-0.24	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
LUAD	cis	rs9847710	0.566	rs2564951	ENSG00000242142.1	SERBP1P3	5.52	5.56e-08	1.84e-05	0.29	0.24	Ulcerative colitis;	chr3:53026433	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000224373.3	IGHV4-59	5.52	5.56e-08	1.84e-05	0.15	0.24	Kawasaki disease;	chr14:106780451	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000224373.3	IGHV4-59	5.52	5.56e-08	1.84e-05	0.15	0.24	Kawasaki disease;	chr14:106781682	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000224373.3	IGHV4-59	5.52	5.56e-08	1.84e-05	0.15	0.24	Kawasaki disease;	chr14:106781820	chr14:106627249~106627825:-
LUAD	cis	rs1015362	0.504	rs6059552	ENSG00000276073.1	RP5-1125A11.7	-5.52	5.57e-08	1.84e-05	-0.3	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33985617~33988989:-
LUAD	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-5.52	5.57e-08	1.85e-05	-0.28	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
LUAD	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	5.52	5.57e-08	1.85e-05	0.28	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
LUAD	cis	rs6964587	0.773	rs12536421	ENSG00000188693.7	CYP51A1-AS1	-5.52	5.57e-08	1.85e-05	-0.29	-0.24	Breast cancer;	chr7:92378906	chr7:92134604~92180725:+
LUAD	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	5.52	5.57e-08	1.85e-05	0.37	0.24	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
LUAD	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	5.52	5.57e-08	1.85e-05	0.33	0.24	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
LUAD	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-5.52	5.58e-08	1.85e-05	-0.28	-0.24	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
LUAD	cis	rs36093844	0.752	rs56396016	ENSG00000279742.1	RP11-700A24.1	-5.52	5.58e-08	1.85e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85885347	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.747	rs17817314	ENSG00000279742.1	RP11-700A24.1	-5.52	5.58e-08	1.85e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85883929	chr11:85852557~85854943:-
LUAD	cis	rs2404602	0.655	rs8028294	ENSG00000259422.1	RP11-593F23.1	5.52	5.58e-08	1.85e-05	0.28	0.24	Blood metabolite levels;	chr15:76792536	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-5.52	5.58e-08	1.85e-05	-0.3	-0.24	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
LUAD	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-5.52	5.59e-08	1.85e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-5.52	5.59e-08	1.85e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	5.52	5.59e-08	1.85e-05	0.27	0.24	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
LUAD	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	5.52	5.59e-08	1.85e-05	0.34	0.24	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
LUAD	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-5.52	5.6e-08	1.86e-05	-0.53	-0.24	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
LUAD	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-5.52	5.6e-08	1.86e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
LUAD	cis	rs2404602	0.692	rs58973160	ENSG00000259422.1	RP11-593F23.1	5.52	5.61e-08	1.86e-05	0.28	0.24	Blood metabolite levels;	chr15:76708001	chr15:76174891~76181486:-
LUAD	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	5.52	5.61e-08	1.86e-05	0.35	0.24	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
LUAD	cis	rs10214930	0.697	rs4722724	ENSG00000235574.1	AC073150.6	5.52	5.61e-08	1.86e-05	0.29	0.24	Hypospadias;	chr7:27615314	chr7:27491682~27492765:-
LUAD	cis	rs30380	1	rs469758	ENSG00000272109.1	CTD-2260A17.3	-5.52	5.62e-08	1.86e-05	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96804353~96806105:+
LUAD	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	5.52	5.62e-08	1.86e-05	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
LUAD	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-5.52	5.62e-08	1.86e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
LUAD	cis	rs2280018	0.963	rs12928424	ENSG00000188599.16	NPIPP1	-5.52	5.62e-08	1.86e-05	-0.2	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15104312~15123498:-
LUAD	cis	rs30380	0.553	rs27527	ENSG00000272109.1	CTD-2260A17.3	-5.52	5.62e-08	1.86e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96816265	chr5:96804353~96806105:+
LUAD	cis	rs5753618	0.583	rs34545960	ENSG00000236132.1	CTA-440B3.1	-5.52	5.63e-08	1.86e-05	-0.3	-0.24	Colorectal cancer;	chr22:31416476	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.583	rs5749270	ENSG00000236132.1	CTA-440B3.1	-5.52	5.63e-08	1.86e-05	-0.3	-0.24	Colorectal cancer;	chr22:31416867	chr22:31816379~31817491:-
LUAD	cis	rs1823874	0.71	rs4246297	ENSG00000182397.13	DNM1P46	-5.52	5.63e-08	1.86e-05	-0.3	-0.24	IgG glycosylation;	chr15:99826723	chr15:99790156~99806927:-
LUAD	cis	rs7618915	0.851	rs34228726	ENSG00000243224.1	RP5-1157M23.2	-5.52	5.63e-08	1.86e-05	-0.26	-0.24	Bipolar disorder;	chr3:52288781	chr3:52239258~52241097:+
LUAD	cis	rs6142102	0.812	rs6120440	ENSG00000275784.1	RP5-1125A11.6	5.52	5.64e-08	1.87e-05	0.29	0.24	Skin pigmentation;	chr20:33929779	chr20:33989480~33991818:-
LUAD	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-5.52	5.65e-08	1.87e-05	-0.26	-0.24	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
LUAD	cis	rs75920871	0.528	rs10892071	ENSG00000254851.1	RP11-109L13.1	5.52	5.65e-08	1.87e-05	0.35	0.24	Subjective well-being;	chr11:117083849	chr11:117135528~117138582:+
LUAD	cis	rs2404602	0.716	rs66754747	ENSG00000259422.1	RP11-593F23.1	5.52	5.65e-08	1.87e-05	0.28	0.24	Blood metabolite levels;	chr15:76536227	chr15:76174891~76181486:-
LUAD	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	5.52	5.65e-08	1.87e-05	0.32	0.24	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
LUAD	cis	rs36093844	0.8	rs79349553	ENSG00000279742.1	RP11-700A24.1	-5.52	5.66e-08	1.87e-05	-0.32	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85856793	chr11:85852557~85854943:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000224373.3	IGHV4-59	5.52	5.66e-08	1.87e-05	0.16	0.24	Kawasaki disease;	chr14:106691290	chr14:106627249~106627825:-
LUAD	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-5.52	5.66e-08	1.87e-05	-0.29	-0.24	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
LUAD	cis	rs891378	0.959	rs1864370	ENSG00000274245.1	RP11-357P18.2	-5.52	5.66e-08	1.87e-05	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207245687	chr1:207372559~207373252:+
LUAD	cis	rs891378	1	rs1429906	ENSG00000274245.1	RP11-357P18.2	-5.52	5.66e-08	1.87e-05	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207246982	chr1:207372559~207373252:+
LUAD	cis	rs10214930	0.651	rs42111	ENSG00000235574.1	AC073150.6	5.52	5.67e-08	1.88e-05	0.3	0.24	Hypospadias;	chr7:27682962	chr7:27491682~27492765:-
LUAD	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	5.52	5.67e-08	1.88e-05	0.28	0.24	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
LUAD	cis	rs10129255	1	rs10129319	ENSG00000224373.3	IGHV4-59	5.52	5.67e-08	1.88e-05	0.16	0.24	Kawasaki disease;	chr14:106767996	chr14:106627249~106627825:-
LUAD	cis	rs2276314	0.512	rs7227264	ENSG00000278986.1	RP11-723J4.3	-5.52	5.67e-08	1.88e-05	-0.26	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35874668	chr18:35972151~35973916:+
LUAD	cis	rs944289	0.553	rs1305576	ENSG00000257826.1	RP11-116N8.4	-5.52	5.68e-08	1.88e-05	-0.27	-0.24	Thyroid cancer;	chr14:36161528	chr14:36061026~36067190:-
LUAD	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-5.52	5.68e-08	1.88e-05	-0.26	-0.24	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-5.52	5.68e-08	1.88e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
LUAD	cis	rs6687821	0.515	rs4656133	ENSG00000267734.1	RP4-604K5.3	-5.52	5.69e-08	1.88e-05	-0.3	-0.24	Yeast infection;	chr1:87000140	chr1:86932199~86934891:-
LUAD	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	5.52	5.69e-08	1.88e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
LUAD	cis	rs9450351	0.744	rs9450317	ENSG00000203875.9	SNHG5	-5.52	5.7e-08	1.88e-05	-0.55	-0.24	Interferon gamma-induced protein 10 levels;	chr6:85715052	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-5.51	5.7e-08	1.89e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-5.51	5.71e-08	1.89e-05	-0.24	-0.24	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
LUAD	cis	rs6565180	1	rs6565180	ENSG00000183604.13	SMG1P5	-5.51	5.72e-08	1.89e-05	-0.26	-0.24	Tonsillectomy;	chr16:30350020	chr16:30267553~30335374:-
LUAD	cis	rs7246657	0.639	rs3112434	ENSG00000276846.1	CTD-3220F14.3	-5.51	5.72e-08	1.89e-05	-0.33	-0.24	Coronary artery calcification;	chr19:37707247	chr19:37314868~37315620:-
LUAD	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-5.51	5.72e-08	1.89e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
LUAD	cis	rs516805	0.596	rs2606625	ENSG00000279453.1	RP3-425C14.4	-5.51	5.73e-08	1.9e-05	-0.33	-0.24	Lymphocyte counts;	chr6:122165363	chr6:122436789~122439223:-
LUAD	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-5.51	5.74e-08	1.9e-05	-0.28	-0.24	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
LUAD	cis	rs910316	1	rs3742780	ENSG00000259138.1	RP11-950C14.7	5.51	5.74e-08	1.9e-05	0.26	0.24	Height;	chr14:75038305	chr14:75127153~75136930:+
LUAD	cis	rs1707322	0.789	rs7540578	ENSG00000234329.1	RP11-767N6.2	5.51	5.75e-08	1.9e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45651039~45651826:-
LUAD	cis	rs7804306	1	rs13225545	ENSG00000233264.2	AC006042.8	5.51	5.75e-08	1.9e-05	0.46	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027509	chr7:7980312~7982228:+
LUAD	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-5.51	5.76e-08	1.9e-05	-0.32	-0.24	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
LUAD	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-5.51	5.76e-08	1.9e-05	-0.29	-0.24	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
LUAD	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-5.51	5.76e-08	1.9e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-5.51	5.76e-08	1.9e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
LUAD	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-5.51	5.76e-08	1.9e-05	-0.28	-0.24	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000211972.2	IGHV3-66	5.51	5.76e-08	1.9e-05	0.21	0.24	Kawasaki disease;	chr14:106783079	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000211972.2	IGHV3-66	5.51	5.76e-08	1.9e-05	0.21	0.24	Kawasaki disease;	chr14:106783685	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000211972.2	IGHV3-66	5.51	5.76e-08	1.9e-05	0.21	0.24	Kawasaki disease;	chr14:106784199	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000211972.2	IGHV3-66	5.51	5.76e-08	1.9e-05	0.21	0.24	Kawasaki disease;	chr14:106784709	chr14:106675017~106675544:-
LUAD	cis	rs1722141	0.634	rs2453850	ENSG00000229628.1	AC073115.7	5.51	5.77e-08	1.91e-05	0.39	0.24	Sitting height ratio;	chr7:45941135	chr7:45990905~46000898:+
LUAD	cis	rs2749097	1	rs2749097	ENSG00000244256.3	RN7SL130P	-5.51	5.77e-08	1.91e-05	-0.35	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63661797	chr1:63655743~63656047:+
LUAD	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-5.51	5.77e-08	1.91e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-5.51	5.77e-08	1.91e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
LUAD	cis	rs12468226	0.938	rs4675274	ENSG00000272966.1	RP11-686O6.1	-5.51	5.77e-08	1.91e-05	-0.41	-0.24	Urate levels;	chr2:202243145	chr2:202336739~202337200:+
LUAD	cis	rs11051970	0.559	rs12578899	ENSG00000274964.1	RP11-817I4.1	-5.51	5.78e-08	1.91e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32332017	chr12:32339368~32340724:+
LUAD	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	5.51	5.78e-08	1.91e-05	0.29	0.24	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
LUAD	cis	rs8098244	0.597	rs883083	ENSG00000264745.1	TTC39C-AS1	5.51	5.78e-08	1.91e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23856448	chr18:23994213~24015339:-
LUAD	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-5.51	5.78e-08	1.91e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
LUAD	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-5.51	5.78e-08	1.91e-05	-0.27	-0.24	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000224373.3	IGHV4-59	5.51	5.8e-08	1.91e-05	0.16	0.24	Kawasaki disease;	chr14:106690981	chr14:106627249~106627825:-
LUAD	cis	rs9287719	0.674	rs12620209	ENSG00000243819.4	RN7SL832P	5.51	5.8e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10580315	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.674	rs12622551	ENSG00000243819.4	RN7SL832P	5.51	5.8e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10580317	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10182589	ENSG00000243819.4	RN7SL832P	5.51	5.8e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10580538	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10208103	ENSG00000243819.4	RN7SL832P	5.51	5.8e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10580741	chr2:10690344~10692099:+
LUAD	cis	rs2412819	0.597	rs2412821	ENSG00000249839.1	AC011330.5	-5.51	5.8e-08	1.92e-05	-0.38	-0.24	Lung cancer;	chr15:43864966	chr15:43663654~43684339:-
LUAD	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	5.51	5.81e-08	1.92e-05	0.48	0.24	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
LUAD	cis	rs910316	1	rs7303	ENSG00000259138.1	RP11-950C14.7	5.51	5.81e-08	1.92e-05	0.26	0.24	Height;	chr14:75053362	chr14:75127153~75136930:+
LUAD	cis	rs910316	1	rs10143132	ENSG00000259138.1	RP11-950C14.7	5.51	5.81e-08	1.92e-05	0.26	0.24	Height;	chr14:75059147	chr14:75127153~75136930:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000211974.3	IGHV2-70	-5.51	5.82e-08	1.92e-05	-0.26	-0.24	Kawasaki disease;	chr14:106771605	chr14:106723574~106724093:-
LUAD	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-5.51	5.82e-08	1.92e-05	-0.2	-0.24	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
LUAD	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	5.51	5.83e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
LUAD	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-5.51	5.83e-08	1.92e-05	-0.28	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000211974.3	IGHV2-70	5.51	5.83e-08	1.93e-05	0.26	0.24	Kawasaki disease;	chr14:106782238	chr14:106723574~106724093:-
LUAD	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	5.51	5.85e-08	1.93e-05	0.3	0.24	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
LUAD	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-5.51	5.85e-08	1.93e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
LUAD	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-5.51	5.86e-08	1.93e-05	-0.26	-0.24	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
LUAD	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	5.51	5.86e-08	1.94e-05	0.22	0.24	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
LUAD	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-5.51	5.87e-08	1.94e-05	-0.29	-0.24	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
LUAD	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	5.51	5.87e-08	1.94e-05	0.28	0.24	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
LUAD	cis	rs9860428	0.564	rs10804503	ENSG00000242770.2	RP11-180K7.1	5.51	5.87e-08	1.94e-05	0.26	0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112794511	chr3:112802478~112812819:+
LUAD	cis	rs7617773	0.746	rs11713476	ENSG00000228638.1	FCF1P2	-5.51	5.87e-08	1.94e-05	-0.29	-0.24	Coronary artery disease;	chr3:48333944	chr3:48290793~48291375:-
LUAD	cis	rs62432291	0.681	rs439126	ENSG00000235086.1	FNDC1-IT1	-5.51	5.87e-08	1.94e-05	-0.42	-0.24	Joint mobility (Beighton score);	chr6:159235600	chr6:159240786~159243329:+
LUAD	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-5.51	5.88e-08	1.94e-05	-0.25	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	5.51	5.88e-08	1.94e-05	0.26	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
LUAD	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	5.51	5.88e-08	1.94e-05	0.26	0.24	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	5.51	5.88e-08	1.94e-05	0.26	0.24	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
LUAD	cis	rs1707322	1	rs7532204	ENSG00000234329.1	RP11-767N6.2	-5.51	5.89e-08	1.95e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.835	rs946525	ENSG00000234329.1	RP11-767N6.2	-5.51	5.89e-08	1.95e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs946524	ENSG00000234329.1	RP11-767N6.2	-5.51	5.89e-08	1.95e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660336	ENSG00000234329.1	RP11-767N6.2	-5.51	5.89e-08	1.95e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-5.51	5.9e-08	1.95e-05	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
LUAD	cis	rs2404602	0.692	rs35557205	ENSG00000259422.1	RP11-593F23.1	5.51	5.9e-08	1.95e-05	0.28	0.24	Blood metabolite levels;	chr15:76838370	chr15:76174891~76181486:-
LUAD	cis	rs6687821	0.515	rs4431894	ENSG00000267734.1	RP4-604K5.3	-5.51	5.9e-08	1.95e-05	-0.3	-0.24	Yeast infection;	chr1:87063801	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs7543542	ENSG00000267734.1	RP4-604K5.3	-5.51	5.9e-08	1.95e-05	-0.3	-0.24	Yeast infection;	chr1:87069356	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs2390264	ENSG00000267734.1	RP4-604K5.3	-5.51	5.9e-08	1.95e-05	-0.3	-0.24	Yeast infection;	chr1:87072743	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs2798674	ENSG00000267734.1	RP4-604K5.3	-5.51	5.9e-08	1.95e-05	-0.3	-0.24	Yeast infection;	chr1:87074834	chr1:86932199~86934891:-
LUAD	cis	rs1707322	0.964	rs6675259	ENSG00000234329.1	RP11-767N6.2	-5.51	5.91e-08	1.95e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45651039~45651826:-
LUAD	cis	rs12468226	1	rs7587234	ENSG00000272966.1	RP11-686O6.1	5.51	5.91e-08	1.95e-05	0.41	0.24	Urate levels;	chr2:202351699	chr2:202336739~202337200:+
LUAD	cis	rs7208859	0.573	rs11654035	ENSG00000263603.1	CTD-2349P21.5	-5.51	5.92e-08	1.95e-05	-0.43	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30729469~30731202:+
LUAD	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	5.51	5.92e-08	1.95e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	5.51	5.92e-08	1.95e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
LUAD	cis	rs6496932	0.563	rs2344083	ENSG00000259630.2	CTD-2262B20.1	-5.51	5.92e-08	1.95e-05	-0.29	-0.24	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85415228~85415633:+
LUAD	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.51	5.92e-08	1.95e-05	0.3	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
LUAD	cis	rs2255336	0.938	rs4548707	ENSG00000245648.1	RP11-277P12.20	-5.51	5.92e-08	1.95e-05	-0.37	-0.24	Blood protein levels;	chr12:10467634	chr12:10363769~10398506:+
LUAD	cis	rs62246343	0.719	rs62246301	ENSG00000254485.4	RP11-380O24.1	5.51	5.93e-08	1.95e-05	0.36	0.24	Fibrinogen levels;	chr3:9409599	chr3:9292588~9363303:-
LUAD	cis	rs62246343	0.719	rs62246302	ENSG00000254485.4	RP11-380O24.1	5.51	5.93e-08	1.95e-05	0.36	0.24	Fibrinogen levels;	chr3:9411761	chr3:9292588~9363303:-
LUAD	cis	rs2832077	0.943	rs11701445	ENSG00000232855.5	AF131217.1	5.51	5.93e-08	1.96e-05	0.27	0.24	Cognitive test performance;	chr21:28788485	chr21:28439346~28674848:-
LUAD	cis	rs1707322	1	rs11211200	ENSG00000234329.1	RP11-767N6.2	5.51	5.93e-08	1.96e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45651039~45651826:-
LUAD	cis	rs853679	0.546	rs200996	ENSG00000219392.1	RP1-265C24.5	-5.51	5.93e-08	1.96e-05	-0.46	-0.24	Depression;	chr6:27844050	chr6:28115628~28116551:+
LUAD	cis	rs36093844	0.8	rs17817326	ENSG00000279742.1	RP11-700A24.1	-5.51	5.95e-08	1.96e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884170	chr11:85852557~85854943:-
LUAD	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-5.51	5.95e-08	1.96e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000224373.3	IGHV4-59	5.51	5.95e-08	1.96e-05	0.16	0.24	Kawasaki disease;	chr14:106785589	chr14:106627249~106627825:-
LUAD	cis	rs9309473	0.606	rs62149804	ENSG00000163016.8	ALMS1P	5.51	5.96e-08	1.96e-05	0.36	0.24	Metabolite levels;	chr2:73609879	chr2:73644919~73685576:+
LUAD	cis	rs2790457	0.792	rs1265841	ENSG00000254635.4	WAC-AS1	-5.51	5.96e-08	1.96e-05	-0.26	-0.24	Multiple myeloma;	chr10:28631772	chr10:28522652~28532743:-
LUAD	cis	rs516805	0.563	rs2606635	ENSG00000279453.1	RP3-425C14.4	-5.51	5.96e-08	1.96e-05	-0.33	-0.24	Lymphocyte counts;	chr6:122101222	chr6:122436789~122439223:-
LUAD	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	5.51	5.96e-08	1.96e-05	0.37	0.24	Pain;	chr19:21567449	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	5.51	5.96e-08	1.96e-05	0.37	0.24	Pain;	chr19:21567846	chr19:21554640~21569237:-
LUAD	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	5.51	5.96e-08	1.96e-05	0.3	0.24	Myopia;	chr6:28302807	chr6:28176188~28176674:+
LUAD	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-5.51	5.96e-08	1.96e-05	-0.26	-0.24	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
LUAD	cis	rs8177876	0.749	rs78707250	ENSG00000261061.1	RP11-303E16.2	-5.51	5.96e-08	1.97e-05	-0.43	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81030770~81031485:+
LUAD	cis	rs858239	0.539	rs4295546	ENSG00000230042.1	AK3P3	-5.51	5.97e-08	1.97e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23129178~23129841:+
LUAD	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	5.51	5.97e-08	1.97e-05	0.26	0.24	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	5.51	5.97e-08	1.97e-05	0.26	0.24	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
LUAD	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	5.51	5.97e-08	1.97e-05	0.36	0.24	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
LUAD	cis	rs7804306	0.826	rs73050940	ENSG00000233264.2	AC006042.8	5.51	5.97e-08	1.97e-05	0.5	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027882	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs56142807	ENSG00000233264.2	AC006042.8	5.51	5.97e-08	1.97e-05	0.5	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8028562	chr7:7980312~7982228:+
LUAD	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	5.51	5.98e-08	1.97e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
LUAD	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-5.51	5.98e-08	1.97e-05	-0.24	-0.24	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
LUAD	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	5.51	5.99e-08	1.97e-05	0.28	0.24	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
LUAD	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	5.51	5.99e-08	1.97e-05	0.35	0.24	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-5.51	5.99e-08	1.97e-05	-0.27	-0.24	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
LUAD	cis	rs1015362	0.503	rs4911371	ENSG00000276073.1	RP5-1125A11.7	-5.51	6e-08	1.98e-05	-0.31	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33985617~33988989:-
LUAD	cis	rs293748	0.713	rs158789	ENSG00000250155.1	CTD-2353F22.1	-5.51	6e-08	1.98e-05	-0.34	-0.24	Obesity-related traits;	chr5:36834955	chr5:36666214~36725195:-
LUAD	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-5.51	6e-08	1.98e-05	-0.3	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
LUAD	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	5.51	6e-08	1.98e-05	0.48	0.24	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
LUAD	cis	rs4713118	0.516	rs6931858	ENSG00000204709.4	LINC01556	5.51	6.01e-08	1.98e-05	0.33	0.24	Parkinson's disease;	chr6:28110633	chr6:28943877~28944537:+
LUAD	cis	rs301901	0.698	rs2886593	ENSG00000250155.1	CTD-2353F22.1	5.51	6.01e-08	1.98e-05	0.26	0.24	Height;	chr5:37427041	chr5:36666214~36725195:-
LUAD	cis	rs11098499	0.874	rs17839089	ENSG00000248280.1	RP11-33B1.2	5.51	6.01e-08	1.98e-05	0.31	0.24	Corneal astigmatism;	chr4:119189914	chr4:119440561~119450157:-
LUAD	cis	rs240993	0.812	rs9400476	ENSG00000230177.1	RP5-1112D6.4	5.5	6.02e-08	1.98e-05	0.24	0.24	Inflammatory skin disease;Psoriasis;	chr6:111463172	chr6:111277932~111278742:+
LUAD	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-5.5	6.02e-08	1.98e-05	-0.31	-0.24	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
LUAD	cis	rs12468226	0.817	rs6722588	ENSG00000272966.1	RP11-686O6.1	-5.5	6.02e-08	1.98e-05	-0.41	-0.24	Urate levels;	chr2:202187163	chr2:202336739~202337200:+
LUAD	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-5.5	6.02e-08	1.98e-05	-0.34	-0.24	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
LUAD	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
LUAD	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	5.5	6.03e-08	1.99e-05	0.3	0.24	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
LUAD	cis	rs516805	0.748	rs562616	ENSG00000279453.1	RP3-425C14.4	-5.5	6.04e-08	1.99e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122467041	chr6:122436789~122439223:-
LUAD	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	5.5	6.04e-08	1.99e-05	0.35	0.24	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	5.5	6.04e-08	1.99e-05	0.35	0.24	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
LUAD	cis	rs9435732	0.524	rs9435660	ENSG00000235241.1	RP11-108M9.5	5.5	6.05e-08	1.99e-05	0.31	0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16987578	chr1:16889095~16889602:+
LUAD	cis	rs2548724	0.588	rs17333350	ENSG00000250682.4	LINC00491	-5.5	6.05e-08	1.99e-05	-0.29	-0.24	Type 2 diabetes;	chr5:102478905	chr5:102609156~102671559:-
LUAD	cis	rs62432291	0.681	rs420054	ENSG00000235086.1	FNDC1-IT1	-5.5	6.05e-08	1.99e-05	-0.41	-0.24	Joint mobility (Beighton score);	chr6:159234052	chr6:159240786~159243329:+
LUAD	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-5.5	6.05e-08	1.99e-05	-0.38	-0.24	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
LUAD	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-5.5	6.06e-08	1.99e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
LUAD	cis	rs7618501	0.574	rs6765484	ENSG00000234667.1	ACTBP13	5.5	6.06e-08	1.99e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50003880	chr3:49873347~49877980:-
LUAD	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	5.5	6.06e-08	1.99e-05	0.33	0.24	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-5.5	6.06e-08	1.99e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-5.5	6.06e-08	1.99e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
LUAD	cis	rs8031584	0.651	rs28664821	ENSG00000259845.1	HERC2P10	-5.5	6.06e-08	1.99e-05	-0.28	-0.24	Huntington's disease progression;	chr15:30880120	chr15:30815271~30844153:+
LUAD	cis	rs1707322	1	rs10890370	ENSG00000234329.1	RP11-767N6.2	5.5	6.06e-08	1.99e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45651039~45651826:-
LUAD	cis	rs783540	0.5	rs7163840	ENSG00000278603.1	RP13-608F4.5	-5.5	6.07e-08	2e-05	-0.32	-0.24	Schizophrenia;	chr15:82729551	chr15:82472203~82472426:+
LUAD	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-5.5	6.08e-08	2e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
LUAD	cis	rs1154275	0.537	rs9832885	ENSG00000242770.2	RP11-180K7.1	5.5	6.08e-08	2e-05	0.26	0.24	Takotsubo syndrome;	chr3:112799612	chr3:112802478~112812819:+
LUAD	cis	rs9595908	0.785	rs9315174	ENSG00000212293.1	SNORA16	5.5	6.08e-08	2e-05	0.26	0.24	Body mass index;	chr13:32645750	chr13:32420390~32420516:-
LUAD	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-5.5	6.08e-08	2e-05	-0.29	-0.24	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-5.5	6.08e-08	2e-05	-0.29	-0.24	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
LUAD	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-5.5	6.08e-08	2e-05	-0.3	-0.24	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000254174.1	IGHV1-12	5.5	6.1e-08	2.01e-05	0.16	0.24	Kawasaki disease;	chr14:106673891	chr14:106122420~106122709:-
LUAD	cis	rs7176527	0.848	rs72630462	ENSG00000188388.10	GOLGA6L3	5.5	6.1e-08	2.01e-05	0.35	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:85240472~85247170:+
LUAD	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	5.5	6.1e-08	2.01e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
LUAD	cis	rs71636778	0.509	rs12738345	ENSG00000260063.1	RP5-968P14.2	-5.5	6.11e-08	2.01e-05	-0.45	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26693253	chr1:26692132~26694131:-
LUAD	cis	rs1707322	1	rs1613296	ENSG00000234329.1	RP11-767N6.2	-5.5	6.11e-08	2.01e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45651039~45651826:-
LUAD	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-5.5	6.12e-08	2.01e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
LUAD	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-5.5	6.12e-08	2.01e-05	-0.27	-0.24	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
LUAD	cis	rs2562456	0.755	rs1879234	ENSG00000268081.1	RP11-678G14.2	-5.5	6.12e-08	2.01e-05	-0.37	-0.24	Pain;	chr19:21521677	chr19:21554640~21569237:-
LUAD	cis	rs9595908	0.758	rs7329120	ENSG00000212293.1	SNORA16	5.5	6.12e-08	2.01e-05	0.26	0.24	Body mass index;	chr13:32646605	chr13:32420390~32420516:-
LUAD	cis	rs516805	0.63	rs2606638	ENSG00000279453.1	RP3-425C14.4	-5.5	6.13e-08	2.01e-05	-0.33	-0.24	Lymphocyte counts;	chr6:122102107	chr6:122436789~122439223:-
LUAD	cis	rs8098244	0.557	rs11660632	ENSG00000264745.1	TTC39C-AS1	5.5	6.13e-08	2.01e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696084	chr18:23994213~24015339:-
LUAD	cis	rs7618501	0.602	rs2624816	ENSG00000234667.1	ACTBP13	5.5	6.13e-08	2.01e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50079879	chr3:49873347~49877980:-
LUAD	cis	rs4938303	0.718	rs10892023	ENSG00000280143.1	AP000892.6	5.5	6.14e-08	2.02e-05	0.34	0.24	Triglycerides;	chr11:116727532	chr11:117204967~117210292:+
LUAD	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-5.5	6.14e-08	2.02e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
LUAD	cis	rs1876905	0.62	rs377716	ENSG00000272356.1	RP5-1112D6.8	-5.5	6.14e-08	2.02e-05	-0.28	-0.24	Mean corpuscular hemoglobin;	chr6:111181705	chr6:111309203~111313517:+
LUAD	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-5.5	6.14e-08	2.02e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
LUAD	cis	rs897984	0.762	rs1870293	ENSG00000260911.2	RP11-196G11.2	-5.5	6.14e-08	2.02e-05	-0.22	-0.24	Dementia with Lewy bodies;	chr16:30959620	chr16:31043150~31049868:+
LUAD	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	5.5	6.15e-08	2.02e-05	0.29	0.24	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	5.5	6.15e-08	2.02e-05	0.36	0.24	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
LUAD	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-5.5	6.16e-08	2.02e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
LUAD	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	5.5	6.17e-08	2.03e-05	0.37	0.24	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
LUAD	cis	rs7618501	0.602	rs2526743	ENSG00000234667.1	ACTBP13	5.5	6.17e-08	2.03e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50077812	chr3:49873347~49877980:-
LUAD	cis	rs1707322	0.928	rs10732844	ENSG00000234329.1	RP11-767N6.2	5.5	6.17e-08	2.03e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45651039~45651826:-
LUAD	cis	rs4908760	0.827	rs11121210	ENSG00000232912.4	RP5-1115A15.1	5.5	6.17e-08	2.03e-05	0.22	0.24	Vitiligo;	chr1:8648470	chr1:8424645~8434838:+
LUAD	cis	rs2562456	0.876	rs11085465	ENSG00000268081.1	RP11-678G14.2	-5.5	6.18e-08	2.03e-05	-0.36	-0.24	Pain;	chr19:21568988	chr19:21554640~21569237:-
LUAD	cis	rs1150668	0.799	rs7206	ENSG00000219392.1	RP1-265C24.5	-5.5	6.18e-08	2.03e-05	-0.31	-0.24	Pubertal anthropometrics;	chr6:28233360	chr6:28115628~28116551:+
LUAD	cis	rs338389	0.591	rs8037902	ENSG00000260657.2	RP11-315D16.4	5.5	6.18e-08	2.03e-05	0.28	0.24	Survival in rectal cancer;	chr15:67988365	chr15:68267792~68277994:-
LUAD	cis	rs6543140	0.964	rs2141781	ENSG00000234389.1	AC007278.3	5.5	6.18e-08	2.03e-05	0.25	0.24	Blood protein levels;	chr2:102466446	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs11903551	ENSG00000234389.1	AC007278.3	5.5	6.18e-08	2.03e-05	0.25	0.24	Blood protein levels;	chr2:102467721	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs6543143	ENSG00000234389.1	AC007278.3	5.5	6.18e-08	2.03e-05	0.25	0.24	Blood protein levels;	chr2:102468960	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs13383602	ENSG00000234389.1	AC007278.3	5.5	6.18e-08	2.03e-05	0.25	0.24	Blood protein levels;	chr2:102469502	chr2:102438713~102440475:+
LUAD	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	5.5	6.19e-08	2.03e-05	0.3	0.24	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
LUAD	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	5.5	6.19e-08	2.03e-05	0.27	0.24	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
LUAD	cis	rs807029	0.533	rs2863095	ENSG00000272572.1	RP11-179B2.2	-5.5	6.2e-08	2.04e-05	-0.35	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100911103~100912739:-
LUAD	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	5.5	6.2e-08	2.04e-05	0.25	0.24	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
LUAD	cis	rs948562	0.69	rs73484144	ENSG00000280010.1	AP001350.4	5.5	6.2e-08	2.04e-05	0.37	0.24	Lymphoma;	chr11:58337718	chr11:58627435~58628528:+
LUAD	cis	rs9847710	0.838	rs2564962	ENSG00000242142.1	SERBP1P3	5.5	6.21e-08	2.04e-05	0.27	0.24	Ulcerative colitis;	chr3:52997622	chr3:53064283~53065091:-
LUAD	cis	rs910316	1	rs12889472	ENSG00000259138.1	RP11-950C14.7	5.5	6.21e-08	2.04e-05	0.26	0.24	Height;	chr14:75077276	chr14:75127153~75136930:+
LUAD	cis	rs62432291	0.681	rs435521	ENSG00000235086.1	FNDC1-IT1	5.5	6.21e-08	2.04e-05	0.41	0.24	Joint mobility (Beighton score);	chr6:159241606	chr6:159240786~159243329:+
LUAD	cis	rs6964587	0.773	rs2097810	ENSG00000188693.7	CYP51A1-AS1	-5.5	6.22e-08	2.04e-05	-0.29	-0.24	Breast cancer;	chr7:92347912	chr7:92134604~92180725:+
LUAD	cis	rs12468226	1	rs13389798	ENSG00000272966.1	RP11-686O6.1	5.5	6.22e-08	2.04e-05	0.41	0.24	Urate levels;	chr2:202348370	chr2:202336739~202337200:+
LUAD	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	5.5	6.23e-08	2.04e-05	0.26	0.24	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
LUAD	cis	rs35740288	0.787	rs2291047	ENSG00000202081.1	RNU6-1280P	5.5	6.23e-08	2.05e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682574	chr15:85651522~85651628:-
LUAD	cis	rs755249	0.501	rs1889830	ENSG00000228060.1	RP11-69E11.8	5.5	6.24e-08	2.05e-05	0.22	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39565160~39573203:+
LUAD	cis	rs10200159	1	rs11676573	ENSG00000272606.1	RP11-554J4.1	5.5	6.24e-08	2.05e-05	0.51	0.24	Vitiligo;	chr2:55572780	chr2:55617909~55618373:+
LUAD	cis	rs62246343	0.719	rs62246303	ENSG00000254485.4	RP11-380O24.1	5.5	6.24e-08	2.05e-05	0.36	0.24	Fibrinogen levels;	chr3:9413078	chr3:9292588~9363303:-
LUAD	cis	rs74233809	1	rs12413409	ENSG00000213277.3	MARCKSL1P1	5.5	6.25e-08	2.05e-05	0.41	0.24	Birth weight;	chr10:102959339	chr10:103175554~103176094:+
LUAD	cis	rs6687821	0.515	rs6663434	ENSG00000267734.1	RP4-604K5.3	-5.5	6.25e-08	2.05e-05	-0.3	-0.24	Yeast infection;	chr1:87042570	chr1:86932199~86934891:-
LUAD	cis	rs4938303	0.718	rs10892020	ENSG00000280143.1	AP000892.6	5.5	6.25e-08	2.05e-05	0.3	0.24	Triglycerides;	chr11:116718936	chr11:117204967~117210292:+
LUAD	cis	rs7804306	0.826	rs112270482	ENSG00000233264.2	AC006042.8	5.5	6.25e-08	2.05e-05	0.44	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7981281	chr7:7980312~7982228:+
LUAD	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	5.5	6.26e-08	2.05e-05	0.49	0.24	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
LUAD	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	5.5	6.26e-08	2.06e-05	0.36	0.24	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-5.5	6.26e-08	2.06e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
LUAD	cis	rs2286492	0.655	rs117841439	ENSG00000228649.7	AC005682.5	-5.5	6.27e-08	2.06e-05	-0.45	-0.24	Bipolar disorder;	chr7:22870922	chr7:22854178~22861579:+
LUAD	cis	rs1823874	0.71	rs58572174	ENSG00000182397.13	DNM1P46	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	IgG glycosylation;	chr15:99822635	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.677	rs1993295	ENSG00000182397.13	DNM1P46	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	IgG glycosylation;	chr15:99823332	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.71	rs1993297	ENSG00000182397.13	DNM1P46	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	IgG glycosylation;	chr15:99823423	chr15:99790156~99806927:-
LUAD	cis	rs6687821	0.515	rs2390219	ENSG00000267734.1	RP4-604K5.3	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	Yeast infection;	chr1:86988738	chr1:86932199~86934891:-
LUAD	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-5.5	6.27e-08	2.06e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-5.5	6.27e-08	2.06e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-5.5	6.27e-08	2.06e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
LUAD	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	5.5	6.27e-08	2.06e-05	0.35	0.24	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
LUAD	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	5.5	6.27e-08	2.06e-05	0.35	0.24	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
LUAD	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	5.5	6.27e-08	2.06e-05	0.35	0.24	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
LUAD	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
LUAD	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	5.5	6.28e-08	2.06e-05	0.35	0.24	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	5.5	6.28e-08	2.06e-05	0.35	0.24	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	5.5	6.28e-08	2.06e-05	0.35	0.24	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	5.5	6.28e-08	2.06e-05	0.35	0.24	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
LUAD	cis	rs2412819	0.571	rs8038068	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43622175	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs56246169	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43628358	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
LUAD	cis	rs10214930	0.723	rs12700826	ENSG00000235574.1	AC073150.6	-5.5	6.3e-08	2.07e-05	-0.29	-0.24	Hypospadias;	chr7:27633107	chr7:27491682~27492765:-
LUAD	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-5.5	6.3e-08	2.07e-05	-0.28	-0.24	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-5.5	6.3e-08	2.07e-05	-0.28	-0.24	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-5.5	6.3e-08	2.07e-05	-0.28	-0.24	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
LUAD	cis	rs4273100	0.646	rs6587216	ENSG00000279825.1	CTC-457L16.1	-5.5	6.31e-08	2.07e-05	-0.28	-0.24	Schizophrenia;	chr17:19321084	chr17:19030857~19033529:+
LUAD	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	5.5	6.31e-08	2.07e-05	0.32	0.24	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	5.5	6.31e-08	2.07e-05	0.32	0.24	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
LUAD	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-5.5	6.32e-08	2.07e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
LUAD	cis	rs14027	0.921	rs16893077	ENSG00000279347.1	RP11-85I17.2	-5.5	6.32e-08	2.07e-05	-0.21	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119838736~119840385:-
LUAD	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-5.5	6.32e-08	2.07e-05	-0.36	-0.24	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-5.5	6.32e-08	2.07e-05	-0.36	-0.24	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
LUAD	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	5.5	6.32e-08	2.07e-05	0.57	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
LUAD	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
LUAD	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-5.5	6.34e-08	2.08e-05	-0.31	-0.24	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-5.5	6.34e-08	2.08e-05	-0.31	-0.24	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
LUAD	cis	rs1876905	0.597	rs354538	ENSG00000272356.1	RP5-1112D6.8	-5.5	6.34e-08	2.08e-05	-0.27	-0.24	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111309203~111313517:+
LUAD	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-5.5	6.34e-08	2.08e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
LUAD	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	5.49	6.35e-08	2.08e-05	0.38	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
LUAD	cis	rs56046484	0.75	rs7173332	ENSG00000259295.5	CSPG4P12	5.49	6.35e-08	2.08e-05	0.38	0.24	Testicular germ cell tumor;	chr15:84978503	chr15:85191438~85213905:+
LUAD	cis	rs1707322	1	rs11211219	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211222	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs9787412	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660896	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs12133129	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs4553121	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs6690652	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs6695421	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45651039~45651826:-
LUAD	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	5.49	6.35e-08	2.08e-05	0.3	0.24	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
LUAD	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	5.49	6.35e-08	2.08e-05	0.3	0.24	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
LUAD	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-5.49	6.35e-08	2.08e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-5.49	6.35e-08	2.08e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-5.49	6.35e-08	2.08e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
LUAD	cis	rs9287719	0.649	rs12621977	ENSG00000243819.4	RN7SL832P	5.49	6.35e-08	2.08e-05	0.26	0.24	Prostate cancer;	chr2:10581805	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs12617968	ENSG00000243819.4	RN7SL832P	5.49	6.35e-08	2.08e-05	0.26	0.24	Prostate cancer;	chr2:10581819	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.614	rs12622053	ENSG00000243819.4	RN7SL832P	5.49	6.35e-08	2.08e-05	0.26	0.24	Prostate cancer;	chr2:10582014	chr2:10690344~10692099:+
LUAD	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	5.49	6.35e-08	2.08e-05	0.25	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
LUAD	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	5.49	6.36e-08	2.08e-05	0.22	0.24	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
LUAD	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	5.49	6.36e-08	2.08e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
LUAD	cis	rs75920871	0.528	rs12274465	ENSG00000254851.1	RP11-109L13.1	5.49	6.36e-08	2.08e-05	0.35	0.24	Subjective well-being;	chr11:117086473	chr11:117135528~117138582:+
LUAD	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-5.49	6.36e-08	2.09e-05	-0.31	-0.24	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
LUAD	cis	rs6751744	0.855	rs7585513	ENSG00000230783.1	AC009961.2	-5.49	6.37e-08	2.09e-05	-0.3	-0.24	Dysphagia;	chr2:159550379	chr2:159689217~159690291:-
LUAD	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	5.49	6.37e-08	2.09e-05	0.3	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
LUAD	cis	rs1032726	0.663	rs61629858	ENSG00000242770.2	RP11-180K7.1	-5.49	6.37e-08	2.09e-05	-0.28	-0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112935600	chr3:112802478~112812819:+
LUAD	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	5.49	6.37e-08	2.09e-05	0.3	0.24	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
LUAD	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-5.49	6.38e-08	2.09e-05	-0.3	-0.24	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
LUAD	cis	rs35740288	0.822	rs34734963	ENSG00000202081.1	RNU6-1280P	5.49	6.38e-08	2.09e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85674413	chr15:85651522~85651628:-
LUAD	cis	rs41307935	0.908	rs34014719	ENSG00000260063.1	RP5-968P14.2	-5.49	6.39e-08	2.09e-05	-0.44	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26746275	chr1:26692132~26694131:-
LUAD	cis	rs11089937	0.597	rs9619794	ENSG00000211638.2	IGLV8-61	-5.49	6.39e-08	2.09e-05	-0.28	-0.24	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22098700~22099212:+
LUAD	cis	rs7662987	0.793	rs7684735	ENSG00000272777.1	RP11-571L19.8	5.49	6.39e-08	2.09e-05	0.38	0.24	Smoking initiation;	chr4:99070355	chr4:99067256~99068125:-
LUAD	cis	rs12468226	0.817	rs2350360	ENSG00000226261.1	AC064836.3	-5.49	6.39e-08	2.09e-05	-0.39	-0.24	Urate levels;	chr2:202222980	chr2:202336024~202336727:-
LUAD	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	5.49	6.4e-08	2.09e-05	0.37	0.24	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
LUAD	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	5.49	6.4e-08	2.1e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
LUAD	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-5.49	6.4e-08	2.1e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
LUAD	cis	rs2919009	0.882	rs3011384	ENSG00000271670.1	RP11-95I16.4	5.49	6.41e-08	2.1e-05	0.31	0.24	Obesity-related traits;	chr10:120833599	chr10:120879256~120880667:-
LUAD	cis	rs853679	0.599	rs156743	ENSG00000204709.4	LINC01556	5.49	6.41e-08	2.1e-05	0.43	0.24	Depression;	chr6:27999311	chr6:28943877~28944537:+
LUAD	cis	rs4660214	0.756	rs11205823	ENSG00000228060.1	RP11-69E11.8	5.49	6.41e-08	2.1e-05	0.22	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39565160~39573203:+
LUAD	cis	rs12699921	0.598	rs1524775	ENSG00000279048.1	RP11-511H23.2	-5.49	6.42e-08	2.1e-05	-0.2	-0.24	Fibrinogen levels;	chr7:17896742	chr7:17940503~17942922:+
LUAD	cis	rs4654783	0.521	rs59709264	ENSG00000228397.1	RP1-224A6.3	5.49	6.42e-08	2.1e-05	0.3	0.24	Endometriosis;	chr1:22122832	chr1:22023994~22024968:-
LUAD	cis	rs896854	0.654	rs10104909	ENSG00000253528.2	RP11-347C18.4	5.49	6.42e-08	2.1e-05	0.23	0.24	Type 2 diabetes;	chr8:94965745	chr8:94974573~94974853:-
LUAD	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-5.49	6.42e-08	2.1e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-5.49	6.42e-08	2.1e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
LUAD	cis	rs35740288	0.787	rs11635418	ENSG00000202081.1	RNU6-1280P	5.49	6.42e-08	2.1e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700947	chr15:85651522~85651628:-
LUAD	cis	rs453301	0.686	rs11785634	ENSG00000253981.4	ALG1L13P	-5.49	6.43e-08	2.1e-05	-0.28	-0.24	Joint mobility (Beighton score);	chr8:9035087	chr8:8236003~8244667:-
LUAD	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-5.49	6.43e-08	2.1e-05	-0.33	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
LUAD	cis	rs1426063	0.614	rs17266308	ENSG00000249717.1	RP11-44F21.3	-5.49	6.43e-08	2.1e-05	-0.43	-0.24	QT interval;	chr4:75137695	chr4:74955974~74970362:-
LUAD	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	5.49	6.43e-08	2.11e-05	0.29	0.24	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
LUAD	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	5.49	6.43e-08	2.11e-05	0.29	0.24	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-5.49	6.43e-08	2.11e-05	-0.34	-0.24	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.716	rs67204011	ENSG00000259422.1	RP11-593F23.1	5.49	6.43e-08	2.11e-05	0.28	0.24	Blood metabolite levels;	chr15:76554214	chr15:76174891~76181486:-
LUAD	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-5.49	6.45e-08	2.11e-05	-0.31	-0.24	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
LUAD	cis	rs1707322